Tricuspid	0 9 B-Disease
valve	10 5 I-Disease
regurgitation	16 13 I-Disease
and	30 3 O
lithium	34 7 B-Chemical
carbonate	42 9 I-Chemical
toxicity	52 8 B-Disease
in	61 2 O
a	64 1 O
newborn	66 7 O
infant	74 6 O
.	80 1 O

A	82 1 O
newborn	84 7 O
with	92 4 O
massive	97 7 O
tricuspid	105 9 B-Disease
regurgitation	115 13 I-Disease
,	128 1 O
atrial	130 6 B-Disease
flutter	137 7 I-Disease
,	144 1 O
congestive	146 10 B-Disease
heart	157 5 I-Disease
failure	163 7 I-Disease
,	170 1 O
and	172 3 O
a	176 1 O
high	178 4 O
serum	183 5 O
lithium	189 7 B-Chemical
level	197 5 O
is	203 2 O
described	206 9 O
.	215 1 O

This	217 4 O
is	222 2 O
the	225 3 O
first	229 5 O
patient	235 7 O
to	243 2 O
initially	246 9 O
manifest	256 8 O
tricuspid	265 9 B-Disease
regurgitation	275 13 I-Disease
and	289 3 O
atrial	293 6 B-Disease
flutter	300 7 I-Disease
,	307 1 O
and	309 3 O
the	313 3 O
11th	317 4 O
described	322 9 O
patient	332 7 O
with	340 4 O
cardiac	345 7 B-Disease
disease	353 7 I-Disease
among	361 5 O
infants	367 7 O
exposed	375 7 O
to	383 2 O
lithium	386 7 B-Chemical
compounds	394 9 O
in	404 2 O
the	407 3 O
first	411 5 O
trimester	417 9 O
of	427 2 O
pregnancy	430 9 O
.	439 1 O

Sixty	441 5 O
-	446 1 O
three	447 5 O
percent	453 7 O
of	461 2 O
these	464 5 O
infants	470 7 O
had	478 3 O
tricuspid	482 9 O
valve	492 5 O
involvement	498 11 O
.	509 1 O

Lithium	511 7 B-Chemical
carbonate	519 9 I-Chemical
may	529 3 O
be	533 2 O
a	536 1 O
factor	538 6 O
in	545 2 O
the	548 3 O
increasing	552 10 O
incidence	563 9 O
of	573 2 O
congenital	576 10 B-Disease
heart	587 5 I-Disease
disease	593 7 I-Disease
when	601 4 O
taken	606 5 O
during	612 6 O
early	619 5 O
pregnancy	625 9 O
.	634 1 O

It	636 2 O
also	639 4 O
causes	644 6 O
neurologic	651 10 B-Disease
depression	662 10 I-Disease
,	672 1 O
cyanosis	674 8 B-Disease
,	682 1 O
and	684 3 O
cardiac	688 7 B-Disease
arrhythmia	696 10 I-Disease
when	707 4 O
consumed	712 8 O
prior	721 5 O
to	727 2 O
delivery	730 8 O
.	738 1 O

Phenobarbital	0 13 B-Chemical
-	13 1 O
induced	14 7 O
dyskinesia	22 10 B-Disease
in	33 2 O
a	36 1 O
neurologically	38 14 B-Disease
-	52 1 I-Disease
impaired	53 8 I-Disease
child	62 5 O
.	67 1 O

A	69 1 O
2	71 1 O
-	72 1 O
year	73 4 O
-	77 1 O
old	78 3 O
child	82 5 O
with	88 4 O
known	93 5 O
neurologic	99 10 B-Disease
impairment	110 10 I-Disease
developed	121 9 O
a	131 1 O
dyskinesia	133 10 B-Disease
soon	144 4 O
after	149 5 O
starting	155 8 O
phenobarbital	164 13 B-Chemical
therapy	178 7 O
for	186 3 O
seizures	190 8 B-Disease
.	198 1 O

Known	200 5 O
causes	206 6 O
of	213 2 O
movement	216 8 B-Disease
disorders	225 9 I-Disease
were	235 4 O
eliminated	240 10 O
after	251 5 O
evaluation	257 10 O
.	267 1 O

On	269 2 O
repeat	272 6 O
challenge	279 9 O
with	289 4 O
phenobarbital	294 13 B-Chemical
,	307 1 O
the	309 3 O
dyskinesia	313 10 B-Disease
recurred	324 8 O
.	332 1 O

Phenobarbital	334 13 B-Chemical
should	348 6 O
be	355 2 O
added	358 5 O
to	364 2 O
the	367 3 O
list	371 4 O
of	376 2 O
anticonvulsant	379 14 O
drugs	394 5 O
that	400 4 O
can	405 3 O
cause	409 5 O
movement	415 8 B-Disease
disorders	424 9 I-Disease
.	433 1 O

Acute	0 5 O
changes	6 7 O
of	14 2 O
blood	17 5 O
ammonia	23 7 B-Chemical
may	31 3 O
predict	35 7 O
short	43 5 O
-	48 1 O
term	49 4 O
adverse	54 7 O
effects	62 7 O
of	70 2 O
valproic	73 8 B-Chemical
acid	82 4 I-Chemical
.	86 1 O

Valproic	88 8 B-Chemical
acid	97 4 I-Chemical
(	102 1 O
VPA	103 3 B-Chemical
)	106 1 O
was	108 3 O
given	112 5 O
to	118 2 O
24	121 2 O
epileptic	124 9 B-Disease
patients	134 8 O
who	143 3 O
were	147 4 O
already	152 7 O
being	160 5 O
treated	166 7 O
with	174 4 O
other	179 5 O
antiepileptic	185 13 O
drugs	199 5 O
.	204 1 O

A	206 1 O
standardized	208 12 O
loading	221 7 O
dose	229 4 O
of	234 2 O
VPA	237 3 B-Chemical
was	241 3 O
administered	245 12 O
,	257 1 O
and	259 3 O
venous	263 6 O
blood	270 5 O
was	276 3 O
sampled	280 7 O
at	288 2 O
0	291 1 O
,	292 1 O
1	294 1 O
,	295 1 O
2	297 1 O
,	298 1 O
3	300 1 O
,	301 1 O
and	303 3 O
4	307 1 O
hours	309 5 O
.	314 1 O

Ammonia	316 7 B-Chemical
(	324 1 O
NH3	325 3 B-Chemical
)	328 1 O
was	330 3 O
higher	334 6 O
in	341 2 O
patients	344 8 O
who	353 3 O
,	356 1 O
during	358 6 O
continuous	365 10 O
therapy	376 7 O
,	383 1 O
complained	385 10 O
of	396 2 O
drowsiness	399 10 B-Disease
(	410 1 O
7	411 1 O
patients	413 8 O
)	421 1 O
than	423 4 O
in	428 2 O
those	431 5 O
who	437 3 O
were	441 4 O
symptom	446 7 O
-	453 1 O
free	454 4 O
(	459 1 O
17	460 2 O
patients	463 8 O
)	471 1 O
,	472 1 O
although	474 8 O
VPA	483 3 B-Chemical
plasma	487 6 O
levels	494 6 O
were	501 4 O
similar	506 7 O
in	514 2 O
both	517 4 O
groups	522 6 O
.	528 1 O

By	530 2 O
measuring	533 9 O
VPA	543 3 B-Chemical
-	546 1 O
induced	547 7 O
changes	555 7 O
of	563 2 O
blood	566 5 O
NH3	572 3 B-Chemical
content	576 7 O
,	583 1 O
it	585 2 O
may	588 3 O
be	592 2 O
possible	595 8 O
to	604 2 O
identify	607 8 O
patients	616 8 O
at	625 2 O
higher	628 6 O
risk	635 4 O
of	640 2 O
obtundation	643 11 O
when	655 4 O
VPA	660 3 B-Chemical
is	664 2 O
given	667 5 O
chronically	673 11 O
.	684 1 O

Effects	0 7 O
of	8 2 O
calcitonin	11 10 O
on	22 2 O
rat	25 3 O
extrapyramidal	29 14 O
motor	44 5 O
system	50 6 O
:	56 1 O
behavioral	58 10 O
and	69 3 O
biochemical	73 11 O
data	85 4 O
.	89 1 O

The	91 3 O
effects	95 7 O
of	103 2 O
i	106 1 O
.	107 1 O
v	108 1 O
.	109 1 O
c	110 1 O
.	111 1 O
injection	113 9 O
of	123 2 O
human	126 5 O
and	132 3 O
salmon	136 6 O
calcitonin	143 10 O
on	154 2 O
biochemical	157 11 O
and	169 3 O
behavioral	173 10 O
parameters	184 10 O
related	195 7 O
to	203 2 O
the	206 3 O
extrapyramidal	210 14 O
motor	225 5 O
system	231 6 O
,	237 1 O
were	239 4 O
investigated	244 12 O
in	257 2 O
male	260 4 O
rats	265 4 O
.	269 1 O

Calcitonin	271 10 O
injection	282 9 O
resulted	292 8 O
in	301 2 O
a	304 1 O
potentiation	306 12 O
of	319 2 O
haloperidol	322 11 B-Chemical
-	333 1 O
induced	334 7 O
catalepsy	342 9 B-Disease
and	352 3 O
a	356 1 O
partial	358 7 O
prevention	366 10 O
of	377 2 O
apomorphine	380 11 B-Chemical
-	391 1 O
induced	392 7 O
hyperactivity	400 13 B-Disease
.	413 1 O

Moreover	415 8 O
calcitonin	424 10 O
induced	435 7 O
a	443 1 O
significant	445 11 O
decrease	457 8 O
in	466 2 O
nigral	469 6 O
GAD	476 3 O
activity	480 8 O
but	489 3 O
no	493 2 O
change	496 6 O
in	503 2 O
striatal	506 8 O
DA	515 2 B-Chemical
and	518 3 O
DOPAC	522 5 B-Chemical
concentration	528 13 O
or	542 2 O
GAD	545 3 O
activity	549 8 O
.	557 1 O

The	559 3 O
results	563 7 O
are	571 3 O
discussed	575 9 O
in	585 2 O
view	588 4 O
of	593 2 O
a	596 1 O
primary	598 7 O
action	606 6 O
of	613 2 O
calcitonin	616 10 O
on	627 2 O
the	630 3 O
striatonigral	634 13 O
GABAergic	648 9 O
pathway	658 7 O
mediating	666 9 O
the	676 3 O
DA	680 2 B-Chemical
-	682 1 O
related	683 7 O
behavioral	691 10 O
messages	702 8 O
of	711 2 O
striatal	714 8 O
origin	723 6 O
.	729 1 O

Development	0 11 O
of	12 2 O
isoproterenol	15 13 B-Chemical
-	28 1 O
induced	29 7 O
cardiac	37 7 B-Disease
hypertrophy	45 11 I-Disease
.	56 1 O

The	58 3 O
development	62 11 O
of	74 2 O
cardiac	77 7 B-Disease
hypertrophy	85 11 I-Disease
was	97 3 O
studied	101 7 O
in	109 2 O
adult	112 5 O
female	118 6 O
Wistar	125 6 O
rats	132 4 O
following	137 9 O
daily	147 5 O
subcutaneous	153 12 O
injections	166 10 O
of	177 2 O
isoproterenol	180 13 B-Chemical
(	194 1 O
ISO	195 3 B-Chemical
)	198 1 O
(	200 1 O
0	201 1 O
.	202 1 O
3	203 1 O
mg	205 2 O
/	207 1 O
kg	208 2 O
body	211 4 O
weight	216 6 O
)	222 1 O
.	223 1 O

A	225 1 O
time	227 4 O
course	232 6 O
was	239 3 O
established	243 11 O
for	255 3 O
the	259 3 O
change	263 6 O
in	270 2 O
tissue	273 6 O
mass	280 4 O
,	284 1 O
RNA	286 3 O
and	290 3 O
DNA	294 3 O
content	298 7 O
,	305 1 O
as	307 2 O
well	310 4 O
as	315 2 O
hydroxyproline	318 14 B-Chemical
content	333 7 O
.	340 1 O

Heart	342 5 O
weight	348 6 O
increased	355 9 O
44	365 2 O
%	367 1 O
after	369 5 O
8	375 1 O
days	377 4 O
of	382 2 O
treatment	385 9 O
with	395 4 O
a	400 1 O
half	402 4 O
time	407 4 O
of	412 2 O
3	415 1 O
.	416 1 O
4	417 1 O
days	419 4 O
.	423 1 O

Ventricular	425 11 O
RNA	437 3 O
content	441 7 O
was	449 3 O
elevated	453 8 O
26	462 2 O
%	464 1 O
after	466 5 O
24	472 2 O
h	475 1 O
of	477 2 O
a	480 1 O
single	482 6 O
injection	489 9 O
and	499 3 O
reached	503 7 O
a	511 1 O
maximal	513 7 O
level	521 5 O
following	527 9 O
8	537 1 O
days	539 4 O
of	544 2 O
therapy	547 7 O
.	554 1 O

The	556 3 O
half	560 4 O
time	565 4 O
for	570 3 O
RNA	574 3 O
accumulation	578 12 O
was	591 3 O
2	595 1 O
.	596 1 O
0	597 1 O
days	599 4 O
.	603 1 O

The	605 3 O
total	609 5 O
content	615 7 O
of	623 2 O
hydroxyproline	626 14 B-Chemical
remained	641 8 O
stable	650 6 O
during	657 6 O
the	664 3 O
first	668 5 O
2	674 1 O
days	676 4 O
of	681 2 O
treatment	684 9 O
but	694 3 O
increased	698 9 O
46	708 2 O
%	710 1 O
after	712 5 O
4	718 1 O
days	720 4 O
of	725 2 O
therapy	728 7 O
.	735 1 O

Ventricular	737 11 O
DNA	749 3 O
content	753 7 O
was	761 3 O
unchanged	765 9 O
during	775 6 O
the	782 3 O
early	786 5 O
stage	792 5 O
(	798 1 O
1	799 1 O
-	800 1 O
4	801 1 O
days	803 4 O
)	807 1 O
of	809 2 O
hypertrophic	812 12 B-Disease
growth	825 6 O
but	832 3 O
increased	836 9 O
to	846 2 O
a	849 1 O
new	851 3 O
steady	855 6 O
-	861 1 O
state	862 5 O
level	868 5 O
19	874 2 O
%	876 1 O
above	878 5 O
the	884 3 O
controls	888 8 O
after	897 5 O
8	903 1 O
days	905 4 O
of	910 2 O
treatment	913 9 O
.	922 1 O

Intraventricular	924 16 O
pressures	941 9 O
and	951 3 O
coronary	955 8 O
flow	964 4 O
measures	969 8 O
were	978 4 O
similar	983 7 O
for	991 3 O
control	995 7 O
and	1003 3 O
experimental	1007 12 O
animals	1020 7 O
following	1028 9 O
4	1038 1 O
days	1040 4 O
of	1045 2 O
developed	1048 9 O
hypertrophy	1058 11 B-Disease
.	1069 1 O

However	1071 7 O
,	1078 1 O
dP	1080 2 O
/	1082 1 O
dt	1083 2 O
in	1086 2 O
the	1089 3 O
ISO	1093 3 B-Chemical
-	1096 1 O
treated	1097 7 O
hearts	1105 6 O
was	1112 3 O
slightly	1116 8 O
but	1125 3 O
significantly	1129 13 O
(	1143 1 O
P	1144 1 O
less	1146 4 O
than	1151 4 O
0	1156 1 O
.	1157 1 O
05	1158 2 O
)	1160 1 O
elevated	1162 8 O
.	1170 1 O

These	1172 5 O
data	1178 4 O
indicate	1183 8 O
that	1192 4 O
the	1197 3 O
adaptive	1201 8 O
response	1210 8 O
to	1219 2 O
ISO	1222 3 B-Chemical
shows	1226 5 O
an	1232 2 O
early	1235 5 O
hypertrophic	1241 12 B-Disease
phase	1254 5 O
(	1260 1 O
1	1261 1 O
-	1262 1 O
4	1263 1 O
days	1265 4 O
)	1269 1 O
characterized	1271 13 O
by	1285 2 O
a	1288 1 O
substantial	1290 11 O
increase	1302 8 O
in	1311 2 O
RNA	1314 3 O
content	1318 7 O
and	1326 3 O
cardiac	1330 7 O
mass	1338 4 O
in	1343 2 O
the	1346 3 O
absence	1350 7 O
of	1358 2 O
changes	1361 7 O
in	1369 2 O
DNA	1372 3 O
.	1375 1 O

However	1377 7 O
,	1384 1 O
prolonged	1386 9 O
stimulation	1396 11 O
(	1408 1 O
8	1409 1 O
-	1410 1 O
12	1411 2 O
days	1414 4 O
)	1418 1 O
appears	1420 7 O
to	1428 2 O
represent	1431 9 O
a	1441 1 O
complex	1443 7 O
integration	1451 11 O
of	1463 2 O
both	1466 4 O
cellular	1471 8 O
hypertrophy	1480 11 B-Disease
and	1492 3 O
hyperplasia	1496 11 B-Disease
within	1508 6 O
the	1515 3 O
heart	1519 5 O
.	1524 1 O

Co	0 2 O
-	2 1 O
carcinogenic	3 12 B-Disease
effect	16 6 O
of	23 2 O
retinyl	26 7 B-Chemical
acetate	34 7 I-Chemical
on	42 2 O
forestomach	45 11 B-Disease
carcinogenesis	57 14 I-Disease
of	72 2 O
male	75 4 O
F344	80 4 O
rats	85 4 O
induced	90 7 O
with	98 4 O
butylated	103 9 B-Chemical
hydroxyanisole	113 14 I-Chemical
.	127 1 O

The	129 3 O
potential	133 9 O
modifying	143 9 O
effect	153 6 O
of	160 2 O
retinyl	163 7 B-Chemical
acetate	171 7 I-Chemical
(	179 1 O
RA	180 2 B-Chemical
)	182 1 O
on	184 2 O
butylated	187 9 B-Chemical
hydroxyanisole	197 14 I-Chemical
(	212 1 O
BHA	213 3 B-Chemical
)	216 1 O
-	217 1 O
induced	218 7 O
rat	226 3 O
forestomach	230 11 B-Disease
tumorigenesis	242 13 I-Disease
was	256 3 O
examined	260 8 O
.	268 1 O

Male	270 4 O
F344	275 4 O
rats	280 4 O
,	284 1 O
5	286 1 O
weeks	288 5 O
of	294 2 O
age	297 3 O
,	300 1 O
were	302 4 O
maintained	307 10 O
on	318 2 O
diet	321 4 O
containing	326 10 O
1	337 1 O
%	338 1 O
or	340 2 O
2	343 1 O
%	344 1 O
BHA	346 3 B-Chemical
by	350 2 O
weight	353 6 O
and	360 3 O
simultaneously	364 14 O
on	379 2 O
drinking	382 8 O
water	391 5 O
supplemented	397 12 O
with	410 4 O
RA	415 2 B-Chemical
at	418 2 O
various	421 7 O
concentrations	429 14 O
(	444 1 O
w	445 1 O
/	446 1 O
v	447 1 O
)	448 1 O
for	450 3 O
52	454 2 O
weeks	457 5 O
.	462 1 O

In	464 2 O
groups	467 6 O
given	474 5 O
2	480 1 O
%	481 1 O
BHA	483 3 B-Chemical
,	486 1 O
although	488 8 O
marked	497 6 O
hyperplastic	504 12 O
changes	517 7 O
of	525 2 O
the	528 3 O
forestomach	532 11 O
epithelium	544 10 O
were	555 4 O
observed	560 8 O
in	569 2 O
all	572 3 O
animals	576 7 O
,	583 1 O
co	585 2 O
-	587 1 O
administration	588 14 O
of	603 2 O
0	606 1 O
.	607 1 O
25	608 2 O
%	610 1 O
RA	612 2 B-Chemical
significantly	615 13 O
(	629 1 O
P	630 1 O
less	632 4 O
than	637 4 O
0	642 1 O
.	643 1 O
05	644 2 O
)	646 1 O
increased	648 9 O
the	658 3 O
incidence	662 9 O
of	672 2 O
forestomach	675 11 B-Disease
tumors	687 6 I-Disease
(	694 1 O
squamous	695 8 B-Disease
cell	704 4 I-Disease
papilloma	709 9 I-Disease
and	719 3 O
carcinoma	723 9 B-Disease
)	732 1 O
to	734 2 O
60	737 2 O
%	739 1 O
(	741 1 O
9	742 1 O
/	743 1 O
15	744 2 O
,	746 1 O
2	748 1 O
rats	750 4 O
with	755 4 O
carcinoma	760 9 B-Disease
)	769 1 O
from	771 4 O
15	776 2 O
%	778 1 O
(	780 1 O
3	781 1 O
/	782 1 O
20	783 2 O
,	785 1 O
one	787 3 O
rat	791 3 O
with	795 4 O
carcinoma	800 9 B-Disease
)	809 1 O
in	811 2 O
the	814 3 O
group	818 5 O
given	824 5 O
RA	830 2 B-Chemical
-	832 1 O
free	833 4 O
water	838 5 O
.	843 1 O

In	845 2 O
rats	848 4 O
given	853 5 O
1	859 1 O
%	860 1 O
BHA	862 3 B-Chemical
,	865 1 O
RA	867 2 B-Chemical
co	870 2 O
-	872 1 O
administered	873 12 O
at	886 2 O
a	889 1 O
dose	891 4 O
of	896 2 O
0	899 1 O
.	900 1 O
05	901 2 O
,	903 1 O
0	905 1 O
.	906 1 O
1	907 1 O
,	908 1 O
0	910 1 O
.	911 1 O
2	912 1 O
or	914 2 O
0	917 1 O
.	918 1 O
25	919 2 O
%	921 1 O
showed	923 6 O
a	930 1 O
dose	932 4 O
-	936 1 O
dependent	937 9 O
enhancing	947 9 O
effect	957 6 O
on	964 2 O
the	967 3 O
development	971 11 O
of	983 2 O
the	986 3 O
BHA	990 3 B-Chemical
-	993 1 O
induced	994 7 O
epithelial	1002 10 B-Disease
hyperplasia	1013 11 I-Disease
.	1024 1 O

Tumors	1026 6 B-Disease
,	1032 1 O
all	1034 3 O
papillomas	1038 10 B-Disease
,	1048 1 O
were	1050 4 O
induced	1055 7 O
in	1063 2 O
3	1066 1 O
rats	1068 4 O
(	1073 1 O
17	1074 2 O
%	1076 1 O
)	1077 1 O
with	1079 4 O
0	1084 1 O
.	1085 1 O
25	1086 2 O
%	1088 1 O
RA	1090 2 B-Chemical
and	1093 3 O
in	1097 2 O
one	1100 3 O
rat	1104 3 O
(	1108 1 O
10	1109 2 O
%	1111 1 O
)	1112 1 O
with	1114 4 O
0	1119 1 O
.	1120 1 O
05	1121 2 O
%	1123 1 O
RA	1125 2 B-Chemical
co	1128 2 O
-	1130 1 O
administration	1131 14 O
.	1145 1 O

RA	1147 2 B-Chemical
alone	1150 5 O
did	1156 3 O
not	1160 3 O
induce	1164 6 O
hyperplastic	1171 12 O
changes	1184 7 O
in	1192 2 O
the	1195 3 O
forestomach	1199 11 O
.	1210 1 O

These	1212 5 O
findings	1218 8 O
indicate	1227 8 O
that	1236 4 O
RA	1241 2 B-Chemical
acted	1244 5 O
as	1250 2 O
a	1253 1 O
co	1255 2 O
-	1257 1 O
carcinogen	1258 10 O
in	1269 2 O
the	1272 3 O
BHA	1276 3 B-Chemical
forestomach	1280 11 B-Disease
carcinogenesis	1292 14 I-Disease
of	1307 2 O
the	1310 3 O
rat	1314 3 O
.	1317 1 O

Ketanserin	0 10 B-Chemical
pretreatment	11 12 O
reverses	24 8 O
alfentanil	33 10 B-Chemical
-	43 1 O
induced	44 7 O
muscle	52 6 B-Disease
rigidity	59 8 I-Disease
.	67 1 O

Systemic	69 8 O
pretreatment	78 12 O
with	91 4 O
ketanserin	96 10 B-Chemical
,	106 1 O
a	108 1 O
relatively	110 10 O
specific	121 8 O
type	130 4 O
-	134 1 O
2	135 1 O
serotonin	137 9 B-Chemical
receptor	147 8 O
antagonist	156 10 O
,	166 1 O
significantly	168 13 O
attenuated	182 10 O
the	193 3 O
muscle	197 6 B-Disease
rigidity	204 8 I-Disease
produced	213 8 O
in	222 2 O
rats	225 4 O
by	230 2 O
the	233 3 O
potent	237 6 O
short	244 5 O
-	249 1 O
acting	250 6 O
opiate	257 6 O
agonist	264 7 O
alfentanil	272 10 B-Chemical
.	282 1 O

Following	284 9 O
placement	294 9 O
of	304 2 O
subcutaneous	307 12 O
electrodes	320 10 O
in	331 2 O
each	334 4 O
animal	339 6 O
'	345 1 O
s	346 1 O
left	348 4 O
gastrocnemius	353 13 O
muscle	367 6 O
,	373 1 O
rigidity	375 8 B-Disease
was	384 3 O
assessed	388 8 O
by	397 2 O
analyzing	400 9 O
root	410 4 O
-	414 1 O
mean	415 4 O
-	419 1 O
square	420 6 O
electromyographic	427 17 O
activity	445 8 O
.	453 1 O

Intraperitoneal	455 15 O
ketanserin	471 10 B-Chemical
administration	482 14 O
at	497 2 O
doses	500 5 O
of	506 2 O
0	509 1 O
.	510 1 O
63	511 2 O
and	514 3 O
2	518 1 O
.	519 1 O
5	520 1 O
mg	522 2 O
/	524 1 O
kg	525 2 O
prevented	528 9 O
the	538 3 O
alfentanil	542 10 B-Chemical
-	552 1 O
induced	553 7 O
increase	561 8 O
in	570 2 O
electromyographic	573 17 O
activity	591 8 O
compared	600 8 O
with	609 4 O
animals	614 7 O
pretreated	622 10 O
with	633 4 O
saline	638 6 O
.	644 1 O

Chlordiazepoxide	646 16 B-Chemical
at	663 2 O
doses	666 5 O
up	672 2 O
to	675 2 O
10	678 2 O
mg	681 2 O
/	683 1 O
kg	684 2 O
failed	687 6 O
to	694 2 O
significantly	697 13 O
influence	711 9 O
the	721 3 O
rigidity	725 8 B-Disease
produced	734 8 O
by	743 2 O
alfentanil	746 10 B-Chemical
.	756 1 O

Despite	758 7 O
the	766 3 O
absence	770 7 O
of	778 2 O
rigidity	781 8 B-Disease
,	789 1 O
animals	791 7 O
that	799 4 O
received	804 8 O
ketanserin	813 10 B-Chemical
(	824 1 O
greater	825 7 O
than	833 4 O
0	838 1 O
.	839 1 O
31	840 2 O
mg	843 2 O
/	845 1 O
kg	846 2 O
i	849 1 O
.	850 1 O
p	851 1 O
.	852 1 O
)	853 1 O
followed	855 8 O
by	864 2 O
alfentanil	867 10 B-Chemical
were	878 4 O
motionless	883 10 O
,	893 1 O
flaccid	895 7 O
,	902 1 O
and	904 3 O
less	908 4 O
responsive	913 10 O
to	924 2 O
external	927 8 O
stimuli	936 7 O
than	944 4 O
were	949 4 O
animals	954 7 O
receiving	962 9 O
alfentanil	972 10 B-Chemical
alone	983 5 O
.	988 1 O

Rats	990 4 O
that	995 4 O
received	1000 8 O
ketanserin	1009 10 B-Chemical
and	1020 3 O
alfentanil	1024 10 B-Chemical
exhibited	1035 9 O
less	1045 4 O
rearing	1050 7 O
and	1058 3 O
exploratory	1062 11 O
behavior	1074 8 O
at	1083 2 O
the	1086 3 O
end	1090 3 O
of	1094 2 O
the	1097 3 O
60	1101 2 O
-	1103 1 O
min	1104 3 O
recording	1108 9 O
period	1118 6 O
than	1125 4 O
did	1130 3 O
animals	1134 7 O
that	1142 4 O
received	1147 8 O
ketanserin	1156 10 B-Chemical
alone	1167 5 O
.	1172 1 O

These	1174 5 O
results	1180 7 O
,	1187 1 O
in	1189 2 O
combination	1192 11 O
with	1204 4 O
previous	1209 8 O
work	1218 4 O
,	1222 1 O
suggest	1224 7 O
that	1232 4 O
muscle	1237 6 B-Disease
rigidity	1244 8 I-Disease
,	1252 1 O
a	1254 1 O
clinically	1256 10 O
relevant	1267 8 O
side	1276 4 O
-	1280 1 O
effect	1281 6 O
of	1288 2 O
parenteral	1291 10 O
narcotic	1302 8 O
administration	1311 14 O
,	1325 1 O
may	1327 3 O
be	1331 2 O
partly	1334 6 O
mediated	1341 8 O
via	1350 3 O
serotonergic	1354 12 O
pathways	1367 8 O
.	1375 1 O

Pretreatment	1377 12 O
with	1390 4 O
type	1395 4 O
-	1399 1 O
2	1400 1 O
serotonin	1402 9 B-Chemical
antagonists	1412 11 O
may	1424 3 O
be	1428 2 O
clinically	1431 10 O
useful	1442 6 O
in	1449 2 O
attenuating	1452 11 O
opiate	1464 6 O
-	1470 1 O
induced	1471 7 O
rigidity	1479 8 B-Disease
,	1487 1 O
although	1489 8 O
further	1498 7 O
studies	1506 7 O
will	1514 4 O
be	1519 2 O
necessary	1522 9 O
to	1532 2 O
assess	1535 6 O
the	1542 3 O
interaction	1546 11 O
of	1558 2 O
possibly	1561 8 O
enhanced	1570 8 O
CNS	1579 3 O
,	1582 1 O
cardiovascular	1584 14 B-Disease
,	1598 1 I-Disease
and	1600 3 I-Disease
respiratory	1604 11 I-Disease
depression	1616 10 I-Disease
.	1626 1 O

Glycopyrronium	0 14 B-Chemical
requirements	15 12 O
for	28 3 O
antagonism	32 10 O
of	43 2 O
the	46 3 O
muscarinic	50 10 O
side	61 4 O
effects	66 7 O
of	74 2 O
edrophonium	77 11 B-Chemical
.	88 1 O

We	90 2 O
have	93 4 O
compared	98 8 O
,	106 1 O
in	108 2 O
60	111 2 O
adult	114 5 O
patients	120 8 O
,	128 1 O
the	130 3 O
cardiovascular	134 14 O
effects	149 7 O
of	157 2 O
glycopyrronium	160 14 B-Chemical
5	175 1 O
micrograms	177 10 O
kg	188 2 O
-	190 1 O
1	191 1 O
and	193 3 O
10	197 2 O
micrograms	200 10 O
kg	211 2 O
-	213 1 O
1	214 1 O
given	216 5 O
either	222 6 O
simultaneously	229 14 O
or	244 2 O
1	247 1 O
min	249 3 O
before	253 6 O
edrophonium	260 11 B-Chemical
1	272 1 O
mg	274 2 O
kg	277 2 O
-	279 1 O
1	280 1 O
.	281 1 O

Significant	283 11 O
differences	295 11 O
between	307 7 O
the	315 3 O
four	319 4 O
groups	324 6 O
were	331 4 O
detected	336 8 O
(	345 1 O
P	346 1 O
less	348 4 O
than	353 4 O
0	358 1 O
.	359 1 O
001	360 3 O
)	363 1 O
.	364 1 O

Both	366 4 O
groups	371 6 O
receiving	378 9 O
10	388 2 O
micrograms	391 10 O
kg	402 2 O
-	404 1 O
1	405 1 O
showed	407 6 O
increases	414 9 O
in	424 2 O
heart	427 5 O
rate	433 4 O
of	438 2 O
up	441 2 O
to	444 2 O
30	447 2 O
beat	450 4 O
min	455 3 O
-	458 1 O
1	459 1 O
(	461 1 O
95	462 2 O
%	464 1 O
confidence	466 10 O
limits	477 6 O
28	484 2 O
-	486 1 O
32	487 2 O
beat	490 4 O
min	495 3 O
-	498 1 O
1	499 1 O
)	500 1 O
.	501 1 O

Use	503 3 O
of	507 2 O
glycopyrronium	510 14 B-Chemical
5	525 1 O
micrograms	527 10 O
kg	538 2 O
-	540 1 O
1	541 1 O
provided	543 8 O
greater	552 7 O
cardiovascular	560 14 O
stability	575 9 O
and	585 3 O
,	588 1 O
given	590 5 O
1	596 1 O
min	598 3 O
before	602 6 O
the	609 3 O
edrophonium	613 11 B-Chemical
,	624 1 O
was	626 3 O
sufficient	630 10 O
to	641 2 O
minimize	644 8 O
early	653 5 O
,	658 1 O
edrophonium	660 11 B-Chemical
-	671 1 O
induced	672 7 O
bradycardias	680 12 B-Disease
.	692 1 O

This	694 4 O
low	699 3 O
dose	703 4 O
of	708 2 O
glycopyrronium	711 14 B-Chemical
provided	726 8 O
good	735 4 O
control	740 7 O
of	748 2 O
oropharyngeal	751 13 O
secretions	765 10 O
.	775 1 O

Involvement	0 11 O
of	12 2 O
locus	15 5 O
coeruleus	21 9 O
and	31 3 O
noradrenergic	35 13 O
neurotransmission	49 17 O
in	67 2 O
fentanyl	70 8 B-Chemical
-	78 1 O
induced	79 7 O
muscular	87 8 B-Disease
rigidity	96 8 I-Disease
in	105 2 O
the	108 3 O
rat	112 3 O
.	115 1 O

Whereas	117 7 O
muscular	125 8 B-Disease
rigidity	134 8 I-Disease
is	143 2 O
a	146 1 O
well	148 4 O
-	152 1 O
known	153 5 O
side	159 4 O
effect	164 6 O
that	171 4 O
is	176 2 O
associated	179 10 O
with	190 4 O
high	195 4 O
-	199 1 O
dose	200 4 O
fentanyl	205 8 B-Chemical
anesthesia	214 10 O
,	224 1 O
a	226 1 O
paucity	228 7 O
of	236 2 O
information	239 11 O
exists	251 6 O
with	258 4 O
regard	263 6 O
to	270 2 O
its	273 3 O
underlying	277 10 O
mechanism	288 9 O
(	297 1 O
s	298 1 O
)	299 1 O
.	300 1 O

We	302 2 O
investigated	305 12 O
in	318 2 O
this	321 4 O
study	326 5 O
the	332 3 O
possible	336 8 O
engagement	345 10 O
of	356 2 O
locus	359 5 O
coeruleus	365 9 O
of	375 2 O
the	378 3 O
pons	382 4 O
in	387 2 O
this	390 4 O
phenomenon	395 10 O
,	405 1 O
using	407 5 O
male	413 4 O
Sprague	418 7 O
-	425 1 O
Dawley	426 6 O
rats	433 4 O
anesthetized	438 12 O
with	451 4 O
ketamine	456 8 B-Chemical
.	464 1 O

Under	466 5 O
proper	472 6 O
control	479 7 O
of	487 2 O
respiration	490 11 O
,	501 1 O
body	503 4 O
temperature	508 11 O
and	520 3 O
end	524 3 O
-	527 1 O
tidal	528 5 O
CO2	534 3 B-Chemical
,	537 1 O
intravenous	539 11 O
administration	551 14 O
of	566 2 O
fentanyl	569 8 B-Chemical
(	578 1 O
50	579 2 O
or	582 2 O
100	585 3 O
micrograms	589 10 O
/	599 1 O
kg	600 2 O
)	602 1 O
consistently	604 12 O
promoted	617 8 O
an	626 2 O
increase	629 8 O
in	638 2 O
electromyographic	641 17 O
activity	659 8 O
recorded	668 8 O
from	677 4 O
the	682 3 O
gastrocnemius	686 13 O
and	700 3 O
abdominal	704 9 O
rectus	714 6 O
muscles	721 7 O
.	728 1 O

Such	730 4 O
an	735 2 O
induced	738 7 O
muscular	746 8 B-Disease
rigidity	755 8 I-Disease
by	764 2 O
the	767 3 O
narcotic	771 8 O
agent	780 5 O
was	786 3 O
significantly	790 13 O
antagonized	804 11 O
or	816 2 O
even	819 4 O
reduced	824 7 O
by	832 2 O
prior	835 5 O
electrolytic	841 12 O
lesions	854 7 O
of	862 2 O
the	865 3 O
locus	869 5 O
coeruleus	875 9 O
or	885 2 O
pretreatment	888 12 O
with	901 4 O
the	906 3 O
alpha	910 5 O
-	915 1 O
adrenoceptor	916 12 O
blocker	929 7 O
,	936 1 O
prazosin	938 8 B-Chemical
.	946 1 O

Microinjection	948 14 O
of	963 2 O
fentanyl	966 8 B-Chemical
(	975 1 O
2	976 1 O
.	977 1 O
5	978 1 O
micrograms	980 10 O
/	990 1 O
50	991 2 O
nl	994 2 O
)	996 1 O
directly	998 8 O
into	1007 4 O
this	1012 4 O
pontine	1017 7 O
nucleus	1025 7 O
,	1032 1 O
on	1034 2 O
the	1037 3 O
other	1041 5 O
hand	1047 4 O
,	1051 1 O
elicited	1053 8 O
discernible	1062 11 O
electromyographic	1074 17 O
excitation	1092 10 O
.	1102 1 O

It	1104 2 O
is	1107 2 O
speculated	1110 10 O
that	1121 4 O
the	1126 3 O
induction	1130 9 O
of	1140 2 O
muscular	1143 8 B-Disease
rigidity	1152 8 I-Disease
by	1161 2 O
fentanyl	1164 8 B-Chemical
may	1173 3 O
involve	1177 7 O
the	1185 3 O
coerulospinal	1189 13 O
noradrenergic	1203 13 O
fibers	1217 6 O
to	1224 2 O
the	1227 3 O
spinal	1231 6 O
motoneurons	1238 11 O
.	1249 1 O

Cerebral	0 8 B-Disease
sinus	9 5 I-Disease
thrombosis	15 10 I-Disease
as	26 2 O
a	29 1 O
potential	31 9 O
hazard	41 6 O
of	48 2 O
antifibrinolytic	51 16 O
treatment	68 9 O
in	78 2 O
menorrhagia	81 11 B-Disease
.	92 1 O

We	94 2 O
describe	97 8 O
a	106 1 O
42	108 2 O
-	110 1 O
year	111 4 O
-	115 1 O
old	116 3 O
woman	120 5 O
who	126 3 O
developed	130 9 O
superior	140 8 O
sagittal	149 8 B-Disease
and	158 3 I-Disease
left	162 4 I-Disease
transverse	167 10 I-Disease
sinus	178 5 I-Disease
thrombosis	184 10 I-Disease
associated	195 10 O
with	206 4 O
prolonged	211 9 O
epsilon	221 7 B-Chemical
-	228 1 I-Chemical
aminocaproic	229 12 I-Chemical
acid	242 4 I-Chemical
therapy	247 7 O
for	255 3 O
menorrhagia	259 11 B-Disease
.	270 1 O

This	272 4 O
antifibrinolytic	277 16 O
agent	294 5 O
has	300 3 O
been	304 4 O
used	309 4 O
in	314 2 O
women	317 5 O
with	323 4 O
menorrhagia	328 11 B-Disease
to	340 2 O
promote	343 7 O
clotting	351 8 O
and	360 3 O
reduce	364 6 O
blood	371 5 B-Disease
loss	377 4 I-Disease
.	381 1 O

Although	383 8 O
increased	392 9 O
risk	402 4 O
of	407 2 O
thromboembolic	410 14 B-Disease
disease	425 7 I-Disease
has	433 3 O
been	437 4 O
reported	442 8 O
during	451 6 O
treatment	458 9 O
with	468 4 O
epsilon	473 7 B-Chemical
-	480 1 I-Chemical
aminocaproic	481 12 I-Chemical
acid	494 4 I-Chemical
,	498 1 O
cerebral	500 8 B-Disease
sinus	509 5 I-Disease
thrombosis	515 10 I-Disease
has	526 3 O
not	530 3 O
been	534 4 O
previously	539 10 O
described	550 9 O
.	559 1 O

Careful	561 7 O
use	569 3 O
of	573 2 O
epsilon	576 7 B-Chemical
-	583 1 I-Chemical
aminocaproic	584 12 I-Chemical
acid	597 4 I-Chemical
therapy	602 7 O
is	610 2 O
recommended	613 11 O
.	624 1 O

Hemorrhagic	0 11 B-Disease
cystitis	12 8 I-Disease
complicating	21 12 O
bone	34 4 O
marrow	39 6 O
transplantation	46 15 O
.	61 1 O

Hemorrhagic	63 11 B-Disease
cystitis	75 8 I-Disease
is	84 2 O
a	87 1 O
potentially	89 11 O
serious	101 7 O
complication	109 12 O
of	122 2 O
high	125 4 O
-	129 1 O
dose	130 4 O
cyclophosphamide	135 16 B-Chemical
therapy	152 7 O
administered	160 12 O
before	173 6 O
bone	180 4 O
marrow	185 6 O
transplantation	192 15 O
.	207 1 O

As	209 2 O
standard	212 8 O
practice	221 8 O
at	230 2 O
our	233 3 O
institution	237 11 O
,	248 1 O
patients	250 8 O
who	259 3 O
are	263 3 O
scheduled	267 9 O
to	277 2 O
receive	280 7 O
a	288 1 O
bone	290 4 O
marrow	295 6 O
transplant	302 10 O
are	313 3 O
treated	317 7 O
prophylactically	325 16 O
with	342 4 O
forced	347 6 O
hydration	354 9 O
and	364 3 O
bladder	368 7 O
irrigation	376 10 O
.	386 1 O

In	388 2 O
an	391 2 O
attempt	394 7 O
to	402 2 O
obviate	405 7 O
the	413 3 O
inconvenience	417 13 O
of	431 2 O
bladder	434 7 O
irrigation	442 10 O
,	452 1 O
we	454 2 O
conducted	457 9 O
a	467 1 O
feasibility	469 11 O
trial	481 5 O
of	487 2 O
uroprophylaxis	490 14 O
with	505 4 O
mesna	510 5 B-Chemical
,	515 1 O
which	517 5 O
neutralizes	523 11 O
the	535 3 O
hepatic	539 7 O
metabolite	547 10 O
of	558 2 O
cyclophosphamide	561 16 B-Chemical
that	578 4 O
causes	583 6 O
hemorrhagic	590 11 B-Disease
cystitis	602 8 I-Disease
.	610 1 O

Of	612 2 O
97	615 2 O
patients	618 8 O
who	627 3 O
received	631 8 O
standard	640 8 O
prophylaxis	649 11 O
,	660 1 O
4	662 1 O
had	664 3 O
symptomatic	668 11 O
hemorrhagic	680 11 B-Disease
cystitis	692 8 I-Disease
.	700 1 O

In	702 2 O
contrast	705 8 O
,	713 1 O
two	715 3 O
of	719 2 O
four	722 4 O
consecutive	727 11 O
patients	739 8 O
who	748 3 O
received	752 8 O
mesna	761 5 B-Chemical
uroprophylaxis	767 14 O
before	782 6 O
allogeneic	789 10 O
bone	800 4 O
marrow	805 6 O
transplantation	812 15 O
had	828 3 O
severe	832 6 O
hemorrhagic	839 11 B-Disease
cystitis	851 8 I-Disease
for	860 3 O
at	864 2 O
least	867 5 O
2	873 1 O
weeks	875 5 O
.	880 1 O

Because	882 7 O
of	890 2 O
this	893 4 O
suboptimal	898 10 O
result	909 6 O
,	915 1 O
we	917 2 O
resumed	920 7 O
the	928 3 O
use	932 3 O
of	936 2 O
bladder	939 7 O
irrigation	947 10 O
and	958 3 O
forced	962 6 O
hydration	969 9 O
to	979 2 O
minimize	982 8 O
the	991 3 O
risk	995 4 O
of	1000 2 O
hemorrhagic	1003 11 B-Disease
cystitis	1015 8 I-Disease
.	1023 1 O

Reversal	0 8 O
of	9 2 O
central	12 7 O
benzodiazepine	20 14 B-Chemical
effects	35 7 O
by	43 2 O
flumazenil	46 10 B-Chemical
after	57 5 O
intravenous	63 11 O
conscious	75 9 O
sedation	85 8 O
with	94 4 O
diazepam	99 8 B-Chemical
and	108 3 O
opioids	112 7 O
:	119 1 O
report	121 6 O
of	128 2 O
a	131 1 O
double	133 6 O
-	139 1 O
blind	140 5 O
multicenter	146 11 O
study	158 5 O
.	163 1 O

The	165 3 O
Flumazenil	169 10 B-Chemical
in	180 2 O
Intravenous	183 11 O
Conscious	195 9 O
Sedation	205 8 O
with	214 4 O
Diazepam	219 8 B-Chemical
Multicenter	228 11 O
Study	240 5 O
Group	246 5 O
II	252 2 O
.	254 1 O

The	256 3 O
efficacy	260 8 O
and	269 3 O
safety	273 6 O
of	280 2 O
a	283 1 O
new	285 3 O
benzodiazepine	289 14 B-Chemical
antagonist	304 10 O
,	314 1 O
flumazenil	316 10 B-Chemical
,	326 1 O
were	328 4 O
assessed	333 8 O
in	342 2 O
a	345 1 O
double	347 6 O
-	353 1 O
blind	354 5 O
multicenter	360 11 O
study	372 5 O
.	377 1 O

Flumazenil	379 10 B-Chemical
(	390 1 O
mean	391 4 O
dose	396 4 O
,	400 1 O
0	402 1 O
.	403 1 O
76	404 2 O
mg	407 2 O
)	409 1 O
or	411 2 O
placebo	414 7 O
(	422 1 O
mean	423 4 O
dose	428 4 O
,	432 1 O
8	434 1 O
.	435 1 O
9	436 1 O
ml	438 2 O
)	440 1 O
was	442 3 O
administered	446 12 O
intravenously	459 13 O
to	473 2 O
130	476 3 O
and	480 3 O
67	484 2 O
patients	487 8 O
,	495 1 O
respectively	497 12 O
,	509 1 O
who	511 3 O
had	515 3 O
been	519 4 O
given	524 5 O
diazepam	530 8 B-Chemical
in	539 2 O
conjunction	542 11 O
with	554 4 O
an	559 2 O
opioid	562 6 O
(	569 1 O
fentanyl	570 8 B-Chemical
,	578 1 O
meperidine	580 10 B-Chemical
,	590 1 O
or	592 2 O
morphine	595 8 B-Chemical
)	603 1 O
for	605 3 O
the	609 3 O
induction	613 9 O
and	623 3 O
maintenance	627 11 O
of	639 2 O
intravenous	642 11 O
conscious	654 9 O
sedation	664 8 O
for	673 3 O
diagnostic	677 10 O
or	688 2 O
therapeutic	691 11 O
surgical	703 8 O
procedures	712 10 O
.	722 1 O

The	724 3 O
group	728 5 O
assessable	734 10 O
for	745 3 O
efficacy	749 8 O
comprised	758 9 O
122	768 3 O
patients	772 8 O
treated	781 7 O
with	789 4 O
flumazenil	794 10 B-Chemical
and	805 3 O
64	809 2 O
patients	812 8 O
given	821 5 O
placebo	827 7 O
.	834 1 O

After	836 5 O
5	842 1 O
minutes	844 7 O
,	851 1 O
80	853 2 O
/	855 1 O
115	856 3 O
(	860 1 O
70	861 2 O
%	863 1 O
)	864 1 O
flumazenil	866 10 B-Chemical
-	876 1 O
treated	877 7 O
patients	885 8 O
,	893 1 O
compared	895 8 O
with	904 4 O
21	909 2 O
/	911 1 O
63	912 2 O
(	915 1 O
33	916 2 O
%	918 1 O
)	919 1 O
placebo	921 7 O
-	928 1 O
treated	929 7 O
patients	937 8 O
,	945 1 O
were	947 4 O
completely	952 10 O
awake	963 5 O
and	969 3 O
alert	973 5 O
,	978 1 O
as	980 2 O
indicated	983 9 O
by	993 2 O
a	996 1 O
score	998 5 O
of	1004 2 O
5	1007 1 O
on	1009 2 O
the	1012 3 O
Observer	1016 8 O
'	1024 1 O
s	1025 1 O
Assessment	1027 10 O
of	1038 2 O
Alertness	1041 9 O
/	1050 1 O
Sedation	1051 8 O
Scale	1060 5 O
.	1065 1 O

Ninety	1067 6 O
-	1073 1 O
five	1074 4 O
percent	1079 7 O
of	1087 2 O
patients	1090 8 O
in	1099 2 O
each	1102 4 O
group	1107 5 O
who	1113 3 O
attained	1117 8 O
a	1126 1 O
score	1128 5 O
of	1134 2 O
5	1137 1 O
at	1139 2 O
the	1142 3 O
5	1146 1 O
-	1147 1 O
minute	1148 6 O
assessment	1155 10 O
showed	1166 6 O
no	1173 2 O
loss	1176 4 O
of	1181 2 O
alertness	1184 9 O
throughout	1194 10 O
the	1205 3 O
180	1209 3 O
-	1212 1 O
minute	1213 6 O
assessment	1220 10 O
period	1231 6 O
.	1237 1 O

Flumazenil	1239 10 B-Chemical
-	1249 1 O
treated	1250 7 O
patients	1258 8 O
also	1267 4 O
performed	1272 9 O
significantly	1282 13 O
better	1296 6 O
on	1303 2 O
the	1306 3 O
Finger	1310 6 O
-	1316 1 O
to	1317 2 O
-	1319 1 O
Nose	1320 4 O
Test	1325 4 O
and	1330 3 O
the	1334 3 O
recall	1338 6 O
of	1345 2 O
pictures	1348 8 O
shown	1357 5 O
at	1363 2 O
the	1366 3 O
5	1370 1 O
-	1371 1 O
minute	1372 6 O
assessment	1379 10 O
.	1389 1 O

Flumazenil	1391 10 B-Chemical
was	1402 3 O
well	1406 4 O
tolerated	1411 9 O
,	1420 1 O
with	1422 4 O
no	1427 2 O
serious	1430 7 O
adverse	1438 7 O
effects	1446 7 O
reported	1454 8 O
.	1462 1 O

Thirty	1464 6 O
-	1470 1 O
nine	1471 4 O
(	1476 1 O
30	1477 2 O
%	1479 1 O
)	1480 1 O
of	1482 2 O
flumazenil	1485 10 B-Chemical
-	1495 1 O
treated	1496 7 O
patients	1504 8 O
,	1512 1 O
compared	1514 8 O
with	1523 4 O
17	1528 2 O
(	1531 1 O
25	1532 2 O
%	1534 1 O
)	1535 1 O
of	1537 2 O
placebo	1540 7 O
-	1547 1 O
treated	1548 7 O
patients	1556 8 O
had	1565 3 O
one	1569 3 O
or	1573 2 O
more	1576 4 O
drug	1581 4 O
-	1585 1 O
related	1586 7 O
adverse	1594 7 O
experiences	1602 11 O
.	1613 1 O

The	1615 3 O
most	1619 4 O
common	1624 6 O
adverse	1631 7 O
effects	1639 7 O
were	1647 4 O
nausea	1652 6 B-Disease
and	1659 3 O
vomiting	1663 8 B-Disease
in	1672 2 O
the	1675 3 O
flumazenil	1679 10 B-Chemical
group	1690 5 O
and	1696 3 O
nausea	1700 6 B-Disease
and	1707 3 O
injection	1711 9 O
-	1720 1 O
site	1721 4 O
pain	1726 4 B-Disease
in	1731 2 O
the	1734 3 O
placebo	1738 7 O
group	1746 5 O
.	1751 1 O

Flumazenil	1753 10 B-Chemical
was	1764 3 O
found	1768 5 O
to	1774 2 O
promptly	1777 8 O
reverse	1786 7 O
sedation	1794 8 O
induced	1803 7 O
by	1811 2 O
diazepam	1814 8 B-Chemical
in	1823 2 O
the	1826 3 O
presence	1830 8 O
of	1839 2 O
opioids	1842 7 O
.	1849 1 O

Hepatic	0 7 O
adenomas	8 8 B-Disease
and	17 3 O
focal	21 5 B-Disease
nodular	27 7 I-Disease
hyperplasia	35 11 I-Disease
of	47 2 O
the	50 3 O
liver	54 5 O
in	60 2 O
young	63 5 O
women	69 5 O
on	75 2 O
oral	78 4 B-Chemical
contraceptives	83 14 I-Chemical
:	97 1 O
case	99 4 O
reports	104 7 O
.	111 1 O

Two	113 3 O
cases	117 5 O
of	123 2 O
hepatic	126 7 O
adenoma	134 7 B-Disease
and	142 3 O
one	146 3 O
of	150 2 O
focal	153 5 B-Disease
nodular	159 7 I-Disease
hyperplasia	167 11 I-Disease
presumably	179 10 O
associated	190 10 O
with	201 4 O
the	206 3 O
use	210 3 O
of	214 2 O
oral	217 4 B-Chemical
contraceptives	222 14 I-Chemical
,	236 1 O
are	238 3 O
reported	242 8 O
.	250 1 O

Special	252 7 O
reference	260 9 O
is	270 2 O
made	273 4 O
to	278 2 O
their	281 5 O
clinical	287 8 O
presentation	296 12 O
,	308 1 O
which	310 5 O
may	316 3 O
be	320 2 O
totally	323 7 O
asymptomatic	331 12 O
.	343 1 O

Liver	345 5 O
-	350 1 O
function	351 8 O
tests	360 5 O
are	366 3 O
of	370 2 O
little	373 6 O
diagnostic	380 10 O
value	391 5 O
,	396 1 O
but	398 3 O
valuable	402 8 O
information	411 11 O
may	423 3 O
be	427 2 O
obtained	430 8 O
from	439 4 O
both	444 4 O
liver	449 5 O
scanning	455 8 O
and	464 3 O
hepatic	468 7 O
angiography	476 11 O
.	487 1 O

Histologic	489 10 O
differences	500 11 O
and	512 3 O
clinical	516 8 O
similarities	525 12 O
between	538 7 O
hepatic	546 7 O
adenoma	554 7 B-Disease
and	562 3 O
focal	566 5 B-Disease
nodular	572 7 I-Disease
hyperplasia	580 11 I-Disease
of	592 2 O
the	595 3 O
liver	599 5 O
are	605 3 O
discussed	609 9 O
.	618 1 O

Arterial	0 8 O
thromboembolism	9 15 B-Disease
in	25 2 O
patients	28 8 O
receiving	37 9 O
systemic	47 8 O
heparin	56 7 B-Chemical
therapy	64 7 O
:	71 1 O
a	73 1 O
complication	75 12 O
associated	88 10 O
with	99 4 O
heparin	104 7 B-Chemical
-	111 1 O
induced	112 7 O
thrombocytopenia	120 16 B-Disease
.	136 1 O

Arterial	138 8 O
thromboembolism	147 15 B-Disease
is	163 2 O
a	166 1 O
recognized	168 10 O
complication	179 12 O
of	192 2 O
systemic	195 8 O
heparin	204 7 B-Chemical
therapy	212 7 O
.	219 1 O

Characteristic	221 14 O
of	236 2 O
the	239 3 O
entity	243 6 O
is	250 2 O
arterial	253 8 B-Disease
occlusion	262 9 I-Disease
by	272 2 O
platelet	275 8 O
-	283 1 O
fibrin	284 6 O
thrombi	291 7 B-Disease
with	299 4 O
distal	304 6 O
ischemia	311 8 B-Disease
occurring	320 9 O
four	330 4 O
to	335 2 O
twenty	338 6 O
days	345 4 O
after	350 5 O
the	356 3 O
initiation	360 10 O
of	371 2 O
heparin	374 7 B-Chemical
therapy	382 7 O
,	389 1 O
preceded	391 8 O
by	400 2 O
profound	403 8 O
thrombocytopenia	412 16 B-Disease
with	429 4 O
platelet	434 8 O
counts	443 6 O
in	450 2 O
the	453 3 O
range	457 5 O
of	463 2 O
30	466 2 O
,	468 1 O
000	469 3 O
to	473 2 O
40	476 2 O
,	478 1 O
000	479 3 O
per	483 3 O
cubic	487 5 O
millimeter	493 10 O
.	503 1 O

The	505 3 O
clinically	509 10 O
apparent	520 8 O
occlusion	529 9 O
may	539 3 O
be	543 2 O
preceded	546 8 O
by	555 2 O
gastrointestinal	558 16 B-Disease
and	575 3 I-Disease
musculoskeletal	579 15 I-Disease
symptoms	595 8 I-Disease
that	604 4 O
appear	609 6 O
to	616 2 O
be	619 2 O
ischemic	622 8 B-Disease
in	631 2 O
origin	634 6 O
,	640 1 O
and	642 3 O
might	646 5 O
serve	652 5 O
to	658 2 O
warn	661 4 O
the	666 3 O
clinician	670 9 O
of	680 2 O
these	683 5 O
complications	689 13 O
.	702 1 O

Previous	704 8 O
reports	713 7 O
of	721 2 O
these	724 5 O
phenomena	730 9 O
as	740 2 O
well	743 4 O
as	748 2 O
recent	751 6 O
studies	758 7 O
of	766 2 O
the	769 3 O
effect	773 6 O
of	780 2 O
heparin	783 7 B-Chemical
are	791 3 O
reviewed	795 8 O
.	803 1 O

The	805 3 O
common	809 6 O
factor	816 6 O
relating	823 8 O
thromboembolism	832 15 B-Disease
and	848 3 O
thrombocytopenia	852 16 B-Disease
is	869 2 O
heparin	872 7 B-Chemical
-	879 1 O
induced	880 7 O
platelet	888 8 B-Disease
aggregation	897 11 I-Disease
.	908 1 O

Appropriate	910 11 O
treatment	922 9 O
consists	932 8 O
of	941 2 O
discontinuation	944 15 O
of	960 2 O
heparin	963 7 B-Chemical
,	970 1 O
and	972 3 O
anticoagulation	976 15 O
with	992 4 O
sodium	997 6 B-Chemical
warfarin	1004 8 I-Chemical
if	1013 2 O
necessary	1016 9 O
.	1025 1 O

Vascular	1027 8 O
procedures	1036 10 O
are	1047 3 O
performed	1051 9 O
as	1061 2 O
indicated	1064 9 O
.	1073 1 O

Long	0 4 O
-	4 1 O
term	5 4 O
prognosis	10 9 O
for	20 3 O
transplant	24 10 O
-	34 1 O
free	35 4 O
survivors	40 9 O
of	50 2 O
paracetamol	53 11 B-Chemical
-	64 1 O
induced	65 7 O
acute	73 5 B-Disease
liver	79 5 I-Disease
failure	85 7 I-Disease
.	92 1 O

BACKGROUND	94 10 O
:	104 1 O
The	106 3 O
prognosis	110 9 O
for	120 3 O
transplant	124 10 O
-	134 1 O
free	135 4 O
survivors	140 9 O
of	150 2 O
paracetamol	153 11 B-Chemical
-	164 1 O
induced	165 7 O
acute	173 5 B-Disease
liver	179 5 I-Disease
failure	185 7 I-Disease
remains	193 7 O
unknown	201 7 O
.	208 1 O

AIM	210 3 O
:	213 1 O
To	215 2 O
examine	218 7 O
whether	226 7 O
paracetamol	234 11 B-Chemical
-	245 1 O
induced	246 7 O
acute	254 5 B-Disease
liver	260 5 I-Disease
failure	266 7 I-Disease
increases	274 9 O
long	284 4 O
-	288 1 O
term	289 4 O
mortality	294 9 O
.	303 1 O

METHODS	305 7 O
:	312 1 O
We	314 2 O
followed	317 8 O
up	326 2 O
all	329 3 O
transplant	333 10 O
-	343 1 O
free	344 4 O
survivors	349 9 O
of	359 2 O
paracetamol	362 11 B-Chemical
-	373 1 O
induced	374 7 O
acute	382 5 B-Disease
liver	388 5 I-Disease
injury	394 6 I-Disease
,	400 1 O
hospitalized	402 12 O
in	415 2 O
a	418 1 O
Danish	420 6 O
national	427 8 O
referral	436 8 O
centre	445 6 O
during	452 6 O
1984	459 4 O
-	463 1 O
2004	464 4 O
.	468 1 O

We	470 2 O
compared	473 8 O
age	482 3 O
-	485 1 O
specific	486 8 O
mortality	495 9 O
rates	505 5 O
from	511 4 O
1	516 1 O
year	518 4 O
post	523 4 O
-	527 1 O
discharge	528 9 O
through	538 7 O
2008	546 4 O
between	551 7 O
those	559 5 O
in	565 2 O
whom	568 4 O
the	573 3 O
liver	577 5 B-Disease
injury	583 6 I-Disease
led	590 3 O
to	594 2 O
an	597 2 O
acute	600 5 B-Disease
liver	606 5 I-Disease
failure	612 7 I-Disease
and	620 3 O
those	624 5 O
in	630 2 O
whom	633 4 O
it	638 2 O
did	641 3 O
not	645 3 O
.	648 1 O

RESULTS	650 7 O
:	657 1 O
We	659 2 O
included	662 8 O
641	671 3 O
patients	675 8 O
.	683 1 O

On	685 2 O
average	688 7 O
,	695 1 O
age	697 3 O
-	700 1 O
specific	701 8 O
mortality	710 9 O
rates	720 5 O
were	726 4 O
slightly	731 8 O
higher	740 6 O
for	747 3 O
the	751 3 O
101	755 3 O
patients	759 8 O
whose	768 5 O
paracetamol	774 11 B-Chemical
-	785 1 O
induced	786 7 O
liver	794 5 B-Disease
injury	800 6 I-Disease
had	807 3 O
caused	811 6 O
an	818 2 O
acute	821 5 B-Disease
liver	827 5 I-Disease
failure	833 7 I-Disease
(	841 1 O
adjusted	842 8 O
mortality	851 9 O
rate	861 4 O
ratio	866 5 O
=	872 1 O
1	874 1 O
.	875 1 O
70	876 2 O
,	878 1 O
95	880 2 O
%	882 1 O
CI	884 2 O
1	887 1 O
.	888 1 O
02	889 2 O
-	891 1 O
2	892 1 O
.	893 1 O
85	894 2 O
)	896 1 O
,	897 1 O
but	899 3 O
the	903 3 O
association	907 11 O
was	919 3 O
age	923 3 O
-	926 1 O
dependent	927 9 O
,	936 1 O
and	938 3 O
no	942 2 O
survivors	945 9 O
of	955 2 O
acute	958 5 B-Disease
liver	964 5 I-Disease
failure	970 7 I-Disease
died	978 4 O
of	983 2 O
liver	986 5 B-Disease
disease	992 7 I-Disease
,	999 1 O
whereas	1001 7 O
suicides	1009 8 O
were	1018 4 O
frequent	1023 8 O
in	1032 2 O
both	1035 4 O
groups	1040 6 O
.	1046 1 O

These	1048 5 O
observations	1054 12 O
speak	1067 5 O
against	1073 7 O
long	1081 4 O
-	1085 1 O
term	1086 4 O
effects	1091 7 O
of	1099 2 O
acute	1102 5 B-Disease
liver	1108 5 I-Disease
failure	1114 7 I-Disease
.	1121 1 O

More	1123 4 O
likely	1128 6 O
,	1134 1 O
the	1136 3 O
elevated	1140 8 O
mortality	1149 9 O
rate	1159 4 O
ratio	1164 5 O
resulted	1170 8 O
from	1179 4 O
incomplete	1184 10 O
adjustment	1195 10 O
for	1206 3 O
the	1210 3 O
greater	1214 7 O
prevalence	1222 10 O
of	1233 2 O
substance	1236 9 B-Disease
abuse	1246 5 I-Disease
among	1252 5 O
survivors	1258 9 O
of	1268 2 O
acute	1271 5 B-Disease
liver	1277 5 I-Disease
failure	1283 7 I-Disease
.	1290 1 O

CONCLUSIONS	1292 11 O
:	1303 1 O
Paracetamol	1305 11 B-Chemical
-	1316 1 O
induced	1317 7 O
acute	1325 5 B-Disease
liver	1331 5 I-Disease
failure	1337 7 I-Disease
did	1345 3 O
not	1349 3 O
affect	1353 6 O
long	1360 4 O
-	1364 1 O
term	1365 4 O
mortality	1370 9 O
.	1379 1 O

Clinical	1381 8 O
follow	1390 6 O
-	1396 1 O
up	1397 2 O
may	1400 3 O
be	1404 2 O
justified	1407 9 O
by	1417 2 O
the	1420 3 O
cause	1424 5 O
of	1430 2 O
the	1433 3 O
liver	1437 5 B-Disease
failure	1443 7 I-Disease
,	1450 1 O
but	1452 3 O
not	1456 3 O
by	1460 2 O
the	1463 3 O
liver	1467 5 B-Disease
failure	1473 7 I-Disease
itself	1481 6 O
.	1487 1 O

Serotonin	0 9 B-Chemical
6	10 1 O
receptor	12 8 O
gene	21 4 O
is	26 2 O
associated	29 10 O
with	40 4 O
methamphetamine	45 15 B-Chemical
-	60 1 O
induced	61 7 O
psychosis	69 9 B-Disease
in	79 2 O
a	82 1 O
Japanese	84 8 O
population	93 10 O
.	103 1 O

BACKGROUND	105 10 O
:	115 1 O
Altered	117 7 O
serotonergic	125 12 O
neural	138 6 O
transmission	145 12 O
is	158 2 O
hypothesized	161 12 O
to	174 2 O
be	177 2 O
a	180 1 O
susceptibility	182 14 O
factor	197 6 O
for	204 3 O
psychotic	208 9 B-Disease
disorders	218 9 I-Disease
such	228 4 O
as	233 2 O
schizophrenia	236 13 B-Disease
.	249 1 O

The	251 3 O
serotonin	255 9 B-Chemical
6	265 1 O
(	267 1 O
5	268 1 B-Chemical
-	269 1 I-Chemical
HT6	270 3 O
)	273 1 O
receptor	275 8 O
is	284 2 O
therapeutically	287 15 O
targeted	303 8 O
by	312 2 O
several	315 7 O
second	323 6 O
generation	330 10 O
antipsychotics	341 14 O
,	355 1 O
such	357 4 O
as	362 2 O
clozapine	365 9 B-Chemical
and	375 3 O
olanzapine	379 10 B-Chemical
,	389 1 O
and	391 3 O
d	395 1 B-Chemical
-	396 1 I-Chemical
amphetamine	397 11 I-Chemical
-	408 1 O
induced	409 7 O
hyperactivity	417 13 B-Disease
in	431 2 O
rats	434 4 O
is	439 2 O
corrected	442 9 O
with	452 4 O
the	457 3 O
use	461 3 O
of	465 2 O
a	468 1 O
selective	470 9 O
5	480 1 B-Chemical
-	481 1 I-Chemical
HT6	482 3 O
receptor	486 8 O
antagonist	495 10 O
.	505 1 O

In	507 2 O
addition	510 8 O
,	518 1 O
the	520 3 O
disrupted	524 9 O
prepulse	534 8 O
inhibition	543 10 O
induced	554 7 O
by	562 2 O
d	565 1 B-Chemical
-	566 1 I-Chemical
amphetamine	567 11 I-Chemical
or	579 2 O
phencyclidine	582 13 B-Chemical
was	596 3 O
restored	600 8 O
by	609 2 O
5	612 1 B-Chemical
-	613 1 I-Chemical
HT6	614 3 O
receptor	618 8 O
antagonist	627 10 O
in	638 2 O
an	641 2 O
animal	644 6 O
study	651 5 O
using	657 5 O
rats	663 4 O
.	667 1 O

These	669 5 O
animal	675 6 O
models	682 6 O
were	689 4 O
considered	694 10 O
to	705 2 O
reflect	708 7 O
the	716 3 O
positive	720 8 O
symptoms	729 8 O
of	738 2 O
schizophrenia	741 13 B-Disease
,	754 1 O
and	756 3 O
the	760 3 O
above	764 5 O
evidence	770 8 O
suggests	779 8 O
that	788 4 O
altered	793 7 O
5	801 1 B-Chemical
-	802 1 I-Chemical
HT6	803 3 O
receptors	807 9 O
are	817 3 O
involved	821 8 O
in	830 2 O
the	833 3 O
pathophysiology	837 15 O
of	853 2 O
psychotic	856 9 B-Disease
disorders	866 9 I-Disease
.	875 1 O

The	877 3 O
symptoms	881 8 O
of	890 2 O
methamphetamine	893 15 B-Chemical
(	909 1 O
METH	910 4 B-Chemical
)	914 1 O
-	915 1 O
induced	916 7 O
psychosis	924 9 B-Disease
are	934 3 O
similar	938 7 O
to	946 2 O
those	949 5 O
of	955 2 O
paranoid	958 8 B-Disease
type	967 4 I-Disease
schizophrenia	972 13 I-Disease
.	985 1 O

Therefore	987 9 O
,	996 1 O
we	998 2 O
conducted	1001 9 O
an	1011 2 O
analysis	1014 8 O
of	1023 2 O
the	1026 3 O
association	1030 11 O
of	1042 2 O
the	1045 3 O
5	1049 1 B-Chemical
-	1050 1 I-Chemical
HT6	1051 3 O
gene	1055 4 O
(	1060 1 O
HTR6	1061 4 O
)	1065 1 O
with	1067 4 O
METH	1072 4 B-Chemical
-	1076 1 O
induced	1077 7 O
psychosis	1085 9 B-Disease
.	1094 1 O

METHOD	1096 6 O
:	1102 1 O
Using	1104 5 O
five	1110 4 O
tagging	1115 7 O
SNPs	1123 4 O
(	1128 1 O
rs6693503	1129 9 O
,	1138 1 O
rs1805054	1140 9 O
,	1149 1 O
rs4912138	1151 9 O
,	1160 1 O
rs3790757	1162 9 O
and	1172 3 O
rs9659997	1176 9 O
)	1185 1 O
,	1186 1 O
we	1188 2 O
conducted	1191 9 O
a	1201 1 O
genetic	1203 7 O
association	1211 11 O
analysis	1223 8 O
of	1232 2 O
case	1235 4 O
-	1239 1 O
control	1240 7 O
samples	1248 7 O
(	1256 1 O
197	1257 3 O
METH	1261 4 B-Chemical
-	1265 1 O
induced	1266 7 O
psychosis	1274 9 B-Disease
patients	1284 8 O
and	1293 3 O
337	1297 3 O
controls	1301 8 O
)	1309 1 O
in	1311 2 O
the	1314 3 O
Japanese	1318 8 O
population	1327 10 O
.	1337 1 O

The	1339 3 O
age	1343 3 O
and	1347 3 O
sex	1351 3 O
of	1355 2 O
the	1358 3 O
control	1362 7 O
subjects	1370 8 O
did	1379 3 O
not	1383 3 O
differ	1387 6 O
from	1394 4 O
those	1399 5 O
of	1405 2 O
the	1408 3 O
methamphetamine	1412 15 B-Chemical
dependence	1428 10 O
patients	1439 8 O
.	1447 1 O

RESULTS	1449 7 O
:	1456 1 O
rs6693503	1458 9 O
was	1468 3 O
associated	1472 10 O
with	1483 4 O
METH	1488 4 B-Chemical
-	1492 1 O
induced	1493 7 O
psychosis	1501 9 B-Disease
patients	1511 8 O
in	1520 2 O
the	1523 3 O
allele	1527 6 O
/	1533 1 O
genotype	1534 8 O
-	1542 1 O
wise	1543 4 O
analysis	1548 8 O
.	1556 1 O

Moreover	1558 8 O
,	1566 1 O
this	1568 4 O
association	1573 11 O
remained	1585 8 O
significant	1594 11 O
after	1606 5 O
Bonferroni	1612 10 O
correction	1623 10 O
.	1633 1 O

In	1635 2 O
the	1638 3 O
haplotype	1642 9 O
-	1651 1 O
wise	1652 4 O
analysis	1657 8 O
,	1665 1 O
we	1667 2 O
detected	1670 8 O
an	1679 2 O
association	1682 11 O
between	1694 7 O
two	1702 3 O
markers	1706 7 O
(	1714 1 O
rs6693503	1715 9 O
and	1725 3 O
rs1805054	1729 9 O
)	1738 1 O
and	1740 3 O
three	1744 5 O
markers	1750 7 O
(	1758 1 O
rs6693503	1759 9 O
,	1768 1 O
rs1805054	1770 9 O
and	1780 3 O
rs4912138	1784 9 O
)	1793 1 O
in	1795 2 O
HTR6	1798 4 O
and	1803 3 O
METH	1807 4 B-Chemical
-	1811 1 O
induced	1812 7 O
psychosis	1820 9 B-Disease
patients	1830 8 O
,	1838 1 O
respectively	1840 12 O
.	1852 1 O

CONCLUSION	1854 10 O
:	1864 1 O
HTR6	1866 4 O
may	1871 3 O
play	1875 4 O
an	1880 2 O
important	1883 9 O
role	1893 4 O
in	1898 2 O
the	1901 3 O
pathophysiology	1905 15 O
of	1921 2 O
METH	1924 4 B-Chemical
-	1928 1 O
induced	1929 7 O
psychosis	1937 9 B-Disease
in	1947 2 O
the	1950 3 O
Japanese	1954 8 O
population	1963 10 O
.	1973 1 O

Effect	0 6 O
of	7 2 O
increasing	10 10 O
intraperitoneal	21 15 O
infusion	37 8 O
rates	46 5 O
on	52 2 O
bupropion	55 9 B-Chemical
hydrochloride	65 13 I-Chemical
-	78 1 O
induced	79 7 O
seizures	87 8 B-Disease
in	96 2 O
mice	99 4 O
.	103 1 O

BACKGROUND	105 10 O
:	115 1 O
It	117 2 O
is	120 2 O
not	123 3 O
known	127 5 O
if	133 2 O
there	136 5 O
is	142 2 O
a	145 1 O
relationship	147 12 O
between	160 7 O
input	168 5 O
rate	174 4 O
and	179 3 O
incidence	183 9 O
of	193 2 O
bupropion	196 9 B-Chemical
-	205 1 O
induced	206 7 O
seizures	214 8 B-Disease
.	222 1 O

This	224 4 O
is	229 2 O
important	232 9 O
,	241 1 O
since	243 5 O
different	249 9 O
controlled	259 10 O
release	270 7 O
formulations	278 12 O
of	291 2 O
bupropion	294 9 B-Chemical
release	304 7 O
the	312 3 O
active	316 6 O
drug	323 4 O
at	328 2 O
different	331 9 O
rates	341 5 O
.	346 1 O

METHODS	348 7 O
:	355 1 O
We	357 2 O
investigated	360 12 O
the	373 3 O
effect	377 6 O
of	384 2 O
varying	387 7 O
the	395 3 O
intraperitoneal	399 15 O
infusion	415 8 O
rates	424 5 O
of	430 2 O
bupropion	433 9 B-Chemical
HCl	443 3 I-Chemical
120	447 3 O
mg	451 2 O
/	453 1 O
kg	454 2 O
,	456 1 O
a	458 1 O
known	460 5 O
convulsive	466 10 B-Disease
dose	477 4 O
50	482 2 O
(	485 1 O
CD50	486 4 O
)	490 1 O
,	491 1 O
on	493 2 O
the	496 3 O
incidence	500 9 O
and	510 3 O
severity	514 8 O
of	523 2 O
bupropion	526 9 B-Chemical
-	535 1 O
induced	536 7 O
convulsions	544 11 B-Disease
in	556 2 O
the	559 3 O
Swiss	563 5 O
albino	569 6 O
mice	576 4 O
.	580 1 O

A	582 1 O
total	584 5 O
of	590 2 O
69	593 2 O
mice	596 4 O
,	600 1 O
approximately	602 13 O
7	616 1 O
weeks	618 5 O
of	624 2 O
age	627 3 O
,	630 1 O
and	632 3 O
weighing	636 8 O
21	645 2 O
.	647 1 O
0	648 1 O
to	650 2 O
29	653 2 O
.	655 1 O
1	656 1 O
g	658 1 O
were	660 4 O
randomly	665 8 O
assigned	674 8 O
to	683 2 O
bupropion	686 9 B-Chemical
HCl	696 3 I-Chemical
120	700 3 O
mg	704 2 O
/	706 1 O
kg	707 2 O
treatment	710 9 O
by	720 2 O
intraperitoneal	723 15 O
(	739 1 O
IP	740 2 O
)	742 1 O
administration	744 14 O
in	759 2 O
7	762 1 O
groups	764 6 O
(	771 1 O
9	772 1 O
to	774 2 O
10	777 2 O
animals	780 7 O
per	788 3 O
group	792 5 O
)	797 1 O
.	798 1 O

Bupropion	800 9 B-Chemical
HCl	810 3 I-Chemical
was	814 3 O
infused	818 7 O
through	826 7 O
a	834 1 O
surgically	836 10 O
implanted	847 9 O
IP	857 2 O
dosing	860 6 O
catheter	867 8 O
with	876 4 O
infusions	881 9 O
in	891 2 O
each	894 4 O
group	899 5 O
of	905 2 O
0	908 1 O
min	910 3 O
,	913 1 O
15	915 2 O
min	918 3 O
,	921 1 O
30	923 2 O
min	926 3 O
,	929 1 O
60	931 2 O
min	934 3 O
,	937 1 O
90	939 2 O
min	942 3 O
,	945 1 O
120	947 3 O
min	951 3 O
,	954 1 O
and	956 3 O
240	960 3 O
min	964 3 O
.	967 1 O

The	969 3 O
number	973 6 O
,	979 1 O
time	981 4 O
of	986 2 O
onset	989 5 O
,	994 1 O
duration	996 8 O
and	1005 3 O
the	1009 3 O
intensity	1013 9 O
of	1023 2 O
the	1026 3 O
convulsions	1030 11 B-Disease
or	1042 2 O
absence	1045 7 O
of	1053 2 O
convulsions	1056 11 B-Disease
were	1068 4 O
recorded	1073 8 O
.	1081 1 O

RESULTS	1083 7 O
:	1090 1 O
The	1092 3 O
results	1096 7 O
showed	1104 6 O
that	1111 4 O
IP	1116 2 O
administration	1119 14 O
of	1134 2 O
bupropion	1137 9 B-Chemical
HCl	1147 3 I-Chemical
120	1151 3 O
mg	1155 2 O
/	1157 1 O
kg	1158 2 O
by	1161 2 O
bolus	1164 5 O
injection	1170 9 O
induced	1180 7 O
convulsions	1188 11 B-Disease
in	1200 2 O
6	1203 1 O
out	1205 3 O
of	1209 2 O
10	1212 2 O
mice	1215 4 O
(	1220 1 O
60	1221 2 O
%	1223 1 O
of	1225 2 O
convulsing	1228 10 O
mice	1239 4 O
)	1243 1 O
in	1245 2 O
group	1248 5 O
1	1254 1 O
.	1255 1 O

Logistic	1257 8 O
regression	1266 10 O
analysis	1277 8 O
revealed	1286 8 O
that	1295 4 O
infusion	1300 8 O
time	1309 4 O
was	1314 3 O
significant	1318 11 O
(	1330 1 O
p	1331 1 O
=	1333 1 O
0	1335 1 O
.	1336 1 O
0004	1337 4 O
;	1341 1 O
odds	1343 4 O
ratio	1348 5 O
=	1354 1 O
0	1356 1 O
.	1357 1 O
974	1358 3 O
)	1361 1 O
and	1363 3 O
increasing	1367 10 O
the	1378 3 O
IP	1382 2 O
infusion	1385 8 O
time	1394 4 O
of	1399 2 O
bupropion	1402 9 B-Chemical
HCl	1412 3 I-Chemical
120	1416 3 O
mg	1420 2 O
/	1422 1 O
kg	1423 2 O
was	1426 3 O
associated	1430 10 O
with	1441 4 O
a	1446 1 O
91	1448 2 O
%	1450 1 O
reduced	1452 7 O
odds	1460 4 O
of	1465 2 O
convulsions	1468 11 B-Disease
at	1480 2 O
infusion	1483 8 O
times	1492 5 O
of	1498 2 O
15	1501 2 O
to	1504 2 O
90	1507 2 O
min	1510 3 O
compared	1514 8 O
to	1523 2 O
bolus	1526 5 O
injection	1532 9 O
.	1541 1 O

Further	1543 7 O
increase	1551 8 O
in	1560 2 O
infusion	1563 8 O
time	1572 4 O
resulted	1577 8 O
in	1586 2 O
further	1589 7 O
reduction	1597 9 O
in	1607 2 O
the	1610 3 O
odds	1614 4 O
of	1619 2 O
convulsions	1622 11 B-Disease
to	1634 2 O
99	1637 2 O
.	1639 1 O
8	1640 1 O
%	1641 1 O
reduction	1643 9 O
at	1653 2 O
240	1656 3 O
min	1660 3 O
.	1663 1 O

CONCLUSION	1665 10 O
:	1675 1 O
In	1677 2 O
conclusion	1680 10 O
,	1690 1 O
the	1692 3 O
demonstration	1696 13 O
of	1710 2 O
an	1713 2 O
inverse	1716 7 O
relationship	1724 12 O
between	1737 7 O
infusion	1745 8 O
time	1754 4 O
of	1759 2 O
a	1762 1 O
fixed	1764 5 O
and	1770 3 O
convulsive	1774 10 B-Disease
dose	1785 4 O
of	1790 2 O
bupropion	1793 9 B-Chemical
and	1803 3 O
the	1807 3 O
risk	1811 4 O
of	1816 2 O
convulsions	1819 11 B-Disease
in	1831 2 O
a	1834 1 O
prospective	1836 11 O
study	1848 5 O
is	1854 2 O
novel	1857 5 O
.	1862 1 O

Detailed	0 8 O
spectral	9 8 O
profile	18 7 O
analysis	26 8 O
of	35 2 O
penicillin	38 10 B-Chemical
-	48 1 O
induced	49 7 O
epileptiform	57 12 B-Disease
activity	70 8 I-Disease
in	79 2 O
anesthetized	82 12 O
rats	95 4 O
.	99 1 O

Penicillin	101 10 B-Chemical
model	112 5 O
is	118 2 O
a	121 1 O
widely	123 6 O
used	130 4 O
experimental	135 12 O
model	148 5 O
for	154 3 O
epilepsy	158 8 B-Disease
research	167 8 O
.	175 1 O

In	177 2 O
the	180 3 O
present	184 7 O
study	192 5 O
we	198 2 O
aimed	201 5 O
to	207 2 O
portray	210 7 O
a	218 1 O
detailed	220 8 O
spectral	229 8 O
analysis	238 8 O
of	247 2 O
penicillin	250 10 B-Chemical
-	260 1 O
induced	261 7 O
epileptiform	269 12 B-Disease
activity	282 8 I-Disease
in	291 2 O
comparison	294 10 O
with	305 4 O
basal	310 5 O
brain	316 5 O
activity	322 8 O
in	331 2 O
anesthetized	334 12 O
Wistar	347 6 O
rats	354 4 O
.	358 1 O

Male	360 4 O
Wistar	365 6 O
rats	372 4 O
were	377 4 O
anesthetized	382 12 O
with	395 4 O
i	400 1 O
.	401 1 O
p	402 1 O
.	403 1 O
urethane	405 8 B-Chemical
and	414 3 O
connected	418 9 O
to	428 2 O
an	431 2 O
electrocorticogram	434 18 O
setup	453 5 O
.	458 1 O

After	460 5 O
a	466 1 O
short	468 5 O
period	474 6 O
of	481 2 O
basal	484 5 O
activity	490 8 O
recording	499 9 O
,	508 1 O
epileptic	510 9 B-Disease
focus	520 5 O
was	526 3 O
induced	530 7 O
by	538 2 O
injecting	541 9 O
400IU	551 5 O
/	556 1 O
2	557 1 O
microl	559 6 O
penicillin	566 10 B-Chemical
-	576 1 I-Chemical
G	577 1 I-Chemical
potassium	579 9 I-Chemical
into	589 4 O
the	594 3 O
left	598 4 O
lateral	603 7 O
ventricle	611 9 O
while	621 5 O
the	627 3 O
cortical	631 8 O
activity	640 8 O
was	649 3 O
continuously	653 12 O
recorded	666 8 O
.	674 1 O

Basal	676 5 O
activity	682 8 O
,	690 1 O
latent	692 6 O
period	699 6 O
and	706 3 O
the	710 3 O
penicillin	714 10 B-Chemical
-	724 1 O
induced	725 7 O
epileptiform	733 12 B-Disease
activity	746 8 I-Disease
periods	755 7 O
were	763 4 O
then	768 4 O
analyzed	773 8 O
using	782 5 O
both	788 4 O
conventional	793 12 O
methods	806 7 O
and	814 3 O
spectral	818 8 O
analysis	827 8 O
.	835 1 O

Spectral	837 8 O
analyses	846 8 O
were	855 4 O
conducted	860 9 O
by	870 2 O
dividing	873 8 O
the	882 3 O
whole	886 5 O
spectrum	892 8 O
into	901 4 O
different	906 9 O
frequency	916 9 O
bands	926 5 O
including	932 9 O
delta	942 5 O
,	947 1 O
theta	949 5 O
(	955 1 O
slow	956 4 O
and	961 3 O
fast	965 4 O
)	969 1 O
,	970 1 O
alpha	972 5 O
-	977 1 O
sigma	978 5 O
,	983 1 O
beta	985 4 O
(	990 1 O
1	991 1 O
and	993 3 O
2	997 1 O
)	998 1 O
and	1000 3 O
gamma	1004 5 O
(	1010 1 O
1	1011 1 O
and	1013 3 O
2	1017 1 O
)	1018 1 O
bands	1020 5 O
.	1025 1 O

Our	1027 3 O
results	1031 7 O
show	1039 4 O
that	1044 4 O
the	1049 3 O
most	1053 4 O
affected	1058 8 O
frequency	1067 9 O
bands	1077 5 O
were	1083 4 O
delta	1088 5 O
,	1093 1 O
theta	1095 5 O
,	1100 1 O
beta	1102 4 O
-	1106 1 O
2	1107 1 O
and	1109 3 O
gamma	1113 5 O
-	1118 1 O
2	1119 1 O
bands	1121 5 O
during	1127 6 O
the	1134 3 O
epileptiform	1138 12 B-Disease
activity	1151 8 I-Disease
and	1160 3 O
there	1164 5 O
were	1170 4 O
marked	1175 6 O
differences	1182 11 O
in	1194 2 O
terms	1197 5 O
of	1203 2 O
spectral	1206 8 O
densities	1215 9 O
between	1225 7 O
three	1233 5 O
investigated	1239 12 O
episodes	1252 8 O
(	1261 1 O
basal	1262 5 O
activity	1268 8 O
,	1276 1 O
latent	1278 6 O
period	1285 6 O
and	1292 3 O
epileptiform	1296 12 B-Disease
activity	1309 8 I-Disease
)	1317 1 O
.	1318 1 O

Our	1320 3 O
results	1324 7 O
may	1332 3 O
help	1336 4 O
to	1341 2 O
analyze	1344 7 O
novel	1352 5 O
data	1358 4 O
obtained	1363 8 O
using	1372 5 O
similar	1378 7 O
experimental	1386 12 O
models	1399 6 O
and	1406 3 O
the	1410 3 O
simple	1414 6 O
analysis	1421 8 O
method	1430 6 O
described	1437 9 O
here	1447 4 O
can	1452 3 O
be	1456 2 O
used	1459 4 O
in	1464 2 O
similar	1467 7 O
studies	1475 7 O
to	1483 2 O
investigate	1486 11 O
the	1498 3 O
basic	1502 5 O
neuronal	1508 8 O
mechanism	1517 9 O
of	1527 2 O
this	1530 4 O
or	1535 2 O
other	1538 5 O
types	1544 5 O
of	1550 2 O
experimental	1553 12 O
epilepsies	1566 10 B-Disease
.	1576 1 O

High	0 4 O
dose	5 4 O
dexmedetomidine	10 15 B-Chemical
as	26 2 O
the	29 3 O
sole	33 4 O
sedative	38 8 O
for	47 3 O
pediatric	51 9 O
MRI	61 3 O
.	64 1 O

OBJECTIVE	66 9 O
:	75 1 O
This	77 4 O
large	82 5 O
-	87 1 O
scale	88 5 O
retrospective	94 13 O
review	108 6 O
evaluates	115 9 O
the	125 3 O
sedation	129 8 O
profile	138 7 O
of	146 2 O
dexmedetomidine	149 15 B-Chemical
.	164 1 O

AIM	166 3 O
:	169 1 O
To	171 2 O
determine	174 9 O
the	184 3 O
hemodynamic	188 11 O
responses	200 9 O
,	209 1 O
efficacy	211 8 O
and	220 3 O
adverse	224 7 O
events	232 6 O
associated	239 10 O
with	250 4 O
the	255 3 O
use	259 3 O
of	263 2 O
high	266 4 O
dose	271 4 O
dexmedetomidine	276 15 B-Chemical
as	292 2 O
the	295 3 O
sole	299 4 O
sedative	304 8 O
for	313 3 O
magnetic	317 8 O
resonance	326 9 O
imaging	336 7 O
(	344 1 O
MRI	345 3 O
)	348 1 O
studies	350 7 O
.	357 1 O

BACKGROUND	359 10 O
:	369 1 O
Dexmedetomidine	371 15 B-Chemical
has	387 3 O
been	391 4 O
used	396 4 O
at	401 2 O
our	404 3 O
institution	408 11 O
since	420 5 O
2005	426 4 O
to	431 2 O
provide	434 7 O
sedation	442 8 O
for	451 3 O
pediatric	455 9 O
radiological	465 12 O
imaging	478 7 O
studies	486 7 O
.	493 1 O

Over	495 4 O
time	500 4 O
,	504 1 O
an	506 2 O
effective	509 9 O
protocol	519 8 O
utilizing	528 9 O
high	538 4 O
dose	543 4 O
dexmedetomidine	548 15 B-Chemical
as	564 2 O
the	567 3 O
sole	571 4 O
sedative	576 8 O
agent	585 5 O
has	591 3 O
evolved	595 7 O
.	602 1 O

METHODS	604 7 O
/	611 1 O
MATERIALS	612 9 O
:	621 1 O
As	623 2 O
part	626 4 O
of	631 2 O
the	634 3 O
ongoing	638 7 O
Quality	646 7 O
Assurance	654 9 O
process	664 7 O
,	671 1 O
data	673 4 O
on	678 2 O
all	681 3 O
sedations	685 9 O
are	695 3 O
reviewed	699 8 O
monthly	708 7 O
and	716 3 O
protocols	720 9 O
modified	730 8 O
as	739 2 O
needed	742 6 O
.	748 1 O

Data	750 4 O
were	755 4 O
analyzed	760 8 O
from	769 4 O
all	774 3 O
747	778 3 O
consecutive	782 11 O
patients	794 8 O
who	803 3 O
received	807 8 O
dexmedetomidine	816 15 B-Chemical
for	832 3 O
MRI	836 3 O
sedation	840 8 O
from	849 4 O
April	854 5 O
2005	860 4 O
to	865 2 O
April	868 5 O
2007	874 4 O
.	878 1 O

RESULTS	880 7 O
:	887 1 O
Since	889 5 O
2005	895 4 O
,	899 1 O
the	901 3 O
10	905 2 O
-	907 1 O
min	908 3 O
loading	912 7 O
dose	920 4 O
of	925 2 O
our	928 3 O
dexmedetomidine	932 15 B-Chemical
protocol	948 8 O
increased	957 9 O
from	967 4 O
2	972 1 O
to	974 2 O
3	977 1 O
microg	979 6 O
.	985 1 O
kg	986 2 O
(	988 1 O
-	989 1 O
1	990 1 O
)	991 1 O
,	992 1 O
and	994 3 O
the	998 3 O
infusion	1002 8 O
rate	1011 4 O
increased	1016 9 O
from	1026 4 O
1	1031 1 O
to	1033 2 O
1	1036 1 O
.	1037 1 O
5	1038 1 O
to	1040 2 O
2	1043 1 O
microg	1045 6 O
.	1051 1 O
kg	1052 2 O
(	1054 1 O
-	1055 1 O
1	1056 1 O
)	1057 1 O
.	1058 1 O
h	1059 1 O
(	1060 1 O
-	1061 1 O
1	1062 1 O
)	1063 1 O
.	1064 1 O

The	1066 3 O
current	1070 7 O
sedation	1078 8 O
protocol	1087 8 O
progressively	1096 13 O
increased	1110 9 O
the	1120 3 O
rate	1124 4 O
of	1129 2 O
successful	1132 10 O
sedation	1143 8 O
(	1152 1 O
able	1153 4 O
to	1158 2 O
complete	1161 8 O
the	1170 3 O
imaging	1174 7 O
study	1182 5 O
)	1187 1 O
when	1189 4 O
using	1194 5 O
dexmedetomidine	1200 15 B-Chemical
alone	1216 5 O
from	1222 4 O
91	1227 2 O
.	1229 1 O
8	1230 1 O
%	1231 1 O
to	1233 2 O
97	1236 2 O
.	1238 1 O
6	1239 1 O
%	1240 1 O
(	1242 1 O
P	1243 1 O
=	1245 1 O
0	1247 1 O
.	1248 1 O
009	1249 3 O
)	1252 1 O
,	1253 1 O
reducing	1255 8 O
the	1264 3 O
requirement	1268 11 O
for	1280 3 O
adjuvant	1284 8 O
pentobarbital	1293 13 B-Chemical
in	1307 2 O
the	1310 3 O
event	1314 5 O
of	1320 2 O
sedation	1323 8 O
failure	1332 7 O
with	1340 4 O
dexmedetomidine	1345 15 B-Chemical
alone	1361 5 O
and	1367 3 O
decreased	1371 9 O
the	1381 3 O
mean	1385 4 O
recovery	1390 8 O
time	1399 4 O
by	1404 2 O
10	1407 2 O
min	1410 3 O
(	1414 1 O
P	1415 1 O
<	1417 1 O
0	1419 1 O
.	1420 1 O
001	1421 3 O
)	1424 1 O
.	1425 1 O

Although	1427 8 O
dexmedetomidine	1436 15 B-Chemical
sedation	1452 8 O
was	1461 3 O
associated	1465 10 O
with	1476 4 O
a	1481 1 O
16	1483 2 O
%	1485 1 O
incidence	1487 9 O
of	1497 2 O
bradycardia	1500 11 B-Disease
,	1511 1 O
all	1513 3 O
concomitant	1517 11 O
mean	1529 4 O
arterial	1534 8 O
blood	1543 5 O
pressures	1549 9 O
were	1559 4 O
within	1564 6 O
20	1571 2 O
%	1573 1 O
of	1575 2 O
age	1578 3 O
-	1581 1 O
adjusted	1582 8 O
normal	1591 6 O
range	1598 5 O
and	1604 3 O
oxygen	1608 6 B-Chemical
saturations	1615 11 O
were	1627 4 O
95	1632 2 O
%	1634 1 O
or	1636 2 O
higher	1639 6 O
.	1645 1 O

CONCLUSION	1647 10 O
:	1657 1 O
Dexmedetomidine	1659 15 B-Chemical
in	1675 2 O
high	1678 4 O
doses	1683 5 O
provides	1689 8 O
adequate	1698 8 O
sedation	1707 8 O
for	1716 3 O
pediatric	1720 9 O
MRI	1730 3 O
studies	1734 7 O
.	1741 1 O

While	1743 5 O
use	1749 3 O
of	1753 2 O
high	1756 4 O
dose	1761 4 O
dexmedetomidine	1766 15 B-Chemical
is	1782 2 O
associated	1785 10 O
with	1796 4 O
decreases	1801 9 O
in	1811 2 O
heart	1814 5 O
rate	1820 4 O
and	1825 3 O
blood	1829 5 O
pressure	1835 8 O
outside	1844 7 O
the	1852 3 O
established	1856 11 O
'	1868 1 O
awake	1869 5 O
'	1874 1 O
norms	1876 5 O
,	1881 1 O
this	1883 4 O
deviation	1888 9 O
is	1898 2 O
generally	1901 9 O
within	1911 6 O
20	1918 2 O
%	1920 1 O
of	1922 2 O
norms	1925 5 O
,	1930 1 O
and	1932 3 O
is	1936 2 O
not	1939 3 O
associated	1943 10 O
with	1954 4 O
adverse	1959 7 O
sequelae	1967 8 O
.	1975 1 O

Dexmedetomidine	1977 15 B-Chemical
is	1993 2 O
useful	1996 6 O
as	2003 2 O
the	2006 3 O
sole	2010 4 O
sedative	2015 8 O
for	2024 3 O
pediatric	2028 9 O
MRI	2038 3 O
.	2041 1 O

Methamphetamine	0 15 B-Chemical
causes	16 6 O
alterations	23 11 O
in	35 2 O
the	38 3 O
MAP	42 3 O
kinase	46 6 O
-	52 1 O
related	53 7 O
pathways	61 8 O
in	70 2 O
the	73 3 O
brains	77 6 O
of	84 2 O
mice	87 4 O
that	92 4 O
display	97 7 O
increased	105 9 O
aggressiveness	115 14 B-Disease
.	129 1 O

Aggressive	131 10 B-Disease
behaviors	142 9 I-Disease
have	152 4 O
been	157 4 O
reported	162 8 O
in	171 2 O
patients	174 8 O
who	183 3 O
suffer	187 6 O
from	194 4 O
some	199 4 O
psychiatric	204 11 B-Disease
disorders	216 9 I-Disease
,	225 1 O
and	227 3 O
are	231 3 O
common	235 6 O
in	242 2 O
methamphetamine	245 15 B-Chemical
(	261 1 O
METH	262 4 B-Chemical
)	266 1 O
abusers	268 7 O
.	275 1 O

Herein	277 6 O
,	283 1 O
we	285 2 O
report	288 6 O
that	295 4 O
multiple	300 8 O
(	309 1 O
but	310 3 O
not	314 3 O
single	318 6 O
)	324 1 O
injections	326 10 O
of	337 2 O
METH	340 4 B-Chemical
significantly	345 13 O
increased	359 9 O
aggressiveness	369 14 B-Disease
in	384 2 O
male	387 4 O
CD	392 2 O
-	394 1 O
1	395 1 O
mice	397 4 O
.	401 1 O

This	403 4 O
increase	408 8 O
in	417 2 O
aggressiveness	420 14 B-Disease
was	435 3 O
not	439 3 O
secondary	443 9 O
to	453 2 O
METH	456 4 B-Chemical
-	460 1 O
induced	461 7 O
hyperactivity	469 13 B-Disease
.	482 1 O

Analysis	484 8 O
of	493 2 O
protein	496 7 O
expression	504 10 O
using	515 5 O
antibody	521 8 O
microarrays	530 11 O
and	542 3 O
Western	546 7 O
blotting	554 8 O
revealed	563 8 O
differential	572 12 O
changes	585 7 O
in	593 2 O
MAP	596 3 O
kinase	600 6 O
-	606 1 O
related	607 7 O
pathways	615 8 O
after	624 5 O
multiple	630 8 O
and	639 3 O
single	643 6 O
METH	650 4 B-Chemical
injections	655 10 O
.	665 1 O

There	667 5 O
were	673 4 O
statistically	678 13 O
significant	692 11 O
(	704 1 O
p	705 1 O
<	706 1 O
0	707 1 O
.	708 1 O
05	709 2 O
)	711 1 O
decreases	713 9 O
in	723 2 O
MEK1	726 4 O
,	730 1 O
Erk2p	732 5 O
,	737 1 O
GSK3alpha	739 9 O
,	748 1 O
14	750 2 O
-	752 1 O
3	753 1 O
-	754 1 O
3e	755 2 O
,	757 1 O
and	759 3 O
MEK7	763 4 O
in	768 2 O
the	771 3 O
striata	775 7 O
of	783 2 O
mice	786 4 O
after	791 5 O
multiple	797 8 O
injections	806 10 O
of	817 2 O
METH	820 4 B-Chemical
.	824 1 O

MEK1	826 4 O
was	831 3 O
significantly	835 13 O
decreased	849 9 O
also	859 4 O
after	864 5 O
a	870 1 O
single	872 6 O
injection	879 9 O
of	889 2 O
METH	892 4 B-Chemical
,	896 1 O
but	898 3 O
to	902 2 O
a	905 1 O
much	907 4 O
lesser	912 6 O
degree	919 6 O
than	926 4 O
after	931 5 O
multiple	937 8 O
injections	946 10 O
of	957 2 O
METH	960 4 B-Chemical
.	964 1 O

In	966 2 O
the	969 3 O
frontal	973 7 O
cortex	981 6 O
,	987 1 O
there	989 5 O
was	995 3 O
a	999 1 O
statistically	1001 13 O
significant	1015 11 O
decrease	1027 8 O
in	1036 2 O
GSK3alpha	1039 9 O
after	1049 5 O
multiple	1055 8 O
(	1064 1 O
but	1065 3 O
not	1069 3 O
single	1073 6 O
)	1079 1 O
injections	1081 10 O
of	1092 2 O
METH	1095 4 B-Chemical
.	1099 1 O

These	1101 5 O
findings	1107 8 O
suggest	1116 7 O
that	1124 4 O
alterations	1129 11 O
in	1141 2 O
MAP	1144 3 O
kinase	1148 6 O
-	1154 1 O
related	1155 7 O
pathways	1163 8 O
in	1172 2 O
the	1175 3 O
prefronto	1179 9 O
-	1188 1 O
striatal	1189 8 O
circuitries	1198 11 O
might	1210 5 O
be	1216 2 O
involved	1219 8 O
in	1228 2 O
the	1231 3 O
manifestation	1235 13 O
of	1249 2 O
aggressive	1252 10 B-Disease
behaviors	1263 9 I-Disease
in	1273 2 O
mice	1276 4 O
.	1280 1 O

Lamotrigine	0 11 B-Chemical
associated	12 10 O
with	23 4 O
exacerbation	28 12 O
or	41 2 O
de	44 2 O
novo	47 4 O
myoclonus	52 9 B-Disease
in	62 2 O
idiopathic	65 10 B-Disease
generalized	76 11 I-Disease
epilepsies	88 10 I-Disease
.	98 1 O

Five	100 4 O
patients	105 8 O
with	114 4 O
idiopathic	119 10 B-Disease
generalized	130 11 I-Disease
epilepsies	142 10 I-Disease
(	153 1 O
IGE	154 3 B-Disease
)	157 1 O
treated	159 7 O
with	167 4 O
lamotrigine	172 11 B-Chemical
(	184 1 O
LTG	185 3 B-Chemical
)	188 1 O
experienced	190 11 O
exacerbation	202 12 O
or	215 2 O
de	218 2 O
novo	221 4 O
appearance	226 10 O
of	237 2 O
myoclonic	240 9 B-Disease
jerks	250 5 I-Disease
(	256 1 O
MJ	257 2 B-Disease
)	259 1 O
.	260 1 O

In	262 2 O
three	265 5 O
patients	271 8 O
,	279 1 O
LTG	281 3 B-Chemical
exacerbated	285 11 O
MJ	297 2 B-Disease
in	300 2 O
a	303 1 O
dose	305 4 O
-	309 1 O
dependent	310 9 O
manner	320 6 O
with	327 4 O
early	332 5 O
aggravation	338 11 O
during	350 6 O
titration	357 9 O
.	366 1 O

MJ	368 2 B-Disease
disappeared	371 11 O
when	383 4 O
LTG	388 3 B-Chemical
dose	392 4 O
was	397 3 O
decreased	401 9 O
by	411 2 O
25	414 2 O
to	417 2 O
50	420 2 O
%	422 1 O
.	423 1 O

In	425 2 O
two	428 3 O
patients	432 8 O
,	440 1 O
LTG	442 3 B-Chemical
exacerbated	446 11 O
MJ	458 2 B-Disease
in	461 2 O
a	464 1 O
delayed	466 7 O
but	474 3 O
more	478 4 O
severe	483 6 O
manner	490 6 O
,	496 1 O
with	498 4 O
myoclonic	503 9 B-Disease
status	513 6 I-Disease
that	520 4 O
only	525 4 O
ceased	530 6 O
after	537 5 O
LTG	543 3 B-Chemical
withdrawal	547 10 O
.	557 1 O

rTMS	0 4 O
of	5 2 O
supplementary	8 13 O
motor	22 5 O
area	28 4 O
modulates	33 9 O
therapy	43 7 O
-	50 1 O
induced	51 7 O
dyskinesias	59 11 B-Disease
in	71 2 O
Parkinson	74 9 B-Disease
disease	84 7 I-Disease
.	91 1 O

The	93 3 O
neural	97 6 O
mechanisms	104 10 O
and	115 3 O
circuitry	119 9 O
involved	129 8 O
in	138 2 O
levodopa	141 8 B-Chemical
-	149 1 O
induced	150 7 O
dyskinesia	158 10 B-Disease
are	169 3 O
unclear	173 7 O
.	180 1 O

Using	182 5 O
repetitive	188 10 O
transcranial	199 12 O
magnetic	212 8 O
stimulation	221 11 O
(	233 1 O
rTMS	234 4 O
)	238 1 O
over	240 4 O
the	245 3 O
supplementary	249 13 O
motor	263 5 O
area	269 4 O
(	274 1 O
SMA	275 3 O
)	278 1 O
in	280 2 O
a	283 1 O
group	285 5 O
of	291 2 O
patients	294 8 O
with	303 4 O
advanced	308 8 O
Parkinson	317 9 B-Disease
disease	327 7 I-Disease
,	334 1 O
the	336 3 O
authors	340 7 O
investigated	348 12 O
whether	361 7 O
modulation	369 10 O
of	380 2 O
SMA	383 3 O
excitability	387 12 O
may	400 3 O
result	404 6 O
in	411 2 O
a	414 1 O
modification	416 12 O
of	429 2 O
a	432 1 O
dyskinetic	434 10 B-Disease
state	445 5 O
induced	451 7 O
by	459 2 O
continuous	462 10 O
apomorphine	473 11 B-Chemical
infusion	485 8 O
.	493 1 O

rTMS	495 4 O
at	500 2 O
1	503 1 O
Hz	505 2 O
was	508 3 O
observed	512 8 O
to	521 2 O
markedly	524 8 O
reduce	533 6 O
drug	540 4 B-Disease
-	544 1 I-Disease
induced	545 7 I-Disease
dyskinesias	553 11 I-Disease
,	564 1 O
whereas	566 7 O
5	574 1 O
-	575 1 O
Hz	576 2 O
rTMS	579 4 O
induced	584 7 O
a	592 1 O
slight	594 6 O
but	601 3 O
not	605 3 O
significant	609 11 O
increase	621 8 O
.	629 1 O

Assessment	0 10 O
of	11 2 O
the	14 3 O
onset	18 5 O
and	24 3 O
persistence	28 11 O
of	40 2 O
amnesia	43 7 B-Disease
during	51 6 O
procedural	58 10 O
sedation	69 8 O
with	78 4 O
propofol	83 8 B-Chemical
.	91 1 O

OBJECTIVES	93 10 O
:	103 1 O
To	105 2 O
assess	108 6 O
patients	115 8 O
'	123 1 O
ability	125 7 O
to	133 2 O
repeat	136 6 O
and	143 3 O
recall	147 6 O
words	154 5 O
presented	160 9 O
to	170 2 O
them	173 4 O
while	178 5 O
undergoing	184 10 O
procedural	195 10 O
sedation	206 8 O
with	215 4 O
propofol	220 8 B-Chemical
,	228 1 O
and	230 3 O
correlate	234 9 O
their	244 5 O
recall	250 6 O
with	257 4 O
their	262 5 O
level	268 5 O
of	274 2 O
awareness	277 9 O
as	287 2 O
measured	290 8 O
by	299 2 O
bispectral	302 10 O
index	313 5 O
(	319 1 O
BIS	320 3 O
)	323 1 O
monitoring	325 10 O
.	335 1 O

METHODS	337 7 O
:	344 1 O
This	346 4 O
was	351 3 O
a	355 1 O
prospective	357 11 O
,	368 1 O
single	370 6 O
-	376 1 O
intervention	377 12 O
study	390 5 O
of	396 2 O
consenting	399 10 O
adult	410 5 O
patients	416 8 O
undergoing	425 10 O
procedural	436 10 O
sedation	447 8 O
with	456 4 O
propofol	461 8 B-Chemical
between	470 7 O
December	478 8 O
28	487 2 O
,	489 1 O
2002	491 4 O
,	495 1 O
and	497 3 O
October	501 7 O
31	509 2 O
,	511 1 O
2003	513 4 O
.	517 1 O

BIS	519 3 O
monitoring	523 10 O
was	534 3 O
initiated	538 9 O
starting	548 8 O
3	557 1 O
minutes	559 7 O
before	567 6 O
the	574 3 O
procedure	578 9 O
and	588 3 O
continuing	592 10 O
until	603 5 O
the	609 3 O
patient	613 7 O
had	621 3 O
regained	625 8 O
baseline	634 8 O
mental	643 6 O
status	650 6 O
.	656 1 O

At	658 2 O
1	661 1 O
-	662 1 O
minute	663 6 O
intervals	670 9 O
during	680 6 O
the	687 3 O
procedural	691 10 O
sedation	702 8 O
,	710 1 O
until	712 5 O
the	718 3 O
patient	722 7 O
regained	730 8 O
baseline	739 8 O
mental	748 6 O
status	755 6 O
at	762 2 O
the	765 3 O
end	769 3 O
of	773 2 O
the	776 3 O
procedure	780 9 O
,	789 1 O
a	791 1 O
word	793 4 O
from	798 4 O
a	803 1 O
standardized	805 12 O
list	818 4 O
was	823 3 O
read	827 4 O
aloud	832 5 O
,	837 1 O
and	839 3 O
the	843 3 O
patient	847 7 O
was	855 3 O
asked	859 5 O
to	865 2 O
immediately	868 11 O
repeat	880 6 O
the	887 3 O
word	891 4 O
to	896 2 O
the	899 3 O
investigator	903 12 O
.	915 1 O

The	917 3 O
BIS	921 3 O
score	925 5 O
at	931 2 O
the	934 3 O
time	938 4 O
the	943 3 O
word	947 4 O
was	952 3 O
read	956 4 O
and	961 3 O
the	965 3 O
patient	969 7 O
'	976 1 O
s	977 1 O
ability	979 7 O
to	987 2 O
repeat	990 6 O
the	997 3 O
word	1001 4 O
were	1006 4 O
recorded	1011 8 O
.	1019 1 O

After	1021 5 O
the	1027 3 O
procedure	1031 9 O
,	1040 1 O
the	1042 3 O
patient	1046 7 O
was	1054 3 O
asked	1058 5 O
to	1064 2 O
state	1067 5 O
all	1073 3 O
of	1077 2 O
the	1080 3 O
words	1084 5 O
from	1090 4 O
the	1095 3 O
list	1099 4 O
that	1104 4 O
he	1109 2 O
or	1112 2 O
she	1115 3 O
could	1119 5 O
recall	1125 6 O
,	1131 1 O
and	1133 3 O
to	1137 2 O
identify	1140 8 O
the	1149 3 O
last	1153 4 O
word	1158 4 O
recalled	1163 8 O
from	1172 4 O
prior	1177 5 O
to	1183 2 O
the	1186 3 O
start	1190 5 O
of	1196 2 O
the	1199 3 O
procedure	1203 9 O
and	1213 3 O
the	1217 3 O
first	1221 5 O
word	1227 4 O
recalled	1232 8 O
from	1241 4 O
after	1246 5 O
the	1252 3 O
procedure	1256 9 O
was	1266 3 O
completed	1270 9 O
.	1279 1 O

RESULTS	1281 7 O
:	1288 1 O
Seventy	1290 7 O
-	1297 1 O
five	1298 4 O
consenting	1303 10 O
patients	1314 8 O
were	1323 4 O
enrolled	1328 8 O
;	1336 1 O
one	1338 3 O
patient	1342 7 O
was	1350 3 O
excluded	1354 8 O
from	1363 4 O
data	1368 4 O
analysis	1373 8 O
for	1382 3 O
a	1386 1 O
protocol	1388 8 O
violation	1397 9 O
.	1406 1 O

No	1408 2 O
serious	1411 7 O
adverse	1419 7 O
events	1427 6 O
were	1434 4 O
noted	1439 5 O
during	1445 6 O
the	1452 3 O
procedural	1456 10 O
sedations	1467 9 O
.	1476 1 O

The	1478 3 O
mean	1482 4 O
(	1487 1 O
+	1488 1 O
/	1489 1 O
-	1490 1 O
standard	1491 8 O
deviation	1500 9 O
)	1509 1 O
time	1511 4 O
of	1516 2 O
data	1519 4 O
collection	1524 10 O
was	1535 3 O
16	1539 2 O
.	1541 1 O
4	1542 1 O
minutes	1544 7 O
(	1552 1 O
+	1553 1 O
/	1554 1 O
-	1555 1 O
7	1556 1 O
.	1557 1 O
1	1558 1 O
;	1559 1 O
range	1561 5 O
5	1567 1 O
to	1569 2 O
34	1572 2 O
minutes	1575 7 O
)	1582 1 O
.	1583 1 O

The	1585 3 O
mean	1589 4 O
initial	1594 7 O
(	1602 1 O
preprocedure	1603 12 O
)	1615 1 O
BIS	1617 3 O
score	1621 5 O
was	1627 3 O
97	1631 2 O
.	1633 1 O
1	1634 1 O
(	1636 1 O
+	1637 1 O
/	1638 1 O
-	1639 1 O
2	1640 1 O
.	1641 1 O
3	1642 1 O
;	1643 1 O
range	1645 5 O
92	1651 2 O
to	1654 2 O
99	1657 2 O
)	1659 1 O
.	1660 1 O

The	1662 3 O
mean	1666 4 O
lowest	1671 6 O
BIS	1678 3 O
score	1682 5 O
occurring	1688 9 O
during	1698 6 O
these	1705 5 O
procedural	1711 10 O
sedations	1722 9 O
was	1732 3 O
66	1736 2 O
.	1738 1 O
9	1739 1 O
(	1741 1 O
+	1742 1 O
/	1743 1 O
-	1744 1 O
14	1745 2 O
.	1747 1 O
4	1748 1 O
;	1749 1 O
range	1751 5 O
33	1757 2 O
to	1760 2 O
91	1763 2 O
)	1765 1 O
.	1766 1 O

The	1768 3 O
mean	1772 4 O
lowest	1777 6 O
BIS	1784 3 O
score	1788 5 O
corresponding	1794 13 O
to	1808 2 O
the	1811 3 O
ability	1815 7 O
of	1823 2 O
the	1826 3 O
patient	1830 7 O
to	1838 2 O
immediately	1841 11 O
repeat	1853 6 O
words	1860 5 O
read	1866 4 O
from	1871 4 O
the	1876 3 O
list	1880 4 O
was	1885 3 O
77	1889 2 O
.	1891 1 O
1	1892 1 O
(	1894 1 O
95	1895 2 O
%	1897 1 O
CI	1899 2 O
=	1902 1 O
74	1904 2 O
.	1906 1 O
3	1907 1 O
to	1909 2 O
80	1912 2 O
.	1914 1 O
0	1915 1 O
)	1916 1 O
.	1917 1 O

The	1919 3 O
mean	1923 4 O
highest	1928 7 O
BIS	1936 3 O
score	1940 5 O
corresponding	1946 13 O
to	1960 2 O
the	1963 3 O
inability	1967 9 B-Disease
to	1977 2 I-Disease
repeat	1980 6 I-Disease
words	1987 5 I-Disease
was	1993 3 O
81	1997 2 O
.	1999 1 O
5	2000 1 O
(	2002 1 O
95	2003 2 O
%	2005 1 O
CI	2007 2 O
=	2010 1 O
78	2012 2 O
.	2014 1 O
1	2015 1 O
to	2017 2 O
84	2020 2 O
.	2022 1 O
8	2023 1 O
)	2024 1 O
.	2025 1 O

The	2027 3 O
mean	2031 4 O
BIS	2036 3 O
score	2040 5 O
corresponding	2046 13 O
to	2060 2 O
the	2063 3 O
last	2067 4 O
word	2072 4 O
recalled	2077 8 O
from	2086 4 O
prior	2091 5 O
to	2097 2 O
the	2100 3 O
initiation	2104 10 O
of	2115 2 O
the	2118 3 O
sedation	2122 8 O
was	2131 3 O
96	2135 2 O
.	2137 1 O
7	2138 1 O
(	2140 1 O
+	2141 1 O
/	2142 1 O
-	2143 1 O
2	2144 1 O
.	2145 1 O
4	2146 1 O
;	2147 1 O
range	2149 5 O
84	2155 2 O
to	2158 2 O
98	2161 2 O
)	2163 1 O
.	2164 1 O

The	2166 3 O
mean	2170 4 O
BIS	2175 3 O
score	2179 5 O
corresponding	2185 13 O
to	2199 2 O
the	2202 3 O
first	2206 5 O
word	2212 4 O
recalled	2217 8 O
after	2226 5 O
the	2232 3 O
procedure	2236 9 O
was	2246 3 O
completed	2250 9 O
was	2260 3 O
91	2264 2 O
.	2266 1 O
2	2267 1 O
(	2269 1 O
95	2270 2 O
%	2272 1 O
CI	2274 2 O
=	2277 1 O
88	2279 2 O
.	2281 1 O
1	2282 1 O
to	2284 2 O
94	2287 2 O
.	2289 1 O
3	2290 1 O
)	2291 1 O
.	2292 1 O

All	2294 3 O
patients	2298 8 O
recalled	2307 8 O
at	2316 2 O
least	2319 5 O
one	2325 3 O
word	2329 4 O
that	2334 4 O
had	2339 3 O
been	2343 4 O
read	2348 4 O
to	2353 2 O
them	2356 4 O
during	2361 6 O
the	2368 3 O
protocol	2372 8 O
.	2380 1 O

The	2382 3 O
mean	2386 4 O
lowest	2391 6 O
BIS	2398 3 O
score	2402 5 O
for	2408 3 O
any	2412 3 O
recalled	2416 8 O
word	2425 4 O
was	2430 3 O
91	2434 2 O
.	2436 1 O
5	2437 1 O
(	2439 1 O
+	2440 1 O
/	2441 1 O
-	2442 1 O
11	2443 2 O
.	2445 1 O
1	2446 1 O
;	2447 1 O
range	2449 5 O
79	2455 2 O
to	2458 2 O
98	2461 2 O
)	2463 1 O
,	2464 1 O
and	2466 3 O
no	2470 2 O
words	2473 5 O
were	2479 4 O
recalled	2484 8 O
when	2493 4 O
the	2498 3 O
corresponding	2502 13 O
BIS	2516 3 O
score	2520 5 O
was	2526 3 O
less	2530 4 O
than	2535 4 O
90	2540 2 O
.	2542 1 O

CONCLUSIONS	2544 11 O
:	2555 1 O
There	2557 5 O
is	2563 2 O
a	2566 1 O
range	2568 5 O
of	2574 2 O
BIS	2577 3 O
scores	2581 6 O
during	2588 6 O
which	2595 5 O
sedated	2601 7 O
patients	2609 8 O
are	2618 3 O
able	2622 4 O
to	2627 2 O
repeat	2630 6 O
words	2637 5 O
read	2643 4 O
to	2648 2 O
them	2651 4 O
but	2656 3 O
are	2660 3 O
not	2664 3 O
able	2668 4 O
to	2673 2 O
subsequently	2676 12 O
recall	2689 6 O
these	2696 5 O
words	2702 5 O
.	2707 1 O

Furthermore	2709 11 O
,	2720 1 O
patients	2722 8 O
had	2731 3 O
no	2735 2 O
recall	2738 6 O
of	2745 2 O
words	2748 5 O
repeated	2754 8 O
prior	2763 5 O
to	2769 2 O
procedural	2772 10 O
sedation	2783 8 O
in	2792 2 O
BIS	2795 3 O
ranges	2799 6 O
associated	2806 10 O
with	2817 4 O
recall	2822 6 O
after	2829 5 O
procedural	2835 10 O
sedation	2846 8 O
,	2854 1 O
suggestive	2856 10 O
of	2867 2 O
retrograde	2870 10 B-Disease
amnesia	2881 7 I-Disease
.	2888 1 O

Assessment	0 10 O
of	11 2 O
perinatal	14 9 O
hepatitis	24 9 B-Disease
B	34 1 I-Disease
and	36 3 O
rubella	40 7 B-Disease
prevention	48 10 O
in	59 2 O
New	62 3 O
Hampshire	66 9 O
delivery	76 8 O
hospitals	85 9 O
.	94 1 O

OBJECTIVE	96 9 O
:	105 1 O
To	107 2 O
evaluate	110 8 O
current	119 7 O
performance	127 11 O
on	139 2 O
recommended	142 11 O
perinatal	154 9 O
hepatitis	164 9 B-Disease
B	174 1 I-Disease
and	176 3 O
rubella	180 7 B-Disease
prevention	188 10 O
practices	199 9 O
in	209 2 O
New	212 3 O
Hampshire	216 9 O
.	225 1 O

METHODS	227 7 O
:	234 1 O
Data	236 4 O
were	241 4 O
extracted	246 9 O
from	256 4 O
2021	261 4 O
paired	266 6 O
mother	273 6 O
-	279 1 O
infant	280 6 O
records	287 7 O
for	295 3 O
the	299 3 O
year	303 4 O
2000	308 4 O
birth	313 5 O
cohort	319 6 O
in	326 2 O
New	329 3 O
Hampshire	333 9 O
'	342 1 O
s	343 1 O
25	345 2 O
delivery	348 8 O
hospitals	357 9 O
.	366 1 O

Assessment	368 10 O
was	379 3 O
done	383 4 O
on	388 2 O
the	391 3 O
following	395 9 O
:	404 1 O
prenatal	406 8 O
screening	415 9 O
for	425 3 O
hepatitis	429 9 B-Disease
B	439 1 I-Disease
and	441 3 O
rubella	445 7 B-Disease
,	452 1 O
administration	454 14 O
of	469 2 O
the	472 3 O
hepatitis	476 9 B-Disease
B	486 1 I-Disease
vaccine	488 7 O
birth	496 5 O
dose	502 4 O
to	507 2 O
all	510 3 O
infants	514 7 O
,	521 1 O
administration	523 14 O
of	538 2 O
hepatitis	541 9 B-Disease
B	551 1 I-Disease
immune	553 6 O
globulin	560 8 O
to	569 2 O
infants	572 7 O
who	580 3 O
were	584 4 O
born	589 4 O
to	594 2 O
hepatitis	597 9 B-Chemical
B	607 1 I-Chemical
surface	609 7 I-Chemical
antigen	617 7 I-Chemical
-	624 1 O
positive	625 8 O
mothers	634 7 O
,	641 1 O
rubella	643 7 B-Disease
immunity	651 8 O
,	659 1 O
and	661 3 O
administration	665 14 O
of	680 2 O
in	683 2 O
-	685 1 O
hospital	686 8 O
postpartum	695 10 O
rubella	706 7 B-Disease
vaccine	714 7 O
to	722 2 O
rubella	725 7 B-Disease
nonimmune	733 9 O
women	743 5 O
.	748 1 O

RESULTS	750 7 O
:	757 1 O
Prenatal	759 8 O
screening	768 9 O
rates	778 5 O
for	784 3 O
hepatitis	788 9 B-Disease
B	798 1 I-Disease
(	800 1 O
98	801 2 O
.	803 1 O
8	804 1 O
%	805 1 O
)	806 1 O
and	808 3 O
rubella	812 7 B-Disease
(	820 1 O
99	821 2 O
.	823 1 O
4	824 1 O
%	825 1 O
)	826 1 O
were	828 4 O
high	833 4 O
.	837 1 O

Hepatitis	839 9 B-Disease
B	849 1 I-Disease
vaccine	851 7 O
birth	859 5 O
dose	865 4 O
was	870 3 O
administered	874 12 O
to	887 2 O
76	890 2 O
.	892 1 O
2	893 1 O
%	894 1 O
of	896 2 O
all	899 3 O
infants	903 7 O
.	910 1 O

All	912 3 O
infants	916 7 O
who	924 3 O
were	928 4 O
born	933 4 O
to	938 2 O
hepatitis	941 9 B-Chemical
B	951 1 I-Chemical
surface	953 7 I-Chemical
antigen	961 7 I-Chemical
-	968 1 O
positive	969 8 O
mothers	978 7 O
also	986 4 O
received	991 8 O
hepatitis	1000 9 B-Disease
B	1010 1 I-Disease
immune	1012 6 O
globulin	1019 8 O
.	1027 1 O

Multivariate	1029 12 O
logistic	1042 8 O
regression	1051 10 O
showed	1062 6 O
that	1069 4 O
the	1074 3 O
month	1078 5 O
of	1084 2 O
delivery	1087 8 O
and	1096 3 O
infant	1100 6 O
birth	1107 5 O
weight	1113 6 O
were	1120 4 O
independent	1125 11 O
predictors	1137 10 O
of	1148 2 O
hepatitis	1151 9 B-Disease
B	1161 1 I-Disease
vaccination	1163 11 O
.	1174 1 O

The	1176 3 O
proportion	1180 10 O
of	1191 2 O
infants	1194 7 O
who	1202 3 O
were	1206 4 O
vaccinated	1211 10 O
in	1222 2 O
January	1225 7 O
and	1233 3 O
February	1237 8 O
2000	1246 4 O
(	1251 1 O
48	1252 2 O
.	1254 1 O
5	1255 1 O
%	1256 1 O
and	1258 3 O
67	1262 2 O
.	1264 1 O
5	1265 1 O
%	1266 1 O
,	1267 1 O
respectively	1269 12 O
)	1281 1 O
was	1283 3 O
less	1287 4 O
than	1292 4 O
any	1297 3 O
other	1301 5 O
months	1307 6 O
,	1313 1 O
whereas	1315 7 O
the	1323 3 O
proportion	1327 10 O
who	1338 3 O
were	1342 4 O
vaccinated	1347 10 O
in	1358 2 O
December	1361 8 O
2000	1370 4 O
(	1375 1 O
88	1376 2 O
.	1378 1 O
2	1379 1 O
%	1380 1 O
)	1381 1 O
was	1383 3 O
the	1387 3 O
highest	1391 7 O
.	1398 1 O

Women	1400 5 O
who	1406 3 O
were	1410 4 O
born	1415 4 O
between	1420 7 O
1971	1428 4 O
and	1433 3 O
1975	1437 4 O
had	1442 3 O
the	1446 3 O
highest	1450 7 O
rate	1458 4 O
of	1463 2 O
rubella	1466 7 B-Disease
nonimmunity	1474 11 O
(	1486 1 O
9	1487 1 O
.	1488 1 O
5	1489 1 O
%	1490 1 O
)	1491 1 O
.	1492 1 O

In	1494 2 O
-	1496 1 O
hospital	1497 8 O
postpartum	1506 10 O
rubella	1517 7 B-Disease
vaccine	1525 7 O
administration	1533 14 O
was	1548 3 O
documented	1552 10 O
for	1563 3 O
75	1567 2 O
.	1569 1 O
6	1570 1 O
%	1571 1 O
of	1573 2 O
nonimmune	1576 9 O
women	1586 5 O
.	1591 1 O

CONCLUSION	1593 10 O
:	1603 1 O
This	1605 4 O
study	1610 5 O
documents	1616 9 O
good	1626 4 O
compliance	1631 10 O
in	1642 2 O
New	1645 3 O
Hampshire	1649 9 O
'	1658 1 O
s	1659 1 O
birthing	1661 8 O
hospitals	1670 9 O
with	1680 4 O
national	1685 8 O
guidelines	1694 10 O
for	1705 3 O
perinatal	1709 9 O
hepatitis	1719 9 B-Disease
B	1729 1 I-Disease
and	1731 3 O
rubella	1735 7 B-Disease
prevention	1743 10 O
and	1754 3 O
highlights	1758 10 O
potential	1769 9 O
areas	1779 5 O
for	1785 3 O
improvement	1789 11 O
.	1800 1 O

Expression	0 10 O
of	11 2 O
p300	14 4 O
protects	19 8 O
cardiac	28 7 O
myocytes	36 8 O
from	45 4 O
apoptosis	50 9 O
in	60 2 O
vivo	63 4 O
.	67 1 O

Doxorubicin	69 11 B-Chemical
is	81 2 O
an	84 2 O
anti	87 4 O
-	91 1 O
tumor	92 5 B-Disease
agent	98 5 O
that	104 4 O
represses	109 9 O
cardiac	119 7 O
-	126 1 O
specific	127 8 O
gene	136 4 O
expression	141 10 O
and	152 3 O
induces	156 7 O
myocardial	164 10 O
cell	175 4 O
apoptosis	180 9 O
.	189 1 O

Doxorubicin	191 11 B-Chemical
depletes	203 8 O
cardiac	212 7 O
p300	220 4 O
,	224 1 O
a	226 1 O
transcriptional	228 15 O
coactivator	244 11 O
that	256 4 O
is	261 2 O
required	264 8 O
for	273 3 O
the	277 3 O
maintenance	281 11 O
of	293 2 O
the	296 3 O
differentiated	300 14 O
phenotype	315 9 O
of	325 2 O
cardiac	328 7 O
myocytes	336 8 O
.	344 1 O

However	346 7 O
,	353 1 O
the	355 3 O
role	359 4 O
of	364 2 O
p300	367 4 O
in	372 2 O
protection	375 10 O
against	386 7 O
doxorubicin	394 11 B-Chemical
-	405 1 O
induced	406 7 O
apoptosis	414 9 O
is	424 2 O
unknown	427 7 O
.	434 1 O

Transgenic	436 10 O
mice	447 4 O
overexpressing	452 14 O
p300	467 4 O
in	472 2 O
the	475 3 O
heart	479 5 O
and	485 3 O
wild	489 4 O
-	493 1 O
type	494 4 O
mice	499 4 O
were	504 4 O
subjected	509 9 O
to	519 2 O
doxorubicin	522 11 B-Chemical
treatment	534 9 O
.	543 1 O

Compared	545 8 O
with	554 4 O
wild	559 4 O
-	563 1 O
type	564 4 O
mice	569 4 O
,	573 1 O
transgenic	575 10 O
mice	586 4 O
exhibited	591 9 O
higher	601 6 O
survival	608 8 O
rate	617 4 O
as	622 2 O
well	625 4 O
as	630 2 O
more	633 4 O
preserved	638 9 O
left	648 4 O
ventricular	653 11 O
function	665 8 O
and	674 3 O
cardiac	678 7 O
expression	686 10 O
of	697 2 O
alpha	700 5 O
-	705 1 O
sarcomeric	706 10 O
actin	717 5 O
.	722 1 O

Doxorubicin	724 11 B-Chemical
induced	736 7 O
myocardial	744 10 O
cell	755 4 O
apoptosis	760 9 O
in	770 2 O
wild	773 4 O
-	777 1 O
type	778 4 O
mice	783 4 O
but	788 3 O
not	792 3 O
in	796 2 O
transgenic	799 10 O
mice	810 4 O
.	814 1 O

Expression	816 10 O
of	827 2 O
p300	830 4 O
increased	835 9 O
the	845 3 O
cardiac	849 7 O
level	857 5 O
of	863 2 O
bcl	866 3 O
-	869 1 O
2	870 1 O
and	872 3 O
mdm	876 3 O
-	879 1 O
2	880 1 O
,	881 1 O
but	883 3 O
not	887 3 O
that	891 4 O
of	896 2 O
p53	899 3 O
or	903 2 O
other	906 5 O
members	912 7 O
of	920 2 O
the	923 3 O
bcl	927 3 O
-	930 1 O
2	931 1 O
family	933 6 O
.	939 1 O

These	941 5 O
findings	947 8 O
demonstrate	956 11 O
that	968 4 O
overexpression	973 14 O
of	988 2 O
p300	991 4 O
protects	996 8 O
cardiac	1005 7 O
myocytes	1013 8 O
from	1022 4 O
doxorubicin	1027 11 B-Chemical
-	1038 1 O
induced	1039 7 O
apoptosis	1047 9 O
and	1057 3 O
reduces	1061 7 O
the	1069 3 O
extent	1073 6 O
of	1080 2 O
acute	1083 5 O
heart	1089 5 B-Disease
failure	1095 7 I-Disease
in	1103 2 O
adult	1106 5 O
mice	1112 4 O
in	1117 2 O
vivo	1120 4 O
.	1124 1 O

Mitochondrial	0 13 O
DNA	14 3 O
and	18 3 O
its	22 3 O
respiratory	26 11 O
chain	38 5 O
products	44 8 O
are	53 3 O
defective	57 9 O
in	67 2 O
doxorubicin	70 11 B-Chemical
nephrosis	82 9 B-Disease
.	91 1 O

BACKGROUND	93 10 O
:	103 1 O
Doxorubicin	105 11 B-Chemical
induces	117 7 O
a	125 1 O
self	127 4 O
-	131 1 O
perpetuating	132 12 O
nephropathy	145 11 B-Disease
characterized	157 13 O
by	171 2 O
early	174 5 O
glomerular	180 10 B-Disease
and	191 3 I-Disease
late	195 4 I-Disease
-	199 1 I-Disease
onset	200 5 I-Disease
tubular	206 7 I-Disease
lesions	214 7 I-Disease
in	222 2 O
rats	225 4 O
.	229 1 O

We	231 2 O
investigated	234 12 O
the	247 3 O
potential	251 9 O
role	261 4 O
of	266 2 O
mitochondrial	269 13 B-Disease
injury	283 6 I-Disease
in	290 2 O
the	293 3 O
onset	297 5 O
of	303 2 O
these	306 5 O
lesions	312 7 O
.	319 1 O

METHODS	321 7 O
:	328 1 O
Rats	330 4 O
were	335 4 O
treated	340 7 O
with	348 4 O
intravenous	353 11 O
doxorubicin	365 11 B-Chemical
(	377 1 O
1	378 1 O
mg	380 2 O
kg	383 2 O
(	385 1 O
-	386 1 O
1	387 1 O
)	388 1 O
week	390 4 O
(	394 1 O
-	395 1 O
1	396 1 O
)	397 1 O
)	398 1 O
for	400 3 O
7	404 1 O
weeks	406 5 O
and	412 3 O
were	416 4 O
sacrificed	421 10 O
either	432 6 O
1	439 1 O
week	441 4 O
(	446 1 O
'	447 1 O
short	448 5 O
-	453 1 O
term	454 4 O
'	458 1 O
)	459 1 O
or	461 2 O
30	464 2 O
weeks	467 5 O
(	473 1 O
'	474 1 O
long	475 4 O
-	479 1 O
term	480 4 O
'	484 1 O
)	485 1 O
following	487 9 O
the	497 3 O
last	501 4 O
dose	506 4 O
.	510 1 O

Additional	512 10 O
rats	523 4 O
received	528 8 O
a	537 1 O
single	539 6 O
dose	546 4 O
either	551 6 O
6	558 1 O
days	560 4 O
or	565 2 O
2	568 1 O
h	570 1 O
prior	572 5 O
to	578 2 O
euthanasia	581 10 O
.	591 1 O

All	593 3 O
rats	597 4 O
were	602 4 O
killed	607 6 O
at	614 2 O
48	617 2 O
weeks	620 5 O
of	626 2 O
age	629 3 O
.	632 1 O

Glomerular	634 10 B-Disease
and	645 3 I-Disease
tubular	649 7 I-Disease
injury	657 6 I-Disease
was	664 3 O
monitored	668 9 O
and	678 3 O
correlated	682 10 O
to	693 2 O
the	696 3 O
activity	700 8 O
or	709 2 O
expression	712 10 O
of	723 2 O
respiratory	726 11 O
chain	738 5 O
components	744 10 O
.	754 1 O

Finally	756 7 O
,	763 1 O
we	765 2 O
quantified	768 10 O
both	779 4 O
nuclear	784 7 O
and	792 3 O
mitochondrial	796 13 O
DNA	810 3 O
(	814 1 O
mtDNA	815 5 O
)	820 1 O
as	822 2 O
well	825 4 O
as	830 2 O
superoxide	833 10 B-Chemical
production	844 10 O
and	855 3 O
the	859 3 O
4834	863 4 O
base	868 4 O
pair	873 4 O
'	878 1 O
common	879 6 O
'	885 1 O
mtDNA	887 5 O
deletion	893 8 O
.	901 1 O

RESULTS	903 7 O
:	910 1 O
The	912 3 O
'	916 1 O
long	917 4 O
-	921 1 O
term	922 4 O
'	926 1 O
group	928 5 O
had	934 3 O
significant	938 11 O
glomerular	950 10 B-Disease
and	961 3 I-Disease
tubular	965 7 I-Disease
lesions	973 7 I-Disease
,	980 1 O
depressed	982 9 O
activities	992 10 O
of	1003 2 O
mtDNA	1006 5 O
-	1011 1 O
encoded	1012 7 O
NADH	1020 4 O
dehydrogenase	1025 13 O
and	1039 3 O
cytochrome	1043 10 O
-	1053 1 O
c	1054 1 O
oxidase	1056 7 O
(	1064 1 O
COX	1065 3 O
)	1068 1 O
and	1070 3 O
increased	1074 9 O
citrate	1084 7 B-Chemical
synthase	1092 8 O
activity	1101 8 O
.	1109 1 O

In	1111 2 O
addition	1114 8 O
,	1122 1 O
expression	1124 10 O
of	1135 2 O
the	1138 3 O
mtDNA	1142 5 O
-	1147 1 O
encoded	1148 7 O
COX	1156 3 O
subunit	1160 7 O
I	1168 1 O
was	1170 3 O
reduced	1174 7 O
and	1182 3 O
mtDNA	1186 5 O
levels	1192 6 O
were	1199 4 O
decreased	1204 9 O
.	1213 1 O

In	1215 2 O
'	1218 1 O
short	1219 5 O
-	1224 1 O
term	1225 4 O
'	1229 1 O
rats	1231 4 O
,	1235 1 O
there	1237 5 O
were	1243 4 O
fewer	1248 5 O
tubular	1254 7 B-Disease
lesions	1262 7 I-Disease
,	1269 1 O
but	1271 3 O
similar	1275 7 O
numbers	1283 7 O
of	1291 2 O
glomerular	1294 10 B-Disease
lesions	1305 7 I-Disease
activity	1313 8 O
.	1321 1 O

Among	1323 5 O
all	1329 3 O
animals	1333 7 O
,	1340 1 O
glomerular	1342 10 B-Disease
and	1353 3 I-Disease
tubular	1357 7 I-Disease
injury	1365 6 I-Disease
were	1372 4 O
inversely	1377 9 O
correlated	1387 10 O
with	1398 4 O
mtDNA	1403 5 O
levels	1409 6 O
,	1415 1 O
mtDNA	1417 5 O
-	1422 1 O
encoded	1423 7 O
respiratory	1431 11 O
chain	1443 5 O
activities	1449 10 O
and	1460 3 O
with	1464 4 O
the	1469 3 O
expression	1473 10 O
of	1484 2 O
the	1487 3 O
mtDNA	1491 5 O
-	1496 1 O
encoded	1497 7 O
respiratory	1505 11 O
chain	1517 5 O
subunit	1523 7 O
COX	1531 3 O
-	1534 1 O
I	1535 1 O
.	1536 1 O

Injury	1538 6 O
was	1545 3 O
positively	1549 10 O
correlated	1560 10 O
with	1571 4 O
superoxide	1576 10 B-Chemical
production	1587 10 O
and	1598 3 O
the	1602 3 O
activities	1606 10 O
of	1617 2 O
nucleus	1620 7 O
-	1627 1 O
encoded	1628 7 O
mitochondrial	1636 13 O
or	1650 2 O
cytoplasmic	1653 11 O
enzymes	1665 7 O
.	1672 1 O

Kidneys	1674 7 O
from	1682 4 O
the	1687 3 O
'	1691 1 O
long	1692 4 O
-	1696 1 O
term	1697 4 O
'	1701 1 O
group	1703 5 O
showed	1709 6 O
more	1716 4 O
mtDNA	1721 5 O
deletions	1727 9 O
than	1737 4 O
in	1742 2 O
'	1745 1 O
short	1746 5 O
-	1751 1 O
term	1752 4 O
'	1756 1 O
animals	1758 7 O
and	1766 3 O
these	1770 5 O
were	1776 4 O
not	1781 3 O
observed	1785 8 O
in	1794 2 O
the	1797 3 O
other	1801 5 O
groups	1807 6 O
.	1813 1 O

CONCLUSIONS	1815 11 O
:	1826 1 O
These	1828 5 O
results	1834 7 O
suggest	1842 7 O
an	1850 2 O
important	1853 9 O
role	1863 4 O
for	1868 3 O
quantitative	1872 12 O
and	1885 3 O
qualitative	1889 11 O
mtDNA	1901 5 O
alterations	1907 11 O
through	1919 7 O
the	1927 3 O
reduction	1931 9 O
of	1941 2 O
mtDNA	1944 5 O
-	1949 1 O
encoded	1950 7 O
respiratory	1958 11 O
chain	1970 5 O
function	1976 8 O
and	1985 3 O
induction	1989 9 O
of	1999 2 O
superoxide	2002 10 B-Chemical
in	2013 2 O
doxorubicin	2016 11 B-Chemical
-	2027 1 O
induced	2028 7 O
renal	2036 5 B-Disease
lesions	2042 7 I-Disease
.	2049 1 O

Amphotericin	0 12 B-Chemical
B	13 1 I-Chemical
-	14 1 O
induced	15 7 O
seizures	23 8 B-Disease
in	32 2 O
a	35 1 O
patient	37 7 O
with	45 4 O
AIDS	50 4 B-Disease
.	54 1 O

OBJECTIVE	56 9 O
:	65 1 O
To	67 2 O
report	70 6 O
a	77 1 O
case	79 4 O
of	84 2 O
multiple	87 8 O
episodes	96 8 O
of	105 2 O
seizure	108 7 B-Disease
activity	116 8 O
in	125 2 O
an	128 2 O
AIDS	131 4 B-Disease
patent	136 6 O
following	143 9 O
amphotericin	153 12 B-Chemical
B	166 1 I-Chemical
infusion	168 8 O
.	176 1 O

CASE	178 4 O
SUMMARY	183 7 O
:	190 1 O
A	192 1 O
46	194 2 O
-	196 1 O
year	197 4 O
-	201 1 O
old	202 3 O
African	206 7 O
-	213 1 O
American	214 8 O
man	223 3 O
experienced	227 11 O
recurrent	239 9 O
grand	249 5 B-Disease
mal	255 3 I-Disease
seizures	259 8 I-Disease
during	268 6 O
intravenous	275 11 O
infusion	287 8 O
of	296 2 O
amphotericin	299 12 B-Chemical
B	312 1 I-Chemical
,	313 1 O
then	315 4 O
petit	320 5 O
mal	326 3 O
seizures	330 8 B-Disease
as	339 2 O
the	342 3 O
infusion	346 8 O
was	355 3 O
stopped	359 7 O
and	367 3 O
the	371 3 O
drug	375 4 O
concentrations	380 14 O
decreased	395 9 O
with	405 4 O
time	410 4 O
.	414 1 O

The	416 3 O
patients	420 8 O
concurrent	429 10 O
medications	440 11 O
included	452 8 O
didanosine	461 10 B-Chemical
,	471 1 O
hydroxyzine	473 11 B-Chemical
,	484 1 O
promethazine	486 12 B-Chemical
,	498 1 O
hydrocortisone	500 14 B-Chemical
,	514 1 O
and	516 3 O
prochlorperazine	520 16 B-Chemical
.	536 1 O

Despite	538 7 O
administration	546 14 O
of	561 2 O
phenytoin	564 9 B-Chemical
and	574 3 O
lorazepam	578 9 B-Chemical
,	587 1 O
the	589 3 O
seizures	593 8 B-Disease
persisted	602 9 O
and	612 3 O
occurred	616 8 O
only	625 4 O
during	630 6 O
amphotercin	637 11 B-Chemical
B	649 1 I-Chemical
administration	651 14 O
.	665 1 O

DISCUSSION	667 10 O
:	677 1 O
AIDS	679 4 B-Disease
and	684 3 O
cryptococcal	688 12 B-Disease
meningitis	701 10 I-Disease
,	711 1 O
both	713 4 O
of	718 2 O
which	721 5 O
the	727 3 O
patient	731 7 O
had	739 3 O
,	742 1 O
can	744 3 O
potentially	748 11 O
cause	760 5 O
seizures	766 8 B-Disease
.	774 1 O

The	776 3 O
patient	780 7 O
had	788 3 O
a	792 1 O
history	794 7 O
of	802 2 O
alcohol	805 7 B-Disease
abuse	813 5 I-Disease
;	818 1 O
alcohol	820 7 B-Chemical
intake	828 6 O
as	835 2 O
well	838 4 O
as	843 2 O
withdrawal	846 10 O
can	857 3 O
also	861 4 O
cause	866 5 O
seizures	872 8 B-Disease
.	880 1 O

Didanosine	882 10 B-Chemical
also	893 4 O
has	898 3 O
a	902 1 O
potential	904 9 O
for	914 3 O
inducing	918 8 O
seizures	927 8 B-Disease
.	935 1 O

However	937 7 O
,	944 1 O
these	946 5 O
other	952 5 O
potential	958 9 O
causes	968 6 O
of	975 2 O
seizure	978 7 B-Disease
were	986 4 O
ruled	991 5 O
out	997 3 O
.	1000 1 O

The	1002 3 O
time	1006 4 O
course	1011 6 O
of	1018 2 O
events	1021 6 O
suggested	1028 9 O
that	1038 4 O
amphotericin	1043 12 B-Chemical
B	1056 1 I-Chemical
was	1058 3 O
the	1062 3 O
cause	1066 5 O
of	1072 2 O
the	1075 3 O
seizures	1079 8 B-Disease
in	1088 2 O
this	1091 4 O
AIDS	1096 4 B-Disease
patient	1101 7 O
.	1108 1 O

CONCLUSIONS	1110 11 O
:	1121 1 O
Amphotericin	1123 12 B-Chemical
B	1136 1 I-Chemical
seems	1138 5 O
to	1144 2 O
be	1147 2 O
the	1150 3 O
probable	1154 8 O
cause	1163 5 O
of	1169 2 O
the	1172 3 O
seizures	1176 8 B-Disease
.	1184 1 O

To	1186 2 O
date	1189 4 O
,	1193 1 O
only	1195 4 O
three	1200 5 O
cases	1206 5 O
of	1212 2 O
seizures	1215 8 B-Disease
associated	1224 10 O
with	1235 4 O
amphotericin	1240 12 B-Chemical
B	1253 1 I-Chemical
have	1255 4 O
been	1260 4 O
reported	1265 8 O
in	1274 2 O
the	1277 3 O
literature	1281 10 O
,	1291 1 O
but	1293 3 O
healthcare	1297 10 O
providers	1308 9 O
should	1318 6 O
be	1325 2 O
aware	1328 5 O
of	1334 2 O
the	1337 3 O
potential	1341 9 O
for	1351 3 O
this	1355 4 O
rare	1360 4 O
adverse	1365 7 O
effect	1373 6 O
.	1379 1 O

Therapeutic	0 11 O
drug	12 4 O
monitoring	17 10 O
of	28 2 O
tobramycin	31 10 B-Chemical
:	41 1 O
once	43 4 O
-	47 1 O
daily	48 5 O
versus	54 6 O
twice	61 5 O
-	66 1 O
daily	67 5 O
dosage	73 6 O
schedules	80 9 O
.	89 1 O

OBJECTIVE	91 9 O
:	100 1 O
To	102 2 O
evaluate	105 8 O
the	114 3 O
effect	118 6 O
of	125 2 O
dosage	128 6 O
regimen	135 7 O
(	143 1 O
once	144 4 O
-	148 1 O
daily	149 5 O
vs	155 2 O
.	157 1 O
twice	159 5 O
-	164 1 O
daily	165 5 O
)	170 1 O
of	172 2 O
tobramicyn	175 10 B-Chemical
on	186 2 O
steady	189 6 O
-	195 1 O
state	196 5 O
serum	202 5 O
concentrations	208 14 O
and	223 3 O
toxicity	227 8 B-Disease
.	235 1 O

MATERIALS	237 9 O
AND	247 3 O
METHODS	251 7 O
:	258 1 O
Patients	260 8 O
undergoing	269 10 O
treatment	280 9 O
with	290 4 O
i	295 1 O
.	296 1 O
v	297 1 O
.	298 1 O
tobramycin	300 10 B-Chemical
(	311 1 O
4	312 1 O
mg	314 2 O
/	316 1 O
kg	317 2 O
/	319 1 O
day	320 3 O
)	323 1 O
were	325 4 O
randomised	330 10 O
to	341 2 O
two	344 3 O
groups	348 6 O
.	354 1 O

Group	356 5 O
OD	362 2 O
(	365 1 O
n	366 1 O
=	368 1 O
22	370 2 O
)	372 1 O
received	374 8 O
a	383 1 O
once	385 4 O
-	389 1 O
daily	390 5 O
dose	396 4 O
of	401 2 O
tobramycin	404 10 B-Chemical
and	415 3 O
group	419 5 O
TD	425 2 O
(	428 1 O
n	429 1 O
=	431 1 O
21	433 2 O
)	435 1 O
received	437 8 O
the	446 3 O
same	450 4 O
dose	455 4 O
divided	460 7 O
into	468 4 O
two	473 3 O
doses	477 5 O
daily	483 5 O
.	488 1 O

Tobramycin	490 10 B-Chemical
serum	501 5 O
concentrations	507 14 O
(	522 1 O
peak	523 4 O
and	528 3 O
trough	532 6 O
)	538 1 O
were	540 4 O
measured	545 8 O
by	554 2 O
enzyme	557 6 O
multiplied	564 10 O
immunoassay	575 11 O
.	586 1 O

The	588 3 O
renal	592 5 O
and	598 3 O
auditory	602 8 O
functions	611 9 O
of	621 2 O
the	624 3 O
patients	628 8 O
were	637 4 O
monitored	642 9 O
before	652 6 O
,	658 1 O
during	660 6 O
and	667 3 O
immediately	671 11 O
after	683 5 O
treatment	689 9 O
.	698 1 O

RESULTS	700 7 O
:	707 1 O
The	709 3 O
two	713 3 O
groups	717 6 O
were	724 4 O
comparable	729 10 O
with	740 4 O
respect	745 7 O
to	753 2 O
sex	756 3 O
,	759 1 O
age	761 3 O
,	764 1 O
body	766 4 O
weight	771 6 O
and	778 3 O
renal	782 5 O
function	788 8 O
.	796 1 O

No	798 2 O
statistically	801 13 O
significant	815 11 O
differences	827 11 O
were	839 4 O
found	844 5 O
in	850 2 O
mean	853 4 O
daily	858 5 O
dose	864 4 O
,	868 1 O
duration	870 8 O
of	879 2 O
treatment	882 9 O
,	891 1 O
or	893 2 O
cumulative	896 10 O
dose	907 4 O
.	911 1 O

Trough	913 6 O
concentrations	920 14 O
were	935 4 O
<	940 1 O
2	942 1 O
g	944 1 O
/	945 1 O
ml	946 2 O
in	949 2 O
the	952 3 O
two	956 3 O
groups	960 6 O
(	967 1 O
100	968 3 O
%	971 1 O
)	972 1 O
.	973 1 O

Peak	975 4 O
concentrations	980 14 O
were	995 4 O
>	1000 1 O
6	1002 1 O
microg	1004 6 O
/	1010 1 O
ml	1011 2 O
in	1014 2 O
100	1017 3 O
%	1020 1 O
of	1022 2 O
the	1025 3 O
OD	1029 2 O
group	1032 5 O
and	1038 3 O
in	1042 2 O
67	1045 2 O
%	1047 1 O
of	1049 2 O
the	1052 3 O
TD	1056 2 O
group	1059 5 O
(	1065 1 O
P	1066 1 O
<	1067 1 O
0	1069 1 O
.	1070 1 O
01	1071 2 O
)	1073 1 O
.	1074 1 O

Mean	1076 4 O
peak	1081 4 O
concentrations	1086 14 O
were	1101 4 O
markedly	1106 8 O
different	1115 9 O
:	1124 1 O
11	1126 2 O
.	1128 1 O
00	1129 2 O
+	1131 1 O
/	1132 1 O
-	1133 1 O
2	1134 1 O
.	1135 1 O
89	1136 2 O
microg	1139 6 O
/	1145 1 O
ml	1146 2 O
in	1149 2 O
OD	1152 2 O
vs	1155 2 O
.	1157 1 O
6	1159 1 O
.	1160 1 O
53	1161 2 O
+	1163 1 O
/	1164 1 O
-	1165 1 O
1	1166 1 O
.	1167 1 O
45	1168 2 O
microg	1171 6 O
/	1177 1 O
ml	1178 2 O
in	1181 2 O
TD	1184 2 O
(	1187 1 O
P	1188 1 O
<	1189 1 O
0	1191 1 O
.	1192 1 O
01	1193 2 O
)	1195 1 O
.	1196 1 O

The	1198 3 O
pharmacokinetics	1202 16 O
parameters	1219 10 O
were	1230 4 O
:	1234 1 O
Ke	1236 2 O
,	1238 1 O
(	1240 1 O
0	1241 1 O
.	1242 1 O
15	1243 2 O
+	1245 1 O
/	1246 1 O
-	1247 1 O
0	1248 1 O
.	1249 1 O
03	1250 2 O
/	1252 1 O
h	1253 1 O
in	1255 2 O
OD	1258 2 O
vs	1261 2 O
.	1263 1 O
0	1265 1 O
.	1266 1 O
24	1267 2 O
+	1269 1 O
/	1270 1 O
-	1271 1 O
0	1272 1 O
.	1273 1 O
06	1274 2 O
/	1276 1 O
h	1277 1 O
in	1279 2 O
TD	1282 2 O
)	1284 1 O
,	1285 1 O
t1	1287 2 O
/	1289 1 O
2	1290 1 O
,	1291 1 O
(	1293 1 O
4	1294 1 O
.	1295 1 O
95	1296 2 O
+	1298 1 O
/	1299 1 O
-	1300 1 O
1	1301 1 O
.	1302 1 O
41	1303 2 O
h	1306 1 O
in	1308 2 O
OD	1311 2 O
vs	1314 2 O
.	1316 1 O
3	1318 1 O
.	1319 1 O
07	1320 2 O
+	1322 1 O
/	1323 1 O
-	1324 1 O
0	1325 1 O
.	1326 1 O
71	1327 2 O
h	1330 1 O
in	1332 2 O
TD	1335 2 O
)	1337 1 O
,	1338 1 O
Vd	1340 2 O
(	1343 1 O
0	1344 1 O
.	1345 1 O
35	1346 2 O
+	1348 1 O
/	1349 1 O
-	1350 1 O
0	1351 1 O
.	1352 1 O
11	1353 2 O
l	1356 1 O
/	1357 1 O
kg	1358 2 O
in	1361 2 O
OD	1364 2 O
vs	1367 2 O
.	1369 1 O
0	1371 1 O
.	1372 1 O
33	1373 2 O
+	1375 1 O
/	1376 1 O
-	1377 1 O
0	1378 1 O
.	1379 1 O
09	1380 2 O
l	1383 1 O
/	1384 1 O
kg	1385 2 O
in	1388 2 O
TD	1391 2 O
)	1393 1 O
,	1394 1 O
Cl	1396 2 O
(	1399 1 O
0	1400 1 O
.	1401 1 O
86	1402 2 O
+	1404 1 O
/	1405 1 O
-	1406 1 O
0	1407 1 O
.	1408 1 O
29	1409 2 O
ml	1412 2 O
/	1414 1 O
min	1415 3 O
/	1418 1 O
kg	1419 2 O
in	1422 2 O
OD	1425 2 O
vs	1428 2 O
.	1430 1 O
1	1432 1 O
.	1433 1 O
28	1434 2 O
+	1436 1 O
/	1437 1 O
-	1438 1 O
0	1439 1 O
.	1440 1 O
33	1441 2 O
ml	1444 2 O
/	1446 1 O
min	1447 3 O
/	1450 1 O
kg	1451 2 O
in	1454 2 O
TD	1457 2 O
)	1459 1 O
.	1460 1 O

Increased	1462 9 O
serum	1472 5 O
creatinine	1478 10 B-Chemical
was	1489 3 O
observed	1493 8 O
in	1502 2 O
73	1505 2 O
%	1507 1 O
of	1509 2 O
patients	1512 8 O
in	1521 2 O
OD	1524 2 O
versus	1527 6 O
57	1534 2 O
%	1536 1 O
of	1538 2 O
patients	1541 8 O
in	1550 2 O
TD	1553 2 O
,	1555 1 O
without	1557 7 O
evidence	1565 8 O
of	1574 2 O
nephrotoxicity	1577 14 B-Disease
.	1591 1 O

In	1593 2 O
TD	1596 2 O
group	1599 5 O
,	1604 1 O
three	1606 5 O
patients	1612 8 O
developed	1621 9 O
decreased	1631 9 B-Disease
auditory	1641 8 I-Disease
function	1650 8 I-Disease
,	1658 1 O
of	1660 2 O
which	1663 5 O
one	1669 3 O
presented	1673 9 O
with	1683 4 O
an	1688 2 O
auditory	1691 8 B-Disease
loss	1700 4 I-Disease
of	1705 2 O
-	1708 1 O
30	1709 2 O
dB	1712 2 O
,	1714 1 O
whereas	1716 7 O
in	1724 2 O
the	1727 3 O
OD	1731 2 O
group	1734 5 O
only	1740 4 O
one	1745 3 O
patient	1749 7 O
presented	1757 9 O
decreased	1767 9 B-Disease
auditory	1777 8 I-Disease
function	1786 8 I-Disease
.	1794 1 O

CONCLUSION	1796 10 O
:	1806 1 O
This	1808 4 O
small	1813 5 O
study	1819 5 O
suggests	1825 8 O
that	1834 4 O
a	1839 1 O
once	1841 4 O
-	1845 1 O
daily	1846 5 O
dosing	1852 6 O
regimen	1859 7 O
of	1867 2 O
tobramycin	1870 10 B-Chemical
is	1881 2 O
at	1884 2 O
least	1887 5 O
as	1893 2 O
effective	1896 9 O
as	1906 2 O
and	1909 3 O
is	1913 2 O
no	1916 2 O
more	1919 4 O
and	1924 3 O
possibly	1928 8 O
less	1937 4 O
toxic	1942 5 O
than	1948 4 O
the	1953 3 O
twice	1957 5 O
-	1962 1 O
daily	1963 5 O
regimen	1969 7 O
.	1976 1 O

Using	1978 5 O
a	1984 1 O
single	1986 6 O
-	1992 1 O
dose	1993 4 O
therapy	1998 7 O
,	2005 1 O
peak	2007 4 O
concentration	2012 13 O
determination	2026 13 O
is	2040 2 O
not	2043 3 O
necessary	2047 9 O
,	2056 1 O
only	2058 4 O
trough	2063 6 O
samples	2070 7 O
should	2078 6 O
be	2085 2 O
monitored	2088 9 O
to	2098 2 O
ensure	2101 6 O
levels	2108 6 O
below	2115 5 O
2	2121 1 O
microg	2123 6 O
/	2129 1 O
ml	2130 2 O
.	2132 1 O

Chronic	0 7 O
effects	8 7 O
of	16 2 O
a	19 1 O
novel	21 5 O
synthetic	27 9 O
anthracycline	37 13 B-Chemical
derivative	51 10 O
(	62 1 O
SM	63 2 B-Chemical
-	65 1 I-Chemical
5887	66 4 I-Chemical
)	70 1 O
on	72 2 O
normal	75 6 O
heart	82 5 O
and	88 3 O
doxorubicin	92 11 B-Chemical
-	103 1 O
induced	104 7 O
cardiomyopathy	112 14 B-Disease
in	127 2 O
beagle	130 6 O
dogs	137 4 O
.	141 1 O

This	143 4 O
study	148 5 O
was	154 3 O
designed	158 8 O
to	167 2 O
investigate	170 11 O
the	182 3 O
chronic	186 7 O
cardiotoxic	194 11 B-Disease
potential	206 9 O
of	216 2 O
SM	219 2 B-Chemical
-	221 1 I-Chemical
5887	222 4 I-Chemical
and	227 3 O
a	231 1 O
possible	233 8 O
deteriorating	242 13 O
effect	256 6 O
of	263 2 O
SM	266 2 B-Chemical
-	268 1 I-Chemical
5887	269 4 I-Chemical
on	274 2 O
low	277 3 O
-	280 1 O
grade	281 5 O
cardiotoxicity	287 14 B-Disease
pre	302 3 O
-	305 1 O
induced	306 7 O
by	314 2 O
doxorubicin	317 11 B-Chemical
in	329 2 O
beagle	332 6 O
dogs	339 4 O
.	343 1 O

In	345 2 O
the	348 3 O
chronic	352 7 O
treatment	360 9 O
,	369 1 O
beagle	371 6 O
dogs	378 4 O
of	383 2 O
each	386 4 O
sex	391 3 O
were	395 4 O
given	400 5 O
intravenously	406 13 O
once	420 4 O
every	425 5 O
3	431 1 O
weeks	433 5 O
,	438 1 O
either	440 6 O
a	447 1 O
sublethal	449 9 O
dose	459 4 O
of	464 2 O
doxorubicin	467 11 B-Chemical
(	479 1 O
1	480 1 O
.	481 1 O
5	482 1 O
mg	484 2 O
/	486 1 O
kg	487 2 O
)	489 1 O
or	491 2 O
SM	494 2 B-Chemical
-	496 1 I-Chemical
5887	497 4 I-Chemical
(	502 1 O
2	503 1 O
.	504 1 O
5	505 1 O
mg	507 2 O
/	509 1 O
kg	510 2 O
)	512 1 O
.	513 1 O

The	515 3 O
experiment	519 10 O
was	530 3 O
terminated	534 10 O
3	545 1 O
weeks	547 5 O
after	553 5 O
the	559 3 O
ninth	563 5 O
dosing	569 6 O
.	575 1 O

Animals	577 7 O
which	585 5 O
received	591 8 O
over	600 4 O
six	605 3 O
courses	609 7 O
of	617 2 O
doxorubicin	620 11 B-Chemical
demonstrated	632 12 O
the	645 3 O
electrocardiogram	649 17 O
(	667 1 O
ECG	668 3 O
)	671 1 O
changes	673 7 O
,	680 1 O
decrease	682 8 O
of	691 2 O
blood	694 5 O
pressure	700 8 O
and	709 3 O
high	713 4 O
-	717 1 O
grade	718 5 O
histopathological	724 17 O
cardiomyopathy	742 14 B-Disease
,	756 1 O
while	758 5 O
animals	764 7 O
which	772 5 O
were	778 4 O
terminally	783 10 O
sacrificed	794 10 O
after	805 5 O
the	811 3 O
SM	815 2 B-Chemical
-	817 1 I-Chemical
5887	818 4 I-Chemical
administration	823 14 O
did	838 3 O
not	842 3 O
show	846 4 O
any	851 3 O
changes	855 7 O
in	863 2 O
ECG	866 3 O
,	869 1 O
blood	871 5 O
pressure	877 8 O
and	886 3 O
histopathological	890 17 O
examinations	908 12 O
.	920 1 O

To	922 2 O
examine	925 7 O
a	933 1 O
possibly	935 8 O
deteriorating	944 13 O
cardiotoxic	958 11 B-Disease
effect	970 6 O
of	977 2 O
SM	980 2 B-Chemical
-	982 1 I-Chemical
5887	983 4 I-Chemical
,	987 1 O
low	989 3 O
-	992 1 O
grade	993 5 O
cardiomyopathy	999 14 B-Disease
was	1014 3 O
induced	1018 7 O
in	1026 2 O
dogs	1029 4 O
by	1034 2 O
four	1037 4 O
courses	1042 7 O
of	1050 2 O
doxorubicin	1053 11 B-Chemical
(	1065 1 O
1	1066 1 O
.	1067 1 O
5	1068 1 O
mg	1070 2 O
/	1072 1 O
kg	1073 2 O
)	1075 1 O
.	1076 1 O

Nine	1078 4 O
weeks	1083 5 O
after	1089 5 O
pre	1095 3 O
-	1098 1 O
treatment	1099 9 O
,	1108 1 O
dogs	1110 4 O
were	1115 4 O
given	1120 5 O
four	1126 4 O
courses	1131 7 O
of	1139 2 O
either	1142 6 O
doxorubicin	1149 11 B-Chemical
(	1161 1 O
1	1162 1 O
.	1163 1 O
5	1164 1 O
mg	1166 2 O
/	1168 1 O
kg	1169 2 O
)	1171 1 O
or	1173 2 O
SM	1176 2 B-Chemical
-	1178 1 I-Chemical
5887	1179 4 I-Chemical
(	1184 1 O
2	1185 1 O
.	1186 1 O
5	1187 1 O
mg	1189 2 O
/	1191 1 O
kg	1192 2 O
)	1194 1 O
once	1196 4 O
every	1201 5 O
3	1207 1 O
weeks	1209 5 O
.	1214 1 O

The	1216 3 O
low	1220 3 O
-	1223 1 O
grade	1224 5 O
cardiotoxic	1230 11 B-Disease
changes	1242 7 O
were	1250 4 O
enhanced	1255 8 O
by	1264 2 O
the	1267 3 O
additional	1271 10 O
doxorubicin	1282 11 B-Chemical
treatment	1294 9 O
.	1303 1 O

On	1305 2 O
the	1308 3 O
contrary	1312 8 O
,	1320 1 O
the	1322 3 O
SM	1326 2 B-Chemical
-	1328 1 I-Chemical
5887	1329 4 I-Chemical
treatment	1334 9 O
did	1344 3 O
not	1348 3 O
progress	1352 8 O
the	1361 3 O
grade	1365 5 O
of	1371 2 O
cardiomyopathy	1374 14 B-Disease
.	1388 1 O

In	1390 2 O
conclusion	1393 10 O
,	1403 1 O
SM	1405 2 B-Chemical
-	1407 1 I-Chemical
5887	1408 4 I-Chemical
does	1413 4 O
not	1418 3 O
have	1422 4 O
any	1427 3 O
potential	1431 9 O
of	1441 2 O
chronic	1444 7 O
cardiotoxicity	1452 14 B-Disease
and	1467 3 O
deteriorating	1471 13 O
effect	1485 6 O
on	1492 2 O
doxorubicin	1495 11 B-Chemical
-	1506 1 O
induced	1507 7 O
cardiotoxicity	1515 14 B-Disease
in	1530 2 O
dogs	1533 4 O
.	1537 1 O

Posteroventral	0 14 O
medial	15 6 O
pallidotomy	22 11 O
in	34 2 O
advanced	37 8 O
Parkinson	46 9 B-Disease
'	55 1 I-Disease
s	56 1 I-Disease
disease	58 7 I-Disease
.	65 1 O

BACKGROUND	67 10 O
:	77 1 O
Posteroventral	79 14 O
medial	94 6 O
pallidotomy	101 11 O
sometimes	113 9 O
produces	123 8 O
striking	132 8 O
improvement	141 11 O
in	153 2 O
patients	156 8 O
with	165 4 O
advanced	170 8 O
Parkinson	179 9 B-Disease
'	188 1 I-Disease
s	189 1 I-Disease
disease	191 7 I-Disease
,	198 1 O
but	200 3 O
the	204 3 O
studies	208 7 O
to	216 2 O
date	219 4 O
have	224 4 O
involved	229 8 O
small	238 5 O
numbers	244 7 O
of	252 2 O
patients	255 8 O
and	264 3 O
short	268 5 O
-	273 1 O
term	274 4 O
follow	279 6 O
-	285 1 O
up	286 2 O
.	288 1 O

METHODS	290 7 O
:	297 1 O
Forty	299 5 O
patients	305 8 O
with	314 4 O
Parkinson	319 9 B-Disease
'	328 1 I-Disease
s	329 1 I-Disease
disease	331 7 I-Disease
underwent	339 9 O
serial	349 6 O
,	355 1 O
detailed	357 8 O
assessments	366 11 O
both	378 4 O
after	383 5 O
drug	389 4 O
withdrawal	394 10 O
(	405 1 O
"	406 1 O
off	407 3 O
"	410 1 O
period	412 6 O
)	418 1 O
and	420 3 O
while	424 5 O
taking	430 6 O
their	437 5 O
optimal	443 7 O
medical	451 7 O
regimens	459 8 O
(	468 1 O
"	469 1 O
on	470 2 O
"	472 1 O
period	474 6 O
)	480 1 O
.	481 1 O

All	483 3 O
patients	487 8 O
were	496 4 O
examined	501 8 O
preoperatively	510 14 O
and	525 3 O
39	529 2 O
were	532 4 O
examined	537 8 O
at	546 2 O
six	549 3 O
months	553 6 O
;	559 1 O
27	561 2 O
of	564 2 O
the	567 3 O
patients	571 8 O
were	580 4 O
also	585 4 O
examined	590 8 O
at	599 2 O
one	602 3 O
year	606 4 O
,	610 1 O
and	612 3 O
11	616 2 O
at	619 2 O
two	622 3 O
years	626 5 O
.	631 1 O

RESULTS	633 7 O
:	640 1 O
The	642 3 O
percent	646 7 O
improvements	654 12 O
at	667 2 O
six	670 3 O
months	674 6 O
were	681 4 O
as	686 2 O
follows	689 7 O
:	696 1 O
off	698 3 O
-	701 1 O
period	702 6 O
score	709 5 O
for	715 3 O
overall	719 7 O
motor	727 5 O
function	733 8 O
,	741 1 O
28	743 2 O
percent	746 7 O
(	754 1 O
95	755 2 O
percent	758 7 O
confidence	766 10 O
interval	777 8 O
,	785 1 O
19	787 2 O
to	790 2 O
38	793 2 O
percent	796 7 O
)	803 1 O
,	804 1 O
with	806 4 O
most	811 4 O
of	816 2 O
the	819 3 O
improvement	823 11 O
in	835 2 O
the	838 3 O
contralateral	842 13 O
limbs	856 5 O
;	861 1 O
off	863 3 O
-	866 1 O
period	867 6 O
score	874 5 O
for	880 3 O
activities	884 10 O
of	895 2 O
daily	898 5 O
living	904 6 O
,	910 1 O
29	912 2 O
percent	915 7 O
(	923 1 O
95	924 2 O
percent	927 7 O
confidence	935 10 O
interval	946 8 O
,	954 1 O
19	956 2 O
to	959 2 O
39	962 2 O
percent	965 7 O
)	972 1 O
;	973 1 O
on	975 2 O
-	977 1 O
period	978 6 O
score	985 5 O
for	991 3 O
contralateral	995 13 O
dyskinesias	1009 11 B-Disease
,	1020 1 O
82	1022 2 O
percent	1025 7 O
(	1033 1 O
95	1034 2 O
percent	1037 7 O
confidence	1045 10 O
interval	1056 8 O
,	1064 1 O
72	1066 2 O
to	1069 2 O
91	1072 2 O
percent	1075 7 O
)	1082 1 O
;	1083 1 O
and	1085 3 O
on	1089 2 O
-	1091 1 O
period	1092 6 O
score	1099 5 O
for	1105 3 O
ipsilateral	1109 11 O
dyskinesias	1121 11 B-Disease
,	1132 1 O
44	1134 2 O
percent	1137 7 O
(	1145 1 O
95	1146 2 O
percent	1149 7 O
confidence	1157 10 O
interval	1168 8 O
,	1176 1 O
29	1178 2 O
to	1181 2 O
59	1184 2 O
percent	1187 7 O
)	1194 1 O
.	1195 1 O

The	1197 3 O
improvements	1201 12 O
in	1214 2 O
dyskinesias	1217 11 B-Disease
and	1229 3 O
the	1233 3 O
total	1237 5 O
scores	1243 6 O
for	1250 3 O
off	1254 3 O
-	1257 1 O
period	1258 6 O
parkinsonism	1265 12 B-Disease
,	1277 1 O
contralateral	1279 13 O
bradykinesia	1293 12 B-Disease
,	1305 1 O
and	1307 3 O
rigidity	1311 8 B-Disease
were	1320 4 O
sustained	1325 9 O
in	1335 2 O
the	1338 3 O
11	1342 2 O
patients	1345 8 O
examined	1354 8 O
at	1363 2 O
two	1366 3 O
years	1370 5 O
.	1375 1 O

The	1377 3 O
improvement	1381 11 O
in	1393 2 O
ipsilateral	1396 11 O
dyskinesias	1408 11 B-Disease
was	1420 3 O
lost	1424 4 O
after	1429 5 O
one	1435 3 O
year	1439 4 O
,	1443 1 O
and	1445 3 O
the	1449 3 O
improvements	1453 12 O
in	1466 2 O
postural	1469 8 O
stability	1478 9 O
and	1488 3 O
gait	1492 4 O
lasted	1497 6 O
only	1504 4 O
three	1509 5 O
to	1515 2 O
six	1518 3 O
months	1522 6 O
.	1528 1 O

Approximately	1530 13 O
half	1544 4 O
the	1549 3 O
patients	1553 8 O
who	1562 3 O
had	1566 3 O
been	1570 4 O
dependent	1575 9 O
on	1585 2 O
assistance	1588 10 O
in	1599 2 O
activities	1602 10 O
of	1613 2 O
daily	1616 5 O
living	1622 6 O
in	1629 2 O
the	1632 3 O
off	1636 3 O
period	1640 6 O
before	1647 6 O
surgery	1654 7 O
became	1662 6 O
independent	1669 11 O
after	1681 5 O
surgery	1687 7 O
.	1694 1 O

The	1696 3 O
complications	1700 13 O
of	1714 2 O
surgery	1717 7 O
were	1725 4 O
generally	1730 9 O
well	1740 4 O
tolerated	1745 9 O
,	1754 1 O
and	1756 3 O
there	1760 5 O
were	1766 4 O
no	1771 2 O
significant	1774 11 O
changes	1786 7 O
in	1794 2 O
the	1797 3 O
use	1801 3 O
of	1805 2 O
medication	1808 10 O
.	1818 1 O

CONCLUSIONS	1820 11 O
:	1831 1 O
In	1833 2 O
late	1836 4 O
-	1840 1 O
stage	1841 5 O
Parkinson	1847 9 B-Disease
'	1856 1 I-Disease
s	1857 1 I-Disease
disease	1859 7 I-Disease
,	1866 1 O
pallidotomy	1868 11 O
significantly	1880 13 O
reduces	1894 7 O
levodopa	1902 8 B-Chemical
-	1910 1 O
induced	1911 7 O
dyskinesias	1919 11 B-Disease
and	1931 3 O
off	1935 3 O
-	1938 1 O
period	1939 6 O
disability	1946 10 O
.	1956 1 O

Much	1958 4 O
of	1963 2 O
the	1966 3 O
benefit	1970 7 O
is	1978 2 O
sustained	1981 9 O
at	1991 2 O
two	1994 3 O
years	1998 5 O
,	2003 1 O
although	2005 8 O
some	2014 4 O
improvements	2019 12 O
,	2031 1 O
such	2033 4 O
as	2038 2 O
those	2041 5 O
on	2047 2 O
the	2050 3 O
ipsilateral	2054 11 O
side	2066 4 O
and	2071 3 O
in	2075 2 O
axial	2078 5 O
symptoms	2084 8 O
,	2092 1 O
wane	2094 4 O
within	2099 6 O
the	2106 3 O
first	2110 5 O
year	2116 4 O
.	2120 1 O

The	2122 3 O
on	2126 2 O
-	2128 1 O
period	2129 6 O
symptoms	2136 8 O
that	2145 4 O
are	2150 3 O
resistant	2154 9 O
to	2164 2 O
dopaminergic	2167 12 O
therapy	2180 7 O
do	2188 2 O
not	2191 3 O
respond	2195 7 O
to	2203 2 O
pallidotomy	2206 11 O
.	2217 1 O

Neuropeptide	0 12 O
-	12 1 O
Y	13 1 O
immunoreactivity	15 16 O
in	32 2 O
the	35 3 O
pilocarpine	39 11 B-Chemical
model	51 5 O
of	57 2 O
temporal	60 8 B-Disease
lobe	69 4 I-Disease
epilepsy	74 8 I-Disease
.	82 1 O

Neuropeptide	84 12 O
-	96 1 O
Y	97 1 O
(	99 1 O
NPY	100 3 O
)	103 1 O
is	105 2 O
expressed	108 9 O
by	118 2 O
granule	121 7 O
cells	129 5 O
and	135 3 O
mossy	139 5 O
fibres	145 6 O
of	152 2 O
the	155 3 O
hippocampal	159 11 O
dentate	171 7 O
gyrus	179 5 O
during	185 6 O
experimental	192 12 O
temporal	205 8 B-Disease
lobe	214 4 I-Disease
epilepsy	219 8 I-Disease
(	228 1 O
TLE	229 3 B-Disease
)	232 1 O
.	233 1 O

This	235 4 O
expression	240 10 O
may	251 3 O
represent	255 9 O
an	265 2 O
endogenous	268 10 O
damping	279 7 O
mechanism	287 9 O
since	297 5 O
NPY	303 3 O
has	307 3 O
been	311 4 O
shown	316 5 O
to	322 2 O
block	325 5 O
seizure	331 7 B-Disease
-	338 1 O
like	339 4 O
events	344 6 O
following	351 9 O
high	361 4 O
-	365 1 O
frequency	366 9 O
stimulation	376 11 O
in	388 2 O
hippocampal	391 11 O
slices	403 6 O
.	409 1 O

The	411 3 O
pilocarpine	415 11 B-Chemical
(	427 1 O
PILO	428 4 B-Chemical
)	432 1 O
model	434 5 O
of	440 2 O
epilepsy	443 8 B-Disease
is	452 2 O
characterized	455 13 O
by	469 2 O
an	472 2 O
acute	475 5 O
period	481 6 O
of	488 2 O
status	491 6 B-Disease
epilepticus	498 11 I-Disease
followed	510 8 O
by	519 2 O
spontaneous	522 11 O
recurrent	534 9 O
seizures	544 8 B-Disease
and	553 3 O
related	557 7 O
brain	565 5 B-Disease
damage	571 6 I-Disease
.	577 1 O

We	579 2 O
report	582 6 O
peroxidase	589 10 O
-	599 1 O
antiperoxidase	600 14 O
immunostaining	615 14 O
for	630 3 O
NPY	634 3 O
in	638 2 O
several	641 7 O
brain	649 5 O
regions	655 7 O
in	663 2 O
this	666 4 O
model	671 5 O
.	676 1 O

PILO	678 4 B-Chemical
-	682 1 O
injected	683 8 O
animals	692 7 O
exhibited	700 9 O
NPY	710 3 O
immunoreactivity	714 16 O
in	731 2 O
the	734 3 O
region	738 6 O
of	745 2 O
the	748 3 O
mossy	752 5 O
fibre	758 5 O
terminals	764 9 O
,	773 1 O
in	775 2 O
the	778 3 O
dentate	782 7 O
gyrus	790 5 O
inner	796 5 O
molecular	802 9 O
layer	812 5 O
and	818 3 O
,	821 1 O
in	823 2 O
a	826 1 O
few	828 3 O
cases	832 5 O
,	837 1 O
within	839 6 O
presumed	846 8 O
granule	855 7 O
cells	863 5 O
.	868 1 O

NPY	870 3 O
immunoreactivity	874 16 O
was	891 3 O
also	895 4 O
dramatically	900 12 O
changed	913 7 O
in	921 2 O
the	924 3 O
entorhinal	928 10 O
cortex	939 6 O
,	945 1 O
amygdala	947 8 O
and	956 3 O
sensorimotor	960 12 O
areas	973 5 O
.	978 1 O

In	980 2 O
addition	983 8 O
,	991 1 O
PILO	993 4 B-Chemical
injected	998 8 O
animals	1007 7 O
exhibited	1015 9 O
a	1025 1 O
reduction	1027 9 O
in	1037 2 O
the	1040 3 O
number	1044 6 O
of	1051 2 O
NPY	1054 3 O
-	1057 1 O
immunoreactive	1058 14 O
interneurons	1073 12 O
compared	1086 8 O
with	1095 4 O
controls	1100 8 O
.	1108 1 O

The	1110 3 O
results	1114 7 O
demonstrate	1122 11 O
that	1134 4 O
changes	1139 7 O
in	1147 2 O
NPY	1150 3 O
expression	1154 10 O
,	1164 1 O
including	1166 9 O
expression	1176 10 O
in	1187 2 O
the	1190 3 O
granule	1194 7 O
cells	1202 5 O
and	1208 3 O
mossy	1212 5 O
fibres	1218 6 O
and	1225 3 O
the	1229 3 O
loss	1233 4 O
of	1238 2 O
vulnerable	1241 10 O
NPY	1252 3 O
neurons	1256 7 O
,	1263 1 O
are	1265 3 O
present	1269 7 O
in	1277 2 O
the	1280 3 O
PILO	1284 4 B-Chemical
model	1289 5 O
of	1295 2 O
TLE	1298 3 B-Disease
.	1301 1 O

However	1303 7 O
,	1310 1 O
the	1312 3 O
significance	1316 12 O
of	1329 2 O
this	1332 4 O
changed	1337 7 O
synthesis	1345 9 O
of	1355 2 O
NPY	1358 3 O
remains	1362 7 O
to	1370 2 O
be	1373 2 O
determined	1376 10 O
.	1386 1 O

Effect	0 6 O
of	7 2 O
myopic	10 6 O
excimer	17 7 O
laser	25 5 O
photorefractive	31 15 O
keratectomy	47 11 O
on	59 2 O
the	62 3 O
electrophysiologic	66 18 O
function	85 8 O
of	94 2 O
the	97 3 O
retina	101 6 O
and	108 3 O
optic	112 5 O
nerve	118 5 O
.	123 1 O

PURPOSE	125 7 O
:	132 1 O
To	134 2 O
assess	137 6 O
by	144 2 O
electrophysiologic	147 18 O
testing	166 7 O
the	174 3 O
effect	178 6 O
of	185 2 O
photorefractive	188 15 O
keratectomy	204 11 O
(	216 1 O
PRK	217 3 O
)	220 1 O
on	222 2 O
the	225 3 O
retina	229 6 O
and	236 3 O
optic	240 5 O
nerve	246 5 O
.	251 1 O

SETTING	253 7 O
:	260 1 O
Eye	262 3 O
Clinic	266 6 O
,	272 1 O
S	274 1 O
.	275 1 O

Salvatore	277 9 O
Hospital	287 8 O
,	295 1 O
L	297 1 O
'	298 1 O
Aquila	299 6 O
University	306 10 O
,	316 1 O
Italy	318 5 O
.	323 1 O

METHODS	325 7 O
:	332 1 O
Standard	334 8 O
pattern	343 7 O
electroretinograms	351 18 O
(	370 1 O
P	371 1 O
-	372 1 O
ERGs	373 4 O
)	377 1 O
and	379 3 O
standard	383 8 O
pattern	392 7 O
visual	400 6 O
evoked	407 6 O
potentials	414 10 O
(	425 1 O
P	426 1 O
-	427 1 O
VEPs	428 4 O
)	432 1 O
were	434 4 O
done	439 4 O
in	444 2 O
25	447 2 O
eyes	450 4 O
of	455 2 O
25	458 2 O
patients	461 8 O
who	470 3 O
had	474 3 O
myopic	478 6 O
PRK	485 3 O
for	489 3 O
an	493 2 O
attempted	496 9 O
correction	506 10 O
between	517 7 O
5	525 1 O
.	526 1 O
00	527 2 O
and	530 3 O
15	534 2 O
.	536 1 O
00	537 2 O
diopters	540 8 O
(	549 1 O
D	550 1 O
)	551 1 O
(	553 1 O
mean	554 4 O
8	559 1 O
.	560 1 O
00	561 2 O
D	564 1 O
)	565 1 O
.	566 1 O

Testing	568 7 O
was	576 3 O
done	580 4 O
preoperatively	585 14 O
and	600 3 O
3	604 1 O
,	605 1 O
6	607 1 O
,	608 1 O
12	610 2 O
,	612 1 O
and	614 3 O
18	618 2 O
months	621 6 O
postoperatively	628 15 O
.	643 1 O

The	645 3 O
contralateral	649 13 O
eyes	663 4 O
served	668 6 O
as	675 2 O
controls	678 8 O
.	686 1 O

During	688 6 O
the	695 3 O
follow	699 6 O
-	705 1 O
up	706 2 O
,	708 1 O
3	710 1 O
patients	712 8 O
(	721 1 O
12	722 2 O
%	724 1 O
)	725 1 O
developed	727 9 O
steroid	737 7 B-Chemical
-	744 1 O
induced	745 7 O
elevated	753 8 B-Disease
intraocular	762 11 I-Disease
pressure	774 8 I-Disease
(	783 1 O
IOP	784 3 O
)	787 1 O
that	789 4 O
resolved	794 8 O
after	803 5 O
corticosteroid	809 14 B-Chemical
therapy	824 7 O
was	832 3 O
discontinued	836 12 O
.	848 1 O

RESULTS	850 7 O
:	857 1 O
No	859 2 O
statistically	862 13 O
significant	876 11 O
differences	888 11 O
were	900 4 O
seen	905 4 O
between	910 7 O
treated	918 7 O
and	926 3 O
control	930 7 O
eyes	938 4 O
nor	943 3 O
between	947 7 O
treated	955 7 O
eyes	963 4 O
preoperatively	968 14 O
and	983 3 O
postoperatively	987 15 O
.	1002 1 O

CONCLUSION	1004 10 O
:	1014 1 O
Myopic	1016 6 O
excimer	1023 7 O
laser	1031 5 O
PRK	1037 3 O
did	1041 3 O
not	1045 3 O
seem	1049 4 O
to	1054 2 O
affect	1057 6 O
the	1064 3 O
posterior	1068 9 O
segment	1078 7 O
.	1085 1 O

The	1087 3 O
transient	1091 9 O
steroid	1101 7 B-Chemical
-	1108 1 O
induced	1109 7 O
IOP	1117 3 B-Disease
rise	1121 4 I-Disease
did	1126 3 O
not	1130 3 O
seem	1134 4 O
to	1139 2 O
cause	1142 5 O
functional	1148 10 O
impairment	1159 10 O
.	1169 1 O

Liposomal	0 9 O
daunorubicin	10 12 B-Chemical
in	23 2 O
advanced	26 8 O
Kaposi	35 6 B-Disease
'	41 1 I-Disease
s	42 1 I-Disease
sarcoma	44 7 I-Disease
:	51 1 O
a	53 1 O
phase	55 5 O
II	61 2 O
study	64 5 O
.	69 1 O

We	71 2 O
report	74 6 O
a	81 1 O
non	83 3 O
-	86 1 O
randomized	87 10 O
Phase	98 5 O
II	104 2 O
clinical	107 8 O
trial	116 5 O
to	122 2 O
assess	125 6 O
the	132 3 O
efficacy	136 8 O
and	145 3 O
safety	149 6 O
of	156 2 O
liposomal	159 9 O
daunorubicin	169 12 B-Chemical
(	182 1 O
DaunoXome	183 9 O
)	192 1 O
in	194 2 O
the	197 3 O
treatment	201 9 O
of	211 2 O
AIDS	214 4 B-Disease
related	219 7 O
Kaposi	227 6 B-Disease
'	233 1 I-Disease
s	234 1 I-Disease
sarcoma	236 7 I-Disease
.	243 1 O

Eleven	245 6 O
homosexual	252 10 O
men	263 3 O
with	267 4 O
advanced	272 8 O
Kaposi	281 6 B-Disease
'	287 1 I-Disease
s	288 1 I-Disease
sarcoma	290 7 I-Disease
were	298 4 O
entered	303 7 O
in	311 2 O
the	314 3 O
trial	318 5 O
.	323 1 O

Changes	325 7 O
in	333 2 O
size	336 4 O
,	340 1 O
colour	342 6 O
and	349 3 O
associated	353 10 O
oedema	364 6 B-Disease
of	371 2 O
selected	374 8 O
'	383 1 O
target	384 6 O
'	390 1 O
lesions	392 7 O
were	400 4 O
measured	405 8 O
.	413 1 O

Clinical	415 8 O
,	423 1 O
biochemical	425 11 O
and	437 3 O
haematological	441 14 O
toxicities	456 10 B-Disease
were	467 4 O
assessed	472 8 O
.	480 1 O

Ten	482 3 O
subjects	486 8 O
were	495 4 O
evaluated	500 9 O
.	509 1 O

A	511 1 O
partial	513 7 O
response	521 8 O
was	530 3 O
achieved	534 8 O
in	543 2 O
four	546 4 O
,	550 1 O
of	552 2 O
whom	555 4 O
two	560 3 O
subsequently	564 12 O
relapsed	577 8 O
.	585 1 O

Stabilization	587 13 O
of	601 2 O
Kaposi	604 6 B-Disease
'	610 1 I-Disease
s	611 1 I-Disease
sarcoma	613 7 I-Disease
occurred	621 8 O
in	630 2 O
the	633 3 O
remaining	637 9 O
six	647 3 O
,	650 1 O
maintained	652 10 O
until	663 5 O
the	669 3 O
end	673 3 O
of	677 2 O
the	680 3 O
trial	684 5 O
period	690 6 O
in	697 2 O
four	700 4 O
.	704 1 O

The	706 3 O
drug	710 4 O
was	715 3 O
generally	719 9 O
well	729 4 O
tolerated	734 9 O
,	743 1 O
with	745 4 O
few	750 3 O
mild	754 4 O
symptoms	759 8 O
of	768 2 O
toxicity	771 8 B-Disease
.	779 1 O

The	781 3 O
main	785 4 O
problem	790 7 O
encountered	798 11 O
was	810 3 O
haematological	814 14 O
toxicity	829 8 B-Disease
,	837 1 O
with	839 4 O
three	844 5 O
subjects	850 8 O
experiencing	859 12 O
severe	872 6 O
neutropenia	879 11 B-Disease
(	891 1 O
neutrophil	892 10 O
count	903 5 O
<	909 1 O
0	911 1 O
.	912 1 O
5	913 1 O
x	915 1 O
10	917 2 O
(	919 1 O
9	920 1 O
)	921 1 O
/	922 1 O
l	923 1 O
)	924 1 O
.	925 1 O

There	927 5 O
was	933 3 O
no	937 2 O
evidence	940 8 O
of	949 2 O
cardiotoxicity	952 14 B-Disease
.	966 1 O

In	968 2 O
this	971 4 O
small	976 5 O
patient	982 7 O
sample	990 6 O
,	996 1 O
liposomal	998 9 O
daunorubicin	1008 12 B-Chemical
was	1021 3 O
an	1025 2 O
effective	1028 9 O
and	1038 3 O
well	1042 4 O
tolerated	1047 9 O
agent	1057 5 O
in	1063 2 O
the	1066 3 O
treatment	1070 9 O
of	1080 2 O
Kaposi	1083 6 B-Disease
'	1089 1 I-Disease
s	1090 1 I-Disease
sarcoma	1092 7 I-Disease
.	1099 1 O

Failure	0 7 O
of	8 2 O
ancrod	11 6 O
in	18 2 O
the	21 3 O
treatment	25 9 O
of	35 2 O
heparin	38 7 B-Chemical
-	45 1 O
induced	46 7 O
arterial	54 8 O
thrombosis	63 10 B-Disease
.	73 1 O

The	75 3 O
morbidity	79 9 O
and	89 3 O
mortality	93 9 O
associated	103 10 O
with	114 4 O
heparin	119 7 B-Chemical
-	126 1 O
induced	127 7 O
thrombosis	135 10 B-Disease
remain	146 6 O
high	153 4 O
despite	158 7 O
numerous	166 8 O
empirical	175 9 O
therapies	185 9 O
.	194 1 O

Ancrod	196 6 O
has	203 3 O
been	207 4 O
used	212 4 O
successfully	217 12 O
for	230 3 O
prophylaxis	234 11 O
against	246 7 O
development	254 11 O
of	266 2 O
thrombosis	269 10 B-Disease
in	280 2 O
patients	283 8 O
with	292 4 O
heparin	297 7 B-Chemical
induced	305 7 O
platelet	313 8 B-Disease
aggregation	322 11 I-Disease
who	334 3 O
require	338 7 O
brief	346 5 O
reexposure	352 10 O
to	363 2 O
heparin	366 7 B-Chemical
,	373 1 O
but	375 3 O
its	379 3 O
success	383 7 O
in	391 2 O
patients	394 8 O
who	403 3 O
have	407 4 O
developed	412 9 O
the	422 3 O
thrombosis	426 10 B-Disease
syndrome	437 8 O
is	446 2 O
not	449 3 O
well	453 4 O
defined	458 7 O
.	465 1 O

The	467 3 O
authors	471 7 O
present	479 7 O
a	487 1 O
case	489 4 O
of	494 2 O
failure	497 7 O
of	505 2 O
ancrod	508 6 O
treatment	515 9 O
in	525 2 O
a	528 1 O
patient	530 7 O
with	538 4 O
heparin	543 7 B-Chemical
-	550 1 O
induced	551 7 O
thrombosis	559 10 B-Disease
.	569 1 O

Seizure	0 7 B-Disease
after	8 5 O
flumazenil	14 10 B-Chemical
administration	25 14 O
in	40 2 O
a	43 1 O
pediatric	45 9 O
patient	55 7 O
.	62 1 O

Flumazenil	64 10 B-Chemical
is	75 2 O
a	78 1 O
benzodiazepine	80 14 B-Chemical
receptor	95 8 O
antagonist	104 10 O
used	115 4 O
to	120 2 O
reverse	123 7 O
sedation	131 8 O
and	140 3 O
respiratory	144 11 B-Disease
depression	156 10 I-Disease
induced	167 7 O
by	175 2 O
benzodiazepines	178 15 B-Chemical
.	193 1 O

Seizures	195 8 B-Disease
and	204 3 O
cardiac	208 7 B-Disease
arrhythmias	216 11 I-Disease
have	228 4 O
complicated	233 11 O
its	245 3 O
use	249 3 O
in	253 2 O
adult	256 5 O
patients	262 8 O
.	270 1 O

Overdose	272 8 B-Disease
patients	281 8 O
who	290 3 O
have	294 4 O
coingested	299 10 O
tricyclic	310 9 O
antidepressants	320 15 O
have	336 4 O
a	341 1 O
higher	343 6 O
risk	350 4 O
of	355 2 O
these	358 5 O
complications	364 13 O
.	377 1 O

Little	379 6 O
information	386 11 O
exists	398 6 O
concerning	405 10 O
adverse	416 7 O
effects	424 7 O
of	432 2 O
flumazenil	435 10 B-Chemical
in	446 2 O
children	449 8 O
.	457 1 O

We	459 2 O
report	462 6 O
the	469 3 O
occurrence	473 10 O
of	484 2 O
a	487 1 O
generalized	489 11 O
tonic	501 5 B-Disease
-	506 1 I-Disease
clonic	507 6 I-Disease
seizure	514 7 I-Disease
in	522 2 O
a	525 1 O
pediatric	527 9 O
patient	537 7 O
following	545 9 O
the	555 3 O
administration	559 14 O
of	574 2 O
flumazenil	577 10 B-Chemical
.	587 1 O

Remodelling	0 11 O
of	12 2 O
nerve	15 5 O
structure	21 9 O
in	31 2 O
experimental	34 12 O
isoniazid	47 9 B-Chemical
neuropathy	57 10 B-Disease
in	68 2 O
the	71 3 O
rat	75 3 O
.	78 1 O

The	80 3 O
neuropathy	84 10 B-Disease
caused	95 6 O
by	102 2 O
a	105 1 O
single	107 6 O
dose	114 4 O
of	119 2 O
isoniazid	122 9 B-Chemical
in	132 2 O
rats	135 4 O
was	140 3 O
studied	144 7 O
with	152 4 O
a	157 1 O
computer	159 8 O
-	167 1 O
assisted	168 8 O
morphometric	177 12 O
method	190 6 O
.	196 1 O

Scatter	198 7 O
diagrams	206 8 O
of	215 2 O
the	218 3 O
g	222 1 O
ratio	224 5 O
(	230 1 O
quotient	231 8 O
fibre	240 5 O
diameter	246 8 O
/	254 1 O
axon	255 4 O
diameter	260 8 O
)	268 1 O
define	270 6 O
regenerating	277 12 O
fibres	290 6 O
as	297 2 O
a	300 1 O
distinct	302 8 O
population	311 10 O
,	321 1 O
distinguishable	323 15 O
from	339 4 O
the	344 3 O
surviving	348 9 O
fibres	358 6 O
by	365 2 O
reduced	368 7 O
sheath	376 6 O
thickness	383 9 O
and	393 3 O
reduced	397 7 O
axon	405 4 O
calibre	410 7 O
.	417 1 O

There	419 5 O
was	425 3 O
also	429 4 O
evidence	434 8 O
of	443 2 O
a	446 1 O
subtle	448 6 O
direct	455 6 O
toxic	462 5 O
effect	468 6 O
on	475 2 O
the	478 3 O
entire	482 6 O
fibre	489 5 O
population	495 10 O
,	505 1 O
causing	507 7 O
axon	515 4 O
shrinkage	520 9 O
masked	530 6 O
by	537 2 O
readjustment	540 12 O
of	553 2 O
the	556 3 O
myelin	560 6 O
sheath	567 6 O
.	573 1 O

Selective	0 9 O
injection	10 9 O
of	20 2 O
iopentol	23 8 B-Chemical
,	31 1 O
iohexol	33 7 B-Chemical
and	41 3 O
metrizoate	45 10 B-Chemical
into	56 4 O
the	61 3 O
left	65 4 O
coronary	70 8 O
artery	79 6 O
of	86 2 O
the	89 3 O
dog	93 3 O
.	96 1 O

Induction	98 9 O
of	108 2 O
ventricular	111 11 B-Disease
fibrillation	123 12 I-Disease
and	136 3 O
decrease	140 8 O
of	149 2 O
aortic	152 6 O
pressure	159 8 O
.	167 1 O

In	169 2 O
twenty	172 6 O
beagle	179 6 O
dogs	186 4 O
selective	191 9 O
injections	201 10 O
were	212 4 O
made	217 4 O
into	222 4 O
the	227 3 O
left	231 4 O
coronary	236 8 O
artery	245 6 O
with	252 4 O
iopentol	257 8 B-Chemical
,	265 1 O
iohexol	267 7 B-Chemical
and	275 3 O
metrizoate	279 10 B-Chemical
in	290 2 O
doses	293 5 O
of	299 2 O
4	302 1 O
ml	304 2 O
,	306 1 O
8	308 1 O
ml	310 2 O
and	313 3 O
16	317 2 O
ml	320 2 O
.	322 1 O

Thirty	324 6 O
-	330 1 O
six	331 3 O
iopentol	335 8 B-Chemical
injections	344 10 O
,	354 1 O
35	356 2 O
iohexol	359 7 B-Chemical
injections	367 10 O
and	378 3 O
37	382 2 O
metrizoate	385 10 B-Chemical
injections	396 10 O
were	407 4 O
made	412 4 O
.	416 1 O

Frequencies	418 11 O
of	430 2 O
ventricular	433 11 B-Disease
fibrillation	445 12 I-Disease
were	458 4 O
significantly	463 13 O
lower	477 5 O
(	483 1 O
p	484 1 O
less	486 4 O
than	491 4 O
0	496 1 O
.	497 1 O
05	498 2 O
)	500 1 O
after	502 5 O
iopentol	508 8 B-Chemical
(	517 1 O
0	518 1 O
%	519 1 O
)	520 1 O
and	522 3 O
iohexol	526 7 B-Chemical
(	534 1 O
3	535 1 O
%	536 1 O
)	537 1 O
than	539 4 O
after	544 5 O
metrizoate	550 10 B-Chemical
(	561 1 O
22	562 2 O
%	564 1 O
)	565 1 O
.	566 1 O

Iopentol	568 8 B-Chemical
and	577 3 O
iohexol	581 7 B-Chemical
also	589 4 O
produced	594 8 O
significantly	603 13 O
less	617 4 O
decrease	622 8 O
in	631 2 O
aortic	634 6 O
blood	641 5 O
pressure	647 8 O
than	656 4 O
metrizoate	661 10 B-Chemical
at	672 2 O
the	675 3 O
different	679 9 O
doses	689 5 O
.	694 1 O

Magnetic	0 8 O
resonance	9 9 O
imaging	19 7 O
of	27 2 O
cerebral	30 8 O
venous	39 6 B-Disease
thrombosis	46 10 I-Disease
secondary	57 9 O
to	67 2 O
"	70 1 O
low	71 3 O
-	74 1 O
dose	75 4 O
"	79 1 O
birth	81 5 O
control	87 7 O
pills	95 5 O
.	100 1 O

The	102 3 O
clinical	106 8 O
and	115 3 O
radiographic	119 12 O
features	132 8 O
of	141 2 O
cerebral	144 8 O
deep	153 4 B-Disease
venous	158 6 I-Disease
thrombosis	165 10 I-Disease
in	176 2 O
a	179 1 O
21	181 2 O
-	183 1 O
year	184 4 O
-	188 1 O
old	189 3 O
white	193 5 O
woman	199 5 O
are	205 3 O
presented	209 9 O
.	218 1 O

This	220 4 O
nulliparous	225 11 O
patient	237 7 O
presented	245 9 O
with	255 4 O
relatively	260 10 O
mild	271 4 O
clinical	276 8 O
symptoms	285 8 O
and	294 3 O
progressing	298 11 O
mental	310 6 O
status	317 6 O
changes	324 7 O
.	331 1 O

The	333 3 O
only	337 4 O
known	342 5 O
risk	348 4 O
factor	353 6 O
was	360 3 O
"	364 1 O
low	365 3 O
-	368 1 O
dose	369 4 O
"	373 1 O
oral	375 4 B-Chemical
contraceptive	380 13 I-Chemical
pills	394 5 O
.	399 1 O

The	401 3 O
magnetic	405 8 O
resonance	414 9 O
image	424 5 O
(	430 1 O
MRI	431 3 O
)	434 1 O
showed	436 6 O
increased	443 9 O
signal	453 6 O
intensity	460 9 O
from	470 4 O
the	475 3 O
internal	479 8 O
cerebral	488 8 O
veins	497 5 O
,	502 1 O
vein	504 4 O
of	509 2 O
Galen	512 5 O
,	517 1 O
and	519 3 O
straight	523 8 O
sinus	532 5 O
.	537 1 O

The	539 3 O
diagnosis	543 9 O
was	553 3 O
confirmed	557 9 O
by	567 2 O
arterial	570 8 O
angiography	579 11 O
.	590 1 O

Relation	0 8 O
of	9 2 O
perfusion	12 9 O
defects	22 7 O
observed	30 8 O
with	39 4 O
myocardial	44 10 O
contrast	55 8 O
echocardiography	64 16 O
to	81 2 O
the	84 3 O
severity	88 8 O
of	97 2 O
coronary	100 8 B-Disease
stenosis	109 8 I-Disease
:	117 1 O
correlation	119 11 O
with	131 4 O
thallium	136 8 B-Chemical
-	144 1 O
201	145 3 O
single	149 6 O
-	155 1 O
photon	156 6 O
emission	163 8 O
tomography	172 10 O
.	182 1 O

It	184 2 O
has	187 3 O
been	191 4 O
previously	196 10 O
shown	207 5 O
that	213 4 O
myocardial	218 10 O
contrast	229 8 O
echocardiography	238 16 O
is	255 2 O
a	258 1 O
valuable	260 8 O
technique	269 9 O
for	279 3 O
delineating	283 11 O
regions	295 7 O
of	303 2 O
myocardial	306 10 O
underperfusion	317 14 O
secondary	332 9 O
to	342 2 O
coronary	345 8 B-Disease
occlusion	354 9 I-Disease
and	364 3 O
to	368 2 O
critical	371 8 O
coronary	380 8 B-Disease
stenoses	389 8 I-Disease
in	398 2 O
the	401 3 O
presence	405 8 O
of	414 2 O
hyperemic	417 9 B-Disease
stimulation	427 11 O
.	438 1 O

The	440 3 O
aim	444 3 O
of	448 2 O
this	451 4 O
study	456 5 O
was	462 3 O
to	466 2 O
determine	469 9 O
whether	479 7 O
myocardial	487 10 O
contrast	498 8 O
echocardiography	507 16 O
performed	524 9 O
with	534 4 O
a	539 1 O
stable	541 6 O
solution	548 8 O
of	557 2 O
sonicated	560 9 O
albumin	570 7 O
could	578 5 O
detect	584 6 O
regions	591 7 O
of	599 2 O
myocardial	602 10 O
underperfusion	613 14 O
resulting	628 9 O
from	638 4 O
various	643 7 O
degrees	651 7 O
of	659 2 O
coronary	662 8 B-Disease
stenosis	671 8 I-Disease
.	679 1 O

The	681 3 O
perfusion	685 9 O
defect	695 6 O
produced	702 8 O
in	711 2 O
16	714 2 O
open	717 4 O
chest	722 5 O
dogs	728 4 O
was	733 3 O
compared	737 8 O
with	746 4 O
the	751 3 O
anatomic	755 8 O
area	764 4 O
at	769 2 O
risk	772 4 O
measured	777 8 O
by	786 2 O
the	789 3 O
postmortem	793 10 O
dual	804 4 O
-	808 1 O
perfusion	809 9 O
technique	819 9 O
and	829 3 O
with	833 4 O
thallium	838 8 B-Chemical
-	846 1 O
201	847 3 O
single	851 6 O
-	857 1 O
photon	858 6 O
emission	865 8 O
tomography	874 10 O
(	885 1 O
SPECT	886 5 O
)	891 1 O
.	892 1 O

During	894 6 O
a	901 1 O
transient	903 9 O
(	913 1 O
20	914 2 O
-	916 1 O
s	917 1 O
)	918 1 O
coronary	920 8 B-Disease
occlusion	929 9 I-Disease
,	938 1 O
a	940 1 O
perfusion	942 9 O
defect	952 6 O
was	959 3 O
observed	963 8 O
with	972 4 O
contrast	977 8 O
echocardiography	986 16 O
in	1003 2 O
14	1006 2 O
of	1009 2 O
the	1012 3 O
15	1016 2 O
dogs	1019 4 O
in	1024 2 O
which	1027 5 O
the	1033 3 O
occlusion	1037 9 O
was	1047 3 O
produced	1051 8 O
.	1059 1 O

The	1061 3 O
perfusion	1065 9 O
defect	1075 6 O
correlated	1082 10 O
significantly	1093 13 O
with	1107 4 O
the	1112 3 O
anatomic	1116 8 O
area	1125 4 O
at	1130 2 O
risk	1133 4 O
(	1138 1 O
r	1139 1 O
=	1141 1 O
0	1143 1 O
.	1144 1 O
74	1145 2 O
;	1147 1 O
p	1149 1 O
less	1151 4 O
than	1156 4 O
0	1161 1 O
.	1162 1 O
002	1163 3 O
)	1166 1 O
.	1167 1 O

During	1169 6 O
dipyridamole	1176 12 B-Chemical
-	1188 1 O
induced	1189 7 O
hyperemia	1197 9 B-Disease
,	1206 1 O
12	1208 2 O
of	1211 2 O
the	1214 3 O
16	1218 2 O
dogs	1221 4 O
with	1226 4 O
a	1231 1 O
partial	1233 7 O
coronary	1241 8 B-Disease
stenosis	1250 8 I-Disease
had	1259 3 O
a	1263 1 O
visible	1265 7 O
area	1273 4 O
of	1278 2 O
hypoperfusion	1281 13 O
by	1295 2 O
contrast	1298 8 O
echocardiography	1307 16 O
.	1323 1 O

The	1325 3 O
four	1329 4 O
dogs	1334 4 O
without	1339 7 O
a	1347 1 O
perfusion	1349 9 O
defect	1359 6 O
had	1366 3 O
a	1370 1 O
stenosis	1372 8 O
that	1381 4 O
resulted	1386 8 O
in	1395 2 O
a	1398 1 O
mild	1400 4 O
(	1405 1 O
0	1406 1 O
%	1407 1 O
to	1409 2 O
50	1412 2 O
%	1414 1 O
)	1415 1 O
reduction	1417 9 O
in	1427 2 O
dipyridamole	1430 12 B-Chemical
-	1442 1 O
induced	1443 7 O
hyperemia	1451 9 B-Disease
.	1460 1 O

The	1462 3 O
size	1466 4 O
of	1471 2 O
the	1474 3 O
perfusion	1478 9 O
defect	1488 6 O
during	1495 6 O
stenosis	1502 8 O
correlated	1511 10 O
significantly	1522 13 O
with	1536 4 O
the	1541 3 O
anatomic	1545 8 O
area	1554 4 O
at	1559 2 O
risk	1562 4 O
(	1567 1 O
r	1568 1 O
=	1570 1 O
0	1572 1 O
.	1573 1 O
61	1574 2 O
;	1576 1 O
p	1578 1 O
=	1580 1 O
0	1582 1 O
.	1583 1 O
02	1584 2 O
)	1586 1 O
.	1587 1 O

Thallium	1589 8 B-Chemical
-	1597 1 O
201	1598 3 O
SPECT	1602 5 O
demonstrated	1608 12 O
a	1621 1 O
perfusion	1623 9 O
defect	1633 6 O
in	1640 2 O
all	1643 3 O
14	1647 2 O
dogs	1650 4 O
analyzed	1655 8 O
during	1664 6 O
dipyridamole	1671 12 B-Chemical
-	1683 1 O
induced	1684 7 O
hyperemia	1692 9 B-Disease
;	1701 1 O
the	1703 3 O
size	1707 4 O
of	1712 2 O
the	1715 3 O
perfusion	1719 9 O
defect	1729 6 O
correlated	1736 10 O
with	1747 4 O
the	1752 3 O
anatomic	1756 8 O
area	1765 4 O
at	1770 2 O
risk	1773 4 O
(	1778 1 O
r	1779 1 O
=	1781 1 O
0	1783 1 O
.	1784 1 O
58	1785 2 O
;	1787 1 O
p	1789 1 O
less	1791 4 O
than	1796 4 O
0	1801 1 O
.	1802 1 O
03	1803 2 O
)	1805 1 O
and	1807 3 O
with	1811 4 O
the	1816 3 O
perfusion	1820 9 O
defect	1830 6 O
by	1837 2 O
contrast	1840 8 O
echocardiography	1849 16 O
(	1866 1 O
r	1867 1 O
=	1869 1 O
0	1871 1 O
.	1872 1 O
58	1873 2 O
;	1875 1 O
p	1877 1 O
less	1879 4 O
than	1884 4 O
0	1889 1 O
.	1890 1 O
03	1891 2 O
)	1893 1 O
.	1894 1 O

Thus	1896 4 O
,	1900 1 O
myocardial	1902 10 O
contrast	1913 8 O
echocardiography	1922 16 O
can	1939 3 O
be	1943 2 O
used	1946 4 O
to	1951 2 O
visualize	1954 9 O
and	1964 3 O
quantitate	1968 10 O
the	1979 3 O
amount	1983 6 O
of	1990 2 O
jeopardized	1993 11 O
myocardium	2005 10 O
during	2016 6 O
moderate	2023 8 O
to	2032 2 O
severe	2035 6 O
degrees	2042 7 O
of	2050 2 O
coronary	2053 8 B-Disease
stenosis	2062 8 I-Disease
.	2070 1 O

The	2072 3 O
results	2076 7 O
obtained	2084 8 O
show	2093 4 O
a	2098 1 O
correlation	2100 11 O
with	2112 4 O
the	2117 3 O
anatomic	2121 8 O
area	2130 4 O
at	2135 2 O
risk	2138 4 O
similar	2143 7 O
to	2151 2 O
that	2154 4 O
obtained	2159 8 O
with	2168 4 O
thallium	2173 8 B-Chemical
-	2181 1 O
201	2182 3 O
SPECT	2186 5 O
.	2191 1 O

Potential	0 9 O
deleterious	10 11 O
effect	22 6 O
of	29 2 O
furosemide	32 10 B-Chemical
in	43 2 O
radiocontrast	46 13 O
nephropathy	60 11 B-Disease
.	71 1 O

The	73 3 O
purpose	77 7 O
of	85 2 O
the	88 3 O
study	92 5 O
was	98 3 O
to	102 2 O
determine	105 9 O
the	115 3 O
efficacy	119 8 O
of	128 2 O
furosemide	131 10 B-Chemical
in	142 2 O
addition	145 8 O
to	154 2 O
intravenous	157 11 O
fluids	169 6 O
in	176 2 O
the	179 3 O
prevention	183 10 O
of	194 2 O
radiocontrast	197 13 O
nephropathy	211 11 B-Disease
.	222 1 O

18	224 2 O
patients	227 8 O
,	235 1 O
referred	237 8 O
to	246 2 O
a	249 1 O
radiocontrast	251 13 O
study	265 5 O
,	270 1 O
considered	272 10 O
at	283 2 O
risk	286 4 O
because	291 7 O
of	299 2 O
preexisting	302 11 O
renal	314 5 B-Disease
insufficiency	320 13 I-Disease
,	333 1 O
were	335 4 O
enrolled	340 8 O
in	349 2 O
a	352 1 O
prospective	354 11 O
,	365 1 O
randomized	367 10 O
,	377 1 O
controlled	379 10 O
trial	390 5 O
,	395 1 O
performed	397 9 O
at	407 2 O
the	410 3 O
secondary	414 9 O
care	424 4 O
center	429 6 O
of	436 2 O
a	439 1 O
1	441 1 O
,	442 1 O
100	443 3 O
-	446 1 O
bed	447 3 O
private	451 7 O
university	459 10 O
hospital	470 8 O
.	478 1 O

In	480 2 O
addition	483 8 O
to	492 2 O
fluids	495 6 O
,	501 1 O
the	503 3 O
treatment	507 9 O
group	517 5 O
received	523 8 O
furosemide	532 10 B-Chemical
(	543 1 O
mean	544 4 O
dose	549 4 O
110	554 3 O
mg	558 2 O
)	560 1 O
intravenously	562 13 O
30	576 2 O
min	579 3 O
prior	583 5 O
to	589 2 O
the	592 3 O
injection	596 9 O
of	606 2 O
contrast	609 8 O
material	618 8 O
.	626 1 O

The	628 3 O
control	632 7 O
group	640 5 O
received	646 8 O
fluids	655 6 O
(	662 1 O
mean	663 4 O
3	668 1 O
liters	670 6 O
)	676 1 O
.	677 1 O

Radiological	679 12 O
studies	692 7 O
were	700 4 O
mostly	705 6 O
angiographies	712 13 O
performed	726 9 O
with	736 4 O
both	741 4 O
ionic	746 5 O
and	752 3 O
non	756 3 O
-	759 1 O
ionic	760 5 O
contrast	766 8 O
material	775 8 O
,	783 1 O
at	785 2 O
an	788 2 O
average	791 7 O
dose	799 4 O
of	804 2 O
245	807 3 O
ml	811 2 O
.	813 1 O

Renal	815 5 B-Disease
function	821 8 I-Disease
significantly	830 13 I-Disease
deteriorated	844 12 I-Disease
in	857 2 O
the	860 3 O
group	864 5 O
pretreated	870 10 O
with	881 4 O
furosemide	886 10 B-Chemical
(	897 1 O
p	898 1 O
<	900 1 O
0	902 1 O
.	903 1 O
005	904 3 O
by	908 2 O
ANOVA	911 5 O
)	916 1 O
,	917 1 O
with	919 4 O
a	924 1 O
rise	926 4 O
in	931 2 O
serum	934 5 O
creatinine	940 10 B-Chemical
from	951 4 O
145	956 3 O
+	960 1 O
/	961 1 O
-	962 1 O
13	964 2 O
to	967 2 O
182	970 3 O
+	974 1 O
/	975 1 O
-	976 1 O
16	978 2 O
mumol	981 5 O
/	986 1 O
l	987 1 O
at	989 2 O
24	992 2 O
h	995 1 O
,	996 1 O
while	998 5 O
no	1004 2 O
change	1007 6 O
occurred	1014 8 O
in	1023 2 O
the	1026 3 O
control	1030 7 O
group	1038 5 O
(	1044 1 O
from	1045 4 O
141	1050 3 O
+	1054 1 O
/	1055 1 O
-	1056 1 O
6	1058 1 O
to	1060 2 O
142	1063 3 O
+	1067 1 O
/	1068 1 O
-	1069 1 O
7	1071 1 O
mumol	1073 5 O
/	1078 1 O
l	1079 1 O
)	1080 1 O
.	1081 1 O

Renal	1083 5 B-Disease
failure	1089 7 I-Disease
was	1097 3 O
associated	1101 10 O
with	1112 4 O
weight	1117 6 B-Disease
loss	1124 4 I-Disease
in	1129 2 O
the	1132 3 O
furosemide	1136 10 B-Chemical
-	1146 1 O
treated	1147 7 O
group	1155 5 O
.	1160 1 O

Furosemide	1162 10 B-Chemical
may	1173 3 O
be	1177 2 O
deleterious	1180 11 O
in	1192 2 O
the	1195 3 O
prevention	1199 10 O
of	1210 2 O
radiocontrast	1213 13 O
nephropathy	1227 11 B-Disease
.	1238 1 O

The	0 3 O
renal	4 5 O
pathology	10 9 O
in	20 2 O
a	23 1 O
case	25 4 O
of	30 2 O
lithium	33 7 B-Chemical
-	40 1 O
induced	41 7 O
diabetes	49 8 B-Disease
insipidus	58 9 I-Disease
.	67 1 O

A	69 1 O
case	71 4 O
of	76 2 O
lithium	79 7 B-Chemical
-	86 1 O
induced	87 7 O
diabetes	95 8 B-Disease
insipidus	104 9 I-Disease
is	114 2 O
reported	117 8 O
.	125 1 O

At	127 2 O
necropsy	130 8 O
microscopy	139 10 O
shoed	150 5 O
unique	156 6 O
and	163 3 O
extensive	167 9 O
damage	177 6 O
to	184 2 O
cells	187 5 O
lining	193 6 O
the	200 3 O
distal	204 6 O
nephron	211 7 O
.	218 1 O

It	220 2 O
is	223 2 O
suggested	226 9 O
that	236 4 O
these	241 5 O
changes	247 7 O
represent	255 9 O
a	265 1 O
specific	267 8 O
toxic	276 5 O
effect	282 6 O
of	289 2 O
lithium	292 7 B-Chemical
,	299 1 O
reported	301 8 O
here	310 4 O
for	315 3 O
the	319 3 O
first	323 5 O
time	329 4 O
in	334 2 O
man	337 3 O
.	340 1 O

Etiologic	0 9 O
factors	10 7 O
in	18 2 O
the	21 3 O
pathogenesis	25 12 O
of	38 2 O
liver	41 5 B-Disease
tumors	47 6 I-Disease
associated	54 10 O
with	65 4 O
oral	70 4 B-Chemical
contraceptives	75 14 I-Chemical
.	89 1 O

Within	91 6 O
the	98 3 O
last	102 4 O
several	107 7 O
years	115 5 O
,	120 1 O
previously	122 10 O
rare	133 4 O
liver	138 5 B-Disease
tumors	144 6 I-Disease
have	151 4 O
been	156 4 O
seen	161 4 O
in	166 2 O
young	169 5 O
women	175 5 O
using	181 5 O
oral	187 4 B-Chemical
contraceptive	192 13 I-Chemical
steroids	206 8 B-Chemical
.	214 1 O

The	216 3 O
Registry	220 8 O
for	229 3 O
Liver	233 5 B-Disease
Tumors	239 6 I-Disease
Associated	246 10 O
with	257 4 O
Oral	262 4 B-Chemical
Contraceptives	267 14 I-Chemical
at	282 2 O
the	285 3 O
University	289 10 O
of	300 2 O
California	303 10 O
,	313 1 O
Irvine	315 6 O
,	321 1 O
has	323 3 O
clearly	327 7 O
identified	335 10 O
27	346 2 O
cases	349 5 O
.	354 1 O

The	356 3 O
recent	360 6 O
literature	367 10 O
contains	378 8 O
44	387 2 O
case	390 4 O
reports	395 7 O
.	402 1 O

Common	404 6 O
to	411 2 O
these	414 5 O
71	420 2 O
cases	423 5 O
has	429 3 O
been	433 4 O
a	438 1 O
histopathologic	440 15 O
diagnosis	456 9 O
of	466 2 O
focal	469 5 B-Disease
nodular	475 7 I-Disease
hyperplasia	483 11 I-Disease
,	494 1 O
adenoma	496 7 B-Disease
,	503 1 O
hamartoma	505 9 B-Disease
,	514 1 O
and	516 3 O
hepatoma	520 8 B-Disease
.	528 1 O

Significant	530 11 O
statistical	542 11 O
etiologic	554 9 O
factors	564 7 O
include	572 7 O
prolonged	580 9 O
uninterrupted	590 13 O
usage	604 5 O
of	610 2 O
oral	613 4 B-Chemical
contraceptive	618 13 I-Chemical
steroids	632 8 B-Chemical
.	640 1 O

Eight	642 5 O
deaths	648 6 O
and	655 3 O
liver	659 5 O
rupture	665 7 B-Disease
in	673 2 O
18	676 2 O
patients	679 8 O
attest	688 6 O
to	695 2 O
the	698 3 O
seriousness	702 11 O
of	714 2 O
this	717 4 O
new	722 3 O
potentially	726 11 O
lethal	738 6 O
adverse	745 7 O
phenomenon	753 10 O
.	763 1 O

Graft	0 5 B-Disease
-	5 1 I-Disease
versus	6 6 I-Disease
-	12 1 I-Disease
host	13 4 I-Disease
disease	18 7 I-Disease
prophylaxis	26 11 O
with	38 4 O
everolimus	43 10 B-Chemical
and	54 3 O
tacrolimus	58 10 B-Chemical
is	69 2 O
associated	72 10 O
with	83 4 O
a	88 1 O
high	90 4 O
incidence	95 9 O
of	105 2 O
sinusoidal	108 10 B-Disease
obstruction	119 11 I-Disease
syndrome	131 8 I-Disease
and	140 3 O
microangiopathy	144 15 B-Disease
:	159 1 O
results	161 7 O
of	169 2 O
the	172 3 O
EVTAC	176 5 O
trial	182 5 O
.	187 1 O

A	189 1 O
calcineurin	191 11 O
inhibitor	203 9 O
combined	213 8 O
with	222 4 O
methotrexate	227 12 B-Chemical
is	240 2 O
the	243 3 O
standard	247 8 O
prophylaxis	256 11 O
for	268 3 O
graft	272 5 B-Disease
-	277 1 I-Disease
versus	278 6 I-Disease
-	284 1 I-Disease
host	285 4 I-Disease
disease	290 7 I-Disease
(	298 1 O
GVHD	299 4 B-Disease
)	303 1 O
after	305 5 O
allogeneic	311 10 O
hematopoietic	322 13 O
stem	336 4 O
cell	341 4 O
transplantation	346 15 O
(	362 1 O
HSCT	363 4 O
)	367 1 O
.	368 1 O

Everolimus	370 10 B-Chemical
,	380 1 O
a	382 1 O
derivative	384 10 O
of	395 2 O
sirolimus	398 9 B-Chemical
,	407 1 O
seems	409 5 O
to	415 2 O
mediate	418 7 O
antileukemia	426 12 O
effects	439 7 O
.	446 1 O

We	448 2 O
report	451 6 O
on	458 2 O
a	461 1 O
combination	463 11 O
of	475 2 O
everolimus	478 10 B-Chemical
and	489 3 O
tacrolimus	493 10 B-Chemical
in	504 2 O
24	507 2 O
patients	510 8 O
(	519 1 O
median	520 6 O
age	527 3 O
,	530 1 O
62	532 2 O
years	535 5 O
)	540 1 O
with	542 4 O
either	547 6 O
myelodysplastic	554 15 B-Disease
syndrome	570 8 I-Disease
(	579 1 O
MDS	580 3 B-Disease
;	583 1 O
n	585 1 O
=	587 1 O
17	589 2 O
)	591 1 O
or	593 2 O
acute	596 5 B-Disease
myeloid	602 7 I-Disease
leukemia	610 8 I-Disease
(	619 1 O
AML	620 3 B-Disease
;	623 1 O
n	625 1 O
=	627 1 O
7	629 1 O
)	630 1 O
undergoing	632 10 O
intensive	643 9 O
conditioning	653 12 O
followed	666 8 O
by	675 2 O
HSCT	678 4 O
from	683 4 O
related	688 7 O
(	696 1 O
n	697 1 O
=	699 1 O
4	701 1 O
)	702 1 O
or	704 2 O
unrelated	707 9 O
(	717 1 O
n	718 1 O
=	720 1 O
20	722 2 O
)	724 1 O
donors	726 6 O
.	732 1 O

All	734 3 O
patients	738 8 O
engrafted	747 9 O
,	756 1 O
and	758 3 O
only	762 4 O
1	767 1 O
patient	769 7 O
experienced	777 11 O
grade	789 5 O
IV	795 2 O
mucositis	798 9 B-Disease
.	807 1 O

Nine	809 4 O
patients	814 8 O
(	823 1 O
37	824 2 O
%	826 1 O
)	827 1 O
developed	829 9 O
acute	839 5 O
grade	845 5 O
II	851 2 O
-	853 1 O
IV	854 2 O
GVHD	857 4 B-Disease
,	861 1 O
and	863 3 O
11	867 2 O
of	870 2 O
17	873 2 O
evaluable	876 9 O
patients	886 8 O
(	895 1 O
64	896 2 O
%	898 1 O
)	899 1 O
developed	901 9 O
chronic	911 7 O
extensive	919 9 O
GVHD	929 4 B-Disease
.	933 1 O

Transplantation	935 15 B-Disease
-	950 1 I-Disease
associated	951 10 I-Disease
microangiopathy	962 15 I-Disease
(	978 1 O
TMA	979 3 B-Disease
)	982 1 O
occurred	984 8 O
in	993 2 O
7	996 1 O
patients	998 8 O
(	1007 1 O
29	1008 2 O
%	1010 1 O
)	1011 1 O
,	1012 1 O
with	1014 4 O
2	1019 1 O
cases	1021 5 O
of	1027 2 O
acute	1030 5 B-Disease
renal	1036 5 I-Disease
failure	1042 7 I-Disease
.	1049 1 O

The	1051 3 O
study	1055 5 O
was	1061 3 O
terminated	1065 10 O
prematurely	1076 11 O
because	1088 7 O
an	1096 2 O
additional	1099 10 O
6	1110 1 O
patients	1112 8 O
(	1121 1 O
25	1122 2 O
%	1124 1 O
)	1125 1 O
developed	1127 9 O
sinusoidal	1137 10 B-Disease
obstruction	1148 11 I-Disease
syndrome	1160 8 I-Disease
(	1169 1 O
SOS	1170 3 B-Disease
)	1173 1 O
,	1174 1 O
which	1176 5 O
was	1182 3 O
fatal	1186 5 O
in	1192 2 O
2	1195 1 O
cases	1197 5 O
.	1202 1 O

With	1204 4 O
a	1209 1 O
median	1211 6 O
follow	1218 6 O
-	1224 1 O
up	1225 2 O
of	1228 2 O
26	1231 2 O
months	1234 6 O
,	1240 1 O
the	1242 3 O
2	1246 1 O
-	1247 1 O
year	1248 4 O
overall	1253 7 O
survival	1261 8 O
rate	1270 4 O
was	1275 3 O
47	1279 2 O
%	1281 1 O
.	1282 1 O

Although	1284 8 O
this	1293 4 O
new	1298 3 O
combination	1302 11 O
appears	1314 7 O
to	1322 2 O
be	1325 2 O
effective	1328 9 O
as	1338 2 O
a	1341 1 O
prophylactic	1343 12 O
regimen	1356 7 O
for	1364 3 O
acute	1368 5 O
GVHD	1374 4 B-Disease
,	1378 1 O
the	1380 3 O
incidence	1384 9 O
of	1394 2 O
TMA	1397 3 B-Disease
and	1401 3 O
SOS	1405 3 B-Disease
is	1409 2 O
considerably	1412 12 O
higher	1425 6 O
than	1432 4 O
seen	1437 4 O
with	1442 4 O
other	1447 5 O
regimens	1453 8 O
.	1461 1 O

Effect	0 6 O
of	7 2 O
some	10 4 O
convulsants	15 11 O
on	27 2 O
the	30 3 O
protective	34 10 O
activity	45 8 O
of	54 2 O
loreclezole	57 11 B-Chemical
and	69 3 O
its	73 3 O
combinations	77 12 O
with	90 4 O
valproate	95 9 B-Chemical
or	105 2 O
clonazepam	108 10 B-Chemical
in	119 2 O
amygdala	122 8 O
-	130 1 O
kindled	131 7 O
rats	139 4 O
.	143 1 O

Loreclezole	145 11 B-Chemical
(	157 1 O
5	158 1 O
mg	160 2 O
/	162 1 O
kg	163 2 O
)	165 1 O
exerted	167 7 O
a	175 1 O
significant	177 11 O
protective	189 10 O
action	200 6 O
in	207 2 O
amygdala	210 8 O
-	218 1 O
kindled	219 7 O
rats	227 4 O
,	231 1 O
reducing	233 8 O
both	242 4 O
seizure	247 7 B-Disease
and	255 3 O
afterdischarge	259 14 O
durations	274 9 O
.	283 1 O

The	285 3 O
combinations	289 12 O
of	302 2 O
loreclezole	305 11 B-Chemical
(	317 1 O
2	318 1 O
.	319 1 O
5	320 1 O
mg	322 2 O
/	324 1 O
kg	325 2 O
)	327 1 O
with	329 4 O
valproate	334 9 B-Chemical
,	343 1 O
clonazepam	345 10 B-Chemical
,	355 1 O
or	357 2 O
carbamazepine	360 13 B-Chemical
(	374 1 O
applied	375 7 O
at	383 2 O
their	386 5 O
subprotective	392 13 O
doses	406 5 O
)	411 1 O
also	413 4 O
exhibited	418 9 O
antiseizure	428 11 O
effect	440 6 O
in	447 2 O
this	450 4 O
test	455 4 O
.	459 1 O

However	461 7 O
,	468 1 O
only	470 4 O
two	475 3 O
first	479 5 O
combinations	485 12 O
occurred	498 8 O
to	507 2 O
be	510 2 O
of	513 2 O
pharmacodynamic	516 15 O
nature	532 6 O
.	538 1 O

Among	540 5 O
several	546 7 O
chemoconvulsants	554 16 O
,	570 1 O
bicuculline	572 11 B-Chemical
,	583 1 O
N	585 1 B-Chemical
-	586 1 I-Chemical
methyl	587 6 I-Chemical
-	593 1 I-Chemical
D	594 1 I-Chemical
-	595 1 I-Chemical
aspartic	596 8 I-Chemical
acid	605 4 I-Chemical
and	610 3 O
BAY	614 3 B-Chemical
k	618 1 I-Chemical
-	619 1 I-Chemical
8644	620 4 I-Chemical
(	625 1 O
the	626 3 O
opener	630 6 O
of	637 2 O
L	640 1 O
-	641 1 O
type	642 4 O
calcium	647 7 B-Chemical
channels	655 8 O
)	663 1 O
reversed	665 8 O
the	674 3 O
protective	678 10 O
activity	689 8 O
of	698 2 O
loreclezole	701 11 B-Chemical
alone	713 5 O
and	719 3 O
its	723 3 O
combination	727 11 O
with	739 4 O
valproate	744 9 B-Chemical
.	753 1 O

On	755 2 O
the	758 3 O
other	762 5 O
hand	768 4 O
,	772 1 O
bicuculline	774 11 B-Chemical
,	785 1 O
aminophylline	787 13 B-Chemical
and	801 3 O
BAY	805 3 B-Chemical
k	809 1 I-Chemical
-	810 1 I-Chemical
8644	811 4 I-Chemical
inhibited	816 9 O
the	826 3 O
anticonvulsive	830 14 O
action	845 6 O
of	852 2 O
loreclezole	855 11 B-Chemical
combined	867 8 O
with	876 4 O
clonazepam	881 10 B-Chemical
.	891 1 O

The	893 3 O
results	897 7 O
support	905 7 O
the	913 3 O
hypothesis	917 10 O
that	928 4 O
the	933 3 O
protective	937 10 O
activity	948 8 O
of	957 2 O
loreclezole	960 11 B-Chemical
and	972 3 O
its	976 3 O
combinations	980 12 O
with	993 4 O
other	998 5 O
antiepileptics	1004 14 O
may	1019 3 O
involve	1023 7 O
potentiation	1031 12 O
of	1044 2 O
GABAergic	1047 9 O
neurotransmission	1057 17 O
and	1075 3 O
blockade	1079 8 O
of	1088 2 O
L	1091 1 O
-	1092 1 O
type	1093 4 O
of	1098 2 O
calcium	1101 7 B-Chemical
channels	1109 8 O
.	1117 1 O

Acute	0 5 B-Disease
liver	6 5 I-Disease
failure	12 7 I-Disease
with	20 4 O
concurrent	25 10 O
bupropion	36 9 B-Chemical
and	46 3 O
carbimazole	50 11 B-Chemical
therapy	62 7 O
.	69 1 O

OBJECTIVE	71 9 O
:	80 1 O
To	82 2 O
report	85 6 O
a	92 1 O
case	94 4 O
of	99 2 O
fatal	102 5 O
liver	108 5 B-Disease
failure	114 7 I-Disease
possibly	122 8 O
associated	131 10 O
with	142 4 O
concurrent	147 10 O
use	158 3 O
of	162 2 O
bupropion	165 9 B-Chemical
and	175 3 O
carbimazole	179 11 B-Chemical
.	190 1 O

CASE	192 4 O
SUMMARY	197 7 O
:	204 1 O
A	206 1 O
41	208 2 O
-	210 1 O
year	211 4 O
-	215 1 O
old	216 3 O
Chinese	220 7 O
man	228 3 O
with	232 4 O
a	237 1 O
history	239 7 O
of	247 2 O
hyperthyroidism	250 15 B-Disease
had	266 3 O
been	270 4 O
treated	275 7 O
with	283 4 O
carbimazole	288 11 B-Chemical
and	300 3 O
propranolol	304 11 B-Chemical
for	316 3 O
the	320 3 O
past	324 4 O
5	329 1 O
years	331 5 O
.	336 1 O

He	338 2 O
received	341 8 O
a	350 1 O
10	352 2 O
-	354 1 O
day	355 3 O
course	359 6 O
of	366 2 O
bupropion	369 9 B-Chemical
as	379 2 O
an	382 2 O
aid	385 3 O
for	389 3 O
smoking	393 7 O
cessation	401 9 O
10	411 2 O
weeks	414 5 O
prior	420 5 O
to	426 2 O
presentation	429 12 O
.	441 1 O

He	443 2 O
developed	446 9 O
acute	456 5 B-Disease
liver	462 5 I-Disease
failure	468 7 I-Disease
with	476 4 O
rapid	481 5 O
deterioration	487 13 O
of	501 2 O
renal	504 5 O
function	510 8 O
.	518 1 O

Liver	520 5 O
biopsy	526 6 O
showed	533 6 O
evidence	540 8 O
of	549 2 O
nonspecific	552 11 O
drug	564 4 B-Disease
-	568 1 I-Disease
induced	569 7 I-Disease
acute	577 5 I-Disease
liver	583 5 I-Disease
injury	589 6 I-Disease
.	595 1 O

His	597 3 O
condition	601 9 O
was	611 3 O
further	615 7 O
complicated	623 11 O
by	635 2 O
sepsis	638 6 B-Disease
and	645 3 O
coagulopathy	649 12 B-Disease
.	661 1 O

Death	663 5 O
resulted	669 8 O
19	678 2 O
days	681 4 O
after	686 5 O
the	692 3 O
onset	696 5 O
of	702 2 O
symptoms	705 8 O
.	713 1 O

The	715 3 O
likelihood	719 10 O
that	730 4 O
bupropion	735 9 B-Chemical
induced	745 7 O
hepatotoxicity	753 14 B-Disease
in	768 2 O
our	771 3 O
patient	775 7 O
was	783 3 O
possible	787 8 O
,	795 1 O
based	797 5 O
on	803 2 O
the	806 3 O
Naranjo	810 7 O
probability	818 11 O
scale	830 5 O
.	835 1 O

DISCUSSION	837 10 O
:	847 1 O
Although	849 8 O
there	858 5 O
is	864 2 O
increasing	867 10 O
evidence	878 8 O
of	887 2 O
hepatotoxicity	890 14 B-Disease
induced	905 7 O
by	913 2 O
bupropion	916 9 B-Chemical
,	925 1 O
this	927 4 O
is	932 2 O
the	935 3 O
first	939 5 O
case	945 4 O
of	950 2 O
fatality	953 8 O
that	962 4 O
could	967 5 O
have	973 4 O
resulted	978 8 O
from	987 4 O
acute	992 5 B-Disease
liver	998 5 I-Disease
failure	1004 7 I-Disease
in	1012 2 O
a	1015 1 O
patient	1017 7 O
receiving	1025 9 O
bupropion	1035 9 B-Chemical
while	1045 5 O
on	1051 2 O
concomitant	1054 11 O
treatment	1066 9 O
with	1076 4 O
carbimazole	1081 11 B-Chemical
.	1092 1 O

CONCLUSIONS	1094 11 O
:	1105 1 O
Clinicians	1107 10 O
should	1118 6 O
be	1125 2 O
aware	1128 5 O
of	1134 2 O
the	1137 3 O
possibility	1141 11 O
of	1153 2 O
acute	1156 5 B-Disease
liver	1162 5 I-Disease
insult	1168 6 I-Disease
induced	1175 7 O
by	1183 2 O
bupropion	1186 9 B-Chemical
given	1196 5 O
concurrently	1202 12 O
with	1215 4 O
other	1220 5 O
hepatotoxic	1226 11 B-Disease
drugs	1238 5 O
.	1243 1 O

Long	0 4 O
term	5 4 O
hormone	10 7 O
therapy	18 7 O
for	26 3 O
perimenopausal	30 14 O
and	45 3 O
postmenopausal	49 14 O
women	64 5 O
.	69 1 O

BACKGROUND	71 10 O
:	81 1 O
Hormone	83 7 O
therapy	91 7 O
(	99 1 O
HT	100 2 O
)	102 1 O
is	104 2 O
widely	107 6 O
used	114 4 O
for	119 3 O
controlling	123 11 O
menopausal	135 10 O
symptoms	146 8 O
and	155 3 O
has	159 3 O
also	163 4 O
been	168 4 O
used	173 4 O
for	178 3 O
the	182 3 O
management	186 10 O
and	197 3 O
prevention	201 10 O
of	212 2 O
cardiovascular	215 14 B-Disease
disease	230 7 I-Disease
,	237 1 O
osteoporosis	239 12 B-Disease
and	252 3 O
dementia	256 8 B-Disease
in	265 2 O
older	268 5 O
women	274 5 O
.	279 1 O

This	281 4 O
is	286 2 O
an	289 2 O
updated	292 7 O
version	300 7 O
of	308 2 O
the	311 3 O
original	315 8 O
Cochrane	324 8 O
review	333 6 O
first	340 5 O
published	346 9 O
in	356 2 O
2005	359 4 O
.	363 1 O

OBJECTIVES	365 10 O
:	375 1 O
To	377 2 O
assess	380 6 O
the	387 3 O
effect	391 6 O
of	398 2 O
long	401 4 O
-	405 1 O
term	406 4 O
HT	411 2 O
on	414 2 O
mortality	417 9 O
,	426 1 O
cardiovascular	428 14 O
outcomes	443 8 O
,	451 1 O
cancer	453 6 B-Disease
,	459 1 O
gallbladder	461 11 B-Disease
disease	473 7 I-Disease
,	480 1 O
cognition	482 9 O
,	491 1 O
fractures	493 9 B-Disease
and	503 3 O
quality	507 7 O
of	515 2 O
life	518 4 O
.	522 1 O

SEARCH	524 6 O
STRATEGY	531 8 O
:	539 1 O
We	541 2 O
searched	544 8 O
the	553 3 O
following	557 9 O
databases	567 9 O
to	577 2 O
November	580 8 O
2007	589 4 O
:	593 1 O
Trials	595 6 O
Register	602 8 O
of	611 2 O
the	614 3 O
Cochrane	618 8 O
Menstrual	627 9 B-Disease
Disorders	637 9 I-Disease
and	647 3 O
Subfertility	651 12 O
Group	664 5 O
,	669 1 O
Cochrane	671 8 O
Central	680 7 O
Register	688 8 O
of	697 2 O
Controlled	700 10 O
Trials	711 6 O
,	717 1 O
MEDLINE	719 7 O
,	726 1 O
EMBASE	728 6 O
,	734 1 O
Biological	736 10 O
Abstracts	747 9 O
.	756 1 O

Also	758 4 O
relevant	763 8 O
non	772 3 O
-	775 1 O
indexed	776 7 O
journals	784 8 O
and	793 3 O
conference	797 10 O
abstracts	808 9 O
.	817 1 O

SELECTION	819 9 O
CRITERIA	829 8 O
:	837 1 O
Randomised	839 10 O
double	850 6 O
-	856 1 O
blind	857 5 O
trials	863 6 O
of	870 2 O
HT	873 2 O
versus	876 6 O
placebo	883 7 O
,	890 1 O
taken	892 5 O
for	898 3 O
at	902 2 O
least	905 5 O
one	911 3 O
year	915 4 O
by	920 2 O
perimenopausal	923 14 O
or	938 2 O
postmenopausal	941 14 O
women	956 5 O
.	961 1 O

HT	963 2 O
included	966 8 O
oestrogens	975 10 B-Chemical
,	985 1 O
with	987 4 O
or	992 2 O
without	995 7 O
progestogens	1003 12 B-Chemical
,	1015 1 O
via	1017 3 O
oral	1021 4 O
,	1025 1 O
transdermal	1027 11 O
,	1038 1 O
subcutaneous	1040 12 O
or	1053 2 O
transnasal	1056 10 O
routes	1067 6 O
.	1073 1 O

DATA	1075 4 O
COLLECTION	1080 10 O
AND	1091 3 O
ANALYSIS	1095 8 O
:	1103 1 O
Two	1105 3 O
authors	1109 7 O
independently	1117 13 O
assessed	1131 8 O
trial	1140 5 O
quality	1146 7 O
and	1154 3 O
extracted	1158 9 O
data	1168 4 O
.	1172 1 O

MAIN	1174 4 O
RESULTS	1179 7 O
:	1186 1 O
Nineteen	1188 8 O
trials	1197 6 O
involving	1204 9 O
41	1214 2 O
,	1216 1 O
904	1217 3 O
women	1221 5 O
were	1227 4 O
included	1232 8 O
.	1240 1 O

In	1242 2 O
relatively	1245 10 O
healthy	1256 7 O
women	1264 5 O
,	1269 1 O
combined	1271 8 O
continuous	1280 10 O
HT	1291 2 O
significantly	1294 13 O
increased	1308 9 O
the	1318 3 O
risk	1322 4 O
of	1327 2 O
venous	1330 6 B-Disease
thrombo	1337 7 I-Disease
-	1344 1 I-Disease
embolism	1345 8 I-Disease
or	1354 2 O
coronary	1357 8 O
event	1366 5 O
(	1372 1 O
after	1373 5 O
one	1379 3 O
year	1383 4 O
'	1387 1 O
s	1388 1 O
use	1390 3 O
)	1393 1 O
,	1394 1 O
stroke	1396 6 B-Disease
(	1403 1 O
after	1404 5 O
three	1410 5 O
years	1416 5 O
)	1421 1 O
,	1422 1 O
breast	1424 6 B-Disease
cancer	1431 6 I-Disease
and	1438 3 O
gallbladder	1442 11 B-Disease
disease	1454 7 I-Disease
.	1461 1 O

Long	1463 4 O
-	1467 1 O
term	1468 4 O
oestrogen	1473 9 B-Chemical
-	1482 1 O
only	1483 4 O
HT	1488 2 O
significantly	1491 13 O
increased	1505 9 O
the	1515 3 O
risk	1519 4 O
of	1524 2 O
venous	1527 6 B-Disease
thrombo	1534 7 I-Disease
-	1541 1 I-Disease
embolism	1542 8 I-Disease
,	1550 1 O
stroke	1552 6 B-Disease
and	1559 3 O
gallbladder	1563 11 B-Disease
disease	1575 7 I-Disease
(	1583 1 O
after	1584 5 O
one	1590 3 O
to	1594 2 O
two	1597 3 O
years	1601 5 O
,	1606 1 O
three	1608 5 O
years	1614 5 O
and	1620 3 O
seven	1624 5 O
years	1630 5 O
'	1635 1 O
use	1637 3 O
respectively	1641 12 O
)	1653 1 O
,	1654 1 O
but	1656 3 O
did	1660 3 O
not	1664 3 O
significantly	1668 13 O
increase	1682 8 O
the	1691 3 O
risk	1695 4 O
of	1700 2 O
breast	1703 6 B-Disease
cancer	1710 6 I-Disease
.	1716 1 O

The	1718 3 O
only	1722 4 O
statistically	1727 13 O
significant	1741 11 O
benefits	1753 8 O
of	1762 2 O
HT	1765 2 O
were	1768 4 O
a	1773 1 O
decreased	1775 9 O
incidence	1785 9 O
of	1795 2 O
fractures	1798 9 B-Disease
and	1808 3 O
(	1812 1 O
for	1813 3 O
combined	1817 8 O
HT	1826 2 O
)	1828 1 O
colon	1830 5 B-Disease
cancer	1836 6 I-Disease
,	1842 1 O
with	1844 4 O
long	1849 4 O
-	1853 1 O
term	1854 4 O
use	1859 3 O
.	1862 1 O

Among	1864 5 O
women	1870 5 O
aged	1876 4 O
over	1881 4 O
65	1886 2 O
who	1889 3 O
were	1893 4 O
relatively	1898 10 O
healthy	1909 7 O
(	1917 1 O
i	1918 1 O
.	1919 1 O
e	1920 1 O
.	1921 1 O
generally	1923 9 O
fit	1933 3 O
,	1936 1 O
without	1938 7 O
overt	1946 5 O
disease	1952 7 O
)	1959 1 O
and	1961 3 O
taking	1965 6 O
continuous	1972 10 O
combined	1983 8 O
HT	1992 2 O
,	1994 1 O
there	1996 5 O
was	2002 3 O
a	2006 1 O
statistically	2008 13 O
significant	2022 11 O
increase	2034 8 O
in	2043 2 O
the	2046 3 O
incidence	2050 9 O
of	2060 2 O
dementia	2063 8 B-Disease
.	2071 1 O

Among	2073 5 O
women	2079 5 O
with	2085 4 O
cardiovascular	2090 14 B-Disease
disease	2105 7 I-Disease
,	2112 1 O
long	2114 4 O
-	2118 1 O
term	2119 4 O
use	2124 3 O
of	2128 2 O
combined	2131 8 O
continuous	2140 10 O
HT	2151 2 O
significantly	2154 13 O
increased	2168 9 O
the	2178 3 O
risk	2182 4 O
of	2187 2 O
venous	2190 6 B-Disease
thrombo	2197 7 I-Disease
-	2204 1 I-Disease
embolism	2205 8 I-Disease
.	2213 1 O
One	2214 3 O
trial	2218 5 O
analysed	2224 8 O
subgroups	2233 9 O
of	2243 2 O
2839	2246 4 O
relatively	2251 10 O
healthy	2262 7 O
50	2270 2 O
to	2273 2 O
59	2276 2 O
year	2279 4 O
old	2284 3 O
women	2288 5 O
taking	2294 6 O
combined	2301 8 O
continuous	2310 10 O
HT	2321 2 O
and	2324 3 O
1637	2328 4 O
taking	2333 6 O
oestrogen	2340 9 B-Chemical
-	2349 1 O
only	2350 4 O
HT	2355 2 O
,	2357 1 O
versus	2359 6 O
similar	2366 7 O
-	2373 1 O
sized	2374 5 O
placebo	2380 7 O
groups	2388 6 O
.	2394 1 O

The	2396 3 O
only	2400 4 O
significantly	2405 13 O
increased	2419 9 O
risk	2429 4 O
reported	2434 8 O
was	2443 3 O
for	2447 3 O
venous	2451 6 B-Disease
thrombo	2458 7 I-Disease
-	2465 1 I-Disease
embolism	2466 8 I-Disease
in	2475 2 O
women	2478 5 O
taking	2484 6 O
combined	2491 8 O
continuous	2500 10 O
HT	2511 2 O
:	2513 1 O
their	2515 5 O
absolute	2521 8 O
risk	2530 4 O
remained	2535 8 O
low	2544 3 O
,	2547 1 O
at	2549 2 O
less	2552 4 O
than	2557 4 O
1	2562 1 O
/	2563 1 O
500	2564 3 O
.	2567 1 O

However	2569 7 O
,	2576 1 O
this	2578 4 O
study	2583 5 O
was	2589 3 O
not	2593 3 O
powered	2597 7 O
to	2605 2 O
detect	2608 6 O
differences	2615 11 O
between	2627 7 O
groups	2635 6 O
of	2642 2 O
younger	2645 7 O
women	2653 5 O
.	2658 1 O

AUTHORS	2660 7 O
'	2667 1 O
CONCLUSIONS	2669 11 O
:	2680 1 O
HT	2682 2 O
is	2685 2 O
not	2688 3 O
indicated	2692 9 O
for	2702 3 O
the	2706 3 O
routine	2710 7 O
management	2718 10 O
of	2729 2 O
chronic	2732 7 O
disease	2740 7 O
.	2747 1 O

We	2749 2 O
need	2752 4 O
more	2757 4 O
evidence	2762 8 O
on	2771 2 O
the	2774 3 O
safety	2778 6 O
of	2785 2 O
HT	2788 2 O
for	2791 3 O
menopausal	2795 10 O
symptom	2806 7 O
control	2814 7 O
,	2821 1 O
though	2823 6 O
short	2830 5 O
-	2835 1 O
term	2836 4 O
use	2841 3 O
appears	2845 7 O
to	2853 2 O
be	2856 2 O
relatively	2859 10 O
safe	2870 4 O
for	2875 3 O
healthy	2879 7 O
younger	2887 7 O
women	2895 5 O
.	2900 1 O

Passage	0 7 O
of	8 2 O
mannitol	11 8 B-Chemical
into	20 4 O
the	25 3 O
brain	29 5 O
around	35 6 O
gliomas	42 7 B-Disease
:	49 1 O
a	51 1 O
potential	53 9 O
cause	63 5 O
of	69 2 O
rebound	72 7 O
phenomenon	80 10 O
.	90 1 O

A	92 1 O
study	94 5 O
on	100 2 O
21	103 2 O
patients	106 8 O
.	114 1 O

AIM	116 3 O
:	119 1 O
Widespread	121 10 O
use	132 3 O
of	136 2 O
mannitol	139 8 B-Chemical
to	148 2 O
reduce	151 6 O
brain	158 5 B-Disease
edema	164 5 I-Disease
and	170 3 O
lower	174 5 O
elevated	180 8 B-Disease
ICP	189 3 I-Disease
in	193 2 O
brain	196 5 B-Disease
tumor	202 5 I-Disease
patients	208 8 O
continues	217 9 O
to	227 2 O
be	230 2 O
afflicted	233 9 O
by	243 2 O
the	246 3 O
so	250 2 O
-	252 1 O
called	253 6 O
rebound	260 7 O
phenomenon	268 10 O
.	278 1 O

Leakage	280 7 O
of	288 2 O
mannitol	291 8 B-Chemical
into	300 4 O
the	305 3 O
brain	309 5 O
parenchyma	315 10 O
through	326 7 O
an	334 2 O
altered	337 7 O
BBB	345 3 O
and	349 3 O
secondary	353 9 O
reversal	363 8 O
of	372 2 O
osmotic	375 7 O
gradient	383 8 O
is	392 2 O
considered	395 10 O
the	406 3 O
major	410 5 O
cause	416 5 O
of	422 2 O
rebound	425 7 O
.	433 1 O

This	435 4 O
has	440 3 O
only	444 4 O
been	449 4 O
demonstrated	454 12 O
experimentally	467 14 O
in	482 2 O
animals	485 7 O
.	492 1 O

As	494 2 O
a	497 1 O
contribution	499 12 O
to	512 2 O
this	515 4 O
issue	520 5 O
we	526 2 O
decided	529 7 O
to	537 2 O
research	540 8 O
the	549 3 O
possible	553 8 O
passage	562 7 O
of	570 2 O
mannitol	573 8 B-Chemical
into	582 4 O
the	587 3 O
brain	591 5 O
after	597 5 O
administration	603 14 O
to	618 2 O
21	621 2 O
brain	624 5 B-Disease
tumor	630 5 I-Disease
patients	636 8 O
.	644 1 O

METHODS	646 7 O
:	653 1 O
Mannitol	655 8 B-Chemical
(	664 1 O
18	665 2 O
%	667 1 O
solution	669 8 O
;	677 1 O
1	679 1 O
g	681 1 O
/	682 1 O
kg	683 2 O
)	685 1 O
was	687 3 O
administered	691 12 O
as	704 2 O
a	707 1 O
bolus	709 5 O
to	715 2 O
patients	718 8 O
(	727 1 O
ten	728 3 O
had	732 3 O
malignant	736 9 B-Disease
glioma	746 6 I-Disease
,	752 1 O
seven	754 5 O
brain	760 5 O
metastases	766 10 B-Disease
and	777 3 O
four	781 4 O
meningioma	786 10 B-Disease
)	796 1 O
about	798 5 O
30	804 2 O
minutes	807 7 O
before	815 6 O
craniotomy	822 10 O
.	832 1 O

During	834 6 O
resection	841 9 O
,	850 1 O
a	852 1 O
sample	854 6 O
of	861 2 O
the	864 3 O
surrounding	868 11 O
edematous	880 9 B-Disease
white	890 5 O
matter	896 6 O
was	903 3 O
taken	907 5 O
at	913 2 O
the	916 3 O
same	920 4 O
time	925 4 O
as	930 2 O
a	933 1 O
10	935 2 O
ml	938 2 O
venous	941 6 O
blood	948 5 O
sample	954 6 O
.	960 1 O

Mannitol	962 8 B-Chemical
concentrations	971 14 O
were	986 4 O
measured	991 8 O
in	1000 2 O
plasma	1003 6 O
and	1010 3 O
white	1014 5 O
matter	1020 6 O
by	1027 2 O
a	1030 1 O
modified	1032 8 O
version	1041 7 O
of	1049 2 O
the	1052 3 O
enzyme	1056 6 O
assay	1063 5 O
of	1069 2 O
Blonquist	1072 9 O
et	1082 2 O
al	1085 2 O
.	1087 1 O

RESULTS	1089 7 O
:	1096 1 O
In	1098 2 O
most	1101 4 O
glioma	1106 6 B-Disease
patients	1113 8 O
,	1121 1 O
mannitol	1123 8 B-Chemical
concentrations	1132 14 O
in	1147 2 O
white	1150 5 O
matter	1156 6 O
were	1163 4 O
2	1168 1 O
to	1170 2 O
6	1173 1 O
times	1175 5 O
higher	1181 6 O
than	1188 4 O
in	1193 2 O
plasma	1196 6 O
(	1203 1 O
mean	1204 4 O
3	1209 1 O
.	1210 1 O
5	1211 1 O
times	1213 5 O
)	1218 1 O
.	1219 1 O

In	1221 2 O
meningioma	1224 10 B-Disease
and	1235 3 O
metastases	1239 10 B-Disease
patients	1250 8 O
plasma	1259 6 O
concentrations	1266 14 O
of	1281 2 O
mannitol	1284 8 B-Chemical
were	1293 4 O
higher	1298 6 O
than	1305 4 O
white	1310 5 O
matter	1316 6 O
concentrations	1323 14 O
except	1338 6 O
in	1345 2 O
three	1348 5 O
cases	1354 5 O
with	1360 4 O
infiltration	1365 12 O
by	1378 2 O
neoplastic	1381 10 O
cells	1392 5 O
.	1397 1 O

CONCLUSIONS	1399 11 O
:	1410 1 O
The	1412 3 O
results	1416 7 O
of	1424 2 O
our	1427 3 O
study	1431 5 O
show	1437 4 O
that	1442 4 O
even	1447 4 O
after	1452 5 O
a	1458 1 O
single	1460 6 O
bolus	1467 5 O
,	1472 1 O
mannitol	1474 8 B-Chemical
may	1483 3 O
leak	1487 4 O
through	1492 7 O
the	1500 3 O
altered	1504 7 O
BBB	1512 3 O
near	1516 4 O
gliomas	1521 7 B-Disease
,	1528 1 O
reversing	1530 9 O
the	1540 3 O
initial	1544 7 O
plasma	1552 6 O
-	1558 1 O
to	1559 2 O
-	1561 1 O
blood	1562 5 O
osmotic	1568 7 O
gradient	1576 8 O
,	1584 1 O
aggravating	1586 11 O
peritumoral	1598 11 O
edema	1610 5 B-Disease
and	1616 3 O
promoting	1620 9 O
rebound	1630 7 O
of	1638 2 O
ICP	1641 3 O
.	1644 1 O

Can	0 3 O
lidocaine	4 9 B-Chemical
reduce	14 6 O
succinylcholine	21 15 B-Chemical
induced	37 7 O
postoperative	45 13 B-Disease
myalgia	59 7 I-Disease
?	66 1 O

This	68 4 O
study	73 5 O
was	79 3 O
undertaken	83 10 O
to	94 2 O
determine	97 9 O
the	107 3 O
effect	111 6 O
of	118 2 O
lidocaine	121 9 B-Chemical
pretreatment	131 12 O
on	144 2 O
reduction	147 9 O
of	157 2 O
succinylcholine	160 15 B-Chemical
-	175 1 O
induced	176 7 O
myalgia	184 7 B-Disease
in	192 2 O
patients	195 8 O
undergoing	204 10 O
general	215 7 O
anesthesia	223 10 O
for	234 3 O
gynecological	238 13 O
surgery	252 7 O
.	259 1 O

One	261 3 O
hundred	265 7 O
and	273 3 O
thirty	277 6 O
-	283 1 O
five	284 4 O
patients	289 8 O
were	298 4 O
assigned	303 8 O
to	312 2 O
one	315 3 O
of	319 2 O
three	322 5 O
groups	328 6 O
in	335 2 O
a	338 1 O
prospective	340 11 O
,	351 1 O
double	353 6 O
blind	360 5 O
,	365 1 O
randomized	367 10 O
manner	378 6 O
.	384 1 O

Group	386 5 O
PS	392 2 O
,	394 1 O
the	396 3 O
control	400 7 O
group	408 5 O
,	413 1 O
received	415 8 O
normal	424 6 O
saline	431 6 O
and	438 3 O
succinylcholine	442 15 B-Chemical
1	458 1 O
.	459 1 O
5	460 1 O
mg	462 2 O
x	465 1 O
kg	467 2 O
(	469 1 O
-	470 1 O
1	471 1 O
)	472 1 O
;	473 1 O
Group	475 5 O
LS	481 2 O
,	483 1 O
lidocaine	485 9 B-Chemical
1	495 1 O
.	496 1 O
5	497 1 O
mg	499 2 O
x	502 1 O
kg	504 2 O
(	506 1 O
-	507 1 O
1	508 1 O
)	509 1 O
and	511 3 O
succinylcholine	515 15 B-Chemical
1	531 1 O
.	532 1 O
5	533 1 O
mg	535 2 O
x	538 1 O
kg	540 2 O
(	542 1 O
-	543 1 O
1	544 1 O
)	545 1 O
;	546 1 O
Group	548 5 O
PR	554 2 O
,	556 1 O
normal	558 6 O
saline	565 6 O
and	572 3 O
rocuronium	576 10 B-Chemical
0	587 1 O
.	588 1 O
6	589 1 O
mg	591 2 O
x	594 1 O
kg	596 2 O
(	598 1 O
-	599 1 O
1	600 1 O
)	601 1 O
.	602 1 O

Morphine	604 8 B-Chemical
0	613 1 O
.	614 1 O
1	615 1 O
mg	617 2 O
x	620 1 O
kg	622 2 O
(	624 1 O
-	625 1 O
1	626 1 O
)	627 1 O
iv	629 2 O
was	632 3 O
given	636 5 O
for	642 3 O
premedication	646 13 O
and	660 3 O
all	664 3 O
patients	668 8 O
were	677 4 O
monitored	682 9 O
with	692 4 O
a	697 1 O
noninvasive	699 11 O
blood	711 5 O
pressure	717 8 O
monitor	726 7 O
,	733 1 O
ECG	735 3 O
and	739 3 O
pulse	743 5 O
oximetry	749 8 O
.	757 1 O

Anesthesia	759 10 O
was	770 3 O
induced	774 7 O
with	782 4 O
5	787 1 O
mg	789 2 O
.	791 1 O
kg	792 2 O
(	794 1 O
-	795 1 O
1	796 1 O
)	797 1 O
thiopental	799 10 B-Chemical
iv	810 2 O
.	812 1 O
followed	814 8 O
by	823 2 O
succinylcholine	826 15 B-Chemical
(	842 1 O
Group	843 5 O
PS	849 2 O
,	851 1 O
LS	853 2 O
)	855 1 O
or	857 2 O
rocuronium	860 10 B-Chemical
(	871 1 O
Group	872 5 O
PR	878 2 O
)	880 1 O
for	882 3 O
tracheal	886 8 O
intubation	895 10 O
.	905 1 O

Following	907 9 O
administration	917 14 O
of	932 2 O
these	935 5 O
agents	941 6 O
,	947 1 O
the	949 3 O
presence	953 8 O
,	961 1 O
and	963 3 O
degree	967 6 O
of	974 2 O
fasciculation	977 13 B-Disease
were	991 4 O
assessed	996 8 O
visually	1005 8 O
on	1014 2 O
a	1017 1 O
four	1019 4 O
point	1024 5 O
scale	1030 5 O
by	1036 2 O
one	1039 3 O
investigator	1043 12 O
who	1056 3 O
was	1060 3 O
blinded	1064 7 O
to	1072 2 O
the	1075 3 O
drug	1079 4 O
administered	1084 12 O
.	1096 1 O

The	1098 3 O
blood	1102 5 O
pressure	1108 8 O
and	1117 3 O
heart	1121 5 O
rate	1127 4 O
of	1132 2 O
each	1135 4 O
patient	1140 7 O
were	1148 4 O
monitored	1153 9 O
on	1163 2 O
nine	1166 4 O
occasions	1171 9 O
.	1180 1 O

Twenty	1182 6 O
-	1188 1 O
four	1189 4 O
hours	1194 5 O
later	1200 5 O
,	1205 1 O
any	1207 3 O
myalgia	1211 7 B-Disease
experienced	1219 11 O
was	1231 3 O
assessed	1235 8 O
according	1244 9 O
to	1254 2 O
a	1257 1 O
structured	1259 10 O
questionaire	1270 12 O
and	1283 3 O
graded	1287 6 O
by	1294 2 O
a	1297 1 O
four	1299 4 O
point	1304 5 O
scale	1310 5 O
by	1316 2 O
one	1319 3 O
investigator	1323 12 O
blinded	1336 7 O
to	1344 2 O
the	1347 3 O
intraoperative	1351 14 O
management	1366 10 O
.	1376 1 O

The	1378 3 O
results	1382 7 O
indicate	1390 8 O
that	1399 4 O
muscle	1404 6 B-Disease
fasciculation	1411 13 I-Disease
was	1425 3 O
not	1429 3 O
found	1433 5 O
in	1439 2 O
Group	1442 5 O
PR	1448 2 O
while	1451 5 O
the	1457 3 O
patients	1461 8 O
in	1470 2 O
Group	1473 5 O
LS	1479 2 O
had	1482 3 O
a	1486 1 O
lower	1488 5 O
incidence	1494 9 O
of	1504 2 O
muscle	1507 6 B-Disease
fasciculation	1514 13 I-Disease
than	1528 4 O
those	1533 5 O
in	1539 2 O
Group	1542 5 O
PS	1548 2 O
(	1551 1 O
p	1552 1 O
<	1554 1 O
0	1556 1 O
.	1557 1 O
001	1558 3 O
)	1561 1 O
.	1562 1 O

At	1564 2 O
24	1567 2 O
h	1570 1 O
,	1571 1 O
the	1573 3 O
incidence	1577 9 O
of	1587 2 O
myalgia	1590 7 B-Disease
was	1598 3 O
higher	1602 6 O
in	1609 2 O
Group	1612 5 O
PS	1618 2 O
than	1621 4 O
in	1626 2 O
Group	1629 5 O
LS	1635 2 O
and	1638 3 O
PR	1642 2 O
(	1645 1 O
p	1646 1 O
<	1648 1 O
0	1650 1 O
.	1651 1 O
05	1652 2 O
)	1654 1 O
.	1655 1 O

A	1657 1 O
correlation	1659 11 O
was	1671 3 O
not	1675 3 O
found	1679 5 O
between	1685 7 O
the	1693 3 O
incidence	1697 9 O
of	1707 2 O
myalgia	1710 7 B-Disease
and	1718 3 O
the	1722 3 O
occurrence	1726 10 O
of	1737 2 O
muscle	1740 6 B-Disease
fasciculation	1747 13 I-Disease
.	1760 1 O

The	1762 3 O
changes	1766 7 O
in	1774 2 O
systolic	1777 8 O
and	1786 3 O
diastolic	1790 9 O
blood	1800 5 O
pressure	1806 8 O
and	1815 3 O
heart	1819 5 O
rate	1825 4 O
were	1830 4 O
not	1835 3 O
significant	1839 11 O
among	1851 5 O
the	1857 3 O
three	1861 5 O
groups	1867 6 O
.	1873 1 O

In	1875 2 O
conclusion	1878 10 O
,	1888 1 O
where	1890 5 O
succinylcholine	1896 15 B-Chemical
is	1912 2 O
used	1915 4 O
,	1919 1 O
lidocaine	1921 9 B-Chemical
is	1931 2 O
proven	1934 6 O
to	1941 2 O
be	1944 2 O
the	1947 3 O
useful	1951 6 O
pretreatment	1958 12 O
agent	1971 5 O
for	1977 3 O
the	1981 3 O
reduction	1985 9 O
of	1995 2 O
postoperative	1998 13 B-Disease
myalgia	2012 7 I-Disease
.	2019 1 O

Open	0 4 O
-	4 1 O
label	5 5 O
assessment	11 10 O
of	22 2 O
levofloxacin	25 12 B-Chemical
for	38 3 O
the	42 3 O
treatment	46 9 O
of	56 2 O
acute	59 5 O
bacterial	65 9 O
sinusitis	75 9 B-Disease
in	85 2 O
adults	88 6 O
.	94 1 O

PURPOSE	96 7 O
:	103 1 O
To	105 2 O
evaluate	108 8 O
the	117 3 O
efficacy	121 8 O
and	130 3 O
safety	134 6 O
of	141 2 O
levofloxacin	144 12 B-Chemical
(	157 1 O
500	158 3 O
mg	162 2 O
orally	165 6 O
once	172 4 O
daily	177 5 O
for	183 3 O
10	187 2 O
to	190 2 O
14	193 2 O
days	196 4 O
)	200 1 O
in	202 2 O
treating	205 8 O
adult	214 5 O
outpatients	220 11 O
with	232 4 O
acute	237 5 O
bacterial	243 9 O
sinusitis	253 9 B-Disease
.	262 1 O

PATIENTS	264 8 O
AND	273 3 O
METHODS	277 7 O
:	284 1 O
A	286 1 O
total	288 5 O
of	294 2 O
329	297 3 O
patients	301 8 O
enrolled	310 8 O
in	319 2 O
the	322 3 O
study	326 5 O
at	332 2 O
24	335 2 O
centers	338 7 O
.	345 1 O

All	347 3 O
patients	351 8 O
had	360 3 O
a	364 1 O
pre	366 3 O
-	369 1 O
therapy	370 7 O
Gram	378 4 O
'	382 1 O
s	383 1 O
stain	385 5 O
and	391 3 O
culture	395 7 O
of	403 2 O
sinus	406 5 O
exudate	412 7 O
obtained	420 8 O
by	429 2 O
antral	432 6 O
puncture	439 8 O
or	448 2 O
nasal	451 5 O
endoscopy	457 9 O
.	466 1 O

Clinical	468 8 O
response	477 8 O
was	486 3 O
assessed	490 8 O
on	499 2 O
the	502 3 O
basis	506 5 O
of	512 2 O
signs	515 5 O
and	521 3 O
symptoms	525 8 O
and	534 3 O
sinus	538 5 O
radiograph	544 10 O
or	555 2 O
computed	558 8 O
tomography	567 10 O
results	578 7 O
.	585 1 O

Microbiologic	587 13 O
cure	601 4 O
rates	606 5 O
were	612 4 O
determined	617 10 O
on	628 2 O
the	631 3 O
basis	635 5 O
of	641 2 O
presumed	644 8 O
plus	653 4 O
documented	658 10 O
eradication	669 11 O
of	681 2 O
the	684 3 O
pre	688 3 O
-	691 1 O
therapy	692 7 O
pathogen	700 8 O
(	708 1 O
s	709 1 O
)	710 1 O
.	711 1 O

RESULTS	713 7 O
:	720 1 O
The	722 3 O
most	726 4 O
common	731 6 O
pathogens	738 9 O
were	748 4 O
Haemophilus	753 11 O
influenzae	765 10 O
,	775 1 O
Streptococcus	777 13 O
pneumoniae	791 10 O
,	801 1 O
Staphylococcus	803 14 O
aureus	818 6 O
,	824 1 O
and	826 3 O
Moraxella	830 9 O
catarrhalis	840 11 O
.	851 1 O

Of	853 2 O
300	856 3 O
clinically	860 10 O
evaluable	871 9 O
patients	881 8 O
,	889 1 O
175	891 3 O
(	895 1 O
58	896 2 O
%	898 1 O
)	899 1 O
were	901 4 O
cured	906 5 O
and	912 3 O
90	916 2 O
(	919 1 O
30	920 2 O
%	922 1 O
)	923 1 O
were	925 4 O
improved	930 8 O
at	939 2 O
the	942 3 O
post	946 4 O
-	950 1 O
therapy	951 7 O
evaluation	959 10 O
,	969 1 O
resulting	971 9 O
in	981 2 O
a	984 1 O
clinical	986 8 O
success	995 7 O
rate	1003 4 O
of	1008 2 O
88	1011 2 O
%	1013 1 O
.	1014 1 O

Thirty	1016 6 O
-	1022 1 O
five	1023 4 O
patients	1028 8 O
(	1037 1 O
12	1038 2 O
%	1040 1 O
)	1041 1 O
clinically	1043 10 O
failed	1054 6 O
treatment	1061 9 O
.	1070 1 O

The	1072 3 O
microbiologic	1076 13 O
eradication	1090 11 O
rate	1102 4 O
(	1107 1 O
presumed	1108 8 O
plus	1117 4 O
documented	1122 10 O
)	1132 1 O
among	1134 5 O
138	1140 3 O
microbiologically	1144 17 O
evaluable	1162 9 O
patients	1172 8 O
was	1181 3 O
92	1185 2 O
%	1187 1 O
.	1188 1 O

Microbiologic	1190 13 O
eradication	1204 11 O
rates	1216 5 O
(	1222 1 O
presumed	1223 8 O
plus	1232 4 O
documented	1237 10 O
)	1247 1 O
of	1249 2 O
the	1252 3 O
most	1256 4 O
common	1261 6 O
pathogens	1268 9 O
ranged	1278 6 O
from	1285 4 O
93	1290 2 O
%	1292 1 O
(	1294 1 O
M	1295 1 O
.	1296 1 O
catarrhalis	1298 11 O
)	1309 1 O
to	1311 2 O
100	1314 3 O
%	1317 1 O
(	1319 1 O
S	1320 1 O
.	1321 1 O
pneumoniae	1323 10 O
)	1333 1 O
at	1335 2 O
the	1338 3 O
post	1342 4 O
-	1346 1 O
therapy	1347 7 O
visit	1355 5 O
.	1360 1 O

All	1362 3 O
but	1366 3 O
one	1370 3 O
of	1374 2 O
the	1377 3 O
265	1381 3 O
patients	1385 8 O
who	1394 3 O
were	1398 4 O
cured	1403 5 O
or	1409 2 O
improved	1412 8 O
at	1421 2 O
post	1424 4 O
-	1428 1 O
therapy	1429 7 O
returned	1437 8 O
for	1446 3 O
a	1450 1 O
long	1452 4 O
-	1456 1 O
term	1457 4 O
follow	1462 6 O
-	1468 1 O
up	1469 2 O
visit	1472 5 O
;	1477 1 O
243	1479 3 O
(	1483 1 O
92	1484 2 O
%	1486 1 O
)	1487 1 O
remained	1489 8 O
well	1498 4 O
4	1503 1 O
to	1505 2 O
6	1508 1 O
weeks	1510 5 O
after	1516 5 O
therapy	1522 7 O
;	1529 1 O
and	1531 3 O
21	1535 2 O
(	1538 1 O
8	1539 1 O
%	1540 1 O
)	1541 1 O
had	1543 3 O
a	1547 1 O
relapse	1549 7 O
of	1557 2 O
symptoms	1560 8 O
.	1568 1 O

Adverse	1570 7 O
events	1578 6 O
considered	1585 10 O
to	1596 2 O
be	1599 2 O
related	1602 7 O
to	1610 2 O
levofloxacin	1613 12 B-Chemical
administration	1626 14 O
were	1641 4 O
reported	1646 8 O
by	1655 2 O
29	1658 2 O
patients	1661 8 O
(	1670 1 O
9	1671 1 O
%	1672 1 O
)	1673 1 O
.	1674 1 O

The	1676 3 O
most	1680 4 O
common	1685 6 O
drug	1692 4 O
-	1696 1 O
related	1697 7 O
adverse	1705 7 O
events	1713 6 O
were	1720 4 O
diarrhea	1725 8 B-Disease
,	1733 1 O
flatulence	1735 10 B-Disease
,	1745 1 O
and	1747 3 O
nausea	1751 6 B-Disease
;	1757 1 O
most	1759 4 O
adverse	1764 7 O
events	1772 6 O
were	1779 4 O
mild	1784 4 O
to	1789 2 O
moderate	1792 8 O
in	1801 2 O
severity	1804 8 O
.	1812 1 O

CONCLUSION	1814 10 O
:	1824 1 O
The	1826 3 O
results	1830 7 O
of	1838 2 O
this	1841 4 O
study	1846 5 O
indicate	1852 8 O
that	1861 4 O
levofloxacin	1866 12 B-Chemical
500	1879 3 O
mg	1883 2 O
once	1886 4 O
daily	1891 5 O
is	1897 2 O
an	1900 2 O
effective	1903 9 O
and	1913 3 O
safe	1917 4 O
treatment	1922 9 O
for	1932 3 O
acute	1936 5 O
bacterial	1942 9 O
sinusitis	1952 9 B-Disease
.	1961 1 O

Clinical	0 8 O
evaluation	9 10 O
on	20 2 O
combined	23 8 O
administration	32 14 O
of	47 2 O
oral	50 4 O
prostacyclin	55 12 B-Chemical
analogue	68 8 O
beraprost	77 9 B-Chemical
and	87 3 O
phosphodiesterase	91 17 O
inhibitor	109 9 O
cilostazol	119 10 B-Chemical
.	129 1 O

Among	131 5 O
various	137 7 O
oral	145 4 O
antiplatelets	150 13 O
,	163 1 O
a	165 1 O
combination	167 11 O
of	179 2 O
a	182 1 O
novel	184 5 O
prostacyclin	190 12 B-Chemical
analogue	203 8 O
beraprost	212 9 B-Chemical
(	222 1 O
BPT	223 3 B-Chemical
)	226 1 O
and	228 3 O
a	232 1 O
potent	234 6 O
phosphodiesterase	241 17 O
inhibitor	259 9 O
cilostazol	269 10 B-Chemical
(	280 1 O
CLZ	281 3 B-Chemical
)	284 1 O
may	286 3 O
result	290 6 O
in	297 2 O
untoward	300 8 O
clinical	309 8 O
effects	318 7 O
due	326 3 O
to	330 2 O
possible	333 8 O
synergistic	342 11 O
elevation	354 9 O
of	364 2 O
intracellular	367 13 O
cAMP	381 4 B-Chemical
(	386 1 O
cyclic	387 6 B-Chemical
adenosine	394 9 I-Chemical
3	404 1 I-Chemical
'	405 1 I-Chemical
,	406 1 I-Chemical
5	407 1 I-Chemical
'	408 1 I-Chemical
-	409 1 I-Chemical
monophosphate	410 13 I-Chemical
)	423 1 O
.	424 1 O

Thereby	426 7 O
,	433 1 O
a	435 1 O
clinical	437 8 O
study	446 5 O
of	452 2 O
the	455 3 O
combined	459 8 O
administration	468 14 O
of	483 2 O
the	486 3 O
two	490 3 O
agents	494 6 O
was	501 3 O
attempted	505 9 O
.	514 1 O

Twelve	516 6 O
healthy	523 7 O
volunteers	531 10 O
were	542 4 O
assigned	547 8 O
to	556 2 O
take	559 4 O
BPT	564 3 B-Chemical
/	567 1 O
CLZ	568 3 B-Chemical
in	572 2 O
the	575 3 O
following	579 9 O
schedule	589 8 O
;	597 1 O
BPT	599 3 B-Chemical
:	602 1 O
40	604 2 O
micrograms	607 10 O
at	618 2 O
day	621 3 O
1	625 1 O
and	627 3 O
120	631 3 O
micrograms	635 10 O
t	646 1 O
.	647 1 O
i	648 1 O
.	649 1 O
d	650 1 O
.	651 1 O
from	653 4 O
day	658 3 O
7	662 1 O
to	664 2 O
14	667 2 O
,	669 1 O
CLZ	671 3 B-Chemical
:	674 1 O
200	676 3 O
mg	680 2 O
t	683 1 O
.	684 1 O
i	685 1 O
.	686 1 O
d	687 1 O
.	688 1 O
from	690 4 O
day	695 3 O
3	699 1 O
to	701 2 O
14	704 2 O
.	706 1 O

At	708 2 O
various	711 7 O
time	719 4 O
intervals	724 9 O
,	733 1 O
physical	735 8 O
examination	744 11 O
and	756 3 O
blood	760 5 O
collection	766 10 O
for	777 3 O
ex	781 2 O
vivo	784 4 O
platelet	789 8 B-Disease
aggregation	798 11 I-Disease
and	810 3 O
determination	814 13 O
of	828 2 O
intraplatelet	831 13 O
cAMP	845 4 B-Chemical
were	850 4 O
performed	855 9 O
.	864 1 O

Throughout	866 10 O
the	877 3 O
observation	881 11 O
period	893 6 O
,	899 1 O
no	901 2 O
significant	904 11 O
alteration	916 10 O
in	927 2 O
vital	930 5 O
signs	936 5 O
was	942 3 O
observed	946 8 O
.	954 1 O

Seven	956 5 O
out	962 3 O
of	966 2 O
12	969 2 O
subjects	972 8 O
experienced	981 11 O
headache	993 8 B-Disease
of	1002 2 O
a	1005 1 O
short	1007 5 O
duration	1013 8 O
accompanying	1022 12 O
facial	1035 6 B-Disease
flush	1042 5 I-Disease
in	1048 2 O
one	1051 3 O
and	1055 3 O
nausea	1059 6 B-Disease
in	1066 2 O
one	1069 3 O
,	1072 1 O
especially	1074 10 O
after	1085 5 O
ingestion	1091 9 O
of	1101 2 O
CLZ	1104 3 B-Chemical
.	1107 1 O

All	1109 3 O
of	1113 2 O
these	1116 5 O
symptoms	1122 8 O
,	1130 1 O
probably	1132 8 O
caused	1141 6 O
by	1148 2 O
the	1151 3 O
vasodilating	1155 12 O
effect	1168 6 O
of	1175 2 O
the	1178 3 O
two	1182 3 O
agents	1186 6 O
,	1192 1 O
were	1194 4 O
of	1199 2 O
mild	1202 4 O
degree	1207 6 O
and	1214 3 O
no	1218 2 O
special	1221 7 O
treatment	1229 9 O
was	1239 3 O
required	1243 8 O
.	1251 1 O

Intraplatelet	1253 13 O
cAMP	1267 4 B-Chemical
content	1272 7 O
was	1280 3 O
gradually	1284 9 O
but	1294 3 O
significantly	1298 13 O
increased	1312 9 O
to	1322 2 O
9	1325 1 O
.	1326 1 O
84	1327 2 O
+	1330 1 O
/	1331 1 O
-	1332 1 O
4	1334 1 O
.	1335 1 O
59	1336 2 O
pmol	1339 4 O
per	1344 3 O
10	1348 2 O
(	1350 1 O
9	1351 1 O
)	1352 1 O
platelets	1354 9 O
at	1364 2 O
day	1367 3 O
14	1371 2 O
in	1374 2 O
comparison	1377 10 O
with	1388 4 O
the	1393 3 O
initial	1397 7 O
value	1405 5 O
(	1411 1 O
6	1412 1 O
.	1413 1 O
87	1414 2 O
+	1417 1 O
/	1418 1 O
-	1419 1 O
2	1421 1 O
.	1422 1 O
25	1423 2 O
pmol	1426 4 O
)	1430 1 O
.	1431 1 O

The	1433 3 O
platelet	1437 8 O
aggregability	1446 13 O
was	1460 3 O
significantly	1464 13 O
suppressed	1478 10 O
at	1489 2 O
various	1492 7 O
time	1500 4 O
intervals	1505 9 O
but	1515 3 O
no	1519 2 O
additive	1522 8 O
or	1531 2 O
synergistic	1534 11 O
inhibitory	1546 10 O
effect	1557 6 O
by	1564 2 O
the	1567 3 O
combined	1571 8 O
administration	1580 14 O
was	1595 3 O
noted	1599 5 O
.	1604 1 O

In	1606 2 O
conclusion	1609 10 O
,	1619 1 O
the	1621 3 O
combined	1625 8 O
administration	1634 14 O
of	1649 2 O
BPT	1652 3 B-Chemical
/	1655 1 O
CLZ	1656 3 B-Chemical
is	1660 2 O
safe	1663 4 O
at	1668 2 O
doses	1671 5 O
used	1677 4 O
in	1682 2 O
the	1685 3 O
study	1689 5 O
,	1694 1 O
though	1696 6 O
the	1703 3 O
beneficial	1707 10 O
clinical	1718 8 O
effect	1727 6 O
of	1734 2 O
the	1737 3 O
combined	1741 8 O
administration	1750 14 O
has	1765 3 O
yet	1769 3 O
to	1773 2 O
be	1776 2 O
elucidated	1779 10 O
.	1789 1 O

Gastrointestinal	0 16 O
tolerability	17 12 O
of	30 2 O
etoricoxib	33 10 B-Chemical
in	44 2 O
rheumatoid	47 10 B-Disease
arthritis	58 9 I-Disease
patients	68 8 O
:	76 1 O
results	78 7 O
of	86 2 O
the	89 3 O
etoricoxib	93 10 B-Chemical
vs	104 2 O
diclofenac	107 10 B-Chemical
sodium	118 6 I-Chemical
gastrointestinal	125 16 O
tolerability	142 12 O
and	155 3 O
effectiveness	159 13 O
trial	173 5 O
(	179 1 O
EDGE	180 4 O
-	184 1 O
II	185 2 O
)	187 1 O
.	188 1 O

OBJECTIVE	190 9 O
:	199 1 O
A	201 1 O
randomised	203 10 O
,	213 1 O
double	215 6 O
-	221 1 O
blind	222 5 O
study	228 5 O
to	234 2 O
compare	237 7 O
the	245 3 O
gastrointestinal	249 16 O
(	266 1 O
GI	267 2 O
)	269 1 O
tolerability	271 12 O
,	283 1 O
safety	285 6 O
and	292 3 O
efficacy	296 8 O
of	305 2 O
etoricoxib	308 10 B-Chemical
and	319 3 O
diclofenac	323 10 B-Chemical
in	334 2 O
patients	337 8 O
with	346 4 O
rheumatoid	351 10 B-Disease
arthritis	362 9 I-Disease
(	372 1 O
RA	373 2 B-Disease
)	375 1 O
.	376 1 O

PATIENTS	378 8 O
AND	387 3 O
METHODS	391 7 O
:	398 1 O
A	400 1 O
total	402 5 O
of	408 2 O
4086	411 4 O
patients	416 8 O
(	425 1 O
mean	426 4 O
age	431 3 O
60	435 2 O
.	437 1 O
8	438 1 O
years	440 5 O
)	445 1 O
diagnosed	447 9 O
with	457 4 O
RA	462 2 B-Disease
were	465 4 O
enrolled	470 8 O
and	479 3 O
received	483 8 O
etoricoxib	492 10 B-Chemical
90	503 2 O
mg	506 2 O
daily	509 5 O
(	515 1 O
n	516 1 O
=	518 1 O
2032	520 4 O
)	524 1 O
or	526 2 O
diclofenac	529 10 B-Chemical
75	540 2 O
mg	543 2 O
twice	546 5 O
daily	552 5 O
(	558 1 O
n	559 1 O
=	561 1 O
2054	563 4 O
)	567 1 O
.	568 1 O

Use	570 3 O
of	574 2 O
gastroprotective	577 16 O
agents	594 6 O
and	601 3 O
low	605 3 O
-	608 1 O
dose	609 4 O
aspirin	614 7 B-Chemical
was	622 3 O
allowed	626 7 O
.	633 1 O

The	635 3 O
prespecified	639 12 O
primary	652 7 O
end	660 3 O
point	664 5 O
consisted	670 9 O
of	680 2 O
the	683 3 O
cumulative	687 10 O
rate	698 4 O
of	703 2 O
patient	706 7 O
discontinuations	714 16 O
due	731 3 O
to	735 2 O
clinical	738 8 O
and	747 3 O
laboratory	751 10 O
GI	762 2 O
adverse	765 7 O
experiences	773 11 O
(	785 1 O
AEs	786 3 O
)	789 1 O
.	790 1 O

General	792 7 O
safety	800 6 O
was	807 3 O
also	811 4 O
assessed	816 8 O
,	824 1 O
including	826 9 O
adjudicated	836 11 O
thrombotic	848 10 B-Disease
cardiovascular	859 14 I-Disease
event	874 5 O
data	880 4 O
.	884 1 O

Efficacy	886 8 O
was	895 3 O
evaluated	899 9 O
using	909 5 O
the	915 3 O
Patient	919 7 O
Global	927 6 O
Assessment	934 10 O
of	945 2 O
Disease	948 7 O
Status	956 6 O
(	963 1 O
PGADS	964 5 O
;	969 1 O
0	971 1 O
-	972 1 O
4	973 1 O
point	975 5 O
scale	981 5 O
)	986 1 O
.	987 1 O

RESULTS	989 7 O
:	996 1 O
Mean	998 4 O
(	1003 1 O
SD	1004 2 O
;	1006 1 O
maximum	1008 7 O
)	1015 1 O
duration	1017 8 O
of	1026 2 O
treatment	1029 9 O
was	1039 3 O
19	1043 2 O
.	1045 1 O
3	1046 1 O
(	1048 1 O
10	1049 2 O
.	1051 1 O
3	1052 1 O
;	1053 1 O
32	1055 2 O
.	1057 1 O
9	1058 1 O
)	1059 1 O
and	1061 3 O
19	1065 2 O
.	1067 1 O
1	1068 1 O
(	1070 1 O
10	1071 2 O
.	1073 1 O
4	1074 1 O
;	1075 1 O
33	1077 2 O
.	1079 1 O
1	1080 1 O
)	1081 1 O
months	1083 6 O
in	1090 2 O
the	1093 3 O
etoricoxib	1097 10 B-Chemical
and	1108 3 O
diclofenac	1112 10 B-Chemical
groups	1123 6 O
,	1129 1 O
respectively	1131 12 O
.	1143 1 O

The	1145 3 O
cumulative	1149 10 O
discontinuation	1160 15 O
rate	1176 4 O
due	1181 3 O
to	1185 2 O
GI	1188 2 B-Disease
AEs	1191 3 I-Disease
was	1195 3 O
significantly	1199 13 O
lower	1213 5 O
with	1219 4 O
etoricoxib	1224 10 B-Chemical
than	1235 4 O
diclofenac	1240 10 B-Chemical
(	1251 1 O
5	1252 1 O
.	1253 1 O
2	1254 1 O
vs	1256 2 O
8	1259 1 O
.	1260 1 O
5	1261 1 O
events	1263 6 O
per	1270 3 O
100	1274 3 O
patient	1278 7 O
-	1285 1 O
years	1286 5 O
,	1291 1 O
respectively	1293 12 O
;	1305 1 O
hazard	1307 6 O
ratio	1314 5 O
0	1320 1 O
.	1321 1 O
62	1322 2 O
(	1325 1 O
95	1326 2 O
%	1328 1 O
CI	1330 2 O
:	1332 1 O
0	1334 1 O
.	1335 1 O
47	1336 2 O
,	1338 1 O
0	1340 1 O
.	1341 1 O
81	1342 2 O
;	1344 1 O
p	1346 1 O
<	1347 1 O
or	1348 2 O
=	1350 1 O
0	1351 1 O
.	1352 1 O
001	1353 3 O
)	1356 1 O
)	1357 1 O
.	1358 1 O

The	1360 3 O
incidence	1364 9 O
of	1374 2 O
discontinuations	1377 16 O
for	1394 3 O
hypertension	1398 12 B-Disease
-	1410 1 O
related	1411 7 O
and	1419 3 O
oedema	1423 6 B-Disease
-	1429 1 O
related	1430 7 O
AEs	1438 3 O
were	1442 4 O
significantly	1447 13 O
higher	1461 6 O
with	1468 4 O
etoricoxib	1473 10 B-Chemical
(	1484 1 O
2	1485 1 O
.	1486 1 O
5	1487 1 O
%	1488 1 O
and	1490 3 O
1	1494 1 O
.	1495 1 O
1	1496 1 O
%	1497 1 O
respectively	1499 12 O
)	1511 1 O
compared	1513 8 O
with	1522 4 O
diclofenac	1527 10 B-Chemical
(	1538 1 O
1	1539 1 O
.	1540 1 O
5	1541 1 O
%	1542 1 O
and	1544 3 O
0	1548 1 O
.	1549 1 O
4	1550 1 O
%	1551 1 O
respectively	1553 12 O
;	1565 1 O
p	1567 1 O
<	1568 1 O
0	1569 1 O
.	1570 1 O
001	1571 3 O
for	1575 3 O
hypertension	1579 12 B-Disease
and	1592 3 O
p	1596 1 O
<	1597 1 O
0	1598 1 O
.	1599 1 O
01	1600 2 O
for	1603 3 O
oedema	1607 6 B-Disease
)	1613 1 O
.	1614 1 O

Etoricoxib	1616 10 B-Chemical
and	1627 3 O
diclofenac	1631 10 B-Chemical
treatment	1642 9 O
resulted	1652 8 O
in	1661 2 O
similar	1664 7 O
efficacy	1672 8 O
(	1681 1 O
PGADS	1682 5 O
mean	1688 4 O
changes	1693 7 O
from	1701 4 O
baseline	1706 8 O
-	1715 1 O
0	1716 1 O
.	1717 1 O
62	1718 2 O
vs	1721 2 O
-	1724 1 O
0	1725 1 O
.	1726 1 O
58	1727 2 O
,	1729 1 O
respectively	1731 12 O
)	1743 1 O
.	1744 1 O

CONCLUSIONS	1746 11 O
:	1757 1 O
Etoricoxib	1759 10 B-Chemical
90	1770 2 O
mg	1773 2 O
demonstrated	1776 12 O
a	1789 1 O
significantly	1791 13 O
lower	1805 5 O
risk	1811 4 O
for	1816 3 O
discontinuing	1820 13 O
treatment	1834 9 O
due	1844 3 O
to	1848 2 O
GI	1851 2 B-Disease
AEs	1854 3 I-Disease
compared	1858 8 O
with	1867 4 O
diclofenac	1872 10 B-Chemical
150	1883 3 O
mg	1887 2 O
.	1889 1 O

Discontinuations	1891 16 O
from	1908 4 O
renovascular	1913 12 O
AEs	1926 3 O
,	1929 1 O
although	1931 8 O
less	1940 4 O
common	1945 6 O
than	1952 4 O
discontinuations	1957 16 O
from	1974 4 O
GI	1979 2 B-Disease
AEs	1982 3 I-Disease
,	1985 1 O
were	1987 4 O
significantly	1992 13 O
higher	2006 6 O
with	2013 4 O
etoricoxib	2018 10 B-Chemical
.	2028 1 O

Placebo	0 7 O
-	7 1 O
level	8 5 O
incidence	14 9 O
of	24 2 O
extrapyramidal	27 14 B-Disease
symptoms	42 8 I-Disease
(	51 1 O
EPS	52 3 B-Disease
)	55 1 O
with	57 4 O
quetiapine	62 10 B-Chemical
in	73 2 O
controlled	76 10 O
studies	87 7 O
of	95 2 O
patients	98 8 O
with	107 4 O
bipolar	112 7 B-Disease
mania	120 5 I-Disease
.	125 1 O

OBJECTIVES	127 10 O
:	137 1 O
To	139 2 O
evaluate	142 8 O
extrapyramidal	151 14 B-Disease
symptoms	166 8 I-Disease
(	175 1 O
EPS	176 3 B-Disease
)	179 1 O
,	180 1 O
including	182 9 O
akathisia	192 9 B-Disease
,	201 1 O
with	203 4 O
quetiapine	208 10 B-Chemical
in	219 2 O
patients	222 8 O
with	231 4 O
bipolar	236 7 B-Disease
mania	244 5 I-Disease
.	249 1 O

METHODS	251 7 O
:	258 1 O
Data	260 4 O
were	265 4 O
analyzed	270 8 O
from	279 4 O
four	284 4 O
similarly	289 9 O
designed	299 8 O
,	307 1 O
randomized	309 10 O
,	319 1 O
double	321 6 O
-	327 1 O
blind	328 5 O
,	333 1 O
3	335 1 O
-	336 1 O
to	338 2 O
12	341 2 O
-	343 1 O
week	344 4 O
studies	349 7 O
.	356 1 O

Two	358 3 O
studies	362 7 O
evaluated	370 9 O
quetiapine	380 10 B-Chemical
monotherapy	391 11 O
(	403 1 O
up	404 2 O
to	407 2 O
800	410 3 O
mg	414 2 O
/	416 1 O
day	417 3 O
)	420 1 O
(	422 1 O
n	423 1 O
=	425 1 O
209	427 3 O
)	430 1 O
versus	432 6 O
placebo	439 7 O
(	447 1 O
n	448 1 O
=	450 1 O
198	452 3 O
)	455 1 O
,	456 1 O
with	458 4 O
lithium	463 7 B-Chemical
or	471 2 O
haloperidol	474 11 B-Chemical
monotherapy	486 11 O
as	498 2 O
respective	501 10 O
active	512 6 O
controls	519 8 O
.	527 1 O

Two	529 3 O
studies	533 7 O
evaluated	541 9 O
quetiapine	551 10 B-Chemical
(	562 1 O
up	563 2 O
to	566 2 O
800	569 3 O
mg	573 2 O
/	575 1 O
day	576 3 O
)	579 1 O
in	581 2 O
combination	584 11 O
with	596 4 O
a	601 1 O
mood	603 4 O
stabilizer	608 10 O
(	619 1 O
lithium	620 7 B-Chemical
or	628 2 O
divalproex	631 10 B-Chemical
,	641 1 O
QTP	643 3 B-Chemical
+	647 1 O
Li	649 2 B-Chemical
/	651 1 O
DVP	652 3 B-Chemical
)	655 1 O
(	657 1 O
n	658 1 O
=	660 1 O
196	662 3 O
)	665 1 O
compared	667 8 O
to	676 2 O
placebo	679 7 O
and	687 3 O
mood	691 4 O
stabilizer	696 10 O
(	707 1 O
PBO	708 3 O
+	712 1 O
Li	714 2 B-Chemical
/	716 1 O
DVP	717 3 B-Chemical
)	720 1 O
(	722 1 O
n	723 1 O
=	725 1 O
203	727 3 O
)	730 1 O
.	731 1 O

Extrapyramidal	733 14 B-Disease
symptoms	748 8 I-Disease
were	757 4 O
evaluated	762 9 O
using	772 5 O
the	778 3 O
Simpson	782 7 O
-	789 1 O
Angus	790 5 O
Scale	796 5 O
(	802 1 O
SAS	803 3 O
)	806 1 O
,	807 1 O
the	809 3 O
Barnes	813 6 O
Akathisia	820 9 O
Rating	830 6 O
Scale	837 5 O
(	843 1 O
BARS	844 4 O
)	848 1 O
,	849 1 O
adverse	851 7 O
event	859 5 O
reports	865 7 O
and	873 3 O
anticholinergic	877 15 O
drug	893 4 O
usage	898 5 O
.	903 1 O

RESULTS	905 7 O
:	912 1 O
The	914 3 O
incidence	918 9 O
of	928 2 O
EPS	931 3 B-Disease
-	934 1 O
related	935 7 O
adverse	943 7 O
events	951 6 O
,	957 1 O
including	959 9 O
akathisia	969 9 B-Disease
,	978 1 O
was	980 3 O
no	984 2 O
different	987 9 O
with	997 4 O
quetiapine	1002 10 B-Chemical
monotherapy	1013 11 O
(	1025 1 O
12	1026 2 O
.	1028 1 O
9	1029 1 O
%	1030 1 O
)	1031 1 O
than	1033 4 O
with	1038 4 O
placebo	1043 7 O
(	1051 1 O
13	1052 2 O
.	1054 1 O
1	1055 1 O
%	1056 1 O
)	1057 1 O
.	1058 1 O

Similarly	1060 9 O
,	1069 1 O
EPS	1071 3 B-Disease
-	1074 1 O
related	1075 7 O
adverse	1083 7 O
events	1091 6 O
with	1098 4 O
QTP	1103 3 B-Chemical
+	1107 1 O
Li	1109 2 B-Chemical
/	1111 1 O
DVP	1112 3 B-Chemical
(	1116 1 O
21	1117 2 O
.	1119 1 O
4	1120 1 O
%	1121 1 O
)	1122 1 O
were	1124 4 O
no	1129 2 O
different	1132 9 O
than	1142 4 O
with	1147 4 O
PBO	1152 3 O
+	1156 1 O
Li	1158 2 B-Chemical
/	1160 1 O
DVP	1161 3 B-Chemical
(	1165 1 O
19	1166 2 O
.	1168 1 O
2	1169 1 O
%	1170 1 O
)	1171 1 O
.	1172 1 O

Adverse	1174 7 O
events	1182 6 O
related	1189 7 O
to	1197 2 O
EPS	1200 3 B-Disease
occurred	1204 8 O
in	1213 2 O
59	1216 2 O
.	1218 1 O
6	1219 1 O
%	1220 1 O
of	1222 2 O
patients	1225 8 O
treated	1234 7 O
with	1242 4 O
haloperidol	1247 11 B-Chemical
(	1259 1 O
n	1260 1 O
=	1262 1 O
99	1264 2 O
)	1266 1 O
monotherapy	1268 11 O
,	1279 1 O
whereas	1281 7 O
26	1289 2 O
.	1291 1 O
5	1292 1 O
%	1293 1 O
of	1295 2 O
patients	1298 8 O
treated	1307 7 O
with	1315 4 O
lithium	1320 7 B-Chemical
(	1328 1 O
n	1329 1 O
=	1331 1 O
98	1333 2 O
)	1335 1 O
monotherapy	1337 11 O
experienced	1349 11 O
adverse	1361 7 O
events	1369 6 O
related	1376 7 O
to	1384 2 O
EPS	1387 3 B-Disease
.	1390 1 O

The	1392 3 O
incidence	1396 9 O
of	1406 2 O
akathisia	1409 9 B-Disease
was	1419 3 O
low	1423 3 O
and	1427 3 O
similar	1431 7 O
with	1439 4 O
quetiapine	1444 10 B-Chemical
monotherapy	1455 11 O
(	1467 1 O
3	1468 1 O
.	1469 1 O
3	1470 1 O
%	1471 1 O
)	1472 1 O
and	1474 3 O
placebo	1478 7 O
(	1486 1 O
6	1487 1 O
.	1488 1 O
1	1489 1 O
%	1490 1 O
)	1491 1 O
,	1492 1 O
and	1494 3 O
with	1498 4 O
QTP	1503 3 B-Chemical
+	1507 1 O
Li	1509 2 B-Chemical
/	1511 1 O
DVP	1512 3 B-Chemical
(	1516 1 O
3	1517 1 O
.	1518 1 O
6	1519 1 O
%	1520 1 O
)	1521 1 O
and	1523 3 O
PBO	1527 3 O
+	1531 1 O
Li	1533 2 B-Chemical
/	1535 1 O
DVP	1536 3 B-Chemical
(	1540 1 O
4	1541 1 O
.	1542 1 O
9	1543 1 O
%	1544 1 O
)	1545 1 O
.	1546 1 O

Lithium	1548 7 B-Chemical
was	1556 3 O
associated	1560 10 O
with	1571 4 O
a	1576 1 O
significantly	1578 13 O
higher	1592 6 O
incidence	1599 9 O
(	1609 1 O
p	1610 1 O
<	1612 1 O
0	1614 1 O
.	1615 1 O
05	1616 2 O
)	1618 1 O
of	1620 2 O
tremor	1623 6 B-Disease
(	1630 1 O
18	1631 2 O
.	1633 1 O
4	1634 1 O
%	1635 1 O
)	1636 1 O
than	1638 4 O
quetiapine	1643 10 B-Chemical
(	1654 1 O
5	1655 1 O
.	1656 1 O
6	1657 1 O
%	1658 1 O
)	1659 1 O
;	1660 1 O
cerebellar	1662 10 O
tremor	1673 6 B-Disease
,	1679 1 O
which	1681 5 O
is	1687 2 O
a	1690 1 O
known	1692 5 O
adverse	1698 7 O
effect	1706 6 O
of	1713 2 O
lithium	1716 7 B-Chemical
,	1723 1 O
may	1725 3 O
have	1729 4 O
contributed	1734 11 O
to	1746 2 O
the	1749 3 O
elevated	1753 8 O
rate	1762 4 O
of	1767 2 O
tremor	1770 6 B-Disease
in	1777 2 O
patients	1780 8 O
receiving	1789 9 O
lithium	1799 7 B-Chemical
therapy	1807 7 O
.	1814 1 O

Haloperidol	1816 11 B-Chemical
induced	1828 7 O
a	1836 1 O
significantly	1838 13 O
higher	1852 6 O
incidence	1859 9 O
(	1869 1 O
p	1870 1 O
<	1872 1 O
0	1874 1 O
.	1875 1 O
001	1876 3 O
)	1879 1 O
of	1881 2 O
akathisia	1884 9 B-Disease
(	1894 1 O
33	1895 2 O
.	1897 1 O
3	1898 1 O
%	1899 1 O
versus	1901 6 O
5	1908 1 O
.	1909 1 O
9	1910 1 O
%	1911 1 O
)	1912 1 O
,	1913 1 O
tremor	1915 6 B-Disease
(	1922 1 O
30	1923 2 O
.	1925 1 O
3	1926 1 O
%	1927 1 O
versus	1929 6 O
7	1936 1 O
.	1937 1 O
8	1938 1 O
%	1939 1 O
)	1940 1 O
,	1941 1 O
and	1943 3 O
extrapyramidal	1947 14 B-Disease
syndrome	1962 8 I-Disease
(	1971 1 O
35	1972 2 O
.	1974 1 O
4	1975 1 O
%	1976 1 O
versus	1978 6 O
5	1985 1 O
.	1986 1 O
9	1987 1 O
%	1988 1 O
)	1989 1 O
than	1991 4 O
quetiapine	1996 10 B-Chemical
.	2006 1 O

No	2008 2 O
significant	2011 11 O
differences	2023 11 O
were	2035 4 O
observed	2040 8 O
between	2049 7 O
quetiapine	2057 10 B-Chemical
and	2068 3 O
placebo	2072 7 O
on	2080 2 O
SAS	2083 3 O
and	2087 3 O
BARS	2091 4 O
scores	2096 6 O
.	2102 1 O

Anticholinergic	2104 15 O
use	2120 3 O
was	2124 3 O
low	2128 3 O
and	2132 3 O
similar	2136 7 O
with	2144 4 O
quetiapine	2149 10 B-Chemical
or	2160 2 O
placebo	2163 7 O
.	2170 1 O

CONCLUSIONS	2172 11 O
:	2183 1 O
In	2185 2 O
bipolar	2188 7 B-Disease
mania	2196 5 I-Disease
,	2201 1 O
the	2203 3 O
incidence	2207 9 O
of	2217 2 O
EPS	2220 3 B-Disease
,	2223 1 O
including	2225 9 O
akathisia	2235 9 B-Disease
,	2244 1 O
with	2246 4 O
quetiapine	2251 10 B-Chemical
therapy	2262 7 O
is	2270 2 O
similar	2273 7 O
to	2281 2 O
that	2284 4 O
with	2289 4 O
placebo	2294 7 O
.	2301 1 O

Contribution	0 12 O
of	13 2 O
the	16 3 O
sympathetic	20 11 O
nervous	32 7 O
system	40 6 O
to	47 2 O
salt	50 4 O
-	54 1 O
sensitivity	55 11 O
in	67 2 O
lifetime	70 8 O
captopril	79 9 B-Chemical
-	88 1 O
treated	89 7 O
spontaneously	97 13 O
hypertensive	111 12 B-Disease
rats	124 4 O
.	128 1 O

OBJECTIVE	130 9 O
:	139 1 O
To	141 2 O
test	144 4 O
the	149 3 O
hypothesis	153 10 O
that	164 4 O
,	168 1 O
in	170 2 O
lifetime	173 8 O
captopril	182 9 B-Chemical
-	191 1 O
treated	192 7 O
spontaneously	200 13 O
hypertensive	214 12 B-Disease
rats	227 4 O
(	232 1 O
SHR	233 3 O
)	236 1 O
,	237 1 O
the	239 3 O
sympathetic	243 11 O
nervous	255 7 O
system	263 6 O
contributes	270 11 O
importantly	282 11 O
to	294 2 O
the	297 3 O
hypertensive	301 12 B-Disease
effect	314 6 O
of	321 2 O
dietary	324 7 B-Chemical
sodium	332 6 I-Chemical
chloride	339 8 I-Chemical
supplementation	348 15 O
.	363 1 O

METHODS	365 7 O
:	372 1 O
Male	374 4 O
SHR	379 3 O
(	383 1 O
aged	384 4 O
6	389 1 O
weeks	391 5 O
)	396 1 O
that	398 4 O
had	403 3 O
been	407 4 O
treated	412 7 O
from	420 4 O
conception	425 10 O
onward	436 6 O
with	443 4 O
either	448 6 O
captopril	455 9 B-Chemical
or	465 2 O
vehicle	468 7 O
remained	476 8 O
on	485 2 O
a	488 1 O
basal	490 5 O
sodium	496 6 B-Chemical
chloride	503 8 I-Chemical
diet	512 4 O
or	517 2 O
were	520 4 O
fed	525 3 O
a	529 1 O
high	531 4 O
sodium	536 6 B-Chemical
chloride	543 8 I-Chemical
diet	552 4 O
.	556 1 O

After	558 5 O
2	564 1 O
weeks	566 5 O
,	571 1 O
the	573 3 O
rats	577 4 O
were	582 4 O
subjected	587 9 O
to	597 2 O
ganglionic	600 10 O
blockade	611 8 O
and	620 3 O
2	624 1 O
days	626 4 O
later	631 5 O
,	636 1 O
an	638 2 O
infusion	641 8 O
of	650 2 O
clonidine	653 9 B-Chemical
.	662 1 O

RESULTS	664 7 O
:	671 1 O
Lifetime	673 8 O
captopril	682 9 B-Chemical
treatment	692 9 O
significantly	702 13 O
lowered	716 7 O
mean	724 4 O
arterial	729 8 O
pressure	738 8 O
in	747 2 O
both	750 4 O
groups	755 6 O
.	761 1 O

Intravenous	763 11 O
infusion	775 8 O
of	784 2 O
the	787 3 O
ganglionic	791 10 O
blocker	802 7 O
hexamethonium	810 13 B-Chemical
resulted	824 8 O
in	833 2 O
a	836 1 O
rapid	838 5 O
decline	844 7 O
in	852 2 O
MAP	855 3 O
that	859 4 O
eliminated	864 10 O
the	875 3 O
dietary	879 7 B-Chemical
sodium	887 6 I-Chemical
chloride	894 8 I-Chemical
-	902 1 O
induced	903 7 O
increase	911 8 B-Disease
in	920 2 I-Disease
MAP	923 3 I-Disease
in	927 2 O
both	930 4 O
groups	935 6 O
.	941 1 O

Infusion	943 8 O
of	952 2 O
the	955 3 O
central	959 7 O
nervous	967 7 O
system	975 6 O
alpha2	982 6 B-Chemical
-	988 1 I-Chemical
adrenergic	989 10 I-Chemical
receptor	1000 8 I-Chemical
agonist	1009 7 I-Chemical
clonidine	1017 9 B-Chemical
also	1027 4 O
resulted	1032 8 O
in	1041 2 O
a	1044 1 O
greater	1046 7 O
reduction	1054 9 O
in	1064 2 O
MAP	1067 3 O
in	1071 2 O
both	1074 4 O
groups	1079 6 O
of	1086 2 O
SHR	1089 3 O
that	1093 4 O
were	1098 4 O
fed	1103 3 O
the	1107 3 O
high	1111 4 O
(	1116 1 O
compared	1117 8 O
with	1126 4 O
the	1131 3 O
basal	1135 5 O
)	1140 1 O
sodium	1142 6 B-Chemical
chloride	1149 8 I-Chemical
diet	1158 4 O
.	1162 1 O

CONCLUSIONS	1164 11 O
:	1175 1 O
In	1177 2 O
both	1180 4 O
lifetime	1185 8 O
captopril	1194 9 B-Chemical
-	1203 1 O
treated	1204 7 O
and	1212 3 O
control	1216 7 O
SHR	1224 3 O
,	1227 1 O
the	1229 3 O
sympathetic	1233 11 O
nervous	1245 7 O
system	1253 6 O
contributes	1260 11 O
to	1272 2 O
the	1275 3 O
pressor	1279 7 O
effects	1287 7 O
of	1295 2 O
a	1298 1 O
high	1300 4 O
sodium	1305 6 B-Chemical
chloride	1312 8 I-Chemical
diet	1321 4 O
.	1325 1 O

Dose	0 4 O
-	4 1 O
related	5 7 O
beneficial	13 10 O
and	24 3 O
adverse	28 7 O
effects	36 7 O
of	44 2 O
dietary	47 7 O
corticosterone	55 14 B-Chemical
on	70 2 O
organophosphorus	73 16 B-Chemical
-	89 1 O
induced	90 7 O
delayed	98 7 O
neuropathy	106 10 B-Disease
in	117 2 O
chickens	120 8 O
.	128 1 O

Tri	130 3 B-Chemical
-	133 1 I-Chemical
ortho	134 5 I-Chemical
-	139 1 I-Chemical
tolyl	140 5 I-Chemical
phosphate	146 9 I-Chemical
(	156 1 O
TOTP	157 4 B-Chemical
)	161 1 O
,	162 1 O
360	164 3 O
mg	168 2 O
/	170 1 O
kg	171 2 O
,	173 1 O
po	175 2 O
,	177 1 O
and	179 3 O
0	183 1 B-Chemical
,	184 1 I-Chemical
0	185 1 I-Chemical
'	186 1 I-Chemical
-	187 1 I-Chemical
diisopropyl	188 11 I-Chemical
phosphorofluoridate	200 19 I-Chemical
(	220 1 O
DFP	221 3 B-Chemical
)	224 1 O
,	225 1 O
1	227 1 O
mg	229 2 O
/	231 1 O
kg	232 2 O
sc	235 2 O
,	237 1 O
were	239 4 O
administered	244 12 O
to	257 2 O
adult	260 5 O
White	266 5 O
Leghorn	272 7 O
chickens	280 8 O
24	289 2 O
hr	292 2 O
after	295 5 O
they	301 4 O
were	306 4 O
placed	311 6 O
on	318 2 O
diets	321 5 O
containing	327 10 O
0	338 1 O
to	340 2 O
300	343 3 O
ppm	347 3 O
corticosterone	351 14 B-Chemical
.	365 1 O

Supplemented	367 12 O
diets	380 5 O
were	386 4 O
continued	391 9 O
until	401 5 O
clinical	407 8 O
signs	416 5 O
and	422 3 O
lesions	426 7 O
of	434 2 O
delayed	437 7 O
neuropathy	445 10 B-Disease
appeared	456 8 O
.	464 1 O

Although	466 8 O
low	475 3 O
concentrations	479 14 O
(	494 1 O
less	495 4 O
than	500 4 O
or	505 2 O
equal	508 5 O
to	514 2 O
50	517 2 O
ppm	520 3 O
)	523 1 O
of	525 2 O
corticosterone	528 14 B-Chemical
had	543 3 O
beneficial	547 10 O
effects	558 7 O
on	566 2 O
TOTP	569 4 B-Chemical
-	573 1 O
induced	574 7 O
neuropathy	582 10 B-Disease
,	592 1 O
greater	594 7 O
than	602 4 O
or	607 2 O
equal	610 5 O
to	616 2 O
200	619 3 O
ppm	623 3 O
exacerbated	627 11 O
clinical	639 8 O
signs	648 5 O
in	654 2 O
chickens	657 8 O
given	666 5 O
either	672 6 O
TOTP	679 4 B-Chemical
or	684 2 O
DFP	687 3 B-Chemical
.	690 1 O

Neurotoxic	692 10 B-Disease
esterase	703 8 O
activities	712 10 O
24	723 2 O
hr	726 2 O
after	729 5 O
TOTP	735 4 B-Chemical
or	740 2 O
DFP	743 3 B-Chemical
were	747 4 O
less	752 4 O
than	757 4 O
20	762 2 O
%	764 1 O
of	766 2 O
values	769 6 O
measured	776 8 O
in	785 2 O
chickens	788 8 O
not	797 3 O
given	801 5 O
organophosphorous	807 17 B-Chemical
compounds	825 9 O
.	834 1 O

Chickens	836 8 O
given	845 5 O
200	851 3 O
ppm	855 3 O
corticosterone	859 14 B-Chemical
without	874 7 O
TOTP	882 4 B-Chemical
or	887 2 O
DFP	890 3 B-Chemical
had	894 3 O
significantly	898 13 O
elevated	912 8 O
activity	921 8 O
of	930 2 O
plasma	933 6 O
cholinesterase	940 14 O
and	955 3 O
significantly	959 13 O
inhibited	973 9 O
activity	983 8 O
of	992 2 O
liver	995 5 O
carboxylesterase	1001 16 O
.	1017 1 O

Degenerating	1019 12 B-Disease
myelinated	1032 10 I-Disease
fibers	1043 6 I-Disease
were	1050 4 O
also	1055 4 O
evident	1060 7 O
in	1068 2 O
distal	1071 6 O
levels	1078 6 O
of	1085 2 O
the	1088 3 O
peripheral	1092 10 O
nerves	1103 6 O
of	1110 2 O
chickens	1113 8 O
given	1122 5 O
TOTP	1128 4 B-Chemical
or	1133 2 O
DFP	1136 3 B-Chemical
.	1139 1 O

In	0 2 O
vivo	3 4 O
characterization	8 16 O
of	25 2 O
a	28 1 O
dual	30 4 O
adenosine	35 9 B-Chemical
A2A	45 3 I-Chemical
/	48 1 I-Chemical
A1	49 2 I-Chemical
receptor	52 8 I-Chemical
antagonist	61 10 I-Chemical
in	72 2 O
animal	75 6 O
models	82 6 O
of	89 2 O
Parkinson	92 9 B-Disease
'	101 1 I-Disease
s	102 1 I-Disease
disease	104 7 I-Disease
.	111 1 O

The	113 3 O
in	117 2 O
vivo	120 4 O
characterization	125 16 O
of	142 2 O
a	145 1 O
dual	147 4 O
adenosine	152 9 B-Chemical
A	162 1 I-Chemical
(	163 1 I-Chemical
2A	164 2 I-Chemical
)	166 1 I-Chemical
/	167 1 I-Chemical
A	168 1 I-Chemical
(	169 1 I-Chemical
1	170 1 I-Chemical
)	171 1 I-Chemical
receptor	173 8 I-Chemical
antagonist	182 10 I-Chemical
in	193 2 O
several	196 7 O
animal	204 6 O
models	211 6 O
of	218 2 O
Parkinson	221 9 B-Disease
'	230 1 I-Disease
s	231 1 I-Disease
disease	233 7 I-Disease
is	241 2 O
described	244 9 O
.	253 1 O

Discovery	255 9 O
and	265 3 O
scale	269 5 O
-	274 1 O
up	275 2 O
syntheses	278 9 O
of	288 2 O
compound	291 8 O
1	300 1 O
are	302 3 O
described	306 9 O
in	316 2 O
detail	319 6 O
,	325 1 O
highlighting	327 12 O
optimization	340 12 O
steps	353 5 O
that	359 4 O
increased	364 9 O
the	374 3 O
overall	378 7 O
yield	386 5 O
of	392 2 O
1	395 1 O
from	397 4 O
10	402 2 O
.	404 1 O
0	405 1 O
%	406 1 O
to	408 2 O
30	411 2 O
.	413 1 O
5	414 1 O
%	415 1 O
.	416 1 O

Compound	418 8 O
1	427 1 O
is	429 2 O
a	432 1 O
potent	434 6 O
A	441 1 O
(	442 1 O
2A	443 2 O
)	445 1 O
/	446 1 O
A	447 1 O
(	448 1 O
1	449 1 O
)	450 1 O
receptor	452 8 O
antagonist	461 10 O
in	472 2 O
vitro	475 5 O
(	481 1 O
A	482 1 O
(	483 1 O
2A	484 2 O
)	486 1 O
K	488 1 O
(	489 1 O
i	490 1 O
)	491 1 O
=	493 1 O
4	495 1 O
.	496 1 O
1	497 1 O
nM	499 2 O
;	501 1 O
A	503 1 O
(	504 1 O
1	505 1 O
)	506 1 O
K	508 1 O
(	509 1 O
i	510 1 O
)	511 1 O
=	513 1 O
17	515 2 O
.	517 1 O
0	518 1 O
nM	520 2 O
)	522 1 O
that	524 4 O
has	529 3 O
excellent	533 9 O
activity	543 8 O
,	551 1 O
after	553 5 O
oral	559 4 O
administration	564 14 O
,	578 1 O
across	580 6 O
a	587 1 O
number	589 6 O
of	596 2 O
animal	599 6 O
models	606 6 O
of	613 2 O
Parkinson	616 9 B-Disease
'	625 1 I-Disease
s	626 1 I-Disease
disease	628 7 I-Disease
including	636 9 O
mouse	646 5 O
and	652 3 O
rat	656 3 O
models	660 6 O
of	667 2 O
haloperidol	670 11 B-Chemical
-	681 1 O
induced	682 7 O
catalepsy	690 9 B-Disease
,	699 1 O
mouse	701 5 O
model	707 5 O
of	713 2 O
reserpine	716 9 B-Chemical
-	725 1 O
induced	726 7 O
akinesia	734 8 B-Disease
,	742 1 O
rat	744 3 O
6	748 1 B-Chemical
-	749 1 I-Chemical
hydroxydopamine	750 15 I-Chemical
(	766 1 O
6	767 1 B-Chemical
-	768 1 I-Chemical
OHDA	769 4 I-Chemical
)	773 1 O
lesion	775 6 O
model	782 5 O
of	788 2 O
drug	791 4 O
-	795 1 O
induced	796 7 O
rotation	804 8 O
,	812 1 O
and	814 3 O
MPTP	818 4 B-Chemical
-	822 1 O
treated	823 7 O
non	831 3 O
-	834 1 O
human	835 5 O
primate	841 7 O
model	849 5 O
.	854 1 O

An	0 2 O
extremely	3 9 O
rare	13 4 O
case	18 4 O
of	23 2 O
delusional	26 10 B-Disease
parasitosis	37 11 I-Disease
in	49 2 O
a	52 1 O
chronic	54 7 B-Disease
hepatitis	62 9 I-Disease
C	72 1 I-Disease
patient	74 7 O
during	82 6 O
pegylated	89 9 B-Chemical
interferon	99 10 I-Chemical
alpha	110 5 I-Chemical
-	115 1 I-Chemical
2b	116 2 I-Chemical
and	119 3 O
ribavirin	123 9 B-Chemical
treatment	133 9 O
.	142 1 O

During	144 6 O
treatment	151 9 O
of	161 2 O
chronic	164 7 B-Disease
hepatitis	172 9 I-Disease
C	182 1 I-Disease
patients	184 8 O
with	193 4 O
interferon	198 10 O
and	209 3 O
ribavirin	213 9 B-Chemical
,	222 1 O
a	224 1 O
lot	226 3 O
of	230 2 O
side	233 4 O
effects	238 7 O
are	246 3 O
described	250 9 O
.	259 1 O

Twenty	261 6 O
-	267 1 O
three	268 5 O
percent	274 7 O
to	282 2 O
44	285 2 O
%	287 1 O
of	289 2 O
patients	292 8 O
develop	301 7 O
depression	309 10 B-Disease
.	319 1 O

A	321 1 O
minority	323 8 O
of	332 2 O
patients	335 8 O
evolve	344 6 O
to	351 2 O
psychosis	354 9 B-Disease
.	363 1 O

To	365 2 O
the	368 3 O
best	372 4 O
of	377 2 O
our	380 3 O
knowledge	384 9 O
,	393 1 O
no	395 2 O
cases	398 5 O
of	404 2 O
psychogenic	407 11 B-Disease
parasitosis	419 11 I-Disease
occurring	431 9 O
during	441 6 O
interferon	448 10 O
therapy	459 7 O
have	467 4 O
been	472 4 O
described	477 9 O
in	487 2 O
the	490 3 O
literature	494 10 O
.	504 1 O

We	506 2 O
present	509 7 O
a	517 1 O
49	519 2 O
-	521 1 O
year	522 4 O
-	526 1 O
old	527 3 O
woman	531 5 O
who	537 3 O
developed	541 9 O
a	551 1 O
delusional	553 10 B-Disease
parasitosis	564 11 I-Disease
during	576 6 O
treatment	583 9 O
with	593 4 O
pegylated	598 9 B-Chemical
interferon	608 10 I-Chemical
alpha	619 5 I-Chemical
-	624 1 I-Chemical
2b	625 2 I-Chemical
weekly	628 6 O
and	635 3 O
ribavirin	639 9 B-Chemical
.	648 1 O

She	650 3 O
complained	654 10 O
of	665 2 O
seeing	668 6 O
parasites	675 9 O
and	685 3 O
the	689 3 O
larvae	693 6 O
of	700 2 O
fleas	703 5 O
in	709 2 O
her	712 3 O
stools	716 6 O
.	722 1 O

This	724 4 O
could	729 5 O
not	735 3 O
be	739 2 O
confirmed	742 9 O
by	752 2 O
any	755 3 O
technical	759 9 O
examination	769 11 O
.	780 1 O

All	782 3 O
the	786 3 O
complaints	790 10 O
disappeared	801 11 O
after	813 5 O
stopping	819 8 O
pegylated	828 9 B-Chemical
interferon	838 10 I-Chemical
alpha	849 5 I-Chemical
-	854 1 I-Chemical
2b	855 2 I-Chemical
and	858 3 O
reappeared	862 10 O
after	873 5 O
restarting	879 10 O
it	890 2 O
.	892 1 O

She	894 3 O
had	898 3 O
a	902 1 O
complete	904 8 O
sustained	913 9 O
viral	923 5 O
response	929 8 O
.	937 1 O

Possible	0 8 O
neuroleptic	9 11 B-Disease
malignant	21 9 I-Disease
syndrome	31 8 I-Disease
related	40 7 O
to	48 2 O
concomitant	51 11 O
treatment	63 9 O
with	73 4 O
paroxetine	78 10 B-Chemical
and	89 3 O
alprazolam	93 10 B-Chemical
.	103 1 O

A	105 1 O
74	107 2 O
-	109 1 O
year	110 4 O
-	114 1 O
old	115 3 O
man	119 3 O
with	123 4 O
depressive	128 10 B-Disease
symptoms	139 8 I-Disease
was	148 3 O
admitted	152 8 O
to	161 2 O
a	164 1 O
psychiatric	166 11 B-Disease
hospital	178 8 O
due	187 3 O
to	191 2 O
insomnia	194 8 B-Disease
,	202 1 O
loss	204 4 B-Disease
of	209 2 I-Disease
appetite	212 8 I-Disease
,	220 1 O
exhaustion	222 10 O
,	232 1 O
and	234 3 O
agitation	238 9 B-Disease
.	247 1 O

Medical	249 7 O
treatment	257 9 O
was	267 3 O
initiated	271 9 O
at	281 2 O
a	284 1 O
daily	286 5 O
dose	292 4 O
of	297 2 O
20	300 2 O
mg	303 2 O
paroxetine	306 10 B-Chemical
and	317 3 O
1	321 1 O
.	322 1 O
2	323 1 O
mg	325 2 O
alprazolam	328 10 B-Chemical
.	338 1 O

On	340 2 O
the	343 3 O
10th	347 4 O
day	352 3 O
of	356 2 O
paroxetine	359 10 B-Chemical
and	370 3 O
alprazolam	374 10 B-Chemical
treatment	385 9 O
,	394 1 O
the	396 3 O
patient	400 7 O
exhibited	408 9 O
marked	418 6 O
psychomotor	425 11 B-Disease
retardation	437 11 I-Disease
,	448 1 O
disorientation	450 14 O
,	464 1 O
and	466 3 O
severe	470 6 O
muscle	477 6 B-Disease
rigidity	484 8 I-Disease
with	493 4 O
tremors	498 7 B-Disease
.	505 1 O

The	507 3 O
patient	511 7 O
had	519 3 O
a	523 1 O
fever	525 5 B-Disease
(	531 1 O
38	532 2 O
.	534 1 O
2	535 1 O
degrees	537 7 O
C	545 1 O
)	546 1 O
,	547 1 O
fluctuating	549 11 O
blood	561 5 O
pressure	567 8 O
(	576 1 O
between	577 7 O
165	585 3 O
/	588 1 O
90	589 2 O
and	592 3 O
130	596 3 O
/	599 1 O
70	600 2 O
mg	603 2 O
mm	606 2 O
Hg	609 2 O
)	611 1 O
,	612 1 O
and	614 3 O
severe	618 6 O
extrapyramidal	625 14 B-Disease
symptoms	640 8 I-Disease
.	648 1 O

Laboratory	650 10 O
tests	661 5 O
showed	667 6 O
an	674 2 O
elevation	677 9 O
of	687 2 O
creatine	690 8 B-Chemical
phosphokinase	699 13 O
(	713 1 O
2218	714 4 O
IU	719 2 O
/	721 1 O
L	722 1 O
)	723 1 O
,	724 1 O
aspartate	726 9 B-Chemical
aminotransferase	736 16 O
(	753 1 O
134	754 3 O
IU	758 2 O
/	760 1 O
L	761 1 O
)	762 1 O
,	763 1 O
alanine	765 7 B-Chemical
aminotransferase	773 16 O
(	790 1 O
78	791 2 O
IU	794 2 O
/	796 1 O
L	797 1 O
)	798 1 O
,	799 1 O
and	801 3 O
BUN	805 3 O
(	809 1 O
27	810 2 O
.	812 1 O
9	813 1 O
mg	815 2 O
/	817 1 O
ml	818 2 O
)	820 1 O
levels	822 6 O
.	828 1 O

The	830 3 O
patient	834 7 O
received	842 8 O
bromocriptine	851 13 B-Chemical
and	865 3 O
diazepam	869 8 B-Chemical
to	878 2 O
treat	881 5 O
his	887 3 O
symptoms	891 8 O
.	899 1 O

7	901 1 O
days	903 4 O
later	908 5 O
,	913 1 O
the	915 3 O
fever	919 5 B-Disease
disappeared	925 11 O
and	937 3 O
the	941 3 O
patient	945 7 O
'	952 1 O
s	953 1 O
serum	955 5 O
CPK	961 3 O
levels	965 6 O
were	972 4 O
normalized	977 10 O
(	988 1 O
175	989 3 O
IU	993 2 O
/	995 1 O
L	996 1 O
)	997 1 O
.	998 1 O

This	1000 4 O
patient	1005 7 O
presented	1013 9 O
with	1023 4 O
symptoms	1028 8 O
of	1037 2 O
neuroleptic	1040 11 B-Disease
malignant	1052 9 I-Disease
syndrome	1062 8 I-Disease
(	1071 1 O
NMS	1072 3 B-Disease
)	1075 1 O
,	1076 1 O
thus	1078 4 O
demonstrating	1083 13 O
that	1097 4 O
NMS	1102 3 B-Disease
-	1105 1 O
like	1106 4 O
symptoms	1111 8 O
can	1120 3 O
occur	1124 5 O
after	1130 5 O
combined	1136 8 O
paroxetine	1145 10 B-Chemical
and	1156 3 O
alprazolam	1160 10 B-Chemical
treatment	1171 9 O
.	1180 1 O

The	1182 3 O
adverse	1186 7 O
drug	1194 4 O
reaction	1199 8 O
score	1208 5 O
obtained	1214 8 O
by	1223 2 O
the	1226 3 O
Naranjo	1230 7 O
algorithm	1238 9 O
was	1248 3 O
6	1252 1 O
in	1254 2 O
our	1257 3 O
case	1261 4 O
,	1265 1 O
indicating	1267 10 O
a	1278 1 O
probable	1280 8 O
relationship	1289 12 O
between	1302 7 O
the	1310 3 O
patient	1314 7 O
'	1321 1 O
s	1322 1 O
NMS	1324 3 B-Disease
-	1327 1 O
like	1328 4 O
adverse	1333 7 O
symptoms	1341 8 O
and	1350 3 O
the	1354 3 O
combined	1358 8 O
treatment	1367 9 O
used	1377 4 O
in	1382 2 O
this	1385 4 O
case	1390 4 O
.	1394 1 O

The	1396 3 O
involvement	1400 11 O
of	1412 2 O
physiologic	1415 11 O
and	1427 3 O
environmental	1431 13 O
aspects	1445 7 O
specific	1453 8 O
to	1462 2 O
this	1465 4 O
patient	1470 7 O
was	1478 3 O
suspected	1482 9 O
.	1491 1 O

Several	1493 7 O
risk	1501 4 O
factors	1506 7 O
for	1514 3 O
NMS	1518 3 B-Disease
should	1522 6 O
be	1529 2 O
noted	1532 5 O
in	1538 2 O
elderly	1541 7 O
depressive	1549 10 B-Disease
patients	1560 8 O
whose	1569 5 O
symptoms	1575 8 O
often	1584 5 O
include	1590 7 O
dehydration	1598 11 B-Disease
,	1609 1 O
agitation	1611 9 B-Disease
,	1620 1 O
malnutrition	1622 12 B-Disease
,	1634 1 O
and	1636 3 O
exhaustion	1640 10 O
.	1650 1 O

Careful	1652 7 O
therapeutic	1660 11 O
intervention	1672 12 O
is	1685 2 O
necessary	1688 9 O
in	1698 2 O
cases	1701 5 O
involving	1707 9 O
elderly	1717 7 O
patients	1725 8 O
who	1734 3 O
suffer	1738 6 O
from	1745 4 O
depression	1750 10 B-Disease
.	1760 1 O

Pilocarpine	0 11 B-Chemical
seizures	12 8 B-Disease
cause	21 5 O
age	27 3 O
-	30 1 O
dependent	31 9 O
impairment	41 10 B-Disease
in	52 2 I-Disease
auditory	55 8 I-Disease
location	64 8 I-Disease
discrimination	73 14 I-Disease
.	87 1 O

Children	89 8 O
who	98 3 O
have	102 4 O
status	107 6 B-Disease
epilepticus	114 11 I-Disease
have	126 4 O
continuous	131 10 O
or	142 2 O
rapidly	145 7 O
repeating	153 9 O
seizures	163 8 B-Disease
that	172 4 O
may	177 3 O
be	181 2 O
life	184 4 O
-	188 1 O
threatening	189 11 O
and	201 3 O
may	205 3 O
cause	209 5 O
life	215 4 O
-	219 1 O
long	220 4 O
changes	225 7 O
in	233 2 O
brain	236 5 O
and	242 3 O
behavior	246 8 O
.	254 1 O

The	256 3 O
extent	260 6 O
to	267 2 O
which	270 5 O
status	276 6 B-Disease
epilepticus	283 11 I-Disease
causes	295 6 O
deficits	302 8 B-Disease
in	311 2 I-Disease
auditory	314 8 I-Disease
discrimination	323 14 I-Disease
is	338 2 O
unknown	341 7 O
.	348 1 O

A	350 1 O
naturalistic	352 12 O
auditory	365 8 O
location	374 8 O
discrimination	383 14 O
method	398 6 O
was	405 3 O
used	409 4 O
to	414 2 O
evaluate	417 8 O
this	426 4 O
question	431 8 O
using	440 5 O
an	446 2 O
animal	449 6 O
model	456 5 O
of	462 2 O
status	465 6 B-Disease
epilepticus	472 11 I-Disease
.	483 1 O

Male	485 4 O
Sprague	490 7 O
-	497 1 O
Dawley	498 6 O
rats	505 4 O
were	510 4 O
injected	515 8 O
with	524 4 O
saline	529 6 O
on	536 2 O
postnatal	539 9 O
day	549 3 O
(	553 1 O
P	554 1 O
)	555 1 O
20	557 2 O
,	559 1 O
or	561 2 O
a	564 1 O
convulsant	566 10 O
dose	577 4 O
of	582 2 O
pilocarpine	585 11 B-Chemical
on	597 2 O
P20	600 3 O
or	604 2 O
P45	607 3 O
.	610 1 O

Pilocarpine	612 11 B-Chemical
on	624 2 O
either	627 6 O
day	634 3 O
induced	638 7 O
status	646 6 B-Disease
epilepticus	653 11 I-Disease
;	664 1 O
status	666 6 B-Disease
epilepticus	673 11 I-Disease
at	685 2 O
P45	688 3 O
resulted	692 8 O
in	701 2 O
CA3	704 3 O
cell	708 4 O
loss	713 4 O
and	718 3 O
spontaneous	722 11 O
seizures	734 8 B-Disease
,	742 1 O
whereas	744 7 O
P20	752 3 O
rats	756 4 O
had	761 3 O
no	765 2 O
cell	768 4 O
loss	773 4 O
or	778 2 O
spontaneous	781 11 O
seizures	793 8 B-Disease
.	801 1 O

Mature	803 6 O
rats	810 4 O
were	815 4 O
trained	820 7 O
with	828 4 O
sound	833 5 O
-	838 1 O
source	839 6 O
location	846 8 O
and	855 3 O
sound	859 5 O
-	864 1 O
silence	865 7 O
discriminations	873 15 O
.	888 1 O

Control	890 7 O
(	898 1 O
saline	899 6 O
P20	906 3 O
)	909 1 O
rats	911 4 O
acquired	916 8 O
both	925 4 O
discriminations	930 15 O
immediately	946 11 O
.	957 1 O

In	959 2 O
status	962 6 B-Disease
epilepticus	969 11 I-Disease
(	981 1 O
P20	982 3 O
)	985 1 O
rats	987 4 O
,	991 1 O
acquisition	993 11 O
of	1005 2 O
the	1008 3 O
sound	1012 5 O
-	1017 1 O
source	1018 6 O
location	1025 8 O
discrimination	1034 14 O
was	1049 3 O
moderately	1053 10 O
impaired	1064 8 O
.	1072 1 O

Status	1074 6 B-Disease
epilepticus	1081 11 I-Disease
(	1093 1 O
P45	1094 3 O
)	1097 1 O
rats	1099 4 O
failed	1104 6 O
to	1111 2 O
acquire	1114 7 O
either	1122 6 O
sound	1129 5 O
-	1134 1 O
source	1135 6 O
location	1142 8 O
or	1151 2 O
sound	1154 5 O
-	1159 1 O
silence	1160 7 O
discriminations	1168 15 O
.	1183 1 O

Status	1185 6 B-Disease
epilepticus	1192 11 I-Disease
in	1204 2 O
rat	1207 3 O
causes	1211 6 O
an	1218 2 O
age	1221 3 O
-	1224 1 O
dependent	1225 9 O
,	1234 1 O
long	1236 4 O
-	1240 1 O
term	1241 4 O
impairment	1246 10 B-Disease
in	1257 2 I-Disease
auditory	1260 8 I-Disease
discrimination	1269 14 I-Disease
.	1283 1 O

This	1285 4 O
impairment	1290 10 O
may	1301 3 O
explain	1305 7 O
one	1313 3 O
cause	1317 5 O
of	1323 2 O
impaired	1326 8 B-Disease
auditory	1335 8 I-Disease
location	1344 8 I-Disease
discrimination	1353 14 I-Disease
in	1368 2 O
humans	1371 6 O
.	1377 1 O

Cardiovascular	0 14 O
risk	15 4 O
with	20 4 O
cyclooxygenase	25 14 B-Chemical
inhibitors	40 10 I-Chemical
:	50 1 O
general	52 7 O
problem	60 7 O
with	68 4 O
substance	73 9 O
specific	83 8 O
differences	92 11 O
?	103 1 O

Randomised	105 10 O
clinical	116 8 O
trials	125 6 O
and	132 3 O
observational	136 13 O
studies	150 7 O
have	158 4 O
shown	163 5 O
an	169 2 O
increased	172 9 O
risk	182 4 O
of	187 2 O
myocardial	190 10 B-Disease
infarction	201 10 I-Disease
,	211 1 O
stroke	213 6 B-Disease
,	219 1 O
hypertension	221 12 B-Disease
and	234 3 O
heart	238 5 B-Disease
failure	244 7 I-Disease
during	252 6 O
treatment	259 9 O
with	269 4 O
cyclooxygenase	274 14 B-Chemical
inhibitors	289 10 I-Chemical
.	299 1 O

Adverse	301 7 O
cardiovascular	309 14 O
effects	324 7 O
occurred	332 8 O
mainly	341 6 O
,	347 1 O
but	349 3 O
not	353 3 O
exclusively	357 11 O
,	368 1 O
in	370 2 O
patients	373 8 O
with	382 4 O
concomitant	387 11 O
risk	399 4 O
factors	404 7 O
.	411 1 O

Cyclooxygenase	413 14 B-Chemical
inhibitors	428 10 I-Chemical
cause	439 5 O
complex	445 7 O
changes	453 7 O
in	461 2 O
renal	464 5 O
,	469 1 O
vascular	471 8 O
and	480 3 O
cardiac	484 7 O
prostanoid	492 10 O
profiles	503 8 O
thereby	512 7 O
increasing	520 10 O
vascular	531 8 O
resistance	540 10 O
and	551 3 O
fluid	555 5 O
retention	561 9 O
.	570 1 O

The	572 3 O
incidence	576 9 O
of	586 2 O
cardiovascular	589 14 O
adverse	604 7 O
events	612 6 O
tends	619 5 O
to	625 2 O
increase	628 8 O
with	637 4 O
the	642 3 O
daily	646 5 O
dose	652 4 O
and	657 3 O
total	661 5 O
exposure	667 8 O
time	676 4 O
.	680 1 O

A	682 1 O
comparison	684 10 O
of	695 2 O
individual	698 10 O
selective	709 9 O
and	719 3 O
unselective	723 11 O
cyclooxygenase	735 14 B-Chemical
inhibitors	750 10 I-Chemical
suggests	761 8 O
substance	770 9 O
-	779 1 O
specific	780 8 O
differences	789 11 O
,	800 1 O
which	802 5 O
may	808 3 O
depend	812 6 O
on	819 2 O
differences	822 11 O
in	834 2 O
pharmacokinetic	837 15 O
parameters	853 10 O
or	864 2 O
inhibitory	867 10 O
potency	878 7 O
and	886 3 O
may	890 3 O
be	894 2 O
contributed	897 11 O
by	909 2 O
prostaglandin	912 13 B-Chemical
-	925 1 O
independent	926 11 O
effects	938 7 O
.	945 1 O

Diagnostic	947 10 O
markers	958 7 O
such	966 4 O
as	971 2 O
N	974 1 B-Chemical
-	975 1 I-Chemical
terminal	976 8 I-Chemical
pro	985 3 I-Chemical
brain	989 5 I-Chemical
natriuretic	995 11 I-Chemical
peptide	1007 7 I-Chemical
(	1015 1 O
NT	1016 2 B-Chemical
-	1018 1 I-Chemical
proBNP	1019 6 I-Chemical
)	1025 1 O
or	1027 2 O
high	1030 4 O
-	1034 1 O
sensitive	1035 9 O
C	1045 1 O
-	1046 1 O
reactive	1047 8 O
protein	1056 7 O
might	1064 5 O
help	1070 4 O
in	1075 2 O
the	1078 3 O
early	1082 5 O
identification	1088 14 O
of	1103 2 O
patients	1106 8 O
at	1115 2 O
risk	1118 4 O
,	1122 1 O
thus	1124 4 O
avoiding	1129 8 O
the	1138 3 O
occurrence	1142 10 O
of	1153 2 O
serious	1156 7 O
cardiovascular	1164 14 B-Disease
toxicity	1179 8 I-Disease
.	1187 1 O

Predictors	0 10 O
of	11 2 O
decreased	14 9 B-Disease
renal	24 5 I-Disease
function	30 8 I-Disease
in	39 2 O
patients	42 8 O
with	51 4 O
heart	56 5 B-Disease
failure	62 7 I-Disease
during	70 6 O
angiotensin	77 11 B-Chemical
-	88 1 O
converting	89 10 O
enzyme	100 6 O
inhibitor	107 9 O
therapy	117 7 O
:	124 1 O
results	126 7 O
from	134 4 O
the	139 3 O
studies	143 7 O
of	151 2 O
left	154 4 B-Disease
ventricular	159 11 I-Disease
dysfunction	171 11 I-Disease
(	183 1 O
SOLVD	184 5 O
)	189 1 O

BACKGROUND	191 10 O
:	201 1 O
Although	203 8 O
angiotensin	212 11 B-Chemical
-	223 1 O
converting	224 10 O
enzyme	235 6 O
inhibitor	242 9 O
therapy	252 7 O
reduces	260 7 O
mortality	268 9 O
rates	278 5 O
in	284 2 O
patients	287 8 O
with	296 4 O
congestive	301 10 B-Disease
heart	312 5 I-Disease
failure	318 7 I-Disease
(	326 1 O
CHF	327 3 B-Disease
)	330 1 O
,	331 1 O
it	333 2 O
may	336 3 O
also	340 4 O
cause	345 5 O
decreased	351 9 B-Disease
renal	361 5 I-Disease
function	367 8 I-Disease
.	375 1 O

Little	377 6 O
information	384 11 O
is	396 2 O
available	399 9 O
to	409 2 O
predict	412 7 O
which	420 5 O
patients	426 8 O
are	435 3 O
at	439 2 O
highest	442 7 O
risk	450 4 O
for	455 3 O
this	459 4 O
complication	464 12 O
.	476 1 O

OBJECTIVE	478 9 O
:	487 1 O
To	489 2 O
quantify	492 8 O
specific	501 8 O
clinical	510 8 O
predictors	519 10 O
of	530 2 O
reduction	533 9 B-Disease
in	543 2 I-Disease
renal	546 5 I-Disease
function	552 8 I-Disease
in	561 2 O
patients	564 8 O
with	573 4 O
CHF	578 3 B-Disease
who	582 3 O
are	586 3 O
prescribed	590 10 O
angiotensin	601 11 B-Chemical
-	612 1 O
converting	613 10 O
enzyme	624 6 O
inhibitor	631 9 O
therapy	641 7 O
.	648 1 O

METHOD	650 6 O
:	656 1 O
We	658 2 O
analyzed	661 8 O
data	670 4 O
from	675 4 O
the	680 3 O
Studies	684 7 O
of	692 2 O
Left	695 4 B-Disease
Ventricular	700 11 I-Disease
Dysfunction	712 11 I-Disease
(	724 1 O
SOLVD	725 5 O
)	730 1 O
,	731 1 O
a	733 1 O
randomized	735 10 O
,	745 1 O
double	747 6 O
-	753 1 O
blind	754 5 O
,	759 1 O
placebo	761 7 O
-	768 1 O
controlled	769 10 O
trial	780 5 O
of	786 2 O
enalapril	789 9 B-Chemical
for	799 3 O
the	803 3 O
treatment	807 9 O
of	817 2 O
CHF	820 3 B-Disease
.	823 1 O

There	825 5 O
were	831 4 O
3379	836 4 O
patients	841 8 O
randomly	850 8 O
assigned	859 8 O
to	868 2 O
enalapril	871 9 B-Chemical
with	881 4 O
a	886 1 O
median	888 6 O
follow	895 6 O
-	901 1 O
up	902 2 O
of	905 2 O
974	908 3 O
days	912 4 O
and	917 3 O
3379	921 4 O
patients	926 8 O
randomly	935 8 O
assigned	944 8 O
to	953 2 O
placebo	956 7 O
with	964 4 O
a	969 1 O
mean	971 4 O
follow	976 6 O
-	982 1 O
up	983 2 O
of	986 2 O
967	989 3 O
days	993 4 O
.	997 1 O

Decreased	999 9 B-Disease
renal	1009 5 I-Disease
function	1015 8 I-Disease
was	1024 3 O
defined	1028 7 O
as	1036 2 O
a	1039 1 O
rise	1041 4 O
in	1046 2 O
serum	1049 5 O
creatinine	1055 10 B-Chemical
>	1066 1 O
/	1067 1 O
=	1068 1 O
0	1069 1 O
.	1070 1 O
5	1071 1 O
mg	1073 2 O
/	1075 1 O
dL	1076 2 O
(	1079 1 O
44	1080 2 O
micromol	1083 8 O
/	1091 1 O
L	1092 1 O
)	1093 1 O
from	1095 4 O
baseline	1100 8 O
.	1108 1 O

We	1110 2 O
used	1113 4 O
time	1118 4 O
-	1122 1 O
to	1123 2 O
-	1125 1 O
event	1126 5 O
analysis	1132 8 O
to	1141 2 O
identify	1144 8 O
potential	1153 9 O
predictors	1163 10 O
of	1174 2 O
decrease	1177 8 O
in	1186 2 O
renal	1189 5 O
function	1195 8 O
including	1204 9 O
age	1214 3 O
,	1217 1 O
baseline	1219 8 O
ejection	1228 8 O
fraction	1237 8 O
,	1245 1 O
baseline	1247 8 O
creatinine	1256 10 B-Chemical
,	1266 1 O
low	1268 3 O
systolic	1272 8 O
blood	1281 5 O
pressure	1287 8 O
(	1296 1 O
<	1297 1 O
100	1298 3 O
mm	1302 2 O
Hg	1305 2 O
)	1307 1 O
,	1308 1 O
history	1310 7 O
of	1318 2 O
hypertension	1321 12 B-Disease
,	1333 1 O
diabetes	1335 8 B-Disease
,	1343 1 O
and	1345 3 O
use	1349 3 O
of	1353 2 O
antiplatelet	1356 12 O
,	1368 1 O
diuretic	1370 8 B-Chemical
,	1378 1 O
and	1380 3 O
beta	1384 4 O
-	1388 1 O
blocker	1389 7 O
therapy	1397 7 O
.	1404 1 O

RESULTS	1406 7 O
:	1413 1 O
Patients	1415 8 O
randomly	1424 8 O
assigned	1433 8 O
to	1442 2 O
enalapril	1445 9 B-Chemical
had	1455 3 O
a	1459 1 O
33	1461 2 O
%	1463 1 O
greater	1465 7 O
likelihood	1473 10 O
of	1484 2 O
decreased	1487 9 B-Disease
renal	1497 5 I-Disease
function	1503 8 I-Disease
than	1512 4 O
controls	1517 8 O
(	1526 1 O
P	1527 1 O
=	1529 1 O
.	1530 1 O
003	1531 3 O
)	1534 1 O
.	1535 1 O

By	1537 2 O
multivariate	1540 12 O
analysis	1553 8 O
,	1561 1 O
in	1563 2 O
both	1566 4 O
the	1571 3 O
placebo	1575 7 O
and	1583 3 O
enalapril	1587 9 B-Chemical
groups	1597 6 O
older	1604 5 O
age	1610 3 O
,	1613 1 O
diuretic	1615 8 B-Chemical
therapy	1624 7 O
,	1631 1 O
and	1633 3 O
diabetes	1637 8 B-Disease
were	1646 4 O
associated	1651 10 O
with	1662 4 O
decreased	1667 9 B-Disease
renal	1677 5 I-Disease
function	1683 8 I-Disease
,	1691 1 O
whereas	1693 7 O
beta	1701 4 O
-	1705 1 O
blocker	1706 7 O
therapy	1714 7 O
and	1722 3 O
higher	1726 6 O
ejection	1733 8 O
fraction	1742 8 O
were	1751 4 O
renoprotective	1756 14 O
.	1770 1 O

Older	1772 5 O
age	1778 3 O
was	1782 3 O
associated	1786 10 O
with	1797 4 O
a	1802 1 O
greater	1804 7 O
risk	1812 4 O
of	1817 2 O
developing	1820 10 O
decreased	1831 9 B-Disease
renal	1841 5 I-Disease
function	1847 8 I-Disease
in	1856 2 O
both	1859 4 O
groups	1864 6 O
,	1870 1 O
but	1872 3 O
significantly	1876 13 O
more	1890 4 O
so	1895 2 O
in	1898 2 O
the	1901 3 O
enalapril	1905 9 B-Chemical
group	1915 5 O
(	1921 1 O
enalapril	1922 9 B-Chemical
:	1931 1 O
risk	1933 4 O
ratio	1938 5 O
[	1944 1 O
RR	1945 2 O
]	1947 1 O
1	1949 1 O
.	1950 1 O
42	1951 2 O
per	1954 3 O
10	1958 2 O
years	1961 5 O
,	1966 1 O
95	1968 2 O
%	1970 1 O
confidence	1972 10 O
interval	1983 8 O
[	1992 1 O
CI	1993 2 O
]	1995 1 O
1	1997 1 O
.	1998 1 O
32	1999 2 O
-	2001 1 O
1	2002 1 O
.	2003 1 O
52	2004 2 O
with	2007 4 O
enalapril	2012 9 B-Chemical
;	2021 1 O
placebo	2023 7 O
:	2030 1 O
RR	2032 2 O
1	2035 1 O
.	2036 1 O
18	2037 2 O
,	2039 1 O
95	2041 2 O
%	2043 1 O
CI	2045 2 O
1	2048 1 O
.	2049 1 O
12	2050 2 O
-	2052 1 O
1	2053 1 O
.	2054 1 O
25	2055 2 O
)	2057 1 O
.	2058 1 O

Diuretic	2060 8 B-Chemical
therapy	2069 7 O
was	2077 3 O
likewise	2081 8 O
associated	2090 10 O
with	2101 4 O
a	2106 1 O
greater	2108 7 O
risk	2116 4 O
of	2121 2 O
decreased	2124 9 B-Disease
renal	2134 5 I-Disease
function	2140 8 I-Disease
in	2149 2 O
the	2152 3 O
enalapril	2156 9 B-Chemical
group	2166 5 O
(	2172 1 O
RR	2173 2 O
1	2176 1 O
.	2177 1 O
89	2178 2 O
,	2180 1 O
95	2182 2 O
%	2184 1 O
CI	2186 2 O
1	2189 1 O
.	2190 1 O
70	2191 2 O
-	2193 1 O
2	2194 1 O
.	2195 1 O
08	2196 2 O
)	2198 1 O
than	2200 4 O
in	2205 2 O
the	2208 3 O
placebo	2212 7 O
group	2220 5 O
(	2226 1 O
RR	2227 2 O
1	2230 1 O
.	2231 1 O
35	2232 2 O
,	2234 1 O
95	2236 2 O
%	2238 1 O
CI	2240 2 O
1	2243 1 O
.	2244 1 O
09	2245 2 O
-	2247 1 O
1	2248 1 O
.	2249 1 O
66	2250 2 O
)	2252 1 O
.	2253 1 O

Conversely	2255 10 O
,	2265 1 O
enalapril	2267 9 B-Chemical
had	2277 3 O
a	2281 1 O
relative	2283 8 O
renoprotective	2292 14 O
effect	2307 6 O
(	2314 1 O
RR	2315 2 O
1	2318 1 O
.	2319 1 O
33	2320 2 O
,	2322 1 O
95	2324 2 O
%	2326 1 O
CI	2328 2 O
1	2331 1 O
.	2332 1 O
13	2333 2 O
-	2335 1 O
1	2336 1 O
.	2337 1 O
53	2338 2 O
)	2340 1 O
compared	2342 8 O
with	2351 4 O
placebo	2356 7 O
(	2364 1 O
RR	2365 2 O
1	2368 1 O
.	2369 1 O
96	2370 2 O
,	2372 1 O
95	2374 2 O
%	2376 1 O
CI	2378 2 O
1	2381 1 O
.	2382 1 O
57	2383 2 O
-	2385 1 O
2	2386 1 O
.	2387 1 O
44	2388 2 O
)	2390 1 O
in	2392 2 O
patients	2395 8 O
with	2404 4 O
diabetes	2409 8 B-Disease
.	2417 1 O

A	2419 1 O
lower	2421 5 O
risk	2427 4 O
of	2432 2 O
renal	2435 5 B-Disease
impairment	2441 10 I-Disease
was	2452 3 O
seen	2456 4 O
in	2461 2 O
both	2464 4 O
groups	2469 6 O
with	2476 4 O
beta	2481 4 O
-	2485 1 O
blocker	2486 7 O
therapy	2494 7 O
(	2502 1 O
RR	2503 2 O
0	2506 1 O
.	2507 1 O
70	2508 2 O
,	2510 1 O
95	2512 2 O
%	2514 1 O
CI	2516 2 O
0	2519 1 O
.	2520 1 O
57	2521 2 O
-	2523 1 O
0	2524 1 O
.	2525 1 O
85	2526 2 O
)	2528 1 O
and	2530 3 O
higher	2534 6 O
baseline	2541 8 O
ejection	2550 8 O
fraction	2559 8 O
(	2568 1 O
RR	2569 2 O
0	2572 1 O
.	2573 1 O
93	2574 2 O
per	2577 3 O
5	2581 1 O
%	2582 1 O
increment	2584 9 O
,	2593 1 O
95	2595 2 O
%	2597 1 O
CI	2599 2 O
0	2602 1 O
.	2603 1 O
91	2604 2 O
-	2606 1 O
0	2607 1 O
.	2608 1 O
96	2610 2 O
)	2612 1 O
.	2613 1 O

CONCLUSIONS	2615 11 O
:	2626 1 O
Enalapril	2628 9 B-Chemical
use	2638 3 O
caused	2642 6 O
a	2649 1 O
33	2651 2 O
%	2653 1 O
increase	2655 8 O
in	2664 2 O
the	2667 3 O
risk	2671 4 O
of	2676 2 O
decreased	2679 9 B-Disease
renal	2689 5 I-Disease
function	2695 8 I-Disease
in	2704 2 O
patients	2707 8 O
with	2716 4 O
CHF	2721 3 B-Disease
.	2724 1 O

Diuretic	2726 8 B-Chemical
use	2735 3 O
and	2739 3 O
advanced	2743 8 O
age	2752 3 O
increased	2756 9 O
this	2766 4 O
risk	2771 4 O
.	2775 1 O

Diabetes	2777 8 B-Disease
was	2786 3 O
associated	2790 10 O
with	2801 4 O
an	2806 2 O
increased	2809 9 O
risk	2819 4 O
of	2824 2 O
renal	2827 5 B-Disease
impairment	2833 10 I-Disease
in	2844 2 O
all	2847 3 O
patients	2851 8 O
with	2860 4 O
CHF	2865 3 B-Disease
,	2868 1 O
but	2870 3 O
this	2874 4 O
risk	2879 4 O
was	2884 3 O
reduced	2888 7 O
in	2896 2 O
the	2899 3 O
enalapril	2903 9 B-Chemical
group	2913 5 O
compared	2919 8 O
with	2928 4 O
the	2933 3 O
placebo	2937 7 O
group	2945 5 O
.	2950 1 O

beta	2952 4 O
-	2956 1 O
Blocker	2957 7 O
therapy	2965 7 O
and	2973 3 O
higher	2977 6 O
ejection	2984 8 O
fraction	2993 8 O
were	3002 4 O
renoprotective	3007 14 O
in	3022 2 O
all	3025 3 O
patients	3029 8 O
regardless	3038 10 O
of	3049 2 O
therapy	3052 7 O
.	3059 1 O

Pemoline	0 8 B-Chemical
induced	9 7 O
acute	17 5 O
choreoathetosis	23 15 B-Disease
:	38 1 O
case	40 4 O
report	45 6 O
and	52 3 O
review	56 6 O
of	63 2 O
the	66 3 O
literature	70 10 O
.	80 1 O

BACKGROUND	82 10 O
:	92 1 O
Pemoline	94 8 B-Chemical
is	103 2 O
an	106 2 O
oxazolidine	109 11 B-Chemical
derivative	121 10 O
that	132 4 O
is	137 2 O
structurally	140 12 O
different	153 9 O
from	163 4 O
amphetamines	168 12 B-Chemical
and	181 3 O
used	185 4 O
in	190 2 O
the	193 3 O
treatment	197 9 O
of	207 2 O
attention	210 9 B-Disease
deficit	220 7 I-Disease
disorder	228 8 I-Disease
.	236 1 O

Pemoline	238 8 B-Chemical
has	247 3 O
not	251 3 O
been	255 4 O
commonly	260 8 O
associated	269 10 O
in	280 2 O
the	283 3 O
literature	287 10 O
as	298 2 O
a	301 1 O
cause	303 5 O
of	309 2 O
acute	312 5 O
movement	318 8 B-Disease
disorders	327 9 I-Disease
.	336 1 O

The	338 3 O
following	342 9 O
case	352 4 O
describes	357 9 O
two	367 3 O
children	371 8 O
acutely	380 7 O
poisoned	388 8 O
with	397 4 O
pemoline	402 8 B-Chemical
who	411 3 O
experienced	415 11 O
profound	427 8 O
choreoathetosis	436 15 B-Disease
.	451 1 O

CASE	453 4 O
REPORT	458 6 O
:	464 1 O
Two	466 3 O
,	469 1 O
3	471 1 O
-	472 1 O
year	473 4 O
-	477 1 O
old	478 3 O
male	482 4 O
,	486 1 O
identical	488 9 O
twin	498 4 O
siblings	503 8 O
presented	512 9 O
to	522 2 O
the	525 3 O
emergency	529 9 O
department	539 10 O
after	550 5 O
found	556 5 O
playing	562 7 O
with	570 4 O
a	575 1 O
an	577 2 O
empty	580 5 O
bottle	586 6 O
of	593 2 O
pemoline	596 8 B-Chemical
originally	605 10 O
containing	616 10 O
59	627 2 O
tablets	630 7 O
.	637 1 O

The	639 3 O
children	643 8 O
had	652 3 O
a	656 1 O
medical	658 7 O
history	666 7 O
significant	674 11 O
for	686 3 O
attention	690 9 B-Disease
deficit	700 7 I-Disease
disorder	708 8 I-Disease
previously	717 10 O
treated	728 7 O
with	736 4 O
methylphenidate	741 15 B-Chemical
without	757 7 O
success	765 7 O
.	772 1 O

This	774 4 O
was	779 3 O
their	783 5 O
first	789 5 O
day	795 3 O
of	799 2 O
pemoline	802 8 B-Chemical
therapy	811 7 O
.	818 1 O

The	820 3 O
choreoathetoid	824 14 B-Disease
movements	839 9 O
began	849 5 O
45	855 2 O
min	858 3 O
to	862 2 O
1	865 1 O
h	867 1 O
after	869 5 O
ingestion	875 9 O
.	884 1 O

The	886 3 O
children	890 8 O
gave	899 4 O
no	904 2 O
history	907 7 O
of	915 2 O
prior	918 5 O
movement	924 8 B-Disease
disorders	933 9 I-Disease
and	943 3 O
there	947 5 O
was	953 3 O
no	957 2 O
family	960 6 O
history	967 7 O
of	975 2 O
movement	978 8 B-Disease
disorders	987 9 I-Disease
.	996 1 O

The	998 3 O
children	1002 8 O
received	1011 8 O
gastrointestinal	1020 16 O
decontamination	1037 15 O
and	1053 3 O
high	1057 4 O
doses	1062 5 O
of	1068 2 O
intravenous	1071 11 O
benzodiazepines	1083 15 B-Chemical
in	1099 2 O
an	1102 2 O
attempt	1105 7 O
to	1113 2 O
control	1116 7 O
the	1124 3 O
choreoathetoid	1128 14 B-Disease
movements	1143 9 O
.	1152 1 O

Despite	1154 7 O
treatment	1162 9 O
,	1171 1 O
the	1173 3 O
children	1177 8 O
continued	1186 9 O
to	1196 2 O
have	1199 4 O
choreoathetosis	1204 15 B-Disease
for	1220 3 O
approximately	1224 13 O
24	1238 2 O
hours	1241 5 O
.	1246 1 O

Forty	1248 5 O
-	1253 1 O
eight	1254 5 O
hours	1260 5 O
after	1266 5 O
admission	1272 9 O
,	1281 1 O
the	1283 3 O
children	1287 8 O
appeared	1296 8 O
to	1305 2 O
be	1308 2 O
at	1311 2 O
their	1314 5 O
baseline	1320 8 O
and	1329 3 O
were	1333 4 O
discharged	1338 10 O
home	1349 4 O
.	1353 1 O

CONCLUSION	1355 10 O
:	1365 1 O
Pemoline	1367 8 B-Chemical
associated	1376 10 O
movement	1387 8 B-Disease
disorder	1396 8 I-Disease
has	1405 3 O
been	1409 4 O
rarely	1414 6 O
reported	1421 8 O
in	1430 2 O
the	1433 3 O
acute	1437 5 O
toxicology	1443 10 O
literature	1454 10 O
.	1464 1 O

The	1466 3 O
possibility	1470 11 O
of	1482 2 O
choreoathetoid	1485 14 B-Disease
movements	1500 9 O
should	1510 6 O
be	1517 2 O
considered	1520 10 O
in	1531 2 O
patients	1534 8 O
presenting	1543 10 O
after	1554 5 O
pemoline	1560 8 B-Chemical
overdose	1569 8 B-Disease
.	1577 1 O

Continuous	0 10 O
subcutaneous	11 12 O
administration	24 14 O
of	39 2 O
mesna	42 5 B-Chemical
to	48 2 O
prevent	51 7 O
ifosfamide	59 10 B-Chemical
-	69 1 O
induced	70 7 O
hemorrhagic	78 11 B-Disease
cystitis	90 8 I-Disease
.	98 1 O

Hemorrhagic	100 11 B-Disease
cystitis	112 8 I-Disease
is	121 2 O
a	124 1 O
major	126 5 O
potential	132 9 O
toxicity	142 8 B-Disease
of	151 2 O
ifosfamide	154 10 B-Chemical
that	165 4 O
can	170 3 O
be	174 2 O
prevented	177 9 O
by	187 2 O
administering	190 13 O
mesna	204 5 B-Chemical
along	210 5 O
with	216 4 O
the	221 3 O
cytotoxic	225 9 O
agent	235 5 O
.	240 1 O

Mesna	242 5 B-Chemical
is	248 2 O
generally	251 9 O
administered	261 12 O
by	274 2 O
the	277 3 O
intravenous	281 11 O
route	293 5 O
,	298 1 O
although	300 8 O
experience	309 10 O
with	320 4 O
oral	325 4 O
delivery	330 8 O
of	339 2 O
the	342 3 O
drug	346 4 O
has	351 3 O
increased	355 9 O
.	364 1 O

The	366 3 O
continuous	370 10 O
subcutaneous	381 12 O
administration	394 14 O
of	409 2 O
mesna	412 5 B-Chemical
has	418 3 O
the	422 3 O
advantage	426 9 O
of	436 2 O
not	439 3 O
requiring	443 9 O
intravenous	453 11 O
access	465 6 O
.	471 1 O

In	473 2 O
addition	476 8 O
,	484 1 O
subcutaneous	486 12 O
delivery	499 8 O
of	508 2 O
the	511 3 O
neutralizing	515 12 O
agent	528 5 O
will	534 4 O
not	539 3 O
be	543 2 O
associated	546 10 O
with	557 4 O
the	562 3 O
risk	566 4 O
of	571 2 O
inadequate	574 10 O
urinary	585 7 O
mesna	593 5 B-Chemical
concentrations	599 14 O
,	613 1 O
such	615 4 O
as	620 2 O
in	623 2 O
a	626 1 O
patient	628 7 O
taking	636 6 O
oral	643 4 O
mesna	648 5 B-Chemical
who	654 3 O
experiences	658 11 O
severe	670 6 O
ifosfamide	677 10 B-Chemical
-	687 1 O
induced	688 7 O
emesis	696 6 B-Disease
and	703 3 O
is	707 2 O
unable	710 6 O
to	717 2 O
absorb	720 6 O
the	727 3 O
drug	731 4 O
.	735 1 O

Limited	737 7 O
clinical	745 8 O
experience	754 10 O
with	765 4 O
continuous	770 10 O
subcutaneous	781 12 O
mesna	794 5 B-Chemical
administration	800 14 O
suggests	815 8 O
it	824 2 O
is	827 2 O
a	830 1 O
safe	832 4 O
,	836 1 O
practical	838 9 O
,	847 1 O
and	849 3 O
economic	853 8 O
method	862 6 O
of	869 2 O
drug	872 4 O
delivery	877 8 O
that	886 4 O
permits	891 7 O
ifosfamide	899 10 B-Chemical
to	910 2 O
be	913 2 O
administered	916 12 O
successfully	929 12 O
in	942 2 O
the	945 3 O
outpatient	949 10 O
setting	960 7 O
.	967 1 O

Modification	0 12 O
of	13 2 O
drug	16 4 O
action	21 6 O
by	28 2 O
hyperammonemia	31 14 B-Disease
.	45 1 O

Pretreatment	47 12 O
with	60 4 O
ammonium	65 8 B-Chemical
acetate	74 7 I-Chemical
(	82 1 O
NH4Ac	83 5 B-Chemical
)	88 1 O
(	90 1 O
6	91 1 O
mmol	93 4 O
/	97 1 O
kg	98 2 O
s	101 1 O
.	102 1 O
c	103 1 O
.	104 1 O
)	105 1 O
approximately	107 13 O
doubled	121 7 O
the	129 3 O
time	133 4 O
morphine	138 8 B-Chemical
-	146 1 O
treated	147 7 O
mice	155 4 O
remained	160 8 O
on	169 2 O
a	172 1 O
hot	174 3 O
surface	178 7 O
and	186 3 O
similarly	190 9 O
increased	200 9 O
muscular	210 8 O
incoordination	219 14 B-Disease
by	234 2 O
diazepam	237 8 B-Chemical
,	245 1 O
but	247 3 O
NH4Ac	251 5 B-Chemical
treatment	257 9 O
alone	267 5 O
had	273 3 O
no	277 2 O
effect	280 6 O
.	286 1 O

Thus	288 4 O
,	292 1 O
hyperammonemia	294 14 B-Disease
is	309 2 O
capable	312 7 O
of	320 2 O
altering	323 8 O
drug	332 4 O
action	337 6 O
and	344 3 O
must	348 4 O
be	353 2 O
considered	356 10 O
along	367 5 O
with	373 4 O
impaired	378 8 O
drug	387 4 O
metabolism	392 10 O
in	403 2 O
enhanced	406 8 O
drug	415 4 O
responses	420 9 O
associated	430 10 O
with	441 4 O
liver	446 5 B-Disease
disease	452 7 I-Disease
.	459 1 O

Experiments	461 11 O
in	473 2 O
vitro	476 5 O
showed	482 6 O
that	489 4 O
acetylcholine	494 13 B-Chemical
-	507 1 O
induced	508 7 O
catecholamine	516 13 B-Chemical
release	530 7 O
from	538 4 O
bovine	543 6 O
adrenal	550 7 O
medulla	558 7 O
is	566 2 O
depressed	569 9 O
as	579 2 O
much	582 4 O
as	587 2 O
50	590 2 O
%	592 1 O
by	594 2 O
0	597 1 O
.	598 1 O
3	599 1 O
mM	601 2 O
NH4Ac	604 5 B-Chemical
and	610 3 O
KCl	614 3 B-Chemical
-	617 1 O
induced	618 7 O
contractions	626 12 O
of	639 2 O
guinea	642 6 O
-	648 1 O
pig	649 3 O
ileum	653 5 O
were	659 4 O
inhibited	664 9 O
20	674 2 O
%	676 1 O
by	678 2 O
5	681 1 O
mM	683 2 O
NH4Ac	686 5 B-Chemical
.	691 1 O

Addition	693 8 O
of	702 2 O
excess	705 6 O
calcium	712 7 B-Chemical
reversed	720 8 O
the	729 3 O
depression	733 10 B-Disease
in	744 2 O
both	747 4 O
tissues	752 7 O
,	759 1 O
but	761 3 O
calcium	765 7 B-Chemical
-	772 1 O
independent	773 11 O
catecholamine	785 13 B-Chemical
release	799 7 O
by	807 2 O
acetaldehyde	810 12 B-Chemical
was	823 3 O
not	827 3 O
blocked	831 7 O
by	839 2 O
NH4Ac	842 5 B-Chemical
.	847 1 O

These	849 5 O
results	855 7 O
suggested	863 9 O
that	873 4 O
ammonia	878 7 B-Chemical
blocks	886 6 O
calcium	893 7 B-Chemical
channels	901 8 O
.	909 1 O

Parallels	911 9 O
in	921 2 O
the	924 3 O
actions	928 7 O
of	936 2 O
NH4Ac	939 5 B-Chemical
and	945 3 O
the	949 3 O
calcium	953 7 B-Chemical
channel	961 7 O
blocker	969 7 O
verapamil	977 9 B-Chemical
support	987 7 O
this	995 4 O
concept	1000 7 O
.	1007 1 O

Both	1009 4 O
verapamil	1014 9 B-Chemical
(	1024 1 O
10	1025 2 O
mg	1028 2 O
/	1030 1 O
kg	1031 2 O
i	1034 1 O
.	1035 1 O
p	1036 1 O
.	1037 1 O
)	1038 1 O
and	1040 3 O
NH4Ac	1044 5 B-Chemical
pretreatment	1050 12 O
enhanced	1063 8 O
morphine	1072 8 B-Chemical
analgesia	1081 9 B-Disease
-	1090 1 O
and	1092 3 O
diazepam	1096 8 B-Chemical
-	1104 1 O
induced	1105 7 O
muscular	1113 8 O
incoordination	1122 14 B-Disease
and	1137 3 O
antagonized	1141 11 O
amphetamine	1153 11 B-Chemical
-	1164 1 O
induced	1165 7 O
motor	1173 5 O
activity	1179 8 O
,	1187 1 O
and	1189 3 O
neither	1193 7 O
verapamil	1201 9 B-Chemical
nor	1211 3 O
NH4Ac	1215 5 B-Chemical
affected	1221 8 O
the	1230 3 O
convulsant	1234 10 O
action	1245 6 O
of	1252 2 O
metrazol	1255 8 B-Chemical
.	1263 1 O

The	1265 3 O
data	1269 4 O
suggest	1274 7 O
that	1282 4 O
hyperammonemia	1287 14 B-Disease
exerts	1302 6 O
a	1309 1 O
calcium	1311 7 B-Chemical
channel	1319 7 O
blocking	1327 8 O
action	1336 6 O
which	1343 5 O
enhances	1349 8 O
the	1358 3 O
effects	1362 7 O
of	1370 2 O
central	1373 7 O
nervous	1381 7 O
system	1389 6 O
depressants	1396 11 O
and	1408 3 O
certain	1412 7 O
opioid	1420 6 O
analgesics	1427 10 O
.	1437 1 O

Risk	0 4 O
of	5 2 O
nephropathy	8 11 B-Disease
after	20 5 O
consumption	26 11 O
of	38 2 O
nonionic	41 8 O
contrast	50 8 B-Chemical
media	59 5 I-Chemical
by	65 2 O
children	68 8 O
undergoing	77 10 O
cardiac	88 7 O
angiography	96 11 O
:	107 1 O
a	109 1 O
prospective	111 11 O
study	123 5 O
.	128 1 O

Despite	130 7 O
increasing	138 10 O
reports	149 7 O
on	157 2 O
nonionic	160 8 O
contrast	169 8 B-Chemical
media	178 5 I-Chemical
-	183 1 O
induced	184 7 O
nephropathy	192 11 B-Disease
(	204 1 O
CIN	205 3 B-Disease
)	208 1 O
in	210 2 O
hospitalized	213 12 O
adult	226 5 O
patients	232 8 O
during	241 6 O
cardiac	248 7 O
procedures	256 10 O
,	266 1 O
the	268 3 O
studies	272 7 O
in	280 2 O
pediatrics	283 10 O
are	294 3 O
limited	298 7 O
,	305 1 O
with	307 4 O
even	312 4 O
less	317 4 O
focus	322 5 O
on	328 2 O
possible	331 8 O
predisposing	340 12 O
factors	353 7 O
and	361 3 O
preventive	365 10 O
measures	376 8 O
for	385 3 O
patients	389 8 O
undergoing	398 10 O
cardiac	409 7 O
angiography	417 11 O
.	428 1 O

This	430 4 O
prospective	435 11 O
study	447 5 O
determined	453 10 O
the	464 3 O
incidence	468 9 O
of	478 2 O
CIN	481 3 B-Disease
for	485 3 O
two	489 3 O
nonionic	493 8 O
contrast	502 8 B-Chemical
media	511 5 I-Chemical
(	517 1 O
CM	518 2 B-Chemical
)	520 1 O
,	521 1 O
iopromide	523 9 B-Chemical
and	533 3 O
iohexol	537 7 B-Chemical
,	544 1 O
among	546 5 O
80	552 2 O
patients	555 8 O
younger	564 7 O
than	572 4 O
18	577 2 O
years	580 5 O
and	586 3 O
compared	590 8 O
the	599 3 O
rates	603 5 O
for	609 3 O
this	613 4 O
complication	618 12 O
in	631 2 O
relation	634 8 O
to	643 2 O
the	646 3 O
type	650 4 O
and	655 3 O
dosage	659 6 O
of	666 2 O
CM	669 2 B-Chemical
and	672 3 O
the	676 3 O
presence	680 8 O
of	689 2 O
cyanosis	692 8 B-Disease
.	700 1 O

The	702 3 O
80	706 2 O
patients	709 8 O
in	718 2 O
the	721 3 O
study	725 5 O
consecutively	731 13 O
received	745 8 O
either	754 6 O
iopromide	761 9 B-Chemical
(	771 1 O
group	772 5 O
A	778 1 O
,	779 1 O
n	781 1 O
=	783 1 O
40	785 2 O
)	787 1 O
or	789 2 O
iohexol	792 7 B-Chemical
(	800 1 O
group	801 5 O
B	807 1 O
,	808 1 O
n	810 1 O
=	812 1 O
40	814 2 O
)	816 1 O
.	817 1 O

Serum	819 5 O
sodium	825 6 B-Chemical
(	832 1 O
Na	833 2 B-Chemical
)	835 1 O
,	836 1 O
potassium	838 9 B-Chemical
(	848 1 O
K	849 1 B-Chemical
)	850 1 O
,	851 1 O
and	853 3 O
creatinine	857 10 B-Chemical
(	868 1 O
Cr	869 2 B-Chemical
)	871 1 O
were	873 4 O
measured	878 8 O
24	887 2 O
h	890 1 O
before	892 6 O
angiography	899 11 O
as	911 2 O
baseline	914 8 O
values	923 6 O
,	929 1 O
then	931 4 O
measured	936 8 O
again	945 5 O
at	951 2 O
12	954 2 O
-	956 1 O
,	957 1 O
24	959 2 O
-	961 1 O
,	962 1 O
and	964 3 O
48	968 2 O
-	970 1 O
h	971 1 O
intervals	973 9 O
after	983 5 O
CM	989 2 B-Chemical
use	992 3 O
.	995 1 O

Urine	997 5 O
samples	1003 7 O
for	1011 3 O
Na	1015 2 B-Chemical
and	1018 3 O
Cr	1022 2 B-Chemical
also	1025 4 O
were	1030 4 O
checked	1035 7 O
at	1043 2 O
the	1046 3 O
same	1050 4 O
intervals	1055 9 O
.	1064 1 O

Risk	1066 4 O
of	1071 2 O
renal	1074 5 B-Disease
failure	1080 7 I-Disease
,	1087 1 O
Injury	1089 6 B-Disease
to	1096 2 I-Disease
the	1099 3 I-Disease
kidney	1103 6 I-Disease
,	1109 1 O
Failure	1111 7 B-Disease
of	1119 2 I-Disease
kidney	1122 6 I-Disease
function	1129 8 I-Disease
,	1137 1 O
Loss	1139 4 B-Disease
of	1144 2 I-Disease
kidney	1147 6 I-Disease
function	1154 8 I-Disease
,	1162 1 O
and	1164 3 O
End	1168 3 O
-	1171 1 O
stage	1172 5 O
renal	1178 5 B-Disease
damage	1184 6 I-Disease
(	1191 1 O
RIFLE	1192 5 O
criteria	1198 8 O
)	1206 1 O
were	1208 4 O
used	1213 4 O
to	1218 2 O
define	1221 6 O
CIN	1228 3 B-Disease
and	1232 3 O
its	1236 3 O
incidence	1240 9 O
in	1250 2 O
the	1253 3 O
study	1257 5 O
population	1263 10 O
.	1273 1 O

Accordingly	1275 11 O
,	1286 1 O
among	1288 5 O
the	1294 3 O
15	1298 2 O
CIN	1301 3 B-Disease
patients	1305 8 O
(	1314 1 O
18	1315 2 O
.	1317 1 O
75	1318 2 O
%	1320 1 O
)	1321 1 O
,	1322 1 O
7	1324 1 O
.	1325 1 O
5	1326 1 O
%	1327 1 O
of	1329 2 O
the	1332 3 O
patients	1336 8 O
in	1345 2 O
group	1348 5 O
A	1354 1 O
had	1356 3 O
increased	1360 9 O
risk	1370 4 O
and	1375 3 O
3	1379 1 O
.	1380 1 O
75	1381 2 O
%	1383 1 O
had	1385 3 O
renal	1389 5 B-Disease
injury	1395 6 I-Disease
,	1401 1 O
whereas	1403 7 O
5	1411 1 O
%	1412 1 O
of	1414 2 O
group	1417 5 O
B	1423 1 O
had	1425 3 O
increased	1429 9 O
risk	1439 4 O
and	1444 3 O
2	1448 1 O
.	1449 1 O
5	1450 1 O
%	1451 1 O
had	1453 3 O
renal	1457 5 B-Disease
injury	1463 6 I-Disease
.	1469 1 O

Whereas	1471 7 O
33	1479 2 O
.	1481 1 O
3	1482 1 O
%	1483 1 O
of	1485 2 O
the	1488 3 O
patients	1492 8 O
with	1501 4 O
CIN	1506 3 B-Disease
were	1510 4 O
among	1515 5 O
those	1521 5 O
who	1527 3 O
received	1531 8 O
the	1540 3 O
proper	1544 6 O
dosage	1551 6 O
of	1558 2 O
CM	1561 2 B-Chemical
,	1563 1 O
the	1565 3 O
percentage	1569 10 O
increased	1580 9 O
to	1590 2 O
66	1593 2 O
.	1595 1 O
6	1596 1 O
%	1597 1 O
among	1599 5 O
those	1605 5 O
who	1611 3 O
received	1615 8 O
larger	1624 6 O
doses	1631 5 O
,	1636 1 O
with	1638 4 O
a	1643 1 O
significant	1645 11 O
difference	1657 10 O
in	1668 2 O
the	1671 3 O
incidence	1675 9 O
of	1685 2 O
CIN	1688 3 B-Disease
related	1692 7 O
to	1700 2 O
the	1703 3 O
different	1707 9 O
dosages	1717 7 O
of	1725 2 O
CM	1728 2 B-Chemical
(	1731 1 O
p	1732 1 O
=	1734 1 O
0	1736 1 O
.	1737 1 O
014	1738 3 O
)	1741 1 O
.	1742 1 O

Among	1744 5 O
the	1750 3 O
15	1754 2 O
patients	1757 8 O
with	1766 4 O
CIN	1771 3 B-Disease
,	1774 1 O
6	1776 1 O
had	1778 3 O
cyanotic	1782 8 O
congenital	1791 10 B-Disease
heart	1802 5 I-Disease
diseases	1808 8 I-Disease
,	1816 1 O
but	1818 3 O
the	1822 3 O
incidence	1826 9 O
did	1836 3 O
not	1840 3 O
differ	1844 6 O
significantly	1851 13 O
from	1865 4 O
that	1870 4 O
for	1875 3 O
the	1879 3 O
noncyanotic	1883 11 O
patients	1895 8 O
(	1904 1 O
p	1905 1 O
=	1907 1 O
0	1909 1 O
.	1910 1 O
243	1911 3 O
)	1914 1 O
.	1915 1 O

Although	1917 8 O
clinically	1926 10 O
silent	1937 6 O
,	1943 1 O
CIN	1945 3 B-Disease
is	1949 2 O
not	1952 3 O
rare	1956 4 O
in	1961 2 O
pediatrics	1964 10 O
.	1974 1 O

The	1976 3 O
incidence	1980 9 O
depends	1990 7 O
on	1998 2 O
dosage	2001 6 O
but	2008 3 O
not	2012 3 O
on	2016 2 O
the	2019 3 O
type	2023 4 O
of	2028 2 O
consumed	2031 8 O
nonionic	2040 8 O
CM	2049 2 B-Chemical
,	2051 1 O
nor	2053 3 O
on	2057 2 O
the	2060 3 O
presence	2064 8 O
of	2073 2 O
cyanosis	2076 8 B-Disease
,	2084 1 O
and	2086 3 O
although	2090 8 O
CIN	2099 3 B-Disease
usually	2103 7 O
is	2111 2 O
reversible	2114 10 O
,	2124 1 O
more	2126 4 O
concern	2131 7 O
is	2139 2 O
needed	2142 6 O
for	2149 3 O
the	2153 3 O
prevention	2157 10 O
of	2168 2 O
such	2171 4 O
a	2176 1 O
complication	2178 12 O
in	2191 2 O
children	2194 8 O
.	2202 1 O

A	0 1 O
case	2 4 O
of	7 2 O
ventricular	10 11 B-Disease
tachycardia	22 11 I-Disease
related	34 7 O
to	42 2 O
caffeine	45 8 B-Chemical
pretreatment	54 12 O
.	66 1 O

Suboptimal	68 10 O
seizure	79 7 B-Disease
duration	87 8 O
is	96 2 O
commonly	99 8 O
encountered	108 11 O
in	120 2 O
electroconvulsive	123 17 O
therapy	141 7 O
practice	149 8 O
,	157 1 O
especially	159 10 O
in	170 2 O
older	173 5 O
patients	179 8 O
with	188 4 O
higher	193 6 O
seizure	200 7 B-Disease
thresholds	208 10 O
.	218 1 O

Intravenous	220 11 O
caffeine	232 8 B-Chemical
is	241 2 O
commonly	244 8 O
used	253 4 O
to	258 2 O
improve	261 7 O
seizure	269 7 B-Disease
duration	277 8 O
and	286 3 O
quality	290 7 O
in	298 2 O
such	301 4 O
patients	306 8 O
and	315 3 O
is	319 2 O
generally	322 9 O
well	332 4 O
tolerated	337 9 O
aside	347 5 O
from	353 4 O
occasional	358 10 O
reports	369 7 O
of	377 2 O
relatively	380 10 O
benign	391 6 O
ventricular	398 11 B-Disease
ectopy	410 6 I-Disease
.	416 1 O

We	418 2 O
describe	421 8 O
a	430 1 O
patient	432 7 O
with	440 4 O
no	445 2 O
previous	448 8 O
history	457 7 O
of	465 2 O
cardiac	468 7 B-Disease
disease	476 7 I-Disease
or	484 2 O
arrhythmia	487 10 B-Disease
who	498 3 O
developed	502 9 O
sustained	512 9 O
bigeminy	522 8 O
and	531 3 O
2	535 1 O
brief	537 5 O
runs	543 4 O
of	548 2 O
ventricular	551 11 B-Disease
tachycardia	563 11 I-Disease
after	575 5 O
caffeine	581 8 B-Chemical
administration	590 14 O
.	604 1 O

Although	606 8 O
intravenous	615 11 O
caffeine	627 8 B-Chemical
is	636 2 O
generally	639 9 O
well	649 4 O
tolerated	654 9 O
,	663 1 O
the	665 3 O
clinician	669 9 O
should	679 6 O
be	686 2 O
aware	689 5 O
of	695 2 O
the	698 3 O
potential	702 9 O
for	712 3 O
unpredictable	716 13 O
and	730 3 O
serious	734 7 O
ventricular	742 11 B-Disease
arrhythmias	754 11 I-Disease
.	765 1 O

Optical	0 7 O
coherence	8 9 O
tomography	18 10 O
can	29 3 O
measure	33 7 O
axonal	41 6 O
loss	48 4 O
in	53 2 O
patients	56 8 O
with	65 4 O
ethambutol	70 10 B-Chemical
-	80 1 O
induced	81 7 O
optic	89 5 B-Disease
neuropathy	95 10 I-Disease
.	105 1 O

PURPOSE	107 7 O
:	114 1 O
To	116 2 O
map	119 3 O
and	123 3 O
identify	127 8 O
the	136 3 O
pattern	140 7 O
,	147 1 O
in	149 2 O
vivo	152 4 O
,	156 1 O
of	158 2 O
axonal	161 6 B-Disease
degeneration	168 12 I-Disease
in	181 2 O
ethambutol	184 10 B-Chemical
-	194 1 O
induced	195 7 O
optic	203 5 B-Disease
neuropathy	209 10 I-Disease
using	220 5 O
optical	226 7 O
coherence	234 9 O
tomography	244 10 O
(	255 1 O
OCT	256 3 O
)	259 1 O
.	260 1 O

Ethambutol	262 10 B-Chemical
is	273 2 O
an	276 2 O
antimycobacterial	279 17 O
agent	297 5 O
often	303 5 O
used	309 4 O
to	314 2 O
treat	317 5 O
tuberculosis	323 12 B-Disease
.	335 1 O

A	337 1 O
serious	339 7 O
complication	347 12 O
of	360 2 O
ethambutol	363 10 B-Chemical
is	374 2 O
an	377 2 O
optic	380 5 B-Disease
neuropathy	386 10 I-Disease
that	397 4 O
impairs	402 7 O
visual	410 6 O
acuity	417 6 O
,	423 1 O
contrast	425 8 O
sensitivity	434 11 O
,	445 1 O
and	447 3 O
color	451 5 O
vision	457 6 O
.	463 1 O

However	465 7 O
,	472 1 O
early	474 5 O
on	480 2 O
,	482 1 O
when	484 4 O
the	489 3 O
toxic	493 5 O
optic	499 5 B-Disease
neuropathy	505 10 I-Disease
is	516 2 O
mild	519 4 O
and	524 3 O
partly	528 6 O
reversible	535 10 O
,	545 1 O
the	547 3 O
funduscopic	551 11 O
findings	563 8 O
are	572 3 O
often	576 5 O
subtle	582 6 O
and	589 3 O
easy	593 4 O
to	598 2 O
miss	601 4 O
.	605 1 O

METHODS	607 7 O
:	614 1 O
Three	616 5 O
subjects	622 8 O
with	631 4 O
a	636 1 O
history	638 7 O
of	646 2 O
ethambutol	649 10 B-Chemical
(	660 1 O
EMB	661 3 B-Chemical
)	664 1 O
-	665 1 O
induced	666 7 O
optic	674 5 B-Disease
neuropathy	680 10 I-Disease
of	691 2 O
short	694 5 O
-	699 1 O
,	700 1 O
intermediate	702 12 O
-	714 1 O
,	715 1 O
and	717 3 O
long	721 4 O
-	725 1 O
term	726 4 O
visual	731 6 B-Disease
deficits	738 8 I-Disease
were	747 4 O
administered	752 12 O
a	765 1 O
full	767 4 O
neuro	772 5 O
-	777 1 O
ophthalmologic	778 14 O
examination	793 11 O
including	805 9 O
visual	815 6 O
acuity	822 6 O
,	828 1 O
color	830 5 O
vision	836 6 O
,	842 1 O
contrast	844 8 O
sensitivity	853 11 O
,	864 1 O
and	866 3 O
fundus	870 6 O
examination	877 11 O
.	888 1 O

In	890 2 O
addition	893 8 O
,	901 1 O
OCT	903 3 O
(	907 1 O
OCT	908 3 O
3000	912 4 O
,	916 1 O
Humphrey	918 8 O
-	926 1 O
Zeiss	927 5 O
,	932 1 O
Dublin	934 6 O
,	940 1 O
CA	942 2 O
)	944 1 O
was	946 3 O
performed	950 9 O
on	960 2 O
both	963 4 O
eyes	968 4 O
of	973 2 O
each	976 4 O
subject	981 7 O
using	989 5 O
the	995 3 O
retinal	999 7 O
nerve	1007 5 O
fiber	1013 5 O
layer	1019 5 O
(	1025 1 O
RNFL	1026 4 O
)	1030 1 O
analysis	1032 8 O
protocol	1041 8 O
.	1049 1 O

OCT	1051 3 O
interpolates	1055 12 O
data	1068 4 O
from	1073 4 O
100	1078 3 O
points	1082 6 O
around	1089 6 O
the	1096 3 O
optic	1100 5 O
nerve	1106 5 O
to	1112 2 O
effectively	1115 11 O
map	1127 3 O
out	1131 3 O
the	1135 3 O
RNFL	1139 4 O
.	1143 1 O

RESULTS	1145 7 O
:	1152 1 O
The	1154 3 O
results	1158 7 O
were	1166 4 O
compared	1171 8 O
to	1180 2 O
the	1183 3 O
calculated	1187 10 O
average	1198 7 O
RNFL	1206 4 O
of	1211 2 O
normal	1214 6 O
eyes	1221 4 O
accumulated	1226 11 O
from	1238 4 O
four	1243 4 O
prior	1248 5 O
studies	1254 7 O
using	1262 5 O
OCT	1268 3 O
,	1271 1 O
n	1273 1 O
=	1274 1 O
661	1275 3 O
.	1278 1 O

In	1280 2 O
all	1283 3 O
subjects	1287 8 O
with	1296 4 O
history	1301 7 O
of	1309 2 O
EMB	1312 3 B-Chemical
-	1315 1 O
induced	1316 7 O
optic	1324 5 B-Disease
neuropathy	1330 10 I-Disease
,	1340 1 O
there	1342 5 O
was	1348 3 O
a	1352 1 O
mean	1354 4 O
loss	1359 4 O
of	1364 2 O
72	1367 2 O
%	1369 1 O
nerve	1371 5 O
fiber	1377 5 O
layer	1383 5 O
thickness	1389 9 O
in	1399 2 O
the	1402 3 O
temporal	1406 8 O
quadrant	1415 8 O
(	1424 1 O
patient	1425 7 O
A	1433 1 O
,	1434 1 O
with	1436 4 O
eventual	1441 8 O
recovery	1450 8 O
of	1459 2 O
visual	1462 6 O
acuity	1469 6 O
and	1476 3 O
fields	1480 6 O
,	1486 1 O
58	1488 2 O
%	1490 1 O
loss	1492 4 O
;	1496 1 O
patient	1498 7 O
B	1506 1 O
,	1507 1 O
with	1509 4 O
intermediate	1514 12 O
visual	1527 6 B-Disease
deficits	1534 8 I-Disease
,	1542 1 O
68	1544 2 O
%	1546 1 O
loss	1548 4 O
;	1552 1 O
patient	1554 7 O
C	1562 1 O
,	1563 1 O
with	1565 4 O
chronic	1570 7 O
visual	1578 6 B-Disease
deficits	1585 8 I-Disease
,	1593 1 O
90	1595 2 O
%	1597 1 O
loss	1599 4 O
)	1603 1 O
,	1604 1 O
with	1606 4 O
an	1611 2 O
average	1614 7 O
mean	1622 4 O
optic	1627 5 O
nerve	1633 5 O
thickness	1639 9 O
of	1649 2 O
26	1652 2 O
+	1654 1 O
/	1655 1 O
-	1656 1 O
16	1657 2 O
microm	1660 6 O
.	1666 1 O

There	1668 5 O
was	1674 3 O
a	1678 1 O
combined	1680 8 O
mean	1689 4 O
loss	1694 4 O
of	1699 2 O
46	1702 2 O
%	1704 1 O
of	1706 2 O
fibers	1709 6 O
from	1716 4 O
the	1721 3 O
superior	1725 8 O
,	1733 1 O
inferior	1735 8 O
,	1743 1 O
and	1745 3 O
nasal	1749 5 O
quadrants	1755 9 O
in	1765 2 O
the	1768 3 O
(	1772 1 O
six	1773 3 O
)	1776 1 O
eyes	1778 4 O
of	1783 2 O
all	1786 3 O
three	1790 5 O
subjects	1796 8 O
(	1805 1 O
mean	1806 4 O
average	1811 7 O
thickness	1819 9 O
of	1829 2 O
55	1832 2 O
+	1834 1 O
/	1835 1 O
-	1836 1 O
29	1837 2 O
microm	1840 6 O
)	1846 1 O
.	1847 1 O

In	1849 2 O
both	1852 4 O
sets	1857 4 O
(	1862 1 O
four	1863 4 O
)	1867 1 O
of	1869 2 O
eyes	1872 4 O
of	1877 2 O
the	1880 3 O
subjects	1884 8 O
with	1893 4 O
persistent	1898 10 O
visual	1909 6 B-Disease
deficits	1916 8 I-Disease
(	1925 1 O
patients	1926 8 O
B	1935 1 O
and	1937 3 O
C	1941 1 O
)	1942 1 O
,	1943 1 O
there	1945 5 O
was	1951 3 O
an	1955 2 O
average	1958 7 O
loss	1966 4 O
of	1971 2 O
79	1974 2 O
%	1976 1 O
of	1978 2 O
nerve	1981 5 O
fiber	1987 5 O
thickness	1993 9 O
in	2003 2 O
the	2006 3 O
temporal	2010 8 O
quadrant	2019 8 O
.	2027 1 O

CONCLUSIONS	2029 11 O
:	2040 1 O
The	2042 3 O
OCT	2046 3 O
results	2050 7 O
in	2058 2 O
these	2061 5 O
patients	2067 8 O
with	2076 4 O
EMB	2081 3 B-Chemical
-	2084 1 O
induced	2085 7 O
optic	2093 5 B-Disease
neuropathy	2099 10 I-Disease
show	2110 4 O
considerable	2115 12 O
loss	2128 4 O
especially	2133 10 O
of	2144 2 O
the	2147 3 O
temporal	2151 8 O
fibers	2160 6 O
.	2166 1 O

This	2168 4 O
is	2173 2 O
consistent	2176 10 O
with	2187 4 O
prior	2192 5 O
histopathological	2198 17 O
studies	2216 7 O
that	2224 4 O
show	2229 4 O
predominant	2234 11 O
loss	2246 4 O
of	2251 2 O
parvo	2254 5 O
-	2259 1 O
cellular	2260 8 O
axons	2269 5 O
(	2275 1 O
or	2276 2 O
small	2279 5 O
-	2284 1 O
caliber	2285 7 O
axons	2293 5 O
)	2298 1 O
within	2300 6 O
the	2307 3 O
papillo	2311 7 O
-	2318 1 O
macular	2319 7 O
bundle	2327 6 O
in	2334 2 O
toxic	2337 5 O
or	2343 2 O
hereditary	2346 10 O
optic	2357 5 B-Disease
neuropathies	2363 12 I-Disease
.	2375 1 O

OCT	2377 3 O
can	2381 3 O
be	2385 2 O
a	2388 1 O
valuable	2390 8 O
tool	2399 4 O
in	2404 2 O
the	2407 3 O
quantitative	2411 12 O
analysis	2424 8 O
of	2433 2 O
optic	2436 5 B-Disease
neuropathies	2442 12 I-Disease
.	2454 1 O

Additionally	2456 12 O
,	2468 1 O
in	2470 2 O
terms	2473 5 O
of	2479 2 O
management	2482 10 O
of	2493 2 O
EMB	2496 3 B-Chemical
-	2499 1 O
induced	2500 7 O
optic	2508 5 B-Disease
neuropathy	2514 10 I-Disease
,	2524 1 O
it	2526 2 O
is	2529 2 O
important	2532 9 O
to	2542 2 O
properly	2545 8 O
manage	2554 6 O
ethambutol	2561 10 B-Chemical
dosing	2572 6 O
in	2579 2 O
patients	2582 8 O
with	2591 4 O
renal	2596 5 B-Disease
impairment	2602 10 I-Disease
and	2613 3 O
to	2617 2 O
achieve	2620 7 O
proper	2628 6 O
transition	2635 10 O
to	2646 2 O
a	2649 1 O
maintenance	2651 11 O
dose	2663 4 O
once	2668 4 O
an	2673 2 O
appropriate	2676 11 O
loading	2688 7 O
dose	2696 4 O
has	2701 3 O
been	2705 4 O
reached	2710 7 O
.	2717 1 O

Effects	0 7 O
of	8 2 O
the	11 3 O
cyclooxygenase	15 14 O
-	29 1 O
2	30 1 O
specific	32 8 O
inhibitor	41 9 O
valdecoxib	51 10 B-Chemical
versus	62 6 O
nonsteroidal	69 12 O
antiinflammatory	82 16 O
agents	99 6 O
and	106 3 O
placebo	110 7 O
on	118 2 O
cardiovascular	121 14 O
thrombotic	136 10 B-Disease
events	147 6 O
in	154 2 O
patients	157 8 O
with	166 4 O
arthritis	171 9 B-Disease
.	180 1 O

There	182 5 O
have	188 4 O
been	193 4 O
concerns	198 8 O
that	207 4 O
the	212 3 O
risk	216 4 O
of	221 2 O
cardiovascular	224 14 O
thrombotic	239 10 B-Disease
events	250 6 O
may	257 3 O
be	261 2 O
higher	264 6 O
with	271 4 O
cyclooxygenase	276 14 O
(	291 1 O
COX	292 3 O
)	295 1 O
-	296 1 O
2	297 1 O
-	298 1 O
specific	299 8 O
inhibitors	308 10 O
than	319 4 O
nonselective	324 12 O
nonsteroidal	337 12 O
antiinflammatory	350 16 O
drugs	367 5 O
(	373 1 O
NSAIDs	374 6 O
)	380 1 O
.	381 1 O

We	383 2 O
evaluated	386 9 O
cardiovascular	396 14 O
event	411 5 O
data	417 4 O
for	422 3 O
valdecoxib	426 10 B-Chemical
,	436 1 O
a	438 1 O
new	440 3 O
COX	444 3 O
-	447 1 O
2	448 1 O
-	449 1 O
specific	450 8 O
inhibitor	459 9 O
in	469 2 O
approximately	472 13 O
8000	486 4 O
patients	491 8 O
with	500 4 O
osteoarthritis	505 14 B-Disease
and	520 3 O
rheumatoid	524 10 B-Disease
arthritis	535 9 I-Disease
treated	545 7 O
with	553 4 O
this	558 4 O
agent	563 5 O
in	569 2 O
randomized	572 10 O
clinical	583 8 O
trials	592 6 O
.	598 1 O

The	600 3 O
incidence	604 9 O
of	614 2 O
cardiovascular	617 14 O
thrombotic	632 10 B-Disease
events	643 6 O
(	650 1 O
cardiac	651 7 O
,	658 1 O
cerebrovascular	660 15 O
and	676 3 O
peripheral	680 10 O
vascular	691 8 O
,	699 1 O
or	701 2 O
arterial	704 8 O
thrombotic	713 10 B-Disease
)	723 1 O
was	725 3 O
determined	729 10 O
by	740 2 O
analyzing	743 9 O
pooled	753 6 O
valdecoxib	760 10 B-Chemical
(	771 1 O
10	772 2 O
-	774 1 O
80	775 2 O
mg	778 2 O
daily	781 5 O
)	786 1 O
,	787 1 O
nonselective	789 12 O
NSAID	802 5 O
(	808 1 O
diclofenac	809 10 B-Chemical
75	820 2 O
mg	823 2 O
bid	826 3 O
,	829 1 O
ibuprofen	831 9 B-Chemical
800	841 3 O
mg	845 2 O
tid	848 3 O
,	851 1 O
or	853 2 O
naproxen	856 8 B-Chemical
500	865 3 O
mg	869 2 O
bid	872 3 O
)	875 1 O
and	877 3 O
placebo	881 7 O
data	889 4 O
from	894 4 O
10	899 2 O
randomized	902 10 O
osteoarthritis	913 14 B-Disease
and	928 3 O
rheumatoid	932 10 B-Disease
arthritis	943 9 I-Disease
trials	953 6 O
that	960 4 O
were	965 4 O
6	970 1 O
-	971 1 O
52	972 2 O
weeks	975 5 O
in	981 2 O
duration	984 8 O
.	992 1 O

The	994 3 O
incidence	998 9 O
rates	1008 5 O
of	1014 2 O
events	1017 6 O
were	1024 4 O
determined	1029 10 O
in	1040 2 O
all	1043 3 O
patients	1047 8 O
(	1056 1 O
n	1057 1 O
=	1059 1 O
7934	1061 4 O
)	1065 1 O
and	1067 3 O
in	1071 2 O
users	1074 5 O
of	1080 2 O
low	1083 3 O
-	1086 1 O
dose	1087 4 O
(	1092 1 O
<	1093 1 O
or	1095 2 O
=	1098 1 O
325	1099 3 O
mg	1103 2 O
daily	1106 5 O
)	1111 1 O
aspirin	1113 7 B-Chemical
(	1121 1 O
n	1122 1 O
=	1124 1 O
1051	1126 4 O
)	1130 1 O
and	1132 3 O
nonusers	1136 8 O
of	1145 2 O
aspirin	1148 7 B-Chemical
(	1156 1 O
n	1157 1 O
=	1159 1 O
6883	1161 4 O
)	1165 1 O
.	1166 1 O

Crude	1168 5 O
and	1174 3 O
exposure	1178 8 O
-	1186 1 O
adjusted	1187 8 O
incidences	1196 10 O
of	1207 2 O
thrombotic	1210 10 B-Disease
events	1221 6 O
were	1228 4 O
similar	1233 7 O
for	1241 3 O
valdecoxib	1245 10 B-Chemical
,	1255 1 O
NSAIDs	1257 6 O
,	1263 1 O
and	1265 3 O
placebo	1269 7 O
.	1276 1 O

The	1278 3 O
risk	1282 4 O
of	1287 2 O
serious	1290 7 O
thrombotic	1298 10 B-Disease
events	1309 6 O
was	1316 3 O
also	1320 4 O
similar	1325 7 O
for	1333 3 O
each	1337 4 O
valdecoxib	1342 10 B-Chemical
dose	1353 4 O
.	1357 1 O

Thrombotic	1359 10 B-Disease
risk	1370 4 O
was	1375 3 O
consistently	1379 12 O
higher	1392 6 O
for	1399 3 O
users	1403 5 O
of	1409 2 O
aspirin	1412 7 B-Chemical
users	1420 5 O
than	1426 4 O
nonusers	1431 8 O
of	1440 2 O
aspirin	1443 7 B-Chemical
(	1451 1 O
placebo	1452 7 O
,	1459 1 O
1	1461 1 O
.	1462 1 O
4	1463 1 O
%	1464 1 O
vs	1466 2 O
.	1468 1 O
0	1470 1 O
%	1471 1 O
;	1472 1 O
valdecoxib	1474 10 B-Chemical
,	1484 1 O
1	1486 1 O
.	1487 1 O
7	1488 1 O
%	1489 1 O
vs	1491 2 O
.	1493 1 O
0	1495 1 O
.	1496 1 O
2	1497 1 O
%	1498 1 O
;	1499 1 O
NSAIDs	1501 6 O
,	1507 1 O
1	1509 1 O
.	1510 1 O
9	1511 1 O
%	1512 1 O
vs	1514 2 O
.	1516 1 O
0	1518 1 O
.	1519 1 O
5	1520 1 O
%	1521 1 O
)	1522 1 O
.	1523 1 O

The	1525 3 O
rates	1529 5 O
of	1535 2 O
events	1538 6 O
in	1545 2 O
users	1548 5 O
of	1554 2 O
aspirin	1557 7 B-Chemical
were	1565 4 O
similar	1570 7 O
for	1578 3 O
all	1582 3 O
3	1586 1 O
treatment	1588 9 O
groups	1598 6 O
and	1605 3 O
across	1609 6 O
valdecoxib	1616 10 B-Chemical
doses	1627 5 O
.	1632 1 O

Short	1634 5 O
-	1639 1 O
and	1641 3 O
intermediate	1645 12 O
-	1657 1 O
term	1658 4 O
treatment	1663 9 O
with	1673 4 O
therapeutic	1678 11 O
(	1690 1 O
10	1691 2 O
or	1694 2 O
20	1697 2 O
mg	1700 2 O
daily	1703 5 O
)	1708 1 O
and	1710 3 O
supratherapeutic	1714 16 O
(	1731 1 O
40	1732 2 O
or	1735 2 O
80	1738 2 O
mg	1741 2 O
daily	1744 5 O
)	1749 1 O
valdecoxib	1751 10 B-Chemical
doses	1762 5 O
was	1768 3 O
not	1772 3 O
associated	1776 10 O
with	1787 4 O
an	1792 2 O
increased	1795 9 O
incidence	1805 9 O
of	1815 2 O
thrombotic	1818 10 B-Disease
events	1829 6 O
relative	1836 8 O
to	1845 2 O
nonselective	1848 12 O
NSAIDs	1861 6 O
or	1868 2 O
placebo	1871 7 O
in	1879 2 O
osteoarthritis	1882 14 B-Disease
and	1897 3 O
rheumatoid	1901 10 B-Disease
arthritis	1912 9 I-Disease
patients	1922 8 O
in	1931 2 O
controlled	1934 10 O
clinical	1945 8 O
trials	1954 6 O
.	1960 1 O

A	0 1 O
randomized	2 10 O
,	12 1 O
placebo	14 7 O
-	21 1 O
controlled	22 10 O
,	32 1 O
crossover	34 9 O
study	44 5 O
of	50 2 O
ephedrine	53 9 B-Chemical
for	63 3 O
SSRI	67 4 O
-	71 1 O
induced	72 7 O
female	80 6 O
sexual	87 6 B-Disease
dysfunction	94 11 I-Disease
.	105 1 O

The	107 3 O
objective	111 9 O
of	121 2 O
this	124 4 O
study	129 5 O
was	135 3 O
to	139 2 O
determine	142 9 O
whether	152 7 O
ephedrine	160 9 B-Chemical
,	169 1 O
an	171 2 O
alpha	174 5 O
-	179 1 O
and	181 3 O
beta	185 4 O
-	189 1 O
adrenergic	190 10 O
agonist	201 7 O
previously	209 10 O
shown	220 5 O
to	226 2 O
enhance	229 7 O
genital	237 7 O
blood	245 5 O
flow	251 4 O
in	256 2 O
women	259 5 O
,	264 1 O
has	266 3 O
beneficial	270 10 O
effects	281 7 O
in	289 2 O
reversing	292 9 O
antidepressant	302 14 O
-	316 1 O
induced	317 7 O
sexual	325 6 B-Disease
dysfunction	332 11 I-Disease
.	343 1 O

Nineteen	345 8 O
sexually	354 8 B-Disease
dysfunctional	363 13 I-Disease
women	377 5 O
receiving	383 9 O
either	393 6 O
fluoxetine	400 10 B-Chemical
,	410 1 O
sertraline	412 10 B-Chemical
,	422 1 O
or	424 2 O
paroxetine	427 10 B-Chemical
participated	438 12 O
in	451 2 O
an	454 2 O
eight	457 5 O
-	462 1 O
week	463 4 O
,	467 1 O
double	469 6 O
-	475 1 O
blind	476 5 O
,	481 1 O
placebo	483 7 O
-	490 1 O
controlled	491 10 O
,	501 1 O
cross	503 5 O
-	508 1 O
over	509 4 O
study	514 5 O
of	520 2 O
the	523 3 O
effects	527 7 O
of	535 2 O
ephedrine	538 9 B-Chemical
(	548 1 O
50	549 2 O
mg	552 2 O
)	554 1 O
on	556 2 O
self	559 4 O
-	563 1 O
report	564 6 O
measures	571 8 O
of	580 2 O
sexual	583 6 O
desire	590 6 O
,	596 1 O
arousal	598 7 O
,	605 1 O
orgasm	607 6 O
,	613 1 O
and	615 3 O
sexual	619 6 O
satisfaction	626 12 O
.	638 1 O

Although	640 8 O
there	649 5 O
were	655 4 O
significant	660 11 O
improvements	672 12 O
relative	685 8 O
to	694 2 O
baseline	697 8 O
in	706 2 O
sexual	709 6 O
desire	716 6 O
and	723 3 O
orgasm	727 6 O
intensity	734 9 O
/	743 1 O
pleasure	744 8 O
on	753 2 O
50	756 2 O
mg	759 2 O
ephedrine	762 9 B-Chemical
1	772 1 O
-	773 1 O
hr	774 2 O
prior	777 5 O
to	783 2 O
sexual	786 6 O
activity	793 8 O
,	801 1 O
significant	803 11 O
improvements	815 12 O
in	828 2 O
these	831 5 O
measures	837 8 O
,	845 1 O
as	847 2 O
well	850 4 O
as	855 2 O
in	858 2 O
sexual	861 6 O
arousal	868 7 O
and	876 3 O
orgasmic	880 8 O
ability	889 7 O
also	897 4 O
were	902 4 O
noted	907 5 O
with	913 4 O
placebo	918 7 O
.	925 1 O

These	927 5 O
findings	933 8 O
highlight	942 9 O
the	952 3 O
importance	956 10 O
of	967 2 O
conducting	970 10 O
placebo	981 7 O
-	988 1 O
controlled	989 10 O
trials	1000 6 O
for	1007 3 O
this	1011 4 O
condition	1016 9 O
.	1025 1 O

Erectile	0 8 B-Disease
dysfunction	9 11 I-Disease
occurs	21 6 O
following	28 9 O
substantia	38 10 O
nigra	49 5 O
lesions	55 7 O
in	63 2 O
the	66 3 O
rat	70 3 O
.	73 1 O

Erectile	75 8 O
function	84 8 O
was	93 3 O
assessed	97 8 O
6	106 1 O
weeks	108 5 O
following	114 9 O
uni	124 3 O
-	127 1 O
and	129 3 O
bilateral	133 9 O
injections	143 10 O
of	154 2 O
6	157 1 B-Chemical
-	158 1 I-Chemical
hydroxydopamine	159 15 I-Chemical
in	175 2 O
the	178 3 O
substantia	182 10 O
nigra	193 5 O
nucleus	199 7 O
of	207 2 O
the	210 3 O
brain	214 5 O
.	219 1 O

Behavioral	221 10 O
apomorphine	232 11 B-Chemical
-	243 1 O
induced	244 7 O
penile	252 6 O
erections	259 9 O
were	269 4 O
reduced	274 7 O
(	282 1 O
5	283 1 O
/	284 1 O
8	285 1 O
)	286 1 O
and	288 3 O
increased	292 9 O
(	302 1 O
3	303 1 O
/	304 1 O
8	305 1 O
)	306 1 O
in	308 2 O
uni	311 3 O
-	314 1 O
and	316 3 O
bilateral	320 9 O
lesioned	330 8 O
animals	339 7 O
.	346 1 O

Intracavernous	348 14 O
pressures	363 9 O
,	372 1 O
following	374 9 O
electrical	384 10 O
stimulation	395 11 O
of	407 2 O
the	410 3 O
cavernous	414 9 O
nerve	424 5 O
,	429 1 O
decreased	431 9 O
in	441 2 O
lesioned	444 8 O
animals	453 7 O
.	460 1 O

Lesions	462 7 O
of	470 2 O
the	473 3 O
substantia	477 10 O
nigra	488 5 O
were	494 4 O
confirmed	499 9 O
by	509 2 O
histology	512 9 O
.	521 1 O

Concentration	523 13 O
of	537 2 O
dopamine	540 8 B-Chemical
and	549 3 O
its	553 3 O
metabolites	557 11 O
were	569 4 O
decreased	574 9 O
in	584 2 O
the	587 3 O
striatum	591 8 O
of	600 2 O
substantia	603 10 O
nigra	614 5 O
lesioned	620 8 O
rats	629 4 O
.	633 1 O

Lesions	635 7 O
of	643 2 O
the	646 3 O
substantia	650 10 O
nigra	661 5 O
are	667 3 O
therefore	671 9 O
associated	681 10 O
with	692 4 O
erectile	697 8 B-Disease
dysfunction	706 11 I-Disease
in	718 2 O
rats	721 4 O
and	726 3 O
may	730 3 O
serve	734 5 O
as	740 2 O
a	743 1 O
model	745 5 O
to	751 2 O
study	754 5 O
erectile	760 8 B-Disease
dysfunction	769 11 I-Disease
in	781 2 O
Parkinson	784 9 B-Disease
'	793 1 I-Disease
s	794 1 I-Disease
disease	796 7 I-Disease
.	803 1 O

Potential	0 9 O
therapeutic	10 11 O
use	22 3 O
of	26 2 O
the	29 3 O
selective	33 9 O
dopamine	43 8 B-Chemical
D1	52 2 O
receptor	55 8 O
agonist	64 7 O
,	71 1 O
A	73 1 B-Chemical
-	74 1 I-Chemical
86929	75 5 I-Chemical
:	80 1 O
an	82 2 O
acute	85 5 O
study	91 5 O
in	97 2 O
parkinsonian	100 12 B-Disease
levodopa	113 8 B-Chemical
-	121 1 O
primed	122 6 O
monkeys	129 7 O
.	136 1 O

The	138 3 O
clinical	142 8 O
utility	151 7 O
of	159 2 O
dopamine	162 8 B-Chemical
(	171 1 O
DA	172 2 B-Chemical
)	174 1 O
D1	176 2 O
receptor	179 8 O
agonists	188 8 O
in	197 2 O
the	200 3 O
treatment	204 9 O
of	214 2 O
Parkinson	217 9 B-Disease
'	226 1 I-Disease
s	227 1 I-Disease
disease	229 7 I-Disease
(	237 1 O
PD	238 2 B-Disease
)	240 1 O
is	242 2 O
still	245 5 O
unclear	251 7 O
.	258 1 O

The	260 3 O
therapeutic	264 11 O
use	276 3 O
of	280 2 O
selective	283 9 O
DA	293 2 B-Chemical
D1	296 2 O
receptor	299 8 O
agonists	308 8 O
such	317 4 O
as	322 2 O
SKF	325 3 B-Chemical
-	328 1 I-Chemical
82958	329 5 I-Chemical
(	335 1 O
6	336 1 B-Chemical
-	337 1 I-Chemical
chloro	338 6 I-Chemical
-	344 1 I-Chemical
7	345 1 I-Chemical
,	346 1 I-Chemical
8	347 1 I-Chemical
-	348 1 I-Chemical
dihydroxy	349 9 I-Chemical
-	358 1 I-Chemical
3	359 1 I-Chemical
-	360 1 I-Chemical
allyl	361 5 I-Chemical
-	366 1 I-Chemical
1	367 1 I-Chemical
-	368 1 I-Chemical
phenyl	369 6 I-Chemical
-	375 1 I-Chemical
2	376 1 I-Chemical
,	377 1 I-Chemical
3	378 1 I-Chemical
,	379 1 I-Chemical
4	380 1 I-Chemical
,	381 1 I-Chemical
5	382 1 I-Chemical
-	383 1 I-Chemical
tetrahydro	384 10 I-Chemical
-	394 1 I-Chemical
1H	395 2 I-Chemical
-	397 1 I-Chemical
3	398 1 I-Chemical
-	399 1 I-Chemical
benzaze	400 7 I-Chemical
pine	408 4 I-Chemical
hydrobromide	413 12 I-Chemical
)	425 1 O
and	427 3 O
A	431 1 B-Chemical
-	432 1 I-Chemical
77636	433 5 I-Chemical
(	439 1 O
[	440 1 B-Chemical
1R	441 2 I-Chemical
,	443 1 I-Chemical
3S	445 2 I-Chemical
]	447 1 I-Chemical
3	449 1 I-Chemical
-	450 1 I-Chemical
[	451 1 I-Chemical
1	452 1 I-Chemical
'	453 1 I-Chemical
-	454 1 I-Chemical
admantyl	455 8 I-Chemical
]	463 1 I-Chemical
-	464 1 I-Chemical
1	465 1 I-Chemical
-	466 1 I-Chemical
aminomethyl	467 11 I-Chemical
-	478 1 I-Chemical
3	479 1 I-Chemical
,	480 1 I-Chemical
4	481 1 I-Chemical
-	482 1 I-Chemical
dihydro	483 7 I-Chemical
-	490 1 I-Chemical
5	491 1 I-Chemical
,	492 1 I-Chemical
6	493 1 I-Chemical
-	494 1 I-Chemical
dihydroxy	495 9 I-Chemical
-	504 1 I-Chemical
1H	505 2 I-Chemical
-	507 1 I-Chemical
2	508 1 I-Chemical
-	509 1 I-Chemical
benzo	510 5 I-Chemical
pyran	516 5 I-Chemical
hydrochloride	522 13 I-Chemical
)	535 1 O
seems	537 5 O
limited	543 7 O
because	551 7 O
of	559 2 O
their	562 5 O
duration	568 8 O
of	577 2 O
action	580 6 O
,	586 1 O
which	588 5 O
is	594 2 O
too	597 3 O
short	601 5 O
for	607 3 O
SKF	611 3 B-Chemical
-	614 1 I-Chemical
82958	615 5 I-Chemical
(	621 1 O
<	622 1 O
1	624 1 O
hr	626 2 O
)	628 1 O
and	630 3 O
too	634 3 O
long	638 4 O
for	643 3 O
A	647 1 B-Chemical
-	648 1 I-Chemical
77636	649 5 I-Chemical
(	655 1 O
>	656 1 O
20	658 2 O
hr	661 2 O
,	663 1 O
leading	665 7 O
to	673 2 O
behavioral	676 10 O
tolerance	687 9 O
)	696 1 O
.	697 1 O

We	699 2 O
therefore	702 9 O
conducted	712 9 O
the	722 3 O
present	726 7 O
acute	734 5 O
dose	740 4 O
-	744 1 O
response	745 8 O
study	754 5 O
in	760 2 O
four	763 4 O
1	768 1 B-Chemical
-	769 1 I-Chemical
methyl	770 6 I-Chemical
-	776 1 I-Chemical
4	777 1 I-Chemical
-	778 1 I-Chemical
phenyl	779 6 I-Chemical
-	785 1 I-Chemical
1	786 1 I-Chemical
,	787 1 I-Chemical
2	788 1 I-Chemical
,	789 1 I-Chemical
3	790 1 I-Chemical
,	791 1 I-Chemical
6	792 1 I-Chemical
-	793 1 I-Chemical
tetrahydropyridine	794 18 I-Chemical
(	813 1 O
MPTP	814 4 B-Chemical
)	818 1 O
-	819 1 O
exposed	820 7 O
cynomolgus	828 10 O
monkeys	839 7 O
primed	847 6 O
to	854 2 O
exhibit	857 7 O
levodopa	865 8 B-Chemical
-	873 1 O
induced	874 7 O
dyskinesias	882 11 B-Disease
to	894 2 O
evaluate	897 8 O
the	906 3 O
locomotor	910 9 O
and	920 3 O
dyskinetic	924 10 B-Disease
effects	935 7 O
on	943 2 O
challenge	946 9 O
with	956 4 O
four	961 4 O
doses	966 5 O
(	972 1 O
from	973 4 O
0	978 1 O
.	979 1 O
03	980 2 O
to	983 2 O
1	986 1 O
.	987 1 O
0	988 1 O
mg	990 2 O
/	992 1 O
kg	993 2 O
)	995 1 O
of	997 2 O
A	1000 1 B-Chemical
-	1001 1 I-Chemical
86929	1002 5 I-Chemical
(	1008 1 O
[	1009 1 B-Chemical
-	1010 1 I-Chemical
]	1011 1 I-Chemical
-	1012 1 I-Chemical
[	1013 1 I-Chemical
5aR	1014 3 I-Chemical
,	1017 1 I-Chemical
11bS	1018 4 I-Chemical
]	1022 1 I-Chemical
-	1023 1 I-Chemical
4	1024 1 I-Chemical
,	1025 1 I-Chemical
5	1026 1 I-Chemical
,	1027 1 I-Chemical
5a	1028 2 I-Chemical
,	1030 1 I-Chemical
6	1031 1 I-Chemical
,	1032 1 I-Chemical
7	1033 1 I-Chemical
,	1034 1 I-Chemical
11b	1035 3 I-Chemical
-	1038 1 I-Chemical
hexahydro	1039 9 I-Chemical
-	1048 1 I-Chemical
2	1049 1 I-Chemical
-	1050 1 I-Chemical
propyl	1051 6 I-Chemical
-	1057 1 I-Chemical
3	1058 1 I-Chemical
-	1059 1 I-Chemical
thia	1060 4 I-Chemical
-	1064 1 I-Chemical
5	1065 1 I-Chemical
-	1066 1 I-Chemical
+	1067 1 I-Chemical
+	1069 1 I-Chemical
+	1070 1 I-Chemical
azacyclopent	1071 12 I-Chemical
-	1083 1 I-Chemical
1	1084 1 I-Chemical
-	1085 1 I-Chemical
ena	1087 3 I-Chemical
[	1090 1 I-Chemical
c	1091 1 I-Chemical
]	1092 1 I-Chemical
phenathrene	1093 11 I-Chemical
-	1104 1 I-Chemical
9	1105 1 I-Chemical
-	1106 1 I-Chemical
10	1107 2 I-Chemical
-	1109 1 I-Chemical
diol	1110 4 I-Chemical
)	1114 1 O
,	1115 1 O
a	1117 1 O
selective	1119 9 O
and	1129 3 O
full	1133 4 O
DA	1138 2 B-Chemical
D1	1141 2 O
-	1143 1 O
like	1144 4 O
receptor	1149 8 O
agonist	1158 7 O
with	1166 4 O
an	1171 2 O
intermediate	1174 12 O
duration	1187 8 O
of	1196 2 O
action	1199 6 O
.	1205 1 O

Levodopa	1207 8 B-Chemical
and	1216 3 O
the	1220 3 O
DA	1224 2 B-Chemical
D2	1227 2 O
-	1229 1 O
like	1230 4 O
receptor	1235 8 O
agonist	1244 7 O
,	1251 1 O
LY	1253 2 B-Chemical
-	1255 1 I-Chemical
171555	1256 6 I-Chemical
(	1263 1 O
[	1264 1 B-Chemical
4aR	1265 3 I-Chemical
-	1268 1 I-Chemical
trans	1269 5 I-Chemical
]	1274 1 I-Chemical
-	1275 1 I-Chemical
4	1276 1 I-Chemical
,	1277 1 I-Chemical
4a	1278 2 I-Chemical
,	1280 1 I-Chemical
5	1281 1 I-Chemical
,	1282 1 I-Chemical
6	1283 1 I-Chemical
,	1284 1 I-Chemical
7	1285 1 I-Chemical
,	1286 1 I-Chemical
8	1287 1 I-Chemical
,	1288 1 I-Chemical
8a	1289 2 I-Chemical
,	1291 1 I-Chemical
9	1292 1 I-Chemical
-	1293 1 I-Chemical
o	1294 1 I-Chemical
-	1295 1 I-Chemical
dihydro	1296 7 I-Chemical
-	1303 1 I-Chemical
5n	1304 2 I-Chemical
-	1306 1 I-Chemical
propyl	1307 6 I-Chemical
-	1313 1 I-Chemical
2H	1314 2 I-Chemical
-	1316 1 I-Chemical
pyrazo	1317 6 I-Chemical
lo	1324 2 I-Chemical
-	1326 1 I-Chemical
3	1327 1 I-Chemical
-	1328 1 I-Chemical
4	1329 1 I-Chemical
-	1330 1 I-Chemical
quinoline	1331 9 I-Chemical
hydrochloride	1341 13 I-Chemical
)	1354 1 O
were	1356 4 O
also	1361 4 O
used	1366 4 O
for	1371 3 O
comparison	1375 10 O
.	1385 1 O

Acute	1387 5 O
administration	1393 14 O
of	1408 2 O
A	1411 1 B-Chemical
-	1412 1 I-Chemical
86929	1413 5 I-Chemical
was	1419 3 O
as	1423 2 O
efficacious	1426 11 O
in	1438 2 O
alleviating	1441 11 O
MPTP	1453 4 B-Chemical
-	1457 1 O
induced	1458 7 O
parkinsonism	1466 12 B-Disease
as	1479 2 O
levodopa	1482 8 B-Chemical
and	1491 3 O
LY	1495 2 B-Chemical
-	1497 1 I-Chemical
171555	1498 6 I-Chemical
,	1504 1 O
but	1506 3 O
was	1510 3 O
less	1514 4 O
likely	1519 6 O
to	1526 2 O
reproduce	1529 9 O
the	1539 3 O
levodopa	1543 8 B-Chemical
-	1551 1 O
induced	1552 7 O
dyskinesias	1560 11 B-Disease
in	1572 2 O
these	1575 5 O
animals	1581 7 O
than	1589 4 O
with	1594 4 O
either	1599 6 O
LY	1606 2 B-Chemical
-	1608 1 I-Chemical
171555	1609 6 I-Chemical
or	1616 2 O
subsequent	1619 10 O
challenge	1630 9 O
of	1640 2 O
levodopa	1643 8 B-Chemical
.	1651 1 O

Selective	1653 9 O
stimulation	1663 11 O
of	1675 2 O
the	1678 3 O
DA	1682 2 B-Chemical
D1	1685 2 O
receptor	1688 8 O
may	1697 3 O
provide	1701 7 O
better	1709 6 O
integration	1716 11 O
of	1728 2 O
neural	1731 6 O
inputs	1738 6 O
transmitted	1745 11 O
to	1757 2 O
the	1760 3 O
internal	1764 8 O
segment	1773 7 O
of	1781 2 O
the	1784 3 O
globus	1788 6 O
pallidus	1795 8 O
(	1804 1 O
referred	1805 8 O
to	1814 2 O
as	1817 2 O
the	1820 3 O
basal	1824 5 O
ganglia	1830 7 O
output	1838 6 O
)	1844 1 O
compared	1846 8 O
with	1855 4 O
levodopa	1860 8 B-Chemical
and	1869 3 O
selective	1873 9 O
DA	1883 2 B-Chemical
D2	1886 2 O
receptor	1889 8 O
agonist	1898 7 O
.	1905 1 O

Potent	1907 6 O
DA	1914 2 B-Chemical
D1	1917 2 O
receptor	1920 8 O
agents	1929 6 O
with	1936 4 O
an	1941 2 O
intermediate	1944 12 O
duration	1957 8 O
of	1966 2 O
efficacy	1969 8 O
such	1978 4 O
as	1983 2 O
A	1986 1 B-Chemical
-	1987 1 I-Chemical
86929	1988 5 I-Chemical
(	1994 1 O
approximately	1995 13 O
4	2009 1 O
hr	2011 2 O
at	2014 2 O
higher	2017 6 O
doses	2024 5 O
tested	2030 6 O
)	2036 1 O
are	2038 3 O
potential	2042 9 O
therapeutic	2052 11 O
tools	2064 5 O
in	2070 2 O
PD	2073 2 B-Disease
and	2076 3 O
merit	2080 5 O
further	2086 7 O
attention	2094 9 O
.	2103 1 O

Deaths	0 6 O
from	7 4 O
local	12 5 O
anesthetic	18 10 O
-	28 1 O
induced	29 7 O
convulsions	37 11 B-Disease
in	49 2 O
mice	52 4 O
.	56 1 O

Median	58 6 O
convulsant	65 10 O
(	76 1 O
CD50	77 4 O
)	81 1 O
and	83 3 O
median	87 6 O
lethal	94 6 O
(	101 1 O
LD50	102 4 O
)	106 1 O
doses	108 5 O
of	114 2 O
three	117 5 O
representative	123 14 O
local	138 5 O
anesthetics	144 11 O
were	156 4 O
determined	161 10 O
in	172 2 O
adult	175 5 O
mice	181 4 O
to	186 2 O
evaluate	189 8 O
the	198 3 O
threat	202 6 O
to	209 2 O
life	212 4 O
of	217 2 O
local	220 5 O
anesthetic	226 10 O
-	236 1 O
induced	237 7 O
convulsions	245 11 B-Disease
.	256 1 O

The	258 3 O
CD50	262 4 O
and	267 3 O
LD50	271 4 O
,	275 1 O
respectively	277 12 O
,	289 1 O
were	291 4 O
57	296 2 O
.	298 1 O
7	299 1 O
and	301 3 O
58	305 2 O
.	307 1 O
7	308 1 O
mg	310 2 O
/	312 1 O
kg	313 2 O
for	316 3 O
bupivacaine	320 11 B-Chemical
,	331 1 O
111	333 3 O
.	336 1 O
0	337 1 O
and	339 3 O
133	343 3 O
.	346 1 O
1	347 1 O
mg	349 2 O
/	351 1 O
kg	352 2 O
for	355 3 O
lidocaine	359 9 B-Chemical
,	368 1 O
and	370 3 O
243	374 3 O
.	377 1 O
4	378 1 O
and	380 3 O
266	384 3 O
.	387 1 O
5	388 1 O
mg	390 2 O
/	392 1 O
kg	393 2 O
for	396 3 O
chloroprocaine	400 14 B-Chemical
.	414 1 O

When	416 4 O
given	421 5 O
intraperitoneally	427 17 O
,	444 1 O
bupivacaine	446 11 B-Chemical
thus	458 4 O
was	463 3 O
only	467 4 O
about	472 5 O
twice	478 5 O
as	484 2 O
toxic	487 5 O
as	493 2 O
lidocaine	496 9 B-Chemical
and	506 3 O
four	510 4 O
times	515 5 O
as	521 2 O
toxic	524 5 O
as	530 2 O
chloroprocaine	533 14 B-Chemical
.	547 1 O

Convulsions	549 11 B-Disease
always	561 6 O
preceded	568 8 O
death	577 5 O
,	582 1 O
except	584 6 O
after	591 5 O
precipitous	597 11 O
cardiopulmonary	609 15 B-Disease
arrest	625 6 I-Disease
from	632 4 O
extreme	637 7 O
doses	645 5 O
.	650 1 O

A	652 1 O
CD50	654 4 O
dose	659 4 O
of	664 2 O
local	667 5 O
anesthetic	673 10 O
(	684 1 O
causing	685 7 O
convulsions	693 11 B-Disease
in	705 2 O
50	708 2 O
%	710 1 O
of	712 2 O
mice	715 4 O
)	719 1 O
was	721 3 O
fatal	725 5 O
in	731 2 O
90	734 2 O
%	736 1 O
of	738 2 O
bupivacaine	741 11 B-Chemical
-	752 1 O
induced	753 7 O
seizures	761 8 B-Disease
,	769 1 O
in	771 2 O
57	774 2 O
%	776 1 O
of	778 2 O
the	781 3 O
chloroprocaine	785 14 B-Chemical
group	800 5 O
,	805 1 O
and	807 3 O
in	811 2 O
6	814 1 O
%	815 1 O
of	817 2 O
the	820 3 O
lidocaine	824 9 B-Chemical
group	834 5 O
.	839 1 O

The	841 3 O
narrow	845 6 O
gap	852 3 O
between	856 7 O
convulsant	864 10 O
and	875 3 O
lethal	879 6 O
doses	886 5 O
of	892 2 O
local	895 5 O
anesthetics	901 11 O
indicates	913 9 O
that	923 4 O
untreated	928 9 O
convulsions	938 11 B-Disease
present	950 7 O
much	958 4 O
more	963 4 O
of	968 2 O
a	971 1 O
threat	973 6 O
to	980 2 O
life	983 4 O
than	988 4 O
heretofore	993 10 O
appreciated	1004 11 O
.	1015 1 O

Myoclonic	0 9 B-Disease
,	9 1 I-Disease
atonic	11 6 I-Disease
,	17 1 I-Disease
and	19 3 I-Disease
absence	23 7 I-Disease
seizures	31 8 I-Disease
following	40 9 O
institution	50 11 O
of	62 2 O
carbamazepine	65 13 B-Chemical
therapy	79 7 O
in	87 2 O
children	90 8 O
.	98 1 O

Five	100 4 O
children	105 8 O
,	113 1 O
aged	115 4 O
3	120 1 O
to	122 2 O
11	125 2 O
years	128 5 O
,	133 1 O
treated	135 7 O
with	143 4 O
carbamazepine	148 13 B-Chemical
for	162 3 O
epilepsy	166 8 B-Disease
,	174 1 O
had	176 3 O
an	180 2 O
acute	183 5 O
aberrant	189 8 O
reaction	198 8 O
characterized	207 13 O
by	221 2 O
the	224 3 O
onset	228 5 O
of	234 2 O
myoclonic	237 9 B-Disease
,	246 1 I-Disease
atypical	248 8 I-Disease
absence	257 7 I-Disease
and	265 3 I-Disease
/	268 1 I-Disease
or	269 2 I-Disease
atonic	272 6 I-Disease
(	279 1 I-Disease
minor	280 5 I-Disease
motor	286 5 I-Disease
)	291 1 I-Disease
seizures	293 8 I-Disease
within	302 6 O
a	309 1 O
few	311 3 O
days	315 4 O
.	319 1 O

When	321 4 O
the	326 3 O
carbamazepine	330 13 B-Chemical
was	344 3 O
discontinued	348 12 O
,	360 1 O
two	362 3 O
of	366 2 O
the	369 3 O
children	373 8 O
returned	382 8 O
to	391 2 O
their	394 5 O
former	400 6 O
state	407 5 O
very	413 4 O
quickly	418 7 O
,	425 1 O
two	427 3 O
had	431 3 O
the	435 3 O
minor	439 5 O
motor	445 5 O
seizures	451 8 B-Disease
resolve	460 7 O
in	468 2 O
3	471 1 O
and	473 3 O
6	477 1 O
months	479 6 O
,	485 1 O
and	487 3 O
one	491 3 O
had	495 3 O
the	499 3 O
seizures	503 8 B-Disease
persist	512 7 O
.	519 1 O

The	521 3 O
child	525 5 O
in	531 2 O
whom	534 4 O
the	539 3 O
seizures	543 8 B-Disease
persisted	552 9 O
was	562 3 O
later	566 5 O
found	572 5 O
to	578 2 O
have	581 4 O
ceroid	586 6 B-Disease
lipofuscinosis	593 14 I-Disease
.	607 1 O

The	609 3 O
other	613 5 O
children	619 8 O
are	628 3 O
doing	632 5 O
well	638 4 O
on	643 2 O
other	646 5 O
anticonvulsants	652 15 O
.	667 1 O

Naloxone	0 8 B-Chemical
reversal	9 8 O
of	18 2 O
hypotension	21 11 B-Disease
due	33 3 O
to	37 2 O
captopril	40 9 B-Chemical
overdose	50 8 B-Disease
.	58 1 O

The	60 3 O
hemodynamic	64 11 O
effects	76 7 O
of	84 2 O
captopril	87 9 B-Chemical
and	97 3 O
other	101 5 O
angiotensin	107 11 B-Chemical
-	118 1 I-Chemical
converting	119 10 I-Chemical
enzyme	130 6 I-Chemical
inhibitors	137 10 I-Chemical
may	148 3 O
be	152 2 O
mediated	155 8 O
by	164 2 O
the	167 3 O
endogenous	171 10 O
opioid	182 6 O
system	189 6 O
.	195 1 O

The	197 3 O
opioid	201 6 O
antagonist	208 10 O
naloxone	219 8 B-Chemical
has	228 3 O
been	232 4 O
shown	237 5 O
to	243 2 O
block	246 5 O
or	252 2 O
reverse	255 7 O
the	263 3 O
hypotensive	267 11 B-Disease
actions	279 7 O
of	287 2 O
captopril	290 9 B-Chemical
.	299 1 O

We	301 2 O
report	304 6 O
a	311 1 O
case	313 4 O
of	318 2 O
an	321 2 O
intentional	324 11 O
captopril	336 9 B-Chemical
overdose	346 8 B-Disease
,	354 1 O
manifested	356 10 O
by	367 2 O
marked	370 6 O
hypotension	377 11 B-Disease
,	388 1 O
that	390 4 O
resolved	395 8 O
promptly	404 8 O
with	413 4 O
the	418 3 O
administration	422 14 O
of	437 2 O
naloxone	440 8 B-Chemical
.	448 1 O

To	450 2 O
our	453 3 O
knowledge	457 9 O
,	466 1 O
this	468 4 O
is	473 2 O
the	476 3 O
first	480 5 O
reported	486 8 O
case	495 4 O
of	500 2 O
captopril	503 9 B-Chemical
-	512 1 O
induced	513 7 O
hypotension	521 11 B-Disease
treated	533 7 O
with	541 4 O
naloxone	546 8 B-Chemical
.	554 1 O

Our	556 3 O
experience	560 10 O
demonstrates	571 12 O
a	584 1 O
possible	586 8 O
role	595 4 O
of	600 2 O
naloxone	603 8 B-Chemical
in	612 2 O
the	615 3 O
reversal	619 8 O
of	628 2 O
hypotension	631 11 B-Disease
resulting	643 9 O
from	653 4 O
captopril	658 9 B-Chemical
.	667 1 O

Carbamazepine	0 13 B-Chemical
-	13 1 O
induced	14 7 O
cardiac	22 7 B-Disease
dysfunction	30 11 I-Disease
.	41 1 O

Characterization	43 16 O
of	60 2 O
two	63 3 O
distinct	67 8 O
clinical	76 8 O
syndromes	85 9 O
.	94 1 O

A	96 1 O
patient	98 7 O
with	106 4 O
sinus	111 5 O
bradycardia	117 11 B-Disease
and	129 3 O
atrioventricular	133 16 B-Disease
block	150 5 I-Disease
,	155 1 O
induced	157 7 O
by	165 2 O
carbamazepine	168 13 B-Chemical
,	181 1 O
prompted	183 8 O
an	192 2 O
extensive	195 9 O
literature	205 10 O
review	216 6 O
of	223 2 O
all	226 3 O
previously	230 10 O
reported	241 8 O
cases	250 5 O
.	255 1 O

From	257 4 O
the	262 3 O
analysis	266 8 O
of	275 2 O
these	278 5 O
cases	284 5 O
,	289 1 O
two	291 3 O
distinct	295 8 O
forms	304 5 O
of	310 2 O
carbamazepine	313 13 B-Chemical
-	326 1 O
associated	327 10 O
cardiac	338 7 B-Disease
dysfunction	346 11 I-Disease
emerged	358 7 O
.	365 1 O

One	367 3 O
patient	371 7 O
group	379 5 O
developed	385 9 O
sinus	395 5 B-Disease
tachycardias	401 12 I-Disease
in	414 2 O
the	417 3 O
setting	421 7 O
of	429 2 O
a	432 1 O
massive	434 7 O
carbamazepine	442 13 B-Chemical
overdose	456 8 B-Disease
.	464 1 O

The	466 3 O
second	470 6 O
group	477 5 O
consisted	483 9 O
almost	493 6 O
exclusively	500 11 O
of	512 2 O
elderly	515 7 O
women	523 5 O
who	529 3 O
developed	533 9 O
potentially	543 11 O
life	555 4 O
-	559 1 O
threatening	560 11 O
bradyarrhythmias	572 16 B-Disease
or	589 2 O
atrioventricular	592 16 B-Disease
conduction	609 10 I-Disease
delay	620 5 I-Disease
,	625 1 O
associated	627 10 O
with	638 4 O
either	643 6 O
therapeutic	650 11 O
or	662 2 O
modestly	665 8 O
elevated	674 8 O
carbamazepine	683 13 B-Chemical
serum	697 5 O
levels	703 6 O
.	709 1 O

Because	711 7 O
carbamazepine	719 13 B-Chemical
is	733 2 O
widely	736 6 O
used	743 4 O
in	748 2 O
the	751 3 O
treatment	755 9 O
of	765 2 O
many	768 4 O
neurologic	773 10 O
and	784 3 O
psychiatric	788 11 B-Disease
conditions	800 10 O
,	810 1 O
the	812 3 O
recognition	816 11 O
of	828 2 O
the	831 3 O
latter	835 6 O
syndrome	842 8 O
has	851 3 O
important	855 9 O
implications	865 12 O
for	878 3 O
the	882 3 O
use	886 3 O
of	890 2 O
this	893 4 O
drug	898 4 O
in	903 2 O
elderly	906 7 O
patients	914 8 O
.	922 1 O

Glutamatergic	0 13 O
neurotransmission	14 17 O
mediated	32 8 O
by	41 2 O
NMDA	44 4 B-Chemical
receptors	49 9 O
in	59 2 O
the	62 3 O
inferior	66 8 O
colliculus	75 10 O
can	86 3 O
modulate	90 8 O
haloperidol	99 11 B-Chemical
-	110 1 O
induced	111 7 O
catalepsy	119 9 B-Disease
.	128 1 O

The	130 3 O
inferior	134 8 O
colliculus	143 10 O
(	154 1 O
IC	155 2 O
)	157 1 O
is	159 2 O
primarily	162 9 O
involved	172 8 O
in	181 2 O
the	184 3 O
processing	188 10 O
of	199 2 O
auditory	202 8 O
information	211 11 O
,	222 1 O
but	224 3 O
it	228 2 O
is	231 2 O
distinguished	234 13 O
from	248 4 O
other	253 5 O
auditory	259 8 O
nuclei	268 6 O
in	275 2 O
the	278 3 O
brainstem	282 9 O
by	292 2 O
its	295 3 O
connections	299 11 O
with	311 4 O
structures	316 10 O
of	327 2 O
the	330 3 O
motor	334 5 O
system	340 6 O
.	346 1 O

Functional	348 10 O
evidence	359 8 O
relating	368 8 O
the	377 3 O
IC	381 2 O
to	384 2 O
motor	387 5 O
behavior	393 8 O
derives	402 7 O
from	410 4 O
experiments	415 11 O
showing	427 7 O
that	435 4 O
activation	440 10 O
of	451 2 O
the	454 3 O
IC	458 2 O
by	461 2 O
electrical	464 10 O
stimulation	475 11 O
or	487 2 O
excitatory	490 10 O
amino	501 5 B-Chemical
acid	507 4 I-Chemical
microinjection	512 14 O
causes	527 6 O
freezing	534 8 O
,	542 1 O
escape	544 6 O
-	550 1 O
like	551 4 O
behavior	556 8 O
,	564 1 O
and	566 3 O
immobility	570 10 O
.	580 1 O

However	582 7 O
,	589 1 O
the	591 3 O
nature	595 6 O
of	602 2 O
this	605 4 O
immobility	610 10 O
is	621 2 O
still	624 5 O
unclear	630 7 O
.	637 1 O

The	639 3 O
present	643 7 O
study	651 5 O
examined	657 8 O
the	666 3 O
influence	670 9 O
of	680 2 O
excitatory	683 10 O
amino	694 5 B-Chemical
acid	700 4 I-Chemical
-	704 1 O
mediated	705 8 O
mechanisms	714 10 O
in	725 2 O
the	728 3 O
IC	732 2 O
on	735 2 O
the	738 3 O
catalepsy	742 9 B-Disease
induced	752 7 O
by	760 2 O
the	763 3 O
dopamine	767 8 B-Chemical
receptor	776 8 O
blocker	785 7 O
haloperidol	793 11 B-Chemical
administered	805 12 O
systemically	818 12 O
(	831 1 O
1	832 1 O
or	834 2 O
0	837 1 O
.	838 1 O
5	839 1 O
mg	841 2 O
/	843 1 O
kg	844 2 O
)	846 1 O
in	848 2 O
rats	851 4 O
.	855 1 O

Haloperidol	857 11 B-Chemical
-	868 1 O
induced	869 7 O
catalepsy	877 9 B-Disease
was	887 3 O
challenged	891 10 O
with	902 4 O
prior	907 5 O
intracollicular	913 15 O
microinjections	929 15 O
of	945 2 O
glutamate	948 9 B-Chemical
NMDA	958 4 B-Chemical
receptor	963 8 O
antagonists	972 11 O
,	983 1 O
MK	985 2 B-Chemical
-	987 1 I-Chemical
801	988 3 I-Chemical
(	992 1 O
15	993 2 O
or	996 2 O
30	999 2 O
mmol	1002 4 O
/	1006 1 O
0	1007 1 O
.	1008 1 O
5	1009 1 O
microl	1011 6 O
)	1017 1 O
and	1019 3 O
AP7	1023 3 B-Chemical
(	1027 1 O
10	1028 2 O
or	1031 2 O
20	1034 2 O
nmol	1037 4 O
/	1041 1 O
0	1042 1 O
.	1043 1 O
5	1044 1 O
microl	1046 6 O
)	1052 1 O
,	1053 1 O
or	1055 2 O
of	1058 2 O
the	1061 3 O
NMDA	1065 4 B-Chemical
receptor	1070 8 O
agonist	1079 7 O
N	1087 1 B-Chemical
-	1088 1 I-Chemical
methyl	1089 6 I-Chemical
-	1095 1 I-Chemical
d	1096 1 I-Chemical
-	1097 1 I-Chemical
aspartate	1098 9 I-Chemical
(	1108 1 O
NMDA	1109 4 B-Chemical
,	1113 1 O
20	1115 2 O
or	1118 2 O
30	1121 2 O
nmol	1124 4 O
/	1128 1 O
0	1129 1 O
.	1130 1 O
5	1131 1 O
microl	1133 6 O
)	1139 1 O
.	1140 1 O

The	1142 3 O
results	1146 7 O
showed	1154 6 O
that	1161 4 O
intracollicular	1166 15 O
microinjection	1182 14 O
of	1197 2 O
MK	1200 2 B-Chemical
-	1202 1 I-Chemical
801	1203 3 I-Chemical
and	1207 3 O
AP7	1211 3 B-Chemical
previous	1215 8 O
to	1224 2 O
systemic	1227 8 O
injections	1236 10 O
of	1247 2 O
haloperidol	1250 11 B-Chemical
significantly	1262 13 O
attenuated	1276 10 O
the	1287 3 O
catalepsy	1291 9 B-Disease
,	1300 1 O
as	1302 2 O
indicated	1305 9 O
by	1315 2 O
a	1318 1 O
reduced	1320 7 O
latency	1328 7 O
to	1336 2 O
step	1339 4 O
down	1344 4 O
from	1349 4 O
a	1354 1 O
horizontal	1356 10 O
bar	1367 3 O
.	1370 1 O

Accordingly	1372 11 O
,	1383 1 O
intracollicular	1385 15 O
microinjection	1401 14 O
of	1416 2 O
NMDA	1419 4 B-Chemical
increased	1424 9 O
the	1434 3 O
latency	1438 7 O
to	1446 2 O
step	1449 4 O
down	1454 4 O
the	1459 3 O
bar	1463 3 O
.	1466 1 O

These	1468 5 O
findings	1474 8 O
suggest	1483 7 O
that	1491 4 O
glutamate	1496 9 B-Chemical
-	1505 1 O
mediated	1506 8 O
mechanisms	1515 10 O
in	1526 2 O
the	1529 3 O
neural	1533 6 O
circuits	1540 8 O
at	1549 2 O
the	1552 3 O
IC	1556 2 O
level	1559 5 O
influence	1565 9 O
haloperidol	1575 11 B-Chemical
-	1586 1 O
induced	1587 7 O
catalepsy	1595 9 B-Disease
and	1605 3 O
participate	1609 11 O
in	1621 2 O
the	1624 3 O
regulation	1628 10 O
of	1639 2 O
motor	1642 5 O
activity	1648 8 O
.	1656 1 O

Metabotropic	0 12 O
glutamate	13 9 B-Chemical
7	23 1 O
receptor	25 8 O
subtype	34 7 O
modulates	42 9 O
motor	52 5 O
symptoms	58 8 O
in	67 2 O
rodent	70 6 O
models	77 6 O
of	84 2 O
Parkinson	87 9 B-Disease
'	96 1 I-Disease
s	97 1 I-Disease
disease	99 7 I-Disease
.	106 1 O

Metabotropic	108 12 O
glutamate	121 9 B-Chemical
(	131 1 O
mGlu	132 4 O
)	136 1 O
receptors	138 9 O
modulate	148 8 O
synaptic	157 8 O
transmission	166 12 O
in	179 2 O
the	182 3 O
central	186 7 O
nervous	194 7 O
system	202 6 O
and	209 3 O
represent	213 9 O
promising	223 9 O
therapeutic	233 11 O
targets	245 7 O
for	253 3 O
symptomatic	257 11 O
treatment	269 9 O
of	279 2 O
Parkinson	282 9 B-Disease
'	291 1 I-Disease
s	292 1 I-Disease
disease	294 7 I-Disease
(	302 1 O
PD	303 2 B-Disease
)	305 1 O
.	306 1 O

Among	308 5 O
the	314 3 O
eight	318 5 O
mGlu	324 4 O
receptor	329 8 O
subtypes	338 8 O
,	346 1 O
mGlu7	348 5 O
receptor	354 8 O
is	363 2 O
prominently	366 11 O
expressed	378 9 O
in	388 2 O
the	391 3 O
basal	395 5 O
ganglia	401 7 O
,	408 1 O
but	410 3 O
its	414 3 O
role	418 4 O
in	423 2 O
restoring	426 9 O
motor	436 5 O
function	442 8 O
in	451 2 O
animal	454 6 O
models	461 6 O
of	468 2 O
PD	471 2 B-Disease
is	474 2 O
not	477 3 O
known	481 5 O
.	486 1 O

The	488 3 O
effects	492 7 O
of	500 2 O
N	503 1 B-Chemical
,	504 1 I-Chemical
N	505 1 I-Chemical
'	506 1 I-Chemical
-	507 1 I-Chemical
dibenzhydrylethane	508 18 I-Chemical
-	526 1 I-Chemical
1	527 1 I-Chemical
,	528 1 I-Chemical
2	529 1 I-Chemical
-	530 1 I-Chemical
diamine	531 7 I-Chemical
dihydrochloride	539 15 I-Chemical
(	555 1 O
AMN082	556 6 B-Chemical
)	562 1 O
,	563 1 O
the	565 3 O
first	569 5 O
selective	575 9 O
allosteric	585 10 O
activator	596 9 O
of	606 2 O
mGlu7	609 5 O
receptors	615 9 O
,	624 1 O
were	626 4 O
thus	631 4 O
tested	636 6 O
in	643 2 O
different	646 9 O
rodent	656 6 O
models	663 6 O
of	670 2 O
PD	673 2 B-Disease
.	675 1 O

Here	677 4 O
,	681 1 O
we	683 2 O
show	686 4 O
that	691 4 O
oral	696 4 O
(	701 1 O
5	702 1 O
mg	704 2 O
/	706 1 O
kg	707 2 O
)	709 1 O
or	711 2 O
intrastriatal	714 13 O
administration	728 14 O
(	743 1 O
0	744 1 O
.	745 1 O
1	746 1 O
and	748 3 O
0	752 1 O
.	753 1 O
5	754 1 O
nmol	756 4 O
)	760 1 O
of	762 2 O
AMN082	765 6 B-Chemical
reverses	772 8 O
haloperidol	781 11 B-Chemical
-	792 1 O
induced	793 7 O
catalepsy	801 9 B-Disease
in	811 2 O
rats	814 4 O
.	818 1 O

AMN082	820 6 B-Chemical
(	827 1 O
2	828 1 O
.	829 1 O
5	830 1 O
and	832 3 O
5	836 1 O
mg	838 2 O
/	840 1 O
kg	841 2 O
)	843 1 O
reduces	845 7 O
apomorphine	853 11 B-Chemical
-	864 1 O
induced	865 7 O
rotations	873 9 O
in	883 2 O
unilateral	886 10 O
6	897 1 B-Chemical
-	898 1 I-Chemical
hydroxydopamine	899 15 I-Chemical
(	915 1 O
6	916 1 B-Chemical
-	917 1 I-Chemical
OHDA	918 4 I-Chemical
)	922 1 O
-	923 1 O
lesioned	924 8 O
rats	933 4 O
.	937 1 O

In	939 2 O
a	942 1 O
more	944 4 O
complex	949 7 O
task	957 4 O
commonly	962 8 O
used	971 4 O
to	976 2 O
evaluate	979 8 O
major	988 5 O
akinetic	994 8 B-Disease
symptoms	1003 8 O
of	1012 2 O
PD	1015 2 B-Disease
patients	1018 8 O
,	1026 1 O
5	1028 1 O
mg	1030 2 O
/	1032 1 O
kg	1033 2 O
AMN082	1036 6 B-Chemical
reverses	1043 8 O
the	1052 3 O
increased	1056 9 O
reaction	1066 8 O
time	1075 4 O
to	1080 2 O
respond	1083 7 O
to	1091 2 O
a	1094 1 O
cue	1096 3 O
of	1100 2 O
bilateral	1103 9 O
6	1113 1 B-Chemical
-	1114 1 I-Chemical
OHDA	1115 4 I-Chemical
-	1119 1 O
lesioned	1120 8 O
rats	1129 4 O
.	1133 1 O

In	1135 2 O
addition	1138 8 O
,	1146 1 O
AMN082	1148 6 B-Chemical
reduces	1155 7 O
the	1163 3 O
duration	1167 8 O
of	1176 2 O
haloperidol	1179 11 B-Chemical
-	1190 1 O
induced	1191 7 O
catalepsy	1199 9 B-Disease
in	1209 2 O
a	1212 1 O
mGlu7	1214 5 O
receptor	1220 8 O
-	1228 1 O
dependent	1229 9 O
manner	1239 6 O
in	1246 2 O
wild	1249 4 O
-	1253 1 O
type	1254 4 O
but	1259 3 O
not	1263 3 O
mGlu7	1267 5 O
receptor	1273 8 O
knockout	1282 8 O
mice	1291 4 O
.	1295 1 O

Higher	1297 6 O
doses	1304 5 O
of	1310 2 O
AMN082	1313 6 B-Chemical
(	1320 1 O
10	1321 2 O
and	1324 3 O
20	1328 2 O
mg	1331 2 O
/	1333 1 O
kg	1334 2 O
p	1337 1 O
.	1338 1 O
o	1339 1 O
.	1340 1 O
)	1341 1 O
have	1343 4 O
no	1348 2 O
effect	1351 6 O
on	1358 2 O
the	1361 3 O
same	1365 4 O
models	1370 6 O
of	1377 2 O
PD	1380 2 B-Disease
.	1382 1 O

Overall	1384 7 O
these	1392 5 O
findings	1398 8 O
suggest	1407 7 O
that	1415 4 O
mGlu7	1420 5 O
receptor	1426 8 O
activation	1435 10 O
can	1446 3 O
reverse	1450 7 O
motor	1458 5 O
dysfunction	1464 11 O
associated	1476 10 O
with	1487 4 O
reduced	1492 7 O
dopamine	1500 8 B-Chemical
activity	1509 8 O
.	1517 1 O

Selective	1519 9 O
ligands	1529 7 O
of	1537 2 O
mGlu7	1540 5 O
receptor	1546 8 O
subtypes	1555 8 O
may	1564 3 O
thus	1568 4 O
be	1573 2 O
considered	1576 10 O
as	1587 2 O
promising	1590 9 O
compounds	1600 9 O
for	1610 3 O
the	1614 3 O
development	1618 11 O
of	1630 2 O
antiparkinsonian	1633 16 O
therapeutic	1650 11 O
strategies	1662 10 O
.	1672 1 O

Nimodipine	0 10 B-Chemical
prevents	11 8 O
memory	20 6 B-Disease
impairment	27 10 I-Disease
caused	38 6 O
by	45 2 O
nitroglycerin	48 13 B-Chemical
-	61 1 O
induced	62 7 O
hypotension	70 11 B-Disease
in	82 2 O
adult	85 5 O
mice	91 4 O
.	95 1 O

BACKGROUND	97 10 O
:	107 1 O
Hypotension	109 11 B-Disease
and	121 3 O
a	125 1 O
resultant	127 9 O
decrease	137 8 O
in	146 2 O
cerebral	149 8 O
blood	158 5 O
flow	164 4 O
have	169 4 O
been	174 4 O
implicated	179 10 O
in	190 2 O
the	193 3 O
development	197 11 O
of	209 2 O
cognitive	212 9 B-Disease
dysfunction	222 11 I-Disease
.	233 1 O

We	235 2 O
tested	238 6 O
the	245 3 O
hypothesis	249 10 O
that	260 4 O
nimodipine	265 10 B-Chemical
(	276 1 O
NIMO	277 4 B-Chemical
)	281 1 O
administered	283 12 O
at	296 2 O
the	299 3 O
onset	303 5 O
of	309 2 O
nitroglycerin	312 13 B-Chemical
(	326 1 O
NTG	327 3 B-Chemical
)	330 1 O
-	331 1 O
induced	332 7 O
hypotension	340 11 B-Disease
would	352 5 O
preserve	358 8 O
long	367 4 O
-	371 1 O
term	372 4 O
associative	377 11 O
memory	389 6 O
.	395 1 O

METHODS	397 7 O
:	404 1 O
The	406 3 O
passive	410 7 O
avoidance	418 9 O
(	428 1 O
PA	429 2 O
)	431 1 O
paradigm	433 8 O
was	442 3 O
used	446 4 O
to	451 2 O
assess	454 6 O
memory	461 6 O
retention	468 9 O
.	477 1 O

For	479 3 O
PA	483 2 O
training	486 8 O
,	494 1 O
latencies	496 9 O
(	506 1 O
seconds	507 7 O
)	514 1 O
were	516 4 O
recorded	521 8 O
for	530 3 O
entry	534 5 O
from	540 4 O
a	545 1 O
suspended	547 9 O
platform	557 8 O
into	566 4 O
a	571 1 O
Plexiglas	573 9 O
tube	583 4 O
where	588 5 O
a	594 1 O
shock	596 5 O
was	602 3 O
automatically	606 13 O
delivered	620 9 O
.	629 1 O

Latencies	631 9 O
were	641 4 O
recorded	646 8 O
48	655 2 O
h	658 1 O
later	660 5 O
for	666 3 O
a	670 1 O
testing	672 7 O
trial	680 5 O
.	685 1 O

Ninety	687 6 O
-	693 1 O
six	694 3 O
Swiss	698 5 O
-	703 1 O
Webster	704 7 O
mice	712 4 O
(	717 1 O
30	718 2 O
-	720 1 O
35	721 2 O
g	724 1 O
,	725 1 O
6	727 1 O
-	728 1 O
8	729 1 O
wk	731 2 O
)	733 1 O
,	734 1 O
were	736 4 O
randomized	741 10 O
into	752 4 O
6	757 1 O
groups	759 6 O
1	766 1 O
)	767 1 O
saline	769 6 O
(	776 1 O
control	777 7 O
)	784 1 O
,	785 1 O
2	787 1 O
)	788 1 O
NTG	790 3 B-Chemical
immediately	794 11 O
after	806 5 O
learning	812 8 O
,	820 1 O
3	822 1 O
)	823 1 O
NTG	825 3 B-Chemical
3	829 1 O
h	831 1 O
after	833 5 O
learning	839 8 O
,	847 1 O
4	849 1 O
)	850 1 O
NTG	852 3 B-Chemical
and	856 3 O
NIMO	860 4 B-Chemical
,	864 1 O
5	866 1 O
)	867 1 O
vehicle	869 7 O
,	876 1 O
and	878 3 O
6	882 1 O
)	883 1 O
NIMO	885 4 B-Chemical
alone	890 5 O
.	895 1 O

The	897 3 O
extent	901 6 O
of	908 2 O
hypotension	911 11 B-Disease
and	923 3 O
changes	927 7 O
in	935 2 O
brain	938 5 O
tissue	944 6 O
oxygenation	951 11 O
(	963 1 O
PbtO	964 4 O
(	968 1 O
2	969 1 O
)	970 1 O
)	971 1 O
and	973 3 O
in	977 2 O
cerebral	980 8 O
blood	989 5 O
flow	995 4 O
were	1000 4 O
studied	1005 7 O
in	1013 2 O
a	1016 1 O
separate	1018 8 O
group	1027 5 O
of	1033 2 O
animals	1036 7 O
.	1043 1 O

RESULTS	1045 7 O
:	1052 1 O
All	1054 3 O
groups	1058 6 O
exhibited	1065 9 O
similar	1075 7 O
training	1083 8 O
latencies	1092 9 O
(	1102 1 O
17	1103 2 O
.	1105 1 O
0	1106 1 O
+	1108 1 O
/	1109 1 O
-	1110 1 O
4	1112 1 O
.	1113 1 O
6	1114 1 O
s	1116 1 O
)	1117 1 O
.	1118 1 O

Mice	1120 4 O
subjected	1125 9 O
to	1135 2 O
hypotensive	1138 11 B-Disease
episodes	1150 8 O
showed	1159 6 O
a	1166 1 O
significant	1168 11 O
decrease	1180 8 O
in	1189 2 O
latency	1192 7 O
time	1200 4 O
(	1205 1 O
178	1206 3 O
+	1210 1 O
/	1211 1 O
-	1212 1 O
156	1214 3 O
s	1218 1 O
)	1219 1 O
compared	1221 8 O
with	1230 4 O
those	1235 5 O
injected	1241 8 O
with	1250 4 O
saline	1255 6 O
,	1261 1 O
NTG	1263 3 B-Chemical
+	1267 1 O
NIMO	1269 4 B-Chemical
,	1273 1 O
or	1275 2 O
delayed	1278 7 O
NTG	1286 3 B-Chemical
(	1290 1 O
580	1291 3 O
+	1295 1 O
/	1296 1 O
-	1297 1 O
81	1299 2 O
s	1302 1 O
,	1303 1 O
557	1305 3 O
+	1309 1 O
/	1310 1 O
-	1311 1 O
67	1313 2 O
s	1316 1 O
,	1317 1 O
and	1319 3 O
493	1323 3 O
+	1327 1 O
/	1328 1 O
-	1329 1 O
146	1331 3 O
s	1335 1 O
,	1336 1 O
respectively	1338 12 O
)	1350 1 O
.	1351 1 O

A	1353 1 O
Kruskal	1355 7 O
-	1362 1 O
Wallis	1363 6 O
1	1370 1 O
-	1371 1 O
way	1372 3 O
analysis	1376 8 O
of	1385 2 O
variance	1388 8 O
indicated	1397 9 O
a	1407 1 O
significant	1409 11 O
difference	1421 10 O
among	1432 5 O
the	1438 3 O
4	1442 1 O
treatment	1444 9 O
groups	1454 6 O
(	1461 1 O
H	1462 1 O
=	1464 1 O
15	1466 2 O
.	1468 1 O
34	1469 2 O
;	1471 1 O
P	1473 1 O
<	1475 1 O
0	1477 1 O
.	1478 1 O
001	1479 3 O
)	1482 1 O
.	1483 1 O

In	1485 2 O
a	1488 1 O
separate	1490 8 O
group	1499 5 O
of	1505 2 O
mice	1508 4 O
not	1513 3 O
subjected	1517 9 O
to	1527 2 O
behavioral	1530 10 O
studies	1541 7 O
,	1548 1 O
the	1550 3 O
same	1554 4 O
dose	1559 4 O
of	1564 2 O
NTG	1567 3 B-Chemical
(	1571 1 O
n	1572 1 O
=	1574 1 O
3	1576 1 O
)	1577 1 O
and	1579 3 O
NTG	1583 3 B-Chemical
+	1587 1 O
NIMO	1589 4 B-Chemical
(	1594 1 O
n	1595 1 O
=	1597 1 O
3	1599 1 O
)	1600 1 O
caused	1602 6 O
mean	1609 4 O
arterial	1614 8 O
blood	1623 5 O
pressure	1629 8 O
to	1638 2 O
decrease	1641 8 O
from	1650 4 O
85	1655 2 O
.	1657 1 O
9	1658 1 O
+	1660 1 O
/	1661 1 O
-	1662 1 O
3	1664 1 O
.	1665 1 O
8	1666 1 O
mm	1668 2 O
Hg	1671 2 O
sem	1674 3 O
to	1678 2 O
31	1681 2 O
.	1683 1 O
6	1684 1 O
+	1686 1 O
/	1687 1 O
-	1688 1 O
0	1690 1 O
.	1691 1 O
8	1692 1 O
mm	1694 2 O
Hg	1697 2 O
sem	1700 3 O
and	1704 3 O
from	1708 4 O
86	1713 2 O
.	1715 1 O
2	1716 1 O
+	1718 1 O
/	1719 1 O
-	1720 1 O
3	1722 1 O
.	1723 1 O
7	1724 1 O
mm	1726 2 O
Hg	1729 2 O
sem	1732 3 O
to	1736 2 O
32	1739 2 O
.	1741 1 O
6	1742 1 O
+	1744 1 O
/	1745 1 O
-	1746 1 O
0	1748 1 O
.	1749 1 O
2	1750 1 O
mm	1752 2 O
Hg	1755 2 O
sem	1758 3 O
,	1761 1 O
respectively	1763 12 O
.	1775 1 O

Mean	1777 4 O
arterial	1782 8 O
blood	1791 5 O
pressure	1797 8 O
in	1806 2 O
mice	1809 4 O
treated	1814 7 O
with	1822 4 O
NIMO	1827 4 B-Chemical
alone	1832 5 O
decreased	1838 9 O
from	1848 4 O
88	1853 2 O
.	1855 1 O
1	1856 1 O
+	1858 1 O
/	1859 1 O
-	1860 1 O
3	1862 1 O
.	1863 1 O
8	1864 1 O
mm	1866 2 O
Hg	1869 2 O
to	1872 2 O
80	1875 2 O
.	1877 1 O
0	1878 1 O
+	1880 1 O
/	1881 1 O
-	1882 1 O
2	1884 1 O
.	1885 1 O
9	1886 1 O
mm	1888 2 O
Hg	1891 2 O
.	1893 1 O

The	1895 3 O
intergroup	1899 10 O
difference	1910 10 O
was	1921 3 O
statistically	1925 13 O
significant	1939 11 O
(	1951 1 O
P	1952 1 O
<	1954 1 O
0	1956 1 O
.	1957 1 O
05	1958 2 O
)	1960 1 O
.	1961 1 O

PbtO	1963 4 O
(	1967 1 O
2	1968 1 O
)	1969 1 O
decreased	1971 9 O
from	1981 4 O
51	1986 2 O
.	1988 1 O
7	1989 1 O
+	1991 1 O
/	1992 1 O
-	1993 1 O
4	1995 1 O
.	1996 1 O
5	1997 1 O
mm	1999 2 O
Hg	2002 2 O
sem	2005 3 O
to	2009 2 O
33	2012 2 O
.	2014 1 O
8	2015 1 O
+	2017 1 O
/	2018 1 O
-	2019 1 O
5	2021 1 O
.	2022 1 O
2	2023 1 O
mm	2025 2 O
Hg	2028 2 O
sem	2031 3 O
in	2035 2 O
the	2038 3 O
NTG	2042 3 B-Chemical
group	2046 5 O
and	2052 3 O
from	2056 4 O
38	2061 2 O
.	2063 1 O
6	2064 1 O
+	2066 1 O
/	2067 1 O
-	2068 1 O
6	2070 1 O
.	2071 1 O
1	2072 1 O
mm	2074 2 O
Hg	2077 2 O
sem	2080 3 O
to	2084 2 O
25	2087 2 O
.	2089 1 O
4	2090 1 O
+	2092 1 O
/	2093 1 O
-	2094 1 O
2	2096 1 O
.	2097 1 O
0	2098 1 O
mm	2100 2 O
Hg	2103 2 O
sem	2106 3 O
in	2110 2 O
the	2113 3 O
NTG	2117 3 B-Chemical
+	2121 1 O
NIMO	2123 4 B-Chemical
groups	2128 6 O
,	2134 1 O
respectively	2136 12 O
.	2148 1 O

There	2150 5 O
were	2156 4 O
no	2161 2 O
significant	2164 11 O
differences	2176 11 O
among	2188 5 O
groups	2194 6 O
.	2200 1 O

CONCLUSION	2202 10 O
:	2212 1 O
In	2214 2 O
a	2217 1 O
PA	2219 2 O
retention	2222 9 O
paradigm	2232 8 O
,	2240 1 O
the	2242 3 O
injection	2246 9 O
of	2256 2 O
NTG	2259 3 B-Chemical
immediately	2263 11 O
after	2275 5 O
learning	2281 8 O
produced	2290 8 O
a	2299 1 O
significant	2301 11 O
impairment	2313 10 O
of	2324 2 O
long	2327 4 O
-	2331 1 O
term	2332 4 O
associative	2337 11 O
memory	2349 6 O
in	2356 2 O
mice	2359 4 O
,	2363 1 O
whereas	2365 7 O
delayed	2373 7 O
induced	2381 7 O
hypotension	2389 11 B-Disease
had	2401 3 O
no	2405 2 O
effect	2408 6 O
.	2414 1 O

NIMO	2416 4 B-Chemical
attenuated	2421 10 O
the	2432 3 O
disruption	2436 10 O
in	2447 2 O
consolidation	2450 13 O
of	2464 2 O
long	2467 4 O
-	2471 1 O
term	2472 4 O
memory	2477 6 O
caused	2484 6 O
by	2491 2 O
NTG	2494 3 B-Chemical
but	2498 3 O
did	2502 3 O
not	2506 3 O
improve	2510 7 O
latency	2518 7 O
in	2526 2 O
the	2529 3 O
absence	2533 7 O
of	2541 2 O
hypotension	2544 11 B-Disease
.	2555 1 O

The	2557 3 O
observed	2561 8 O
effect	2570 6 O
of	2577 2 O
NIMO	2580 4 B-Chemical
may	2585 3 O
have	2589 4 O
been	2594 4 O
attributable	2599 12 O
to	2612 2 O
the	2615 3 O
preservation	2619 12 O
of	2632 2 O
calcium	2635 7 B-Chemical
homeostasis	2643 11 O
during	2655 6 O
hypotension	2662 11 B-Disease
,	2673 1 O
because	2675 7 O
there	2683 5 O
were	2689 4 O
no	2694 2 O
differences	2697 11 O
in	2709 2 O
the	2712 3 O
PbtO	2716 4 O
(	2720 1 O
2	2721 1 O
)	2722 1 O
indices	2724 7 O
among	2732 5 O
groups	2738 6 O
.	2744 1 O

Fatal	0 5 O
haemopericardium	6 16 B-Disease
and	23 3 O
gastrointestinal	27 16 B-Disease
haemorrhage	44 11 I-Disease
due	56 3 O
to	60 2 O
possible	63 8 O
interaction	72 11 O
of	84 2 O
cranberry	87 9 O
juice	97 5 O
with	103 4 O
warfarin	108 8 B-Chemical
.	116 1 O

We	118 2 O
report	121 6 O
a	128 1 O
case	130 4 O
of	135 2 O
fatal	138 5 O
internal	144 8 O
haemorrhage	153 11 B-Disease
in	165 2 O
an	168 2 O
elderly	171 7 O
man	179 3 O
who	183 3 O
consumed	187 8 O
only	196 4 O
cranberry	201 9 O
juice	211 5 O
for	217 3 O
two	221 3 O
weeks	225 5 O
while	231 5 O
maintaining	237 11 O
his	249 3 O
usual	253 5 O
dosage	259 6 O
of	266 2 O
warfarin	269 8 B-Chemical
.	277 1 O

We	279 2 O
propose	282 7 O
that	290 4 O
naturally	295 9 O
occurring	305 9 O
compounds	315 9 O
such	325 4 O
as	330 2 O
flavonoids	333 10 B-Chemical
,	343 1 O
which	345 5 O
are	351 3 O
present	355 7 O
in	363 2 O
fruit	366 5 O
juices	372 6 O
,	378 1 O
may	380 3 O
increase	384 8 O
the	393 3 O
potency	397 7 O
of	405 2 O
warfarin	408 8 B-Chemical
by	417 2 O
competing	420 9 O
for	430 3 O
the	434 3 O
enzymes	438 7 O
that	446 4 O
normally	451 8 O
inactivate	460 10 O
warfarin	471 8 B-Chemical
.	479 1 O

While	481 5 O
traditionally	487 13 O
regarded	501 8 O
as	510 2 O
foodstuffs	513 10 O
,	523 1 O
consumption	525 11 O
of	537 2 O
fruit	540 5 O
juices	546 6 O
should	553 6 O
be	560 2 O
considered	563 10 O
when	574 4 O
patients	579 8 O
develop	588 7 O
adverse	596 7 O
drug	604 4 O
reactions	609 9 O
.	618 1 O

Isoproterenol	0 13 B-Chemical
induces	14 7 O
primary	22 7 O
loss	30 4 O
of	35 2 O
dystrophin	38 10 O
in	49 2 O
rat	52 3 O
hearts	56 6 O
:	62 1 O
correlation	64 11 O
with	76 4 O
myocardial	81 10 B-Disease
injury	92 6 I-Disease
.	98 1 O

The	100 3 O
mechanism	104 9 O
of	114 2 O
isoproterenol	117 13 B-Chemical
-	130 1 O
induced	131 7 O
myocardial	139 10 B-Disease
damage	150 6 I-Disease
is	157 2 O
unknown	160 7 O
,	167 1 O
but	169 3 O
a	173 1 O
mismatch	175 8 O
of	184 2 O
oxygen	187 6 B-Chemical
supply	194 6 O
vs	201 2 O
.	203 1 O
demand	205 6 O
following	212 9 O
coronary	222 8 O
hypotension	231 11 B-Disease
and	243 3 O
myocardial	247 10 B-Disease
hyperactivity	258 13 I-Disease
is	272 2 O
the	275 3 O
best	279 4 O
explanation	284 11 O
for	296 3 O
the	300 3 O
complex	304 7 O
morphological	312 13 O
alterations	326 11 O
observed	338 8 O
.	346 1 O

Severe	348 6 O
alterations	355 11 O
in	367 2 O
the	370 3 O
structural	374 10 O
integrity	385 9 O
of	395 2 O
the	398 3 O
sarcolemma	402 10 O
of	413 2 O
cardiomyocytes	416 14 O
have	431 4 O
been	436 4 O
demonstrated	441 12 O
to	454 2 O
be	457 2 O
caused	460 6 O
by	467 2 O
isoproterenol	470 13 B-Chemical
.	483 1 O

Taking	485 6 O
into	492 4 O
account	497 7 O
that	505 4 O
the	510 3 O
sarcolemmal	514 11 O
integrity	526 9 O
is	536 2 O
stabilized	539 10 O
by	550 2 O
the	553 3 O
dystrophin	557 10 O
-	567 1 O
glycoprotein	568 12 O
complex	581 7 O
(	589 1 O
DGC	590 3 O
)	593 1 O
that	595 4 O
connects	600 8 O
actin	609 5 O
and	615 3 O
laminin	619 7 O
in	627 2 O
contractile	630 11 O
machinery	642 9 O
and	652 3 O
extracellular	656 13 O
matrix	670 6 O
and	677 3 O
by	681 2 O
integrins	684 9 O
,	693 1 O
this	695 4 O
study	700 5 O
tests	706 5 O
the	712 3 O
hypothesis	716 10 O
that	727 4 O
isoproterenol	732 13 B-Chemical
affects	746 7 O
sarcolemmal	754 11 O
stability	766 9 O
through	776 7 O
changes	784 7 O
in	792 2 O
the	795 3 O
DGC	799 3 O
and	803 3 O
integrins	807 9 O
.	816 1 O

We	818 2 O
found	821 5 O
different	827 9 O
sensitivity	837 11 O
of	849 2 O
the	852 3 O
DGC	856 3 O
and	860 3 O
integrin	864 8 O
to	873 2 O
isoproterenol	876 13 B-Chemical
subcutaneous	890 12 O
administration	903 14 O
.	917 1 O

Immunofluorescent	919 17 O
staining	937 8 O
revealed	946 8 O
that	955 4 O
dystrophin	960 10 O
is	971 2 O
the	974 3 O
most	978 4 O
sensitive	983 9 O
among	993 5 O
the	999 3 O
structures	1003 10 O
connecting	1014 10 O
the	1025 3 O
actin	1029 5 O
in	1035 2 O
the	1038 3 O
cardiomyocyte	1042 13 O
cytoskeleton	1056 12 O
and	1069 3 O
the	1073 3 O
extracellular	1077 13 O
matrix	1091 6 O
.	1097 1 O

The	1099 3 O
sarcomeric	1103 10 O
actin	1114 5 O
dissolution	1120 11 O
occurred	1132 8 O
after	1141 5 O
the	1147 3 O
reduction	1151 9 O
or	1161 2 O
loss	1164 4 O
of	1169 2 O
dystrophin	1172 10 O
.	1182 1 O

Subsequently	1184 12 O
,	1196 1 O
after	1198 5 O
lysis	1204 5 O
of	1210 2 O
myofilaments	1213 12 O
,	1225 1 O
gamma	1227 5 O
-	1232 1 O
sarcoglycan	1233 11 O
,	1244 1 O
beta	1246 4 O
-	1250 1 O
dystroglycan	1251 12 O
,	1263 1 O
beta1	1265 5 O
-	1270 1 O
integrin	1271 8 O
,	1279 1 O
and	1281 3 O
laminin	1285 7 O
alpha	1293 5 O
-	1298 1 O
2	1299 1 O
expressions	1301 11 O
were	1313 4 O
reduced	1318 7 O
followed	1326 8 O
by	1335 2 O
their	1338 5 O
breakdown	1344 9 O
,	1353 1 O
as	1355 2 O
epiphenomena	1358 12 O
of	1371 2 O
the	1374 3 O
myocytolytic	1378 12 O
process	1391 7 O
.	1398 1 O

In	1400 2 O
conclusion	1403 10 O
,	1413 1 O
administration	1415 14 O
of	1430 2 O
isoproterenol	1433 13 B-Chemical
to	1447 2 O
rats	1450 4 O
results	1455 7 O
in	1463 2 O
primary	1466 7 O
loss	1474 4 O
of	1479 2 O
dystrophin	1482 10 O
,	1492 1 O
the	1494 3 O
most	1498 4 O
sensitive	1503 9 O
among	1513 5 O
the	1519 3 O
structural	1523 10 O
proteins	1534 8 O
that	1543 4 O
form	1548 4 O
the	1553 3 O
DGC	1557 3 O
that	1561 4 O
connects	1566 8 O
the	1575 3 O
extracellular	1579 13 O
matrix	1593 6 O
and	1600 3 O
the	1604 3 O
cytoskeleton	1608 12 O
in	1621 2 O
cardiomyocyte	1624 13 O
.	1637 1 O

These	1639 5 O
changes	1645 7 O
,	1652 1 O
related	1654 7 O
to	1662 2 O
ischaemic	1665 9 B-Disease
injury	1675 6 I-Disease
,	1681 1 O
explain	1683 7 O
the	1691 3 O
severe	1695 6 O
alterations	1702 11 O
in	1714 2 O
the	1717 3 O
structural	1721 10 O
integrity	1732 9 O
of	1742 2 O
the	1745 3 O
sarcolemma	1749 10 O
of	1760 2 O
cardiomyocytes	1763 14 O
and	1778 3 O
hence	1782 5 O
severe	1788 6 O
and	1795 3 O
irreversible	1799 12 O
injury	1812 6 O
induced	1819 7 O
by	1827 2 O
isoproterenol	1830 13 B-Chemical
.	1843 1 O

High	0 4 O
fat	5 3 B-Chemical
diet	9 4 O
-	13 1 O
fed	14 3 O
obese	18 5 B-Disease
rats	24 4 O
are	29 3 O
highly	33 6 O
sensitive	40 9 O
to	50 2 O
doxorubicin	53 11 B-Chemical
-	64 1 O
induced	65 7 O
cardiotoxicity	73 14 B-Disease
.	87 1 O

Often	89 5 O
,	94 1 O
chemotherapy	96 12 O
by	109 2 O
doxorubicin	112 11 B-Chemical
(	124 1 O
Adriamycin	125 10 B-Chemical
)	135 1 O
is	137 2 O
limited	140 7 O
due	148 3 O
to	152 2 O
life	155 4 O
threatening	160 11 O
cardiotoxicity	172 14 B-Disease
in	187 2 O
patients	190 8 O
during	199 6 O
and	206 3 O
posttherapy	210 11 O
.	221 1 O

Recently	223 8 O
,	231 1 O
we	233 2 O
have	236 4 O
shown	241 5 O
that	247 4 O
moderate	252 8 O
diet	261 4 O
restriction	266 11 O
remarkably	278 10 O
protects	289 8 O
against	298 7 O
doxorubicin	306 11 B-Chemical
-	317 1 O
induced	318 7 O
cardiotoxicity	326 14 B-Disease
.	340 1 O

This	342 4 O
cardioprotection	347 16 O
is	364 2 O
accompanied	367 11 O
by	379 2 O
decreased	382 9 O
cardiac	392 7 O
oxidative	400 9 O
stress	410 6 O
and	417 3 O
triglycerides	421 13 B-Chemical
and	435 3 O
increased	439 9 O
cardiac	449 7 O
fatty	457 5 O
-	462 1 O
acid	463 4 O
oxidation	468 9 O
,	477 1 O
ATP	479 3 B-Chemical
synthesis	483 9 O
,	492 1 O
and	494 3 O
upregulated	498 11 O
JAK	510 3 O
/	513 1 O
STAT3	514 5 O
pathway	520 7 O
.	527 1 O

In	529 2 O
the	532 3 O
current	536 7 O
study	544 5 O
,	549 1 O
we	551 2 O
investigated	554 12 O
whether	567 7 O
a	575 1 O
physiological	577 13 O
intervention	591 12 O
by	604 2 O
feeding	607 7 O
40	615 2 O
%	617 1 O
high	619 4 O
fat	624 3 B-Chemical
diet	628 4 O
(	633 1 O
HFD	634 3 O
)	637 1 O
,	638 1 O
which	640 5 O
induces	646 7 O
obesity	654 7 B-Disease
in	662 2 O
male	665 4 O
Sprague	670 7 O
-	677 1 O
Dawley	678 6 O
rats	685 4 O
(	690 1 O
250	691 3 O
-	694 1 O
275	695 3 O
g	699 1 O
)	700 1 O
,	701 1 O
sensitizes	703 10 O
to	714 2 O
doxorubicin	717 11 B-Chemical
-	728 1 O
induced	729 7 O
cardiotoxicity	737 14 B-Disease
.	751 1 O

A	753 1 O
LD	755 2 O
(	757 1 O
10	758 2 O
)	760 1 O
dose	762 4 O
(	767 1 O
8	768 1 O
mg	770 2 O
doxorubicin	773 11 B-Chemical
/	784 1 O
kg	785 2 O
,	787 1 O
ip	789 2 O
)	791 1 O
administered	793 12 O
on	806 2 O
day	809 3 O
43	813 2 O
of	816 2 O
the	819 3 O
HFD	823 3 O
feeding	827 7 O
regimen	835 7 O
led	843 3 O
to	847 2 O
higher	850 6 O
cardiotoxicity	857 14 B-Disease
,	871 1 O
cardiac	873 7 B-Disease
dysfunction	881 11 I-Disease
,	892 1 O
lipid	894 5 O
peroxidation	900 12 O
,	912 1 O
and	914 3 O
80	918 2 O
%	920 1 O
mortality	922 9 O
in	932 2 O
the	935 3 O
obese	939 5 B-Disease
(	945 1 O
OB	946 2 B-Disease
)	948 1 O
rats	950 4 O
in	955 2 O
the	958 3 O
absence	962 7 O
of	970 2 O
any	973 3 O
significant	977 11 O
renal	989 5 B-Disease
or	995 2 I-Disease
hepatic	998 7 I-Disease
toxicity	1006 8 I-Disease
.	1014 1 O

Doxorubicin	1016 11 B-Chemical
toxicokinetics	1028 14 O
studies	1043 7 O
revealed	1051 8 O
no	1060 2 O
change	1063 6 O
in	1070 2 O
accumulation	1073 12 O
of	1086 2 O
doxorubicin	1089 11 B-Chemical
and	1101 3 O
doxorubicinol	1105 13 B-Chemical
(	1119 1 O
toxic	1120 5 O
metabolite	1126 10 O
)	1136 1 O
in	1138 2 O
the	1141 3 O
normal	1145 6 O
diet	1152 4 O
-	1156 1 O
fed	1157 3 O
(	1161 1 O
ND	1162 2 O
)	1164 1 O
and	1166 3 O
OB	1170 2 B-Disease
hearts	1173 6 O
.	1179 1 O

Mechanistic	1181 11 O
studies	1193 7 O
revealed	1201 8 O
that	1210 4 O
OB	1215 2 B-Disease
rats	1218 4 O
are	1223 3 O
sensitized	1227 10 O
due	1238 3 O
to	1242 2 O
:	1244 1 O
(	1246 1 O
1	1247 1 O
)	1248 1 O
higher	1250 6 O
oxyradical	1257 10 O
stress	1268 6 O
leading	1275 7 O
to	1283 2 O
upregulation	1286 12 O
of	1299 2 O
uncoupling	1302 10 O
proteins	1313 8 O
2	1322 1 O
and	1324 3 O
3	1328 1 O
,	1329 1 O
(	1331 1 O
2	1332 1 O
)	1333 1 O
downregulation	1335 14 O
of	1350 2 O
cardiac	1353 7 O
peroxisome	1361 10 O
proliferators	1372 13 O
activated	1386 9 O
receptor	1396 8 O
-	1404 1 O
alpha	1405 5 O
,	1410 1 O
(	1412 1 O
3	1413 1 O
)	1414 1 O
decreased	1416 9 O
plasma	1426 6 O
adiponectin	1433 11 O
levels	1445 6 O
,	1451 1 O
(	1453 1 O
4	1454 1 O
)	1455 1 O
decreased	1457 9 O
cardiac	1467 7 O
fatty	1475 5 O
-	1480 1 O
acid	1481 4 O
oxidation	1486 9 O
(	1496 1 O
666	1497 3 O
.	1500 1 O
9	1501 1 O
+	1502 1 O
/	1503 1 O
-	1504 1 O
14	1505 2 O
.	1507 1 O
0	1508 1 O
nmol	1510 4 O
/	1514 1 O
min	1515 3 O
/	1518 1 O
g	1519 1 O
heart	1521 5 O
in	1527 2 O
ND	1530 2 O
versus	1533 6 O
400	1540 3 O
.	1543 1 O
2	1544 1 O
+	1545 1 O
/	1546 1 O
-	1547 1 O
11	1548 2 O
.	1550 1 O
8	1551 1 O
nmol	1553 4 O
/	1557 1 O
min	1558 3 O
/	1561 1 O
g	1562 1 O
heart	1564 5 O
in	1570 2 O
OB	1573 2 B-Disease
)	1575 1 O
,	1576 1 O
(	1578 1 O
5	1579 1 O
)	1580 1 O
decreased	1582 9 O
mitochondrial	1592 13 O
AMP	1606 3 B-Chemical
-	1609 1 O
alpha2	1610 6 O
protein	1617 7 O
kinase	1625 6 O
,	1631 1 O
and	1633 3 O
(	1637 1 O
6	1638 1 O
)	1639 1 O
86	1641 2 O
%	1643 1 O
drop	1645 4 O
in	1650 2 O
cardiac	1653 7 O
ATP	1661 3 B-Chemical
levels	1665 6 O
accompanied	1672 11 O
by	1684 2 O
decreased	1687 9 O
ATP	1697 3 B-Chemical
/	1700 1 O
ADP	1701 3 B-Chemical
ratio	1705 5 O
after	1711 5 O
doxorubicin	1717 11 B-Chemical
administration	1729 14 O
.	1743 1 O

Decreased	1745 9 O
cardiac	1755 7 O
erythropoietin	1763 14 O
and	1778 3 O
increased	1782 9 O
SOCS3	1792 5 O
further	1798 7 O
downregulated	1806 13 O
the	1820 3 O
cardioprotective	1824 16 O
JAK	1841 3 O
/	1844 1 O
STAT3	1845 5 O
pathway	1851 7 O
.	1858 1 O

In	1860 2 O
conclusion	1863 10 O
,	1873 1 O
HFD	1875 3 O
-	1878 1 O
induced	1879 7 O
obese	1887 5 B-Disease
rats	1893 4 O
are	1898 3 O
highly	1902 6 O
sensitized	1909 10 O
to	1920 2 O
doxorubicin	1923 11 B-Chemical
-	1934 1 O
induced	1935 7 O
cardiotoxicity	1943 14 B-Disease
by	1958 2 O
substantially	1961 13 O
downregulating	1975 14 O
cardiac	1990 7 O
mitochondrial	1998 13 O
ATP	2012 3 B-Chemical
generation	2016 10 O
,	2026 1 O
increasing	2028 10 O
oxidative	2039 9 O
stress	2049 6 O
and	2056 3 O
downregulating	2060 14 O
the	2075 3 O
JAK	2079 3 O
/	2082 1 O
STAT3	2083 5 O
pathway	2089 7 O
.	2096 1 O

Complete	0 8 O
atrioventricular	9 16 B-Disease
block	26 5 I-Disease
secondary	32 9 O
to	42 2 O
lithium	45 7 B-Chemical
therapy	53 7 O
.	60 1 O

Sinus	62 5 B-Disease
node	68 4 I-Disease
dysfunction	73 11 I-Disease
has	85 3 O
been	89 4 O
reported	94 8 O
most	103 4 O
frequently	108 10 O
among	119 5 O
the	125 3 O
adverse	129 7 O
cardiovascular	137 14 O
effects	152 7 O
of	160 2 O
lithium	163 7 B-Chemical
.	170 1 O

In	172 2 O
the	175 3 O
present	179 7 O
case	187 4 O
,	191 1 O
complete	193 8 O
atrioventricular	202 16 B-Disease
(	219 1 I-Disease
AV	220 2 I-Disease
)	222 1 I-Disease
block	224 5 I-Disease
with	230 4 O
syncopal	235 8 B-Disease
attacks	244 7 I-Disease
developed	252 9 O
secondary	262 9 O
to	272 2 O
lithium	275 7 B-Chemical
therapy	283 7 O
,	290 1 O
necessitating	292 13 O
permanent	306 9 O
pacemaker	316 9 O
implantation	326 12 O
.	338 1 O

Serum	340 5 O
lithium	346 7 B-Chemical
levels	354 6 O
remained	361 8 O
under	370 5 O
or	376 2 O
within	379 6 O
the	386 3 O
therapeutic	390 11 O
range	402 5 O
during	408 6 O
the	415 3 O
syncopal	419 8 B-Disease
attacks	428 7 I-Disease
.	435 1 O

Lithium	437 7 B-Chemical
should	445 6 O
be	452 2 O
used	455 4 O
with	460 4 O
extreme	465 7 O
caution	473 7 O
,	480 1 O
especially	482 10 O
in	493 2 O
patients	496 8 O
with	505 4 O
mild	510 4 O
disturbance	515 11 O
of	527 2 O
AV	530 2 O
conduction	533 10 O
.	543 1 O

Neuroleptic	0 11 B-Disease
malignant	12 9 I-Disease
syndrome	22 8 I-Disease
induced	31 7 O
by	39 2 O
ziprasidone	42 11 B-Chemical
on	54 2 O
the	57 3 O
second	61 6 O
day	68 3 O
of	72 2 O
treatment	75 9 O
.	84 1 O

Neuroleptic	86 11 B-Disease
malignant	98 9 I-Disease
syndrome	108 8 I-Disease
(	117 1 O
NMS	118 3 B-Disease
)	121 1 O
is	123 2 O
the	126 3 O
rarest	130 6 O
and	137 3 O
most	141 4 O
serious	146 7 O
of	154 2 O
the	157 3 O
neuroleptic	161 11 O
-	172 1 O
induced	173 7 O
movement	181 8 B-Disease
disorders	190 9 I-Disease
.	199 1 O

We	201 2 O
describe	204 8 O
a	213 1 O
case	215 4 O
of	220 2 O
neuroleptic	223 11 B-Disease
malignant	235 9 I-Disease
syndrome	245 8 I-Disease
(	254 1 O
NMS	255 3 B-Disease
)	258 1 O
associated	260 10 O
with	271 4 O
the	276 3 O
use	280 3 O
of	284 2 O
ziprasidone	287 11 B-Chemical
.	298 1 O

Although	300 8 O
conventional	309 12 O
neuroleptics	322 12 O
are	335 3 O
more	339 4 O
frequently	344 10 O
associated	355 10 O
with	366 4 O
NMS	371 3 B-Disease
,	374 1 O
atypical	376 8 O
antipsychotic	385 13 O
drugs	399 5 O
like	405 4 O
ziprasidone	410 11 B-Chemical
may	422 3 O
also	426 4 O
be	431 2 O
a	434 1 O
cause	436 5 O
.	441 1 O

The	443 3 O
patient	447 7 O
is	455 2 O
a	458 1 O
24	460 2 O
-	462 1 O
year	463 4 O
-	467 1 O
old	468 3 O
male	472 4 O
with	477 4 O
a	482 1 O
history	484 7 O
of	492 2 O
schizophrenia	495 13 B-Disease
who	509 3 O
developed	513 9 O
signs	523 5 O
and	529 3 O
symptoms	533 8 O
of	542 2 O
NMS	545 3 B-Disease
after	549 5 O
2	555 1 O
days	557 4 O
of	562 2 O
treatment	565 9 O
with	575 4 O
an	580 2 O
80	583 2 O
-	585 1 O
mg	586 2 O
/	588 1 O
day	589 3 O
dose	593 4 O
of	598 2 O
orally	601 6 O
administrated	608 13 O
ziprasidone	622 11 B-Chemical
.	633 1 O

This	635 4 O
case	640 4 O
is	645 2 O
the	648 3 O
earliest	652 8 O
(	661 1 O
second	662 6 O
day	669 3 O
of	673 2 O
treatment	676 9 O
)	685 1 O
NMS	687 3 B-Disease
due	691 3 O
to	695 2 O
ziprasidone	698 11 B-Chemical
reported	710 8 O
in	719 2 O
the	722 3 O
literature	726 10 O
.	736 1 O

Role	0 4 O
of	5 2 O
mangiferin	8 10 B-Chemical
on	19 2 O
biochemical	22 11 O
alterations	34 11 O
and	46 3 O
antioxidant	50 11 O
status	62 6 O
in	69 2 O
isoproterenol	72 13 B-Chemical
-	85 1 O
induced	86 7 O
myocardial	94 10 B-Disease
infarction	105 10 I-Disease
in	116 2 O
rats	119 4 O
.	123 1 O

The	125 3 O
current	129 7 O
study	137 5 O
dealt	143 5 O
with	149 4 O
the	154 3 O
protective	158 10 O
role	169 4 O
of	174 2 O
mangiferin	177 10 B-Chemical
,	187 1 O
a	189 1 O
polyphenol	191 10 B-Chemical
from	202 4 O
Mangifera	207 9 O
indica	217 6 O
Linn	224 4 O
.	228 1 O

(	230 1 O
Anacardiaceae	231 13 O
)	244 1 O
,	245 1 O
on	247 2 O
isoproterenol	250 13 B-Chemical
(	264 1 O
ISPH	265 4 B-Chemical
)	269 1 O
-	270 1 O
induced	271 7 O
myocardial	279 10 B-Disease
infarction	290 10 I-Disease
(	301 1 O
MI	302 2 B-Disease
)	304 1 O
in	306 2 O
rats	309 4 O
through	314 7 O
its	322 3 O
antioxidative	326 13 O
mechanism	340 9 O
.	349 1 O

Subcutaneous	351 12 O
injection	364 9 O
of	374 2 O
ISPH	377 4 B-Chemical
(	382 1 O
200	383 3 O
mg	387 2 O
/	389 1 O
kg	390 2 O
body	393 4 O
weight	398 6 O
in	405 2 O
1	408 1 O
ml	410 2 O
saline	413 6 O
)	419 1 O
to	421 2 O
rats	424 4 O
for	429 3 O
2	433 1 O
consecutive	435 11 O
days	447 4 O
caused	452 6 O
myocardial	459 10 B-Disease
damage	470 6 I-Disease
in	477 2 O
rat	480 3 O
heart	484 5 O
,	489 1 O
which	491 5 O
was	497 3 O
determined	501 10 O
by	512 2 O
the	515 3 O
increased	519 9 O
activity	529 8 O
of	538 2 O
serum	541 5 O
lactate	547 7 B-Chemical
dehydrogenase	555 13 O
(	569 1 O
LDH	570 3 O
)	573 1 O
and	575 3 O
creatine	579 8 B-Chemical
phosphokinase	588 13 O
isoenzymes	602 10 O
(	613 1 O
CK	614 2 O
-	616 1 O
MB	617 2 O
)	619 1 O
,	620 1 O
increased	622 9 O
uric	632 4 B-Chemical
acid	637 4 I-Chemical
level	642 5 O
and	648 3 O
reduced	652 7 O
plasma	660 6 O
iron	667 4 B-Chemical
binding	672 7 O
capacity	680 8 O
.	688 1 O

The	690 3 O
protective	694 10 O
role	705 4 O
of	710 2 O
mangiferin	713 10 B-Chemical
was	724 3 O
analyzed	728 8 O
by	737 2 O
triphenyl	740 9 B-Chemical
tetrazolium	750 11 I-Chemical
chloride	762 8 I-Chemical
(	771 1 O
TTC	772 3 B-Chemical
)	775 1 O
test	777 4 O
used	782 4 O
for	787 3 O
macroscopic	791 11 O
enzyme	803 6 O
mapping	810 7 O
assay	818 5 O
of	824 2 O
the	827 3 O
ischemic	831 8 B-Disease
myocardium	840 10 I-Disease
.	850 1 O

The	852 3 O
heart	856 5 O
tissue	862 6 O
antioxidant	869 11 O
enzymes	881 7 O
such	889 4 O
as	894 2 O
superoxide	897 10 B-Chemical
dismutase	908 9 O
,	917 1 O
catalase	919 8 O
,	927 1 O
glutathione	929 11 B-Chemical
peroxidase	941 10 O
,	951 1 O
glutathione	953 11 B-Chemical
transferase	965 11 O
and	977 3 O
glutathione	981 11 B-Chemical
reductase	993 9 O
activities	1003 10 O
,	1013 1 O
non	1015 3 O
-	1018 1 O
enzymic	1019 7 O
antioxidants	1027 12 O
such	1040 4 O
as	1045 2 O
cerruloplasmin	1048 14 O
,	1062 1 O
Vitamin	1064 7 B-Chemical
C	1072 1 I-Chemical
,	1073 1 O
Vitamin	1075 7 B-Chemical
E	1083 1 I-Chemical
and	1085 3 O
glutathione	1089 11 B-Chemical
levels	1101 6 O
were	1108 4 O
altered	1113 7 O
in	1121 2 O
MI	1124 2 B-Disease
rats	1127 4 O
.	1131 1 O

Upon	1133 4 O
pretreatment	1138 12 O
with	1151 4 O
mangiferin	1156 10 B-Chemical
(	1167 1 O
100	1168 3 O
mg	1172 2 O
/	1174 1 O
kg	1175 2 O
body	1178 4 O
weight	1183 6 O
suspended	1190 9 O
in	1200 2 O
2	1203 1 O
ml	1205 2 O
of	1208 2 O
dimethyl	1211 8 B-Chemical
sulphoxide	1220 10 I-Chemical
)	1230 1 O
given	1232 5 O
intraperitoneally	1238 17 O
for	1256 3 O
28	1260 2 O
days	1263 4 O
to	1268 2 O
MI	1271 2 B-Disease
rats	1274 4 O
protected	1279 9 O
the	1289 3 O
above	1293 5 O
-	1298 1 O
mentioned	1299 9 O
parameters	1309 10 O
to	1320 2 O
fall	1323 4 O
from	1328 4 O
the	1333 3 O
normal	1337 6 O
levels	1344 6 O
.	1350 1 O

Activities	1352 10 O
of	1363 2 O
heart	1366 5 O
tissue	1372 6 O
enzymic	1379 7 O
antioxidants	1387 12 O
and	1400 3 O
serum	1404 5 O
non	1410 3 O
-	1413 1 O
enzymic	1414 7 O
antioxidants	1422 12 O
levels	1435 6 O
rose	1442 4 O
significantly	1447 13 O
upon	1461 4 O
mangiferin	1466 10 B-Chemical
administration	1477 14 O
as	1492 2 O
compared	1495 8 O
to	1504 2 O
ISPH	1507 4 B-Chemical
-	1511 1 O
induced	1512 7 O
MI	1520 2 B-Disease
rats	1523 4 O
.	1527 1 O

From	1529 4 O
the	1534 3 O
present	1538 7 O
study	1546 5 O
it	1552 2 O
is	1555 2 O
concluded	1558 9 O
that	1568 4 O
mangiferin	1573 10 B-Chemical
exerts	1584 6 O
a	1591 1 O
beneficial	1593 10 O
effect	1604 6 O
against	1611 7 O
ISPH	1619 4 B-Chemical
-	1623 1 O
induced	1624 7 O
MI	1632 2 B-Disease
due	1635 3 O
to	1639 2 O
its	1642 3 O
antioxidant	1646 11 O
potential	1658 9 O
,	1667 1 O
which	1669 5 O
regulated	1675 9 O
the	1685 3 O
tissues	1689 7 O
defense	1697 7 O
system	1705 6 O
against	1712 7 O
cardiac	1720 7 B-Disease
damage	1728 6 I-Disease
.	1734 1 O

Remifentanil	0 12 B-Chemical
pretreatment	13 12 O
reduces	26 7 O
myoclonus	34 9 B-Disease
after	44 5 O
etomidate	50 9 B-Chemical
.	59 1 O

STUDY	61 5 O
OBJECTIVE	67 9 O
:	76 1 O
The	78 3 O
aim	82 3 O
of	86 2 O
the	89 3 O
study	93 5 O
was	99 3 O
to	103 2 O
compare	106 7 O
the	114 3 O
effect	118 6 O
of	125 2 O
pretreatment	128 12 O
with	141 4 O
remifentanil	146 12 B-Chemical
1	159 1 O
microg	161 6 O
/	167 1 O
kg	168 2 O
and	171 3 O
the	175 3 O
effect	179 6 O
of	186 2 O
gender	189 6 O
on	196 2 O
the	199 3 O
incidence	203 9 O
of	213 2 O
myoclonus	216 9 B-Disease
after	226 5 O
anesthesia	232 10 O
induction	243 9 O
with	253 4 O
etomidate	258 9 B-Chemical
.	267 1 O

DESIGN	269 6 O
:	275 1 O
This	277 4 O
was	282 3 O
a	286 1 O
randomized	288 10 O
,	298 1 O
double	300 6 O
-	306 1 O
blind	307 5 O
study	313 5 O
.	318 1 O

SETTING	320 7 O
:	327 1 O
The	329 3 O
study	333 5 O
was	339 3 O
conducted	343 9 O
at	353 2 O
a	356 1 O
university	358 10 O
hospital	369 8 O
.	377 1 O

PATIENTS	379 8 O
:	387 1 O
Sixty	389 5 O
patients	395 8 O
were	404 4 O
pretreated	409 10 O
in	420 2 O
a	423 1 O
randomized	425 10 O
double	436 6 O
-	442 1 O
blinded	443 7 O
fashion	451 7 O
with	459 4 O
remifentanil	464 12 B-Chemical
1	477 1 O
microg	479 6 O
/	485 1 O
kg	486 2 O
or	489 2 O
placebo	492 7 O
.	499 1 O

Two	501 3 O
minutes	505 7 O
after	513 5 O
remifentanil	519 12 B-Chemical
or	532 2 O
placebo	535 7 O
injection	543 9 O
,	552 1 O
etomidate	554 9 B-Chemical
0	564 1 O
.	565 1 O
3	566 1 O
mg	568 2 O
/	570 1 O
kg	571 2 O
was	574 3 O
given	578 5 O
.	583 1 O

MEASUREMENTS	585 12 O
:	597 1 O
Myoclonus	599 9 B-Disease
was	609 3 O
recorded	613 8 O
with	622 4 O
a	627 1 O
scale	629 5 O
of	635 2 O
0	638 1 O
to	640 2 O
3	643 1 O
.	644 1 O

The	646 3 O
grade	650 5 O
of	656 2 O
sedation	659 8 O
(	668 1 O
none	669 4 O
,	673 1 O
mild	675 4 O
,	679 1 O
moderate	681 8 O
,	689 1 O
severe	691 6 O
)	697 1 O
,	698 1 O
nausea	700 6 B-Disease
,	706 1 O
pruritus	708 8 B-Disease
,	716 1 O
and	718 3 O
apnea	722 5 B-Disease
were	728 4 O
recorded	733 8 O
after	742 5 O
injection	748 9 O
of	758 2 O
both	761 4 O
drugs	766 5 O
.	771 1 O

MAIN	773 4 O
RESULTS	778 7 O
:	785 1 O
The	787 3 O
incidence	791 9 O
of	801 2 O
myoclonus	804 9 B-Disease
was	814 3 O
significantly	818 13 O
lower	832 5 O
in	838 2 O
the	841 3 O
remifentanil	845 12 B-Chemical
group	858 5 O
(	864 1 O
6	865 1 O
.	866 1 O
7	867 1 O
%	868 1 O
)	869 1 O
than	871 4 O
in	876 2 O
the	879 3 O
placebo	883 7 O
group	891 5 O
(	897 1 O
70	898 2 O
%	900 1 O
)	901 1 O
(	903 1 O
P	904 1 O
<	906 1 O
0	908 1 O
.	909 1 O
001	910 3 O
)	913 1 O
.	914 1 O

None	916 4 O
of	921 2 O
the	924 3 O
patients	928 8 O
experienced	937 11 O
sedation	949 8 O
,	957 1 O
apnea	959 5 B-Disease
,	964 1 O
nausea	966 6 B-Disease
,	972 1 O
or	974 2 O
pruritus	977 8 B-Disease
after	986 5 O
injection	992 9 O
of	1002 2 O
both	1005 4 O
drugs	1010 5 O
.	1015 1 O

In	1017 2 O
the	1020 3 O
placebo	1024 7 O
group	1032 5 O
,	1037 1 O
male	1039 4 O
patients	1044 8 O
were	1053 4 O
associated	1058 10 O
with	1069 4 O
significantly	1074 13 O
increased	1088 9 O
incidence	1098 9 O
of	1108 2 O
myoclonus	1111 9 B-Disease
after	1121 5 O
etomidate	1127 9 B-Chemical
administration	1137 14 O
.	1151 1 O

CONCLUSION	1153 10 O
:	1163 1 O
Pretreatment	1165 12 O
with	1178 4 O
remifentanil	1183 12 B-Chemical
1	1196 1 O
microg	1198 6 O
/	1204 1 O
kg	1205 2 O
reduced	1208 7 O
myoclonus	1216 9 B-Disease
after	1226 5 O
etomidate	1232 9 B-Chemical
induction	1242 9 O
without	1252 7 O
side	1260 4 O
effects	1265 7 O
such	1273 4 O
as	1278 2 O
sedation	1281 8 O
,	1289 1 O
apnea	1291 5 B-Disease
,	1296 1 O
nausea	1298 6 B-Disease
,	1304 1 O
or	1306 2 O
pruritus	1309 8 B-Disease
.	1317 1 O

Men	1319 3 O
experience	1323 10 O
increased	1334 9 O
incidence	1344 9 O
of	1354 2 O
myoclonus	1357 9 B-Disease
than	1367 4 O
women	1372 5 O
after	1378 5 O
etomidate	1384 9 B-Chemical
administration	1394 14 O
.	1408 1 O

Daidzein	0 8 B-Chemical
activates	9 9 O
choline	19 7 B-Chemical
acetyltransferase	27 17 O
from	45 4 O
MC	50 2 O
-	52 1 O
IXC	53 3 O
cells	57 5 O
and	63 3 O
improves	67 8 O
drug	76 4 O
-	80 1 O
induced	81 7 O
amnesia	89 7 B-Disease
.	96 1 O

The	98 3 O
choline	102 7 B-Chemical
acetyltransferase	110 17 O
(	128 1 O
ChAT	129 4 O
)	133 1 O
activator	135 9 O
,	144 1 O
which	146 5 O
enhances	152 8 O
cholinergic	161 11 O
transmission	173 12 O
via	186 3 O
an	190 2 O
augmentation	193 12 O
of	206 2 O
the	209 3 O
enzymatic	213 9 O
production	223 10 O
of	234 2 O
acetylcholine	237 13 B-Chemical
(	251 1 O
ACh	252 3 B-Chemical
)	255 1 O
,	256 1 O
is	258 2 O
an	261 2 O
important	264 9 O
factor	274 6 O
in	281 2 O
the	284 3 O
treatment	288 9 O
of	298 2 O
Alzheimer	301 9 B-Disease
'	310 1 I-Disease
s	311 1 I-Disease
disease	313 7 I-Disease
(	321 1 O
AD	322 2 B-Disease
)	324 1 O
.	325 1 O

Methanolic	327 10 O
extracts	338 8 O
from	347 4 O
Pueraria	352 8 O
thunbergiana	361 12 O
exhibited	374 9 O
an	384 2 O
activation	387 10 O
effect	398 6 O
(	405 1 O
46	406 2 O
%	408 1 O
)	409 1 O
on	411 2 O
ChAT	414 4 O
in	419 2 O
vitro	422 5 O
.	427 1 O

Via	429 3 O
the	433 3 O
sequential	437 10 O
isolation	448 9 O
of	458 2 O
Pueraria	461 8 O
thunbergiana	470 12 O
,	482 1 O
the	484 3 O
active	488 6 O
component	495 9 O
was	505 3 O
ultimately	509 10 O
identified	520 10 O
as	531 2 O
daidzein	534 8 B-Chemical
(	543 1 O
4	544 1 B-Chemical
'	545 1 I-Chemical
,	546 1 I-Chemical
7	547 1 I-Chemical
-	548 1 I-Chemical
dihydroxy	549 9 I-Chemical
-	558 1 I-Chemical
isoflavone	559 10 I-Chemical
)	569 1 O
.	570 1 O

In	572 2 O
order	575 5 O
to	581 2 O
investigate	584 11 O
the	596 3 O
effects	600 7 O
of	608 2 O
daidzein	611 8 B-Chemical
from	620 4 O
Pueraria	625 8 O
thunbergiana	634 12 O
on	647 2 O
scopolamine	650 11 B-Chemical
-	661 1 O
induced	662 7 O
impairments	670 11 B-Disease
of	682 2 I-Disease
learning	685 8 I-Disease
and	694 3 I-Disease
memory	698 6 I-Disease
,	704 1 O
we	706 2 O
conducted	709 9 O
a	719 1 O
series	721 6 O
of	728 2 O
in	731 2 O
vivo	734 4 O
tests	739 5 O
.	744 1 O

Administration	746 14 O
of	761 2 O
daidzein	764 8 B-Chemical
(	773 1 O
4	774 1 O
.	775 1 O
5	776 1 O
mg	778 2 O
/	780 1 O
kg	781 2 O
body	784 4 O
weight	789 6 O
)	795 1 O
to	797 2 O
mice	800 4 O
was	805 3 O
shown	809 5 O
significantly	815 13 O
to	829 2 O
reverse	832 7 O
scopolamine	840 11 B-Chemical
-	851 1 O
induced	852 7 O
amnesia	860 7 B-Disease
,	867 1 O
according	869 9 O
to	879 2 O
the	882 3 O
results	886 7 O
of	894 2 O
a	897 1 O
Y	899 1 O
-	900 1 O
maze	901 4 O
test	906 4 O
.	910 1 O

Injections	912 10 O
of	923 2 O
scopolamine	926 11 B-Chemical
into	938 4 O
mice	943 4 O
resulted	948 8 O
in	957 2 O
impaired	960 8 O
performance	969 11 O
on	981 2 O
Y	984 1 O
-	985 1 O
maze	986 4 O
tests	991 5 O
(	997 1 O
a	998 1 O
37	1000 2 O
%	1002 1 O
decreases	1004 9 O
in	1014 2 O
alternation	1017 11 O
behavior	1029 8 O
)	1037 1 O
.	1038 1 O

By	1040 2 O
way	1043 3 O
of	1047 2 O
contrast	1050 8 O
,	1058 1 O
mice	1060 4 O
treated	1065 7 O
with	1073 4 O
daidzein	1078 8 B-Chemical
prior	1087 5 O
to	1093 2 O
the	1096 3 O
scopolamine	1100 11 B-Chemical
injections	1112 10 O
were	1123 4 O
noticeably	1128 10 O
protected	1139 9 O
from	1149 4 O
this	1154 4 O
performance	1159 11 O
impairment	1171 10 O
(	1182 1 O
an	1183 2 O
approximately	1186 13 O
12	1200 2 O
%	1202 1 O
-	1203 1 O
21	1204 2 O
%	1206 1 O
decrease	1208 8 O
in	1217 2 O
alternation	1220 11 O
behavior	1232 8 O
)	1240 1 O
.	1241 1 O

These	1243 5 O
results	1249 7 O
indicate	1257 8 O
that	1266 4 O
daidzein	1271 8 B-Chemical
might	1280 5 O
play	1286 4 O
a	1291 1 O
role	1293 4 O
in	1298 2 O
acetylcholine	1301 13 B-Chemical
biosynthesis	1315 12 O
as	1328 2 O
a	1331 1 O
ChAT	1333 4 O
activator	1338 9 O
,	1347 1 O
and	1349 3 O
that	1353 4 O
it	1358 2 O
also	1361 4 O
ameliorates	1366 11 O
scopolamine	1378 11 B-Chemical
-	1389 1 O
induced	1390 7 O
amnesia	1398 7 B-Disease
.	1405 1 O

Possible	0 8 O
azithromycin	9 12 B-Chemical
-	21 1 O
associated	22 10 O
hiccups	33 7 B-Disease
.	40 1 O

OBJECTIVE	42 9 O
:	51 1 O
To	53 2 O
report	56 6 O
a	63 1 O
case	65 4 O
of	70 2 O
persistent	73 10 O
hiccups	84 7 B-Disease
associated	92 10 O
by	103 2 O
azithromycin	106 12 B-Chemical
therapy	119 7 O
.	126 1 O

CASE	128 4 O
SUMMARY	133 7 O
:	140 1 O
A	142 1 O
76	144 2 O
-	146 1 O
year	147 4 O
-	151 1 O
old	152 3 O
man	156 3 O
presented	160 9 O
with	170 4 O
persistent	175 10 O
hiccups	186 7 B-Disease
after	194 5 O
beginning	200 9 O
azithromycin	210 12 B-Chemical
for	223 3 O
the	227 3 O
treatment	231 9 O
of	241 2 O
pharyngitis	244 11 B-Disease
.	255 1 O

Hiccups	257 7 B-Disease
were	265 4 O
persistent	270 10 O
and	281 3 O
exhausting	285 10 O
.	295 1 O

Discontinuation	297 15 O
of	313 2 O
azithromycin	316 12 B-Chemical
and	329 3 O
therapy	333 7 O
with	341 4 O
baclofen	346 8 B-Chemical
finally	355 7 O
resolved	363 8 O
hiccups	372 7 B-Disease
.	379 1 O

No	381 2 O
organic	384 7 O
cause	392 5 O
of	398 2 O
hiccups	401 7 B-Disease
was	409 3 O
identified	413 10 O
despite	424 7 O
extensive	432 9 O
investigation	442 13 O
.	455 1 O

DISCUSSION	457 10 O
:	467 1 O
Pharmacotherapeutic	469 19 O
agents	489 6 O
have	496 4 O
been	501 4 O
uncommonly	506 10 O
associated	517 10 O
with	528 4 O
hiccups	533 7 B-Disease
.	540 1 O

Corticosteroids	542 15 O
(	558 1 O
dexamethasone	559 13 B-Chemical
and	573 3 O
methylprednisolone	577 18 B-Chemical
)	595 1 O
,	596 1 O
benzodiazepines	598 15 B-Chemical
(	614 1 O
midazolam	615 9 B-Chemical
)	624 1 O
and	626 3 O
general	630 7 O
anaesthesia	638 11 O
have	650 4 O
been	655 4 O
the	660 3 O
specific	664 8 O
agents	673 6 O
mentioned	680 9 O
most	690 4 O
frequently	695 10 O
in	706 2 O
the	709 3 O
literature	713 10 O
as	724 2 O
being	727 5 O
associated	733 10 O
with	744 4 O
the	749 3 O
development	753 11 O
of	765 2 O
hiccups	768 7 B-Disease
.	775 1 O

Few	777 3 O
cases	781 5 O
of	787 2 O
drug	790 4 O
-	794 1 O
induced	795 7 O
hiccups	803 7 B-Disease
have	811 4 O
been	816 4 O
reported	821 8 O
related	830 7 O
to	838 2 O
macrolide	841 9 B-Chemical
antimicrobials	851 14 O
.	865 1 O

Using	867 5 O
the	873 3 O
Naranjo	877 7 O
adverse	885 7 O
effect	893 6 O
reaction	900 8 O
probability	909 11 O
scale	921 5 O
this	927 4 O
event	932 5 O
could	938 5 O
be	944 2 O
classified	947 10 O
as	958 2 O
possible	961 8 O
(	970 1 O
score	971 5 O
5	977 1 O
points	979 6 O
)	985 1 O
,	986 1 O
mostly	988 6 O
because	995 7 O
of	1003 2 O
the	1006 3 O
close	1010 5 O
temporal	1016 8 O
sequence	1025 8 O
,	1033 1 O
previous	1035 8 O
reports	1044 7 O
on	1052 2 O
this	1055 4 O
reaction	1060 8 O
with	1069 4 O
other	1074 5 O
macrolides	1080 10 B-Chemical
and	1091 3 O
the	1095 3 O
absence	1099 7 O
of	1107 2 O
any	1110 3 O
alternative	1114 11 O
explanation	1126 11 O
for	1138 3 O
hiccups	1142 7 B-Disease
.	1149 1 O

Our	1151 3 O
hypothesis	1155 10 O
is	1166 2 O
that	1169 4 O
a	1174 1 O
vagal	1176 5 O
mechanism	1182 9 O
mediated	1192 8 O
by	1201 2 O
azithromycin	1204 12 B-Chemical
could	1217 5 O
be	1223 2 O
the	1226 3 O
pathogenesis	1230 12 O
of	1243 2 O
hiccups	1246 7 B-Disease
in	1254 2 O
our	1257 3 O
patient	1261 7 O
.	1268 1 O

CONCLUSIONS	1270 11 O
:	1281 1 O
Diagnosis	1283 9 O
of	1293 2 O
drug	1296 4 O
-	1300 1 O
induced	1301 7 O
hiccups	1309 7 B-Disease
is	1317 2 O
difficult	1320 9 O
and	1330 3 O
often	1334 5 O
achieved	1340 8 O
only	1349 4 O
by	1354 2 O
a	1357 1 O
process	1359 7 O
of	1367 2 O
elimination	1370 11 O
.	1381 1 O

However	1383 7 O
,	1390 1 O
macrolide	1392 9 B-Chemical
antimicrobials	1402 14 O
have	1417 4 O
been	1422 4 O
reported	1427 8 O
to	1436 2 O
be	1439 2 O
associated	1442 10 O
with	1453 4 O
hiccups	1458 7 B-Disease
and	1466 3 O
vagal	1470 5 O
mechanism	1476 9 O
could	1486 5 O
explain	1492 7 O
the	1500 3 O
development	1504 11 O
of	1516 2 O
this	1519 4 O
side	1524 4 O
-	1528 1 O
effect	1529 6 O
.	1535 1 O

Time	0 4 O
trends	5 6 O
in	12 2 O
warfarin	15 8 B-Chemical
-	23 1 O
associated	24 10 O
hemorrhage	35 10 B-Disease
.	45 1 O

The	47 3 O
annual	51 6 O
incidence	58 9 O
of	68 2 O
warfarin	71 8 B-Chemical
-	79 1 O
related	80 7 O
bleeding	88 8 B-Disease
at	97 2 O
Brigham	100 7 O
and	108 3 O
Women	112 5 O
'	117 1 O
s	118 1 O
Hospital	120 8 O
increased	129 9 O
from	139 4 O
0	144 1 O
.	145 1 O
97	146 2 O
/	148 1 O
1	149 1 O
,	150 1 O
000	151 3 O
patient	155 7 O
admissions	163 10 O
in	174 2 O
the	177 3 O
first	181 5 O
time	187 4 O
period	192 6 O
(	199 1 O
January	200 7 O
1995	208 4 O
to	213 2 O
October	216 7 O
1998	224 4 O
)	228 1 O
to	230 2 O
1	233 1 O
.	234 1 O
19	235 2 O
/	237 1 O
1	238 1 O
,	239 1 O
000	240 3 O
patient	244 7 O
admissions	252 10 O
in	263 2 O
the	266 3 O
second	270 6 O
time	277 4 O
period	282 6 O
(	289 1 O
November	290 8 O
1998	299 4 O
to	304 2 O
August	307 6 O
2002	314 4 O
)	318 1 O
of	320 2 O
this	323 4 O
study	328 5 O
.	333 1 O

The	335 3 O
proportion	339 10 O
of	350 2 O
patients	353 8 O
with	362 4 O
major	367 5 O
and	373 3 O
intracranial	377 12 B-Disease
bleeding	390 8 I-Disease
increased	399 9 O
from	409 4 O
20	414 2 O
.	416 1 O
2	417 1 O
%	418 1 O
and	420 3 O
1	424 1 O
.	425 1 O
9	426 1 O
%	427 1 O
,	428 1 O
respectively	430 12 O
,	442 1 O
in	444 2 O
the	447 3 O
first	451 5 O
time	457 4 O
period	462 6 O
,	468 1 O
to	470 2 O
33	473 2 O
.	475 1 O
3	476 1 O
%	477 1 O
and	479 3 O
7	483 1 O
.	484 1 O
8	485 1 O
%	486 1 O
,	487 1 O
respectively	489 12 O
,	501 1 O
in	503 2 O
the	506 3 O
second	510 6 O
.	516 1 O

Fatal	0 5 O
haemorrhagic	6 12 B-Disease
myocarditis	19 11 I-Disease
secondary	31 9 O
to	41 2 O
cyclophosphamide	44 16 B-Chemical
therapy	61 7 O
.	68 1 O

Haemorrhagic	70 12 B-Disease
myocarditis	83 11 I-Disease
is	95 2 O
a	98 1 O
rare	100 4 O
but	105 3 O
important	109 9 O
complication	119 12 O
of	132 2 O
cyclophosphamide	135 16 B-Chemical
therapy	152 7 O
.	159 1 O

Echocardiographic	161 17 O
identification	179 14 O
of	194 2 O
the	197 3 O
disorder	201 8 O
can	210 3 O
be	214 2 O
made	217 4 O
.	221 1 O

We	223 2 O
believe	226 7 O
that	234 4 O
the	239 3 O
ultrasound	243 10 O
features	254 8 O
of	263 2 O
this	266 4 O
disorder	271 8 O
have	280 4 O
not	285 3 O
been	289 4 O
previously	294 10 O
reported	305 8 O
.	313 1 O

Glyceryl	0 8 B-Chemical
trinitrate	9 10 I-Chemical
induces	20 7 O
attacks	28 7 O
of	36 2 O
migraine	39 8 B-Disease
without	48 7 I-Disease
aura	56 4 I-Disease
in	61 2 O
sufferers	64 9 O
of	74 2 O
migraine	77 8 B-Disease
with	86 4 I-Disease
aura	91 4 I-Disease
.	95 1 O

Migraine	97 8 B-Disease
with	106 4 I-Disease
aura	111 4 I-Disease
and	116 3 O
migraine	120 8 B-Disease
without	129 7 I-Disease
aura	137 4 I-Disease
have	142 4 O
the	147 3 O
same	151 4 O
pain	156 4 B-Disease
phase	161 5 O
,	166 1 O
thus	168 4 O
indicating	173 10 O
that	184 4 O
migraine	189 8 B-Disease
with	198 4 I-Disease
aura	203 4 I-Disease
and	208 3 O
migraine	212 8 B-Disease
without	221 7 I-Disease
aura	229 4 I-Disease
share	234 5 O
a	240 1 O
common	242 6 O
pathway	249 7 O
of	257 2 O
nociception	260 11 O
.	271 1 O

In	273 2 O
recent	276 6 O
years	283 5 O
,	288 1 O
increasing	290 10 O
evidence	301 8 O
has	310 3 O
suggested	314 9 O
that	324 4 O
the	329 3 O
messenger	333 9 O
molecule	343 8 O
nitric	352 6 B-Chemical
oxide	359 5 I-Chemical
(	365 1 O
NO	366 2 B-Chemical
)	368 1 O
is	370 2 O
involved	373 8 O
in	382 2 O
pain	385 4 B-Disease
mechanisms	390 10 O
of	401 2 O
migraine	404 8 B-Disease
without	413 7 I-Disease
aura	421 4 I-Disease
.	425 1 O

In	427 2 O
order	430 5 O
to	436 2 O
clarify	439 7 O
whether	447 7 O
the	455 3 O
same	459 4 O
is	464 2 O
true	467 4 O
for	472 3 O
migraine	476 8 B-Disease
with	485 4 I-Disease
aura	490 4 I-Disease
,	494 1 O
in	496 2 O
the	499 3 O
present	503 7 O
study	511 5 O
we	517 2 O
examined	520 8 O
the	529 3 O
headache	533 8 B-Disease
response	542 8 O
to	551 2 O
intravenous	554 11 O
infusion	566 8 O
of	575 2 O
glyceryl	578 8 B-Chemical
trinitrate	587 10 I-Chemical
(	598 1 O
GTN	599 3 B-Chemical
)	602 1 O
(	604 1 O
0	605 1 O
.	606 1 O
5	607 1 O
microg	609 6 O
/	615 1 O
kg	616 2 O
/	618 1 O
min	619 3 O
for	623 3 O
20	627 2 O
min	630 3 O
)	633 1 O
in	635 2 O
12	638 2 O
sufferers	641 9 O
of	651 2 O
migraine	654 8 B-Disease
with	663 4 I-Disease
aura	668 4 I-Disease
.	672 1 O

The	674 3 O
specific	678 8 O
aim	687 3 O
was	691 3 O
to	695 2 O
elucidate	698 9 O
whether	708 7 O
an	716 2 O
aura	719 4 O
and	724 3 O
/	727 1 O
or	728 2 O
an	731 2 O
attack	734 6 O
of	741 2 O
migraine	744 8 B-Disease
without	753 7 I-Disease
aura	761 4 I-Disease
could	766 5 O
be	772 2 O
induced	775 7 O
.	782 1 O

Fourteen	784 8 O
healthy	793 7 O
subjects	801 8 O
served	810 6 O
as	817 2 O
controls	820 8 O
.	828 1 O

Aura	830 4 O
symptoms	835 8 O
were	844 4 O
not	849 3 O
elicited	853 8 O
in	862 2 O
any	865 3 O
subject	869 7 O
.	876 1 O

Headache	878 8 B-Disease
was	887 3 O
more	891 4 O
severe	896 6 O
in	903 2 O
migraineurs	906 11 B-Disease
than	918 4 O
in	923 2 O
the	926 3 O
controls	930 8 O
during	939 6 O
and	946 3 O
immediately	950 11 O
after	962 5 O
GTN	968 3 B-Chemical
infusion	972 8 O
(	981 1 O
p	982 1 O
=	983 1 O
0	984 1 O
.	985 1 O
037	986 3 O
)	989 1 O
as	991 2 O
well	994 4 O
as	999 2 O
during	1002 6 O
the	1009 3 O
following	1013 9 O
11	1023 2 O
h	1026 1 O
(	1028 1 O
p	1029 1 O
=	1031 1 O
0	1033 1 O
.	1034 1 O
008	1035 3 O
)	1038 1 O
.	1039 1 O

In	1041 2 O
the	1044 3 O
controls	1048 8 O
,	1056 1 O
the	1058 3 O
GTN	1062 3 B-Chemical
-	1065 1 O
induced	1066 7 O
headache	1074 8 B-Disease
gradually	1083 9 O
disappeared	1093 11 O
,	1104 1 O
whereas	1106 7 O
in	1114 2 O
migraineurs	1117 11 B-Disease
peak	1129 4 O
headache	1134 8 B-Disease
intensity	1143 9 O
occurred	1153 8 O
at	1162 2 O
a	1165 1 O
mean	1167 4 O
time	1172 4 O
of	1177 2 O
240	1180 3 O
min	1184 3 O
post	1188 4 O
-	1192 1 O
infusion	1193 8 O
.	1201 1 O

At	1203 2 O
this	1206 4 O
time	1211 4 O
the	1216 3 O
induced	1220 7 O
headache	1228 8 B-Disease
in	1237 2 O
6	1240 1 O
of	1242 2 O
12	1245 2 O
migraineurs	1248 11 B-Disease
fulfilled	1260 9 O
the	1270 3 O
diagnostic	1274 10 O
criteria	1285 8 O
for	1294 3 O
migraine	1298 8 B-Disease
without	1307 7 I-Disease
aura	1315 4 I-Disease
of	1320 2 O
the	1323 3 O
International	1327 13 O
Headache	1341 8 B-Disease
Society	1350 7 O
.	1357 1 O

The	1359 3 O
results	1363 7 O
therefore	1371 9 O
suggest	1381 7 O
that	1389 4 O
NO	1394 2 B-Chemical
is	1397 2 O
involved	1400 8 O
in	1409 2 O
the	1412 3 O
pain	1416 4 B-Disease
mechanisms	1421 10 O
of	1432 2 O
migraine	1435 8 B-Disease
with	1444 4 I-Disease
aura	1449 4 I-Disease
.	1453 1 O

Since	1455 5 O
cortical	1461 8 O
spreading	1470 9 O
depression	1480 10 B-Disease
has	1491 3 O
been	1495 4 O
shown	1500 5 O
to	1506 2 O
liberate	1509 8 O
NO	1518 2 B-Chemical
in	1521 2 O
animals	1524 7 O
,	1531 1 O
this	1533 4 O
finding	1538 7 O
may	1546 3 O
help	1550 4 O
our	1555 3 O
understanding	1559 13 O
of	1573 2 O
the	1576 3 O
coupling	1580 8 O
between	1589 7 O
cortical	1597 8 O
spreading	1606 9 O
depression	1616 10 B-Disease
and	1627 3 O
headache	1631 8 B-Disease
in	1640 2 O
migraine	1643 8 B-Disease
with	1652 4 I-Disease
aura	1657 4 I-Disease
.	1661 1 O

Stroke	0 6 B-Disease
and	7 3 O
cocaine	11 7 B-Chemical
or	19 2 O
amphetamine	22 11 B-Chemical
use	34 3 O
.	37 1 O

The	39 3 O
association	43 11 O
of	55 2 O
cocaine	58 7 B-Chemical
and	66 3 O
amphetamine	70 11 B-Chemical
use	82 3 O
with	86 4 O
hemorrhagic	91 11 O
and	103 3 O
ischemic	107 8 B-Disease
stroke	116 6 B-Disease
is	123 2 O
based	126 5 O
almost	132 6 O
solely	139 6 O
on	146 2 O
data	149 4 O
from	154 4 O
case	159 4 O
series	164 6 O
.	170 1 O

The	172 3 O
limited	176 7 O
number	184 6 O
of	191 2 O
epidemiologic	194 13 O
studies	208 7 O
of	216 2 O
stroke	219 6 B-Disease
and	226 3 O
use	230 3 O
of	234 2 O
cocaine	237 7 B-Chemical
and	245 3 O
/	248 1 O
or	249 2 O
amphetamine	252 11 B-Chemical
have	264 4 O
been	269 4 O
done	274 4 O
in	279 2 O
settings	282 8 O
that	291 4 O
serve	296 5 O
mostly	302 6 O
the	309 3 O
poor	313 4 O
and	318 3 O
/	321 1 O
or	322 2 O
minorities	325 10 O
.	335 1 O

This	337 4 O
case	342 4 O
-	346 1 O
control	347 7 O
study	355 5 O
was	361 3 O
conducted	365 9 O
in	375 2 O
the	378 3 O
defined	382 7 O
population	390 10 O
comprising	401 10 O
members	412 7 O
of	420 2 O
Kaiser	423 6 O
Permanente	430 10 O
of	441 2 O
Northern	444 8 O
and	453 3 O
Southern	457 8 O
California	466 10 O
.	476 1 O

We	478 2 O
attempted	481 9 O
to	491 2 O
identify	494 8 O
all	503 3 O
incident	507 8 O
strokes	516 7 B-Disease
in	524 2 O
women	527 5 O
ages	533 4 O
15	538 2 O
-	540 1 O
44	541 2 O
years	544 5 O
during	550 6 O
a	557 1 O
3	559 1 O
-	560 1 O
year	561 4 O
period	566 6 O
using	573 5 O
hospital	579 8 O
admission	588 9 O
and	598 3 O
discharge	602 9 O
records	612 7 O
,	619 1 O
emergency	621 9 O
department	631 10 O
logs	642 4 O
,	646 1 O
and	648 3 O
payment	652 7 O
requests	660 8 O
for	669 3 O
out	673 3 O
-	676 1 O
of	677 2 O
-	679 1 O
plan	680 4 O
hospitalizations	685 16 O
.	701 1 O

We	703 2 O
selected	706 8 O
controls	715 8 O
,	723 1 O
matched	725 7 O
on	733 2 O
age	736 3 O
and	740 3 O
facility	744 8 O
of	753 2 O
usual	756 5 O
care	762 4 O
,	766 1 O
at	768 2 O
random	771 6 O
from	778 4 O
healthy	783 7 O
members	791 7 O
of	799 2 O
the	802 3 O
health	806 6 O
plan	813 4 O
.	817 1 O

We	819 2 O
obtained	822 8 O
information	831 11 O
in	843 2 O
face	846 4 O
-	850 1 O
to	851 2 O
-	853 1 O
face	854 4 O
interviews	859 10 O
.	869 1 O

There	871 5 O
were	877 4 O
347	882 3 O
confirmed	886 9 O
stroke	896 6 B-Disease
cases	903 5 O
and	909 3 O
1	913 1 O
,	914 1 O
021	915 3 O
controls	919 8 O
.	927 1 O

The	929 3 O
univariate	933 10 O
matched	944 7 O
odds	952 4 O
ratio	957 5 O
for	963 3 O
stroke	967 6 B-Disease
in	974 2 O
women	977 5 O
who	983 3 O
admitted	987 8 O
to	996 2 O
using	999 5 O
cocaine	1005 7 B-Chemical
and	1013 3 O
/	1016 1 O
or	1017 2 O
amphetamine	1020 11 B-Chemical
was	1032 3 O
8	1036 1 O
.	1037 1 O
5	1038 1 O
(	1040 1 O
95	1041 2 O
%	1043 1 O
confidence	1045 10 O
interval	1056 8 O
=	1065 1 O
3	1067 1 O
.	1068 1 O
6	1069 1 O
-	1070 1 O
20	1071 2 O
.	1073 1 O
0	1074 1 O
)	1075 1 O
.	1076 1 O

After	1078 5 O
further	1084 7 O
adjustment	1092 10 O
for	1103 3 O
potential	1107 9 O
confounders	1117 11 O
,	1128 1 O
the	1130 3 O
odds	1134 4 O
ratio	1139 5 O
in	1145 2 O
women	1148 5 O
who	1154 3 O
reported	1158 8 O
using	1167 5 O
cocaine	1173 7 B-Chemical
and	1181 3 O
/	1184 1 O
or	1185 2 O
amphetamine	1188 11 B-Chemical
was	1200 3 O
7	1204 1 O
.	1205 1 O
0	1206 1 O
(	1208 1 O
95	1209 2 O
%	1211 1 O
confidence	1213 10 O
interval	1224 8 O
=	1233 1 O
2	1235 1 O
.	1236 1 O
8	1237 1 O
-	1238 1 O
17	1239 2 O
.	1241 1 O
9	1242 1 O
)	1243 1 O
.	1244 1 O

The	1246 3 O
use	1250 3 O
of	1254 2 O
cocaine	1257 7 B-Chemical
and	1265 3 O
/	1268 1 O
or	1269 2 O
amphetamine	1272 11 B-Chemical
is	1284 2 O
a	1287 1 O
strong	1289 6 O
risk	1296 4 O
factor	1301 6 O
for	1308 3 O
stroke	1312 6 B-Disease
in	1319 2 O
this	1322 4 O
socioeconomically	1327 17 O
heterogeneous	1345 13 O
,	1358 1 O
insured	1360 7 O
urban	1368 5 O
population	1374 10 O
.	1384 1 O

Prevention	0 10 O
of	11 2 O
breast	14 6 B-Disease
cancer	21 6 I-Disease
with	28 4 O
tamoxifen	33 9 B-Chemical
:	42 1 O
preliminary	44 11 O
findings	56 8 O
from	65 4 O
the	70 3 O
Italian	74 7 O
randomised	82 10 O
trial	93 5 O
among	99 5 O
hysterectomised	105 15 O
women	121 5 O
.	126 1 O

Italian	128 7 O
Tamoxifen	136 9 B-Chemical
Prevention	146 10 O
Study	157 5 O
.	162 1 O

BACKGROUND	164 10 O
:	174 1 O
Tamoxifen	176 9 B-Chemical
is	186 2 O
a	189 1 O
candidate	191 9 O
chemopreventive	201 15 O
agent	217 5 O
in	223 2 O
breast	226 6 B-Disease
cancer	233 6 I-Disease
,	239 1 O
although	241 8 O
the	250 3 O
drug	254 4 O
may	259 3 O
be	263 2 O
associated	266 10 O
with	277 4 O
the	282 3 O
development	286 11 O
of	298 2 O
endometrial	301 11 B-Disease
cancer	313 6 I-Disease
.	319 1 O

Therefore	321 9 O
we	331 2 O
did	334 3 O
a	338 1 O
trial	340 5 O
in	346 2 O
hysterectomised	349 15 O
women	365 5 O
of	371 2 O
tamoxifen	374 9 B-Chemical
as	384 2 O
a	387 1 O
chemopreventive	389 15 O
.	404 1 O

METHODS	406 7 O
:	413 1 O
In	415 2 O
October	418 7 O
,	425 1 O
1992	427 4 O
,	431 1 O
we	433 2 O
started	436 7 O
a	444 1 O
double	446 6 O
-	452 1 O
blind	453 5 O
placebo	459 7 O
-	466 1 O
controlled	467 10 O
,	477 1 O
randomised	479 10 O
trial	490 5 O
of	496 2 O
tamoxifen	499 9 B-Chemical
in	509 2 O
women	512 5 O
(	518 1 O
mainly	519 6 O
in	526 2 O
Italy	529 5 O
)	534 1 O
who	536 3 O
did	540 3 O
not	544 3 O
have	548 4 O
breast	553 6 B-Disease
cancer	560 6 I-Disease
and	567 3 O
who	571 3 O
had	575 3 O
had	579 3 O
a	583 1 O
hysterectomy	585 12 O
.	597 1 O

Women	599 5 O
were	605 4 O
randomised	610 10 O
to	621 2 O
receive	624 7 O
tamoxifen	632 9 B-Chemical
20	642 2 O
mg	645 2 O
per	648 3 O
day	652 3 O
or	656 2 O
placebo	659 7 O
,	666 1 O
both	668 4 O
orally	673 6 O
for	680 3 O
5	684 1 O
years	686 5 O
.	691 1 O

The	693 3 O
original	697 8 O
plan	706 4 O
was	711 3 O
to	715 2 O
follow	718 6 O
the	725 3 O
intervention	729 12 O
phase	742 5 O
by	748 2 O
5	751 1 O
years	753 5 O
'	758 1 O
follow	760 6 O
-	766 1 O
up	767 2 O
.	769 1 O

In	771 2 O
June	774 4 O
,	778 1 O
1997	780 4 O
,	784 1 O
the	786 3 O
trialists	790 9 O
and	800 3 O
the	804 3 O
data	808 4 O
-	812 1 O
monitoring	813 10 O
committee	824 9 O
decided	834 7 O
to	842 2 O
end	845 3 O
recruitment	849 11 O
primarily	861 9 O
because	871 7 O
of	879 2 O
the	882 3 O
number	886 6 O
of	893 2 O
women	896 5 O
dropping	902 8 O
out	911 3 O
of	915 2 O
the	918 3 O
study	922 5 O
.	927 1 O

Recruitment	929 11 O
ended	941 5 O
on	947 2 O
July	950 4 O
11	955 2 O
,	957 1 O
1997	959 4 O
,	963 1 O
and	965 3 O
the	969 3 O
study	973 5 O
will	979 4 O
continue	984 8 O
as	993 2 O
planned	996 7 O
.	1003 1 O

The	1005 3 O
primary	1009 7 O
endpoints	1017 9 O
are	1027 3 O
the	1031 3 O
occurrence	1035 10 O
of	1046 2 O
and	1049 3 O
deaths	1053 6 O
from	1060 4 O
breast	1065 6 B-Disease
cancer	1072 6 I-Disease
.	1078 1 O

This	1080 4 O
preliminary	1085 11 O
interim	1097 7 O
analysis	1105 8 O
is	1114 2 O
based	1117 5 O
on	1123 2 O
intention	1126 9 O
-	1135 1 O
to	1136 2 O
-	1138 1 O
treat	1139 5 O
.	1144 1 O

FINDINGS	1146 8 O
:	1154 1 O
5408	1156 4 O
women	1161 5 O
were	1167 4 O
randomised	1172 10 O
;	1182 1 O
participating	1184 13 O
women	1198 5 O
have	1204 4 O
a	1209 1 O
median	1211 6 O
follow	1218 6 O
-	1224 1 O
up	1225 2 O
of	1228 2 O
46	1231 2 O
months	1234 6 O
for	1241 3 O
major	1245 5 O
endpoints	1251 9 O
.	1260 1 O

41	1262 2 O
cases	1265 5 O
of	1271 2 O
breast	1274 6 B-Disease
cancer	1281 6 I-Disease
occurred	1288 8 O
so	1297 2 O
far	1300 3 O
;	1303 1 O
there	1305 5 O
have	1311 4 O
been	1316 4 O
no	1321 2 O
deaths	1324 6 O
from	1331 4 O
breast	1336 6 B-Disease
cancer	1343 6 I-Disease
.	1349 1 O

There	1351 5 O
is	1357 2 O
no	1360 2 O
difference	1363 10 O
in	1374 2 O
breast	1377 6 B-Disease
-	1383 1 I-Disease
cancer	1384 6 I-Disease
frequency	1391 9 O
between	1401 7 O
the	1409 3 O
placebo	1413 7 O
(	1421 1 O
22	1422 2 O
cases	1425 5 O
)	1430 1 O
and	1432 3 O
tamoxifen	1436 9 B-Chemical
(	1446 1 O
19	1447 2 O
)	1449 1 O
arms	1451 4 O
.	1455 1 O

There	1457 5 O
is	1463 2 O
a	1466 1 O
statistically	1468 13 O
significant	1482 11 O
reduction	1494 9 O
of	1504 2 O
breast	1507 6 B-Disease
cancer	1514 6 I-Disease
among	1521 5 O
women	1527 5 O
receiving	1533 9 O
tamoxifen	1543 9 B-Chemical
who	1553 3 O
also	1557 4 O
used	1562 4 O
hormone	1567 7 O
-	1574 1 O
replacement	1575 11 O
therapy	1587 7 O
during	1595 6 O
the	1602 3 O
trial	1606 5 O
:	1611 1 O
among	1613 5 O
390	1619 3 O
women	1623 5 O
on	1629 2 O
such	1632 4 O
therapy	1637 7 O
and	1645 3 O
allocated	1649 9 O
to	1659 2 O
placebo	1662 7 O
,	1669 1 O
we	1671 2 O
found	1674 5 O
eight	1680 5 O
cases	1686 5 O
of	1692 2 O
breast	1695 6 B-Disease
cancer	1702 6 I-Disease
compared	1709 8 O
with	1718 4 O
one	1723 3 O
case	1727 4 O
among	1732 5 O
362	1738 3 O
women	1742 5 O
allocated	1748 9 O
to	1758 2 O
tamoxifen	1761 9 B-Chemical
.	1770 1 O

Compared	1772 8 O
with	1781 4 O
the	1786 3 O
placebo	1790 7 O
group	1798 5 O
,	1803 1 O
there	1805 5 O
was	1811 3 O
a	1815 1 O
significantly	1817 13 O
increased	1831 9 O
risk	1841 4 O
of	1846 2 O
vascular	1849 8 B-Disease
events	1858 6 I-Disease
and	1865 3 O
hypertriglyceridaemia	1869 21 B-Disease
among	1891 5 O
women	1897 5 O
on	1903 2 O
tamoxifen	1906 9 B-Chemical
.	1915 1 O

INTERPRETATION	1917 14 O
:	1931 1 O
Although	1933 8 O
this	1942 4 O
preliminary	1947 11 O
analysis	1959 8 O
has	1968 3 O
low	1972 3 O
power	1976 5 O
,	1981 1 O
in	1983 2 O
this	1986 4 O
cohort	1991 6 O
of	1998 2 O
women	2001 5 O
at	2007 2 O
low	2010 3 O
-	2013 1 O
to	2014 2 O
-	2016 1 O
normal	2017 6 O
risk	2024 4 O
of	2029 2 O
breast	2032 6 B-Disease
cancer	2039 6 I-Disease
,	2045 1 O
the	2047 3 O
postulated	2051 10 O
protective	2062 10 O
effects	2073 7 O
of	2081 2 O
tamoxifen	2084 9 B-Chemical
are	2094 3 O
not	2098 3 O
yet	2102 3 O
apparent	2106 8 O
.	2114 1 O

Women	2116 5 O
using	2122 5 O
hormone	2128 7 O
-	2135 1 O
replacement	2136 11 O
therapy	2148 7 O
appear	2156 6 O
to	2163 2 O
have	2166 4 O
benefited	2171 9 O
from	2181 4 O
use	2186 3 O
of	2190 2 O
tamoxifen	2193 9 B-Chemical
.	2202 1 O

There	2204 5 O
were	2210 4 O
no	2215 2 O
deaths	2218 6 O
from	2225 4 O
breast	2230 6 B-Disease
cancer	2237 6 I-Disease
recorded	2244 8 O
in	2253 2 O
women	2256 5 O
in	2262 2 O
the	2265 3 O
study	2269 5 O
.	2274 1 O

It	2276 2 O
is	2279 2 O
essential	2282 9 O
to	2292 2 O
continue	2295 8 O
follow	2304 6 O
-	2310 1 O
up	2311 2 O
to	2314 2 O
quantify	2317 8 O
the	2326 3 O
long	2330 4 O
-	2334 1 O
term	2335 4 O
risks	2340 5 O
and	2346 3 O
benefits	2350 8 O
of	2359 2 O
tamoxifen	2362 9 B-Chemical
therapy	2372 7 O
.	2379 1 O

A	0 1 O
measure	2 7 O
of	10 2 O
pupillary	13 9 B-Disease
oscillation	23 11 I-Disease
as	35 2 O
a	38 1 O
marker	40 6 O
of	47 2 O
cocaine	50 7 B-Chemical
-	57 1 O
induced	58 7 O
paranoia	66 8 B-Disease
.	74 1 O

Cocaine	76 7 B-Chemical
-	83 1 O
induced	84 7 O
paranoia	92 8 B-Disease
(	101 1 O
CIP	102 3 B-Disease
)	105 1 O
remains	107 7 O
an	115 2 O
important	118 9 O
drug	128 4 O
-	132 1 O
induced	133 7 O
model	141 5 O
of	147 2 O
idiopathic	150 10 O
paranoia	161 8 B-Disease
for	170 3 O
which	174 5 O
no	180 2 O
psychophysiologic	183 17 O
marker	201 6 O
has	208 3 O
yet	212 3 O
emerged	216 7 O
.	223 1 O

Measures	225 8 O
of	234 2 O
pupillary	237 9 B-Disease
oscillation	247 11 I-Disease
were	259 4 O
able	264 4 O
to	269 2 O
significantly	272 13 O
distinguish	286 11 O
a	298 1 O
group	300 5 O
of	306 2 O
abstinent	309 9 O
crack	319 5 B-Chemical
cocaine	325 7 I-Chemical
abusers	333 7 O
endorsing	341 9 O
past	351 4 O
CIP	356 3 B-Disease
(	360 1 O
n	361 1 O
=	363 1 O
32	365 2 O
)	367 1 O
from	369 4 O
another	374 7 O
group	382 5 O
of	388 2 O
crack	391 5 B-Chemical
addicts	397 7 O
who	405 3 O
denied	409 6 O
past	416 4 O
CIP	421 3 B-Disease
(	425 1 O
n	426 1 O
=	428 1 O
29	430 2 O
)	432 1 O
.	433 1 O

Seizures	0 8 B-Disease
induced	9 7 O
by	17 2 O
combined	20 8 O
levomepromazine	29 15 B-Chemical
-	44 1 O
fluvoxamine	45 11 B-Chemical
treatment	57 9 O
.	66 1 O

We	68 2 O
report	71 6 O
a	78 1 O
case	80 4 O
of	85 2 O
combined	88 8 O
levomepromazine	97 15 B-Chemical
-	112 1 O
fluvoxamine	113 11 B-Chemical
treatment	125 9 O
-	134 1 O
induced	135 7 O
seizures	143 8 B-Disease
.	151 1 O

It	153 2 O
seems	156 5 O
that	162 4 O
combined	167 8 O
treatment	176 9 O
of	186 2 O
fluvoxamine	189 11 B-Chemical
with	201 4 O
phenothiazines	206 14 B-Chemical
may	221 3 O
possess	225 7 O
proconvulsive	233 13 O
activity	247 8 O
.	255 1 O

Why	0 3 O
may	4 3 O
epsilon	8 7 B-Chemical
-	15 1 I-Chemical
aminocaproic	16 12 I-Chemical
acid	29 4 I-Chemical
(	34 1 O
EACA	35 4 B-Chemical
)	39 1 O
induce	41 6 O
myopathy	48 8 B-Disease
in	57 2 O
man	60 3 O
?	63 1 O

Report	65 6 O
of	72 2 O
a	75 1 O
case	77 4 O
and	82 3 O
literature	86 10 O
review	97 6 O
.	103 1 O

A	105 1 O
case	107 4 O
of	112 2 O
necrotizing	115 11 B-Disease
myopathy	127 8 I-Disease
due	136 3 O
to	140 2 O
a	143 1 O
short	145 5 O
epsilon	151 7 B-Chemical
-	158 1 I-Chemical
aminocaproic	159 12 I-Chemical
acid	172 4 I-Chemical
(	177 1 O
EACA	178 4 B-Chemical
)	182 1 O
treatment	184 9 O
in	194 2 O
a	197 1 O
72	199 2 O
year	202 4 O
-	206 1 O
old	207 3 O
patient	211 7 O
with	219 4 O
subarachnoid	224 12 B-Disease
haemorrhage	237 11 I-Disease
(	249 1 O
SAH	250 3 B-Disease
)	253 1 O
is	255 2 O
described	258 9 O
.	267 1 O

Pathogenetic	269 12 O
hypotheses	282 10 O
are	293 3 O
discussed	297 9 O
.	306 1 O

Comparison	0 10 O
of	11 2 O
the	14 3 O
effectiveness	18 13 O
of	32 2 O
ranitidine	35 10 B-Chemical
and	46 3 O
cimetidine	50 10 B-Chemical
in	61 2 O
inhibiting	64 10 O
acid	75 4 O
secretion	80 9 O
in	90 2 O
patients	93 8 O
with	102 4 O
gastric	107 7 O
hypersecretory	115 14 O
states	130 6 O
.	136 1 O

The	138 3 O
H2	142 2 O
-	144 1 O
histamine	145 9 B-Chemical
receptor	155 8 O
antagonists	164 11 O
ranitidine	176 10 B-Chemical
and	187 3 O
cimetidine	191 10 B-Chemical
were	202 4 O
compared	207 8 O
for	216 3 O
their	220 5 O
abilities	226 9 O
to	236 2 O
control	239 7 O
gastric	247 7 O
acid	255 4 O
hypersecretion	260 14 O
on	275 2 O
a	278 1 O
short	280 5 O
-	285 1 O
and	287 3 O
long	291 4 O
-	295 1 O
term	296 4 O
basis	301 5 O
in	307 2 O
22	310 2 O
patients	313 8 O
with	322 4 O
gastric	327 7 O
acid	335 4 O
hypersecretory	340 14 O
states	355 6 O
.	361 1 O

Nineteen	363 8 O
patients	372 8 O
had	381 3 O
Zollinger	385 9 B-Disease
-	394 1 I-Disease
Ellison	395 7 I-Disease
syndrome	403 8 I-Disease
,	411 1 O
one	413 3 O
patient	417 7 O
had	425 3 O
systemic	429 8 B-Disease
mastocytosis	438 12 I-Disease
,	450 1 O
and	452 3 O
two	456 3 O
patients	460 8 O
had	469 3 O
idiopathic	473 10 O
hypersecretion	484 14 O
.	498 1 O

The	500 3 O
rates	504 5 O
of	510 2 O
onset	513 5 O
of	519 2 O
the	522 3 O
action	526 6 O
of	533 2 O
cimetidine	536 10 B-Chemical
and	547 3 O
ranitidine	551 10 B-Chemical
were	562 4 O
the	567 3 O
same	571 4 O
.	575 1 O

The	577 3 O
actions	581 7 O
of	589 2 O
both	592 4 O
drugs	597 5 O
were	603 4 O
increased	608 9 O
by	618 2 O
anticholinergic	621 15 O
agents	637 6 O
,	643 1 O
and	645 3 O
there	649 5 O
was	655 3 O
a	659 1 O
close	661 5 O
correlation	667 11 O
between	679 7 O
the	687 3 O
daily	691 5 O
maintenance	697 11 O
dose	709 4 O
of	714 2 O
each	717 4 O
drug	722 4 O
needed	727 6 O
to	734 2 O
control	737 7 O
acid	745 4 O
secretion	750 9 O
.	759 1 O

However	761 7 O
,	768 1 O
ranitidine	770 10 B-Chemical
was	781 3 O
threefold	785 9 O
more	795 4 O
potent	800 6 O
than	807 4 O
cimetidine	812 10 B-Chemical
both	823 4 O
in	828 2 O
acute	831 5 O
inhibition	837 10 O
studies	848 7 O
and	856 3 O
in	860 2 O
the	863 3 O
median	867 6 O
maintenance	874 11 O
dose	886 4 O
needed	891 6 O
(	898 1 O
1	899 1 O
.	900 1 O
2	901 1 O
g	903 1 O
per	905 3 O
day	909 3 O
for	913 3 O
ranitidine	917 10 B-Chemical
and	928 3 O
3	932 1 O
.	933 1 O
6	934 1 O
g	936 1 O
per	938 3 O
day	942 3 O
for	946 3 O
cimetidine	950 10 B-Chemical
)	960 1 O
.	961 1 O

Sixty	963 5 O
percent	969 7 O
of	977 2 O
the	980 3 O
males	984 5 O
developed	990 9 O
breast	1000 6 O
changes	1007 7 O
or	1015 2 O
impotence	1018 9 B-Disease
while	1028 5 O
taking	1034 6 O
cimetidine	1041 10 B-Chemical
and	1052 3 O
in	1056 2 O
all	1059 3 O
cases	1063 5 O
these	1069 5 O
changes	1075 7 O
disappeared	1083 11 O
when	1095 4 O
cimetidine	1100 10 B-Chemical
was	1111 3 O
replaced	1115 8 O
by	1124 2 O
ranitidine	1127 10 B-Chemical
.	1137 1 O

Treatment	1139 9 O
with	1149 4 O
high	1154 4 O
doses	1159 5 O
of	1165 2 O
cimetidine	1168 10 B-Chemical
(	1179 1 O
one	1180 3 O
to	1184 2 O
60	1187 2 O
months	1190 6 O
;	1196 1 O
median	1198 6 O
,	1204 1 O
11	1206 2 O
months	1209 6 O
)	1215 1 O
or	1217 2 O
ranitidine	1220 10 B-Chemical
(	1231 1 O
two	1232 3 O
to	1236 2 O
31	1239 2 O
months	1242 6 O
;	1248 1 O
median	1250 6 O
,	1256 1 O
14	1258 2 O
months	1261 6 O
)	1267 1 O
was	1269 3 O
not	1273 3 O
associated	1277 10 O
with	1288 4 O
hepatic	1293 7 B-Disease
or	1301 2 I-Disease
hematologic	1304 11 I-Disease
toxicity	1316 8 I-Disease
or	1325 2 O
alterations	1328 11 O
of	1340 2 O
serum	1343 5 O
gastrin	1349 7 O
concentrations	1357 14 O
,	1371 1 O
but	1373 3 O
ranitidine	1377 10 B-Chemical
therapy	1388 7 O
was	1396 3 O
associated	1400 10 O
with	1411 4 O
a	1416 1 O
significantly	1418 13 O
lower	1432 5 O
serum	1438 5 O
creatinine	1444 10 B-Chemical
level	1455 5 O
than	1461 4 O
seen	1466 4 O
with	1471 4 O
cimetidine	1476 10 B-Chemical
therapy	1487 7 O
.	1494 1 O

The	1496 3 O
results	1500 7 O
show	1508 4 O
that	1513 4 O
both	1518 4 O
drugs	1523 5 O
can	1529 3 O
adequately	1533 10 O
inhibit	1544 7 O
acid	1552 4 O
secretion	1557 9 O
in	1567 2 O
patients	1570 8 O
with	1579 4 O
gastric	1584 7 O
hypersecretory	1592 14 O
states	1607 6 O
.	1613 1 O

Both	1615 4 O
are	1620 3 O
safe	1624 4 O
at	1629 2 O
high	1632 4 O
doses	1637 5 O
,	1642 1 O
but	1644 3 O
ranitidine	1648 10 B-Chemical
is	1659 2 O
threefold	1662 9 O
more	1672 4 O
potent	1677 6 O
and	1684 3 O
does	1688 4 O
not	1693 3 O
cause	1697 5 O
the	1703 3 O
antiandrogen	1707 12 O
side	1720 4 O
effects	1725 7 O
frequently	1733 10 O
seen	1744 4 O
with	1749 4 O
high	1754 4 O
doses	1759 5 O
of	1765 2 O
cimetidine	1768 10 B-Chemical
.	1778 1 O

A	0 1 O
catch	2 5 O
in	8 2 O
the	11 3 O
Reye	15 4 B-Disease
.	19 1 O

Twenty	21 6 O
-	27 1 O
six	28 3 O
cases	32 5 O
of	38 2 O
Reye	41 4 B-Disease
syndrome	46 8 I-Disease
from	55 4 O
The	60 3 O
Children	64 8 O
'	72 1 O
s	73 1 O
Hospital	75 8 O
,	83 1 O
Camperdown	85 10 O
,	95 1 O
Australia	97 9 O
,	106 1 O
occurring	108 9 O
between	118 7 O
1973	126 4 O
and	131 3 O
1982	135 4 O
were	140 4 O
reviewed	145 8 O
.	153 1 O

Of	155 2 O
these	158 5 O
,	163 1 O
20	165 2 O
cases	168 5 O
met	174 3 O
the	178 3 O
US	182 2 O
Public	185 6 O
Health	192 6 O
Service	199 7 O
Centers	207 7 O
for	215 3 O
Disease	219 7 O
Control	227 7 O
criteria	235 8 O
for	244 3 O
the	248 3 O
diagnosis	252 9 O
of	262 2 O
Reye	265 4 B-Disease
syndrome	270 8 I-Disease
.	278 1 O

Aspirin	280 7 B-Chemical
or	288 2 O
salicylate	291 10 B-Chemical
ingestion	302 9 O
had	312 3 O
occurred	316 8 O
in	325 2 O
only	328 4 O
one	333 3 O
of	337 2 O
the	340 3 O
20	344 2 O
cases	347 5 O
(	353 1 O
5	354 1 O
%	355 1 O
)	356 1 O
,	357 1 O
and	359 3 O
paracetamol	363 11 B-Chemical
(	375 1 O
acetaminophen	376 13 B-Chemical
)	389 1 O
had	391 3 O
been	395 4 O
administered	400 12 O
in	413 2 O
only	416 4 O
six	421 3 O
of	425 2 O
the	428 3 O
cases	432 5 O
(	438 1 O
30	439 2 O
%	441 1 O
)	442 1 O
.	443 1 O

Pathologic	445 10 O
confirmation	456 12 O
of	469 2 O
the	472 3 O
diagnosis	476 9 O
of	486 2 O
Reye	489 4 B-Disease
syndrome	494 8 I-Disease
was	503 3 O
accomplished	507 12 O
in	520 2 O
90	523 2 O
%	525 1 O
of	527 2 O
the	530 3 O
cases	534 5 O
.	539 1 O

The	541 3 O
incidence	545 9 O
of	555 2 O
Reye	558 4 B-Disease
syndrome	563 8 I-Disease
in	572 2 O
New	575 3 O
South	579 5 O
Wales	585 5 O
,	590 1 O
Australia	592 9 O
,	601 1 O
is	603 2 O
estimated	606 9 O
from	616 4 O
this	621 4 O
study	626 5 O
to	632 2 O
be	635 2 O
approximately	638 13 O
nine	652 4 O
cases	657 5 O
per	663 3 O
1	667 1 O
million	669 7 O
children	677 8 O
compared	686 8 O
with	695 4 O
recent	700 6 O
US	707 2 O
data	710 4 O
of	715 2 O
ten	718 3 O
to	722 2 O
20	725 2 O
cases	728 5 O
per	734 3 O
1	738 1 O
million	740 7 O
children	748 8 O
and	757 3 O
three	761 5 O
to	767 2 O
seven	770 5 O
cases	776 5 O
per	782 3 O
1	786 1 O
million	788 7 O
children	796 8 O
in	805 2 O
Great	808 5 O
Britain	814 7 O
.	821 1 O

The	823 3 O
mortality	827 9 O
for	837 3 O
these	841 5 O
Reye	847 4 B-Disease
syndrome	852 8 I-Disease
cases	861 5 O
in	867 2 O
Australia	870 9 O
was	880 3 O
45	884 2 O
%	886 1 O
as	888 2 O
compared	891 8 O
with	900 4 O
a	905 1 O
32	907 2 O
%	909 1 O
case	911 4 O
-	915 1 O
fatality	916 8 O
rate	925 4 O
in	930 2 O
the	933 3 O
United	937 6 O
States	944 6 O
.	950 1 O

In	952 2 O
Australia	955 9 O
,	964 1 O
the	966 3 O
pediatric	970 9 O
usage	980 5 O
of	986 2 O
aspirin	989 7 B-Chemical
has	997 3 O
been	1001 4 O
extremely	1006 9 O
low	1016 3 O
for	1020 3 O
the	1024 3 O
past	1028 4 O
25	1033 2 O
years	1036 5 O
(	1042 1 O
less	1043 4 O
than	1048 4 O
1	1053 1 O
%	1054 1 O
of	1056 2 O
total	1059 5 O
dosage	1065 6 O
units	1072 5 O
sold	1078 4 O
)	1082 1 O
,	1083 1 O
with	1085 4 O
paracetamol	1090 11 B-Chemical
(	1102 1 O
acetaminophen	1103 13 B-Chemical
)	1116 1 O
dominating	1118 10 O
the	1129 3 O
pediatric	1133 9 O
analgesic	1143 9 O
and	1153 3 O
antipyretic	1157 11 O
market	1169 6 O
.	1175 1 O

Reye	1177 4 B-Disease
syndrome	1182 8 I-Disease
may	1191 3 O
be	1195 2 O
disappearing	1198 12 O
from	1211 4 O
Australia	1216 9 O
despite	1226 7 O
a	1234 1 O
total	1236 5 O
lack	1242 4 O
of	1247 2 O
association	1250 11 O
with	1262 4 O
salicylates	1267 11 B-Chemical
or	1279 2 O
aspirin	1282 7 B-Chemical
ingestion	1290 9 O
,	1299 1 O
since	1301 5 O
there	1307 5 O
were	1313 4 O
no	1318 2 O
cases	1321 5 O
found	1327 5 O
at	1333 2 O
The	1336 3 O
Children	1340 8 O
'	1348 1 O
s	1349 1 O
Hospital	1351 8 O
in	1360 2 O
1983	1363 4 O
,	1367 1 O
1984	1369 4 O
,	1373 1 O
or	1375 2 O
1985	1378 4 O
.	1382 1 O

St	0 2 B-Disease
.	2 1 I-Disease

Anthony	4 7 I-Disease
'	11 1 I-Disease
s	12 1 I-Disease
fire	14 4 I-Disease
,	18 1 O
then	20 4 O
and	25 3 O
now	29 3 O
:	32 1 O
a	34 1 O
case	36 4 O
report	41 6 O
and	48 3 O
historical	52 10 O
review	63 6 O
.	69 1 O

A	71 1 O
rare	73 4 O
case	78 4 O
of	83 2 O
morbid	86 6 O
vasospasm	93 9 B-Disease
,	102 1 O
together	104 8 O
with	113 4 O
striking	118 8 O
angiographic	127 12 O
findings	140 8 O
,	148 1 O
is	150 2 O
described	153 9 O
secondary	163 9 O
to	173 2 O
the	176 3 O
ingestion	180 9 O
of	190 2 O
methysergide	193 12 B-Chemical
by	206 2 O
a	209 1 O
48	211 2 O
-	213 1 O
year	214 4 O
-	218 1 O
old	219 3 O
woman	223 5 O
.	228 1 O

A	230 1 O
brief	232 5 O
review	238 6 O
of	245 2 O
the	248 3 O
literature	252 10 O
on	263 2 O
similar	266 7 O
cases	274 5 O
is	280 2 O
presented	283 9 O
.	292 1 O

A	294 1 O
discussion	296 10 O
of	307 2 O
the	310 3 O
history	314 7 O
of	322 2 O
ergot	325 5 B-Chemical
includes	331 8 O
its	340 3 O
original	344 8 O
discovery	353 9 O
,	362 1 O
the	364 3 O
epidemics	368 9 O
of	378 2 O
gangrene	381 8 B-Disease
that	390 4 O
it	395 2 O
has	398 3 O
caused	402 6 O
through	409 7 O
the	417 3 O
ages	421 4 O
and	426 3 O
its	430 3 O
past	434 4 O
and	439 3 O
present	443 7 O
role	451 4 O
in	456 2 O
the	459 3 O
management	463 10 O
of	474 2 O
migraine	477 8 B-Disease
headache	486 8 I-Disease
.	494 1 O

Despite	496 7 O
the	504 3 O
advent	508 6 O
of	515 2 O
calcium	518 7 B-Chemical
channel	526 7 O
blockers	534 8 O
and	543 3 O
beta	547 4 O
-	551 1 O
adrenergic	552 10 O
antagonists	563 11 O
,	574 1 O
ergot	576 5 B-Chemical
preparations	582 12 O
continue	595 8 O
to	604 2 O
play	607 4 O
a	612 1 O
major	614 5 O
role	620 4 O
in	625 2 O
migraine	628 8 B-Disease
therapy	637 7 O
,	644 1 O
so	646 2 O
that	649 4 O
the	654 3 O
danger	658 6 O
of	665 2 O
St	668 2 B-Disease
.	670 1 I-Disease

Anthony	672 7 I-Disease
'	679 1 I-Disease
s	680 1 I-Disease
fire	682 4 I-Disease
persists	687 8 O
.	695 1 O

Beta	0 4 O
-	4 1 O
2	5 1 O
-	6 1 O
adrenoceptor	7 12 O
-	19 1 O
mediated	20 8 O
hypokalemia	29 11 B-Disease
and	41 3 O
its	45 3 O
abolishment	49 11 O
by	61 2 O
oxprenolol	64 10 B-Chemical
.	74 1 O

The	76 3 O
time	80 4 O
course	85 6 O
and	92 3 O
concentration	96 13 O
-	109 1 O
effect	110 6 O
relationship	117 12 O
of	130 2 O
terbutaline	133 11 B-Chemical
-	144 1 O
induced	145 7 O
hypokalemia	153 11 B-Disease
was	165 3 O
studied	169 7 O
,	176 1 O
using	178 5 O
computer	184 8 O
-	192 1 O
aided	193 5 O
pharmacokinetic	199 15 O
-	214 1 O
dynamic	215 7 O
modeling	223 8 O
.	231 1 O

Subsequently	233 12 O
we	246 2 O
investigated	249 12 O
the	262 3 O
efficacy	266 8 O
of	275 2 O
oxprenolol	278 10 B-Chemical
in	289 2 O
antagonizing	292 12 O
such	305 4 O
hypokalemia	310 11 B-Disease
,	321 1 O
together	323 8 O
with	332 4 O
the	337 3 O
pharmacokinetic	341 15 O
interaction	357 11 O
between	369 7 O
both	377 4 O
drugs	382 5 O
.	387 1 O

Six	389 3 O
healthy	393 7 O
subjects	401 8 O
were	410 4 O
given	415 5 O
a	421 1 O
0	423 1 O
.	424 1 O
5	425 1 O
mg	427 2 O
subcutaneous	430 12 O
dose	443 4 O
of	448 2 O
terbutaline	451 11 B-Chemical
on	463 2 O
two	466 3 O
occasions	470 9 O
:	479 1 O
1	481 1 O
hour	483 4 O
after	488 5 O
oral	494 4 O
administration	499 14 O
of	514 2 O
a	517 1 O
placebo	519 7 O
and	527 3 O
1	531 1 O
hour	533 4 O
after	538 5 O
80	544 2 O
mg	547 2 O
oxprenolol	550 10 B-Chemical
orally	561 6 O
.	567 1 O

In	569 2 O
the	572 3 O
7	576 1 O
-	577 1 O
hour	578 4 O
period	583 6 O
after	590 5 O
terbutaline	596 11 B-Chemical
administration	608 14 O
,	622 1 O
plasma	624 6 O
samples	631 7 O
were	639 4 O
taken	644 5 O
for	650 3 O
determination	654 13 O
of	668 2 O
plasma	671 6 O
potassium	678 9 B-Chemical
levels	688 6 O
and	695 3 O
drug	699 4 O
concentrations	704 14 O
.	718 1 O

The	720 3 O
sigmoid	724 7 O
Emax	732 4 O
model	737 5 O
offered	743 7 O
a	751 1 O
good	753 4 O
description	758 11 O
of	770 2 O
the	773 3 O
relation	777 8 O
between	786 7 O
terbutaline	794 11 B-Chemical
concentrations	806 14 O
and	821 3 O
potassium	825 9 B-Chemical
effects	835 7 O
.	842 1 O

Oxprenolol	844 10 B-Chemical
caused	855 6 O
decreases	862 9 O
of	872 2 O
65	875 2 O
%	877 1 O
and	879 3 O
56	883 2 O
%	885 1 O
of	887 2 O
terbutaline	890 11 B-Chemical
volume	902 6 O
of	909 2 O
distribution	912 12 O
and	925 3 O
clearance	929 9 O
,	938 1 O
respectively	940 12 O
,	952 1 O
and	954 3 O
an	958 2 O
increase	961 8 O
of	970 2 O
130	973 3 O
%	976 1 O
of	978 2 O
its	981 3 O
AUC	985 3 O
.	988 1 O

In	990 2 O
spite	993 5 O
of	999 2 O
higher	1002 6 O
terbutaline	1009 11 B-Chemical
concentrations	1021 14 O
after	1036 5 O
oxprenolol	1042 10 B-Chemical
pretreatment	1053 12 O
,	1065 1 O
the	1067 3 O
hypokalemia	1071 11 B-Disease
was	1083 3 O
almost	1087 6 O
completely	1094 10 O
antagonized	1105 11 O
by	1117 2 O
the	1120 3 O
beta	1124 4 O
2	1129 1 O
-	1130 1 O
blocking	1131 8 O
action	1140 6 O
.	1146 1 O

Midline	0 7 O
B3	8 2 O
serotonin	11 9 B-Chemical
nerves	21 6 O
in	28 2 O
rat	31 3 O
medulla	35 7 O
are	43 3 O
involved	47 8 O
in	56 2 O
hypotensive	59 11 B-Disease
effect	71 6 O
of	78 2 O
methyldopa	81 10 B-Chemical
.	91 1 O

Previous	93 8 O
experiments	102 11 O
in	114 2 O
this	117 4 O
laboratory	122 10 O
have	133 4 O
shown	138 5 O
that	144 4 O
microinjection	149 14 O
of	164 2 O
methyldopa	167 10 B-Chemical
onto	178 4 O
the	183 3 O
ventrolateral	187 13 O
cells	201 5 O
of	207 2 O
the	210 3 O
B3	214 2 O
serotonin	217 9 B-Chemical
neurons	227 7 O
in	235 2 O
the	238 3 O
medulla	242 7 O
elicits	250 7 O
a	258 1 O
hypotensive	260 11 B-Disease
response	272 8 O
mediated	281 8 O
by	290 2 O
a	293 1 O
projection	295 10 O
descending	306 10 O
into	317 4 O
the	322 3 O
spinal	326 6 O
cord	333 4 O
.	337 1 O

The	339 3 O
present	343 7 O
experiments	351 11 O
were	363 4 O
designed	368 8 O
to	377 2 O
investigate	380 11 O
the	392 3 O
role	396 4 O
of	401 2 O
the	404 3 O
midline	408 7 O
cells	416 5 O
of	422 2 O
the	425 3 O
B3	429 2 O
serotonin	432 9 B-Chemical
neurons	442 7 O
in	450 2 O
the	453 3 O
medulla	457 7 O
,	464 1 O
coinciding	466 10 O
with	477 4 O
the	482 3 O
raphe	486 5 O
magnus	492 6 O
.	498 1 O

In	500 2 O
spontaneously	503 13 O
hypertensive	517 12 B-Disease
,	529 1 O
stroke	531 6 B-Disease
-	537 1 O
prone	538 5 O
rats	544 4 O
,	548 1 O
microinjection	550 14 O
of	565 2 O
methyldopa	568 10 B-Chemical
into	579 4 O
the	584 3 O
area	588 4 O
of	593 2 O
the	596 3 O
midline	600 7 O
B3	608 2 O
serotonin	611 9 B-Chemical
cell	621 4 O
group	626 5 O
in	632 2 O
the	635 3 O
ventral	639 7 O
medulla	647 7 O
caused	655 6 O
a	662 1 O
potent	664 6 O
hypotension	671 11 B-Disease
of	683 2 O
30	686 2 O
-	688 1 O
40	689 2 O
mm	692 2 O
Hg	695 2 O
,	697 1 O
which	699 5 O
was	705 3 O
maximal	709 7 O
2	717 1 O
-	718 1 O
3	719 1 O
h	721 1 O
after	723 5 O
administration	729 14 O
and	744 3 O
was	748 3 O
abolished	752 9 O
by	762 2 O
the	765 3 O
serotonin	769 9 B-Chemical
neurotoxin	779 10 O
5	790 1 B-Chemical
,	791 1 I-Chemical
7	792 1 I-Chemical
-	793 1 I-Chemical
dihydroxytryptamine	794 19 I-Chemical
(	814 1 O
5	815 1 B-Chemical
,	816 1 I-Chemical
7	817 1 I-Chemical
-	818 1 I-Chemical
DHT	819 3 I-Chemical
)	822 1 O
injected	824 8 O
intracerebroventricularly	833 25 O
.	858 1 O

However	860 7 O
,	867 1 O
intraspinal	869 11 O
injection	881 9 O
of	891 2 O
5	894 1 B-Chemical
,	895 1 I-Chemical
7	896 1 I-Chemical
-	897 1 I-Chemical
DHT	898 3 I-Chemical
to	902 2 O
produce	905 7 O
a	913 1 O
more	915 4 O
selective	920 9 O
lesion	930 6 O
of	937 2 O
only	940 4 O
descending	945 10 O
serotonin	956 9 B-Chemical
projections	966 11 O
in	978 2 O
the	981 3 O
spinal	985 6 O
cord	992 4 O
did	997 3 O
not	1001 3 O
affect	1005 6 O
this	1012 4 O
hypotension	1017 11 B-Disease
.	1028 1 O

Further	1030 7 O
,	1037 1 O
5	1039 1 B-Chemical
,	1040 1 I-Chemical
7	1041 1 I-Chemical
-	1042 1 I-Chemical
DHT	1043 3 I-Chemical
lesion	1047 6 O
of	1054 2 O
serotonin	1057 9 B-Chemical
nerves	1067 6 O
travelling	1074 10 O
in	1085 2 O
the	1088 3 O
median	1092 6 O
forebrain	1099 9 O
bundle	1109 6 O
,	1115 1 O
one	1117 3 O
of	1121 2 O
the	1124 3 O
main	1128 4 O
ascending	1133 9 O
pathways	1143 8 O
from	1152 4 O
the	1157 3 O
B3	1161 2 O
serotonin	1164 9 B-Chemical
cells	1174 5 O
,	1179 1 O
did	1181 3 O
not	1185 3 O
affect	1189 6 O
the	1196 3 O
fall	1200 4 O
in	1205 2 O
blood	1208 5 O
pressure	1214 8 O
associated	1223 10 O
with	1234 4 O
a	1239 1 O
midline	1241 7 O
B3	1249 2 O
serotonin	1252 9 B-Chemical
methyldopa	1262 10 B-Chemical
injection	1273 9 O
.	1282 1 O

It	1284 2 O
is	1287 2 O
concluded	1290 9 O
therefore	1300 9 O
that	1310 4 O
,	1314 1 O
unlike	1316 6 O
the	1323 3 O
ventrolateral	1327 13 O
B3	1341 2 O
cells	1344 5 O
which	1350 5 O
mediate	1356 7 O
a	1364 1 O
methyldopa	1366 10 B-Chemical
-	1376 1 O
induced	1377 7 O
hypotension	1385 11 B-Disease
via	1397 3 O
descending	1401 10 O
projections	1412 11 O
,	1423 1 O
the	1425 3 O
midline	1429 7 O
serotonin	1437 9 B-Chemical
B3	1447 2 O
cells	1450 5 O
in	1456 2 O
the	1459 3 O
medulla	1463 7 O
contribute	1471 10 O
to	1482 2 O
the	1485 3 O
hypotensive	1489 11 B-Disease
action	1501 6 O
of	1508 2 O
methyldopa	1511 10 B-Chemical
,	1521 1 O
either	1523 6 O
by	1530 2 O
way	1533 3 O
of	1537 2 O
an	1540 2 O
ascending	1543 9 O
projection	1553 10 O
which	1564 5 O
does	1570 4 O
not	1575 3 O
pass	1579 4 O
through	1584 7 O
the	1592 3 O
median	1596 6 O
forebrain	1603 9 O
bundle	1613 6 O
,	1619 1 O
or	1621 2 O
through	1624 7 O
a	1632 1 O
projection	1634 10 O
restricted	1645 10 O
to	1656 2 O
the	1659 3 O
caudal	1663 6 O
brainstem	1670 9 O
.	1679 1 O

Yohimbine	0 9 B-Chemical
treatment	10 9 O
of	20 2 O
sexual	23 6 B-Disease
side	30 4 I-Disease
effects	35 7 I-Disease
induced	43 7 O
by	51 2 O
serotonin	54 9 B-Chemical
reuptake	64 8 O
blockers	73 8 O
.	81 1 O

BACKGROUND	83 10 O
:	93 1 O
Preclinical	95 11 O
and	107 3 O
clinical	111 8 O
studies	120 7 O
suggest	128 7 O
that	136 4 O
yohimbine	141 9 B-Chemical
facilitates	151 11 O
sexual	163 6 O
behavior	170 8 O
and	179 3 O
may	183 3 O
be	187 2 O
helpful	190 7 O
in	198 2 O
the	201 3 O
treatment	205 9 O
of	215 2 O
male	218 4 B-Disease
impotence	223 9 I-Disease
.	232 1 O

A	234 1 O
single	236 6 O
case	243 4 O
report	248 6 O
suggests	255 8 O
that	264 4 O
yohimbine	269 9 B-Chemical
may	279 3 O
be	283 2 O
used	286 4 O
to	291 2 O
treat	294 5 O
the	300 3 O
sexual	304 6 B-Disease
side	311 4 I-Disease
effects	316 7 I-Disease
of	324 2 O
clomipramine	327 12 B-Chemical
.	339 1 O

This	341 4 O
study	346 5 O
evaluated	352 9 O
yohimbine	362 9 B-Chemical
as	372 2 O
a	375 1 O
treatment	377 9 O
for	387 3 O
the	391 3 O
sexual	395 6 B-Disease
side	402 4 I-Disease
effects	407 7 I-Disease
caused	415 6 O
by	422 2 O
serotonin	425 9 B-Chemical
reuptake	435 8 O
blockers	444 8 O
.	452 1 O

METHOD	454 6 O
:	460 1 O
Six	462 3 O
patients	466 8 O
with	475 4 O
either	480 6 O
obsessive	487 9 B-Disease
compulsive	497 10 I-Disease
disorder	508 8 I-Disease
,	516 1 O
trichotillomania	518 16 B-Disease
,	534 1 O
anxiety	536 7 B-Disease
,	543 1 O
or	545 2 O
affective	548 9 B-Disease
disorders	558 9 I-Disease
who	568 3 O
suffered	572 8 O
sexual	581 6 B-Disease
side	588 4 I-Disease
effects	593 7 I-Disease
after	601 5 O
treatment	607 9 O
with	617 4 O
serotonin	622 9 B-Chemical
reuptake	632 8 O
blockers	641 8 O
were	650 4 O
given	655 5 O
yohimbine	661 9 B-Chemical
on	671 2 O
a	674 1 O
p	676 1 O
.	677 1 O
r	678 1 O
.	679 1 O
n	680 1 O
.	681 1 O
basis	683 5 O
in	689 2 O
an	692 2 O
open	695 4 O
clinical	700 8 O
trial	709 5 O
.	714 1 O

Various	716 7 O
doses	724 5 O
of	730 2 O
yohimbine	733 9 B-Chemical
were	743 4 O
used	748 4 O
to	753 2 O
determine	756 9 O
the	766 3 O
ideal	770 5 O
dose	776 4 O
for	781 3 O
each	785 4 O
patient	790 7 O
.	797 1 O

RESULTS	799 7 O
:	806 1 O
Five	808 4 O
of	813 2 O
the	816 3 O
six	820 3 O
patients	824 8 O
experienced	833 11 O
improved	845 8 O
sexual	854 6 O
functioning	861 11 O
after	873 5 O
taking	879 6 O
yohimbine	886 9 B-Chemical
.	895 1 O

One	897 3 O
patient	901 7 O
who	909 3 O
failed	913 6 O
to	920 2 O
comply	923 6 O
with	930 4 O
yohimbine	935 9 B-Chemical
treatment	945 9 O
had	955 3 O
no	959 2 O
therapeutic	962 11 O
effects	974 7 O
.	981 1 O

Side	983 4 O
effects	988 7 O
of	996 2 O
yohimbine	999 9 B-Chemical
included	1009 8 O
excessive	1018 9 O
sweating	1028 8 O
,	1036 1 O
increased	1038 9 O
anxiety	1048 7 B-Disease
,	1055 1 O
and	1057 3 O
a	1061 1 O
wound	1063 5 O
-	1068 1 O
up	1069 2 O
feeling	1072 7 O
in	1080 2 O
some	1083 4 O
patients	1088 8 O
.	1096 1 O

CONCLUSION	1098 10 O
:	1108 1 O
The	1110 3 O
results	1114 7 O
of	1122 2 O
this	1125 4 O
study	1130 5 O
indicate	1136 8 O
that	1145 4 O
yohimbine	1150 9 B-Chemical
may	1160 3 O
be	1164 2 O
an	1167 2 O
effective	1170 9 O
treatment	1180 9 O
for	1190 3 O
the	1194 3 O
sexual	1198 6 B-Disease
side	1205 4 I-Disease
effects	1210 7 I-Disease
caused	1218 6 O
by	1225 2 O
serotonin	1228 9 B-Chemical
reuptake	1238 8 O
blockers	1247 8 O
.	1255 1 O

Future	1257 6 O
controlled	1264 10 O
studies	1275 7 O
are	1283 3 O
needed	1287 6 O
to	1294 2 O
further	1297 7 O
investigate	1305 11 O
the	1317 3 O
effectiveness	1321 13 O
and	1335 3 O
safety	1339 6 O
of	1346 2 O
yohimbine	1349 9 B-Chemical
for	1359 3 O
this	1363 4 O
indication	1368 10 O
.	1378 1 O

Hypersensitivity	0 16 B-Disease
immune	17 6 O
reaction	24 8 O
as	33 2 O
a	36 1 O
mechanism	38 9 O
for	48 3 O
dilevalol	52 9 B-Chemical
-	61 1 O
associated	62 10 O
hepatitis	73 9 B-Disease
.	82 1 O

OBJECTIVE	84 9 O
:	93 1 O
To	95 2 O
assess	98 6 O
lymphocyte	105 10 O
reactivity	116 10 O
to	127 2 O
dilevalol	130 9 B-Chemical
and	140 3 O
to	144 2 O
serum	147 5 O
containing	153 10 O
putative	164 8 O
ex	173 2 O
vivo	176 4 O
dilevalol	181 9 B-Chemical
antigens	191 8 O
or	200 2 O
metabolites	203 11 O
in	215 2 O
a	218 1 O
case	220 4 O
of	225 2 O
dilevalol	228 9 B-Chemical
-	237 1 O
induced	238 7 O
liver	246 5 B-Disease
injury	252 6 I-Disease
.	258 1 O

PATIENT	260 7 O
:	267 1 O
A	269 1 O
58	271 2 O
-	273 1 O
year	274 4 O
-	278 1 O
old	279 3 O
woman	283 5 O
with	289 4 O
a	294 1 O
clinical	296 8 O
diagnosis	305 9 O
of	315 2 O
dilevalol	318 9 B-Chemical
-	327 1 O
induced	328 7 O
liver	336 5 B-Disease
injury	342 6 I-Disease
.	348 1 O

METHODS	350 7 O
:	357 1 O
Peripheral	359 10 O
blood	370 5 O
mononuclear	376 11 O
cells	388 5 O
collected	394 9 O
from	404 4 O
the	409 3 O
patient	413 7 O
were	421 4 O
cultured	426 8 O
in	435 2 O
the	438 3 O
presence	442 8 O
of	451 2 O
a	454 1 O
solution	456 8 O
of	465 2 O
dilevalol	468 9 B-Chemical
and	478 3 O
also	482 4 O
with	487 4 O
sera	492 4 O
collected	497 9 O
from	507 4 O
a	512 1 O
volunteer	514 9 O
before	524 6 O
and	531 3 O
after	535 5 O
dilevalol	541 9 B-Chemical
intake	551 6 O
.	557 1 O

A	559 1 O
similar	561 7 O
protocol	569 8 O
was	578 3 O
performed	582 9 O
with	592 4 O
lymphocytes	597 11 O
from	609 4 O
a	614 1 O
healthy	616 7 O
subject	624 7 O
.	631 1 O

RESULTS	633 7 O
:	640 1 O
No	642 2 O
lymphocyte	645 10 O
proliferation	656 13 O
was	670 3 O
observed	674 8 O
either	683 6 O
in	690 2 O
the	693 3 O
patient	697 7 O
or	705 2 O
in	708 2 O
the	711 3 O
healthy	715 7 O
volunteer	723 9 O
in	733 2 O
the	736 3 O
presence	740 8 O
of	749 2 O
dilevalol	752 9 B-Chemical
solutions	762 9 O
.	771 1 O

A	773 1 O
significant	775 11 O
proliferative	787 13 O
response	801 8 O
to	810 2 O
serum	813 5 O
collected	819 9 O
after	829 5 O
dilevalol	835 9 B-Chemical
intake	845 6 O
was	852 3 O
observed	856 8 O
in	865 2 O
the	868 3 O
case	872 4 O
of	877 2 O
the	880 3 O
patient	884 7 O
compared	892 8 O
with	901 4 O
the	906 3 O
proliferative	910 13 O
response	924 8 O
to	933 2 O
the	936 3 O
serum	940 5 O
collected	946 9 O
before	956 6 O
the	963 3 O
drug	967 4 O
intake	972 6 O
.	978 1 O

No	980 2 O
reactivity	983 10 O
was	994 3 O
found	998 5 O
when	1004 4 O
lymphocytes	1009 11 O
from	1021 4 O
the	1026 3 O
healthy	1030 7 O
subject	1038 7 O
were	1046 4 O
tested	1051 6 O
under	1058 5 O
similar	1064 7 O
conditions	1072 10 O
.	1082 1 O

CONCLUSIONS	1084 11 O
:	1095 1 O
The	1097 3 O
methodology	1101 11 O
used	1113 4 O
allowed	1118 7 O
the	1126 3 O
detection	1130 9 O
of	1140 2 O
lymphocyte	1143 10 O
sensitization	1154 13 O
to	1168 2 O
sera	1171 4 O
containing	1176 10 O
ex	1187 2 O
vivo	1190 4 O
-	1194 1 O
prepared	1195 8 O
dilevalol	1204 9 B-Chemical
antigens	1214 8 O
,	1222 1 O
suggesting	1224 10 O
the	1235 3 O
involvement	1239 11 O
of	1251 2 O
an	1254 2 O
immunologic	1257 11 O
mechanism	1269 9 O
in	1279 2 O
dilevalol	1282 9 B-Chemical
-	1291 1 O
induced	1292 7 O
liver	1300 5 B-Disease
injury	1306 6 I-Disease
.	1312 1 O

Reversible	0 10 O
myocardial	11 10 B-Disease
hypertrophy	22 11 I-Disease
induced	34 7 O
by	42 2 O
tacrolimus	45 10 B-Chemical
in	56 2 O
a	59 1 O
pediatric	61 9 O
heart	71 5 O
transplant	77 10 O
recipient	88 9 O
:	97 1 O
case	99 4 O
report	104 6 O
.	110 1 O

Tacrolimus	112 10 B-Chemical
is	123 2 O
a	126 1 O
potent	128 6 O
immunosuppressant	135 17 O
that	153 4 O
is	158 2 O
frequently	161 10 O
used	172 4 O
in	177 2 O
organ	180 5 O
transplantation	186 15 O
.	201 1 O

However	203 7 O
,	210 1 O
adverse	212 7 O
effects	220 7 O
include	228 7 O
cardiac	236 7 B-Disease
toxicity	244 8 I-Disease
.	252 1 O

Herein	254 6 O
we	261 2 O
describe	264 8 O
transient	273 9 O
myocardial	283 10 B-Disease
hypertrophy	294 11 I-Disease
induced	306 7 O
by	314 2 O
tacrolimus	317 10 B-Chemical
after	328 5 O
heart	334 5 O
transplantation	340 15 O
.	355 1 O

The	357 3 O
hypertrophy	361 11 B-Disease
caused	373 6 O
no	380 2 O
clinical	383 8 O
symptoms	392 8 O
but	401 3 O
was	405 3 O
noted	409 5 O
because	415 7 O
of	423 2 O
elevation	426 9 O
of	436 2 O
plasma	439 6 O
brain	446 5 O
natriuretic	452 11 O
peptide	464 7 O
concentration	472 13 O
and	486 3 O
confirmed	490 9 O
at	500 2 O
echocardiography	503 16 O
.	519 1 O

Initially	521 9 O
,	530 1 O
allograft	532 9 O
rejection	542 9 O
was	552 3 O
feared	556 6 O
;	562 1 O
however	564 7 O
,	571 1 O
myocardial	573 10 O
biopsy	584 6 O
samples	591 7 O
revealed	599 8 O
only	608 4 O
interstitial	613 12 O
edema	626 5 B-Disease
and	632 3 O
mild	636 4 O
myocardial	641 10 B-Disease
hypertrophy	652 11 I-Disease
;	663 1 O
neither	665 7 O
cellular	673 8 O
nor	682 3 O
humoral	686 7 O
rejection	694 9 O
was	704 3 O
detected	708 8 O
.	716 1 O

The	718 3 O
blood	722 5 O
tacrolimus	728 10 B-Chemical
concentration	739 13 O
was	753 3 O
higher	757 6 O
than	764 4 O
usual	769 5 O
at	775 2 O
that	778 4 O
time	783 4 O
;	787 1 O
thus	789 4 O
,	793 1 O
tacrolimus	795 10 B-Chemical
dosage	806 6 O
was	813 3 O
reduced	817 7 O
.	824 1 O

Myocardial	826 10 B-Disease
hypertrophy	837 11 I-Disease
completely	849 10 O
resolved	860 8 O
upon	869 4 O
reducing	874 8 O
the	883 3 O
target	887 6 O
concentration	894 13 O
of	908 2 O
tacrolimus	911 10 B-Chemical
and	922 3 O
did	926 3 O
not	930 3 O
recur	934 5 O
,	939 1 O
as	941 2 O
confirmed	944 9 O
at	954 2 O
echocardiography	957 16 O
and	974 3 O
myocardial	978 10 O
biopsy	989 6 O
.	995 1 O

Thus	997 4 O
,	1001 1 O
we	1003 2 O
conclude	1006 8 O
that	1015 4 O
tacrolimus	1020 10 B-Chemical
induces	1031 7 O
reversible	1039 10 O
myocardial	1050 10 B-Disease
hypertrophy	1061 11 I-Disease
.	1072 1 O

In	1074 2 O
patients	1077 8 O
receiving	1086 9 O
tacrolimus	1096 10 B-Chemical
therapy	1107 7 O
,	1114 1 O
blood	1116 5 O
concentration	1122 13 O
should	1136 6 O
be	1143 2 O
carefully	1146 9 O
controlled	1156 10 O
and	1167 3 O
extreme	1171 7 O
attention	1179 9 O
paid	1189 4 O
to	1194 2 O
cardiac	1197 7 O
involvement	1205 11 O
.	1216 1 O

Comparison	0 10 O
of	11 2 O
unilateral	14 10 O
pallidotomy	25 11 O
and	37 3 O
subthalamotomy	41 14 O
findings	56 8 O
in	65 2 O
advanced	68 8 O
idiopathic	77 10 B-Disease
Parkinson	88 9 I-Disease
'	97 1 I-Disease
s	98 1 I-Disease
disease	100 7 I-Disease
.	107 1 O

A	109 1 O
prospective	111 11 O
,	122 1 O
randomized	124 10 O
,	134 1 O
double	136 6 O
-	142 1 O
blind	143 5 O
pilot	149 5 O
study	155 5 O
to	161 2 O
compare	164 7 O
the	172 3 O
results	176 7 O
of	184 2 O
stereotactic	187 12 O
unilateral	200 10 O
pallidotomy	211 11 O
and	223 3 O
subthalamotomy	227 14 O
in	242 2 O
advanced	245 8 O
idiopathic	254 10 B-Disease
Parkinson	265 9 I-Disease
'	274 1 I-Disease
s	275 1 I-Disease
disease	277 7 I-Disease
(	285 1 O
PD	286 2 B-Disease
)	288 1 O
refractory	290 10 O
to	301 2 O
medical	304 7 O
treatment	312 9 O
was	322 3 O
designed	326 8 O
.	334 1 O

Ten	336 3 O
consecutive	340 11 O
patients	352 8 O
(	361 1 O
mean	362 4 O
age	367 3 O
,	370 1 O
58	372 2 O
.	374 1 O
4	375 1 O
+	377 1 O
/	378 1 O
-	379 1 O
6	381 1 O
.	382 1 O
8	383 1 O
years	385 5 O
;	390 1 O
7	392 1 O
men	394 3 O
,	397 1 O
3	399 1 O
women	401 5 O
)	406 1 O
with	408 4 O
similar	413 7 O
characteristics	421 15 O
at	437 2 O
the	440 3 O
duration	444 8 O
of	453 2 O
disease	456 7 O
(	464 1 O
mean	465 4 O
disease	470 7 O
time	478 4 O
,	482 1 O
8	484 1 O
.	485 1 O
4	486 1 O
+	488 1 O
/	489 1 O
-	490 1 O
3	492 1 O
.	493 1 O
5	494 1 O
years	496 5 O
)	501 1 O
,	502 1 O
disabling	504 9 O
motor	514 5 O
fluctuations	520 12 O
(	533 1 O
Hoehn	534 5 O
_	540 1 O
Yahr	542 4 O
stage	547 5 O
3	553 1 O
-	554 1 O
5	555 1 O
in	557 2 O
off	560 3 O
-	563 1 O
drug	564 4 O
phases	569 6 O
)	575 1 O
and	577 3 O
levodopa	581 8 B-Chemical
-	589 1 O
induced	590 7 O
dyskinesias	598 11 B-Disease
were	610 4 O
selected	615 8 O
.	623 1 O

All	625 3 O
patients	629 8 O
had	638 3 O
bilateral	642 9 O
symptoms	652 8 O
and	661 3 O
their	665 5 O
levodopa	671 8 B-Chemical
equivalent	680 10 O
dosing	691 6 O
were	698 4 O
analysed	703 8 O
.	711 1 O

Six	713 3 O
patients	717 8 O
were	726 4 O
operated	731 8 O
on	740 2 O
in	743 2 O
the	746 3 O
globus	750 6 O
pallidus	757 8 O
interna	766 7 O
(	774 1 O
GPi	775 3 O
)	778 1 O
and	780 3 O
four	784 4 O
in	789 2 O
the	792 3 O
subthalamic	796 11 O
nucleus	808 7 O
(	816 1 O
STN	817 3 O
)	820 1 O
.	821 1 O

Clinical	823 8 O
evaluation	832 10 O
included	843 8 O
the	852 3 O
use	856 3 O
of	860 2 O
the	863 3 O
Unified	867 7 O
Parkinson	875 9 B-Disease
'	884 1 I-Disease
s	885 1 I-Disease
Disease	887 7 I-Disease
Rating	895 6 O
Scale	902 5 O
(	908 1 O
UPDRS	909 5 O
)	914 1 O
,	915 1 O
Hoehn	917 5 O
_	922 1 O
Yahr	923 4 O
score	928 5 O
and	934 3 O
Schwab	938 6 O
England	945 7 O
activities	953 10 O
of	964 2 O
daily	967 5 O
living	973 6 O
(	980 1 O
ADL	981 3 O
)	984 1 O
score	986 5 O
in	992 2 O
'	995 1 O
on	996 2 O
'	998 1 O
-	999 1 O
and	1001 3 O
'	1005 1 O
off	1006 3 O
'	1009 1 O
-	1010 1 O
drug	1011 4 O
conditions	1016 10 O
before	1027 6 O
surgery	1034 7 O
and	1042 3 O
6	1046 1 O
months	1048 6 O
after	1055 5 O
surgery	1061 7 O
.	1068 1 O

There	1070 5 O
was	1076 3 O
statistically	1080 13 O
significant	1094 11 O
improvement	1106 11 O
in	1118 2 O
all	1121 3 O
contralateral	1125 13 O
major	1139 5 O
parkinsonian	1145 12 B-Disease
motor	1158 5 O
signs	1164 5 O
in	1170 2 O
all	1173 3 O
patients	1177 8 O
followed	1186 8 O
for	1195 3 O
6	1199 1 O
months	1201 6 O
.	1207 1 O

Levodopa	1209 8 B-Chemical
equivalent	1218 10 O
daily	1229 5 O
intake	1235 6 O
was	1242 3 O
significantly	1246 13 O
reduced	1260 7 O
in	1268 2 O
the	1271 3 O
STN	1275 3 O
group	1279 5 O
.	1284 1 O

Changes	1286 7 O
in	1294 2 O
UPDRS	1297 5 O
,	1302 1 O
Hoehn	1304 5 O
_	1310 1 O
Yahr	1312 4 O
and	1317 3 O
Schwab	1321 6 O
England	1328 7 O
ADL	1336 3 O
scores	1340 6 O
were	1347 4 O
similar	1352 7 O
in	1360 2 O
both	1363 4 O
groups	1368 6 O
.	1374 1 O

Cognitive	1376 9 O
functions	1386 9 O
were	1396 4 O
unchanged	1401 9 O
in	1411 2 O
both	1414 4 O
groups	1419 6 O
.	1425 1 O

Complications	1427 13 O
were	1441 4 O
observed	1446 8 O
in	1455 2 O
two	1458 3 O
patients	1462 8 O
:	1470 1 O
one	1472 3 O
had	1476 3 O
a	1480 1 O
left	1482 4 O
homonymous	1487 10 B-Disease
hemianopsia	1498 11 I-Disease
after	1510 5 O
pallidotomy	1516 11 O
and	1528 3 O
another	1532 7 O
one	1540 3 O
developed	1544 9 O
left	1554 4 O
hemiballistic	1559 13 O
movements	1573 9 O
3	1583 1 O
days	1585 4 O
after	1590 5 O
subthalamotomy	1596 14 O
which	1611 5 O
partly	1617 6 O
improved	1624 8 O
within	1633 6 O
1	1640 1 O
month	1642 5 O
with	1648 4 O
Valproate	1653 9 B-Chemical
1000	1663 4 O
mg	1668 2 O
/	1670 1 O
day	1671 3 O
.	1674 1 O

The	1676 3 O
findings	1680 8 O
of	1689 2 O
this	1692 4 O
study	1697 5 O
suggest	1703 7 O
that	1711 4 O
lesions	1716 7 O
of	1724 2 O
the	1727 3 O
unilateral	1731 10 O
STN	1742 3 O
and	1746 3 O
GPi	1750 3 O
are	1754 3 O
equally	1758 7 O
effective	1766 9 O
treatment	1776 9 O
for	1786 3 O
patients	1790 8 O
with	1799 4 O
advanced	1804 8 O
PD	1813 2 B-Disease
refractory	1816 10 O
to	1827 2 O
medical	1830 7 O
treatment	1838 9 O
.	1847 1 O

Protective	0 10 O
effects	11 7 O
of	19 2 O
antithrombin	22 12 O
on	35 2 O
puromycin	38 9 B-Chemical
aminonucleoside	48 15 I-Chemical
nephrosis	64 9 B-Disease
in	74 2 O
rats	77 4 O
.	81 1 O

We	83 2 O
investigated	86 12 O
the	99 3 O
effects	103 7 O
of	111 2 O
antithrombin	114 12 O
,	126 1 O
a	128 1 O
plasma	130 6 O
inhibitor	137 9 O
of	147 2 O
coagulation	150 11 O
factors	162 7 O
,	169 1 O
in	171 2 O
rats	174 4 O
with	179 4 O
puromycin	184 9 B-Chemical
aminonucleoside	194 15 I-Chemical
-	209 1 O
induced	210 7 O
nephrosis	218 9 B-Disease
,	227 1 O
which	229 5 O
is	235 2 O
an	238 2 O
experimental	241 12 O
model	254 5 O
of	260 2 O
human	263 5 O
nephrotic	269 9 B-Disease
syndrome	279 8 I-Disease
.	287 1 O

Antithrombin	289 12 O
(	302 1 O
50	303 2 O
or	306 2 O
500	309 3 O
IU	313 2 O
/	315 1 O
kg	316 2 O
/	318 1 O
i	319 1 O
.	320 1 O
v	321 1 O
.	322 1 O
)	323 1 O
was	325 3 O
administered	329 12 O
to	342 2 O
rats	345 4 O
once	350 4 O
a	355 1 O
day	357 3 O
for	361 3 O
10	365 2 O
days	368 4 O
immediately	373 11 O
after	385 5 O
the	391 3 O
injection	395 9 O
of	405 2 O
puromycin	408 9 B-Chemical
aminonucleoside	418 15 I-Chemical
(	434 1 O
50	435 2 O
mg	438 2 O
/	440 1 O
kg	441 2 O
/	443 1 O
i	444 1 O
.	445 1 O
v	446 1 O
.	447 1 O
)	448 1 O
.	449 1 O

Treatment	451 9 O
with	461 4 O
antithrombin	466 12 O
attenuated	479 10 O
the	490 3 O
puromycin	494 9 B-Chemical
aminonucleoside	504 15 I-Chemical
-	519 1 O
induced	520 7 O
hematological	528 13 B-Disease
abnormalities	542 13 I-Disease
.	555 1 O

Puromycin	557 9 B-Chemical
aminonucleoside	567 15 I-Chemical
-	582 1 O
induced	583 7 O
renal	591 5 B-Disease
dysfunction	597 11 I-Disease
and	609 3 O
hyperlipidemia	613 14 B-Disease
were	628 4 O
also	633 4 O
suppressed	638 10 O
.	648 1 O

Histopathological	650 17 O
examination	668 11 O
revealed	680 8 O
severe	689 6 O
renal	696 5 B-Disease
damage	702 6 I-Disease
such	709 4 O
as	714 2 O
proteinaceous	717 13 O
casts	731 5 O
in	737 2 O
tubuli	740 6 O
and	747 3 O
tubular	751 7 O
expansion	759 9 O
in	769 2 O
the	772 3 O
kidney	776 6 O
of	783 2 O
control	786 7 O
rats	794 4 O
,	798 1 O
while	800 5 O
an	806 2 O
improvement	809 11 O
of	821 2 O
the	824 3 O
damage	828 6 O
was	835 3 O
seen	839 4 O
in	844 2 O
antithrombin	847 12 O
-	859 1 O
treated	860 7 O
rats	868 4 O
.	872 1 O

In	874 2 O
addition	877 8 O
,	885 1 O
antithrombin	887 12 O
treatment	900 9 O
markedly	910 8 O
suppressed	919 10 O
puromycin	930 9 B-Chemical
aminonucleoside	940 15 I-Chemical
-	955 1 O
induced	956 7 O
apoptosis	964 9 O
of	974 2 O
renal	977 5 O
tubular	983 7 O
epithelial	991 10 O
cells	1002 5 O
.	1007 1 O

Furthermore	1009 11 O
,	1020 1 O
puromycin	1022 9 B-Chemical
aminonucleoside	1032 15 I-Chemical
-	1047 1 O
induced	1048 7 O
increases	1056 9 O
in	1066 2 O
renal	1069 5 O
cytokine	1075 8 O
content	1084 7 O
were	1092 4 O
also	1097 4 O
decreased	1102 9 O
.	1111 1 O

These	1113 5 O
findings	1119 8 O
suggest	1128 7 O
that	1136 4 O
thrombin	1141 8 O
plays	1150 5 O
an	1156 2 O
important	1159 9 O
role	1169 4 O
in	1174 2 O
the	1177 3 O
pathogenesis	1181 12 O
of	1194 2 O
puromycin	1197 9 B-Chemical
aminonucleoside	1207 15 I-Chemical
-	1222 1 O
induced	1223 7 O
nephrotic	1231 9 B-Disease
syndrome	1241 8 I-Disease
.	1249 1 O

Treatment	1251 9 O
with	1261 4 O
antithrombin	1266 12 O
may	1279 3 O
be	1283 2 O
clinically	1286 10 O
effective	1297 9 O
in	1307 2 O
patients	1310 8 O
with	1319 4 O
nephrotic	1324 9 B-Disease
syndrome	1334 8 I-Disease
.	1342 1 O

Reverse	0 7 O
or	8 2 O
inverted	11 8 O
left	20 4 B-Disease
ventricular	25 11 I-Disease
apical	37 6 I-Disease
ballooning	44 10 I-Disease
syndrome	55 8 I-Disease
(	64 1 O
reverse	65 7 O
Takotsubo	73 9 B-Disease
cardiomyopathy	83 14 I-Disease
)	97 1 O
in	99 2 O
a	102 1 O
young	104 5 O
woman	110 5 O
in	116 2 O
the	119 3 O
setting	123 7 O
of	131 2 O
amphetamine	134 11 B-Chemical
use	146 3 O
.	149 1 O

Transient	151 9 O
left	161 4 B-Disease
ventricular	166 11 I-Disease
apical	178 6 I-Disease
ballooning	185 10 I-Disease
syndrome	196 8 I-Disease
was	205 3 O
first	209 5 O
described	215 9 O
in	225 2 O
Japan	228 5 O
as	234 2 O
"	237 1 O
Takotsubo	238 9 B-Disease
cardiomyopathy	248 14 I-Disease
.	262 1 O
"	263 1 O
This	265 4 O
syndrome	270 8 O
has	279 3 O
been	283 4 O
identified	288 10 O
in	299 2 O
many	302 4 O
other	307 5 O
countries	313 9 O
.	322 1 O

Many	324 4 O
variations	329 10 O
of	340 2 O
this	343 4 O
syndrome	348 8 O
have	357 4 O
been	362 4 O
recently	367 8 O
described	376 9 O
in	386 2 O
the	389 3 O
literature	393 10 O
.	403 1 O

One	405 3 O
of	409 2 O
the	412 3 O
rarest	416 6 O
is	423 2 O
the	426 3 O
reverse	430 7 O
type	438 4 O
of	443 2 O
this	446 4 O
syndrome	451 8 O
,	459 1 O
with	461 4 O
hyperdynamic	466 12 O
apex	479 4 O
and	484 3 O
complete	488 8 O
akinesia	497 8 B-Disease
of	506 2 O
the	509 3 O
base	513 4 O
(	518 1 O
as	519 2 O
opposed	522 7 O
to	530 2 O
the	533 3 O
classic	537 7 O
apical	545 6 B-Disease
ballooning	552 10 I-Disease
)	562 1 O
.	563 1 O

In	565 2 O
this	568 4 O
article	573 7 O
,	580 1 O
we	582 2 O
report	585 6 O
an	592 2 O
interesting	595 11 O
case	607 4 O
of	612 2 O
a	615 1 O
young	617 5 O
woman	623 5 O
who	629 3 O
presented	633 9 O
with	643 4 O
this	648 4 O
rare	653 4 O
type	658 4 O
of	663 2 O
reverse	666 7 O
apical	674 6 B-Disease
ballooning	681 10 I-Disease
syndrome	692 8 I-Disease
occurring	701 9 O
after	711 5 O
amphetamine	717 11 B-Chemical
use	729 3 O
.	732 1 O

This	734 4 O
report	739 6 O
is	746 2 O
followed	749 8 O
by	758 2 O
review	761 6 O
of	768 2 O
the	771 3 O
literature	775 10 O
.	785 1 O

Attenuated	0 10 O
disruption	11 10 O
of	22 2 O
prepulse	25 8 O
inhibition	34 10 O
by	45 2 O
dopaminergic	48 12 O
stimulation	61 11 O
after	73 5 O
maternal	79 8 O
deprivation	88 11 O
and	100 3 O
adolescent	104 10 O
corticosterone	115 14 B-Chemical
treatment	130 9 O
in	140 2 O
rats	143 4 O
.	147 1 O

The	149 3 O
development	153 11 O
of	165 2 O
schizophrenia	168 13 B-Disease
may	182 3 O
include	186 7 O
an	194 2 O
early	197 5 O
neurodevelopmental	203 18 O
stress	222 6 O
component	229 9 O
which	239 5 O
increases	245 9 O
vulnerability	255 13 O
to	269 2 O
later	272 5 O
stressful	278 9 O
life	288 4 O
events	293 6 O
,	299 1 O
in	301 2 O
combination	304 11 O
leading	316 7 O
to	324 2 O
overt	327 5 O
disease	333 7 O
.	340 1 O

We	342 2 O
investigated	345 12 O
the	358 3 O
effect	362 6 O
of	369 2 O
an	372 2 O
early	375 5 O
stress	381 6 O
,	387 1 O
in	389 2 O
the	392 3 O
form	396 4 O
of	401 2 O
maternal	404 8 O
deprivation	413 11 O
,	424 1 O
combined	426 8 O
with	435 4 O
a	440 1 O
later	442 5 O
stress	448 6 O
,	454 1 O
simulated	456 9 O
by	466 2 O
chronic	469 7 O
periadolescent	477 14 O
corticosterone	492 14 B-Chemical
treatment	507 9 O
,	516 1 O
on	518 2 O
behaviour	521 9 O
in	531 2 O
rats	534 4 O
.	538 1 O

Acute	540 5 O
treatment	546 9 O
with	556 4 O
apomorphine	561 11 B-Chemical
caused	573 6 O
disruption	580 10 O
of	591 2 O
prepulse	594 8 O
inhibition	603 10 O
(	614 1 O
PPI	615 3 O
)	618 1 O
in	620 2 O
controls	623 8 O
and	632 3 O
in	636 2 O
rats	639 4 O
that	644 4 O
had	649 3 O
undergone	653 9 O
either	663 6 O
maternal	670 8 O
deprivation	679 11 O
or	691 2 O
corticosterone	694 14 B-Chemical
treatment	709 9 O
,	718 1 O
but	720 3 O
was	724 3 O
surprisingly	728 12 O
absent	741 6 O
in	748 2 O
rats	751 4 O
that	756 4 O
had	761 3 O
undergone	765 9 O
the	775 3 O
combined	779 8 O
early	788 5 O
and	794 3 O
late	798 4 O
stress	803 6 O
.	809 1 O

Amphetamine	811 11 B-Chemical
treatment	823 9 O
significantly	833 13 O
disrupted	847 9 O
PPI	857 3 O
in	861 2 O
both	864 4 O
non	869 3 O
-	872 1 O
deprived	873 8 O
groups	882 6 O
,	888 1 O
but	890 3 O
was	894 3 O
absent	898 6 O
in	905 2 O
both	908 4 O
maternally	913 10 O
deprived	924 8 O
groups	933 6 O
.	939 1 O

The	941 3 O
serotonin	945 9 B-Chemical
-	954 1 O
1A	955 2 O
receptor	958 8 O
agonist	967 7 O
,	974 1 O
8	976 1 B-Chemical
-	977 1 I-Chemical
OH	978 2 I-Chemical
-	980 1 I-Chemical
DPAT	981 4 I-Chemical
,	985 1 O
induced	987 7 O
a	995 1 O
significant	997 11 O
disruption	1009 10 O
of	1020 2 O
PPI	1023 3 O
in	1027 2 O
all	1030 3 O
groups	1034 6 O
.	1040 1 O

Amphetamine	1042 11 B-Chemical
-	1053 1 O
induced	1054 7 O
locomotor	1062 9 B-Disease
hyperactivity	1072 13 I-Disease
was	1086 3 O
similar	1090 7 O
in	1098 2 O
all	1101 3 O
groups	1105 6 O
.	1111 1 O

These	1113 5 O
results	1119 7 O
show	1127 4 O
an	1132 2 O
inhibitory	1135 10 O
interaction	1146 11 O
of	1158 2 O
early	1161 5 O
stress	1167 6 O
,	1173 1 O
caused	1175 6 O
by	1182 2 O
maternal	1185 8 O
deprivation	1194 11 O
,	1205 1 O
combined	1207 8 O
with	1216 4 O
'	1221 1 O
adolescent	1222 10 O
'	1232 1 O
stress	1234 6 O
,	1240 1 O
simulated	1242 9 O
by	1252 2 O
corticosterone	1255 14 B-Chemical
treatment	1270 9 O
,	1279 1 O
on	1281 2 O
dopaminergic	1284 12 O
regulation	1297 10 O
of	1308 2 O
PPI	1311 3 O
.	1314 1 O

The	1316 3 O
altered	1320 7 O
effects	1328 7 O
of	1336 2 O
apomorphine	1339 11 B-Chemical
and	1351 3 O
amphetamine	1355 11 B-Chemical
could	1367 5 O
indicate	1373 8 O
differential	1382 12 O
changes	1395 7 O
in	1403 2 O
dopamine	1406 8 B-Chemical
receptor	1415 8 O
signalling	1424 10 O
leading	1435 7 O
to	1443 2 O
functional	1446 10 O
desensitisation	1457 15 O
,	1472 1 O
or	1474 2 O
altered	1477 7 O
modulation	1485 10 O
of	1496 2 O
sensory	1499 7 O
gating	1507 6 O
in	1514 2 O
the	1517 3 O
nucleus	1521 7 O
accumbens	1529 9 O
by	1539 2 O
limbic	1542 6 O
structures	1549 10 O
such	1560 4 O
as	1565 2 O
the	1568 3 O
hippocampus	1572 11 O
.	1583 1 O

Peripheral	0 10 O
iron	11 4 B-Chemical
dextran	16 7 I-Chemical
induced	24 7 O
degeneration	32 12 B-Disease
of	45 2 I-Disease
dopaminergic	48 12 I-Disease
neurons	61 7 I-Disease
in	69 2 O
rat	72 3 O
substantia	76 10 O
nigra	87 5 O
.	92 1 O

Iron	94 4 B-Chemical
accumulation	99 12 O
is	112 2 O
considered	115 10 O
to	126 2 O
be	129 2 O
involved	132 8 O
in	141 2 O
the	144 3 O
pathogenesis	148 12 O
of	161 2 O
Parkinson	164 9 B-Disease
'	173 1 I-Disease
s	174 1 I-Disease
disease	176 7 I-Disease
.	183 1 O

To	185 2 O
demonstrate	188 11 O
the	200 3 O
relationship	204 12 O
between	217 7 O
peripheral	225 10 O
iron	236 4 B-Chemical
overload	241 8 O
and	250 3 O
dopaminergic	254 12 O
neuron	267 6 O
loss	274 4 O
in	279 2 O
rat	282 3 O
substantia	286 10 O
nigra	297 5 O
(	303 1 O
SN	304 2 O
)	306 1 O
,	307 1 O
in	309 2 O
the	312 3 O
present	316 7 O
study	324 5 O
we	330 2 O
used	333 4 O
fast	338 4 O
cyclic	343 6 O
voltammetry	350 11 O
,	361 1 O
tyrosine	363 8 B-Chemical
hydroxylase	372 11 O
(	384 1 O
TH	385 2 O
)	387 1 O
immunohistochemistry	389 20 O
,	409 1 O
Perls	411 5 O
'	416 1 O
iron	418 4 B-Chemical
staining	423 8 O
,	431 1 O
and	433 3 O
high	437 4 O
performance	442 11 O
liquid	454 6 O
chromatography	461 14 O
-	475 1 O
electrochemical	476 15 O
detection	492 9 O
to	502 2 O
study	505 5 O
the	511 3 O
degeneration	515 12 B-Disease
of	528 2 I-Disease
dopaminergic	531 12 I-Disease
neurons	544 7 I-Disease
and	552 3 O
increased	556 9 O
iron	566 4 B-Chemical
content	571 7 O
in	579 2 O
the	582 3 O
SN	586 2 O
of	589 2 O
iron	592 4 B-Chemical
dextran	597 7 I-Chemical
overloaded	605 10 O
animals	616 7 O
.	623 1 O

The	625 3 O
findings	629 8 O
showed	638 6 O
that	645 4 O
peripheral	650 10 O
iron	661 4 B-Chemical
dextran	666 7 I-Chemical
overload	674 8 O
increased	683 9 O
the	693 3 O
iron	697 4 B-Chemical
staining	702 8 O
positive	711 8 O
cells	720 5 O
and	726 3 O
reduced	730 7 O
the	738 3 O
number	742 6 O
of	749 2 O
TH	752 2 O
-	754 1 O
immunoreactive	755 14 O
neurons	770 7 O
in	778 2 O
the	781 3 O
SN	785 2 O
.	787 1 O

As	789 2 O
a	792 1 O
result	794 6 O
,	800 1 O
dopamine	802 8 B-Chemical
release	811 7 O
and	819 3 O
content	823 7 O
,	830 1 O
as	832 2 O
well	835 4 O
as	840 2 O
its	843 3 O
metabolites	847 11 O
contents	859 8 O
were	868 4 O
decreased	873 9 O
in	883 2 O
caudate	886 7 O
putamen	894 7 O
.	901 1 O

Even	903 4 O
more	908 4 O
dramatic	913 8 O
changes	922 7 O
were	930 4 O
found	935 5 O
in	941 2 O
chronic	944 7 O
overload	952 8 O
group	961 5 O
.	966 1 O

These	968 5 O
results	974 7 O
suggest	982 7 O
that	990 4 O
peripheral	995 10 O
iron	1006 4 B-Chemical
dextran	1011 7 I-Chemical
can	1019 3 O
increase	1023 8 O
the	1032 3 O
iron	1036 4 B-Chemical
level	1041 5 O
in	1047 2 O
the	1050 3 O
SN	1054 2 O
,	1056 1 O
where	1058 5 O
excessive	1064 9 O
iron	1074 4 B-Chemical
causes	1079 6 O
the	1086 3 O
degeneration	1090 12 B-Disease
of	1103 2 I-Disease
dopaminergic	1106 12 I-Disease
neurons	1119 7 I-Disease
.	1126 1 O

The	1128 3 O
chronic	1132 7 O
iron	1140 4 B-Chemical
overload	1145 8 O
may	1154 3 O
be	1158 2 O
more	1161 4 O
destructive	1166 11 O
to	1178 2 O
dopaminergic	1181 12 O
neurons	1194 7 O
than	1202 4 O
the	1207 3 O
acute	1211 5 O
iron	1217 4 B-Chemical
overload	1222 8 O
.	1230 1 O

Warfarin	0 8 B-Chemical
-	8 1 O
induced	9 7 O
leukocytoclastic	17 16 B-Disease
vasculitis	34 10 I-Disease
.	44 1 O

Skin	46 4 O
reactions	51 9 O
associated	61 10 O
with	72 4 O
oral	77 4 O
coumarin	82 8 B-Chemical
-	90 1 O
derived	91 7 O
anticoagulants	99 14 O
are	114 3 O
an	118 2 O
uncommon	121 8 O
occurrence	130 10 O
.	140 1 O

Leukocytoclastic	142 16 B-Disease
vasculitis	159 10 I-Disease
(	170 1 O
LV	171 2 B-Disease
)	173 1 O
is	175 2 O
primarily	178 9 O
a	188 1 O
cutaneous	190 9 B-Disease
small	200 5 I-Disease
vessel	206 6 I-Disease
vasculitis	213 10 I-Disease
,	223 1 O
though	225 6 O
systemic	232 8 O
involvement	241 11 O
may	253 3 O
be	257 2 O
encountered	260 11 O
.	271 1 O

We	273 2 O
report	276 6 O
4	283 1 O
patients	285 8 O
with	294 4 O
late	299 4 O
-	303 1 O
onset	304 5 O
LV	310 2 B-Disease
probably	313 8 O
due	322 3 O
to	326 2 O
warfarin	329 8 B-Chemical
.	337 1 O

All	339 3 O
4	343 1 O
patients	345 8 O
presented	354 9 O
with	364 4 O
skin	369 4 B-Disease
eruptions	374 9 I-Disease
that	384 4 O
developed	389 9 O
after	399 5 O
receiving	405 9 O
warfarin	415 8 B-Chemical
for	424 3 O
several	428 7 O
years	436 5 O
.	441 1 O

The	443 3 O
results	447 7 O
of	455 2 O
skin	458 4 B-Disease
lesion	463 6 I-Disease
biopsies	470 8 O
were	479 4 O
available	484 9 O
in	494 2 O
3	497 1 O
patients	499 8 O
,	507 1 O
confirming	509 10 O
LV	520 2 B-Disease
Cutaneous	523 9 I-Disease
lesions	533 7 I-Disease
resolved	541 8 O
in	550 2 O
all	553 3 O
patients	557 8 O
after	566 5 O
warfarin	572 8 B-Chemical
was	581 3 O
discontinued	585 12 O
.	597 1 O

In	599 2 O
2	602 1 O
of	604 2 O
the	607 3 O
4	611 1 O
patients	613 8 O
,	621 1 O
rechallenge	623 11 O
with	635 4 O
warfarin	640 8 B-Chemical
led	649 3 O
to	653 2 O
recurrence	656 10 O
of	667 2 O
the	670 3 O
lesions	674 7 O
.	681 1 O

LV	683 2 B-Disease
may	686 3 O
be	690 2 O
a	693 1 O
late	695 4 O
-	699 1 O
onset	700 5 O
adverse	706 7 O
reaction	714 8 O
associated	723 10 O
with	734 4 O
warfarin	739 8 B-Chemical
therapy	748 7 O
.	755 1 O

The	0 3 O
activation	4 10 O
of	15 2 O
spinal	18 6 O
N	25 1 B-Chemical
-	26 1 I-Chemical
methyl	27 6 I-Chemical
-	33 1 I-Chemical
D	34 1 I-Chemical
-	35 1 I-Chemical
aspartate	36 9 I-Chemical
receptors	46 9 O
may	56 3 O
contribute	60 10 O
to	71 2 O
degeneration	74 12 O
of	87 2 O
spinal	90 6 O
motor	97 5 O
neurons	103 7 O
induced	111 7 O
by	119 2 O
neuraxial	122 9 O
morphine	132 8 B-Chemical
after	141 5 O
a	147 1 O
noninjurious	149 12 O
interval	162 8 O
of	171 2 O
spinal	174 6 B-Disease
cord	181 4 I-Disease
ischemia	186 8 I-Disease
.	194 1 O

We	196 2 O
investigated	199 12 O
the	212 3 O
relationship	216 12 O
between	229 7 O
the	237 3 O
degeneration	241 12 O
of	254 2 O
spinal	257 6 O
motor	264 5 O
neurons	270 7 O
and	278 3 O
activation	282 10 O
of	293 2 O
N	296 1 B-Chemical
-	297 1 I-Chemical
methyl	298 6 I-Chemical
-	304 1 I-Chemical
d	305 1 I-Chemical
-	306 1 I-Chemical
aspartate	307 9 I-Chemical
(	317 1 O
NMDA	318 4 B-Chemical
)	322 1 O
receptors	324 9 O
after	334 5 O
neuraxial	340 9 O
morphine	350 8 B-Chemical
following	359 9 O
a	369 1 O
noninjurious	371 12 O
interval	384 8 O
of	393 2 O
aortic	396 6 B-Disease
occlusion	403 9 I-Disease
in	413 2 O
rats	416 4 O
.	420 1 O

Spinal	422 6 B-Disease
cord	429 4 I-Disease
ischemia	434 8 I-Disease
was	443 3 O
induced	447 7 O
by	455 2 O
aortic	458 6 B-Disease
occlusion	465 9 I-Disease
for	475 3 O
6	479 1 O
min	481 3 O
with	485 4 O
a	490 1 O
balloon	492 7 O
catheter	500 8 O
.	508 1 O

In	510 2 O
a	513 1 O
microdialysis	515 13 O
study	529 5 O
,	534 1 O
10	536 2 O
muL	539 3 O
of	543 2 O
saline	546 6 O
(	553 1 O
group	554 5 O
C	560 1 O
;	561 1 O
n	563 1 O
=	565 1 O
8	567 1 O
)	568 1 O
or	570 2 O
30	573 2 O
mug	576 3 O
of	580 2 O
morphine	583 8 B-Chemical
(	592 1 O
group	593 5 O
M	599 1 O
;	600 1 O
n	602 1 O
=	604 1 O
8	606 1 O
)	607 1 O
was	609 3 O
injected	613 8 O
intrathecally	622 13 O
(	636 1 O
IT	637 2 O
)	639 1 O
0	641 1 O
.	642 1 O
5	643 1 O
h	645 1 O
after	647 5 O
reflow	653 6 O
,	659 1 O
and	661 3 O
30	665 2 O
mug	668 3 O
of	672 2 O
morphine	675 8 B-Chemical
(	684 1 O
group	685 5 O
SM	691 2 O
;	693 1 O
n	695 1 O
=	697 1 O
8	699 1 O
)	700 1 O
or	702 2 O
10	705 2 O
muL	708 3 O
of	712 2 O
saline	715 6 O
(	722 1 O
group	723 5 O
SC	729 2 O
;	731 1 O
n	733 1 O
=	735 1 O
8	737 1 O
)	738 1 O
was	740 3 O
injected	744 8 O
IT	753 2 O
0	756 1 O
.	757 1 O
5	758 1 O
h	760 1 O
after	762 5 O
sham	768 4 O
operation	773 9 O
.	782 1 O

Microdialysis	784 13 O
samples	798 7 O
were	806 4 O
collected	811 9 O
preischemia	821 11 O
,	832 1 O
before	834 6 O
IT	841 2 O
injection	844 9 O
,	853 1 O
and	855 3 O
at	859 2 O
2	862 1 O
,	863 1 O
4	865 1 O
,	866 1 O
8	868 1 O
,	869 1 O
24	871 2 O
,	873 1 O
and	875 3 O
48	879 2 O
h	882 1 O
of	884 2 O
reperfusion	887 11 O
(	899 1 O
after	900 5 O
IT	906 2 O
injection	909 9 O
)	918 1 O
.	919 1 O

Second	921 6 O
,	927 1 O
we	929 2 O
investigated	932 12 O
the	945 3 O
effect	949 6 O
of	956 2 O
IT	959 2 O
MK	962 2 B-Chemical
-	964 1 I-Chemical
801	965 3 I-Chemical
(	969 1 O
30	970 2 O
mug	973 3 O
)	976 1 O
on	978 2 O
the	981 3 O
histopathologic	985 15 O
changes	1001 7 O
in	1009 2 O
the	1012 3 O
spinal	1016 6 O
cord	1023 4 O
after	1028 5 O
morphine	1034 8 B-Chemical
-	1042 1 O
induced	1043 7 O
spastic	1051 7 B-Disease
paraparesis	1059 11 I-Disease
.	1070 1 O

After	1072 5 O
IT	1078 2 O
morphine	1081 8 B-Chemical
,	1089 1 O
the	1091 3 O
cerebrospinal	1095 13 O
fluid	1109 5 O
(	1115 1 O
CSF	1116 3 O
)	1119 1 O
glutamate	1121 9 B-Chemical
concentration	1131 13 O
was	1145 3 O
increased	1149 9 O
in	1159 2 O
group	1162 5 O
M	1168 1 O
relative	1170 8 O
to	1179 2 O
both	1182 4 O
baseline	1187 8 O
and	1196 3 O
group	1200 5 O
C	1206 1 O
(	1208 1 O
P	1209 1 O
<	1211 1 O
0	1213 1 O
.	1214 1 O
05	1215 2 O
)	1217 1 O
.	1218 1 O

This	1220 4 O
increase	1225 8 O
persisted	1234 9 O
for	1244 3 O
8	1248 1 O
hrs	1250 3 O
.	1253 1 O

IT	1255 2 O
MK	1258 2 B-Chemical
-	1260 1 I-Chemical
801	1261 3 I-Chemical
significantly	1265 13 O
reduced	1279 7 O
the	1287 3 O
number	1291 6 O
of	1298 2 O
dark	1301 4 O
-	1305 1 O
stained	1306 7 O
alpha	1314 5 O
-	1319 1 O
motoneurons	1320 11 O
after	1332 5 O
morphine	1338 8 B-Chemical
-	1346 1 O
induced	1347 7 O
spastic	1355 7 B-Disease
paraparesis	1363 11 I-Disease
compared	1375 8 O
with	1384 4 O
the	1389 3 O
saline	1393 6 O
group	1400 5 O
.	1405 1 O

These	1407 5 O
data	1413 4 O
indicate	1418 8 O
that	1427 4 O
IT	1432 2 O
morphine	1435 8 B-Chemical
induces	1444 7 O
spastic	1452 7 B-Disease
paraparesis	1460 11 I-Disease
with	1472 4 O
a	1477 1 O
concomitant	1479 11 O
increase	1491 8 O
in	1500 2 O
CSF	1503 3 O
glutamate	1507 9 B-Chemical
,	1516 1 O
which	1518 5 O
is	1524 2 O
involved	1527 8 O
in	1536 2 O
NMDA	1539 4 B-Chemical
receptor	1544 8 O
activation	1553 10 O
.	1563 1 O

We	1565 2 O
suggest	1568 7 O
that	1576 4 O
opioids	1581 7 O
may	1589 3 O
be	1593 2 O
neurotoxic	1596 10 B-Disease
in	1607 2 O
the	1610 3 O
setting	1614 7 O
of	1622 2 O
spinal	1625 6 B-Disease
cord	1632 4 I-Disease
ischemia	1637 8 I-Disease
via	1646 3 O
NMDA	1650 4 B-Chemical
receptor	1655 8 O
activation	1664 10 O
.	1674 1 O

Reduced	0 7 O
sodium	8 6 B-Chemical
channel	15 7 O
density	23 7 O
,	30 1 O
altered	32 7 O
voltage	40 7 O
dependence	48 10 O
of	59 2 O
inactivation	62 12 O
,	74 1 O
and	76 3 O
increased	80 9 O
susceptibility	90 14 O
to	105 2 O
seizures	108 8 B-Disease
in	117 2 O
mice	120 4 O
lacking	125 7 O
sodium	133 6 B-Chemical
channel	140 7 O
beta	148 4 O
2	153 1 O
-	154 1 O
subunits	155 8 O
.	163 1 O

Sodium	165 6 B-Chemical
channel	172 7 O
beta	180 4 O
-	184 1 O
subunits	185 8 O
modulate	194 8 O
channel	203 7 O
gating	211 6 O
,	217 1 O
assembly	219 8 O
,	227 1 O
and	229 3 O
cell	233 4 O
surface	238 7 O
expression	246 10 O
in	257 2 O
heterologous	260 12 O
cell	273 4 O
systems	278 7 O
.	285 1 O

We	287 2 O
generated	290 9 O
beta2	300 5 O
(	305 1 O
-	306 1 O
/	307 1 O
-	308 1 O
)	309 1 O
mice	311 4 O
to	316 2 O
investigate	319 11 O
the	331 3 O
role	335 4 O
of	340 2 O
beta2	343 5 O
in	349 2 O
control	352 7 O
of	360 2 O
sodium	363 6 B-Chemical
channel	370 7 O
density	378 7 O
,	385 1 O
localization	387 12 O
,	399 1 O
and	401 3 O
function	405 8 O
in	414 2 O
neurons	417 7 O
in	425 2 O
vivo	428 4 O
.	432 1 O

Measurements	434 12 O
of	447 2 O
[	450 1 O
(	451 1 O
3	452 1 O
)	453 1 O
H	454 1 O
]	455 1 O
saxitoxin	456 9 B-Chemical
(	466 1 O
STX	467 3 B-Chemical
)	470 1 O
binding	472 7 O
showed	480 6 O
a	487 1 O
significant	489 11 O
reduction	501 9 O
in	511 2 O
the	514 3 O
level	518 5 O
of	524 2 O
plasma	527 6 O
membrane	534 8 O
sodium	543 6 B-Chemical
channels	550 8 O
in	559 2 O
beta2	562 5 O
(	567 1 O
-	568 1 O
/	569 1 O
-	570 1 O
)	571 1 O
neurons	573 7 O
.	580 1 O

The	582 3 O
loss	586 4 O
of	591 2 O
beta2	594 5 O
resulted	600 8 O
in	609 2 O
negative	612 8 O
shifts	621 6 O
in	628 2 O
the	631 3 O
voltage	635 7 O
dependence	643 10 O
of	654 2 O
inactivation	657 12 O
as	670 2 O
well	673 4 O
as	678 2 O
significant	681 11 O
decreases	693 9 O
in	703 2 O
sodium	706 6 B-Chemical
current	713 7 O
density	721 7 O
in	729 2 O
acutely	732 7 O
dissociated	740 11 O
hippocampal	752 11 O
neurons	764 7 O
.	771 1 O

The	773 3 O
integral	777 8 O
of	786 2 O
the	789 3 O
compound	793 8 O
action	802 6 O
potential	809 9 O
in	819 2 O
optic	822 5 O
nerve	828 5 O
was	834 3 O
significantly	838 13 O
reduced	852 7 O
,	859 1 O
and	861 3 O
the	865 3 O
threshold	869 9 O
for	879 3 O
action	883 6 O
potential	890 9 O
generation	900 10 O
was	911 3 O
increased	915 9 O
,	924 1 O
indicating	926 10 O
a	937 1 O
reduction	939 9 O
in	949 2 O
the	952 3 O
level	956 5 O
of	962 2 O
functional	965 10 O
plasma	976 6 O
membrane	983 8 O
sodium	992 6 B-Chemical
channels	999 8 O
.	1007 1 O

In	1009 2 O
contrast	1012 8 O
,	1020 1 O
the	1022 3 O
conduction	1026 10 O
velocity	1037 8 O
,	1045 1 O
the	1047 3 O
number	1051 6 O
and	1058 3 O
size	1062 4 O
of	1067 2 O
axons	1070 5 O
in	1076 2 O
the	1079 3 O
optic	1083 5 O
nerve	1089 5 O
,	1094 1 O
and	1096 3 O
the	1100 3 O
specific	1104 8 O
localization	1113 12 O
of	1126 2 O
Na	1129 2 B-Chemical
(	1131 1 O
v	1132 1 O
)	1133 1 O
1	1134 1 O
.	1135 1 O
6	1136 1 O
channels	1138 8 O
in	1147 2 O
the	1150 3 O
nodes	1154 5 O
of	1160 2 O
Ranvier	1163 7 O
were	1171 4 O
unchanged	1176 9 O
.	1185 1 O

beta2	1187 5 O
(	1192 1 O
-	1193 1 O
/	1194 1 O
-	1195 1 O
)	1196 1 O
mice	1198 4 O
displayed	1203 9 O
increased	1213 9 O
susceptibility	1223 14 O
to	1238 2 O
seizures	1241 8 B-Disease
,	1249 1 O
as	1251 2 O
indicated	1254 9 O
by	1264 2 O
reduced	1267 7 O
latency	1275 7 O
and	1283 3 O
threshold	1287 9 O
for	1297 3 O
pilocarpine	1301 11 B-Chemical
-	1312 1 O
induced	1313 7 O
seizures	1321 8 B-Disease
,	1329 1 O
but	1331 3 O
seemed	1335 6 O
normal	1342 6 O
in	1349 2 O
other	1352 5 O
neurological	1358 12 O
tests	1371 5 O
.	1376 1 O

Our	1378 3 O
observations	1382 12 O
show	1395 4 O
that	1400 4 O
beta2	1405 5 O
-	1410 1 O
subunits	1411 8 O
play	1420 4 O
an	1425 2 O
important	1428 9 O
role	1438 4 O
in	1443 2 O
the	1446 3 O
regulation	1450 10 O
of	1461 2 O
sodium	1464 6 B-Chemical
channel	1471 7 O
density	1479 7 O
and	1487 3 O
function	1491 8 O
in	1500 2 O
neurons	1503 7 O
in	1511 2 O
vivo	1514 4 O
and	1519 3 O
are	1523 3 O
required	1527 8 O
for	1536 3 O
normal	1540 6 O
action	1547 6 O
potential	1554 9 O
generation	1564 10 O
and	1575 3 O
control	1579 7 O
of	1587 2 O
excitability	1590 12 O
.	1602 1 O

Screening	0 9 O
for	10 3 O
stimulant	14 9 O
use	24 3 O
in	28 2 O
adult	31 5 O
emergency	37 9 O
department	47 10 O
seizure	58 7 B-Disease
patients	66 8 O
.	74 1 O

OBJECTIVE	76 9 O
:	85 1 O
The	87 3 O
objective	91 9 O
of	101 2 O
this	104 4 O
study	109 5 O
was	115 3 O
to	119 2 O
determine	122 9 O
the	132 3 O
prevalence	136 10 O
of	147 2 O
positive	150 8 O
plasma	159 6 O
drug	166 4 O
screening	171 9 O
for	181 3 O
cocaine	185 7 B-Chemical
or	193 2 O
amphetamine	196 11 B-Chemical
in	208 2 O
adult	211 5 O
emergency	217 9 O
department	227 10 O
seizure	238 7 B-Disease
patients	246 8 O
.	254 1 O

METHODS	256 7 O
:	263 1 O
This	265 4 O
prospective	270 11 O
study	282 5 O
evaluated	288 9 O
consecutive	298 11 O
eligible	310 8 O
seizure	319 7 B-Disease
patients	327 8 O
who	336 3 O
had	340 3 O
a	344 1 O
plasma	346 6 O
sample	353 6 O
collected	360 9 O
as	370 2 O
part	373 4 O
of	378 2 O
their	381 5 O
clinical	387 8 O
evaluation	396 10 O
.	406 1 O

Plasma	408 6 O
was	415 3 O
tested	419 6 O
for	426 3 O
amphetamine	430 11 B-Chemical
and	442 3 O
the	446 3 O
cocaine	450 7 B-Chemical
metabolite	458 10 O
benzoylecgonine	469 15 B-Chemical
using	485 5 O
enzyme	491 6 O
-	497 1 O
mediated	498 8 O
immunoassay	507 11 O
methodology	519 11 O
.	530 1 O

Plasma	532 6 O
samples	539 7 O
with	547 4 O
benzoylecgonine	552 15 B-Chemical
greater	568 7 O
than	576 4 O
150	581 3 O
ng	585 2 O
/	587 1 O
mL	588 2 O
or	591 2 O
an	594 2 O
amphetamine	597 11 B-Chemical
greater	609 7 O
than	617 4 O
500	622 3 O
ng	626 2 O
/	628 1 O
mL	629 2 O
were	632 4 O
defined	637 7 O
as	645 2 O
positive	648 8 O
.	656 1 O

Patient	658 7 O
demographics	666 12 O
,	678 1 O
history	680 7 O
of	688 2 O
underlying	691 10 O
drug	702 4 O
or	707 2 O
alcohol	710 7 B-Chemical
-	717 1 O
related	718 7 O
seizure	726 7 B-Disease
disorder	734 8 O
,	742 1 O
estimated	744 9 O
time	754 4 O
from	759 4 O
seizure	764 7 B-Disease
to	772 2 O
sample	775 6 O
collection	782 10 O
,	792 1 O
history	794 7 O
or	802 2 O
suspicion	805 9 O
of	815 2 O
cocaine	818 7 B-Disease
or	826 2 I-Disease
amphetamine	829 11 I-Disease
abuse	841 5 I-Disease
,	846 1 O
results	848 7 O
of	856 2 O
clinical	859 8 O
urine	868 5 O
testing	874 7 O
for	882 3 O
drugs	886 5 O
of	892 2 O
abuse	895 5 O
,	900 1 O
and	902 3 O
assay	906 5 O
results	912 7 O
were	920 4 O
recorded	925 8 O
without	934 7 O
patient	942 7 O
identifiers	950 11 O
.	961 1 O

RESULTS	963 7 O
:	970 1 O
Fourteen	972 8 O
of	981 2 O
248	984 3 O
(	988 1 O
5	989 1 O
.	990 1 O
6	991 1 O
%	992 1 O
,	993 1 O
95	995 2 O
%	997 1 O
CI	999 2 O
2	1002 1 O
.	1003 1 O
7	1004 1 O
%	1005 1 O
-	1006 1 O
8	1007 1 O
.	1008 1 O
5	1009 1 O
%	1010 1 O
)	1011 1 O
plasma	1013 6 O
samples	1020 7 O
were	1028 4 O
positive	1033 8 O
by	1042 2 O
immunoassay	1045 11 O
testing	1057 7 O
for	1065 3 O
benzoylecgonine	1069 15 B-Chemical
and	1085 3 O
no	1089 2 O
samples	1092 7 O
(	1100 1 O
0	1101 1 O
%	1102 1 O
,	1103 1 O
95	1105 2 O
%	1107 1 O
CI	1109 2 O
0	1112 1 O
-	1113 1 O
1	1114 1 O
.	1115 1 O
2	1116 1 O
%	1117 1 O
)	1118 1 O
were	1120 4 O
positive	1125 8 O
for	1134 3 O
amphetamine	1138 11 B-Chemical
.	1149 1 O

Positive	1151 8 O
test	1160 4 O
results	1165 7 O
were	1173 4 O
more	1178 4 O
common	1183 6 O
in	1190 2 O
patient	1193 7 O
visits	1201 6 O
where	1208 5 O
there	1214 5 O
was	1220 3 O
a	1224 1 O
history	1226 7 O
or	1234 2 O
suspicion	1237 9 O
of	1247 2 O
cocaine	1250 7 B-Disease
or	1258 2 I-Disease
amphetamine	1261 11 I-Disease
abuse	1273 5 I-Disease
(	1279 1 O
p	1280 1 O
<	1282 1 O
0	1284 1 O
.	1285 1 O
0005	1286 4 O
)	1290 1 O
.	1291 1 O

CONCLUSIONS	1293 11 O
:	1304 1 O
During	1306 6 O
this	1313 4 O
study	1318 5 O
period	1324 6 O
,	1330 1 O
routine	1332 7 O
plasma	1340 6 O
screening	1347 9 O
for	1357 3 O
cocaine	1361 7 B-Chemical
and	1369 3 O
amphetamines	1373 12 B-Chemical
in	1386 2 O
adult	1389 5 O
seizure	1395 7 B-Disease
patients	1403 8 O
had	1412 3 O
a	1416 1 O
low	1418 3 O
yield	1422 5 O
.	1427 1 O

As	1429 2 O
a	1432 1 O
result	1434 6 O
,	1440 1 O
routine	1442 7 O
plasma	1450 6 O
screening	1457 9 O
would	1467 5 O
yield	1473 5 O
few	1479 3 O
cases	1483 5 O
of	1489 2 O
stimulant	1492 9 O
drug	1502 4 O
in	1507 2 O
which	1510 5 O
there	1516 5 O
was	1522 3 O
neither	1526 7 O
a	1534 1 O
history	1536 7 O
nor	1544 3 O
suspicion	1548 9 O
of	1558 2 O
drug	1561 4 B-Disease
abuse	1566 5 I-Disease
in	1572 2 O
this	1575 4 O
population	1580 10 O
.	1590 1 O

Evidence	0 8 O
of	9 2 O
functional	12 10 O
somatotopy	23 10 O
in	34 2 O
GPi	37 3 O
from	41 4 O
results	46 7 O
of	54 2 O
pallidotomy	57 11 O
.	68 1 O

The	70 3 O
objective	74 9 O
of	84 2 O
this	87 4 O
study	92 5 O
was	98 3 O
to	102 2 O
explore	105 7 O
the	113 3 O
functional	117 10 O
anatomy	128 7 O
of	136 2 O
the	139 3 O
globus	143 6 O
pallidus	150 8 O
internus	159 8 O
(	168 1 O
GPi	169 3 O
)	172 1 O
by	174 2 O
studying	177 8 O
the	186 3 O
effects	190 7 O
of	198 2 O
unilateral	201 10 O
pallidotomy	212 11 O
on	224 2 O
parkinsonian	227 12 B-Disease
'	240 1 O
off	241 3 O
'	244 1 O
signs	246 5 O
and	252 3 O
levodopa	256 8 B-Chemical
-	264 1 O
induced	265 7 O
dyskinesias	273 11 B-Disease
(	285 1 O
LID	286 3 B-Disease
)	289 1 O
.	290 1 O

We	292 2 O
found	295 5 O
significant	301 11 O
positive	313 8 O
correlations	322 12 O
between	335 7 O
the	343 3 O
preoperative	347 12 O
levodopa	360 8 B-Chemical
responsiveness	369 14 O
of	384 2 O
motor	387 5 O
signs	393 5 O
and	399 3 O
the	403 3 O
levodopa	407 8 B-Chemical
responsiveness	416 14 O
of	431 2 O
scores	434 6 O
in	441 2 O
timed	444 5 O
tests	450 5 O
(	456 1 O
Core	457 4 O
Assessment	462 10 O
Program	473 7 O
for	481 3 O
Intracerebral	485 13 O
Transplantations	499 16 O
)	515 1 O
in	517 2 O
the	520 3 O
contralateral	524 13 O
limbs	538 5 O
and	544 3 O
the	548 3 O
improvement	552 11 O
in	564 2 O
these	567 5 O
scores	573 6 O
after	580 5 O
surgery	586 7 O
,	593 1 O
whereas	595 7 O
there	603 5 O
was	609 3 O
no	613 2 O
correlation	616 11 O
with	628 4 O
the	633 3 O
improvement	637 11 O
in	649 2 O
LID	652 3 B-Disease
.	655 1 O

We	657 2 O
also	660 4 O
found	665 5 O
a	671 1 O
highly	673 6 O
significant	680 11 O
correlation	692 11 O
(	704 1 O
P	705 1 O
:	706 1 O
<	708 1 O
0	710 1 O
.	711 1 O
0001	712 4 O
,	716 1 O
r	718 1 O
=	720 1 O
0	722 1 O
.	723 1 O
8	724 1 O
)	725 1 O
between	727 7 O
the	735 3 O
volume	739 6 O
of	746 2 O
the	749 3 O
ventral	753 7 O
lesion	761 6 O
in	768 2 O
the	771 3 O
GPi	775 3 O
and	779 3 O
the	783 3 O
improvement	787 11 O
in	799 2 O
LID	802 3 B-Disease
in	806 2 O
the	809 3 O
contralateral	813 13 O
limbs	827 5 O
,	832 1 O
whereas	834 7 O
there	842 5 O
was	848 3 O
no	852 2 O
correlation	855 11 O
between	867 7 O
the	875 3 O
ventral	879 7 O
volume	887 6 O
and	894 3 O
the	898 3 O
improvement	902 11 O
in	914 2 O
parkinsonian	917 12 B-Disease
'	930 1 O
off	931 3 O
'	934 1 O
signs	936 5 O
.	941 1 O

The	943 3 O
volumes	947 7 O
of	955 2 O
the	958 3 O
total	962 5 O
lesion	968 6 O
cylinder	975 8 O
and	984 3 O
the	988 3 O
dorsal	992 6 O
lesion	999 6 O
did	1006 3 O
not	1010 3 O
correlate	1014 9 O
with	1024 4 O
the	1029 3 O
outcome	1033 7 O
of	1041 2 O
either	1044 6 O
dyskinesias	1051 11 B-Disease
or	1063 2 O
parkinsonian	1066 12 B-Disease
'	1079 1 O
off	1080 3 O
'	1083 1 O
signs	1085 5 O
.	1090 1 O

The	1092 3 O
differential	1096 12 O
predictive	1109 10 O
value	1120 5 O
of	1126 2 O
levodopa	1129 8 B-Chemical
responsiveness	1138 14 O
for	1153 3 O
the	1157 3 O
outcome	1161 7 O
of	1169 2 O
parkinsonian	1172 12 B-Disease
'	1185 1 O
off	1186 3 O
'	1189 1 O
signs	1191 5 O
and	1197 3 O
LID	1201 3 B-Disease
and	1205 3 O
the	1209 3 O
different	1213 9 O
correlations	1223 12 O
of	1236 2 O
ventral	1239 7 O
lesion	1247 6 O
volume	1254 6 O
with	1261 4 O
dyskinesias	1266 11 B-Disease
and	1278 3 O
parkinsonian	1282 12 B-Disease
'	1295 1 O
off	1296 3 O
'	1299 1 O
signs	1301 5 O
indicate	1307 8 O
that	1316 4 O
different	1321 9 O
anatomical	1331 10 O
or	1342 2 O
pathophysiological	1345 18 O
substrates	1364 10 O
may	1375 3 O
be	1379 2 O
responsible	1382 11 O
for	1394 3 O
the	1398 3 O
generation	1402 10 O
of	1413 2 O
parkinsonian	1416 12 B-Disease
'	1429 1 O
off	1430 3 O
'	1433 1 O
signs	1435 5 O
and	1441 3 O
dyskinesias	1445 11 B-Disease
.	1456 1 O

Whereas	1458 7 O
cells	1466 5 O
in	1472 2 O
a	1475 1 O
wider	1477 5 O
area	1483 4 O
of	1488 2 O
the	1491 3 O
GPi	1495 3 O
may	1499 3 O
be	1503 2 O
implicated	1506 10 O
in	1517 2 O
parkinsonism	1520 12 B-Disease
,	1532 1 O
the	1534 3 O
ventral	1538 7 O
GPi	1546 3 O
seems	1550 5 O
to	1556 2 O
be	1559 2 O
crucial	1562 7 O
for	1570 3 O
the	1574 3 O
manifestation	1578 13 O
of	1592 2 O
LID	1595 3 B-Disease
.	1598 1 O

We	1600 2 O
suggest	1603 7 O
that	1611 4 O
our	1616 3 O
observations	1620 12 O
are	1633 3 O
additional	1637 10 O
proof	1648 5 O
of	1654 2 O
the	1657 3 O
functional	1661 10 O
somatotopy	1672 10 O
of	1683 2 O
the	1686 3 O
systems	1690 7 O
within	1698 6 O
the	1705 3 O
GPi	1709 3 O
that	1713 4 O
mediate	1718 7 O
parkinsonism	1726 12 B-Disease
and	1739 3 O
dyskinesias	1743 11 B-Disease
,	1754 1 O
especially	1756 10 O
along	1767 5 O
the	1773 3 O
dorsoventral	1777 12 O
trajectory	1790 10 O
used	1801 4 O
in	1806 2 O
pallidotomy	1809 11 O
.	1820 1 O

The	1822 3 O
outcome	1826 7 O
of	1834 2 O
pallidotomy	1837 11 O
in	1849 2 O
which	1852 5 O
the	1858 3 O
lesion	1862 6 O
involves	1869 8 O
the	1878 3 O
ventral	1882 7 O
and	1890 3 O
dorsal	1894 6 O
GPi	1901 3 O
could	1905 5 O
be	1911 2 O
the	1914 3 O
net	1918 3 O
effect	1922 6 O
of	1929 2 O
alteration	1932 10 O
in	1943 2 O
the	1946 3 O
activity	1950 8 O
of	1959 2 O
pathways	1962 8 O
which	1971 5 O
mediate	1977 7 O
different	1985 9 O
symptoms	1995 8 O
,	2003 1 O
and	2005 3 O
hence	2009 5 O
could	2015 5 O
be	2021 2 O
variable	2024 8 O
.	2032 1 O

Pain	0 4 B-Disease
responses	5 9 O
in	15 2 O
methadone	18 9 B-Chemical
-	27 1 O
maintained	28 10 O
opioid	39 6 O
abusers	46 7 O
.	53 1 O

Providing	55 9 O
pain	65 4 B-Disease
management	70 10 O
for	81 3 O
known	85 5 O
opioid	91 6 O
abusers	98 7 O
is	106 2 O
a	109 1 O
challenging	111 11 O
clinical	123 8 O
task	132 4 O
,	136 1 O
in	138 2 O
part	141 4 O
because	146 7 O
little	154 6 O
is	161 2 O
known	164 5 O
about	170 5 O
their	176 5 O
pain	182 4 B-Disease
experience	187 10 O
and	198 3 O
analgesic	202 9 O
requirements	212 12 O
.	224 1 O

This	226 4 O
study	231 5 O
was	237 3 O
designed	241 8 O
to	250 2 O
describe	253 8 O
pain	262 4 B-Disease
tolerance	267 9 O
and	277 3 O
analgesic	281 9 O
response	291 8 O
in	300 2 O
a	303 1 O
sample	305 6 O
of	312 2 O
opioid	315 6 B-Disease
addicts	322 7 I-Disease
stabilized	330 10 O
in	341 2 O
methadone	344 9 B-Chemical
-	353 1 O
maintenance	354 11 O
(	366 1 O
MM	367 2 O
)	369 1 O
treatment	371 9 O
(	381 1 O
n	382 1 O
=	384 1 O
60	386 2 O
)	388 1 O
in	390 2 O
comparison	393 10 O
to	404 2 O
matched	407 7 O
nondependent	415 12 O
control	428 7 O
subjects	436 8 O
(	445 1 O
n	446 1 O
=	448 1 O
60	450 2 O
)	452 1 O
.	453 1 O

By	455 2 O
using	458 5 O
a	464 1 O
placebo	466 7 O
-	473 1 O
controlled	474 10 O
,	484 1 O
two	486 3 O
-	489 1 O
way	490 3 O
factorial	494 9 O
design	504 6 O
,	510 1 O
tolerance	512 9 O
to	522 2 O
cold	525 4 O
-	529 1 O
pressor	530 7 O
(	538 1 O
CP	539 2 O
)	541 1 O
pain	543 4 B-Disease
was	548 3 O
examined	552 8 O
,	560 1 O
both	562 4 O
before	567 6 O
and	574 3 O
after	578 5 O
oral	584 4 O
administration	589 14 O
of	604 2 O
therapeutic	607 11 O
doses	619 5 O
of	625 2 O
common	628 6 O
opioid	635 6 O
(	642 1 O
hydromorphone	643 13 B-Chemical
2	657 1 O
mg	659 2 O
)	661 1 O
and	663 3 O
nonsteroidal	667 12 O
anti	680 4 O
-	684 1 O
inflammatory	685 12 O
(	698 1 O
ketorolac	699 9 B-Chemical
10	709 2 O
mg	712 2 O
)	714 1 O
analgesic	716 9 O
agents	726 6 O
.	732 1 O

Results	734 7 O
showed	742 6 O
that	749 4 O
MM	754 2 O
individuals	757 11 O
were	769 4 O
significantly	774 13 O
less	788 4 O
tolerant	793 8 O
of	802 2 O
CP	805 2 O
pain	808 4 B-Disease
than	813 4 O
control	818 7 O
subjects	826 8 O
,	834 1 O
replicating	836 11 O
previous	848 8 O
work	857 4 O
.	861 1 O

Analgesic	863 9 O
effects	873 7 O
were	881 4 O
significant	886 11 O
neither	898 7 O
for	906 3 O
medication	910 10 O
nor	921 3 O
group	925 5 O
.	930 1 O

These	932 5 O
data	938 4 O
indicate	943 8 O
that	952 4 O
MM	957 2 O
opioid	960 6 O
abusers	967 7 O
represent	975 9 O
a	985 1 O
pain	987 4 B-Disease
-	991 1 I-Disease
intolerant	992 10 I-Disease
subset	1003 6 O
of	1010 2 O
clinical	1013 8 O
patients	1022 8 O
.	1030 1 O

Their	1032 5 O
complaints	1038 10 O
of	1049 2 O
pain	1052 4 B-Disease
should	1057 6 O
be	1064 2 O
evaluated	1067 9 O
seriously	1077 9 O
and	1087 3 O
managed	1091 7 O
aggressively	1099 12 O
.	1111 1 O

Urine	0 5 O
N	6 1 O
-	7 1 O
acetyl	8 6 O
-	14 1 O
beta	15 4 O
-	19 1 O
D	20 1 O
-	21 1 O
glucosaminidase	22 15 O
-	37 1 O
-	38 1 O
a	39 1 O
marker	41 6 O
of	48 2 O
tubular	51 7 O
damage	59 6 O
?	65 1 O

BACKGROUND	67 10 O
:	77 1 O
Although	79 8 O
an	88 2 O
indicator	91 9 O
of	101 2 O
renal	104 5 B-Disease
tubular	110 7 I-Disease
dysfunction	118 11 I-Disease
,	129 1 O
an	131 2 O
increased	134 9 O
urinary	144 7 O
N	152 1 O
-	153 1 O
acetyl	154 6 O
-	160 1 O
beta	161 4 O
-	165 1 O
D	166 1 O
-	167 1 O
glucosaminidase	168 15 O
(	184 1 O
NAG	185 3 O
)	188 1 O
activity	190 8 O
might	199 5 O
reflect	205 7 O
increased	213 9 O
lysosomal	223 9 O
activity	233 8 O
in	242 2 O
renal	245 5 O
tubular	251 7 O
cells	259 5 O
.	264 1 O

METHODS	266 7 O
:	273 1 O
Puromycin	275 9 B-Chemical
aminonucleoside	285 15 I-Chemical
(	301 1 O
PAN	302 3 B-Chemical
)	305 1 O
was	307 3 O
administered	311 12 O
to	324 2 O
Sprague	327 7 O
Dawley	335 6 O
rats	342 4 O
to	347 2 O
induce	350 6 O
proteinuria	357 11 B-Disease
.	368 1 O

Total	370 5 O
protein	376 7 O
,	383 1 O
albumin	385 7 O
,	392 1 O
NAG	394 3 O
activity	398 8 O
and	407 3 O
protein	411 7 O
electrophoretic	419 15 O
pattern	435 7 O
were	443 4 O
assessed	448 8 O
in	457 2 O
daily	460 5 O
urine	466 5 O
samples	472 7 O
for	480 3 O
33	484 2 O
days	487 4 O
.	491 1 O

The	493 3 O
morphological	497 13 O
appearance	511 10 O
of	522 2 O
the	525 3 O
kidneys	529 7 O
was	537 3 O
examined	541 8 O
on	550 2 O
days	553 4 O
three	558 5 O
,	563 1 O
four	565 4 O
,	569 1 O
six	571 3 O
,	574 1 O
eight	576 5 O
and	582 3 O
thirty	586 6 O
three	593 5 O
and	599 3 O
the	603 3 O
NAG	607 3 O
isoenzyme	611 9 O
patterns	621 8 O
on	630 2 O
days	633 4 O
zero	638 4 O
,	642 1 O
four	644 4 O
,	648 1 O
eight	650 5 O
and	656 3 O
thirty	660 6 O
three	667 5 O
.	672 1 O

RESULTS	674 7 O
:	681 1 O
Following	683 9 O
intravenous	693 11 O
PAN	705 3 B-Chemical
urine	709 5 O
volume	715 6 O
and	722 3 O
urine	726 5 O
NAG	732 3 O
activity	736 8 O
increased	745 9 O
significantly	755 13 O
by	769 2 O
day	772 3 O
two	776 3 O
,	779 1 O
but	781 3 O
returned	785 8 O
to	794 2 O
normal	797 6 O
by	804 2 O
day	807 3 O
four	811 4 O
.	815 1 O

After	817 5 O
day	823 3 O
four	827 4 O
all	832 3 O
treated	836 7 O
animals	844 7 O
exhibited	852 9 O
a	862 1 O
marked	864 6 O
rise	871 4 O
in	876 2 O
urine	879 5 O
albumin	885 7 O
,	892 1 O
total	894 5 O
protein	900 7 O
excretion	908 9 O
and	918 3 O
NAG	922 3 O
activity	926 8 O
.	934 1 O

Electrophoresis	936 15 O
showed	952 6 O
a	959 1 O
generalised	961 11 O
increase	973 8 O
in	982 2 O
middle	985 6 O
and	992 3 O
high	996 4 O
molecular	1001 9 O
weight	1011 6 O
urine	1018 5 O
proteins	1024 8 O
from	1033 4 O
day	1038 3 O
four	1042 4 O
onwards	1047 7 O
.	1054 1 O

Protein	1056 7 O
droplets	1064 8 O
first	1073 5 O
appeared	1079 8 O
prominent	1088 9 O
in	1098 2 O
tubular	1101 7 O
cells	1109 5 O
on	1115 2 O
day	1118 3 O
four	1122 4 O
.	1126 1 O

Peak	1128 4 O
urine	1133 5 O
NAG	1139 3 O
activity	1143 8 O
and	1152 3 O
a	1156 1 O
change	1158 6 O
in	1165 2 O
NAG	1168 3 O
isoenzyme	1172 9 O
pattern	1182 7 O
coincided	1190 9 O
with	1200 4 O
both	1205 4 O
the	1210 3 O
peak	1214 4 O
proteinuria	1219 11 B-Disease
and	1231 3 O
the	1235 3 O
reduction	1239 9 O
in	1249 2 O
intracellular	1252 13 O
protein	1266 7 O
and	1274 3 O
NAG	1278 3 O
droplets	1282 8 O
(	1291 1 O
day	1292 3 O
six	1296 3 O
onwards	1300 7 O
)	1307 1 O
.	1308 1 O

CONCLUSIONS	1310 11 O
:	1321 1 O
This	1323 4 O
animal	1328 6 O
model	1335 5 O
demonstrates	1341 12 O
that	1354 4 O
an	1359 2 O
increase	1362 8 O
in	1371 2 O
lysosomal	1374 9 O
turnover	1384 8 O
and	1393 3 O
hence	1397 5 O
urine	1403 5 O
NAG	1409 3 O
activity	1413 8 O
,	1421 1 O
occurs	1423 6 O
when	1430 4 O
increased	1435 9 O
protein	1445 7 O
is	1453 2 O
presented	1456 9 O
to	1466 2 O
the	1469 3 O
tubular	1473 7 O
cells	1481 5 O
.	1486 1 O

Urine	1488 5 O
NAG	1494 3 O
activity	1498 8 O
is	1507 2 O
thus	1510 4 O
a	1515 1 O
measure	1517 7 O
of	1525 2 O
altered	1528 7 O
function	1536 8 O
in	1545 2 O
the	1548 3 O
renal	1552 5 O
tubules	1558 7 O
and	1566 3 O
not	1570 3 O
simply	1574 6 O
an	1581 2 O
indicator	1584 9 O
of	1594 2 O
damage	1597 6 O
.	1603 1 O

Over	0 4 O
expression	5 10 O
of	16 2 O
vascular	19 8 O
endothelial	28 11 O
growth	40 6 O
factor	47 6 O
and	54 3 O
its	58 3 O
receptor	62 8 O
during	71 6 O
the	78 3 O
development	82 11 O
of	94 2 O
estrogen	97 8 B-Chemical
-	105 1 O
induced	106 7 O
rat	114 3 O
pituitary	118 9 B-Disease
tumors	128 6 I-Disease
may	135 3 O
mediate	139 7 O
estrogen	147 8 B-Chemical
-	155 1 O
initiated	156 9 O
tumor	166 5 B-Disease
angiogenesis	172 12 O
.	184 1 O

Estrogens	186 9 B-Chemical
,	195 1 O
which	197 5 O
have	203 4 O
been	208 4 O
associated	213 10 O
with	224 4 O
several	229 7 O
types	237 5 O
of	243 2 O
human	246 5 O
and	252 3 O
animal	256 6 O
cancers	263 7 B-Disease
,	270 1 O
can	272 3 O
induce	276 6 O
tumor	283 5 B-Disease
angiogenesis	289 12 O
in	302 2 O
the	305 3 O
pituitary	309 9 O
of	319 2 O
Fischer	322 7 O
344	330 3 O
rats	334 4 O
.	338 1 O

The	340 3 O
mechanistic	344 11 O
details	356 7 O
of	364 2 O
tumor	367 5 B-Disease
angiogenesis	373 12 O
induction	386 9 O
,	395 1 O
during	397 6 O
estrogen	404 8 B-Chemical
carcinogenesis	413 14 B-Disease
,	427 1 O
are	429 3 O
still	433 5 O
unknown	439 7 O
.	446 1 O

To	448 2 O
elucidate	451 9 O
the	461 3 O
role	465 4 O
of	470 2 O
estrogen	473 8 B-Chemical
in	482 2 O
the	485 3 O
regulation	489 10 O
of	500 2 O
tumor	503 5 B-Disease
angiogenesis	509 12 O
in	522 2 O
the	525 3 O
pituitary	529 9 O
of	539 2 O
female	542 6 O
rats	549 4 O
,	553 1 O
the	555 3 O
density	559 7 O
of	567 2 O
blood	570 5 O
vessels	576 7 O
was	584 3 O
analysed	588 8 O
using	597 5 O
factor	603 6 O
VIII	610 4 O
related	615 7 O
antigen	623 7 O
(	631 1 O
FVIIIRAg	632 8 O
)	640 1 O
immunohistochemistry	642 20 O
and	663 3 O
the	667 3 O
expression	671 10 O
of	682 2 O
vascular	685 8 O
endothelial	694 11 O
growth	706 6 O
factor	713 6 O
/	719 1 O
vascular	720 8 O
permeability	729 12 O
factor	742 6 O
(	749 1 O
VEGF	750 4 O
/	754 1 O
VPF	755 3 O
)	758 1 O
was	760 3 O
examined	764 8 O
by	773 2 O
Western	776 7 O
blot	784 4 O
and	789 3 O
immunohistochemical	793 19 O
analysis	813 8 O
.	821 1 O

The	823 3 O
expression	827 10 O
of	838 2 O
VEGF	841 4 O
receptor	846 8 O
(	855 1 O
VEGFR	856 5 O
-	861 1 O
2	862 1 O
/	863 1 O
Flk	864 3 O
-	867 1 O
1	868 1 O
/	869 1 O
KDR	870 3 O
)	873 1 O
was	875 3 O
also	879 4 O
examined	884 8 O
by	893 2 O
immunohistochemistry	896 20 O
.	916 1 O

The	918 3 O
results	922 7 O
demonstrated	930 12 O
that	943 4 O
17beta	948 6 B-Chemical
-	954 1 I-Chemical
estradiol	955 9 I-Chemical
(	965 1 O
E2	966 2 B-Chemical
)	968 1 O
induces	970 7 O
neovascularization	978 18 O
,	996 1 O
as	998 2 O
well	1001 4 O
as	1006 2 O
the	1009 3 O
growth	1013 6 O
and	1020 3 O
enlargement	1024 11 O
of	1036 2 O
blood	1039 5 O
vessels	1045 7 O
after	1053 5 O
7	1059 1 O
days	1061 4 O
of	1066 2 O
exposure	1069 8 O
.	1077 1 O

The	1079 3 O
high	1083 4 O
tumor	1088 5 B-Disease
angiogenic	1094 10 O
potential	1105 9 O
was	1115 3 O
associated	1119 10 O
with	1130 4 O
an	1135 2 O
elevated	1138 8 O
VEGF	1147 4 O
/	1151 1 O
VPF	1152 3 O
protein	1156 7 O
expression	1164 10 O
in	1175 2 O
the	1178 3 O
E2	1182 2 B-Chemical
exposed	1185 7 O
pituitary	1193 9 O
of	1203 2 O
ovariectomized	1206 14 O
(	1221 1 O
OVEX	1222 4 O
)	1226 1 O
rats	1228 4 O
.	1232 1 O

VEGF	1234 4 O
/	1238 1 O
VPF	1239 3 O
and	1243 3 O
FVIIIRAg	1247 8 O
immunohistochemistry	1256 20 O
and	1277 3 O
endothelial	1281 11 O
specific	1293 8 O
lectin	1302 6 O
(	1309 1 O
UEA1	1310 4 O
)	1314 1 O
binding	1316 7 O
studies	1324 7 O
,	1331 1 O
indicate	1333 8 O
that	1342 4 O
the	1347 3 O
elevation	1351 9 O
of	1361 2 O
VEGF	1364 4 O
protein	1369 7 O
expression	1377 10 O
initially	1388 9 O
occurred	1398 8 O
in	1407 2 O
both	1410 4 O
blood	1415 5 O
vessels	1421 7 O
and	1429 3 O
non	1433 3 O
-	1436 1 O
endothelial	1437 11 O
cells	1449 5 O
.	1454 1 O

After	1456 5 O
15	1462 2 O
days	1465 4 O
of	1470 2 O
E2	1473 2 B-Chemical
exposure	1476 8 O
,	1484 1 O
VEGF	1486 4 O
/	1490 1 O
VPF	1491 3 O
protein	1495 7 O
expression	1503 10 O
,	1513 1 O
in	1515 2 O
the	1518 3 O
non	1522 3 O
-	1525 1 O
endothelial	1526 11 O
cell	1538 4 O
population	1543 10 O
,	1553 1 O
sharply	1555 7 O
declined	1563 8 O
and	1572 3 O
was	1576 3 O
restricted	1580 10 O
to	1591 2 O
the	1594 3 O
blood	1598 5 O
vessels	1604 7 O
.	1611 1 O

The	1613 3 O
function	1617 8 O
of	1626 2 O
non	1629 3 O
-	1632 1 O
endothelial	1633 11 O
-	1644 1 O
derived	1645 7 O
VEGF	1653 4 O
is	1658 2 O
not	1661 3 O
clear	1665 5 O
.	1670 1 O

Furthermore	1672 11 O
,	1683 1 O
immunohistochemical	1685 19 O
studies	1705 7 O
demonstrated	1713 12 O
that	1726 4 O
VEGFR	1731 5 O
-	1736 1 O
2	1737 1 O
(	1739 1 O
flk	1740 3 O
-	1743 1 O
1	1744 1 O
/	1745 1 O
KDR	1746 3 O
)	1749 1 O
,	1750 1 O
expression	1752 10 O
was	1763 3 O
elevated	1767 8 O
significantly	1776 13 O
in	1790 2 O
the	1793 3 O
endothelial	1797 11 O
cells	1809 5 O
of	1815 2 O
microblood	1818 10 O
vessels	1829 7 O
after	1837 5 O
7	1843 1 O
days	1845 4 O
of	1850 2 O
E2	1853 2 B-Chemical
exposure	1856 8 O
.	1864 1 O

These	1866 5 O
findings	1872 8 O
suggest	1881 7 O
that	1889 4 O
over	1894 4 O
expression	1899 10 O
of	1910 2 O
VEGF	1913 4 O
and	1918 3 O
its	1922 3 O
receptor	1926 8 O
(	1935 1 O
VEGFR	1936 5 O
-	1941 1 O
2	1942 1 O
)	1943 1 O
may	1945 3 O
play	1949 4 O
an	1954 2 O
important	1957 9 O
role	1967 4 O
in	1972 2 O
the	1975 3 O
initial	1979 7 O
step	1987 4 O
of	1992 2 O
the	1995 3 O
regulation	1999 10 O
of	2010 2 O
estrogen	2013 8 B-Chemical
induced	2022 7 O
tumor	2030 5 B-Disease
angiogenesis	2036 12 O
in	2049 2 O
the	2052 3 O
rat	2056 3 O
pituitary	2060 9 O
.	2069 1 O

Pravastatin	0 11 B-Chemical
-	11 1 O
associated	12 10 O
myopathy	23 8 B-Disease
.	31 1 O

Report	33 6 O
of	40 2 O
a	43 1 O
case	45 4 O
.	49 1 O

A	51 1 O
case	53 4 O
of	58 2 O
acute	61 5 O
inflammatory	67 12 B-Disease
myopathy	80 8 I-Disease
associated	89 10 O
with	100 4 O
the	105 3 O
use	109 3 O
of	113 2 O
pravastatin	116 11 B-Chemical
,	127 1 O
a	129 1 O
new	131 3 O
hydrophilic	135 11 O
3	147 1 O
-	148 1 O
hydroxy	149 7 O
-	156 1 O
3	157 1 O
methylglutaril	159 14 O
coenzyme	174 8 O
A	183 1 O
reductase	185 9 O
inhibitor	195 9 O
,	204 1 O
is	206 2 O
reported	209 8 O
.	217 1 O

The	219 3 O
patient	223 7 O
,	230 1 O
a	232 1 O
69	234 2 O
-	236 1 O
year	237 4 O
-	241 1 O
old	242 3 O
man	246 3 O
was	250 3 O
affected	254 8 O
by	263 2 O
non	266 3 B-Disease
-	269 1 I-Disease
insulin	270 7 I-Disease
-	277 1 I-Disease
dependent	278 9 I-Disease
diabetes	288 8 I-Disease
mellitus	297 8 I-Disease
and	306 3 O
hypertension	310 12 B-Disease
.	322 1 O

He	324 2 O
assumed	327 7 O
pravastatin	335 11 B-Chemical
(	347 1 O
20	348 2 O
mg	351 2 O
/	353 1 O
day	354 3 O
)	357 1 O
because	359 7 O
of	367 2 O
hypercholesterolemia	370 20 B-Disease
.	390 1 O

He	392 2 O
was	395 3 O
admitted	399 8 O
with	408 4 O
acute	413 5 O
myopathy	419 8 B-Disease
of	428 2 O
the	431 3 O
lower	435 5 O
limbs	441 5 O
which	447 5 O
resolved	453 8 O
in	462 2 O
a	465 1 O
few	467 3 O
days	471 4 O
after	476 5 O
pravastatin	482 11 B-Chemical
discontinuation	494 15 O
.	509 1 O

A	511 1 O
previously	513 10 O
unknown	524 7 O
hypothyroidism	532 14 B-Disease
,	546 1 O
probably	548 8 O
due	557 3 O
to	561 2 O
chronic	564 7 O
autoimmune	572 10 B-Disease
thyroiditis	583 11 I-Disease
,	594 1 O
was	596 3 O
evidenced	600 9 O
.	609 1 O

Muscle	611 6 O
biopsy	618 6 O
(	625 1 O
left	626 4 O
gastrocnemius	631 13 O
)	644 1 O
revealed	646 8 O
a	655 1 O
perimysial	657 10 O
and	668 3 O
endomysial	672 10 O
inflammatory	683 12 O
infiltrate	696 10 O
with	707 4 O
a	712 1 O
prevalence	714 10 O
of	725 2 O
CD4	728 3 O
+	731 1 O
lymphocytes	733 11 O
.	744 1 O

While	746 5 O
lovastatin	752 10 B-Chemical
and	763 3 O
simvastatin	767 11 B-Chemical
have	779 4 O
been	784 4 O
associated	789 10 O
with	800 4 O
toxic	805 5 O
myopathy	811 8 B-Disease
,	819 1 O
pravastatin	821 11 B-Chemical
-	832 1 O
associated	833 10 O
myopathy	844 8 B-Disease
could	853 5 O
represent	859 9 O
a	869 1 O
distinct	871 8 O
,	879 1 O
inflammatory	881 12 O
entity	894 6 O
.	900 1 O

Dose	0 4 O
-	4 1 O
effect	5 6 O
and	12 3 O
structure	16 9 O
-	25 1 O
function	26 8 O
relationships	35 13 O
in	49 2 O
doxorubicin	52 11 B-Chemical
cardiomyopathy	64 14 B-Disease
.	78 1 O

The	80 3 O
cardiomyopathy	84 14 B-Disease
(	99 1 O
CM	100 2 B-Disease
)	102 1 O
produced	104 8 O
by	113 2 O
the	116 3 O
anticancer	120 10 O
drug	131 4 O
doxorubicin	136 11 B-Chemical
(	148 1 O
DXR	149 3 B-Chemical
)	152 1 O
(	154 1 O
Adriamycin	155 10 B-Chemical
)	165 1 O
provides	167 8 O
a	176 1 O
unique	178 6 O
opportunity	185 11 O
to	197 2 O
analyze	200 7 O
dose	208 4 O
-	212 1 O
effect	213 6 O
and	220 3 O
structure	224 9 O
-	233 1 O
function	234 8 O
relationships	243 13 O
during	257 6 O
development	264 11 O
of	276 2 O
myocardial	279 10 B-Disease
disease	290 7 I-Disease
.	297 1 O

We	299 2 O
measured	302 8 O
the	311 3 O
degree	315 6 O
of	322 2 O
morphologic	325 11 O
damage	337 6 O
by	344 2 O
ultrastructural	347 15 O
examination	363 11 O
of	375 2 O
endomyocardial	378 14 O
biopsy	393 6 O
and	400 3 O
the	404 3 O
degree	408 6 O
of	415 2 O
performance	418 11 O
abnormally	430 10 O
by	441 2 O
right	444 5 O
heart	450 5 O
catheterization	456 15 O
in	472 2 O
patients	475 8 O
receiving	484 9 O
DXR	494 3 B-Chemical
.	497 1 O

Morphologic	499 11 O
damage	511 6 O
was	518 3 O
variable	522 8 O
but	531 3 O
was	535 3 O
proportional	539 12 O
to	552 2 O
the	555 3 O
total	559 5 O
cumulative	565 10 O
DXR	576 3 B-Chemical
dose	580 4 O
between	585 7 O
100	593 3 O
and	597 3 O
600	601 3 O
mg	605 2 O
/	607 1 O
m2	608 2 O
.	610 1 O

Performance	612 11 O
abnormalities	624 13 O
correlated	638 10 O
weakly	649 6 O
with	656 4 O
dose	661 4 O
,	665 1 O
exhibited	667 9 O
a	677 1 O
curvilinear	679 11 O
relationship	691 12 O
,	703 1 O
and	705 3 O
had	709 3 O
a	713 1 O
"	715 1 O
threshold	716 9 O
"	725 1 O
for	727 3 O
expression	731 10 O
.	741 1 O

Catheterization	743 15 O
abnormalities	759 13 O
correlated	773 10 O
well	784 4 O
with	789 4 O
morphologic	794 11 O
damage	806 6 O
(	813 1 O
r	814 1 O
=	816 1 O
0	818 1 O
.	819 1 O
57	820 2 O
to	823 2 O
0	826 1 O
.	827 1 O
78	828 2 O
)	830 1 O
in	832 2 O
a	835 1 O
subgroup	837 8 O
of	846 2 O
patients	849 8 O
in	858 2 O
whom	861 4 O
exercise	866 8 O
hemodynamics	875 12 O
were	888 4 O
measured	893 8 O
,	901 1 O
and	903 3 O
this	907 4 O
relationship	912 12 O
also	925 4 O
exhibited	930 9 O
a	940 1 O
curvilinear	942 11 O
,	953 1 O
threshold	955 9 O
configuration	965 13 O
.	978 1 O

In	980 2 O
DXR	983 3 B-Chemical
-	986 1 O
CM	987 2 B-Disease
myocardial	990 10 B-Disease
damage	1001 6 I-Disease
is	1008 2 O
proportional	1011 12 O
to	1024 2 O
the	1027 3 O
degree	1031 6 O
of	1038 2 O
cytotoxic	1041 9 O
insult	1051 6 O
(	1058 1 O
DXR	1059 3 B-Chemical
dose	1063 4 O
)	1067 1 O
while	1069 5 O
myocardial	1075 10 O
function	1086 8 O
is	1095 2 O
preserved	1098 9 O
until	1108 5 O
a	1114 1 O
critical	1116 8 O
dose	1125 4 O
or	1130 2 O
degree	1133 6 O
of	1140 2 O
damage	1143 6 O
is	1150 2 O
reached	1153 7 O
,	1160 1 O
after	1162 5 O
which	1168 5 O
myocardial	1174 10 O
performance	1185 11 O
deteriorates	1197 12 O
rapidly	1210 7 O
.	1217 1 O

Fatal	0 5 O
aplastic	6 8 B-Disease
anemia	15 6 I-Disease
following	22 9 O
topical	32 7 O
administration	40 14 O
of	55 2 O
ophthalmic	58 10 O
chloramphenicol	69 15 B-Chemical
.	84 1 O

A	86 1 O
73	88 2 O
-	90 1 O
year	91 4 O
-	95 1 O
old	96 3 O
woman	100 5 O
died	106 4 O
of	111 2 O
aplastic	114 8 B-Disease
anemia	123 6 I-Disease
less	130 4 O
than	135 4 O
two	140 3 O
months	144 6 O
after	151 5 O
undergoing	157 10 O
cataract	168 8 B-Disease
extraction	177 10 O
and	188 3 O
beginning	192 9 O
topical	202 7 O
therapy	210 7 O
with	218 4 O
chloramphenicol	223 15 B-Chemical
.	238 1 O

The	240 3 O
first	244 5 O
signs	250 5 O
of	256 2 O
pancytopenia	259 12 B-Disease
began	272 5 O
within	278 6 O
one	285 3 O
month	289 5 O
of	295 2 O
the	298 3 O
surgery	302 7 O
.	309 1 O

The	311 3 O
pattern	315 7 O
of	323 2 O
the	326 3 O
aplastic	330 8 B-Disease
anemia	339 6 I-Disease
was	346 3 O
associated	350 10 O
with	361 4 O
an	366 2 O
idiosyncratic	369 13 O
response	383 8 O
to	392 2 O
chloramphenicol	395 15 B-Chemical
.	410 1 O

This	412 4 O
was	417 3 O
the	421 3 O
second	425 6 O
report	432 6 O
of	439 2 O
fatal	442 5 O
aplastic	448 8 B-Disease
anemia	457 6 I-Disease
after	464 5 O
topical	470 7 O
treatment	478 9 O
with	488 4 O
chloramphenicol	493 15 B-Chemical
for	509 3 O
ocular	513 6 O
conditions	520 10 O
,	530 1 O
although	532 8 O
two	541 3 O
cases	545 5 O
of	551 2 O
reversible	554 10 O
bone	565 4 B-Disease
marrow	570 6 I-Disease
hypoplasia	577 10 I-Disease
have	588 4 O
also	593 4 O
been	598 4 O
reported	603 8 O
.	611 1 O

Any	613 3 O
other	617 5 O
suspected	623 9 O
cases	633 5 O
of	639 2 O
ocular	642 6 B-Disease
toxicity	649 8 I-Disease
associated	658 10 O
with	669 4 O
topically	674 9 O
applied	684 7 O
chloramphenicol	692 15 B-Chemical
should	708 6 O
be	715 2 O
reported	718 8 O
to	727 2 O
the	730 3 O
National	734 8 O
Registry	743 8 O
of	752 2 O
Drug	755 4 O
-	759 1 O
Induced	760 7 O
Ocular	768 6 O
Side	775 4 O
Effects	780 7 O
,	787 1 O
Oregon	789 6 O
Health	796 6 O
Sciences	803 8 O
University	812 10 O
,	822 1 O
Portland	824 8 O
,	832 1 O
OR	834 2 O
97201	837 5 O
.	842 1 O

Bradycardia	0 11 B-Disease
due	12 3 O
to	16 2 O
trihexyphenidyl	19 15 B-Chemical
hydrochloride	35 13 I-Chemical
.	48 1 O

A	50 1 O
chronic	52 7 O
schizophrenic	60 13 B-Disease
patient	74 7 O
was	82 3 O
treated	86 7 O
with	94 4 O
an	99 2 O
anticholinergic	102 15 O
drug	118 4 O
,	122 1 O
trihexyphenidyl	124 15 B-Chemical
hydrochloride	140 13 I-Chemical
.	153 1 O

The	155 3 O
patient	159 7 O
developed	167 9 O
,	176 1 O
paradoxically	178 13 O
,	191 1 O
sinus	193 5 O
bradycardia	199 11 B-Disease
.	210 1 O

The	212 3 O
reaction	216 8 O
was	225 3 O
specific	229 8 O
to	238 2 O
trihexyphenidyl	241 15 B-Chemical
and	257 3 O
not	261 3 O
to	265 2 O
other	268 5 O
anticholinergic	274 15 O
drugs	290 5 O
.	295 1 O

This	297 4 O
antidyskinetic	302 14 O
drug	317 4 O
is	322 2 O
widely	325 6 O
used	332 4 O
in	337 2 O
clinical	340 8 O
psychiatric	349 11 B-Disease
practice	361 8 O
and	370 3 O
physicians	374 10 O
should	385 6 O
be	392 2 O
aware	395 5 O
of	401 2 O
this	404 4 O
side	409 4 O
effect	414 6 O
.	420 1 O

Experimental	0 12 O
cyclosporine	13 12 B-Chemical
nephrotoxicity	26 14 B-Disease
:	40 1 O
risk	42 4 O
of	47 2 O
concomitant	50 11 O
chemotherapy	62 12 O
.	74 1 O

The	76 3 O
role	80 4 O
of	85 2 O
cyclosporine	88 12 B-Chemical
(	101 1 O
CSA	102 3 B-Chemical
)	105 1 O
alone	107 5 O
or	113 2 O
in	116 2 O
combination	119 11 O
with	131 4 O
various	136 7 O
chemotherapeutics	144 17 O
in	162 2 O
the	165 3 O
development	169 11 O
of	181 2 O
renal	184 5 B-Disease
toxicity	190 8 I-Disease
was	199 3 O
evaluated	203 9 O
in	213 2 O
rats	216 4 O
.	220 1 O

Administration	222 14 O
of	237 2 O
20	240 2 O
mg	243 2 O
/	245 1 O
kg	246 2 O
/	248 1 O
day	249 3 O
CSA	253 3 B-Chemical
for	257 3 O
4	261 1 O
weeks	263 5 O
caused	269 6 O
renal	276 5 O
functional	282 10 O
and	293 3 O
structural	297 10 O
changes	308 7 O
similar	316 7 O
to	324 2 O
those	327 5 O
reported	333 8 O
in	342 2 O
man	345 3 O
.	348 1 O

The	350 3 O
combined	354 8 O
administration	363 14 O
of	378 2 O
CSA	381 3 B-Chemical
and	385 3 O
various	389 7 O
chemotherapeutic	397 16 O
drugs	414 5 O
with	420 4 O
a	425 1 O
nephrotoxic	427 11 B-Disease
potential	439 9 O
,	448 1 O
such	450 4 O
as	455 2 O
gentamicin	458 10 B-Chemical
(	469 1 O
at	470 2 O
therapeutic	473 11 O
doses	485 5 O
)	490 1 O
,	491 1 O
amphothericin	493 13 B-Chemical
B	507 1 I-Chemical
and	509 3 O
ketoconazole	513 12 B-Chemical
,	525 1 O
which	527 5 O
are	533 3 O
frequently	537 10 O
used	548 4 O
in	553 2 O
immunosuppressed	556 16 O
patients	573 8 O
,	581 1 O
did	583 3 O
not	587 3 O
aggravate	591 9 O
the	601 3 O
CSA	605 3 B-Chemical
induced	609 7 O
toxicity	617 8 B-Disease
in	626 2 O
the	629 3 O
rat	633 3 O
model	637 5 O
.	642 1 O

Gentamicin	644 10 B-Chemical
at	655 2 O
toxic	658 5 O
doses	664 5 O
,	669 1 O
however	671 7 O
,	678 1 O
increased	680 9 O
CSA	690 3 B-Chemical
nephrotoxicity	694 14 B-Disease
.	708 1 O

Thus	710 4 O
,	714 1 O
the	716 3 O
nephrotoxicity	720 14 B-Disease
induced	735 7 O
by	743 2 O
CSA	746 3 B-Chemical
has	750 3 O
a	754 1 O
different	756 9 O
pathogenetic	766 12 O
mechanism	779 9 O
.	788 1 O

Receptor	0 8 O
mechanisms	9 10 O
of	20 2 O
nicotine	23 8 B-Chemical
-	31 1 O
induced	32 7 O
locomotor	40 9 B-Disease
hyperactivity	50 13 I-Disease
in	64 2 O
chronic	67 7 O
nicotine	75 8 B-Chemical
-	83 1 O
treated	84 7 O
rats	92 4 O
.	96 1 O

Rats	98 4 O
were	103 4 O
pretreated	108 10 O
with	119 4 O
saline	124 6 O
or	131 2 O
nicotine	134 8 B-Chemical
(	143 1 O
1	144 1 O
.	145 1 O
5	146 1 O
mg	148 2 O
/	150 1 O
kg	151 2 O
per	154 3 O
day	158 3 O
)	161 1 O
by	163 2 O
subcutaneously	166 14 O
implanting	181 10 O
each	192 4 O
animal	197 6 O
with	204 4 O
an	209 2 O
Alzet	212 5 O
osmotic	218 7 O
mini	226 4 O
-	230 1 O
pump	231 4 O
which	236 5 O
continuously	242 12 O
released	255 8 O
saline	264 6 O
or	271 2 O
nicotine	274 8 B-Chemical
for	283 3 O
1	287 1 O
,	288 1 O
5	290 1 O
and	292 3 O
14	296 2 O
days	299 4 O
.	303 1 O

At	305 2 O
the	308 3 O
end	312 3 O
of	316 2 O
each	319 4 O
pretreatment	324 12 O
period	337 6 O
,	343 1 O
animals	345 7 O
were	353 4 O
used	358 4 O
for	363 3 O
(	367 1 O
i	368 1 O
)	369 1 O
determining	371 11 O
their	383 5 O
locomotor	389 9 O
response	399 8 O
to	408 2 O
acutely	411 7 O
injected	419 8 O
nicotine	428 8 B-Chemical
(	437 1 O
0	438 1 O
.	439 1 O
2	440 1 O
mg	442 2 O
/	444 1 O
kg	445 2 O
,	447 1 O
s	449 1 O
.	450 1 O
c	451 1 O
.	452 1 O
)	453 1 O
and	455 3 O
(	459 1 O
ii	460 2 O
)	462 1 O
measuring	464 9 O
the	474 3 O
density	478 7 O
of	486 2 O
L	489 1 O
-	490 1 O
[	491 1 O
3H	492 2 O
]	494 1 O
nicotine	495 8 B-Chemical
and	504 3 O
[	508 1 O
3H	509 2 O
]	511 1 O
spiperone	512 9 B-Chemical
binding	522 7 O
sites	530 5 O
in	536 2 O
the	539 3 O
striatum	543 8 O
.	551 1 O

We	553 2 O
observed	556 8 O
no	565 2 O
changes	568 7 O
in	576 2 O
nicotine	579 8 B-Chemical
-	587 1 O
induced	588 7 O
locomotor	596 9 O
response	606 8 O
,	614 1 O
striatal	616 8 O
L	625 1 O
-	626 1 O
[	627 1 O
3H	628 2 O
]	630 1 O
nicotine	631 8 B-Chemical
and	640 3 O
[	644 1 O
3H	645 2 O
]	647 1 O
spiperone	648 9 B-Chemical
binding	658 7 O
in	666 2 O
the	669 3 O
animals	673 7 O
pretreated	681 10 O
with	692 4 O
nicotine	697 8 B-Chemical
for	706 3 O
1	710 1 O
day	712 3 O
.	715 1 O

In	717 2 O
rats	720 4 O
which	725 5 O
were	731 4 O
pretreated	736 10 O
with	747 4 O
nicotine	752 8 B-Chemical
for	761 3 O
5	765 1 O
days	767 4 O
,	771 1 O
there	773 5 O
was	779 3 O
a	783 1 O
significant	785 11 O
increase	797 8 O
in	806 2 O
the	809 3 O
nicotine	813 8 B-Chemical
-	821 1 O
stimulated	822 10 O
locomotor	833 9 O
response	843 8 O
which	852 5 O
was	858 3 O
associated	862 10 O
with	873 4 O
an	878 2 O
increase	881 8 O
in	890 2 O
the	893 3 O
number	897 6 O
of	904 2 O
L	907 1 O
-	908 1 O
[	909 1 O
3H	910 2 O
]	912 1 O
nicotine	913 8 B-Chemical
binding	922 7 O
sites	930 5 O
and	936 3 O
also	940 4 O
with	945 4 O
an	950 2 O
elevated	953 8 O
dopamine	962 8 B-Chemical
(	971 1 O
DA	972 2 B-Chemical
)	974 1 O
level	976 5 O
in	982 2 O
the	985 3 O
striatum	989 8 O
.	997 1 O

The	999 3 O
number	1003 6 O
of	1010 2 O
striatal	1013 8 O
[	1022 1 O
3H	1023 2 O
]	1025 1 O
spiperone	1026 9 B-Chemical
binding	1036 7 O
sites	1044 5 O
was	1050 3 O
not	1054 3 O
affected	1058 8 O
.	1066 1 O

In	1068 2 O
animals	1071 7 O
pretreated	1079 10 O
with	1090 4 O
nicotine	1095 8 B-Chemical
for	1104 3 O
14	1108 2 O
days	1111 4 O
,	1115 1 O
the	1117 3 O
nicotine	1121 8 B-Chemical
-	1129 1 O
induced	1130 7 O
locomotor	1138 9 O
response	1148 8 O
remained	1157 8 O
to	1166 2 O
be	1169 2 O
potentiated	1172 11 O
.	1183 1 O

However	1185 7 O
,	1192 1 O
this	1194 4 O
response	1199 8 O
was	1208 3 O
correlated	1212 10 O
with	1223 4 O
an	1228 2 O
elevated	1231 8 O
number	1240 6 O
of	1247 2 O
striatal	1250 8 O
[	1259 1 O
3H	1260 2 O
]	1262 1 O
spiperone	1263 9 B-Chemical
binding	1273 7 O
sites	1281 5 O
,	1286 1 O
whereas	1288 7 O
the	1296 3 O
number	1300 6 O
of	1307 2 O
striatal	1310 8 O
L	1319 1 O
-	1320 1 O
[	1321 1 O
3H	1322 2 O
]	1324 1 O
nicotine	1325 8 B-Chemical
binding	1334 7 O
sites	1342 5 O
and	1348 3 O
the	1352 3 O
striatal	1356 8 O
DA	1365 2 B-Chemical
level	1368 5 O
were	1374 4 O
normal	1379 6 O
.	1385 1 O

These	1387 5 O
results	1393 7 O
suggest	1401 7 O
that	1409 4 O
chronic	1414 7 O
nicotine	1422 8 B-Chemical
-	1430 1 O
treated	1431 7 O
rats	1439 4 O
develop	1444 7 O
locomotor	1452 9 B-Disease
hyperactivity	1462 13 I-Disease
in	1476 2 O
response	1479 8 O
to	1488 2 O
nicotine	1491 8 B-Chemical
initially	1500 9 O
due	1510 3 O
to	1514 2 O
increases	1517 9 O
of	1527 2 O
both	1530 4 O
the	1535 3 O
density	1539 7 O
of	1547 2 O
nicotinic	1550 9 O
receptors	1560 9 O
and	1570 3 O
DA	1574 2 B-Chemical
concentration	1577 13 O
,	1590 1 O
followed	1592 8 O
by	1601 2 O
inducing	1604 8 O
DA	1613 2 B-Chemical
receptor	1616 8 O
supersensitivity	1625 16 O
in	1642 2 O
the	1645 3 O
striatum	1649 8 O
.	1657 1 O

Hydrocortisone	0 14 B-Chemical
-	14 1 O
induced	15 7 O
hypertension	23 12 B-Disease
in	36 2 O
humans	39 6 O
:	45 1 O
pressor	47 7 O
responsiveness	55 14 O
and	70 3 O
sympathetic	74 11 O
function	86 8 O
.	94 1 O

Oral	96 4 O
hydrocortisone	101 14 B-Chemical
increases	116 9 O
blood	126 5 O
pressure	132 8 O
and	141 3 O
enhances	145 8 O
pressor	154 7 O
responsiveness	162 14 O
in	177 2 O
normal	180 6 O
human	187 5 O
subjects	193 8 O
.	201 1 O

We	203 2 O
studied	206 7 O
the	214 3 O
effects	218 7 O
of	226 2 O
1	229 1 O
week	231 4 O
of	236 2 O
oral	239 4 O
hydrocortisone	244 14 B-Chemical
(	259 1 O
200	260 3 O
mg	264 2 O
/	266 1 O
day	267 3 O
)	270 1 O
on	272 2 O
blood	275 5 O
pressure	281 8 O
,	289 1 O
cardiac	291 7 O
output	299 6 O
,	305 1 O
total	307 5 O
peripheral	313 10 O
resistance	324 10 O
,	334 1 O
forearm	336 7 O
vascular	344 8 O
resistance	353 10 O
,	363 1 O
and	365 3 O
norepinephrine	369 14 B-Chemical
spillover	384 9 O
to	394 2 O
plasma	397 6 O
in	404 2 O
eight	407 5 O
healthy	413 7 O
male	421 4 O
volunteers	426 10 O
.	436 1 O

Although	438 8 O
diastolic	447 9 O
blood	457 5 O
pressure	463 8 O
remained	472 8 O
unchanged	481 9 O
,	490 1 O
systolic	492 8 O
blood	501 5 O
pressure	507 8 O
increased	516 9 O
from	526 4 O
119	531 3 O
to	535 2 O
135	538 3 O
mm	542 2 O
Hg	545 2 O
(	548 1 O
SED	549 3 O
+	553 1 O
/	554 1 O
-	555 1 O
3	557 1 O
.	558 1 O
4	559 1 O
,	560 1 O
p	562 1 O
less	564 4 O
than	569 4 O
0	574 1 O
.	575 1 O
01	576 2 O
)	578 1 O
,	579 1 O
associated	581 10 O
with	592 4 O
an	597 2 O
increased	600 9 B-Disease
cardiac	610 7 I-Disease
output	618 6 I-Disease
(	625 1 O
5	626 1 O
.	627 1 O
85	628 2 O
-	630 1 O
7	631 1 O
.	632 1 O
73	633 2 O
l	636 1 O
/	637 1 O
min	638 3 O
,	641 1 O
SED	643 3 O
+	647 1 O
/	648 1 O
-	649 1 O
0	651 1 O
.	652 1 O
46	653 2 O
,	655 1 O
p	657 1 O
less	659 4 O
than	664 4 O
0	669 1 O
.	670 1 O
01	671 2 O
)	673 1 O
.	674 1 O

Total	676 5 O
peripheral	682 10 O
vascular	693 8 O
resistance	702 10 O
fell	713 4 O
from	718 4 O
15	723 2 O
.	725 1 O
1	726 1 O
to	728 2 O
12	731 2 O
.	733 1 O
2	734 1 O
mm	736 2 O
Hg	739 2 O
/	741 1 O
l	742 1 O
/	743 1 O
min	744 3 O
(	748 1 O
SED	749 3 O
+	753 1 O
/	754 1 O
-	755 1 O
1	757 1 O
.	758 1 O
03	759 2 O
,	761 1 O
p	763 1 O
less	765 4 O
than	770 4 O
0	775 1 O
.	776 1 O
05	777 2 O
)	779 1 O
.	780 1 O

Resting	782 7 O
forearm	790 7 O
vascular	798 8 O
resistance	807 10 O
remained	818 8 O
unchanged	827 9 O
,	836 1 O
but	838 3 O
the	842 3 O
reflex	846 6 O
response	853 8 O
to	862 2 O
the	865 3 O
cold	869 4 O
pressor	874 7 O
test	882 4 O
was	887 3 O
accentuated	891 11 O
,	902 1 O
the	904 3 O
rise	908 4 O
in	913 2 O
resistance	916 10 O
increasing	927 10 O
from	938 4 O
10	943 2 O
.	945 1 O
5	946 1 O
mm	948 2 O
Hg	951 2 O
/	953 1 O
ml	954 2 O
/	956 1 O
100	957 3 O
ml	961 2 O
/	963 1 O
min	964 3 O
(	968 1 O
R	969 1 O
units	971 5 O
)	976 1 O
before	978 6 O
treatment	985 9 O
to	995 2 O
32	998 2 O
.	1000 1 O
6	1001 1 O
R	1003 1 O
units	1005 5 O
after	1011 5 O
treatment	1017 9 O
(	1027 1 O
SED	1028 3 O
+	1032 1 O
/	1033 1 O
-	1034 1 O
6	1036 1 O
.	1037 1 O
4	1038 1 O
,	1039 1 O
p	1041 1 O
less	1043 4 O
than	1048 4 O
0	1053 1 O
.	1054 1 O
025	1055 3 O
)	1058 1 O
.	1059 1 O

The	1061 3 O
rise	1065 4 O
in	1070 2 O
forearm	1073 7 O
vascular	1081 8 O
resistance	1090 10 O
accompanying	1101 12 O
intra	1114 5 O
-	1119 1 O
arterial	1120 8 O
norepinephrine	1129 14 B-Chemical
(	1144 1 O
25	1145 2 O
,	1147 1 O
50	1149 2 O
,	1151 1 O
and	1153 3 O
100	1157 3 O
ng	1161 2 O
/	1163 1 O
min	1164 3 O
)	1167 1 O
was	1169 3 O
also	1173 4 O
significantly	1178 13 O
greater	1192 7 O
after	1200 5 O
hydrocortisone	1206 14 B-Chemical
,	1220 1 O
increasing	1222 10 O
from	1233 4 O
an	1238 2 O
average	1241 7 O
of	1249 2 O
14	1252 2 O
.	1254 1 O
9	1255 1 O
+	1257 1 O
/	1258 1 O
-	1259 1 O
2	1261 1 O
.	1262 1 O
4	1263 1 O
R	1265 1 O
units	1267 5 O
before	1273 6 O
treatment	1280 9 O
to	1290 2 O
35	1293 2 O
.	1295 1 O
1	1296 1 O
+	1298 1 O
/	1299 1 O
-	1300 1 O
5	1302 1 O
.	1303 1 O
5	1304 1 O
R	1306 1 O
units	1308 5 O
after	1314 5 O
hydrocortisone	1320 14 B-Chemical
(	1335 1 O
SED	1336 3 O
+	1340 1 O
/	1341 1 O
-	1342 1 O
6	1344 1 O
.	1345 1 O
0	1346 1 O
,	1347 1 O
p	1349 1 O
less	1351 4 O
than	1356 4 O
0	1361 1 O
.	1362 1 O
05	1363 2 O
)	1365 1 O
.	1366 1 O

A	1368 1 O
shift	1370 5 O
to	1376 2 O
the	1379 3 O
left	1383 4 O
in	1388 2 O
the	1391 3 O
dose	1395 4 O
-	1399 1 O
response	1400 8 O
relation	1409 8 O
and	1418 3 O
fall	1422 4 O
in	1427 2 O
threshold	1430 9 O
suggested	1440 9 O
increased	1450 9 O
sensitivity	1460 11 O
to	1472 2 O
norepinephrine	1475 14 B-Chemical
after	1490 5 O
treatment	1496 9 O
.	1505 1 O

Measurement	1507 11 O
of	1519 2 O
resting	1522 7 O
norepinephrine	1530 14 B-Chemical
spillover	1545 9 O
rate	1555 4 O
to	1560 2 O
plasma	1563 6 O
and	1570 3 O
norepinephrine	1574 14 B-Chemical
uptake	1589 6 O
indicated	1596 9 O
that	1606 4 O
overall	1611 7 O
resting	1619 7 O
sympathetic	1627 11 O
nervous	1639 7 O
system	1647 6 O
activity	1654 8 O
was	1663 3 O
not	1667 3 O
increased	1671 9 O
.	1680 1 O

The	1682 3 O
rise	1686 4 B-Disease
in	1691 2 I-Disease
resting	1694 7 I-Disease
blood	1702 5 I-Disease
pressure	1708 8 I-Disease
with	1717 4 O
hydrocortisone	1722 14 B-Chemical
is	1737 2 O
associated	1740 10 O
with	1751 4 O
an	1756 2 O
increased	1759 9 B-Disease
cardiac	1769 7 I-Disease
output	1777 6 I-Disease
(	1784 1 O
presumably	1785 10 O
due	1796 3 O
to	1800 2 O
increased	1803 9 O
blood	1813 5 O
volume	1819 6 O
)	1825 1 O
.	1826 1 O
(	1827 1 O
ABSTRACT	1828 8 O
TRUNCATED	1837 9 O
AT	1847 2 O
250	1850 3 O
WORDS	1854 5 O
)	1859 1 O

Effects	0 7 O
of	8 2 O
suprofen	11 8 B-Chemical
on	20 2 O
the	23 3 O
isolated	27 8 O
perfused	36 8 O
rat	45 3 O
kidney	49 6 O
.	55 1 O

Although	57 8 O
suprofen	66 8 B-Chemical
has	75 3 O
been	79 4 O
associated	84 10 O
with	95 4 O
the	100 3 O
development	104 11 O
of	116 2 O
acute	119 5 B-Disease
renal	125 5 I-Disease
failure	131 7 I-Disease
in	139 2 O
greater	142 7 O
than	150 4 O
100	155 3 O
subjects	159 8 O
,	167 1 O
the	169 3 O
mechanism	173 9 O
of	183 2 O
damage	186 6 O
remains	193 7 O
unclear	201 7 O
.	208 1 O

The	210 3 O
direct	214 6 O
nephrotoxic	221 11 B-Disease
effects	233 7 O
of	241 2 O
a	244 1 O
single	246 6 O
dose	253 4 O
of	258 2 O
15	261 2 O
mg	264 2 O
of	267 2 O
suprofen	270 8 B-Chemical
were	279 4 O
compared	284 8 O
in	293 2 O
the	296 3 O
recirculating	300 13 O
isolated	314 8 O
rat	323 3 O
kidney	327 6 O
perfused	334 8 O
with	343 4 O
cell	348 4 O
-	352 1 O
free	353 4 O
buffer	358 6 O
with	365 4 O
or	370 2 O
without	373 7 O
the	381 3 O
addition	385 8 O
of	394 2 O
5	397 1 O
mg	399 2 O
/	401 1 O
dL	402 2 O
of	405 2 O
uric	408 4 B-Chemical
acid	413 4 I-Chemical
.	417 1 O

There	419 5 O
were	425 4 O
no	430 2 O
significant	433 11 O
differences	445 11 O
in	457 2 O
renal	460 5 O
sodium	466 6 B-Chemical
excretion	473 9 O
,	482 1 O
oxygen	484 6 B-Chemical
consumption	491 11 O
,	502 1 O
or	504 2 O
urinary	507 7 O
flow	515 4 O
rates	520 5 O
in	526 2 O
kidneys	529 7 O
perfused	537 8 O
with	546 4 O
suprofen	551 8 B-Chemical
compared	560 8 O
with	569 4 O
the	574 3 O
drug	578 4 O
-	582 1 O
free	583 4 O
control	588 7 O
groups	596 6 O
.	602 1 O

In	604 2 O
contrast	607 8 O
,	615 1 O
a	617 1 O
significant	619 11 O
decline	631 7 O
in	639 2 O
glomerular	642 10 O
filtration	653 10 O
rate	664 4 O
was	669 3 O
found	673 5 O
after	679 5 O
the	685 3 O
introduction	689 12 O
of	702 2 O
suprofen	705 8 B-Chemical
to	714 2 O
the	717 3 O
kidney	721 6 O
perfused	728 8 O
with	737 4 O
uric	742 4 B-Chemical
acid	747 4 I-Chemical
;	751 1 O
no	753 2 O
changes	756 7 O
were	764 4 O
found	769 5 O
with	775 4 O
suprofen	780 8 B-Chemical
in	789 2 O
the	792 3 O
absence	796 7 O
of	804 2 O
uric	807 4 B-Chemical
acid	812 4 I-Chemical
.	816 1 O

A	818 1 O
significant	820 11 O
decrease	832 8 O
in	841 2 O
the	844 3 O
baseline	848 8 O
excretion	857 9 O
rate	867 4 O
of	872 2 O
uric	875 4 B-Chemical
acid	880 4 I-Chemical
was	885 3 O
found	889 5 O
in	895 2 O
rats	898 4 O
given	903 5 O
suprofen	909 8 B-Chemical
,	917 1 O
compared	919 8 O
with	928 4 O
drug	933 4 O
-	937 1 O
free	938 4 O
controls	943 8 O
.	951 1 O

However	953 7 O
,	960 1 O
the	962 3 O
fractional	966 10 O
excretion	977 9 O
of	987 2 O
uric	990 4 B-Chemical
acid	995 4 I-Chemical
was	1000 3 O
unchanged	1004 9 O
between	1014 7 O
the	1022 3 O
groups	1026 6 O
over	1033 4 O
the	1038 3 O
experimental	1042 12 O
period	1055 6 O
.	1061 1 O

In	1063 2 O
summary	1066 7 O
,	1073 1 O
suprofen	1075 8 B-Chemical
causes	1084 6 O
acute	1091 5 B-Disease
declines	1097 8 I-Disease
in	1106 2 I-Disease
renal	1109 5 I-Disease
function	1115 8 I-Disease
,	1123 1 O
most	1125 4 O
likely	1130 6 O
by	1137 2 O
directly	1140 8 O
altering	1149 8 O
the	1158 3 O
intrarenal	1162 10 O
distribution	1173 12 O
of	1186 2 O
uric	1189 4 B-Chemical
acid	1194 4 I-Chemical
.	1198 1 O

Cocaine	0 7 B-Chemical
-	7 1 O
induced	8 7 O
brainstem	16 9 O
seizures	26 8 B-Disease
and	35 3 O
behavior	39 8 O
.	47 1 O

A	49 1 O
variety	51 7 O
of	59 2 O
abnormal	62 8 O
sensory	71 7 O
/	78 1 O
motor	79 5 O
behaviors	85 9 O
associated	95 10 O
with	106 4 O
electrical	111 10 O
discharges	122 10 O
recorded	133 8 O
from	142 4 O
the	147 3 O
bilateral	151 9 O
brainstem	161 9 O
were	171 4 O
induced	176 7 O
in	184 2 O
adult	187 5 O
WKY	193 3 O
rats	197 4 O
by	202 2 O
mechanical	205 10 O
(	216 1 O
electrode	217 9 O
implants	227 8 O
)	235 1 O
and	237 3 O
DC	241 2 O
electrical	244 10 O
current	255 7 O
stimulations	263 12 O
and	276 3 O
by	280 2 O
acute	283 5 O
and	289 3 O
chronic	293 7 O
administration	301 14 O
of	316 2 O
cocaine	319 7 B-Chemical
.	326 1 O

The	328 3 O
electrode	332 9 O
implant	342 7 O
implicated	350 10 O
one	361 3 O
side	365 4 O
or	370 2 O
the	373 3 O
other	377 5 O
of	383 2 O
the	386 3 O
reticular	390 9 O
system	400 6 O
of	407 2 O
the	410 3 O
brainstem	414 9 O
but	424 3 O
subjects	428 8 O
were	437 4 O
not	442 3 O
incapacitated	446 13 O
by	460 2 O
the	463 3 O
stimulations	467 12 O
.	479 1 O

Cocaine	481 7 B-Chemical
(	489 1 O
40	490 2 O
mg	493 2 O
/	495 1 O
kg	496 2 O
)	498 1 O
was	500 3 O
injected	504 8 O
subcutaneously	513 14 O
for	528 3 O
an	532 2 O
acute	535 5 O
experiment	541 10 O
and	552 3 O
subsequent	556 10 O
20	567 2 O
mg	570 2 O
/	572 1 O
kg	573 2 O
doses	576 5 O
twice	582 5 O
daily	588 5 O
for	594 3 O
3	598 1 O
days	600 4 O
in	605 2 O
a	608 1 O
chronic	610 7 O
study	618 5 O
.	623 1 O

Cocaine	625 7 B-Chemical
generated	633 9 O
more	643 4 O
abnormal	648 8 O
behaviors	657 9 O
in	667 2 O
the	670 3 O
brainstem	674 9 O
perturbation	684 12 O
group	697 5 O
,	702 1 O
especially	704 10 O
the	715 3 O
electrically	719 12 O
perturbated	732 11 O
subjects	744 8 O
.	752 1 O

The	754 3 O
abnormal	758 8 O
behaviors	767 9 O
were	777 4 O
yawning	782 7 O
,	789 1 O
retrocollis	791 11 O
,	802 1 O
hyperactivity	804 13 B-Disease
,	817 1 O
hypersensitivity	819 16 B-Disease
,	835 1 O
"	837 1 O
beating	838 7 O
drum	846 4 O
"	850 1 O
behavior	852 8 O
,	860 1 O
squealing	862 9 O
,	871 1 O
head	873 4 O
bobbing	878 7 O
,	885 1 O
circling	887 8 O
,	895 1 O
sniffing	897 8 O
,	905 1 O
abnormal	907 8 O
posturing	916 9 O
,	925 1 O
and	927 3 O
facial	931 6 O
twitching	938 9 O
.	947 1 O

Shifts	949 6 O
in	956 2 O
the	959 3 O
power	963 5 O
frequency	969 9 O
spectra	979 7 O
of	987 2 O
the	990 3 O
discharge	994 9 O
patterns	1004 8 O
were	1013 4 O
noted	1018 5 O
between	1024 7 O
quiet	1032 5 O
and	1038 3 O
pacing	1042 6 O
behavioral	1049 10 O
states	1060 6 O
.	1066 1 O

Hypersensitivity	1068 16 B-Disease
to	1085 2 O
various	1088 7 O
auditory	1096 8 O
,	1104 1 O
tactile	1106 7 O
,	1113 1 O
and	1115 3 O
visual	1119 6 O
stimulation	1126 11 O
was	1138 3 O
present	1142 7 O
and	1150 3 O
shifts	1154 6 O
in	1161 2 O
the	1164 3 O
brainstem	1168 9 O
ambient	1178 7 O
power	1186 5 O
spectral	1192 8 O
frequency	1201 9 O
occurred	1211 8 O
in	1220 2 O
response	1223 8 O
to	1232 2 O
tactile	1235 7 O
stimulation	1243 11 O
.	1254 1 O

These	1256 5 O
findings	1262 8 O
suggest	1271 7 O
that	1279 4 O
the	1284 3 O
brainstem	1288 9 O
generates	1298 9 O
and	1308 3 O
propagates	1312 10 O
pathological	1323 12 O
discharges	1336 10 O
that	1347 4 O
can	1352 3 O
be	1356 2 O
elicited	1359 8 O
by	1368 2 O
mechanical	1371 10 O
and	1382 3 O
DC	1386 2 O
electrical	1389 10 O
perturbation	1400 12 O
.	1412 1 O

Cocaine	1414 7 B-Chemical
was	1422 3 O
found	1426 5 O
to	1432 2 O
activate	1435 8 O
the	1444 3 O
discharge	1448 9 O
system	1458 6 O
and	1465 3 O
thus	1469 4 O
induce	1474 6 O
abnormal	1481 8 O
behaviors	1490 9 O
that	1500 4 O
are	1505 3 O
generated	1509 9 O
at	1519 2 O
the	1522 3 O
discharge	1526 9 O
site	1536 4 O
and	1541 3 O
at	1545 2 O
distant	1548 7 O
sites	1556 5 O
to	1562 2 O
which	1565 5 O
the	1571 3 O
discharge	1575 9 O
propagates	1585 10 O
.	1595 1 O

Cognitive	1597 9 O
functions	1607 9 O
may	1617 3 O
also	1621 4 O
be	1626 2 O
involved	1629 8 O
since	1638 5 O
dopaminergic	1644 12 O
and	1657 3 O
serotonergic	1661 12 O
cellular	1674 8 O
elements	1683 8 O
at	1692 2 O
the	1695 3 O
brainstem	1699 9 O
level	1709 5 O
are	1715 3 O
also	1719 4 O
implicated	1724 10 O
.	1734 1 O

Increased	0 9 O
sulfation	10 9 O
and	20 3 O
decreased	24 9 O
7alpha	34 6 O
-	40 1 O
hydroxylation	41 13 O
of	55 2 O
deoxycholic	58 11 B-Chemical
acid	70 4 I-Chemical
in	75 2 O
ethinyl	78 7 B-Chemical
estradiol	86 9 I-Chemical
-	95 1 O
induced	96 7 O
cholestasis	104 11 B-Disease
in	116 2 O
rats	119 4 O
.	123 1 O

Deoxycholic	125 11 B-Chemical
acid	137 4 I-Chemical
conjugation	142 11 O
,	153 1 O
transport	155 9 O
capacity	165 8 O
,	173 1 O
and	175 3 O
metabolism	179 10 O
were	190 4 O
compared	195 8 O
in	204 2 O
control	207 7 O
and	215 3 O
ethinyl	219 7 B-Chemical
estradiol	227 9 I-Chemical
-	236 1 O
treated	237 7 O
rats	245 4 O
.	249 1 O

Control	251 7 O
rats	259 4 O
were	264 4 O
found	269 5 O
to	275 2 O
have	278 4 O
a	283 1 O
lower	285 5 O
capacity	291 8 O
to	300 2 O
transport	303 9 O
deoxycholic	313 11 B-Chemical
acid	325 4 I-Chemical
than	330 4 O
taurodeoxycholic	335 16 B-Chemical
acid	352 4 I-Chemical
,	356 1 O
and	358 3 O
both	362 4 O
were	367 4 O
decreased	372 9 O
by	382 2 O
ethinyl	385 7 B-Chemical
estradiol	393 9 I-Chemical
treatment	403 9 O
.	412 1 O

During	414 6 O
[	421 1 O
24	422 2 O
-	424 1 O
14C	425 3 O
]	428 1 O
sodium	429 6 B-Chemical
deoxycholate	436 12 I-Chemical
infusion	449 8 O
,	457 1 O
[	459 1 O
14C	460 3 O
]	463 1 O
biliary	464 7 O
bile	472 4 B-Chemical
acid	477 4 I-Chemical
secretion	482 9 O
increased	492 9 O
,	501 1 O
but	503 3 O
bile	507 4 O
flow	512 4 O
did	517 3 O
not	521 3 O
change	525 6 O
significantly	532 13 O
in	546 2 O
either	549 6 O
control	556 7 O
or	564 2 O
ethinyl	567 7 B-Chemical
estradiol	575 9 I-Chemical
-	584 1 O
treated	585 7 O
rats	593 4 O
.	597 1 O

Ethinyl	599 7 B-Chemical
estradiol	607 9 I-Chemical
-	616 1 O
treated	617 7 O
animals	625 7 O
excreted	633 8 O
significantly	642 13 O
less	656 4 O
14C	661 3 O
as	665 2 O
taurocholic	668 11 B-Chemical
acid	680 4 I-Chemical
than	685 4 O
did	690 3 O
control	694 7 O
animals	702 7 O
,	709 1 O
consistent	711 10 O
with	722 4 O
an	727 2 O
impairment	730 10 O
of	741 2 O
7alpha	744 6 O
-	750 1 O
hydroxylation	751 13 O
of	765 2 O
taurodeoxycholic	768 16 B-Chemical
acid	785 4 I-Chemical
.	789 1 O

Ethinyl	791 7 B-Chemical
estradiol	799 9 I-Chemical
treatment	809 9 O
did	819 3 O
not	823 3 O
impair	827 6 O
conjugation	834 11 O
of	846 2 O
deoxycholic	849 11 B-Chemical
acid	861 4 I-Chemical
,	865 1 O
but	867 3 O
did	871 3 O
result	875 6 O
in	882 2 O
an	885 2 O
increase	888 8 O
in	897 2 O
sulfation	900 9 O
of	910 2 O
taurodeoxycholic	913 16 B-Chemical
acid	930 4 I-Chemical
from	935 4 O
1	940 1 O
.	941 1 O
5	942 1 O
%	943 1 O
in	945 2 O
controls	948 8 O
to	957 2 O
nearly	960 6 O
4	967 1 O
.	968 1 O
0	969 1 O
%	970 1 O
(	972 1 O
P	973 1 O
less	975 4 O
than	980 4 O
0	985 1 O
.	986 1 O
01	987 2 O
)	989 1 O
.	990 1 O

These	992 5 O
results	998 7 O
are	1006 3 O
consistent	1010 10 O
with	1021 4 O
the	1026 3 O
hypothesis	1030 10 O
that	1041 4 O
the	1046 3 O
rat	1050 3 O
has	1054 3 O
a	1058 1 O
poorer	1060 6 O
tolerance	1067 9 O
for	1077 3 O
deoxycholic	1081 11 B-Chemical
acid	1093 4 I-Chemical
than	1098 4 O
do	1103 2 O
certain	1106 7 O
other	1114 5 O
species	1120 7 O
.	1127 1 O

Furthermore	1129 11 O
,	1140 1 O
the	1142 3 O
rat	1146 3 O
converts	1150 8 O
deoxycholic	1159 11 B-Chemical
acid	1171 4 I-Chemical
,	1175 1 O
a	1177 1 O
poor	1179 4 O
choleretic	1184 10 O
,	1194 1 O
to	1196 2 O
taurocholic	1199 11 B-Chemical
acid	1211 4 I-Chemical
,	1215 1 O
a	1217 1 O
good	1219 4 O
choleretic	1224 10 O
.	1234 1 O

When	1236 4 O
this	1241 4 O
conversion	1246 10 O
is	1257 2 O
impaired	1260 8 O
with	1269 4 O
ethinyl	1274 7 B-Chemical
estradiol	1282 9 I-Chemical
treatment	1292 9 O
,	1301 1 O
sulfation	1303 9 O
may	1313 3 O
be	1317 2 O
an	1320 2 O
important	1323 9 O
alternate	1333 9 O
pathway	1343 7 O
for	1351 3 O
excretion	1355 9 O
of	1365 2 O
this	1368 4 O
potentially	1373 11 O
harmful	1385 7 O
bile	1393 4 B-Chemical
acid	1398 4 I-Chemical
.	1402 1 O

Effects	0 7 O
of	8 2 O
ouabain	11 7 B-Chemical
on	19 2 O
myocardial	22 10 O
oxygen	33 6 B-Chemical
supply	40 6 O
and	47 3 O
demand	51 6 O
in	58 2 O
patients	61 8 O
with	70 4 O
chronic	75 7 O
coronary	83 8 B-Disease
artery	92 6 I-Disease
disease	99 7 I-Disease
.	106 1 O

A	108 1 O
hemodynamic	110 11 O
,	121 1 O
volumetric	123 10 O
,	133 1 O
and	135 3 O
metabolic	139 9 O
study	149 5 O
in	155 2 O
patients	158 8 O
without	167 7 O
heart	175 5 B-Disease
failure	181 7 I-Disease
.	188 1 O

The	190 3 O
effects	194 7 O
of	202 2 O
digitalis	205 9 B-Chemical
glycosides	215 10 I-Chemical
on	226 2 O
myocardial	229 10 O
oxygen	240 6 B-Chemical
supply	247 6 O
and	254 3 O
demand	258 6 O
are	265 3 O
of	269 2 O
particular	272 10 O
interest	283 8 O
in	292 2 O
the	295 3 O
presence	299 8 O
of	308 2 O
obstructive	311 11 O
coronary	323 8 B-Disease
artery	332 6 I-Disease
disease	339 7 I-Disease
,	346 1 O
but	348 3 O
have	352 4 O
not	357 3 O
been	361 4 O
measured	366 8 O
previously	375 10 O
in	386 2 O
man	389 3 O
.	392 1 O

We	394 2 O
assessed	397 8 O
the	406 3 O
effects	410 7 O
of	418 2 O
ouabain	421 7 B-Chemical
(	429 1 O
0	430 1 O
.	431 1 O
015	432 3 O
mg	436 2 O
/	438 1 O
kg	439 2 O
body	442 4 O
weight	447 6 O
)	453 1 O
on	455 2 O
hemodynamic	458 11 O
,	469 1 O
volumetric	471 10 O
,	481 1 O
and	483 3 O
metabolic	487 9 O
parameters	497 10 O
in	508 2 O
11	511 2 O
patients	514 8 O
with	523 4 O
severe	528 6 O
chronic	535 7 O
coronary	543 8 B-Disease
artery	552 6 I-Disease
disease	559 7 I-Disease
without	567 7 O
clinical	575 8 O
congestive	584 10 B-Disease
heart	595 5 I-Disease
failure	601 7 I-Disease
.	608 1 O

Because	610 7 O
the	618 3 O
protocol	622 8 O
was	631 3 O
long	635 4 O
and	640 3 O
involved	644 8 O
interventions	653 13 O
which	667 5 O
might	673 5 O
affect	679 6 O
the	686 3 O
determinations	690 14 O
,	704 1 O
we	706 2 O
also	709 4 O
studied	714 7 O
in	722 2 O
nine	725 4 O
patients	730 8 O
using	739 5 O
an	745 2 O
identical	748 9 O
protocol	758 8 O
except	767 6 O
that	774 4 O
ouabain	779 7 B-Chemical
administration	787 14 O
was	802 3 O
omitted	806 7 O
.	813 1 O

Left	815 4 O
ventricular	820 11 O
end	832 3 O
-	835 1 O
diastolic	836 9 O
pressure	846 8 O
and	855 3 O
left	859 4 O
ventricular	864 11 O
end	876 3 O
-	879 1 O
diastolic	880 9 O
volume	890 6 O
fell	897 4 O
in	902 2 O
each	905 4 O
patient	910 7 O
given	918 5 O
ouabain	924 7 B-Chemical
,	931 1 O
even	933 4 O
though	938 6 O
they	945 4 O
were	950 4 O
initially	955 9 O
elevated	965 8 O
in	974 2 O
only	977 4 O
two	982 3 O
patients	986 8 O
.	994 1 O

Left	996 4 O
ventricular	1001 11 O
end	1013 3 O
-	1016 1 O
diastolic	1017 9 O
pressure	1027 8 O
fell	1036 4 O
from	1041 4 O
11	1046 2 O
.	1048 1 O
5	1049 1 O
+	1050 1 O
/	1051 1 O
-	1052 1 O
1	1053 1 O
.	1054 1 O
4	1055 1 O
(	1057 1 O
mean	1058 4 O
+	1062 1 O
/	1063 1 O
-	1064 1 O
SE	1065 2 O
)	1067 1 O
to	1069 2 O
5	1072 1 O
.	1073 1 O
6	1074 1 O
+	1075 1 O
/	1076 1 O
-	1077 1 O
0	1078 1 O
.	1079 1 O
9	1080 1 O
mm	1082 2 O
Hg	1085 2 O
(	1088 1 O
P	1089 1 O
less	1091 4 O
than	1096 4 O
0	1101 1 O
.	1102 1 O
001	1103 3 O
)	1106 1 O
and	1108 3 O
left	1112 4 O
ventricular	1117 11 O
end	1129 3 O
-	1132 1 O
diastolic	1133 9 O
volume	1143 6 O
fell	1150 4 O
from	1155 4 O
100	1160 3 O
+	1163 1 O
/	1164 1 O
-	1165 1 O
17	1166 2 O
to	1169 2 O
82	1172 2 O
+	1174 1 O
/	1175 1 O
-	1176 1 O
12	1177 2 O
ml	1180 2 O
/	1182 1 O
m2	1183 2 O
(	1186 1 O
P	1187 1 O
less	1189 4 O
than	1194 4 O
0	1199 1 O
.	1200 1 O
01	1201 2 O
)	1203 1 O
1	1205 1 O
h	1207 1 O
after	1209 5 O
ouabain	1215 7 B-Chemical
infusion	1223 8 O
was	1232 3 O
completed	1236 9 O
.	1245 1 O

The	1247 3 O
maximum	1251 7 O
velocity	1259 8 O
of	1268 2 O
contractile	1271 11 O
element	1283 7 O
shortening	1291 10 O
increased	1302 9 O
from	1312 4 O
1	1317 1 O
.	1318 1 O
68	1319 2 O
+	1321 1 O
/	1322 1 O
-	1323 1 O
0	1324 1 O
.	1325 1 O
11	1326 2 O
ml	1329 2 O
/	1331 1 O
s	1332 1 O
to	1334 2 O
2	1337 1 O
.	1338 1 O
18	1339 2 O
+	1341 1 O
/	1342 1 O
-	1343 1 O
0	1344 1 O
.	1345 1 O
21	1346 2 O
muscle	1349 6 O
-	1355 1 O
lengths	1356 7 O
/	1363 1 O
s	1364 1 O
(	1366 1 O
P	1367 1 O
less	1369 4 O
than	1374 4 O
0	1379 1 O
.	1380 1 O
05	1381 2 O
)	1383 1 O
and	1385 3 O
is	1389 2 O
consistent	1392 10 O
with	1403 4 O
an	1408 2 O
increase	1411 8 O
in	1420 2 O
contractility	1423 13 O
.	1436 1 O

No	1438 2 O
significant	1441 11 O
change	1453 6 O
in	1460 2 O
these	1463 5 O
parameters	1469 10 O
occurred	1480 8 O
in	1489 2 O
the	1492 3 O
control	1496 7 O
patients	1504 8 O
.	1512 1 O

No	1514 2 O
significant	1517 11 O
change	1529 6 O
in	1536 2 O
myocardial	1539 10 O
oxygen	1550 6 B-Chemical
consumption	1557 11 O
occurred	1569 8 O
after	1578 5 O
ouabain	1584 7 B-Chemical
administration	1592 14 O
but	1607 3 O
this	1611 4 O
may	1616 3 O
be	1620 2 O
related	1623 7 O
to	1631 2 O
a	1634 1 O
greater	1636 7 O
decrease	1644 8 O
in	1653 2 O
mean	1656 4 O
arterial	1661 8 O
pressure	1670 8 O
in	1679 2 O
the	1682 3 O
ouabain	1686 7 B-Chemical
patients	1694 8 O
than	1703 4 O
in	1708 2 O
the	1711 3 O
control	1715 7 O
patients	1723 8 O
.	1731 1 O

We	1733 2 O
conclude	1736 8 O
that	1745 4 O
in	1750 2 O
patients	1753 8 O
with	1762 4 O
chronic	1767 7 O
coronary	1775 8 B-Disease
artery	1784 6 I-Disease
disease	1791 7 I-Disease
who	1799 3 O
are	1803 3 O
not	1807 3 O
in	1811 2 O
clinical	1814 8 O
congestive	1823 10 B-Disease
heart	1834 5 I-Disease
failure	1840 7 I-Disease
left	1848 4 B-Disease
ventricular	1853 11 I-Disease
end	1865 3 I-Disease
-	1868 1 I-Disease
diastolic	1869 9 I-Disease
volume	1879 6 I-Disease
falls	1886 5 I-Disease
after	1892 5 O
ouabain	1898 7 B-Chemical
administration	1906 14 O
even	1921 4 O
when	1926 4 O
it	1931 2 O
is	1934 2 O
initially	1937 9 O
normal	1947 6 O
.	1953 1 O

Though	1955 6 O
this	1962 4 O
fall	1967 4 O
would	1972 5 O
be	1978 2 O
associated	1981 10 O
with	1992 4 O
a	1997 1 O
decrease	1999 8 O
in	2008 2 O
wall	2011 4 O
tension	2016 7 O
,	2023 1 O
and	2025 3 O
,	2028 1 O
therefore	2030 9 O
,	2039 1 O
of	2041 2 O
myocardial	2044 10 O
oxygen	2055 6 B-Chemical
consumption	2062 11 O
,	2073 1 O
it	2075 2 O
may	2078 3 O
not	2082 3 O
be	2086 2 O
of	2089 2 O
sufficient	2092 10 O
magnitude	2103 9 O
to	2113 2 O
prevent	2116 7 O
a	2124 1 O
net	2126 3 O
increase	2130 8 O
in	2139 2 O
myocardial	2142 10 O
oxygen	2153 6 B-Chemical
consumption	2160 11 O
.	2171 1 O

Nevertheless	2173 12 O
,	2185 1 O
compensatory	2187 12 O
mechanisms	2200 10 O
prevent	2211 7 O
a	2219 1 O
deterioration	2221 13 O
of	2235 2 O
resting	2238 7 O
myocardial	2246 10 O
metabolism	2257 10 O
.	2267 1 O

Prolongation	0 12 B-Disease
of	13 2 I-Disease
the	16 3 I-Disease
QT	20 2 I-Disease
interval	23 8 I-Disease
related	32 7 O
to	40 2 O
cisapride	43 9 B-Chemical
-	52 1 O
diltiazem	53 9 B-Chemical
interaction	63 11 O
.	74 1 O

Cisapride	76 9 B-Chemical
,	85 1 O
a	87 1 O
cytochrome	89 10 O
P450	100 4 O
3A4	105 3 O
(	109 1 O
CYP3A4	110 6 O
)	116 1 O
substrate	118 9 O
,	127 1 O
is	129 2 O
widely	132 6 O
prescribed	139 10 O
for	150 3 O
the	154 3 O
treatment	158 9 O
of	168 2 O
gastrointestinal	171 16 B-Disease
motility	188 8 I-Disease
disorders	197 9 I-Disease
.	206 1 O

Prolongation	208 12 B-Disease
of	221 2 I-Disease
QT	224 2 I-Disease
interval	227 8 I-Disease
,	235 1 O
torsades	237 8 B-Disease
de	246 2 I-Disease
pointes	249 7 I-Disease
,	256 1 O
and	258 3 O
sudden	262 6 B-Disease
cardiac	269 7 I-Disease
death	277 5 I-Disease
have	283 4 O
been	288 4 O
reported	293 8 O
after	302 5 O
concomitant	308 11 O
administration	320 14 O
with	335 4 O
erythromycin	340 12 B-Chemical
or	353 2 O
azole	356 5 B-Chemical
antifungal	362 10 O
agents	373 6 O
,	379 1 O
but	381 3 O
not	385 3 O
with	389 4 O
other	394 5 O
CYP3A4	400 6 O
inhibitors	407 10 O
.	417 1 O

A	419 1 O
possible	421 8 O
drug	430 4 O
interaction	435 11 O
occurred	447 8 O
in	456 2 O
a	459 1 O
45	461 2 O
-	463 1 O
year	464 4 O
-	468 1 O
old	469 3 O
woman	473 5 O
who	479 3 O
was	483 3 O
taking	487 6 O
cisapride	494 9 B-Chemical
for	504 3 O
gastroesophageal	508 16 B-Disease
reflux	525 6 I-Disease
disorder	532 8 I-Disease
and	541 3 O
diltiazem	545 9 B-Chemical
,	554 1 O
an	556 2 O
agent	559 5 O
that	565 4 O
has	570 3 O
inhibitory	574 10 O
effect	585 6 O
on	592 2 O
CYP3A4	595 6 O
,	601 1 O
for	603 3 O
hypertension	607 12 B-Disease
.	619 1 O

The	621 3 O
patient	625 7 O
was	633 3 O
in	637 2 O
near	640 4 O
syncope	645 7 B-Disease
and	653 3 O
had	657 3 O
QT	661 2 B-Disease
-	663 1 I-Disease
interval	664 8 I-Disease
prolongation	673 12 I-Disease
.	685 1 O

After	687 5 O
discontinuing	693 13 O
cisapride	707 9 B-Chemical
,	716 1 O
the	718 3 O
QT	722 2 O
interval	725 8 O
returned	734 8 O
to	743 2 O
normal	746 6 O
and	753 3 O
symptoms	757 8 O
did	766 3 O
not	770 3 O
recur	774 5 O
.	779 1 O

We	781 2 O
suggest	784 7 O
that	792 4 O
caution	797 7 O
be	805 2 O
taken	808 5 O
when	814 4 O
cisapride	819 9 B-Chemical
is	829 2 O
prescribed	832 10 O
with	843 4 O
any	848 3 O
potent	852 6 O
inhibitor	859 9 O
of	869 2 O
CYP3A4	872 6 O
,	878 1 O
including	880 9 O
diltiazem	890 9 B-Chemical
.	899 1 O

Paclitaxel	0 10 B-Chemical
combined	11 8 O
with	20 4 O
carboplatin	25 11 B-Chemical
in	37 2 O
the	40 3 O
first	44 5 O
-	49 1 O
line	50 4 O
treatment	55 9 O
of	65 2 O
advanced	68 8 O
ovarian	77 7 B-Disease
cancer	85 6 I-Disease
.	91 1 O

In	93 2 O
a	96 1 O
phase	98 5 O
I	104 1 O
study	106 5 O
to	112 2 O
determine	115 9 O
the	125 3 O
maximum	129 7 O
tolerated	137 9 O
dose	147 4 O
of	152 2 O
paclitaxel	155 10 B-Chemical
(	166 1 O
Taxol	167 5 B-Chemical
;	172 1 O
Bristol	174 7 O
-	181 1 O
Myers	182 5 O
Squibb	188 6 O
Company	195 7 O
,	202 1 O
Princeton	204 9 O
,	213 1 O
NJ	215 2 O
)	217 1 O
given	219 5 O
as	225 2 O
a	228 1 O
3	230 1 O
-	231 1 O
hour	232 4 O
infusion	237 8 O
in	246 2 O
combination	249 11 O
with	261 4 O
carboplatin	266 11 B-Chemical
administered	278 12 O
every	291 5 O
21	297 2 O
days	300 4 O
to	305 2 O
women	308 5 O
with	314 4 O
advanced	319 8 O
ovarian	328 7 B-Disease
cancer	336 6 I-Disease
,	342 1 O
paclitaxel	344 10 B-Chemical
doses	355 5 O
were	361 4 O
escalated	366 9 O
as	376 2 O
follows	379 7 O
:	386 1 O
level	388 5 O
1	394 1 O
,	395 1 O
135	397 3 O
mg	401 2 O
/	403 1 O
m2	404 2 O
;	406 1 O
level	408 5 O
2	414 1 O
,	415 1 O
160	417 3 O
mg	421 2 O
/	423 1 O
m2	424 2 O
;	426 1 O
level	428 5 O
3	434 1 O
,	435 1 O
185	437 3 O
mg	441 2 O
/	443 1 O
m2	444 2 O
;	446 1 O
and	448 3 O
level	452 5 O
4	458 1 O
,	459 1 O
210	460 3 O
mg	464 2 O
/	466 1 O
m2	467 2 O
.	469 1 O

The	471 3 O
fixed	475 5 O
dose	481 4 O
of	486 2 O
carboplatin	489 11 B-Chemical
at	501 2 O
levels	504 6 O
1	511 1 O
through	513 7 O
4	521 1 O
was	523 3 O
given	527 5 O
to	533 2 O
achieve	536 7 O
an	544 2 O
area	547 4 O
under	552 5 O
the	558 3 O
concentration	562 13 O
-	575 1 O
time	576 4 O
curve	581 5 O
(	587 1 O
AUC	588 3 O
)	591 1 O
of	593 2 O
5	596 1 O
using	598 5 O
the	604 3 O
Calvert	608 7 O
formula	616 7 O
.	623 1 O

In	625 2 O
levels	628 6 O
5	635 1 O
and	637 3 O
6	641 1 O
the	643 3 O
carboplatin	647 11 B-Chemical
dose	659 4 O
was	664 3 O
targeted	668 8 O
at	677 2 O
AUCs	680 4 O
of	685 2 O
6	688 1 O
and	690 3 O
7	694 1 O
.	695 1 O
5	696 1 O
,	697 1 O
respectively	699 12 O
,	711 1 O
combined	713 8 O
with	722 4 O
a	727 1 O
fixed	729 5 O
paclitaxel	735 10 B-Chemical
dose	746 4 O
of	751 2 O
185	754 3 O
mg	758 2 O
/	760 1 O
m2	761 2 O
.	763 1 O

To	765 2 O
date	768 4 O
,	772 1 O
30	774 2 O
previously	777 10 O
untreated	788 9 O
patients	798 8 O
,	806 1 O
all	808 3 O
with	812 4 O
a	817 1 O
good	819 4 O
performance	824 11 O
status	836 6 O
(	843 1 O
Eastern	844 7 O
Cooperative	852 11 O
Oncology	864 8 O
Group	873 5 O
0	879 1 O
to	881 2 O
2	884 1 O
)	885 1 O
have	887 4 O
been	892 4 O
entered	897 7 O
into	905 4 O
this	910 4 O
ongoing	915 7 O
study	923 5 O
.	928 1 O

The	930 3 O
dose	934 4 O
-	938 1 O
limiting	939 8 O
toxicity	948 8 B-Disease
of	957 2 O
the	960 3 O
combination	964 11 O
was	976 3 O
myelosuppression	980 16 B-Disease
(	997 1 O
leukopenia	998 10 B-Disease
,	1008 1 O
granulocytopenia	1010 16 B-Disease
,	1026 1 O
and	1028 3 O
thrombocytopenia	1032 16 B-Disease
)	1048 1 O
.	1049 1 O

Neurotoxicity	1051 13 B-Disease
was	1065 3 O
largely	1069 7 O
moderate	1077 8 O
.	1085 1 O

So	1087 2 O
far	1090 3 O
,	1093 1 O
14	1095 2 O
patients	1098 8 O
are	1107 3 O
evaluable	1111 9 O
for	1121 3 O
response	1125 8 O
;	1133 1 O
of	1135 2 O
these	1138 5 O
,	1143 1 O
eight	1145 5 O
(	1151 1 O
57	1152 2 O
%	1154 1 O
)	1155 1 O
showed	1157 6 O
objective	1164 9 O
(	1174 1 O
complete	1175 8 O
or	1184 2 O
partial	1187 7 O
)	1194 1 O
response	1196 8 O
and	1205 3 O
disease	1209 7 O
stabilized	1217 10 O
in	1228 2 O
six	1231 3 O
patients	1235 8 O
.	1243 1 O

No	1245 2 O
patient	1248 7 O
had	1256 3 O
disease	1260 7 O
progression	1268 11 O
.	1279 1 O

We	1281 2 O
conclude	1284 8 O
that	1293 4 O
the	1298 3 O
combination	1302 11 O
of	1314 2 O
paclitaxel	1317 10 B-Chemical
185	1328 3 O
mg	1332 2 O
/	1334 1 O
m2	1335 2 O
administered	1338 12 O
as	1351 2 O
a	1354 1 O
3	1356 1 O
-	1357 1 O
hour	1358 4 O
infusion	1363 8 O
followed	1372 8 O
immediately	1381 11 O
by	1393 2 O
a	1396 1 O
1	1398 1 O
-	1399 1 O
hour	1400 4 O
infusion	1405 8 O
of	1414 2 O
carboplatin	1417 11 B-Chemical
at	1429 2 O
an	1432 2 O
AUC	1435 3 O
of	1439 2 O
6	1442 1 O
can	1444 3 O
be	1448 2 O
administered	1451 12 O
safely	1464 6 O
in	1471 2 O
a	1474 1 O
21	1476 2 O
-	1478 1 O
day	1479 3 O
schedule	1483 8 O
in	1492 2 O
the	1495 3 O
outpatient	1499 10 O
setting	1510 7 O
.	1517 1 O

The	1519 3 O
recommended	1523 11 O
dose	1535 4 O
for	1540 3 O
phase	1544 5 O
III	1550 3 O
studies	1554 7 O
is	1562 2 O
paclitaxel	1565 10 B-Chemical
185	1576 3 O
mg	1580 2 O
/	1582 1 O
m2	1583 2 O
and	1586 3 O
carboplatin	1590 11 B-Chemical
AUC	1602 3 O
6	1606 1 O
.	1607 1 O

Treatment	0 9 O
of	10 2 O
tacrolimus	13 10 B-Chemical
-	23 1 O
related	24 7 O
adverse	32 7 O
effects	40 7 O
by	48 2 O
conversion	51 10 O
to	62 2 O
cyclosporine	65 12 B-Chemical
in	78 2 O
liver	81 5 O
transplant	87 10 O
recipients	98 10 O
.	108 1 O

When	110 4 O
tacrolimus	115 10 B-Chemical
side	126 4 O
effects	131 7 O
persist	139 7 O
despite	147 7 O
dose	155 4 O
reduction	160 9 O
,	169 1 O
conversion	171 10 O
to	182 2 O
cyclosporine	185 12 B-Chemical
-	197 1 O
based	198 5 O
immunosuppression	204 17 O
(	222 1 O
CyA	223 3 O
)	226 1 O
is	228 2 O
necessary	231 9 O
.	240 1 O

We	242 2 O
characterized	245 13 O
tacrolimus	259 10 B-Chemical
side	270 4 O
effects	275 7 O
that	283 4 O
warranted	288 9 O
discontinuation	298 15 O
of	314 2 O
the	317 3 O
drug	321 4 O
,	325 1 O
and	327 3 O
outcomes	331 8 O
after	340 5 O
conversion	346 10 O
.	356 1 O

Of	358 2 O
388	361 3 O
liver	365 5 O
recipients	371 10 O
who	382 3 O
received	386 8 O
tacrolimus	395 10 B-Chemical
as	406 2 O
primary	409 7 O
immunosuppression	417 17 O
,	434 1 O
70	436 2 O
required	439 8 O
conversion	448 10 O
to	459 2 O
CyA	462 3 O
.	465 1 O

We	467 2 O
recorded	470 8 O
indication	479 10 O
for	490 3 O
conversion	494 10 O
,	504 1 O
whether	506 7 O
conversion	514 10 O
was	525 3 O
early	529 5 O
or	535 2 O
late	538 4 O
after	543 5 O
transplantation	549 15 O
,	564 1 O
tacrolimus	566 10 B-Chemical
dose	577 4 O
and	582 3 O
trough	586 6 O
blood	593 5 O
level	599 5 O
at	605 2 O
conversion	608 10 O
,	618 1 O
and	620 3 O
incidence	624 9 O
of	634 2 O
rejection	637 9 O
after	647 5 O
conversion	653 10 O
.	663 1 O

Conversion	665 10 O
was	676 3 O
early	680 5 O
in	686 2 O
29	689 2 O
patients	692 8 O
(	701 1 O
41	702 2 O
.	704 1 O
4	705 1 O
%	706 1 O
)	707 1 O
and	709 3 O
late	713 4 O
in	718 2 O
41	721 2 O
(	724 1 O
58	725 2 O
.	727 1 O
6	728 1 O
%	729 1 O
)	730 1 O
.	731 1 O

Indications	733 11 O
for	745 3 O
early	749 5 O
conversion	755 10 O
were	766 4 O
neurotoxicity	771 13 B-Disease
(	785 1 O
20	786 2 O
)	788 1 O
,	789 1 O
(	791 1 B-Disease
insulin	792 7 I-Disease
-	799 1 I-Disease
dependent	800 9 I-Disease
)	809 1 I-Disease
diabetes	811 8 I-Disease
mellitus	820 8 I-Disease
(	829 1 O
IDDM	830 4 B-Disease
)	834 1 O
(	836 1 O
5	837 1 O
)	838 1 O
,	839 1 O
nephrotoxicity	841 14 B-Disease
(	856 1 O
3	857 1 O
)	858 1 O
,	859 1 O
gastrointestinal	861 16 B-Disease
(	878 1 I-Disease
GI	879 2 I-Disease
)	881 1 I-Disease
toxicity	883 8 I-Disease
(	892 1 O
6	893 1 O
)	894 1 O
,	895 1 O
and	897 3 O
cardiomyopathy	901 14 B-Disease
(	916 1 O
1	917 1 O
)	918 1 O
,	919 1 O
and	921 3 O
for	925 3 O
late	929 4 O
conversion	934 10 O
were	945 4 O
neurotoxicity	950 13 B-Disease
(	964 1 O
15	965 2 O
)	967 1 O
,	968 1 O
IDDM	970 4 B-Disease
(	975 1 O
12	976 2 O
)	978 1 O
,	979 1 O
nephrotoxicity	981 14 B-Disease
(	996 1 O
3	997 1 O
)	998 1 O
,	999 1 O
GI	1001 2 B-Disease
toxicity	1004 8 I-Disease
(	1013 1 O
5	1014 1 O
)	1015 1 O
,	1016 1 O
hepatotoxicity	1018 14 B-Disease
(	1033 1 O
6	1034 1 O
)	1035 1 O
,	1036 1 O
post	1038 4 B-Disease
-	1042 1 I-Disease
transplant	1043 10 I-Disease
lmphoproliferate	1054 16 I-Disease
disease	1071 7 I-Disease
(	1079 1 O
PTLD	1080 4 B-Disease
)	1084 1 O
(	1086 1 O
2	1087 1 O
)	1088 1 O
,	1089 1 O
cardiomyopathy	1091 14 B-Disease
(	1106 1 O
1	1107 1 O
)	1108 1 O
,	1109 1 O
hemolytic	1111 9 B-Disease
anemia	1121 6 I-Disease
(	1128 1 O
1	1129 1 O
)	1130 1 O
,	1131 1 O
and	1133 3 O
pruritus	1137 8 B-Disease
(	1146 1 O
1	1147 1 O
)	1148 1 O
.	1149 1 O

All	1151 3 O
early	1155 5 O
-	1160 1 O
conversion	1161 10 O
patients	1172 8 O
showed	1181 6 O
improvement	1188 11 O
/	1199 1 O
resolution	1200 10 O
of	1211 2 O
symptoms	1214 8 O
.	1222 1 O

Among	1224 5 O
late	1230 4 O
-	1234 1 O
conversion	1235 10 O
patients	1246 8 O
,	1254 1 O
37	1256 2 O
(	1259 1 O
90	1260 2 O
.	1262 1 O
2	1263 1 O
%	1264 1 O
)	1265 1 O
had	1267 3 O
improvement	1271 11 O
/	1282 1 O
resolution	1283 10 O
;	1293 1 O
in	1295 2 O
4	1298 1 O
(	1300 1 O
9	1301 1 O
.	1302 1 O
8	1303 1 O
%	1304 1 O
)	1305 1 O
,	1306 1 O
adverse	1308 7 O
effects	1316 7 O
persisted	1324 9 O
.	1333 1 O

The	1335 3 O
overall	1339 7 O
rejection	1347 9 O
rate	1357 4 O
was	1362 3 O
30	1366 2 O
%	1368 1 O
.	1369 1 O

Sixty	1371 5 O
-	1376 1 O
two	1377 3 O
patients	1381 8 O
(	1390 1 O
88	1391 2 O
.	1393 1 O
6	1394 1 O
%	1395 1 O
)	1396 1 O
are	1398 3 O
alive	1402 5 O
with	1408 4 O
functioning	1413 11 O
grafts	1425 6 O
686	1432 3 O
+	1436 1 O
/	1437 1 O
-	1438 1 O
362	1440 3 O
days	1444 4 O
(	1449 1 O
range	1450 5 O
,	1455 1 O
154	1457 3 O
-	1460 1 O
1433	1461 4 O
days	1466 4 O
)	1470 1 O
after	1472 5 O
conversion	1478 10 O
.	1488 1 O

When	1490 4 O
tacrolimus	1495 10 B-Chemical
side	1506 4 O
effects	1511 7 O
are	1519 3 O
unresponsive	1523 12 O
to	1536 2 O
dose	1539 4 O
reduction	1544 9 O
,	1553 1 O
conversion	1555 10 O
to	1566 2 O
CyA	1569 3 O
can	1573 3 O
be	1577 2 O
accomplished	1580 12 O
safely	1593 6 O
,	1599 1 O
with	1601 4 O
no	1606 2 O
increased	1609 9 O
risk	1619 4 O
of	1624 2 O
rejection	1627 9 O
and	1637 3 O
excellent	1641 9 O
long	1651 4 O
-	1655 1 O
term	1656 4 O
outcome	1661 7 O
.	1668 1 O

Relative	0 8 O
efficacy	9 8 O
and	18 3 O
toxicity	22 8 B-Disease
of	31 2 O
netilmicin	34 10 B-Chemical
and	45 3 O
tobramycin	49 10 B-Chemical
in	60 2 O
oncology	63 8 O
patients	72 8 O
.	80 1 O

We	82 2 O
prospectively	85 13 O
compared	99 8 O
the	108 3 O
efficacy	112 8 O
and	121 3 O
safety	125 6 O
of	132 2 O
netilmicin	135 10 B-Chemical
sulfate	146 7 I-Chemical
or	154 2 O
tobramycin	157 10 B-Chemical
sulfate	168 7 I-Chemical
in	176 2 O
conjunction	179 11 O
with	191 4 O
piperacillin	196 12 B-Chemical
sodium	209 6 I-Chemical
in	216 2 O
118	219 3 O
immunocompromised	223 17 O
patients	241 8 O
with	250 4 O
presumed	255 8 O
severe	264 6 O
infections	271 10 B-Disease
.	281 1 O

The	283 3 O
two	287 3 O
treatment	291 9 O
regimens	301 8 O
were	310 4 O
equally	315 7 O
efficacious	323 11 O
.	334 1 O

Nephrotoxicity	336 14 B-Disease
occurred	351 8 O
in	360 2 O
a	363 1 O
similar	365 7 O
proportion	373 10 O
in	384 2 O
patients	387 8 O
treated	396 7 O
with	404 4 O
netilmicin	409 10 B-Chemical
and	420 3 O
tobramycin	424 10 B-Chemical
(	435 1 O
17	436 2 O
%	438 1 O
vs	440 2 O
11	443 2 O
%	445 1 O
)	446 1 O
.	447 1 O

Ototoxicity	449 11 B-Disease
occurred	461 8 O
in	470 2 O
four	473 4 O
(	478 1 O
9	479 1 O
.	480 1 O
5	481 1 O
%	482 1 O
)	483 1 O
of	485 2 O
42	488 2 O
netilmicin	491 10 B-Chemical
and	502 3 O
piperacillin	506 12 B-Chemical
and	519 3 O
in	523 2 O
12	526 2 O
(	529 1 O
22	530 2 O
%	532 1 O
)	533 1 O
of	535 2 O
54	538 2 O
tobramycin	541 10 B-Chemical
and	552 3 O
piperacillin	556 12 B-Chemical
-	568 1 O
treated	569 7 O
patients	577 8 O
.	585 1 O

Of	587 2 O
those	590 5 O
evaluated	596 9 O
with	606 4 O
posttherapy	611 11 O
audiograms	623 10 O
,	633 1 O
three	635 5 O
of	641 2 O
four	644 4 O
netilmicin	649 10 B-Chemical
and	660 3 O
piperacillin	664 12 B-Chemical
-	676 1 O
treated	677 7 O
patients	685 8 O
had	694 3 O
auditory	698 8 O
thresholds	707 10 O
return	718 6 O
to	725 2 O
baseline	728 8 O
compared	737 8 O
with	746 4 O
one	751 3 O
of	755 2 O
nine	758 4 O
tobramycin	763 10 B-Chemical
and	774 3 O
piperacillin	778 12 B-Chemical
-	790 1 O
treated	791 7 O
patients	799 8 O
.	807 1 O

The	809 3 O
number	813 6 O
of	820 2 O
greater	823 7 O
than	831 4 O
or	836 2 O
equal	839 5 O
to	845 2 O
15	848 2 O
-	850 1 O
dB	851 2 O
increases	854 9 O
in	864 2 O
auditory	867 8 O
threshold	876 9 O
as	886 2 O
a	889 1 O
proportion	891 10 O
of	902 2 O
total	905 5 O
greater	911 7 O
than	919 4 O
or	924 2 O
equal	927 5 O
to	933 2 O
15	936 2 O
-	938 1 O
dB	939 2 O
changes	942 7 O
(	950 1 O
increases	951 9 O
and	961 3 O
decreases	965 9 O
)	974 1 O
was	976 3 O
significantly	980 13 O
lower	994 5 O
in	1000 2 O
netilmicin	1003 10 B-Chemical
and	1014 3 O
piperacillin	1018 12 B-Chemical
-	1030 1 O
vs	1032 2 O
tobramycin	1035 10 B-Chemical
and	1046 3 O
piperacillin	1050 12 B-Chemical
-	1062 1 O
treated	1063 7 O
patients	1071 8 O
(	1080 1 O
18	1081 2 O
of	1084 2 O
78	1087 2 O
vs	1090 2 O
67	1093 2 O
of	1096 2 O
115	1099 3 O
)	1102 1 O
.	1103 1 O

We	1105 2 O
conclude	1108 8 O
that	1117 4 O
aminoglycoside	1122 14 B-Chemical
-	1136 1 O
associated	1137 10 O
ototoxicity	1148 11 B-Disease
was	1160 3 O
less	1164 4 O
severe	1169 6 O
and	1176 3 O
more	1180 4 O
often	1185 5 O
reversible	1191 10 O
with	1202 4 O
netilmicin	1207 10 B-Chemical
than	1218 4 O
with	1223 4 O
tobramycin	1228 10 B-Chemical
.	1238 1 O

Effect	0 6 O
of	7 2 O
prostaglandin	10 13 B-Chemical
synthetase	24 10 O
inhibitors	35 10 O
on	46 2 O
experimentally	49 14 O
induced	64 7 O
convulsions	72 11 B-Disease
in	84 2 O
rats	87 4 O
.	91 1 O

To	93 2 O
investigate	96 11 O
the	108 3 O
relationship	112 12 O
of	125 2 O
prostaglandins	128 14 B-Chemical
(	143 1 O
PGs	144 3 B-Chemical
)	147 1 O
to	149 2 O
seizure	152 7 B-Disease
induction	160 9 O
,	169 1 O
the	171 3 O
effects	175 7 O
of	183 2 O
six	186 3 O
PG	190 2 O
synthetase	193 10 O
inhibitors	204 10 O
on	215 2 O
convulsions	218 11 B-Disease
induced	230 7 O
by	238 2 O
flurothyl	241 9 B-Chemical
,	250 1 O
picrotoxin	252 10 B-Chemical
,	262 1 O
pentetrazol	264 11 B-Chemical
(	276 1 O
PTZ	277 3 B-Chemical
)	280 1 O
,	281 1 O
electroshock	283 12 O
or	296 2 O
bicuculline	299 11 B-Chemical
were	311 4 O
evaluated	316 9 O
.	325 1 O

Ibuprofen	327 9 B-Chemical
,	336 1 O
sulindac	338 8 B-Chemical
,	346 1 O
mefenamic	348 9 B-Chemical
acid	358 4 I-Chemical
,	362 1 O
and	364 3 O
low	368 3 O
dose	372 4 O
meclofenamic	377 12 B-Chemical
acid	390 4 I-Chemical
increased	395 9 O
the	405 3 O
latency	409 7 O
-	416 1 O
to	417 2 O
-	419 1 O
onset	420 5 O
in	426 2 O
the	429 3 O
flurothyl	433 9 B-Chemical
and	443 3 O
/	446 1 O
or	447 2 O
PTZ	450 3 B-Chemical
models	454 6 O
;	460 1 O
the	462 3 O
electroshock	466 12 O
,	478 1 O
picrotoxin	480 10 B-Chemical
and	491 3 O
bicuculline	495 11 B-Chemical
models	507 6 O
were	514 4 O
not	519 3 O
significantly	523 13 O
affected	537 8 O
by	546 2 O
any	549 3 O
of	553 2 O
the	556 3 O
pretreatment	560 12 O
agents	573 6 O
.	579 1 O

These	581 5 O
results	587 7 O
suggest	595 7 O
that	603 4 O
PGs	608 3 B-Chemical
are	612 3 O
involved	616 8 O
in	625 2 O
the	628 3 O
mechanism	632 9 O
(	641 1 O
s	642 1 O
)	643 1 O
underlying	645 10 O
fluorthyl	656 9 B-Chemical
-	665 1 O
and	667 3 O
PTZ	671 3 B-Chemical
-	674 1 O
induced	675 7 O
convulsions	683 11 B-Disease
,	694 1 O
but	696 3 O
not	700 3 O
picrotoxin	704 10 B-Chemical
-	714 1 O
,	715 1 O
electroshock	717 12 O
-	729 1 O
,	730 1 O
or	732 2 O
bicuculline	735 11 B-Chemical
-	746 1 O
induced	747 7 O
convulsions	755 11 B-Disease
.	766 1 O

Angiotensin	0 11 O
-	11 1 O
converting	12 10 O
enzyme	23 6 O
(	30 1 O
ACE	31 3 O
)	34 1 O
inhibitor	36 9 O
-	45 1 O
associated	46 10 O
angioedema	57 10 B-Disease
of	68 2 O
the	71 3 O
stomach	75 7 O
and	83 3 O
small	87 5 O
intestine	93 9 O
:	102 1 O
a	104 1 O
case	106 4 O
report	111 6 O
.	117 1 O

This	119 4 O
is	124 2 O
a	127 1 O
case	129 4 O
report	134 6 O
on	141 2 O
a	144 1 O
45	146 2 O
-	148 1 O
year	149 4 O
old	154 3 O
African	158 7 O
-	165 1 O
American	166 8 O
female	175 6 O
with	182 4 O
newly	187 5 O
diagnosed	193 9 O
hypertension	203 12 B-Disease
,	215 1 O
who	217 3 O
was	221 3 O
started	225 7 O
on	233 2 O
a	236 1 O
combination	238 11 O
pill	250 4 O
of	255 2 O
amlodipine	258 10 B-Chemical
/	268 1 O
benazapril	269 10 B-Chemical
10	280 2 O
/	282 1 O
5	283 1 O
mg	285 2 O
.	287 1 O

The	289 3 O
very	293 4 O
next	298 4 O
day	303 3 O
,	306 1 O
she	308 3 O
presented	312 9 O
at	322 2 O
the	325 3 O
emergency	329 9 O
room	339 4 O
(	344 1 O
ER	345 2 O
)	347 1 O
with	349 4 O
abdominal	354 9 B-Disease
pain	364 4 I-Disease
,	368 1 O
nausea	370 6 B-Disease
and	377 3 O
vomiting	381 8 B-Disease
.	389 1 O

Physical	391 8 O
exam	400 4 O
,	404 1 O
complete	406 8 O
metabolic	415 9 O
panel	425 5 O
,	430 1 O
and	432 3 O
hemogram	436 8 O
were	445 4 O
in	450 2 O
the	453 3 O
normal	457 6 O
range	464 5 O
.	469 1 O

She	471 3 O
was	475 3 O
discharged	479 10 O
from	490 4 O
the	495 3 O
ER	499 2 O
after	502 5 O
a	508 1 O
few	510 3 O
hours	514 5 O
of	520 2 O
treatment	523 9 O
with	533 4 O
fluid	538 5 O
and	544 3 O
analgesics	548 10 O
.	558 1 O

However	560 7 O
,	567 1 O
she	569 3 O
returned	573 8 O
to	582 2 O
the	585 3 O
ER	589 2 O
the	592 3 O
next	596 4 O
day	601 3 O
with	605 4 O
the	610 3 O
same	614 4 O
complaints	619 10 O
.	629 1 O

This	631 4 O
time	636 4 O
the	641 3 O
physical	645 8 O
exam	654 4 O
was	659 3 O
significant	663 11 O
for	675 3 O
a	679 1 O
distended	681 9 O
abdomen	691 7 O
with	699 4 O
dullness	704 8 O
to	713 2 O
percussion	716 10 O
.	726 1 O

CT	728 2 O
scan	731 4 O
of	736 2 O
the	739 3 O
abdomen	743 7 O
revealed	751 8 O
markedly	760 8 O
thickened	769 9 O
antrum	779 6 O
of	786 2 O
the	789 3 O
stomach	793 7 O
,	800 1 O
duodenum	802 8 O
and	811 3 O
jejunum	815 7 O
,	822 1 O
along	824 5 O
with	830 4 O
fluid	835 5 O
in	841 2 O
the	844 3 O
abdominal	848 9 O
and	858 3 O
pelvic	862 6 O
cavity	869 6 O
.	875 1 O

Angiotensin	877 11 O
-	888 1 O
converting	889 10 O
enzyme	900 6 O
inhibitor	907 9 O
(	917 1 O
ACEI	918 4 O
)	922 1 O
-	923 1 O
induced	924 7 O
angioedema	932 10 B-Disease
was	943 3 O
suspected	947 9 O
,	956 1 O
and	958 3 O
anti	962 4 O
-	966 1 O
hypertensive	967 12 B-Disease
medications	980 11 O
were	992 4 O
discontinued	997 12 O
.	1009 1 O

Her	1011 3 O
symptoms	1015 8 O
improved	1024 8 O
within	1033 6 O
the	1040 3 O
next	1044 4 O
24	1049 2 O
hours	1052 5 O
,	1057 1 O
and	1059 3 O
repeat	1063 6 O
CT	1070 2 O
after	1073 5 O
72	1079 2 O
hours	1082 5 O
revealed	1088 8 O
marked	1097 6 O
improvement	1104 11 O
in	1116 2 O
stomach	1119 7 O
and	1127 3 O
small	1131 5 O
bowel	1137 5 O
thickening	1143 10 O
and	1154 3 O
resolution	1158 10 O
of	1169 2 O
ascites	1172 7 B-Disease
.	1179 1 O

The	1181 3 O
recognition	1185 11 O
of	1197 2 O
angiotensin	1200 11 B-Chemical
-	1211 1 O
converting	1212 10 O
enzyme	1223 6 O
(	1230 1 O
ACE	1231 3 O
)	1234 1 O
and	1236 3 O
angiotensin	1240 11 B-Chemical
receptor	1252 8 O
blocker	1261 7 O
(	1269 1 O
ARB	1270 3 O
)	1273 1 O
intestinal	1275 10 B-Disease
angioedema	1286 10 I-Disease
constitutes	1297 11 O
a	1309 1 O
challenge	1311 9 O
to	1321 2 O
primary	1324 7 O
care	1332 4 O
physicians	1337 10 O
,	1347 1 O
internists	1349 10 O
,	1359 1 O
emergency	1361 9 O
room	1371 4 O
personal	1376 8 O
and	1385 3 O
surgeons	1389 8 O
.	1397 1 O

Valproic	0 8 B-Chemical
acid	9 4 I-Chemical
I	14 1 O
:	15 1 O
time	17 4 O
course	22 6 O
of	29 2 O
lipid	32 5 O
peroxidation	38 12 O
biomarkers	51 10 O
,	61 1 O
liver	63 5 B-Disease
toxicity	69 8 I-Disease
,	77 1 O
and	79 3 O
valproic	83 8 B-Chemical
acid	92 4 I-Chemical
metabolite	97 10 O
levels	108 6 O
in	115 2 O
rats	118 4 O
.	122 1 O

A	124 1 O
single	126 6 O
dose	133 4 O
of	138 2 O
valproic	141 8 B-Chemical
acid	150 4 I-Chemical
(	155 1 O
VPA	156 3 B-Chemical
)	159 1 O
,	160 1 O
which	162 5 O
is	168 2 O
a	171 1 O
widely	173 6 O
used	180 4 O
antiepileptic	185 13 O
drug	199 4 O
,	203 1 O
is	205 2 O
associated	208 10 O
with	219 4 O
oxidative	224 9 O
stress	234 6 O
in	241 2 O
rats	244 4 O
,	248 1 O
as	250 2 O
recently	253 8 O
demonstrated	262 12 O
by	275 2 O
elevated	278 8 O
levels	287 6 O
of	294 2 O
15	297 2 B-Chemical
-	299 1 I-Chemical
F	300 1 I-Chemical
(	301 1 I-Chemical
2t	302 2 I-Chemical
)	304 1 I-Chemical
-	305 1 I-Chemical
isoprostane	306 11 I-Chemical
(	318 1 O
15	319 2 B-Chemical
-	321 1 I-Chemical
F	322 1 I-Chemical
(	323 1 I-Chemical
2t	324 2 I-Chemical
)	326 1 I-Chemical
-	327 1 I-Chemical
IsoP	328 4 I-Chemical
)	332 1 O
.	333 1 O

To	335 2 O
determine	338 9 O
whether	348 7 O
there	356 5 O
was	362 3 O
a	366 1 O
temporal	368 8 O
relationship	377 12 O
between	390 7 O
VPA	398 3 B-Chemical
-	401 1 O
associated	402 10 O
oxidative	413 9 O
stress	423 6 O
and	430 3 O
hepatotoxicity	434 14 B-Disease
,	448 1 O
adult	450 5 O
male	456 4 O
Sprague	461 7 O
-	468 1 O
Dawley	469 6 O
rats	476 4 O
were	481 4 O
treated	486 7 O
ip	494 2 O
with	497 4 O
VPA	502 3 B-Chemical
(	506 1 O
500	507 3 O
mg	511 2 O
/	513 1 O
kg	514 2 O
)	516 1 O
or	518 2 O
0	521 1 O
.	522 1 O
9	523 1 O
%	524 1 O
saline	526 6 O
(	533 1 O
vehicle	534 7 O
)	541 1 O
once	543 4 O
daily	548 5 O
for	554 3 O
2	558 1 O
,	559 1 O
4	561 1 O
,	562 1 O
7	564 1 O
,	565 1 O
10	567 2 O
,	569 1 O
or	571 2 O
14	574 2 O
days	577 4 O
.	581 1 O

Oxidative	583 9 O
stress	593 6 O
was	600 3 O
assessed	604 8 O
by	613 2 O
determining	616 11 O
plasma	628 6 O
and	635 3 O
liver	639 5 O
levels	645 6 O
of	652 2 O
15	655 2 B-Chemical
-	657 1 I-Chemical
F	658 1 I-Chemical
(	659 1 I-Chemical
2t	660 2 I-Chemical
)	662 1 I-Chemical
-	663 1 I-Chemical
IsoP	664 4 I-Chemical
,	668 1 O
lipid	670 5 B-Chemical
hydroperoxides	676 14 I-Chemical
(	691 1 O
LPO	692 3 B-Chemical
)	695 1 O
,	696 1 O
and	698 3 O
thiobarbituric	702 14 B-Chemical
acid	717 4 I-Chemical
reactive	722 8 I-Chemical
substances	731 10 I-Chemical
(	742 1 O
TBARs	743 5 B-Chemical
)	748 1 O
.	749 1 O

Plasma	751 6 O
and	758 3 O
liver	762 5 O
15	768 2 B-Chemical
-	770 1 I-Chemical
F	771 1 I-Chemical
(	772 1 I-Chemical
2t	773 2 I-Chemical
)	775 1 I-Chemical
-	776 1 I-Chemical
IsoP	777 4 I-Chemical
were	782 4 O
elevated	787 8 O
and	796 3 O
reached	800 7 O
a	808 1 O
plateau	810 7 O
after	818 5 O
day	824 3 O
2	828 1 O
of	830 2 O
VPA	833 3 B-Chemical
treatment	837 9 O
compared	847 8 O
to	856 2 O
control	859 7 O
.	866 1 O

Liver	868 5 O
LPO	874 3 B-Chemical
levels	878 6 O
were	885 4 O
not	890 3 O
elevated	894 8 O
until	903 5 O
day	909 3 O
7	913 1 O
of	915 2 O
treatment	918 9 O
(	928 1 O
1	929 1 O
.	930 1 O
8	931 1 O
-	932 1 O
fold	933 4 O
versus	938 6 O
control	945 7 O
,	952 1 O
p	954 1 O
<	956 1 O
0	958 1 O
.	959 1 O
05	960 2 O
)	962 1 O
.	963 1 O

Liver	965 5 O
and	971 3 O
plasma	975 6 O
TBARs	982 5 B-Chemical
were	988 4 O
not	993 3 O
increased	997 9 O
until	1007 5 O
14	1013 2 O
days	1016 4 O
(	1021 1 O
2	1022 1 O
-	1023 1 O
fold	1024 4 O
vs	1029 2 O
.	1031 1 O
control	1033 7 O
,	1040 1 O
p	1042 1 O
<	1044 1 O
0	1046 1 O
.	1047 1 O
05	1048 2 O
)	1050 1 O
.	1051 1 O

Liver	1053 5 B-Disease
toxicity	1059 8 I-Disease
was	1068 3 O
evaluated	1072 9 O
based	1082 5 O
on	1088 2 O
serum	1091 5 O
levels	1097 6 O
of	1104 2 O
alpha	1107 5 O
-	1112 1 O
glutathione	1113 11 B-Chemical
S	1125 1 O
-	1126 1 O
transferase	1127 11 O
(	1139 1 O
alpha	1140 5 O
-	1145 1 O
GST	1146 3 O
)	1149 1 O
and	1151 3 O
by	1155 2 O
histology	1158 9 O
.	1167 1 O

Serum	1169 5 O
alpha	1175 5 O
-	1180 1 O
GST	1181 3 O
levels	1185 6 O
were	1192 4 O
significantly	1197 13 O
elevated	1211 8 O
by	1220 2 O
day	1223 3 O
4	1227 1 O
,	1228 1 O
which	1230 5 O
corresponded	1236 12 O
to	1249 2 O
hepatotoxicity	1252 14 B-Disease
as	1267 2 O
shown	1270 5 O
by	1276 2 O
the	1279 3 O
increasing	1283 10 O
incidence	1294 9 O
of	1304 2 O
inflammation	1307 12 B-Disease
of	1320 2 O
the	1323 3 O
liver	1327 5 O
capsule	1333 7 O
,	1340 1 O
necrosis	1342 8 B-Disease
,	1350 1 O
and	1352 3 O
steatosis	1356 9 B-Disease
throughout	1366 10 O
the	1377 3 O
study	1381 5 O
.	1386 1 O

The	1388 3 O
liver	1392 5 O
levels	1398 6 O
of	1405 2 O
beta	1408 4 O
-	1412 1 O
oxidation	1413 9 O
metabolites	1423 11 O
of	1435 2 O
VPA	1438 3 B-Chemical
were	1442 4 O
decreased	1447 9 O
by	1457 2 O
day	1460 3 O
14	1464 2 O
,	1466 1 O
while	1468 5 O
the	1474 3 O
levels	1478 6 O
of	1485 2 O
4	1488 1 B-Chemical
-	1489 1 I-Chemical
ene	1490 3 I-Chemical
-	1493 1 I-Chemical
VPA	1494 3 I-Chemical
and	1498 3 O
(	1502 1 O
E	1503 1 O
)	1504 1 O
-	1505 1 O
2	1506 1 B-Chemical
,	1507 1 I-Chemical
4	1508 1 I-Chemical
-	1509 1 I-Chemical
diene	1510 5 I-Chemical
-	1515 1 I-Chemical
VPA	1516 3 I-Chemical
were	1520 4 O
not	1525 3 O
elevated	1529 8 O
throughout	1538 10 O
the	1549 3 O
study	1553 5 O
.	1558 1 O

Overall	1560 7 O
,	1567 1 O
these	1569 5 O
findings	1575 8 O
indicate	1584 8 O
that	1593 4 O
VPA	1598 3 B-Chemical
treatment	1602 9 O
results	1612 7 O
in	1620 2 O
oxidative	1623 9 O
stress	1633 6 O
,	1639 1 O
as	1641 2 O
measured	1644 8 O
by	1653 2 O
levels	1656 6 O
of	1663 2 O
15	1666 2 B-Chemical
-	1668 1 I-Chemical
F	1669 1 I-Chemical
(	1670 1 I-Chemical
2t	1671 2 I-Chemical
)	1673 1 I-Chemical
-	1674 1 I-Chemical
IsoP	1675 4 I-Chemical
,	1679 1 O
which	1681 5 O
precedes	1687 8 O
the	1696 3 O
onset	1700 5 O
of	1706 2 O
necrosis	1709 8 B-Disease
,	1717 1 O
steatosis	1719 9 B-Disease
,	1728 1 O
and	1730 3 O
elevated	1734 8 O
levels	1743 6 O
of	1750 2 O
serum	1753 5 O
alpha	1759 5 O
-	1764 1 O
GST	1765 3 O
.	1768 1 O

Pheochromocytoma	0 16 B-Disease
unmasked	17 8 O
by	26 2 O
amisulpride	29 11 B-Chemical
and	41 3 O
tiapride	45 8 B-Chemical
.	53 1 O

OBJECTIVE	55 9 O
:	64 1 O
To	66 2 O
describe	69 8 O
the	78 3 O
unmasking	82 9 O
of	92 2 O
pheochromocytoma	95 16 B-Disease
in	112 2 O
a	115 1 O
patient	117 7 O
treated	125 7 O
with	133 4 O
amisulpride	138 11 B-Chemical
and	150 3 O
tiapride	154 8 B-Chemical
.	162 1 O

CASE	164 4 O
SUMMARY	169 7 O
:	176 1 O
A	178 1 O
42	180 2 O
-	182 1 O
year	183 4 O
-	187 1 O
old	188 3 O
white	192 5 O
man	198 3 O
developed	202 9 O
acute	212 5 O
hypertension	218 12 B-Disease
with	231 4 O
severe	236 6 O
headache	243 8 B-Disease
and	252 3 O
vomiting	256 8 B-Disease
2	265 1 O
hours	267 5 O
after	273 5 O
the	279 3 O
first	283 5 O
doses	289 5 O
of	295 2 O
amisulpride	298 11 B-Chemical
100	310 3 O
mg	314 2 O
and	317 3 O
tiapride	321 8 B-Chemical
100	330 3 O
mg	334 2 O
.	336 1 O

Both	338 4 O
drugs	343 5 O
were	349 4 O
immediately	354 11 O
discontinued	366 12 O
,	378 1 O
and	380 3 O
the	384 3 O
patient	388 7 O
recovered	396 9 O
after	406 5 O
subsequent	412 10 O
nicardipine	423 11 B-Chemical
and	435 3 O
verapamil	439 9 B-Chemical
treatment	449 9 O
.	458 1 O

Abdominal	460 9 O
ultrasound	470 10 O
showed	481 6 O
an	488 2 O
adrenal	491 7 O
mass	499 4 O
,	503 1 O
and	505 3 O
postoperative	509 13 O
histologic	523 10 O
examination	534 11 O
confirmed	546 9 O
the	556 3 O
diagnosis	560 9 O
of	570 2 O
pheochromocytoma	573 16 B-Disease
.	589 1 O

DISCUSSION	591 10 O
:	601 1 O
Drug	603 4 O
-	607 1 O
induced	608 7 O
symptoms	616 8 O
of	625 2 O
pheochromocytoma	628 16 B-Disease
are	645 3 O
often	649 5 O
associated	655 10 O
with	666 4 O
the	671 3 O
use	675 3 O
of	679 2 O
substituted	682 11 O
benzamide	694 9 B-Chemical
drugs	704 5 O
,	709 1 O
but	711 3 O
the	715 3 O
underlying	719 10 O
mechanism	730 9 O
is	740 2 O
unknown	743 7 O
.	750 1 O

In	752 2 O
our	755 3 O
case	759 4 O
,	763 1 O
use	765 3 O
of	769 2 O
the	772 3 O
Naranjo	776 7 O
probability	784 11 O
scale	796 5 O
indicated	802 9 O
a	812 1 O
possible	814 8 O
relationship	823 12 O
between	836 7 O
the	844 3 O
hypertensive	848 12 B-Disease
crisis	861 6 O
and	868 3 O
amisulpride	872 11 B-Chemical
and	884 3 O
tiapride	888 8 B-Chemical
therapy	897 7 O
.	904 1 O

CONCLUSIONS	906 11 O
:	917 1 O
As	919 2 O
of	922 2 O
March	925 5 O
24	931 2 O
,	933 1 O
2005	935 4 O
,	939 1 O
this	941 4 O
is	946 2 O
the	949 3 O
first	953 5 O
reported	959 8 O
case	968 4 O
of	973 2 O
amisulpride	976 11 B-Chemical
-	987 1 O
and	989 3 O
tiapride	993 8 B-Chemical
-	1001 1 O
induced	1002 7 O
hypertensive	1010 12 B-Disease
crisis	1023 6 O
in	1030 2 O
a	1033 1 O
patient	1035 7 O
with	1043 4 O
pheochromocytoma	1048 16 B-Disease
.	1064 1 O

Physicians	1066 10 O
and	1077 3 O
other	1081 5 O
healthcare	1087 10 O
professionals	1098 13 O
should	1112 6 O
be	1119 2 O
aware	1122 5 O
of	1128 2 O
this	1131 4 O
potential	1136 9 O
adverse	1146 7 O
effect	1154 6 O
of	1161 2 O
tiapride	1164 8 B-Chemical
and	1173 3 O
amisulpride	1177 11 B-Chemical
.	1188 1 O

Quantitative	0 12 O
drug	13 4 O
levels	18 6 O
in	25 2 O
stimulant	28 9 O
psychosis	38 9 B-Disease
:	47 1 O
relationship	49 12 O
to	62 2 O
symptom	65 7 O
severity	73 8 O
,	81 1 O
catecholamines	83 14 B-Chemical
and	98 3 O
hyperkinesia	102 12 B-Disease
.	114 1 O

To	116 2 O
examine	119 7 O
the	127 3 O
relationship	131 12 O
between	144 7 O
quantitative	152 12 O
stimulant	165 9 O
drug	175 4 O
levels	180 6 O
,	186 1 O
catecholamines	188 14 B-Chemical
,	202 1 O
and	204 3 O
psychotic	208 9 B-Disease
symptoms	218 8 I-Disease
,	226 1 O
nineteen	228 8 O
patients	237 8 O
in	246 2 O
a	249 1 O
psychiatric	251 11 B-Disease
emergency	263 9 O
service	273 7 O
with	281 4 O
a	286 1 O
diagnosis	288 9 O
of	298 2 O
amphetamine	301 11 B-Chemical
-	312 1 O
or	314 2 O
cocaine	317 7 B-Chemical
-	324 1 O
induced	325 7 O
psychosis	333 9 B-Disease
were	343 4 O
interviewed	348 11 O
,	359 1 O
and	361 3 O
plasma	365 6 O
and	372 3 O
urine	376 5 O
were	382 4 O
collected	387 9 O
for	397 3 O
quantitative	401 12 O
assays	414 6 O
of	421 2 O
stimulant	424 9 O
drug	434 4 O
and	439 3 O
catecholamine	443 13 B-Chemical
metabolite	457 10 O
levels	468 6 O
.	474 1 O

Methamphetamine	476 15 B-Chemical
or	492 2 O
amphetamine	495 11 B-Chemical
levels	507 6 O
were	514 4 O
related	519 7 O
to	527 2 O
several	530 7 O
psychopathology	538 15 O
scores	554 6 O
and	561 3 O
the	565 3 O
global	569 6 O
hyperkinesia	576 12 B-Disease
rating	589 6 O
.	595 1 O

HVA	597 3 O
levels	601 6 O
were	608 4 O
related	613 7 O
to	621 2 O
global	624 6 O
hyperkinesia	631 12 B-Disease
but	644 3 O
not	648 3 O
to	652 2 O
psychopathology	655 15 O
ratings	671 7 O
.	678 1 O

Although	680 8 O
many	689 4 O
other	694 5 O
factors	700 7 O
such	708 4 O
as	713 2 O
sensitization	716 13 O
may	730 3 O
play	734 4 O
a	739 1 O
role	741 4 O
,	745 1 O
intensity	747 9 O
of	757 2 O
stimulant	760 9 O
-	769 1 O
induced	770 7 O
psychotic	778 9 B-Disease
symptoms	788 8 I-Disease
and	797 3 O
stereotypies	801 12 B-Disease
appears	814 7 O
to	822 2 O
be	825 2 O
at	828 2 O
least	831 5 O
in	837 2 O
part	840 4 O
dose	845 4 O
-	849 1 O
related	850 7 O
.	857 1 O

Delayed	0 7 O
asystolic	8 9 B-Disease
cardiac	18 7 B-Disease
arrest	26 6 I-Disease
after	33 5 O
diltiazem	39 9 B-Chemical
overdose	49 8 B-Disease
;	57 1 O
resuscitation	59 13 O
with	73 4 O
high	78 4 O
dose	83 4 O
intravenous	88 11 O
calcium	100 7 B-Chemical
.	107 1 O

A	109 1 O
51	111 2 O
year	114 4 O
old	119 3 O
man	123 3 O
took	127 4 O
a	132 1 O
mixed	134 5 O
overdose	140 8 B-Disease
including	149 9 O
1	159 1 O
.	160 1 O
8	161 1 O
-	162 1 O
3	163 1 O
.	164 1 O
6	165 1 O
g	167 1 O
of	169 2 O
diltiazem	172 9 B-Chemical
,	181 1 O
paracetamol	183 11 B-Chemical
,	194 1 O
aspirin	196 7 B-Chemical
,	203 1 O
isosorbide	205 10 B-Chemical
nitrate	216 7 B-Chemical
,	223 1 O
and	225 3 O
alcohol	229 7 B-Chemical
.	236 1 O

He	238 2 O
initially	241 9 O
presented	251 9 O
to	261 2 O
hospital	264 8 O
after	273 5 O
six	279 3 O
hours	283 5 O
with	289 4 O
mild	294 4 O
hypotension	299 11 B-Disease
and	311 3 O
was	315 3 O
treated	319 7 O
with	327 4 O
activated	332 9 O
charcoal	342 8 O
and	351 3 O
intravenous	355 11 O
fluids	367 6 O
.	373 1 O

Eighteen	375 8 O
hours	384 5 O
after	390 5 O
the	396 3 O
overdose	400 8 B-Disease
he	409 2 O
had	412 3 O
two	416 3 O
generalised	420 11 O
tonic	432 5 B-Disease
-	437 1 I-Disease
clonic	438 6 I-Disease
seizures	445 8 I-Disease
.	453 1 O

The	455 3 O
patient	459 7 O
remained	467 8 O
unresponsive	476 12 O
with	489 4 O
junctional	494 10 O
bradycardia	505 11 B-Disease
,	516 1 O
unrecordable	518 12 O
blood	531 5 O
pressure	537 8 O
,	545 1 O
and	547 3 O
then	551 4 O
became	556 6 O
asystolic	563 9 B-Disease
.	572 1 O

He	574 2 O
was	577 3 O
resuscitated	581 12 O
with	594 4 O
high	599 4 O
dose	604 4 O
(	609 1 O
13	610 2 O
.	612 1 O
5	613 1 O
g	615 1 O
)	616 1 O
intravenous	618 11 O
calcium	630 7 B-Chemical
and	638 3 O
adrenaline	642 10 B-Chemical
(	653 1 O
epinephrine	654 11 B-Chemical
)	665 1 O
.	666 1 O

He	668 2 O
required	671 8 O
inotropic	680 9 O
support	690 7 O
and	698 3 O
temporary	702 9 O
pacing	712 6 O
over	719 4 O
the	724 3 O
next	728 4 O
48	733 2 O
hours	736 5 O
.	741 1 O

This	743 4 O
case	748 4 O
suggests	753 8 O
there	762 5 O
is	768 2 O
a	771 1 O
role	773 4 O
for	778 3 O
aggressive	782 10 O
high	793 4 O
dose	798 4 O
intravenous	803 11 O
calcium	815 7 B-Chemical
therapy	823 7 O
in	831 2 O
severe	834 6 O
diltiazem	841 9 B-Chemical
overdose	851 8 B-Disease
,	859 1 O
particularly	861 12 O
with	874 4 O
the	879 3 O
onset	883 5 O
of	889 2 O
asystole	892 8 B-Disease
.	900 1 O

It	902 2 O
should	905 6 O
be	912 2 O
considered	915 10 O
early	926 5 O
in	932 2 O
cases	935 5 O
of	941 2 O
cardiac	944 7 B-Disease
arrest	952 6 I-Disease
after	959 5 O
diltiazem	965 9 B-Chemical
overdose	975 8 B-Disease
.	983 1 O

The	985 3 O
case	989 4 O
also	994 4 O
highlights	999 10 O
the	1010 3 O
problems	1014 8 O
with	1023 4 O
delayed	1028 7 O
toxicity	1036 8 B-Disease
when	1045 4 O
whole	1050 5 O
bowel	1056 5 O
irrigation	1062 10 O
is	1073 2 O
not	1076 3 O
administered	1080 12 O
.	1092 1 O

Renal	0 5 B-Disease
papillary	6 9 I-Disease
necrosis	16 8 I-Disease
due	25 3 O
to	29 2 O
naproxen	32 8 B-Chemical
.	40 1 O

A	42 1 O
31	44 2 O
-	46 1 O
year	47 4 O
-	51 1 O
old	52 3 O
man	56 3 O
with	60 4 O
rheumatoid	65 10 B-Disease
arthritis	76 9 I-Disease
,	85 1 O
who	87 3 O
had	91 3 O
previously	95 10 O
been	106 4 O
treated	111 7 O
with	119 4 O
sulindac	124 8 B-Chemical
,	132 1 O
fenoprofen	134 10 B-Chemical
calcium	145 7 I-Chemical
,	152 1 O
high	154 4 O
dose	159 4 O
salicylates	164 11 B-Chemical
and	176 3 O
gold	180 4 B-Chemical
salts	185 5 O
,	190 1 O
developed	192 9 O
renal	202 5 B-Disease
papillary	208 9 I-Disease
necrosis	218 8 I-Disease
(	227 1 O
RPN	228 3 B-Disease
)	231 1 O
4	233 1 O
months	235 6 O
after	242 5 O
institution	248 11 O
of	260 2 O
naproxen	263 8 B-Chemical
therapy	272 7 O
.	279 1 O

No	281 2 O
other	284 5 O
factor	290 6 O
predisposing	297 12 O
to	310 2 O
RPN	313 3 B-Disease
could	317 5 O
be	323 2 O
discovered	326 10 O
.	336 1 O

Sulindac	338 8 B-Chemical
was	347 3 O
substituted	351 11 O
for	363 3 O
naproxen	367 8 B-Chemical
and	376 3 O
no	380 2 O
further	383 7 O
adverse	391 7 O
renal	399 5 O
effects	405 7 O
occurred	413 8 O
over	422 4 O
the	427 3 O
next	431 4 O
12	436 2 O
months	439 6 O
.	445 1 O

We	447 2 O
review	450 6 O
previous	457 8 O
reports	466 7 O
linking	474 7 O
RPN	482 3 B-Disease
to	486 2 O
antiinflammatory	489 16 O
drug	506 4 O
use	511 3 O
and	515 3 O
discuss	519 7 O
possible	527 8 O
advantages	536 10 O
of	547 2 O
sulindac	550 8 B-Chemical
in	559 2 O
patients	562 8 O
who	571 3 O
have	575 4 O
experienced	580 11 O
renal	592 5 B-Disease
toxicity	598 8 I-Disease
from	607 4 O
other	612 5 O
antiinflammatory	618 16 O
agents	635 6 O
.	641 1 O

Adverse	0 7 O
interaction	8 11 O
between	20 7 O
beta	28 4 B-Chemical
-	32 1 I-Chemical
adrenergic	33 10 I-Chemical
blocking	44 8 I-Chemical
drugs	53 5 I-Chemical
and	59 3 O
verapamil	63 9 B-Chemical
-	72 1 O
-	73 1 O
report	74 6 O
of	81 2 O
three	84 5 O
cases	90 5 O
.	95 1 O

Three	97 5 O
patients	103 8 O
with	112 4 O
ischaemic	117 9 B-Disease
heart	127 5 I-Disease
disease	133 7 I-Disease
developed	141 9 O
profound	151 8 O
cardiac	160 7 B-Disease
failure	168 7 I-Disease
,	175 1 O
hypotension	177 11 B-Disease
and	189 3 O
bradycardia	193 11 B-Disease
during	205 6 O
combined	212 8 O
therapy	221 7 O
with	229 4 O
verapamil	234 9 B-Chemical
and	244 3 O
beta	248 4 B-Chemical
-	252 1 I-Chemical
adrenergic	253 10 I-Chemical
blocking	264 8 I-Chemical
drugs	273 5 I-Chemical
.	278 1 O

This	280 4 O
clinical	285 8 O
picture	294 7 O
resolved	302 8 O
completely	311 10 O
with	322 4 O
cessation	327 9 O
of	337 2 O
the	340 3 O
combined	344 8 O
therapy	353 7 O
.	360 1 O

Baseline	362 8 O
left	371 4 O
ventricular	376 11 O
function	388 8 O
,	396 1 O
assessed	398 8 O
by	407 2 O
cardiac	410 7 O
catheterisation	418 15 O
or	434 2 O
nuclear	437 7 O
angiography	445 11 O
,	456 1 O
was	458 3 O
normal	462 6 O
in	469 2 O
two	472 3 O
patients	476 8 O
and	485 3 O
only	489 4 O
mildly	494 6 O
reduced	501 7 O
in	509 2 O
the	512 3 O
other	516 5 O
.	521 1 O

Simultaneously	523 14 O
administration	538 14 O
of	553 2 O
beta	556 4 B-Chemical
-	560 1 I-Chemical
adrenergic	561 10 I-Chemical
blocking	572 8 I-Chemical
drugs	581 5 I-Chemical
and	587 3 O
verapamil	591 9 B-Chemical
may	601 3 O
result	605 6 O
in	612 2 O
profound	615 8 O
adverse	624 7 O
interactions	632 12 O
and	645 3 O
should	649 6 O
only	656 4 O
be	661 2 O
administered	664 12 O
with	677 4 O
great	682 5 O
caution	688 7 O
.	695 1 O

Adverse	0 7 O
reactions	8 9 O
to	18 2 O
bendrofluazide	21 14 B-Chemical
and	36 3 O
propranolol	40 11 B-Chemical
for	52 3 O
the	56 3 O
treatment	60 9 O
of	70 2 O
mild	73 4 O
hypertension	78 12 B-Disease
.	90 1 O

Report	92 6 O
of	99 2 O
Medical	102 7 O
Research	110 8 O
Council	119 7 O
Working	127 7 O
Party	135 5 O
on	141 2 O
Mild	144 4 O
to	149 2 O
Moderate	152 8 O
Hypertension	161 12 B-Disease
.	173 1 O

Participants	175 12 O
in	188 2 O
the	191 3 O
Medical	195 7 O
Research	203 8 O
Council	212 7 O
treatment	220 9 O
trial	230 5 O
for	236 3 O
mild	240 4 O
hypertension	245 12 B-Disease
are	258 3 O
randomly	262 8 O
allocated	271 9 O
to	281 2 O
one	284 3 O
of	288 2 O
four	291 4 O
treatment	296 9 O
groups	306 6 O
:	312 1 O
bendrofluazide	314 14 B-Chemical
,	328 1 O
propranolol	330 11 B-Chemical
,	341 1 O
or	343 2 O
a	346 1 O
placebo	348 7 O
for	356 3 O
either	360 6 O
of	367 2 O
these	370 5 O
drugs	376 5 O
.	381 1 O

The	383 3 O
trial	387 5 O
is	393 2 O
single	396 6 O
-	402 1 O
blind	403 5 O
.	408 1 O

23	410 2 O
582	413 3 O
patient	417 7 O
-	424 1 O
years	425 5 O
of	431 2 O
observation	434 11 O
have	446 4 O
been	451 4 O
completed	456 9 O
so	466 2 O
far	469 3 O
,	472 1 O
10	474 2 O
684	477 3 O
on	481 2 O
active	484 6 O
drugs	491 5 O
and	497 3 O
12	501 2 O
898	504 3 O
on	508 2 O
placebos	511 8 O
.	519 1 O

The	521 3 O
results	525 7 O
show	533 4 O
an	538 2 O
association	541 11 O
between	553 7 O
bendrofluazide	561 14 B-Chemical
treatment	576 9 O
and	586 3 O
impotence	590 9 B-Disease
,	599 1 O
and	601 3 O
impotence	605 9 B-Disease
also	615 4 O
occurred	620 8 O
more	629 4 O
frequently	634 10 O
in	645 2 O
patients	648 8 O
taking	657 6 O
propranolol	664 11 B-Chemical
than	676 4 O
in	681 2 O
those	684 5 O
taking	690 6 O
placebos	697 8 O
.	705 1 O

Other	707 5 O
adverse	713 7 O
reactions	721 9 O
significantly	731 13 O
linked	745 6 O
with	752 4 O
active	757 6 O
drugs	764 5 O
include	770 7 O
impaired	778 8 B-Disease
glucose	787 7 I-Disease
tolerance	795 9 I-Disease
in	805 2 O
men	808 3 O
and	812 3 O
women	816 5 O
and	822 3 O
gout	826 4 B-Disease
in	831 2 O
men	834 3 O
,	837 1 O
associated	839 10 O
with	850 4 O
bendrofluazide	855 14 B-Chemical
treatment	870 9 O
,	879 1 O
and	881 3 O
Raynaud	885 7 B-Disease
'	892 1 I-Disease
s	893 1 I-Disease
phenomenon	895 10 I-Disease
and	906 3 O
dyspnoea	910 8 B-Disease
in	919 2 O
men	922 3 O
and	926 3 O
women	930 5 O
taking	936 6 O
propranolol	943 11 B-Chemical
.	954 1 O

No	956 2 O
corneal	959 7 B-Disease
disease	967 7 I-Disease
is	975 2 O
known	978 5 O
to	984 2 O
have	987 4 O
occurred	992 8 O
in	1001 2 O
the	1004 3 O
propranolol	1008 11 B-Chemical
group	1020 5 O
.	1025 1 O

Mean	1027 4 O
serum	1032 5 O
potassium	1038 9 B-Chemical
level	1048 5 O
fell	1054 4 O
,	1058 1 O
and	1060 3 O
urea	1064 4 B-Chemical
and	1069 3 O
uric	1073 4 B-Chemical
acid	1078 4 I-Chemical
levels	1083 6 O
rose	1090 4 O
,	1094 1 O
in	1096 2 O
men	1099 3 O
and	1103 3 O
women	1107 5 O
taking	1113 6 O
bendrofluazide	1120 14 B-Chemical
.	1134 1 O

In	1136 2 O
the	1139 3 O
propranolol	1143 11 B-Chemical
group	1155 5 O
,	1160 1 O
serum	1162 5 O
potassium	1168 9 B-Chemical
and	1178 3 O
uric	1182 4 B-Chemical
acid	1187 4 I-Chemical
levels	1192 6 O
rose	1199 4 O
in	1204 2 O
both	1207 4 O
sexes	1212 5 O
,	1217 1 O
but	1219 3 O
the	1223 3 O
urea	1227 4 B-Chemical
level	1232 5 O
rose	1238 4 O
significantly	1243 13 O
in	1257 2 O
women	1260 5 O
only	1266 4 O
.	1270 1 O

Dexmedetomidine	0 15 B-Chemical
and	16 3 O
cardiac	20 7 O
protection	28 10 O
for	39 3 O
non	43 3 O
-	46 1 O
cardiac	47 7 O
surgery	55 7 O
:	62 1 O
a	64 1 O
meta	66 4 O
-	70 1 O
analysis	71 8 O
of	80 2 O
randomised	83 10 O
controlled	94 10 O
trials	105 6 O
.	111 1 O

We	113 2 O
conducted	116 9 O
a	126 1 O
systematic	128 10 O
review	139 6 O
of	146 2 O
the	149 3 O
effects	153 7 O
of	161 2 O
dexmedetomidine	164 15 B-Chemical
on	180 2 O
cardiac	183 7 O
outcomes	191 8 O
following	200 9 O
non	210 3 O
-	213 1 O
cardiac	214 7 O
surgery	222 7 O
.	229 1 O

We	231 2 O
included	234 8 O
prospective	243 11 O
,	254 1 O
randomised	256 10 O
peri	267 4 O
-	271 1 O
operative	272 9 O
studies	282 7 O
of	290 2 O
dexmedetomidine	293 15 B-Chemical
that	309 4 O
reported	314 8 O
mortality	323 9 O
,	332 1 O
cardiac	334 7 O
morbidity	342 9 O
or	352 2 O
adverse	355 7 O
drug	363 4 O
events	368 6 O
.	374 1 O

A	376 1 O
PubMed	378 6 O
Central	385 7 O
and	393 3 O
EMBASE	397 6 O
search	404 6 O
was	411 3 O
conducted	415 9 O
up	425 2 O
to	428 2 O
July	431 4 O
2007	436 4 O
.	440 1 O

The	442 3 O
reference	446 9 O
lists	456 5 O
of	462 2 O
identified	465 10 O
papers	476 6 O
were	483 4 O
examined	488 8 O
for	497 3 O
further	501 7 O
trials	509 6 O
.	515 1 O

Of	517 2 O
425	520 3 O
studies	524 7 O
identified	532 10 O
,	542 1 O
20	544 2 O
were	547 4 O
included	552 8 O
in	561 2 O
the	564 3 O
meta	568 4 O
-	572 1 O
analysis	573 8 O
(	582 1 O
840	583 3 O
patients	587 8 O
)	595 1 O
.	596 1 O

Dexmedetomidine	598 15 B-Chemical
was	614 3 O
associated	618 10 O
with	629 4 O
a	634 1 O
trend	636 5 O
towards	642 7 O
improved	650 8 O
cardiac	659 7 O
outcomes	667 8 O
;	675 1 O
all	677 3 O
-	680 1 O
cause	681 5 O
mortality	687 9 O
(	697 1 O
OR	698 2 O
0	701 1 O
.	702 1 O
27	703 2 O
,	705 1 O
95	707 2 O
%	709 1 O
CI	711 2 O
0	714 1 O
.	715 1 O
01	716 2 O
-	718 1 O
7	719 1 O
.	720 1 O
13	721 2 O
,	723 1 O
p	725 1 O
=	727 1 O
0	729 1 O
.	730 1 O
44	731 2 O
)	733 1 O
,	734 1 O
non	736 3 O
-	739 1 O
fatal	740 5 O
myocardial	746 10 B-Disease
infarction	757 10 I-Disease
(	768 1 O
OR	769 2 O
0	772 1 O
.	773 1 O
26	774 2 O
,	776 1 O
95	778 2 O
%	780 1 O
CI	782 2 O
0	785 1 O
.	786 1 O
04	787 2 O
-	789 1 O
1	790 1 O
.	791 1 O
60	792 2 O
,	794 1 O
p	796 1 O
=	798 1 O
0	800 1 O
.	801 1 O
14	802 2 O
)	804 1 O
,	805 1 O
and	807 3 O
myocardial	811 10 B-Disease
ischaemia	822 9 I-Disease
(	832 1 O
OR	833 2 O
0	836 1 O
.	837 1 O
65	838 2 O
,	840 1 O
95	842 2 O
%	844 1 O
CI	846 2 O
0	849 1 O
.	850 1 O
26	851 2 O
-	853 1 O
1	854 1 O
.	855 1 O
63	856 2 O
,	858 1 O
p	860 1 O
=	862 1 O
0	864 1 O
.	865 1 O
36	866 2 O
)	868 1 O
.	869 1 O

Peri	871 4 O
-	875 1 O
operative	876 9 O
hypotension	886 11 B-Disease
(	898 1 O
26	899 2 O
%	901 1 O
,	902 1 O
OR	904 2 O
3	907 1 O
.	908 1 O
80	909 2 O
,	911 1 O
95	913 2 O
%	915 1 O
CI	917 2 O
1	920 1 O
.	921 1 O
91	922 2 O
-	924 1 O
7	925 1 O
.	926 1 O
54	927 2 O
,	929 1 O
p	931 1 O
=	933 1 O
0	935 1 O
.	936 1 O
0001	937 4 O
)	941 1 O
and	943 3 O
bradycardia	947 11 B-Disease
(	959 1 O
17	960 2 O
%	962 1 O
,	963 1 O
OR	965 2 O
5	968 1 O
.	969 1 O
45	970 2 O
,	972 1 O
95	974 2 O
%	976 1 O
CI	978 2 O
2	981 1 O
.	982 1 O
98	983 2 O
-	985 1 O
9	986 1 O
.	987 1 O
95	988 2 O
,	990 1 O
p	992 1 O
<	994 1 O
0	996 1 O
.	997 1 O
00001	998 5 O
)	1003 1 O
were	1005 4 O
significantly	1010 13 O
increased	1024 9 O
.	1033 1 O

An	1035 2 O
anticholinergic	1038 15 O
did	1054 3 O
not	1058 3 O
reduce	1062 6 O
the	1069 3 O
incidence	1073 9 O
of	1083 2 O
bradycardia	1086 11 B-Disease
(	1098 1 O
p	1099 1 O
=	1101 1 O
0	1103 1 O
.	1104 1 O
43	1105 2 O
)	1107 1 O
.	1108 1 O

A	1110 1 O
randomised	1112 10 O
placebo	1123 7 O
-	1130 1 O
controlled	1131 10 O
trial	1142 5 O
of	1148 2 O
dexmedetomidine	1151 15 B-Chemical
is	1167 2 O
warranted	1170 9 O
.	1179 1 O

Differential	0 12 O
diagnosis	13 9 O
of	23 2 O
high	26 4 O
serum	31 5 O
creatine	37 8 B-Chemical
kinase	46 6 O
levels	53 6 O
in	60 2 O
systemic	63 8 B-Disease
lupus	72 5 I-Disease
erythematosus	78 13 I-Disease
.	91 1 O

We	93 2 O
report	96 6 O
the	103 3 O
clinical	107 8 O
and	116 3 O
bioptic	120 7 O
findings	128 8 O
for	137 3 O
a	141 1 O
57	143 2 O
-	145 1 O
year	146 4 O
-	150 1 O
old	151 3 O
woman	155 5 O
with	161 4 O
severe	166 6 O
chloroquine	173 11 B-Chemical
-	184 1 O
induced	185 7 O
myopathy	193 8 B-Disease
.	201 1 O

Since	203 5 O
1989	209 4 O
,	213 1 O
she	215 3 O
had	219 3 O
been	223 4 O
suffering	228 9 O
from	238 4 O
systemic	243 8 B-Disease
lupus	252 5 I-Disease
erythematosus	258 13 I-Disease
(	272 1 O
SLE	273 3 B-Disease
)	276 1 O
with	278 4 O
renal	283 5 B-Disease
involvement	289 11 I-Disease
and	301 3 O
undergone	305 9 O
periods	315 7 O
of	323 2 O
treatment	326 9 O
with	336 4 O
azathioprine	341 12 B-Chemical
and	354 3 O
cyclophosphamide	358 16 B-Chemical
.	374 1 O

Additional	376 10 O
therapy	387 7 O
with	395 4 O
chloroquine	400 11 B-Chemical
(	412 1 O
CQ	413 2 B-Chemical
)	415 1 O
was	417 3 O
started	421 7 O
because	429 7 O
of	437 2 O
arthralgia	440 10 B-Disease
.	450 1 O

At	452 2 O
the	455 3 O
same	459 4 O
time	464 4 O
,	468 1 O
slightly	470 8 O
increased	479 9 O
creatine	489 8 B-Chemical
kinase	498 6 O
(	505 1 O
CK	506 2 O
)	508 1 O
levels	510 6 O
were	517 4 O
noted	522 5 O
.	527 1 O

Myositis	529 8 B-Disease
was	538 3 O
suspected	542 9 O
,	551 1 O
and	553 3 O
the	557 3 O
patient	561 7 O
was	569 3 O
treated	573 7 O
with	581 4 O
steroids	586 8 B-Chemical
.	594 1 O

The	596 3 O
CK	600 2 O
increase	603 8 O
persisted	612 9 O
,	621 1 O
however	623 7 O
,	630 1 O
and	632 3 O
she	636 3 O
developed	640 9 O
progressive	650 11 O
muscular	662 8 B-Disease
weakness	671 8 I-Disease
and	680 3 O
muscular	684 8 B-Disease
atrophy	693 7 I-Disease
.	700 1 O

Routine	702 7 O
controls	710 8 O
revealed	719 8 O
markedly	728 8 O
elevated	737 8 O
CK	746 2 O
levels	749 6 O
of	756 2 O
1	759 1 O
,	760 1 O
700	761 3 O
U	765 1 O
/	766 1 O
l	767 1 O
.	768 1 O

The	770 3 O
neurological	774 12 O
and	787 3 O
electrophysiological	791 20 O
findings	812 8 O
were	821 4 O
not	826 3 O
typical	830 7 O
of	838 2 O
myositis	841 8 B-Disease
.	849 1 O

Thus	851 4 O
,	855 1 O
muscle	857 6 O
biopsy	864 6 O
of	871 2 O
the	874 3 O
deltoid	878 7 O
muscle	886 6 O
was	893 3 O
performed	897 9 O
in	907 2 O
order	910 5 O
to	916 2 O
exclude	919 7 O
polymyositis	927 12 B-Disease
or	940 2 O
toxic	943 5 O
myopathy	949 8 B-Disease
.	957 1 O

As	959 2 O
it	962 2 O
revealed	965 8 O
chloroquine	974 11 B-Chemical
-	985 1 O
induced	986 7 O
myopathy	994 8 B-Disease
,	1002 1 O
medication	1004 10 O
was	1015 3 O
stopped	1019 7 O
.	1026 1 O

Discriminating	1028 14 O
between	1043 7 O
primary	1051 7 O
SLE	1059 3 B-Disease
-	1062 1 O
induced	1063 7 O
affection	1071 9 B-Disease
of	1081 2 I-Disease
the	1084 3 I-Disease
musculoskeletal	1088 15 I-Disease
system	1104 6 I-Disease
and	1111 3 O
drug	1115 4 O
-	1119 1 O
induced	1120 7 O
side	1128 4 O
effects	1133 7 O
is	1141 2 O
important	1144 9 O
for	1154 3 O
appropriate	1158 11 O
treatment	1170 9 O
of	1180 2 O
SLE	1183 3 B-Disease
patients	1187 8 O
.	1195 1 O

Intravenous	0 11 O
ribavirin	12 9 B-Chemical
treatment	22 9 O
for	32 3 O
severe	36 6 O
adenovirus	43 10 B-Disease
disease	54 7 I-Disease
in	62 2 O
immunocompromised	65 17 O
children	83 8 O
.	91 1 O

BACKGROUND	93 10 O
:	103 1 O
Adenovirus	105 10 O
is	116 2 O
an	119 2 O
important	122 9 O
cause	132 5 O
of	138 2 O
morbidity	141 9 O
and	151 3 O
mortality	155 9 O
in	165 2 O
the	168 3 O
immunocompromised	172 17 O
host	190 4 O
.	194 1 O

The	196 3 O
incidence	200 9 O
of	210 2 O
severe	213 6 O
adenovirus	220 10 B-Disease
disease	231 7 I-Disease
in	239 2 O
pediatrics	242 10 O
is	253 2 O
increasing	256 10 O
in	267 2 O
association	270 11 O
with	282 4 O
growing	287 7 O
numbers	295 7 O
of	303 2 O
immunocompromised	306 17 O
children	324 8 O
,	332 1 O
where	334 5 O
case	340 4 O
fatality	345 8 O
rates	354 5 O
as	360 2 O
high	363 4 O
as	368 2 O
50	371 2 O
%	373 1 O
to	375 2 O
80	378 2 O
%	380 1 O
have	382 4 O
been	387 4 O
reported	392 8 O
.	400 1 O

There	402 5 O
are	408 3 O
no	412 2 O
approved	415 8 O
antiviral	424 9 O
agents	434 6 O
with	441 4 O
proven	446 6 O
efficacy	453 8 O
for	462 3 O
the	466 3 O
treatment	470 9 O
of	480 2 O
severe	483 6 O
adenovirus	490 10 B-Disease
disease	501 7 I-Disease
,	508 1 O
nor	510 3 O
are	514 3 O
there	518 5 O
any	524 3 O
prospective	528 11 O
randomized	540 10 O
,	550 1 O
controlled	552 10 O
trials	563 6 O
of	570 2 O
potentially	573 11 O
useful	585 6 O
anti	592 4 O
-	596 1 O
adenovirus	597 10 O
therapies	608 9 O
.	617 1 O

Apparent	619 8 O
clinical	628 8 O
success	637 7 O
in	645 2 O
the	648 3 O
treatment	652 9 O
of	662 2 O
severe	665 6 O
adenovirus	672 10 B-Disease
disease	683 7 I-Disease
is	691 2 O
limited	694 7 O
to	702 2 O
a	705 1 O
few	707 3 O
case	711 4 O
reports	716 7 O
and	724 3 O
small	728 5 O
series	734 6 O
.	740 1 O

Experience	742 10 O
is	753 2 O
greatest	756 8 O
with	765 4 O
intravenous	770 11 O
ribavirin	782 9 B-Chemical
and	792 3 O
cidofovir	796 9 B-Chemical
.	805 1 O

Ribavirin	807 9 B-Chemical
,	816 1 O
a	818 1 O
guanosine	820 9 B-Chemical
analogue	830 8 O
,	838 1 O
has	840 3 O
broad	844 5 O
antiviral	850 9 O
activity	860 8 O
against	869 7 O
both	877 4 O
RNA	882 3 O
and	886 3 O
DNA	890 3 O
viruses	894 7 O
,	901 1 O
including	903 9 O
documented	913 10 O
activity	924 8 O
against	933 7 O
adenovirus	941 10 O
in	952 2 O
vitro	955 5 O
.	960 1 O

Ribavirin	962 9 B-Chemical
is	972 2 O
licensed	975 8 O
in	984 2 O
aerosol	987 7 O
form	995 4 O
for	1000 3 O
the	1004 3 O
treatment	1008 9 O
of	1018 2 O
respiratory	1021 11 B-Disease
syncytial	1033 9 I-Disease
virus	1043 5 I-Disease
infection	1049 9 I-Disease
,	1058 1 O
and	1060 3 O
orally	1064 6 O
in	1071 2 O
combination	1074 11 O
with	1086 4 O
interferon	1091 10 O
to	1102 2 O
treat	1105 5 O
hepatitis	1111 9 B-Disease
C	1121 1 I-Disease
.	1122 1 O

Intravenous	1124 11 O
ribavirin	1136 9 B-Chemical
is	1146 2 O
the	1149 3 O
treatment	1153 9 O
of	1163 2 O
choice	1166 6 O
for	1173 3 O
infection	1177 9 B-Disease
with	1187 4 I-Disease
hemorrhagic	1192 11 I-Disease
fever	1204 5 I-Disease
viruses	1210 7 I-Disease
.	1217 1 O

The	1219 3 O
most	1223 4 O
common	1228 6 O
adverse	1235 7 O
effect	1243 6 O
of	1250 2 O
intravenous	1253 11 O
ribavirin	1265 9 B-Chemical
is	1275 2 O
reversible	1278 10 O
mild	1289 4 O
anemia	1294 6 B-Disease
.	1300 1 O

The	1302 3 O
use	1306 3 O
of	1310 2 O
cidofovir	1313 9 B-Chemical
in	1323 2 O
severe	1326 6 O
adenovirus	1333 10 B-Disease
infection	1344 9 I-Disease
has	1354 3 O
been	1358 4 O
limited	1363 7 O
by	1371 2 O
adverse	1374 7 O
effects	1382 7 O
,	1389 1 O
the	1391 3 O
most	1395 4 O
significant	1400 11 O
of	1412 2 O
which	1415 5 O
is	1421 2 O
nephrotoxicity	1424 14 B-Disease
.	1438 1 O

OBJECTIVE	1440 9 O
:	1449 1 O
We	1451 2 O
report	1454 6 O
our	1461 3 O
experience	1465 10 O
with	1476 4 O
intravenous	1481 11 O
ribavirin	1493 9 B-Chemical
therapy	1503 7 O
for	1511 3 O
severe	1515 6 O
adenovirus	1522 10 B-Disease
disease	1533 7 I-Disease
in	1541 2 O
a	1544 1 O
series	1546 6 O
of	1553 2 O
immunocompromised	1556 17 O
children	1574 8 O
and	1583 3 O
review	1587 6 O
the	1594 3 O
literature	1598 10 O
.	1608 1 O

DESIGN	1610 6 O
/	1616 1 O
METHODS	1617 7 O
:	1624 1 O
We	1626 2 O
retrospectively	1629 15 O
reviewed	1645 8 O
the	1654 3 O
medical	1658 7 O
records	1666 7 O
of	1674 2 O
5	1677 1 O
children	1679 8 O
treated	1688 7 O
with	1696 4 O
intravenous	1701 11 O
ribavirin	1713 9 B-Chemical
for	1723 3 O
documented	1727 10 O
severe	1738 6 O
adenovirus	1745 10 B-Disease
disease	1756 7 I-Disease
.	1763 1 O

Two	1765 3 O
patients	1769 8 O
developed	1778 9 O
adenovirus	1788 10 O
hemorrhagic	1799 11 B-Disease
cystitis	1811 8 I-Disease
after	1820 5 O
cardiac	1826 7 O
and	1834 3 O
bone	1838 4 O
marrow	1843 6 O
transplants	1850 11 O
,	1861 1 O
respectively	1863 12 O
.	1875 1 O

The	1877 3 O
bone	1881 4 O
marrow	1886 6 O
transplant	1893 10 O
patient	1904 7 O
also	1912 4 O
received	1917 8 O
intravenous	1926 11 O
cidofovir	1938 9 B-Chemical
for	1948 3 O
progressive	1952 11 O
disseminated	1964 12 O
disease	1977 7 O
.	1984 1 O

An	1986 2 O
additional	1989 10 O
3	2000 1 O
children	2002 8 O
developed	2011 9 O
adenovirus	2021 10 B-Disease
pneumonia	2032 9 I-Disease
;	2041 1 O
2	2043 1 O
were	2045 4 O
neonates	2050 8 O
,	2058 1 O
1	2060 1 O
of	2062 2 O
whom	2065 4 O
had	2070 3 O
partial	2074 7 O
DiGeorge	2082 8 B-Disease
syndrome	2091 8 I-Disease
.	2099 1 O

The	2101 3 O
remaining	2105 9 O
infant	2115 6 O
had	2122 3 O
recently	2126 8 O
undergone	2135 9 O
a	2145 1 O
cardiac	2147 7 O
transplant	2155 10 O
.	2165 1 O

Intravenous	2167 11 O
ribavirin	2179 9 B-Chemical
was	2189 3 O
administered	2193 12 O
on	2206 2 O
a	2209 1 O
compassionate	2211 13 O
-	2224 1 O
use	2225 3 O
protocol	2229 8 O
.	2237 1 O

RESULTS	2239 7 O
:	2246 1 O
Complete	2248 8 O
clinical	2257 8 O
recovery	2266 8 O
followed	2275 8 O
later	2284 5 O
by	2290 2 O
viral	2293 5 O
clearance	2299 9 O
was	2309 3 O
observed	2313 8 O
in	2322 2 O
2	2325 1 O
children	2327 8 O
:	2335 1 O
the	2337 3 O
cardiac	2341 7 O
transplant	2349 10 O
recipient	2360 9 O
with	2370 4 O
adenovirus	2375 10 O
hemorrhagic	2386 11 B-Disease
cystitis	2398 8 I-Disease
and	2407 3 O
the	2411 3 O
immunocompetent	2415 15 O
neonate	2431 7 O
with	2439 4 O
adenovirus	2444 10 B-Disease
pneumonia	2455 9 I-Disease
.	2464 1 O

The	2466 3 O
remaining	2470 9 O
3	2480 1 O
children	2482 8 O
died	2491 4 O
of	2496 2 O
adenovirus	2499 10 B-Disease
disease	2510 7 I-Disease
.	2517 1 O

Intravenous	2519 11 O
ribavirin	2531 9 B-Chemical
therapy	2541 7 O
was	2549 3 O
well	2553 4 O
tolerated	2558 9 O
.	2567 1 O

Use	2569 3 O
of	2573 2 O
cidofovir	2576 9 B-Chemical
in	2586 2 O
1	2589 1 O
child	2591 5 O
was	2597 3 O
associated	2601 10 O
with	2612 4 O
progressive	2617 11 B-Disease
renal	2629 5 I-Disease
failure	2635 7 I-Disease
and	2643 3 O
neutropenia	2647 11 B-Disease
.	2658 1 O

DISCUSSION	2660 10 O
:	2670 1 O
Our	2672 3 O
series	2676 6 O
of	2683 2 O
patients	2686 8 O
is	2695 2 O
representative	2698 14 O
of	2713 2 O
the	2716 3 O
spectrum	2720 8 O
of	2729 2 O
immunocompromised	2732 17 O
children	2750 8 O
at	2759 2 O
greatest	2762 8 O
risk	2771 4 O
for	2776 3 O
severe	2780 6 O
adenovirus	2787 10 B-Disease
disease	2798 7 I-Disease
,	2805 1 O
namely	2807 6 O
solid	2814 5 O
-	2819 1 O
organ	2820 5 O
and	2826 3 O
bone	2830 4 O
marrow	2835 6 O
transplant	2842 10 O
recipients	2853 10 O
,	2863 1 O
neonates	2865 8 O
,	2873 1 O
and	2875 3 O
children	2879 8 O
with	2888 4 O
immunodeficiency	2893 16 B-Disease
.	2909 1 O

Although	2911 8 O
intravenous	2920 11 O
ribavirin	2932 9 B-Chemical
was	2942 3 O
not	2946 3 O
effective	2950 9 O
for	2960 3 O
all	2964 3 O
children	2968 8 O
with	2977 4 O
severe	2982 6 O
adenovirus	2989 10 B-Disease
disease	3000 7 I-Disease
in	3008 2 O
this	3011 4 O
series	3016 6 O
or	3023 2 O
in	3026 2 O
the	3029 3 O
literature	3033 10 O
,	3043 1 O
therapy	3045 7 O
is	3053 2 O
unlikely	3056 8 O
to	3065 2 O
be	3068 2 O
of	3071 2 O
benefit	3074 7 O
if	3082 2 O
begun	3085 5 O
late	3091 4 O
in	3096 2 O
the	3099 3 O
course	3103 6 O
of	3110 2 O
the	3113 3 O
infection	3117 9 B-Disease
.	3126 1 O

Early	3128 5 O
identification	3134 14 O
,	3148 1 O
eg	3150 2 O
by	3153 2 O
polymerase	3156 10 O
chain	3167 5 O
reaction	3173 8 O
of	3182 2 O
those	3185 5 O
patients	3191 8 O
at	3200 2 O
risk	3203 4 O
of	3208 2 O
disseminated	3211 12 O
adenovirus	3224 10 B-Disease
disease	3235 7 I-Disease
may	3243 3 O
permit	3247 6 O
earlier	3254 7 O
antiviral	3262 9 O
treatment	3272 9 O
and	3282 3 O
better	3286 6 O
evaluation	3293 10 O
of	3304 2 O
therapeutic	3307 11 O
response	3319 8 O
.	3327 1 O

CONCLUSIONS	3329 11 O
:	3340 1 O
Two	3342 3 O
of	3346 2 O
5	3349 1 O
children	3351 8 O
with	3360 4 O
severe	3365 6 O
adenovirus	3372 10 B-Disease
disease	3383 7 I-Disease
treated	3391 7 O
with	3399 4 O
intravenous	3404 11 O
ribavirin	3416 9 B-Chemical
recovered	3426 9 O
.	3435 1 O

The	3437 3 O
availability	3441 12 O
of	3454 2 O
newer	3457 5 O
rapid	3463 5 O
diagnostic	3469 10 O
techniques	3480 10 O
,	3490 1 O
such	3492 4 O
as	3497 2 O
polymerase	3500 10 O
chain	3511 5 O
reaction	3517 8 O
,	3525 1 O
may	3527 3 O
make	3531 4 O
earlier	3536 7 O
,	3543 1 O
more	3545 4 O
effective	3550 9 O
treatment	3560 9 O
of	3570 2 O
adenovirus	3573 10 B-Disease
infection	3584 9 I-Disease
possible	3594 8 O
.	3602 1 O

Given	3604 5 O
the	3610 3 O
seriousness	3614 11 O
and	3626 3 O
increasing	3630 10 O
prevalence	3641 10 O
of	3652 2 O
adenovirus	3655 10 B-Disease
disease	3666 7 I-Disease
in	3674 2 O
certain	3677 7 O
hosts	3685 5 O
,	3690 1 O
especially	3692 10 O
children	3703 8 O
,	3711 1 O
a	3713 1 O
large	3715 5 O
,	3720 1 O
multicenter	3722 11 O
clinical	3734 8 O
trial	3743 5 O
of	3749 2 O
potentially	3752 11 O
useful	3764 6 O
anti	3771 4 O
-	3775 1 O
adenoviral	3776 10 O
therapies	3787 9 O
,	3796 1 O
such	3798 4 O
as	3803 2 O
intravenous	3806 11 O
ribavirin	3818 9 B-Chemical
,	3827 1 O
is	3829 2 O
clearly	3832 7 O
required	3840 8 O
to	3849 2 O
demonstrate	3852 11 O
the	3864 3 O
most	3868 4 O
effective	3873 9 O
and	3883 3 O
least	3887 5 O
toxic	3893 5 O
therapy	3899 7 O
.	3906 1 O

Hepatotoxicity	0 14 B-Disease
of	15 2 O
amiodarone	18 10 B-Chemical
.	28 1 O

Amiodarone	30 10 B-Chemical
has	41 3 O
proved	45 6 O
very	52 4 O
effective	57 9 O
in	67 2 O
the	70 3 O
treatment	74 9 O
of	84 2 O
otherwise	87 9 O
resistant	97 9 O
cardiac	107 7 O
tachyarrhythmias	115 16 B-Disease
.	131 1 O

The	133 3 O
use	137 3 O
of	141 2 O
amiodarone	144 10 B-Chemical
has	155 3 O
,	158 1 O
however	160 7 O
,	167 1 O
been	169 4 O
limited	174 7 O
due	182 3 O
to	186 2 O
its	189 3 O
serious	193 7 O
side	201 4 O
-	205 1 O
effects	206 7 O
.	213 1 O

A	215 1 O
patient	217 7 O
with	225 4 O
cholestatic	230 11 B-Disease
hepatitis	242 9 I-Disease
due	252 3 O
to	256 2 O
amiodarone	259 10 B-Chemical
treatment	270 9 O
is	280 2 O
presented	283 9 O
below	293 5 O
and	299 3 O
a	303 1 O
review	305 6 O
of	312 2 O
the	315 3 O
hepatotoxicity	319 14 B-Disease
of	334 2 O
amiodarone	337 10 B-Chemical
is	348 2 O
given	351 5 O
.	356 1 O

It	358 2 O
is	361 2 O
concluded	364 9 O
that	374 4 O
solid	379 5 O
evidence	385 8 O
exists	394 6 O
of	401 2 O
hepatic	404 7 B-Disease
injury	412 6 I-Disease
due	419 3 O
to	423 2 O
amiodarone	426 10 B-Chemical
treatment	437 9 O
,	446 1 O
including	448 9 O
steatosis	458 9 B-Disease
,	467 1 O
alterations	469 11 O
resembling	481 10 O
alcoholic	492 9 B-Disease
hepatitis	502 9 I-Disease
,	511 1 O
cholestatic	513 11 B-Disease
hepatitis	525 9 I-Disease
and	535 3 O
micronodular	539 12 O
cirrhosis	552 9 B-Disease
of	562 2 I-Disease
the	565 3 I-Disease
liver	569 5 I-Disease
.	574 1 O

Patients	576 8 O
receiving	585 9 O
amiodarone	595 10 B-Chemical
should	606 6 O
be	613 2 O
regularly	616 9 O
screened	626 8 O
with	635 4 O
respect	640 7 O
to	648 2 O
hepatic	651 7 O
enzyme	659 6 O
levels	666 6 O
.	672 1 O

Therapy	674 7 O
should	682 6 O
be	689 2 O
discontinued	692 12 O
on	705 2 O
the	708 3 O
suspicion	712 9 O
of	722 2 O
cholestatic	725 11 B-Disease
injury	737 6 I-Disease
or	744 2 O
hepatomegaly	747 12 B-Disease
.	759 1 O

Catalepsy	0 9 B-Disease
induced	10 7 O
by	18 2 O
combinations	21 12 O
of	34 2 O
ketamine	37 8 B-Chemical
and	46 3 O
morphine	50 8 B-Chemical
:	58 1 O
potentiation	60 12 O
,	72 1 O
antagonism	74 10 O
,	84 1 O
tolerance	86 9 O
and	96 3 O
cross	100 5 O
-	105 1 O
tolerance	106 9 O
in	116 2 O
the	119 3 O
rat	123 3 O
.	126 1 O

Previous	128 8 O
studies	137 7 O
demonstrated	145 12 O
that	158 4 O
both	163 4 O
ketamine	168 8 B-Chemical
and	177 3 O
morphine	181 8 B-Chemical
induced	190 7 O
analgesia	198 9 B-Disease
and	208 3 O
catalepsy	212 9 B-Disease
in	222 2 O
the	225 3 O
rat	229 3 O
.	232 1 O

Pre	234 3 O
-	237 1 O
treatment	238 9 O
with	248 4 O
ketamine	253 8 B-Chemical
produced	262 8 O
cross	271 5 O
-	276 1 O
tolerance	277 9 O
to	287 2 O
morphine	290 8 B-Chemical
,	298 1 O
whereas	300 7 O
pretreatment	308 12 O
with	321 4 O
morphine	326 8 B-Chemical
did	335 3 O
not	339 3 O
induce	343 6 O
cross	350 5 O
-	355 1 O
tolerance	356 9 O
to	366 2 O
ketamine	369 8 B-Chemical
but	378 3 O
rather	382 6 O
augmented	389 9 O
the	399 3 O
cataleptic	403 10 B-Disease
response	414 8 O
;	422 1 O
this	424 4 O
augmentation	429 12 O
was	442 3 O
attributed	446 10 O
to	457 2 O
residual	460 8 O
morphine	469 8 B-Chemical
in	478 2 O
the	481 3 O
brain	485 5 O
.	490 1 O

The	492 3 O
present	496 7 O
studies	504 7 O
explored	512 8 O
the	521 3 O
duration	525 8 O
of	534 2 O
the	537 3 O
loss	541 4 O
of	546 2 O
righting	549 8 O
reflex	558 6 O
induced	565 7 O
by	573 2 O
sub	576 3 O
-	579 1 O
effective	580 9 O
doses	590 5 O
of	596 2 O
ketamine	599 8 B-Chemical
and	608 3 O
morphine	612 8 B-Chemical
,	620 1 O
administered	622 12 O
simultaneously	635 14 O
.	649 1 O

There	651 5 O
was	657 3 O
mutual	661 6 O
potentiation	668 12 O
between	681 7 O
sub	689 3 O
-	692 1 O
effective	693 9 O
doses	703 5 O
of	709 2 O
ketamine	712 8 B-Chemical
and	721 3 O
morphine	725 8 B-Chemical
,	733 1 O
but	735 3 O
sub	739 3 O
-	742 1 O
effective	743 9 O
doses	753 5 O
of	759 2 O
ketamine	762 8 B-Chemical
partly	771 6 O
antagonized	778 11 O
fully	790 5 O
-	795 1 O
effective	796 9 O
doses	806 5 O
of	812 2 O
morphine	815 8 B-Chemical
.	823 1 O

Latency	825 7 O
to	833 2 O
the	836 3 O
loss	840 4 O
of	845 2 O
righting	848 8 O
reflex	857 6 O
,	863 1 O
rigidity	865 8 B-Disease
and	874 3 O
behavior	878 8 O
on	887 2 O
recovery	890 8 O
,	898 1 O
reflected	900 9 O
the	910 3 O
relative	914 8 O
predominance	923 12 O
of	936 2 O
ketamine	939 8 B-Chemical
or	948 2 O
morphine	951 8 B-Chemical
in	960 2 O
each	963 4 O
combination	968 11 O
.	979 1 O

Naloxone	981 8 B-Chemical
inhibited	990 9 O
the	1000 3 O
induced	1004 7 O
cataleptic	1012 10 B-Disease
effects	1023 7 O
.	1030 1 O

The	1032 3 O
degree	1036 6 O
and	1043 3 O
time	1047 4 O
course	1052 6 O
of	1059 2 O
development	1062 11 O
of	1074 2 O
tolerance	1077 9 O
to	1087 2 O
daily	1090 5 O
administration	1096 14 O
of	1111 2 O
sub	1114 3 O
-	1117 1 O
effective	1118 9 O
dose	1128 4 O
combinations	1133 12 O
of	1146 2 O
ketamine	1149 8 B-Chemical
and	1158 3 O
morphine	1162 8 B-Chemical
were	1171 4 O
similar	1176 7 O
.	1183 1 O

Rats	1185 4 O
,	1189 1 O
tolerant	1191 8 O
to	1200 2 O
ketamine	1203 8 B-Chemical
-	1211 1 O
dominant	1212 8 O
combinations	1221 12 O
,	1233 1 O
were	1235 4 O
cross	1240 5 O
-	1245 1 O
tolerant	1246 8 O
to	1255 2 O
both	1258 4 O
drugs	1263 5 O
,	1268 1 O
while	1270 5 O
those	1276 5 O
tolerant	1282 8 O
to	1291 2 O
morphine	1294 8 B-Chemical
-	1302 1 O
dominant	1303 8 O
combinations	1312 12 O
were	1325 4 O
cross	1330 5 O
-	1335 1 O
tolerant	1336 8 O
to	1345 2 O
morphine	1348 8 B-Chemical
but	1357 3 O
showed	1361 6 O
either	1368 6 O
no	1375 2 O
cross	1378 5 O
-	1383 1 O
tolerance	1384 9 O
or	1394 2 O
an	1397 2 O
augmented	1400 9 O
response	1410 8 O
to	1419 2 O
ketamine	1422 8 B-Chemical
.	1430 1 O

While	1432 5 O
the	1438 3 O
mutual	1442 6 O
potentiation	1449 12 O
,	1461 1 O
antagonism	1463 10 O
and	1474 3 O
tolerance	1478 9 O
suggest	1488 7 O
common	1496 6 O
mechanisms	1503 10 O
for	1514 3 O
the	1518 3 O
induced	1522 7 O
catalepsy	1530 9 B-Disease
,	1539 1 O
differences	1541 11 O
in	1553 2 O
latency	1556 7 O
,	1563 1 O
rigidity	1565 8 B-Disease
and	1574 3 O
behavior	1578 8 O
,	1586 1 O
asymmetry	1588 9 O
of	1598 2 O
cross	1601 5 O
-	1606 1 O
tolerance	1607 9 O
and	1617 3 O
a	1621 1 O
widely	1623 6 O
-	1629 1 O
different	1630 9 O
ID50	1640 4 O
for	1645 3 O
naloxone	1649 8 B-Chemical
would	1658 5 O
argue	1664 5 O
against	1670 7 O
an	1678 2 O
action	1681 6 O
at	1688 2 O
a	1691 1 O
single	1693 6 O
opioid	1700 6 O
site	1707 4 O
.	1711 1 O

Acute	0 5 B-Disease
renal	6 5 I-Disease
failure	12 7 I-Disease
in	20 2 O
patients	23 8 O
with	32 4 O
AIDS	37 4 B-Disease
on	42 2 O
tenofovir	45 9 B-Chemical
while	55 5 O
receiving	61 9 O
prolonged	71 9 O
vancomycin	81 10 B-Chemical
course	92 6 O
for	99 3 O
osteomyelitis	103 13 B-Disease
.	116 1 O

Renal	118 5 B-Disease
failure	124 7 I-Disease
developed	132 9 O
after	142 5 O
a	148 1 O
prolonged	150 9 O
course	160 6 O
of	167 2 O
vancomycin	170 10 B-Chemical
therapy	181 7 O
in	189 2 O
2	192 1 O
patients	194 8 O
who	203 3 O
were	207 4 O
receiving	212 9 O
tenofovir	222 9 B-Chemical
disoproxil	232 10 I-Chemical
fumarate	243 8 I-Chemical
as	252 2 O
part	255 4 O
of	260 2 O
an	263 2 O
antiretroviral	266 14 O
regimen	281 7 O
.	288 1 O

Tenofovir	290 9 B-Chemical
has	300 3 O
been	304 4 O
implicated	309 10 O
in	320 2 O
the	323 3 O
development	327 11 O
of	339 2 O
Fanconi	342 7 B-Disease
syndrome	350 8 I-Disease
and	359 3 O
renal	363 5 B-Disease
insufficiency	369 13 I-Disease
because	383 7 O
of	391 2 O
its	394 3 O
effects	398 7 O
on	406 2 O
the	409 3 O
proximal	413 8 O
renal	422 5 O
tubule	428 6 O
.	434 1 O

Vancomycin	436 10 B-Chemical
nephrotoxicity	447 14 B-Disease
is	462 2 O
infrequent	465 10 O
but	476 3 O
may	480 3 O
result	484 6 O
from	491 4 O
coadministration	496 16 O
with	513 4 O
a	518 1 O
nephrotoxic	520 11 B-Disease
agent	532 5 O
.	537 1 O

Clinicians	539 10 O
should	550 6 O
be	557 2 O
aware	560 5 O
that	566 4 O
tenofovir	571 9 B-Chemical
may	581 3 O
raise	585 5 O
the	591 3 O
risk	595 4 O
of	600 2 O
renal	603 5 B-Disease
failure	609 7 I-Disease
during	617 6 O
prolonged	624 9 O
administration	634 14 O
of	649 2 O
vancomycin	652 10 B-Chemical
.	662 1 O

Delayed	0 7 O
leukoencephalopathy	8 19 B-Disease
with	28 4 O
stroke	33 6 B-Disease
-	39 1 O
like	40 4 O
presentation	45 12 O
in	58 2 O
chemotherapy	61 12 O
recipients	74 10 O
.	84 1 O

BACKGROUND	86 10 O
:	96 1 O
A	98 1 O
transient	100 9 O
leukoencephalopathy	110 19 B-Disease
mimicking	130 9 O
cerebrovascular	140 15 B-Disease
accident	156 8 I-Disease
has	165 3 O
been	169 4 O
described	174 9 O
as	184 2 O
a	187 1 O
complication	189 12 O
of	202 2 O
chemotherapy	205 12 O
,	217 1 O
most	219 4 O
commonly	224 8 O
in	233 2 O
recipients	236 10 O
of	247 2 O
intrathecal	250 11 O
methotrexate	262 12 B-Chemical
for	275 3 O
childhood	279 9 O
leukaemia	289 9 B-Disease
.	298 1 O

Recently	300 8 O
published	309 9 O
neuroimaging	319 12 O
data	332 4 O
suggest	337 7 O
a	345 1 O
common	347 6 O
pathophysiology	354 15 O
associated	370 10 O
with	381 4 O
a	386 1 O
variety	388 7 O
of	396 2 O
chemotherapy	399 12 O
agents	412 6 O
and	419 3 O
modes	423 5 O
of	429 2 O
administration	432 14 O
.	446 1 O

METHODS	448 7 O
:	455 1 O
We	457 2 O
reviewed	460 8 O
the	469 3 O
medical	473 7 O
literature	481 10 O
for	492 3 O
single	496 6 O
reports	503 7 O
and	511 3 O
case	515 4 O
series	520 6 O
of	527 2 O
patients	530 8 O
presenting	539 10 O
with	550 4 O
stroke	555 6 B-Disease
-	561 1 O
like	562 4 O
episodes	567 8 O
while	576 5 O
receiving	582 9 O
systemic	592 8 O
or	601 2 O
intrathecal	604 11 O
chemotherapy	616 12 O
.	628 1 O

We	630 2 O
only	633 4 O
included	638 8 O
studies	647 7 O
providing	655 9 O
detailed	665 8 O
neuroimaging	674 12 O
data	687 4 O
.	691 1 O

Patients	693 8 O
with	702 4 O
cerebrovascular	707 15 B-Disease
accidents	723 9 I-Disease
were	733 4 O
excluded	738 8 O
.	746 1 O

RESULTS	748 7 O
:	755 1 O
We	757 2 O
identified	760 10 O
27	771 2 O
reports	774 7 O
of	782 2 O
toxic	785 5 O
leukoencephalopathy	791 19 B-Disease
in	811 2 O
patients	814 8 O
treated	823 7 O
with	831 4 O
methotrexate	836 12 B-Chemical
(	849 1 O
intrathecal	850 11 O
,	861 1 O
systemic	863 8 O
)	871 1 O
,	872 1 O
5	874 1 B-Chemical
-	875 1 I-Chemical
fluorouracil	876 12 I-Chemical
and	889 3 O
its	893 3 O
derivative	897 10 O
carmofur	908 8 B-Chemical
,	916 1 O
and	918 3 O
capecitabine	922 12 B-Chemical
.	934 1 O

Diffusion	936 9 O
weighted	946 8 O
imaging	955 7 O
(	963 1 O
DWI	964 3 O
)	967 1 O
of	969 2 O
all	972 3 O
patients	976 8 O
revealed	985 8 O
well	994 4 O
demarcated	999 10 O
hyperintense	1010 12 O
lesions	1023 7 B-Disease
within	1031 6 I-Disease
the	1038 3 I-Disease
subcortical	1042 11 I-Disease
white	1054 5 I-Disease
matter	1060 6 I-Disease
of	1067 2 O
the	1070 3 O
cerebral	1074 8 O
hemispheres	1083 11 O
and	1095 3 O
the	1099 3 O
corpus	1103 6 O
callosum	1110 8 O
,	1118 1 O
corresponding	1120 13 O
to	1134 2 O
areas	1137 5 O
of	1143 2 O
decreased	1146 9 O
proton	1156 6 O
diffusion	1163 9 O
on	1173 2 O
apparent	1176 8 O
diffusion	1185 9 O
coefficient	1195 11 O
(	1207 1 O
ADC	1208 3 O
)	1211 1 O
maps	1213 4 O
(	1218 1 O
available	1219 9 O
in	1229 2 O
21	1232 2 O
/	1234 1 O
27	1235 2 O
patients	1238 8 O
)	1246 1 O
.	1247 1 O

Lesions	1249 7 O
exceeded	1257 8 O
the	1266 3 O
confines	1270 8 O
of	1279 2 O
adjacent	1282 8 O
vascular	1291 8 O
territories	1300 11 O
.	1311 1 O

Complete	1313 8 O
resolution	1322 10 O
of	1333 2 O
symptoms	1336 8 O
within	1345 6 O
1	1352 1 O
-	1353 1 O
4	1354 1 O
days	1356 4 O
was	1361 3 O
accompanied	1365 11 O
by	1377 2 O
normalisation	1380 13 O
of	1394 2 O
ADC	1397 3 O
abnormalities	1401 13 O
.	1414 1 O

However	1416 7 O
,	1423 1 O
fluid	1425 5 O
attenuated	1431 10 O
inversion	1442 9 O
recovery	1452 8 O
(	1461 1 O
FLAIR	1462 5 O
)	1467 1 O
sequences	1469 9 O
frequently	1479 10 O
revealed	1490 8 O
persistent	1499 10 O
white	1510 5 B-Disease
matter	1516 6 I-Disease
abnormalities	1523 13 I-Disease
.	1536 1 O

CONCLUSIONS	1538 11 O
:	1549 1 O
Several	1551 7 O
pathophysiological	1559 18 O
models	1578 6 O
of	1585 2 O
delayed	1588 7 O
leukoencephalopathy	1596 19 B-Disease
after	1616 5 O
exposure	1622 8 O
to	1631 2 O
intrathecal	1634 11 O
or	1646 2 O
systemic	1649 8 O
chemotherapy	1658 12 O
have	1671 4 O
been	1676 4 O
proposed	1681 8 O
.	1689 1 O

DWI	1691 3 O
findings	1695 8 O
in	1704 2 O
this	1707 4 O
cohort	1712 6 O
are	1719 3 O
indicative	1723 10 O
of	1734 2 O
cytotoxic	1737 9 B-Disease
oedema	1747 6 I-Disease
within	1754 6 I-Disease
cerebral	1761 8 I-Disease
white	1770 5 I-Disease
matter	1776 6 I-Disease
and	1783 3 O
lend	1787 4 O
support	1792 7 O
to	1800 2 O
an	1803 2 O
at	1806 2 O
least	1809 5 O
partially	1815 9 O
reversible	1825 10 O
metabolic	1836 9 O
derangement	1846 11 O
as	1858 2 O
the	1861 3 O
basis	1865 5 O
for	1871 3 O
this	1875 4 O
syndrome	1880 8 O
.	1888 1 O

Down	0 4 O
-	4 1 O
regulation	5 10 O
of	16 2 O
norepinephrine	19 14 B-Chemical
transporter	34 11 O
function	46 8 O
induced	55 7 O
by	63 2 O
chronic	66 7 O
administration	74 14 O
of	89 2 O
desipramine	92 11 B-Chemical
linking	104 7 O
to	112 2 O
the	115 3 O
alteration	119 10 O
of	130 2 O
sensitivity	133 11 O
of	145 2 O
local	148 5 O
-	153 1 O
anesthetics	154 11 O
-	165 1 O
induced	166 7 O
convulsions	174 11 B-Disease
and	186 3 O
the	190 3 O
counteraction	194 13 O
by	208 2 O
co	211 2 O
-	213 1 O
administration	214 14 O
with	229 4 O
local	234 5 O
anesthetics	240 11 O
.	251 1 O

Alterations	253 11 O
of	265 2 O
norepinephrine	268 14 B-Chemical
transporter	283 11 O
(	295 1 O
NET	296 3 O
)	299 1 O
function	301 8 O
by	310 2 O
chronic	313 7 O
inhibition	321 10 O
of	332 2 O
NET	335 3 O
in	339 2 O
relation	342 8 O
to	351 2 O
sensitization	354 13 O
to	368 2 O
seizures	371 8 B-Disease
induce	380 6 O
by	387 2 O
cocaine	390 7 B-Chemical
and	398 3 O
local	402 5 O
anesthetics	408 11 O
were	420 4 O
studied	425 7 O
in	433 2 O
mice	436 4 O
.	440 1 O

Daily	442 5 O
administration	448 14 O
of	463 2 O
desipramine	466 11 B-Chemical
,	477 1 O
an	479 2 O
inhibitor	482 9 O
of	492 2 O
the	495 3 O
NET	499 3 O
,	502 1 O
for	504 3 O
5	508 1 O
days	510 4 O
decreased	515 9 O
[	525 1 O
(	526 1 O
3	527 1 O
)	528 1 O
H	529 1 O
]	530 1 O
norepinephrine	531 14 B-Chemical
uptake	546 6 O
in	553 2 O
the	556 3 O
P2	560 2 O
fractions	563 9 O
of	573 2 O
hippocampus	576 11 O
but	588 3 O
not	592 3 O
cortex	596 6 O
,	602 1 O
striatum	604 8 O
or	613 2 O
amygdalae	616 9 O
.	625 1 O

Co	627 2 O
-	629 1 O
administration	630 14 O
of	645 2 O
lidocaine	648 9 B-Chemical
,	657 1 O
bupivacaine	659 11 B-Chemical
or	671 2 O
tricaine	674 8 B-Chemical
with	683 4 O
desipramine	688 11 B-Chemical
reversed	700 8 O
this	709 4 O
effect	714 6 O
.	720 1 O

Daily	722 5 O
treatment	728 9 O
of	738 2 O
cocaine	741 7 B-Chemical
increased	749 9 O
[	759 1 O
(	760 1 O
3	761 1 O
)	762 1 O
H	763 1 O
]	764 1 O
norepinephrine	765 14 B-Chemical
uptake	780 6 O
into	787 4 O
the	792 3 O
hippocampus	796 11 O
.	807 1 O

Daily	809 5 O
administration	815 14 O
of	830 2 O
desipramine	833 11 B-Chemical
increased	845 9 O
the	855 3 O
incidence	859 9 O
of	869 2 O
appearance	872 10 O
of	883 2 O
lidocaine	886 9 B-Chemical
-	895 1 O
induced	896 7 O
convulsions	904 11 B-Disease
and	916 3 O
decreased	920 9 O
that	930 4 O
of	935 2 O
cocaine	938 7 B-Chemical
-	945 1 O
induced	946 7 O
convulsions	954 11 B-Disease
.	965 1 O

Co	967 2 O
-	969 1 O
administration	970 14 O
of	985 2 O
lidocaine	988 9 B-Chemical
with	998 4 O
desipramine	1003 11 B-Chemical
reversed	1015 8 O
the	1024 3 O
changes	1028 7 O
of	1036 2 O
convulsive	1039 10 B-Disease
activity	1050 8 O
of	1059 2 O
lidocaine	1062 9 B-Chemical
and	1072 3 O
cocaine	1076 7 B-Chemical
induced	1084 7 O
by	1092 2 O
repeated	1095 8 O
administration	1104 14 O
of	1119 2 O
desipramine	1122 11 B-Chemical
.	1133 1 O

These	1135 5 O
results	1141 7 O
suggest	1149 7 O
that	1157 4 O
down	1162 4 O
-	1166 1 O
regulation	1167 10 O
of	1178 2 O
hippocampal	1181 11 O
NET	1193 3 O
induced	1197 7 O
by	1205 2 O
chronic	1208 7 O
administration	1216 14 O
of	1231 2 O
desipramine	1234 11 B-Chemical
may	1246 3 O
be	1250 2 O
relevant	1253 8 O
to	1262 2 O
desipramine	1265 11 B-Chemical
-	1276 1 O
induced	1277 7 O
sensitization	1285 13 O
of	1299 2 O
lidocaine	1302 9 B-Chemical
convulsions	1312 11 B-Disease
.	1323 1 O

Inhibition	1325 10 O
of	1336 2 O
Na	1339 2 B-Chemical
(	1341 1 O
+	1342 1 O
)	1343 1 O
channels	1345 8 O
by	1354 2 O
local	1357 5 O
anesthetics	1363 11 O
may	1375 3 O
regulate	1379 8 O
desipramine	1388 11 B-Chemical
-	1399 1 O
induced	1400 7 O
down	1408 4 O
-	1412 1 O
regulation	1413 10 O
of	1424 2 O
NET	1427 3 O
function	1431 8 O
.	1439 1 O

Repeated	1441 8 O
administration	1450 14 O
of	1465 2 O
cocaine	1468 7 B-Chemical
induces	1476 7 O
up	1484 2 O
-	1486 1 O
regulation	1487 10 O
of	1498 2 O
hippocampal	1501 11 O
NET	1513 3 O
function	1517 8 O
.	1525 1 O

Desipramine	1527 11 B-Chemical
-	1538 1 O
induced	1539 7 O
sensitization	1547 13 O
of	1561 2 O
lidocaine	1564 9 B-Chemical
seizures	1574 8 B-Disease
may	1583 3 O
have	1587 4 O
a	1592 1 O
mechanism	1594 9 O
distinct	1604 8 O
from	1613 4 O
kindling	1618 8 O
resulting	1627 9 O
from	1637 4 O
repeated	1642 8 O
administration	1651 14 O
of	1666 2 O
cocaine	1669 7 B-Chemical
.	1676 1 O

Definition	0 10 O
and	11 3 O
management	15 10 O
of	26 2 O
anemia	29 6 B-Disease
in	36 2 O
patients	39 8 O
infected	48 8 B-Disease
with	57 4 I-Disease
hepatitis	62 9 I-Disease
C	72 1 I-Disease
virus	74 5 I-Disease
.	79 1 O

Chronic	81 7 B-Disease
infection	89 9 I-Disease
with	99 4 I-Disease
hepatitis	104 9 I-Disease
C	114 1 I-Disease
virus	116 5 I-Disease
(	122 1 O
HCV	123 3 O
)	126 1 O
can	128 3 O
progress	132 8 O
to	141 2 O
cirrhosis	144 9 B-Disease
,	153 1 O
hepatocellular	155 14 B-Disease
carcinoma	170 9 I-Disease
,	179 1 O
and	181 3 O
end	185 3 B-Disease
-	188 1 I-Disease
stage	189 5 I-Disease
liver	195 5 I-Disease
disease	201 7 I-Disease
.	208 1 O

The	210 3 O
current	214 7 O
best	222 4 O
treatment	227 9 O
for	237 3 O
HCV	241 3 B-Disease
infection	245 9 I-Disease
is	255 2 O
combination	258 11 O
therapy	270 7 O
with	278 4 O
pegylated	283 9 O
interferon	293 10 B-Chemical
and	304 3 O
ribavirin	308 9 B-Chemical
.	317 1 O

Although	319 8 O
this	328 4 O
regimen	333 7 O
produces	341 8 O
sustained	350 9 O
virologic	360 9 O
responses	370 9 O
(	380 1 O
SVRs	381 4 O
)	385 1 O
in	387 2 O
approximately	390 13 O
50	404 2 O
%	406 1 O
of	408 2 O
patients	411 8 O
,	419 1 O
it	421 2 O
can	424 3 O
be	428 2 O
associated	431 10 O
with	442 4 O
a	447 1 O
potentially	449 11 O
dose	461 4 O
-	465 1 O
limiting	466 8 O
hemolytic	475 9 B-Disease
anemia	485 6 I-Disease
.	491 1 O

Hemoglobin	493 10 O
concentrations	504 14 O
decrease	519 8 O
mainly	528 6 O
as	535 2 O
a	538 1 O
result	540 6 O
of	547 2 O
ribavirin	550 9 B-Chemical
-	559 1 O
induced	560 7 O
hemolysis	568 9 B-Disease
,	577 1 O
and	579 3 O
this	583 4 O
anemia	588 6 B-Disease
can	595 3 O
be	599 2 O
problematic	602 11 O
in	614 2 O
patients	617 8 O
with	626 4 O
HCV	631 3 B-Disease
infection	635 9 I-Disease
,	644 1 O
especially	646 10 O
those	657 5 O
who	663 3 O
have	667 4 O
comorbid	672 8 O
renal	681 5 B-Disease
or	687 2 I-Disease
cardiovascular	690 14 I-Disease
disorders	705 9 I-Disease
.	714 1 O

In	716 2 O
general	719 7 O
,	726 1 O
anemia	728 6 B-Disease
can	735 3 O
increase	739 8 O
the	748 3 O
risk	752 4 O
of	757 2 O
morbidity	760 9 O
and	770 3 O
mortality	774 9 O
,	783 1 O
and	785 3 O
may	789 3 O
have	793 4 O
negative	798 8 O
effects	807 7 O
on	815 2 O
cerebral	818 8 O
function	827 8 O
and	836 3 O
quality	840 7 O
of	848 2 O
life	851 4 O
.	855 1 O

Although	857 8 O
ribavirin	866 9 B-Chemical
-	875 1 O
associated	876 10 O
anemia	887 6 B-Disease
can	894 3 O
be	898 2 O
reversed	901 8 O
by	910 2 O
dose	913 4 O
reduction	918 9 O
or	928 2 O
discontinuation	931 15 O
,	946 1 O
this	948 4 O
approach	953 8 O
compromises	962 11 O
outcomes	974 8 O
by	983 2 O
significantly	986 13 O
decreasing	1000 10 O
SVR	1011 3 O
rates	1015 5 O
.	1020 1 O

Recombinant	1022 11 O
human	1034 5 O
erythropoietin	1040 14 O
has	1055 3 O
been	1059 4 O
used	1064 4 O
to	1069 2 O
manage	1072 6 O
ribavirin	1079 9 B-Chemical
-	1088 1 O
associated	1089 10 O
anemia	1100 6 B-Disease
but	1107 3 O
has	1111 3 O
other	1115 5 O
potential	1121 9 O
disadvantages	1131 13 O
.	1144 1 O

Viramidine	1146 10 B-Chemical
,	1156 1 O
a	1158 1 O
liver	1160 5 O
-	1165 1 O
targeting	1166 9 O
prodrug	1176 7 O
of	1184 2 O
ribavirin	1187 9 B-Chemical
,	1196 1 O
has	1198 3 O
the	1202 3 O
potential	1206 9 O
to	1216 2 O
maintain	1219 8 O
the	1228 3 O
virologic	1232 9 O
efficacy	1242 8 O
of	1251 2 O
ribavirin	1254 9 B-Chemical
while	1264 5 O
decreasing	1270 10 O
the	1281 3 O
risk	1285 4 O
of	1290 2 O
hemolytic	1293 9 B-Disease
anemia	1303 6 I-Disease
in	1310 2 O
patients	1313 8 O
with	1322 4 O
chronic	1327 7 B-Disease
hepatitis	1335 9 I-Disease
C	1345 1 I-Disease
.	1346 1 O

Calcium	0 7 B-Chemical
carbonate	8 9 I-Chemical
toxicity	18 8 B-Disease
:	26 1 O
the	28 3 O
updated	32 7 O
milk	40 4 B-Disease
-	44 1 I-Disease
alkali	45 6 I-Disease
syndrome	52 8 I-Disease
;	60 1 O
report	62 6 O
of	69 2 O
3	72 1 O
cases	74 5 O
and	80 3 O
review	84 6 O
of	91 2 O
the	94 3 O
literature	98 10 O
.	108 1 O

OBJECTIVE	110 9 O
:	119 1 O
To	121 2 O
describe	124 8 O
3	133 1 O
patients	135 8 O
with	144 4 O
calcium	149 7 B-Chemical
carbonate	157 9 I-Chemical
-	166 1 O
induced	167 7 O
hypercalcemia	175 13 B-Disease
and	189 3 O
gain	193 4 O
insights	198 8 O
into	207 4 O
the	212 3 O
cause	216 5 O
and	222 3 O
management	226 10 O
of	237 2 O
the	240 3 O
milk	244 4 B-Disease
-	248 1 I-Disease
alkali	249 6 I-Disease
syndrome	256 8 I-Disease
.	264 1 O

METHODS	266 7 O
:	273 1 O
We	275 2 O
report	278 6 O
the	285 3 O
clinical	289 8 O
and	298 3 O
laboratory	302 10 O
data	313 4 O
in	318 2 O
3	321 1 O
patients	323 8 O
who	332 3 O
presented	336 9 O
with	346 4 O
severe	351 6 O
hypercalcemia	358 13 B-Disease
(	372 1 O
corrected	373 9 O
serum	383 5 O
calcium	389 7 B-Chemical
>	397 1 O
or	399 2 O
=	402 1 O
14	404 2 O
mg	407 2 O
/	409 1 O
dL	410 2 O
)	412 1 O
and	414 3 O
review	418 6 O
the	425 3 O
pertinent	429 9 O
literature	439 10 O
on	450 2 O
milk	453 4 B-Disease
-	457 1 I-Disease
alkali	458 6 I-Disease
syndrome	465 8 I-Disease
.	473 1 O

RESULTS	475 7 O
:	482 1 O
The	484 3 O
3	488 1 O
patients	490 8 O
had	499 3 O
acute	503 5 B-Disease
renal	509 5 I-Disease
insufficiency	515 13 I-Disease
,	528 1 O
relative	530 8 O
metabolic	539 9 B-Disease
alkalosis	549 9 I-Disease
,	558 1 O
and	560 3 O
low	564 3 O
parathyroid	568 11 O
hormone	580 7 O
(	588 1 O
PTH	589 3 O
)	592 1 O
,	593 1 O
PTH	595 3 O
-	598 1 O
related	599 7 O
peptide	607 7 O
,	614 1 O
and	616 3 O
1	620 1 B-Chemical
,	621 1 I-Chemical
25	622 2 I-Chemical
-	624 1 I-Chemical
dihydroxyvitamin	625 16 I-Chemical
D	642 1 I-Chemical
concentrations	644 14 O
.	658 1 O

No	660 2 O
malignant	663 9 O
lesion	673 6 O
was	680 3 O
found	684 5 O
.	689 1 O

Treatment	691 9 O
included	701 8 O
aggressive	710 10 O
hydration	721 9 O
and	731 3 O
varied	735 6 O
amounts	742 7 O
of	750 2 O
furosemide	753 10 B-Chemical
.	763 1 O

The	765 3 O
2	769 1 O
patients	771 8 O
with	780 4 O
the	785 3 O
higher	789 6 O
serum	796 5 O
calcium	802 7 B-Chemical
concentrations	810 14 O
received	825 8 O
pamidronate	834 11 B-Chemical
intravenously	846 13 O
(	860 1 O
60	861 2 O
and	864 3 O
30	868 2 O
mg	871 2 O
,	873 1 O
respectively	875 12 O
)	887 1 O
,	888 1 O
which	890 5 O
caused	896 6 O
severe	903 6 O
hypocalcemia	910 12 B-Disease
.	922 1 O

Of	924 2 O
the	927 3 O
3	931 1 O
patients	933 8 O
,	941 1 O
2	943 1 O
were	945 4 O
ingesting	950 9 O
acceptable	960 10 O
doses	971 5 O
of	977 2 O
elemental	980 9 O
calcium	990 7 B-Chemical
(	998 1 O
1	999 1 O
g	1001 1 O
and	1003 3 O
2	1007 1 O
g	1009 1 O
daily	1011 5 O
,	1016 1 O
respectively	1018 12 O
)	1030 1 O
in	1032 2 O
the	1035 3 O
form	1039 4 O
of	1044 2 O
calcium	1047 7 B-Chemical
carbonate	1055 9 I-Chemical
.	1064 1 O

In	1066 2 O
addition	1069 8 O
to	1078 2 O
our	1081 3 O
highlighted	1085 11 O
cases	1097 5 O
,	1102 1 O
we	1104 2 O
review	1107 6 O
the	1114 3 O
history	1118 7 O
,	1125 1 O
classification	1127 14 O
,	1141 1 O
pathophysiologic	1143 16 O
features	1160 8 O
,	1168 1 O
and	1170 3 O
treatment	1174 9 O
of	1184 2 O
milk	1187 4 B-Disease
-	1191 1 I-Disease
alkali	1192 6 I-Disease
syndrome	1199 8 I-Disease
and	1208 3 O
summarize	1212 9 O
the	1222 3 O
cases	1226 5 O
reported	1232 8 O
from	1241 4 O
early	1246 5 O
1995	1252 4 O
to	1257 2 O
November	1260 8 O
2003	1269 4 O
.	1273 1 O

CONCLUSION	1275 10 O
:	1285 1 O
Milk	1287 4 B-Disease
-	1291 1 I-Disease
alkali	1292 6 I-Disease
syndrome	1299 8 I-Disease
may	1308 3 O
be	1312 2 O
a	1315 1 O
common	1317 6 O
cause	1324 5 O
of	1330 2 O
unexplained	1333 11 O
hypercalcemia	1345 13 B-Disease
and	1359 3 O
can	1363 3 O
be	1367 2 O
precipitated	1370 12 O
by	1383 2 O
small	1386 5 O
amounts	1392 7 O
of	1400 2 O
orally	1403 6 O
ingested	1410 8 O
calcium	1419 7 B-Chemical
carbonate	1427 9 I-Chemical
in	1437 2 O
susceptible	1440 11 O
persons	1452 7 O
.	1459 1 O

Treatment	1461 9 O
with	1471 4 O
hydration	1476 9 O
,	1485 1 O
furosemide	1487 10 B-Chemical
,	1497 1 O
and	1499 3 O
discontinuation	1503 15 O
of	1519 2 O
the	1522 3 O
calcium	1526 7 B-Chemical
and	1534 3 O
vitamin	1538 7 B-Chemical
D	1546 1 I-Chemical
source	1548 6 O
is	1555 2 O
adequate	1558 8 O
.	1566 1 O

Pamidronate	1568 11 B-Chemical
treatment	1580 9 O
is	1590 2 O
associated	1593 10 O
with	1604 4 O
considerable	1609 12 O
risk	1622 4 O
for	1627 3 O
hypocalcemia	1631 12 B-Disease
,	1643 1 O
even	1645 4 O
in	1650 2 O
cases	1653 5 O
of	1659 2 O
initially	1662 9 O
severe	1672 6 O
hypercalcemia	1679 13 B-Disease
.	1692 1 O

Management	0 10 O
strategies	11 10 O
for	22 3 O
ribavirin	26 9 B-Chemical
-	35 1 O
induced	36 7 O
hemolytic	44 9 B-Disease
anemia	54 6 I-Disease
in	61 2 O
the	64 3 O
treatment	68 9 O
of	78 2 O
hepatitis	81 9 B-Disease
C	91 1 I-Disease
:	92 1 O
clinical	94 8 O
and	103 3 O
economic	107 8 O
implications	116 12 O
.	128 1 O

OBJECTIVES	130 10 O
:	140 1 O
Recently	142 8 O
published	151 9 O
studies	161 7 O
have	169 4 O
demonstrated	174 12 O
increased	187 9 O
efficacy	197 8 O
and	206 3 O
cost	210 4 O
-	214 1 O
effectiveness	215 13 O
of	229 2 O
combination	232 11 O
therapy	244 7 O
with	252 4 O
interferon	257 10 O
and	268 3 O
alpha	272 5 O
-	277 1 O
2b	278 2 O
/	280 1 O
ribavirin	281 9 B-Chemical
compared	291 8 O
with	300 4 O
interferon	305 10 B-Chemical
-	315 1 I-Chemical
alpha	316 5 I-Chemical
monotherapy	322 11 O
in	334 2 O
the	337 3 O
treatment	341 9 O
of	351 2 O
chronic	354 7 B-Disease
hepatitis	362 9 I-Disease
C	372 1 I-Disease
(	374 1 O
CHC	375 3 B-Disease
)	378 1 O
.	379 1 O

Combination	381 11 O
therapy	393 7 O
is	401 2 O
associated	404 10 O
with	415 4 O
a	420 1 O
clinically	422 10 O
important	433 9 O
adverse	443 7 O
effect	451 6 O
:	457 1 O
ribavirin	459 9 B-Chemical
-	468 1 O
induced	469 7 O
hemolytic	477 9 B-Disease
anemia	487 6 I-Disease
(	494 1 O
RIHA	495 4 B-Disease
)	499 1 O
.	500 1 O

The	502 3 O
objective	506 9 O
of	516 2 O
this	519 4 O
study	524 5 O
was	530 3 O
to	534 2 O
evaluate	537 8 O
the	546 3 O
direct	550 6 O
health	557 6 O
-	563 1 O
care	564 4 O
costs	569 5 O
and	575 3 O
management	579 10 O
of	590 2 O
RIHA	593 4 B-Disease
during	598 6 O
treatment	605 9 O
of	615 2 O
CHC	618 3 B-Disease
in	622 2 O
a	625 1 O
clinical	627 8 O
trial	636 5 O
setting	642 7 O
.	649 1 O

METHODS	651 7 O
:	658 1 O
A	660 1 O
systematic	662 10 O
literature	673 10 O
review	684 6 O
was	691 3 O
conducted	695 9 O
to	705 2 O
synthesize	708 10 O
information	719 11 O
on	731 2 O
the	734 3 O
incidence	738 9 O
and	748 3 O
management	752 10 O
of	763 2 O
RIHA	766 4 B-Disease
.	770 1 O

Decision	772 8 O
-	780 1 O
analytic	781 8 O
techniques	790 10 O
were	801 4 O
used	806 4 O
to	811 2 O
estimate	814 8 O
the	823 3 O
cost	827 4 O
of	832 2 O
treating	835 8 O
RIHA	844 4 B-Disease
.	848 1 O

Uncertainty	850 11 O
was	862 3 O
evaluated	866 9 O
using	876 5 O
sensitivity	882 11 O
analyses	894 8 O
.	902 1 O

RESULTS	904 7 O
:	911 1 O
RIHA	913 4 B-Disease
,	917 1 O
defined	919 7 O
as	927 2 O
a	930 1 O
reduction	932 9 O
in	942 2 O
hemoglobin	945 10 O
to	956 2 O
less	959 4 O
than	964 4 O
100	969 3 O
g	973 1 O
/	974 1 O
L	975 1 O
,	976 1 O
occurs	978 6 O
in	985 2 O
approximately	988 13 O
7	1002 1 O
%	1003 1 O
to	1005 2 O
9	1008 1 O
%	1009 1 O
of	1011 2 O
patients	1014 8 O
treated	1023 7 O
with	1031 4 O
combination	1036 11 O
therapy	1048 7 O
.	1055 1 O

The	1057 3 O
standard	1061 8 O
of	1070 2 O
care	1073 4 O
for	1078 3 O
management	1082 10 O
of	1093 2 O
RIHA	1096 4 B-Disease
is	1101 2 O
reduction	1104 9 O
or	1114 2 O
discontinuation	1117 15 O
of	1133 2 O
the	1136 3 O
ribavirin	1140 9 B-Chemical
dosage	1150 6 O
.	1156 1 O

We	1158 2 O
estimated	1161 9 O
the	1171 3 O
direct	1175 6 O
cost	1182 4 O
of	1187 2 O
treating	1190 8 O
clinically	1199 10 O
significant	1210 11 O
RIHA	1222 4 B-Disease
to	1227 2 O
be	1230 2 O
170	1234 3 O
per	1238 3 O
patient	1242 7 O
receiving	1250 9 O
combination	1260 11 O
therapy	1272 7 O
per	1280 3 O
48	1284 2 O
-	1286 1 O
week	1287 4 O
treatment	1292 9 O
course	1302 6 O
(	1309 1 O
range	1310 5 O
68	1317 2 O
-	1319 1 O
692	1321 3 O
)	1324 1 O
.	1325 1 O

The	1327 3 O
results	1331 7 O
of	1339 2 O
the	1342 3 O
one	1346 3 O
-	1349 1 O
way	1350 3 O
sensitivity	1354 11 O
analyses	1366 8 O
ranged	1375 6 O
from	1382 4 O
57	1388 2 O
to	1391 2 O
317	1395 3 O
.	1398 1 O

In	1400 2 O
comparison	1403 10 O
,	1413 1 O
the	1415 3 O
cost	1419 4 O
of	1424 2 O
48	1427 2 O
weeks	1430 5 O
of	1436 2 O
combination	1439 11 O
therapy	1451 7 O
is	1459 2 O
16	1463 2 O
,	1465 1 O
459	1466 3 O
.	1469 1 O

CONCLUSIONS	1471 11 O
:	1482 1 O
The	1484 3 O
direct	1488 6 O
cost	1495 4 O
of	1500 2 O
treating	1503 8 O
clinically	1512 10 O
significant	1523 11 O
RIHA	1535 4 B-Disease
is	1540 2 O
1	1543 1 O
%	1544 1 O
(	1546 1 O
170	1548 3 O
/	1551 1 O
16	1553 2 O
,	1555 1 O
459	1556 3 O
)	1559 1 O
of	1561 2 O
drug	1564 4 O
treatment	1569 9 O
costs	1579 5 O
.	1584 1 O

Questions	1586 9 O
remain	1596 6 O
about	1603 5 O
the	1609 3 O
optimal	1613 7 O
dose	1621 4 O
of	1626 2 O
ribavirin	1629 9 B-Chemical
and	1639 3 O
the	1643 3 O
incidence	1647 9 O
of	1657 2 O
RIHA	1660 4 B-Disease
in	1665 2 O
a	1668 1 O
real	1670 4 O
-	1674 1 O
world	1675 5 O
population	1681 10 O
.	1691 1 O

Despite	1693 7 O
these	1701 5 O
uncertainties	1707 13 O
,	1720 1 O
this	1722 4 O
initial	1727 7 O
evaluation	1735 10 O
of	1746 2 O
the	1749 3 O
direct	1753 6 O
cost	1760 4 O
of	1765 2 O
treating	1768 8 O
RIHA	1777 4 B-Disease
provides	1782 8 O
an	1791 2 O
estimate	1794 8 O
of	1803 2 O
the	1806 3 O
cost	1810 4 O
and	1815 3 O
management	1819 10 O
implications	1830 12 O
of	1843 2 O
this	1846 4 O
clinically	1851 10 O
important	1862 9 O
adverse	1872 7 O
effect	1880 6 O
.	1886 1 O

Effects	0 7 O
of	8 2 O
amine	11 5 B-Chemical
pretreatment	17 12 O
on	30 2 O
ketamine	33 8 B-Chemical
catatonia	42 9 B-Disease
in	52 2 O
pinealectomized	55 15 O
or	71 2 O
hypophysectomized	74 17 O
animals	92 7 O
.	99 1 O

The	101 3 O
present	105 7 O
studies	113 7 O
were	121 4 O
designed	126 8 O
to	135 2 O
clarify	138 7 O
the	146 3 O
role	150 4 O
of	155 2 O
catecholamines	158 14 B-Chemical
and	173 3 O
pineal	177 6 O
idolamines	184 10 O
on	195 2 O
ketamine	198 8 B-Chemical
-	206 1 O
induced	207 7 O
catatonia	215 9 B-Disease
in	225 2 O
the	228 3 O
intact	232 6 O
,	238 1 O
pinealectomized	240 15 O
or	256 2 O
hypophysectomized	259 17 O
chick	277 5 O
and	283 3 O
rat	287 3 O
.	290 1 O

In	292 2 O
the	295 3 O
pinealectomized	299 15 O
chick	315 5 O
,	320 1 O
pretreatment	322 12 O
with	335 4 O
dopamine	340 8 B-Chemical
increased	349 9 O
the	359 3 O
duration	363 8 O
of	372 2 O
catatonia	375 9 B-Disease
(	385 1 O
DOC	386 3 O
)	389 1 O
after	391 5 O
ketamine	397 8 B-Chemical
,	405 1 O
but	407 3 O
pretreatment	411 12 O
with	424 4 O
norepinephrine	429 14 B-Chemical
did	444 3 O
not	448 3 O
.	451 1 O

The	453 3 O
pineal	457 6 O
indolamines	464 11 O
exhibited	476 9 O
mixed	486 5 O
actions	492 7 O
.	499 1 O

Serotonin	501 9 B-Chemical
and	511 3 O
N	515 1 B-Chemical
-	516 1 I-Chemical
acetyl	517 6 I-Chemical
serotonin	524 9 I-Chemical
which	534 5 O
augmented	540 9 O
ketamine	550 8 B-Chemical
DOC	559 3 O
,	562 1 O
did	564 3 O
not	568 3 O
do	572 2 O
so	575 2 O
in	578 2 O
the	581 3 O
absence	585 7 O
of	593 2 O
the	596 3 O
pineal	600 6 O
gland	607 5 O
,	612 1 O
whereas	614 7 O
melatonin	622 9 B-Chemical
potentiated	632 11 O
the	644 3 O
ketamine	648 8 B-Chemical
DOC	657 3 O
in	661 2 O
both	664 4 O
the	669 3 O
intact	673 6 O
and	680 3 O
pinealectomized	684 15 O
chick	700 5 O
.	705 1 O

Ketamine	707 8 B-Chemical
was	716 3 O
more	720 4 O
potent	725 6 O
in	732 2 O
the	735 3 O
hypophysectomized	739 17 O
chick	757 5 O
and	763 3 O
the	767 3 O
circadian	771 9 O
rhythm	781 6 O
noted	788 5 O
in	794 2 O
the	797 3 O
intact	801 6 O
chick	808 5 O
was	814 3 O
absent	818 6 O
;	824 1 O
furthermore	826 11 O
,	837 1 O
melatonin	839 9 B-Chemical
did	849 3 O
not	853 3 O
augment	857 7 O
the	865 3 O
ketamine	869 8 B-Chemical
DOC	878 3 O
whereas	882 7 O
dopamine	890 8 B-Chemical
continued	899 9 O
to	909 2 O
do	912 2 O
so	915 2 O
.	917 1 O

This	919 4 O
study	924 5 O
did	930 3 O
not	934 3 O
demonstrate	938 11 O
a	950 1 O
species	952 7 O
difference	960 10 O
regarding	971 9 O
the	981 3 O
role	985 4 O
of	990 2 O
the	993 3 O
amines	997 6 B-Chemical
on	1004 2 O
the	1007 3 O
pineal	1011 6 O
in	1018 2 O
spite	1021 5 O
of	1027 2 O
the	1030 3 O
immature	1034 8 O
blood	1043 5 O
-	1048 1 O
brain	1049 5 O
barrier	1055 7 O
in	1063 2 O
the	1066 3 O
young	1070 5 O
chick	1076 5 O
and	1082 3 O
the	1086 3 O
intact	1090 6 O
barrier	1097 7 O
in	1105 2 O
the	1108 3 O
rat	1112 3 O
.	1115 1 O

In	1117 2 O
addition	1120 8 O
,	1128 1 O
these	1130 5 O
data	1136 4 O
indicate	1141 8 O
a	1150 1 O
direct	1152 6 O
role	1159 4 O
of	1164 2 O
the	1167 3 O
pituitary	1171 9 O
in	1181 2 O
the	1184 3 O
augmentation	1188 12 O
of	1201 2 O
ketamine	1204 8 B-Chemical
DOC	1213 3 O
induced	1217 7 O
by	1225 2 O
melatonin	1228 9 B-Chemical
.	1237 1 O

Furthermore	1239 11 O
,	1250 1 O
dopamine	1252 8 B-Chemical
appeared	1261 8 O
to	1270 2 O
act	1273 3 O
on	1277 2 O
systems	1280 7 O
more	1288 4 O
closely	1293 7 O
involved	1301 8 O
with	1310 4 O
the	1315 3 O
induction	1319 9 O
of	1329 2 O
ketamine	1332 8 B-Chemical
catatonia	1341 9 B-Disease
rather	1351 6 O
than	1358 4 O
directly	1363 8 O
on	1372 2 O
the	1375 3 O
pituitary	1379 9 O
.	1388 1 O

Multicenter	0 11 O
,	11 1 O
double	13 6 O
-	19 1 O
blind	20 5 O
,	25 1 O
multiple	27 8 O
-	35 1 O
dose	36 4 O
,	40 1 O
parallel	42 8 O
-	50 1 O
groups	51 6 O
efficacy	58 8 O
and	67 3 O
safety	71 6 O
trial	78 5 O
of	84 2 O
azelastine	87 10 B-Chemical
,	97 1 O
chlorpheniramine	99 16 B-Chemical
,	115 1 O
and	117 3 O
placebo	121 7 O
in	129 2 O
the	132 3 O
treatment	136 9 O
of	146 2 O
spring	149 6 B-Disease
allergic	156 8 I-Disease
rhinitis	165 8 I-Disease
.	173 1 O

Azelastine	175 10 B-Chemical
,	185 1 O
a	187 1 O
novel	189 5 O
antiallergic	195 12 O
medication	208 10 O
,	218 1 O
was	220 3 O
compared	224 8 O
with	233 4 O
chlorpheniramine	238 16 B-Chemical
maleate	255 7 I-Chemical
and	263 3 O
placebo	267 7 O
for	275 3 O
efficacy	279 8 O
and	288 3 O
safety	292 6 O
in	299 2 O
the	302 3 O
treatment	306 9 O
of	316 2 O
spring	319 6 B-Disease
allergic	326 8 I-Disease
rhinitis	335 8 I-Disease
in	344 2 O
a	347 1 O
multicenter	349 11 O
,	360 1 O
double	362 6 O
-	368 1 O
blind	369 5 O
,	374 1 O
multiple	376 8 O
-	384 1 O
dose	385 4 O
,	389 1 O
parallel	391 8 O
-	399 1 O
groups	400 6 O
study	407 5 O
.	412 1 O

One	414 3 O
hundred	418 7 O
fifty	426 5 O
-	431 1 O
five	432 4 O
subjects	437 8 O
participated	446 12 O
.	458 1 O

Subjects	460 8 O
ranged	469 6 O
in	476 2 O
age	479 3 O
from	483 4 O
18	488 2 O
to	491 2 O
60	494 2 O
years	497 5 O
of	503 2 O
age	506 3 O
and	510 3 O
had	514 3 O
at	518 2 O
least	521 5 O
a	527 1 O
2	529 1 O
-	530 1 O
year	531 4 O
history	536 7 O
of	544 2 O
spring	547 6 B-Disease
allergic	554 8 I-Disease
rhinitis	563 8 I-Disease
,	571 1 O
confirmed	573 9 O
by	583 2 O
positive	586 8 O
skin	595 4 O
test	600 4 O
to	605 2 O
spring	608 6 O
aeroallergens	615 13 O
.	628 1 O

Medications	630 11 O
were	642 4 O
given	647 5 O
four	653 4 O
times	658 5 O
daily	664 5 O
;	669 1 O
the	671 3 O
azelastine	675 10 B-Chemical
groups	686 6 O
received	693 8 O
0	702 1 O
.	703 1 O
5	704 1 O
,	705 1 O
1	707 1 O
.	708 1 O
0	709 1 O
,	710 1 O
or	712 2 O
2	715 1 O
.	716 1 O
0	717 1 O
mg	719 2 O
in	722 2 O
the	725 3 O
morning	729 7 O
and	737 3 O
evening	741 7 O
with	749 4 O
placebo	754 7 O
in	762 2 O
the	765 3 O
early	769 5 O
and	775 3 O
late	779 4 O
afternoon	784 9 O
;	793 1 O
the	795 3 O
chlorpheniramine	799 16 B-Chemical
group	816 5 O
received	822 8 O
4	831 1 O
.	832 1 O
0	833 1 O
mg	835 2 O
four	838 4 O
times	843 5 O
daily	849 5 O
.	854 1 O

Daily	856 5 O
subject	862 7 O
symptom	870 7 O
cards	878 5 O
were	884 4 O
completed	889 9 O
during	899 6 O
a	906 1 O
screening	908 9 O
period	918 6 O
to	925 2 O
assess	928 6 O
pretreatment	935 12 O
symptoms	948 8 O
and	957 3 O
during	961 6 O
a	968 1 O
4	970 1 O
-	971 1 O
week	972 4 O
treatment	977 9 O
period	987 6 O
while	994 5 O
subjects	1000 8 O
received	1009 8 O
study	1018 5 O
medications	1024 11 O
.	1035 1 O

Individual	1037 10 O
symptoms	1048 8 O
,	1056 1 O
total	1058 5 O
symptoms	1064 8 O
,	1072 1 O
and	1074 3 O
major	1078 5 O
symptoms	1084 8 O
were	1093 4 O
compared	1098 8 O
to	1107 2 O
determine	1110 9 O
efficacy	1120 8 O
of	1129 2 O
medication	1132 10 O
.	1142 1 O

Elicited	1144 8 O
,	1152 1 O
volunteered	1154 11 O
,	1165 1 O
and	1167 3 O
observed	1171 8 O
adverse	1180 7 O
experiences	1188 11 O
were	1200 4 O
recorded	1205 8 O
for	1214 3 O
each	1218 4 O
subject	1223 7 O
and	1231 3 O
compared	1235 8 O
among	1244 5 O
groups	1250 6 O
.	1256 1 O

Vital	1258 5 O
signs	1264 5 O
,	1269 1 O
body	1271 4 O
weights	1276 7 O
,	1283 1 O
serum	1285 5 O
chemistry	1291 9 O
values	1301 6 O
,	1307 1 O
complete	1309 8 O
blood	1318 5 O
cell	1324 4 O
counts	1329 6 O
,	1335 1 O
urine	1337 5 O
studies	1343 7 O
,	1350 1 O
and	1352 3 O
electrocardiograms	1356 18 O
were	1375 4 O
obtained	1380 8 O
for	1389 3 O
each	1393 4 O
subject	1398 7 O
and	1406 3 O
compared	1410 8 O
among	1419 5 O
groups	1425 6 O
.	1431 1 O

Symptoms	1433 8 O
relief	1442 6 O
in	1449 2 O
the	1452 3 O
group	1456 5 O
receiving	1462 9 O
the	1472 3 O
highest	1476 7 O
concentration	1484 13 O
of	1498 2 O
azelastine	1501 10 B-Chemical
(	1512 1 O
2	1513 1 O
.	1514 1 O
0	1515 1 O
mg	1517 2 O
twice	1520 5 O
daily	1526 5 O
)	1531 1 O
was	1533 3 O
statistically	1537 13 O
greater	1551 7 O
than	1559 4 O
in	1564 2 O
the	1567 3 O
placebo	1571 7 O
group	1579 5 O
during	1585 6 O
all	1592 3 O
weeks	1596 5 O
of	1602 2 O
the	1605 3 O
study	1609 5 O
.	1614 1 O

Lower	1616 5 O
doses	1622 5 O
of	1628 2 O
azelastine	1631 10 B-Chemical
were	1642 4 O
statistically	1647 13 O
more	1661 4 O
effective	1666 9 O
than	1676 4 O
placebo	1681 7 O
only	1689 4 O
during	1694 6 O
portions	1701 8 O
of	1710 2 O
the	1713 3 O
first	1717 5 O
3	1723 1 O
weeks	1725 5 O
of	1731 2 O
the	1734 3 O
study	1738 5 O
.	1743 1 O

In	1745 2 O
contrast	1748 8 O
,	1756 1 O
although	1758 8 O
the	1767 3 O
chlorpheniramine	1771 16 B-Chemical
group	1788 5 O
did	1794 3 O
have	1798 4 O
fewer	1803 5 O
symptoms	1809 8 O
than	1818 4 O
the	1823 3 O
placebo	1827 7 O
group	1835 5 O
during	1841 6 O
the	1848 3 O
study	1852 5 O
,	1857 1 O
the	1859 3 O
difference	1863 10 O
never	1874 5 O
reached	1880 7 O
statistical	1888 11 O
significance	1900 12 O
during	1913 6 O
any	1920 3 O
week	1924 4 O
of	1929 2 O
the	1932 3 O
study	1936 5 O
.	1941 1 O

There	1943 5 O
were	1949 4 O
no	1954 2 O
serious	1957 7 O
side	1965 4 O
effects	1970 7 O
in	1978 2 O
any	1981 3 O
of	1985 2 O
the	1988 3 O
treatment	1992 9 O
groups	2002 6 O
.	2008 1 O

Drowsiness	2010 10 B-Disease
and	2021 3 O
altered	2025 7 B-Disease
taste	2033 5 I-Disease
perception	2039 10 I-Disease
were	2050 4 O
increased	2055 9 O
significantly	2065 13 O
over	2079 4 O
placebo	2084 7 O
only	2092 4 O
in	2097 2 O
the	2100 3 O
high	2104 4 O
-	2108 1 O
dose	2109 4 O
azelastine	2114 10 B-Chemical
group	2125 5 O
.	2130 1 O

Azelastine	2132 10 B-Chemical
appears	2143 7 O
to	2151 2 O
be	2154 2 O
a	2157 1 O
safe	2159 4 O
,	2163 1 O
efficacious	2165 11 O
medication	2177 10 O
for	2188 3 O
seasonal	2192 8 B-Disease
allergic	2201 8 I-Disease
rhinitis	2210 8 I-Disease
.	2218 1 O

Obsolete	0 8 O
but	9 3 O
dangerous	13 9 O
antacid	23 7 O
preparations	31 12 O
.	43 1 O

One	45 3 O
case	49 4 O
of	54 2 O
acute	57 5 O
hypercalcaemia	63 14 B-Disease
and	78 3 O
two	82 3 O
of	86 2 O
recurrent	89 9 O
nephrolithiasis	99 15 B-Disease
are	115 3 O
reported	119 8 O
in	128 2 O
patients	131 8 O
who	140 3 O
had	144 3 O
regularly	148 9 O
consumed	158 8 O
large	167 5 O
amounts	173 7 O
of	181 2 O
calcium	184 7 B-Chemical
carbon	192 6 I-Chemical
-	198 1 I-Chemical
ate	199 3 I-Chemical
-	202 1 O
sodium	203 6 B-Chemical
bicarbonate	210 11 I-Chemical
powders	222 7 O
for	230 3 O
more	234 4 O
than	239 4 O
20	244 2 O
years	247 5 O
.	252 1 O

The	254 3 O
powders	258 7 O
had	266 3 O
been	270 4 O
obtained	275 8 O
from	284 4 O
pharmacists	289 11 O
unknown	301 7 O
to	309 2 O
the	312 3 O
patients	316 8 O
'	324 1 O
medical	326 7 O
practitioners	334 13 O
.	347 1 O

It	349 2 O
is	352 2 O
suggested	355 9 O
that	365 4 O
these	370 5 O
preparations	376 12 O
were	389 4 O
responsible	394 11 O
for	406 3 O
the	410 3 O
patient	414 7 O
'	421 1 O
s	422 1 O
problems	424 8 O
,	432 1 O
and	434 3 O
that	438 4 O
such	443 4 O
powders	448 7 O
should	456 6 O
no	463 2 O
longer	466 6 O
be	473 2 O
freely	476 6 O
obtainable	483 10 O
.	493 1 O

Prolonged	0 9 O
paralysis	10 9 B-Disease
due	20 3 O
to	24 2 O
nondepolarizing	27 15 B-Chemical
neuromuscular	43 13 I-Chemical
blocking	57 8 I-Chemical
agents	66 6 I-Chemical
and	73 3 O
corticosteroids	77 15 B-Chemical
.	92 1 O

The	94 3 O
long	98 4 O
-	102 1 O
term	103 4 O
use	108 3 O
of	112 2 O
nondepolarizing	115 15 B-Chemical
neuromuscular	131 13 I-Chemical
blocking	145 8 I-Chemical
agents	154 6 I-Chemical
(	161 1 O
ND	162 2 B-Chemical
-	164 1 I-Chemical
NMBA	165 4 I-Chemical
)	169 1 O
has	171 3 O
recently	175 8 O
been	184 4 O
implicated	189 10 O
as	200 2 O
a	203 1 O
cause	205 5 O
of	211 2 O
prolonged	214 9 O
muscle	224 6 B-Disease
weakness	231 8 I-Disease
,	239 1 O
although	241 8 O
the	250 3 O
site	254 4 O
of	259 2 O
the	262 3 O
lesion	266 6 O
and	273 3 O
the	277 3 O
predisposing	281 12 O
factors	294 7 O
have	302 4 O
been	307 4 O
unclear	312 7 O
.	319 1 O

We	321 2 O
report	324 6 O
3	331 1 O
patients	333 8 O
(	342 1 O
age	343 3 O
37	347 2 O
-	349 1 O
52	350 2 O
years	353 5 O
)	358 1 O
with	360 4 O
acute	365 5 O
respiratory	371 11 B-Disease
insufficiency	383 13 I-Disease
who	397 3 O
developed	401 9 O
prolonged	411 9 O
weakness	421 8 B-Disease
following	430 9 O
the	440 3 O
discontinuation	444 15 O
of	460 2 O
ND	463 2 B-Chemical
-	465 1 I-Chemical
NMBAs	466 5 I-Chemical
.	471 1 O

Two	473 3 O
patients	477 8 O
also	486 4 O
received	491 8 O
intravenous	500 11 O
corticosteroids	512 15 B-Chemical
.	527 1 O

Renal	529 5 O
function	535 8 O
was	544 3 O
normal	548 6 O
but	555 3 O
hepatic	559 7 O
function	567 8 O
was	576 3 O
impaired	580 8 O
in	589 2 O
all	592 3 O
patients	596 8 O
,	604 1 O
and	606 3 O
all	610 3 O
had	614 3 O
acidosis	618 8 B-Disease
.	626 1 O

Electrophysiologic	628 18 O
studies	647 7 O
revealed	655 8 O
low	664 3 O
amplitude	668 9 O
compound	678 8 O
motor	687 5 O
action	693 6 O
potentials	700 10 O
,	710 1 O
normal	712 6 O
sensory	719 7 O
studies	727 7 O
,	734 1 O
and	736 3 O
fibrillations	740 13 O
.	753 1 O

Repetitive	755 10 O
stimulation	766 11 O
at	778 2 O
2	781 1 O
Hz	783 2 O
showed	786 6 O
a	793 1 O
decremental	795 11 O
response	807 8 O
in	816 2 O
2	819 1 O
patients	821 8 O
.	829 1 O

The	831 3 O
serum	835 5 O
vecuronium	841 10 B-Chemical
level	852 5 O
measured	858 8 O
in	867 2 O
1	870 1 O
patient	872 7 O
14	880 2 O
days	883 4 O
after	888 5 O
the	894 3 O
drug	898 4 O
had	903 3 O
been	907 4 O
discontinued	912 12 O
was	925 3 O
172	929 3 O
ng	933 2 O
/	935 1 O
mL	936 2 O
.	938 1 O

A	940 1 O
muscle	942 6 O
biopsy	949 6 O
in	956 2 O
this	959 4 O
patient	964 7 O
showed	972 6 O
loss	979 4 B-Disease
of	984 2 I-Disease
thick	987 5 I-Disease
,	992 1 I-Disease
myosin	994 6 I-Disease
filaments	1001 9 I-Disease
.	1010 1 O

The	1012 3 O
weakness	1016 8 B-Disease
in	1025 2 O
these	1028 5 O
patients	1034 8 O
is	1043 2 O
due	1046 3 O
to	1050 2 O
pathology	1053 9 B-Disease
at	1063 2 I-Disease
both	1066 4 I-Disease
the	1071 3 I-Disease
neuromuscular	1075 13 I-Disease
junction	1089 8 I-Disease
(	1098 1 O
most	1099 4 O
likely	1104 6 O
due	1111 3 O
to	1115 2 O
ND	1118 2 B-Chemical
-	1120 1 I-Chemical
NMBA	1121 4 I-Chemical
)	1125 1 O
and	1127 3 O
muscle	1131 6 O
(	1138 1 O
most	1139 4 O
likely	1144 6 O
due	1151 3 O
to	1155 2 O
corticosteroids	1158 15 B-Chemical
)	1173 1 O
.	1174 1 O

Hepatic	1176 7 B-Disease
dysfunction	1184 11 I-Disease
and	1196 3 O
acidosis	1200 8 B-Disease
are	1209 3 O
contributing	1213 12 O
risk	1226 4 O
factors	1231 7 O
.	1238 1 O

Prostaglandin	0 13 B-Chemical
E2	14 2 I-Chemical
-	16 1 O
induced	17 7 O
bladder	25 7 B-Disease
hyperactivity	33 13 I-Disease
in	47 2 O
normal	50 6 O
,	56 1 O
conscious	58 9 O
rats	68 4 O
:	72 1 O
involvement	74 11 O
of	86 2 O
tachykinins	89 11 B-Chemical
?	100 1 O

In	102 2 O
normal	105 6 O
conscious	112 9 O
rats	122 4 O
investigated	127 12 O
by	140 2 O
continuous	143 10 O
cystometry	154 10 O
,	164 1 O
intravesically	166 14 O
instilled	181 9 O
prostaglandin	191 13 B-Chemical
(	205 1 I-Chemical
PG	206 2 I-Chemical
)	208 1 I-Chemical
E2	210 2 I-Chemical
facilitated	213 11 O
micturition	225 11 O
and	237 3 O
increased	241 9 O
basal	251 5 O
intravesical	257 12 O
pressure	270 8 O
.	278 1 O

The	280 3 O
effect	284 6 O
was	291 3 O
attenuated	295 10 O
by	306 2 O
both	309 4 O
the	314 3 O
NK1	318 3 O
receptor	322 8 O
selective	331 9 O
antagonist	341 10 O
RP	352 2 B-Chemical
67	355 2 I-Chemical
,	357 1 I-Chemical
580	358 3 I-Chemical
and	362 3 O
the	366 3 O
NK2	370 3 O
receptor	374 8 O
selective	383 9 O
antagonist	393 10 O
SR	404 2 B-Chemical
48	407 2 I-Chemical
,	409 1 I-Chemical
968	410 3 I-Chemical
,	413 1 O
given	415 5 O
intra	421 5 O
-	426 1 O
arterially	427 10 O
,	437 1 O
suggesting	439 10 O
that	450 4 O
it	455 2 O
was	458 3 O
mediated	462 8 O
by	471 2 O
stimulation	474 11 O
of	486 2 O
both	489 4 O
NK1	494 3 O
and	498 3 O
NK2	502 3 O
receptors	506 9 O
.	515 1 O

Intra	517 5 O
-	522 1 O
arterially	523 10 O
given	534 5 O
PGE2	540 4 B-Chemical
produced	545 8 O
a	554 1 O
distinct	556 8 O
increase	565 8 O
in	574 2 O
bladder	577 7 O
pressure	585 8 O
before	594 6 O
initiating	601 10 O
a	612 1 O
micturition	614 11 O
reflex	626 6 O
,	632 1 O
indicating	634 10 O
that	645 4 O
the	650 3 O
PG	654 2 B-Chemical
had	657 3 O
a	661 1 O
direct	663 6 O
contractant	670 11 O
effect	682 6 O
on	689 2 O
the	692 3 O
detrusor	696 8 O
smooth	705 6 O
muscle	712 6 O
.	718 1 O

The	720 3 O
effect	724 6 O
of	731 2 O
intra	734 5 O
-	739 1 O
arterial	740 8 O
PGE2	749 4 B-Chemical
could	754 5 O
not	760 3 O
be	764 2 O
blocked	767 7 O
by	775 2 O
intra	778 5 O
-	783 1 O
arterial	784 8 O
RP	793 2 B-Chemical
67	796 2 I-Chemical
,	798 1 I-Chemical
580	799 3 I-Chemical
or	803 2 O
SR	806 2 B-Chemical
48	809 2 I-Chemical
,	811 1 I-Chemical
968	812 3 I-Chemical
,	815 1 O
which	817 5 O
opens	823 5 O
the	829 3 O
possibility	833 11 O
that	845 4 O
the	850 3 O
micturition	854 11 O
reflex	866 6 O
elicited	873 8 O
by	882 2 O
intra	885 5 O
-	890 1 O
arterial	891 8 O
PGE2	900 4 B-Chemical
was	905 3 O
mediated	909 8 O
by	918 2 O
pathways	921 8 O
other	930 5 O
than	936 4 O
the	941 3 O
reflex	945 6 O
initiated	952 9 O
when	962 4 O
the	967 3 O
PG	971 2 B-Chemical
was	974 3 O
given	978 5 O
intravesically	984 14 O
.	998 1 O

The	1000 3 O
present	1004 7 O
results	1012 7 O
thus	1020 4 O
suggest	1025 7 O
that	1033 4 O
intra	1038 5 O
-	1043 1 O
arterial	1044 8 O
PGE2	1053 4 B-Chemical
,	1057 1 O
given	1059 5 O
near	1065 4 O
the	1070 3 O
bladder	1074 7 O
,	1081 1 O
may	1083 3 O
initiate	1087 8 O
micturition	1096 11 O
in	1108 2 O
the	1111 3 O
normal	1115 6 O
rat	1122 3 O
chiefly	1126 7 O
by	1134 2 O
directly	1137 8 O
contracting	1146 11 O
the	1158 3 O
smooth	1162 6 O
muscle	1169 6 O
of	1176 2 O
the	1179 3 O
detrusor	1183 8 O
.	1191 1 O

However	1193 7 O
,	1200 1 O
when	1202 4 O
given	1207 5 O
intravesically	1213 14 O
,	1227 1 O
PGE2	1229 4 B-Chemical
may	1234 3 O
stimulate	1238 9 O
micturition	1248 11 O
by	1260 2 O
releasing	1263 9 O
tachykinins	1273 11 B-Chemical
from	1285 4 O
nerves	1290 6 O
in	1297 2 O
and	1300 3 O
/	1303 1 O
or	1304 2 O
immediately	1307 11 O
below	1319 5 O
the	1325 3 O
urothelium	1329 10 O
.	1339 1 O

These	1341 5 O
tachykinins	1347 11 B-Chemical
,	1358 1 O
in	1360 2 O
turn	1363 4 O
,	1367 1 O
initiate	1369 8 O
a	1378 1 O
micturition	1380 11 O
reflex	1392 6 O
by	1399 2 O
stimulating	1402 11 O
NK1	1414 3 O
and	1418 3 O
NK2	1422 3 O
receptors	1426 9 O
.	1435 1 O

Prostanoids	1437 11 B-Chemical
may	1449 3 O
,	1452 1 O
via	1454 3 O
release	1458 7 O
of	1466 2 O
tachykinins	1469 11 B-Chemical
,	1480 1 O
contribute	1482 10 O
to	1493 2 O
both	1496 4 O
urge	1501 4 O
and	1506 3 O
bladder	1510 7 B-Disease
hyperactivity	1518 13 I-Disease
seen	1532 4 O
in	1537 2 O
inflammatory	1540 12 O
conditions	1553 10 O
of	1564 2 O
the	1567 3 O
lower	1571 5 O
urinary	1577 7 O
tract	1585 5 O
.	1590 1 O

Thiazide	0 8 B-Chemical
diuretics	9 9 O
,	18 1 O
hypokalemia	20 11 B-Disease
and	32 3 O
cardiac	36 7 B-Disease
arrhythmias	44 11 I-Disease
.	55 1 O

Thiazide	57 8 B-Chemical
diuretics	66 9 O
are	76 3 O
widely	80 6 O
accepted	87 8 O
as	96 2 O
the	99 3 O
cornerstone	103 11 O
of	115 2 O
antihypertensive	118 16 O
treatment	135 9 O
programs	145 8 O
.	153 1 O

Hypokalemia	155 11 B-Disease
is	167 2 O
a	170 1 O
commonly	172 8 O
encountered	181 11 O
metabolic	193 9 O
consequence	203 11 O
of	215 2 O
chronic	218 7 O
thiazide	226 8 B-Chemical
therapy	235 7 O
.	242 1 O

We	244 2 O
treated	247 7 O
38	255 2 O
patients	258 8 O
(	267 1 O
22	268 2 O
low	271 3 O
renin	275 5 O
,	280 1 O
16	282 2 O
normal	285 6 O
renin	292 5 O
)	297 1 O
with	299 4 O
moderate	304 8 O
diastolic	313 9 B-Disease
hypertension	323 12 I-Disease
with	336 4 O
hydrochlorothiazide	341 19 B-Chemical
(	361 1 O
HCTC	362 4 B-Chemical
)	366 1 O
administered	368 12 O
on	381 2 O
a	384 1 O
twice	386 5 O
daily	392 5 O
schedule	398 8 O
.	406 1 O

Initial	408 7 O
dose	416 4 O
was	421 3 O
50	425 2 O
mg	428 2 O
and	431 3 O
the	435 3 O
dose	439 4 O
was	444 3 O
increased	448 9 O
at	458 2 O
monthly	461 7 O
intervals	469 9 O
to	479 2 O
100	482 3 O
mg	486 2 O
,	488 1 O
150	490 3 O
mg	494 2 O
and	497 3 O
200	501 3 O
mg	505 2 O
daily	508 5 O
until	514 5 O
blood	520 5 O
pressure	526 8 O
normalized	535 10 O
.	545 1 O

The	547 3 O
serum	551 5 O
K	557 1 B-Chemical
during	559 6 O
the	566 3 O
control	570 7 O
period	578 6 O
was	585 3 O
4	589 1 O
.	590 1 O
5	591 1 O
+	593 1 O
/	594 1 O
-	595 1 O
0	597 1 O
.	598 1 O
2	599 1 O
mEq	601 3 O
/	604 1 O
l	605 1 O
an	607 2 O
on	610 2 O
50	613 2 O
,	615 1 O
100	617 3 O
,	620 1 O
150	622 3 O
and	626 3 O
200	630 3 O
mg	634 2 O
HCTZ	637 4 B-Chemical
daily	642 5 O
3	648 1 O
.	649 1 O
9	650 1 O
+	652 1 O
/	653 1 O
-	654 1 O
0	656 1 O
.	657 1 O
3	658 1 O
,	659 1 O
3	661 1 O
.	662 1 O
4	663 1 O
+	665 1 O
/	666 1 O
-	667 1 O
0	669 1 O
.	670 1 O
2	671 1 O
,	672 1 O
2	674 1 O
.	675 1 O
9	676 1 O
+	678 1 O
/	679 1 O
-	680 1 O
0	682 1 O
.	683 1 O
2	684 1 O
,	685 1 O
and	687 3 O
2	691 1 O
.	692 1 O
4	693 1 O
+	695 1 O
/	696 1 O
-	697 1 O
0	699 1 O
.	700 1 O
3	701 1 O
mEq	703 3 O
/	706 1 O
l	707 1 O
,	708 1 O
respectively	710 12 O
.	722 1 O

Corresponding	724 13 O
figures	738 7 O
for	746 3 O
whole	750 5 O
body	756 4 O
K	761 1 B-Chemical
were	763 4 O
4107	768 4 O
+	773 1 O
/	774 1 O
-	775 1 O
208	777 3 O
,	780 1 O
3722	782 4 O
+	787 1 O
/	788 1 O
-	789 1 O
319	791 3 O
,	794 1 O
3628	796 4 O
+	801 1 O
/	802 1 O
-	803 1 O
257	805 3 O
,	808 1 O
3551	810 4 O
+	815 1 O
/	816 1 O
-	817 1 O
336	819 3 O
,	822 1 O
and	824 3 O
3269	828 4 O
+	833 1 O
/	834 1 O
-	835 1 O
380	837 3 O
mEq	841 3 O
,	844 1 O
respectively	846 12 O
.	858 1 O

In	860 2 O
13	863 2 O
patients	866 8 O
we	875 2 O
observed	878 8 O
the	887 3 O
effects	891 7 O
of	899 2 O
HCTZ	902 4 B-Chemical
therapy	907 7 O
(	915 1 O
100	916 3 O
mg	920 2 O
daily	923 5 O
)	928 1 O
on	930 2 O
the	933 3 O
occurrence	937 10 O
of	948 2 O
PVC	951 3 O
'	954 1 O
s	955 1 O
during	957 6 O
rest	964 4 O
as	969 2 O
well	972 4 O
as	977 2 O
during	980 6 O
static	987 6 O
and	994 3 O
dynamic	998 7 O
exercise	1006 8 O
.	1014 1 O

During	1016 6 O
rest	1023 4 O
we	1028 2 O
observed	1031 8 O
0	1040 1 O
.	1041 1 O
6	1042 1 O
+	1044 1 O
/	1045 1 O
-	1046 1 O
0	1048 1 O
.	1049 1 O
08	1050 2 O
PVC	1053 3 O
beats	1057 5 O
/	1062 1 O
min	1063 3 O
+	1067 1 O
/	1068 1 O
-	1069 1 O
SEM	1071 3 O
and	1075 3 O
during	1079 6 O
static	1086 6 O
and	1093 3 O
dynamic	1097 7 O
exercise	1105 8 O
0	1114 1 O
.	1115 1 O
6	1116 1 O
+	1118 1 O
/	1119 1 O
-	1120 1 O
0	1122 1 O
.	1123 1 O
06	1124 2 O
and	1127 3 O
0	1131 1 O
.	1132 1 O
8	1133 1 O
+	1135 1 O
/	1136 1 O
-	1137 1 O
0	1139 1 O
.	1140 1 O
15	1141 2 O
,	1143 1 O
respectively	1145 12 O
.	1157 1 O

Corresponding	1159 13 O
figures	1173 7 O
during	1181 6 O
HCTZ	1188 4 B-Chemical
therapy	1193 7 O
100	1201 3 O
mg	1205 2 O
daily	1208 5 O
were	1214 4 O
1	1219 1 O
.	1220 1 O
4	1221 1 O
+	1223 1 O
/	1224 1 O
-	1225 1 O
0	1227 1 O
.	1228 1 O
1	1229 1 O
,	1230 1 O
3	1232 1 O
.	1233 1 O
6	1234 1 O
+	1236 1 O
/	1237 1 O
-	1238 1 O
0	1240 1 O
.	1241 1 O
7	1242 1 O
and	1244 3 O
5	1248 1 O
.	1249 1 O
7	1250 1 O
4	1252 1 O
/	1253 1 O
-	1254 1 O
0	1256 1 O
.	1257 1 O
8	1258 1 O
,	1259 1 O
respectively	1261 12 O
.	1273 1 O

The	1275 3 O
occurrence	1279 10 O
of	1290 2 O
PVC	1293 3 O
'	1296 1 O
s	1297 1 O
correlated	1299 10 O
significantly	1310 13 O
with	1324 4 O
the	1329 3 O
fall	1333 4 O
in	1338 2 O
serum	1341 5 O
K	1347 1 B-Chemical
+	1348 1 O
observed	1350 8 O
r	1359 1 O
=	1361 1 O
0	1363 1 O
.	1364 1 O
72	1365 2 O
,	1367 1 O
p	1369 1 O
less	1371 4 O
than	1376 4 O
0	1381 1 O
.	1382 1 O
001	1383 3 O
.	1386 1 O

In	1388 2 O
conclusion	1391 10 O
we	1402 2 O
found	1405 5 O
that	1411 4 O
thiazide	1416 8 B-Chemical
diuretics	1425 9 O
cause	1435 5 O
hypokalemia	1441 11 B-Disease
and	1453 3 O
depletion	1457 9 O
of	1467 2 O
body	1470 4 O
potassium	1475 9 B-Chemical
.	1484 1 O

The	1486 3 O
more	1490 4 O
profound	1495 8 O
hypokalemia	1504 11 B-Disease
,	1515 1 O
the	1517 3 O
greater	1521 7 O
the	1529 3 O
propensity	1533 10 O
for	1544 3 O
the	1548 3 O
occurrence	1552 10 O
of	1563 2 O
PVC	1566 3 O
'	1569 1 O
s	1570 1 O
.	1571 1 O

Diuretics	0 9 O
,	9 1 O
potassium	11 9 B-Chemical
and	21 3 O
arrhythmias	25 11 B-Disease
in	37 2 O
hypertensive	40 12 B-Disease
coronary	53 8 B-Disease
disease	62 7 I-Disease
.	69 1 O

It	71 2 O
has	74 3 O
been	78 4 O
proposed	83 8 O
that	92 4 O
modest	97 6 O
changes	104 7 O
in	112 2 O
plasma	115 6 O
potassium	122 9 B-Chemical
can	132 3 O
alter	136 5 O
the	142 3 O
tendency	146 8 O
towards	155 7 O
cardiac	163 7 B-Disease
arrhythmias	171 11 I-Disease
.	182 1 O

If	184 2 O
this	187 4 O
were	192 4 O
so	197 2 O
,	199 1 O
patients	201 8 O
with	210 4 O
coronary	215 8 B-Disease
artery	224 6 I-Disease
disease	231 7 I-Disease
might	239 5 O
be	245 2 O
especially	248 10 O
susceptible	259 11 O
.	270 1 O

Thus	272 4 O
,	276 1 O
myocardial	278 10 O
electrical	289 10 O
excitability	300 12 O
was	313 3 O
measured	317 8 O
in	326 2 O
patients	329 8 O
with	338 4 O
mild	343 4 O
essential	348 9 O
hypertension	358 12 B-Disease
and	371 3 O
known	375 5 O
coronary	381 8 B-Disease
artery	390 6 I-Disease
disease	397 7 I-Disease
after	405 5 O
8	411 1 O
weeks	413 5 O
of	419 2 O
treatment	422 9 O
with	432 4 O
a	437 1 O
potassium	439 9 B-Chemical
-	448 1 O
conserving	449 10 O
diuretic	460 8 O
(	469 1 O
amiloride	470 9 B-Chemical
)	479 1 O
and	481 3 O
a	485 1 O
similar	487 7 O
period	495 6 O
on	502 2 O
a	505 1 O
potassium	507 9 B-Chemical
-	516 1 O
losing	517 6 O
diuretic	524 8 O
(	533 1 O
chlorthalidone	534 14 B-Chemical
)	548 1 O
in	550 2 O
a	553 1 O
randomised	555 10 O
study	566 5 O
.	571 1 O

Plasma	573 6 O
potassium	580 9 B-Chemical
concentrations	590 14 O
were	605 4 O
on	610 2 O
average	613 7 O
1	621 1 O
mmol	623 4 O
/	627 1 O
L	628 1 O
lower	630 5 O
during	636 6 O
the	643 3 O
chlorthalidone	647 14 B-Chemical
phase	662 5 O
compared	668 8 O
to	677 2 O
amiloride	680 9 B-Chemical
therapy	690 7 O
.	697 1 O

Blood	699 5 O
pressure	705 8 O
and	714 3 O
volume	718 6 O
states	725 6 O
as	732 2 O
assessed	735 8 O
by	744 2 O
bodyweight	747 10 O
,	757 1 O
plasma	759 6 O
renin	766 5 O
and	772 3 O
noradrenaline	776 13 B-Chemical
(	790 1 O
norepinephrine	791 14 B-Chemical
)	805 1 O
concentrations	807 14 O
were	822 4 O
similar	827 7 O
on	835 2 O
the	838 3 O
2	842 1 O
regimens	844 8 O
.	852 1 O

Compared	854 8 O
to	863 2 O
amiloride	866 9 B-Chemical
treatment	876 9 O
,	885 1 O
the	887 3 O
chlorthalidone	891 14 B-Chemical
phase	906 5 O
was	912 3 O
associated	916 10 O
with	927 4 O
an	932 2 O
increased	935 9 O
frequency	945 9 O
of	955 2 O
ventricular	958 11 B-Disease
ectopic	970 7 I-Disease
beats	978 5 I-Disease
(	984 1 O
24	985 2 O
-	987 1 O
hour	988 4 O
Holter	993 6 O
monitoring	1000 10 O
)	1010 1 O
and	1012 3 O
a	1016 1 O
higher	1018 6 O
Lown	1025 4 O
grading	1030 7 O
,	1037 1 O
increased	1039 9 O
upslope	1049 7 O
and	1057 3 O
duration	1061 8 O
of	1070 2 O
the	1073 3 O
monophasic	1077 10 O
action	1088 6 O
potential	1095 9 O
,	1104 1 O
prolonged	1106 9 O
ventricular	1116 11 O
effective	1128 9 O
refractory	1138 10 O
period	1149 6 O
,	1155 1 O
and	1157 3 O
increased	1161 9 O
electrical	1171 10 O
instability	1182 11 O
during	1194 6 O
programmed	1201 10 O
ventricular	1212 11 O
stimulation	1224 11 O
.	1235 1 O

The	1237 3 O
above	1241 5 O
results	1247 7 O
indicate	1255 8 O
that	1264 4 O
because	1269 7 O
potassium	1277 9 B-Chemical
-	1286 1 O
losing	1287 6 O
diuretic	1294 8 O
therapy	1303 7 O
can	1311 3 O
increase	1315 8 O
myocardial	1324 10 O
electrical	1335 10 O
excitability	1346 12 O
in	1359 2 O
patients	1362 8 O
with	1371 4 O
ischaemic	1376 9 B-Disease
heart	1386 5 I-Disease
disease	1392 7 I-Disease
,	1399 1 O
even	1401 4 O
minor	1406 5 O
falls	1412 5 O
in	1418 2 O
plasma	1421 6 O
potassium	1428 9 B-Chemical
concentrations	1438 14 O
are	1453 3 O
probably	1457 8 O
best	1466 4 O
avoided	1471 7 O
in	1479 2 O
such	1482 4 O
patients	1487 8 O
.	1495 1 O

GABA	0 4 B-Chemical
involvement	5 11 O
in	17 2 O
naloxone	20 8 B-Chemical
induced	29 7 O
reversal	37 8 O
of	46 2 O
respiratory	49 11 B-Disease
paralysis	61 9 I-Disease
produced	71 8 O
by	80 2 O
thiopental	83 10 B-Chemical
.	93 1 O

No	95 2 O
agent	98 5 O
is	104 2 O
yet	107 3 O
available	111 9 O
to	121 2 O
reverse	124 7 O
respiratory	132 11 B-Disease
paralysis	144 9 I-Disease
produced	154 8 O
by	163 2 O
CNS	166 3 O
depressants	170 11 O
,	181 1 O
such	183 4 O
as	188 2 O
general	191 7 O
anesthetics	199 11 O
.	210 1 O

In	212 2 O
this	215 4 O
study	220 5 O
naloxone	226 8 B-Chemical
reversed	235 8 O
respiratory	244 11 B-Disease
paralysis	256 9 I-Disease
induced	266 7 O
by	274 2 O
thiopental	277 10 B-Chemical
in	288 2 O
rats	291 4 O
.	295 1 O

25	297 2 O
mg	300 2 O
/	302 1 O
kg	303 2 O
,	305 1 O
i	307 1 O
.	308 1 O
v	309 1 O
.	310 1 O
thiopental	312 10 B-Chemical
produced	323 8 O
anesthesia	332 10 O
without	343 7 O
altering	351 8 O
respiratory	360 11 O
rate	372 4 O
,	376 1 O
increased	378 9 O
GABA	388 4 B-Chemical
,	392 1 O
decreased	394 9 O
glutamate	404 9 B-Chemical
,	413 1 O
and	415 3 O
had	419 3 O
no	423 2 O
effect	426 6 O
on	433 2 O
aspartate	436 9 B-Chemical
or	446 2 O
glycine	449 7 B-Chemical
levels	457 6 O
compared	464 8 O
to	473 2 O
controls	476 8 O
in	485 2 O
rat	488 3 O
cortex	492 6 O
and	499 3 O
brain	503 5 O
stem	509 4 O
.	513 1 O

Pretreatment	515 12 O
of	528 2 O
rats	531 4 O
with	536 4 O
thiosemicarbazide	541 17 B-Chemical
for	559 3 O
30	563 2 O
minutes	566 7 O
abolished	574 9 O
the	584 3 O
anesthetic	588 10 O
action	599 6 O
as	606 2 O
well	609 4 O
as	614 2 O
the	617 3 O
respiratory	621 11 O
depressant	633 10 O
action	644 6 O
of	651 2 O
thiopental	654 10 B-Chemical
.	664 1 O

50	666 2 O
mg	669 2 O
/	671 1 O
kg	672 2 O
,	674 1 O
i	676 1 O
.	677 1 O
v	678 1 O
.	679 1 O
thiopental	681 10 B-Chemical
produced	692 8 O
respiratory	701 11 B-Disease
arrest	713 6 I-Disease
with	720 4 O
further	725 7 O
increase	733 8 O
in	742 2 O
GABA	745 4 B-Chemical
and	750 3 O
decrease	754 8 O
in	763 2 O
glutamate	766 9 B-Chemical
again	776 5 O
in	782 2 O
cortex	785 6 O
and	792 3 O
brain	796 5 O
stem	802 4 O
without	807 7 O
affecting	815 9 O
any	825 3 O
of	829 2 O
the	832 3 O
amino	836 5 B-Chemical
acids	842 5 I-Chemical
studied	848 7 O
in	856 2 O
four	859 4 O
regions	864 7 O
of	872 2 O
rat	875 3 O
brain	879 5 O
.	884 1 O

Naloxone	886 8 B-Chemical
(	895 1 O
2	896 1 O
.	897 1 O
5	898 1 O
mg	900 2 O
/	902 1 O
kg	903 2 O
,	905 1 O
i	907 1 O
.	908 1 O
v	909 1 O
.	910 1 O
)	911 1 O
reversed	913 8 O
respiratory	922 11 B-Disease
paralysis	934 9 I-Disease
,	943 1 O
glutamate	945 9 B-Chemical
and	955 3 O
GABA	959 4 B-Chemical
levels	964 6 O
to	971 2 O
control	974 7 O
values	982 6 O
in	989 2 O
brain	992 5 O
stem	998 4 O
and	1003 3 O
cortex	1007 6 O
with	1014 4 O
no	1019 2 O
changes	1022 7 O
in	1030 2 O
caudate	1033 7 O
or	1041 2 O
cerebellum	1044 10 O
.	1054 1 O

These	1056 5 O
data	1062 4 O
suggest	1067 7 O
naloxone	1075 8 B-Chemical
reverses	1084 8 O
respiratory	1093 11 B-Disease
paralysis	1105 9 I-Disease
produced	1115 8 O
by	1124 2 O
thiopental	1127 10 B-Chemical
and	1138 3 O
involves	1142 8 O
GABA	1151 4 B-Chemical
in	1156 2 O
its	1159 3 O
action	1163 6 O
.	1169 1 O

National	0 8 O
project	9 7 O
on	17 2 O
the	20 3 O
prevention	24 10 O
of	35 2 O
mother	38 6 O
-	44 1 O
to	45 2 O
-	47 1 O
infant	48 6 O
infection	55 9 B-Disease
by	65 2 I-Disease
hepatitis	68 9 I-Disease
B	78 1 I-Disease
virus	80 5 I-Disease
in	86 2 O
Japan	89 5 O
.	94 1 O

In	96 2 O
Japan	99 5 O
,	104 1 O
a	106 1 O
nationwide	108 10 O
prevention	119 10 O
program	130 7 O
against	138 7 O
mother	146 6 O
-	152 1 O
to	153 2 O
-	155 1 O
infant	156 6 O
infection	163 9 B-Disease
by	173 2 I-Disease
hepatitis	176 9 I-Disease
B	186 1 I-Disease
virus	188 5 I-Disease
(	194 1 O
HBV	195 3 O
)	198 1 O
started	200 7 O
in	208 2 O
1985	211 4 O
.	215 1 O

This	217 4 O
program	222 7 O
consists	230 8 O
of	239 2 O
double	242 6 O
screenings	249 10 O
of	260 2 O
pregnant	263 8 O
women	272 5 O
and	278 3 O
prophylactic	282 12 O
treatment	295 9 O
to	305 2 O
the	308 3 O
infants	312 7 O
born	320 4 O
to	325 2 O
both	328 4 O
hepatitis	333 9 B-Chemical
B	343 1 I-Chemical
surface	345 7 I-Chemical
antigen	353 7 I-Chemical
(	361 1 O
HBsAg	362 5 B-Chemical
)	367 1 O
and	369 3 O
hepatitis	373 9 B-Chemical
B	383 1 I-Chemical
e	385 1 I-Chemical
antigen	387 7 I-Chemical
(	395 1 O
HBeAg	396 5 B-Chemical
)	401 1 O
positive	403 8 O
mothers	412 7 O
.	419 1 O

These	421 5 O
infants	427 7 O
are	435 3 O
treated	439 7 O
with	447 4 O
two	452 3 O
injections	456 10 O
of	467 2 O
hepatitis	470 9 B-Disease
B	480 1 I-Disease
immune	482 6 O
globulin	489 8 O
(	498 1 O
HBIG	499 4 O
)	503 1 O
and	505 3 O
at	509 2 O
least	512 5 O
three	518 5 O
injections	524 10 O
of	535 2 O
plasma	538 6 O
derived	545 7 O
hepatitis	553 9 B-Chemical
B	563 1 I-Chemical
vaccine	565 7 I-Chemical
.	572 1 O

We	574 2 O
sent	577 4 O
questionnaires	582 14 O
about	597 5 O
the	603 3 O
numbers	607 7 O
of	615 2 O
each	618 4 O
procedure	623 9 O
or	633 2 O
examination	636 11 O
during	648 6 O
nine	655 4 O
months	660 6 O
of	667 2 O
investigation	670 13 O
period	684 6 O
to	691 2 O
each	694 4 O
local	699 5 O
government	705 10 O
in	716 2 O
1986	719 4 O
and	724 3 O
1987	728 4 O
.	732 1 O

93	734 2 O
.	736 1 O
4	737 1 O
%	738 1 O
pregnant	740 8 O
women	749 5 O
had	755 3 O
the	759 3 O
chance	763 6 O
to	770 2 O
be	773 2 O
examined	776 8 O
for	785 3 O
HBsAg	789 5 B-Chemical
,	794 1 O
and	796 3 O
the	800 3 O
positive	804 8 O
rate	813 4 O
was	818 3 O
1	822 1 O
.	823 1 O
4	824 1 O
to	826 2 O
1	829 1 O
.	830 1 O
5	831 1 O
%	832 1 O
.	833 1 O

The	835 3 O
HBeAg	839 5 B-Chemical
positive	845 8 O
rate	854 4 O
in	859 2 O
HBsAg	862 5 B-Chemical
positive	868 8 O
was	877 3 O
23	881 2 O
to	884 2 O
26	887 2 O
%	889 1 O
.	890 1 O

The	892 3 O
HBsAg	896 5 B-Chemical
positive	902 8 O
rate	911 4 O
in	916 2 O
neonates	919 8 O
and	928 3 O
in	932 2 O
infants	935 7 O
before	943 6 O
two	950 3 O
months	954 6 O
were	961 4 O
3	966 1 O
%	967 1 O
and	969 3 O
2	973 1 O
%	974 1 O
respectively	976 12 O
.	988 1 O

Some	990 4 O
problems	995 8 O
may	1004 3 O
arise	1008 5 O
,	1013 1 O
because	1015 7 O
27	1023 2 O
to	1026 2 O
30	1029 2 O
%	1031 1 O
of	1033 2 O
infants	1036 7 O
need	1044 4 O
the	1049 3 O
fourth	1053 6 O
vaccination	1060 11 O
in	1072 2 O
some	1075 4 O
restricted	1080 10 O
areas	1091 5 O
.	1096 1 O

Nociceptive	0 11 O
effects	12 7 O
induced	20 7 O
by	28 2 O
intrathecal	31 11 O
administration	43 14 O
of	58 2 O
prostaglandin	61 13 B-Chemical
D2	75 2 I-Chemical
,	77 1 I-Chemical
E2	79 2 I-Chemical
,	81 1 I-Chemical
or	83 2 I-Chemical
F2	86 2 I-Chemical
alpha	89 5 I-Chemical
to	95 2 O
conscious	98 9 O
mice	108 4 O
.	112 1 O

The	114 3 O
effects	118 7 O
of	126 2 O
intrathecal	129 11 O
administration	141 14 O
of	156 2 O
prostaglandins	159 14 B-Chemical
on	174 2 O
pain	177 4 B-Disease
responses	182 9 O
in	192 2 O
conscious	195 9 O
mice	205 4 O
were	210 4 O
evaluated	215 9 O
by	225 2 O
using	228 5 O
hot	234 3 O
plate	238 5 O
and	244 3 O
acetic	248 6 B-Chemical
acid	255 4 I-Chemical
writhing	260 8 O
tests	269 5 O
.	274 1 O

Prostaglandin	276 13 B-Chemical
D2	290 2 I-Chemical
(	293 1 O
0	294 1 O
.	295 1 O
5	296 1 O
-	297 1 O
3	298 1 O
ng	300 2 O
/	302 1 O
mouse	303 5 O
)	308 1 O
had	310 3 O
a	314 1 O
hyperalgesic	316 12 B-Disease
action	329 6 O
on	336 2 O
the	339 3 O
response	343 8 O
to	352 2 O
a	355 1 O
hot	357 3 O
plate	361 5 O
during	367 6 O
a	374 1 O
3	376 1 O
-	377 1 O
60	378 2 O
min	381 3 O
period	385 6 O
after	392 5 O
injection	398 9 O
.	407 1 O

Prostaglandin	409 13 B-Chemical
E2	423 2 I-Chemical
showed	426 6 O
a	433 1 O
hyperalgesic	435 12 B-Disease
effect	448 6 O
at	455 2 O
doses	458 5 O
of	464 2 O
1	467 1 O
pg	469 2 B-Chemical
to	472 2 O
10	475 2 O
ng	478 2 O
/	480 1 O
mouse	481 5 O
,	486 1 O
but	488 3 O
the	492 3 O
effect	496 6 O
lasted	503 6 O
shorter	510 7 O
(	518 1 O
3	519 1 O
-	520 1 O
30	521 2 O
min	524 3 O
)	527 1 O
than	529 4 O
that	534 4 O
of	539 2 O
prostaglandin	542 13 B-Chemical
D2	556 2 I-Chemical
.	558 1 O

Similar	560 7 O
results	568 7 O
were	576 4 O
obtained	581 8 O
by	590 2 O
acetic	593 6 B-Chemical
acid	600 4 I-Chemical
writhing	605 8 O
tests	614 5 O
.	619 1 O

The	621 3 O
hyperalgesic	625 12 B-Disease
effect	638 6 O
of	645 2 O
prostaglandin	648 13 B-Chemical
D2	662 2 I-Chemical
was	665 3 O
blocked	669 7 O
by	677 2 O
simultaneous	680 12 O
injection	693 9 O
of	703 2 O
a	706 1 O
substance	708 9 O
P	718 1 O
antagonist	720 10 O
(	731 1 O
greater	732 7 O
than	740 4 O
or	745 2 O
equal	748 5 O
to	754 2 O
100	757 3 O
ng	761 2 O
)	763 1 O
but	765 3 O
not	769 3 O
by	773 2 O
AH6809	776 6 B-Chemical
,	782 1 O
a	784 1 O
prostanoid	786 10 O
EP1	797 3 O
-	800 1 O
receptor	801 8 O
antagonist	810 10 O
.	820 1 O

Conversely	822 10 O
,	832 1 O
prostaglandin	834 13 B-Chemical
E2	848 2 I-Chemical
-	850 1 O
induced	851 7 O
hyperalgesia	859 12 B-Disease
was	872 3 O
blocked	876 7 O
by	884 2 O
AH6809	887 6 B-Chemical
(	894 1 O
greater	895 7 O
than	903 4 O
or	908 2 O
equal	911 5 O
to	917 2 O
500	920 3 O
ng	924 2 O
)	926 1 O
but	928 3 O
not	932 3 O
by	936 2 O
the	939 3 O
substance	943 9 O
P	953 1 O
antagonist	955 10 O
.	965 1 O

Prostaglandin	967 13 B-Chemical
F2	981 2 I-Chemical
alpha	984 5 I-Chemical
had	990 3 O
little	994 6 O
effect	1001 6 O
on	1008 2 O
pain	1011 4 B-Disease
responses	1016 9 O
.	1025 1 O

These	1027 5 O
results	1033 7 O
demonstrate	1041 11 O
that	1053 4 O
both	1058 4 O
prostaglandin	1063 13 B-Chemical
D2	1077 2 I-Chemical
and	1080 3 O
prostaglandin	1084 13 B-Chemical
E2	1098 2 I-Chemical
exert	1101 5 O
hyperalgesia	1107 12 B-Disease
in	1120 2 O
the	1123 3 O
spinal	1127 6 O
cord	1134 4 O
,	1138 1 O
but	1140 3 O
in	1144 2 O
different	1147 9 O
ways	1157 4 O
.	1161 1 O

Swallowing	0 10 O
-	10 1 O
induced	11 7 O
atrial	19 6 B-Disease
tachyarrhythmia	26 15 I-Disease
triggered	42 9 O
by	52 2 O
salbutamol	55 10 B-Chemical
:	65 1 O
case	67 4 O
report	72 6 O
and	79 3 O
review	83 6 O
of	90 2 O
the	93 3 O
literature	97 10 O
.	107 1 O

CASE	109 4 O
:	113 1 O
A	115 1 O
49	117 2 O
-	119 1 O
year	120 4 O
-	124 1 O
old	125 3 O
patient	129 7 O
experienced	137 11 O
chest	149 5 O
discomfort	155 10 O
while	166 5 O
swallowing	172 10 O
.	182 1 O

On	184 2 O
electrocardiogram	187 17 O
,	204 1 O
episodes	206 8 O
of	215 2 O
atrial	218 6 B-Disease
tachyarrhythmia	225 15 I-Disease
were	241 4 O
recorded	246 8 O
immediately	255 11 O
after	267 5 O
swallowing	273 10 O
;	283 1 O
24	285 2 O
-	287 1 O
hour	288 4 O
Holter	293 6 O
monitoring	300 10 O
recorded	311 8 O
several	320 7 O
events	328 6 O
.	334 1 O

The	336 3 O
arrhythmia	340 10 B-Disease
resolved	351 8 O
after	360 5 O
therapy	366 7 O
with	374 4 O
atenolol	379 8 B-Chemical
,	387 1 O
but	389 3 O
recurred	393 8 O
a	402 1 O
year	404 4 O
later	409 5 O
.	414 1 O

The	416 3 O
patient	420 7 O
noticed	428 7 O
that	436 4 O
before	441 6 O
these	448 5 O
episodes	454 8 O
he	463 2 O
had	466 3 O
been	470 4 O
using	475 5 O
an	481 2 O
inhalator	484 9 O
of	494 2 O
salbutamol	497 10 B-Chemical
.	507 1 O

After	509 5 O
stopping	515 8 O
the	524 3 O
beta	528 4 O
-	532 1 O
agonist	533 7 O
,	540 1 O
and	542 3 O
after	546 5 O
a	552 1 O
week	554 4 O
with	559 4 O
the	564 3 O
atenolol	568 8 B-Chemical
,	576 1 O
the	578 3 O
arrhythmia	582 10 B-Disease
disappeared	593 11 O
.	604 1 O

DISCUSSION	606 10 O
:	616 1 O
Swallowing	618 10 O
-	628 1 O
induced	629 7 O
atrial	637 6 B-Disease
tachyarrhythmia	644 15 I-Disease
(	660 1 O
SIAT	661 4 B-Disease
)	665 1 O
is	667 2 O
a	670 1 O
rare	672 4 O
phenomenon	677 10 O
.	687 1 O

Fewer	689 5 O
than	695 4 O
50	700 2 O
cases	703 5 O
of	709 2 O
SIAT	712 4 B-Disease
have	717 4 O
been	722 4 O
described	727 9 O
in	737 2 O
the	740 3 O
literature	744 10 O
.	754 1 O

This	756 4 O
article	761 7 O
summarizes	769 10 O
all	780 3 O
the	784 3 O
cases	788 5 O
published	794 9 O
,	803 1 O
creating	805 8 O
a	814 1 O
comprehensive	816 13 O
review	830 6 O
of	837 2 O
the	840 3 O
current	844 7 O
knowledge	852 9 O
and	862 3 O
approach	866 8 O
to	875 2 O
SIAT	878 4 B-Disease
.	882 1 O

It	884 2 O
discusses	887 9 O
demographics	897 12 O
,	909 1 O
clinical	911 8 O
characteristics	920 15 O
and	936 3 O
types	940 5 O
of	946 2 O
arrhythmia	949 10 B-Disease
,	959 1 O
postulated	961 10 O
mechanisms	972 10 O
of	983 2 O
SIAT	986 4 B-Disease
,	990 1 O
and	992 3 O
different	996 9 O
treatment	1006 9 O
possibilities	1016 13 O
such	1030 4 O
as	1035 2 O
medications	1038 11 O
,	1049 1 O
surgery	1051 7 O
,	1058 1 O
and	1060 3 O
radiofrequency	1064 14 O
catheter	1079 8 O
ablation	1088 8 O
(	1097 1 O
RFCA	1098 4 O
)	1102 1 O
.	1103 1 O

CONCLUSION	1105 10 O
:	1115 1 O
Salbutamol	1117 10 B-Chemical
is	1128 2 O
presented	1131 9 O
here	1141 4 O
as	1146 2 O
a	1149 1 O
possible	1151 8 O
trigger	1160 7 O
for	1168 3 O
SIAT	1172 4 B-Disease
.	1176 1 O

Although	1178 8 O
it	1187 2 O
is	1190 2 O
difficult	1193 9 O
to	1203 2 O
define	1206 6 O
causality	1213 9 O
in	1223 2 O
a	1226 1 O
case	1228 4 O
report	1233 6 O
,	1239 1 O
it	1241 2 O
is	1244 2 O
logical	1247 7 O
to	1255 2 O
think	1258 5 O
that	1264 4 O
a	1269 1 O
beta	1271 4 O
-	1275 1 O
agonist	1276 7 O
like	1284 4 O
salbutamol	1289 10 B-Chemical
(	1300 1 O
known	1301 5 O
to	1307 2 O
induce	1310 6 O
tachycardia	1317 11 B-Disease
)	1328 1 O
may	1330 3 O
be	1334 2 O
the	1337 3 O
trigger	1341 7 O
of	1349 2 O
adrenergic	1352 10 O
reflexes	1363 8 O
originating	1372 11 O
in	1384 2 O
the	1387 3 O
esophagus	1391 9 O
while	1401 5 O
swallowing	1407 10 O
and	1418 3 O
that	1422 4 O
a	1427 1 O
beta	1429 4 O
-	1433 1 O
blocker	1434 7 O
such	1442 4 O
as	1447 2 O
atenolol	1450 8 B-Chemical
(	1459 1 O
that	1460 4 O
blocks	1465 6 O
the	1472 3 O
adrenergic	1476 10 O
activity	1487 8 O
)	1495 1 O
may	1497 3 O
relieve	1501 7 O
it	1509 2 O
.	1511 1 O

Coenzyme	0 8 B-Chemical
Q10	9 3 I-Chemical
treatment	13 9 O
ameliorates	23 11 O
acute	35 5 O
cisplatin	41 9 B-Chemical
nephrotoxicity	51 14 B-Disease
in	66 2 O
mice	69 4 O
.	73 1 O

The	75 3 O
nephroprotective	79 16 O
effect	96 6 O
of	103 2 O
coenzyme	106 8 B-Chemical
Q10	115 3 I-Chemical
was	119 3 O
investigated	123 12 O
in	136 2 O
mice	139 4 O
with	144 4 O
acute	149 5 B-Disease
renal	155 5 I-Disease
injury	161 6 I-Disease
induced	168 7 O
by	176 2 O
a	179 1 O
single	181 6 O
i	188 1 O
.	189 1 O
p	190 1 O
.	191 1 O
injection	193 9 O
of	203 2 O
cisplatin	206 9 B-Chemical
(	216 1 O
5	217 1 O
mg	219 2 O
/	221 1 O
kg	222 2 O
)	224 1 O
.	225 1 O

Coenzyme	227 8 B-Chemical
Q10	236 3 I-Chemical
treatment	240 9 O
(	250 1 O
10	251 2 O
mg	254 2 O
/	256 1 O
kg	257 2 O
/	259 1 O
day	260 3 O
,	263 1 O
i	265 1 O
.	266 1 O
p	267 1 O
.	268 1 O
)	269 1 O
was	271 3 O
applied	275 7 O
for	283 3 O
6	287 1 O
consecutive	289 11 O
days	301 4 O
,	305 1 O
starting	307 8 O
1	316 1 O
day	318 3 O
before	322 6 O
cisplatin	329 9 B-Chemical
administration	339 14 O
.	353 1 O

Coenzyme	355 8 B-Chemical
Q10	364 3 I-Chemical
significantly	368 13 O
reduced	382 7 O
blood	390 5 B-Chemical
urea	396 4 I-Chemical
nitrogen	401 8 I-Chemical
and	410 3 O
serum	414 5 O
creatinine	420 10 B-Chemical
levels	431 6 O
which	438 5 O
were	444 4 O
increased	449 9 O
by	459 2 O
cisplatin	462 9 B-Chemical
.	471 1 O

Coenzyme	473 8 B-Chemical
Q10	482 3 I-Chemical
significantly	486 13 O
compensated	500 11 O
deficits	512 8 O
in	521 2 O
the	524 3 O
antioxidant	528 11 O
defense	540 7 O
mechanisms	548 10 O
(	559 1 O
reduced	560 7 B-Chemical
glutathione	568 11 I-Chemical
level	580 5 O
and	586 3 O
superoxide	590 10 B-Chemical
dismutase	601 9 O
activity	611 8 O
)	619 1 O
,	620 1 O
suppressed	622 10 O
lipid	633 5 O
peroxidation	639 12 O
,	651 1 O
decreased	653 9 O
the	663 3 O
elevations	667 10 O
of	678 2 O
tumor	681 5 B-Disease
necrosis	687 8 B-Disease
factor	696 6 O
-	702 1 O
alpha	703 5 O
,	708 1 O
nitric	710 6 B-Chemical
oxide	717 5 I-Chemical
and	723 3 O
platinum	727 8 B-Chemical
ion	736 3 O
concentration	740 13 O
,	753 1 O
and	755 3 O
attenuated	759 10 O
the	770 3 O
reductions	774 10 O
of	785 2 O
selenium	788 8 B-Chemical
and	797 3 O
zinc	801 4 B-Chemical
ions	806 4 O
in	811 2 O
renal	814 5 O
tissue	820 6 O
resulted	827 8 O
from	836 4 O
cisplatin	841 9 B-Chemical
administration	851 14 O
.	865 1 O

Also	867 4 O
,	871 1 O
histopathological	873 17 O
renal	891 5 B-Disease
tissue	897 6 I-Disease
damage	904 6 I-Disease
mediated	911 8 O
by	920 2 O
cisplatin	923 9 B-Chemical
was	933 3 O
ameliorated	937 11 O
by	949 2 O
coenzyme	952 8 B-Chemical
Q10	961 3 I-Chemical
treatment	965 9 O
.	974 1 O

Immunohistochemical	976 19 O
analysis	996 8 O
revealed	1005 8 O
that	1014 4 O
coenzyme	1019 8 B-Chemical
Q10	1028 3 I-Chemical
significantly	1032 13 O
decreased	1046 9 O
the	1056 3 O
cisplatin	1060 9 B-Chemical
-	1069 1 O
induced	1070 7 O
overexpression	1078 14 O
of	1093 2 O
inducible	1096 9 O
nitric	1106 6 B-Chemical
oxide	1113 5 I-Chemical
synthase	1119 8 O
,	1127 1 O
nuclear	1129 7 O
factor	1137 6 O
-	1143 1 O
kappaB	1144 6 O
,	1150 1 O
caspase	1152 7 O
-	1159 1 O
3	1160 1 O
and	1162 3 O
p53	1166 3 O
in	1170 2 O
renal	1173 5 O
tissue	1179 6 O
.	1185 1 O

It	1187 2 O
was	1190 3 O
concluded	1194 9 O
that	1204 4 O
coenzyme	1209 8 B-Chemical
Q10	1218 3 I-Chemical
represents	1222 10 O
a	1233 1 O
potential	1235 9 O
therapeutic	1245 11 O
option	1257 6 O
to	1264 2 O
protect	1267 7 O
against	1275 7 O
acute	1283 5 O
cisplatin	1289 9 B-Chemical
nephrotoxicity	1299 14 B-Disease
commonly	1314 8 O
encountered	1323 11 O
in	1335 2 O
clinical	1338 8 O
practice	1347 8 O
.	1355 1 O

Metformin	0 9 B-Chemical
prevents	10 8 O
experimental	19 12 O
gentamicin	32 10 B-Chemical
-	42 1 O
induced	43 7 O
nephropathy	51 11 B-Disease
by	63 2 O
a	66 1 O
mitochondria	68 12 O
-	80 1 O
dependent	81 9 O
pathway	91 7 O
.	98 1 O

The	100 3 O
antidiabetic	104 12 O
drug	117 4 O
metformin	122 9 B-Chemical
can	132 3 O
diminish	136 8 O
apoptosis	145 9 O
induced	155 7 O
by	163 2 O
oxidative	166 9 O
stress	176 6 O
in	183 2 O
endothelial	186 11 O
cells	198 5 O
and	204 3 O
prevent	208 7 O
vascular	216 8 B-Disease
dysfunction	225 11 I-Disease
even	237 4 O
in	242 2 O
nondiabetic	245 11 O
patients	257 8 O
.	265 1 O

Here	267 4 O
we	272 2 O
tested	275 6 O
whether	282 7 O
it	290 2 O
has	293 3 O
a	297 1 O
beneficial	299 10 O
effect	310 6 O
in	317 2 O
a	320 1 O
rat	322 3 O
model	326 5 O
of	332 2 O
gentamicin	335 10 B-Chemical
toxicity	346 8 B-Disease
.	354 1 O

Mitochondrial	356 13 O
analysis	370 8 O
,	378 1 O
respiration	380 11 O
intensity	392 9 O
,	401 1 O
levels	403 6 O
of	410 2 O
reactive	413 8 O
oxygen	422 6 B-Chemical
species	429 7 O
,	436 1 O
permeability	438 12 O
transition	451 10 O
,	461 1 O
and	463 3 O
cytochrome	467 10 O
c	478 1 O
release	480 7 O
were	488 4 O
assessed	493 8 O
3	502 1 O
and	504 3 O
6	508 1 O
days	510 4 O
after	515 5 O
gentamicin	521 10 B-Chemical
administration	532 14 O
.	546 1 O

Metformin	548 9 B-Chemical
treatment	558 9 O
fully	568 5 O
blocked	574 7 O
gentamicin	582 10 B-Chemical
-	592 1 O
mediated	593 8 O
acute	602 5 B-Disease
renal	608 5 I-Disease
failure	614 7 I-Disease
.	621 1 O

This	623 4 O
was	628 3 O
accompanied	632 11 O
by	644 2 O
a	647 1 O
lower	649 5 O
activity	655 8 O
of	664 2 O
N	667 1 O
-	668 1 O
acetyl	669 6 O
-	675 1 O
beta	676 4 O
-	680 1 O
D	681 1 O
-	682 1 O
glucosaminidase	683 15 O
,	698 1 O
together	700 8 O
with	709 4 O
a	714 1 O
decrease	716 8 O
of	725 2 O
lipid	728 5 O
peroxidation	734 12 O
and	747 3 O
increase	751 8 O
of	760 2 O
antioxidant	763 11 O
systems	775 7 O
.	782 1 O

Metformin	784 9 B-Chemical
also	794 4 O
protected	799 9 O
the	809 3 O
kidney	813 6 O
from	820 4 O
histological	825 12 O
damage	838 6 O
6	845 1 O
days	847 4 O
after	852 5 O
gentamicin	858 10 B-Chemical
administration	869 14 O
.	883 1 O

These	885 5 O
in	891 2 O
vivo	894 4 O
markers	899 7 O
of	907 2 O
kidney	910 6 B-Disease
dysfunction	917 11 I-Disease
and	929 3 O
their	933 5 O
correction	939 10 O
by	950 2 O
metformin	953 9 B-Chemical
were	963 4 O
complemented	968 12 O
by	981 2 O
in	984 2 O
vitro	987 5 O
studies	993 7 O
of	1001 2 O
mitochondrial	1004 13 O
function	1018 8 O
.	1026 1 O

We	1028 2 O
found	1031 5 O
that	1037 4 O
gentamicin	1042 10 B-Chemical
treatment	1053 9 O
depleted	1063 8 O
respiratory	1072 11 O
components	1084 10 O
(	1095 1 O
cytochrome	1096 10 O
c	1107 1 O
,	1108 1 O
NADH	1110 4 O
)	1114 1 O
,	1115 1 O
probably	1117 8 O
due	1126 3 O
to	1130 2 O
the	1133 3 O
opening	1137 7 O
of	1145 2 O
mitochondrial	1148 13 O
transition	1162 10 O
pores	1173 5 O
.	1178 1 O

These	1180 5 O
injuries	1186 8 O
,	1194 1 O
partly	1196 6 O
mediated	1203 8 O
by	1212 2 O
a	1215 1 O
rise	1217 4 O
in	1222 2 O
reactive	1225 8 O
oxygen	1234 6 B-Chemical
species	1241 7 O
from	1249 4 O
the	1254 3 O
electron	1258 8 O
transfer	1267 8 O
chain	1276 5 O
,	1281 1 O
were	1283 4 O
significantly	1288 13 O
decreased	1302 9 O
by	1312 2 O
metformin	1315 9 B-Chemical
.	1324 1 O

Thus	1326 4 O
,	1330 1 O
our	1332 3 O
study	1336 5 O
suggests	1342 8 O
that	1351 4 O
pleiotropic	1356 11 O
effects	1368 7 O
of	1376 2 O
metformin	1379 9 B-Chemical
can	1389 3 O
lessen	1393 6 O
gentamicin	1400 10 B-Chemical
nephrotoxicity	1411 14 B-Disease
and	1426 3 O
improve	1430 7 O
mitochondrial	1438 13 O
homeostasis	1452 11 O
.	1463 1 O

Sedation	0 8 O
depth	9 5 O
during	15 6 O
spinal	22 6 O
anesthesia	29 10 O
and	40 3 O
the	44 3 O
development	48 11 O
of	60 2 O
postoperative	63 13 B-Disease
delirium	77 8 I-Disease
in	86 2 O
elderly	89 7 O
patients	97 8 O
undergoing	106 10 O
hip	117 3 B-Disease
fracture	121 8 I-Disease
repair	130 6 O
.	136 1 O

OBJECTIVE	138 9 O
:	147 1 O
To	149 2 O
determine	152 9 O
whether	162 7 O
limiting	170 8 O
intraoperative	179 14 O
sedation	194 8 O
depth	203 5 O
during	209 6 O
spinal	216 6 O
anesthesia	223 10 O
for	234 3 O
hip	238 3 B-Disease
fracture	242 8 I-Disease
repair	251 6 O
in	258 2 O
elderly	261 7 O
patients	269 8 O
can	278 3 O
decrease	282 8 O
the	291 3 O
prevalence	295 10 O
of	306 2 O
postoperative	309 13 B-Disease
delirium	323 8 I-Disease
.	331 1 O

PATIENTS	333 8 O
AND	342 3 O
METHODS	346 7 O
:	353 1 O
We	355 2 O
performed	358 9 O
a	368 1 O
double	370 6 O
-	376 1 O
blind	377 5 O
,	382 1 O
randomized	384 10 O
controlled	395 10 O
trial	406 5 O
at	412 2 O
an	415 2 O
academic	418 8 O
medical	427 7 O
center	435 6 O
of	442 2 O
elderly	445 7 O
patients	453 8 O
(	462 1 O
>	463 1 O
or	464 2 O
=	466 1 O
65	467 2 O
years	470 5 O
)	475 1 O
without	477 7 O
preoperative	485 12 O
delirium	498 8 B-Disease
or	507 2 O
severe	510 6 O
dementia	517 8 B-Disease
who	526 3 O
underwent	530 9 O
hip	540 3 B-Disease
fracture	544 8 I-Disease
repair	553 6 O
under	560 5 O
spinal	566 6 O
anesthesia	573 10 O
with	584 4 O
propofol	589 8 B-Chemical
sedation	598 8 O
.	606 1 O

Sedation	608 8 O
depth	617 5 O
was	623 3 O
titrated	627 8 O
using	636 5 O
processed	642 9 O
electroencephalography	652 22 O
with	675 4 O
the	680 3 O
bispectral	684 10 O
index	695 5 O
(	701 1 O
BIS	702 3 O
)	705 1 O
,	706 1 O
and	708 3 O
patients	712 8 O
were	721 4 O
randomized	726 10 O
to	737 2 O
receive	740 7 O
either	748 6 O
deep	755 4 O
(	760 1 O
BIS	761 3 O
,	764 1 O
approximately	766 13 O
50	780 2 O
)	782 1 O
or	784 2 O
light	787 5 O
(	793 1 O
BIS	794 3 O
,	797 1 O
>	799 1 O
or	800 2 O
=	802 1 O
80	803 2 O
)	805 1 O
sedation	807 8 O
.	815 1 O

Postoperative	817 13 B-Disease
delirium	831 8 I-Disease
was	840 3 O
assessed	844 8 O
as	853 2 O
defined	856 7 O
by	864 2 O
Diagnostic	867 10 O
and	878 3 O
Statistical	882 11 O
Manual	894 6 O
of	901 2 O
Mental	904 6 B-Disease
Disorders	911 9 I-Disease
(	921 1 O
Third	922 5 O
Edition	928 7 O
Revised	936 7 O
)	943 1 O
criteria	945 8 O
using	954 5 O
the	960 3 O
Confusion	964 9 O
Assessment	974 10 O
Method	985 6 O
beginning	992 9 O
at	1002 2 O
any	1005 3 O
time	1009 4 O
from	1014 4 O
the	1019 3 O
second	1023 6 O
day	1030 3 O
after	1034 5 O
surgery	1040 7 O
.	1047 1 O

RESULTS	1049 7 O
:	1056 1 O
From	1058 4 O
April	1063 5 O
2	1069 1 O
,	1070 1 O
2005	1072 4 O
,	1076 1 O
through	1078 7 O
October	1086 7 O
30	1094 2 O
,	1096 1 O
2008	1098 4 O
,	1102 1 O
a	1104 1 O
total	1106 5 O
of	1112 2 O
114	1115 3 O
patients	1119 8 O
were	1128 4 O
randomized	1133 10 O
.	1143 1 O

The	1145 3 O
prevalence	1149 10 O
of	1160 2 O
postoperative	1163 13 B-Disease
delirium	1177 8 I-Disease
was	1186 3 O
significantly	1190 13 O
lower	1204 5 O
in	1210 2 O
the	1213 3 O
light	1217 5 O
sedation	1223 8 O
group	1232 5 O
(	1238 1 O
11	1239 2 O
/	1241 1 O
57	1242 2 O
[	1245 1 O
19	1246 2 O
%	1248 1 O
]	1249 1 O
vs	1251 2 O
23	1254 2 O
/	1256 1 O
57	1257 2 O
[	1260 1 O
40	1261 2 O
%	1263 1 O
]	1264 1 O
in	1266 2 O
the	1269 3 O
deep	1273 4 O
sedation	1278 8 O
group	1287 5 O
;	1292 1 O
P	1294 1 O
=	1295 1 O
.	1296 1 O
02	1297 2 O
)	1299 1 O
,	1300 1 O
indicating	1302 10 O
that	1313 4 O
1	1318 1 O
incident	1320 8 O
of	1329 2 O
delirium	1332 8 B-Disease
will	1341 4 O
be	1346 2 O
prevented	1349 9 O
for	1359 3 O
every	1363 5 O
4	1369 1 O
.	1370 1 O
7	1371 1 O
patients	1373 8 O
treated	1382 7 O
with	1390 4 O
light	1395 5 O
sedation	1401 8 O
.	1409 1 O

The	1411 3 O
mean	1415 4 O
+	1420 1 O
/	1421 1 O
-	1422 1 O
SD	1424 2 O
number	1427 6 O
of	1434 2 O
days	1437 4 O
of	1442 2 O
delirium	1445 8 B-Disease
during	1454 6 O
hospitalization	1461 15 O
was	1477 3 O
lower	1481 5 O
in	1487 2 O
the	1490 3 O
light	1494 5 O
sedation	1500 8 O
group	1509 5 O
than	1515 4 O
in	1520 2 O
the	1523 3 O
deep	1527 4 O
sedation	1532 8 O
group	1541 5 O
(	1547 1 O
0	1548 1 O
.	1549 1 O
5	1550 1 O
+	1551 1 O
/	1552 1 O
-	1553 1 O
1	1554 1 O
.	1555 1 O
5	1556 1 O
days	1558 4 O
vs	1563 2 O
1	1566 1 O
.	1567 1 O
4	1568 1 O
+	1569 1 O
/	1570 1 O
-	1571 1 O
4	1572 1 O
.	1573 1 O
0	1574 1 O
days	1576 4 O
;	1580 1 O
P	1582 1 O
=	1583 1 O
.	1584 1 O
01	1585 2 O
)	1587 1 O
.	1588 1 O

CONCLUSION	1590 10 O
:	1600 1 O
The	1602 3 O
use	1606 3 O
of	1610 2 O
light	1613 5 O
propofol	1619 8 B-Chemical
sedation	1628 8 O
decreased	1637 9 O
the	1647 3 O
prevalence	1651 10 O
of	1662 2 O
postoperative	1665 13 B-Disease
delirium	1679 8 I-Disease
by	1688 2 O
50	1691 2 O
%	1693 1 O
compared	1695 8 O
with	1704 4 O
deep	1709 4 O
sedation	1714 8 O
.	1722 1 O

Limiting	1724 8 O
depth	1733 5 O
of	1739 2 O
sedation	1742 8 O
during	1751 6 O
spinal	1758 6 O
anesthesia	1765 10 O
is	1776 2 O
a	1779 1 O
simple	1781 6 O
,	1787 1 O
safe	1789 4 O
,	1793 1 O
and	1795 3 O
cost	1799 4 O
-	1803 1 O
effective	1804 9 O
intervention	1814 12 O
for	1827 3 O
preventing	1831 10 O
postoperative	1842 13 B-Disease
delirium	1856 8 I-Disease
in	1865 2 O
elderly	1868 7 O
patients	1876 8 O
that	1885 4 O
could	1890 5 O
be	1896 2 O
widely	1899 6 O
and	1906 3 O
readily	1910 7 O
adopted	1918 7 O
.	1925 1 O

Sorafenib	0 9 B-Chemical
-	9 1 O
induced	10 7 O
acute	18 5 O
myocardial	24 10 B-Disease
infarction	35 10 I-Disease
due	46 3 O
to	50 2 O
coronary	53 8 B-Disease
artery	62 6 I-Disease
spasm	69 5 I-Disease
.	74 1 O

A	76 1 O
65	78 2 O
-	80 1 O
year	81 4 O
-	85 1 O
old	86 3 O
man	90 3 O
with	94 4 O
advanced	99 8 O
renal	108 5 B-Disease
cell	114 4 I-Disease
carcinoma	119 9 I-Disease
was	129 3 O
admitted	133 8 O
due	142 3 O
to	146 2 O
continuing	149 10 O
chest	160 5 B-Disease
pain	166 4 I-Disease
at	171 2 O
rest	174 4 O
.	178 1 O

Two	180 3 O
weeks	184 5 O
before	190 6 O
his	197 3 O
admission	201 9 O
,	210 1 O
sorafenib	212 9 B-Chemical
had	222 3 O
been	226 4 O
started	231 7 O
.	238 1 O

He	240 2 O
was	243 3 O
diagnosed	247 9 O
with	257 4 O
non	262 3 O
-	265 1 O
ST	266 2 O
-	268 1 O
elevation	269 9 O
myocardial	279 10 B-Disease
infarction	290 10 I-Disease
by	301 2 O
laboratory	304 10 O
data	315 4 O
and	320 3 O
electrocardiogram	324 17 O
.	341 1 O

Enhanced	343 8 O
heart	352 5 O
magnetic	358 8 O
resonance	367 9 O
imaging	377 7 O
also	385 4 O
showed	390 6 O
subendocardial	397 14 B-Disease
infarction	412 10 I-Disease
.	422 1 O

However	424 7 O
,	431 1 O
there	433 5 O
was	439 3 O
no	443 2 O
stenosis	446 8 O
in	455 2 O
coronary	458 8 O
arteries	467 8 O
on	476 2 O
angiography	479 11 O
.	490 1 O

Coronary	492 8 B-Disease
artery	501 6 I-Disease
spasm	508 5 I-Disease
was	514 3 O
induced	518 7 O
by	526 2 O
a	529 1 O
provocative	531 11 O
test	543 4 O
.	547 1 O

Cessation	549 9 O
of	559 2 O
sorafenib	562 9 B-Chemical
and	572 3 O
administration	576 14 O
of	591 2 O
Ca	594 2 B-Chemical
-	596 1 O
channel	597 7 O
blocker	605 7 O
and	613 3 O
nitrates	617 8 B-Chemical
ameliorated	626 11 O
his	638 3 O
symptoms	642 8 O
,	650 1 O
but	652 3 O
relapse	656 7 O
occurred	664 8 O
after	673 5 O
resumption	679 10 O
of	690 2 O
sorafenib	693 9 B-Chemical
.	702 1 O

Addition	704 8 O
of	713 2 O
oral	716 4 O
nicorandil	721 10 B-Chemical
reduced	732 7 O
his	740 3 O
symptoms	744 8 O
and	753 3 O
maintained	757 10 O
stable	768 6 B-Disease
angina	775 6 I-Disease
status	782 6 O
.	788 1 O

We	790 2 O
report	793 6 O
the	800 3 O
first	804 5 O
case	810 4 O
of	815 2 O
sorafenib	818 9 B-Chemical
-	827 1 O
induced	828 7 O
coronary	836 8 B-Disease
artery	845 6 I-Disease
spasm	852 5 I-Disease
.	857 1 O

Sorafenib	859 9 B-Chemical
is	869 2 O
a	872 1 O
multikinase	874 11 O
inhibitor	886 9 O
that	896 4 O
targets	901 7 O
signaling	909 9 O
pathways	919 8 O
necessary	928 9 O
for	938 3 O
cellular	942 8 O
proliferation	951 13 O
and	965 3 O
survival	969 8 O
.	977 1 O

On	979 2 O
the	982 3 O
other	986 5 O
hand	992 4 O
,	996 1 O
the	998 3 O
Rho	1002 3 O
/	1005 1 O
ROCK	1006 4 O
pathway	1011 7 O
has	1019 3 O
an	1023 2 O
important	1026 9 O
role	1036 4 O
in	1041 2 O
the	1044 3 O
pathogenesis	1048 12 O
of	1061 2 O
coronary	1064 8 B-Disease
artery	1073 6 I-Disease
spasm	1080 5 I-Disease
.	1085 1 O

Our	1087 3 O
report	1091 6 O
may	1098 3 O
show	1102 4 O
an	1107 2 O
adverse	1110 7 O
effect	1118 6 O
on	1125 2 O
the	1128 3 O
Rho	1132 3 O
/	1135 1 O
ROCK	1136 4 O
pathway	1141 7 O
by	1149 2 O
sorafenib	1152 9 B-Chemical
use	1162 3 O
.	1165 1 O

Anxiogenic	0 10 O
potential	11 9 O
of	21 2 O
ciprofloxacin	24 13 B-Chemical
and	38 3 O
norfloxacin	42 11 B-Chemical
in	54 2 O
rats	57 4 O
.	61 1 O

INTRODUCTION	63 12 O
:	75 1 O
The	77 3 O
possible	81 8 O
anxiogenic	90 10 O
effects	101 7 O
of	109 2 O
fluoroquinolones	112 16 B-Chemical
,	128 1 O
namely	130 6 O
ciprofloxacin	137 13 B-Chemical
and	151 3 O
norfloxacin	155 11 B-Chemical
,	166 1 O
were	168 4 O
investigated	173 12 O
in	186 2 O
adult	189 5 O
Charles	195 7 O
Foster	203 6 O
albino	210 6 O
rats	217 4 O
of	222 2 O
either	225 6 O
sex	232 3 O
,	235 1 O
weighing	237 8 O
150	246 3 O
-	249 1 O
200	250 3 O
g	254 1 O
.	255 1 O

METHODS	257 7 O
:	264 1 O
The	266 3 O
drugs	270 5 O
were	276 4 O
given	281 5 O
orally	287 6 O
,	293 1 O
in	295 2 O
doses	298 5 O
of	304 2 O
50	307 2 O
mg	310 2 O
/	312 1 O
kg	313 2 O
for	316 3 O
five	320 4 O
consecutive	325 11 O
days	337 4 O
and	342 3 O
the	346 3 O
experiments	350 11 O
were	362 4 O
performed	367 9 O
on	377 2 O
the	380 3 O
fifth	384 5 O
day	390 3 O
.	393 1 O

The	395 3 O
tests	399 5 O
included	405 8 O
open	414 4 O
-	418 1 O
field	419 5 O
exploratory	425 11 O
behaviour	437 9 O
,	446 1 O
elevated	448 8 O
plus	457 4 O
maze	462 4 O
and	467 3 O
elevated	471 8 O
zero	480 4 O
maze	485 4 O
,	489 1 O
social	491 6 O
interaction	498 11 O
and	510 3 O
novelty	514 7 O
-	521 1 O
suppressed	522 10 O
feeding	533 7 O
latency	541 7 O
behaviour	549 9 O
.	558 1 O

RESULTS	560 7 O
:	567 1 O
The	569 3 O
results	573 7 O
indicate	581 8 O
that	590 4 O
ciprofloxacin	595 13 B-Chemical
-	608 1 O
and	610 3 O
norfloxacin	614 11 B-Chemical
-	625 1 O
treated	626 7 O
rats	634 4 O
showed	639 6 O
anxious	646 7 B-Disease
behaviour	654 9 I-Disease
in	664 2 O
comparison	667 10 O
to	678 2 O
control	681 7 O
rats	689 4 O
in	694 2 O
all	697 3 O
the	701 3 O
parameters	705 10 O
studied	716 7 O
.	723 1 O

However	725 7 O
,	732 1 O
ciprofloxacin	734 13 B-Chemical
-	747 1 O
and	749 3 O
norfloxacin	753 11 B-Chemical
-	764 1 O
treated	765 7 O
rats	773 4 O
did	778 3 O
not	782 3 O
differ	786 6 O
significantly	793 13 O
from	807 4 O
each	812 4 O
other	817 5 O
in	823 2 O
various	826 7 O
behavioural	834 11 O
parameters	846 10 O
.	856 1 O

CONCLUSION	858 10 O
:	868 1 O
The	870 3 O
present	874 7 O
experimental	882 12 O
findings	895 8 O
substantiate	904 12 O
the	917 3 O
clinically	921 10 O
observed	932 8 O
anxiogenic	941 10 O
potential	952 9 O
of	962 2 O
ciprofloxacin	965 13 B-Chemical
and	979 3 O
norfloxacin	983 11 B-Chemical
.	994 1 O

Myocardial	0 10 O
Fas	11 3 O
ligand	15 6 O
expression	22 10 O
increases	33 9 O
susceptibility	43 14 O
to	58 2 O
AZT	61 3 B-Chemical
-	64 1 O
induced	65 7 O
cardiomyopathy	73 14 B-Disease
.	87 1 O

BACKGROUND	89 10 O
:	99 1 O
Dilated	101 7 B-Disease
cardiomyopathy	109 14 I-Disease
(	124 1 O
DCM	125 3 B-Disease
)	128 1 O
and	130 3 O
myocarditis	134 11 B-Disease
occur	146 5 O
in	152 2 O
many	155 4 O
HIV	160 3 B-Disease
-	163 1 I-Disease
infected	164 8 I-Disease
individuals	173 11 O
,	184 1 O
resulting	186 9 O
in	196 2 O
symptomatic	199 11 O
heart	211 5 B-Disease
failure	217 7 I-Disease
in	225 2 O
up	228 2 O
to	231 2 O
5	234 1 O
%	235 1 O
of	237 2 O
patients	240 8 O
.	248 1 O

Highly	250 6 O
active	257 6 O
antiretroviral	264 14 O
therapy	279 7 O
(	287 1 O
HAART	288 5 O
)	293 1 O
has	295 3 O
significantly	299 13 O
reduced	313 7 O
morbidity	321 9 O
and	331 3 O
mortality	335 9 O
of	345 2 O
acquired	348 8 B-Disease
immunodeficiency	357 16 I-Disease
syndrome	374 8 I-Disease
(	383 1 O
AIDS	384 4 B-Disease
)	388 1 O
,	389 1 O
but	391 3 O
has	395 3 O
resulted	399 8 O
in	408 2 O
an	411 2 O
increase	414 8 O
in	423 2 O
cardiac	426 7 B-Disease
and	434 3 I-Disease
skeletal	438 8 I-Disease
myopathies	447 10 I-Disease
.	457 1 O

METHODS	459 7 O
AND	467 3 O
RESULTS	471 7 O
:	478 1 O
In	480 2 O
order	483 5 O
to	489 2 O
investigate	492 11 O
whether	504 7 O
the	512 3 O
HAART	516 5 O
component	522 9 O
zidovudine	532 10 B-Chemical
(	543 1 O
3	544 1 B-Chemical
'	545 1 I-Chemical
-	546 1 I-Chemical
azido	547 5 I-Chemical
-	552 1 I-Chemical
2	553 1 I-Chemical
'	554 1 I-Chemical
,	555 1 I-Chemical
3	556 1 I-Chemical
'	557 1 I-Chemical
-	558 1 I-Chemical
deoxythymidine	559 14 I-Chemical
;	573 1 O
AZT	575 3 B-Chemical
)	578 1 O
triggers	580 8 O
the	589 3 O
Fas	593 3 O
-	596 1 O
dependent	597 9 O
cell	607 4 O
-	611 1 O
death	612 5 O
pathway	618 7 O
and	626 3 O
cause	630 5 O
cytoskeletal	636 12 O
disruption	649 10 O
in	660 2 O
a	663 1 O
murine	665 6 O
model	672 5 O
of	678 2 O
DCM	681 3 B-Disease
,	684 1 O
8	686 1 O
-	687 1 O
week	688 4 O
-	692 1 O
old	693 3 O
transgenic	697 10 O
(	708 1 O
expressing	709 10 O
Fas	720 3 O
ligand	724 6 O
in	731 2 O
the	734 3 O
myocardium	738 10 O
:	748 1 O
FasL	750 4 O
Tg	755 2 O
)	757 1 O
and	759 3 O
non	763 3 O
-	766 1 O
transgenic	767 10 O
(	778 1 O
NTg	779 3 O
)	782 1 O
mice	784 4 O
received	789 8 O
water	798 5 O
ad	804 2 O
libitum	807 7 O
containing	815 10 O
different	826 9 O
concentrations	836 14 O
of	851 2 O
AZT	854 3 B-Chemical
(	858 1 O
0	859 1 O
,	860 1 O
0	862 1 O
.	863 1 O
07	864 2 O
,	866 1 O
0	868 1 O
.	869 1 O
2	870 1 O
,	871 1 O
and	873 3 O
0	877 1 O
.	878 1 O
7	879 1 O
mg	881 2 O
/	883 1 O
ml	884 2 O
)	886 1 O
.	887 1 O

After	889 5 O
6	895 1 O
weeks	897 5 O
,	902 1 O
cardiac	904 7 O
function	912 8 O
was	921 3 O
assessed	925 8 O
by	934 2 O
echocardiography	937 16 O
and	954 3 O
morphology	958 10 O
was	969 3 O
assessed	973 8 O
by	982 2 O
histopathologic	985 15 O
and	1001 3 O
immunohistochemical	1005 19 O
methods	1025 7 O
.	1032 1 O

NTg	1034 3 O
and	1038 3 O
untreated	1042 9 O
FasL	1052 4 O
Tg	1057 2 O
mice	1060 4 O
showed	1065 6 O
little	1072 6 O
or	1079 2 O
no	1082 2 O
change	1085 6 O
in	1092 2 O
cardiac	1095 7 O
structure	1103 9 O
or	1113 2 O
function	1116 8 O
.	1124 1 O

In	1126 2 O
contrast	1129 8 O
,	1137 1 O
AZT	1139 3 B-Chemical
-	1142 1 O
treated	1143 7 O
FasL	1151 4 O
Tg	1156 2 O
mice	1159 4 O
developed	1164 9 O
cardiac	1174 7 B-Disease
dilation	1182 8 I-Disease
and	1191 3 O
depressed	1195 9 O
cardiac	1205 7 O
function	1213 8 O
in	1222 2 O
a	1225 1 O
dose	1227 4 O
-	1231 1 O
dependent	1232 9 O
manner	1242 6 O
,	1248 1 O
with	1250 4 O
concomitant	1255 11 O
inflammatory	1267 12 O
infiltration	1280 12 O
of	1293 2 O
both	1296 4 O
ventricles	1301 10 O
.	1311 1 O

These	1313 5 O
changes	1319 7 O
were	1327 4 O
associated	1332 10 O
with	1343 4 O
an	1348 2 O
increased	1351 9 O
sarcolemmal	1361 11 O
expression	1373 10 O
of	1384 2 O
Fas	1387 3 O
and	1391 3 O
FasL	1395 4 O
,	1399 1 O
as	1401 2 O
well	1404 4 O
as	1409 2 O
increased	1412 9 O
activation	1422 10 O
of	1433 2 O
caspase	1436 7 O
3	1444 1 O
,	1445 1 O
translocation	1447 13 O
of	1461 2 O
calpain	1464 7 O
1	1472 1 O
to	1474 2 O
the	1477 3 O
sarcolemma	1481 10 O
and	1492 3 O
sarcomere	1496 9 O
,	1505 1 O
and	1507 3 O
increased	1511 9 O
numbers	1521 7 O
of	1529 2 O
cells	1532 5 O
undergoing	1538 10 O
apoptosis	1549 9 O
.	1558 1 O

These	1560 5 O
were	1566 4 O
associated	1571 10 O
with	1582 4 O
changes	1587 7 O
in	1595 2 O
dystrophin	1598 10 O
and	1609 3 O
cardiac	1613 7 O
troponin	1621 8 O
I	1630 1 O
localization	1632 12 O
,	1644 1 O
as	1646 2 O
well	1649 4 O
as	1654 2 O
loss	1657 4 O
of	1662 2 O
sarcolemmal	1665 11 O
integrity	1677 9 O
.	1686 1 O

CONCLUSIONS	1688 11 O
:	1699 1 O
The	1701 3 O
expression	1705 10 O
of	1716 2 O
Fas	1719 3 O
ligand	1723 6 O
in	1730 2 O
the	1733 3 O
myocardium	1737 10 O
,	1747 1 O
as	1749 2 O
identified	1752 10 O
in	1763 2 O
HIV	1766 3 O
-	1769 1 O
positive	1770 8 O
patients	1779 8 O
,	1787 1 O
might	1789 5 O
increase	1795 8 O
the	1804 3 O
susceptibility	1808 14 O
to	1823 2 O
HAART	1826 5 O
-	1831 1 O
induced	1832 7 O
cardiomyopathy	1840 14 B-Disease
due	1855 3 O
to	1859 2 O
activation	1862 10 O
of	1873 2 O
apoptotic	1876 9 O
pathways	1886 8 O
,	1894 1 O
resulting	1896 9 O
in	1906 2 O
cardiac	1909 7 B-Disease
dilation	1917 8 I-Disease
and	1926 3 I-Disease
dysfunction	1930 11 I-Disease
.	1941 1 O

Valproate	0 9 B-Chemical
-	9 1 O
induced	10 7 O
chorea	18 6 B-Disease
and	25 3 O
encephalopathy	29 14 B-Disease
in	44 2 O
atypical	47 8 O
nonketotic	56 10 B-Disease
hyperglycinemia	67 15 I-Disease
.	82 1 O

Nonketotic	84 10 B-Disease
hyperglycinemia	95 15 I-Disease
is	111 2 O
a	114 1 O
disorder	116 8 B-Disease
of	125 2 I-Disease
amino	128 5 I-Disease
acid	134 4 I-Disease
metabolism	139 10 I-Disease
in	150 2 O
which	153 5 O
a	159 1 O
defect	161 6 O
in	168 2 O
the	171 3 O
glycine	175 7 B-Chemical
cleavage	183 8 O
system	192 6 O
leads	199 5 O
to	205 2 O
an	208 2 O
accumulation	211 12 O
of	224 2 O
glycine	227 7 B-Chemical
in	235 2 O
the	238 3 O
brain	242 5 O
and	248 3 O
other	252 5 O
body	258 4 O
compartments	263 12 O
.	275 1 O

In	277 2 O
the	280 3 O
classical	284 9 O
form	294 4 O
it	299 2 O
presents	302 8 O
as	311 2 O
neonatal	314 8 O
apnea	323 5 B-Disease
,	328 1 O
intractable	330 11 O
seizures	342 8 B-Disease
,	350 1 O
and	352 3 O
hypotonia	356 9 B-Disease
,	365 1 O
followed	367 8 O
by	376 2 O
significant	379 11 O
psychomotor	391 11 B-Disease
retardation	403 11 I-Disease
.	414 1 O

An	416 2 O
important	419 9 O
subset	429 6 O
of	436 2 O
children	439 8 O
with	448 4 O
nonketotic	453 10 B-Disease
hyperglycinemia	464 15 I-Disease
are	480 3 O
atypical	484 8 O
variants	493 8 O
who	502 3 O
present	506 7 O
in	514 2 O
a	517 1 O
heterogeneous	519 13 O
manner	533 6 O
.	539 1 O

This	541 4 O
report	546 6 O
describes	553 9 O
a	563 1 O
patient	565 7 O
with	573 4 O
mild	578 4 O
language	583 8 B-Disease
delay	592 5 I-Disease
and	598 3 O
mental	602 6 B-Disease
retardation	609 11 I-Disease
,	620 1 O
who	622 3 O
was	626 3 O
found	630 5 O
to	636 2 O
have	639 4 O
nonketotic	644 10 B-Disease
hyperglycinemia	655 15 I-Disease
following	671 9 O
her	681 3 O
presentation	685 12 O
with	698 4 O
acute	703 5 O
encephalopathy	709 14 B-Disease
and	724 3 O
chorea	728 6 B-Disease
shortly	735 7 O
after	743 5 O
initiation	749 10 O
of	760 2 O
valproate	763 9 B-Chemical
therapy	773 7 O
.	780 1 O

Microinjection	0 14 O
of	15 2 O
ritanserin	18 10 B-Chemical
into	29 4 O
the	34 3 O
CA1	38 3 O
region	42 6 O
of	49 2 O
hippocampus	52 11 O
improves	64 8 O
scopolamine	73 11 B-Chemical
-	84 1 O
induced	85 7 O
amnesia	93 7 B-Disease
in	101 2 O
adult	104 5 O
male	110 4 O
rats	115 4 O
.	119 1 O

The	121 3 O
effect	125 6 O
of	132 2 O
ritanserin	135 10 B-Chemical
(	146 1 O
5	147 1 O
-	148 1 O
HT2	149 3 O
antagonist	153 10 O
)	163 1 O
on	165 2 O
scopolamine	168 11 B-Chemical
(	180 1 O
muscarinic	181 10 O
cholinergic	192 11 O
antagonist	204 10 O
)	214 1 O
-	215 1 O
induced	216 7 O
amnesia	224 7 B-Disease
in	232 2 O
Morris	235 6 O
water	242 5 O
maze	248 4 O
(	253 1 O
MWM	254 3 O
)	257 1 O
was	259 3 O
investigated	263 12 O
.	275 1 O

Rats	277 4 O
were	282 4 O
divided	287 7 O
into	295 4 O
eight	300 5 O
groups	306 6 O
and	313 3 O
bilaterally	317 11 O
cannulated	329 10 O
into	340 4 O
CA1	345 3 O
region	349 6 O
of	356 2 O
the	359 3 O
hippocampus	363 11 O
.	374 1 O

One	376 3 O
week	380 4 O
later	385 5 O
,	390 1 O
they	392 4 O
received	397 8 O
repeatedly	406 10 O
vehicles	417 8 O
(	426 1 O
saline	427 6 O
,	433 1 O
DMSO	435 4 B-Chemical
,	439 1 O
saline	441 6 O
+	447 1 O
DMSO	448 4 B-Chemical
)	452 1 O
,	453 1 O
scopolamine	455 11 B-Chemical
(	467 1 O
2	468 1 O
microg	470 6 O
/	476 1 O
0	477 1 O
.	478 1 O
5	479 1 O
microl	481 6 O
saline	488 6 O
/	494 1 O
side	495 4 O
;	499 1 O
30	501 2 O
min	504 3 O
before	508 6 O
training	515 8 O
)	523 1 O
,	524 1 O
ritanserin	526 10 B-Chemical
(	537 1 O
2	538 1 O
,	539 1 O
4	541 1 O
and	543 3 O
8	547 1 O
microg	549 6 O
/	555 1 O
0	556 1 O
.	557 1 O
5	558 1 O
microl	560 6 O
DMSO	567 4 B-Chemical
/	571 1 O
side	572 4 O
;	576 1 O
20	578 2 O
min	581 3 O
before	585 6 O
training	592 8 O
)	600 1 O
and	602 3 O
scopolamine	606 11 B-Chemical
(	618 1 O
2	619 1 O
microg	621 6 O
/	627 1 O
0	628 1 O
.	629 1 O
5	630 1 O
microl	632 6 O
;	638 1 O
30	640 2 O
min	643 3 O
before	647 6 O
ritanserin	654 10 B-Chemical
injection	665 9 O
)	674 1 O
+	675 1 O
ritanserin	676 10 B-Chemical
(	687 1 O
4	688 1 O
microg	690 6 O
/	696 1 O
0	697 1 O
.	698 1 O
5	699 1 O
microl	701 6 O
DMSO	708 4 B-Chemical
)	712 1 O
through	714 7 O
cannulae	722 8 O
each	731 4 O
day	736 3 O
.	739 1 O

Animals	741 7 O
were	749 4 O
tested	754 6 O
for	761 3 O
four	765 4 O
consecutive	770 11 O
days	782 4 O
(	787 1 O
4	788 1 O
trial	790 5 O
/	795 1 O
day	796 3 O
)	799 1 O
in	801 2 O
MWM	804 3 O
during	808 6 O
which	815 5 O
the	821 3 O
position	825 8 O
of	834 2 O
hidden	837 6 O
platform	844 8 O
was	853 3 O
unchanged	857 9 O
.	866 1 O

In	868 2 O
the	871 3 O
fifth	875 5 O
day	881 3 O
,	884 1 O
the	886 3 O
platform	890 8 O
was	899 3 O
elevated	903 8 O
above	912 5 O
the	918 3 O
water	922 5 O
surface	928 7 O
in	936 2 O
another	939 7 O
position	947 8 O
to	956 2 O
evaluate	959 8 O
the	968 3 O
function	972 8 O
of	981 2 O
motor	984 5 O
,	989 1 O
motivational	991 12 O
and	1004 3 O
visual	1008 6 O
systems	1015 7 O
.	1022 1 O

The	1024 3 O
results	1028 7 O
showed	1036 6 O
a	1043 1 O
significant	1045 11 O
increase	1057 8 O
in	1066 2 O
escape	1069 6 O
latencies	1076 9 O
and	1086 3 O
traveled	1090 8 O
distances	1099 9 O
to	1109 2 O
find	1112 4 O
platform	1117 8 O
in	1126 2 O
scopolamine	1129 11 B-Chemical
-	1140 1 O
treated	1141 7 O
group	1149 5 O
as	1155 2 O
compared	1158 8 O
to	1167 2 O
saline	1170 6 O
group	1177 5 O
.	1182 1 O

Ritanserin	1184 10 B-Chemical
-	1194 1 O
treated	1195 7 O
rats	1203 4 O
(	1208 1 O
4	1209 1 O
microg	1211 6 O
/	1217 1 O
0	1218 1 O
.	1219 1 O
5	1220 1 O
microl	1222 6 O
/	1228 1 O
side	1229 4 O
)	1233 1 O
showed	1235 6 O
a	1242 1 O
significant	1244 11 O
decrease	1256 8 O
in	1265 2 O
the	1268 3 O
mentioned	1272 9 O
parameters	1282 10 O
as	1293 2 O
compared	1296 8 O
to	1305 2 O
DMSO	1308 4 B-Chemical
-	1312 1 O
treated	1313 7 O
group	1321 5 O
.	1326 1 O

However	1328 7 O
,	1335 1 O
scopolamine	1337 11 B-Chemical
and	1349 3 O
ritanserin	1353 10 B-Chemical
co	1364 2 O
-	1366 1 O
administration	1367 14 O
resulted	1382 8 O
in	1391 2 O
a	1394 1 O
significant	1396 11 O
decrease	1408 8 O
in	1417 2 O
escape	1420 6 O
latencies	1427 9 O
and	1437 3 O
traveled	1441 8 O
distances	1450 9 O
as	1460 2 O
compared	1463 8 O
to	1472 2 O
the	1475 3 O
scopolamine	1479 11 B-Chemical
-	1490 1 O
treated	1491 7 O
rats	1499 4 O
.	1503 1 O

Our	1505 3 O
findings	1509 8 O
show	1518 4 O
that	1523 4 O
microinjection	1528 14 O
of	1543 2 O
ritanserin	1546 10 B-Chemical
into	1557 4 O
the	1562 3 O
CA1	1566 3 O
region	1570 6 O
of	1577 2 O
the	1580 3 O
hippocampus	1584 11 O
improves	1596 8 O
the	1605 3 O
scopolamine	1609 11 B-Chemical
-	1620 1 O
induced	1621 7 O
amnesia	1629 7 B-Disease
.	1636 1 O

Hypoxia	0 7 B-Disease
in	8 2 O
renal	11 5 B-Disease
disease	17 7 I-Disease
with	25 4 O
proteinuria	30 11 B-Disease
and	42 3 O
/	45 1 O
or	46 2 O
glomerular	49 10 O
hypertension	60 12 B-Disease
.	72 1 O

Despite	74 7 O
the	82 3 O
increasing	86 10 O
need	97 4 O
to	102 2 O
identify	105 8 O
and	114 3 O
quantify	118 8 O
tissue	127 6 O
oxygenation	134 11 O
at	146 2 O
the	149 3 O
cellular	153 8 O
level	162 5 O
,	167 1 O
relatively	169 10 O
few	180 3 O
methods	184 7 O
have	192 4 O
been	197 4 O
available	202 9 O
.	211 1 O

In	213 2 O
this	216 4 O
study	221 5 O
,	226 1 O
we	228 2 O
developed	231 9 O
a	241 1 O
new	243 3 O
hypoxia	247 7 B-Disease
-	254 1 O
responsive	255 10 O
reporter	266 8 O
vector	275 6 O
using	282 5 O
a	288 1 O
hypoxia	290 7 B-Disease
-	297 1 O
responsive	298 10 O
element	309 7 O
of	317 2 O
the	320 3 O
5	324 1 O
'	325 1 O
vascular	327 8 O
endothelial	336 11 O
growth	348 6 O
factor	355 6 O
untranslated	362 12 O
region	375 6 O
and	382 3 O
generated	386 9 O
a	396 1 O
novel	398 5 O
hypoxia	404 7 B-Disease
-	411 1 O
sensing	412 7 O
transgenic	420 10 O
rat	431 3 O
.	434 1 O

We	436 2 O
then	439 4 O
applied	444 7 O
this	452 4 O
animal	457 6 O
model	464 5 O
to	470 2 O
the	473 3 O
detection	477 9 O
of	487 2 O
tubulointerstitial	490 18 O
hypoxia	509 7 B-Disease
in	517 2 O
the	520 3 O
diseased	524 8 B-Disease
kidney	533 6 I-Disease
.	539 1 O

With	541 4 O
this	546 4 O
model	551 5 O
,	556 1 O
we	558 2 O
were	561 4 O
able	566 4 O
to	571 2 O
identify	574 8 O
diffuse	583 7 O
cortical	591 8 O
hypoxia	600 7 B-Disease
in	608 2 O
the	611 3 O
puromycin	615 9 B-Chemical
aminonucleoside	625 15 I-Chemical
-	640 1 O
induced	641 7 O
nephrotic	649 9 B-Disease
syndrome	659 8 I-Disease
and	668 3 O
focal	672 5 O
and	678 3 O
segmental	682 9 O
hypoxia	692 7 B-Disease
in	700 2 O
the	703 3 O
remnant	707 7 O
kidney	715 6 O
model	722 5 O
.	727 1 O

Expression	729 10 O
of	740 2 O
the	743 3 O
hypoxia	747 7 B-Disease
-	754 1 O
responsive	755 10 O
transgene	766 9 O
increased	776 9 O
throughout	786 10 O
the	797 3 O
observation	801 11 O
period	813 6 O
,	819 1 O
reaching	821 8 O
2	830 1 O
.	831 1 O
2	832 1 O
-	833 1 O
fold	834 4 O
at	839 2 O
2	842 1 O
weeks	844 5 O
in	850 2 O
the	853 3 O
puromycin	857 9 B-Chemical
aminonucleoside	867 15 I-Chemical
model	883 5 O
and	889 3 O
2	893 1 O
.	894 1 O
6	895 1 O
-	896 1 O
fold	897 4 O
at	902 2 O
4	905 1 O
weeks	907 5 O
in	913 2 O
the	916 3 O
remnant	920 7 O
kidney	928 6 O
model	935 5 O
,	940 1 O
whereas	942 7 O
that	950 4 O
of	955 2 O
vascular	958 8 O
endothelial	967 11 O
growth	979 6 O
factor	986 6 O
showed	993 6 O
a	1000 1 O
mild	1002 4 O
decrease	1007 8 O
,	1015 1 O
reflecting	1017 10 O
distinct	1028 8 O
behaviors	1037 9 O
of	1047 2 O
the	1050 3 O
two	1054 3 O
genes	1058 5 O
.	1063 1 O

The	1065 3 O
degree	1069 6 O
of	1076 2 O
hypoxia	1079 7 B-Disease
showed	1087 6 O
a	1094 1 O
positive	1096 8 O
correlation	1105 11 O
with	1117 4 O
microscopic	1122 11 O
tubulointerstitial	1134 18 B-Disease
injury	1153 6 I-Disease
in	1160 2 O
both	1163 4 O
models	1168 6 O
.	1174 1 O

Finally	1176 7 O
,	1183 1 O
we	1185 2 O
identified	1188 10 O
the	1199 3 O
localization	1203 12 O
of	1216 2 O
proliferating	1219 13 O
cell	1233 4 O
nuclear	1238 7 O
antigen	1246 7 O
-	1253 1 O
positive	1254 8 O
,	1262 1 O
ED	1264 2 O
-	1266 1 O
1	1267 1 O
-	1268 1 O
positive	1269 8 O
,	1277 1 O
and	1279 3 O
terminal	1283 8 O
dUTP	1292 4 O
nick	1297 4 O
-	1301 1 O
end	1302 3 O
labeled	1306 7 O
-	1313 1 O
positive	1314 8 O
cells	1323 5 O
in	1329 2 O
the	1332 3 O
hypoxic	1336 7 B-Disease
cortical	1344 8 O
area	1353 4 O
in	1358 2 O
the	1361 3 O
remnant	1365 7 O
kidney	1373 6 O
model	1380 5 O
.	1385 1 O

We	1387 2 O
propose	1390 7 O
here	1398 4 O
a	1403 1 O
possible	1405 8 O
pathological	1414 12 O
tie	1427 3 O
between	1431 7 O
chronic	1439 7 O
tubulointerstitial	1447 18 O
hypoxia	1466 7 B-Disease
and	1474 3 O
progressive	1478 11 O
glomerular	1490 10 B-Disease
diseases	1501 8 I-Disease
.	1509 1 O

Consensus	0 9 O
statement	10 9 O
concerning	20 10 O
cardiotoxicity	31 14 B-Disease
occurring	46 9 O
during	56 6 O
haematopoietic	63 14 O
stem	78 4 O
cell	83 4 O
transplantation	88 15 O
in	104 2 O
the	107 3 O
treatment	111 9 O
of	121 2 O
autoimmune	124 10 B-Disease
diseases	135 8 I-Disease
,	143 1 O
with	145 4 O
special	150 7 O
reference	158 9 O
to	168 2 O
systemic	171 8 B-Disease
sclerosis	180 9 I-Disease
and	190 3 O
multiple	194 8 B-Disease
sclerosis	203 9 I-Disease
.	212 1 O

Autologous	214 10 O
haematopoietic	225 14 O
stem	240 4 O
cell	245 4 O
transplantation	250 15 O
is	266 2 O
now	269 3 O
a	273 1 O
feasible	275 8 O
and	284 3 O
effective	288 9 O
treatment	298 9 O
for	308 3 O
selected	312 8 O
patients	321 8 O
with	330 4 O
severe	335 6 O
autoimmune	342 10 B-Disease
diseases	353 8 I-Disease
.	361 1 O

Worldwide	363 9 O
,	372 1 O
over	374 4 O
650	379 3 O
patients	383 8 O
have	392 4 O
been	397 4 O
transplanted	402 12 O
in	415 2 O
the	418 3 O
context	422 7 O
of	430 2 O
phase	433 5 O
I	439 1 O
and	441 3 O
II	445 2 O
clinical	448 8 O
trials	457 6 O
.	463 1 O

The	465 3 O
results	469 7 O
are	477 3 O
encouraging	481 11 O
enough	493 6 O
to	500 2 O
begin	503 5 O
randomised	509 10 O
phase	520 5 O
III	526 3 O
trials	530 6 O
.	536 1 O

However	538 7 O
,	545 1 O
as	547 2 O
predicted	550 9 O
,	559 1 O
significant	561 11 O
transplant	573 10 O
-	583 1 O
related	584 7 O
morbidity	592 9 O
and	602 3 O
mortality	606 9 O
have	616 4 O
been	621 4 O
observed	626 8 O
.	634 1 O

This	636 4 O
is	641 2 O
primarily	644 9 O
due	654 3 O
to	658 2 O
complications	661 13 O
related	675 7 O
to	683 2 O
either	686 6 O
the	693 3 O
stage	697 5 O
of	703 2 O
the	706 3 O
disease	710 7 O
at	718 2 O
transplant	721 10 O
or	732 2 O
due	735 3 O
to	739 2 O
infections	742 10 B-Disease
.	752 1 O

The	754 3 O
number	758 6 O
of	765 2 O
deaths	768 6 O
related	775 7 O
to	783 2 O
cardiac	786 7 B-Disease
toxicity	794 8 I-Disease
is	803 2 O
low	806 3 O
.	809 1 O

However	811 7 O
,	818 1 O
caution	820 7 O
is	828 2 O
required	831 8 O
when	840 4 O
cyclophosphamide	845 16 B-Chemical
or	862 2 O
anthracyclines	865 14 B-Chemical
such	880 4 O
as	885 2 O
mitoxantrone	888 12 B-Chemical
are	901 3 O
used	905 4 O
in	910 2 O
patients	913 8 O
with	922 4 O
a	927 1 O
possible	929 8 O
underlying	938 10 O
heart	949 5 B-Disease
damage	955 6 I-Disease
,	961 1 O
for	963 3 O
example	967 7 O
,	974 1 O
systemic	976 8 B-Disease
sclerosis	985 9 I-Disease
patients	995 8 O
.	1003 1 O

In	1005 2 O
November	1008 8 O
2002	1017 4 O
,	1021 1 O
a	1023 1 O
meeting	1025 7 O
was	1033 3 O
held	1037 4 O
in	1042 2 O
Florence	1045 8 O
,	1053 1 O
bringing	1055 8 O
together	1064 8 O
a	1073 1 O
number	1075 6 O
of	1082 2 O
experts	1085 7 O
in	1093 2 O
various	1096 7 O
fields	1104 6 O
,	1110 1 O
including	1112 9 O
rheumatology	1122 12 O
,	1134 1 O
cardiology	1136 10 O
,	1146 1 O
neurology	1148 9 O
,	1157 1 O
pharmacology	1159 12 O
and	1172 3 O
transplantation	1176 15 O
medicine	1192 8 O
.	1200 1 O

The	1202 3 O
object	1206 6 O
of	1213 2 O
the	1216 3 O
meeting	1220 7 O
was	1228 3 O
to	1232 2 O
analyse	1235 7 O
existing	1243 8 O
data	1252 4 O
,	1256 1 O
both	1258 4 O
published	1263 9 O
or	1273 2 O
available	1276 9 O
,	1285 1 O
in	1287 2 O
the	1290 3 O
European	1294 8 O
Group	1303 5 O
for	1309 3 O
Blood	1313 5 O
and	1319 3 O
Marrow	1323 6 O
Transplantation	1330 15 O
autoimmune	1346 10 B-Disease
disease	1357 7 I-Disease
database	1365 8 O
,	1373 1 O
and	1375 3 O
to	1379 2 O
propose	1382 7 O
a	1390 1 O
safe	1392 4 O
approach	1397 8 O
to	1406 2 O
such	1409 4 O
patients	1414 8 O
.	1422 1 O

A	1424 1 O
full	1426 4 O
cardiological	1431 13 O
assessment	1445 10 O
before	1456 6 O
and	1463 3 O
during	1467 6 O
the	1474 3 O
transplant	1478 10 O
emerged	1489 7 O
as	1497 2 O
the	1500 3 O
major	1504 5 O
recommendation	1510 14 O
.	1524 1 O

Immunohistochemical	0 19 O
study	20 5 O
on	26 2 O
inducible	29 9 O
type	39 4 O
of	44 2 O
nitric	47 6 B-Chemical
oxide	54 5 I-Chemical
(	60 1 O
iNOS	61 4 O
)	65 1 O
,	66 1 O
basic	68 5 O
fibroblast	74 10 O
growth	85 6 O
factor	92 6 O
(	99 1 O
bFGF	100 4 O
)	104 1 O
and	106 3 O
tumor	110 5 B-Disease
growth	116 6 O
factor	123 6 O
-	129 1 O
beta1	130 5 O
(	136 1 O
TGF	137 3 O
-	140 1 O
beta1	141 5 O
)	146 1 O
in	148 2 O
arteritis	151 9 B-Disease
induced	161 7 O
in	169 2 O
rats	172 4 O
by	177 2 O
fenoldopam	180 10 B-Chemical
and	191 3 O
theophylline	195 12 B-Chemical
,	207 1 O
vasodilators	209 12 O
.	221 1 O

Arteritis	223 9 B-Disease
induced	233 7 O
in	241 2 O
rats	244 4 O
by	249 2 O
vasodilators	252 12 O
,	264 1 O
fenoldopam	266 10 B-Chemical
and	277 3 O
theophylline	281 12 B-Chemical
,	293 1 O
was	295 3 O
examined	299 8 O
immunohistochemically	308 21 O
for	330 3 O
expressions	334 11 O
of	346 2 O
inducible	349 9 O
type	359 4 O
of	364 2 O
nitric	367 6 B-Chemical
oxide	374 5 I-Chemical
synthase	380 8 O
(	389 1 O
iNOS	390 4 O
)	394 1 O
,	395 1 O
basic	397 5 O
fibroblast	403 10 O
growth	414 6 O
factor	421 6 O
(	428 1 O
bFGF	429 4 O
)	433 1 O
and	435 3 O
tumor	439 5 B-Disease
growth	445 6 O
factor	452 6 O
-	458 1 O
beta1	459 5 O
(	465 1 O
TGF	466 3 O
-	469 1 O
beta1	470 5 O
)	475 1 O
.	476 1 O

Rats	478 4 O
were	483 4 O
administered	488 12 O
fenoldopam	501 10 B-Chemical
for	512 3 O
24	516 2 O
hours	519 5 O
by	525 2 O
intravenous	528 11 O
infusion	540 8 O
with	549 4 O
or	554 2 O
without	557 7 O
following	565 9 O
repeated	575 8 O
daily	584 5 O
oral	590 4 O
administrations	595 15 O
of	611 2 O
theophylline	614 12 B-Chemical
.	626 1 O

Irrespective	628 12 O
of	641 2 O
theophylline	644 12 B-Chemical
administration	657 14 O
,	671 1 O
iNOS	673 4 O
antigens	678 8 O
were	687 4 O
remarkably	692 10 O
abundant	703 8 O
in	712 2 O
ED	715 2 O
-	717 1 O
1	718 1 O
-	719 1 O
positive	720 8 O
cells	729 5 O
on	735 2 O
day	738 3 O
5	742 1 O
and	744 3 O
8	748 1 O
post	750 4 O
-	754 1 O
fenoldopam	755 10 B-Chemical
-	765 1 O
infusion	766 8 O
(	775 1 O
DPI	776 3 O
)	779 1 O
;	780 1 O
bFGF	782 4 O
antigens	787 8 O
were	796 4 O
remarkably	801 10 O
abundant	812 8 O
in	821 2 O
ED	824 2 O
-	826 1 O
1	827 1 O
-	828 1 O
positive	829 8 O
cells	838 5 O
on	844 2 O
1	847 1 O
and	849 3 O
3	853 1 O
DPI	855 3 O
;	858 1 O
TGF	860 3 O
-	863 1 O
beta1	864 5 O
antigens	870 8 O
were	879 4 O
observed	884 8 O
in	893 2 O
ED	896 2 O
-	898 1 O
1	899 1 O
-	900 1 O
positive	901 8 O
cells	910 5 O
on	916 2 O
and	919 3 O
after	923 5 O
5	929 1 O
DPI	931 3 O
.	934 1 O

These	936 5 O
results	942 7 O
suggest	950 7 O
that	958 4 O
the	963 3 O
peak	967 4 O
expression	972 10 O
of	983 2 O
iNOS	986 4 O
antigen	991 7 O
was	999 3 O
followed	1003 8 O
by	1012 2 O
that	1015 4 O
of	1020 2 O
bFGF	1023 4 O
antigen	1028 7 O
,	1035 1 O
and	1037 3 O
bFGF	1041 4 O
may	1046 3 O
have	1050 4 O
a	1055 1 O
suppressive	1057 11 O
effect	1069 6 O
on	1076 2 O
iNOS	1079 4 O
expression	1084 10 O
in	1095 2 O
these	1098 5 O
rat	1104 3 O
arteritis	1108 9 B-Disease
models	1118 6 O
.	1124 1 O

On	1126 2 O
the	1129 3 O
other	1133 5 O
hand	1139 4 O
,	1143 1 O
TGF	1145 3 O
-	1148 1 O
beta1	1149 5 O
was	1155 3 O
not	1159 3 O
considered	1163 10 O
to	1174 2 O
have	1177 4 O
a	1182 1 O
suppressive	1184 11 O
effect	1196 6 O
on	1203 2 O
iNOS	1206 4 O
expression	1211 10 O
in	1222 2 O
these	1225 5 O
models	1231 6 O
.	1237 1 O

Low	0 3 B-Chemical
-	3 1 I-Chemical
molecular	4 9 I-Chemical
-	13 1 I-Chemical
weight	14 6 I-Chemical
heparin	21 7 I-Chemical
for	29 3 O
the	33 3 O
treatment	37 9 O
of	47 2 O
patients	50 8 O
with	59 4 O
mechanical	64 10 O
heart	75 5 O
valves	81 6 O
.	87 1 O

BACKGROUND	89 10 O
:	99 1 O
The	101 3 O
interruption	105 12 O
of	118 2 O
oral	121 4 O
anticoagulant	126 13 O
(	140 1 O
OAC	141 3 O
)	144 1 O
administration	146 14 O
is	161 2 O
sometimes	164 9 O
indicated	174 9 O
in	184 2 O
patients	187 8 O
with	196 4 O
mechanical	201 10 O
heart	212 5 O
valves	218 6 O
,	224 1 O
mainly	226 6 O
before	233 6 O
noncardiac	240 10 O
surgery	251 7 O
,	258 1 O
non	260 3 O
-	263 1 O
surgical	264 8 O
interventions	273 13 O
,	286 1 O
and	288 3 O
pregnancy	292 9 O
.	301 1 O

Unfractionated	303 14 B-Chemical
heparin	318 7 I-Chemical
(	326 1 O
UH	327 2 B-Chemical
)	329 1 O
is	331 2 O
currently	334 9 O
the	344 3 O
substitute	348 10 O
for	359 3 O
selected	363 8 O
patients	372 8 O
.	380 1 O

Low	382 3 B-Chemical
-	385 1 I-Chemical
molecular	386 9 I-Chemical
-	395 1 I-Chemical
weight	396 6 I-Chemical
heparin	403 7 I-Chemical
(	411 1 O
LMWH	412 4 B-Chemical
)	416 1 O
offers	418 6 O
theoretical	425 11 O
advantages	437 10 O
over	448 4 O
UH	453 2 B-Chemical
,	455 1 O
but	457 3 O
is	461 2 O
not	464 3 O
currently	468 9 O
considered	478 10 O
in	489 2 O
clinical	492 8 O
guidelines	501 10 O
as	512 2 O
an	515 2 O
alternative	518 11 O
to	530 2 O
UH	533 2 B-Chemical
in	536 2 O
patients	539 8 O
with	548 4 O
prosthetic	553 10 O
valves	564 6 O
.	570 1 O

HYPOTHESIS	572 10 O
:	582 1 O
The	584 3 O
aim	588 3 O
of	592 2 O
the	595 3 O
present	599 7 O
study	607 5 O
was	613 3 O
to	617 2 O
review	620 6 O
the	627 3 O
data	631 4 O
accumulated	636 11 O
so	648 2 O
far	651 3 O
on	655 2 O
the	658 3 O
use	662 3 O
of	666 2 O
LMWH	669 4 B-Chemical
in	674 2 O
this	677 4 O
patient	682 7 O
population	690 10 O
and	701 3 O
to	705 2 O
discuss	708 7 O
its	716 3 O
applicability	720 13 O
in	734 2 O
common	737 6 O
practice	744 8 O
.	752 1 O

METHODS	754 7 O
:	761 1 O
For	763 3 O
this	767 4 O
paper	772 5 O
,	777 1 O
the	779 3 O
current	783 7 O
medical	791 7 O
literature	799 10 O
on	810 2 O
LMWH	813 4 B-Chemical
in	818 2 O
patients	821 8 O
with	830 4 O
mechanical	835 10 O
heart	846 5 O
valves	852 6 O
was	859 3 O
extensively	863 11 O
reviewed	875 8 O
.	883 1 O

RESULTS	885 7 O
:	892 1 O
There	894 5 O
were	900 4 O
eight	905 5 O
series	911 6 O
and	918 3 O
six	922 3 O
case	926 4 O
reports	931 7 O
.	938 1 O

None	940 4 O
of	945 2 O
the	948 3 O
studies	952 7 O
was	960 3 O
randomized	964 10 O
,	974 1 O
and	976 3 O
only	980 4 O
one	985 3 O
was	989 3 O
prospective	993 11 O
.	1004 1 O

Data	1006 4 O
to	1011 2 O
establish	1014 9 O
the	1024 3 O
thromboembolic	1028 14 B-Disease
risk	1043 4 O
were	1048 4 O
incomplete	1053 10 O
.	1063 1 O

After	1065 5 O
excluding	1071 9 O
case	1081 4 O
reports	1086 7 O
,	1093 1 O
the	1095 3 O
following	1099 9 O
groups	1109 6 O
were	1116 4 O
constructed	1121 11 O
:	1132 1 O
(	1134 1 O
a	1135 1 O
)	1136 1 O
short	1138 5 O
-	1143 1 O
term	1144 4 O
administration	1149 14 O
,	1163 1 O
after	1165 5 O
valve	1171 5 O
insertion	1177 9 O
(	1187 1 O
n	1188 1 O
=	1190 1 O
212	1192 3 O
)	1195 1 O
;	1196 1 O
(	1198 1 O
b	1199 1 O
)	1200 1 O
short	1202 5 O
-	1207 1 O
term	1208 4 O
,	1212 1 O
perioperative	1214 13 O
(	1228 1 O
noncardiac	1229 10 O
)	1239 1 O
/	1240 1 O
periprocedural	1241 14 O
(	1256 1 O
n	1257 1 O
=	1259 1 O
114	1261 3 O
)	1264 1 O
;	1265 1 O
(	1267 1 O
c	1268 1 O
)	1269 1 O
long	1271 4 O
-	1275 1 O
term	1276 4 O
,	1280 1 O
due	1282 3 O
to	1286 2 O
intolerance	1289 11 O
to	1301 2 O
OAC	1304 3 O
(	1308 1 O
n	1309 1 O
=	1311 1 O
16	1313 2 O
)	1315 1 O
;	1316 1 O
(	1318 1 O
d	1319 1 O
)	1320 1 O
long	1322 4 O
-	1326 1 O
term	1327 4 O
,	1331 1 O
in	1333 2 O
pregnancy	1336 9 O
(	1346 1 O
n	1347 1 O
=	1349 1 O
10	1351 2 O
)	1353 1 O
.	1354 1 O

The	1356 3 O
incidence	1360 9 O
rate	1370 4 O
of	1375 2 O
thromboembolism	1378 15 B-Disease
was	1394 3 O
0	1398 1 O
.	1399 1 O
9	1400 1 O
%	1401 1 O
for	1403 3 O
all	1407 3 O
the	1411 3 O
studies	1415 7 O
and	1423 3 O
0	1427 1 O
.	1428 1 O
5	1429 1 O
,	1430 1 O
0	1432 1 O
,	1433 1 O
20	1435 2 O
,	1437 1 O
and	1439 3 O
0	1443 1 O
%	1444 1 O
in	1446 2 O
groups	1449 6 O
a	1456 1 O
,	1457 1 O
b	1459 1 O
,	1460 1 O
c	1462 1 O
,	1463 1 O
and	1465 3 O
d	1469 1 O
,	1470 1 O
respectively	1472 12 O
;	1484 1 O
for	1486 3 O
hemorrhage	1490 10 B-Disease
,	1500 1 O
the	1502 3 O
overall	1506 7 O
rate	1514 4 O
was	1519 3 O
3	1523 1 O
.	1524 1 O
4	1525 1 O
%	1526 1 O
(	1528 1 O
3	1529 1 O
.	1530 1 O
8	1531 1 O
,	1532 1 O
2	1534 1 O
.	1535 1 O
6	1536 1 O
,	1537 1 O
10	1539 2 O
,	1541 1 O
and	1543 3 O
0	1547 1 O
%	1548 1 O
for	1550 3 O
the	1554 3 O
respective	1558 10 O
groups	1569 6 O
)	1575 1 O
.	1576 1 O

CONCLUSIONS	1578 11 O
:	1589 1 O
In	1591 2 O
patients	1594 8 O
with	1603 4 O
mechanical	1608 10 O
heart	1619 5 O
valves	1625 6 O
,	1631 1 O
short	1633 5 O
-	1638 1 O
term	1639 4 O
LMWH	1644 4 B-Chemical
therapy	1649 7 O
compares	1657 8 O
favorably	1666 9 O
with	1676 4 O
UH	1681 2 B-Chemical
.	1683 1 O

Data	1685 4 O
on	1690 2 O
mid	1693 3 O
-	1696 1 O
and	1698 3 O
long	1702 4 O
-	1706 1 O
term	1707 4 O
LMWH	1712 4 B-Chemical
administration	1717 14 O
in	1732 2 O
these	1735 5 O
patients	1741 8 O
are	1750 3 O
sparse	1754 6 O
.	1760 1 O

Further	1762 7 O
randomized	1770 10 O
studies	1781 7 O
are	1789 3 O
needed	1793 6 O
to	1800 2 O
confirm	1803 7 O
the	1811 3 O
safety	1815 6 O
and	1822 3 O
precise	1826 7 O
indications	1834 11 O
for	1846 3 O
the	1850 3 O
use	1854 3 O
of	1858 2 O
LMWH	1861 4 B-Chemical
in	1866 2 O
patients	1869 8 O
with	1878 4 O
mechanical	1883 10 O
heart	1894 5 O
valves	1900 6 O
.	1906 1 O

Topiramate	0 10 B-Chemical
-	10 1 O
induced	11 7 O
nephrolithiasis	19 15 B-Disease
.	34 1 O

Topiramate	36 10 B-Chemical
is	47 2 O
a	50 1 O
recently	52 8 O
developed	61 9 O
antiepileptic	71 13 O
medication	85 10 O
that	96 4 O
is	101 2 O
becoming	104 8 O
more	113 4 O
widely	118 6 O
prescribed	125 10 O
because	136 7 O
of	144 2 O
its	147 3 O
efficacy	151 8 O
in	160 2 O
treating	163 8 O
refractory	172 10 B-Disease
seizures	183 8 I-Disease
.	191 1 O

Urologists	193 10 O
should	204 6 O
be	211 2 O
aware	214 5 O
that	220 4 O
this	225 4 O
medication	230 10 O
can	241 3 O
cause	245 5 O
metabolic	251 9 B-Disease
acidosis	261 8 I-Disease
in	270 2 O
patients	273 8 O
secondary	282 9 O
to	292 2 O
inhibition	295 10 O
of	306 2 O
carbonic	309 8 O
anhydrase	318 9 O
.	327 1 O

In	329 2 O
addition	332 8 O
,	340 1 O
a	342 1 O
distal	344 6 O
tubular	351 7 O
acidification	359 13 O
defect	373 6 O
may	380 3 O
result	384 6 O
,	390 1 O
thus	392 4 O
impairing	397 9 O
the	407 3 O
normal	411 6 O
compensatory	418 12 O
drop	431 4 O
in	436 2 O
urine	439 5 O
pH	445 2 O
.	447 1 O

These	449 5 O
factors	455 7 O
can	463 3 O
lead	467 4 O
to	472 2 O
the	475 3 O
development	479 11 O
of	491 2 O
calcium	494 7 B-Chemical
phosphate	502 9 I-Chemical
nephrolithiasis	512 15 B-Disease
.	527 1 O

We	529 2 O
report	532 6 O
the	539 3 O
first	543 5 O
two	549 3 O
cases	553 5 O
of	559 2 O
topiramate	562 10 B-Chemical
-	572 1 O
induced	573 7 O
nephrolithiasis	581 15 B-Disease
in	597 2 O
the	600 3 O
urologic	604 8 O
literature	613 10 O
.	623 1 O

Spironolactone	0 14 B-Chemical
:	14 1 O
is	16 2 O
it	19 2 O
a	22 1 O
novel	24 5 O
drug	30 4 O
for	35 3 O
the	39 3 O
prevention	43 10 O
of	54 2 O
amphotericin	57 12 B-Chemical
B	70 1 I-Chemical
-	71 1 O
related	72 7 O
hypokalemia	80 11 B-Disease
in	92 2 O
cancer	95 6 B-Disease
patients	102 8 O
?	110 1 O

OBJECTIVE	112 9 O
:	121 1 O
Nephrotoxicity	123 14 B-Disease
is	138 2 O
the	141 3 O
major	145 5 O
adverse	151 7 O
effect	159 6 O
of	166 2 O
amphotericin	169 12 B-Chemical
B	182 1 I-Chemical
(	184 1 O
AmB	185 3 B-Chemical
)	188 1 O
,	189 1 O
often	191 5 O
limiting	197 8 O
administration	206 14 O
of	221 2 O
full	224 4 O
dosage	229 6 O
.	235 1 O

Selective	237 9 O
distal	247 6 O
tubular	254 7 O
epithelial	262 10 O
toxicity	273 8 B-Disease
seems	282 5 O
to	288 2 O
be	291 2 O
responsible	294 11 O
for	306 3 O
the	310 3 O
profound	314 8 O
potassium	323 9 B-Chemical
wasting	333 7 O
that	341 4 O
is	346 2 O
a	349 1 O
major	351 5 O
clinical	357 8 O
side	366 4 O
effect	371 6 O
of	378 2 O
treatment	381 9 O
with	391 4 O
AmB	396 3 B-Chemical
.	399 1 O

Potassium	401 9 B-Chemical
depletion	411 9 O
also	421 4 O
potentiates	426 11 O
the	438 3 O
tubular	442 7 O
toxicity	450 8 B-Disease
of	459 2 O
AmB	462 3 B-Chemical
.	465 1 O

This	467 4 O
study	472 5 O
was	478 3 O
designed	482 8 O
to	491 2 O
assess	494 6 O
the	501 3 O
ability	505 7 O
of	513 2 O
spironolactone	516 14 B-Chemical
to	531 2 O
reduce	534 6 O
potassium	541 9 B-Chemical
requirements	551 12 O
and	564 3 O
to	568 2 O
prevent	571 7 O
hypokalemia	579 11 B-Disease
in	591 2 O
neutropenic	594 11 B-Disease
patients	606 8 O
on	615 2 O
AmB	618 3 B-Chemical
treatment	622 9 O
.	631 1 O

METHODS	633 7 O
:	640 1 O
In	642 2 O
this	645 4 O
study	650 5 O
26	656 2 O
patients	659 8 O
with	668 4 O
various	673 7 O
hematological	681 13 B-Disease
disorders	695 9 I-Disease
were	705 4 O
randomized	710 10 O
to	721 2 O
receive	724 7 O
either	732 6 O
intravenous	739 11 O
AmB	751 3 B-Chemical
alone	755 5 O
or	761 2 O
AmB	764 3 B-Chemical
and	768 3 O
oral	772 4 O
spironolactone	777 14 B-Chemical
100	792 3 O
mg	796 2 O
twice	799 5 O
daily	805 5 O
when	811 4 O
developing	816 10 O
a	827 1 O
proven	829 6 O
or	836 2 O
suspected	839 9 O
fungal	849 6 B-Disease
infection	856 9 I-Disease
.	865 1 O

RESULTS	867 7 O
:	874 1 O
Patients	876 8 O
receiving	885 9 O
concomitant	895 11 O
AmB	907 3 B-Chemical
and	911 3 O
spironolactone	915 14 B-Chemical
had	930 3 O
significantly	934 13 O
higher	948 6 O
plasma	955 6 O
potassium	962 9 B-Chemical
levels	972 6 O
than	979 4 O
those	984 5 O
receiving	990 9 O
AmB	1000 3 B-Chemical
alone	1004 5 O
(	1010 1 O
P	1011 1 O
=	1013 1 O
0	1015 1 O
.	1016 1 O
0027	1017 4 O
)	1021 1 O
.	1022 1 O

Those	1024 5 O
patients	1030 8 O
receiving	1039 9 O
AmB	1049 3 B-Chemical
and	1053 3 O
spironolactone	1057 14 B-Chemical
required	1072 8 O
significantly	1081 13 O
less	1095 4 O
potassium	1100 9 B-Chemical
supplementation	1110 15 O
to	1126 2 O
maintain	1129 8 O
their	1138 5 O
plasma	1144 6 O
potassium	1151 9 B-Chemical
within	1161 6 O
the	1168 3 O
normal	1172 6 O
range	1179 5 O
(	1185 1 O
P	1186 1 O
=	1188 1 O
0	1190 1 O
.	1191 1 O
022	1192 3 O
)	1195 1 O
.	1196 1 O

Moreover	1198 8 O
,	1206 1 O
urinary	1208 7 O
potassium	1216 9 B-Chemical
losses	1226 6 O
were	1233 4 O
significantly	1238 13 O
less	1252 4 O
in	1257 2 O
patients	1260 8 O
receiving	1269 9 O
AmB	1279 3 B-Chemical
and	1283 3 O
spironolactone	1287 14 B-Chemical
than	1302 4 O
those	1307 5 O
receiving	1313 9 O
AmB	1323 3 B-Chemical
alone	1327 5 O
(	1333 1 O
P	1334 1 O
=	1336 1 O
0	1338 1 O
.	1339 1 O
040	1340 3 O
)	1343 1 O
.	1344 1 O

CONCLUSION	1346 10 O
:	1356 1 O
This	1358 4 O
study	1363 5 O
showed	1369 6 O
that	1376 4 O
spironolactone	1381 14 B-Chemical
can	1396 3 O
reduce	1400 6 O
potassium	1407 9 B-Chemical
requirements	1417 12 O
and	1430 3 O
prevent	1434 7 O
hypokalemia	1442 11 B-Disease
by	1454 2 O
reducing	1457 8 O
urinary	1466 7 O
potassium	1474 9 B-Chemical
loss	1484 4 O
in	1489 2 O
neutropenic	1492 11 B-Disease
patients	1504 8 O
on	1513 2 O
AmB	1516 3 B-Chemical
treatment	1520 9 O
.	1529 1 O

Dopamine	0 8 B-Chemical
D2	9 2 O
receptor	12 8 O
signaling	21 9 O
controls	31 8 O
neuronal	40 8 O
cell	49 4 O
death	54 5 O
induced	60 7 O
by	68 2 O
muscarinic	71 10 O
and	82 3 O
glutamatergic	86 13 O
drugs	100 5 O
.	105 1 O

Dopamine	107 8 B-Chemical
(	116 1 O
DA	117 2 B-Chemical
)	119 1 O
,	120 1 O
through	122 7 O
D1	130 2 O
/	132 1 O
D2	133 2 O
receptor	136 8 O
-	144 1 O
mediated	145 8 O
signaling	154 9 O
,	163 1 O
plays	165 5 O
a	171 1 O
major	173 5 O
role	179 4 O
in	184 2 O
the	187 3 O
control	191 7 O
of	199 2 O
epileptic	202 9 B-Disease
seizures	212 8 I-Disease
arising	221 7 O
in	229 2 O
the	232 3 O
limbic	236 6 O
system	243 6 O
.	249 1 O

Excitotoxicity	251 14 B-Disease
leading	266 7 O
to	274 2 O
neuronal	277 8 O
cell	286 4 O
death	291 5 O
in	297 2 O
the	300 3 O
affected	304 8 O
areas	313 5 O
is	319 2 O
a	322 1 O
major	324 5 O
consequence	330 11 O
of	342 2 O
seizures	345 8 B-Disease
at	354 2 O
the	357 3 O
cellular	361 8 O
level	370 5 O
.	375 1 O

In	377 2 O
this	380 4 O
respect	385 7 O
,	392 1 O
little	394 6 O
is	401 2 O
known	404 5 O
about	410 5 O
the	416 3 O
role	420 4 O
of	425 2 O
DA	428 2 B-Chemical
receptors	431 9 O
in	441 2 O
the	444 3 O
occurrence	448 10 O
of	459 2 O
epilepsy	462 8 B-Disease
-	470 1 O
induced	471 7 O
neuronal	479 8 O
cell	488 4 O
death	493 5 O
.	498 1 O

Here	500 4 O
we	505 2 O
analyze	508 7 O
the	516 3 O
occurrence	520 10 O
of	531 2 O
seizures	534 8 B-Disease
and	543 3 O
neurotoxicity	547 13 B-Disease
in	561 2 O
D2R	564 3 O
-	568 1 O
/	569 1 O
-	570 1 O
mice	572 4 O
treated	577 7 O
with	585 4 O
the	590 3 O
cholinergic	594 11 O
agonist	606 7 O
pilocarpine	614 11 B-Chemical
.	625 1 O

We	627 2 O
compared	630 8 O
these	639 5 O
results	645 7 O
with	653 4 O
those	658 5 O
previously	664 10 O
obtained	675 8 O
with	684 4 O
kainic	689 6 B-Chemical
acid	696 4 I-Chemical
(	701 1 O
KA	702 2 B-Chemical
)	704 1 O
,	705 1 O
a	707 1 O
potent	709 6 O
glutamate	716 9 B-Chemical
agonist	726 7 O
.	733 1 O

Importantly	735 11 O
,	746 1 O
D2R	748 3 O
-	752 1 O
/	753 1 O
-	754 1 O
mice	756 4 O
develop	761 7 O
seizures	769 8 B-Disease
at	778 2 O
doses	781 5 O
of	787 2 O
both	790 4 O
drugs	795 5 O
that	801 4 O
are	806 3 O
not	810 3 O
epileptogenic	814 13 O
for	828 3 O
WT	832 2 O
littermates	835 11 O
and	847 3 O
show	851 4 O
greater	856 7 O
neurotoxicity	864 13 B-Disease
.	877 1 O

However	879 7 O
,	886 1 O
pilocarpine	888 11 B-Chemical
-	899 1 O
induced	900 7 O
seizures	908 8 B-Disease
result	917 6 O
in	924 2 O
a	927 1 O
more	929 4 O
widespread	934 10 O
neuronal	945 8 O
death	954 5 O
in	960 2 O
both	963 4 O
WT	968 2 O
and	971 3 O
D2R	975 3 O
-	979 1 O
/	980 1 O
-	981 1 O
brains	983 6 O
in	990 2 O
comparison	993 10 O
to	1004 2 O
KA	1007 2 B-Chemical
.	1009 1 O

Thus	1011 4 O
,	1015 1 O
the	1017 3 O
absence	1021 7 O
of	1029 2 O
D2R	1032 3 O
lowers	1036 6 O
the	1043 3 O
threshold	1047 9 O
for	1057 3 O
seizures	1061 8 B-Disease
induced	1070 7 O
by	1078 2 O
both	1081 4 O
glutamate	1086 9 B-Chemical
and	1096 3 O
acetylcholine	1100 13 B-Chemical
.	1113 1 O

Moreover	1115 8 O
,	1123 1 O
the	1125 3 O
dopaminergic	1129 12 O
control	1142 7 O
of	1150 2 O
epilepsy	1153 8 B-Disease
-	1161 1 O
induced	1162 7 O
neurodegeneration	1170 17 B-Disease
seems	1188 5 O
to	1194 2 O
be	1197 2 O
mediated	1200 8 O
by	1209 2 O
distinct	1212 8 O
interactions	1221 12 O
of	1234 2 O
D2R	1237 3 O
signaling	1241 9 O
with	1251 4 O
these	1256 5 O
two	1262 3 O
neurotransmitters	1266 17 O
.	1283 1 O

Treatment	0 9 O
of	10 2 O
risperidone	13 11 B-Chemical
-	24 1 O
induced	25 7 O
hyperprolactinemia	33 18 B-Disease
with	52 4 O
a	57 1 O
dopamine	59 8 B-Chemical
agonist	68 7 O
in	76 2 O
children	79 8 O
.	87 1 O

BACKGROUND	89 10 O
:	99 1 O
Risperidone	101 11 B-Chemical
,	112 1 O
a	114 1 O
potent	116 6 O
antagonist	123 10 O
of	134 2 O
both	137 4 O
serotonergic	142 12 O
(	155 1 O
5HT2A	156 5 O
)	161 1 O
and	163 3 O
dopaminergic	167 12 O
D2	180 2 O
receptors	183 9 O
is	193 2 O
associated	196 10 O
with	207 4 O
hyperprolactinemia	212 18 B-Disease
in	231 2 O
adults	234 6 O
and	241 3 O
children	245 8 O
.	253 1 O

Chronically	255 11 O
elevated	267 8 O
prolactin	276 9 O
levels	286 6 O
in	293 2 O
children	296 8 O
with	305 4 O
prolactinomas	310 13 B-Disease
may	324 3 O
be	328 2 O
associated	331 10 O
with	342 4 O
arrested	347 8 O
growth	356 6 O
and	363 3 O
development	367 11 O
resulting	379 9 O
in	389 2 O
either	392 6 O
delayed	399 7 B-Disease
puberty	407 7 I-Disease
or	415 2 O
short	418 5 O
stature	424 7 O
.	431 1 O

These	433 5 O
possibilities	439 13 O
stress	453 6 O
the	460 3 O
importance	464 10 O
of	475 2 O
developing	478 10 O
a	489 1 O
safe	491 4 O
and	496 3 O
effective	500 9 O
approach	510 8 O
to	519 2 O
drug	522 4 O
-	526 1 O
induced	527 7 O
hyperprolactinemia	535 18 B-Disease
in	554 2 O
youth	557 5 O
.	562 1 O

We	564 2 O
report	567 6 O
the	574 3 O
successful	578 10 O
treatment	589 9 O
of	599 2 O
risperidone	602 11 B-Chemical
-	613 1 O
induced	614 7 O
hyperprolactinemia	622 18 B-Disease
with	641 4 O
cabergoline	646 11 B-Chemical
in	658 2 O
youth	661 5 O
.	666 1 O

METHODS	668 7 O
:	675 1 O
We	677 2 O
undertook	680 9 O
a	690 1 O
retrospective	692 13 O
case	706 4 O
review	711 6 O
of	718 2 O
four	721 4 O
children	726 8 O
with	735 4 O
risperidone	740 11 B-Chemical
-	751 1 O
induced	752 7 O
hyperprolactinemia	760 18 B-Disease
treated	779 7 O
with	787 4 O
cabergoline	792 11 B-Chemical
.	803 1 O

RESULTS	805 7 O
:	812 1 O
Four	814 4 O
males	819 5 O
(	825 1 O
age	826 3 O
6	830 1 O
-	831 1 O
11	832 2 O
years	835 5 O
)	840 1 O
with	842 4 O
Diagnostic	847 10 O
and	858 3 O
Statistical	862 11 O
Manual	874 6 O
of	881 2 O
Mental	884 6 B-Disease
Disorders	891 9 I-Disease
(	901 1 O
fourth	902 6 O
edition	909 7 O
)	916 1 O
bipolar	918 7 B-Disease
disorder	926 8 I-Disease
or	935 2 O
psychoses	938 9 B-Disease
,	947 1 O
with	949 4 O
risperidone	954 11 B-Chemical
-	965 1 O
induced	966 7 O
elevations	974 10 O
in	985 2 O
serum	988 5 O
prolactin	994 9 O
levels	1004 6 O
(	1011 1 O
57	1012 2 O
.	1014 1 O
5	1015 1 O
-	1016 1 O
129	1017 3 O
ng	1021 2 O
/	1023 1 O
mL	1024 2 O
,	1026 1 O
normal	1028 6 O
5	1035 1 O
-	1036 1 O
15	1037 2 O
ng	1040 2 O
/	1042 1 O
mL	1043 2 O
)	1045 1 O
,	1046 1 O
were	1048 4 O
treated	1053 7 O
with	1061 4 O
cabergoline	1066 11 B-Chemical
(	1078 1 O
mean	1079 4 O
dose	1084 4 O
2	1089 1 O
.	1090 1 O
13	1091 2 O
+	1094 1 O
/	1095 1 O
-	1096 1 O
0	1098 1 O
.	1099 1 O
09	1100 2 O
mg	1103 2 O
/	1105 1 O
week	1106 4 O
)	1110 1 O
.	1111 1 O

When	1113 4 O
serum	1118 5 O
prolactin	1124 9 O
levels	1134 6 O
normalized	1141 10 O
in	1152 2 O
all	1155 3 O
four	1159 4 O
subjects	1164 8 O
(	1173 1 O
mean	1174 4 O
11	1179 2 O
.	1181 1 O
2	1182 1 O
+	1184 1 O
/	1185 1 O
-	1186 1 O
10	1188 2 O
.	1190 1 O
9	1191 1 O
ng	1193 2 O
/	1195 1 O
mL	1196 2 O
)	1198 1 O
,	1199 1 O
the	1201 3 O
cabergoline	1205 11 B-Chemical
dose	1217 4 O
was	1222 3 O
reduced	1226 7 O
to	1234 2 O
1	1237 1 O
mg	1239 2 O
/	1241 1 O
week	1242 4 O
in	1247 2 O
three	1250 5 O
of	1256 2 O
four	1259 4 O
subjects	1264 8 O
.	1272 1 O

The	1274 3 O
mean	1278 4 O
duration	1283 8 O
of	1292 2 O
therapy	1295 7 O
with	1303 4 O
cabergoline	1308 11 B-Chemical
was	1320 3 O
523	1324 3 O
.	1327 1 O
5	1328 1 O
+	1330 1 O
/	1331 1 O
-	1332 1 O
129	1334 3 O
.	1337 1 O
7	1338 1 O
days	1340 4 O
,	1344 1 O
and	1346 3 O
the	1350 3 O
mean	1354 4 O
duration	1359 8 O
of	1368 2 O
therapy	1371 7 O
with	1379 4 O
risperidone	1384 11 B-Chemical
was	1396 3 O
788	1400 3 O
.	1403 1 O
5	1404 1 O
+	1406 1 O
/	1407 1 O
-	1408 1 O
162	1410 3 O
.	1413 1 O
5	1414 1 O
days	1416 4 O
.	1420 1 O

Cabergoline	1422 11 B-Chemical
was	1434 3 O
well	1438 4 O
tolerated	1443 9 O
without	1453 7 O
adverse	1461 7 O
effects	1469 7 O
.	1476 1 O

CONCLUSIONS	1478 11 O
:	1489 1 O
Cabergoline	1491 11 B-Chemical
may	1503 3 O
be	1507 2 O
useful	1510 6 O
for	1517 3 O
the	1521 3 O
treatment	1525 9 O
of	1535 2 O
risperidone	1538 11 B-Chemical
-	1549 1 O
induced	1550 7 O
hyperprolactinemia	1558 18 B-Disease
in	1577 2 O
youth	1580 5 O
;	1585 1 O
however	1587 7 O
,	1594 1 O
further	1596 7 O
research	1604 8 O
is	1613 2 O
needed	1616 6 O
.	1622 1 O

Cholestatic	0 11 B-Disease
jaundice	12 8 I-Disease
associated	21 10 O
with	32 4 O
the	37 3 O
use	41 3 O
of	45 2 O
metformin	48 9 B-Chemical
.	57 1 O

We	59 2 O
report	62 6 O
a	69 1 O
patient	71 7 O
who	79 3 O
developed	83 9 O
cholestatic	93 11 B-Disease
jaundice	105 8 I-Disease
shortly	114 7 O
after	122 5 O
initiation	128 10 O
of	139 2 O
treatment	142 9 O
with	152 4 O
metformin	157 9 B-Chemical
hydrochloride	167 13 I-Chemical
.	180 1 O

Ultrasound	182 10 O
of	193 2 O
the	196 3 O
liver	200 5 O
and	206 3 O
abdominal	210 9 O
CT	220 2 O
were	223 4 O
normal	228 6 O
.	234 1 O

An	236 2 O
ERCP	239 4 O
showed	244 6 O
normal	251 6 O
biliary	258 7 O
anatomy	266 7 O
.	273 1 O

A	275 1 O
percutaneous	277 12 O
liver	290 5 O
biopsy	296 6 O
was	303 3 O
obtained	307 8 O
showing	316 7 O
marked	324 6 O
cholestasis	331 11 B-Disease
,	342 1 O
with	344 4 O
portal	349 6 O
edema	356 5 B-Disease
,	361 1 O
ductular	363 8 O
proliferation	372 13 O
,	385 1 O
and	387 3 O
acute	391 5 O
inflammation	397 12 B-Disease
.	409 1 O

Metformin	411 9 B-Chemical
hydrochloride	421 13 I-Chemical
was	435 3 O
discontinued	439 12 O
,	451 1 O
and	453 3 O
the	457 3 O
patient	461 7 O
'	468 1 O
s	469 1 O
jaundice	471 8 B-Disease
resolved	480 8 O
slowly	489 6 O
over	496 4 O
a	501 1 O
period	503 6 O
of	510 2 O
several	513 7 O
months	521 6 O
.	527 1 O

Given	529 5 O
the	535 3 O
onset	539 5 O
of	545 2 O
his	548 3 O
jaundice	552 8 B-Disease
2	561 1 O
wk	563 2 O
after	566 5 O
the	572 3 O
initiation	576 10 O
of	587 2 O
metformin	590 9 B-Chemical
,	599 1 O
we	601 2 O
believe	604 7 O
that	612 4 O
this	617 4 O
case	622 4 O
represents	627 10 O
an	638 2 O
example	641 7 O
of	649 2 O
metformin	652 9 B-Chemical
-	661 1 O
associated	662 10 O
hepatotoxicity	673 14 B-Disease
,	687 1 O
the	689 3 O
first	693 5 O
such	699 4 O
case	704 4 O
reported	709 8 O
.	717 1 O

Electro	0 7 O
-	7 1 O
oculography	8 11 O
,	19 1 O
electroretinography	21 19 O
,	40 1 O
visual	42 6 O
evoked	49 6 O
potentials	56 10 O
,	66 1 O
and	68 3 O
multifocal	72 10 O
electroretinography	83 19 O
in	103 2 O
patients	106 8 O
with	115 4 O
vigabatrin	120 10 B-Chemical
-	130 1 O
attributed	131 10 O
visual	142 6 B-Disease
field	149 5 I-Disease
constriction	155 12 I-Disease
.	167 1 O

PURPOSE	169 7 O
:	176 1 O
Symptomatic	178 11 O
visual	190 6 B-Disease
field	197 5 I-Disease
constriction	203 12 I-Disease
thought	216 7 O
to	224 2 O
be	227 2 O
associated	230 10 O
with	241 4 O
vigabatrin	246 10 B-Chemical
has	257 3 O
been	261 4 O
reported	266 8 O
.	274 1 O

The	276 3 O
current	280 7 O
study	288 5 O
investigated	294 12 O
the	307 3 O
visual	311 6 O
fields	318 6 O
and	325 3 O
visual	329 6 O
electrophysiology	336 17 O
of	354 2 O
eight	357 5 O
patients	363 8 O
with	372 4 O
known	377 5 O
vigabatrin	383 10 B-Chemical
-	393 1 O
attributed	394 10 O
visual	405 6 B-Disease
field	412 5 I-Disease
loss	418 4 I-Disease
,	422 1 O
three	424 5 O
of	430 2 O
whom	433 4 O
were	438 4 O
reported	443 8 O
previously	452 10 O
.	462 1 O

Six	464 3 O
of	468 2 O
the	471 3 O
patients	475 8 O
were	484 4 O
no	489 2 O
longer	492 6 O
receiving	499 9 O
vigabatrin	509 10 B-Chemical
.	519 1 O

METHODS	521 7 O
:	528 1 O
The	530 3 O
central	534 7 O
and	542 3 O
peripheral	546 10 O
fields	557 6 O
were	564 4 O
examined	569 8 O
with	578 4 O
the	583 3 O
Humphrey	587 8 O
Visual	596 6 O
Field	603 5 O
Analyzer	609 8 O
.	617 1 O

Full	619 4 O
visual	624 6 O
electrophysiology	631 17 O
,	648 1 O
including	650 9 O
flash	660 5 O
electroretinography	666 19 O
(	686 1 O
ERG	687 3 O
)	690 1 O
,	691 1 O
pattern	693 7 O
electroretinography	701 19 O
,	720 1 O
multifocal	722 10 O
ERG	733 3 O
using	737 5 O
the	743 3 O
VERIS	747 5 O
system	753 6 O
,	759 1 O
electro	761 7 O
-	768 1 O
oculography	769 11 O
,	780 1 O
and	782 3 O
flash	786 5 O
and	792 3 O
pattern	796 7 O
visual	804 6 O
evoked	811 6 O
potentials	818 10 O
,	828 1 O
was	830 3 O
undertaken	834 10 O
.	844 1 O

RESULTS	846 7 O
:	853 1 O
Seven	855 5 O
patients	861 8 O
showed	870 6 O
marked	877 6 O
visual	884 6 B-Disease
field	891 5 I-Disease
constriction	897 12 I-Disease
with	910 4 O
some	915 4 O
sparing	920 7 O
of	928 2 O
the	931 3 O
temporal	935 8 O
visual	944 6 O
field	951 5 O
.	956 1 O

The	958 3 O
eighth	962 6 O
exhibited	969 9 O
concentric	979 10 O
constriction	990 12 O
.	1002 1 O

Most	1004 4 O
electrophysiological	1009 20 O
responses	1030 9 O
were	1040 4 O
usually	1045 7 O
just	1053 4 O
within	1058 6 O
normal	1065 6 O
limits	1072 6 O
;	1078 1 O
two	1080 3 O
patients	1084 8 O
had	1093 3 O
subnormal	1097 9 O
Arden	1107 5 O
electro	1113 7 O
-	1120 1 O
oculography	1121 11 O
indices	1133 7 O
;	1140 1 O
and	1142 3 O
one	1146 3 O
patient	1150 7 O
showed	1158 6 O
an	1165 2 O
abnormally	1168 10 O
delayed	1179 7 O
photopic	1187 8 O
b	1196 1 O
wave	1198 4 O
.	1202 1 O

However	1204 7 O
,	1211 1 O
five	1213 4 O
patients	1218 8 O
showed	1227 6 O
delayed	1234 7 O
30	1242 2 O
-	1244 1 O
Hz	1245 2 O
flicker	1248 7 O
b	1256 1 O
waves	1258 5 O
,	1263 1 O
and	1265 3 O
seven	1269 5 O
patients	1275 8 O
showed	1284 6 O
delayed	1291 7 O
oscillatory	1299 11 O
potentials	1311 10 O
.	1321 1 O

Multifocal	1323 10 O
ERG	1334 3 O
showed	1338 6 O
abnormalities	1345 13 O
that	1359 4 O
sometimes	1364 9 O
correlated	1374 10 O
with	1385 4 O
the	1390 3 O
visual	1394 6 O
field	1401 5 O
appearance	1407 10 O
and	1418 3 O
confirmed	1422 9 O
that	1432 4 O
the	1437 3 O
deficit	1441 7 O
occurs	1449 6 O
at	1456 2 O
the	1459 3 O
retinal	1463 7 O
level	1471 5 O
.	1476 1 O

CONCLUSION	1478 10 O
:	1488 1 O
Marked	1490 6 O
visual	1497 6 B-Disease
field	1504 5 I-Disease
constriction	1510 12 I-Disease
appears	1523 7 O
to	1531 2 O
be	1534 2 O
associated	1537 10 O
with	1548 4 O
vigabatrin	1553 10 B-Chemical
therapy	1564 7 O
.	1571 1 O

The	1573 3 O
field	1577 5 O
defects	1583 7 O
and	1591 3 O
some	1595 4 O
electrophysiological	1600 20 O
abnormalities	1621 13 O
persist	1635 7 O
when	1643 4 O
vigabatrin	1648 10 B-Chemical
therapy	1659 7 O
is	1667 2 O
withdrawn	1670 9 O
.	1679 1 O

Conversion	0 10 O
to	11 2 O
rapamycin	14 9 B-Chemical
immunosuppression	24 17 O
in	42 2 O
renal	45 5 O
transplant	51 10 O
recipients	62 10 O
:	72 1 O
report	74 6 O
of	81 2 O
an	84 2 O
initial	87 7 O
experience	95 10 O
.	105 1 O

BACKGROUND	107 10 O
:	117 1 O
The	119 3 O
aim	123 3 O
of	127 2 O
this	130 4 O
study	135 5 O
is	141 2 O
to	144 2 O
evaluate	147 8 O
the	156 3 O
effects	160 7 O
of	168 2 O
RAPA	171 4 B-Chemical
conversion	176 10 O
in	187 2 O
patients	190 8 O
undergoing	199 10 O
cyclosporine	210 12 B-Chemical
(	223 1 O
CsA	224 3 B-Chemical
)	227 1 O
or	229 2 O
tacrolimus	232 10 B-Chemical
(	243 1 O
Tac	244 3 B-Chemical
)	247 1 O
toxicity	249 8 B-Disease
.	257 1 O

METHODS	259 7 O
:	266 1 O
Twenty	268 6 O
renal	275 5 O
transplant	281 10 O
recipients	292 10 O
were	303 4 O
switched	308 8 O
to	317 2 O
fixed	320 5 O
dose	326 4 O
rapamycin	331 9 B-Chemical
(	341 1 O
RAPA	342 4 B-Chemical
)	346 1 O
(	348 1 O
5	349 1 O
mg	351 2 O
/	353 1 O
day	354 3 O
)	357 1 O
0	359 1 O
to	361 2 O
204	364 3 O
months	368 6 O
posttransplant	375 14 O
.	389 1 O

Drug	391 4 O
monitoring	396 10 O
was	407 3 O
not	411 3 O
initially	415 9 O
used	425 4 O
to	430 2 O
adjust	433 6 O
doses	440 5 O
.	445 1 O

The	447 3 O
indications	451 11 O
for	463 3 O
switch	467 6 O
were	474 4 O
chronic	479 7 O
CsA	487 3 B-Chemical
or	491 2 O
Tac	494 3 B-Chemical
nephrotoxicity	498 14 B-Disease
(	513 1 O
12	514 2 O
)	516 1 O
,	517 1 O
acute	519 5 O
CsA	525 3 B-Chemical
or	529 2 O
Tac	532 3 B-Chemical
toxicity	536 8 B-Disease
(	545 1 O
3	546 1 O
)	547 1 O
,	548 1 O
severe	550 6 O
facial	557 6 B-Disease
dysmorphism	564 11 I-Disease
(	576 1 O
2	577 1 O
)	578 1 O
,	579 1 O
posttransplant	581 14 B-Disease
lymphoproliferative	596 19 I-Disease
disorder	616 8 I-Disease
(	625 1 O
PTLD	626 4 B-Disease
)	630 1 O
in	632 2 O
remission	635 9 O
(	645 1 O
2	646 1 O
)	647 1 O
,	648 1 O
and	650 3 O
hepatotoxicity	654 14 B-Disease
in	669 2 O
1	672 1 O
.	673 1 O

Follow	675 6 O
-	681 1 O
up	682 2 O
is	685 2 O
7	688 1 O
to	690 2 O
24	693 2 O
months	696 6 O
.	702 1 O

RESULTS	704 7 O
:	711 1 O
In	713 2 O
the	716 3 O
12	720 2 O
patients	723 8 O
switched	732 8 O
because	741 7 O
of	749 2 O
chronic	752 7 O
nephrotoxicity	760 14 B-Disease
there	775 5 O
was	781 3 O
a	785 1 O
significant	787 11 O
decrease	799 8 O
in	808 2 O
serum	811 5 O
creatinine	817 10 B-Chemical
[	828 1 O
233	829 3 O
+	832 1 O
/	833 1 O
-	834 1 O
34	835 2 O
to	838 2 O
210	841 3 O
+	844 1 O
/	845 1 O
-	846 1 O
56	847 2 O
micromol	850 8 O
/	858 1 O
liter	859 5 O
(	865 1 O
P	866 1 O
<	867 1 O
0	868 1 O
.	869 1 O
05	870 2 O
)	872 1 O
at	874 2 O
6	877 1 O
months	879 6 O
]	885 1 O
.	886 1 O

Facial	888 6 B-Disease
dysmorphism	895 11 I-Disease
improved	907 8 O
in	916 2 O
two	919 3 O
patients	923 8 O
.	931 1 O

No	933 2 O
relapse	936 7 O
of	944 2 O
PTLD	947 4 B-Disease
was	952 3 O
observed	956 8 O
.	964 1 O

Five	966 4 O
patients	971 8 O
developed	980 9 O
pneumonia	990 9 B-Disease
(	1000 1 O
two	1001 3 O
Pneumocystis	1005 12 B-Disease
carinii	1018 7 I-Disease
pneumonia	1026 9 I-Disease
,	1035 1 O
one	1037 3 O
infectious	1041 10 B-Disease
mononucleosis	1052 13 I-Disease
with	1066 4 O
polyclonal	1071 10 O
PTLD	1082 4 B-Disease
lung	1087 4 O
infiltrate	1092 10 O
)	1102 1 O
and	1104 3 O
two	1108 3 O
had	1112 3 O
bronchiolitis	1116 13 B-Disease
obliterans	1130 10 I-Disease
.	1140 1 O

There	1142 5 O
were	1148 4 O
no	1153 2 O
deaths	1156 6 O
.	1162 1 O

RAPA	1164 4 B-Chemical
was	1169 3 O
discontinued	1173 12 O
in	1186 2 O
four	1189 4 O
patients	1194 8 O
,	1202 1 O
because	1204 7 O
of	1212 2 O
pneumonia	1215 9 B-Disease
in	1225 2 O
two	1228 3 O
,	1231 1 O
PTLD	1233 4 B-Disease
in	1238 2 O
one	1241 3 O
,	1244 1 O
and	1246 3 O
oral	1250 4 O
aphtous	1255 7 B-Disease
ulcers	1263 6 I-Disease
in	1270 2 O
one	1273 3 O
.	1276 1 O

RAPA	1278 4 B-Chemical
levels	1283 6 O
were	1290 4 O
high	1295 4 O
(	1300 1 O
>	1301 1 O
15	1302 2 O
ng	1305 2 O
/	1307 1 O
ml	1308 2 O
)	1310 1 O
in	1312 2 O
7	1315 1 O
of	1317 2 O
13	1320 2 O
(	1323 1 O
54	1324 2 O
%	1326 1 O
)	1327 1 O
patients	1329 8 O
.	1337 1 O

CONCLUSIONS	1339 11 O
:	1350 1 O
RAPA	1352 4 B-Chemical
conversion	1357 10 O
provides	1368 8 O
adequate	1377 8 O
immunosuppression	1386 17 O
to	1404 2 O
enable	1407 6 O
CsA	1414 3 B-Chemical
withdrawal	1418 10 O
.	1428 1 O

However	1430 7 O
,	1437 1 O
when	1439 4 O
converting	1444 10 O
patients	1455 8 O
to	1464 2 O
RAPA	1467 4 B-Chemical
drug	1472 4 O
levels	1477 6 O
should	1484 6 O
be	1491 2 O
monitored	1494 9 O
to	1504 2 O
avoid	1507 5 O
over	1513 4 O
-	1517 1 O
immunosuppression	1518 17 O
and	1536 3 O
adequate	1540 8 O
antiviral	1549 9 O
and	1559 3 O
Pneumocystis	1563 12 B-Disease
carinii	1576 7 I-Disease
pneumonia	1584 9 I-Disease
prophylaxis	1594 11 O
should	1606 6 O
be	1613 2 O
given	1616 5 O
.	1621 1 O

Worsening	0 9 O
of	10 2 O
levodopa	13 8 B-Chemical
-	21 1 O
induced	22 7 O
dyskinesias	30 11 B-Disease
by	42 2 O
motor	45 5 O
and	51 3 O
mental	55 6 O
tasks	62 5 O
.	67 1 O

Ten	69 3 O
patients	73 8 O
who	82 3 O
had	86 3 O
Parkinson	90 9 B-Disease
'	99 1 I-Disease
s	100 1 I-Disease
disease	102 7 I-Disease
with	110 4 O
disabling	115 9 O
dyskinesia	125 10 B-Disease
were	136 4 O
included	141 8 O
in	150 2 O
this	153 4 O
study	158 5 O
to	164 2 O
evaluate	167 8 O
the	176 3 O
role	180 4 O
of	185 2 O
mental	188 6 O
(	195 1 O
mental	196 6 O
calculation	203 11 O
)	214 1 O
and	216 3 O
motor	220 5 O
(	226 1 O
flexion	227 7 O
/	234 1 O
extension	235 9 O
of	245 2 O
right	248 5 O
fingers	254 7 O
,	261 1 O
flexion	263 7 O
/	270 1 O
extension	271 9 O
of	281 2 O
left	284 4 O
fingers	289 7 O
,	296 1 O
flexion	298 7 O
/	305 1 O
extension	306 9 O
of	316 2 O
the	319 3 O
neck	323 4 O
,	327 1 O
speaking	329 8 O
aloud	338 5 O
)	343 1 O
tasks	345 5 O
on	351 2 O
the	354 3 O
worsening	358 9 O
of	368 2 O
peak	371 4 O
-	375 1 O
dose	376 4 O
dyskinesia	381 10 B-Disease
following	392 9 O
administration	402 14 O
of	417 2 O
an	420 2 O
effective	423 9 O
single	433 6 O
dose	440 4 O
of	445 2 O
apomorphine	448 11 B-Chemical
.	459 1 O

Compared	461 8 O
with	470 4 O
the	475 3 O
score	479 5 O
at	485 2 O
rest	488 4 O
(	493 1 O
1	494 1 O
.	495 1 O
3	496 1 O
+	497 1 O
/	498 1 O
-	499 1 O
0	500 1 O
.	501 1 O
3	502 1 O
)	503 1 O
,	504 1 O
a	506 1 O
significant	508 11 O
aggravation	520 11 O
of	532 2 O
the	535 3 O
dyskinesia	539 10 B-Disease
score	550 5 O
was	556 3 O
observed	560 8 O
during	569 6 O
speaking	576 8 O
aloud	585 5 O
(	591 1 O
5	592 1 O
.	593 1 O
2	594 1 O
+	595 1 O
/	596 1 O
-	597 1 O
1	598 1 O
.	599 1 O
1	600 1 O
,	601 1 O
p	603 1 O
<	604 1 O
0	605 1 O
.	606 1 O
05	607 2 O
)	609 1 O
,	610 1 O
movements	612 9 O
of	622 2 O
right	625 5 O
(	631 1 O
4	632 1 O
.	633 1 O
5	634 1 O
+	635 1 O
/	636 1 O
-	637 1 O
1	638 1 O
.	639 1 O
0	640 1 O
,	641 1 O
p	643 1 O
<	644 1 O
0	645 1 O
.	646 1 O
05	647 2 O
)	649 1 O
and	651 3 O
left	655 4 O
(	660 1 O
3	661 1 O
.	662 1 O
7	663 1 O
+	664 1 O
/	665 1 O
-	666 1 O
0	667 1 O
.	668 1 O
8	669 1 O
,	670 1 O
p	672 1 O
<	673 1 O
0	674 1 O
.	675 1 O
05	676 2 O
)	678 1 O
fingers	680 7 O
,	687 1 O
movements	689 9 O
of	699 2 O
the	702 3 O
neck	706 4 O
(	711 1 O
5	712 1 O
.	713 1 O
1	714 1 O
+	715 1 O
/	716 1 O
-	717 1 O
1	718 1 O
.	719 1 O
0	720 1 O
,	721 1 O
p	723 1 O
<	724 1 O
0	725 1 O
.	726 1 O
05	727 2 O
)	729 1 O
,	730 1 O
and	732 3 O
mental	736 6 O
calculation	743 11 O
(	755 1 O
3	756 1 O
.	757 1 O
1	758 1 O
+	759 1 O
/	760 1 O
-	761 1 O
1	762 1 O
.	763 1 O
0	764 1 O
,	765 1 O
p	767 1 O
<	768 1 O
0	769 1 O
.	770 1 O
05	771 2 O
)	773 1 O
.	774 1 O

These	776 5 O
results	782 7 O
suggest	790 7 O
that	798 4 O
activation	803 10 O
tasks	814 5 O
such	820 4 O
as	825 2 O
"	828 1 O
speaking	829 8 O
aloud	838 5 O
"	843 1 O
could	845 5 O
be	851 2 O
used	854 4 O
for	859 3 O
objective	863 9 O
assessment	873 10 O
of	884 2 O
dyskinesia	887 10 B-Disease
severity	898 8 O
.	906 1 O

Structural	0 10 B-Disease
and	11 3 I-Disease
functional	15 10 I-Disease
impairment	26 10 I-Disease
of	37 2 I-Disease
mitochondria	40 12 I-Disease
in	53 2 O
adriamycin	56 10 B-Chemical
-	66 1 O
induced	67 7 O
cardiomyopathy	75 14 B-Disease
in	90 2 O
mice	93 4 O
:	97 1 O
suppression	99 11 O
of	111 2 O
cytochrome	114 10 O
c	125 1 O
oxidase	127 7 O
II	135 2 O
gene	138 4 O
expression	143 10 O
.	153 1 O

The	155 3 O
use	159 3 O
of	163 2 O
adriamycin	166 10 B-Chemical
(	177 1 O
ADR	178 3 B-Chemical
)	181 1 O
in	183 2 O
cancer	186 6 B-Disease
chemotherapy	193 12 O
has	206 3 O
been	210 4 O
limited	215 7 O
due	223 3 O
to	227 2 O
its	230 3 O
cumulative	234 10 O
cardiovascular	245 14 B-Disease
toxicity	260 8 I-Disease
.	268 1 O

Earlier	270 7 O
observations	278 12 O
that	291 4 O
ADR	296 3 B-Chemical
interacts	300 9 O
with	310 4 O
mitochondrial	315 13 O
cytochrome	329 10 O
c	340 1 O
oxidase	342 7 O
(	350 1 O
COX	351 3 O
)	354 1 O
and	356 3 O
suppresses	360 10 O
its	371 3 O
enzyme	375 6 O
activity	382 8 O
led	391 3 O
us	395 2 O
to	398 2 O
investigate	401 11 O
ADR	413 3 B-Chemical
'	416 1 O
s	417 1 O
action	419 6 O
on	426 2 O
the	429 3 O
cardiovascular	433 14 O
functions	448 9 O
and	458 3 O
heart	462 5 O
mitochondrial	468 13 O
morphology	482 10 O
in	493 2 O
Balb	496 4 O
-	500 1 O
c	501 1 O
mice	503 4 O
i	508 1 O
.	509 1 O
p	510 1 O
.	511 1 O
treated	513 7 O
with	521 4 O
ADR	526 3 B-Chemical
for	530 3 O
several	534 7 O
weeks	542 5 O
.	547 1 O

At	549 2 O
various	552 7 O
times	560 5 O
during	566 6 O
treatment	573 9 O
,	582 1 O
the	584 3 O
animals	588 7 O
were	596 4 O
assessed	601 8 O
for	610 3 O
cardiovascular	614 14 O
functions	629 9 O
by	639 2 O
electrocardiography	642 19 O
and	662 3 O
for	666 3 O
heart	670 5 O
tissue	676 6 O
damage	683 6 O
by	690 2 O
electron	693 8 O
microscopy	702 10 O
.	712 1 O

In	714 2 O
parallel	717 8 O
,	725 1 O
total	727 5 O
RNA	733 3 O
was	737 3 O
extracted	741 9 O
from	751 4 O
samples	756 7 O
of	764 2 O
dissected	767 9 O
heart	777 5 O
and	783 3 O
analyzed	787 8 O
by	796 2 O
Northern	799 8 O
blot	808 4 O
hybridization	813 13 O
to	827 2 O
determine	830 9 O
the	840 3 O
steady	844 6 O
-	850 1 O
state	851 5 O
level	857 5 O
of	863 2 O
three	866 5 O
RNA	872 3 O
transcripts	876 11 O
encoded	888 7 O
by	896 2 O
the	899 3 O
COXII	903 5 O
,	908 1 O
COXIII	910 6 O
,	916 1 O
and	918 3 O
COXIV	922 5 O
genes	928 5 O
.	933 1 O

Similarly	935 9 O
,	944 1 O
samples	946 7 O
obtained	954 8 O
from	963 4 O
the	968 3 O
liver	972 5 O
of	978 2 O
the	981 3 O
same	985 4 O
animals	990 7 O
were	998 4 O
analyzed	1003 8 O
for	1012 3 O
comparative	1016 11 O
studies	1028 7 O
.	1035 1 O

Our	1037 3 O
results	1041 7 O
indicated	1049 9 O
that	1059 4 O
1	1064 1 O
)	1065 1 O
treatment	1067 9 O
of	1077 2 O
mice	1080 4 O
with	1085 4 O
ADR	1090 3 B-Chemical
caused	1094 6 O
cardiovascular	1101 14 B-Disease
arrhythmias	1116 11 I-Disease
characterized	1128 13 O
by	1142 2 O
bradycardia	1145 11 B-Disease
,	1156 1 O
extension	1158 9 O
of	1168 2 O
ventricular	1171 11 O
depolarization	1183 14 O
time	1198 4 O
(	1203 1 O
tQRS	1204 4 O
)	1208 1 O
,	1209 1 O
and	1211 3 O
failure	1215 7 O
of	1223 2 O
QRS	1226 3 O
at	1230 2 O
high	1233 4 O
concentrations	1238 14 O
(	1253 1 O
10	1254 2 O
-	1256 1 O
14	1257 2 O
mg	1260 2 O
/	1262 1 O
kg	1263 2 O
body	1266 4 O
weight	1271 6 O
cumulative	1278 10 O
dose	1289 4 O
)	1293 1 O
;	1294 1 O
2	1296 1 O
)	1297 1 O
the	1299 3 O
heart	1303 5 O
mitochondria	1309 12 O
underwent	1322 9 O
swelling	1332 8 B-Disease
,	1340 1 O
fusion	1342 6 O
,	1348 1 O
dissolution	1350 11 O
,	1361 1 O
and	1363 3 O
/	1366 1 O
or	1367 2 O
disruption	1370 10 O
of	1381 2 O
mitochondrial	1384 13 O
cristae	1398 7 O
after	1406 5 O
several	1412 7 O
weeks	1420 5 O
of	1426 2 O
treatment	1429 9 O
.	1438 1 O

Such	1440 4 O
abnormalities	1445 13 O
were	1459 4 O
not	1464 3 O
observed	1468 8 O
in	1477 2 O
the	1480 3 O
mitochondria	1484 12 O
of	1497 2 O
liver	1500 5 O
tissue	1506 6 O
;	1512 1 O
and	1514 3 O
3	1518 1 O
)	1519 1 O
among	1521 5 O
the	1527 3 O
three	1531 5 O
genes	1537 5 O
of	1543 2 O
COX	1546 3 O
enzyme	1550 6 O
examined	1557 8 O
,	1565 1 O
only	1567 4 O
COXII	1572 5 O
gene	1578 4 O
expression	1583 10 O
was	1594 3 O
suppressed	1598 10 O
by	1609 2 O
ADR	1612 3 B-Chemical
treatment	1616 9 O
,	1625 1 O
mainly	1627 6 O
after	1634 5 O
8	1640 1 O
weeks	1642 5 O
in	1648 2 O
both	1651 4 O
heart	1656 5 O
and	1662 3 O
liver	1666 5 O
.	1671 1 O

Knowing	1673 7 O
that	1681 4 O
heart	1686 5 O
mitochondria	1692 12 O
represent	1705 9 O
almost	1715 6 O
40	1722 2 O
%	1724 1 O
of	1726 2 O
heart	1729 5 O
muscle	1735 6 O
by	1742 2 O
weight	1745 6 O
,	1751 1 O
we	1753 2 O
conclude	1756 8 O
that	1765 4 O
the	1770 3 O
deteriorating	1774 13 O
effects	1788 7 O
of	1796 2 O
ADR	1799 3 B-Chemical
on	1803 2 O
cardiovascular	1806 14 O
function	1821 8 O
involve	1830 7 O
mitochondrial	1838 13 B-Disease
structural	1852 10 I-Disease
and	1863 3 I-Disease
functional	1867 10 I-Disease
impairment	1878 10 I-Disease
.	1888 1 O

Enhanced	0 8 O
bradycardia	9 11 B-Disease
induced	21 7 O
by	29 2 O
beta	32 4 O
-	36 1 O
adrenoceptor	37 12 O
antagonists	50 11 O
in	62 2 O
rats	65 4 O
pretreated	70 10 O
with	81 4 O
isoniazid	86 9 B-Chemical
.	95 1 O

High	97 4 O
doses	102 5 O
of	108 2 O
isoniazid	111 9 B-Chemical
increase	121 8 O
hypotension	130 11 B-Disease
induced	142 7 O
by	150 2 O
vasodilators	153 12 O
and	166 3 O
change	170 6 O
the	177 3 O
accompanying	181 12 O
reflex	194 6 O
tachycardia	201 11 B-Disease
to	213 2 O
bradycardia	216 11 B-Disease
,	227 1 O
an	229 2 O
interaction	232 11 O
attributed	244 10 O
to	255 2 O
decreased	258 9 O
synthesis	268 9 O
of	278 2 O
brain	281 5 O
gamma	287 5 B-Chemical
-	292 1 I-Chemical
aminobutyric	293 12 I-Chemical
acid	306 4 I-Chemical
(	311 1 O
GABA	312 4 B-Chemical
)	316 1 O
.	317 1 O

In	319 2 O
the	322 3 O
present	326 7 O
study	334 5 O
,	339 1 O
the	341 3 O
possible	345 8 O
enhancement	354 11 O
by	366 2 O
isoniazid	369 9 B-Chemical
of	379 2 O
bradycardia	382 11 B-Disease
induced	394 7 O
by	402 2 O
beta	405 4 O
-	409 1 O
adrenoceptor	410 12 O
antagonists	423 11 O
was	435 3 O
determined	439 10 O
in	450 2 O
rats	453 4 O
anaesthetised	458 13 O
with	472 4 O
chloralose	477 10 B-Chemical
-	487 1 O
urethane	488 8 B-Chemical
.	496 1 O

Isoniazid	498 9 B-Chemical
significantly	508 13 O
increased	522 9 O
bradycardia	532 11 B-Disease
after	544 5 O
propranolol	550 11 B-Chemical
,	561 1 O
pindolol	563 8 B-Chemical
,	571 1 O
labetalol	573 9 B-Chemical
and	583 3 O
atenolol	587 8 B-Chemical
,	595 1 O
as	597 2 O
well	600 4 O
as	605 2 O
after	608 5 O
clonidine	614 9 B-Chemical
,	623 1 O
but	625 3 O
not	629 3 O
after	633 5 O
hexamethonium	639 13 B-Chemical
or	653 2 O
carbachol	656 9 B-Chemical
.	665 1 O

Enhancement	667 11 O
was	679 3 O
not	683 3 O
observed	687 8 O
in	696 2 O
rats	699 4 O
pretreated	704 10 O
with	715 4 O
methylatropine	720 14 B-Chemical
or	735 2 O
previously	738 10 O
vagotomised	749 11 O
.	760 1 O

These	762 5 O
results	768 7 O
are	776 3 O
compatible	780 10 O
with	791 4 O
interference	796 12 O
by	809 2 O
isoniazid	812 9 B-Chemical
with	822 4 O
GABAergic	827 9 O
inhibition	837 10 O
of	848 2 O
cardiac	851 7 O
parasympathetic	859 15 O
tone	875 4 O
.	879 1 O

Such	881 4 O
interference	886 12 O
could	899 5 O
be	905 2 O
exerted	908 7 O
centrally	916 9 O
,	925 1 O
possibly	927 8 O
at	936 2 O
the	939 3 O
nucleus	943 7 O
ambiguus	951 8 O
,	959 1 O
or	961 2 O
peripherally	964 12 O
at	977 2 O
the	980 3 O
sinus	984 5 O
node	990 4 O
.	994 1 O

Epileptogenic	0 13 O
activity	14 8 O
of	23 2 O
folic	26 5 B-Chemical
acid	32 4 I-Chemical
after	37 5 O
drug	43 4 O
induces	48 7 O
SLE	56 3 B-Disease
(	60 1 O
folic	61 5 B-Chemical
acid	67 4 I-Chemical
and	72 3 O
epilepsy	76 8 B-Disease
)	84 1 O

OBJECTIVE	86 9 O
:	95 1 O
To	97 2 O
study	100 5 O
the	106 3 O
effect	110 6 O
of	117 2 O
folic	120 5 B-Chemical
acid	126 4 I-Chemical
-	130 1 O
containing	131 10 O
multivitamin	142 12 O
supplementation	155 15 O
in	171 2 O
epileptic	174 9 B-Disease
women	184 5 O
before	190 6 O
and	197 3 O
during	201 6 O
pregnancy	208 9 O
in	218 2 O
order	221 5 O
to	227 2 O
determine	230 9 O
the	240 3 O
rate	244 4 O
of	249 2 O
structural	252 10 O
birth	263 5 B-Disease
defects	269 7 I-Disease
and	277 3 O
epilepsy	281 8 B-Disease
-	289 1 O
related	290 7 O
side	298 4 O
effects	303 7 O
.	310 1 O

STUDY	312 5 O
DESIGN	318 6 O
:	324 1 O
First	326 5 O
a	332 1 O
randomised	334 10 O
trial	345 5 O
,	350 1 O
later	352 5 O
periconception	358 14 O
care	373 4 O
including	378 9 O
in	388 2 O
total	391 5 O
12225	397 5 O
females	403 7 O
.	410 1 O

RESULTS	412 7 O
:	419 1 O
Of	421 2 O
60	424 2 O
epileptic	427 9 B-Disease
women	437 5 O
with	443 4 O
periconceptional	448 16 O
folic	465 5 B-Chemical
acid	471 4 I-Chemical
(	476 1 O
0	477 1 O
.	478 1 O
8	479 1 O
mg	481 2 O
)	483 1 O
-	484 1 O
containing	485 10 O
multivitamin	496 12 O
supplementation	509 15 O
,	524 1 O
no	526 2 O
one	529 3 O
developed	533 9 O
epilepsy	543 8 B-Disease
-	551 1 O
related	552 7 O
side	560 4 O
effects	565 7 O
during	573 6 O
the	580 3 O
periconception	584 14 O
period	599 6 O
.	605 1 O

One	607 3 O
epileptic	611 9 B-Disease
woman	621 5 O
delivered	627 9 O
a	637 1 O
newborn	639 7 O
with	647 4 O
cleft	652 5 B-Disease
lip	658 3 I-Disease
and	662 3 I-Disease
palate	666 6 I-Disease
.	672 1 O

Another	674 7 O
patient	682 7 O
exhibited	690 9 O
with	700 4 O
a	705 1 O
cluster	707 7 O
of	715 2 O
seizures	718 8 B-Disease
after	727 5 O
the	733 3 O
periconception	737 14 O
period	752 6 O
using	759 5 O
another	765 7 O
multivitamin	773 12 O
.	785 1 O

This	787 4 O
22	792 2 O
-	794 1 O
year	795 4 O
-	799 1 O
old	800 3 O
epileptic	804 9 B-Disease
woman	814 5 O
was	820 3 O
treated	824 7 O
continuously	832 12 O
by	845 2 O
carbamazepine	848 13 B-Chemical
and	862 3 O
a	866 1 O
folic	868 5 B-Chemical
acid	874 4 I-Chemical
(	879 1 O
1	880 1 O
mg	882 2 O
)	884 1 O
-	885 1 O
containing	886 10 O
multivitamin	897 12 O
from	910 4 O
the	915 3 O
20th	919 4 O
week	924 4 O
of	929 2 O
gestation	932 9 O
.	941 1 O

She	943 3 O
developed	947 9 O
status	957 6 B-Disease
epilepticus	964 11 I-Disease
and	976 3 O
later	980 5 O
symptoms	986 8 O
of	995 2 O
systemic	998 8 B-Disease
lupus	1007 5 I-Disease
erythematodes	1013 13 I-Disease
.	1026 1 O

Her	1028 3 O
pregnancy	1032 9 O
ended	1042 5 O
with	1048 4 O
stillbirth	1053 10 B-Disease
.	1063 1 O

CONCLUSIONS	1065 11 O
:	1076 1 O
The	1078 3 O
epileptic	1082 9 B-Disease
pregnant	1092 8 O
patient	1101 7 O
'	1108 1 O
s	1109 1 O
autoimmune	1111 10 B-Disease
disease	1122 7 I-Disease
(	1130 1 O
probably	1131 8 O
drug	1140 4 O
-	1144 1 O
induced	1145 7 O
lupus	1153 5 B-Disease
)	1158 1 O
could	1160 5 O
damage	1166 6 O
the	1173 3 O
blood	1177 5 O
-	1182 1 O
brain	1183 5 O
barrier	1189 7 O
,	1196 1 O
therefore	1198 9 O
the	1208 3 O
therapeutic	1212 11 O
dose	1224 4 O
(	1229 1 O
>	1230 1 O
or	1232 2 O
=	1235 1 O
1	1236 1 O
mg	1238 2 O
)	1240 1 O
of	1242 2 O
folic	1245 5 B-Chemical
acid	1251 4 I-Chemical
triggered	1256 9 O
a	1266 1 O
cluster	1268 7 O
of	1276 2 O
seizures	1279 8 B-Disease
.	1287 1 O

Physiological	1289 13 O
dose	1303 4 O
(	1308 1 O
<	1309 1 O
1	1310 1 O
mg	1312 2 O
)	1314 1 O
of	1316 2 O
folic	1319 5 B-Chemical
acid	1325 4 I-Chemical
both	1330 4 O
in	1335 2 O
healthy	1338 7 O
and	1346 3 O
60	1350 2 O
epileptic	1353 9 B-Disease
women	1363 5 O
,	1368 1 O
all	1370 3 O
without	1374 7 O
any	1382 3 O
autoimmune	1386 10 B-Disease
disease	1397 7 I-Disease
,	1404 1 O
did	1406 3 O
not	1410 3 O
increase	1414 8 O
the	1423 3 O
risk	1427 4 O
for	1432 3 O
epileptic	1436 9 B-Disease
seizures	1446 8 I-Disease
.	1454 1 O

Effects	0 7 O
of	8 2 O
cisapride	11 9 B-Chemical
on	21 2 O
symptoms	24 8 O
and	33 3 O
postcibal	37 9 O
small	47 5 O
-	52 1 O
bowel	53 5 O
motor	59 5 O
function	65 8 O
in	74 2 O
patients	77 8 O
with	86 4 O
irritable	91 9 B-Disease
bowel	101 5 I-Disease
syndrome	107 8 I-Disease
.	115 1 O

BACKGROUND	117 10 O
:	127 1 O
Irritable	129 9 B-Disease
bowel	139 5 I-Disease
syndrome	145 8 I-Disease
is	154 2 O
a	157 1 O
common	159 6 O
cause	166 5 O
of	172 2 O
abdominal	175 9 B-Disease
pain	185 4 I-Disease
and	190 3 O
discomfort	194 10 O
and	205 3 O
may	209 3 O
be	213 2 O
related	216 7 O
to	224 2 O
disordered	227 10 B-Disease
gastrointestinal	238 16 I-Disease
motility	255 8 I-Disease
.	263 1 O

Our	265 3 O
aim	269 3 O
was	273 3 O
to	277 2 O
assess	280 6 O
the	287 3 O
effects	291 7 O
of	299 2 O
long	302 4 O
-	306 1 O
term	307 4 O
treatment	312 9 O
with	322 4 O
a	327 1 O
prokinetic	329 10 O
agent	340 5 O
,	345 1 O
cisapride	347 9 B-Chemical
,	356 1 O
on	358 2 O
postprandial	361 12 O
jejunal	374 7 O
motility	382 8 O
and	391 3 O
symptoms	395 8 O
in	404 2 O
the	407 3 O
irritable	411 9 B-Disease
bowel	421 5 I-Disease
syndrome	427 8 I-Disease
(	436 1 O
IBS	437 3 B-Disease
)	440 1 O
.	441 1 O

METHODS	443 7 O
:	450 1 O
Thirty	452 6 O
-	458 1 O
eight	459 5 O
patients	465 8 O
with	474 4 O
IBS	479 3 B-Disease
(	483 1 O
constipation	484 12 B-Disease
-	496 1 O
predominant	497 11 O
,	508 1 O
n	510 1 O
=	512 1 O
17	514 2 O
;	516 1 O
diarrhoea	518 9 B-Disease
-	527 1 O
predominant	528 11 O
,	539 1 O
n	541 1 O
=	543 1 O
21	545 2 O
)	547 1 O
underwent	549 9 O
24	559 2 O
-	561 1 O
h	562 1 O
ambulatory	564 10 O
jejunal	575 7 O
manometry	583 9 O
before	593 6 O
and	600 3 O
after	604 5 O
12	610 2 O
week	613 4 O
'	617 1 O
s	618 1 O
treatment	620 9 O
[	630 1 O
cisapride	631 9 B-Chemical
,	640 1 O
5	642 1 O
mg	644 2 O
three	647 5 O
times	653 5 O
daily	659 5 O
(	665 1 O
n	666 1 O
=	668 1 O
19	670 2 O
)	672 1 O
or	674 2 O
placebo	677 7 O
(	685 1 O
n	686 1 O
=	688 1 O
19	690 2 O
)	692 1 O
]	693 1 O
.	694 1 O

RESULTS	696 7 O
:	703 1 O
In	705 2 O
diarrhoea	708 9 B-Disease
-	717 1 O
predominant	718 11 O
patients	730 8 O
significant	739 11 O
differences	751 11 O
in	763 2 O
contraction	766 11 O
characteristics	778 15 O
were	794 4 O
observed	799 8 O
between	808 7 O
the	816 3 O
cisapride	820 9 B-Chemical
and	830 3 O
placebo	834 7 O
groups	842 6 O
.	848 1 O

In	850 2 O
cisapride	853 9 B-Chemical
-	862 1 O
treated	863 7 O
diarrhoea	871 9 B-Disease
-	880 1 O
predominant	881 11 O
patients	893 8 O
the	902 3 O
mean	906 4 O
contraction	911 11 O
amplitude	923 9 O
was	933 3 O
higher	937 6 O
(	944 1 O
29	945 2 O
.	947 1 O
3	948 1 O
+	950 1 O
/	951 1 O
-	952 1 O
3	954 1 O
.	955 1 O
2	956 1 O
versus	958 6 O
24	965 2 O
.	967 1 O
9	968 1 O
+	970 1 O
/	971 1 O
-	972 1 O
2	974 1 O
.	975 1 O
6	976 1 O
mm	978 2 O
Hg	981 2 O
,	983 1 O
cisapride	985 9 B-Chemical
versus	995 6 O
placebo	1002 7 O
(	1010 1 O
P	1011 1 O
<	1013 1 O
0	1015 1 O
.	1016 1 O
001	1017 3 O
)	1020 1 O
;	1021 1 O
pretreatment	1023 12 O
,	1035 1 O
25	1037 2 O
.	1039 1 O
7	1040 1 O
+	1042 1 O
/	1043 1 O
-	1044 1 O
6	1046 1 O
.	1047 1 O
0	1048 1 O
mm	1050 2 O
Hg	1053 2 O
)	1055 1 O
,	1056 1 O
the	1058 3 O
mean	1062 4 O
contraction	1067 11 O
duration	1079 8 O
longer	1088 6 O
(	1095 1 O
3	1096 1 O
.	1097 1 O
4	1098 1 O
+	1100 1 O
/	1101 1 O
-	1102 1 O
0	1104 1 O
.	1105 1 O
2	1106 1 O
versus	1108 6 O
3	1115 1 O
.	1116 1 O
0	1117 1 O
+	1119 1 O
/	1120 1 O
-	1121 1 O
0	1123 1 O
.	1124 1 O
2	1125 1 O
sec	1127 3 O
,	1130 1 O
cisapride	1132 9 B-Chemical
versus	1142 6 O
placebo	1149 7 O
(	1157 1 O
P	1158 1 O
<	1160 1 O
0	1162 1 O
.	1163 1 O
001	1164 3 O
)	1167 1 O
;	1168 1 O
pretreatment	1170 12 O
,	1182 1 O
3	1184 1 O
.	1185 1 O
1	1186 1 O
+	1188 1 O
/	1189 1 O
-	1190 1 O
0	1192 1 O
.	1193 1 O
5	1194 1 O
sec	1196 3 O
)	1199 1 O
,	1200 1 O
and	1202 3 O
the	1206 3 O
mean	1210 4 O
contraction	1215 11 O
frequency	1227 9 O
lower	1237 5 O
(	1243 1 O
2	1244 1 O
.	1245 1 O
0	1246 1 O
+	1248 1 O
/	1249 1 O
-	1250 1 O
0	1252 1 O
.	1253 1 O
2	1254 1 O
versus	1256 6 O
2	1263 1 O
.	1264 1 O
5	1265 1 O
+	1267 1 O
/	1268 1 O
-	1269 1 O
0	1271 1 O
.	1272 1 O
4	1273 1 O
cont	1275 4 O
.	1279 1 O
/	1280 1 O
min	1281 3 O
,	1284 1 O
cisapride	1286 9 B-Chemical
versus	1296 6 O
placebo	1303 7 O
(	1311 1 O
P	1312 1 O
<	1314 1 O
0	1316 1 O
.	1317 1 O
001	1318 3 O
)	1321 1 O
;	1322 1 O
pretreatment	1324 12 O
,	1336 1 O
2	1338 1 O
.	1339 1 O
5	1340 1 O
+	1342 1 O
/	1343 1 O
-	1344 1 O
1	1346 1 O
.	1347 1 O
1	1348 1 O
cont	1350 4 O
.	1354 1 O
/	1355 1 O
min	1356 3 O
]	1359 1 O
than	1361 4 O
patients	1366 8 O
treated	1375 7 O
with	1383 4 O
placebo	1388 7 O
.	1395 1 O

No	1397 2 O
significant	1400 11 O
differences	1412 11 O
in	1424 2 O
jejunal	1427 7 O
motility	1435 8 O
were	1444 4 O
found	1449 5 O
in	1455 2 O
the	1458 3 O
constipation	1462 12 B-Disease
-	1474 1 O
predominant	1475 11 O
IBS	1487 3 B-Disease
group	1491 5 O
.	1496 1 O

Symptoms	1498 8 O
were	1507 4 O
assessed	1512 8 O
by	1521 2 O
using	1524 5 O
a	1530 1 O
visual	1532 6 O
analogue	1539 8 O
scale	1548 5 O
before	1554 6 O
and	1561 3 O
after	1565 5 O
treatment	1571 9 O
.	1580 1 O

Symptom	1582 7 O
scores	1590 6 O
relating	1597 8 O
to	1606 2 O
the	1609 3 O
severity	1613 8 O
of	1622 2 O
constipation	1625 12 B-Disease
were	1638 4 O
lower	1643 5 O
in	1649 2 O
cisapride	1652 9 B-Chemical
-	1661 1 O
treated	1662 7 O
constipation	1670 12 B-Disease
-	1682 1 O
predominant	1683 11 O
IBS	1695 3 B-Disease
patients	1699 8 O
[	1708 1 O
score	1709 5 O
,	1714 1 O
54	1716 2 O
+	1719 1 O
/	1720 1 O
-	1721 1 O
5	1723 1 O
versus	1725 6 O
67	1732 2 O
+	1735 1 O
/	1736 1 O
-	1737 1 O
14	1739 2 O
mm	1742 2 O
,	1744 1 O
cisapride	1746 9 B-Chemical
versus	1756 6 O
placebo	1763 7 O
(	1771 1 O
P	1772 1 O
<	1774 1 O
0	1776 1 O
.	1777 1 O
05	1778 2 O
)	1780 1 O
;	1781 1 O
pretreatment	1783 12 O
,	1795 1 O
62	1797 2 O
+	1800 1 O
/	1801 1 O
-	1802 1 O
19	1804 2 O
mm	1807 2 O
]	1809 1 O
.	1810 1 O

Diarrhoea	1812 9 B-Disease
-	1821 1 O
predominant	1822 11 O
IBS	1834 3 B-Disease
patients	1838 8 O
had	1847 3 O
a	1851 1 O
higher	1853 6 O
pain	1860 4 B-Disease
score	1865 5 O
after	1871 5 O
cisapride	1877 9 B-Chemical
therapy	1887 7 O
[	1895 1 O
score	1896 5 O
,	1901 1 O
55	1903 2 O
+	1906 1 O
/	1907 1 O
-	1908 1 O
15	1910 2 O
versus	1913 6 O
34	1920 2 O
+	1923 1 O
/	1924 1 O
-	1925 1 O
12	1927 2 O
mm	1930 2 O
,	1932 1 O
cisapride	1934 9 B-Chemical
versus	1944 6 O
placebo	1951 7 O
(	1959 1 O
P	1960 1 O
<	1962 1 O
0	1964 1 O
.	1965 1 O
05	1966 2 O
)	1968 1 O
;	1969 1 O
pretreatment	1971 12 O
,	1983 1 O
67	1985 2 O
+	1988 1 O
/	1989 1 O
-	1990 1 O
19	1992 2 O
mm	1995 2 O
]	1997 1 O
.	1998 1 O

CONCLUSION	2000 10 O
:	2010 1 O
Cisapride	2012 9 B-Chemical
affects	2022 7 O
jejunal	2030 7 O
contraction	2038 11 O
characteristics	2050 15 O
and	2066 3 O
some	2070 4 O
symptoms	2075 8 O
in	2084 2 O
IBS	2087 3 B-Disease
.	2090 1 O

Clarithromycin	0 14 B-Chemical
-	14 1 O
induced	15 7 O
ventricular	23 11 B-Disease
tachycardia	35 11 I-Disease
.	46 1 O

Clarithromycin	48 14 B-Chemical
is	63 2 O
a	66 1 O
relatively	68 10 O
new	79 3 O
macrolide	83 9 B-Chemical
antibiotic	93 10 O
that	104 4 O
offers	109 6 O
twice	116 5 O
-	121 1 O
daily	122 5 O
dosing	128 6 O
.	134 1 O

It	136 2 O
differs	139 7 O
from	147 4 O
erythromycin	152 12 B-Chemical
only	165 4 O
in	170 2 O
the	173 3 O
methylation	177 11 O
of	189 2 O
the	192 3 O
hydroxyl	196 8 O
group	205 5 O
at	211 2 O
position	214 8 O
6	223 1 O
.	224 1 O

Although	226 8 O
the	235 3 O
side	239 4 O
-	243 1 O
effect	244 6 O
profile	251 7 O
of	259 2 O
erythromycin	262 12 B-Chemical
is	275 2 O
established	278 11 O
,	289 1 O
including	291 9 O
gastroenteritis	301 15 B-Disease
and	317 3 O
interactions	321 12 O
with	334 4 O
other	339 5 O
drugs	345 5 O
subject	351 7 O
to	359 2 O
hepatic	362 7 O
mixed	370 5 O
-	375 1 O
function	376 8 O
oxidase	385 7 O
metabolism	393 10 O
,	403 1 O
experience	405 10 O
with	416 4 O
the	421 3 O
newer	425 5 O
macrolides	431 10 B-Chemical
is	442 2 O
still	445 5 O
being	451 5 O
recorded	457 8 O
.	465 1 O

Cardiotoxicity	467 14 B-Disease
has	482 3 O
been	486 4 O
demonstrated	491 12 O
after	504 5 O
both	510 4 O
intravenous	515 11 O
and	527 3 O
oral	531 4 O
administration	536 14 O
of	551 2 O
erythromycin	554 12 B-Chemical
but	567 3 O
has	571 3 O
never	575 5 O
been	581 4 O
reported	586 8 O
with	595 4 O
the	600 3 O
newer	604 5 O
macrolides	610 10 B-Chemical
.	620 1 O

We	622 2 O
report	625 6 O
a	632 1 O
case	634 4 O
of	639 2 O
ventricular	642 11 B-Disease
dysrhythmias	654 12 I-Disease
that	667 4 O
occurred	672 8 O
after	681 5 O
six	687 3 O
therapeutic	691 11 O
doses	703 5 O
of	709 2 O
clarithromycin	712 14 B-Chemical
.	726 1 O

The	728 3 O
dysrhythmias	732 12 B-Disease
resolved	745 8 O
after	754 5 O
discontinuation	760 15 O
of	776 2 O
the	779 3 O
drug	783 4 O
.	787 1 O

Persistent	0 10 O
nephrogenic	11 11 B-Disease
diabetes	23 8 I-Disease
insipidus	32 9 I-Disease
following	42 9 O
lithium	52 7 B-Chemical
therapy	60 7 O
.	67 1 O

We	69 2 O
report	72 6 O
the	79 3 O
case	83 4 O
of	88 2 O
a	91 1 O
patient	93 7 O
who	101 3 O
developed	105 9 O
severe	115 6 O
hypernatraemic	122 14 O
dehydration	137 11 B-Disease
following	149 9 O
a	159 1 O
head	161 4 B-Disease
injury	166 6 I-Disease
.	172 1 O

Ten	174 3 O
years	178 5 O
previously	184 10 O
he	195 2 O
had	198 3 O
been	202 4 O
diagnosed	207 9 O
to	217 2 O
have	220 4 O
lithium	225 7 B-Chemical
-	232 1 O
induced	233 7 O
nephrogenic	241 11 B-Disease
diabetes	253 8 I-Disease
insipidus	262 9 I-Disease
,	271 1 O
and	273 3 O
lithium	277 7 B-Chemical
therapy	285 7 O
had	293 3 O
been	297 4 O
discontinued	302 12 O
.	314 1 O

He	316 2 O
remained	319 8 O
thirsty	328 7 O
and	336 3 O
polyuric	340 8 B-Disease
despite	349 7 O
cessation	357 9 O
of	367 2 O
lithium	370 7 B-Chemical
and	378 3 O
investigations	382 14 O
on	397 2 O
admission	400 9 O
showed	410 6 O
him	417 3 O
to	421 2 O
have	424 4 O
normal	429 6 O
osmoregulated	436 13 O
thirst	450 6 O
and	457 3 O
vasopressin	461 11 B-Chemical
secretion	473 9 O
,	482 1 O
with	484 4 O
clear	489 5 O
evidence	495 8 O
of	504 2 O
nephrogenic	507 11 B-Disease
diabetes	519 8 I-Disease
insipidus	528 9 I-Disease
.	537 1 O

Lithium	539 7 B-Chemical
induced	547 7 O
nephrogenic	555 11 B-Disease
diabetes	567 8 I-Disease
insipidus	576 9 I-Disease
is	586 2 O
considered	589 10 O
to	600 2 O
be	603 2 O
reversible	606 10 O
on	617 2 O
cessation	620 9 O
of	630 2 O
therapy	633 7 O
but	641 3 O
polyuria	645 8 B-Disease
persisted	654 9 O
in	664 2 O
this	667 4 O
patient	672 7 O
for	680 3 O
ten	684 3 O
years	688 5 O
after	694 5 O
lithium	700 7 B-Chemical
was	708 3 O
stopped	712 7 O
.	719 1 O

We	721 2 O
discuss	724 7 O
the	732 3 O
possible	736 8 O
renal	745 5 O
mechanisms	751 10 O
and	762 3 O
the	766 3 O
implications	770 12 O
for	783 3 O
management	787 10 O
of	798 2 O
patients	801 8 O
with	810 4 O
lithium	815 7 B-Chemical
-	822 1 O
induced	823 7 O
nephrogenic	831 11 B-Disease
diabetes	843 8 I-Disease
insipidus	852 9 I-Disease
.	861 1 O

Late	0 4 O
cardiotoxicity	5 14 B-Disease
after	20 5 O
treatment	26 9 O
for	36 3 O
a	40 1 O
malignant	42 9 O
bone	52 4 B-Disease
tumor	57 5 I-Disease
.	62 1 O

Cardiac	64 7 O
function	72 8 O
was	81 3 O
assessed	85 8 O
in	94 2 O
long	97 4 O
-	101 1 O
term	102 4 O
survivors	107 9 O
of	117 2 O
malignant	120 9 O
bone	130 4 B-Disease
tumors	135 6 I-Disease
who	142 3 O
were	146 4 O
treated	151 7 O
according	159 9 O
to	169 2 O
Rosen	172 5 B-Chemical
'	177 1 I-Chemical
s	178 1 I-Chemical
T5	180 2 I-Chemical
or	183 2 I-Chemical
T10	186 3 I-Chemical
protocol	190 8 I-Chemical
,	198 1 O
both	200 4 O
including	205 9 O
doxorubicin	215 11 B-Chemical
.	226 1 O

Thirty	228 6 O
-	234 1 O
one	235 3 O
patients	239 8 O
,	247 1 O
age	249 3 O
10	253 2 O
-	255 1 O
45	256 2 O
years	259 5 O
(	265 1 O
median	266 6 O
age	273 3 O
17	277 2 O
.	279 1 O
8	280 1 O
years	282 5 O
)	287 1 O
were	289 4 O
evaluated	294 9 O
2	304 1 O
.	305 1 O
3	306 1 O
-	307 1 O
14	308 2 O
.	310 1 O
1	311 1 O
years	313 5 O
(	319 1 O
median	320 6 O
8	327 1 O
.	328 1 O
9	329 1 O
years	331 5 O
)	336 1 O
following	338 9 O
completion	348 10 O
of	359 2 O
treatment	362 9 O
.	371 1 O

Cumulative	373 10 O
doses	384 5 O
of	390 2 O
doxorubicin	393 11 B-Chemical
were	405 4 O
225	410 3 O
-	413 1 O
550	414 3 O
mg	418 2 O
/	420 1 O
m2	421 2 O
(	424 1 O
median	425 6 O
dose	432 4 O
360	437 3 O
)	440 1 O
.	441 1 O

The	443 3 O
evaluation	447 10 O
consisted	458 9 O
of	468 2 O
a	471 1 O
history	473 7 O
,	480 1 O
physical	482 8 O
examination	491 11 O
,	502 1 O
electrocardiogram	504 17 O
(	522 1 O
ECG	523 3 O
)	526 1 O
,	527 1 O
signal	529 6 O
averaged	536 8 O
ECG	545 3 O
,	548 1 O
24	550 2 O
-	552 1 O
hour	553 4 O
ambulatory	558 10 O
ECG	569 3 O
,	572 1 O
echocardiography	574 16 O
and	591 3 O
radionuclide	595 12 O
angiography	608 11 O
.	619 1 O

Eighteen	621 8 O
of	630 2 O
31	633 2 O
(	636 1 O
58	637 2 O
%	639 1 O
)	640 1 O
patients	642 8 O
showed	651 6 O
cardiac	658 7 B-Disease
toxicity	666 8 I-Disease
,	674 1 O
defined	676 7 O
as	684 2 O
having	687 6 O
one	694 3 O
or	698 2 O
more	701 4 O
of	706 2 O
the	709 3 O
following	713 9 O
abnormalities	723 13 O
:	736 1 O
late	738 4 O
potentials	743 10 O
,	753 1 O
complex	755 7 O
ventricular	763 11 B-Disease
arrhythmias	775 11 I-Disease
,	786 1 O
left	788 4 O
ventricular	793 11 B-Disease
dilation	805 8 I-Disease
,	813 1 O
decreased	815 9 O
shortening	825 10 O
fraction	836 8 O
,	844 1 O
or	846 2 O
decreased	849 9 O
ejection	859 8 O
fraction	868 8 O
.	876 1 O

The	878 3 O
incidence	882 9 O
of	892 2 O
cardiac	895 7 B-Disease
abnormalities	903 13 I-Disease
increased	917 9 O
with	927 4 O
length	932 6 O
of	939 2 O
follow	942 6 O
-	948 1 O
up	949 2 O
(	952 1 O
P	953 1 O
<	954 1 O
or	956 2 O
=	959 1 O
.	961 1 O
05	962 2 O
)	964 1 O
.	965 1 O

No	967 2 O
correlation	970 11 O
could	982 5 O
be	988 2 O
demonstrated	991 12 O
between	1004 7 O
cumulative	1012 10 O
dose	1023 4 O
of	1028 2 O
doxorubicin	1031 11 B-Chemical
and	1043 3 O
cardiac	1047 7 O
status	1055 6 O
,	1061 1 O
except	1063 6 O
for	1070 3 O
heart	1074 5 O
rate	1080 4 O
variability	1085 11 O
.	1096 1 O

When	1098 4 O
adjusted	1103 8 O
to	1112 2 O
body	1115 4 O
surface	1120 7 O
area	1128 4 O
,	1132 1 O
the	1134 3 O
left	1138 4 O
ventricular	1143 11 O
posterior	1155 9 O
wall	1165 4 O
thickness	1170 9 O
(	1180 1 O
LVPW	1181 4 O
index	1186 5 O
)	1191 1 O
was	1193 3 O
decreased	1197 9 O
in	1207 2 O
all	1210 3 O
patients	1214 8 O
.	1222 1 O

The	1224 3 O
incidence	1228 9 O
of	1238 2 O
doxorubicin	1241 11 B-Chemical
-	1252 1 O
induced	1253 7 O
cardiotoxicity	1261 14 B-Disease
is	1276 2 O
high	1279 4 O
and	1284 3 O
increases	1288 9 O
with	1298 4 O
follow	1303 6 O
-	1309 1 O
up	1310 2 O
,	1312 1 O
irrespective	1314 12 O
of	1327 2 O
cumulative	1330 10 O
dose	1341 4 O
.	1345 1 O

Life	1347 4 O
-	1351 1 O
long	1352 4 O
cardiac	1357 7 O
follow	1365 6 O
-	1371 1 O
up	1372 2 O
in	1375 2 O
these	1378 5 O
patients	1384 8 O
is	1393 2 O
warranted	1396 9 O
.	1405 1 O

The	1407 3 O
results	1411 7 O
of	1419 2 O
our	1422 3 O
study	1426 5 O
suggest	1432 7 O
that	1440 4 O
heart	1445 5 O
rate	1451 4 O
variability	1456 11 O
and	1468 3 O
LVPW	1472 4 O
index	1477 5 O
could	1483 5 O
be	1489 2 O
sensitive	1492 9 O
indicators	1502 10 O
for	1513 3 O
cardiotoxicity	1517 14 B-Disease
.	1531 1 O

Venous	0 6 B-Disease
complications	7 13 I-Disease
of	21 2 O
midazolam	24 9 B-Chemical
versus	34 6 O
diazepam	41 8 B-Chemical
.	49 1 O

Although	51 8 O
some	60 4 O
studies	65 7 O
have	73 4 O
suggested	78 9 O
fewer	88 5 O
venous	94 6 B-Disease
complications	101 13 I-Disease
are	115 3 O
associated	119 10 O
with	130 4 O
midazolam	135 9 B-Chemical
than	145 4 O
with	150 4 O
diazepam	155 8 B-Chemical
for	164 3 O
endoscopic	168 10 O
procedures	179 10 O
,	189 1 O
this	191 4 O
variable	196 8 O
has	205 3 O
not	209 3 O
been	213 4 O
well	218 4 O
documented	223 10 O
.	233 1 O

We	235 2 O
prospectively	238 13 O
evaluated	252 9 O
the	262 3 O
incidence	266 9 O
of	276 2 O
venous	279 6 B-Disease
complications	286 13 I-Disease
after	300 5 O
intravenous	306 11 O
injection	318 9 O
of	328 2 O
diazepam	331 8 B-Chemical
or	340 2 O
midazolam	343 9 B-Chemical
in	353 2 O
122	356 3 O
consecutive	360 11 O
patients	372 8 O
undergoing	381 10 O
colonoscopy	392 11 O
and	404 3 O
esophagogastroduodenoscopy	408 26 O
.	434 1 O

Overall	436 7 O
,	443 1 O
venous	445 6 B-Disease
complications	452 13 I-Disease
were	466 4 O
more	471 4 O
frequent	476 8 O
with	485 4 O
diazepam	490 8 B-Chemical
(	499 1 O
22	500 2 O
of	503 2 O
62	506 2 O
patients	509 8 O
)	517 1 O
than	519 4 O
with	524 4 O
midazolam	529 9 B-Chemical
(	539 1 O
4	540 1 O
of	542 2 O
60	545 2 O
patients	548 8 O
)	556 1 O
(	558 1 O
p	559 1 O
<	561 1 O
0	563 1 O
.	564 1 O
001	565 3 O
)	568 1 O
.	569 1 O

A	571 1 O
palpable	573 8 O
venous	582 6 O
cord	589 4 O
was	594 3 O
present	598 7 O
in	606 2 O
23	609 2 O
%	611 1 O
(	613 1 O
14	614 2 O
of	617 2 O
62	620 2 O
)	622 1 O
of	624 2 O
patients	627 8 O
in	636 2 O
the	639 3 O
diazepam	643 8 B-Chemical
group	652 5 O
,	657 1 O
compared	659 8 O
with	668 4 O
2	673 1 O
%	674 1 O
(	676 1 O
1	677 1 O
of	679 2 O
60	682 2 O
patients	685 8 O
)	693 1 O
in	695 2 O
the	698 3 O
midazolam	702 9 B-Chemical
group	712 5 O
(	718 1 O
p	719 1 O
<	721 1 O
0	723 1 O
.	724 1 O
002	725 3 O
)	728 1 O
.	729 1 O

Pain	731 4 B-Disease
at	736 2 O
the	739 3 O
injection	743 9 O
site	753 4 O
occurred	758 8 O
in	767 2 O
35	770 2 O
%	772 1 O
(	774 1 O
22	775 2 O
of	778 2 O
62	781 2 O
)	783 1 O
of	785 2 O
patients	788 8 O
in	797 2 O
the	800 3 O
diazepam	804 8 B-Chemical
group	813 5 O
compared	819 8 O
with	828 4 O
7	833 1 O
%	834 1 O
(	836 1 O
4	837 1 O
of	839 2 O
60	842 2 O
patients	845 8 O
)	853 1 O
in	855 2 O
the	858 3 O
midazolam	862 9 B-Chemical
group	872 5 O
(	878 1 O
p	879 1 O
<	881 1 O
0	883 1 O
.	884 1 O
001	885 3 O
)	888 1 O
.	889 1 O

Swelling	891 8 B-Disease
and	900 3 O
warmth	904 6 O
at	911 2 O
the	914 3 O
injection	918 9 O
site	928 4 O
were	933 4 O
not	938 3 O
significantly	942 13 O
different	956 9 O
between	966 7 O
the	974 3 O
two	978 3 O
groups	982 6 O
.	988 1 O

Smoking	990 7 O
,	997 1 O
nonsteroidal	999 12 O
anti	1012 4 O
-	1016 1 O
inflammatory	1017 12 O
drug	1030 4 O
use	1035 3 O
,	1038 1 O
intravenous	1040 11 O
catheter	1052 8 O
site	1061 4 O
,	1065 1 O
dwell	1067 5 O
time	1073 4 O
of	1078 2 O
the	1081 3 O
needle	1085 6 O
,	1091 1 O
alcohol	1093 7 B-Chemical
use	1101 3 O
,	1104 1 O
and	1106 3 O
pain	1110 4 B-Disease
during	1115 6 O
the	1122 3 O
injection	1126 9 O
had	1136 3 O
no	1140 2 O
effect	1143 6 O
on	1150 2 O
the	1153 3 O
incidence	1157 9 O
of	1167 2 O
venous	1170 6 B-Disease
complications	1177 13 I-Disease
.	1190 1 O

Tetany	0 6 B-Disease
and	7 3 O
rhabdomyolysis	11 14 B-Disease
due	26 3 O
to	30 2 O
surreptitious	33 13 O
furosemide	47 10 B-Chemical
-	57 1 O
-	58 1 O
importance	59 10 O
of	70 2 O
magnesium	73 9 B-Chemical
supplementation	83 15 O
.	98 1 O

Diuretics	100 9 O
may	110 3 O
induce	114 6 O
hypokalemia	121 11 B-Disease
,	132 1 O
hypocalcemia	134 12 B-Disease
and	147 3 O
hypomagnesemia	151 14 B-Disease
.	165 1 O

While	167 5 O
severe	173 6 O
hypokalemia	180 11 B-Disease
may	192 3 O
cause	196 5 O
muscle	202 6 B-Disease
weakness	209 8 I-Disease
,	217 1 O
severe	219 6 O
hypomagnesemia	226 14 B-Disease
is	241 2 O
associated	244 10 O
with	255 4 O
muscle	260 6 B-Disease
spasms	267 6 I-Disease
and	274 3 O
tetany	278 6 B-Disease
which	285 5 O
cannot	291 6 O
be	298 2 O
corrected	301 9 O
by	311 2 O
potassium	314 9 B-Chemical
and	324 3 O
calcium	328 7 B-Chemical
supplementation	336 15 O
alone	352 5 O
(	358 1 O
1	359 1 O
,	360 1 O
2	361 1 O
)	362 1 O
.	363 1 O

Surreptitious	365 13 O
diuretic	379 8 O
ingestion	388 9 O
has	398 3 O
been	402 4 O
described	407 9 O
,	416 1 O
mainly	418 6 O
in	425 2 O
women	428 5 O
who	434 3 O
are	438 3 O
concerned	442 9 O
that	452 4 O
they	457 4 O
are	462 3 O
obese	466 5 B-Disease
or	472 2 O
edematous	475 9 B-Disease
.	484 1 O

Symptomatic	486 11 O
hypokalemia	498 11 B-Disease
has	510 3 O
been	514 4 O
reported	519 8 O
in	528 2 O
such	531 4 O
patients	536 8 O
(	545 1 O
3	546 1 O
-	547 1 O
7	548 1 O
)	549 1 O
and	551 3 O
in	555 2 O
one	558 3 O
case	562 4 O
hypocalcemia	567 12 B-Disease
was	580 3 O
observed	584 8 O
(	593 1 O
8	594 1 O
)	595 1 O
,	596 1 O
but	598 3 O
the	602 3 O
effects	606 7 O
of	614 2 O
magnesium	617 9 B-Chemical
depletion	627 9 O
were	637 4 O
not	642 3 O
noted	646 5 O
in	652 2 O
these	655 5 O
patients	661 8 O
.	669 1 O

Loss	0 4 O
of	5 2 O
glutamate	8 9 B-Chemical
decarboxylase	18 13 O
mRNA	32 4 O
-	36 1 O
containing	37 10 O
neurons	48 7 O
in	56 2 O
the	59 3 O
rat	63 3 O
dentate	67 7 O
gyrus	75 5 O
following	81 9 O
pilocarpine	91 11 B-Chemical
-	102 1 O
induced	103 7 O
seizures	111 8 B-Disease
.	119 1 O

In	121 2 O
situ	124 4 O
hybridization	129 13 O
methods	143 7 O
were	151 4 O
used	156 4 O
to	161 2 O
determine	164 9 O
if	174 2 O
glutamic	177 8 B-Chemical
acid	186 4 I-Chemical
decarboxylase	191 13 O
(	205 1 O
GAD	206 3 O
)	209 1 O
mRNA	211 4 O
-	215 1 O
containing	216 10 O
neurons	227 7 O
within	235 6 O
the	242 3 O
hilus	246 5 O
of	252 2 O
the	255 3 O
dentate	259 7 O
gyrus	267 5 O
are	273 3 O
vulnerable	277 10 O
to	288 2 O
seizure	291 7 B-Disease
-	298 1 O
induced	299 7 O
damage	307 6 O
in	314 2 O
a	317 1 O
model	319 5 O
of	325 2 O
chronic	328 7 O
seizures	336 8 B-Disease
.	344 1 O

Sprague	346 7 O
-	353 1 O
Dawley	354 6 O
rats	361 4 O
were	366 4 O
injected	371 8 O
intraperitoneally	380 17 O
with	398 4 O
pilocarpine	403 11 B-Chemical
,	414 1 O
and	416 3 O
the	420 3 O
hippocampal	424 11 O
formation	436 9 O
was	446 3 O
studied	450 7 O
histologically	458 14 O
at	473 2 O
1	476 1 O
,	477 1 O
2	479 1 O
,	480 1 O
4	482 1 O
,	483 1 O
and	485 3 O
8	489 1 O
week	491 4 O
intervals	496 9 O
after	506 5 O
pilocarpine	512 11 B-Chemical
-	523 1 O
induced	524 7 O
seizures	532 8 B-Disease
.	540 1 O

In	542 2 O
situ	545 4 O
hybridization	550 13 O
histochemistry	564 14 O
,	578 1 O
using	580 5 O
a	586 1 O
digoxigenin	588 11 B-Chemical
-	599 1 O
labeled	600 7 O
GAD	608 3 O
cRNA	612 4 O
probe	617 5 O
,	622 1 O
demonstrated	624 12 O
a	637 1 O
substantial	639 11 O
decrease	651 8 O
in	660 2 O
the	663 3 O
number	667 6 O
of	674 2 O
GAD	677 3 O
mRNA	681 4 O
-	685 1 O
containing	686 10 O
neurons	697 7 O
in	705 2 O
the	708 3 O
hilus	712 5 O
of	718 2 O
the	721 3 O
dentate	725 7 O
gyrus	733 5 O
in	739 2 O
the	742 3 O
pilocarpine	746 11 B-Chemical
-	757 1 O
treated	758 7 O
rats	766 4 O
as	771 2 O
compared	774 8 O
to	783 2 O
controls	786 8 O
at	795 2 O
all	798 3 O
time	802 4 O
intervals	807 9 O
.	816 1 O

Additional	818 10 O
neuronanatomical	829 16 O
studies	846 7 O
,	853 1 O
including	855 9 O
cresyl	865 6 B-Chemical
violet	872 6 I-Chemical
staining	879 8 O
,	887 1 O
neuronal	889 8 B-Disease
degeneration	898 12 I-Disease
methods	911 7 O
,	918 1 O
and	920 3 O
histochemical	924 13 O
localization	938 12 O
of	951 2 O
glial	954 5 O
fibrillary	960 10 O
acidic	971 6 O
protein	978 7 O
,	985 1 O
suggested	987 9 O
that	997 4 O
the	1002 3 O
decrease	1006 8 O
in	1015 2 O
the	1018 3 O
number	1022 6 O
of	1029 2 O
GAD	1032 3 O
mRNA	1036 4 O
-	1040 1 O
containing	1041 10 O
neurons	1052 7 O
was	1060 3 O
related	1064 7 O
to	1072 2 O
neuronal	1075 8 B-Disease
loss	1084 4 I-Disease
rather	1089 6 O
than	1096 4 O
to	1101 2 O
a	1104 1 O
decrease	1106 8 O
in	1115 2 O
GAD	1118 3 O
mRNA	1122 4 O
levels	1127 6 O
.	1133 1 O

The	1135 3 O
loss	1139 4 O
of	1144 2 O
GAD	1147 3 O
mRNA	1151 4 O
-	1155 1 O
containing	1156 10 O
neurons	1167 7 O
in	1175 2 O
the	1178 3 O
hilus	1182 5 O
contrasted	1188 10 O
with	1199 4 O
the	1204 3 O
relative	1208 8 O
preservation	1217 12 O
of	1230 2 O
labeled	1233 7 O
putative	1241 8 O
basket	1250 6 O
cells	1257 5 O
along	1263 5 O
the	1269 3 O
inner	1273 5 O
margin	1279 6 O
of	1286 2 O
the	1289 3 O
granule	1293 7 O
cell	1301 4 O
layer	1306 5 O
.	1311 1 O

Quantitative	1313 12 O
analyses	1326 8 O
of	1335 2 O
labeled	1338 7 O
neurons	1346 7 O
in	1354 2 O
three	1357 5 O
regions	1363 7 O
of	1371 2 O
the	1374 3 O
dentate	1378 7 O
gyrus	1386 5 O
in	1392 2 O
the	1395 3 O
1	1399 1 O
and	1401 3 O
2	1405 1 O
week	1407 4 O
groups	1412 6 O
showed	1419 6 O
statistically	1426 13 O
significant	1440 11 O
decreases	1452 9 O
in	1462 2 O
the	1465 3 O
mean	1469 4 O
number	1474 6 O
of	1481 2 O
GAD	1484 3 O
mRNA	1488 4 O
-	1492 1 O
containing	1493 10 O
neurons	1504 7 O
in	1512 2 O
the	1515 3 O
hilus	1519 5 O
of	1525 2 O
both	1528 4 O
groups	1533 6 O
of	1540 2 O
experimental	1543 12 O
animals	1556 7 O
.	1563 1 O

No	1565 2 O
significant	1568 11 O
differences	1580 11 O
were	1592 4 O
found	1597 5 O
in	1603 2 O
the	1606 3 O
molecular	1610 9 O
layer	1620 5 O
or	1626 2 O
the	1629 3 O
granule	1633 7 O
cell	1641 4 O
layer	1646 5 O
,	1651 1 O
which	1653 5 O
included	1659 8 O
labeled	1668 7 O
neurons	1676 7 O
along	1684 5 O
the	1690 3 O
lower	1694 5 O
margin	1700 6 O
of	1707 2 O
the	1710 3 O
granule	1714 7 O
cell	1722 4 O
layer	1727 5 O
.	1732 1 O

The	1734 3 O
results	1738 7 O
indicate	1746 8 O
that	1755 4 O
,	1759 1 O
in	1761 2 O
this	1764 4 O
model	1769 5 O
,	1774 1 O
a	1776 1 O
subpopulation	1778 13 O
of	1792 2 O
GAD	1795 3 O
mRNA	1799 4 O
-	1803 1 O
containing	1804 10 O
neurons	1815 7 O
within	1823 6 O
the	1830 3 O
dentate	1834 7 O
gyrus	1842 5 O
is	1848 2 O
selectively	1851 11 O
vulnerable	1863 10 O
to	1874 2 O
seizure	1877 7 B-Disease
-	1884 1 O
induced	1885 7 O
damage	1893 6 O
.	1899 1 O

Such	1901 4 O
differential	1906 12 O
vulnerability	1919 13 O
appears	1933 7 O
to	1941 2 O
be	1944 2 O
another	1947 7 O
indication	1955 10 O
of	1966 2 O
the	1969 3 O
heterogeneity	1973 13 O
of	1987 2 O
GABA	1990 4 B-Chemical
neurons	1995 7 O
.	2002 1 O

Protective	0 10 O
effect	11 6 O
of	18 2 O
misoprostol	21 11 B-Chemical
on	33 2 O
indomethacin	36 12 B-Chemical
induced	49 7 O
renal	57 5 B-Disease
dysfunction	63 11 I-Disease
in	75 2 O
elderly	78 7 O
patients	86 8 O
.	94 1 O

OBJECTIVE	96 9 O
:	105 1 O
To	107 2 O
evaluate	110 8 O
the	119 3 O
possible	123 8 O
protective	132 10 O
effects	143 7 O
of	151 2 O
misoprostol	154 11 B-Chemical
on	166 2 O
renal	169 5 O
function	175 8 O
in	184 2 O
hospitalized	187 12 O
elderly	200 7 O
patients	208 8 O
treated	217 7 O
with	225 4 O
indomethacin	230 12 B-Chemical
.	242 1 O

METHODS	244 7 O
:	251 1 O
Forty	253 5 O
-	258 1 O
five	259 4 O
hospitalized	264 12 O
elderly	277 7 O
patients	285 8 O
(	294 1 O
>	295 1 O
65	297 2 O
years	300 5 O
old	306 3 O
)	309 1 O
who	311 3 O
required	315 8 O
therapy	324 7 O
with	332 4 O
nonsteroidal	337 12 O
antiinflammatory	350 16 O
drugs	367 5 O
(	373 1 O
NSAID	374 5 O
)	379 1 O
were	381 4 O
randomly	386 8 O
assigned	395 8 O
to	404 2 O
receive	407 7 O
either	415 6 O
indomethacin	422 12 B-Chemical
,	434 1 O
150	436 3 O
mg	440 2 O
/	442 1 O
day	443 3 O
(	447 1 O
Group	448 5 O
A	454 1 O
)	455 1 O
,	456 1 O
or	458 2 O
indomethacin	461 12 B-Chemical
150	474 3 O
mg	478 2 O
/	480 1 O
day	481 3 O
plus	485 4 O
misoprostol	490 11 B-Chemical
at	502 2 O
0	505 1 O
.	506 1 O
6	507 1 O
mg	509 2 O
/	511 1 O
day	512 3 O
(	516 1 O
Group	517 5 O
B	523 1 O
)	524 1 O
.	525 1 O

Laboratory	527 10 O
variables	538 9 O
of	548 2 O
renal	551 5 O
function	557 8 O
[	566 1 O
serum	567 5 O
creatinine	573 10 B-Chemical
,	583 1 O
blood	585 5 B-Chemical
urea	591 4 I-Chemical
nitrogen	596 8 I-Chemical
(	605 1 O
BUN	606 3 B-Chemical
)	609 1 O
and	611 3 O
electrolytes	615 12 O
]	627 1 O
were	629 4 O
evaluated	634 9 O
before	644 6 O
initiation	651 10 O
of	662 2 O
therapy	665 7 O
and	673 3 O
every	677 5 O
2	683 1 O
days	685 4 O
,	689 1 O
until	691 5 O
termination	697 11 O
of	709 2 O
the	712 3 O
study	716 5 O
(	722 1 O
a	723 1 O
period	725 6 O
of	732 2 O
at	735 2 O
least	738 5 O
6	744 1 O
days	746 4 O
)	750 1 O
.	751 1 O

Response	753 8 O
to	762 2 O
treatment	765 9 O
was	775 3 O
estimated	779 9 O
by	789 2 O
the	792 3 O
visual	796 6 O
analog	803 6 O
scale	810 5 O
for	816 3 O
severity	820 8 O
of	829 2 O
pain	832 4 B-Disease
.	836 1 O

RESULTS	838 7 O
:	845 1 O
Forty	847 5 O
-	852 1 O
two	853 3 O
patients	857 8 O
completed	866 9 O
the	876 3 O
study	880 5 O
,	885 1 O
22	887 2 O
in	890 2 O
Group	893 5 O
A	899 1 O
and	901 3 O
20	905 2 O
in	908 2 O
Group	911 5 O
B	917 1 O
.	918 1 O

BUN	920 3 B-Chemical
and	924 3 O
creatinine	928 10 B-Chemical
increased	939 9 O
by	949 2 O
>	952 1 O
50	954 2 O
%	956 1 O
of	958 2 O
baseline	961 8 O
levels	970 6 O
in	977 2 O
54	980 2 O
and	983 3 O
45	987 2 O
%	989 1 O
of	991 2 O
Group	994 5 O
A	1000 1 O
patients	1002 8 O
,	1010 1 O
respectively	1012 12 O
,	1024 1 O
compared	1026 8 O
to	1035 2 O
only	1038 4 O
20	1043 2 O
and	1046 3 O
10	1050 2 O
%	1052 1 O
of	1054 2 O
Group	1057 5 O
B	1063 1 O
patients	1065 8 O
(	1074 1 O
p	1075 1 O
<	1077 1 O
0	1079 1 O
.	1080 1 O
05	1081 2 O
)	1083 1 O
.	1084 1 O

Potassium	1086 9 B-Chemical
(	1096 1 O
K	1097 1 B-Chemical
)	1098 1 O
increment	1100 9 O
of	1110 2 O
0	1113 1 O
.	1114 1 O
6	1115 1 O
mEq	1117 3 O
/	1120 1 O
l	1121 1 O
or	1123 2 O
more	1126 4 O
was	1131 3 O
observed	1135 8 O
in	1144 2 O
50	1147 2 O
%	1149 1 O
of	1151 2 O
Group	1154 5 O
A	1160 1 O
,	1161 1 O
but	1163 3 O
in	1167 2 O
only	1170 4 O
15	1175 2 O
%	1177 1 O
of	1179 2 O
Group	1182 5 O
B	1188 1 O
patients	1190 8 O
(	1199 1 O
p	1200 1 O
<	1202 1 O
0	1204 1 O
.	1205 1 O
05	1206 2 O
)	1208 1 O
.	1209 1 O

The	1211 3 O
mean	1215 4 O
increments	1220 10 O
in	1231 2 O
BUN	1234 3 B-Chemical
,	1237 1 O
creatinine	1239 10 B-Chemical
,	1249 1 O
and	1251 3 O
K	1255 1 B-Chemical
were	1257 4 O
reduced	1262 7 O
by	1270 2 O
63	1273 2 O
,	1275 1 O
80	1277 2 O
,	1279 1 O
and	1281 3 O
42	1285 2 O
%	1287 1 O
,	1288 1 O
respectively	1290 12 O
,	1302 1 O
in	1304 2 O
Group	1307 5 O
B	1313 1 O
patients	1315 8 O
compared	1324 8 O
to	1333 2 O
Group	1336 5 O
A	1342 1 O
.	1343 1 O
Response	1345 8 O
to	1354 2 O
treatment	1357 9 O
did	1367 3 O
not	1371 3 O
differ	1375 6 O
significantly	1382 13 O
between	1396 7 O
the	1404 3 O
2	1408 1 O
groups	1410 6 O
.	1416 1 O

CONCLUSION	1418 10 O
:	1428 1 O
Hospitalized	1430 12 O
elderly	1443 7 O
patients	1451 8 O
are	1460 3 O
at	1464 2 O
risk	1467 4 O
for	1472 3 O
developing	1476 10 O
indomethacin	1487 12 B-Chemical
related	1500 7 O
renal	1508 5 B-Disease
dysfunction	1514 11 I-Disease
.	1525 1 O

Addition	1527 8 O
of	1536 2 O
misoprostol	1539 11 B-Chemical
can	1551 3 O
minimize	1555 8 O
this	1564 4 O
renal	1569 5 B-Disease
impairment	1575 10 I-Disease
without	1586 7 O
affecting	1594 9 O
pain	1604 4 B-Disease
control	1609 7 O
.	1616 1 O

Nephrotoxic	0 11 B-Disease
effects	12 7 O
of	20 2 O
aminoglycoside	23 14 B-Chemical
treatment	38 9 O
on	48 2 O
renal	51 5 O
protein	57 7 O
reabsorption	65 12 O
and	78 3 O
accumulation	82 12 O
.	94 1 O

To	96 2 O
quantify	99 8 O
the	108 3 O
effects	112 7 O
of	120 2 O
gentamicin	123 10 B-Chemical
,	133 1 O
kanamycin	135 9 B-Chemical
and	145 3 O
netilmicin	149 10 B-Chemical
on	160 2 O
renal	163 5 O
protein	169 7 O
reabsorption	177 12 O
and	190 3 O
accumulation	194 12 O
,	206 1 O
these	208 5 O
drugs	214 5 O
were	220 4 O
administered	225 12 O
to	238 2 O
rats	241 4 O
intraperitoneally	246 17 O
(	264 1 O
30	265 2 O
mg	268 2 O
/	270 1 O
kg	271 2 O
/	273 1 O
day	274 3 O
)	277 1 O
for	279 3 O
7	283 1 O
,	284 1 O
14	286 2 O
or	289 2 O
21	292 2 O
days	295 4 O
.	299 1 O

Scanning	301 8 O
electron	310 8 O
microscopy	319 10 O
of	330 2 O
the	333 3 O
glomerular	337 10 O
endothelia	348 10 O
,	358 1 O
urinary	360 7 O
measurements	368 12 O
of	381 2 O
sodium	384 6 B-Chemical
,	390 1 O
potassium	392 9 B-Chemical
,	401 1 O
endogenous	403 10 O
lysozyme	414 8 O
,	422 1 O
N	424 1 O
-	425 1 O
acetyl	426 6 O
-	432 1 O
beta	433 4 O
-	437 1 O
D	438 1 O
-	439 1 O
glucosaminidase	440 15 O
(	456 1 O
NAG	457 3 O
)	460 1 O
as	462 2 O
well	465 4 O
as	470 2 O
clearance	473 9 O
and	483 3 O
accumulation	487 12 O
experiments	500 11 O
after	512 5 O
i	518 1 O
.	519 1 O
v	520 1 O
.	521 1 O
administration	523 14 O
of	538 2 O
egg	541 3 O
-	544 1 O
white	545 5 O
lysozyme	551 8 O
and	560 3 O
measurements	564 12 O
of	577 2 O
inulin	580 6 O
clearance	587 9 O
(	597 1 O
GFR	598 3 O
)	601 1 O
were	603 4 O
done	608 4 O
in	613 2 O
each	616 4 O
treatment	621 9 O
group	631 5 O
.	636 1 O

Gentamicin	638 10 B-Chemical
administration	649 14 O
decreased	664 9 O
diameter	674 8 O
,	682 1 O
density	684 7 O
and	692 3 O
shape	696 5 O
of	702 2 O
endothelial	705 11 O
fenestrae	717 9 O
.	726 1 O

Kanamycin	728 9 B-Chemical
and	738 3 O
netilmicin	742 10 B-Chemical
appeared	753 8 O
to	762 2 O
have	765 4 O
no	770 2 O
effect	773 6 O
at	780 2 O
the	783 3 O
dose	787 4 O
used	792 4 O
.	796 1 O

All	798 3 O
three	802 5 O
aminoglycosides	808 15 B-Chemical
decreased	824 9 O
GFR	834 3 O
and	838 3 O
increased	842 9 O
urinary	852 7 O
excretion	860 9 O
of	870 2 O
sodium	873 6 B-Chemical
and	880 3 O
potassium	884 9 B-Chemical
.	893 1 O

While	895 5 O
gentamicin	901 10 B-Chemical
and	912 3 O
kanamycin	916 9 B-Chemical
decreased	926 9 O
the	936 3 O
percentage	940 10 O
reabsorption	951 12 O
and	964 3 O
accumulation	968 12 O
of	981 2 O
lysozyme	984 8 O
after	993 5 O
i	999 1 O
.	1000 1 O
v	1001 1 O
.	1002 1 O
administration	1004 14 O
of	1019 2 O
egg	1022 3 O
-	1025 1 O
white	1026 5 O
lysozyme	1032 8 O
netilmicin	1041 10 B-Chemical
had	1052 3 O
no	1056 2 O
effect	1059 6 O
.	1065 1 O

Daily	1067 5 O
excretion	1073 9 O
of	1083 2 O
total	1086 5 O
protein	1092 7 O
,	1099 1 O
endogenous	1101 10 O
lysozyme	1112 8 O
and	1121 3 O
NAG	1125 3 O
increased	1129 9 O
only	1139 4 O
after	1144 5 O
treatment	1150 9 O
with	1160 4 O
kanamycin	1165 9 B-Chemical
and	1175 3 O
gentamicin	1179 10 B-Chemical
.	1189 1 O

Thus	1191 4 O
,	1195 1 O
aminoglycosides	1197 15 B-Chemical
may	1213 3 O
act	1217 3 O
as	1221 2 O
nephrotoxicants	1224 15 O
at	1240 2 O
glomerular	1243 10 O
and	1254 3 O
/	1257 1 O
or	1258 2 O
tubular	1261 7 O
level	1269 5 O
inducing	1275 8 O
impairment	1284 10 B-Disease
of	1295 2 I-Disease
renal	1298 5 I-Disease
reabsorption	1304 12 I-Disease
and	1317 3 O
accumulation	1321 12 O
of	1334 2 O
proteins	1337 8 O
.	1345 1 O

Pharmacology	0 12 O
of	13 2 O
GYKI	16 4 B-Chemical
-	20 1 I-Chemical
41	21 2 I-Chemical
099	24 3 I-Chemical
(	28 1 O
chlorpropanol	29 13 B-Chemical
,	42 1 O
Tobanum	44 7 B-Chemical
)	51 1 O
a	53 1 O
new	55 3 O
potent	59 6 O
beta	66 4 O
-	70 1 O
adrenergic	71 10 O
antagonist	82 10 O
.	92 1 O

The	94 3 O
compound	98 8 O
GYKI	107 4 B-Chemical
-	111 1 I-Chemical
41	112 2 I-Chemical
099	115 3 I-Chemical
,	118 1 O
as	120 2 O
a	123 1 O
beta	125 4 O
-	129 1 O
adrenergic	130 10 O
antagonist	141 10 O
,	151 1 O
is	153 2 O
3	156 1 O
-	157 1 O
8	158 1 O
times	160 5 O
more	166 4 O
potent	171 6 O
than	178 4 O
propranolol	183 11 B-Chemical
in	195 2 O
vitro	198 5 O
and	204 3 O
in	208 2 O
vivo	211 4 O
.	215 1 O

Its	217 3 O
antiarrhythmic	221 14 O
effectiveness	236 13 O
surpasses	250 9 O
that	260 4 O
of	265 2 O
propranolol	268 11 B-Chemical
and	280 3 O
pindolol	284 8 B-Chemical
inhibiting	293 10 O
the	304 3 O
ouabain	308 7 B-Chemical
arrhythmia	316 10 B-Disease
in	327 2 O
dogs	330 4 O
and	335 3 O
cats	339 4 O
.	343 1 O

GYKI	345 4 B-Chemical
-	349 1 I-Chemical
41	350 2 I-Chemical
900	353 3 I-Chemical
has	357 3 O
a	361 1 O
negligible	363 10 O
cardiodepressant	374 16 O
activity	391 8 O
;	399 1 O
it	401 2 O
is	404 2 O
not	407 3 O
cardioselective	411 15 O
.	426 1 O

The	428 3 O
compound	432 8 O
shows	441 5 O
a	447 1 O
rapid	449 5 O
and	455 3 O
long	459 4 O
lasting	464 7 O
effect	472 6 O
.	478 1 O

There	480 5 O
was	486 3 O
a	490 1 O
prolonged	492 9 O
elimination	502 11 O
of	514 2 O
the	517 3 O
radioactivity	521 13 O
after	535 5 O
the	541 3 O
injection	545 9 O
of	555 2 O
14C	558 3 B-Chemical
-	561 1 I-Chemical
41	562 2 I-Chemical
099	565 3 I-Chemical
to	569 2 O
rats	572 4 O
and	577 3 O
dogs	581 4 O
.	585 1 O

The	587 3 O
half	591 4 O
life	596 4 O
of	601 2 O
the	604 3 O
unlabeled	608 9 O
substance	618 9 O
in	628 2 O
humans	631 6 O
was	638 3 O
more	642 4 O
than	647 4 O
10	652 2 O
hours	655 5 O
.	660 1 O

Chorea	0 6 B-Disease
associated	7 10 O
with	18 4 O
oral	23 4 B-Chemical
contraception	28 13 I-Chemical
.	41 1 O

Three	43 5 O
patients	49 8 O
developed	58 9 O
chorea	68 6 B-Disease
while	75 5 O
receiving	81 9 O
oral	91 4 B-Chemical
contraceptives	96 14 I-Chemical
.	110 1 O

Two	112 3 O
were	116 4 O
young	121 5 O
patients	127 8 O
whose	136 5 O
chorea	142 6 B-Disease
developed	149 9 O
long	159 4 O
after	164 5 O
treatment	170 9 O
had	180 3 O
been	184 4 O
started	189 7 O
and	197 3 O
disappeared	201 11 O
soon	213 4 O
after	218 5 O
it	224 2 O
had	227 3 O
been	231 4 O
discontinued	236 12 O
.	248 1 O

The	250 3 O
third	254 5 O
patient	260 7 O
had	268 3 O
acute	272 5 O
amphetamine	278 11 B-Chemical
-	289 1 O
induced	290 7 O
chorea	298 6 B-Disease
after	305 5 O
prolonged	311 9 O
oral	321 4 B-Chemical
contraception	326 13 I-Chemical
.	339 1 O

Prolonged	341 9 O
administration	351 14 O
of	366 2 O
female	369 6 O
sex	376 3 O
hormones	380 8 O
is	389 2 O
a	392 1 O
possible	394 8 O
cause	403 5 O
of	409 2 O
chorea	412 6 B-Disease
in	419 2 O
women	422 5 O
who	428 3 O
have	432 4 O
not	437 3 O
previously	441 10 O
had	452 3 O
chorea	456 6 B-Disease
or	463 2 O
rheumatic	466 9 B-Disease
fever	476 5 I-Disease
.	481 1 O

Reversal	0 8 O
of	9 2 O
ammonia	12 7 B-Chemical
coma	20 4 B-Disease
in	25 2 O
rats	28 4 O
by	33 2 O
L	36 1 B-Chemical
-	37 1 I-Chemical
dopa	38 4 I-Chemical
:	42 1 O
a	44 1 O
peripheral	46 10 O
effect	57 6 O
.	63 1 O

Ammonia	65 7 B-Chemical
coma	73 4 B-Disease
was	78 3 O
produced	82 8 O
in	91 2 O
rats	94 4 O
within	99 6 O
10	106 2 O
to	109 2 O
15	112 2 O
minutes	115 7 O
of	123 2 O
an	126 2 O
intraperitonealinjection	129 24 O
of	154 2 O
1	157 1 O
.	158 1 O
7	159 1 O
mmol	161 4 O
NH4CL	166 5 B-Chemical
.	171 1 O

This	173 4 O
coma	178 4 B-Disease
was	183 3 O
prevented	187 9 O
with	197 4 O
1	202 1 O
.	203 1 O
68	204 2 O
mmol	207 4 O
L	212 1 B-Chemical
-	213 1 I-Chemical
dopa	214 4 I-Chemical
given	219 5 O
by	225 2 O
gastric	228 7 O
intubation	236 10 O
15	247 2 O
minutes	250 7 O
before	258 6 O
the	265 3 O
ammonium	269 8 B-Chemical
salt	278 4 I-Chemical
injection	283 9 O
.	292 1 O

The	294 3 O
effect	298 6 O
of	305 2 O
L	308 1 B-Chemical
-	309 1 I-Chemical
dopa	310 4 I-Chemical
was	315 3 O
correlated	319 10 O
with	330 4 O
a	335 1 O
decrease	337 8 O
in	346 2 O
blood	349 5 O
and	355 3 O
brain	359 5 O
ammonia	365 7 B-Chemical
,	372 1 O
an	374 2 O
increase	377 8 O
in	386 2 O
brain	389 5 O
dopamine	395 8 B-Chemical
,	403 1 O
and	405 3 O
an	409 2 O
increase	412 8 O
in	421 2 O
renal	424 5 O
excretion	430 9 O
of	440 2 O
ammonia	443 7 B-Chemical
and	451 3 O
urea	455 4 B-Chemical
.	459 1 O

Intraventricular	461 16 O
infusion	478 8 O
of	487 2 O
dopamine	490 8 B-Chemical
sufficient	499 10 O
to	510 2 O
raise	513 5 O
the	519 3 O
brain	523 5 O
dopamine	529 8 B-Chemical
to	538 2 O
the	541 3 O
same	545 4 O
extent	550 6 O
did	557 3 O
not	561 3 O
prevent	565 7 O
the	573 3 O
ammonia	577 7 B-Chemical
coma	585 4 B-Disease
nor	590 3 O
affect	594 6 O
the	601 3 O
blood	605 5 O
and	611 3 O
brain	615 5 O
ammonia	621 7 B-Chemical
concentrations	629 14 O
.	643 1 O

Bilateral	645 9 O
nephrectomy	655 11 O
eliminated	667 10 O
the	678 3 O
beneficial	682 10 O
effect	693 6 O
of	700 2 O
L	703 1 B-Chemical
-	704 1 I-Chemical
dopa	705 4 I-Chemical
on	710 2 O
blood	713 5 O
and	719 3 O
brain	723 5 O
ammonia	729 7 B-Chemical
and	737 3 O
the	741 3 O
ammonia	745 7 B-Chemical
coma	753 4 B-Disease
was	758 3 O
not	762 3 O
prevented	766 9 O
.	775 1 O

Thus	777 4 O
,	781 1 O
the	783 3 O
reduction	787 9 O
in	797 2 O
blood	800 5 O
and	806 3 O
brain	810 5 O
ammonia	816 7 B-Chemical
and	824 3 O
the	828 3 O
prevention	832 10 O
of	843 2 O
ammonia	846 7 B-Chemical
coma	854 4 B-Disease
after	859 5 O
L	865 1 B-Chemical
-	866 1 I-Chemical
dopa	867 4 I-Chemical
,	871 1 O
can	873 3 O
be	877 2 O
accounted	880 9 O
for	890 3 O
by	894 2 O
the	897 3 O
peripheral	901 10 O
effect	912 6 O
of	919 2 O
dopamine	922 8 B-Chemical
on	931 2 O
renal	934 5 O
function	940 8 O
rather	949 6 O
than	956 4 O
its	961 3 O
central	965 7 O
action	973 6 O
.	979 1 O

These	981 5 O
results	987 7 O
provide	995 7 O
a	1003 1 O
reasonable	1005 10 O
explanation	1016 11 O
for	1028 3 O
the	1032 3 O
beneficial	1036 10 O
effects	1047 7 O
observed	1055 8 O
in	1064 2 O
some	1067 4 O
encephalopathic	1072 15 B-Disease
patients	1088 8 O
receiving	1097 9 O
L	1107 1 B-Chemical
-	1108 1 I-Chemical
dopa	1109 4 I-Chemical
.	1113 1 O

Heparin	0 7 B-Chemical
-	7 1 O
induced	8 7 O
thrombocytopenia	16 16 B-Disease
after	33 5 O
liver	39 5 O
transplantation	45 15 O
.	60 1 O

BACKGROUND	62 10 O
:	72 1 O
Unfractionated	74 14 B-Chemical
heparin	89 7 I-Chemical
sodium	97 6 I-Chemical
(	104 1 O
UFH	105 3 B-Chemical
)	108 1 O
or	110 2 O
low	113 3 B-Chemical
-	116 1 I-Chemical
molecular	117 9 I-Chemical
weight	127 6 I-Chemical
heparin	134 7 I-Chemical
(	142 1 O
LMWH	143 4 O
)	147 1 O
is	149 2 O
used	152 4 O
in	157 2 O
anticoagulant	160 13 O
protocols	174 9 O
at	184 2 O
several	187 7 O
institutions	195 12 O
to	208 2 O
prevent	211 7 O
thrombosis	219 10 B-Disease
after	230 5 O
liver	236 5 O
transplantation	242 15 O
.	257 1 O

Heparin	259 7 B-Chemical
-	266 1 O
induced	267 7 O
thrombocytopenia	275 16 B-Disease
(	292 1 O
HIT	293 3 B-Disease
)	296 1 O
is	298 2 O
an	301 2 O
adverse	304 7 O
immune	312 6 O
-	318 1 O
mediated	319 8 O
reaction	328 8 O
to	337 2 O
heparin	340 7 B-Chemical
,	347 1 O
resulting	349 9 O
in	359 2 O
platelet	362 8 O
count	371 5 O
decreases	377 9 O
of	387 2 O
more	390 4 O
than	395 4 O
50	400 2 O
%	402 1 O
.	403 1 O

The	405 3 O
frequencies	409 11 O
of	421 2 O
HIT	424 3 B-Disease
after	428 5 O
liver	434 5 O
transplantation	440 15 O
and	456 3 O
platelet	460 8 O
factor	469 6 O
4	476 1 O
/	477 1 O
heparin	478 7 B-Chemical
-	485 1 O
reactive	486 8 O
antibody	495 8 O
(	504 1 O
HIT	505 3 B-Disease
antibody	509 8 O
)	517 1 O
positivity	519 10 O
in	530 2 O
liver	533 5 O
transplantation	539 15 O
patients	555 8 O
,	563 1 O
however	565 7 O
,	572 1 O
are	574 3 O
unknown	578 7 O
.	585 1 O

PATIENTS	587 8 O
AND	596 3 O
METHODS	600 7 O
:	607 1 O
The	609 3 O
32	613 2 O
men	616 3 O
and	620 3 O
20	624 2 O
women	627 5 O
underwent	633 9 O
living	643 6 O
donor	650 5 O
liver	656 5 O
transplantation	662 15 O
.	677 1 O

We	679 2 O
started	682 7 O
LMWH	690 4 O
(	695 1 O
25	696 2 O
IU	699 2 O
/	701 1 O
kg	702 2 O
/	704 1 O
h	705 1 O
)	706 1 O
on	708 2 O
postoperative	711 13 O
day	725 3 O
(	729 1 O
POD	730 3 O
)	733 1 O
1	735 1 O
,	736 1 O
switching	738 9 O
to	748 2 O
UFH	751 3 B-Chemical
(	755 1 O
5000	756 4 O
U	761 1 O
/	762 1 O
d	763 1 O
)	764 1 O
on	766 2 O
POD	769 3 O
2	773 1 O
or	775 2 O
3	778 1 O
.	779 1 O

The	781 3 O
dose	785 4 O
of	790 2 O
UFH	793 3 B-Chemical
was	797 3 O
changed	801 7 O
according	809 9 O
to	819 2 O
the	822 3 O
activated	826 9 O
clotting	836 8 O
time	845 4 O
level	850 5 O
.	855 1 O

HIT	857 3 B-Disease
antibody	861 8 O
levels	870 6 O
were	877 4 O
measured	882 8 O
the	891 3 O
day	895 3 O
before	899 6 O
surgery	906 7 O
and	914 3 O
on	918 2 O
POD	921 3 O
7	925 1 O
and	927 3 O
14	931 2 O
.	933 1 O

Platelet	935 8 O
count	944 5 O
was	950 3 O
measured	954 8 O
daily	963 5 O
for	969 3 O
3	973 1 O
weeks	975 5 O
.	980 1 O

RESULTS	982 7 O
:	989 1 O
The	991 3 O
average	995 7 O
platelet	1003 8 O
counts	1012 6 O
preoperatively	1019 14 O
,	1033 1 O
and	1035 3 O
on	1039 2 O
POD	1042 3 O
7	1046 1 O
,	1047 1 O
14	1049 2 O
,	1051 1 O
and	1053 3 O
21	1057 2 O
were	1060 4 O
65	1065 2 O
,	1067 1 O
88	1069 2 O
,	1071 1 O
149	1073 3 O
,	1076 1 O
and	1078 3 O
169	1082 3 O
x	1086 1 O
10	1088 2 O
(	1090 1 O
9	1091 1 O
)	1092 1 O
/	1093 1 O
L	1094 1 O
,	1095 1 O
respectively	1097 12 O
.	1109 1 O

Two	1111 3 O
patients	1115 8 O
developed	1124 9 O
hepatic	1134 7 O
artery	1142 6 O
thrombosis	1149 10 B-Disease
on	1160 2 O
POD	1163 3 O
11	1167 2 O
and	1170 3 O
19	1174 2 O
,	1176 1 O
respectively	1178 12 O
,	1190 1 O
although	1192 8 O
they	1201 4 O
were	1206 4 O
HIT	1211 3 B-Disease
antibody	1215 8 O
-	1223 1 O
negative	1224 8 O
and	1233 3 O
their	1237 5 O
platelet	1243 8 O
counts	1252 6 O
were	1259 4 O
stable	1264 6 O
.	1270 1 O

In	1272 2 O
2	1275 1 O
other	1277 5 O
patients	1283 8 O
,	1291 1 O
the	1293 3 O
platelet	1297 8 O
count	1306 5 O
decreased	1312 9 O
suddenly	1322 8 O
from	1331 4 O
107	1336 3 O
x	1340 1 O
10	1342 2 O
(	1344 1 O
9	1345 1 O
)	1346 1 O
/	1347 1 O
L	1348 1 O
on	1350 2 O
POD	1353 3 O
4	1357 1 O
to	1359 2 O
65	1362 2 O
x	1365 1 O
10	1367 2 O
(	1369 1 O
9	1370 1 O
)	1371 1 O
/	1372 1 O
L	1373 1 O
on	1375 2 O
POD	1378 3 O
6	1382 1 O
and	1384 3 O
from	1388 4 O
76	1393 2 O
x	1396 1 O
10	1398 2 O
(	1400 1 O
9	1401 1 O
)	1402 1 O
/	1403 1 O
L	1404 1 O
on	1406 2 O
POD	1409 3 O
7	1413 1 O
to	1415 2 O
33	1418 2 O
x	1421 1 O
10	1423 2 O
(	1425 1 O
9	1426 1 O
)	1427 1 O
/	1428 1 O
L	1429 1 O
on	1431 2 O
POD	1434 3 O
9	1438 1 O
,	1439 1 O
respectively	1441 12 O
.	1453 1 O

The	1455 3 O
heparin	1459 7 B-Chemical
-	1466 1 O
induced	1467 7 O
platelet	1475 8 B-Disease
aggregation	1484 11 I-Disease
test	1496 4 O
was	1501 3 O
negative	1505 8 O
in	1514 2 O
these	1517 5 O
patients	1523 8 O
.	1531 1 O

The	1533 3 O
percentage	1537 10 O
of	1548 2 O
HIT	1551 3 B-Disease
antibody	1555 8 O
-	1563 1 O
positive	1564 8 O
patients	1573 8 O
was	1582 3 O
0	1586 1 O
.	1587 1 O
5	1588 1 O
%	1589 1 O
preoperatively	1591 14 O
,	1605 1 O
5	1607 1 O
.	1608 1 O
6	1609 1 O
%	1610 1 O
on	1612 2 O
POD	1615 3 O
7	1619 1 O
,	1620 1 O
and	1622 3 O
5	1626 1 O
.	1627 1 O
6	1628 1 O
%	1629 1 O
on	1631 2 O
POD	1634 3 O
14	1638 2 O
.	1640 1 O

None	1642 4 O
of	1647 2 O
the	1650 3 O
subjects	1654 8 O
/	1662 1 O
patients	1663 8 O
developed	1672 9 O
UFH	1682 3 B-Chemical
-	1685 1 O
related	1686 7 O
HIT	1694 3 B-Disease
.	1697 1 O

CONCLUSIONS	1699 11 O
:	1710 1 O
In	1712 2 O
our	1715 3 O
series	1719 6 O
,	1725 1 O
the	1727 3 O
occurrence	1731 10 O
of	1742 2 O
HIT	1745 3 B-Disease
after	1749 5 O
liver	1755 5 O
transplantation	1761 15 O
was	1777 3 O
uncommon	1781 8 O
.	1789 1 O

PTU	0 3 B-Chemical
-	3 1 O
associated	4 10 O
vasculitis	15 10 B-Disease
in	26 2 O
a	29 1 O
girl	31 4 O
with	36 4 O
Turner	41 6 B-Disease
Syndrome	48 8 I-Disease
and	57 3 O
Graves	61 6 B-Disease
'	67 1 I-Disease
disease	69 7 I-Disease
.	76 1 O

Palpable	78 8 O
purpura	87 7 B-Disease
is	95 2 O
a	98 1 O
concerning	100 10 O
clinical	111 8 O
finding	120 7 O
in	128 2 O
pediatric	131 9 O
patients	141 8 O
and	150 3 O
can	154 3 O
have	158 4 O
many	163 4 O
causes	168 6 O
,	174 1 O
including	176 9 O
infectious	186 10 O
and	197 3 O
autoimmune	201 10 O
processes	212 9 O
.	221 1 O

A	223 1 O
rare	225 4 O
cause	230 5 O
,	235 1 O
drug	237 4 O
-	241 1 O
induced	242 7 O
vasculitis	250 10 B-Disease
,	260 1 O
may	262 3 O
result	266 6 O
from	273 4 O
the	278 3 O
production	282 10 O
of	293 2 O
antineutrophil	296 14 O
cytoplasmic	311 11 O
antibodies	323 10 O
(	334 1 O
ANCAs	335 5 O
)	340 1 O
in	342 2 O
response	345 8 O
to	354 2 O
a	357 1 O
medication	359 10 O
.	369 1 O

We	371 2 O
report	374 6 O
a	381 1 O
girl	383 4 O
with	388 4 O
Turner	393 6 B-Disease
syndrome	400 8 I-Disease
and	409 3 O
Graves	413 6 B-Disease
'	419 1 I-Disease
disease	421 7 I-Disease
who	429 3 O
presented	433 9 O
with	443 4 O
palpable	448 8 O
purpuric	457 8 B-Disease
lesions	466 7 I-Disease
.	473 1 O

The	475 3 O
diagnosis	479 9 O
of	489 2 O
propylthiouracil	492 16 B-Chemical
(	509 1 O
PTU	510 3 B-Chemical
)	513 1 O
-	514 1 O
associated	515 10 O
vasculitis	526 10 B-Disease
was	537 3 O
made	541 4 O
by	546 2 O
observation	549 11 O
of	561 2 O
consistent	564 10 O
clinical	575 8 O
features	584 8 O
,	592 1 O
the	594 3 O
detection	598 9 O
of	608 2 O
elevated	611 8 O
ANA	620 3 O
and	624 3 O
ANCA	628 4 O
in	633 2 O
the	636 3 O
blood	640 5 O
,	645 1 O
and	647 3 O
the	651 3 O
observed	655 8 O
clinical	664 8 O
resolution	673 10 O
of	684 2 O
symptoms	687 8 O
following	696 9 O
withdrawal	706 10 O
of	717 2 O
PTU	720 3 B-Chemical
.	723 1 O

Subsequent	725 10 O
treatment	736 9 O
of	746 2 O
persistent	749 10 O
hyperthyroidism	760 15 B-Disease
with	776 4 O
radioablation	781 13 O
did	795 3 O
not	799 3 O
result	803 6 O
in	810 2 O
an	813 2 O
exacerbation	816 12 O
of	829 2 O
the	832 3 O
vasculitis	836 10 B-Disease
,	846 1 O
a	848 1 O
complication	850 12 O
described	863 9 O
in	873 2 O
prior	876 5 O
case	882 4 O
reports	887 7 O
.	894 1 O

Succinylcholine	0 15 B-Chemical
-	15 1 O
induced	16 7 O
masseter	24 8 B-Disease
muscle	33 6 I-Disease
rigidity	40 8 I-Disease
during	49 6 O
bronchoscopic	56 13 O
removal	70 7 O
of	78 2 O
a	81 1 O
tracheal	83 8 O
foreign	92 7 O
body	100 4 O
.	104 1 O

Masseter	106 8 B-Disease
muscle	115 6 I-Disease
rigidity	122 8 I-Disease
during	131 6 O
general	138 7 O
anesthesia	146 10 O
is	157 2 O
considered	160 10 O
an	171 2 O
early	174 5 O
warning	180 7 O
sign	188 4 O
of	193 2 O
a	196 1 O
possible	198 8 O
episode	207 7 O
of	215 2 O
malignant	218 9 B-Disease
hyperthermia	228 12 I-Disease
.	240 1 O

The	242 3 O
decision	246 8 O
whether	255 7 O
to	263 2 O
continue	266 8 O
or	275 2 O
discontinue	278 11 O
the	290 3 O
procedure	294 9 O
depends	304 7 O
on	312 2 O
the	315 3 O
urgency	319 7 O
of	327 2 O
the	330 3 O
surgery	334 7 O
and	342 3 O
severity	346 8 O
of	355 2 O
masseter	358 8 B-Disease
muscle	367 6 I-Disease
rigidity	374 8 I-Disease
.	382 1 O

Here	384 4 O
,	388 1 O
we	390 2 O
describe	393 8 O
a	402 1 O
case	404 4 O
of	409 2 O
severe	412 6 O
masseter	419 8 B-Disease
muscle	428 6 I-Disease
rigidity	435 8 I-Disease
(	444 1 O
jaw	445 3 B-Disease
of	449 2 I-Disease
steel	452 5 I-Disease
)	457 1 O
after	459 5 O
succinylcholine	465 15 B-Chemical
(	481 1 O
Sch	482 3 B-Chemical
)	485 1 O
administration	487 14 O
during	502 6 O
general	509 7 O
anesthetic	517 10 O
management	528 10 O
for	539 3 O
rigid	543 5 O
bronchoscopic	549 13 O
removal	563 7 O
of	571 2 O
a	574 1 O
tracheal	576 8 O
foreign	585 7 O
body	593 4 O
.	597 1 O

Anesthesia	599 10 O
was	610 3 O
continued	614 9 O
uneventfully	624 12 O
with	637 4 O
propofol	642 8 B-Chemical
infusion	651 8 O
while	660 5 O
all	666 3 O
facilities	670 10 O
were	681 4 O
available	686 9 O
to	696 2 O
detect	699 6 O
and	706 3 O
treat	710 5 O
malignant	716 9 B-Disease
hyperthermia	726 12 I-Disease
.	738 1 O

Minor	0 5 O
neurological	6 12 B-Disease
dysfunction	19 11 I-Disease
,	30 1 O
cognitive	32 9 O
development	42 11 O
,	53 1 O
and	55 3 O
somatic	59 7 O
development	67 11 O
at	79 2 O
the	82 3 O
age	86 3 O
of	90 2 O
3	93 1 O
to	95 2 O
7	98 1 O
years	100 5 O
after	106 5 O
dexamethasone	112 13 B-Chemical
treatment	126 9 O
in	136 2 O
very	139 4 O
-	143 1 O
low	144 3 O
birth	148 5 O
-	153 1 O
weight	154 6 O
infants	161 7 O
.	168 1 O

The	170 3 O
objective	174 9 O
of	184 2 O
this	187 4 O
study	192 5 O
was	198 3 O
to	202 2 O
assess	205 6 O
minor	212 5 O
neurological	218 12 B-Disease
dysfunction	231 11 I-Disease
,	242 1 O
cognitive	244 9 O
development	254 11 O
,	265 1 O
and	267 3 O
somatic	271 7 O
development	279 11 O
after	291 5 O
dexamethasone	297 13 B-Chemical
therapy	311 7 O
in	319 2 O
very	322 4 O
-	326 1 O
low	327 3 O
-	330 1 O
birthweight	331 11 O
infants	343 7 O
.	350 1 O

Thirty	352 6 O
-	358 1 O
three	359 5 O
children	365 8 O
after	374 5 O
dexamethasone	380 13 B-Chemical
treatment	394 9 O
were	404 4 O
matched	409 7 O
to	417 2 O
33	420 2 O
children	423 8 O
without	432 7 O
dexamethasone	440 13 B-Chemical
treatment	454 9 O
.	463 1 O

Data	465 4 O
were	470 4 O
assessed	475 8 O
at	484 2 O
the	487 3 O
age	491 3 O
of	495 2 O
3	498 1 O
-	499 1 O
7	500 1 O
years	502 5 O
.	507 1 O

Dexamethasone	509 13 B-Chemical
was	523 3 O
started	527 7 O
between	535 7 O
the	543 3 O
7th	547 3 O
and	551 3 O
the	555 3 O
28th	559 4 O
day	564 3 O
of	568 2 O
life	571 4 O
over	576 4 O
7	581 1 O
days	583 4 O
with	588 4 O
a	593 1 O
total	595 5 O
dose	601 4 O
of	606 2 O
2	609 1 O
.	610 1 O
35	611 2 O
mg	614 2 O
/	616 1 O
kg	617 2 O
/	619 1 O
day	620 3 O
.	623 1 O

Exclusion	625 9 O
criteria	635 8 O
were	644 4 O
asphyxia	649 8 B-Disease
,	657 1 O
malformations	659 13 B-Disease
,	672 1 O
major	674 5 O
surgical	680 8 O
interventions	689 13 O
,	702 1 O
small	704 5 O
for	710 3 O
gestational	714 11 O
age	726 3 O
,	729 1 O
intraventricular	731 16 O
haemorrhage	748 11 B-Disease
grades	760 6 O
III	767 3 O
and	771 3 O
IV	775 2 O
,	777 1 O
periventricular	779 15 B-Disease
leukomalacia	795 12 I-Disease
,	807 1 O
and	809 3 O
severe	813 6 O
psychomotor	820 11 B-Disease
retardation	832 11 I-Disease
.	843 1 O

Each	845 4 O
child	850 5 O
was	856 3 O
examined	860 8 O
by	869 2 O
a	872 1 O
neuropediatrician	874 17 O
for	892 3 O
minor	896 5 O
neurological	902 12 B-Disease
dysfunctions	915 12 I-Disease
and	928 3 O
tested	932 6 O
by	939 2 O
a	942 1 O
psychologist	944 12 O
for	957 3 O
cognitive	961 9 O
development	971 11 O
with	983 4 O
a	988 1 O
Kaufman	990 7 O
Assessment	998 10 O
Battery	1009 7 O
for	1017 3 O
Children	1021 8 O
and	1030 3 O
a	1034 1 O
Draw	1036 4 O
-	1040 1 O
a	1041 1 O
-	1042 1 O
Man	1043 3 O
Test	1047 4 O
.	1051 1 O

There	1053 5 O
were	1059 4 O
no	1064 2 O
differences	1067 11 O
in	1079 2 O
demographic	1082 11 O
data	1094 4 O
,	1098 1 O
growth	1100 6 O
,	1106 1 O
and	1108 3 O
socio	1112 5 O
-	1117 1 O
economic	1118 8 O
status	1127 6 O
between	1134 7 O
the	1142 3 O
two	1146 3 O
groups	1150 6 O
.	1156 1 O

Fine	1158 4 O
motor	1163 5 O
skills	1169 6 O
and	1176 3 O
gross	1180 5 O
motor	1186 5 O
function	1192 8 O
were	1201 4 O
significantly	1206 13 O
better	1220 6 O
in	1227 2 O
the	1230 3 O
control	1234 7 O
group	1242 5 O
(	1248 1 O
p	1249 1 O
<	1250 1 O
0	1251 1 O
.	1252 1 O
01	1253 2 O
)	1255 1 O
.	1256 1 O

In	1258 2 O
the	1261 3 O
Draw	1265 4 O
-	1269 1 O
a	1270 1 O
-	1271 1 O
Man	1272 3 O
Test	1276 4 O
,	1280 1 O
the	1282 3 O
control	1286 7 O
group	1294 5 O
showed	1300 6 O
better	1307 6 O
results	1314 7 O
(	1322 1 O
p	1323 1 O
<	1324 1 O
0	1325 1 O
.	1326 1 O
001	1327 3 O
)	1330 1 O
.	1331 1 O

There	1333 5 O
were	1339 4 O
no	1344 2 O
differences	1347 11 O
in	1359 2 O
development	1362 11 O
of	1374 2 O
speech	1377 6 O
,	1383 1 O
social	1385 6 O
development	1392 11 O
,	1403 1 O
and	1405 3 O
the	1409 3 O
Kaufman	1413 7 O
Assessment	1421 10 O
Battery	1432 7 O
for	1440 3 O
Children	1444 8 O
.	1452 1 O

After	1454 5 O
dexamethasone	1460 13 B-Chemical
treatment	1474 9 O
,	1483 1 O
children	1485 8 O
showed	1494 6 O
a	1501 1 O
higher	1503 6 O
rate	1510 4 O
of	1515 2 O
minor	1518 5 O
neurological	1524 12 B-Disease
dysfunctions	1537 12 I-Disease
.	1549 1 O

Neurological	1551 12 O
development	1564 11 O
was	1576 3 O
affected	1580 8 O
even	1589 4 O
without	1594 7 O
neurological	1602 12 O
diagnosis	1615 9 O
.	1624 1 O

Further	1626 7 O
long	1634 4 O
-	1638 1 O
term	1639 4 O
follow	1644 6 O
-	1650 1 O
up	1651 2 O
studies	1654 7 O
will	1662 4 O
be	1667 2 O
necessary	1670 9 O
to	1680 2 O
fully	1683 5 O
evaluate	1689 8 O
the	1698 3 O
impact	1702 6 O
of	1709 2 O
dexamethasone	1712 13 B-Chemical
on	1726 2 O
neurological	1729 12 O
and	1742 3 O
cognitive	1746 9 O
development	1756 11 O
.	1767 1 O

Force	0 5 O
overflow	6 8 O
and	15 3 O
levodopa	19 8 B-Chemical
-	27 1 O
induced	28 7 O
dyskinesias	36 11 B-Disease
in	48 2 O
Parkinson	51 9 B-Disease
'	60 1 I-Disease
s	61 1 I-Disease
disease	63 7 I-Disease
.	70 1 O

We	72 2 O
assessed	75 8 O
force	84 5 O
coordination	90 12 O
of	103 2 O
the	106 3 O
hand	110 4 O
in	115 2 O
Parkinson	118 9 B-Disease
'	127 1 I-Disease
s	128 1 I-Disease
disease	130 7 I-Disease
and	138 3 O
its	142 3 O
relationship	146 12 O
to	159 2 O
motor	162 5 O
complications	168 13 O
of	182 2 O
levodopa	185 8 B-Chemical
therapy	194 7 O
,	201 1 O
particularly	203 12 O
to	216 2 O
levodopa	219 8 B-Chemical
-	227 1 O
induced	228 7 O
dyskinesias	236 11 B-Disease
(	248 1 O
LID	249 3 B-Disease
)	252 1 O
.	253 1 O

We	255 2 O
studied	258 7 O
two	266 3 O
groups	270 6 O
of	277 2 O
Parkinson	280 9 B-Disease
'	289 1 I-Disease
s	290 1 I-Disease
disease	292 7 I-Disease
patients	300 8 O
with	309 4 O
(	314 1 O
Parkinson	315 9 B-Disease
'	324 1 I-Disease
s	325 1 I-Disease
disease	327 7 I-Disease
+	335 1 O
LID	337 3 B-Disease
,	340 1 O
n	342 1 O
=	344 1 O
23	346 2 O
)	348 1 O
and	350 3 O
without	354 7 O
levodopa	362 8 B-Chemical
-	370 1 O
induced	371 7 O
dyskinesias	379 11 B-Disease
(	391 1 O
Parkinson	392 9 B-Disease
'	401 1 I-Disease
s	402 1 I-Disease
disease	404 7 I-Disease
-	412 1 O
LID	414 3 B-Disease
,	417 1 O
n	419 1 O
=	421 1 O
10	423 2 O
)	425 1 O
,	426 1 O
and	428 3 O
age	432 3 O
-	435 1 O
matched	436 7 O
healthy	444 7 O
controls	452 8 O
.	460 1 O

The	462 3 O
motor	466 5 O
score	472 5 O
of	478 2 O
the	481 3 O
Unified	485 7 O
Parkinson	493 9 B-Disease
'	502 1 I-Disease
s	503 1 I-Disease
Disease	505 7 I-Disease
Rating	513 6 O
Scale	520 5 O
,	525 1 O
a	527 1 O
dyskinesia	529 10 B-Disease
score	540 5 O
and	546 3 O
force	550 5 O
in	556 2 O
a	559 1 O
grip	561 4 O
-	565 1 O
lift	566 4 O
paradigm	571 8 O
were	580 4 O
assessed	585 8 O
ON	594 2 O
and	597 3 O
OFF	601 3 O
levodopa	605 8 B-Chemical
.	613 1 O

A	615 1 O
pathological	617 12 O
increase	630 8 O
of	639 2 O
forces	642 6 O
was	649 3 O
seen	653 4 O
in	658 2 O
ON	661 2 O
-	663 1 O
state	664 5 O
in	670 2 O
Parkinson	673 9 B-Disease
'	682 1 I-Disease
s	683 1 I-Disease
disease	685 7 I-Disease
+	693 1 O
LID	695 3 B-Disease
only	699 4 O
.	703 1 O

In	705 2 O
Parkinson	708 9 B-Disease
'	717 1 I-Disease
s	718 1 I-Disease
disease	720 7 I-Disease
+	728 1 O
LID	730 3 B-Disease
,	733 1 O
the	735 3 O
force	739 5 O
involved	745 8 O
in	754 2 O
pressing	757 8 O
down	766 4 O
the	771 3 O
object	775 6 O
before	782 6 O
lifting	789 7 O
was	797 3 O
significantly	801 13 O
increased	815 9 O
by	825 2 O
levodopa	828 8 B-Chemical
(	837 1 O
by	838 2 O
61	841 2 O
%	843 1 O
,	844 1 O
P	846 1 O
<	848 1 O
0	850 1 O
.	851 1 O
05	852 2 O
)	854 1 O
.	855 1 O

An	857 2 O
overshooting	860 12 O
of	873 2 O
peak	876 4 O
grip	881 4 O
force	886 5 O
by	892 2 O
51	895 2 O
%	897 1 O
(	899 1 O
P	900 1 O
<	902 1 O
0	904 1 O
.	905 1 O
05	906 2 O
)	908 1 O
and	910 3 O
of	914 2 O
static	917 6 O
grip	924 4 O
force	929 5 O
by	935 2 O
45	938 2 O
%	940 1 O
(	942 1 O
P	943 1 O
<	945 1 O
0	947 1 O
.	948 1 O
01	949 2 O
)	951 1 O
was	953 3 O
observed	957 8 O
in	966 2 O
the	969 3 O
ON	973 2 O
-	975 1 O
compared	977 8 O
with	986 4 O
the	991 3 O
OFF	995 3 O
-	998 1 O
drug	999 4 O
condition	1004 9 O
.	1013 1 O

In	1015 2 O
contrast	1018 8 O
,	1026 1 O
no	1028 2 O
excessive	1031 9 O
force	1041 5 O
was	1047 3 O
found	1051 5 O
in	1057 2 O
Parkinson	1060 9 B-Disease
'	1069 1 I-Disease
s	1070 1 I-Disease
disease	1072 7 I-Disease
-	1080 1 O
LID	1082 3 B-Disease
.	1085 1 O

Peak	1087 4 O
grip	1092 4 O
force	1097 5 O
in	1103 2 O
ON	1106 2 O
-	1108 1 O
state	1109 5 O
was	1115 3 O
140	1119 3 O
%	1122 1 O
(	1124 1 O
P	1125 1 O
<	1127 1 O
0	1129 1 O
.	1130 1 O
05	1131 2 O
)	1133 1 O
higher	1135 6 O
in	1142 2 O
Parkinson	1145 9 B-Disease
'	1154 1 I-Disease
s	1155 1 I-Disease
disease	1157 7 I-Disease
+	1165 1 O
LID	1167 3 B-Disease
than	1171 4 O
in	1176 2 O
Parkinson	1179 9 B-Disease
'	1188 1 I-Disease
s	1189 1 I-Disease
disease	1191 7 I-Disease
-	1199 1 O
LID	1201 3 B-Disease
,	1204 1 O
while	1206 5 O
static	1212 6 O
grip	1219 4 O
force	1224 5 O
was	1230 3 O
increased	1234 9 O
by	1244 2 O
138	1247 3 O
%	1250 1 O
(	1252 1 O
P	1253 1 O
<	1255 1 O
0	1257 1 O
.	1258 1 O
01	1259 2 O
)	1261 1 O
between	1263 7 O
groups	1271 6 O
.	1277 1 O

Severity	1279 8 O
of	1288 2 O
peak	1291 4 O
-	1295 1 O
dose	1296 4 O
dyskinesias	1301 11 B-Disease
was	1313 3 O
strongly	1317 8 O
correlated	1326 10 O
with	1337 4 O
grip	1342 4 O
force	1347 5 O
in	1353 2 O
ON	1356 2 O
-	1358 1 O
state	1359 5 O
(	1365 1 O
r	1366 1 O
=	1368 1 O
0	1370 1 O
.	1371 1 O
79	1372 2 O
with	1375 4 O
peak	1380 4 O
force	1385 5 O
,	1390 1 O
P	1392 1 O
<	1394 1 O
0	1396 1 O
.	1397 1 O
01	1398 2 O
)	1400 1 O
.	1401 1 O

No	1403 2 O
correlation	1406 11 O
was	1418 3 O
observed	1422 8 O
between	1431 7 O
forces	1439 6 O
and	1446 3 O
the	1450 3 O
motor	1454 5 O
score	1460 5 O
as	1466 2 O
well	1469 4 O
as	1474 2 O
with	1477 4 O
the	1482 3 O
daily	1486 5 O
dose	1492 4 O
of	1497 2 O
dopaminergic	1500 12 O
medication	1513 10 O
.	1523 1 O

Force	1525 5 O
excess	1531 6 O
was	1538 3 O
only	1542 4 O
observed	1547 8 O
in	1556 2 O
patients	1559 8 O
with	1568 4 O
LID	1573 3 B-Disease
and	1577 3 O
motor	1581 5 O
fluctuations	1587 12 O
.	1599 1 O

A	1601 1 O
close	1603 5 O
relationship	1609 12 O
was	1622 3 O
seen	1626 4 O
between	1631 7 O
the	1639 3 O
overshooting	1643 12 O
of	1656 2 O
forces	1659 6 O
and	1666 3 O
dyskinesias	1670 11 B-Disease
in	1682 2 O
the	1685 3 O
ON	1689 2 O
-	1691 1 O
drug	1692 4 O
condition	1697 9 O
.	1706 1 O

We	1708 2 O
postulate	1711 9 O
that	1721 4 O
both	1726 4 O
LID	1731 3 B-Disease
and	1735 3 O
grip	1739 4 O
force	1744 5 O
excess	1750 6 O
share	1757 5 O
common	1763 6 O
pathophysiological	1770 18 O
mechanisms	1789 10 O
related	1800 7 O
to	1808 2 O
motor	1811 5 O
fluctuations	1817 12 O
.	1829 1 O

Postinfarction	0 14 O
ventricular	15 11 B-Disease
septal	27 6 I-Disease
defect	34 6 I-Disease
associated	41 10 O
with	52 4 O
long	57 4 O
-	61 1 O
term	62 4 O
steroid	67 7 B-Chemical
therapy	75 7 O
.	82 1 O

Two	84 3 O
cases	88 5 O
of	94 2 O
postinfarction	97 14 O
ventricular	112 11 B-Disease
septal	124 6 I-Disease
rupture	131 7 I-Disease
in	139 2 O
patients	142 8 O
on	151 2 O
long	154 4 O
-	158 1 O
term	159 4 O
steroid	164 7 B-Chemical
therapy	172 7 O
are	180 3 O
presented	184 9 O
and	194 3 O
the	198 3 O
favourable	202 10 O
outcome	213 7 O
in	221 2 O
both	224 4 O
cases	229 5 O
described	235 9 O
.	244 1 O

A	246 1 O
possible	248 8 O
association	257 11 O
between	269 7 O
steroid	277 7 B-Chemical
therapy	285 7 O
and	293 3 O
subsequent	297 10 O
postinfarction	308 14 O
septal	323 6 B-Disease
rupture	330 7 I-Disease
is	338 2 O
discussed	341 9 O
.	350 1 O

Angioedema	0 10 B-Disease
associated	11 10 O
with	22 4 O
droperidol	27 10 B-Chemical
administration	38 14 O
.	52 1 O

Angioedema	54 10 B-Disease
,	64 1 O
also	66 4 O
known	71 5 O
as	77 2 O
angioneurotic	80 13 B-Disease
edema	94 5 I-Disease
or	100 2 O
Quincke	103 7 B-Disease
'	110 1 I-Disease
s	111 1 I-Disease
disease	113 7 I-Disease
,	120 1 O
is	122 2 O
a	125 1 O
well	127 4 O
-	131 1 O
demarcated	132 10 O
,	142 1 O
localized	144 9 O
edema	154 5 B-Disease
involving	160 9 O
the	170 3 O
subcutaneous	174 12 O
tissues	187 7 O
that	195 4 O
may	200 3 O
cause	204 5 O
upper	210 5 B-Disease
-	215 1 I-Disease
airway	216 6 I-Disease
obstruction	223 11 I-Disease
.	234 1 O

We	236 2 O
report	239 6 O
the	246 3 O
case	250 4 O
of	255 2 O
a	258 1 O
previously	260 10 O
healthy	271 7 O
19	279 2 O
-	281 1 O
year	282 4 O
-	286 1 O
old	287 3 O
man	291 3 O
with	295 4 O
no	300 2 O
known	303 5 O
drug	309 4 B-Disease
allergies	314 9 I-Disease
in	324 2 O
whom	327 4 O
angioedema	332 10 B-Disease
with	343 4 O
significant	348 11 O
tongue	360 6 B-Disease
swelling	367 8 I-Disease
and	376 3 O
protrusion	380 10 O
developed	391 9 O
within	401 6 O
10	408 2 O
minutes	411 7 O
of	419 2 O
the	422 3 O
administration	426 14 O
of	441 2 O
a	444 1 O
single	446 6 O
IV	453 2 O
dose	456 4 O
of	461 2 O
droperidol	464 10 B-Chemical
.	474 1 O

Clarithromycin	0 14 B-Chemical
-	14 1 O
associated	15 10 O
visual	26 6 B-Disease
hallucinations	33 14 I-Disease
in	48 2 O
a	51 1 O
patient	53 7 O
with	61 4 O
chronic	66 7 B-Disease
renal	74 5 I-Disease
failure	80 7 I-Disease
on	88 2 O
continuous	91 10 O
ambulatory	102 10 O
peritoneal	113 10 O
dialysis	124 8 O
.	132 1 O

Visual	134 6 B-Disease
hallucinations	141 14 I-Disease
are	156 3 O
a	160 1 O
rare	162 4 O
event	167 5 O
in	173 2 O
chronic	176 7 B-Disease
renal	184 5 I-Disease
failure	190 7 I-Disease
and	198 3 O
not	202 3 O
related	206 7 O
to	214 2 O
uremia	217 6 B-Disease
per	224 3 O
se	228 2 O
.	230 1 O

Unreported	232 10 O
in	243 2 O
the	246 3 O
literature	250 10 O
is	261 2 O
visual	264 6 B-Disease
hallucinations	271 14 I-Disease
occurring	286 9 O
in	296 2 O
association	299 11 O
with	311 4 O
the	316 3 O
new	320 3 O
macrolide	324 9 B-Chemical
antibiotic	334 10 O
,	344 1 O
clarithromycin	346 14 B-Chemical
.	360 1 O

We	362 2 O
describe	365 8 O
such	374 4 O
a	379 1 O
case	381 4 O
in	386 2 O
a	389 1 O
patient	391 7 O
with	399 4 O
end	404 3 B-Disease
-	407 1 I-Disease
stage	408 5 I-Disease
renal	414 5 I-Disease
disease	420 7 I-Disease
(	428 1 O
ESRD	429 4 B-Disease
)	433 1 O
maintained	435 10 O
on	446 2 O
continuous	449 10 O
ambulatory	460 10 O
peritoneal	471 10 O
dialysis	482 8 O
(	491 1 O
CAPD	492 4 O
)	496 1 O
.	497 1 O

The	499 3 O
combination	503 11 O
of	515 2 O
a	518 1 O
relatively	520 10 O
high	531 4 O
dose	536 4 O
of	541 2 O
clarithromycin	544 14 B-Chemical
in	559 2 O
face	562 4 O
of	567 2 O
chronic	570 7 B-Disease
renal	578 5 I-Disease
failure	584 7 I-Disease
in	592 2 O
a	595 1 O
functionally	597 12 O
anephric	610 8 O
patient	619 7 O
,	626 1 O
with	628 4 O
underlying	633 10 O
aluminum	644 8 B-Chemical
intoxication	653 12 O
,	665 1 O
may	667 3 O
have	671 4 O
facilitated	676 11 O
the	688 3 O
appearance	692 10 O
of	703 2 O
this	706 4 O
neurotoxic	711 10 B-Disease
side	722 4 O
effect	727 6 O
.	733 1 O

It	735 2 O
is	738 2 O
important	741 9 O
to	751 2 O
understand	754 10 O
the	765 3 O
pharmacokinetics	769 16 O
of	786 2 O
medications	789 11 O
in	801 2 O
face	804 4 O
of	809 2 O
chronic	812 7 B-Disease
renal	820 5 I-Disease
failure	826 7 I-Disease
,	833 1 O
the	835 3 O
possibility	839 11 O
of	851 2 O
drug	854 4 O
interactions	859 12 O
,	871 1 O
and	873 3 O
how	877 3 O
these	881 5 O
factors	887 7 O
should	895 6 O
help	902 4 O
guide	907 5 O
medication	913 10 O
therapy	924 7 O
in	932 2 O
the	935 3 O
ESRD	939 4 B-Disease
patient	944 7 O
.	951 1 O

Acute	0 5 O
renal	6 5 B-Disease
toxicity	12 8 I-Disease
of	21 2 O
doxorubicin	24 11 B-Chemical
(	36 1 O
adriamycin	37 10 B-Chemical
)	47 1 O
-	48 1 O
loaded	49 6 O
cyanoacrylate	56 13 B-Chemical
nanoparticles	70 13 O
.	83 1 O

Acute	85 5 O
doxorubicin	91 11 B-Chemical
-	102 1 O
loaded	103 6 O
nanoparticle	110 12 O
(	123 1 O
DXNP	124 4 O
)	128 1 O
renal	130 5 B-Disease
toxicity	136 8 I-Disease
was	145 3 O
explored	149 8 O
in	158 2 O
both	161 4 O
normal	166 6 O
rats	173 4 O
and	178 3 O
rats	182 4 O
with	187 4 O
experimental	192 12 O
glomerulonephritis	205 18 B-Disease
.	223 1 O

In	225 2 O
normal	228 6 O
rats	235 4 O
,	239 1 O
2	241 1 O
/	242 1 O
6	243 1 O
rats	245 4 O
given	250 5 O
free	256 4 O
doxorubicin	261 11 B-Chemical
(	273 1 O
DX	274 2 B-Chemical
)	276 1 O
(	278 1 O
5	279 1 O
mg	281 2 O
/	283 1 O
kg	284 2 O
)	286 1 O
died	288 4 O
within	293 6 O
one	300 3 O
week	304 4 O
,	308 1 O
whereas	310 7 O
all	318 3 O
control	322 7 O
animals	330 7 O
and	338 3 O
all	342 3 O
rats	346 4 O
having	351 6 O
received	358 8 O
free	367 4 O
NP	372 2 O
or	375 2 O
DXNP	378 4 O
survived	383 8 O
.	391 1 O

A	393 1 O
3	395 1 O
times	397 5 O
higher	403 6 O
proteinuria	410 11 B-Disease
appeared	422 8 O
in	431 2 O
animals	434 7 O
treated	442 7 O
with	450 4 O
DXNP	455 4 O
than	460 4 O
in	465 2 O
those	468 5 O
treated	474 7 O
with	482 4 O
DX	487 2 B-Chemical
.	489 1 O

Free	491 4 O
NP	496 2 O
did	499 3 O
not	503 3 O
provoke	507 7 O
any	515 3 O
proteinuria	519 11 B-Disease
.	530 1 O

Two	532 3 O
hr	536 2 O
post	539 4 O
-	543 1 O
injection	544 9 O
,	553 1 O
DXNP	555 4 O
was	560 3 O
2	564 1 O
.	565 1 O
7	566 1 O
times	568 5 O
more	574 4 O
concentrated	579 12 O
in	592 2 O
kidneys	595 7 O
than	603 4 O
free	608 4 O
DX	613 2 B-Chemical
(	616 1 O
p	617 1 O
<	619 1 O
0	621 1 O
.	622 1 O
025	623 3 O
)	626 1 O
.	627 1 O

In	629 2 O
rats	632 4 O
with	637 4 O
immune	642 6 O
experimental	649 12 O
glomerulonephritis	662 18 B-Disease
,	680 1 O
5	682 1 O
/	683 1 O
6	684 1 O
rats	686 4 O
given	691 5 O
DX	697 2 B-Chemical
died	700 4 O
within	705 6 O
7	712 1 O
days	714 4 O
,	718 1 O
in	720 2 O
contrast	723 8 O
to	732 2 O
animals	735 7 O
treated	743 7 O
by	751 2 O
DXNP	754 4 O
,	758 1 O
NP	760 2 O
,	762 1 O
or	764 2 O
untreated	767 9 O
,	776 1 O
which	778 5 O
all	784 3 O
survived	788 8 O
.	796 1 O

Proteinuria	798 11 B-Disease
appeared	810 8 O
in	819 2 O
all	822 3 O
series	826 6 O
,	832 1 O
but	834 3 O
was	838 3 O
2	842 1 O
-	843 1 O
5	844 1 O
times	846 5 O
more	852 4 O
intense	857 7 O
(	865 1 O
p	866 1 O
>	868 1 O
0	870 1 O
.	871 1 O
001	872 3 O
)	875 1 O
and	877 3 O
prolonged	881 9 O
after	891 5 O
doxorubicin	897 11 B-Chemical
treatment	909 9 O
(	919 1 O
400	920 3 O
-	923 1 O
700	924 3 O
mg	928 2 O
/	930 1 O
day	931 3 O
)	934 1 O
,	935 1 O
without	937 7 O
significant	945 11 O
difference	957 10 O
between	968 7 O
DXNP	976 4 O
and	981 3 O
DX	985 2 B-Chemical
.	987 1 O

Rats	989 4 O
treated	994 7 O
by	1002 2 O
unloaded	1005 8 O
NP	1014 2 O
behaved	1017 7 O
as	1025 2 O
controls	1028 8 O
.	1036 1 O

These	1038 5 O
results	1044 7 O
demonstrate	1052 11 O
that	1064 4 O
,	1068 1 O
in	1070 2 O
these	1073 5 O
experimental	1079 12 O
conditions	1092 10 O
,	1102 1 O
DXNP	1104 4 O
killed	1109 6 O
less	1116 4 O
animals	1121 7 O
than	1129 4 O
free	1134 4 O
DX	1139 2 B-Chemical
,	1141 1 O
despite	1143 7 O
of	1151 2 O
an	1154 2 O
enhanced	1157 8 O
renal	1166 5 B-Disease
toxicity	1172 8 I-Disease
of	1181 2 O
the	1184 3 O
former	1188 6 O
.	1194 1 O

Both	1196 4 O
effects	1201 7 O
(	1209 1 O
better	1210 6 O
survival	1217 8 O
and	1226 3 O
nephrosis	1230 9 B-Disease
)	1239 1 O
are	1241 3 O
most	1245 4 O
probably	1250 8 O
related	1259 7 O
to	1267 2 O
an	1270 2 O
enhanced	1273 8 O
capture	1282 7 O
of	1290 2 O
DXNP	1293 4 O
by	1298 2 O
cells	1301 5 O
of	1307 2 O
the	1310 3 O
mononuclear	1314 11 O
phagocyte	1326 9 O
system	1336 6 O
,	1342 1 O
including	1344 9 O
mesangial	1354 9 O
cells	1364 5 O
.	1369 1 O

Etoposide	0 9 B-Chemical
-	9 1 O
related	10 7 O
myocardial	18 10 B-Disease
infarction	29 10 I-Disease
.	39 1 O

The	41 3 O
occurrence	45 10 O
of	56 2 O
a	59 1 O
myocardial	61 10 B-Disease
infarction	72 10 I-Disease
is	83 2 O
reported	86 8 O
after	95 5 O
chemotherapy	101 12 O
containing	114 10 O
etoposide	125 9 B-Chemical
,	134 1 O
in	136 2 O
a	139 1 O
man	141 3 O
with	145 4 O
no	150 2 O
risk	153 4 O
factors	158 7 O
for	166 3 O
coronary	170 8 B-Disease
heart	179 5 I-Disease
disease	185 7 I-Disease
.	192 1 O

Possible	194 8 O
causal	203 6 O
mechanisms	210 10 O
are	221 3 O
discussed	225 9 O
.	234 1 O

Subjective	0 10 O
assessment	11 10 O
of	22 2 O
sexual	25 6 B-Disease
dysfunction	32 11 I-Disease
of	44 2 O
patients	47 8 O
on	56 2 O
long	59 4 O
-	63 1 O
term	64 4 O
administration	69 14 O
of	84 2 O
digoxin	87 7 B-Chemical
.	94 1 O

Various	96 7 O
data	104 4 O
suggest	109 7 O
that	117 4 O
male	122 4 O
patients	127 8 O
who	136 3 O
have	140 4 O
received	145 8 O
digoxin	154 7 B-Chemical
on	162 2 O
a	165 1 O
longterm	167 8 O
basis	176 5 O
have	182 4 O
increased	187 9 O
levels	197 6 O
of	204 2 O
serum	207 5 O
estrogen	213 8 B-Chemical
and	222 3 O
decreased	226 9 O
levels	236 6 O
of	243 2 O
plasma	246 6 O
testosterone	253 12 B-Chemical
and	266 3 O
luteinizing	270 11 O
hormone	282 7 O
(	290 1 O
LH	291 2 O
)	293 1 O
.	294 1 O

This	296 4 O
study	301 5 O
was	307 3 O
undertaken	311 10 O
to	322 2 O
investigate	325 11 O
the	337 3 O
links	341 5 O
between	347 7 O
the	355 3 O
long	359 4 O
-	363 1 O
term	364 4 O
administration	369 14 O
of	384 2 O
digoxin	387 7 B-Chemical
therapy	395 7 O
and	403 3 O
sexual	407 6 O
behavior	414 8 O
,	422 1 O
and	424 3 O
the	428 3 O
effect	432 6 O
of	439 2 O
digoxin	442 7 B-Chemical
on	450 2 O
plasma	453 6 O
levels	460 6 O
of	467 2 O
estradiol	470 9 B-Chemical
,	479 1 O
testosterone	481 12 B-Chemical
,	493 1 O
and	495 3 O
LH	499 2 O
.	501 1 O

The	503 3 O
patients	507 8 O
of	516 2 O
the	519 3 O
study	523 5 O
and	529 3 O
control	533 7 O
group	541 5 O
(	547 1 O
without	548 7 O
digoxin	556 7 B-Chemical
)	563 1 O
were	565 4 O
of	570 2 O
similar	573 7 O
cardiac	581 7 O
functional	589 10 O
capacity	600 8 O
and	609 3 O
age	613 3 O
(	617 1 O
25	618 2 O
-	620 1 O
40	621 2 O
years	624 5 O
)	629 1 O
and	631 3 O
were	635 4 O
randomly	640 8 O
selected	649 8 O
from	658 4 O
the	663 3 O
rheumatic	667 9 B-Disease
heart	677 5 I-Disease
disease	683 7 I-Disease
patients	691 8 O
.	699 1 O

A	701 1 O
subjective	703 10 O
assessment	714 10 O
of	725 2 O
sexual	728 6 O
behavior	735 8 O
in	744 2 O
the	747 3 O
study	751 5 O
and	757 3 O
control	761 7 O
groups	769 6 O
was	776 3 O
carried	780 7 O
out	788 3 O
,	791 1 O
using	793 5 O
parameters	799 10 O
such	810 4 O
as	815 2 O
sexual	818 6 O
desire	825 6 O
,	831 1 O
sexual	833 6 O
excitement	840 10 O
,	850 1 O
and	852 3 O
frequency	856 9 O
of	866 2 O
sexual	869 6 O
relations	876 9 O
.	885 1 O

Personal	887 8 O
interviews	896 10 O
and	907 3 O
a	911 1 O
questionnaire	913 13 O
were	927 4 O
also	932 4 O
used	937 4 O
for	942 3 O
the	946 3 O
evaluation	950 10 O
of	961 2 O
sexual	964 6 O
behavior	971 8 O
.	979 1 O

The	981 3 O
findings	985 8 O
support	994 7 O
the	1002 3 O
reports	1006 7 O
concerning	1014 10 O
digoxin	1025 7 B-Chemical
effect	1033 6 O
on	1040 2 O
plasma	1043 6 O
estradiol	1050 9 B-Chemical
,	1059 1 O
testosterone	1061 12 B-Chemical
,	1073 1 O
and	1075 3 O
LH	1079 2 O
.	1081 1 O

The	1083 3 O
differences	1087 11 O
in	1099 2 O
the	1102 3 O
means	1106 5 O
were	1112 4 O
significant	1117 11 O
.	1128 1 O

Tests	1130 5 O
used	1136 4 O
to	1141 2 O
evaluate	1144 8 O
the	1153 3 O
changes	1157 7 O
in	1165 2 O
sexual	1168 6 O
behavior	1175 8 O
showed	1184 6 O
a	1191 1 O
significant	1193 11 O
decrease	1205 8 B-Disease
in	1214 2 I-Disease
sexual	1217 6 I-Disease
desire	1224 6 I-Disease
,	1230 1 O
sexual	1232 6 O
excitement	1239 10 O
phase	1250 5 O
(	1256 1 O
erection	1257 8 O
)	1265 1 O
,	1266 1 O
and	1268 3 O
frequency	1272 9 O
of	1282 2 O
sexual	1285 6 O
relations	1292 9 O
in	1302 2 O
the	1305 3 O
study	1309 5 O
group	1315 5 O
.	1320 1 O

Fatal	0 5 O
aplastic	6 8 B-Disease
anemia	15 6 I-Disease
due	22 3 O
to	26 2 O
indomethacin	29 12 B-Chemical
-	41 1 O
-	42 1 O
lymphocyte	43 10 O
transformation	54 14 O
tests	69 5 O
in	75 2 O
vitro	78 5 O
.	83 1 O

Although	85 8 O
indomethacin	94 12 B-Chemical
has	107 3 O
been	111 4 O
implicated	116 10 O
as	127 2 O
a	130 1 O
possible	132 8 O
cause	141 5 O
of	147 2 O
aplastic	150 8 B-Disease
anemia	159 6 I-Disease
on	166 2 O
the	169 3 O
basis	173 5 O
of	179 2 O
a	182 1 O
few	184 3 O
clinical	188 8 O
observations	197 12 O
,	209 1 O
its	211 3 O
role	215 4 O
has	220 3 O
not	224 3 O
been	228 4 O
definitely	233 10 O
established	244 11 O
.	255 1 O

A	257 1 O
case	259 4 O
of	264 2 O
fatal	267 5 O
aplastic	273 8 B-Disease
anemia	282 6 I-Disease
is	289 2 O
described	292 9 O
in	302 2 O
which	305 5 O
no	311 2 O
drugs	314 5 O
other	320 5 O
than	326 4 O
allopurinol	331 11 B-Chemical
and	343 3 O
indomethacin	347 12 B-Chemical
were	360 4 O
given	365 5 O
.	370 1 O

Indomethacin	372 12 B-Chemical
was	385 3 O
first	389 5 O
given	395 5 O
four	401 4 O
weeks	406 5 O
prior	412 5 O
to	418 2 O
the	421 3 O
onset	425 5 O
of	431 2 O
symptoms	434 8 O
.	442 1 O

A	444 1 O
positive	446 8 O
lymphocyte	455 10 O
transformation	466 14 O
test	481 4 O
with	486 4 O
indomethacin	491 12 B-Chemical
in	504 2 O
vitro	507 5 O
further	513 7 O
substantiates	521 13 O
the	535 3 O
potential	539 9 O
role	549 4 O
of	554 2 O
this	557 4 O
drug	562 4 O
in	567 2 O
causing	570 7 O
aplastic	578 8 B-Disease
anemia	587 6 I-Disease
in	594 2 O
a	597 1 O
susceptible	599 11 O
patient	611 7 O
.	618 1 O

Fortunately	620 11 O
,	631 1 O
this	633 4 O
seems	638 5 O
to	644 2 O
be	647 2 O
a	650 1 O
very	652 4 O
rare	657 4 O
complication	662 12 O
.	674 1 O

Plasma	0 6 O
and	7 3 O
urinary	11 7 O
lipids	19 6 O
and	26 3 O
lipoproteins	30 12 O
during	43 6 O
the	50 3 O
development	54 11 O
of	66 2 O
nephrotic	69 9 B-Disease
syndrome	79 8 I-Disease
induced	88 7 O
in	96 2 O
the	99 3 O
rat	103 3 O
by	107 2 O
puromycin	110 9 B-Chemical
aminonucleoside	120 15 I-Chemical
.	135 1 O

This	137 4 O
study	142 5 O
was	148 3 O
undertaken	152 10 O
to	163 2 O
ascertain	166 9 O
whether	176 7 O
the	184 3 O
alterations	188 11 O
of	200 2 O
plasma	203 6 O
lipoproteins	210 12 O
found	223 5 O
in	229 2 O
nephrotic	232 9 B-Disease
syndrome	242 8 I-Disease
induced	251 7 O
by	259 2 O
puromycin	262 9 B-Chemical
aminonucleoside	272 15 I-Chemical
were	288 4 O
due	293 3 O
to	297 2 O
nephrotic	300 9 B-Disease
syndrome	310 8 I-Disease
per	319 3 O
se	323 2 O
,	325 1 O
or	327 2 O
,	329 1 O
at	331 2 O
least	334 5 O
in	340 2 O
part	343 4 O
,	347 1 O
to	349 2 O
the	352 3 O
aminonucleoside	356 15 B-Chemical
.	371 1 O

The	373 3 O
purpose	377 7 O
of	385 2 O
the	388 3 O
present	392 7 O
study	400 5 O
was	406 3 O
to	410 2 O
investigate	413 11 O
the	425 3 O
changes	429 7 O
in	437 2 O
plasma	440 6 O
and	447 3 O
urinary	451 7 O
lipoproteins	459 12 O
during	472 6 O
the	479 3 O
administration	483 14 O
of	498 2 O
puromycin	501 9 B-Chemical
aminonucleoside	511 15 I-Chemical
(	527 1 O
20	528 2 O
mg	531 2 O
/	533 1 O
kg	534 2 O
for	537 3 O
7	541 1 O
days	543 4 O
)	547 1 O
and	549 3 O
the	553 3 O
subsequent	557 10 O
development	568 11 O
of	580 2 O
nephrotic	583 9 B-Disease
syndrome	593 8 I-Disease
.	601 1 O

Since	603 5 O
massive	609 7 O
albuminuria	617 11 B-Disease
occurred	629 8 O
after	638 5 O
6	644 1 O
days	646 4 O
of	651 2 O
treatment	654 9 O
,	663 1 O
the	665 3 O
time	669 4 O
-	673 1 O
course	674 6 O
study	681 5 O
was	687 3 O
divided	691 7 O
into	699 4 O
two	704 3 O
stages	708 6 O
:	714 1 O
pre	716 3 O
-	719 1 O
nephrotic	720 9 B-Disease
stage	730 5 O
(	736 1 O
day	737 3 O
1	741 1 O
-	742 1 O
5	743 1 O
)	744 1 O
and	746 3 O
nephrotic	750 9 B-Disease
stage	760 5 O
(	766 1 O
day	767 3 O
6	771 1 O
-	772 1 O
11	773 2 O
)	775 1 O
.	776 1 O

In	778 2 O
pre	781 3 O
-	784 1 O
nephrotic	785 9 B-Disease
stage	795 5 O
the	801 3 O
plasma	805 6 O
level	812 5 O
of	818 2 O
fatty	821 5 B-Chemical
acids	827 5 I-Chemical
,	832 1 O
triacylglycerol	834 15 B-Chemical
and	850 3 O
VLDL	854 4 O
decreased	859 9 O
while	869 5 O
that	875 4 O
of	880 2 O
phospholipid	883 12 O
,	895 1 O
cholesteryl	897 11 B-Chemical
esters	909 6 I-Chemical
and	916 3 O
HDL	920 3 O
remained	924 8 O
constant	933 8 O
.	941 1 O

Plasma	943 6 O
apolipoprotein	950 14 O
A	965 1 O
-	966 1 O
I	967 1 O
tended	969 6 O
to	976 2 O
increase	979 8 O
(	988 1 O
40	989 2 O
%	991 1 O
increase	993 8 O
at	1002 2 O
day	1005 3 O
5	1009 1 O
)	1010 1 O
.	1011 1 O

At	1013 2 O
the	1016 3 O
beginning	1020 9 O
of	1030 2 O
nephrotic	1033 9 B-Disease
stage	1043 5 O
(	1049 1 O
day	1050 3 O
6	1054 1 O
)	1055 1 O
the	1057 3 O
concentration	1061 13 O
of	1075 2 O
plasma	1078 6 O
albumin	1085 7 O
dropped	1093 7 O
to	1101 2 O
a	1104 1 O
very	1106 4 O
low	1111 3 O
level	1115 5 O
,	1120 1 O
while	1122 5 O
that	1128 4 O
of	1133 2 O
apolipoprotein	1136 14 O
A	1151 1 O
-	1152 1 O
I	1153 1 O
increased	1155 9 O
abruptly	1165 8 O
(	1174 1 O
4	1175 1 O
-	1176 1 O
fold	1177 4 O
increase	1182 8 O
)	1190 1 O
and	1192 3 O
continued	1196 9 O
to	1206 2 O
rise	1209 4 O
,	1213 1 O
although	1215 8 O
less	1224 4 O
steeply	1229 7 O
,	1236 1 O
in	1238 2 O
the	1241 3 O
following	1245 9 O
days	1255 4 O
.	1259 1 O

The	1261 3 O
plasma	1265 6 O
concentration	1272 13 O
of	1286 2 O
HDL	1289 3 O
followed	1293 8 O
the	1302 3 O
same	1306 4 O
pattern	1311 7 O
.	1318 1 O

Plasma	1320 6 O
VLDL	1327 4 O
and	1332 3 O
LDL	1336 3 O
increased	1340 9 O
at	1350 2 O
a	1353 1 O
later	1355 5 O
stage	1361 5 O
(	1367 1 O
day	1368 3 O
9	1372 1 O
)	1373 1 O
.	1374 1 O

Plasma	1376 6 O
apolipoprotein	1383 14 O
A	1398 1 O
-	1399 1 O
I	1400 1 O
was	1402 3 O
found	1406 5 O
not	1412 3 O
only	1416 4 O
in	1421 2 O
HDL	1424 3 O
(	1428 1 O
1	1429 1 O
.	1430 1 O
063	1431 3 O
-	1434 1 O
1	1435 1 O
.	1436 1 O
210	1437 3 O
g	1441 1 O
/	1442 1 O
ml	1443 2 O
)	1445 1 O
but	1447 3 O
also	1451 4 O
in	1456 2 O
the	1459 3 O
LDL	1463 3 O
density	1467 7 O
class	1475 5 O
(	1481 1 O
1	1482 1 O
.	1483 1 O
025	1484 3 O
-	1487 1 O
1	1488 1 O
.	1489 1 O
050	1490 3 O
g	1494 1 O
/	1495 1 O
ml	1496 2 O
)	1498 1 O
.	1499 1 O

In	1501 2 O
the	1504 3 O
pre	1508 3 O
-	1511 1 O
nephrotic	1512 9 B-Disease
stage	1522 5 O
lipoproteinuria	1528 15 O
was	1544 3 O
negligible	1548 10 O
,	1558 1 O
while	1560 5 O
in	1566 2 O
the	1569 3 O
early	1573 5 O
nephrotic	1579 9 B-Disease
stage	1589 5 O
the	1595 3 O
urinary	1599 7 O
loss	1607 4 O
of	1612 2 O
plasma	1615 6 O
lipoproteins	1622 12 O
consisted	1635 9 O
mainly	1645 6 O
of	1652 2 O
HDL	1655 3 O
.	1658 1 O

These	1660 5 O
observations	1666 12 O
indicate	1679 8 O
that	1688 4 O
puromycin	1693 9 B-Chemical
aminonucleoside	1703 15 I-Chemical
alters	1719 6 O
plasma	1726 6 O
lipoproteins	1733 12 O
by	1746 2 O
lowering	1749 8 O
VLDL	1758 4 O
and	1763 3 O
increasing	1767 10 O
HDL	1778 3 O
.	1781 1 O

It	1783 2 O
is	1786 2 O
likely	1789 6 O
that	1796 4 O
the	1801 3 O
early	1805 5 O
and	1811 3 O
striking	1815 8 O
increase	1824 8 O
of	1833 2 O
plasma	1836 6 O
HDL	1843 3 O
found	1847 5 O
in	1853 2 O
nephrotic	1856 9 B-Disease
rats	1866 4 O
is	1871 2 O
related	1874 7 O
to	1882 2 O
a	1885 1 O
direct	1887 6 O
effect	1894 6 O
of	1901 2 O
the	1904 3 O
drug	1908 4 O
on	1913 2 O
HDL	1916 3 O
metabolism	1920 10 O
.	1930 1 O

Circulating	0 11 O
lysosomal	12 9 O
enzymes	22 7 O
and	30 3 O
acute	34 5 B-Disease
hepatic	40 7 I-Disease
necrosis	48 8 I-Disease
.	56 1 O

The	58 3 O
activities	62 10 O
of	73 2 O
the	76 3 O
lysosomal	80 9 O
enzymes	90 7 O
acid	98 4 O
and	103 3 O
neutral	107 7 O
protease	115 8 O
,	123 1 O
N	125 1 O
-	126 1 O
acetylglucosaminidase	127 21 O
,	148 1 O
and	150 3 O
acid	154 4 O
phosphatase	159 11 O
were	171 4 O
measured	176 8 O
in	185 2 O
the	188 3 O
serum	192 5 O
of	198 2 O
patients	201 8 O
with	210 4 O
fulminant	215 9 B-Disease
hepatic	225 7 I-Disease
failure	233 7 I-Disease
.	240 1 O

Acid	242 4 O
protease	247 8 O
(	256 1 O
cathepsin	257 9 O
D	267 1 O
)	268 1 O
activity	270 8 O
was	279 3 O
increased	283 9 O
about	293 5 O
tenfold	299 7 O
in	307 2 O
patients	310 8 O
who	319 3 O
died	323 4 O
and	328 3 O
nearly	332 6 O
fourfold	339 8 O
in	348 2 O
those	351 5 O
who	357 3 O
survived	361 8 O
fulminant	370 9 B-Disease
hepatic	380 7 I-Disease
failure	388 7 I-Disease
after	396 5 O
paracetamol	402 11 B-Chemical
overdose	414 8 B-Disease
,	422 1 O
whereas	424 7 O
activities	432 10 O
were	443 4 O
increased	448 9 O
equally	458 7 O
in	466 2 O
patients	469 8 O
with	478 4 O
fulminant	483 9 B-Disease
hepatic	493 7 I-Disease
failure	501 7 I-Disease
due	509 3 O
to	513 2 O
viral	516 5 B-Disease
hepatitis	522 9 I-Disease
whether	532 7 O
or	540 2 O
not	543 3 O
they	547 4 O
survived	552 8 O
.	560 1 O

A	562 1 O
correlation	564 11 O
was	576 3 O
found	580 5 O
between	586 7 O
serum	594 5 O
acid	600 4 O
protease	605 8 O
activity	614 8 O
and	623 3 O
prothrombin	627 11 O
time	639 4 O
,	643 1 O
and	645 3 O
the	649 3 O
increase	653 8 O
in	662 2 O
cathepsin	665 9 O
D	675 1 O
activity	677 8 O
was	686 3 O
sustained	690 9 O
over	700 4 O
several	705 7 O
days	713 4 O
compared	718 8 O
with	727 4 O
aspartate	732 9 B-Chemical
aminotransferase	742 16 O
,	758 1 O
which	760 5 O
showed	766 6 O
a	773 1 O
sharp	775 5 O
early	781 5 O
peak	787 4 O
and	792 3 O
then	796 4 O
a	801 1 O
fall	803 4 O
.	807 1 O

Circulating	809 11 O
lysosomal	821 9 O
proteases	831 9 O
can	841 3 O
damage	845 6 O
other	852 5 O
organs	858 6 O
,	864 1 O
and	866 3 O
measurement	870 11 O
of	882 2 O
their	885 5 O
activity	891 8 O
may	900 3 O
therefore	904 9 O
be	914 2 O
of	917 2 O
added	920 5 O
value	926 5 O
in	932 2 O
assessing	935 9 O
prognosis	945 9 O
in	955 2 O
this	958 4 O
condition	963 9 O
.	972 1 O

Transketolase	0 13 O
abnormality	14 11 O
in	26 2 O
tolazamide	29 10 B-Chemical
-	39 1 O
induced	40 7 O
Wernicke	48 8 B-Disease
'	56 1 I-Disease
s	57 1 I-Disease
encephalopathy	59 14 I-Disease
.	73 1 O

We	75 2 O
studied	78 7 O
a	86 1 O
thiamine	88 8 B-Chemical
-	96 1 O
dependent	97 9 O
enzyme	107 6 O
,	113 1 O
transketolase	115 13 O
,	128 1 O
from	130 4 O
fibroblasts	135 11 O
of	147 2 O
a	150 1 O
diabetic	152 8 B-Disease
patient	161 7 O
who	169 3 O
developed	173 9 O
Wernicke	183 8 B-Disease
'	191 1 I-Disease
s	192 1 I-Disease
encephalopathy	194 14 I-Disease
when	209 4 O
treated	214 7 O
with	222 4 O
tolazamide	227 10 B-Chemical
,	237 1 O
in	239 2 O
order	242 5 O
to	248 2 O
delineate	251 9 O
if	261 2 O
this	264 4 O
patient	269 7 O
also	277 4 O
had	282 3 O
transketolase	286 13 O
abnormality	300 11 O
[	312 1 O
high	313 4 O
Km	318 2 O
for	321 3 O
thiamine	325 8 B-Chemical
pyrophosphate	334 13 I-Chemical
(	348 1 O
TPP	349 3 B-Chemical
)	352 1 O
]	353 1 O
,	354 1 O
as	356 2 O
previously	359 10 O
reported	370 8 O
in	379 2 O
postalcoholic	382 13 O
Wernicke	396 8 B-Disease
-	404 1 I-Disease
Korsakoff	405 9 I-Disease
syndrome	415 8 I-Disease
.	423 1 O

In	425 2 O
addition	428 8 O
to	437 2 O
this	440 4 O
patient	445 7 O
,	452 1 O
we	454 2 O
also	457 4 O
studied	462 7 O
this	470 4 O
enzyme	475 6 O
from	482 4 O
three	487 5 O
diabetic	493 8 B-Disease
kindreds	502 8 O
without	511 7 O
any	519 3 O
history	523 7 O
of	531 2 O
Wernicke	534 8 B-Disease
'	542 1 I-Disease
s	543 1 I-Disease
encephalopathy	545 14 I-Disease
and	560 3 O
from	564 4 O
four	569 4 O
normal	574 6 O
controls	581 8 O
.	589 1 O

We	591 2 O
found	594 5 O
that	600 4 O
the	605 3 O
above	609 5 O
-	614 1 O
mentioned	615 9 O
patient	625 7 O
and	633 3 O
one	637 3 O
of	641 2 O
the	644 3 O
diabetic	648 8 B-Disease
kindreds	657 8 O
with	666 4 O
no	671 2 O
history	674 7 O
of	682 2 O
Wernicke	685 8 B-Disease
'	693 1 I-Disease
s	694 1 I-Disease
encephalopathy	696 14 I-Disease
had	711 3 O
abnormal	715 8 O
transketolase	724 13 O
as	738 2 O
determined	741 10 O
by	752 2 O
its	755 3 O
Km	759 2 O
for	762 3 O
TPP	766 3 B-Chemical
.	769 1 O

These	771 5 O
data	777 4 O
suggest	782 7 O
a	790 1 O
similarity	792 10 O
between	803 7 O
postalcoholic	811 13 O
Wernicke	825 8 B-Disease
-	833 1 I-Disease
Korsakoff	834 9 I-Disease
syndrome	844 8 I-Disease
and	853 3 O
the	857 3 O
patient	861 7 O
with	869 4 O
tolazamide	874 10 B-Chemical
-	884 1 O
induced	885 7 O
Wernicke	893 8 B-Disease
'	901 1 I-Disease
s	902 1 I-Disease
encephalopathy	904 14 I-Disease
from	919 4 O
the	924 3 O
standpoint	928 10 O
of	939 2 O
transketolase	942 13 O
abnormality	956 11 O
.	967 1 O

Mechanisms	0 10 O
of	11 2 O
myocardial	14 10 B-Disease
ischemia	25 8 I-Disease
induced	34 7 O
by	42 2 O
epinephrine	45 11 B-Chemical
:	56 1 O
comparison	58 10 O
with	69 4 O
exercise	74 8 O
-	82 1 O
induced	83 7 O
ischemia	91 8 B-Disease
.	99 1 O

The	101 3 O
role	105 4 O
of	110 2 O
epinephrine	113 11 B-Chemical
in	125 2 O
eliciting	128 9 O
myocardial	138 10 B-Disease
ischemia	149 8 I-Disease
was	158 3 O
examined	162 8 O
in	171 2 O
patients	174 8 O
with	183 4 O
coronary	188 8 B-Disease
artery	197 6 I-Disease
disease	204 7 I-Disease
.	211 1 O

Objective	213 9 O
signs	223 5 O
of	229 2 O
ischemia	232 8 B-Disease
and	241 3 O
factors	245 7 O
increasing	253 10 O
myocardial	264 10 O
oxygen	275 6 B-Chemical
consumption	282 11 O
were	294 4 O
compared	299 8 O
during	308 6 O
epinephrine	315 11 B-Chemical
infusion	327 8 O
and	336 3 O
supine	340 6 O
bicycle	347 7 O
exercise	355 8 O
.	363 1 O

Both	365 4 O
epinephrine	370 11 B-Chemical
and	382 3 O
exercise	386 8 O
produced	395 8 O
myocardial	404 10 B-Disease
ischemia	415 8 I-Disease
as	424 2 O
evidenced	427 9 O
by	437 2 O
ST	440 2 O
segment	443 7 O
depression	451 10 B-Disease
and	462 3 O
angina	466 6 B-Disease
.	472 1 O

However	474 7 O
,	481 1 O
the	483 3 O
mechanisms	487 10 O
of	498 2 O
myocardial	501 10 B-Disease
ischemia	512 8 I-Disease
induced	521 7 O
by	529 2 O
epinephrine	532 11 B-Chemical
were	544 4 O
significantly	549 13 O
different	563 9 O
from	573 4 O
those	578 5 O
of	584 2 O
exercise	587 8 O
.	595 1 O

Exercise	597 8 O
-	605 1 O
induced	606 7 O
myocardial	614 10 B-Disease
ischemia	625 8 I-Disease
was	634 3 O
marked	638 6 O
predominantly	645 13 O
by	659 2 O
increased	662 9 O
heart	672 5 O
rate	678 4 O
and	683 3 O
rate	687 4 O
-	691 1 O
pressure	692 8 O
product	701 7 O
with	709 4 O
a	714 1 O
minor	716 5 O
contribution	722 12 O
of	735 2 O
end	738 3 O
-	741 1 O
diastolic	742 9 O
volume	752 6 O
,	758 1 O
while	760 5 O
epinephrine	766 11 B-Chemical
-	777 1 O
induced	778 7 O
ischemia	786 8 B-Disease
was	795 3 O
characterized	799 13 O
by	813 2 O
a	816 1 O
marked	818 6 O
increase	825 8 O
in	834 2 O
contractility	837 13 O
and	851 3 O
a	855 1 O
less	857 4 O
pronounced	862 10 O
increase	873 8 O
in	882 2 O
heart	885 5 O
rate	891 4 O
and	896 3 O
rate	900 4 O
-	904 1 O
pressure	905 8 O
product	914 7 O
.	921 1 O

These	923 5 O
findings	929 8 O
indicate	938 8 O
that	947 4 O
ischemia	952 8 B-Disease
produced	961 8 O
by	970 2 O
epinephrine	973 11 B-Chemical
,	984 1 O
as	986 2 O
may	989 3 O
occur	993 5 O
during	999 6 O
states	1006 6 O
of	1013 2 O
emotional	1016 9 O
distress	1026 8 O
,	1034 1 O
has	1036 3 O
a	1040 1 O
mechanism	1042 9 O
distinct	1052 8 O
from	1061 4 O
that	1066 4 O
due	1071 3 O
to	1075 2 O
physical	1078 8 O
exertion	1087 8 O
.	1095 1 O

Transient	0 9 O
contralateral	10 13 B-Disease
rotation	24 8 I-Disease
following	33 9 O
unilateral	43 10 O
substantia	54 10 B-Disease
nigra	65 5 I-Disease
lesion	71 6 I-Disease
reflects	78 8 O
susceptibility	87 14 O
of	102 2 O
the	105 3 O
nigrostriatal	109 13 O
system	123 6 O
to	130 2 O
exhaustion	133 10 O
by	144 2 O
amphetamine	147 11 B-Chemical
.	158 1 O

Following	160 9 O
unilateral	170 10 O
6	181 1 B-Chemical
-	182 1 I-Chemical
OHDA	183 4 I-Chemical
induced	188 7 O
SN	196 2 B-Disease
lesion	199 6 I-Disease
,	205 1 O
a	207 1 O
transient	209 9 O
period	219 6 O
of	226 2 O
contralateral	229 13 B-Disease
rotation	243 8 I-Disease
has	252 3 O
been	256 4 O
reported	261 8 O
to	270 2 O
precede	273 7 O
the	281 3 O
predominant	285 11 O
ipsilateral	297 11 B-Disease
circling	309 8 I-Disease
.	317 1 O

In	319 2 O
order	322 5 O
to	328 2 O
clarify	331 7 O
the	339 3 O
nature	343 6 O
of	350 2 O
this	353 4 O
initial	358 7 O
contralateral	366 13 B-Disease
rotation	380 8 I-Disease
we	389 2 O
examined	392 8 O
the	401 3 O
effect	405 6 O
of	412 2 O
the	415 3 O
duration	419 8 O
of	428 2 O
recovery	431 8 O
period	440 6 O
after	447 5 O
the	453 3 O
lesion	457 6 O
,	463 1 O
on	465 2 O
amphetamine	468 11 B-Chemical
-	479 1 O
induced	480 7 O
rotational	488 10 B-Disease
behavior	499 8 I-Disease
.	507 1 O

Three	509 5 O
days	515 4 O
post	520 4 O
lesion	525 6 O
,	531 1 O
most	533 4 O
rats	538 4 O
circled	543 7 O
predominantly	551 13 O
contralaterally	565 15 O
to	581 2 O
the	584 3 O
lesion	588 6 O
.	594 1 O

Such	596 4 O
contralateral	601 13 B-Disease
rotation	615 8 I-Disease
may	624 3 O
result	628 6 O
from	635 4 O
either	640 6 O
degeneration	647 12 O
-	659 1 O
induced	660 7 O
breakdown	668 9 O
of	678 2 O
the	681 3 O
DA	685 2 O
pool	688 4 O
,	692 1 O
or	694 2 O
lesion	697 6 O
-	703 1 O
induced	704 7 O
increase	712 8 O
of	721 2 O
DA	724 2 O
turnover	727 8 O
in	736 2 O
the	739 3 O
spared	743 6 O
neurons	750 7 O
.	757 1 O

A	759 1 O
substantial	761 11 O
degree	773 6 O
of	780 2 O
contralateral	783 13 O
preference	797 10 O
was	808 3 O
still	812 5 O
evident	818 7 O
when	826 4 O
amphetamine	831 11 B-Chemical
was	843 3 O
administered	847 12 O
for	860 3 O
the	864 3 O
first	868 5 O
time	874 4 O
24	879 2 O
days	882 4 O
after	887 5 O
lesioning	893 9 O
,	902 1 O
indicating	904 10 O
involvement	915 11 O
of	927 2 O
spared	930 6 O
cells	937 5 O
in	943 2 O
the	946 3 O
contralateral	950 13 B-Disease
rotation	964 8 I-Disease
.	972 1 O

However	974 7 O
,	981 1 O
regardless	983 10 O
of	994 2 O
the	997 3 O
duration	1001 8 O
of	1010 2 O
recovery	1013 8 O
(	1022 1 O
and	1023 3 O
irrespective	1027 12 O
of	1040 2 O
either	1043 6 O
lesion	1050 6 O
volume	1057 6 O
,	1063 1 O
amphetamine	1065 11 B-Chemical
dose	1077 4 O
,	1081 1 O
or	1083 2 O
post	1086 4 O
-	1090 1 O
lesion	1091 6 O
motor	1098 5 O
exercise	1104 8 O
)	1112 1 O
,	1113 1 O
amphetamine	1115 11 B-Chemical
-	1126 1 O
induced	1127 7 O
rotation	1135 8 B-Disease
tended	1144 6 O
to	1151 2 O
become	1154 6 O
gradually	1161 9 O
more	1171 4 O
ipsilateral	1176 11 O
as	1188 2 O
the	1191 3 O
observation	1195 11 O
session	1207 7 O
progressed	1215 10 O
,	1225 1 O
and	1227 3 O
all	1231 3 O
rats	1235 4 O
circled	1240 7 O
ipsilaterally	1248 13 O
to	1262 2 O
the	1265 3 O
lesion	1269 6 O
in	1276 2 O
response	1279 8 O
to	1288 2 O
further	1291 7 O
amphetamine	1299 11 B-Chemical
injections	1311 10 O
.	1321 1 O

These	1323 5 O
findings	1329 8 O
suggest	1338 7 O
that	1346 4 O
amphetamine	1351 11 B-Chemical
has	1363 3 O
an	1367 2 O
irreversible	1370 12 O
effect	1383 6 O
on	1390 2 O
the	1393 3 O
post	1397 4 O
-	1401 1 O
lesion	1402 6 O
DA	1409 2 O
pool	1412 4 O
contributing	1417 12 O
to	1430 2 O
contralateral	1433 13 B-Disease
rotation	1447 8 I-Disease
.	1455 1 O

Thyroid	0 7 O
function	8 8 O
and	17 3 O
urine	21 5 O
-	26 1 O
concentrating	27 13 O
ability	41 7 O
during	49 6 O
lithium	56 7 B-Chemical
treatment	64 9 O
.	73 1 O

It	75 2 O
has	78 3 O
been	82 4 O
suggested	87 9 O
that	97 4 O
adenylate	102 9 O
cyclase	112 7 O
inhibition	120 10 O
may	131 3 O
be	135 2 O
important	138 9 O
in	148 2 O
the	151 3 O
development	155 11 O
of	167 2 O
both	170 4 O
nephrogenic	175 11 B-Disease
diabetes	187 8 I-Disease
insipidus	196 9 I-Disease
and	206 3 O
hypothyroidism	210 14 B-Disease
during	225 6 O
lithium	232 7 B-Chemical
treatment	240 9 O
.	249 1 O

We	251 2 O
measured	254 8 O
serum	263 5 O
thyroxine	269 9 B-Chemical
and	279 3 O
urine	283 5 O
-	288 1 O
concentrating	289 13 O
ability	303 7 O
(	311 1 O
Umax	312 4 O
)	316 1 O
in	318 2 O
response	321 8 O
to	330 2 O
desmopressin	333 12 O
(	346 1 O
DDAVP	347 5 O
)	352 1 O
in	354 2 O
85	357 2 O
patients	360 8 O
receiving	369 9 O
lithium	379 7 B-Chemical
.	386 1 O

Hypothyroidism	388 14 B-Disease
developed	403 9 O
in	413 2 O
eight	416 5 O
patients	422 8 O
while	431 5 O
they	437 4 O
were	442 4 O
taking	447 6 O
lithium	454 7 B-Chemical
.	461 1 O

Impaired	463 8 O
Umax	472 4 O
was	477 3 O
found	481 5 O
in	487 2 O
both	490 4 O
euthyroid	495 9 O
and	505 3 O
hypothyroid	509 11 B-Disease
patients	521 8 O
while	530 5 O
some	536 4 O
hypothyroid	541 11 B-Disease
patients	553 8 O
concentrated	562 12 O
their	575 5 O
urine	581 5 O
well	587 4 O
.	591 1 O

It	593 2 O
is	596 2 O
concluded	599 9 O
that	609 4 O
the	614 3 O
dominant	618 8 O
mechanisms	627 10 O
by	638 2 O
which	641 5 O
lithium	647 7 B-Chemical
exerts	655 6 O
these	662 5 O
two	668 3 O
effects	672 7 O
are	680 3 O
different	684 9 O
.	693 1 O

Sensitivity	0 11 O
of	12 2 O
erythroid	15 9 O
progenitor	25 10 O
colonies	36 8 O
to	45 2 O
erythropoietin	48 14 O
in	63 2 O
azidothymidine	66 14 B-Chemical
treated	81 7 O
immunodeficient	89 15 B-Disease
mice	105 4 O
.	109 1 O

The	111 3 O
anaemia	115 7 B-Disease
induced	123 7 O
by	131 2 O
3	134 1 B-Chemical
'	135 1 I-Chemical
-	136 1 I-Chemical
azido	137 5 I-Chemical
-	142 1 I-Chemical
3	143 1 I-Chemical
'	144 1 I-Chemical
dideoxythymidine	145 16 I-Chemical
(	162 1 O
AZT	163 3 B-Chemical
)	166 1 O
is	168 2 O
poorly	171 6 O
understood	178 10 O
.	188 1 O

We	190 2 O
have	193 4 O
used	198 4 O
a	203 1 O
murine	205 6 O
model	212 5 O
of	218 2 O
AIDS	221 4 B-Disease
,	225 1 O
infection	227 9 B-Disease
of	237 2 O
female	240 6 O
C57BL	247 5 O
/	252 1 O
6	253 1 O
mice	255 4 O
with	260 4 O
LP	265 2 O
-	267 1 O
BM5	268 3 O
murine	272 6 O
leukaemia	279 9 B-Disease
(	289 1 O
MuLV	290 4 O
)	294 1 O
virus	296 5 O
,	301 1 O
to	303 2 O
determine	306 9 O
if	316 2 O
AZT	319 3 B-Chemical
-	322 1 O
induced	323 7 O
anaemia	331 7 B-Disease
is	339 2 O
due	342 3 O
,	345 1 O
in	347 2 O
part	350 4 O
,	354 1 O
to	356 2 O
decreased	359 9 O
responsiveness	369 14 O
of	384 2 O
erythropoietic	387 14 O
precursors	402 10 O
(	413 1 O
BFU	414 3 O
-	417 1 O
e	418 1 O
)	419 1 O
to	421 2 O
erythropoietin	424 14 O
(	439 1 O
EPO	440 3 O
)	443 1 O
.	444 1 O

Mice	446 4 O
in	451 2 O
the	454 3 O
early	458 5 O
stage	464 5 O
of	470 2 O
LP	473 2 O
-	475 1 O
BM5	476 3 O
MuLV	480 4 O
disease	485 7 O
were	493 4 O
given	498 5 O
AZT	504 3 B-Chemical
in	508 2 O
their	511 5 O
drinking	517 8 O
water	526 5 O
at	532 2 O
1	535 1 O
.	536 1 O
0	537 1 O
and	539 3 O
2	543 1 O
.	544 1 O
5	545 1 O
mg	547 2 O
/	549 1 O
ml	550 2 O
.	552 1 O

AZT	554 3 B-Chemical
produced	558 8 O
anaemia	567 7 B-Disease
in	575 2 O
both	578 4 O
groups	583 6 O
,	589 1 O
in	591 2 O
a	594 1 O
dose	596 4 O
-	600 1 O
dependent	601 9 O
fashion	611 7 O
.	618 1 O

Despite	620 7 O
the	628 3 O
anaemia	632 7 B-Disease
,	639 1 O
the	641 3 O
number	645 6 O
of	652 2 O
splenic	655 7 O
and	663 3 O
bone	667 4 O
marrow	672 6 O
BFU	679 3 O
-	682 1 O
e	683 1 O
in	685 2 O
AZT	688 3 B-Chemical
treated	692 7 O
mice	700 4 O
increased	705 9 O
up	715 2 O
to	718 2 O
five	721 4 O
-	725 1 O
fold	726 4 O
over	731 4 O
levels	736 6 O
observed	743 8 O
in	752 2 O
infected	755 8 O
untreated	764 9 O
animals	774 7 O
after	782 5 O
15	788 2 O
d	791 1 O
of	793 2 O
treatment	796 9 O
.	805 1 O

Colony	807 6 O
formation	814 9 O
by	824 2 O
splenic	827 7 O
and	835 3 O
bone	839 4 O
marrow	844 6 O
BFUe	851 4 O
was	856 3 O
stimulated	860 10 O
at	871 2 O
lower	874 5 O
concentrations	880 14 O
of	895 2 O
EPO	898 3 O
in	902 2 O
mice	905 4 O
receiving	910 9 O
AZT	920 3 B-Chemical
for	924 3 O
15	928 2 O
d	931 1 O
than	933 4 O
for	938 3 O
infected	942 8 O
,	950 1 O
untreated	952 9 O
mice	962 4 O
.	966 1 O

By	968 2 O
day	971 3 O
30	975 2 O
,	977 1 O
sensitivity	979 11 O
of	991 2 O
both	994 4 O
splenic	999 7 O
and	1007 3 O
bone	1011 4 O
marrow	1016 6 O
BFU	1023 3 O
-	1026 1 O
e	1027 1 O
of	1029 2 O
treated	1032 7 O
animals	1040 7 O
returned	1048 8 O
to	1057 2 O
that	1060 4 O
observed	1065 8 O
from	1074 4 O
cells	1079 5 O
of	1085 2 O
infected	1088 8 O
untreated	1097 9 O
animals	1107 7 O
.	1114 1 O

The	1116 3 O
mean	1120 4 O
plasma	1125 6 O
levels	1132 6 O
of	1139 2 O
EPO	1142 3 O
observed	1146 8 O
in	1155 2 O
AZT	1158 3 B-Chemical
treated	1162 7 O
mice	1170 4 O
were	1175 4 O
appropriate	1180 11 O
for	1192 3 O
the	1196 3 O
degree	1200 6 O
of	1207 2 O
anaemia	1210 7 B-Disease
observed	1218 8 O
when	1227 4 O
compared	1232 8 O
with	1241 4 O
phenylhydrazine	1246 15 B-Chemical
(	1262 1 O
PHZ	1263 3 B-Chemical
)	1266 1 O
treated	1268 7 O
mice	1276 4 O
.	1280 1 O

The	1282 3 O
numbers	1286 7 O
of	1294 2 O
BFU	1297 3 O
-	1300 1 O
e	1301 1 O
and	1303 3 O
the	1307 3 O
percentage	1311 10 O
of	1322 2 O
bone	1325 4 O
marrow	1330 6 O
erythroblasts	1337 13 O
observed	1351 8 O
were	1360 4 O
comparable	1365 10 O
in	1376 2 O
AZT	1379 3 B-Chemical
and	1383 3 O
PHZ	1387 3 B-Chemical
treated	1391 7 O
mice	1399 4 O
with	1404 4 O
similar	1409 7 O
degrees	1417 7 O
of	1425 2 O
anaemia	1428 7 B-Disease
.	1435 1 O

However	1437 7 O
,	1444 1 O
reticulocytosis	1446 15 B-Disease
was	1462 3 O
inappropriate	1466 13 O
for	1480 3 O
the	1484 3 O
degree	1488 6 O
of	1495 2 O
anaemia	1498 7 B-Disease
observed	1506 8 O
in	1515 2 O
AZT	1518 3 B-Chemical
treated	1522 7 O
infected	1530 8 O
mice	1539 4 O
.	1543 1 O

AZT	1545 3 B-Chemical
-	1548 1 O
induced	1549 7 O
peripheral	1557 10 O
anaemia	1568 7 B-Disease
in	1576 2 O
the	1579 3 O
face	1583 4 O
of	1588 2 O
increased	1591 9 O
numbers	1601 7 O
of	1609 2 O
BFU	1612 3 O
-	1615 1 O
e	1616 1 O
and	1618 3 O
increased	1622 9 O
levels	1632 6 O
of	1639 2 O
plasma	1642 6 O
EPO	1649 3 O
suggest	1653 7 O
a	1661 1 O
lesion	1663 6 O
in	1670 2 O
terminal	1673 8 O
differentiation	1682 15 O
.	1697 1 O

Detection	0 9 O
of	10 2 O
abnormal	13 8 O
cardiac	22 7 O
adrenergic	30 10 O
neuron	41 6 O
activity	48 8 O
in	57 2 O
adriamycin	60 10 B-Chemical
-	70 1 O
induced	71 7 O
cardiomyopathy	79 14 B-Disease
with	94 4 O
iodine	99 6 B-Chemical
-	105 1 I-Chemical
125	106 3 I-Chemical
-	109 1 I-Chemical
metaiodobenzylguanidine	110 23 I-Chemical
.	133 1 O

Radiolabeled	135 12 B-Chemical
metaiodobenzylguanidine	148 23 I-Chemical
(	172 1 O
MIBG	173 4 B-Chemical
)	177 1 O
,	178 1 O
an	180 2 O
analog	183 6 O
of	190 2 O
norepinephrine	193 14 B-Chemical
(	208 1 O
NE	209 2 B-Chemical
)	211 1 O
,	212 1 O
serves	214 6 O
as	221 2 O
an	224 2 O
index	227 5 O
of	233 2 O
adrenergic	236 10 O
neuron	247 6 O
integrity	254 9 O
and	264 3 O
function	268 8 O
.	276 1 O

Using	278 5 O
a	284 1 O
rat	286 3 O
model	290 5 O
of	296 2 O
adriamycin	299 10 B-Chemical
-	309 1 O
induced	310 7 O
cardiomyopathy	318 14 B-Disease
,	332 1 O
we	334 2 O
tested	337 6 O
the	344 3 O
hypothesis	348 10 O
that	359 4 O
abnormal	364 8 O
cardiac	373 7 O
adrenergic	381 10 O
neuron	392 6 O
activity	399 8 O
may	408 3 O
appear	412 6 O
and	419 3 O
be	423 2 O
exacerbated	426 11 O
dose	438 4 O
-	442 1 O
dependently	443 11 O
in	455 2 O
adriamycin	458 10 B-Chemical
cardiomyopathy	469 14 B-Disease
.	483 1 O

The	485 3 O
degree	489 6 O
of	496 2 O
vacuolar	499 8 B-Disease
degeneration	508 12 I-Disease
of	521 2 I-Disease
myocardial	524 10 I-Disease
cells	535 5 I-Disease
was	541 3 O
analyzed	545 8 O
in	554 2 O
relation	557 8 O
to	566 2 O
the	569 3 O
duration	573 8 O
of	582 2 O
adriamycin	585 10 B-Chemical
treatment	596 9 O
(	606 1 O
2	607 1 O
mg	609 2 O
/	611 1 O
kg	612 2 O
,	614 1 O
once	616 4 O
a	621 1 O
week	623 4 O
)	627 1 O
.	628 1 O

There	630 5 O
were	636 4 O
no	641 2 O
abnormalities	644 13 O
or	658 2 O
only	661 4 O
isolated	666 8 O
degeneration	675 12 O
in	688 2 O
the	691 3 O
1	695 1 O
-	696 1 O
or	698 2 O
2	701 1 O
-	702 1 O
wk	703 2 O
treatment	706 9 O
groups	716 6 O
,	722 1 O
isolated	724 8 O
or	733 2 O
scattered	736 9 O
degeneration	746 12 O
in	759 2 O
half	762 4 O
of	767 2 O
the	770 3 O
3	774 1 O
-	775 1 O
wk	776 2 O
group	779 5 O
,	784 1 O
frequent	786 8 O
scattered	795 9 O
degeneration	805 12 O
in	818 2 O
the	821 3 O
4	825 1 O
-	826 1 O
wk	827 2 O
group	830 5 O
,	835 1 O
scattered	837 9 O
or	847 2 O
focal	850 5 O
degeneration	856 12 O
in	869 2 O
the	872 3 O
5	876 1 O
-	877 1 O
wk	878 2 O
group	881 5 O
,	886 1 O
and	888 3 O
extensive	892 9 O
degeneration	902 12 O
in	915 2 O
the	918 3 O
8	922 1 O
-	923 1 O
wk	924 2 O
group	927 5 O
.	932 1 O

Myocardial	934 10 O
accumulation	945 12 O
of	958 2 O
[	961 1 O
125I	962 4 O
]	966 1 O
MIBG	967 4 B-Chemical
4	972 1 O
hr	974 2 O
after	977 5 O
intravenous	983 11 O
injection	995 9 O
did	1005 3 O
not	1009 3 O
differ	1013 6 O
between	1020 7 O
the	1028 3 O
controls	1032 8 O
and	1041 3 O
the	1045 3 O
groups	1049 6 O
treated	1056 7 O
3	1064 1 O
wk	1066 2 O
or	1069 2 O
less	1072 4 O
.	1076 1 O

However	1078 7 O
,	1085 1 O
the	1087 3 O
4	1091 1 O
-	1092 1 O
wk	1093 2 O
group	1096 5 O
had	1102 3 O
a	1106 1 O
slightly	1108 8 O
lower	1117 5 O
accumulation	1123 12 O
in	1136 2 O
the	1139 3 O
right	1143 5 O
ventricular	1149 11 O
wall	1161 4 O
(	1166 1 O
82	1167 2 O
%	1169 1 O
of	1171 2 O
the	1174 3 O
control	1178 7 O
)	1185 1 O
and	1187 3 O
significantly	1191 13 O
lower	1205 5 O
accumulation	1211 12 O
in	1224 2 O
the	1227 3 O
left	1231 4 O
ventricular	1236 11 O
wall	1248 4 O
(	1253 1 O
about	1254 5 O
66	1260 2 O
%	1262 1 O
of	1264 2 O
the	1267 3 O
control	1271 7 O
:	1278 1 O
p	1280 1 O
less	1282 4 O
than	1287 4 O
0	1292 1 O
.	1293 1 O
05	1294 2 O
)	1296 1 O
.	1297 1 O

In	1299 2 O
the	1302 3 O
5	1306 1 O
-	1307 1 O
wk	1308 2 O
group	1311 5 O
,	1316 1 O
MIBG	1318 4 B-Chemical
accumulation	1323 12 O
in	1336 2 O
the	1339 3 O
right	1343 5 O
and	1349 3 O
left	1353 4 O
ventricular	1358 11 O
wall	1370 4 O
was	1375 3 O
35	1379 2 O
%	1381 1 O
and	1383 3 O
27	1387 2 O
%	1389 1 O
of	1391 2 O
that	1394 4 O
in	1399 2 O
controls	1402 8 O
,	1410 1 O
respectively	1412 12 O
(	1425 1 O
p	1426 1 O
less	1428 4 O
than	1433 4 O
0	1438 1 O
.	1439 1 O
001	1440 3 O
)	1443 1 O
.	1444 1 O

In	1446 2 O
the	1449 3 O
8	1453 1 O
-	1454 1 O
wk	1455 2 O
group	1458 5 O
,	1463 1 O
MIBG	1465 4 B-Chemical
accumulation	1470 12 O
in	1483 2 O
the	1486 3 O
right	1490 5 O
and	1496 3 O
left	1500 4 O
ventricular	1505 11 O
wall	1517 4 O
was	1522 3 O
18	1526 2 O
%	1528 1 O
and	1530 3 O
14	1534 2 O
%	1536 1 O
of	1538 2 O
that	1541 4 O
in	1546 2 O
controls	1549 8 O
,	1557 1 O
respectively	1559 12 O
(	1572 1 O
p	1573 1 O
less	1575 4 O
than	1580 4 O
0	1585 1 O
.	1586 1 O
001	1587 3 O
)	1590 1 O
.	1591 1 O

Thus	1593 4 O
,	1597 1 O
MIBG	1599 4 B-Chemical
accumulation	1604 12 O
in	1617 2 O
the	1620 3 O
myocardium	1624 10 O
decreased	1635 9 O
in	1645 2 O
an	1648 2 O
adriamycin	1651 10 B-Chemical
dose	1662 4 O
-	1666 1 O
dependent	1667 9 O
manner	1677 6 O
.	1683 1 O

The	1685 3 O
appearance	1689 10 O
of	1700 2 O
impaired	1703 8 O
cardiac	1712 7 O
adrenergic	1720 10 O
neuron	1731 6 O
activity	1738 8 O
in	1747 2 O
the	1750 3 O
presence	1754 8 O
of	1763 2 O
slight	1766 6 O
myocardial	1773 10 B-Disease
impairment	1784 10 I-Disease
(	1795 1 O
scattered	1796 9 O
or	1806 2 O
focal	1809 5 O
vacuolar	1815 8 B-Disease
degeneration	1824 12 I-Disease
)	1836 1 O
indicates	1838 9 O
that	1848 4 O
MIBG	1853 4 B-Chemical
scintigraphy	1858 12 O
may	1871 3 O
be	1875 2 O
a	1878 1 O
useful	1880 6 O
method	1887 6 O
for	1894 3 O
detection	1898 9 O
of	1908 2 O
adriamycin	1911 10 B-Chemical
-	1921 1 O
induced	1922 7 O
cardiomyopathy	1930 14 B-Disease
.	1944 1 O

Amnestic	0 8 B-Disease
syndrome	9 8 I-Disease
associated	18 10 O
with	29 4 O
propranolol	34 11 B-Chemical
toxicity	46 8 B-Disease
:	54 1 O
a	56 1 O
case	58 4 O
report	63 6 O
.	69 1 O

An	71 2 O
elderly	74 7 O
woman	82 5 O
developed	88 9 O
an	98 2 O
Alzheimer	101 9 B-Disease
-	110 1 O
like	111 4 O
subacute	116 8 O
dementia	125 8 B-Disease
as	134 2 O
a	137 1 O
result	139 6 O
of	146 2 O
propranolol	149 11 B-Chemical
toxicity	161 8 B-Disease
.	169 1 O

Analysis	171 8 O
of	180 2 O
the	183 3 O
manifestations	187 14 O
showed	202 6 O
that	209 4 O
severe	214 6 O
impairment	221 10 O
of	232 2 O
memory	235 6 O
accounted	242 9 O
for	252 3 O
virtually	256 9 O
all	266 3 O
of	270 2 O
the	273 3 O
abnormalities	277 13 O
.	290 1 O

There	292 5 O
is	298 2 O
evidence	301 8 O
that	310 4 O
cerebral	315 8 O
reactions	324 9 O
to	334 2 O
drug	337 4 O
toxicity	342 8 B-Disease
can	351 3 O
exhibit	355 7 O
patterns	363 8 O
that	372 4 O
suggest	377 7 O
highly	385 6 O
selective	392 9 O
involvement	402 11 O
of	414 2 O
functional	417 10 O
subdivisions	428 12 O
of	441 2 O
the	444 3 O
brain	448 5 O
.	453 1 O

Biphasic	0 8 O
response	9 8 O
of	18 2 O
the	21 3 O
SA	25 2 O
node	28 4 O
of	33 2 O
the	36 3 O
dog	40 3 O
heart	44 5 O
in	50 2 O
vivo	53 4 O
to	58 2 O
selective	61 9 O
administration	71 14 O
of	86 2 O
ketamine	89 8 B-Chemical
.	97 1 O

Effect	99 6 O
of	106 2 O
ketamine	109 8 B-Chemical
on	118 2 O
the	121 3 O
SA	125 2 O
node	128 4 O
of	133 2 O
the	136 3 O
dog	140 3 O
heart	144 5 O
was	150 3 O
studied	154 7 O
in	162 2 O
vivo	165 4 O
using	170 5 O
a	176 1 O
selective	178 9 O
perfusion	188 9 O
technique	198 9 O
of	208 2 O
the	211 3 O
SA	215 2 O
node	218 4 O
artery	223 6 O
.	229 1 O

Injections	231 10 O
of	242 2 O
ketamine	245 8 B-Chemical
in	254 2 O
doses	257 5 O
from	263 4 O
100	268 3 O
microgram	272 9 O
to	282 2 O
3	285 1 O
mg	287 2 O
into	290 4 O
the	295 3 O
artery	299 6 O
produced	306 8 O
a	315 1 O
depression	317 10 B-Disease
of	328 2 O
the	331 3 O
SA	335 2 O
nodal	338 5 O
activity	344 8 O
by	353 2 O
a	356 1 O
direct	358 6 O
action	365 6 O
.	371 1 O

This	373 4 O
depression	378 10 B-Disease
was	389 3 O
followed	393 8 O
by	402 2 O
the	405 3 O
sudden	409 6 O
appearance	416 10 O
of	427 2 O
a	430 1 O
stimulatory	432 11 O
phase	444 5 O
.	449 1 O

Bilateral	451 9 O
vagotomy	461 8 O
and	470 3 O
sympathectomy	474 13 O
or	488 2 O
prior	491 5 O
administration	497 14 O
of	512 2 O
a	515 1 O
ganglion	517 8 O
blocker	526 7 O
failed	534 6 O
to	541 2 O
inhibit	544 7 O
the	552 3 O
occurrence	556 10 O
of	567 2 O
the	570 3 O
ketamine	574 8 B-Chemical
-	582 1 O
induced	583 7 O
tachycardia	591 11 B-Disease
,	602 1 O
while	604 5 O
it	610 2 O
was	613 3 O
completely	617 10 O
abolished	628 9 O
in	638 2 O
the	641 3 O
reserpinized	645 12 O
dogs	658 4 O
or	663 2 O
by	666 2 O
a	669 1 O
prior	671 5 O
injection	677 9 O
of	687 2 O
a	690 1 O
beta	692 4 O
-	696 1 O
blocking	697 8 O
agent	706 5 O
into	712 4 O
the	717 3 O
SA	721 2 O
node	724 4 O
artery	729 6 O
.	735 1 O

This	737 4 O
may	742 3 O
indicate	746 8 O
that	755 4 O
an	760 2 O
activation	763 10 O
of	774 2 O
the	777 3 O
peripheral	781 10 O
adrenergic	792 10 O
mechanism	803 9 O
plays	813 5 O
an	819 2 O
important	822 9 O
role	832 4 O
in	837 2 O
the	840 3 O
induction	844 9 O
of	854 2 O
the	857 3 O
excitatory	861 10 O
effect	872 6 O
of	879 2 O
ketamine	882 8 B-Chemical
injected	891 8 O
in	900 2 O
the	903 3 O
SA	907 2 O
node	910 4 O
artery	915 6 O
.	921 1 O

The	0 3 O
use	4 3 O
of	8 2 O
serum	11 5 O
cholinesterase	17 14 O
in	32 2 O
succinylcholine	35 15 B-Chemical
apnoea	51 6 B-Disease
.	57 1 O

Fifteen	59 7 O
patients	67 8 O
demonstrating	76 13 O
unexpected	90 10 O
prolonged	101 9 O
apnoea	111 6 B-Disease
lasting	118 7 O
several	126 7 O
hours	134 5 O
after	140 5 O
succinylcholine	146 15 B-Chemical
have	162 4 O
been	167 4 O
treated	172 7 O
by	180 2 O
a	183 1 O
new	185 3 O
preparation	189 11 O
of	201 2 O
human	204 5 O
serum	210 5 O
cholinesterase	216 14 O
.	230 1 O

Adequate	232 8 O
spontaneous	241 11 O
respiration	253 11 O
was	265 3 O
re	269 2 O
-	271 1 O
established	272 11 O
in	284 2 O
an	287 2 O
average	290 7 O
period	298 6 O
of	305 2 O
ten	308 3 O
minutes	312 7 O
after	320 5 O
the	326 3 O
injection	330 9 O
.	339 1 O

In	341 2 O
12	344 2 O
patients	347 8 O
biochemical	356 11 O
genetic	368 7 O
examinations	376 12 O
confirmed	389 9 O
the	399 3 O
presence	403 8 O
of	412 2 O
an	415 2 O
atypical	418 8 O
serum	427 5 O
cholinesterase	433 14 O
.	447 1 O

In	449 2 O
three	452 5 O
patients	458 8 O
none	467 4 O
of	472 2 O
the	475 3 O
usual	479 5 O
variants	485 8 O
were	494 4 O
found	499 5 O
.	504 1 O

It	506 2 O
is	509 2 O
therefore	512 9 O
supposed	522 8 O
that	531 4 O
other	536 5 O
unknown	542 7 O
variants	550 8 O
of	559 2 O
serum	562 5 O
cholinesterase	568 14 O
exist	583 5 O
which	589 5 O
cannot	595 6 O
hydrolyze	602 9 O
succinylcholine	612 15 B-Chemical
.	627 1 O

The	629 3 O
use	633 3 O
of	637 2 O
serum	640 5 O
cholinesterase	646 14 O
in	661 2 O
succinylcholine	664 15 B-Chemical
apnoea	680 6 B-Disease
provided	687 8 O
considerable	696 12 O
relief	709 6 O
to	716 2 O
both	719 4 O
patient	724 7 O
and	732 3 O
anaesthetist	736 12 O
.	748 1 O

Orthostatic	0 11 B-Disease
hypotension	12 11 I-Disease
occurs	24 6 O
following	31 9 O
alpha	41 5 O
2	47 1 O
-	48 1 O
adrenoceptor	49 12 O
blockade	62 8 O
in	71 2 O
chronic	74 7 O
prazosin	82 8 B-Chemical
-	90 1 O
pretreated	91 10 O
conscious	102 9 O
spontaneously	112 13 O
hypertensive	126 12 B-Disease
rats	139 4 O
.	143 1 O

1	145 1 O
.	146 1 O

Studies	148 7 O
were	156 4 O
performed	161 9 O
to	171 2 O
evaluate	174 8 O
whether	183 7 O
chronic	191 7 O
prazosin	199 8 B-Chemical
treatment	208 9 O
alters	218 6 O
the	225 3 O
alpha	229 5 O
2	235 1 O
-	236 1 O
adrenoceptor	237 12 O
function	250 8 O
for	259 3 O
orthostatic	263 11 O
control	275 7 O
of	283 2 O
arterial	286 8 O
blood	295 5 O
pressure	301 8 O
in	310 2 O
conscious	313 9 O
spontaneously	323 13 O
hypertensive	337 12 B-Disease
rats	350 4 O
(	355 1 O
SHR	356 3 O
)	359 1 O
.	360 1 O

2	362 1 O
.	363 1 O

Conscious	365 9 O
SHR	375 3 O
(	379 1 O
male	380 4 O
300	385 3 O
-	388 1 O
350	389 3 O
g	393 1 O
)	394 1 O
were	396 4 O
subjected	401 9 O
to	411 2 O
90	414 2 O
degrees	417 7 O
head	425 4 O
-	429 1 O
up	430 2 O
tilts	433 5 O
for	439 3 O
60	443 2 O
s	446 1 O
following	448 9 O
acute	458 5 O
administration	464 14 O
of	479 2 O
prazosin	482 8 B-Chemical
(	491 1 O
0	492 1 O
.	493 1 O
1	494 1 O
mg	496 2 O
kg	499 2 O
-	501 1 O
1	502 1 O
i	504 1 O
.	505 1 O
p	506 1 O
.	507 1 O
)	508 1 O
or	510 2 O
rauwolscine	513 11 B-Chemical
(	525 1 O
3	526 1 O
mg	528 2 O
kg	531 2 O
-	533 1 O
1	534 1 O
i	536 1 O
.	537 1 O
v	538 1 O
.	539 1 O
)	540 1 O
.	541 1 O

Orthostatic	543 11 B-Disease
hypotension	555 11 I-Disease
was	567 3 O
determined	571 10 O
by	582 2 O
the	585 3 O
average	589 7 O
decrease	597 8 O
(	606 1 O
%	607 1 O
)	608 1 O
in	610 2 O
mean	613 4 O
arterial	618 8 O
pressure	627 8 O
(	636 1 O
MAP	637 3 O
femoral	641 7 O
)	648 1 O
over	650 4 O
the	655 3 O
60	659 2 O
-	661 1 O
s	662 1 O
tilt	664 4 O
period	669 6 O
.	675 1 O

The	677 3 O
basal	681 5 O
MAP	687 3 O
of	691 2 O
conscious	694 9 O
SHR	704 3 O
was	708 3 O
reduced	712 7 O
to	720 2 O
a	723 1 O
similar	725 7 O
extent	733 6 O
by	740 2 O
prazosin	743 8 B-Chemical
(	752 1 O
-	753 1 O
23	754 2 O
%	756 1 O
(	757 1 O
-	758 1 O
)	759 1 O
-	760 1 O
26	761 2 O
%	763 1 O
MAP	765 3 O
)	768 1 O
and	770 3 O
rauwolscine	774 11 B-Chemical
(	786 1 O
-	787 1 O
16	788 2 O
%	790 1 O
(	791 1 O
-	792 1 O
)	793 1 O
-	794 1 O
33	795 2 O
%	797 1 O
MAP	799 3 O
)	802 1 O
.	803 1 O

However	805 7 O
,	812 1 O
the	814 3 O
head	818 4 O
-	822 1 O
up	823 2 O
tilt	826 4 O
induced	831 7 O
orthostatic	839 11 B-Disease
hypotension	851 11 I-Disease
in	863 2 O
the	866 3 O
SHR	870 3 O
treated	874 7 O
with	882 4 O
prazosin	887 8 B-Chemical
(	896 1 O
-	897 1 O
16	898 2 O
%	900 1 O
MAP	902 3 O
,	905 1 O
n	907 1 O
=	909 1 O
6	911 1 O
)	912 1 O
,	913 1 O
but	915 3 O
not	919 3 O
in	923 2 O
the	926 3 O
SHR	930 3 O
treated	934 7 O
with	942 4 O
rauwolscine	947 11 B-Chemical
(	959 1 O
less	960 4 O
than	965 4 O
+	970 1 O
2	971 1 O
%	972 1 O
MAP	974 3 O
,	977 1 O
n	979 1 O
=	981 1 O
6	983 1 O
)	984 1 O
.	985 1 O

3	987 1 O
.	988 1 O

Conscious	990 9 O
SHR	1000 3 O
were	1004 4 O
treated	1009 7 O
for	1017 3 O
4	1021 1 O
days	1023 4 O
with	1028 4 O
prazosin	1033 8 B-Chemical
at	1042 2 O
2	1045 1 O
mg	1047 2 O
kg	1050 2 O
-	1052 1 O
1	1053 1 O
day	1055 3 O
-	1058 1 O
1	1059 1 O
i	1061 1 O
.	1062 1 O
p	1063 1 O
.	1064 1 O
for	1066 3 O
chronic	1070 7 O
alpha	1078 5 O
1	1084 1 O
-	1085 1 O
adrenoceptor	1086 12 O
blockade	1099 8 O
.	1107 1 O

MAP	1109 3 O
in	1113 2 O
conscious	1116 9 O
SHR	1126 3 O
after	1130 5 O
chronic	1136 7 O
prazosin	1144 8 B-Chemical
treatment	1153 9 O
was	1163 3 O
14	1167 2 O
%	1169 1 O
lower	1171 5 O
than	1177 4 O
in	1182 2 O
the	1185 3 O
untreated	1189 9 O
SHR	1199 3 O
(	1203 1 O
n	1204 1 O
=	1206 1 O
8	1208 1 O
)	1209 1 O
.	1210 1 O

Head	1212 4 O
-	1216 1 O
up	1217 2 O
tilts	1220 5 O
in	1226 2 O
these	1229 5 O
rats	1235 4 O
did	1240 3 O
not	1244 3 O
produce	1248 7 O
orthostatic	1256 11 B-Disease
hypotension	1268 11 I-Disease
when	1280 4 O
performed	1285 9 O
either	1295 6 O
prior	1302 5 O
to	1308 2 O
or	1311 2 O
after	1314 5 O
acute	1320 5 O
dosing	1326 6 O
of	1333 2 O
prazosin	1336 8 B-Chemical
(	1345 1 O
0	1346 1 O
.	1347 1 O
1	1348 1 O
mg	1350 2 O
kg	1353 2 O
-	1355 1 O
1	1356 1 O
i	1358 1 O
.	1359 1 O
p	1360 1 O
.	1361 1 O
)	1362 1 O
.	1363 1 O

Conversely	1365 10 O
,	1375 1 O
administration	1377 14 O
of	1392 2 O
rauwolscine	1395 11 B-Chemical
(	1407 1 O
3	1408 1 O
mg	1410 2 O
kg	1413 2 O
-	1415 1 O
1	1416 1 O
i	1418 1 O
.	1419 1 O
v	1420 1 O
.	1421 1 O
)	1422 1 O
in	1424 2 O
chronic	1427 7 O
prazosin	1435 8 B-Chemical
treated	1444 7 O
SHR	1452 3 O
decreased	1456 9 O
the	1466 3 O
basal	1470 5 O
MAP	1476 3 O
by	1480 2 O
12	1483 2 O
-	1485 1 O
31	1486 2 O
%	1488 1 O
(	1490 1 O
n	1491 1 O
=	1493 1 O
4	1495 1 O
)	1496 1 O
,	1497 1 O
and	1499 3 O
subsequent	1503 10 O
tilts	1514 5 O
induced	1520 7 O
further	1528 7 O
drops	1536 5 O
of	1542 2 O
MAP	1545 3 O
by	1549 2 O
19	1552 2 O
-	1554 1 O
23	1555 2 O
%	1557 1 O
in	1559 2 O
these	1562 5 O
rats	1568 4 O
.	1572 1 O

4	1574 1 O
.	1575 1 O

The	1577 3 O
pressor	1581 7 O
responses	1589 9 O
and	1599 3 O
bradycardia	1603 11 B-Disease
to	1615 2 O
the	1618 3 O
alpha	1622 5 O
1	1628 1 O
-	1629 1 O
agonist	1630 7 O
cirazoline	1638 10 B-Chemical
(	1649 1 O
0	1650 1 O
.	1651 1 O
6	1652 1 O
and	1654 3 O
2	1658 1 O
micrograms	1660 10 O
kg	1671 2 O
-	1673 1 O
1	1674 1 O
i	1676 1 O
.	1677 1 O
v	1678 1 O
.	1679 1 O
)	1680 1 O
,	1681 1 O
the	1683 3 O
alpha	1687 5 O
2	1693 1 O
-	1694 1 O
agonist	1695 7 O
Abbott	1703 6 B-Chemical
-	1709 1 I-Chemical
53693	1710 5 I-Chemical
(	1716 1 O
1	1717 1 O
and	1719 3 O
3	1723 1 O
micrograms	1725 10 O
kg	1736 2 O
-	1738 1 O
1	1739 1 O
i	1741 1 O
.	1742 1 O
v	1743 1 O
.	1744 1 O
)	1745 1 O
,	1746 1 O
and	1748 3 O
noradrenaline	1752 13 B-Chemical
(	1766 1 O
0	1767 1 O
.	1768 1 O
1	1769 1 O
and	1771 3 O
1	1775 1 O
.	1776 1 O
0	1777 1 O
micrograms	1779 10 O
kg	1790 2 O
-	1792 1 O
1	1793 1 O
i	1795 1 O
.	1796 1 O
v	1797 1 O
.	1798 1 O
)	1799 1 O
were	1801 4 O
determined	1806 10 O
in	1817 2 O
conscious	1820 9 O
SHR	1830 3 O
with	1834 4 O
and	1839 3 O
without	1843 7 O
chronic	1851 7 O
prazosin	1859 8 B-Chemical
pretreatment	1868 12 O
.	1880 1 O

Both	1882 4 O
the	1887 3 O
pressor	1891 7 O
and	1899 3 O
bradycardia	1903 11 B-Disease
effects	1915 7 O
of	1923 2 O
cirazoline	1926 10 B-Chemical
were	1937 4 O
abolished	1942 9 O
in	1952 2 O
chronic	1955 7 O
prazosin	1963 8 B-Chemical
treated	1972 7 O
SHR	1980 3 O
(	1984 1 O
n	1985 1 O
=	1987 1 O
4	1989 1 O
)	1990 1 O
as	1992 2 O
compared	1995 8 O
to	2004 2 O
the	2007 3 O
untreated	2011 9 O
SHR	2021 3 O
(	2025 1 O
n	2026 1 O
=	2028 1 O
4	2030 1 O
)	2031 1 O
.	2032 1 O

On	2034 2 O
the	2037 3 O
other	2041 5 O
hand	2047 4 O
,	2051 1 O
the	2053 3 O
pressor	2057 7 O
effects	2065 7 O
of	2073 2 O
Abbott	2076 6 B-Chemical
-	2082 1 I-Chemical
53693	2083 5 I-Chemical
were	2089 4 O
similar	2094 7 O
in	2102 2 O
both	2105 4 O
groups	2110 6 O
of	2117 2 O
SHR	2120 3 O
,	2123 1 O
but	2125 3 O
the	2129 3 O
accompanying	2133 12 O
bradycardia	2146 11 B-Disease
was	2158 3 O
greater	2162 7 O
in	2170 2 O
SHR	2173 3 O
with	2177 4 O
chronic	2182 7 O
prazosin	2190 8 B-Chemical
treatment	2199 9 O
than	2209 4 O
without	2214 7 O
such	2222 4 O
treatment	2227 9 O
.	2236 1 O

Furthermore	2238 11 O
,	2249 1 O
the	2251 3 O
bradycardia	2255 11 B-Disease
that	2267 4 O
accompanied	2272 11 O
the	2284 3 O
noradrenaline	2288 13 B-Chemical
-	2301 1 O
induced	2302 7 O
pressor	2310 7 O
effect	2318 6 O
in	2325 2 O
SHR	2328 3 O
was	2332 3 O
similar	2336 7 O
with	2344 4 O
and	2349 3 O
without	2353 7 O
chronic	2361 7 O
prazosin	2369 8 B-Chemical
treatment	2378 9 O
despite	2388 7 O
a	2396 1 O
47	2398 2 O
-	2400 1 O
71	2401 2 O
%	2403 1 O
reduction	2405 9 O
of	2415 2 O
the	2418 3 O
pressor	2422 7 O
effect	2430 6 O
in	2437 2 O
chronic	2440 7 O
alpha	2448 5 O
1	2454 1 O
-	2455 1 O
receptor	2456 8 O
blocked	2465 7 O
SHR	2473 3 O
.	2476 1 O
(	2477 1 O
ABSTRACT	2478 8 O
TRUNCATED	2487 9 O
AT	2497 2 O
400	2500 3 O
WORDS	2504 5 O
)	2509 1 O

Coexistence	0 11 O
of	12 2 O
cerebral	15 8 B-Disease
venous	24 6 I-Disease
sinus	31 5 I-Disease
and	37 3 I-Disease
internal	41 8 I-Disease
carotid	50 7 I-Disease
artery	58 6 I-Disease
thrombosis	65 10 I-Disease
associated	76 10 O
with	87 4 O
exogenous	92 9 O
sex	102 3 O
hormones	106 8 O
.	114 1 O

A	116 1 O
case	118 4 O
report	123 6 O
.	129 1 O

A	131 1 O
forty	133 5 O
-	138 1 O
six	139 3 O
year	143 4 O
-	147 1 O
old	148 3 O
premenopausal	152 13 O
woman	166 5 O
developed	172 9 O
headache	182 8 B-Disease
,	190 1 O
nausea	192 6 B-Disease
and	199 3 O
vomiting	203 8 B-Disease
,	211 1 O
left	213 4 O
hemiparesis	218 11 B-Disease
and	230 3 O
seizure	234 7 B-Disease
two	242 3 O
days	246 4 O
after	251 5 O
parenteral	257 10 O
use	268 3 O
of	272 2 O
progesterone	275 12 B-Chemical
and	288 3 O
estradiol	292 9 B-Chemical
.	301 1 O

Diabetes	303 8 B-Disease
mellitus	312 8 I-Disease
(	321 1 O
DM	322 2 B-Disease
)	324 1 O
was	326 3 O
found	330 5 O
during	336 6 O
admission	343 9 O
.	352 1 O

Computed	354 8 O
tomography	363 10 O
showed	374 6 O
a	381 1 O
hemorrhagic	383 11 B-Disease
infarct	395 7 I-Disease
in	403 2 O
the	406 3 O
right	410 5 O
frontal	416 7 O
lobe	424 4 O
and	429 3 O
increased	433 9 O
density	443 7 O
in	451 2 O
the	454 3 O
superior	458 8 O
sagittal	467 8 O
sinus	476 5 O
(	482 1 O
SSS	483 3 O
)	486 1 O
.	487 1 O

Left	489 4 O
carotid	494 7 O
angiography	502 11 O
found	514 5 O
occlusion	520 9 B-Disease
of	530 2 I-Disease
the	533 3 I-Disease
left	537 4 I-Disease
internal	542 8 I-Disease
carotid	551 7 I-Disease
artery	559 6 I-Disease
(	566 1 O
ICA	567 3 O
)	570 1 O
.	571 1 O

Right	573 5 O
carotid	579 7 O
angiograms	587 10 O
failed	598 6 O
to	605 2 O
show	608 4 O
the	613 3 O
SSS	617 3 O
and	621 3 O
inferior	625 8 O
sagittal	634 8 O
sinus	643 5 O
,	648 1 O
suggestive	650 10 O
of	661 2 O
venous	664 6 B-Disease
sinus	671 5 I-Disease
thrombosis	677 10 I-Disease
.	687 1 O

Coexistence	689 11 O
of	701 2 O
the	704 3 O
cerebral	708 8 B-Disease
artery	717 6 I-Disease
and	724 3 I-Disease
the	728 3 I-Disease
venous	732 6 I-Disease
sinus	739 5 I-Disease
occlusion	745 9 I-Disease
has	755 3 O
been	759 4 O
described	764 9 O
infrequently	774 12 O
.	786 1 O

In	788 2 O
this	791 4 O
case	796 4 O
,	800 1 O
the	802 3 O
authors	806 7 O
postulate	814 9 O
that	824 4 O
the	829 3 O
use	833 3 O
of	837 2 O
estradiol	840 9 B-Chemical
and	850 3 O
progesterone	854 12 B-Chemical
and	867 3 O
the	871 3 O
underlying	875 10 O
DM	886 2 B-Disease
increased	889 9 O
vascular	899 8 O
thrombogenicity	908 15 O
,	923 1 O
which	925 5 O
provided	931 8 O
a	940 1 O
common	942 6 O
denominator	949 11 O
for	961 3 O
thrombosis	965 10 B-Disease
of	976 2 I-Disease
both	979 4 I-Disease
the	984 3 I-Disease
ICA	988 3 I-Disease
and	992 3 I-Disease
the	996 3 I-Disease
venous	1000 6 I-Disease
sinus	1007 5 I-Disease
.	1012 1 O

Chloroquine	0 11 B-Chemical
related	12 7 O
complete	20 8 O
heart	29 5 B-Disease
block	35 5 I-Disease
with	41 4 O
blindness	46 9 B-Disease
:	55 1 O
case	57 4 O
report	62 6 O
.	68 1 O

A	70 1 O
27	72 2 O
-	74 1 O
year	75 4 O
old	80 3 O
African	84 7 O
woman	92 5 O
with	98 4 O
history	103 7 O
of	111 2 O
regular	114 7 O
chloroquine	122 11 B-Chemical
ingestion	134 9 O
presented	144 9 O
with	154 4 O
progressive	159 11 O
deterioration	171 13 B-Disease
of	185 2 I-Disease
vision	188 6 I-Disease
,	194 1 O
easy	196 4 O
fatiguability	201 13 B-Disease
,	214 1 O
dyspnoea	216 8 B-Disease
,	224 1 O
dizziness	226 9 B-Disease
progressing	236 11 O
to	248 2 O
syncopal	251 8 B-Disease
attacks	260 7 I-Disease
.	267 1 O

Ophthalmological	269 16 O
assessment	286 10 O
revealed	297 8 O
features	306 8 O
of	315 2 O
chloroquine	318 11 B-Chemical
retinopathy	330 11 B-Disease
,	341 1 O
cardiac	343 7 O
assessment	351 10 O
revealed	362 8 O
features	371 8 O
of	380 2 O
heart	383 5 B-Disease
failure	389 7 I-Disease
and	397 3 O
a	401 1 O
complete	403 8 O
heart	412 5 B-Disease
block	418 5 I-Disease
with	424 4 O
right	429 5 B-Disease
bundle	435 6 I-Disease
branch	442 6 I-Disease
block	449 5 I-Disease
pattern	455 7 O
.	462 1 O

The	464 3 O
heart	468 5 B-Disease
block	474 5 I-Disease
was	480 3 O
treated	484 7 O
by	492 2 O
pacemaker	495 9 O
insertion	505 9 O
and	515 3 O
the	519 3 O
heart	523 5 B-Disease
failure	529 7 I-Disease
resolved	537 8 O
spontaneously	546 13 O
following	560 9 O
chloroquine	570 11 B-Chemical
discontinuation	582 15 O
.	597 1 O

She	599 3 O
however	603 7 O
remains	611 7 O
blind	619 5 B-Disease
.	624 1 O

Systemic	0 8 O
toxicity	9 8 B-Disease
and	18 3 O
resuscitation	22 13 O
in	36 2 O
bupivacaine	39 11 B-Chemical
-	50 1 O
,	51 1 O
levobupivacaine	53 15 B-Chemical
-	68 1 O
,	69 1 O
or	71 2 O
ropivacaine	74 11 B-Chemical
-	85 1 O
infused	86 7 O
rats	94 4 O
.	98 1 O

We	100 2 O
compared	103 8 O
the	112 3 O
systemic	116 8 O
toxicity	125 8 B-Disease
of	134 2 O
bupivacaine	137 11 B-Chemical
,	148 1 O
levobupivacaine	150 15 B-Chemical
,	165 1 O
and	167 3 O
ropivacaine	171 11 B-Chemical
in	183 2 O
anesthetized	186 12 O
rats	199 4 O
.	203 1 O

We	205 2 O
also	208 4 O
compared	213 8 O
the	222 3 O
ability	226 7 O
to	234 2 O
resuscitate	237 11 O
rats	249 4 O
after	254 5 O
lethal	260 6 O
doses	267 5 O
of	273 2 O
these	276 5 O
local	282 5 O
anesthetics	288 11 O
.	299 1 O

Bupivacaine	301 11 B-Chemical
,	312 1 O
levobupivacaine	314 15 B-Chemical
,	329 1 O
or	331 2 O
ropivacaine	334 11 B-Chemical
was	346 3 O
infused	350 7 O
at	358 2 O
a	361 1 O
rate	363 4 O
of	368 2 O
2	371 1 O
mg	373 2 O
.	375 1 O

kg	377 2 O
(	379 1 O
-	380 1 O
1	381 1 O
)	382 1 O
.	383 1 O

min	385 3 O
(	388 1 O
-	389 1 O
1	390 1 O
)	391 1 O
while	393 5 O
electrocardiogram	399 17 O
,	416 1 O
electroencephalogram	418 20 O
,	438 1 O
and	440 3 O
arterial	444 8 O
pressure	453 8 O
were	462 4 O
continuously	467 12 O
monitored	480 9 O
.	489 1 O

When	491 4 O
asystole	496 8 B-Disease
was	505 3 O
recorded	509 8 O
,	517 1 O
drug	519 4 O
infusion	524 8 O
was	533 3 O
stopped	537 7 O
and	545 3 O
a	549 1 O
resuscitation	551 13 O
sequence	565 8 O
was	574 3 O
begun	578 5 O
.	583 1 O

Epinephrine	585 11 B-Chemical
0	597 1 O
.	598 1 O
01	599 2 O
mg	602 2 O
/	604 1 O
kg	605 2 O
was	608 3 O
administered	612 12 O
at	625 2 O
1	628 1 O
-	629 1 O
min	630 3 O
intervals	634 9 O
while	644 5 O
external	650 8 O
cardiac	659 7 O
compressions	667 12 O
were	680 4 O
applied	685 7 O
.	692 1 O

Resuscitation	694 13 O
was	708 3 O
considered	712 10 O
successful	723 10 O
when	734 4 O
a	739 1 O
systolic	741 8 O
arterial	750 8 O
pressure	759 8 O
>	768 1 O
or	770 2 O
=	773 1 O
100	774 3 O
mm	778 2 O
Hg	781 2 O
was	784 3 O
achieved	788 8 O
within	797 6 O
5	804 1 O
min	806 3 O
.	809 1 O

The	811 3 O
cumulative	815 10 O
doses	826 5 O
of	832 2 O
levobupivacaine	835 15 B-Chemical
and	851 3 O
ropivacaine	855 11 B-Chemical
that	867 4 O
produced	872 8 O
seizures	881 8 B-Disease
were	890 4 O
similar	895 7 O
and	903 3 O
were	907 4 O
larger	912 6 O
than	919 4 O
those	924 5 O
of	930 2 O
bupivacaine	933 11 B-Chemical
.	944 1 O

The	946 3 O
cumulative	950 10 O
doses	961 5 O
of	967 2 O
levobupivacaine	970 15 B-Chemical
that	986 4 O
produced	991 8 O
dysrhythmias	1000 12 B-Disease
and	1013 3 O
asystole	1017 8 B-Disease
were	1026 4 O
smaller	1031 7 O
than	1039 4 O
the	1044 3 O
corresponding	1048 13 O
doses	1062 5 O
of	1068 2 O
ropivacaine	1071 11 B-Chemical
,	1082 1 O
but	1084 3 O
they	1088 4 O
were	1093 4 O
larger	1098 6 O
than	1105 4 O
those	1110 5 O
of	1116 2 O
bupivacaine	1119 11 B-Chemical
.	1130 1 O

The	1132 3 O
number	1136 6 O
of	1143 2 O
successful	1146 10 O
resuscitations	1157 14 O
did	1172 3 O
not	1176 3 O
differ	1180 6 O
among	1187 5 O
groups	1193 6 O
.	1199 1 O

However	1201 7 O
,	1208 1 O
a	1210 1 O
smaller	1212 7 O
dose	1220 4 O
of	1225 2 O
epinephrine	1228 11 B-Chemical
was	1240 3 O
required	1244 8 O
in	1253 2 O
the	1256 3 O
Ropivacaine	1260 11 B-Chemical
group	1272 5 O
than	1278 4 O
in	1283 2 O
the	1286 3 O
other	1290 5 O
groups	1296 6 O
.	1302 1 O

We	1304 2 O
conclude	1307 8 O
that	1316 4 O
the	1321 3 O
systemic	1325 8 O
toxicity	1334 8 B-Disease
of	1343 2 O
levobupivacaine	1346 15 B-Chemical
is	1362 2 O
intermediate	1365 12 O
between	1378 7 O
that	1386 4 O
of	1391 2 O
ropivacaine	1394 11 B-Chemical
and	1406 3 O
bupivacaine	1410 11 B-Chemical
when	1422 4 O
administered	1427 12 O
at	1440 2 O
the	1443 3 O
same	1447 4 O
rate	1452 4 O
and	1457 3 O
that	1461 4 O
ropivacaine	1466 11 B-Chemical
-	1477 1 O
induced	1478 7 O
cardiac	1486 7 B-Disease
arrest	1494 6 I-Disease
appears	1501 7 O
to	1509 2 O
be	1512 2 O
more	1515 4 O
susceptible	1520 11 O
to	1532 2 O
treatment	1535 9 O
than	1545 4 O
that	1550 4 O
induced	1555 7 O
by	1563 2 O
bupivacaine	1566 11 B-Chemical
or	1578 2 O
levobupivacaine	1581 15 B-Chemical
.	1596 1 O

22	0 2 B-Chemical
-	2 1 I-Chemical
oxacalcitriol	3 13 I-Chemical
suppresses	17 10 O
secondary	28 9 B-Disease
hyperparathyroidism	38 19 I-Disease
without	58 7 O
inducing	66 8 O
low	75 3 B-Disease
bone	79 4 I-Disease
turnover	84 8 I-Disease
in	93 2 O
dogs	96 4 O
with	101 4 O
renal	106 5 B-Disease
failure	112 7 I-Disease
.	119 1 O

BACKGROUND	121 10 O
:	131 1 O
Calcitriol	133 10 B-Chemical
therapy	144 7 O
suppresses	152 10 O
serum	163 5 O
levels	169 6 O
of	176 2 O
parathyroid	179 11 O
hormone	191 7 O
(	199 1 O
PTH	200 3 O
)	203 1 O
in	205 2 O
patients	208 8 O
with	217 4 O
renal	222 5 B-Disease
failure	228 7 I-Disease
but	236 3 O
has	240 3 O
several	244 7 O
drawbacks	252 9 O
,	261 1 O
including	263 9 O
hypercalcemia	273 13 B-Disease
and	287 3 O
/	290 1 O
or	291 2 O
marked	294 6 O
suppression	301 11 B-Disease
of	313 2 I-Disease
bone	316 4 I-Disease
turnover	321 8 I-Disease
,	329 1 O
which	331 5 O
may	337 3 O
lead	341 4 O
to	346 2 O
adynamic	349 8 B-Disease
bone	358 4 I-Disease
disease	363 7 I-Disease
.	370 1 O

A	372 1 O
new	374 3 O
vitamin	378 7 B-Chemical
D	386 1 I-Chemical
analogue	388 8 O
,	396 1 O
22	398 2 B-Chemical
-	400 1 I-Chemical
oxacalcitriol	401 13 I-Chemical
(	415 1 O
OCT	416 3 B-Chemical
)	419 1 O
,	420 1 O
has	422 3 O
been	426 4 O
shown	431 5 O
to	437 2 O
have	440 4 O
promising	445 9 O
characteristics	455 15 O
.	470 1 O

This	472 4 O
study	477 5 O
was	483 3 O
undertaken	487 10 O
to	498 2 O
determine	501 9 O
the	511 3 O
effects	515 7 O
of	523 2 O
OCT	526 3 B-Chemical
on	530 2 O
serum	533 5 O
PTH	539 3 O
levels	543 6 O
and	550 3 O
bone	554 4 O
turnover	559 8 O
in	568 2 O
states	571 6 O
of	578 2 O
normal	581 6 O
or	588 2 O
impaired	591 8 B-Disease
renal	600 5 I-Disease
function	606 8 I-Disease
.	614 1 O

METHODS	616 7 O
:	623 1 O
Sixty	625 5 O
dogs	631 4 O
were	636 4 O
either	641 6 O
nephrectomized	648 14 O
(	663 1 O
Nx	664 2 O
,	666 1 O
N	668 1 O
=	670 1 O
38	672 2 O
)	674 1 O
or	676 2 O
sham	679 4 O
-	683 1 O
operated	684 8 O
(	693 1 O
Sham	694 4 O
,	698 1 O
N	700 1 O
=	702 1 O
22	704 2 O
)	706 1 O
.	707 1 O

The	709 3 O
animals	713 7 O
received	721 8 O
supplemental	730 12 O
phosphate	743 9 B-Chemical
to	753 2 O
enhance	756 7 O
PTH	764 3 O
secretion	768 9 O
.	777 1 O

Fourteen	779 8 O
weeks	788 5 O
after	794 5 O
the	800 3 O
start	804 5 O
of	810 2 O
phosphate	813 9 B-Chemical
supplementation	823 15 O
,	838 1 O
half	840 4 O
of	845 2 O
the	848 3 O
Nx	852 2 O
and	855 3 O
Sham	859 4 O
dogs	864 4 O
received	869 8 O
doses	878 5 O
of	884 2 O
OCT	887 3 B-Chemical
(	891 1 O
three	892 5 O
times	898 5 O
per	904 3 O
week	908 4 O
)	912 1 O
;	913 1 O
the	915 3 O
other	919 5 O
half	925 4 O
were	930 4 O
given	935 5 O
vehicle	941 7 O
for	949 3 O
60	953 2 O
weeks	956 5 O
.	961 1 O

Thereafter	963 10 O
,	973 1 O
the	975 3 O
treatment	979 9 O
modalities	989 10 O
for	1000 3 O
a	1004 1 O
subset	1006 6 O
of	1013 2 O
animals	1016 7 O
were	1024 4 O
crossed	1029 7 O
over	1037 4 O
for	1042 3 O
an	1046 2 O
additional	1049 10 O
eight	1060 5 O
months	1066 6 O
.	1072 1 O

Biochemical	1074 11 O
and	1086 3 O
hormonal	1090 8 O
indices	1099 7 O
of	1107 2 O
calcium	1110 7 B-Chemical
and	1118 3 O
bone	1122 4 O
metabolism	1127 10 O
were	1138 4 O
measured	1143 8 O
throughout	1152 10 O
the	1163 3 O
study	1167 5 O
,	1172 1 O
and	1174 3 O
bone	1178 4 O
biopsies	1183 8 O
were	1192 4 O
done	1197 4 O
at	1202 2 O
baseline	1205 8 O
,	1213 1 O
60	1215 2 O
weeks	1218 5 O
after	1224 5 O
OCT	1230 3 B-Chemical
or	1234 2 O
vehicle	1237 7 O
treatment	1245 9 O
,	1254 1 O
and	1256 3 O
at	1260 2 O
the	1263 3 O
end	1267 3 O
of	1271 2 O
the	1274 3 O
crossover	1278 9 O
period	1288 6 O
.	1294 1 O

RESULTS	1296 7 O
:	1303 1 O
In	1305 2 O
Nx	1308 2 O
dogs	1311 4 O
,	1315 1 O
OCT	1317 3 B-Chemical
significantly	1321 13 O
decreased	1335 9 O
serum	1345 5 O
PTH	1351 3 O
levels	1355 6 O
soon	1362 4 O
after	1367 5 O
the	1373 3 O
induction	1377 9 O
of	1387 2 O
renal	1390 5 B-Disease
insufficiency	1396 13 I-Disease
.	1409 1 O

In	1411 2 O
long	1414 4 O
-	1418 1 O
standing	1419 8 O
secondary	1428 9 B-Disease
hyperparathyroidism	1438 19 I-Disease
,	1457 1 O
OCT	1459 3 B-Chemical
(	1463 1 O
0	1464 1 O
.	1465 1 O
03	1466 2 O
microg	1469 6 O
/	1475 1 O
kg	1476 2 O
)	1478 1 O
stabilized	1480 10 O
serum	1491 5 O
PTH	1497 3 O
levels	1501 6 O
during	1508 6 O
the	1515 3 O
first	1519 5 O
months	1525 6 O
.	1531 1 O

Serum	1533 5 O
PTH	1539 3 O
levels	1543 6 O
rose	1550 4 O
thereafter	1555 10 O
,	1565 1 O
but	1567 3 O
the	1571 3 O
rise	1575 4 O
was	1580 3 O
less	1584 4 O
pronounced	1589 10 O
compared	1600 8 O
with	1609 4 O
baseline	1614 8 O
than	1623 4 O
the	1628 3 O
rise	1632 4 O
seen	1637 4 O
in	1642 2 O
Nx	1645 2 O
control	1648 7 O
.	1655 1 O

These	1657 5 O
effects	1663 7 O
were	1671 4 O
accompanied	1676 11 O
by	1688 2 O
episodes	1691 8 O
of	1700 2 O
hypercalcemia	1703 13 B-Disease
and	1717 3 O
hyperphosphatemia	1721 17 B-Disease
.	1738 1 O

In	1740 2 O
animals	1743 7 O
with	1751 4 O
normal	1756 6 O
renal	1763 5 O
function	1769 8 O
,	1777 1 O
OCT	1779 3 B-Chemical
induced	1783 7 O
a	1791 1 O
transient	1793 9 O
decrease	1803 8 O
in	1812 2 O
serum	1815 5 O
PTH	1821 3 O
levels	1825 6 O
at	1832 2 O
a	1835 1 O
dose	1837 4 O
of	1842 2 O
0	1845 1 O
.	1846 1 O
1	1847 1 O
microg	1849 6 O
/	1855 1 O
kg	1856 2 O
,	1858 1 O
which	1860 5 O
was	1866 3 O
not	1870 3 O
sustained	1874 9 O
with	1884 4 O
lowering	1889 8 O
of	1898 2 O
the	1901 3 O
doses	1905 5 O
.	1910 1 O

In	1912 2 O
Nx	1915 2 O
dogs	1918 4 O
,	1922 1 O
OCT	1924 3 B-Chemical
reversed	1928 8 O
abnormal	1937 8 O
bone	1946 4 O
formation	1951 9 O
,	1960 1 O
such	1962 4 O
as	1967 2 O
woven	1970 5 B-Disease
osteoid	1976 7 I-Disease
and	1984 3 O
fibrosis	1988 8 B-Disease
,	1996 1 O
but	1998 3 O
did	2002 3 O
not	2006 3 O
significantly	2010 13 O
alter	2024 5 O
the	2030 3 O
level	2034 5 O
of	2040 2 O
bone	2043 4 O
turnover	2048 8 O
.	2056 1 O

In	2058 2 O
addition	2061 8 O
,	2069 1 O
OCT	2071 3 B-Chemical
improved	2075 8 O
mineralization	2084 14 O
lag	2099 3 O
time	2103 4 O
,	2107 1 O
(	2109 1 O
that	2110 4 O
is	2115 2 O
,	2117 1 O
the	2119 3 O
rate	2123 4 O
at	2128 2 O
which	2131 5 O
osteoid	2137 7 O
mineralizes	2145 11 O
)	2156 1 O
in	2158 2 O
both	2161 4 O
Nx	2166 2 O
and	2169 3 O
Sham	2173 4 O
dogs	2178 4 O
.	2182 1 O

CONCLUSIONS	2184 11 O
:	2195 1 O
These	2197 5 O
results	2203 7 O
indicate	2211 8 O
that	2220 4 O
even	2225 4 O
though	2230 6 O
OCT	2237 3 B-Chemical
does	2241 4 O
not	2246 3 O
completely	2250 10 O
prevent	2261 7 O
the	2269 3 O
occurrence	2273 10 O
of	2284 2 O
hypercalcemia	2287 13 B-Disease
in	2301 2 O
experimental	2304 12 O
dogs	2317 4 O
with	2322 4 O
renal	2327 5 B-Disease
insufficiency	2333 13 I-Disease
,	2346 1 O
it	2348 2 O
may	2351 3 O
be	2355 2 O
of	2358 2 O
use	2361 3 O
in	2365 2 O
the	2368 3 O
management	2372 10 O
of	2383 2 O
secondary	2386 9 B-Disease
hyperparathyroidism	2396 19 I-Disease
because	2416 7 O
it	2424 2 O
does	2427 4 O
not	2432 3 O
induce	2436 6 O
low	2443 3 B-Disease
bone	2447 4 I-Disease
turnover	2452 8 I-Disease
and	2461 3 O
,	2464 1 O
therefore	2466 9 O
,	2475 1 O
does	2477 4 O
not	2482 3 O
increase	2486 8 O
the	2495 3 O
risk	2499 4 O
of	2504 2 O
adynamic	2507 8 B-Disease
bone	2516 4 I-Disease
disease	2521 7 I-Disease
.	2528 1 O

Chemotherapy	0 12 O
of	13 2 O
advanced	16 8 O
inoperable	25 10 O
non	36 3 B-Disease
-	39 1 I-Disease
small	40 5 I-Disease
cell	46 4 I-Disease
lung	51 4 I-Disease
cancer	56 6 I-Disease
with	63 4 O
paclitaxel	68 10 B-Chemical
:	78 1 O
a	80 1 O
phase	82 5 O
II	88 2 O
trial	91 5 O
.	96 1 O

Paclitaxel	98 10 B-Chemical
(	109 1 O
Taxol	110 5 B-Chemical
;	115 1 O
Bristol	117 7 O
-	124 1 O
Myers	125 5 O
Squibb	131 6 O
Company	138 7 O
,	145 1 O
Princeton	147 9 O
,	156 1 O
NJ	158 2 O
)	160 1 O
has	162 3 O
demonstrated	166 12 O
significant	179 11 O
antineoplastic	191 14 O
activity	206 8 O
against	215 7 O
different	223 9 O
tumor	233 5 B-Disease
types	239 5 O
,	244 1 O
notably	246 7 O
ovarian	254 7 B-Disease
and	262 3 I-Disease
breast	266 6 I-Disease
carcinoma	273 9 I-Disease
.	282 1 O

Two	284 3 O
phase	288 5 O
II	294 2 O
trials	297 6 O
of	304 2 O
24	307 2 O
-	309 1 O
hour	310 4 O
paclitaxel	315 10 B-Chemical
infusions	326 9 O
in	336 2 O
chemotherapy	339 12 O
-	351 1 O
naive	352 5 O
patients	358 8 O
with	367 4 O
stage	372 5 O
IIIB	378 4 O
or	383 2 O
IV	386 2 O
non	389 3 B-Disease
-	392 1 I-Disease
small	393 5 I-Disease
cell	399 4 I-Disease
lung	404 4 I-Disease
cancer	409 6 I-Disease
(	416 1 O
NSCLC	417 5 B-Disease
)	422 1 O
reported	424 8 O
response	433 8 O
rates	442 5 O
of	448 2 O
21	451 2 O
%	453 1 O
and	455 3 O
24	459 2 O
%	461 1 O
.	462 1 O

Leukopenia	464 10 B-Disease
was	475 3 O
dose	479 4 O
limiting	484 8 O
:	492 1 O
as	494 2 O
many	497 4 O
as	502 2 O
62	505 2 O
.	507 1 O
5	508 1 O
%	509 1 O
of	511 2 O
patients	514 8 O
experienced	523 11 O
grade	535 5 O
4	541 1 O
leukopenia	543 10 B-Disease
.	553 1 O

We	555 2 O
investigated	558 12 O
the	571 3 O
efficacy	575 8 O
and	584 3 O
toxicity	588 8 B-Disease
of	597 2 O
a	600 1 O
3	602 1 O
-	603 1 O
hour	604 4 O
paclitaxel	609 10 B-Chemical
infusion	620 8 O
in	629 2 O
a	632 1 O
phase	634 5 O
II	640 2 O
trial	643 5 O
in	649 2 O
patients	652 8 O
with	661 4 O
inoperable	666 10 O
stage	677 5 O
IIIB	683 4 O
or	688 2 O
IV	691 2 O
NSCLC	694 5 B-Disease
.	699 1 O

The	701 3 O
58	705 2 O
patients	708 8 O
treated	717 7 O
(	725 1 O
41	726 2 O
men	729 3 O
and	733 3 O
17	737 2 O
women	740 5 O
)	745 1 O
had	747 3 O
a	751 1 O
median	753 6 O
age	760 3 O
of	764 2 O
59	767 2 O
years	770 5 O
(	776 1 O
age	777 3 O
range	781 5 O
,	786 1 O
25	788 2 O
to	791 2 O
75	794 2 O
)	796 1 O
and	798 3 O
a	802 1 O
performance	804 11 O
status	816 6 O
of	823 2 O
0	826 1 O
through	828 7 O
2	836 1 O
.	837 1 O

Most	839 4 O
patients	844 8 O
(	853 1 O
72	854 2 O
.	856 1 O
4	857 1 O
%	858 1 O
)	859 1 O
had	861 3 O
stage	865 5 O
IV	871 2 O
NSCLC	874 5 B-Disease
.	879 1 O

Paclitaxel	881 10 B-Chemical
225	892 3 O
mg	896 2 O
/	898 1 O
m2	899 2 O
was	902 3 O
infused	906 7 O
over	914 4 O
3	919 1 O
hours	921 5 O
every	927 5 O
3	933 1 O
weeks	935 5 O
with	941 4 O
standard	946 8 O
prophylactic	955 12 O
premedication	968 13 O
.	981 1 O

Of	983 2 O
50	986 2 O
patients	989 8 O
evaluable	998 9 O
for	1008 3 O
response	1012 8 O
,	1020 1 O
12	1022 2 O
(	1025 1 O
24	1026 2 O
%	1028 1 O
)	1029 1 O
had	1031 3 O
partial	1035 7 O
remission	1043 9 O
,	1052 1 O
26	1054 2 O
(	1057 1 O
52	1058 2 O
%	1060 1 O
)	1061 1 O
had	1063 3 O
no	1067 2 O
change	1070 6 O
,	1076 1 O
and	1078 3 O
12	1082 2 O
had	1085 3 O
disease	1089 7 O
progression	1097 11 O
(	1109 1 O
24	1110 2 O
%	1112 1 O
)	1113 1 O
.	1114 1 O

Hematologic	1116 11 O
toxicities	1128 10 B-Disease
were	1139 4 O
mild	1144 4 O
:	1148 1 O
only	1150 4 O
one	1155 3 O
patient	1159 7 O
(	1167 1 O
2	1168 1 O
%	1169 1 O
)	1170 1 O
developed	1172 9 O
grade	1182 5 O
3	1188 1 O
or	1190 2 O
4	1193 1 O
neutropenia	1195 11 B-Disease
,	1206 1 O
while	1208 5 O
29	1214 2 O
%	1216 1 O
had	1218 3 O
grade	1222 5 O
1	1228 1 O
or	1230 2 O
2	1233 1 O
.	1234 1 O

Grade	1236 5 O
1	1242 1 O
or	1244 2 O
2	1247 1 O
polyneuropathy	1249 14 B-Disease
affected	1264 8 O
56	1273 2 O
%	1275 1 O
of	1277 2 O
patients	1280 8 O
while	1289 5 O
only	1295 4 O
one	1300 3 O
(	1304 1 O
2	1305 1 O
%	1306 1 O
)	1307 1 O
experienced	1309 11 O
severe	1321 6 O
polyneuropathy	1328 14 B-Disease
.	1342 1 O

Similarly	1344 9 O
,	1353 1 O
grade	1355 5 O
1	1361 1 O
or	1363 2 O
2	1366 1 O
myalgia	1368 7 B-Disease
/	1375 1 O
arthralgia	1376 10 B-Disease
was	1387 3 O
observed	1391 8 O
in	1400 2 O
63	1403 2 O
.	1405 1 O
2	1406 1 O
%	1407 1 O
of	1409 2 O
patients	1412 8 O
,	1420 1 O
but	1422 3 O
only	1426 4 O
14	1431 2 O
.	1433 1 O
3	1434 1 O
%	1435 1 O
experienced	1437 11 O
grade	1449 5 O
3	1455 1 O
or	1457 2 O
4	1460 1 O
.	1461 1 O

Nausea	1463 6 B-Disease
and	1470 3 O
vomiting	1474 8 B-Disease
were	1483 4 O
infrequent	1488 10 O
,	1498 1 O
with	1500 4 O
14	1505 2 O
%	1507 1 O
of	1509 2 O
patients	1512 8 O
experiencing	1521 12 O
grade	1534 5 O
1	1540 1 O
or	1542 2 O
2	1545 1 O
and	1547 3 O
only	1551 4 O
2	1556 1 O
%	1557 1 O
experiencing	1559 12 O
grade	1572 5 O
3	1578 1 O
or	1580 2 O
4	1583 1 O
.	1584 1 O

Paclitaxel	1586 10 B-Chemical
is	1597 2 O
thus	1600 4 O
an	1605 2 O
active	1608 6 O
single	1615 6 O
agent	1622 5 O
in	1628 2 O
this	1631 4 O
patient	1636 7 O
population	1644 10 O
,	1654 1 O
with	1656 4 O
a	1661 1 O
3	1663 1 O
-	1664 1 O
hour	1665 4 O
infusion	1670 8 O
proving	1679 7 O
comparably	1687 10 O
effective	1698 9 O
to	1708 2 O
a	1711 1 O
24	1713 2 O
-	1715 1 O
hour	1716 4 O
infusion	1721 8 O
and	1730 3 O
superior	1734 8 O
in	1743 2 O
terms	1746 5 O
of	1752 2 O
the	1755 3 O
incidence	1759 9 O
of	1769 2 O
hematologic	1772 11 O
and	1784 3 O
nonhematologic	1788 14 O
toxicity	1803 8 B-Disease
.	1811 1 O

Further	1813 7 O
phase	1821 5 O
II	1827 2 O
studies	1830 7 O
with	1838 4 O
paclitaxel	1843 10 B-Chemical
combined	1854 8 O
with	1863 4 O
other	1868 5 O
drugs	1874 5 O
active	1880 6 O
against	1887 7 O
NSCLC	1895 5 B-Disease
are	1901 3 O
indicated	1905 9 O
,	1914 1 O
and	1916 3 O
phase	1920 5 O
III	1926 3 O
studies	1930 7 O
comparing	1938 9 O
paclitaxel	1948 10 B-Chemical
with	1959 4 O
standard	1964 8 O
chemotherapy	1973 12 O
remain	1986 6 O
to	1993 2 O
be	1996 2 O
completed	1999 9 O
.	2008 1 O

Cerebral	0 8 B-Disease
hemorrhage	9 10 I-Disease
associated	20 10 O
with	31 4 O
phenylpropanolamine	36 19 B-Chemical
in	56 2 O
combination	59 11 O
with	71 4 O
caffeine	76 8 B-Chemical
.	84 1 O

Phenylpropanolamine	86 19 B-Chemical
(	106 1 O
PPA	107 3 B-Chemical
)	110 1 O
is	112 2 O
a	115 1 O
drug	117 4 O
that	122 4 O
has	127 3 O
been	131 4 O
associated	136 10 O
with	147 4 O
serious	152 7 O
side	160 4 O
effects	165 7 O
including	173 9 O
stroke	183 6 B-Disease
.	189 1 O

It	191 2 O
is	194 2 O
often	197 5 O
combined	203 8 O
with	212 4 O
caffeine	217 8 B-Chemical
in	226 2 O
diet	229 4 O
preparations	234 12 O
and	247 3 O
"	251 1 O
look	252 4 O
-	256 1 O
alike	257 5 O
"	262 1 O
pills	264 5 O
.	269 1 O

In	271 2 O
order	274 5 O
to	280 2 O
determine	283 9 O
if	293 2 O
PPA	296 3 B-Chemical
/	299 1 O
caffeine	300 8 B-Chemical
can	309 3 O
lead	313 4 O
to	318 2 O
stroke	321 6 B-Disease
in	328 2 O
normotensive	331 12 O
and	344 3 O
/	347 1 O
or	348 2 O
hypertensive	351 12 B-Disease
rats	364 4 O
,	368 1 O
we	370 2 O
administered	373 12 O
the	386 3 O
combination	390 11 O
in	402 2 O
six	405 3 O
times	409 5 O
the	415 3 O
allowed	419 7 O
human	427 5 O
dose	433 4 O
calculated	438 10 O
on	449 2 O
a	452 1 O
per	454 3 O
weight	458 6 O
basis	465 5 O
for	471 3 O
the	475 3 O
rats	479 4 O
two	484 3 O
times	488 5 O
per	494 3 O
day	498 3 O
for	502 3 O
five	506 4 O
days	511 4 O
.	515 1 O

Subarachnoid	517 12 B-Disease
and	530 3 I-Disease
cerebral	534 8 I-Disease
hemorrhage	543 10 I-Disease
was	554 3 O
noted	558 5 O
in	564 2 O
18	567 2 O
%	569 1 O
of	571 2 O
the	574 3 O
hypertensive	578 12 B-Disease
rats	591 4 O
.	595 1 O

A	597 1 O
single	599 6 O
PPA	606 3 B-Chemical
/	609 1 O
caffeine	610 8 B-Chemical
administration	619 14 O
(	634 1 O
same	635 4 O
dose	640 4 O
)	644 1 O
lead	646 4 O
to	651 2 O
acute	654 5 O
hypertension	660 12 B-Disease
in	673 2 O
both	676 4 O
the	681 3 O
normotensive	685 12 O
and	698 3 O
hypertensive	702 12 B-Disease
animals	715 7 O
.	722 1 O

These	724 5 O
results	730 7 O
suggest	738 7 O
that	746 4 O
PPA	751 3 B-Chemical
/	754 1 O
caffeine	755 8 B-Chemical
can	764 3 O
lead	768 4 O
to	773 2 O
cerebral	776 8 B-Disease
hemorrhage	785 10 I-Disease
in	796 2 O
previously	799 10 O
hypertensive	810 12 B-Disease
animals	823 7 O
when	831 4 O
administered	836 12 O
in	849 2 O
greater	852 7 O
than	860 4 O
the	865 3 O
allowed	869 7 O
dosage	877 6 O
.	883 1 O

An	885 2 O
acute	888 5 O
elevation	894 9 O
in	904 2 O
blood	907 5 O
pressure	913 8 O
may	922 3 O
be	926 2 O
a	929 1 O
contributing	931 12 O
factor	944 6 O
.	950 1 O

Long	0 4 O
-	4 1 O
term	5 4 O
efficacy	10 8 O
and	19 3 O
toxicity	23 8 B-Disease
of	32 2 O
high	35 4 O
-	39 1 O
dose	40 4 O
amiodarone	45 10 B-Chemical
therapy	56 7 O
for	64 3 O
ventricular	68 11 B-Disease
tachycardia	80 11 I-Disease
or	92 2 O
ventricular	95 11 B-Disease
fibrillation	107 12 I-Disease
.	119 1 O

Amiodarone	121 10 B-Chemical
was	132 3 O
administered	136 12 O
to	149 2 O
154	152 3 O
patients	156 8 O
who	165 3 O
had	169 3 O
sustained	173 9 O
,	182 1 O
symptomatic	184 11 O
ventricular	196 11 B-Disease
tachycardia	208 11 I-Disease
(	220 1 O
VT	221 2 B-Disease
)	223 1 O
(	225 1 O
n	226 1 O
=	228 1 O
118	230 3 O
)	233 1 O
or	235 2 O
a	238 1 O
cardiac	240 7 B-Disease
arrest	248 6 I-Disease
(	255 1 O
n	256 1 O
=	258 1 O
36	260 2 O
)	262 1 O
and	264 3 O
who	268 3 O
were	272 4 O
refractory	277 10 O
to	288 2 O
conventional	291 12 O
antiarrhythmic	304 14 O
drugs	319 5 O
.	324 1 O

The	326 3 O
loading	330 7 O
dose	338 4 O
was	343 3 O
800	347 3 O
mg	351 2 O
/	353 1 O
day	354 3 O
for	358 3 O
6	362 1 O
weeks	364 5 O
and	370 3 O
the	374 3 O
maintenance	378 11 O
dose	390 4 O
was	395 3 O
600	399 3 O
mg	403 2 O
/	405 1 O
day	406 3 O
.	409 1 O

Sixty	411 5 O
-	416 1 O
nine	417 4 O
percent	422 7 O
of	430 2 O
patients	433 8 O
continued	442 9 O
treatment	452 9 O
with	462 4 O
amiodarone	467 10 B-Chemical
and	478 3 O
had	482 3 O
no	486 2 O
recurrence	489 10 O
of	500 2 O
symptomatic	503 11 O
VT	515 2 B-Disease
or	518 2 O
ventricular	521 11 B-Disease
fibrillation	533 12 I-Disease
(	546 1 O
VF	547 2 B-Disease
)	549 1 O
over	551 4 O
a	556 1 O
follow	558 6 O
-	564 1 O
up	565 2 O
of	568 2 O
6	571 1 O
to	573 2 O
52	576 2 O
months	579 6 O
(	586 1 O
mean	587 4 O
+	592 1 O
/	593 1 O
-	594 1 O
standard	596 8 O
deviation	605 9 O
14	615 2 O
.	617 1 O
2	618 1 O
+	620 1 O
/	621 1 O
-	622 1 O
8	624 1 O
.	625 1 O
2	626 1 O
)	627 1 O
.	628 1 O

Six	630 3 O
percent	634 7 O
of	642 2 O
the	645 3 O
patients	649 8 O
had	658 3 O
a	662 1 O
nonfatal	664 8 O
recurrence	673 10 O
of	684 2 O
VT	687 2 B-Disease
and	690 3 O
were	694 4 O
successfully	699 12 O
managed	712 7 O
by	720 2 O
continuing	723 10 O
amiodarone	734 10 B-Chemical
at	745 2 O
a	748 1 O
higher	750 6 O
dose	757 4 O
or	762 2 O
by	765 2 O
the	768 3 O
addition	772 8 O
of	781 2 O
a	784 1 O
conventional	786 12 O
antiarrhythmic	799 14 O
drug	814 4 O
.	818 1 O

One	820 3 O
or	824 2 O
more	827 4 O
adverse	832 7 O
drug	840 4 O
reactions	845 9 O
occurred	855 8 O
in	864 2 O
51	867 2 O
%	869 1 O
of	871 2 O
patients	874 8 O
.	882 1 O

Adverse	884 7 O
effects	892 7 O
forced	900 6 O
a	907 1 O
reduction	909 9 O
in	919 2 O
the	922 3 O
dose	926 4 O
of	931 2 O
amiodarone	934 10 B-Chemical
in	945 2 O
41	948 2 O
%	950 1 O
and	952 3 O
discontinuation	956 15 O
of	972 2 O
amiodarone	975 10 B-Chemical
in	986 2 O
10	989 2 O
%	991 1 O
of	993 2 O
patients	996 8 O
.	1004 1 O

The	1006 3 O
most	1010 4 O
common	1015 6 O
symptomatic	1022 11 O
adverse	1034 7 O
reactions	1042 9 O
were	1052 4 O
tremor	1057 6 B-Disease
or	1064 2 O
ataxia	1067 6 B-Disease
(	1074 1 O
35	1075 2 O
%	1077 1 O
)	1078 1 O
,	1079 1 O
nausea	1081 6 B-Disease
and	1088 3 O
anorexia	1092 8 B-Disease
(	1101 1 O
8	1102 1 O
%	1103 1 O
)	1104 1 O
,	1105 1 O
visual	1107 6 B-Disease
halos	1114 5 I-Disease
or	1120 2 I-Disease
blurring	1123 8 I-Disease
(	1132 1 O
6	1133 1 O
%	1134 1 O
)	1135 1 O
,	1136 1 O
thyroid	1138 7 B-Disease
function	1146 8 I-Disease
abnormalities	1155 13 I-Disease
(	1169 1 O
6	1170 1 O
%	1171 1 O
)	1172 1 O
and	1174 3 O
pulmonary	1178 9 B-Disease
interstitial	1188 12 I-Disease
infiltrates	1201 11 I-Disease
(	1213 1 O
5	1214 1 O
%	1215 1 O
)	1216 1 O
.	1217 1 O

Although	1219 8 O
large	1228 5 O
-	1233 1 O
dose	1234 4 O
amiodarone	1239 10 B-Chemical
is	1250 2 O
highly	1253 6 O
effective	1260 9 O
in	1270 2 O
the	1273 3 O
long	1277 4 O
-	1281 1 O
term	1282 4 O
treatment	1287 9 O
of	1297 2 O
VT	1300 2 B-Disease
or	1303 2 O
VF	1306 2 B-Disease
refractory	1309 10 O
to	1320 2 O
conventional	1323 12 O
antiarrhythmic	1336 14 O
drugs	1351 5 O
,	1356 1 O
it	1358 2 O
causes	1361 6 O
significant	1368 11 O
toxicity	1380 8 B-Disease
in	1389 2 O
approximately	1392 13 O
50	1406 2 O
%	1408 1 O
of	1410 2 O
patients	1413 8 O
.	1421 1 O

However	1423 7 O
,	1430 1 O
when	1432 4 O
the	1437 3 O
dose	1441 4 O
is	1446 2 O
adjusted	1449 8 O
based	1458 5 O
on	1464 2 O
clinical	1467 8 O
response	1476 8 O
or	1485 2 O
the	1488 3 O
development	1492 11 O
of	1504 2 O
adverse	1507 7 O
effects	1515 7 O
,	1522 1 O
75	1524 2 O
%	1526 1 O
of	1528 2 O
patients	1531 8 O
with	1540 4 O
VT	1545 2 B-Disease
or	1548 2 O
VF	1551 2 B-Disease
can	1554 3 O
be	1558 2 O
successfully	1561 12 O
managed	1574 7 O
with	1582 4 O
amiodarone	1587 10 B-Chemical
.	1597 1 O

Effect	0 6 O
of	7 2 O
calcium	10 7 B-Chemical
chloride	18 8 I-Chemical
and	27 3 O
4	31 1 B-Chemical
-	32 1 I-Chemical
aminopyridine	33 13 I-Chemical
therapy	47 7 O
on	55 2 O
desipramine	58 11 B-Chemical
toxicity	70 8 B-Disease
in	79 2 O
rats	82 4 O
.	86 1 O

BACKGROUND	88 10 O
:	98 1 O
Hypotension	100 11 B-Disease
is	112 2 O
a	115 1 O
major	117 5 O
contributor	123 11 O
to	135 2 O
mortality	138 9 O
in	148 2 O
tricyclic	151 9 O
antidepressant	161 14 O
overdose	176 8 B-Disease
.	184 1 O

Recent	186 6 O
data	193 4 O
suggest	198 7 O
that	206 4 O
tricyclic	211 9 O
antidepressants	221 15 O
inhibit	237 7 O
calcium	245 7 B-Chemical
influx	253 6 O
in	260 2 O
some	263 4 O
tissues	268 7 O
.	275 1 O

This	277 4 O
study	282 5 O
addressed	288 9 O
the	298 3 O
potential	302 9 O
role	312 4 O
of	317 2 O
calcium	320 7 B-Chemical
channel	328 7 O
blockade	336 8 O
in	345 2 O
tricyclic	348 9 O
antidepressant	358 14 O
-	372 1 O
induced	373 7 O
hypotension	381 11 B-Disease
.	392 1 O

METHODS	394 7 O
:	401 1 O
Two	403 3 O
interventions	407 13 O
were	421 4 O
studied	426 7 O
that	434 4 O
have	439 4 O
been	444 4 O
shown	449 5 O
previously	455 10 O
to	466 2 O
improve	469 7 O
blood	477 5 O
pressure	483 8 O
with	492 4 O
calcium	497 7 B-Chemical
channel	505 7 O
blocker	513 7 O
overdose	521 8 B-Disease
.	529 1 O

CaCl2	531 5 B-Chemical
and	537 3 O
4	541 1 B-Chemical
-	542 1 I-Chemical
aminopyridine	543 13 I-Chemical
.	556 1 O

Anesthetized	558 12 O
rats	571 4 O
received	576 8 O
the	585 3 O
tricyclic	589 9 O
antidepressant	599 14 O
desipramine	614 11 B-Chemical
IP	626 2 O
to	629 2 O
produce	632 7 O
hypotension	640 11 B-Disease
,	651 1 O
QRS	653 3 O
prolongation	657 12 O
,	669 1 O
and	671 3 O
bradycardia	675 11 B-Disease
.	686 1 O

Fifteen	688 7 O
min	696 3 O
later	700 5 O
,	705 1 O
animals	707 7 O
received	715 8 O
CaCl2	724 5 B-Chemical
,	729 1 O
NaHCO3	731 6 B-Chemical
,	737 1 O
or	739 2 O
saline	742 6 O
.	748 1 O

In	750 2 O
a	753 1 O
second	755 6 O
experiment	762 10 O
,	772 1 O
rats	774 4 O
received	779 8 O
tricyclic	788 9 O
antidepressant	798 14 O
desipramine	813 11 B-Chemical
IP	825 2 O
followed	828 8 O
in	837 2 O
15	840 2 O
min	843 3 O
by	847 2 O
4	850 1 B-Chemical
-	851 1 I-Chemical
aminopyridine	852 13 I-Chemical
or	866 2 O
saline	869 6 O
.	875 1 O

RESULTS	877 7 O
:	884 1 O
NaHCO3	886 6 B-Chemical
briefly	893 7 O
(	901 1 O
5	902 1 O
min	904 3 O
)	907 1 O
reversed	909 8 O
hypotension	918 11 B-Disease
and	930 3 O
QRS	934 3 O
prolongation	938 12 O
.	950 1 O

CaCl2	952 5 B-Chemical
and	958 3 O
4	962 1 B-Chemical
-	963 1 I-Chemical
aminopyridine	964 13 I-Chemical
failed	978 6 O
to	985 2 O
improve	988 7 O
blood	996 5 O
pressure	1002 8 O
.	1010 1 O

The	1012 3 O
incidence	1016 9 O
of	1026 2 O
ventricular	1029 11 B-Disease
arrhythmias	1041 11 I-Disease
(	1053 1 O
p	1054 1 O
=	1056 1 O
0	1058 1 O
.	1059 1 O
004	1060 3 O
)	1063 1 O
and	1065 3 O
seizures	1069 8 B-Disease
(	1078 1 O
p	1079 1 O
=	1081 1 O
0	1083 1 O
.	1084 1 O
03	1085 2 O
)	1087 1 O
in	1089 2 O
the	1092 3 O
CaCl2	1096 5 B-Chemical
group	1102 5 O
was	1108 3 O
higher	1112 6 O
than	1119 4 O
the	1124 3 O
other	1128 5 O
groups	1134 6 O
.	1140 1 O

CONCLUSION	1142 10 O
:	1152 1 O
The	1154 3 O
administration	1158 14 O
of	1173 2 O
CaCl2	1176 5 B-Chemical
or	1182 2 O
4	1185 1 B-Chemical
-	1186 1 I-Chemical
aminopyridine	1187 13 I-Chemical
did	1201 3 O
not	1205 3 O
reverse	1209 7 O
tricyclic	1217 9 O
antidepressant	1227 14 O
-	1241 1 O
induced	1242 7 O
hypotension	1250 11 B-Disease
in	1262 2 O
rats	1265 4 O
.	1269 1 O

CaCl2	1271 5 B-Chemical
therapy	1277 7 O
may	1285 3 O
possibly	1289 8 O
worsen	1298 6 O
both	1305 4 O
cardiovascular	1310 14 B-Disease
and	1325 3 I-Disease
central	1329 7 I-Disease
nervous	1337 7 I-Disease
system	1345 6 I-Disease
toxicity	1352 8 I-Disease
.	1360 1 O

These	1362 5 O
findings	1368 8 O
do	1377 2 O
not	1380 3 O
support	1384 7 O
a	1392 1 O
role	1394 4 O
for	1399 3 O
calcium	1403 7 B-Chemical
channel	1411 7 O
inhibition	1419 10 O
in	1430 2 O
the	1433 3 O
pathogenesis	1437 12 O
of	1450 2 O
tricyclic	1453 9 O
antidepressant	1463 14 O
-	1477 1 O
induced	1478 7 O
hypotension	1486 11 B-Disease
.	1497 1 O

Phase	0 5 O
I	6 1 O
trial	8 5 O
of	14 2 O
13	17 2 B-Chemical
-	19 1 I-Chemical
cis	20 3 I-Chemical
-	23 1 I-Chemical
retinoic	24 8 I-Chemical
acid	33 4 I-Chemical
in	38 2 O
children	41 8 O
with	50 4 O
neuroblastoma	55 13 B-Disease
following	69 9 O
bone	79 4 O
marrow	84 6 O
transplantation	91 15 O
.	106 1 O

PURPOSE	108 7 O
:	115 1 O
Treatment	117 9 O
of	127 2 O
neuroblastoma	130 13 B-Disease
cell	144 4 O
lines	149 5 O
with	155 4 O
13	160 2 B-Chemical
-	162 1 I-Chemical
cis	163 3 I-Chemical
-	166 1 I-Chemical
retinoic	167 8 I-Chemical
acid	176 4 I-Chemical
(	181 1 O
cis	182 3 B-Chemical
-	185 1 I-Chemical
RA	186 2 I-Chemical
)	188 1 O
can	190 3 O
cause	194 5 O
sustained	200 9 O
inhibition	210 10 O
of	221 2 O
proliferation	224 13 O
.	237 1 O

Since	239 5 O
cis	245 3 B-Chemical
-	248 1 I-Chemical
RA	249 2 I-Chemical
has	252 3 O
demonstrated	256 12 O
clinical	269 8 O
responses	278 9 O
in	288 2 O
neuroblastoma	291 13 B-Disease
patients	305 8 O
,	313 1 O
it	315 2 O
may	318 3 O
be	322 2 O
effective	325 9 O
in	335 2 O
preventing	338 10 O
relapse	349 7 O
after	357 5 O
cytotoxic	363 9 O
therapy	373 7 O
.	380 1 O

This	382 4 O
phase	387 5 O
I	393 1 O
trial	395 5 O
was	401 3 O
designed	405 8 O
to	414 2 O
determine	417 9 O
the	427 3 O
maximal	431 7 O
-	438 1 O
tolerated	439 9 O
dosage	449 6 O
(	456 1 O
MTD	457 3 O
)	460 1 O
,	461 1 O
toxicities	463 10 B-Disease
,	473 1 O
and	475 3 O
pharmacokinetics	479 16 O
of	496 2 O
cis	499 3 B-Chemical
-	502 1 I-Chemical
RA	503 2 I-Chemical
administered	506 12 O
on	519 2 O
an	522 2 O
intermittent	525 12 O
schedule	538 8 O
in	547 2 O
children	550 8 O
with	559 4 O
neuroblastoma	564 13 B-Disease
following	578 9 O
bone	588 4 O
marrow	593 6 O
transplantation	600 15 O
(	616 1 O
BMT	617 3 O
)	620 1 O
.	621 1 O

PATIENTS	623 8 O
AND	632 3 O
METHODS	636 7 O
:	643 1 O
Fifty	645 5 O
-	650 1 O
one	651 3 O
assessable	655 10 O
patients	666 8 O
,	674 1 O
2	676 1 O
to	678 2 O
12	681 2 O
years	684 5 O
of	690 2 O
age	693 3 O
,	696 1 O
were	698 4 O
treated	703 7 O
with	711 4 O
oral	716 4 O
cis	721 3 B-Chemical
-	724 1 I-Chemical
RA	725 2 I-Chemical
administered	728 12 O
in	741 2 O
two	744 3 O
equally	748 7 O
divided	756 7 O
doses	764 5 O
daily	770 5 O
for	776 3 O
2	780 1 O
weeks	782 5 O
,	787 1 O
followed	789 8 O
by	798 2 O
a	801 1 O
2	803 1 O
-	804 1 O
week	805 4 O
rest	810 4 O
period	815 6 O
,	821 1 O
for	823 3 O
up	827 2 O
to	830 2 O
12	833 2 O
courses	836 7 O
.	843 1 O

The	845 3 O
dose	849 4 O
was	854 3 O
escalated	858 9 O
from	868 4 O
100	873 3 O
to	877 2 O
200	880 3 O
mg	884 2 O
/	886 1 O
m2	887 2 O
/	889 1 O
d	890 1 O
until	892 5 O
dose	898 4 O
-	902 1 O
limiting	903 8 O
toxicity	912 8 B-Disease
(	921 1 O
DLT	922 3 O
)	925 1 O
was	927 3 O
observed	931 8 O
.	939 1 O

A	941 1 O
single	943 6 O
intrapatient	950 12 O
dose	963 4 O
escalation	968 10 O
was	979 3 O
permitted	983 9 O
.	992 1 O

RESULTS	994 7 O
:	1001 1 O
The	1003 3 O
MTD	1007 3 O
of	1011 2 O
cis	1014 3 B-Chemical
-	1017 1 I-Chemical
RA	1018 2 I-Chemical
was	1021 3 O
160	1025 3 O
mg	1029 2 O
/	1031 1 O
m2	1032 2 O
/	1034 1 O
d	1035 1 O
.	1036 1 O

Dose	1038 4 O
-	1042 1 O
limiting	1043 8 O
toxicities	1052 10 B-Disease
in	1063 2 O
six	1066 3 O
of	1070 2 O
nine	1073 4 O
patients	1078 8 O
at	1087 2 O
200	1090 3 O
mg	1094 2 O
/	1096 1 O
m2	1097 2 O
/	1099 1 O
d	1100 1 O
included	1102 8 O
hypercalcemia	1111 13 B-Disease
(	1125 1 O
n	1126 1 O
=	1128 1 O
3	1130 1 O
)	1131 1 O
,	1132 1 O
rash	1134 4 B-Disease
(	1139 1 O
n	1140 1 O
=	1142 1 O
2	1144 1 O
)	1145 1 O
,	1146 1 O
and	1148 3 O
anemia	1152 6 B-Disease
/	1158 1 O
thrombocytopenia	1159 16 B-Disease
/	1175 1 O
emesis	1176 6 B-Disease
/	1182 1 O
rash	1183 4 B-Disease
(	1188 1 O
n	1189 1 O
=	1191 1 O
1	1193 1 O
)	1194 1 O
.	1195 1 O

All	1197 3 O
toxicities	1201 10 B-Disease
resolved	1212 8 O
after	1221 5 O
cis	1227 3 B-Chemical
-	1230 1 I-Chemical
RA	1231 2 I-Chemical
was	1234 3 O
discontinued	1238 12 O
.	1250 1 O

Three	1252 5 O
complete	1258 8 O
responses	1267 9 O
were	1277 4 O
observed	1282 8 O
in	1291 2 O
marrow	1294 6 O
metastases	1301 10 B-Disease
.	1311 1 O

Serum	1313 5 O
levels	1319 6 O
of	1326 2 O
7	1329 1 O
.	1330 1 O
4	1331 1 O
+	1333 1 O
/	1334 1 O
-	1335 1 O
3	1337 1 O
.	1338 1 O
0	1339 1 O
mumol	1341 5 O
/	1346 1 O
L	1347 1 O
(	1349 1 O
peak	1350 4 O
)	1354 1 O
and	1356 3 O
4	1360 1 O
.	1361 1 O
0	1362 1 O
+	1364 1 O
/	1365 1 O
-	1366 1 O
2	1368 1 O
.	1369 1 O
8	1370 1 O
mumol	1372 5 O
/	1377 1 O
L	1378 1 O
(	1380 1 O
trough	1381 6 O
)	1387 1 O
at	1389 2 O
the	1392 3 O
MTD	1396 3 O
were	1400 4 O
maintained	1405 10 O
during	1416 6 O
14	1423 2 O
days	1426 4 O
of	1431 2 O
therapy	1434 7 O
.	1441 1 O

The	1443 3 O
DLT	1447 3 O
correlated	1451 10 O
with	1462 4 O
serum	1467 5 O
levels	1473 6 O
>	1480 1 O
or	1482 2 O
=	1485 1 O
10	1487 2 O
mumol	1490 5 O
/	1495 1 O
L	1496 1 O
.	1497 1 O

CONCLUSION	1499 10 O
:	1509 1 O
The	1511 3 O
MTD	1515 3 O
of	1519 2 O
cis	1522 3 B-Chemical
-	1525 1 I-Chemical
RA	1526 2 I-Chemical
given	1529 5 O
on	1535 2 O
this	1538 4 O
intermittent	1543 12 O
schedule	1556 8 O
was	1565 3 O
160	1569 3 O
mg	1573 2 O
/	1575 1 O
m2	1576 2 O
/	1578 1 O
d	1579 1 O
.	1580 1 O

Serum	1582 5 O
levels	1588 6 O
known	1595 5 O
to	1601 2 O
be	1604 2 O
effective	1607 9 O
against	1617 7 O
neuroblastoma	1625 13 B-Disease
in	1639 2 O
vitro	1642 5 O
were	1648 4 O
achieved	1653 8 O
at	1662 2 O
this	1665 4 O
dose	1670 4 O
.	1674 1 O

The	1676 3 O
DLT	1680 3 O
included	1684 8 O
hypercalcemia	1693 13 B-Disease
,	1706 1 O
and	1708 3 O
may	1712 3 O
be	1716 2 O
predicted	1719 9 O
by	1729 2 O
serum	1732 5 O
cis	1738 3 B-Chemical
-	1741 1 I-Chemical
RA	1742 2 I-Chemical
levels	1745 6 O
.	1751 1 O

Monitoring	1753 10 O
of	1764 2 O
serum	1767 5 O
calcium	1773 7 B-Chemical
and	1781 3 O
cis	1785 3 B-Chemical
-	1788 1 I-Chemical
RA	1789 2 I-Chemical
levels	1792 6 O
is	1799 2 O
indicated	1802 9 O
in	1812 2 O
future	1815 6 O
trials	1822 6 O
.	1828 1 O

Effect	0 6 O
of	7 2 O
calcium	10 7 B-Chemical
chloride	18 8 I-Chemical
on	27 2 O
gross	30 5 O
behavioural	36 11 O
changes	48 7 O
produced	56 8 O
by	65 2 O
carbachol	68 9 B-Chemical
and	78 3 O
eserine	82 7 B-Chemical
in	90 2 O
cats	93 4 O
.	97 1 O

The	99 3 O
effect	103 6 O
of	110 2 O
calcium	113 7 B-Chemical
chloride	121 8 I-Chemical
injected	130 8 O
into	139 4 O
the	144 3 O
cerebral	148 8 O
ventricles	157 10 O
of	168 2 O
group	171 5 O
-	176 1 O
housed	177 6 O
unanaesthetized	184 15 O
cats	200 4 O
upon	205 4 O
vocalization	210 12 O
(	223 1 O
rage	224 4 O
,	228 1 O
hissing	230 7 O
and	238 3 O
snarling	242 8 O
)	250 1 O
,	251 1 O
fighting	253 8 O
(	262 1 O
attack	263 6 O
with	270 4 O
paws	275 4 O
and	280 3 O
claws	284 5 O
,	289 1 O
defense	291 7 O
with	299 4 O
paws	304 4 O
and	309 3 O
claws	313 5 O
and	319 3 O
biting	323 6 O
)	329 1 O
,	330 1 O
mydriasis	332 9 B-Disease
,	341 1 O
tremor	343 6 B-Disease
and	350 3 O
clonic	354 6 B-Disease
-	360 1 I-Disease
tonic	361 5 I-Disease
convulsions	367 11 I-Disease
produced	379 8 O
by	388 2 O
carbachol	391 9 B-Chemical
and	401 3 O
eserine	405 7 B-Chemical
injected	413 8 O
similarly	422 9 O
was	432 3 O
investigated	436 12 O
.	448 1 O

Calcium	450 7 B-Chemical
chloride	458 8 I-Chemical
depressed	467 9 O
or	477 2 O
almost	480 6 O
completely	487 10 O
abolished	498 9 O
the	508 3 O
vocalization	512 12 O
and	525 3 O
fighting	529 8 O
due	538 3 O
to	542 2 O
carbachol	545 9 B-Chemical
and	555 3 O
eserine	559 7 B-Chemical
.	566 1 O

On	568 2 O
the	571 3 O
other	575 5 O
hand	581 4 O
,	585 1 O
mydriasis	587 9 B-Disease
,	596 1 O
tremor	598 6 B-Disease
and	605 3 O
clonic	609 6 B-Disease
-	615 1 I-Disease
tonic	616 5 I-Disease
convulsions	622 11 I-Disease
evoked	634 6 O
by	641 2 O
carbachol	644 9 B-Chemical
and	654 3 O
eserine	658 7 B-Chemical
were	666 4 O
not	671 3 O
significantly	675 13 O
changed	689 7 O
by	697 2 O
calcium	700 7 B-Chemical
chloride	708 8 I-Chemical
.	716 1 O

It	718 2 O
is	721 2 O
apparent	724 8 O
that	733 4 O
calcium	738 7 B-Chemical
chloride	746 8 I-Chemical
can	755 3 O
"	759 1 O
dissociate	760 10 O
"	770 1 O
vocalization	772 12 O
and	785 3 O
fighting	789 8 O
from	798 4 O
autonomic	803 9 O
and	813 3 O
motor	817 5 O
phenomena	823 9 O
such	833 4 O
as	838 2 O
mydriasis	841 9 B-Disease
,	850 1 O
tremor	852 6 B-Disease
and	859 3 O
clonic	863 6 B-Disease
-	869 1 I-Disease
tonic	870 5 I-Disease
convulsions	876 11 I-Disease
caused	888 6 O
by	895 2 O
carbachol	898 9 B-Chemical
and	908 3 O
eserine	912 7 B-Chemical
.	919 1 O

Calcium	921 7 B-Chemical
chloride	929 8 I-Chemical
inhibited	938 9 O
the	948 3 O
vocalization	952 12 O
and	965 3 O
fighting	969 8 O
produced	978 8 O
by	987 2 O
carbachol	990 9 B-Chemical
and	1000 3 O
eserine	1004 7 B-Chemical
most	1012 4 O
probably	1017 8 O
by	1026 2 O
a	1029 1 O
nonspecific	1031 11 O
stabilizing	1043 11 O
action	1055 6 O
on	1062 2 O
central	1065 7 O
muscarinic	1073 10 O
cholinoceptive	1084 14 O
sites	1099 5 O
.	1104 1 O

These	1106 5 O
results	1112 7 O
further	1120 7 O
support	1128 7 O
the	1136 3 O
view	1140 4 O
that	1145 4 O
calcium	1150 7 B-Chemical
ions	1158 4 O
in	1163 2 O
excess	1166 6 O
have	1173 4 O
an	1178 2 O
atropine	1181 8 B-Chemical
-	1189 1 O
like	1190 4 O
action	1195 6 O
also	1202 4 O
in	1207 2 O
the	1210 3 O
central	1214 7 O
nervous	1222 7 O
system	1230 6 O
.	1236 1 O

Multiple	0 8 O
side	9 4 O
effects	14 7 O
of	22 2 O
penicillamine	25 13 B-Chemical
therapy	39 7 O
in	47 2 O
one	50 3 O
patient	54 7 O
with	62 4 O
rheumatoid	67 10 B-Disease
arthritis	78 9 I-Disease
.	87 1 O

Skin	89 4 B-Disease
rashes	94 6 I-Disease
,	100 1 O
proteinuria	102 11 B-Disease
,	113 1 O
systemic	115 8 B-Disease
lupus	124 5 I-Disease
erythematosus	130 13 I-Disease
,	143 1 O
polymyositis	145 12 B-Disease
and	158 3 O
myasthenia	162 10 B-Disease
gravis	173 6 I-Disease
have	180 4 O
all	185 3 O
been	189 4 O
recorded	194 8 O
as	203 2 O
complications	206 13 O
of	220 2 O
penicillamine	223 13 B-Chemical
therapy	237 7 O
in	245 2 O
patients	248 8 O
with	257 4 O
rheumatoid	262 10 B-Disease
arthritis	273 9 I-Disease
.	282 1 O

A	284 1 O
patient	286 7 O
who	294 3 O
had	298 3 O
developed	302 9 O
all	312 3 O
5	316 1 O
is	318 2 O
now	321 3 O
described	325 9 O
.	334 1 O

The	336 3 O
skin	340 4 B-Disease
lesion	345 6 I-Disease
resembled	352 9 O
elastosis	362 9 B-Disease
perforans	372 9 I-Disease
serpiginosa	382 11 I-Disease
,	393 1 O
which	395 5 O
has	401 3 O
been	405 4 O
reported	410 8 O
as	419 2 O
a	422 1 O
rare	424 4 O
side	429 4 O
effect	434 6 O
in	441 2 O
patients	444 8 O
with	453 4 O
Wilson	458 6 B-Disease
'	464 1 I-Disease
s	465 1 I-Disease
disease	467 7 I-Disease
but	475 3 O
not	479 3 O
in	483 2 O
patients	486 8 O
with	495 4 O
rheumatoid	500 10 B-Disease
arthritis	511 9 I-Disease
treated	521 7 O
with	529 4 O
penicillamine	534 13 B-Chemical
.	547 1 O

Electrocardiographic	0 20 O
changes	21 7 O
and	29 3 O
cardiac	33 7 B-Disease
arrhythmias	41 11 I-Disease
in	53 2 O
patients	56 8 O
receiving	65 9 O
psychotropic	75 12 O
drugs	88 5 O
.	93 1 O

Eight	95 5 O
patients	101 8 O
had	110 3 O
cardiac	114 7 O
manifestations	122 14 O
that	137 4 O
were	142 4 O
life	147 4 O
-	151 1 O
threatening	152 11 O
in	164 2 O
five	167 4 O
while	172 5 O
taking	178 6 O
psychotropic	185 12 O
drugs	198 5 O
,	203 1 O
either	205 6 O
phenothiazines	212 14 B-Chemical
or	227 2 O
tricyclic	230 9 O
antidepressants	240 15 O
.	255 1 O

Although	257 8 O
most	266 4 O
patients	271 8 O
were	280 4 O
receiving	285 9 O
several	295 7 O
drugs	303 5 O
,	308 1 O
Mellaril	310 8 B-Chemical
(	319 1 O
thioridazine	320 12 B-Chemical
)	332 1 O
appeared	334 8 O
to	343 2 O
be	346 2 O
responsible	349 11 O
for	361 3 O
five	365 4 O
cases	370 5 O
of	376 2 O
ventricular	379 11 B-Disease
tachycardia	391 11 I-Disease
,	402 1 O
one	404 3 O
of	408 2 O
which	411 5 O
was	417 3 O
fatal	421 5 O
in	427 2 O
a	430 1 O
35	432 2 O
year	435 4 O
old	440 3 O
woman	444 5 O
.	449 1 O

Supraventricular	451 16 B-Disease
tachycardia	468 11 I-Disease
developed	480 9 O
in	490 2 O
one	493 3 O
patient	497 7 O
receiving	505 9 O
Thorazine	515 9 B-Chemical
(	525 1 O
chlorpromazine	526 14 B-Chemical
)	540 1 O
.	541 1 O

Aventyl	543 7 B-Chemical
(	551 1 O
nortriptyline	552 13 B-Chemical
)	565 1 O
and	567 3 O
Elavil	571 6 B-Chemical
(	578 1 O
amitriptyline	579 13 B-Chemical
)	592 1 O
each	594 4 O
produced	599 8 O
left	608 4 B-Disease
bundle	613 6 I-Disease
branch	620 6 I-Disease
block	627 5 I-Disease
in	633 2 O
a	636 1 O
73	638 2 O
year	641 4 O
old	646 3 O
woman	650 5 O
.	655 1 O

Electrocardiographic	657 20 O
T	678 1 O
and	680 3 O
U	684 1 O
wave	686 4 O
abnormalities	691 13 O
were	705 4 O
present	710 7 O
in	718 2 O
most	721 4 O
patients	726 8 O
.	734 1 O

The	736 3 O
ventricular	740 11 B-Disease
arrhythmias	752 11 I-Disease
responded	764 9 O
to	774 2 O
intravenous	777 11 O
administration	789 14 O
of	804 2 O
lidocaine	807 9 B-Chemical
and	817 3 O
to	821 2 O
direct	824 6 O
current	831 7 O
electric	839 8 O
shock	848 5 O
;	853 1 O
ventricular	855 11 O
pacing	867 6 O
was	874 3 O
required	878 8 O
in	887 2 O
some	890 4 O
instances	895 9 O
and	905 3 O
intravenous	909 11 O
administration	921 14 O
of	936 2 O
propranolol	939 11 B-Chemical
combined	951 8 O
with	960 4 O
ventricular	965 11 O
pacing	977 6 O
in	984 2 O
one	987 3 O
.	990 1 O

The	992 3 O
tachyarrhythmias	996 16 B-Disease
generally	1013 9 O
subsided	1023 8 O
within	1032 6 O
48	1039 2 O
hours	1042 5 O
after	1048 5 O
administration	1054 14 O
of	1069 2 O
the	1072 3 O
drugs	1076 5 O
was	1082 3 O
stopped	1086 7 O
.	1093 1 O

Five	1095 4 O
of	1100 2 O
the	1103 3 O
eight	1107 5 O
patients	1113 8 O
were	1122 4 O
50	1127 2 O
years	1130 5 O
of	1136 2 O
age	1139 3 O
or	1143 2 O
younger	1146 7 O
;	1153 1 O
only	1155 4 O
one	1160 3 O
clearly	1164 7 O
had	1172 3 O
antecedent	1176 10 O
heart	1187 5 B-Disease
disease	1193 7 I-Disease
.	1200 1 O

Major	1202 5 O
cardiac	1208 7 B-Disease
arrhythmias	1216 11 I-Disease
are	1228 3 O
a	1232 1 O
potential	1234 9 O
hazard	1244 6 O
in	1251 2 O
patients	1254 8 O
without	1263 7 O
heart	1271 5 B-Disease
disease	1277 7 I-Disease
who	1285 3 O
are	1289 3 O
receiving	1293 9 O
customary	1303 9 O
therapeutic	1313 11 O
doses	1325 5 O
of	1331 2 O
psychotropic	1334 12 O
drugs	1347 5 O
.	1352 1 O

A	1354 1 O
prospective	1356 11 O
clinical	1368 8 O
trial	1377 5 O
is	1383 2 O
suggested	1386 9 O
to	1396 2 O
quantify	1399 8 O
the	1408 3 O
risk	1412 4 O
of	1417 2 O
cardiac	1420 7 B-Disease
complications	1428 13 I-Disease
to	1442 2 O
patients	1445 8 O
receiving	1454 9 O
phenothiazines	1464 14 B-Chemical
or	1479 2 O
tricyclic	1482 9 O
antidepressant	1492 14 O
drugs	1507 5 O
.	1512 1 O

Serotonergic	0 12 O
drugs	13 5 O
,	18 1 O
benzodiazepines	20 15 B-Chemical
and	36 3 O
baclofen	40 8 B-Chemical
block	49 5 O
muscimol	55 8 B-Chemical
-	63 1 O
induced	64 7 O
myoclonic	72 9 B-Disease
jerks	82 5 I-Disease
in	88 2 O
a	91 1 O
strain	93 6 O
of	100 2 O
mice	103 4 O
.	107 1 O

In	109 2 O
male	112 4 O
Swiss	117 5 O
mice	123 4 O
,	127 1 O
muscimol	129 8 B-Chemical
produced	138 8 O
myoclonic	147 9 B-Disease
jerks	157 5 I-Disease
.	162 1 O

A	164 1 O
3	166 1 O
mg	168 2 O
/	170 1 O
kg	171 2 O
(	174 1 O
i	175 1 O
.	176 1 O
p	177 1 O
.	178 1 O
)	179 1 O
dose	181 4 O
induced	186 7 O
this	194 4 O
response	199 8 O
in	208 2 O
all	211 3 O
of	215 2 O
the	218 3 O
mice	222 4 O
tested	227 6 O
and	234 3 O
the	238 3 O
peak	242 4 O
response	247 8 O
of	256 2 O
73	259 2 O
jerks	262 5 O
per	268 3 O
min	272 3 O
was	276 3 O
observed	280 8 O
between	289 7 O
27	297 2 O
and	300 3 O
45	304 2 O
min	307 3 O
.	310 1 O

Increasing	312 10 O
the	323 3 O
brain	327 5 O
serotonin	333 9 B-Chemical
levels	343 6 O
by	350 2 O
the	353 3 O
administration	357 14 O
of	372 2 O
5	375 1 B-Chemical
-	376 1 I-Chemical
hydroxytryptophan	377 17 I-Chemical
(	395 1 O
80	396 2 O
-	398 1 O
160	399 3 O
mg	403 2 O
/	405 1 O
kg	406 2 O
)	408 1 O
in	410 2 O
combination	413 11 O
with	425 4 O
a	430 1 O
peripheral	432 10 O
decarboxylase	443 13 O
inhibitor	457 9 O
resulted	467 8 O
in	476 2 O
an	479 2 O
inhibition	482 10 O
of	493 2 O
the	496 3 O
muscimol	500 8 B-Chemical
effect	509 6 O
.	515 1 O

However	517 7 O
,	524 1 O
in	526 2 O
a	529 1 O
similar	531 7 O
experiment	539 10 O
l	550 1 B-Chemical
-	551 1 I-Chemical
dopa	552 4 I-Chemical
(	557 1 O
80	558 2 O
-	560 1 O
160	561 3 O
mg	565 2 O
/	567 1 O
kg	568 2 O
)	570 1 O
was	572 3 O
without	576 7 O
effect	584 6 O
.	590 1 O

In	592 2 O
doses	595 5 O
of	601 2 O
3	604 1 O
-	605 1 O
10	606 2 O
mg	609 2 O
/	611 1 O
kg	612 2 O
,	614 1 O
the	616 3 O
serotonin	620 9 B-Chemical
receptor	630 8 O
agonist	639 7 O
MK	647 2 B-Chemical
-	649 1 I-Chemical
212	650 3 I-Chemical
caused	654 6 O
a	661 1 O
dose	663 4 O
-	667 1 O
dependent	668 9 O
blockade	678 8 O
of	687 2 O
the	690 3 O
response	694 8 O
of	703 2 O
muscimol	706 8 B-Chemical
.	714 1 O

Of	716 2 O
the	719 3 O
benzodiazepines	723 15 B-Chemical
,	738 1 O
clonazepam	740 10 B-Chemical
(	751 1 O
0	752 1 O
.	753 1 O
1	754 1 O
-	755 1 O
0	756 1 O
.	757 1 O
3	758 1 O
mg	760 2 O
/	762 1 O
kg	763 2 O
)	765 1 O
was	767 3 O
found	771 5 O
to	777 2 O
be	780 2 O
several	783 7 O
fold	791 4 O
more	796 4 O
potent	801 6 O
than	808 4 O
diazepam	813 8 B-Chemical
(	822 1 O
0	823 1 O
.	824 1 O
3	825 1 O
-	826 1 O
3	827 1 O
mg	829 2 O
/	831 1 O
kg	832 2 O
)	834 1 O
in	836 2 O
blocking	839 8 O
the	848 3 O
myoclonic	852 9 B-Disease
jerks	862 5 I-Disease
.	867 1 O

While	869 5 O
(	875 1 O
-	876 1 O
)	877 1 O
-	878 1 O
baclofen	879 8 B-Chemical
(	888 1 O
1	889 1 O
-	890 1 O
3	891 1 O
mg	893 2 O
/	895 1 O
kg	896 2 O
)	898 1 O
proved	900 6 O
to	907 2 O
be	910 2 O
an	913 2 O
effective	916 9 O
antagonist	926 10 O
of	937 2 O
muscimol	940 8 B-Chemical
,	948 1 O
its	950 3 O
(	954 1 O
+	955 1 O
)	956 1 O
-	957 1 O
isomer	958 6 O
(	965 1 O
5	966 1 O
-	967 1 O
20	968 2 O
mg	971 2 O
/	973 1 O
kg	974 2 O
)	976 1 O
lacked	978 6 O
this	985 4 O
property	990 8 O
.	998 1 O

Considering	1000 11 O
the	1012 3 O
fact	1016 4 O
that	1021 4 O
5	1026 1 B-Chemical
-	1027 1 I-Chemical
HTP	1028 3 I-Chemical
and	1032 3 O
the	1036 3 O
benzodiazepines	1040 15 B-Chemical
have	1056 4 O
been	1061 4 O
found	1066 5 O
to	1072 2 O
be	1075 2 O
beneficial	1078 10 O
in	1089 2 O
the	1092 3 O
management	1096 10 O
of	1107 2 O
clinical	1110 8 O
myoclonus	1119 9 B-Disease
,	1128 1 O
the	1130 3 O
muscimol	1134 8 B-Chemical
-	1142 1 O
induced	1143 7 O
myoclonus	1151 9 B-Disease
seems	1161 5 O
to	1167 2 O
be	1170 2 O
a	1173 1 O
satisfactory	1175 12 O
animal	1188 6 O
model	1195 5 O
that	1201 4 O
may	1206 3 O
prove	1210 5 O
useful	1216 6 O
for	1223 3 O
the	1227 3 O
development	1231 11 O
of	1243 2 O
new	1246 3 O
drug	1250 4 O
treatments	1255 10 O
for	1266 3 O
this	1270 4 O
condition	1275 9 O
.	1284 1 O

Our	1286 3 O
present	1290 7 O
study	1298 5 O
indicated	1304 9 O
the	1314 3 O
possible	1318 8 O
value	1327 5 O
of	1333 2 O
MK	1336 2 B-Chemical
-	1338 1 I-Chemical
212	1339 3 I-Chemical
and	1343 3 O
(	1347 1 O
-	1348 1 O
)	1349 1 O
-	1350 1 O
baclofen	1351 8 B-Chemical
in	1360 2 O
the	1363 3 O
management	1367 10 O
of	1378 2 O
clinical	1381 8 O
myoclonus	1390 9 B-Disease
.	1399 1 O

Hyperglycemic	0 13 B-Disease
acidotic	14 8 I-Disease
coma	23 4 I-Disease
and	28 3 O
death	32 5 O
in	38 2 O
Kearns	41 6 B-Disease
-	47 1 I-Disease
Sayre	48 5 I-Disease
syndrome	54 8 I-Disease
.	62 1 O

This	64 4 O
paper	69 5 O
presents	75 8 O
the	84 3 O
clinical	88 8 O
and	97 3 O
metabolic	101 9 O
findings	111 8 O
in	120 2 O
two	123 3 O
young	127 5 O
boys	133 4 O
with	138 4 O
long	143 4 O
-	147 1 O
standing	148 8 O
Kearns	157 6 B-Disease
-	163 1 I-Disease
Sayre	164 5 I-Disease
syndrome	170 8 I-Disease
.	178 1 O

Following	180 9 O
short	190 5 O
exposure	196 8 O
to	205 2 O
oral	208 4 O
prednisone	213 10 B-Chemical
,	223 1 O
both	225 4 O
boys	230 4 O
developed	235 9 O
lethargy	245 8 B-Disease
,	253 1 O
increasing	255 10 O
somnolence	266 10 B-Disease
,	276 1 O
polydipsia	278 10 B-Disease
,	288 1 O
polyphagia	290 10 B-Disease
,	300 1 O
and	302 3 O
polyuria	306 8 B-Disease
.	314 1 O

Both	316 4 O
presented	321 9 O
in	331 2 O
the	334 3 O
emergency	338 9 O
room	348 4 O
with	353 4 O
profound	358 8 O
coma	367 4 B-Disease
,	371 1 O
hypotension	373 11 B-Disease
,	384 1 O
severe	386 6 O
hyperglycemia	393 13 B-Disease
,	406 1 O
and	408 3 O
acidosis	412 8 B-Disease
.	420 1 O

Nonketotic	422 10 O
lactic	433 6 B-Disease
acidosis	440 8 I-Disease
was	449 3 O
present	453 7 O
in	461 2 O
one	464 3 O
and	468 3 O
ketosis	472 7 B-Disease
without	480 7 O
a	488 1 O
known	490 5 O
serum	496 5 O
lactate	502 7 B-Chemical
level	510 5 O
was	516 3 O
present	520 7 O
in	528 2 O
the	531 3 O
other	535 5 O
.	540 1 O

Respiratory	542 11 B-Disease
failure	554 7 I-Disease
rapidly	562 7 O
ensued	570 6 O
and	577 3 O
both	581 4 O
patients	586 8 O
expired	595 7 O
in	603 2 O
spite	606 5 O
of	612 2 O
efforts	615 7 O
at	623 2 O
resuscitation	626 13 O
.	639 1 O

We	641 2 O
believe	644 7 O
these	652 5 O
two	658 3 O
cases	662 5 O
represent	668 9 O
a	678 1 O
newly	680 5 O
described	686 9 O
and	696 3 O
catastrophic	700 12 O
metabolic	713 9 B-Disease
-	722 1 I-Disease
endocrine	723 9 I-Disease
failure	733 7 I-Disease
in	741 2 O
the	744 3 O
Kearns	748 6 B-Disease
-	754 1 I-Disease
Sayre	755 5 I-Disease
syndrome	761 8 I-Disease
.	769 1 O

Effects	0 7 O
of	8 2 O
active	11 6 O
constituents	18 12 O
of	31 2 O
Crocus	34 6 O
sativus	41 7 O
L	49 1 O
.	50 1 O
,	51 1 O
crocin	53 6 B-Chemical
on	60 2 O
streptozocin	63 12 B-Chemical
-	75 1 O
induced	76 7 O
model	84 5 O
of	90 2 O
sporadic	93 8 O
Alzheimer	102 9 B-Disease
'	111 1 I-Disease
s	112 1 I-Disease
disease	114 7 I-Disease
in	122 2 O
male	125 4 O
rats	130 4 O
.	134 1 O

BACKGROUND	136 10 O
:	146 1 O
The	148 3 O
involvement	152 11 O
of	164 2 O
water	167 5 O
-	172 1 O
soluble	173 7 O
carotenoids	181 11 B-Chemical
,	192 1 O
crocins	194 7 B-Chemical
,	201 1 O
as	203 2 O
the	206 3 O
main	210 4 O
and	215 3 O
active	219 6 O
components	226 10 O
of	237 2 O
Crocus	240 6 O
sativus	247 7 O
L	255 1 O
.	256 1 O
extract	258 7 O
in	266 2 O
learning	269 8 O
and	278 3 O
memory	282 6 O
processes	289 9 O
has	299 3 O
been	303 4 O
proposed	308 8 O
.	316 1 O

In	318 2 O
the	321 3 O
present	325 7 O
study	333 5 O
,	338 1 O
the	340 3 O
effect	344 6 O
of	351 2 O
crocins	354 7 B-Chemical
on	362 2 O
sporadic	365 8 O
Alzheimer	374 9 B-Disease
'	383 1 I-Disease
s	384 1 I-Disease
disease	386 7 I-Disease
induced	394 7 O
by	402 2 O
intracerebroventricular	405 23 O
(	429 1 O
icv	430 3 O
)	433 1 O
streptozocin	435 12 B-Chemical
(	448 1 O
STZ	449 3 B-Chemical
)	452 1 O
in	454 2 O
male	457 4 O
rats	462 4 O
was	467 3 O
investigated	471 12 O
.	483 1 O

METHODS	485 7 O
:	492 1 O
Male	494 4 O
adult	499 5 O
Wistar	505 6 O
rats	512 4 O
(	517 1 O
n	518 1 O
=	520 1 O
90	522 2 O
and	525 3 O
260	529 3 O
-	532 1 O
290	533 3 O
g	537 1 O
)	538 1 O
were	540 4 O
divided	545 7 O
into	553 4 O
1	558 1 O
,	559 1 O
control	561 7 O
;	568 1 O
2	570 1 O
and	572 3 O
3	576 1 O
,	577 1 O
crocins	579 7 B-Chemical
(	587 1 O
15	588 2 O
and	591 3 O
30	595 2 O
mg	598 2 O
/	600 1 O
kg	601 2 O
)	603 1 O
;	604 1 O
4	606 1 O
,	607 1 O
STZ	609 3 B-Chemical
;	612 1 O
5	614 1 O
and	616 3 O
6	620 1 O
,	621 1 O
STZ	623 3 B-Chemical
+	627 1 O
crocins	629 7 B-Chemical
(	637 1 O
15	638 2 O
and	641 3 O
30	645 2 O
mg	648 2 O
/	650 1 O
kg	651 2 O
)	653 1 O
groups	655 6 O
.	661 1 O

In	663 2 O
Alzheimer	666 9 B-Disease
'	675 1 I-Disease
s	676 1 I-Disease
disease	678 7 I-Disease
groups	686 6 O
,	692 1 O
rats	694 4 O
were	699 4 O
injected	704 8 O
with	713 4 O
STZ	718 3 B-Chemical
-	721 1 O
icv	722 3 O
bilaterally	726 11 O
(	738 1 O
3	739 1 O
mg	741 2 O
/	743 1 O
kg	744 2 O
)	746 1 O
in	748 2 O
first	751 5 O
day	757 3 O
and	761 3 O
3	765 1 O
days	767 4 O
later	772 5 O
,	777 1 O
a	779 1 O
similar	781 7 O
STZ	789 3 B-Chemical
-	792 1 O
icv	793 3 O
application	797 11 O
was	809 3 O
repeated	813 8 O
.	821 1 O

In	823 2 O
STZ	826 3 B-Chemical
+	830 1 O
crocin	832 6 B-Chemical
animal	839 6 O
groups	846 6 O
,	852 1 O
crocin	854 6 B-Chemical
was	861 3 O
applied	865 7 O
in	873 2 O
doses	876 5 O
of	882 2 O
15	885 2 O
and	888 3 O
30	892 2 O
mg	895 2 O
/	897 1 O
kg	898 2 O
,	900 1 O
i	902 1 O
.	903 1 O
p	904 1 O
.	905 1 O
,	906 1 O
one	908 3 O
day	912 3 O
pre	916 3 O
-	919 1 O
surgery	920 7 O
and	928 3 O
continued	932 9 O
for	942 3 O
three	946 5 O
weeks	952 5 O
.	957 1 O

Prescription	959 12 O
of	972 2 O
crocin	975 6 B-Chemical
in	982 2 O
each	985 4 O
dose	990 4 O
was	995 3 O
repeated	999 8 O
once	1008 4 O
for	1013 3 O
two	1017 3 O
days	1021 4 O
.	1025 1 O

However	1027 7 O
,	1034 1 O
the	1036 3 O
learning	1040 8 O
and	1049 3 O
memory	1053 6 O
performance	1060 11 O
was	1072 3 O
assessed	1076 8 O
using	1085 5 O
passive	1091 7 O
avoidance	1099 9 O
paradigm	1109 8 O
,	1117 1 O
and	1119 3 O
for	1123 3 O
spatial	1127 7 O
cognition	1135 9 O
evaluation	1145 10 O
,	1155 1 O
Y	1157 1 O
-	1158 1 O
maze	1159 4 O
task	1164 4 O
was	1169 3 O
used	1173 4 O
.	1177 1 O

RESULTS	1179 7 O
:	1186 1 O
It	1188 2 O
was	1191 3 O
found	1195 5 O
out	1201 3 O
that	1205 4 O
crocin	1210 6 B-Chemical
(	1217 1 O
30	1218 2 O
mg	1221 2 O
/	1223 1 O
kg	1224 2 O
)	1226 1 O
-	1227 1 O
treated	1228 7 O
STZ	1236 3 B-Chemical
-	1239 1 O
injected	1240 8 O
rats	1249 4 O
show	1254 4 O
higher	1259 6 O
correct	1266 7 O
choices	1274 7 O
and	1282 3 O
lower	1286 5 O
errors	1292 6 O
in	1299 2 O
Y	1302 1 O
-	1303 1 O
maze	1304 4 O
than	1309 4 O
vehicle	1314 7 O
-	1321 1 O
treated	1322 7 O
STZ	1330 3 B-Chemical
-	1333 1 O
injected	1334 8 O
rats	1343 4 O
.	1347 1 O

In	1349 2 O
addition	1352 8 O
,	1360 1 O
crocin	1362 6 B-Chemical
in	1369 2 O
the	1372 3 O
mentioned	1376 9 O
dose	1386 4 O
could	1391 5 O
significantly	1397 13 O
attenuated	1411 10 O
learning	1422 8 B-Disease
and	1431 3 I-Disease
memory	1435 6 I-Disease
impairment	1442 10 I-Disease
in	1453 2 O
treated	1456 7 O
STZ	1464 3 B-Chemical
-	1467 1 O
injected	1468 8 O
group	1477 5 O
in	1483 2 O
passive	1486 7 O
avoidance	1494 9 O
test	1504 4 O
.	1508 1 O

CONCLUSION	1510 10 O
:	1520 1 O
Therefore	1522 9 O
,	1531 1 O
these	1533 5 O
results	1539 7 O
demonstrate	1547 11 O
the	1559 3 O
effectiveness	1563 13 O
of	1577 2 O
crocin	1580 6 B-Chemical
(	1587 1 O
30	1588 2 O
mg	1591 2 O
/	1593 1 O
kg	1594 2 O
)	1596 1 O
in	1598 2 O
antagonizing	1601 12 O
the	1614 3 O
cognitive	1618 9 B-Disease
deficits	1628 8 I-Disease
caused	1637 6 O
by	1644 2 O
STZ	1647 3 B-Chemical
-	1650 1 O
icv	1651 3 O
in	1655 2 O
rats	1658 4 O
and	1663 3 O
its	1667 3 O
potential	1671 9 O
in	1681 2 O
the	1684 3 O
treatment	1688 9 O
of	1698 2 O
neurodegenerative	1701 17 B-Disease
diseases	1719 8 I-Disease
such	1728 4 O
as	1733 2 O
Alzheimer	1736 9 B-Disease
'	1745 1 I-Disease
s	1746 1 I-Disease
disease	1748 7 I-Disease
.	1755 1 O

Rosaceiform	0 11 O
dermatitis	12 10 B-Disease
associated	23 10 O
with	34 4 O
topical	39 7 O
tacrolimus	47 10 B-Chemical
treatment	58 9 O
.	67 1 O

We	69 2 O
describe	72 8 O
herein	81 6 O
3	88 1 O
patients	90 8 O
who	99 3 O
developed	103 9 O
rosacea	113 7 B-Disease
-	120 1 O
like	121 4 O
dermatitis	126 10 B-Disease
eruptions	137 9 B-Disease
while	147 5 O
using	153 5 O
0	159 1 O
.	160 1 O
03	161 2 O
%	163 1 O
or	165 2 O
0	168 1 O
.	169 1 O
1	170 1 O
%	171 1 O
tacrolimus	173 10 B-Chemical
ointment	184 8 O
for	193 3 O
facial	197 6 B-Disease
dermatitis	204 10 I-Disease
.	214 1 O

Skin	216 4 O
biopsy	221 6 O
specimens	228 9 O
showed	238 6 O
telangiectasia	245 14 B-Disease
and	260 3 O
noncaseating	264 12 O
epithelioid	277 11 O
granulomatous	289 13 O
tissue	303 6 O
formation	310 9 O
in	320 2 O
the	323 3 O
papillary	327 9 O
to	337 2 O
mid	340 3 O
dermis	344 6 O
.	350 1 O

Continuous	352 10 O
topical	363 7 O
use	371 3 O
of	375 2 O
immunomodulators	378 16 O
such	395 4 O
as	400 2 O
tacrolimus	403 10 B-Chemical
or	414 2 O
pimecrolimus	417 12 B-Chemical
should	430 6 O
be	437 2 O
regarded	440 8 O
as	449 2 O
a	452 1 O
potential	454 9 O
cause	464 5 O
of	470 2 O
rosaceiform	473 11 O
dermatitis	485 10 B-Disease
,	495 1 O
although	497 8 O
many	506 4 O
cases	511 5 O
have	517 4 O
not	522 3 O
been	526 4 O
reported	531 8 O
.	539 1 O

A	0 1 O
novel	2 5 O
animal	8 6 O
model	15 5 O
to	21 2 O
evaluate	24 8 O
the	33 3 O
ability	37 7 O
of	45 2 O
a	48 1 O
drug	50 4 O
delivery	55 8 O
system	64 6 O
to	71 2 O
promote	74 7 O
the	82 3 O
passage	86 7 O
through	94 7 O
the	102 3 O
BBB	106 3 O
.	109 1 O

The	111 3 O
purpose	115 7 O
of	123 2 O
this	126 4 O
investigation	131 13 O
was	145 3 O
to	149 2 O
explore	152 7 O
the	160 3 O
potentiality	164 12 O
of	177 2 O
a	180 1 O
novel	182 5 O
animal	188 6 O
model	195 5 O
to	201 2 O
be	204 2 O
used	207 4 O
for	212 3 O
the	216 3 O
in	220 2 O
vivo	223 4 O
evaluation	228 10 O
of	239 2 O
the	242 3 O
ability	246 7 O
of	254 2 O
a	257 1 O
drug	259 4 O
delivery	264 8 O
system	273 6 O
to	280 2 O
promote	283 7 O
the	291 3 O
passage	295 7 O
through	303 7 O
the	311 3 O
blood	315 5 O
-	320 1 O
brain	321 5 O
barrier	327 7 O
(	335 1 O
BBB	336 3 O
)	339 1 O
and	341 3 O
/	344 1 O
or	345 2 O
to	348 2 O
improve	351 7 O
the	359 3 O
brain	363 5 O
localization	369 12 O
of	382 2 O
a	385 1 O
bioactive	387 9 O
compound	397 8 O
.	405 1 O

A	407 1 O
Tween	409 5 O
80	415 2 O
-	417 1 O
coated	418 6 O
poly	425 4 B-Chemical
-	429 1 I-Chemical
L	430 1 I-Chemical
-	431 1 I-Chemical
lactid	432 6 I-Chemical
acid	439 4 I-Chemical
nanoparticles	444 13 O
was	458 3 O
used	462 4 O
as	467 2 O
a	470 1 O
model	472 5 O
of	478 2 O
colloidal	481 9 O
drug	491 4 O
delivery	496 8 O
system	505 6 O
,	511 1 O
able	513 4 O
to	518 2 O
trespass	521 8 O
the	530 3 O
BBB	534 3 O
.	537 1 O

Tacrine	539 7 B-Chemical
,	546 1 O
administered	548 12 O
in	561 2 O
LiCl	564 4 B-Chemical
pre	569 3 O
-	572 1 O
treated	573 7 O
rats	581 4 O
,	585 1 O
induces	587 7 O
electrocorticographic	595 21 O
seizures	617 8 B-Disease
and	626 3 O
delayed	630 7 O
hippocampal	638 11 B-Disease
damage	650 6 I-Disease
.	656 1 O

The	658 3 O
toxic	662 5 O
effects	668 7 O
of	676 2 O
tacrine	679 7 B-Chemical
-	686 1 O
loaded	687 6 O
poly	694 4 B-Chemical
-	698 1 I-Chemical
L	699 1 I-Chemical
-	700 1 I-Chemical
lactid	701 6 I-Chemical
acid	708 4 I-Chemical
nanoparticles	713 13 O
(	727 1 O
5mg	728 3 O
/	731 1 O
kg	732 2 O
)	734 1 O
,	735 1 O
a	737 1 O
saline	739 6 O
solution	746 8 O
of	755 2 O
tacrine	758 7 B-Chemical
(	766 1 O
5mg	767 3 O
/	770 1 O
kg	771 2 O
)	773 1 O
and	775 3 O
an	779 2 O
empty	782 5 O
colloidal	788 9 O
nanoparticle	798 12 O
suspension	811 10 O
were	822 4 O
compared	827 8 O
following	836 9 O
i	846 1 O
.	847 1 O
p	848 1 O
.	849 1 O
administration	851 14 O
in	866 2 O
LiCl	869 4 B-Chemical
-	873 1 O
pre	874 3 O
-	877 1 O
treated	878 7 O
Wistar	886 6 O
rats	893 4 O
.	897 1 O

All	899 3 O
the	903 3 O
animals	907 7 O
treated	915 7 O
with	923 4 O
tacrine	928 7 B-Chemical
-	935 1 O
loaded	936 6 O
nanoparticles	943 13 O
showed	957 6 O
an	964 2 O
earlier	967 7 O
outcome	975 7 O
of	983 2 O
CNS	986 3 O
adverse	990 7 O
symptoms	998 8 O
,	1006 1 O
i	1008 1 O
.	1009 1 O
e	1010 1 O
.	1011 1 O
epileptic	1013 9 B-Disease
onset	1023 5 O
,	1028 1 O
with	1030 4 O
respect	1035 7 O
to	1043 2 O
those	1046 5 O
animals	1052 7 O
treated	1060 7 O
with	1068 4 O
the	1073 3 O
free	1077 4 O
compound	1082 8 O
(	1091 1 O
10	1092 2 O
min	1095 3 O
vs	1099 2 O
.	1101 1 O
22	1103 2 O
min	1106 3 O
respectively	1110 12 O
)	1122 1 O
.	1123 1 O

In	1125 2 O
addition	1128 8 O
,	1136 1 O
tacrine	1138 7 B-Chemical
-	1145 1 O
loaded	1146 6 O
nanoparticles	1153 13 O
administration	1167 14 O
induced	1182 7 O
damage	1190 6 B-Disease
of	1197 2 I-Disease
neuronal	1200 8 I-Disease
cells	1209 5 I-Disease
in	1215 2 O
CA1	1218 3 O
field	1222 5 O
of	1228 2 O
the	1231 3 O
hippocampus	1235 11 O
in	1247 2 O
all	1250 3 O
treated	1254 7 O
animals	1262 7 O
,	1269 1 O
while	1271 5 O
the	1277 3 O
saline	1281 6 O
solution	1288 8 O
of	1297 2 O
tacrine	1300 7 B-Chemical
only	1308 4 O
in	1313 2 O
60	1316 2 O
%	1318 1 O
of	1320 2 O
animals	1323 7 O
.	1330 1 O

Empty	1332 5 O
nanoparticles	1338 13 O
provided	1352 8 O
similar	1361 7 O
results	1369 7 O
to	1377 2 O
control	1380 7 O
(	1388 1 O
saline	1389 6 O
-	1395 1 O
treated	1396 7 O
)	1403 1 O
group	1405 5 O
of	1411 2 O
animals	1414 7 O
.	1421 1 O

In	1423 2 O
conclusion	1426 10 O
,	1436 1 O
the	1438 3 O
evaluation	1442 10 O
of	1453 2 O
time	1456 4 O
-	1460 1 O
to	1461 2 O
-	1463 1 O
onset	1464 5 O
of	1470 2 O
symptoms	1473 8 O
and	1482 3 O
the	1486 3 O
severity	1490 8 O
of	1499 2 O
neurodegenerative	1502 17 O
processes	1520 9 O
induced	1530 7 O
by	1538 2 O
the	1541 3 O
tacrine	1545 7 B-Chemical
-	1552 1 O
lithium	1553 7 B-Chemical
model	1561 5 O
of	1567 2 O
epilepsy	1570 8 B-Disease
in	1579 2 O
the	1582 3 O
rat	1586 3 O
,	1589 1 O
could	1591 5 O
be	1597 2 O
used	1600 4 O
to	1605 2 O
evaluate	1608 8 O
preliminarily	1617 13 O
the	1631 3 O
capability	1635 10 O
of	1646 2 O
a	1649 1 O
drug	1651 4 O
delivery	1656 8 O
system	1665 6 O
to	1672 2 O
trespass	1675 8 O
(	1684 1 O
or	1685 2 O
not	1688 3 O
)	1691 1 O
the	1693 3 O
BBB	1697 3 O
in	1701 2 O
vivo	1704 4 O
.	1708 1 O

The	0 3 O
antiarrhythmic	4 14 O
effect	19 6 O
and	26 3 O
possible	30 8 O
ionic	39 5 O
mechanisms	45 10 O
of	56 2 O
pilocarpine	59 11 B-Chemical
on	71 2 O
animal	74 6 O
models	81 6 O
.	87 1 O

This	89 4 O
study	94 5 O
was	100 3 O
designed	104 8 O
to	113 2 O
evaluate	116 8 O
the	125 3 O
effects	129 7 O
of	137 2 O
pilocarpine	140 11 B-Chemical
and	152 3 O
explore	156 7 O
the	164 3 O
underlying	168 10 O
ionic	179 5 O
mechanism	185 9 O
,	194 1 O
using	196 5 O
both	202 4 O
aconitine	207 9 B-Chemical
-	216 1 O
induced	217 7 O
rat	225 3 O
and	229 3 O
ouabain	233 7 B-Chemical
-	240 1 O
induced	241 7 O
guinea	249 6 O
pig	256 3 O
arrhythmia	260 10 B-Disease
models	271 6 O
.	277 1 O

Confocal	279 8 O
microscopy	288 10 O
was	299 3 O
used	303 4 O
to	308 2 O
measure	311 7 O
intracellular	319 13 O
free	333 4 O
-	337 1 O
calcium	338 7 B-Chemical
concentrations	346 14 O
(	361 1 O
[	362 1 O
Ca	363 2 B-Chemical
(	365 1 O
2	366 1 O
+	367 1 O
)	368 1 O
]	369 1 O
(	370 1 O
i	371 1 O
)	372 1 O
)	373 1 O
in	375 2 O
isolated	378 8 O
myocytes	387 8 O
.	395 1 O

The	397 3 O
current	401 7 O
data	409 4 O
showed	414 6 O
that	421 4 O
pilocarpine	426 11 B-Chemical
significantly	438 13 O
delayed	452 7 O
onset	460 5 O
of	466 2 O
arrhythmias	469 11 B-Disease
,	480 1 O
decreased	482 9 O
the	492 3 O
time	496 4 O
course	501 6 O
of	508 2 O
ventricular	511 11 B-Disease
tachycardia	523 11 I-Disease
and	535 3 I-Disease
fibrillation	539 12 I-Disease
,	551 1 O
reduced	553 7 O
arrhythmia	561 10 B-Disease
score	572 5 O
,	577 1 O
and	579 3 O
increased	583 9 O
the	593 3 O
survival	597 8 O
time	606 4 O
of	611 2 O
arrhythmic	614 10 B-Disease
rats	625 4 O
and	630 3 O
guinea	634 6 O
pigs	641 4 O
.	645 1 O

[	647 1 O
Ca	648 2 B-Chemical
(	650 1 O
2	651 1 O
+	652 1 O
)	653 1 O
]	654 1 O
(	655 1 O
i	656 1 O
)	657 1 O
overload	659 8 O
induced	668 7 O
by	676 2 O
aconitine	679 9 B-Chemical
or	689 2 O
ouabain	692 7 B-Chemical
was	700 3 O
reduced	704 7 O
in	712 2 O
isolated	715 8 O
myocytes	724 8 O
pretreated	733 10 O
with	744 4 O
pilocarpine	749 11 B-Chemical
.	760 1 O

Moreover	762 8 O
,	770 1 O
M	772 1 O
(	773 1 O
3	774 1 O
)	775 1 O
-	776 1 O
muscarinic	777 10 O
acetylcholine	788 13 B-Chemical
receptor	802 8 O
(	811 1 O
mAChR	812 5 O
)	817 1 O
antagonist	819 10 O
4	830 1 B-Chemical
-	831 1 I-Chemical
DAMP	832 4 I-Chemical
(	837 1 O
4	838 1 B-Chemical
-	839 1 I-Chemical
diphenylacetoxy	840 15 I-Chemical
-	855 1 I-Chemical
N	856 1 I-Chemical
-	857 1 I-Chemical
methylpiperidine	858 16 I-Chemical
-	874 1 I-Chemical
methiodide	875 10 I-Chemical
)	885 1 O
partially	887 9 O
abolished	897 9 O
the	907 3 O
beneficial	911 10 O
effects	922 7 O
of	930 2 O
pilocarpine	933 11 B-Chemical
.	944 1 O

These	946 5 O
data	952 4 O
suggest	957 7 O
that	965 4 O
pilocarpine	970 11 B-Chemical
produced	982 8 O
antiarrhythmic	991 14 O
actions	1006 7 O
on	1014 2 O
arrhythmic	1017 10 B-Disease
rat	1028 3 O
and	1032 3 O
guinea	1036 6 O
pig	1043 3 O
models	1047 6 O
induced	1054 7 O
by	1062 2 O
aconitine	1065 9 B-Chemical
or	1075 2 O
ouabain	1078 7 B-Chemical
via	1086 3 O
stimulating	1090 11 O
the	1102 3 O
cardiac	1106 7 O
M	1114 1 O
(	1115 1 O
3	1116 1 O
)	1117 1 O
-	1118 1 O
mAChR	1119 5 O
.	1124 1 O

The	1126 3 O
mechanism	1130 9 O
may	1140 3 O
be	1144 2 O
related	1147 7 O
to	1155 2 O
the	1158 3 O
improvement	1162 11 O
of	1174 2 O
Ca	1177 2 B-Chemical
(	1179 1 O
2	1180 1 O
+	1181 1 O
)	1182 1 O
handling	1184 8 O
.	1192 1 O

Disulfiram	0 10 B-Chemical
-	10 1 O
induced	11 7 O
transient	19 9 O
optic	29 5 B-Disease
and	35 3 I-Disease
peripheral	39 10 I-Disease
neuropathy	50 10 I-Disease
:	60 1 O
a	62 1 O
case	64 4 O
report	69 6 O
.	75 1 O

AIM	77 3 O
:	80 1 O
To	82 2 O
report	85 6 O
a	92 1 O
case	94 4 O
of	99 2 O
optic	102 5 B-Disease
and	108 3 I-Disease
peripheral	112 10 I-Disease
neuropathy	123 10 I-Disease
after	134 5 O
chronic	140 7 O
use	148 3 O
of	152 2 O
disulfiram	155 10 B-Chemical
for	166 3 O
alcohol	170 7 B-Disease
dependence	178 10 I-Disease
management	189 10 O
.	199 1 O

MATERIALS	201 9 O
AND	211 3 O
METHODS	215 7 O
:	222 1 O
A	224 1 O
case	226 4 O
report	231 6 O
.	237 1 O

RESULTS	239 7 O
:	246 1 O
A	248 1 O
57	250 2 O
-	252 1 O
year	253 4 O
-	257 1 O
old	258 3 O
male	262 4 O
presented	267 9 O
with	277 4 O
gradual	282 7 O
loss	290 4 B-Disease
of	295 2 I-Disease
vision	298 6 I-Disease
in	305 2 O
both	308 4 O
eyes	313 4 O
with	318 4 O
intermittent	323 12 O
headaches	336 9 B-Disease
for	346 3 O
2	350 1 O
months	352 6 O
.	358 1 O

He	360 2 O
also	363 4 O
complained	368 10 O
of	379 2 O
paraesthesia	382 12 B-Disease
with	395 4 O
numbness	400 8 B-Disease
in	409 2 O
both	412 4 O
feet	417 4 O
.	421 1 O

His	423 3 O
vision	427 6 O
was	434 3 O
6	438 1 O
/	439 1 O
15	440 2 O
and	443 3 O
2	447 1 O
/	448 1 O
60	449 2 O
in	452 2 O
the	455 3 O
right	459 5 O
and	465 3 O
left	469 4 O
eyes	474 4 O
,	478 1 O
respectively	480 12 O
.	492 1 O

Fundoscopy	494 10 O
revealed	505 8 O
bilaterally	514 11 O
swollen	526 7 O
optic	534 5 O
nerve	540 5 O
heads	546 5 O
.	551 1 O

Visual	553 6 O
field	560 5 O
testing	566 7 O
confirmed	574 9 O
bilateral	584 9 O
central	594 7 O
-	601 1 O
caecal	602 6 O
scotomata	609 9 B-Disease
.	618 1 O

He	620 2 O
had	623 3 O
been	627 4 O
taking	632 6 O
disulfiram	639 10 B-Chemical
for	650 3 O
alcohol	654 7 B-Disease
dependence	662 10 I-Disease
for	673 3 O
the	677 3 O
preceding	681 9 O
3	691 1 O
years	693 5 O
.	698 1 O

Disulfiram	700 10 B-Chemical
discontinuation	711 15 O
lead	727 4 O
to	732 2 O
an	735 2 O
immediate	738 9 O
symptomatic	748 11 O
improvement	760 11 O
.	771 1 O

CONCLUSION	773 10 O
:	783 1 O
Physicians	785 10 O
initiating	796 10 O
long	807 4 O
-	811 1 O
term	812 4 O
disulfiram	817 10 B-Chemical
therapy	828 7 O
should	836 6 O
be	843 2 O
aware	846 5 O
of	852 2 O
these	855 5 O
adverse	861 7 O
effects	869 7 O
.	876 1 O

They	878 4 O
should	883 6 O
recommend	890 9 O
annual	900 6 O
ophthalmic	907 10 O
reviews	918 7 O
with	926 4 O
visual	931 6 O
field	938 5 O
testing	944 7 O
.	951 1 O

Patients	953 8 O
should	962 6 O
be	969 2 O
reassured	972 9 O
with	982 4 O
respect	987 7 O
to	995 2 O
the	998 3 O
reversibility	1002 13 O
of	1016 2 O
these	1019 5 O
adverse	1025 7 O
effects	1033 7 O
.	1040 1 O

Sustained	0 9 O
clinical	10 8 O
improvement	19 11 O
of	31 2 O
a	34 1 O
patient	36 7 O
with	44 4 O
decompensated	49 13 O
hepatitis	63 9 B-Disease
B	73 1 I-Disease
virus	75 5 O
-	80 1 O
related	81 7 O
cirrhosis	89 9 B-Disease
after	99 5 O
treatment	105 9 O
with	115 4 O
lamivudine	120 10 B-Chemical
monotherapy	131 11 O
.	142 1 O

Hepatitis	144 9 B-Disease
B	154 1 I-Disease
virus	156 5 I-Disease
(	162 1 I-Disease
HBV	163 3 I-Disease
)	166 1 I-Disease
infection	168 9 I-Disease
,	177 1 O
which	179 5 O
causes	185 6 O
liver	192 5 B-Disease
cirrhosis	198 9 I-Disease
and	208 3 O
hepatocellular	212 14 B-Disease
carcinoma	227 9 I-Disease
,	236 1 O
remains	238 7 O
a	246 1 O
major	248 5 O
health	254 6 O
problem	261 7 O
in	269 2 O
Asian	272 5 O
countries	278 9 O
.	287 1 O

Recent	289 6 O
development	296 11 O
of	308 2 O
vaccine	311 7 O
for	319 3 O
prevention	323 10 O
is	334 2 O
reported	337 8 O
to	346 2 O
be	349 2 O
successful	352 10 O
in	363 2 O
reducing	366 8 O
the	375 3 O
size	379 4 O
of	384 2 O
chronically	387 11 O
infected	399 8 O
carriers	408 8 O
,	416 1 O
although	418 8 O
the	427 3 O
standard	431 8 O
medical	440 7 O
therapies	448 9 O
have	458 4 O
not	463 3 O
been	467 4 O
established	472 11 O
up	484 2 O
to	487 2 O
now	490 3 O
.	493 1 O

In	495 2 O
this	498 4 O
report	503 6 O
,	509 1 O
we	511 2 O
encountered	514 11 O
a	526 1 O
patient	528 7 O
with	536 4 O
decompensated	541 13 O
HBV	555 3 O
-	558 1 O
related	559 7 O
cirrhosis	567 9 B-Disease
who	577 3 O
exhibited	581 9 O
the	591 3 O
dramatic	595 8 O
improvements	604 12 O
after	617 5 O
antiviral	623 9 O
therapy	633 7 O
.	640 1 O

The	642 3 O
patient	646 7 O
was	654 3 O
a	658 1 O
50	660 2 O
-	662 1 O
year	663 4 O
-	667 1 O
old	668 3 O
woman	672 5 O
.	677 1 O

Previous	679 8 O
conventional	688 12 O
medical	701 7 O
treatments	709 10 O
were	720 4 O
not	725 3 O
effective	729 9 O
for	739 3 O
this	743 4 O
patient	748 7 O
,	755 1 O
thus	757 4 O
this	762 4 O
patient	767 7 O
had	775 3 O
been	779 4 O
referred	784 8 O
to	793 2 O
our	796 3 O
hospital	800 8 O
.	808 1 O

However	810 7 O
,	817 1 O
the	819 3 O
administration	823 14 O
of	838 2 O
lamivudine	841 10 B-Chemical
,	851 1 O
a	853 1 O
reverse	855 7 O
transcriptase	863 13 O
inhibitor	877 9 O
,	886 1 O
for	888 3 O
23	892 2 O
months	895 6 O
dramatically	902 12 O
improved	915 8 O
her	924 3 O
liver	928 5 O
severity	934 8 O
.	942 1 O

During	944 6 O
this	951 4 O
period	956 6 O
,	962 1 O
no	964 2 O
drug	967 4 O
resistant	972 9 O
mutant	982 6 O
HBV	989 3 O
emerged	993 7 O
,	1000 1 O
and	1002 3 O
the	1006 3 O
serum	1010 5 O
HBV	1016 3 O
-	1019 1 O
DNA	1020 3 O
level	1024 5 O
was	1030 3 O
continuously	1034 12 O
suppressed	1047 10 O
.	1057 1 O

These	1059 5 O
virological	1065 11 O
responses	1077 9 O
were	1087 4 O
also	1092 4 O
maintained	1097 10 O
even	1108 4 O
after	1113 5 O
the	1119 3 O
antiviral	1123 9 O
therapy	1133 7 O
was	1141 3 O
discontinued	1145 12 O
.	1157 1 O

Moreover	1159 8 O
,	1167 1 O
both	1169 4 O
hepatitis	1174 9 B-Chemical
B	1184 1 I-Chemical
surface	1186 7 I-Chemical
antigen	1194 7 I-Chemical
and	1202 3 I-Chemical
e	1206 1 I-Chemical
antigen	1208 7 I-Chemical
were	1216 4 O
observed	1221 8 O
to	1230 2 O
have	1233 4 O
disappeared	1238 11 O
in	1250 2 O
this	1253 4 O
patient	1258 7 O
.	1265 1 O

The	1267 3 O
administration	1271 14 O
of	1286 2 O
lamivudine	1289 10 B-Chemical
to	1300 2 O
patients	1303 8 O
with	1312 4 O
HBV	1317 3 O
-	1320 1 O
related	1321 7 O
cirrhosis	1329 9 B-Disease
,	1338 1 O
like	1340 4 O
our	1345 3 O
present	1349 7 O
case	1357 4 O
,	1361 1 O
should	1363 6 O
be	1370 2 O
considered	1373 10 O
as	1384 2 O
an	1387 2 O
initial	1390 7 O
medical	1398 7 O
therapeutic	1406 11 O
option	1418 6 O
,	1424 1 O
especially	1426 10 O
in	1437 2 O
countries	1440 9 O
where	1450 5 O
liver	1456 5 O
transplantation	1462 15 O
is	1478 2 O
not	1481 3 O
reliably	1485 8 O
available	1494 9 O
.	1503 1 O

Dual	0 4 O
effects	5 7 O
of	13 2 O
melatonin	16 9 B-Chemical
on	26 2 O
barbiturate	29 11 B-Chemical
-	40 1 O
induced	41 7 O
narcosis	49 8 B-Disease
in	58 2 O
rats	61 4 O
.	65 1 O

Melatonin	67 9 B-Chemical
affects	77 7 O
the	85 3 O
circadian	89 9 O
sleep	99 5 O
/	104 1 O
wake	105 4 O
cycle	110 5 O
,	115 1 O
but	117 3 O
it	121 2 O
is	124 2 O
not	127 3 O
clear	131 5 O
whether	137 7 O
it	145 2 O
may	148 3 O
influence	152 9 O
drug	162 4 O
-	166 1 O
induced	167 7 O
narcosis	175 8 B-Disease
.	183 1 O

Sodium	185 6 B-Chemical
thiopenthal	192 11 I-Chemical
was	204 3 O
administered	208 12 O
intraperitoneally	221 17 O
into	239 4 O
male	244 4 O
rats	249 4 O
pre	254 3 O
-	257 1 O
treated	258 7 O
with	266 4 O
melatonin	271 9 B-Chemical
(	281 1 O
0	282 1 O
.	283 1 O
05	284 2 O
,	286 1 O
0	288 1 O
.	289 1 O
5	290 1 O
,	291 1 O
5	293 1 O
and	295 3 O
50	299 2 O
mg	302 2 O
/	304 1 O
kg	305 2 O
)	307 1 O
.	308 1 O

Melatonin	310 9 B-Chemical
pre	320 3 O
-	323 1 O
treatment	324 9 O
affected	334 8 O
in	343 2 O
a	346 1 O
dual	348 4 O
manner	353 6 O
barbiturate	360 11 B-Chemical
narcosis	372 8 B-Disease
,	380 1 O
however	382 7 O
,	389 1 O
no	391 2 O
dose	394 4 O
-	398 1 O
effect	399 6 O
correlation	406 11 O
was	418 3 O
found	422 5 O
.	427 1 O

In	429 2 O
particular	432 10 O
,	442 1 O
low	444 3 O
doses	448 5 O
reduced	454 7 O
the	462 3 O
latency	466 7 O
to	474 2 O
and	477 3 O
prolonged	481 9 O
the	491 3 O
duration	495 8 O
of	504 2 O
barbiturate	507 11 B-Chemical
narcosis	519 8 B-Disease
.	527 1 O

In	529 2 O
contrast	532 8 O
,	540 1 O
the	542 3 O
highest	546 7 O
dose	554 4 O
of	559 2 O
melatonin	562 9 B-Chemical
(	572 1 O
50	573 2 O
mg	576 2 O
/	578 1 O
kg	579 2 O
)	581 1 O
caused	583 6 O
a	590 1 O
paradoxical	592 11 O
increase	604 8 O
in	613 2 O
the	616 3 O
latency	620 7 O
and	628 3 O
produced	632 8 O
a	641 1 O
sustained	643 9 O
reduction	653 9 O
of	663 2 O
the	666 3 O
duration	670 8 O
of	679 2 O
narcosis	682 8 B-Disease
,	690 1 O
and	692 3 O
a	696 1 O
reduction	698 9 O
in	708 2 O
mortality	711 9 O
rate	721 4 O
.	725 1 O

Melatonin	727 9 B-Chemical
0	737 1 O
.	738 1 O
5	739 1 O
and	741 3 O
5	745 1 O
mg	747 2 O
/	749 1 O
kg	750 2 O
influenced	753 10 O
the	764 3 O
duration	768 8 O
but	777 3 O
not	781 3 O
the	785 3 O
latency	789 7 O
of	797 2 O
ketamine	800 8 B-Chemical
-	808 1 O
or	810 2 O
diazepam	813 8 B-Chemical
-	821 1 O
induced	822 7 O
narcosis	830 8 B-Disease
.	838 1 O

Thus	840 4 O
,	844 1 O
the	846 3 O
dual	850 4 O
action	855 6 O
of	862 2 O
melatonin	865 9 B-Chemical
on	875 2 O
pharmacological	878 15 O
narcosis	894 8 B-Disease
seems	903 5 O
to	909 2 O
be	912 2 O
specific	915 8 O
for	924 3 O
the	928 3 O
barbiturate	932 11 B-Chemical
mechanism	944 9 O
of	954 2 O
action	957 6 O
.	963 1 O

Effects	0 7 O
of	8 2 O
NIK	11 3 B-Chemical
-	14 1 I-Chemical
247	15 3 I-Chemical
on	19 2 O
cholinesterase	22 14 O
and	37 3 O
scopolamine	41 11 B-Chemical
-	52 1 O
induced	53 7 O
amnesia	61 7 B-Disease
.	68 1 O

The	70 3 O
effects	74 7 O
of	82 2 O
NIK	85 3 B-Chemical
-	88 1 I-Chemical
247	89 3 I-Chemical
on	93 2 O
cholinesterase	96 14 O
,	110 1 O
scopolamine	112 11 B-Chemical
-	123 1 O
induced	124 7 O
amnesia	132 7 B-Disease
and	140 3 O
spontaneous	144 11 O
movement	156 8 O
were	165 4 O
examined	170 8 O
and	179 3 O
compared	183 8 O
with	192 4 O
those	197 5 O
of	203 2 O
the	206 3 O
well	210 4 O
-	214 1 O
known	215 5 O
cholinesterase	221 14 O
inhibitors	236 10 O
tacrine	247 7 B-Chemical
and	255 3 O
E	259 1 B-Chemical
-	260 1 I-Chemical
2020	261 4 I-Chemical
.	265 1 O

NIK	267 3 B-Chemical
-	270 1 I-Chemical
247	271 3 I-Chemical
,	274 1 O
tacrine	276 7 B-Chemical
and	284 3 O
E	288 1 B-Chemical
-	289 1 I-Chemical
2020	290 4 I-Chemical
all	295 3 O
strongly	299 8 O
inhibited	308 9 O
acetylcholinesterase	318 20 O
(	339 1 O
AChE	340 4 O
)	344 1 O
in	346 2 O
human	349 5 O
red	355 3 O
blood	359 5 O
cells	365 5 O
(	371 1 O
IC50s	372 5 O
=	378 1 O
1	380 1 O
.	381 1 O
0	382 1 O
x	384 1 O
10	386 2 O
(	388 1 O
-	389 1 O
6	390 1 O
)	391 1 O
,	392 1 O
2	394 1 O
.	395 1 O
9	396 1 O
x	398 1 O
10	400 2 O
(	402 1 O
-	403 1 O
7	404 1 O
)	405 1 O
and	407 3 O
3	411 1 O
.	412 1 O
7	413 1 O
x	415 1 O
10	417 2 O
(	419 1 O
-	420 1 O
8	421 1 O
)	422 1 O
M	424 1 O
,	425 1 O
respectively	427 12 O
)	439 1 O
.	440 1 O

In	442 2 O
addition	445 8 O
,	453 1 O
NIK	455 3 B-Chemical
-	458 1 I-Chemical
247	459 3 I-Chemical
and	463 3 O
tacrine	467 7 B-Chemical
,	474 1 O
but	476 3 O
not	480 3 O
E	484 1 B-Chemical
-	485 1 I-Chemical
2020	486 4 I-Chemical
,	490 1 O
strongly	492 8 O
inhibited	501 9 O
butyrylcholinestrase	511 20 O
(	532 1 O
BuChE	533 5 O
)	538 1 O
in	540 2 O
human	543 5 O
serum	549 5 O
.	554 1 O

All	556 3 O
three	560 5 O
drugs	566 5 O
produced	572 8 O
mixed	581 5 O
inhibition	587 10 O
of	598 2 O
AChE	601 4 O
activity	606 8 O
.	614 1 O

Moreover	616 8 O
,	624 1 O
the	626 3 O
inhibitory	630 10 O
effect	641 6 O
of	648 2 O
NIK	651 3 B-Chemical
-	654 1 I-Chemical
247	655 3 I-Chemical
on	659 2 O
AChE	662 4 O
was	667 3 O
reversible	671 10 O
.	681 1 O

All	683 3 O
compounds	687 9 O
at	697 2 O
0	700 1 O
.	701 1 O
1	702 1 O
-	703 1 O
1	704 1 O
mg	706 2 O
/	708 1 O
kg	709 2 O
p	712 1 O
.	713 1 O
o	714 1 O
.	715 1 O
significantly	717 13 O
improved	731 8 O
the	740 3 O
amnesia	744 7 B-Disease
induced	752 7 O
by	760 2 O
scopolamine	763 11 B-Chemical
(	775 1 O
0	776 1 O
.	777 1 O
5	778 1 O
mg	780 2 O
/	782 1 O
kg	783 2 O
s	786 1 O
.	787 1 O
c	788 1 O
.	789 1 O
)	790 1 O
in	792 2 O
rats	795 4 O
performing	800 10 O
a	811 1 O
passive	813 7 O
avoidance	821 9 O
task	831 4 O
.	835 1 O

The	837 3 O
three	841 5 O
compounds	847 9 O
at	857 2 O
1	860 1 O
and	862 3 O
3	866 1 O
mg	868 2 O
/	870 1 O
kg	871 2 O
p	874 1 O
.	875 1 O
o	876 1 O
.	877 1 O
did	879 3 O
not	883 3 O
significantly	887 13 O
decrease	901 8 O
spontaneous	910 11 O
movement	922 8 O
by	931 2 O
rats	934 4 O
.	938 1 O

These	940 5 O
findings	946 8 O
suggest	955 7 O
that	963 4 O
NIK	968 3 B-Chemical
-	971 1 I-Chemical
247	972 3 I-Chemical
at	976 2 O
a	979 1 O
low	981 3 O
dose	985 4 O
(	990 1 O
0	991 1 O
.	992 1 O
1	993 1 O
-	994 1 O
1	995 1 O
mg	997 2 O
/	999 1 O
kg	1000 2 O
p	1003 1 O
.	1004 1 O
o	1005 1 O
.	1006 1 O
)	1007 1 O
improves	1009 8 O
scopolamine	1018 11 B-Chemical
-	1029 1 O
induced	1030 7 O
amnesia	1038 7 B-Disease
but	1046 3 O
does	1050 4 O
not	1055 3 O
affect	1059 6 O
spontaneous	1066 11 O
movement	1078 8 O
.	1086 1 O

The	1088 3 O
findings	1092 8 O
suggest	1101 7 O
that	1109 4 O
NIK	1114 3 B-Chemical
-	1117 1 I-Chemical
247	1118 3 I-Chemical
may	1122 3 O
be	1126 2 O
a	1129 1 O
useful	1131 6 O
drug	1138 4 O
for	1143 3 O
the	1147 3 O
treatment	1151 9 O
of	1161 2 O
Alzheimer	1164 9 B-Disease
'	1173 1 I-Disease
s	1174 1 I-Disease
disease	1176 7 I-Disease
.	1183 1 O

Nightmares	0 10 O
and	11 3 O
hallucinations	15 14 B-Disease
after	30 5 O
long	36 4 O
-	40 1 O
term	41 4 O
intake	46 6 O
of	53 2 O
tramadol	56 8 B-Chemical
combined	65 8 O
with	74 4 O
antidepressants	79 15 O
.	94 1 O

Tramadol	96 8 B-Chemical
is	105 2 O
a	108 1 O
weak	110 4 O
opioid	115 6 O
with	122 4 O
effects	127 7 O
on	135 2 O
adrenergic	138 10 O
and	149 3 O
serotonergic	153 12 O
neurotransmission	166 17 O
that	184 4 O
is	189 2 O
used	192 4 O
to	197 2 O
treat	200 5 O
cancer	206 6 B-Disease
pain	213 4 B-Disease
and	218 3 O
chronic	222 7 O
non	230 3 O
malignant	234 9 O
pain	244 4 B-Disease
.	248 1 O

This	250 4 O
drug	255 4 O
was	260 3 O
initiated	264 9 O
in	274 2 O
association	277 11 O
with	289 4 O
paroxetine	294 10 B-Chemical
and	305 3 O
dosulepine	309 10 B-Chemical
hydrochloride	320 13 I-Chemical
in	334 2 O
a	337 1 O
tetraparetic	339 12 B-Disease
patient	352 7 O
with	360 4 O
chronic	365 7 B-Disease
pain	373 4 I-Disease
.	377 1 O

Fifty	379 5 O
-	384 1 O
six	385 3 O
days	389 4 O
after	394 5 O
initiation	400 10 O
of	411 2 O
the	414 3 O
treatment	418 9 O
the	428 3 O
patient	432 7 O
presented	440 9 O
hallucinations	450 14 B-Disease
that	465 4 O
only	470 4 O
stopped	475 7 O
after	483 5 O
the	489 3 O
withdrawal	493 10 O
of	504 2 O
psycho	507 6 O
-	513 1 O
active	514 6 O
drugs	521 5 O
and	527 3 O
tramadol	531 8 B-Chemical
.	539 1 O

The	541 3 O
case	545 4 O
report	550 6 O
questions	557 9 O
the	567 3 O
long	571 4 O
term	576 4 O
use	581 3 O
of	585 2 O
pain	588 4 B-Disease
killers	593 7 O
combined	601 8 O
with	610 4 O
psycho	615 6 O
-	621 1 O
active	622 6 O
drugs	629 5 O
in	635 2 O
chronic	638 7 O
non	646 3 O
malignant	650 9 O
pain	660 4 B-Disease
,	664 1 O
especially	666 10 O
if	677 2 O
pain	680 4 B-Disease
is	685 2 O
under	688 5 O
control	694 7 O
.	701 1 O

Apparent	0 8 O
cure	9 4 O
of	14 2 O
rheumatoid	17 10 B-Disease
arthritis	28 9 I-Disease
by	38 2 O
bone	41 4 O
marrow	46 6 O
transplantation	53 15 O
.	68 1 O

We	70 2 O
describe	73 8 O
the	82 3 O
induction	86 9 O
of	96 2 O
sustained	99 9 O
remissions	109 10 O
and	120 3 O
possible	124 8 O
cure	133 4 O
of	138 2 O
severe	141 6 O
erosive	148 7 O
rheumatoid	156 10 B-Disease
arthritis	167 9 I-Disease
(	177 1 O
RA	178 2 B-Disease
)	180 1 O
by	182 2 O
bone	185 4 O
marrow	190 6 O
transplantation	197 15 O
(	213 1 O
BMT	214 3 O
)	217 1 O
in	219 2 O
2	222 1 O
patients	224 8 O
.	232 1 O

BMT	234 3 O
was	238 3 O
used	242 4 O
to	247 2 O
treat	250 5 O
severe	256 6 O
aplastic	263 8 B-Disease
anemia	272 6 I-Disease
which	279 5 O
was	285 3 O
caused	289 6 O
by	296 2 O
gold	299 4 B-Chemical
in	304 2 O
one	307 3 O
case	311 4 O
and	316 3 O
D	320 1 B-Chemical
-	321 1 I-Chemical
penicillamine	322 13 I-Chemical
in	336 2 O
the	339 3 O
other	343 5 O
.	348 1 O

In	350 2 O
the	353 3 O
8	357 1 O
and	359 3 O
6	363 1 O
years	365 5 O
since	371 5 O
the	377 3 O
transplants	381 11 O
(	393 1 O
representing	394 12 O
8	407 1 O
and	409 3 O
4	413 1 O
years	415 5 O
since	421 5 O
cessation	427 9 O
of	437 2 O
all	440 3 O
immunosuppressive	444 17 O
therapy	462 7 O
,	469 1 O
respectively	471 12 O
)	483 1 O
,	484 1 O
the	486 3 O
RA	490 2 B-Disease
in	493 2 O
each	496 4 O
case	501 4 O
has	506 3 O
been	510 4 O
completely	515 10 O
quiescent	526 9 O
.	535 1 O

Although	537 8 O
short	546 5 O
term	552 4 O
remission	557 9 O
of	567 2 O
severe	570 6 O
RA	577 2 B-Disease
following	580 9 O
BMT	590 3 O
has	594 3 O
been	598 4 O
reported	603 8 O
,	611 1 O
these	613 5 O
are	619 3 O
the	623 3 O
first	627 5 O
cases	633 5 O
for	639 3 O
which	643 5 O
prolonged	649 9 O
followup	659 8 O
has	668 3 O
been	672 4 O
available	677 9 O
.	686 1 O

This	688 4 O
experience	693 10 O
raises	704 6 O
the	711 3 O
question	715 8 O
of	724 2 O
the	727 3 O
role	731 4 O
of	736 2 O
BMT	739 3 O
itself	743 6 O
as	750 2 O
a	753 1 O
therapeutic	755 11 O
option	767 6 O
for	774 3 O
patients	778 8 O
with	787 4 O
uncontrolled	792 12 O
destructive	805 11 O
synovitis	817 9 B-Disease
.	826 1 O

Urinary	0 7 O
enzymes	8 7 O
and	16 3 O
protein	20 7 O
patterns	28 8 O
as	37 2 O
indicators	40 10 O
of	51 2 O
injury	54 6 B-Disease
to	61 2 I-Disease
different	64 9 I-Disease
regions	74 7 I-Disease
of	82 2 I-Disease
the	85 3 I-Disease
kidney	89 6 I-Disease
.	95 1 O

Acute	97 5 B-Disease
experimental	103 12 I-Disease
models	116 6 I-Disease
of	123 2 I-Disease
renal	126 5 I-Disease
damage	132 6 I-Disease
to	139 2 O
the	142 3 O
proximal	146 8 O
tubular	155 7 O
,	162 1 O
glomerular	164 10 O
,	174 1 O
and	176 3 O
papillary	180 9 O
regions	190 7 O
of	198 2 O
the	201 3 O
rat	205 3 O
were	209 4 O
produced	214 8 O
by	223 2 O
administration	226 14 O
of	241 2 O
hexachloro	244 10 B-Chemical
-	254 1 I-Chemical
1	255 1 I-Chemical
:	256 1 I-Chemical
3	257 1 I-Chemical
-	258 1 I-Chemical
butadiene	259 9 I-Chemical
(	269 1 O
HCBD	270 4 B-Chemical
)	274 1 O
,	275 1 O
puromycin	277 9 B-Chemical
aminonucleoside	287 15 I-Chemical
(	303 1 O
PAN	304 3 B-Chemical
)	307 1 O
,	308 1 O
and	310 3 O
2	314 1 B-Chemical
-	315 1 I-Chemical
bromoethylamine	316 15 I-Chemical
(	332 1 O
BEA	333 3 B-Chemical
)	336 1 O
,	337 1 O
respectively	339 12 O
.	351 1 O

Several	353 7 O
routine	361 7 O
indicators	369 10 O
of	380 2 O
nephrotoxicity	383 14 B-Disease
,	397 1 O
the	399 3 O
enzymes	403 7 O
alkaline	411 8 O
phosphatase	420 11 O
and	432 3 O
N	436 1 O
-	437 1 O
acetyl	438 6 O
-	444 1 O
beta	445 4 O
-	449 1 O
glucosaminidase	450 15 O
,	465 1 O
and	467 3 O
the	471 3 O
molecular	475 9 O
weight	485 6 O
of	492 2 O
protein	495 7 B-Disease
excretion	503 9 I-Disease
were	513 4 O
determined	518 10 O
on	529 2 O
urine	532 5 O
samples	538 7 O
.	545 1 O

Tubular	547 7 O
damage	555 6 O
produced	562 8 O
by	571 2 O
HCBD	574 4 B-Chemical
or	579 2 O
BEA	582 3 B-Chemical
was	586 3 O
discriminated	590 13 O
both	604 4 O
quantitatively	609 14 O
and	624 3 O
qualitatively	628 13 O
from	642 4 O
glomerular	647 10 B-Disease
damage	658 6 I-Disease
produced	665 8 O
by	674 2 O
PAN	677 3 B-Chemical
.	680 1 O

The	682 3 O
latter	686 6 O
was	693 3 O
characterized	697 13 O
by	711 2 O
a	714 1 O
pronounced	716 10 O
increase	727 8 O
in	736 2 O
protein	739 7 B-Disease
excretion	747 9 I-Disease
,	756 1 O
especially	758 10 O
proteins	769 8 O
with	778 4 O
molecular	783 9 O
weight	793 6 O
greater	800 7 O
than	808 4 O
40	813 2 O
,	815 1 O
000	816 3 O
Da	820 2 O
.	822 1 O

In	824 2 O
contrast	827 8 O
,	835 1 O
protein	837 7 B-Disease
excretion	845 9 I-Disease
in	855 2 O
tubular	858 7 O
damage	866 6 O
was	873 3 O
raised	877 6 O
only	884 4 O
slightly	889 8 O
and	898 3 O
characterized	902 13 O
by	916 2 O
excretion	919 9 B-Disease
of	929 2 I-Disease
proteins	932 8 I-Disease
of	941 2 O
a	944 1 O
wide	946 4 O
range	951 5 O
of	957 2 O
molecular	960 9 O
weights	970 7 O
.	977 1 O

Proximal	979 8 O
tubular	988 7 O
damage	996 6 O
caused	1003 6 O
by	1010 2 O
HCBD	1013 4 B-Chemical
and	1018 3 O
papillary	1022 9 O
damage	1032 6 O
caused	1039 6 O
by	1046 2 O
BEA	1049 3 B-Chemical
were	1053 4 O
distinguished	1058 13 O
both	1072 4 O
by	1077 2 O
conventional	1080 12 O
urinalysis	1093 10 O
(	1104 1 O
volume	1105 6 O
and	1112 3 O
specific	1116 8 O
gravity	1125 7 O
)	1132 1 O
and	1134 3 O
by	1138 2 O
measurement	1141 11 O
of	1153 2 O
the	1156 3 O
two	1160 3 O
urinary	1164 7 O
enzymes	1172 7 O
.	1179 1 O

Alkaline	1181 8 O
phosphatase	1190 11 O
and	1202 3 O
glucose	1206 7 B-Chemical
were	1214 4 O
markedly	1219 8 O
and	1228 3 O
transiently	1232 11 O
elevated	1244 8 O
in	1253 2 O
proximal	1256 8 O
tubular	1265 7 O
damage	1273 6 O
and	1280 3 O
N	1284 1 O
-	1285 1 O
acetyl	1286 6 O
-	1292 1 O
beta	1293 4 O
-	1297 1 O
glucosaminidase	1298 15 O
showed	1314 6 O
a	1321 1 O
sustained	1323 9 O
elevation	1333 9 O
in	1343 2 O
papillary	1346 9 O
damage	1356 6 O
.	1362 1 O

It	1364 2 O
is	1367 2 O
concluded	1370 9 O
that	1380 4 O
both	1385 4 O
selective	1390 9 O
urinary	1400 7 O
enzymes	1408 7 O
and	1416 3 O
the	1420 3 O
molecular	1424 9 O
weight	1434 6 O
pattern	1441 7 O
of	1449 2 O
urinary	1452 7 O
proteins	1460 8 O
can	1469 3 O
be	1473 2 O
used	1476 4 O
to	1481 2 O
provide	1484 7 O
diagnostic	1492 10 O
information	1503 11 O
about	1515 5 O
the	1521 3 O
possible	1525 8 O
site	1534 4 O
of	1539 2 O
renal	1542 5 B-Disease
damage	1548 6 I-Disease
.	1554 1 O

Neuromuscular	0 13 B-Disease
blockade	14 8 I-Disease
with	23 4 O
magnesium	28 9 B-Chemical
sulfate	38 7 I-Chemical
and	46 3 O
nifedipine	50 10 B-Chemical
.	60 1 O

A	62 1 O
patient	64 7 O
who	72 3 O
received	76 8 O
tocolysis	85 9 O
with	95 4 O
nifedipine	100 10 B-Chemical
developed	111 9 O
neuromuscular	121 13 B-Disease
blockade	135 8 I-Disease
after	144 5 O
500	150 3 O
mg	154 2 O
of	157 2 O
magnesium	160 9 B-Chemical
sulfate	170 7 I-Chemical
was	178 3 O
administered	182 12 O
.	194 1 O

This	196 4 O
reaction	201 8 O
demonstrates	210 12 O
that	223 4 O
nifedipine	228 10 B-Chemical
can	239 3 O
seriously	243 9 O
potentiate	253 10 O
the	264 3 O
toxicity	268 8 B-Disease
of	277 2 O
magnesium	280 9 B-Chemical
.	289 1 O

Caution	291 7 O
should	299 6 O
be	306 2 O
exercised	309 9 O
when	319 4 O
these	324 5 O
two	330 3 O
tocolytics	334 10 O
are	345 3 O
combined	349 8 O
.	357 1 O

Ifosfamide	0 10 B-Chemical
continuous	11 10 O
infusion	22 8 O
without	31 7 O
mesna	39 5 B-Chemical
.	44 1 O

A	46 1 O
phase	48 5 O
I	54 1 O
trial	56 5 O
of	62 2 O
a	65 1 O
14	67 2 O
-	69 1 O
day	70 3 O
cycle	74 5 O
.	79 1 O

Twenty	81 6 O
patients	88 8 O
received	97 8 O
27	106 2 O
courses	109 7 O
of	117 2 O
ifosfamide	120 10 B-Chemical
administered	131 12 O
as	144 2 O
a	147 1 O
24	149 2 O
-	151 1 O
hour	152 4 O
continuous	157 10 O
infusion	168 8 O
for	177 3 O
14	181 2 O
days	184 4 O
without	189 7 O
Mesna	197 5 B-Chemical
.	202 1 O

The	204 3 O
goal	208 4 O
of	213 2 O
the	216 3 O
study	220 5 O
was	226 3 O
to	230 2 O
deliver	233 7 O
a	241 1 O
dose	243 4 O
rate	248 4 O
and	253 3 O
total	257 5 O
cumulative	263 10 O
dose	274 4 O
of	279 2 O
ifosfamide	282 10 B-Chemical
that	293 4 O
would	298 5 O
be	304 2 O
comparable	307 10 O
to	318 2 O
standard	321 8 O
bolus	330 5 O
or	336 2 O
short	339 5 O
-	344 1 O
term	345 4 O
infusions	350 9 O
administered	360 12 O
with	373 4 O
Mesna	378 5 B-Chemical
.	383 1 O

Dose	385 4 O
escalations	390 11 O
proceeded	402 9 O
from	412 4 O
200	417 3 O
to	421 2 O
300	424 3 O
,	427 1 O
400	429 3 O
,	432 1 O
450	434 3 O
,	437 1 O
500	439 3 O
,	442 1 O
and	444 3 O
550	448 3 O
mg	452 2 O
/	454 1 O
m2	455 2 O
/	457 1 O
d	458 1 O
.	459 1 O

Four	461 4 O
patients	466 8 O
developed	475 9 O
transient	485 9 O
microscopic	495 11 O
hematuria	507 9 B-Disease
at	517 2 O
400	520 3 O
,	523 1 O
450	525 3 O
,	528 1 O
and	530 3 O
500	534 3 O
mg	538 2 O
/	540 1 O
m2	541 2 O
/	543 1 O
d	544 1 O
.	545 1 O

There	547 5 O
were	553 4 O
no	558 2 O
instances	561 9 O
of	571 2 O
macroscopic	574 11 O
hematuria	586 9 B-Disease
.	595 1 O

At	597 2 O
550	600 3 O
mg	604 2 O
/	606 1 O
m2	607 2 O
/	609 1 O
d	610 1 O
,	611 1 O
three	613 5 O
patients	619 8 O
experienced	628 11 O
nonurologic	640 11 O
toxicity	652 8 B-Disease
;	660 1 O
confusion	662 9 B-Disease
(	672 1 O
1	673 1 O
)	674 1 O
,	675 1 O
nausea	677 6 B-Disease
(	684 1 O
1	685 1 O
)	686 1 O
,	687 1 O
and	689 3 O
Grade	693 5 O
2	699 1 O
leukopenia	701 10 B-Disease
(	712 1 O
1	713 1 O
)	714 1 O
.	715 1 O

The	717 3 O
recommended	721 11 O
dose	733 4 O
of	738 2 O
500	741 3 O
mg	745 2 O
/	747 1 O
m2	748 2 O
/	750 1 O
d	751 1 O
delivers	753 8 O
a	762 1 O
total	764 5 O
dose	770 4 O
of	775 2 O
7	778 1 O
g	780 1 O
/	781 1 O
m2	782 2 O
per	785 3 O
cycle	789 5 O
,	794 1 O
which	796 5 O
is	802 2 O
comparable	805 10 O
to	816 2 O
that	819 4 O
delivered	824 9 O
in	834 2 O
clinical	837 8 O
practice	846 8 O
for	855 3 O
bolus	859 5 O
or	865 2 O
short	868 5 O
-	873 1 O
term	874 4 O
infusion	879 8 O
.	887 1 O

Because	889 7 O
few	897 3 O
patients	901 8 O
received	910 8 O
multiple	919 8 O
courses	928 7 O
over	936 4 O
time	941 4 O
,	945 1 O
the	947 3 O
cumulative	951 10 O
effects	962 7 O
are	970 3 O
indeterminate	974 13 O
in	988 2 O
the	991 3 O
present	995 7 O
trial	1003 5 O
.	1008 1 O

The	1010 3 O
frequency	1014 9 O
and	1024 3 O
predictability	1028 14 O
of	1043 2 O
hematuria	1046 9 B-Disease
are	1056 3 O
not	1060 3 O
precise	1064 7 O
,	1071 1 O
and	1073 3 O
at	1077 2 O
least	1080 5 O
daily	1086 5 O
monitoring	1092 10 O
by	1103 2 O
urine	1106 5 O
Hematest	1112 8 O
is	1121 2 O
essential	1124 9 O
,	1133 1 O
adding	1135 6 O
Mesna	1142 5 B-Chemical
to	1148 2 O
the	1151 3 O
infusate	1155 8 O
in	1164 2 O
patients	1167 8 O
with	1176 4 O
persistent	1181 10 O
hematuria	1192 9 B-Disease
.	1201 1 O

The	1203 3 O
protracted	1207 10 O
infusion	1218 8 O
schedule	1227 8 O
for	1236 3 O
ifosfamide	1240 10 B-Chemical
permits	1251 7 O
convenient	1259 10 O
outpatient	1270 10 O
administration	1281 14 O
without	1296 7 O
Mesna	1304 5 B-Chemical
and	1310 3 O
reduces	1314 7 O
the	1322 3 O
drug	1326 4 O
cost	1331 4 O
of	1336 2 O
clinical	1339 8 O
usage	1348 5 O
of	1354 2 O
this	1357 4 O
agent	1362 5 O
by	1368 2 O
up	1371 2 O
to	1374 2 O
890	1378 3 O
per	1382 3 O
cycle	1386 5 O
.	1391 1 O

Clinical	1393 8 O
activity	1402 8 O
was	1411 3 O
demonstrated	1415 12 O
in	1428 2 O
a	1431 1 O
single	1433 6 O
patient	1440 7 O
,	1447 1 O
but	1449 3 O
a	1453 1 O
comparative	1455 11 O
trial	1467 5 O
of	1473 2 O
standard	1476 8 O
bolus	1485 5 O
schedules	1491 9 O
with	1501 4 O
the	1506 3 O
protracted	1510 10 O
infusion	1521 8 O
schedule	1530 8 O
will	1539 4 O
be	1544 2 O
necessary	1547 9 O
to	1557 2 O
determine	1560 9 O
if	1570 2 O
the	1573 3 O
clinical	1577 8 O
effectiveness	1586 13 O
of	1600 2 O
the	1603 3 O
drug	1607 4 O
is	1612 2 O
maintained	1615 10 O
.	1625 1 O

Myocardial	0 10 B-Disease
infarction	11 10 I-Disease
in	22 2 O
pregnancy	25 9 O
associated	35 10 O
with	46 4 O
clomiphene	51 10 B-Chemical
citrate	62 7 I-Chemical
for	70 3 O
ovulation	74 9 O
induction	84 9 O
:	93 1 O
a	95 1 O
case	97 4 O
report	102 6 O
.	108 1 O

BACKGROUND	110 10 O
:	120 1 O
Clomiphene	122 10 B-Chemical
citrate	133 7 I-Chemical
(	141 1 O
CC	142 2 B-Chemical
)	144 1 O
is	146 2 O
commonly	149 8 O
prescribed	158 10 O
for	169 3 O
ovulation	173 9 O
induction	183 9 O
.	192 1 O

It	194 2 O
is	197 2 O
considered	200 10 O
safe	211 4 O
,	215 1 O
with	217 4 O
minimal	222 7 O
side	230 4 O
effects	235 7 O
.	242 1 O

Thromboembolism	244 15 B-Disease
is	260 2 O
a	263 1 O
rare	265 4 O
but	270 3 O
life	274 4 O
-	278 1 O
threatening	279 11 O
complication	291 12 O
that	304 4 O
has	309 3 O
been	313 4 O
reported	318 8 O
after	327 5 O
ovulation	333 9 O
induction	343 9 O
with	353 4 O
CC	358 2 B-Chemical
.	360 1 O

Spontaneous	362 11 O
coronary	374 8 B-Disease
thrombosis	383 10 I-Disease
or	394 2 O
thromboembolism	397 15 B-Disease
with	413 4 O
subsequent	418 10 O
clot	429 4 O
lysis	434 5 O
has	440 3 O
been	444 4 O
suggested	449 9 O
as	459 2 O
one	462 3 O
of	466 2 O
the	469 3 O
most	473 4 O
common	478 6 O
causes	485 6 O
of	492 2 O
myocardial	495 10 B-Disease
infarction	506 10 I-Disease
(	517 1 O
MI	518 2 B-Disease
)	520 1 O
during	522 6 O
pregnancy	529 9 O
,	538 1 O
with	540 4 O
a	545 1 O
subsequently	547 12 O
normal	560 6 O
coronary	567 8 O
angiogram	576 9 O
.	585 1 O

CASE	587 4 O
:	591 1 O
A	593 1 O
33	595 2 O
-	597 1 O
year	598 4 O
-	602 1 O
old	603 3 O
woman	607 5 O
with	613 4 O
a	618 1 O
5	620 1 O
-	621 1 O
week	622 4 O
gestation	627 9 O
had	637 3 O
recently	641 8 O
received	650 8 O
CC	659 2 B-Chemical
for	662 3 O
ovulation	666 9 O
induction	676 9 O
and	686 3 O
presented	690 9 O
with	700 4 O
chest	705 5 B-Disease
pain	711 4 I-Disease
.	715 1 O

An	717 2 O
electrocardiogram	720 17 O
showed	738 6 O
a	745 1 O
lateral	747 7 O
and	755 3 O
anterior	759 8 O
wall	768 4 O
myocardial	773 10 B-Disease
infarction	784 10 I-Disease
.	794 1 O

Cardiac	796 7 O
enzymes	804 7 O
showed	812 6 O
a	819 1 O
peak	821 4 O
rise	826 4 O
in	831 2 O
troponin	834 8 O
I	843 1 O
to	845 2 O
9	848 1 O
.	849 1 O
10	850 2 O
ng	853 2 O
/	855 1 O
mL	856 2 O
.	858 1 O

An	860 2 O
initial	863 7 O
exercise	871 8 O
stress	880 6 O
test	887 4 O
was	892 3 O
normal	896 6 O
.	902 1 O

At	904 2 O
the	907 3 O
time	911 4 O
of	916 2 O
admission	919 9 O
,	928 1 O
the	930 3 O
patient	934 7 O
was	942 3 O
at	946 2 O
high	949 4 O
risk	954 4 O
of	959 2 O
radiation	962 9 B-Disease
injury	972 6 I-Disease
to	979 2 O
the	982 3 O
fetus	986 5 O
,	991 1 O
so	993 2 O
a	996 1 O
coronary	998 8 O
angiogram	1007 9 O
was	1017 3 O
postponed	1021 9 O
until	1031 5 O
the	1037 3 O
second	1041 6 O
trimester	1048 9 O
.	1057 1 O

It	1059 2 O
showed	1062 6 O
normal	1069 6 O
coronary	1076 8 O
vessels	1085 7 O
.	1092 1 O

CONCLUSION	1094 10 O
:	1104 1 O
This	1106 4 O
appears	1111 7 O
to	1119 2 O
be	1122 2 O
the	1125 3 O
first	1129 5 O
reported	1135 8 O
case	1144 4 O
documenting	1149 11 O
a	1161 1 O
possible	1163 8 O
association	1172 11 O
between	1184 7 O
CC	1192 2 B-Chemical
and	1195 3 O
myocardial	1199 10 B-Disease
infarction	1210 10 I-Disease
.	1220 1 O

Thrombosis	1222 10 B-Disease
might	1233 5 O
be	1239 2 O
a	1242 1 O
rare	1244 4 O
but	1249 3 O
hazardous	1253 9 O
complication	1263 12 O
of	1276 2 O
CC	1279 2 B-Chemical
.	1281 1 O

Given	1283 5 O
this	1289 4 O
life	1294 4 O
-	1298 1 O
threatening	1299 11 O
complication	1311 12 O
,	1323 1 O
appropriate	1325 11 O
prophylactic	1337 12 O
measures	1350 8 O
should	1359 6 O
be	1366 2 O
used	1369 4 O
in	1374 2 O
high	1377 4 O
-	1381 1 O
risk	1382 4 O
woman	1387 5 O
undergoing	1393 10 O
ovarian	1404 7 O
stimulation	1412 11 O
.	1423 1 O

Hepatonecrosis	0 14 B-Disease
and	15 3 O
cholangitis	19 11 B-Disease
related	31 7 O
to	39 2 O
long	42 4 O
-	46 1 O
term	47 4 O
phenobarbital	52 13 B-Chemical
therapy	66 7 O
:	73 1 O
an	75 2 O
autopsy	78 7 O
report	86 6 O
of	93 2 O
two	96 3 O
patients	100 8 O
.	108 1 O

Phenobarbital	110 13 B-Chemical
(	124 1 O
PB	125 2 B-Chemical
)	127 1 O
has	129 3 O
a	133 1 O
reputation	135 10 O
for	146 3 O
safety	150 6 O
,	156 1 O
and	158 3 O
it	162 2 O
is	165 2 O
commonly	168 8 O
believed	177 8 O
that	186 4 O
PB	191 2 B-Chemical
-	193 1 O
related	194 7 O
increases	202 9 O
in	212 2 O
serum	215 5 O
aminotransferase	221 16 O
levels	238 6 O
do	245 2 O
not	248 3 O
indicate	252 8 O
or	261 2 O
predict	264 7 O
the	272 3 O
development	276 11 O
of	288 2 O
significant	291 11 O
chronic	303 7 O
liver	311 5 B-Disease
disease	317 7 I-Disease
.	324 1 O

Here	326 4 O
we	331 2 O
report	334 6 O
of	341 2 O
two	344 3 O
adult	348 5 O
patients	354 8 O
with	363 4 O
a	368 1 O
long	370 4 O
history	375 7 O
of	383 2 O
epilepsy	386 8 B-Disease
treated	395 7 O
with	403 4 O
PB	408 2 B-Chemical
who	411 3 O
died	415 4 O
suddenly	420 8 O
:	428 1 O
one	430 3 O
as	434 2 O
consequence	437 11 O
of	449 2 O
cardiac	452 7 B-Disease
arrest	460 6 I-Disease
,	466 1 O
the	468 3 O
other	472 5 O
of	478 2 O
acute	481 5 O
bronchopneumonia	487 16 B-Disease
.	503 1 O

At	505 2 O
autopsy	508 7 O
,	515 1 O
analysis	517 8 O
of	526 2 O
liver	529 5 O
parenchyma	535 10 O
revealed	546 8 O
rich	555 4 O
portal	560 6 O
inflammatory	567 12 O
infiltrate	580 10 O
,	590 1 O
which	592 5 O
consisted	598 9 O
of	608 2 O
mixed	611 5 O
eosinophil	617 10 O
and	628 3 O
monocyte	632 8 O
cells	641 5 O
,	646 1 O
associated	648 10 O
with	659 4 O
several	664 7 O
foci	672 4 O
of	677 2 O
necrosis	680 8 B-Disease
surrounded	689 10 O
by	700 2 O
a	703 1 O
hard	705 4 O
ring	710 4 O
of	715 2 O
non	718 3 O
-	721 1 O
specific	722 8 O
granulomatous	731 13 O
tissue	745 6 O
.	751 1 O

Inflammatory	753 12 O
reactions	766 9 O
of	776 2 O
internal	779 8 O
and	788 3 O
external	792 8 O
hepatic	801 7 O
biliary	809 7 O
ducts	817 5 O
were	823 4 O
also	828 4 O
seen	833 4 O
.	837 1 O

Our	839 3 O
findings	843 8 O
illustrate	852 10 O
that	863 4 O
PB	868 2 B-Chemical
may	871 3 O
be	875 2 O
associated	878 10 O
with	889 4 O
chronic	894 7 O
liver	902 5 B-Disease
damage	908 6 I-Disease
,	914 1 O
which	916 5 O
may	922 3 O
lead	926 4 O
to	931 2 O
more	934 4 O
serious	939 7 O
and	947 3 O
deleterious	951 11 O
consequences	963 12 O
.	975 1 O

For	977 3 O
this	981 4 O
reason	986 6 O
,	992 1 O
each	994 4 O
clinician	999 9 O
should	1009 6 O
recognize	1016 9 O
this	1026 4 O
entity	1031 6 O
in	1038 2 O
the	1041 3 O
differential	1045 12 O
diagnosis	1058 9 O
of	1068 2 O
PB	1071 2 B-Chemical
-	1073 1 O
related	1074 7 O
asymptomatic	1082 12 O
chronic	1095 7 B-Disease
hepatic	1103 7 I-Disease
enzyme	1111 6 I-Disease
dysfunction	1118 11 I-Disease
.	1129 1 O

Ethambutol	0 10 B-Chemical
-	10 1 O
associated	11 10 O
optic	22 5 B-Disease
neuropathy	28 10 I-Disease
.	38 1 O

INTRODUCTION	40 12 O
:	52 1 O
Ethambutol	54 10 B-Chemical
is	65 2 O
used	68 4 O
in	73 2 O
the	76 3 O
treatment	80 9 O
of	90 2 O
tuberculosis	93 12 B-Disease
,	105 1 O
which	107 5 O
is	113 2 O
still	116 5 O
prevalent	122 9 O
in	132 2 O
Southeast	135 9 O
Asia	145 4 O
,	149 1 O
and	151 3 O
can	155 3 O
be	159 2 O
associated	162 10 O
with	173 4 O
permanent	178 9 O
visual	188 6 B-Disease
loss	195 4 I-Disease
.	199 1 O

We	201 2 O
report	204 6 O
3	211 1 O
cases	213 5 O
which	219 5 O
presented	225 9 O
with	235 4 O
bitemporal	240 10 B-Disease
hemianopia	251 10 I-Disease
.	261 1 O

CLINICAL	263 8 O
PICTURE	272 7 O
:	279 1 O
Three	281 5 O
patients	287 8 O
with	296 4 O
ethambutol	301 10 B-Chemical
-	311 1 O
associated	312 10 O
toxic	323 5 O
optic	329 5 B-Disease
neuropathy	335 10 I-Disease
are	346 3 O
described	350 9 O
.	359 1 O

All	361 3 O
3	365 1 O
patients	367 8 O
had	376 3 O
loss	380 4 B-Disease
of	385 2 I-Disease
central	388 7 I-Disease
visual	396 6 I-Disease
acuity	403 6 I-Disease
,	409 1 I-Disease
colour	411 6 I-Disease
vision	418 6 I-Disease
(	425 1 I-Disease
Ishihara	426 8 I-Disease
)	434 1 I-Disease
and	436 3 I-Disease
visual	440 6 I-Disease
field	447 5 I-Disease
.	452 1 O

The	454 3 O
visual	458 6 B-Disease
field	465 5 I-Disease
loss	471 4 I-Disease
had	476 3 O
a	480 1 O
bitemporal	482 10 O
flavour	493 7 O
,	500 1 O
suggesting	502 10 O
involvement	513 11 O
of	525 2 O
the	528 3 O
optic	532 5 O
chiasm	538 6 O
.	544 1 O

TREATMENT	546 9 O
:	555 1 O
Despite	557 7 O
stopping	565 8 O
ethambutol	574 10 B-Chemical
on	585 2 O
diagnosis	588 9 O
,	597 1 O
visual	599 6 O
function	606 8 O
continued	615 9 O
to	625 2 O
deteriorate	628 11 O
for	640 3 O
a	644 1 O
few	646 3 O
months	650 6 O
.	656 1 O

Subsequent	658 10 O
improvement	669 11 O
was	681 3 O
mild	685 4 O
in	690 2 O
2	693 1 O
cases	695 5 O
.	700 1 O

In	702 2 O
the	705 3 O
third	709 5 O
case	715 4 O
,	719 1 O
visual	721 6 O
acuity	728 6 O
and	735 3 O
colour	739 6 O
vision	746 6 O
normalised	753 10 O
but	764 3 O
the	768 3 O
optic	772 5 O
discs	778 5 O
were	784 4 O
pale	789 4 O
.	793 1 O

OUTCOME	795 7 O
:	802 1 O
All	804 3 O
3	808 1 O
patients	810 8 O
had	819 3 O
some	823 4 O
permanent	828 9 O
loss	838 4 B-Disease
of	843 2 I-Disease
visual	846 6 I-Disease
function	853 8 I-Disease
.	861 1 O

CONCLUSIONS	863 11 O
:	874 1 O
Ethambutol	876 10 B-Chemical
usage	887 5 O
is	893 2 O
associated	896 10 O
with	907 4 O
permanent	912 9 O
visual	922 6 B-Disease
loss	929 4 I-Disease
and	934 3 O
should	938 6 O
be	945 2 O
avoided	948 7 O
if	956 2 O
possible	959 8 O
or	968 2 O
used	971 4 O
with	976 4 O
caution	981 7 O
and	989 3 O
proper	993 6 O
ophthalmological	1000 16 O
follow	1017 6 O
-	1023 1 O
up	1024 2 O
.	1026 1 O

The	1028 3 O
author	1032 6 O
postulates	1039 10 O
that	1050 4 O
in	1055 2 O
cases	1058 5 O
of	1064 2 O
ethambutol	1067 10 B-Chemical
associated	1078 10 O
chiasmopathy	1089 12 O
,	1101 1 O
ethambutol	1103 10 B-Chemical
may	1114 3 O
initially	1118 9 O
affect	1128 6 O
the	1135 3 O
optic	1139 5 O
nerves	1145 6 O
and	1152 3 O
subsequently	1156 12 O
progress	1169 8 O
to	1178 2 O
involve	1181 7 O
the	1189 3 O
optic	1193 5 O
chiasm	1199 6 O
.	1205 1 O

Tolerability	0 12 O
of	13 2 O
nimesulide	16 10 B-Chemical
and	27 3 O
paracetamol	31 11 B-Chemical
in	43 2 O
patients	46 8 O
with	55 4 O
NSAID	60 5 B-Chemical
-	65 1 O
induced	66 7 O
urticaria	74 9 B-Disease
/	83 1 O
angioedema	84 10 B-Disease
.	94 1 O

Previous	96 8 O
studies	105 7 O
evaluated	113 9 O
the	123 3 O
tolerance	127 9 O
of	137 2 O
nimesulide	140 10 B-Chemical
and	151 3 O
paracetamol	155 11 B-Chemical
in	167 2 O
subjects	170 8 O
with	179 4 O
cutaneous	184 9 O
,	193 1 O
respiratory	195 11 O
and	207 3 O
anaphylactoid	211 13 O
reactions	225 9 O
induced	235 7 O
by	243 2 O
nonsteroidal	246 12 B-Chemical
anti	259 4 I-Chemical
-	263 1 I-Chemical
inflammatory	264 12 I-Chemical
drugs	277 5 I-Chemical
(	283 1 O
NSAIDs	284 6 B-Chemical
)	290 1 O
.	291 1 O

In	293 2 O
this	296 4 O
study	301 5 O
we	307 2 O
investigated	310 12 O
tolerability	323 12 O
and	336 3 O
reliability	340 11 O
of	352 2 O
nimesulide	355 10 B-Chemical
and	366 3 O
paracetamol	370 11 B-Chemical
in	382 2 O
a	385 1 O
very	387 4 O
large	392 5 O
number	398 6 O
of	405 2 O
patients	408 8 O
with	417 4 O
an	422 2 O
exclusive	425 9 O
well	435 4 O
-	439 1 O
documented	440 10 O
history	451 7 O
of	459 2 O
NSAID	462 5 B-Chemical
-	467 1 O
induced	468 7 O
urticaria	476 9 B-Disease
/	485 1 O
angioedema	486 10 B-Disease
.	496 1 O

Furthermore	498 11 O
,	509 1 O
we	511 2 O
evaluated	514 9 O
whether	524 7 O
some	532 4 O
factors	537 7 O
have	545 4 O
the	550 3 O
potential	554 9 O
to	564 2 O
increase	567 8 O
the	576 3 O
risk	580 4 O
of	585 2 O
reaction	588 8 O
to	597 2 O
paracetamol	600 11 B-Chemical
and	612 3 O
nimesulide	616 10 B-Chemical
.	626 1 O

A	628 1 O
single	630 6 O
-	636 1 O
placebo	637 7 O
-	644 1 O
controlled	645 10 O
oral	656 4 O
challenge	661 9 O
procedure	671 9 O
with	681 4 O
nimesulide	686 10 B-Chemical
or	697 2 O
paracetamol	700 11 B-Chemical
was	712 3 O
applied	716 7 O
to	724 2 O
829	727 3 O
patients	731 8 O
with	740 4 O
a	745 1 O
history	747 7 O
of	755 2 O
NSAID	758 5 B-Chemical
-	763 1 O
induced	764 7 O
urticaria	772 9 B-Disease
/	781 1 O
angioedema	782 10 B-Disease
.	792 1 O

A	794 1 O
total	796 5 O
of	802 2 O
75	805 2 O
/	807 1 O
829	808 3 O
(	812 1 O
9	813 1 O
.	814 1 O
4	815 1 O
%	816 1 O
)	817 1 O
patients	819 8 O
experienced	828 11 O
reactions	840 9 O
to	850 2 O
nimesulide	853 10 B-Chemical
or	864 2 O
paracetamol	867 11 B-Chemical
.	878 1 O

Of	880 2 O
the	883 3 O
715	887 3 O
patients	891 8 O
tested	900 6 O
with	907 4 O
nimesulide	912 10 B-Chemical
62	923 2 O
(	926 1 O
8	927 1 O
.	928 1 O
6	929 1 O
%	930 1 O
)	931 1 O
showed	933 6 O
a	940 1 O
positive	942 8 O
test	951 4 O
,	955 1 O
while	957 5 O
of	963 2 O
114	966 3 O
subjects	970 8 O
submitted	979 9 O
to	989 2 O
the	992 3 O
challenge	996 9 O
with	1006 4 O
paracetamol	1011 11 B-Chemical
,	1022 1 O
13	1024 2 O
(	1027 1 O
9	1028 1 O
.	1029 1 O
6	1030 1 O
%	1031 1 O
)	1032 1 O
did	1034 3 O
not	1038 3 O
tolerate	1042 8 O
this	1051 4 O
drug	1056 4 O
.	1060 1 O

Furthermore	1062 11 O
,	1073 1 O
18	1075 2 O
.	1077 1 O
28	1078 2 O
%	1080 1 O
of	1082 2 O
patients	1085 8 O
with	1094 4 O
a	1099 1 O
history	1101 7 O
of	1109 2 O
chronic	1112 7 O
urticaria	1120 9 B-Disease
and	1130 3 O
11	1134 2 O
.	1136 1 O
8	1137 1 O
%	1138 1 O
of	1140 2 O
subjects	1143 8 O
with	1152 4 O
an	1157 2 O
history	1160 7 O
of	1168 2 O
NSAID	1171 5 B-Chemical
-	1176 1 O
induced	1177 7 O
urticaria	1185 9 B-Disease
/	1194 1 O
angioedema	1195 10 B-Disease
or	1206 2 O
angioedema	1209 10 B-Disease
alone	1220 5 O
(	1226 1 O
with	1227 4 O
or	1232 2 O
without	1235 7 O
chronic	1243 7 O
urticaria	1251 9 B-Disease
)	1260 1 O
resulted	1262 8 O
to	1271 2 O
be	1274 2 O
intolerant	1277 10 O
to	1288 2 O
alternative	1291 11 O
drugs	1303 5 O
.	1308 1 O

Taken	1310 5 O
together	1316 8 O
,	1324 1 O
our	1326 3 O
results	1330 7 O
confirm	1338 7 O
the	1346 3 O
good	1350 4 O
tolerability	1355 12 O
of	1368 2 O
nimesulide	1371 10 B-Chemical
and	1382 3 O
paracetamol	1386 11 B-Chemical
in	1398 2 O
patients	1401 8 O
who	1410 3 O
experienced	1414 11 O
urticaria	1426 9 B-Disease
/	1435 1 O
angioedema	1436 10 B-Disease
caused	1447 6 O
by	1454 2 O
NSAIDs	1457 6 B-Chemical
.	1463 1 O

However	1465 7 O
,	1472 1 O
the	1474 3 O
risk	1478 4 O
of	1483 2 O
reaction	1486 8 O
to	1495 2 O
these	1498 5 O
alternative	1504 11 O
study	1516 5 O
drugs	1522 5 O
is	1528 2 O
statistically	1531 13 O
increased	1545 9 O
by	1555 2 O
a	1558 1 O
history	1560 7 O
of	1568 2 O
chronic	1571 7 O
urticaria	1579 9 B-Disease
and	1589 3 O
,	1592 1 O
above	1594 5 O
all	1600 3 O
,	1603 1 O
by	1605 2 O
a	1608 1 O
history	1610 7 O
of	1618 2 O
NSAID	1621 5 B-Chemical
-	1626 1 O
induced	1627 7 O
angioedema	1635 10 B-Disease
.	1645 1 O

Effects	0 7 O
of	8 2 O
verapamil	11 9 B-Chemical
on	21 2 O
atrial	24 6 B-Disease
fibrillation	31 12 I-Disease
and	44 3 O
its	48 3 O
electrophysiological	52 20 O
determinants	73 12 O
in	86 2 O
dogs	89 4 O
.	93 1 O

BACKGROUND	95 10 O
:	105 1 O
Atrial	107 6 B-Disease
tachycardia	114 11 I-Disease
-	125 1 O
induced	126 7 O
remodeling	134 10 O
promotes	145 8 O
the	154 3 O
occurrence	158 10 O
and	169 3 O
maintenance	173 11 O
of	185 2 O
atrial	188 6 B-Disease
fibrillation	195 12 I-Disease
(	208 1 O
AF	209 2 B-Disease
)	211 1 O
and	213 3 O
decreases	217 9 O
L	227 1 O
-	228 1 O
type	229 4 O
Ca	234 2 B-Chemical
(	236 1 O
2	237 1 O
+	238 1 O
)	239 1 O
current	241 7 O
.	248 1 O

There	250 5 O
is	256 2 O
also	259 4 O
a	264 1 O
clinical	266 8 O
suggestion	275 10 O
that	286 4 O
acute	291 5 O
L	297 1 O
-	298 1 O
type	299 4 O
Ca	304 2 B-Chemical
(	306 1 O
2	307 1 O
)	308 1 O
channel	310 7 O
blockade	318 8 O
can	327 3 O
promote	331 7 O
AF	339 2 B-Disease
,	341 1 O
consistent	343 10 O
with	354 4 O
an	359 2 O
AF	362 2 B-Disease
promoting	365 9 O
effect	375 6 O
of	382 2 O
Ca	385 2 B-Chemical
(	387 1 O
2	388 1 O
+	389 1 O
)	390 1 O
channel	392 7 O
inhibition	400 10 O
.	410 1 O

METHODS	412 7 O
:	419 1 O
To	421 2 O
evaluate	424 8 O
the	433 3 O
potential	437 9 O
mechanisms	447 10 O
of	458 2 O
AF	461 2 B-Disease
promotion	464 9 O
by	474 2 O
Ca	477 2 B-Chemical
(	479 1 O
2	480 1 O
+	481 1 O
)	482 1 O
channel	484 7 O
blockers	492 8 O
,	500 1 O
we	502 2 O
administered	505 12 O
verapamil	518 9 B-Chemical
to	528 2 O
morphine	531 8 B-Chemical
-	539 1 O
chloralose	540 10 B-Chemical
anesthetized	551 12 O
dogs	564 4 O
.	568 1 O

Diltiazem	570 9 B-Chemical
was	580 3 O
used	584 4 O
as	589 2 O
a	592 1 O
comparison	594 10 O
drug	605 4 O
and	610 3 O
autonomic	614 9 O
blockade	624 8 O
with	633 4 O
atropine	638 8 B-Chemical
and	647 3 O
nadolol	651 7 B-Chemical
was	659 3 O
applied	663 7 O
in	671 2 O
some	674 4 O
experiments	679 11 O
.	690 1 O

Epicardial	692 10 O
mapping	703 7 O
with	711 4 O
240	716 3 O
epicardial	720 10 O
electrodes	731 10 O
was	742 3 O
used	746 4 O
to	751 2 O
evaluate	754 8 O
activation	763 10 O
during	774 6 O
AF	781 2 B-Disease
.	783 1 O

RESULTS	785 7 O
:	792 1 O
Verapamil	794 9 B-Chemical
caused	804 6 O
AF	811 2 B-Disease
promotion	814 9 O
in	824 2 O
six	827 3 O
dogs	831 4 O
,	835 1 O
increasing	837 10 O
mean	848 4 O
duration	853 8 O
of	862 2 O
AF	865 2 B-Disease
induced	868 7 O
by	876 2 O
burst	879 5 O
pacing	885 6 O
,	891 1 O
from	893 4 O
8	898 1 O
+	899 1 O
/	900 1 O
-	901 1 O
4	902 1 O
s	904 1 O
(	906 1 O
mean	907 4 O
+	911 1 O
/	912 1 O
-	913 1 O
S	914 1 O
.	915 1 O
E	916 1 O
.	917 1 O
)	918 1 O
to	920 2 O
95	923 2 O
+	925 1 O
/	926 1 O
-	927 1 O
39	928 2 O
s	931 1 O
(	933 1 O
P	934 1 O
<	935 1 O
0	936 1 O
.	937 1 O
01	938 2 O
vs	941 2 O
.	943 1 O
control	945 7 O
)	952 1 O
at	954 2 O
a	957 1 O
loading	959 7 O
dose	967 4 O
of	972 2 O
0	975 1 O
.	976 1 O
1	977 1 O
mg	979 2 O
/	981 1 O
kg	982 2 O
and	985 3 O
228	989 3 O
+	992 1 O
/	993 1 O
-	994 1 O
101	995 3 O
s	999 1 O
(	1001 1 O
P	1002 1 O
<	1003 1 O
0	1004 1 O
.	1005 1 O
0005	1006 4 O
vs	1011 2 O
.	1013 1 O
control	1015 7 O
)	1022 1 O
at	1024 2 O
a	1027 1 O
dose	1029 4 O
of	1034 2 O
0	1037 1 O
.	1038 1 O
2	1039 1 O
mg	1041 2 O
/	1043 1 O
kg	1044 2 O
.	1046 1 O

Underlying	1048 10 O
electrophysiological	1059 20 O
mechanisms	1080 10 O
were	1091 4 O
studied	1096 7 O
in	1104 2 O
detail	1107 6 O
in	1114 2 O
five	1117 4 O
additional	1122 10 O
dogs	1133 4 O
under	1138 5 O
control	1144 7 O
conditions	1152 10 O
and	1163 3 O
in	1167 2 O
the	1170 3 O
presence	1174 8 O
of	1183 2 O
the	1186 3 O
higher	1190 6 O
dose	1197 4 O
of	1202 2 O
verapamil	1205 9 B-Chemical
.	1214 1 O

In	1216 2 O
these	1219 5 O
experiments	1225 11 O
,	1236 1 O
verapamil	1238 9 B-Chemical
shortened	1248 9 O
mean	1258 4 O
effective	1263 9 O
refractory	1273 10 O
period	1284 6 O
(	1291 1 O
ERP	1292 3 O
)	1295 1 O
from	1297 4 O
122	1302 3 O
+	1305 1 O
/	1306 1 O
-	1307 1 O
5	1308 1 O
to	1310 2 O
114	1313 3 O
+	1316 1 O
/	1317 1 O
-	1318 1 O
4	1319 1 O
ms	1321 2 O
(	1324 1 O
P	1325 1 O
<	1326 1 O
0	1327 1 O
.	1328 1 O
02	1329 2 O
)	1331 1 O
at	1333 2 O
a	1336 1 O
cycle	1338 5 O
length	1344 6 O
of	1351 2 O
300	1354 3 O
ms	1358 2 O
,	1360 1 O
decreased	1362 9 O
ERP	1372 3 O
heterogeneity	1376 13 O
(	1390 1 O
from	1391 4 O
15	1396 2 O
+	1398 1 O
/	1399 1 O
-	1400 1 O
1	1401 1 O
to	1403 2 O
10	1406 2 O
+	1408 1 O
/	1409 1 O
-	1410 1 O
1	1411 1 O
%	1412 1 O
,	1413 1 O
P	1415 1 O
<	1416 1 O
0	1417 1 O
.	1418 1 O
05	1419 2 O
)	1421 1 O
,	1422 1 O
heterogeneously	1424 15 O
accelerated	1440 11 O
atrial	1452 6 O
conduction	1459 10 O
and	1470 3 O
decreased	1474 9 O
the	1484 3 O
cycle	1488 5 O
length	1494 6 O
of	1501 2 O
AF	1504 2 B-Disease
(	1507 1 O
94	1508 2 O
+	1510 1 O
/	1511 1 O
-	1512 1 O
4	1513 1 O
to	1515 2 O
84	1518 2 O
+	1520 1 O
/	1521 1 O
-	1522 1 O
3	1523 1 O
ms	1525 2 O
,	1527 1 O
P	1529 1 O
<	1530 1 O
0	1531 1 O
.	1532 1 O
005	1533 3 O
)	1536 1 O
.	1537 1 O

Diltiazem	1539 9 B-Chemical
did	1549 3 O
not	1553 3 O
affect	1557 6 O
ERP	1564 3 O
,	1567 1 O
AF	1569 2 B-Disease
cycle	1572 5 O
length	1578 6 O
or	1585 2 O
AF	1588 2 B-Disease
duration	1591 8 O
,	1599 1 O
but	1601 3 O
produced	1605 8 O
conduction	1614 10 O
acceleration	1625 12 O
similar	1638 7 O
to	1646 2 O
that	1649 4 O
caused	1654 6 O
by	1661 2 O
verapamil	1664 9 B-Chemical
(	1674 1 O
n	1675 1 O
=	1676 1 O
5	1677 1 O
)	1678 1 O
.	1679 1 O

In	1681 2 O
the	1684 3 O
presence	1688 8 O
of	1697 2 O
autonomic	1700 9 O
blockade	1710 8 O
,	1718 1 O
verapamil	1720 9 B-Chemical
failed	1730 6 O
to	1737 2 O
promote	1740 7 O
AF	1748 2 B-Disease
and	1751 3 O
increased	1755 9 O
,	1764 1 O
rather	1766 6 O
than	1773 4 O
decreasing	1778 10 O
,	1788 1 O
refractoriness	1790 14 O
.	1804 1 O

Neither	1806 7 O
verapamil	1814 9 B-Chemical
nor	1824 3 O
diltiazem	1828 9 B-Chemical
affected	1838 8 O
atrial	1847 6 O
conduction	1854 10 O
in	1865 2 O
the	1868 3 O
presence	1872 8 O
of	1881 2 O
autonomic	1884 9 O
blockade	1894 8 O
.	1902 1 O

Epicardial	1904 10 O
mapping	1915 7 O
suggested	1923 9 O
that	1933 4 O
verapamil	1938 9 B-Chemical
promoted	1948 8 O
AF	1957 2 B-Disease
by	1960 2 O
increasing	1963 10 O
the	1974 3 O
number	1978 6 O
of	1985 2 O
simultaneous	1988 12 O
wavefronts	2001 10 O
reflected	2012 9 O
by	2022 2 O
separate	2025 8 O
zones	2034 5 O
of	2040 2 O
reactivation	2043 12 O
in	2056 2 O
each	2059 4 O
cycle	2064 5 O
.	2069 1 O

CONCLUSIONS	2071 11 O
:	2082 1 O
Verapamil	2084 9 B-Chemical
promotes	2094 8 O
AF	2103 2 B-Disease
in	2106 2 O
normal	2109 6 O
dogs	2116 4 O
by	2121 2 O
promoting	2124 9 O
multiple	2134 8 O
circuit	2143 7 O
reentry	2151 7 O
,	2158 1 O
an	2160 2 O
effect	2163 6 O
dependent	2170 9 O
on	2180 2 O
intact	2183 6 O
autonomic	2190 9 O
tone	2200 4 O
and	2205 3 O
not	2209 3 O
shared	2213 6 O
by	2220 2 O
diltiazem	2223 9 B-Chemical
.	2232 1 O

Hypotension	0 11 B-Disease
,	11 1 O
bradycardia	13 11 B-Disease
,	24 1 O
and	26 3 O
asystole	30 8 B-Disease
after	39 5 O
high	45 4 O
-	49 1 O
dose	50 4 O
intravenous	55 11 O
methylprednisolone	67 18 B-Chemical
in	86 2 O
a	89 1 O
monitored	91 9 O
patient	101 7 O
.	108 1 O

We	110 2 O
report	113 6 O
a	120 1 O
case	122 4 O
of	127 2 O
hypotension	130 11 B-Disease
,	141 1 O
bradycardia	143 11 B-Disease
,	154 1 O
and	156 3 O
asystole	160 8 B-Disease
after	169 5 O
intravenous	175 11 O
administration	187 14 O
of	202 2 O
high	205 4 O
-	209 1 O
dose	210 4 O
methylprednisolone	215 18 B-Chemical
in	234 2 O
a	237 1 O
73	239 2 O
-	241 1 O
year	242 4 O
-	246 1 O
old	247 3 O
patient	251 7 O
who	259 3 O
underwent	263 9 O
electrocardiographic	273 20 O
(	294 1 O
ECG	295 3 O
)	298 1 O
monitoring	300 10 O
throughout	311 10 O
the	322 3 O
episode	326 7 O
.	333 1 O

There	335 5 O
was	341 3 O
a	345 1 O
history	347 7 O
of	355 2 O
ischemic	358 8 B-Disease
cardiac	367 7 B-Disease
disease	375 7 I-Disease
9	383 1 O
years	385 5 O
earlier	391 7 O
.	398 1 O

The	400 3 O
patient	404 7 O
was	412 3 O
admitted	416 8 O
with	425 4 O
a	430 1 O
pulmonary	432 9 B-Disease
-	441 1 I-Disease
renal	442 5 I-Disease
syndrome	448 8 I-Disease
with	457 4 O
hemoptysis	462 10 B-Disease
,	472 1 O
rapidly	474 7 O
progressive	482 11 O
renal	494 5 B-Disease
failure	500 7 I-Disease
,	507 1 O
and	509 3 O
hypoxemia	513 9 B-Disease
that	523 4 O
required	528 8 O
mechanical	537 10 O
ventilation	548 11 O
in	560 2 O
the	563 3 O
intensive	567 9 O
care	577 4 O
unit	582 4 O
.	586 1 O

After	588 5 O
receiving	594 9 O
advanced	604 8 O
cardiopulmonary	613 15 O
resuscitation	629 13 O
,	642 1 O
the	644 3 O
patient	648 7 O
recovered	656 9 O
cardiac	666 7 O
rhythm	674 6 O
.	680 1 O

The	682 3 O
ECG	686 3 O
showed	690 6 O
a	697 1 O
junctional	699 10 O
rhythm	710 6 O
without	717 7 O
ventricular	725 11 B-Disease
arrhythmia	737 10 I-Disease
.	747 1 O

This	749 4 O
study	754 5 O
reviews	760 7 O
the	768 3 O
current	772 7 O
proposed	780 8 O
mechanisms	789 10 O
of	800 2 O
sudden	803 6 B-Disease
death	810 5 I-Disease
after	816 5 O
a	822 1 O
high	824 4 O
dose	829 4 O
of	834 2 O
intravenous	837 11 O
methylprednisolone	849 18 B-Chemical
(	868 1 O
IVMP	869 4 B-Chemical
)	873 1 O
.	874 1 O

These	876 5 O
mechanisms	882 10 O
are	893 3 O
not	897 3 O
well	901 4 O
understood	906 10 O
because	917 7 O
,	924 1 O
in	926 2 O
most	929 4 O
cases	934 5 O
,	939 1 O
the	941 3 O
patients	945 8 O
were	954 4 O
not	959 3 O
monitored	963 9 O
at	973 2 O
the	976 3 O
moment	980 6 O
of	987 2 O
the	990 3 O
event	994 5 O
.	999 1 O

Rapid	1001 5 O
infusion	1007 8 O
and	1016 3 O
underlying	1020 10 O
cardiac	1031 7 B-Disease
disease	1039 7 I-Disease
were	1047 4 O
important	1052 9 O
risk	1062 4 O
factors	1067 7 O
in	1075 2 O
the	1078 3 O
case	1082 4 O
reported	1087 8 O
here	1096 4 O
,	1100 1 O
and	1102 3 O
the	1106 3 O
authors	1110 7 O
discount	1118 8 O
ventricular	1127 11 B-Disease
arrhythmia	1139 10 I-Disease
as	1150 2 O
the	1153 3 O
main	1157 4 O
mechanism	1162 9 O
.	1171 1 O

Lifetime	0 8 O
treatment	9 9 O
of	19 2 O
mice	22 4 O
with	27 4 O
azidothymidine	32 14 B-Chemical
(	47 1 O
AZT	48 3 B-Chemical
)	51 1 O
produces	53 8 O
myelodysplasia	62 14 B-Disease
.	76 1 O

AZT	78 3 B-Chemical
has	82 3 O
induced	86 7 O
a	94 1 O
macrocytic	96 10 B-Disease
anemia	107 6 I-Disease
in	114 2 O
AIDS	117 4 B-Disease
patients	122 8 O
on	131 2 O
long	134 4 O
term	139 4 O
AZT	144 3 B-Chemical
therapy	148 7 O
.	155 1 O

It	157 2 O
is	160 2 O
generally	163 9 O
assumed	173 7 O
that	181 4 O
DNA	186 3 O
elongation	190 10 O
is	201 2 O
stopped	204 7 O
by	212 2 O
the	215 3 O
insertion	219 9 O
of	229 2 O
AZT	232 3 B-Chemical
into	236 4 O
the	241 3 O
chain	245 5 O
in	251 2 O
place	254 5 O
of	260 2 O
thymidine	263 9 B-Chemical
thus	273 4 O
preventing	278 10 O
the	289 3 O
phosphate	293 9 B-Chemical
hydroxyl	303 8 O
linkages	312 8 O
and	321 3 O
therefore	325 9 O
suppresses	335 10 O
hemopoietic	346 11 O
progenitor	358 10 O
cell	369 4 O
proliferation	374 13 O
in	388 2 O
an	391 2 O
early	394 5 O
stage	400 5 O
of	406 2 O
differentiation	409 15 O
.	424 1 O

CBA	426 3 O
/	429 1 O
Ca	430 2 O
male	433 4 O
mice	438 4 O
started	443 7 O
on	451 2 O
AZT	454 3 B-Chemical
0	458 1 O
.	459 1 O
75	460 2 O
mg	463 2 O
/	465 1 O
ml	466 2 O
H2O	469 3 O
at	473 2 O
84	476 2 O
days	479 4 O
of	484 2 O
age	487 3 O
and	491 3 O
kept	495 4 O
on	500 2 O
it	503 2 O
for	506 3 O
687	510 3 O
days	514 4 O
when	519 4 O
dosage	524 6 O
reduced	531 7 O
to	539 2 O
0	542 1 O
.	543 1 O
5	544 1 O
mg	546 2 O
/	548 1 O
ml	549 2 O
H2O	552 3 O
for	556 3 O
a	560 1 O
group	562 5 O
,	567 1 O
another	569 7 O
group	577 5 O
removed	583 7 O
from	591 4 O
AZT	596 3 B-Chemical
to	600 2 O
see	603 3 O
recovery	607 8 O
,	615 1 O
and	617 3 O
third	621 5 O
group	627 5 O
remained	633 8 O
on	642 2 O
0	645 1 O
.	646 1 O
75	647 2 O
mg	650 2 O
.	652 1 O

At	654 2 O
687	657 3 O
days	661 4 O
mice	666 4 O
that	671 4 O
had	676 3 O
been	680 4 O
on	685 2 O
0	688 1 O
.	689 1 O
75	690 2 O
mg	693 2 O
had	696 3 O
average	700 7 O
platelet	708 8 O
counts	717 6 O
of	724 2 O
2	727 1 O
.	728 1 O
5	729 1 O
x	731 1 O
10	733 2 O
(	735 1 O
6	736 1 O
)	737 1 O
.	738 1 O

Histological	740 12 O
examination	753 11 O
on	765 2 O
9	768 1 O
of	770 2 O
10	773 2 O
mice	776 4 O
with	781 4 O
such	786 4 O
thrombocytopenia	791 16 B-Disease
showed	808 6 O
changes	815 7 O
compatible	823 10 O
with	834 4 O
myelodysplastic	839 15 B-Disease
syndrome	855 8 I-Disease
(	864 1 O
MDS	865 3 B-Disease
)	868 1 O
.	869 1 O

A	871 1 O
variety	873 7 O
of	881 2 O
histological	884 12 O
patterns	897 8 O
was	906 3 O
observed	910 8 O
.	918 1 O

There	920 5 O
were	926 4 O
two	931 3 O
cases	935 5 O
of	941 2 O
hypocellular	944 12 O
myelodysplasia	957 14 B-Disease
,	971 1 O
two	973 3 O
cases	977 5 O
of	983 2 O
hypersegmented	986 14 O
myelodysplastic	1001 15 B-Disease
granulocytosis	1017 14 O
,	1031 1 O
two	1033 3 O
cases	1037 5 O
of	1043 2 O
hypercellular	1046 13 O
marrow	1060 6 O
with	1067 4 O
abnormal	1072 8 O
megakaryocytes	1081 14 O
with	1096 4 O
bizarre	1101 7 O
nuclei	1109 6 O
,	1115 1 O
one	1117 3 O
case	1121 4 O
of	1126 2 O
megakaryocytic	1129 14 O
myelosis	1144 8 O
associated	1153 10 O
with	1164 4 O
a	1169 1 O
hyperplastic	1171 12 B-Disease
marrow	1184 6 I-Disease
,	1190 1 O
dysmyelopoiesis	1192 15 B-Disease
and	1208 3 O
a	1212 1 O
hypocellular	1214 12 B-Disease
marrow	1227 6 I-Disease
and	1234 3 O
two	1238 3 O
cases	1242 5 O
of	1248 2 O
myelodysplasia	1251 14 B-Disease
with	1266 4 O
dyserythropoiesis	1271 17 B-Disease
,	1288 1 O
hemosiderosis	1290 13 B-Disease
and	1304 3 O
a	1308 1 O
hypocellular	1310 12 B-Disease
marrow	1323 6 I-Disease
.	1329 1 O

Above	1331 5 O
mentioned	1337 9 O
AZT	1347 3 B-Chemical
incorporation	1351 13 O
may	1365 3 O
have	1369 4 O
induced	1374 7 O
an	1382 2 O
ineffective	1385 11 O
hemopoiesis	1397 11 O
in	1409 2 O
the	1412 3 O
primitive	1416 9 O
hemopoietic	1426 11 O
progenitor	1438 10 O
cells	1449 5 O
,	1454 1 O
which	1456 5 O
is	1462 2 O
known	1465 5 O
to	1471 2 O
be	1474 2 O
seen	1477 4 O
commonly	1482 8 O
in	1491 2 O
the	1494 3 O
myelodysplastic	1498 15 B-Disease
syndrome	1514 8 I-Disease
.	1522 1 O

Influence	0 9 O
of	10 2 O
diet	13 4 O
free	18 4 O
of	23 2 O
NAD	26 3 B-Chemical
-	29 1 O
precursors	30 10 O
on	41 2 O
acetaminophen	44 13 B-Chemical
hepatotoxicity	58 14 B-Disease
in	73 2 O
mice	76 4 O
.	80 1 O

Recently	82 8 O
,	90 1 O
we	92 2 O
demonstrated	95 12 O
the	108 3 O
hepatoprotective	112 16 O
effects	129 7 O
of	137 2 O
nicotinic	140 9 B-Chemical
acid	150 4 I-Chemical
amide	155 5 I-Chemical
,	160 1 O
a	162 1 O
selective	164 9 O
inhibitor	174 9 O
of	184 2 O
poly	187 4 B-Chemical
(	191 1 I-Chemical
ADP	192 3 I-Chemical
-	195 1 I-Chemical
ribose	196 6 I-Chemical
)	202 1 I-Chemical
polymerase	204 10 O
(	215 1 O
PARP	216 4 O
;	220 1 O
EC	222 2 O
2	225 1 O
.	226 1 O
4	227 1 O
.	228 1 O
2	229 1 O
.	230 1 O
30	231 2 O
)	233 1 O
on	235 2 O
mice	238 4 O
suffering	243 9 O
from	253 4 O
acetaminophen	258 13 B-Chemical
(	272 1 O
AAP	273 3 B-Chemical
)	276 1 O
-	277 1 O
hepatitis	278 9 B-Disease
,	287 1 O
suggesting	289 10 O
that	300 4 O
the	305 3 O
AAP	309 3 B-Chemical
-	312 1 O
induced	313 7 O
liver	321 5 B-Disease
injury	327 6 I-Disease
involves	334 8 O
a	343 1 O
step	345 4 O
which	350 5 O
depends	356 7 O
on	364 2 O
adenoribosylation	367 17 O
.	384 1 O

The	386 3 O
present	390 7 O
study	398 5 O
investigates	404 12 O
the	417 3 O
effects	421 7 O
of	429 2 O
a	432 1 O
diet	434 4 O
free	439 4 O
of	444 2 O
precursors	447 10 O
of	458 2 O
NAD	461 3 B-Chemical
,	464 1 O
the	466 3 O
substrate	470 9 O
on	480 2 O
which	483 5 O
PARP	489 4 O
acts	494 4 O
,	498 1 O
in	500 2 O
female	503 6 O
NMRI	510 4 O
mice	515 4 O
with	520 4 O
AAP	525 3 B-Chemical
hepatitis	529 9 B-Disease
and	539 3 O
evaluates	543 9 O
the	553 3 O
influence	557 9 O
of	567 2 O
simultaneous	570 12 O
ethanol	583 7 B-Chemical
consumption	591 11 O
in	603 2 O
these	606 5 O
animals	612 7 O
.	619 1 O

Liver	621 5 B-Disease
injuries	627 8 I-Disease
were	636 4 O
quantified	641 10 O
as	652 2 O
serum	655 5 O
activities	661 10 O
of	672 2 O
glutamate	675 9 B-Chemical
-	684 1 O
oxaloacetate	685 12 B-Chemical
transaminase	698 12 O
(	711 1 O
GOT	712 3 O
)	715 1 O
and	717 3 O
glutamate	721 9 B-Chemical
-	730 1 O
pyruvate	731 8 B-Chemical
transaminase	740 12 O
(	753 1 O
GPT	754 3 O
)	757 1 O
.	758 1 O

While	760 5 O
AAP	766 3 B-Chemical
caused	770 6 O
a	777 1 O
117	779 3 O
-	782 1 O
fold	783 4 O
elevation	788 9 O
of	798 2 O
serum	801 5 O
transaminase	807 12 O
activities	820 10 O
in	831 2 O
mice	834 4 O
kept	839 4 O
on	844 2 O
a	847 1 O
standard	849 8 O
laboratory	858 10 O
diet	869 4 O
,	873 1 O
which	875 5 O
was	881 3 O
significantly	885 13 O
exacerbated	899 11 O
by	911 2 O
ethanol	914 7 B-Chemical
and	922 3 O
inhibited	926 9 O
by	936 2 O
nicotinic	939 9 B-Chemical
acid	949 4 I-Chemical
amide	954 5 I-Chemical
(	960 1 O
NAA	961 3 B-Chemical
)	964 1 O
,	965 1 O
adverse	967 7 O
effects	975 7 O
were	983 4 O
noted	988 5 O
in	994 2 O
animals	997 7 O
fed	1005 3 O
a	1009 1 O
diet	1011 4 O
free	1016 4 O
of	1021 2 O
precursors	1024 10 O
of	1035 2 O
NAD	1038 3 B-Chemical
.	1041 1 O

In	1043 2 O
these	1046 5 O
animals	1052 7 O
,	1059 1 O
only	1061 4 O
minor	1066 5 O
increases	1072 9 O
of	1082 2 O
serum	1085 5 O
transaminase	1091 12 O
activities	1104 10 O
were	1115 4 O
measured	1120 8 O
in	1129 2 O
the	1132 3 O
presence	1136 8 O
of	1145 2 O
AAP	1148 3 B-Chemical
,	1151 1 O
and	1153 3 O
unlike	1157 6 O
the	1164 3 O
exacerbation	1168 12 O
caused	1181 6 O
by	1188 2 O
ethanol	1191 7 B-Chemical
in	1199 2 O
mice	1202 4 O
on	1207 2 O
a	1210 1 O
standard	1212 8 O
diet	1221 4 O
,	1225 1 O
the	1227 3 O
liver	1231 5 B-Disease
damage	1237 6 I-Disease
was	1244 3 O
inhibited	1248 9 O
by	1258 2 O
50	1261 2 O
%	1263 1 O
by	1265 2 O
ethanol	1268 7 B-Chemical
.	1275 1 O

A	1277 1 O
further	1279 7 O
64	1287 2 O
%	1289 1 O
reduction	1291 9 O
of	1301 2 O
hepatitis	1304 9 B-Disease
was	1314 3 O
observed	1318 8 O
,	1326 1 O
when	1328 4 O
NAA	1333 3 B-Chemical
was	1337 3 O
given	1341 5 O
to	1347 2 O
ethanol	1350 7 B-Chemical
/	1357 1 O
AAP	1358 3 B-Chemical
-	1361 1 O
mice	1362 4 O
.	1366 1 O

Our	1368 3 O
results	1372 7 O
provide	1380 7 O
evidence	1388 8 O
that	1397 4 O
the	1402 3 O
AAP	1406 3 B-Chemical
-	1409 1 O
induced	1410 7 O
hepatitis	1418 9 B-Disease
and	1428 3 O
its	1432 3 O
exacerbation	1436 12 O
by	1449 2 O
ethanol	1452 7 B-Chemical
can	1460 3 O
either	1464 6 O
be	1471 2 O
reduced	1474 7 O
by	1482 2 O
end	1485 3 O
-	1488 1 O
product	1489 7 O
inhibition	1497 10 O
of	1508 2 O
PARP	1511 4 O
by	1516 2 O
NAA	1519 3 B-Chemical
or	1523 2 O
by	1526 2 O
dietary	1529 7 O
depletion	1537 9 O
of	1547 2 O
the	1550 3 O
enzyme	1554 6 O
'	1560 1 O
s	1561 1 O
substrate	1563 9 O
NAD	1573 3 B-Chemical
.	1576 1 O

We	1578 2 O
see	1581 3 O
the	1585 3 O
main	1589 4 O
application	1594 11 O
of	1606 2 O
NAA	1609 3 B-Chemical
as	1613 2 O
for	1616 3 O
the	1620 3 O
combinational	1624 13 O
use	1638 3 O
in	1642 2 O
pharmaceutical	1645 14 O
preparations	1660 12 O
of	1673 2 O
acetaminophen	1676 13 B-Chemical
in	1690 2 O
order	1693 5 O
to	1699 2 O
avoid	1702 5 O
hepatic	1708 7 B-Disease
damage	1716 6 I-Disease
in	1723 2 O
patients	1726 8 O
treated	1735 7 O
with	1743 4 O
this	1748 4 O
widely	1753 6 O
used	1760 4 O
analgesic	1765 9 O
.	1774 1 O

Antiarrhythmic	0 14 O
plasma	15 6 O
concentrations	22 14 O
of	37 2 O
cibenzoline	40 11 B-Chemical
on	52 2 O
canine	55 6 O
ventricular	62 11 B-Disease
arrhythmias	74 11 I-Disease
.	85 1 O

Using	87 5 O
two	93 3 O
-	96 1 O
stage	97 5 O
coronary	103 8 O
ligation	112 8 O
-	120 1 O
,	121 1 O
digitalis	123 9 B-Chemical
-	132 1 O
,	133 1 O
and	135 3 O
adrenaline	139 10 B-Chemical
-	149 1 O
induced	150 7 O
canine	158 6 O
ventricular	165 11 B-Disease
arrhythmias	177 11 I-Disease
,	188 1 O
antiarrhythmic	190 14 O
effects	205 7 O
of	213 2 O
cibenzoline	216 11 B-Chemical
were	228 4 O
examined	233 8 O
and	242 3 O
the	246 3 O
minimum	250 7 O
effective	258 9 O
plasma	268 6 O
concentration	275 13 O
for	289 3 O
each	293 4 O
arrhythmia	298 10 B-Disease
model	309 5 O
was	315 3 O
determined	319 10 O
.	329 1 O

Cibenzoline	331 11 B-Chemical
suppressed	343 10 O
all	354 3 O
the	358 3 O
arrhythmias	362 11 B-Disease
,	373 1 O
and	375 3 O
the	379 3 O
minimum	383 7 O
effective	391 9 O
plasma	401 6 O
concentrations	408 14 O
for	423 3 O
arrhythmias	427 11 B-Disease
induced	439 7 O
by	447 2 O
24	450 2 O
-	452 1 O
h	453 1 O
coronary	455 8 O
ligation	464 8 O
,	472 1 O
48	474 2 O
-	476 1 O
h	477 1 O
coronary	479 8 O
ligation	488 8 O
,	496 1 O
digitalis	498 9 B-Chemical
,	507 1 O
and	509 3 O
adrenaline	513 10 B-Chemical
were	524 4 O
1	529 1 O
.	530 1 O
9	531 1 O
+	533 1 O
/	534 1 O
-	535 1 O
0	537 1 O
.	538 1 O
9	539 1 O
(	541 1 O
by	542 2 O
8	545 1 O
mg	547 2 O
/	549 1 O
kg	550 2 O
i	553 1 O
.	554 1 O
v	555 1 O
.	556 1 O
)	557 1 O
,	558 1 O
1	560 1 O
.	561 1 O
6	562 1 O
+	564 1 O
/	565 1 O
-	566 1 O
0	568 1 O
.	569 1 O
5	570 1 O
(	572 1 O
by	573 2 O
8	576 1 O
mg	578 2 O
/	580 1 O
kg	581 2 O
i	584 1 O
.	585 1 O
v	586 1 O
.	587 1 O
)	588 1 O
,	589 1 O
0	591 1 O
.	592 1 O
6	593 1 O
+	595 1 O
/	596 1 O
-	597 1 O
0	599 1 O
.	600 1 O
2	601 1 O
(	603 1 O
by	604 2 O
2	607 1 O
mg	609 2 O
/	611 1 O
kg	612 2 O
i	615 1 O
.	616 1 O
v	617 1 O
.	618 1 O
)	619 1 O
,	620 1 O
and	622 3 O
3	626 1 O
.	627 1 O
5	628 1 O
+	630 1 O
/	631 1 O
-	632 1 O
1	634 1 O
.	635 1 O
3	636 1 O
(	638 1 O
by	639 2 O
5	642 1 O
mg	644 2 O
/	646 1 O
kg	647 2 O
i	650 1 O
.	651 1 O
v	652 1 O
.	653 1 O
)	654 1 O
micrograms	656 10 O
/	666 1 O
ml	667 2 O
,	669 1 O
respectively	671 12 O
(	684 1 O
mean	685 4 O
+	690 1 O
/	691 1 O
-	692 1 O
SDM	694 3 O
,	697 1 O
n	699 1 O
=	701 1 O
6	703 1 O
-	704 1 O
7	705 1 O
)	706 1 O
.	707 1 O

The	709 3 O
concentration	713 13 O
for	727 3 O
adrenaline	731 10 B-Chemical
-	741 1 O
induced	742 7 O
arrhythmia	750 10 B-Disease
was	761 3 O
significantly	765 13 O
higher	779 6 O
than	786 4 O
those	791 5 O
for	797 3 O
the	801 3 O
other	805 5 O
types	811 5 O
of	817 2 O
arrhythmias	820 11 B-Disease
.	831 1 O

This	833 4 O
pharmacological	838 15 O
profile	854 7 O
is	862 2 O
similar	865 7 O
to	873 2 O
those	876 5 O
of	882 2 O
mexiletine	885 10 B-Chemical
and	896 3 O
tocainide	900 9 B-Chemical
,	909 1 O
and	911 3 O
all	915 3 O
three	919 5 O
drugs	925 5 O
have	931 4 O
central	936 7 O
nervous	944 7 O
system	952 6 O
(	959 1 O
CNS	960 3 O
)	963 1 O
stimulant	965 9 O
action	975 6 O
.	981 1 O

Because	983 7 O
cibenzoline	991 11 B-Chemical
had	1003 3 O
only	1007 4 O
weak	1012 4 O
hypotensive	1017 11 B-Disease
and	1029 3 O
sinus	1033 5 O
node	1039 4 O
depressive	1044 10 B-Disease
effects	1055 7 O
and	1063 3 O
was	1067 3 O
found	1071 5 O
to	1077 2 O
be	1080 2 O
orally	1083 6 O
active	1090 6 O
when	1097 4 O
given	1102 5 O
to	1108 2 O
coronary	1111 8 O
ligation	1120 8 O
arrhythmia	1129 10 B-Disease
dogs	1140 4 O
,	1144 1 O
its	1146 3 O
clinical	1150 8 O
usefulness	1159 10 O
is	1170 2 O
expected	1173 8 O
.	1181 1 O

Immunopathology	0 15 O
of	16 2 O
penicillamine	19 13 B-Chemical
-	32 1 O
induced	33 7 O
glomerular	41 10 B-Disease
disease	52 7 I-Disease
.	59 1 O

Four	61 4 O
patients	66 8 O
with	75 4 O
rheumatoid	80 10 B-Disease
arthritis	91 9 I-Disease
developed	101 9 O
heavy	111 5 O
proteinuria	117 11 B-Disease
after	129 5 O
five	135 4 O
to	140 2 O
12	143 2 O
months	146 6 O
of	153 2 O
treatment	156 9 O
with	166 4 O
D	171 1 B-Chemical
-	172 1 I-Chemical
penicillamine	173 13 I-Chemical
.	186 1 O

Light	188 5 O
microscopy	194 10 O
of	205 2 O
renal	208 5 O
biopsy	214 6 O
samples	221 7 O
showed	229 6 O
minimal	236 7 O
glomerular	244 10 O
capillary	255 9 O
wall	265 4 O
thickening	270 10 O
and	281 3 O
mesangial	285 9 O
matrix	295 6 O
increase	302 8 O
,	310 1 O
or	312 2 O
no	315 2 O
departure	318 9 O
from	328 4 O
normal	333 6 O
.	339 1 O

Electron	341 8 O
microscopy	350 10 O
,	360 1 O
however	362 7 O
,	369 1 O
revealed	371 8 O
subepithelial	380 13 O
electron	394 8 O
-	402 1 O
dense	403 5 O
deposits	409 8 O
,	417 1 O
fusion	419 6 O
of	426 2 O
epithelial	429 10 O
cell	440 4 O
foot	445 4 O
processes	450 9 O
,	459 1 O
and	461 3 O
evidence	465 8 O
of	474 2 O
mesangial	477 9 O
cell	487 4 O
hyperactivity	492 13 O
.	505 1 O

Immunofluorescence	507 18 O
microscopy	526 10 O
demonstrated	537 12 O
granular	550 8 O
capillary	559 9 O
wall	569 4 O
deposits	574 8 O
of	583 2 O
IgG	586 3 O
and	590 3 O
C3	594 2 O
.	596 1 O

The	598 3 O
findings	602 8 O
were	611 4 O
similar	616 7 O
to	624 2 O
those	627 5 O
in	633 2 O
early	636 5 O
membranous	642 10 B-Disease
glomerulonephritis	653 18 I-Disease
,	671 1 O
differences	673 11 O
being	685 5 O
observed	691 8 O
however	700 7 O
in	708 2 O
the	711 3 O
results	715 7 O
of	723 2 O
staining	726 8 O
for	735 3 O
the	739 3 O
early	743 5 O
-	748 1 O
acting	749 6 O
complement	756 10 O
components	767 10 O
C1q	778 3 O
and	782 3 O
C4	786 2 O
.	788 1 O

It	790 2 O
is	793 2 O
tentatively	796 11 O
concluded	808 9 O
that	818 4 O
complement	823 10 O
was	834 3 O
activated	838 9 O
by	848 2 O
the	851 3 O
classical	855 9 O
pathway	865 7 O
.	872 1 O

Ventricular	0 11 B-Disease
fibrillation	12 12 I-Disease
from	25 4 O
diatrizoate	30 11 B-Chemical
with	42 4 O
and	47 3 O
without	51 7 O
chelating	59 9 O
agents	69 6 O
.	75 1 O

The	77 3 O
toxicity	81 8 B-Disease
of	90 2 O
Renografin	93 10 B-Chemical
76	104 2 I-Chemical
%	106 1 I-Chemical
was	108 3 O
compared	112 8 O
with	121 4 O
that	126 4 O
of	131 2 O
Hypaque	134 7 B-Chemical
76	142 2 I-Chemical
%	144 1 I-Chemical
by	146 2 O
selective	149 9 O
injection	159 9 O
of	169 2 O
each	172 4 O
into	177 4 O
the	182 3 O
right	186 5 O
coronary	192 8 O
artery	201 6 O
of	208 2 O
dogs	211 4 O
.	215 1 O

Renografin	217 10 B-Chemical
contains	228 8 O
the	237 3 O
chelating	241 9 O
agents	251 6 O
sodium	258 6 B-Chemical
citrate	265 7 I-Chemical
and	273 3 O
disodium	277 8 B-Chemical
edetate	286 7 I-Chemical
,	293 1 O
while	295 5 O
Hypaque	301 7 B-Chemical
contains	309 8 O
calcium	318 7 B-Chemical
disodium	326 8 I-Chemical
edetate	335 7 I-Chemical
and	343 3 O
no	347 2 O
sodium	350 6 B-Chemical
citrate	357 7 I-Chemical
.	364 1 O

Ventricular	366 11 B-Disease
fibrillation	378 12 I-Disease
occurred	391 8 O
significantly	400 13 O
more	414 4 O
often	419 5 O
with	425 4 O
Renografin	430 10 B-Chemical
,	440 1 O
suggesting	442 10 O
that	453 4 O
chelating	458 9 O
agents	468 6 O
contribute	475 10 O
to	486 2 O
toxicity	489 8 B-Disease
in	498 2 O
coronary	501 8 O
angiography	510 11 O
.	521 1 O

Rapid	0 5 O
reversal	6 8 O
of	15 2 O
anticoagulation	18 15 O
reduces	34 7 O
hemorrhage	42 10 B-Disease
volume	53 6 O
in	60 2 O
a	63 1 O
mouse	65 5 O
model	71 5 O
of	77 2 O
warfarin	80 8 B-Chemical
-	88 1 O
associated	89 10 O
intracerebral	100 13 B-Disease
hemorrhage	114 10 I-Disease
.	124 1 O

Warfarin	126 8 B-Chemical
-	134 1 O
associated	135 10 O
intracerebral	146 13 B-Disease
hemorrhage	160 10 I-Disease
(	171 1 O
W	172 1 O
-	173 1 O
ICH	174 3 B-Disease
)	177 1 O
is	179 2 O
a	182 1 O
severe	184 6 O
type	191 4 O
of	196 2 O
stroke	199 6 B-Disease
.	205 1 O

There	207 5 O
is	213 2 O
no	216 2 O
consensus	219 9 O
on	229 2 O
the	232 3 O
optimal	236 7 O
treatment	244 9 O
for	254 3 O
W	258 1 O
-	259 1 O
ICH	260 3 B-Disease
.	263 1 O

Using	265 5 O
a	271 1 O
mouse	273 5 O
model	279 5 O
,	284 1 O
we	286 2 O
tested	289 6 O
whether	296 7 O
the	304 3 O
rapid	308 5 O
reversal	314 8 O
of	323 2 O
anticoagulation	326 15 O
using	342 5 O
human	348 5 O
prothrombin	354 11 B-Chemical
complex	366 7 I-Chemical
concentrate	374 11 I-Chemical
(	386 1 O
PCC	387 3 B-Chemical
)	390 1 O
can	392 3 O
reduce	396 6 O
hemorrhagic	403 11 O
blood	415 5 O
volume	421 6 O
.	427 1 O

Male	429 4 O
CD	434 2 O
-	436 1 O
1	437 1 O
mice	439 4 O
were	444 4 O
treated	449 7 O
with	457 4 O
warfarin	462 8 B-Chemical
(	471 1 O
2	472 1 O
mg	474 2 O
/	476 1 O
kg	477 2 O
over	480 4 O
24	485 2 O
h	488 1 O
)	489 1 O
,	490 1 O
resulting	492 9 O
in	502 2 O
a	505 1 O
mean	507 4 O
(	512 1 O
+	513 1 O
/	514 1 O
-	515 1 O
s	516 1 O
.	517 1 O
d	518 1 O
.	519 1 O
)	520 1 O
International	522 13 O
Normalized	536 10 O
Ratio	547 5 O
of	553 2 O
3	556 1 O
.	557 1 O
5	558 1 O
+	559 1 O
/	560 1 O
-	561 1 O
0	562 1 O
.	563 1 O
9	564 1 O
.	565 1 O

First	567 5 O
,	572 1 O
we	574 2 O
showed	577 6 O
that	584 4 O
an	589 2 O
intravenous	592 11 O
administration	604 14 O
of	619 2 O
human	622 5 O
PCC	628 3 B-Chemical
rapidly	632 7 O
reversed	640 8 O
anticoagulation	649 15 O
in	665 2 O
mice	668 4 O
.	672 1 O

Second	674 6 O
,	680 1 O
a	682 1 O
stereotactic	684 12 O
injection	697 9 O
of	707 2 O
collagenase	710 11 O
was	722 3 O
administered	726 12 O
to	739 2 O
induce	742 6 O
hemorrhage	749 10 B-Disease
in	760 2 O
the	763 3 O
right	767 5 O
striatum	773 8 O
.	781 1 O

Forty	783 5 O
-	788 1 O
five	789 4 O
minutes	794 7 O
later	802 5 O
,	807 1 O
the	809 3 O
animals	813 7 O
were	821 4 O
randomly	826 8 O
treated	835 7 O
with	843 4 O
PCC	848 3 B-Chemical
(	852 1 O
100	853 3 O
U	857 1 O
/	858 1 O
kg	859 2 O
)	861 1 O
or	863 2 O
saline	866 6 O
i	873 1 O
.	874 1 O
v	875 1 O
.	876 1 O
(	878 1 O
n	879 1 O
=	880 1 O
12	881 2 O
per	884 3 O
group	888 5 O
)	893 1 O
.	894 1 O

Twenty	896 6 O
-	902 1 O
four	903 4 O
hours	908 5 O
after	914 5 O
hemorrhage	920 10 B-Disease
induction	931 9 O
,	940 1 O
hemorrhagic	942 11 O
blood	954 5 O
volume	960 6 O
was	967 3 O
quantified	971 10 O
using	982 5 O
a	988 1 O
photometric	990 11 O
hemoglobin	1002 10 O
assay	1013 5 O
.	1018 1 O

The	1020 3 O
mean	1024 4 O
hemorrhagic	1029 11 O
blood	1041 5 O
volume	1047 6 O
was	1054 3 O
reduced	1058 7 O
in	1066 2 O
PCC	1069 3 B-Chemical
-	1072 1 O
treated	1073 7 O
animals	1081 7 O
(	1089 1 O
6	1090 1 O
.	1091 1 O
5	1092 1 O
+	1093 1 O
/	1094 1 O
-	1095 1 O
3	1096 1 O
.	1097 1 O
1	1098 1 O
microL	1100 6 O
)	1106 1 O
compared	1108 8 O
with	1117 4 O
saline	1122 6 O
controls	1129 8 O
(	1138 1 O
15	1139 2 O
.	1141 1 O
3	1142 1 O
+	1143 1 O
/	1144 1 O
-	1145 1 O
11	1146 2 O
.	1148 1 O
2	1149 1 O
microL	1151 6 O
,	1157 1 O
P	1159 1 O
=	1160 1 O
0	1161 1 O
.	1162 1 O
015	1163 3 O
)	1166 1 O
.	1167 1 O

In	1169 2 O
the	1172 3 O
saline	1176 6 O
group	1183 5 O
,	1188 1 O
45	1190 2 O
%	1192 1 O
of	1194 2 O
the	1197 3 O
mice	1201 4 O
developed	1206 9 O
large	1216 5 O
hematomas	1222 9 B-Disease
(	1232 1 O
i	1233 1 O
.	1234 1 O
e	1235 1 O
.	1236 1 O
,	1237 1 O
>	1239 1 O
15	1240 2 O
microL	1243 6 O
)	1249 1 O
.	1250 1 O

In	1252 2 O
contrast	1255 8 O
,	1263 1 O
such	1265 4 O
extensive	1270 9 O
lesions	1280 7 O
were	1288 4 O
never	1293 5 O
found	1299 5 O
in	1305 2 O
the	1308 3 O
PCC	1312 3 B-Chemical
group	1316 5 O
.	1321 1 O

We	1323 2 O
provide	1326 7 O
experimental	1334 12 O
data	1347 4 O
suggesting	1352 10 O
PCC	1363 3 B-Chemical
to	1367 2 O
be	1370 2 O
an	1373 2 O
effective	1376 9 O
acute	1386 5 O
treatment	1392 9 O
for	1402 3 O
W	1406 1 O
-	1407 1 O
ICH	1408 3 B-Disease
in	1412 2 O
terms	1415 5 O
of	1421 2 O
reducing	1424 8 O
hemorrhagic	1433 11 O
blood	1445 5 O
volume	1451 6 O
.	1457 1 O

Future	1459 6 O
studies	1466 7 O
are	1474 3 O
needed	1478 6 O
to	1485 2 O
assess	1488 6 O
the	1495 3 O
therapeutic	1499 11 O
potential	1511 9 O
emerging	1521 8 O
from	1530 4 O
our	1535 3 O
finding	1539 7 O
for	1547 3 O
human	1551 5 O
W	1557 1 O
-	1558 1 O
ICH	1559 3 B-Disease
.	1562 1 O

Impact	0 6 O
of	7 2 O
alcohol	10 7 B-Chemical
exposure	18 8 O
after	27 5 O
pregnancy	33 9 O
recognition	43 11 O
on	55 2 O
ultrasonographic	58 16 O
fetal	75 5 O
growth	81 6 O
measures	88 8 O
.	96 1 O

BACKGROUND	98 10 O
:	108 1 O
More	110 4 O
than	115 4 O
3	120 1 O
decades	122 7 O
after	130 5 O
Jones	136 5 O
and	142 3 O
Smith	146 5 O
(	152 1 O
1973	153 4 O
)	157 1 O
reported	159 8 O
on	168 2 O
the	171 3 O
devastation	175 11 O
caused	187 6 O
by	194 2 O
alcohol	197 7 B-Chemical
exposure	205 8 O
on	214 2 O
fetal	217 5 O
development	223 11 O
,	234 1 O
the	236 3 O
rates	240 5 O
of	246 2 O
heavy	249 5 O
drinking	255 8 O
during	264 6 O
pregnancy	271 9 O
remain	281 6 O
relatively	288 10 O
unchanged	299 9 O
.	308 1 O

Early	310 5 O
identification	316 14 O
of	331 2 O
fetal	334 5 O
alcohol	340 7 B-Chemical
exposure	348 8 O
and	357 3 O
maternal	361 8 O
abstinence	370 10 O
led	381 3 O
to	385 2 O
better	388 6 O
infant	395 6 O
outcomes	402 8 O
.	410 1 O

This	412 4 O
study	417 5 O
examined	423 8 O
the	432 3 O
utility	436 7 O
of	444 2 O
biometry	447 8 O
for	456 3 O
detecting	460 9 O
alcohol	470 7 B-Chemical
-	477 1 O
related	478 7 O
fetal	486 5 O
growth	492 6 B-Disease
impairment	499 10 I-Disease
.	509 1 O

METHODS	511 7 O
:	518 1 O
We	520 2 O
obtained	523 8 O
fetal	532 5 O
ultrasound	538 10 O
measures	549 8 O
from	558 4 O
routine	563 7 O
ultrasound	571 10 O
examinations	582 12 O
for	595 3 O
167	599 3 O
pregnant	603 8 O
hazardous	612 9 O
drinkers	622 8 O
who	631 3 O
were	635 4 O
enrolled	640 8 O
in	649 2 O
a	652 1 O
brief	654 5 O
alcohol	660 7 B-Chemical
intervention	668 12 O
study	681 5 O
.	686 1 O

The	688 3 O
fetal	692 5 O
measures	698 8 O
for	707 3 O
women	711 5 O
who	717 3 O
quit	721 4 O
after	726 5 O
learning	732 8 O
of	741 2 O
their	744 5 O
pregnancies	750 11 O
were	762 4 O
compared	767 8 O
with	776 4 O
measures	781 8 O
for	790 3 O
women	794 5 O
who	800 3 O
continued	804 9 O
some	814 4 O
drinking	819 8 O
throughout	828 10 O
the	839 3 O
course	843 6 O
of	850 2 O
their	853 5 O
pregnancies	859 11 O
.	870 1 O

Because	872 7 O
intensity	880 9 O
of	890 2 O
alcohol	893 7 B-Chemical
consumption	901 11 O
is	913 2 O
associated	916 10 O
with	927 4 O
poorer	932 6 O
fetal	939 5 O
outcomes	945 8 O
,	953 1 O
separate	955 8 O
analyses	964 8 O
were	973 4 O
conducted	978 9 O
for	988 3 O
the	992 3 O
heavy	996 5 O
(	1002 1 O
average	1003 7 O
of	1011 2 O
>	1014 1 O
or	1015 2 O
=	1017 1 O
5	1018 1 O
drinks	1020 6 O
per	1027 3 O
drinking	1031 8 O
day	1040 3 O
)	1043 1 O
alcohol	1045 7 B-Chemical
consumers	1053 9 O
.	1062 1 O

Fetal	1064 5 O
measures	1070 8 O
from	1079 4 O
the	1084 3 O
heavy	1088 5 O
-	1093 1 O
exposed	1094 7 O
fetuses	1102 7 O
were	1110 4 O
also	1115 4 O
compared	1120 8 O
with	1129 4 O
measures	1134 8 O
from	1143 4 O
a	1148 1 O
nondrinking	1150 11 O
group	1162 5 O
that	1168 4 O
was	1173 3 O
representative	1177 14 O
of	1192 2 O
normal	1195 6 O
,	1201 1 O
uncomplicated	1203 13 O
pregnancies	1217 11 O
from	1229 4 O
our	1234 3 O
clinics	1238 7 O
.	1245 1 O

Analyses	1247 8 O
of	1256 2 O
covariance	1259 10 O
were	1270 4 O
used	1275 4 O
to	1280 2 O
determine	1283 9 O
whether	1293 7 O
there	1301 5 O
were	1307 4 O
differences	1312 11 O
between	1324 7 O
groups	1332 6 O
after	1339 5 O
controlling	1345 11 O
for	1357 3 O
influences	1361 10 O
of	1372 2 O
gestational	1375 11 O
age	1387 3 O
and	1391 3 O
drug	1395 4 B-Disease
abuse	1400 5 I-Disease
.	1405 1 O

RESULTS	1407 7 O
:	1414 1 O
Nearly	1416 6 O
half	1423 4 O
of	1428 2 O
the	1431 3 O
pregnant	1435 8 O
drinkers	1444 8 O
abstained	1453 9 O
after	1463 5 O
learning	1469 8 O
of	1478 2 O
their	1481 5 O
pregnancies	1487 11 O
.	1498 1 O

When	1500 4 O
women	1505 5 O
reportedly	1511 10 O
quit	1522 4 O
drinking	1527 8 O
early	1536 5 O
in	1542 2 O
their	1545 5 O
pregnancies	1551 11 O
,	1562 1 O
fetal	1564 5 O
growth	1570 6 O
measures	1577 8 O
were	1586 4 O
not	1591 3 O
significantly	1595 13 O
different	1609 9 O
from	1619 4 O
a	1624 1 O
non	1626 3 O
-	1629 1 O
alcohol	1630 7 B-Chemical
-	1637 1 O
exposed	1638 7 O
group	1646 5 O
,	1651 1 O
regardless	1653 10 O
of	1664 2 O
prior	1667 5 O
drinking	1673 8 O
patterns	1682 8 O
.	1690 1 O

Any	1692 3 O
alcohol	1696 7 B-Chemical
consumption	1704 11 O
postpregnancy	1716 13 O
recognition	1730 11 O
among	1742 5 O
the	1748 3 O
heavy	1752 5 O
drinkers	1758 8 O
resulted	1767 8 O
in	1776 2 O
reduced	1779 7 B-Disease
cerebellar	1787 10 I-Disease
growth	1798 6 I-Disease
as	1805 2 O
well	1808 4 O
as	1813 2 O
decreased	1816 9 B-Disease
cranial	1826 7 I-Disease
to	1834 2 I-Disease
body	1837 4 I-Disease
growth	1842 6 I-Disease
in	1849 2 O
comparison	1852 10 O
with	1863 4 O
women	1868 5 O
who	1874 3 O
either	1878 6 O
quit	1885 4 O
drinking	1890 8 O
or	1899 2 O
who	1902 3 O
were	1906 4 O
nondrinkers	1911 11 O
.	1922 1 O

Amphetamine	1924 11 B-Chemical
abuse	1936 5 O
was	1942 3 O
predictive	1946 10 O
of	1957 2 O
larger	1960 6 O
cranial	1967 7 O
to	1975 2 O
body	1978 4 O
growth	1983 6 O
ratios	1990 6 O
.	1996 1 O

CONCLUSIONS	1998 11 O
:	2009 1 O
Alterations	2011 11 O
in	2023 2 O
fetal	2026 5 O
biometric	2032 9 O
measurements	2042 12 O
were	2055 4 O
observed	2060 8 O
among	2069 5 O
the	2075 3 O
heavy	2079 5 O
drinkers	2085 8 O
only	2094 4 O
when	2099 4 O
they	2104 4 O
continued	2109 9 O
drinking	2119 8 O
after	2128 5 O
becoming	2134 8 O
aware	2143 5 O
of	2149 2 O
their	2152 5 O
pregnancies	2158 11 O
.	2169 1 O

Although	2171 8 O
the	2180 3 O
reliance	2184 8 O
on	2193 2 O
self	2196 4 O
-	2200 1 O
reported	2201 8 O
drinking	2210 8 O
is	2219 2 O
a	2222 1 O
limitation	2224 10 O
in	2235 2 O
this	2238 4 O
study	2243 5 O
,	2248 1 O
these	2250 5 O
findings	2256 8 O
support	2265 7 O
the	2273 3 O
benefits	2277 8 O
of	2286 2 O
early	2289 5 O
abstinence	2295 10 O
and	2306 3 O
the	2310 3 O
potential	2314 9 O
for	2324 3 O
ultrasound	2328 10 O
examinations	2339 12 O
in	2352 2 O
the	2355 3 O
detection	2359 9 O
of	2369 2 O
fetal	2372 5 O
alcohol	2378 7 B-Chemical
effects	2386 7 O
.	2393 1 O

Urinary	0 7 O
symptoms	8 8 O
and	17 3 O
quality	21 7 O
of	29 2 O
life	32 4 O
changes	37 7 O
in	45 2 O
Thai	48 4 O
women	53 5 O
with	59 4 O
overactive	64 10 B-Disease
bladder	75 7 I-Disease
after	83 5 O
tolterodine	89 11 B-Chemical
treatment	101 9 O
.	110 1 O

OBJECTIVES	112 10 O
:	122 1 O
To	124 2 O
study	127 5 O
the	133 3 O
urinary	137 7 O
symptoms	145 8 O
and	154 3 O
quality	158 7 O
of	166 2 O
life	169 4 O
changes	174 7 O
in	182 2 O
Thai	185 4 O
women	190 5 O
with	196 4 O
overactive	201 10 B-Disease
bladder	212 7 I-Disease
(	220 1 O
OAB	221 3 B-Disease
)	224 1 O
after	226 5 O
tolterodine	232 11 B-Chemical
treatment	244 9 O
.	253 1 O

MATERIAL	255 8 O
AND	264 3 O
METHOD	268 6 O
:	274 1 O
Thirty	276 6 O
women	283 5 O
(	289 1 O
aged	290 4 O
30	295 2 O
-	297 1 O
77	298 2 O
years	301 5 O
)	306 1 O
diagnosed	308 9 O
as	318 2 O
having	321 6 O
OAB	328 3 B-Disease
at	332 2 O
the	335 3 O
Gynecology	339 10 O
Clinic	350 6 O
,	356 1 O
King	358 4 O
Chulalongkorn	363 13 O
Memorial	377 8 O
Hospital	386 8 O
from	395 4 O
January	400 7 O
to	408 2 O
April	411 5 O
2004	417 4 O
were	422 4 O
included	427 8 O
in	436 2 O
the	439 3 O
present	443 7 O
study	451 5 O
.	456 1 O

Tolterodine	458 11 B-Chemical
2	470 1 O
mg	472 2 O
,	474 1 O
twice	476 5 O
daily	482 5 O
was	488 3 O
given	492 5 O
.	497 1 O

After	499 5 O
8	505 1 O
weeks	507 5 O
treatment	513 9 O
,	522 1 O
changes	524 7 O
in	532 2 O
micturition	535 11 O
diary	547 5 O
variables	553 9 O
and	563 3 O
tolerability	567 12 O
were	580 4 O
determined	585 10 O
.	595 1 O

Short	597 5 O
form	603 4 O
36	608 2 O
(	611 1 O
SF36	612 4 O
)	616 1 O
questionaires	618 13 O
(	632 1 O
Thai	633 4 O
version	638 7 O
)	645 1 O
were	647 4 O
given	652 5 O
before	658 6 O
and	665 3 O
after	669 5 O
8	675 1 O
weeks	677 5 O
of	683 2 O
treatment	686 9 O
.	695 1 O

RESULTS	697 7 O
:	704 1 O
At	706 2 O
8	709 1 O
weeks	711 5 O
,	716 1 O
all	718 3 O
micturition	722 11 O
per	734 3 O
day	738 3 O
decreased	742 9 O
from	752 4 O
16	757 2 O
.	759 1 O

7	761 1 O
+	763 1 O
/	764 1 O
-	765 1 O
5	767 1 O
.	768 1 O

3	770 1 O
to	772 2 O
6	775 1 O
.	776 1 O

7	778 1 O
+	780 1 O
/	781 1 O
-	782 1 O
2	784 1 O
.	785 1 O
4	786 1 O
times	788 5 O
per	794 3 O
day	798 3 O
.	801 1 O

The	803 3 O
number	807 6 O
of	814 2 O
nocturia	817 8 B-Disease
episodes	826 8 O
decreased	835 9 O
from	845 4 O
5	850 1 O
.	851 1 O
4	852 1 O
+	854 1 O
/	855 1 O
-	856 1 O
4	858 1 O
.	859 1 O
2	860 1 O
to	862 2 O
1	865 1 O
.	866 1 O
1	867 1 O
+	869 1 O
/	870 1 O
-	871 1 O
1	873 1 O
.	874 1 O
0	875 1 O
times	877 5 O
per	883 3 O
night	887 5 O
.	892 1 O

The	894 3 O
most	898 4 O
common	903 6 O
side	910 4 O
effect	915 6 O
was	922 3 O
dry	926 3 B-Disease
month	930 5 I-Disease
in	936 2 O
5	939 1 O
cases	941 5 O
(	947 1 O
16	948 2 O
.	950 1 O
7	951 1 O
%	952 1 O
)	953 1 O
with	955 4 O
2	960 1 O
cases	962 5 O
reporting	968 9 O
a	978 1 O
moderate	980 8 O
degree	989 6 O
and	996 3 O
1	1000 1 O
case	1002 4 O
with	1007 4 O
severe	1012 6 O
degree	1019 6 O
.	1025 1 O

Only	1027 4 O
one	1032 3 O
case	1036 4 O
(	1041 1 O
3	1042 1 O
.	1043 1 O
3	1044 1 O
%	1045 1 O
)	1046 1 O
withdrew	1048 8 O
from	1057 4 O
the	1062 3 O
present	1066 7 O
study	1074 5 O
due	1080 3 O
to	1084 2 O
a	1087 1 O
severe	1089 6 O
dry	1096 3 B-Disease
mouth	1100 5 I-Disease
.	1105 1 O

The	1107 3 O
SF	1111 2 O
-	1113 1 O
36	1114 2 O
scores	1117 6 O
changed	1124 7 O
significantly	1132 13 O
in	1146 2 O
the	1149 3 O
domains	1153 7 O
of	1161 2 O
physical	1164 8 O
functioning	1173 11 O
,	1184 1 O
role	1186 4 O
function	1191 8 O
emotional	1200 9 O
,	1209 1 O
social	1211 6 O
function	1218 8 O
and	1227 3 O
mental	1231 6 O
heath	1238 5 O
.	1243 1 O

CONCLUSION	1245 10 O
:	1255 1 O
Tolterodine	1257 11 B-Chemical
was	1269 3 O
well	1273 4 O
tolerated	1278 9 O
and	1288 3 O
its	1292 3 O
effects	1296 7 O
improved	1304 8 O
the	1313 3 O
quality	1317 7 O
of	1325 2 O
life	1328 4 O
in	1333 2 O
Thai	1336 4 O
women	1341 5 O
with	1347 4 O
OAB	1352 3 B-Disease
.	1355 1 O

Absence	0 7 O
of	8 2 O
acute	11 5 O
cerebral	17 8 O
vasoconstriction	26 16 O
after	43 5 O
cocaine	49 7 B-Chemical
-	56 1 O
associated	57 10 O
subarachnoid	68 12 B-Disease
hemorrhage	81 10 I-Disease
.	91 1 O

INTRODUCTION	93 12 O
:	105 1 O
Cocaine	107 7 B-Chemical
use	115 3 O
has	119 3 O
been	123 4 O
associated	128 10 O
with	139 4 O
neurovascular	144 13 B-Disease
complications	158 13 I-Disease
,	171 1 O
including	173 9 O
arterial	183 8 O
vasoconstriction	192 16 O
and	209 3 O
vasculitis	213 10 B-Disease
.	223 1 O

However	225 7 O
,	232 1 O
there	234 5 O
are	240 3 O
few	244 3 O
studies	248 7 O
of	256 2 O
angiographic	259 12 O
effects	272 7 O
of	280 2 O
cocaine	283 7 B-Chemical
on	291 2 O
human	294 5 O
cerebral	300 8 O
arteries	309 8 O
.	317 1 O

Information	319 11 O
on	331 2 O
these	334 5 O
effects	340 7 O
could	348 5 O
be	354 2 O
obtained	357 8 O
from	366 4 O
angiograms	371 10 O
of	382 2 O
patients	385 8 O
with	394 4 O
cocaine	399 7 B-Chemical
-	406 1 O
associated	407 10 O
subarachnoid	418 12 B-Disease
hemorrhage	431 10 I-Disease
(	442 1 O
SAH	443 3 B-Disease
)	446 1 O
who	448 3 O
underwent	452 9 O
angiography	462 11 O
shortly	474 7 O
after	482 5 O
cocaine	488 7 B-Chemical
use	496 3 O
.	499 1 O

METHODS	501 7 O
:	508 1 O
We	510 2 O
screened	513 8 O
patients	522 8 O
with	531 4 O
SAH	536 3 B-Disease
retrospectively	540 15 O
and	556 3 O
identified	560 10 O
those	571 5 O
with	577 4 O
positive	582 8 O
urine	591 5 O
toxicology	597 10 O
for	608 3 O
cocaine	612 7 B-Chemical
or	620 2 O
its	623 3 O
metabolites	627 11 O
.	638 1 O

Quantitative	640 12 O
arterial	653 8 O
diameter	662 8 O
measurements	671 12 O
from	684 4 O
angiograms	689 10 O
of	700 2 O
these	703 5 O
patients	709 8 O
were	718 4 O
compared	723 8 O
to	732 2 O
measurements	735 12 O
from	748 4 O
control	753 7 O
patients	761 8 O
with	770 4 O
SAH	775 3 B-Disease
who	779 3 O
were	783 4 O
matched	788 7 O
for	796 3 O
factors	800 7 O
known	808 5 O
to	814 2 O
influence	817 9 O
arterial	827 8 O
diameter	836 8 O
.	844 1 O

Qualitative	846 11 O
comparisons	858 11 O
of	870 2 O
small	873 5 O
artery	879 6 O
changes	886 7 O
also	894 4 O
were	899 4 O
made	904 4 O
.	908 1 O

RESULTS	910 7 O
:	917 1 O
Thirteen	919 8 O
patients	928 8 O
with	937 4 O
positive	942 8 O
cocaine	951 7 B-Chemical
toxicology	959 10 O
were	970 4 O
compared	975 8 O
to	984 2 O
26	987 2 O
controls	990 8 O
.	998 1 O

There	1000 5 O
were	1006 4 O
no	1011 2 O
significant	1014 11 O
differences	1026 11 O
between	1038 7 O
groups	1046 6 O
in	1053 2 O
the	1056 3 O
mean	1060 4 O
diameters	1065 9 O
of	1075 2 O
the	1078 3 O
intradural	1082 10 O
internal	1093 8 O
carotid	1102 7 O
,	1109 1 O
sphenoidal	1111 10 O
segment	1122 7 O
of	1130 2 O
the	1133 3 O
middle	1137 6 O
cerebral	1144 8 O
,	1152 1 O
precommunicating	1154 16 O
segment	1171 7 O
of	1179 2 O
the	1182 3 O
anterior	1186 8 O
cerebral	1195 8 O
,	1203 1 O
or	1205 2 O
basilar	1208 7 O
arteries	1216 8 O
(	1225 1 O
p	1226 1 O
greater	1228 7 O
than	1236 4 O
0	1241 1 O
.	1242 1 O
05	1243 2 O
for	1246 3 O
all	1250 3 O
comparisons	1254 11 O
,	1265 1 O
unpaired	1267 8 O
t	1276 1 O
-	1277 1 O
tests	1278 5 O
)	1283 1 O
.	1284 1 O

There	1286 5 O
also	1292 4 O
were	1297 4 O
no	1302 2 O
significant	1305 11 O
differences	1317 11 O
between	1329 7 O
groups	1337 6 O
when	1344 4 O
expressing	1349 10 O
diameters	1360 9 O
as	1370 2 O
the	1373 3 O
sum	1377 3 O
of	1381 2 O
the	1384 3 O
precommunicating	1388 16 O
segment	1405 7 O
of	1413 2 O
the	1416 3 O
anterior	1420 8 O
cerebral	1429 8 O
+	1438 1 O
sphenoidal	1440 10 O
segment	1451 7 O
of	1459 2 O
the	1462 3 O
middle	1466 6 O
cerebral	1473 8 O
+	1482 1 O
supraclinoid	1484 12 O
internal	1497 8 O
carotid	1506 7 O
artery	1514 6 O
+	1521 1 O
basilar	1523 7 O
artery	1531 6 O
divided	1538 7 O
by	1546 2 O
the	1549 3 O
diameter	1553 8 O
of	1562 2 O
the	1565 3 O
petrous	1569 7 O
internal	1577 8 O
carotid	1586 7 O
artery	1594 6 O
(	1601 1 O
p	1602 1 O
greater	1604 7 O
than	1612 4 O
0	1617 1 O
.	1618 1 O
05	1619 2 O
,	1621 1 O
unpaired	1623 8 O
t	1632 1 O
-	1633 1 O
tests	1634 5 O
)	1639 1 O
.	1640 1 O

Qualitative	1642 11 O
assessments	1654 11 O
showed	1666 6 O
two	1673 3 O
arterial	1677 8 O
irregularities	1686 14 O
in	1701 2 O
the	1704 3 O
distal	1708 6 O
vasculature	1715 11 O
in	1727 2 O
each	1730 4 O
group	1735 5 O
.	1740 1 O

CONCLUSION	1742 10 O
:	1752 1 O
No	1754 2 O
quantitative	1757 12 O
evidence	1770 8 O
for	1779 3 O
narrowing	1783 9 O
of	1793 2 O
large	1796 5 O
cerebral	1802 8 O
arteries	1811 8 O
or	1820 2 O
qualitative	1823 11 O
angiographic	1835 12 O
evidence	1848 8 O
for	1857 3 O
distal	1861 6 O
narrowing	1868 9 O
or	1878 2 O
vasculitis	1881 10 B-Disease
could	1892 5 O
be	1898 2 O
found	1901 5 O
in	1907 2 O
patients	1910 8 O
who	1919 3 O
underwent	1923 9 O
angiography	1933 11 O
after	1945 5 O
aneurysmal	1951 10 B-Disease
SAH	1962 3 B-Disease
associated	1966 10 O
with	1977 4 O
cocaine	1982 7 B-Chemical
use	1990 3 O
.	1993 1 O

Atrial	0 6 B-Disease
fibrillation	7 12 I-Disease
following	20 9 O
chemotherapy	30 12 O
for	43 3 O
stage	47 5 O
IIIE	53 4 O
diffuse	58 7 O
large	66 5 O
B	72 1 O
-	73 1 O
cell	74 4 O
gastric	79 7 B-Disease
lymphoma	87 8 I-Disease
in	96 2 O
a	99 1 O
patient	101 7 O
with	109 4 O
myotonic	114 8 B-Disease
dystrophy	123 9 I-Disease
(	133 1 O
Steinert	134 8 B-Disease
'	142 1 I-Disease
s	143 1 I-Disease
disease	145 7 I-Disease
)	152 1 O
.	153 1 O

The	155 3 O
authors	159 7 O
describe	167 8 O
the	176 3 O
unusual	180 7 O
association	188 11 O
between	200 7 O
diffuse	208 7 O
B	216 1 O
-	217 1 O
cell	218 4 O
gastric	223 7 B-Disease
lymphoma	231 8 I-Disease
and	240 3 O
myotonic	244 8 B-Disease
dystrophy	253 9 I-Disease
,	262 1 O
the	264 3 O
most	268 4 O
common	273 6 O
form	280 4 O
of	285 2 O
adult	288 5 O
muscular	294 8 B-Disease
dystrophy	303 9 I-Disease
,	312 1 O
and	314 3 O
sudden	318 6 O
atrial	325 6 B-Disease
fibrillation	332 12 I-Disease
following	345 9 O
one	355 3 O
cycle	359 5 O
of	365 2 O
doxorubicin	368 11 B-Chemical
-	379 1 O
based	380 5 O
chemotherapy	386 12 O
in	399 2 O
the	402 3 O
same	406 4 O
patient	411 7 O
.	418 1 O

Atrial	420 6 B-Disease
fibrillation	427 12 I-Disease
or	440 2 O
other	443 5 O
cardiac	449 7 B-Disease
arrhythmias	457 11 I-Disease
are	469 3 O
unusual	473 7 O
complications	481 13 O
in	495 2 O
patients	498 8 O
treated	507 7 O
with	515 4 O
chemotherapy	520 12 O
.	532 1 O

The	534 3 O
cardiac	538 7 B-Disease
toxicity	546 8 I-Disease
intrinsically	555 13 O
associated	569 10 O
with	580 4 O
the	585 3 O
aggressive	589 10 O
chemotherapy	600 12 O
employed	613 8 O
could	622 5 O
function	628 8 O
as	637 2 O
a	640 1 O
triggering	642 10 O
factor	653 6 O
for	660 3 O
the	664 3 O
arrhythmia	668 10 B-Disease
in	679 2 O
the	682 3 O
predisposed	686 11 O
myocardium	698 10 O
of	709 2 O
this	712 4 O
patient	717 7 O
.	724 1 O

A	0 1 O
phase	2 5 O
II	8 2 O
study	11 5 O
of	17 2 O
thalidomide	20 11 B-Chemical
in	32 2 O
advanced	35 8 O
metastatic	44 10 O
renal	55 5 B-Disease
cell	61 4 I-Disease
carcinoma	66 9 I-Disease
.	75 1 O

OBJECTIVES	77 10 O
:	87 1 O
To	89 2 O
evaluate	92 8 O
the	101 3 O
toxicity	105 8 B-Disease
and	114 3 O
activity	118 8 O
of	127 2 O
thalidomide	130 11 B-Chemical
in	142 2 O
patients	145 8 O
with	154 4 O
advanced	159 8 O
metastatic	168 10 O
renal	179 5 B-Disease
cell	185 4 I-Disease
cancer	190 6 I-Disease
and	197 3 O
to	201 2 O
measure	204 7 O
changes	212 7 O
of	220 2 O
one	223 3 O
angiogenic	227 10 O
factor	238 6 O
,	244 1 O
vascular	246 8 O
endothelial	255 11 O
growth	267 6 O
factor	274 6 O
(	281 1 O
VEGF	282 4 O
)	286 1 O
165	287 3 O
,	290 1 O
with	292 4 O
therapy	297 7 O
.	304 1 O

PATIENTS	306 8 O
AND	315 3 O
METHODS	319 7 O
:	326 1 O
29	328 2 O
patients	331 8 O
were	340 4 O
enrolled	345 8 O
on	354 2 O
a	357 1 O
study	359 5 O
of	365 2 O
thalidomide	368 11 B-Chemical
using	380 5 O
an	386 2 O
intra	389 5 O
-	394 1 O
patient	395 7 O
dose	403 4 O
escalation	408 10 O
schedule	419 8 O
.	427 1 O

Patients	429 8 O
began	438 5 O
thalidomide	444 11 B-Chemical
at	456 2 O
400	459 3 O
mg	463 2 O
/	465 1 O
d	466 1 O
and	468 3 O
escalated	472 9 O
as	482 2 O
tolerated	485 9 O
to	495 2 O
1200	498 4 O
mg	503 2 O
/	505 1 O
d	506 1 O
by	508 2 O
day	511 3 O
54	515 2 O
.	517 1 O

Fifty	519 5 O
-	524 1 O
nine	525 4 O
per	530 3 O
cent	534 4 O
of	539 2 O
patients	542 8 O
had	551 3 O
had	555 3 O
previous	559 8 O
therapy	568 7 O
with	576 4 O
IL	581 2 O
-	583 1 O
2	584 1 O
and	586 3 O
52	590 2 O
%	592 1 O
were	594 4 O
performance	599 11 O
status	611 6 O
2	618 1 O
or	620 2 O
3	623 1 O
.	624 1 O

Systemic	626 8 O
plasma	635 6 O
VEGF165	642 7 O
levels	650 6 O
were	657 4 O
measured	662 8 O
by	671 2 O
dual	674 4 O
monoclonal	679 10 O
ELISA	690 5 O
in	696 2 O
8	699 1 O
patients	701 8 O
.	709 1 O

RESULTS	711 7 O
:	718 1 O
24	720 2 O
patients	723 8 O
were	732 4 O
evaluable	737 9 O
for	747 3 O
response	751 8 O
with	760 4 O
one	765 3 O
partial	769 7 O
response	777 8 O
of	786 2 O
11	789 2 O
months	792 6 O
duration	799 8 O
of	808 2 O
a	811 1 O
patient	813 7 O
with	821 4 O
hepatic	826 7 O
and	834 3 O
pulmonary	838 9 O
metastases	848 10 B-Disease
(	859 1 O
4	860 1 O
%	861 1 O
)	862 1 O
,	863 1 O
one	865 3 O
minor	869 5 O
response	875 8 O
,	883 1 O
and	885 3 O
2	889 1 O
patients	891 8 O
stable	900 6 O
for	907 3 O
over	911 4 O
6	916 1 O
months	918 6 O
.	924 1 O

Somnolence	926 10 B-Disease
and	937 3 O
constipation	941 12 B-Disease
were	954 4 O
prominent	959 9 O
toxicities	969 10 B-Disease
and	980 3 O
most	984 4 O
patients	989 8 O
could	998 5 O
not	1004 3 O
tolerate	1008 8 O
the	1017 3 O
1200	1021 4 O
mg	1026 2 O
/	1028 1 O
day	1029 3 O
dose	1033 4 O
level	1038 5 O
.	1043 1 O

Systemic	1045 8 O
plasma	1054 6 O
VEGF165	1061 7 O
levels	1069 6 O
did	1076 3 O
not	1080 3 O
change	1084 6 O
with	1091 4 O
therapy	1096 7 O
.	1103 1 O

CONCLUSION	1105 10 O
:	1115 1 O
These	1117 5 O
results	1123 7 O
are	1131 3 O
consistent	1135 10 O
with	1146 4 O
a	1151 1 O
low	1153 3 O
level	1157 5 O
of	1163 2 O
activity	1166 8 O
of	1175 2 O
thalidomide	1178 11 B-Chemical
in	1190 2 O
renal	1193 5 B-Disease
cell	1199 4 I-Disease
carcinoma	1204 9 I-Disease
.	1213 1 O

Administration	1215 14 O
of	1230 2 O
doses	1233 5 O
over	1239 4 O
800	1244 3 O
mg	1248 2 O
/	1250 1 O
day	1251 3 O
was	1255 3 O
difficult	1259 9 O
to	1269 2 O
achieve	1272 7 O
in	1280 2 O
this	1283 4 O
patient	1288 7 O
population	1296 10 O
,	1306 1 O
however	1308 7 O
lower	1316 5 O
doses	1322 5 O
were	1328 4 O
practical	1333 9 O
.	1342 1 O

The	1344 3 O
dose	1348 4 O
-	1352 1 O
response	1353 8 O
relationship	1362 12 O
,	1374 1 O
if	1376 2 O
any	1379 3 O
,	1382 1 O
of	1384 2 O
thalidomide	1387 11 B-Chemical
for	1399 3 O
renal	1403 5 B-Disease
cell	1409 4 I-Disease
carcinoma	1414 9 I-Disease
is	1424 2 O
unclear	1427 7 O
.	1434 1 O

The	0 3 O
striatum	4 8 O
as	13 2 O
a	16 1 O
target	18 6 O
for	25 3 O
anti	29 4 O
-	33 1 O
rigor	34 5 O
effects	40 7 O
of	48 2 O
an	51 2 O
antagonist	54 10 O
of	65 2 O
mGluR1	68 6 O
,	74 1 O
but	76 3 O
not	80 3 O
an	84 2 O
agonist	87 7 O
of	95 2 O
group	98 5 O
II	104 2 O
metabotropic	107 12 O
glutamate	120 9 B-Chemical
receptors	130 9 O
.	139 1 O

The	141 3 O
aim	145 3 O
of	149 2 O
the	152 3 O
present	156 7 O
study	164 5 O
was	170 3 O
to	174 2 O
find	177 4 O
out	182 3 O
whether	186 7 O
the	194 3 O
metabotropic	198 12 O
receptor	211 8 O
1	220 1 O
(	222 1 O
mGluR1	223 6 O
)	229 1 O
and	231 3 O
group	235 5 O
II	241 2 O
mGluRs	244 6 O
,	250 1 O
localized	252 9 O
in	262 2 O
the	265 3 O
striatum	269 8 O
,	277 1 O
are	279 3 O
involved	283 8 O
in	292 2 O
antiparkinsonian	295 16 O
-	311 1 O
like	312 4 O
effects	317 7 O
in	325 2 O
rats	328 4 O
.	332 1 O

Haloperidol	334 11 B-Chemical
(	346 1 O
1	347 1 O
mg	349 2 O
/	351 1 O
kg	352 2 O
ip	355 2 O
)	357 1 O
induced	359 7 O
parkinsonian	367 12 B-Disease
-	379 1 O
like	380 4 O
muscle	385 6 B-Disease
rigidity	392 8 I-Disease
,	400 1 O
measured	402 8 O
as	411 2 O
an	414 2 O
increased	417 9 O
resistance	427 10 O
of	438 2 O
a	441 1 O
rat	443 3 O
'	446 1 O
s	447 1 O
hind	449 4 O
foot	454 4 O
to	459 2 O
passive	462 7 O
flexion	470 7 O
and	478 3 O
extension	482 9 O
at	492 2 O
the	495 3 O
ankle	499 5 O
joint	505 5 O
.	510 1 O

(	512 1 B-Chemical
RS	513 2 I-Chemical
)	515 1 I-Chemical
-	516 1 I-Chemical
1	517 1 I-Chemical
-	518 1 I-Chemical
aminoindan	519 10 I-Chemical
-	529 1 I-Chemical
1	530 1 I-Chemical
,	531 1 I-Chemical
5	532 1 I-Chemical
-	533 1 I-Chemical
dicarboxylic	534 12 I-Chemical
acid	547 4 I-Chemical
(	552 1 O
AIDA	553 4 B-Chemical
;	557 1 O
0	559 1 O
.	560 1 O
5	561 1 O
-	562 1 O
15	563 2 O
microg	566 6 O
/	572 1 O
0	573 1 O
.	574 1 O
5	575 1 O
microl	577 6 O
)	583 1 O
,	584 1 O
a	586 1 O
potent	588 6 O
and	595 3 O
selective	599 9 O
mGluR1	609 6 O
antagonist	616 10 O
,	626 1 O
or	628 2 O
(	631 1 B-Chemical
2R	632 2 I-Chemical
,	634 1 I-Chemical
4R	635 2 I-Chemical
)	637 1 I-Chemical
-	638 1 I-Chemical
4	639 1 I-Chemical
-	640 1 I-Chemical
aminopyrrolidine	641 16 I-Chemical
-	657 1 I-Chemical
2	658 1 I-Chemical
,	659 1 I-Chemical
4	660 1 I-Chemical
-	661 1 I-Chemical
dicarboxylate	662 13 I-Chemical
(	676 1 O
2R	677 2 B-Chemical
,	679 1 I-Chemical
4R	680 2 I-Chemical
-	682 1 I-Chemical
APDC	683 4 I-Chemical
;	687 1 O
7	689 1 O
.	690 1 O
5	691 1 O
-	692 1 O
15	693 2 O
microg	696 6 O
/	702 1 O
0	703 1 O
.	704 1 O
5	705 1 O
microl	707 6 O
)	713 1 O
,	714 1 O
a	716 1 O
selective	718 9 O
group	728 5 O
II	734 2 O
agonist	737 7 O
,	744 1 O
was	746 3 O
injected	750 8 O
bilaterally	759 11 O
into	771 4 O
the	776 3 O
striatum	780 8 O
of	789 2 O
haloperidol	792 11 B-Chemical
-	803 1 O
treated	804 7 O
animals	812 7 O
.	819 1 O

AIDA	821 4 B-Chemical
in	826 2 O
doses	829 5 O
of	835 2 O
7	838 1 O
.	839 1 O
5	840 1 O
-	841 1 O
15	842 2 O
microg	845 6 O
/	851 1 O
0	852 1 O
.	853 1 O
5	854 1 O
microl	856 6 O
diminished	863 10 O
the	874 3 O
haloperidol	878 11 B-Chemical
-	889 1 O
induced	890 7 O
muscle	898 6 B-Disease
rigidity	905 8 I-Disease
.	913 1 O

In	915 2 O
contrast	918 8 O
,	926 1 O
2R	928 2 B-Chemical
,	930 1 I-Chemical
4R	931 2 I-Chemical
-	933 1 I-Chemical
APDC	934 4 I-Chemical
injections	939 10 O
were	950 4 O
ineffective	955 11 O
.	966 1 O

The	968 3 O
present	972 7 O
results	980 7 O
may	988 3 O
suggest	992 7 O
that	1000 4 O
the	1005 3 O
blockade	1009 8 O
of	1018 2 O
striatal	1021 8 O
mGluR1	1030 6 O
,	1036 1 O
but	1038 3 O
not	1042 3 O
the	1046 3 O
stimulation	1050 11 O
of	1062 2 O
group	1065 5 O
II	1071 2 O
mGluRs	1074 6 O
,	1080 1 O
may	1082 3 O
ameliorate	1086 10 O
parkinsonian	1097 12 B-Disease
muscle	1110 6 B-Disease
rigidity	1117 8 I-Disease
.	1125 1 O

Acute	0 5 O
cholestatic	6 11 B-Disease
hepatitis	18 9 I-Disease
after	28 5 O
exposure	34 8 O
to	43 2 O
isoflurane	46 10 B-Chemical
.	56 1 O

OBJECTIVE	58 9 O
:	67 1 O
To	69 2 O
report	72 6 O
a	79 1 O
case	81 4 O
of	86 2 O
acute	89 5 O
cholestatic	95 11 B-Disease
hepatitis	107 9 I-Disease
following	117 9 O
exposure	127 8 O
to	136 2 O
the	139 3 O
inhalational	143 12 O
anesthetic	156 10 O
isoflurane	167 10 B-Chemical
.	177 1 O

CASE	179 4 O
SUMMARY	184 7 O
:	191 1 O
A	193 1 O
70	195 2 O
-	197 1 O
year	198 4 O
-	202 1 O
old	203 3 O
healthy	207 7 O
woman	215 5 O
from	221 4 O
Iraq	226 4 O
developed	231 9 O
acute	241 5 O
cholestatic	247 11 B-Disease
hepatitis	259 9 I-Disease
3	269 1 O
weeks	271 5 O
following	277 9 O
repair	287 6 O
of	294 2 O
the	297 3 O
right	301 5 O
rotator	307 7 O
cuff	315 4 O
under	320 5 O
general	326 7 O
anesthesia	334 10 O
.	344 1 O

There	346 5 O
was	352 3 O
no	356 2 O
evidence	359 8 O
for	368 3 O
viral	372 5 O
,	377 1 O
autoimmune	379 10 O
,	389 1 O
or	391 2 O
metabolic	394 9 O
causes	404 6 O
of	411 2 O
hepatitis	414 9 B-Disease
.	423 1 O

No	425 2 O
other	428 5 O
medications	434 11 O
were	446 4 O
involved	451 8 O
except	460 6 O
for	467 3 O
dipyrone	471 8 B-Chemical
for	480 3 O
analgesia	484 9 B-Disease
.	493 1 O

The	495 3 O
alanine	499 7 B-Chemical
aminotransferase	507 16 O
was	524 3 O
elevated	528 8 O
to	537 2 O
a	540 1 O
peak	542 4 O
concentration	547 13 O
of	561 2 O
1533	564 4 O
U	569 1 O
/	570 1 O
L	571 1 O
and	573 3 O
the	577 3 O
serum	581 5 O
bilirubin	587 9 B-Chemical
reached	597 7 O
a	605 1 O
peak	607 4 O
of	612 2 O
17	615 2 O
.	617 1 O
0	618 1 O
mg	620 2 O
/	622 1 O
dL	623 2 O
.	625 1 O

There	627 5 O
was	633 3 O
slow	637 4 O
improvement	642 11 O
over	654 4 O
4	659 1 O
months	661 6 O
.	667 1 O

Accidental	669 10 O
reexposure	680 10 O
by	691 2 O
the	694 3 O
patient	698 7 O
to	706 2 O
dipyrone	709 8 B-Chemical
was	718 3 O
uneventful	722 10 O
.	732 1 O

DISCUSSION	734 10 O
:	744 1 O
The	746 3 O
clinical	750 8 O
and	759 3 O
histologic	763 10 O
picture	774 7 O
of	782 2 O
this	785 4 O
case	790 4 O
resembles	795 9 O
halothane	805 9 B-Disease
hepatitis	815 9 I-Disease
,	824 1 O
which	826 5 O
has	832 3 O
a	836 1 O
significant	838 11 O
mortality	850 9 O
rate	860 4 O
.	864 1 O

CONCLUSIONS	866 11 O
:	877 1 O
Isoflurane	879 10 B-Chemical
,	889 1 O
a	891 1 O
common	893 6 O
anesthetic	900 10 O
agent	911 5 O
,	916 1 O
can	918 3 O
cause	922 5 O
severe	928 6 O
cholestatic	935 11 B-Disease
hepatitis	947 9 I-Disease
.	956 1 O

Calcitonin	0 10 O
gene	11 4 O
-	15 1 O
related	16 7 O
peptide	24 7 O
levels	32 6 O
during	39 6 O
nitric	46 6 B-Chemical
oxide	53 5 I-Chemical
-	58 1 O
induced	59 7 O
headache	67 8 B-Disease
in	76 2 O
patients	79 8 O
with	88 4 O
chronic	93 7 O
tension	101 7 B-Disease
-	108 1 I-Disease
type	109 4 I-Disease
headache	114 8 I-Disease
.	122 1 O

It	124 2 O
has	127 3 O
been	131 4 O
proposed	136 8 O
that	145 4 O
nitric	150 6 B-Chemical
oxide	157 5 I-Chemical
(	163 1 O
NO	164 2 B-Chemical
)	166 1 O
induced	168 7 O
headache	176 8 B-Disease
in	185 2 O
primary	188 7 B-Disease
headaches	196 9 I-Disease
may	206 3 O
be	210 2 O
associated	213 10 O
with	224 4 O
release	229 7 O
of	237 2 O
calcitonin	240 10 O
gene	251 4 O
-	255 1 O
related	256 7 O
peptide	264 7 O
(	272 1 O
CGRP	273 4 O
)	277 1 O
.	278 1 O

In	280 2 O
the	283 3 O
present	287 7 O
study	295 5 O
we	301 2 O
aimed	304 5 O
to	310 2 O
investigate	313 11 O
plasma	325 6 O
levels	332 6 O
of	339 2 O
CGRP	342 4 O
during	347 6 O
headache	354 8 B-Disease
induced	363 7 O
by	371 2 O
the	374 3 O
NO	378 2 B-Chemical
donor	381 5 O
glyceryl	387 8 B-Chemical
trinitrate	396 10 I-Chemical
(	407 1 O
GTN	408 3 B-Chemical
)	411 1 O
in	413 2 O
16	416 2 O
patients	419 8 O
with	428 4 O
chronic	433 7 O
tension	441 7 B-Disease
-	448 1 I-Disease
type	449 4 I-Disease
headache	454 8 I-Disease
and	463 3 O
16	467 2 O
healthy	470 7 O
controls	478 8 O
.	486 1 O

The	488 3 O
subjects	492 8 O
were	501 4 O
randomly	506 8 O
allocated	515 9 O
to	525 2 O
receive	528 7 O
0	536 1 O
.	537 1 O
5	538 1 O
microg	540 6 O
/	546 1 O
kg	547 2 O
/	549 1 O
min	550 3 O
GTN	554 3 B-Chemical
or	558 2 O
placebo	561 7 O
over	569 4 O
20	574 2 O
min	577 3 O
on	581 2 O
two	584 3 O
headache	588 8 B-Disease
-	596 1 O
free	597 4 O
days	602 4 O
.	606 1 O

Blood	608 5 O
samples	614 7 O
were	622 4 O
collected	627 9 O
at	637 2 O
baseline	640 8 O
,	648 1 O
10	650 2 O
,	652 1 O
20	654 2 O
and	657 3 O
60	661 2 O
min	664 3 O
after	668 5 O
start	674 5 O
of	680 2 O
infusion	683 8 O
.	691 1 O

Both	693 4 O
patients	698 8 O
and	707 3 O
controls	711 8 O
developed	720 9 O
significantly	730 13 O
stronger	744 8 O
immediate	753 9 O
headache	763 8 B-Disease
on	772 2 O
the	775 3 O
GTN	779 3 B-Chemical
day	783 3 O
than	787 4 O
on	792 2 O
the	795 3 O
placebo	799 7 O
day	807 3 O
and	811 3 O
the	815 3 O
headache	819 8 B-Disease
was	828 3 O
significantly	832 13 O
more	846 4 O
pronounced	851 10 O
in	862 2 O
patients	865 8 O
than	874 4 O
in	879 2 O
controls	882 8 O
.	890 1 O

There	892 5 O
was	898 3 O
no	902 2 O
difference	905 10 O
between	916 7 O
the	924 3 O
area	928 4 O
under	933 5 O
the	939 3 O
CGRP	943 4 O
curve	948 5 O
(	954 1 O
AUCCGRP	955 7 O
)	962 1 O
on	964 2 O
GTN	967 3 B-Chemical
vs	971 2 O
.	973 1 O
placebo	975 7 O
day	983 3 O
in	987 2 O
either	990 6 O
patients	997 8 O
(	1006 1 O
P	1007 1 O
=	1008 1 O
0	1009 1 O
.	1010 1 O
65	1011 2 O
)	1013 1 O
or	1015 2 O
controls	1018 8 O
(	1027 1 O
P	1028 1 O
=	1029 1 O
0	1030 1 O
.	1031 1 O
48	1032 2 O
)	1034 1 O
.	1035 1 O

The	1037 3 O
AUCCGRP	1041 7 O
recorded	1049 8 O
on	1058 2 O
the	1061 3 O
GTN	1065 3 B-Chemical
day	1069 3 O
did	1073 3 O
not	1077 3 O
differ	1081 6 O
between	1088 7 O
patients	1096 8 O
and	1105 3 O
controls	1109 8 O
(	1118 1 O
P	1119 1 O
=	1120 1 O
0	1121 1 O
.	1122 1 O
36	1123 2 O
)	1125 1 O
.	1126 1 O

Both	1128 4 O
in	1133 2 O
patients	1136 8 O
and	1145 3 O
controls	1149 8 O
,	1157 1 O
CGRP	1159 4 O
levels	1164 6 O
changed	1171 7 O
significantly	1179 13 O
over	1193 4 O
time	1198 4 O
,	1202 1 O
on	1204 2 O
both	1207 4 O
the	1212 3 O
GTN	1216 3 B-Chemical
and	1220 3 O
placebo	1224 7 O
days	1232 4 O
(	1237 1 O
P	1238 1 O
<	1240 1 O
0	1242 1 O
.	1243 1 O
05	1244 2 O
)	1246 1 O
.	1247 1 O

The	1249 3 O
present	1253 7 O
study	1261 5 O
indicates	1267 9 O
that	1277 4 O
NO	1282 2 B-Chemical
-	1284 1 O
induced	1285 7 O
immediate	1293 9 O
headache	1303 8 B-Disease
is	1312 2 O
not	1315 3 O
associated	1319 10 O
with	1330 4 O
release	1335 7 O
of	1343 2 O
CGRP	1346 4 O
.	1350 1 O

Myocardial	0 10 B-Disease
ischemia	11 8 I-Disease
due	20 3 O
to	24 2 O
coronary	27 8 B-Disease
artery	36 6 I-Disease
spasm	43 5 I-Disease
during	49 6 O
dobutamine	56 10 B-Chemical
stress	67 6 O
echocardiography	74 16 O
.	90 1 O

Dobutamine	92 10 B-Chemical
stress	103 6 O
echocardiography	110 16 O
(	127 1 O
DSE	128 3 O
)	131 1 O
is	133 2 O
a	136 1 O
useful	138 6 O
and	145 3 O
safe	149 4 O
provocation	154 11 O
test	166 4 O
for	171 3 O
myocardial	175 10 B-Disease
ischemia	186 8 I-Disease
.	194 1 O

Until	196 5 O
now	202 3 O
,	205 1 O
the	207 3 O
test	211 4 O
has	216 3 O
been	220 4 O
focused	225 7 O
only	233 4 O
on	238 2 O
the	241 3 O
organic	245 7 O
lesion	253 6 O
in	260 2 O
the	263 3 O
coronary	267 8 O
artery	276 6 O
,	282 1 O
and	284 3 O
positive	288 8 O
DSE	297 3 O
has	301 3 O
indicated	305 9 O
the	315 3 O
presence	319 8 O
of	328 2 O
significant	331 11 O
fixed	343 5 O
coronary	349 8 B-Disease
artery	358 6 I-Disease
stenosis	365 8 I-Disease
.	373 1 O

The	375 3 O
aim	379 3 O
of	383 2 O
the	386 3 O
present	390 7 O
study	398 5 O
is	404 2 O
to	407 2 O
examine	410 7 O
whether	418 7 O
myocardial	426 10 B-Disease
ischemia	437 8 I-Disease
due	446 3 O
to	450 2 O
coronary	453 8 B-Disease
spasm	462 5 I-Disease
is	468 2 O
induced	471 7 O
by	479 2 O
dobutamine	482 10 B-Chemical
.	492 1 O

We	494 2 O
performed	497 9 O
DSE	507 3 O
on	511 2 O
51	514 2 O
patients	517 8 O
with	526 4 O
coronary	531 8 B-Disease
spastic	540 7 I-Disease
angina	548 6 I-Disease
but	555 3 O
without	559 7 O
significant	567 11 O
fixed	579 5 O
coronary	585 8 B-Disease
artery	594 6 I-Disease
stenosis	601 8 I-Disease
.	609 1 O

All	611 3 O
patients	615 8 O
had	624 3 O
anginal	628 7 B-Disease
attacks	636 7 O
at	644 2 O
rest	647 4 O
with	652 4 O
ST	657 2 O
elevation	660 9 O
on	670 2 O
the	673 3 O
electrocardiogram	677 17 O
(	695 1 O
variant	696 7 B-Disease
angina	704 6 I-Disease
)	710 1 O
.	711 1 O

Coronary	713 8 O
spasm	722 5 O
was	728 3 O
induced	732 7 O
by	740 2 O
intracoronary	743 13 O
injection	757 9 O
of	767 2 O
acetylcholine	770 13 B-Chemical
,	783 1 O
and	785 3 O
no	789 2 O
fixed	792 5 O
coronary	798 8 B-Disease
artery	807 6 I-Disease
stenosis	814 8 I-Disease
was	823 3 O
documented	827 10 O
on	838 2 O
angiograms	841 10 O
in	852 2 O
all	855 3 O
patients	859 8 O
.	867 1 O

DSE	869 3 O
was	873 3 O
performed	877 9 O
with	887 4 O
intravenous	892 11 O
dobutamine	904 10 B-Chemical
infusion	915 8 O
with	924 4 O
an	929 2 O
incremental	932 11 O
doses	944 5 O
of	950 2 O
5	953 1 O
,	954 1 O
10	956 2 O
,	958 1 O
20	960 2 O
,	962 1 O
30	964 2 O
,	966 1 O
and	968 3 O
40	972 2 O
microg	975 6 O
/	981 1 O
kg	982 2 O
/	984 1 O
min	985 3 O
every	989 5 O
5	995 1 O
minutes	997 7 O
.	1004 1 O

Of	1006 2 O
the	1009 3 O
51	1013 2 O
patients	1016 8 O
,	1024 1 O
7	1026 1 O
patients	1028 8 O
showed	1037 6 O
asynergy	1044 8 O
with	1053 4 O
ST	1058 2 O
elevation	1061 9 O
.	1070 1 O

All	1072 3 O
7	1076 1 O
patients	1078 8 O
(	1087 1 O
13	1088 2 O
.	1090 1 O
7	1091 1 O
%	1092 1 O
)	1093 1 O
had	1095 3 O
chest	1099 5 B-Disease
pain	1105 4 I-Disease
during	1110 6 O
asynergy	1117 8 O
,	1125 1 O
and	1127 3 O
both	1131 4 O
chest	1136 5 B-Disease
pain	1142 4 I-Disease
and	1147 3 O
electrocardiographic	1151 20 O
changes	1172 7 O
were	1180 4 O
preceded	1185 8 O
by	1194 2 O
asynergy	1197 8 O
.	1205 1 O

These	1207 5 O
findings	1213 8 O
indicate	1222 8 O
that	1231 4 O
dobutamine	1236 10 B-Chemical
can	1247 3 O
provoke	1251 7 O
coronary	1259 8 B-Disease
spasm	1268 5 I-Disease
in	1274 2 O
some	1277 4 O
patients	1282 8 O
with	1291 4 O
coronary	1296 8 B-Disease
spastic	1305 7 I-Disease
angina	1313 6 I-Disease
.	1319 1 O

When	1321 4 O
DSE	1326 3 O
is	1330 2 O
performed	1333 9 O
to	1343 2 O
evaluate	1346 8 O
coronary	1355 8 B-Disease
artery	1364 6 I-Disease
disease	1371 7 I-Disease
,	1378 1 O
not	1380 3 O
only	1384 4 O
fixed	1389 5 O
coronary	1395 8 B-Disease
stenosis	1404 8 I-Disease
,	1412 1 O
but	1414 3 O
also	1418 4 O
coronary	1423 8 B-Disease
spasm	1432 5 I-Disease
should	1438 6 O
be	1445 2 O
considered	1448 10 O
as	1459 2 O
a	1462 1 O
genesis	1464 7 O
of	1472 2 O
asynergy	1475 8 O
.	1483 1 O

Nitric	0 6 B-Chemical
oxide	7 5 I-Chemical
synthase	13 8 O
expression	22 10 O
in	33 2 O
the	36 3 O
course	40 6 O
of	47 2 O
lead	50 4 B-Chemical
-	54 1 O
induced	55 7 O
hypertension	63 12 B-Disease
.	75 1 O

We	77 2 O
recently	80 8 O
showed	89 6 O
elevated	96 8 O
reactive	105 8 O
oxygen	114 6 B-Chemical
species	121 7 O
(	129 1 O
ROS	130 3 O
)	133 1 O
,	134 1 O
reduced	136 7 O
urinary	144 7 O
excretion	152 9 O
of	162 2 O
NO	165 2 B-Chemical
metabolites	168 11 O
(	180 1 O
NOx	181 3 O
)	184 1 O
,	185 1 O
and	187 3 O
increased	191 9 O
NO	201 2 B-Chemical
sequestration	204 13 O
as	218 2 O
nitrotyrosine	221 13 B-Chemical
in	235 2 O
various	238 7 O
tissues	246 7 O
in	254 2 O
rats	257 4 O
with	262 4 O
lead	267 4 B-Chemical
-	271 1 O
induced	272 7 O
hypertension	280 12 B-Disease
.	292 1 O

This	294 4 O
study	299 5 O
was	305 3 O
designed	309 8 O
to	318 2 O
discern	321 7 O
whether	329 7 O
the	337 3 O
reduction	341 9 O
in	351 2 O
urinary	354 7 O
NOx	362 3 O
in	366 2 O
lead	369 4 B-Chemical
-	373 1 O
induced	374 7 O
hypertension	382 12 B-Disease
is	395 2 O
,	397 1 O
in	399 2 O
part	402 4 O
,	406 1 O
due	408 3 O
to	412 2 O
depressed	415 9 O
NO	425 2 B-Chemical
synthase	428 8 O
(	437 1 O
NOS	438 3 O
)	441 1 O
expression	443 10 O
.	453 1 O

Male	455 4 O
Sprague	460 7 O
-	467 1 O
Dawley	468 6 O
rats	475 4 O
were	480 4 O
randomly	485 8 O
assigned	494 8 O
to	503 2 O
a	506 1 O
lead	508 4 B-Chemical
-	512 1 O
treated	513 7 O
group	521 5 O
(	527 1 O
given	528 5 O
lead	534 4 B-Chemical
acetate	539 7 I-Chemical
,	546 1 O
100	548 3 O
ppm	552 3 O
,	555 1 O
in	557 2 O
drinking	560 8 O
water	569 5 O
and	575 3 O
regular	579 7 O
rat	587 3 O
chow	591 4 O
)	595 1 O
,	596 1 O
a	598 1 O
group	600 5 O
given	606 5 O
lead	612 4 B-Chemical
and	617 3 O
vitamin	621 7 B-Chemical
E	629 1 I-Chemical
-	630 1 O
fortified	631 9 O
chow	641 4 O
,	645 1 O
or	647 2 O
a	650 1 O
normal	652 6 O
control	659 7 O
group	667 5 O
given	673 5 O
either	679 6 O
regular	686 7 O
food	694 4 O
and	699 3 O
water	703 5 O
or	709 2 O
vitamin	712 7 B-Chemical
E	720 1 I-Chemical
-	721 1 O
fortified	722 9 O
food	732 4 O
for	737 3 O
12	741 2 O
weeks	744 5 O
.	749 1 O

Tail	751 4 O
blood	756 5 O
pressure	762 8 O
,	770 1 O
urinary	772 7 O
NOx	780 3 O
excretion	784 9 O
,	793 1 O
plasma	795 6 O
malondialdehyde	802 15 B-Chemical
(	818 1 O
MDA	819 3 B-Chemical
)	822 1 O
,	823 1 O
and	825 3 O
endothelial	829 11 O
and	841 3 O
inducible	845 9 O
NOS	855 3 O
(	859 1 O
eNOS	860 4 O
and	865 3 O
iNOS	869 4 O
)	873 1 O
isotypes	875 8 O
in	884 2 O
the	887 3 O
aorta	891 5 O
and	897 3 O
kidney	901 6 O
were	908 4 O
measured	913 8 O
.	921 1 O

The	923 3 O
lead	927 4 B-Chemical
-	931 1 O
treated	932 7 O
group	940 5 O
exhibited	946 9 O
a	956 1 O
rise	958 4 O
in	963 2 O
blood	966 5 O
pressure	972 8 O
and	981 3 O
plasma	985 6 O
MDA	992 3 B-Chemical
concentration	996 13 O
,	1009 1 O
a	1011 1 O
fall	1013 4 O
in	1018 2 O
urinary	1021 7 O
NOx	1029 3 O
excretion	1033 9 O
,	1042 1 O
and	1044 3 O
a	1048 1 O
paradoxical	1050 11 O
rise	1062 4 O
in	1067 2 O
vascular	1070 8 O
and	1079 3 O
renal	1083 5 O
tissue	1089 6 O
eNOS	1096 4 O
and	1101 3 O
iNOS	1105 4 O
expression	1110 10 O
.	1120 1 O

Vitamin	1122 7 B-Chemical
E	1130 1 I-Chemical
supplementation	1132 15 O
ameliorated	1148 11 O
hypertension	1160 12 B-Disease
,	1172 1 O
lowered	1174 7 O
plasma	1182 6 O
MDA	1189 3 B-Chemical
concentration	1193 13 O
,	1206 1 O
and	1208 3 O
raised	1212 6 O
urinary	1219 7 O
NOx	1227 3 O
excretion	1231 9 O
while	1241 5 O
significantly	1247 13 O
lowering	1261 8 O
vascular	1270 8 O
,	1278 1 O
but	1280 3 O
not	1284 3 O
renal	1288 5 O
,	1293 1 O
tissue	1295 6 O
eNOS	1302 4 O
and	1307 3 O
iNOS	1311 4 O
expression	1316 10 O
.	1326 1 O

Vitamin	1328 7 B-Chemical
E	1336 1 I-Chemical
supplementation	1338 15 O
had	1354 3 O
no	1358 2 O
effect	1361 6 O
on	1368 2 O
either	1371 6 O
blood	1378 5 O
pressure	1384 8 O
,	1392 1 O
plasma	1394 6 O
MDA	1401 3 B-Chemical
,	1404 1 O
or	1406 2 O
NOS	1409 3 O
expression	1413 10 O
in	1424 2 O
the	1427 3 O
control	1431 7 O
group	1439 5 O
.	1444 1 O

The	1446 3 O
study	1450 5 O
also	1456 4 O
revealed	1461 8 O
significant	1470 11 O
inhibition	1482 10 O
of	1493 2 O
NOS	1496 3 O
enzymatic	1500 9 O
activity	1510 8 O
by	1519 2 O
lead	1522 4 B-Chemical
in	1527 2 O
cell	1530 4 O
-	1534 1 O
free	1535 4 O
preparations	1540 12 O
.	1552 1 O

In	1554 2 O
conclusion	1557 10 O
,	1567 1 O
lead	1569 4 B-Chemical
-	1573 1 O
induced	1574 7 O
hypertension	1582 12 B-Disease
in	1595 2 O
this	1598 4 O
model	1603 5 O
was	1609 3 O
associated	1613 10 O
with	1624 4 O
a	1629 1 O
compensatory	1631 12 O
upregulation	1644 12 O
of	1657 2 O
renal	1660 5 O
and	1666 3 O
vascular	1670 8 O
eNOS	1679 4 O
and	1684 3 O
iNOS	1688 4 O
expression	1693 10 O
.	1703 1 O

This	1705 4 O
is	1710 2 O
,	1712 1 O
in	1714 2 O
part	1717 4 O
,	1721 1 O
due	1723 3 O
to	1727 2 O
ROS	1730 3 O
-	1733 1 O
mediated	1734 8 O
NO	1743 2 B-Chemical
inactivation	1746 12 O
,	1758 1 O
lead	1760 4 B-Chemical
-	1764 1 O
associated	1765 10 O
inhibition	1776 10 O
of	1787 2 O
NOS	1790 3 O
activity	1794 8 O
,	1802 1 O
and	1804 3 O
perhaps	1808 7 O
stimulatory	1816 11 O
actions	1828 7 O
of	1836 2 O
increased	1839 9 O
shear	1849 5 O
stress	1855 6 O
associated	1862 10 O
with	1873 4 O
hypertension	1878 12 B-Disease
.	1890 1 O

Risk	0 4 O
for	5 3 O
valvular	9 8 B-Disease
heart	18 5 I-Disease
disease	24 7 I-Disease
among	32 5 O
users	38 5 O
of	44 2 O
fenfluramine	47 12 B-Chemical
and	60 3 O
dexfenfluramine	64 15 B-Chemical
who	80 3 O
underwent	84 9 O
echocardiography	94 16 O
before	111 6 O
use	118 3 O
of	122 2 O
medication	125 10 O
.	135 1 O

BACKGROUND	137 10 O
:	147 1 O
Because	149 7 O
uncontrolled	157 12 O
echocardiographic	170 17 O
surveys	188 7 O
suggested	196 9 O
that	206 4 O
up	211 2 O
to	214 2 O
30	217 2 O
%	219 1 O
to	221 2 O
38	224 2 O
%	226 1 O
of	228 2 O
users	231 5 O
of	237 2 O
fenfluramine	240 12 B-Chemical
and	253 3 O
dexfenfluramine	257 15 B-Chemical
had	273 3 O
valvular	277 8 B-Disease
disease	286 7 I-Disease
,	293 1 O
these	295 5 O
drugs	301 5 O
were	307 4 O
withdrawn	312 9 O
from	322 4 O
the	327 3 O
market	331 6 O
.	337 1 O

OBJECTIVE	339 9 O
:	348 1 O
To	350 2 O
determine	353 9 O
the	363 3 O
risk	367 4 O
for	372 3 O
new	376 3 O
or	380 2 O
worsening	383 9 O
valvular	393 8 B-Disease
abnormalities	402 13 I-Disease
among	416 5 O
users	422 5 O
of	428 2 O
fenfluramine	431 12 B-Chemical
or	444 2 O
dexfenfluramine	447 15 B-Chemical
who	463 3 O
underwent	467 9 O
echocardiography	477 16 O
before	494 6 O
they	501 4 O
began	506 5 O
to	512 2 O
take	515 4 O
these	520 5 O
medications	526 11 O
.	537 1 O

DESIGN	539 6 O
:	545 1 O
Cohort	547 6 O
study	554 5 O
.	559 1 O

SETTING	561 7 O
:	568 1 O
Academic	570 8 O
primary	579 7 O
care	587 4 O
practices	592 9 O
.	601 1 O

PATIENTS	603 8 O
:	611 1 O
46	613 2 O
patients	616 8 O
who	625 3 O
used	629 4 O
fenfluramine	634 12 B-Chemical
or	647 2 O
dexfenfluramine	650 15 B-Chemical
for	666 3 O
14	670 2 O
days	673 4 O
or	678 2 O
more	681 4 O
and	686 3 O
had	690 3 O
echocardiograms	694 15 O
obtained	710 8 O
before	719 6 O
therapy	726 7 O
.	733 1 O

MEASUREMENTS	735 12 O
:	747 1 O
Follow	749 6 O
-	755 1 O
up	756 2 O
echocardiography	759 16 O
.	775 1 O

The	777 3 O
primary	781 7 O
outcome	789 7 O
was	797 3 O
new	801 3 O
or	805 2 O
worsening	808 9 O
valvulopathy	818 12 B-Disease
,	830 1 O
defined	832 7 O
as	840 2 O
progression	843 11 O
of	855 2 O
either	858 6 O
aortic	865 6 B-Disease
or	872 2 I-Disease
mitral	875 6 I-Disease
regurgitation	882 13 I-Disease
by	896 2 O
at	899 2 O
least	902 5 O
one	908 3 O
degree	912 6 O
of	919 2 O
severity	922 8 O
and	931 3 O
disease	935 7 O
that	943 4 O
met	948 3 O
U	952 1 O
.	953 1 O
S	954 1 O
.	955 1 O

Food	957 4 O
and	962 3 O
Drug	966 4 O
Administration	971 14 O
criteria	986 8 O
(	995 1 O
at	996 2 O
least	999 5 O
mild	1005 4 O
aortic	1010 6 B-Disease
regurgitation	1017 13 I-Disease
or	1031 2 O
moderate	1034 8 O
mitral	1043 6 B-Disease
regurgitation	1050 13 I-Disease
)	1063 1 O
.	1064 1 O

RESULTS	1066 7 O
:	1073 1 O
Two	1075 3 O
patients	1079 8 O
(	1088 1 O
4	1089 1 O
.	1090 1 O
3	1091 1 O
%	1092 1 O
[	1094 1 O
95	1095 2 O
%	1097 1 O
CI	1099 2 O
,	1101 1 O
0	1103 1 O
.	1104 1 O
6	1105 1 O
%	1106 1 O
to	1108 2 O
14	1111 2 O
.	1113 1 O
8	1114 1 O
%	1115 1 O
]	1116 1 O
)	1117 1 O
receiving	1119 9 O
fenfluramine	1129 12 B-Chemical
-	1141 1 O
phentermine	1142 11 B-Chemical
developed	1154 9 O
valvular	1164 8 B-Disease
heart	1173 5 I-Disease
disease	1179 7 I-Disease
.	1186 1 O

One	1188 3 O
had	1192 3 O
baseline	1196 8 O
bicuspid	1205 8 B-Disease
aortic	1214 6 I-Disease
valve	1221 5 I-Disease
and	1227 3 O
mild	1231 4 O
aortic	1236 6 B-Disease
regurgitation	1243 13 I-Disease
that	1257 4 O
progressed	1262 10 O
to	1273 2 O
moderate	1276 8 O
regurgitation	1285 13 O
.	1298 1 O

The	1300 3 O
second	1304 6 O
patient	1311 7 O
developed	1319 9 O
new	1329 3 O
moderate	1333 8 O
aortic	1342 6 B-Disease
insufficiency	1349 13 I-Disease
.	1362 1 O

CONCLUSION	1364 10 O
:	1374 1 O
Users	1376 5 O
of	1382 2 O
diet	1385 4 O
medications	1390 11 O
are	1402 3 O
at	1406 2 O
risk	1409 4 O
for	1414 3 O
valvular	1418 8 B-Disease
heart	1427 5 I-Disease
disease	1433 7 I-Disease
.	1440 1 O

However	1442 7 O
,	1449 1 O
the	1451 3 O
incidence	1455 9 O
may	1465 3 O
be	1469 2 O
lower	1472 5 O
than	1478 4 O
that	1483 4 O
reported	1488 8 O
previously	1497 10 O
.	1507 1 O

Carboplatin	0 11 B-Chemical
toxic	12 5 O
effects	18 7 O
on	26 2 O
the	29 3 O
peripheral	33 10 O
nervous	44 7 O
system	52 6 O
of	59 2 O
the	62 3 O
rat	66 3 O
.	69 1 O

BACKGROUND	71 10 O
:	81 1 O
The	83 3 O
most	87 4 O
striking	92 8 O
of	101 2 O
carboplatin	104 11 B-Chemical
'	115 1 O
s	116 1 O
advantages	118 10 O
(	129 1 O
CBDCA	130 5 B-Chemical
)	135 1 O
over	137 4 O
cisplatin	142 9 B-Chemical
(	152 1 O
CDDP	153 4 B-Chemical
)	157 1 O
is	159 2 O
its	162 3 O
markedly	166 8 O
reduced	175 7 O
rate	183 4 O
of	188 2 O
neurotoxic	191 10 B-Disease
effects	202 7 O
.	209 1 O

However	211 7 O
,	218 1 O
the	220 3 O
use	224 3 O
of	228 2 O
CBDCA	231 5 B-Chemical
higher	237 6 O
-	243 1 O
intensity	244 9 O
schedules	254 9 O
and	264 3 O
the	268 3 O
association	272 11 O
with	284 4 O
other	289 5 O
neurotoxic	295 10 B-Disease
drugs	306 5 O
in	312 2 O
polychemotherapy	315 16 O
may	332 3 O
cause	336 5 O
some	342 4 O
concern	347 7 O
about	355 5 O
its	361 3 O
safety	365 6 O
with	372 4 O
respect	377 7 O
to	385 2 O
peripheral	388 10 B-Disease
nervous	399 7 I-Disease
system	407 6 I-Disease
damage	414 6 I-Disease
.	420 1 O

MATERIALS	422 9 O
AND	432 3 O
METHODS	436 7 O
:	443 1 O
Two	445 3 O
different	449 9 O
schedules	459 9 O
of	469 2 O
CBDCA	472 5 B-Chemical
administration	478 14 O
(	493 1 O
10	494 2 O
mg	497 2 O
/	499 1 O
kg	500 2 O
and	503 3 O
15	507 2 O
mg	510 2 O
/	512 1 O
kg	513 2 O
i	516 1 O
.	517 1 O
p	518 1 O
.	519 1 O
twice	521 5 O
a	527 1 O
week	529 4 O
for	534 3 O
nine	538 4 O
times	543 5 O
)	548 1 O
were	550 4 O
evaluated	555 9 O
in	565 2 O
Wistar	568 6 O
rats	575 4 O
.	579 1 O

Neurotoxicity	581 13 B-Disease
was	595 3 O
assessed	599 8 O
for	608 3 O
behavioral	612 10 O
(	623 1 O
tail	624 4 O
-	628 1 O
flick	629 5 O
test	635 4 O
)	639 1 O
,	640 1 O
neurophysiological	642 18 O
(	661 1 O
nerve	662 5 O
conduction	668 10 O
velocity	679 8 O
in	688 2 O
the	691 3 O
tail	695 4 O
nerve	700 5 O
)	705 1 O
,	706 1 O
morphological	708 13 O
,	721 1 O
morphometrical	723 14 O
and	738 3 O
analytical	742 10 O
effects	753 7 O
.	760 1 O

RESULTS	762 7 O
:	769 1 O
CBDCA	771 5 B-Chemical
administration	777 14 O
induced	792 7 O
dose	800 4 O
-	804 1 O
dependent	805 9 O
peripheral	815 10 B-Disease
neurotoxicity	826 13 I-Disease
.	839 1 O

Pain	841 4 B-Disease
perception	846 10 O
and	857 3 O
nerve	861 5 O
conduction	867 10 O
velocity	878 8 O
in	887 2 O
the	890 3 O
tail	894 4 O
were	899 4 O
significantly	904 13 O
impaired	918 8 O
,	926 1 O
particularly	928 12 O
after	941 5 O
the	947 3 O
high	951 4 O
-	955 1 O
dose	956 4 O
treatment	961 9 O
.	970 1 O

The	972 3 O
dorsal	976 6 O
root	983 4 O
ganglia	988 7 O
sensory	996 7 O
neurons	1004 7 O
and	1012 3 O
,	1015 1 O
to	1017 2 O
a	1020 1 O
lesser	1022 6 O
extent	1029 6 O
,	1035 1 O
satellite	1037 9 O
cells	1047 5 O
showed	1053 6 O
the	1060 3 O
same	1064 4 O
changes	1069 7 O
as	1077 2 O
those	1080 5 O
induced	1086 7 O
by	1094 2 O
CDDP	1097 4 B-Chemical
,	1101 1 O
mainly	1103 6 O
affecting	1110 9 O
the	1120 3 O
nucleus	1124 7 O
and	1132 3 O
nucleolus	1136 9 O
of	1146 2 O
ganglionic	1149 10 O
sensory	1160 7 O
neurons	1168 7 O
.	1175 1 O

Moreover	1177 8 O
,	1185 1 O
significant	1187 11 O
amounts	1199 7 O
of	1207 2 O
platinum	1210 8 B-Chemical
were	1219 4 O
detected	1224 8 O
in	1233 2 O
the	1236 3 O
dorsal	1240 6 O
root	1247 4 O
ganglia	1252 7 O
and	1260 3 O
kidney	1264 6 O
after	1271 5 O
CBDCA	1277 5 B-Chemical
treatment	1283 9 O
.	1292 1 O

CONCLUSIONS	1294 11 O
:	1305 1 O
CBDCA	1307 5 B-Chemical
is	1313 2 O
neurotoxic	1316 10 B-Disease
in	1327 2 O
our	1330 3 O
model	1334 5 O
,	1339 1 O
and	1341 3 O
the	1345 3 O
type	1349 4 O
of	1354 2 O
pathological	1357 12 O
changes	1370 7 O
it	1378 2 O
induces	1381 7 O
are	1389 3 O
so	1393 2 O
closely	1396 7 O
similar	1404 7 O
to	1412 2 O
those	1415 5 O
caused	1421 6 O
by	1428 2 O
CDDP	1431 4 B-Chemical
that	1436 4 O
it	1441 2 O
is	1444 2 O
probable	1447 8 O
that	1456 4 O
neurotoxicity	1461 13 B-Disease
is	1475 2 O
induced	1478 7 O
in	1486 2 O
the	1489 3 O
two	1493 3 O
drugs	1497 5 O
by	1503 2 O
the	1506 3 O
same	1510 4 O
mechanism	1515 9 O
.	1524 1 O

This	1526 4 O
model	1531 5 O
can	1537 3 O
be	1541 2 O
used	1544 4 O
alone	1549 5 O
or	1555 2 O
in	1558 2 O
combination	1561 11 O
with	1573 4 O
other	1578 5 O
drugs	1584 5 O
to	1590 2 O
explore	1593 7 O
the	1601 3 O
effect	1605 6 O
of	1612 2 O
CBDCA	1615 5 B-Chemical
on	1621 2 O
the	1624 3 O
peripheral	1628 10 O
nervous	1639 7 O
system	1647 6 O
.	1653 1 O

Iatrogenic	0 10 O
risks	11 5 O
of	17 2 O
endometrial	20 11 B-Disease
carcinoma	32 9 I-Disease
after	42 5 O
treatment	48 9 O
for	58 3 O
breast	62 6 B-Disease
cancer	69 6 I-Disease
in	76 2 O
a	79 1 O
large	81 5 O
French	87 6 O
case	94 4 O
-	98 1 O
control	99 7 O
study	107 5 O
.	112 1 O

F	114 1 O
d	117 1 O
ration	120 6 O
Nationale	127 9 O
des	137 3 O
Centres	141 7 O
de	149 2 O
Lutte	152 5 O
Contre	158 6 O
le	165 2 O
Cancer	168 6 O
(	175 1 O
FNCLCC	176 6 O
)	182 1 O
.	183 1 O

Since	185 5 O
tamoxifen	191 9 B-Chemical
is	201 2 O
widely	204 6 O
used	211 4 O
in	216 2 O
breast	219 6 B-Disease
cancer	226 6 I-Disease
treatment	233 9 O
and	243 3 O
has	247 3 O
been	251 4 O
proposed	256 8 O
for	265 3 O
the	269 3 O
prevention	273 10 O
of	284 2 O
breast	287 6 B-Disease
cancer	294 6 I-Disease
,	300 1 O
its	302 3 O
endometrial	306 11 O
iatrogenic	318 10 O
effects	329 7 O
must	337 4 O
be	342 2 O
carefully	345 9 O
examined	355 8 O
.	363 1 O

We	365 2 O
have	368 4 O
investigated	373 12 O
the	386 3 O
association	390 11 O
between	402 7 O
endometrial	410 11 B-Disease
cancer	422 6 I-Disease
and	429 3 O
tamoxifen	433 9 B-Chemical
use	443 3 O
or	447 2 O
other	450 5 O
treatments	456 10 O
in	467 2 O
women	470 5 O
treated	476 7 O
for	484 3 O
breast	488 6 B-Disease
cancer	495 6 I-Disease
in	502 2 O
a	505 1 O
case	507 4 O
-	511 1 O
control	512 7 O
study	520 5 O
.	525 1 O

Cases	527 5 O
of	533 2 O
endometrial	536 11 B-Disease
cancer	548 6 I-Disease
diagnosed	555 9 O
after	565 5 O
breast	571 6 B-Disease
cancer	578 6 I-Disease
(	585 1 O
n	586 1 O
=	588 1 O
135	590 3 O
)	593 1 O
and	595 3 O
467	599 3 O
controls	603 8 O
matched	612 7 O
for	620 3 O
age	624 3 O
,	627 1 O
year	629 4 O
of	634 2 O
diagnosis	637 9 O
of	647 2 O
breast	650 6 B-Disease
cancer	657 6 I-Disease
and	664 3 O
hospital	668 8 O
and	677 3 O
survival	681 8 O
time	690 4 O
with	695 4 O
an	700 2 O
intact	703 6 O
uterus	710 6 O
were	717 4 O
included	722 8 O
.	730 1 O

Women	732 5 O
who	738 3 O
had	742 3 O
received	746 8 O
tamoxifen	755 9 B-Chemical
were	765 4 O
significantly	770 13 O
more	784 4 O
likely	789 6 O
to	796 2 O
have	799 4 O
endometrial	804 11 B-Disease
cancer	816 6 I-Disease
diagnosed	823 9 O
than	833 4 O
those	838 5 O
who	844 3 O
had	848 3 O
not	852 3 O
(	856 1 O
crude	857 5 O
relative	863 8 O
risk	872 4 O
=	877 1 O
4	879 1 O
.	880 1 O
9	881 1 O
,	882 1 O
p	884 1 O
=	886 1 O
0	888 1 O
.	889 1 O
0001	890 4 O
)	894 1 O
.	895 1 O

Univariate	897 10 O
and	908 3 O
adjusted	912 8 O
analyses	921 8 O
showed	930 6 O
that	937 4 O
the	942 3 O
risk	946 4 O
increased	951 9 O
with	961 4 O
the	966 3 O
length	970 6 O
of	977 2 O
treatment	980 9 O
(	990 1 O
p	991 1 O
=	993 1 O
0	995 1 O
.	996 1 O
0001	997 4 O
)	1001 1 O
or	1003 2 O
the	1006 3 O
cumulative	1010 10 O
dose	1021 4 O
of	1026 2 O
tamoxifen	1029 9 B-Chemical
received	1039 8 O
(	1048 1 O
p	1049 1 O
=	1051 1 O
0	1053 1 O
.	1054 1 O
0001	1055 4 O
)	1059 1 O
,	1060 1 O
irrespective	1062 12 O
of	1075 2 O
the	1078 3 O
daily	1082 5 O
dose	1088 4 O
.	1092 1 O

Women	1094 5 O
who	1100 3 O
had	1104 3 O
undergone	1108 9 O
pelvic	1118 6 O
radiotherapy	1125 12 O
also	1138 4 O
had	1143 3 O
a	1147 1 O
higher	1149 6 O
risk	1156 4 O
(	1161 1 O
crude	1162 5 O
relative	1168 8 O
risk	1177 4 O
=	1182 1 O
7	1184 1 O
.	1185 1 O
8	1186 1 O
,	1187 1 O
p	1189 1 O
=	1191 1 O
0	1193 1 O
.	1194 1 O
0001	1195 4 O
)	1199 1 O
.	1200 1 O

After	1202 5 O
adjusting	1208 9 O
for	1218 3 O
confounding	1222 11 O
factors	1234 7 O
,	1241 1 O
the	1243 3 O
risk	1247 4 O
was	1252 3 O
higher	1256 6 O
for	1263 3 O
tamoxifen	1267 9 B-Chemical
users	1277 5 O
(	1283 1 O
p	1284 1 O
=	1286 1 O
0	1288 1 O
.	1289 1 O
0012	1290 4 O
)	1294 1 O
,	1295 1 O
treatment	1297 9 O
for	1307 3 O
more	1311 4 O
than	1316 4 O
3	1321 1 O
years	1323 5 O
(	1329 1 O
all	1330 3 O
p	1334 1 O
<	1336 1 O
0	1338 1 O
.	1339 1 O
03	1340 2 O
)	1342 1 O
and	1344 3 O
pelvic	1348 6 O
radiotherapy	1355 12 O
(	1368 1 O
p	1369 1 O
=	1371 1 O
0	1373 1 O
.	1374 1 O
012	1375 3 O
)	1378 1 O
.	1379 1 O

Women	1381 5 O
who	1387 3 O
had	1391 3 O
endometrial	1395 11 B-Disease
cancer	1407 6 I-Disease
and	1414 3 O
had	1418 3 O
received	1422 8 O
tamoxifen	1431 9 B-Chemical
had	1441 3 O
more	1445 4 O
advanced	1450 8 B-Disease
disease	1459 7 I-Disease
and	1467 3 O
poorer	1471 6 O
prognosis	1478 9 O
than	1488 4 O
those	1493 5 O
with	1499 4 O
endometrial	1504 11 B-Disease
cancer	1516 6 I-Disease
who	1523 3 O
had	1527 3 O
not	1531 3 O
received	1535 8 O
this	1544 4 O
treatment	1549 9 O
.	1558 1 O

Our	1560 3 O
results	1564 7 O
suggest	1572 7 O
a	1580 1 O
causal	1582 6 O
role	1589 4 O
of	1594 2 O
tamoxifen	1597 9 B-Chemical
in	1607 2 O
endometrial	1610 11 B-Disease
cancer	1622 6 I-Disease
,	1628 1 O
particularly	1630 12 O
when	1643 4 O
used	1648 4 O
as	1653 2 O
currently	1656 9 O
proposed	1666 8 O
for	1675 3 O
breast	1679 6 B-Disease
cancer	1686 6 I-Disease
prevention	1693 10 O
.	1703 1 O

Pelvic	1705 6 O
radiotherapy	1712 12 O
may	1725 3 O
be	1729 2 O
an	1732 2 O
additional	1735 10 O
iatrogenic	1746 10 O
factor	1757 6 O
for	1764 3 O
women	1768 5 O
with	1774 4 O
breast	1779 6 B-Disease
cancer	1786 6 I-Disease
.	1792 1 O

Endometrial	1794 11 B-Disease
cancers	1806 7 I-Disease
diagnosed	1814 9 O
in	1824 2 O
women	1827 5 O
treated	1833 7 O
with	1841 4 O
tamoxifen	1846 9 B-Chemical
have	1856 4 O
poorer	1861 6 O
prognosis	1868 9 O
.	1877 1 O

Women	1879 5 O
who	1885 3 O
receive	1889 7 O
tamoxifen	1897 9 B-Chemical
for	1907 3 O
breast	1911 6 B-Disease
cancer	1918 6 I-Disease
should	1925 6 O
be	1932 2 O
offered	1935 7 O
gynaecological	1943 14 O
surveillance	1958 12 O
during	1971 6 O
and	1978 3 O
after	1982 5 O
treatment	1988 9 O
.	1997 1 O

A	1999 1 O
long	2001 4 O
-	2005 1 O
term	2006 4 O
evaluation	2011 10 O
of	2022 2 O
the	2025 3 O
risk	2029 4 O
-	2033 1 O
benefit	2034 7 O
ratio	2042 5 O
of	2048 2 O
tamoxifen	2051 9 B-Chemical
as	2061 2 O
a	2064 1 O
preventive	2066 10 O
treatment	2077 9 O
for	2087 3 O
breast	2091 6 B-Disease
cancer	2098 6 I-Disease
is	2105 2 O
clearly	2108 7 O
warranted	2116 9 O
.	2125 1 O

Granulosa	0 9 B-Disease
cell	10 4 I-Disease
tumor	15 5 I-Disease
of	21 2 I-Disease
the	24 3 I-Disease
ovary	28 5 I-Disease
associated	34 10 O
with	45 4 O
antecedent	50 10 O
tamoxifen	61 9 B-Chemical
use	71 3 O
.	74 1 O

BACKGROUND	76 10 O
:	86 1 O
Increased	88 9 O
attention	98 9 O
has	108 3 O
been	112 4 O
focused	117 7 O
recently	125 8 O
on	134 2 O
the	137 3 O
estrogenic	141 10 O
effects	152 7 O
of	160 2 O
tamoxifen	163 9 B-Chemical
.	172 1 O

Review	174 6 O
of	181 2 O
the	184 3 O
literature	188 10 O
reveals	199 7 O
an	207 2 O
association	210 11 O
between	222 7 O
tamoxifen	230 9 B-Chemical
use	240 3 O
and	244 3 O
gynecologic	248 11 O
tumors	260 6 B-Disease
.	266 1 O

CASE	268 4 O
:	272 1 O
A	274 1 O
52	276 2 O
-	278 1 O
year	279 4 O
-	283 1 O
old	284 3 O
postmenopausal	288 14 O
woman	303 5 O
was	309 3 O
treated	313 7 O
with	321 4 O
tamoxifen	326 9 B-Chemical
for	336 3 O
stage	340 5 O
II	346 2 O
estrogen	349 8 B-Chemical
receptor	358 8 O
-	366 1 O
positive	367 8 O
breast	376 6 B-Disease
carcinoma	383 9 I-Disease
.	392 1 O

Her	394 3 O
aspartate	398 9 B-Chemical
transaminase	408 12 O
and	421 3 O
alanine	425 7 B-Chemical
transaminase	433 12 O
levels	446 6 O
increase	453 8 O
markedly	462 8 O
after	471 5 O
6	477 1 O
months	479 6 O
of	486 2 O
tamoxifen	489 9 B-Chemical
use	499 3 O
.	502 1 O

After	504 5 O
an	510 2 O
additional	513 10 O
17	524 2 O
months	527 6 O
of	534 2 O
elevated	537 8 O
serum	546 5 O
transaminases	552 13 O
,	565 1 O
the	567 3 O
patient	571 7 O
was	579 3 O
found	583 5 O
to	589 2 O
have	592 4 O
a	597 1 O
stage	599 5 O
Ic	605 2 O
granulosa	608 9 B-Disease
cell	618 4 I-Disease
tumor	623 5 I-Disease
of	629 2 I-Disease
the	632 3 I-Disease
ovary	636 5 I-Disease
.	641 1 O

CONCLUSION	643 10 O
:	653 1 O
Patients	655 8 O
with	664 4 O
tamoxifen	669 9 B-Chemical
-	678 1 O
induced	679 7 O
liver	687 5 B-Disease
dysfunction	693 11 I-Disease
may	705 3 O
be	709 2 O
at	712 2 O
increased	715 9 O
risk	725 4 O
for	730 3 O
granulosa	734 9 B-Disease
cell	744 4 I-Disease
tumors	749 6 I-Disease
because	756 7 O
of	764 2 O
alterations	767 11 O
in	779 2 O
tamoxifen	782 9 B-Chemical
metabolism	792 10 O
.	802 1 O

A	0 1 O
murine	2 6 O
model	9 5 O
of	15 2 O
adenomyosis	18 11 B-Disease
:	29 1 O
the	31 3 O
effects	35 7 O
of	43 2 O
hyperprolactinemia	46 18 B-Disease
induced	65 7 O
by	73 2 O
fluoxetine	76 10 B-Chemical
hydrochloride	87 13 I-Chemical
,	100 1 O
a	102 1 O
selective	104 9 O
serotonin	114 9 B-Chemical
reuptake	124 8 O
inhibitor	133 9 O
,	142 1 O
on	144 2 O
adenomyosis	147 11 B-Disease
induction	159 9 O
in	169 2 O
Wistar	172 6 O
albino	179 6 O
rats	186 4 O
.	190 1 O

OBJECTIVE	192 9 O
:	201 1 O
The	203 3 O
aim	207 3 O
of	211 2 O
this	214 4 O
study	219 5 O
was	225 3 O
to	229 2 O
investigate	232 11 O
whether	244 7 O
fluoxetine	252 10 B-Chemical
given	263 5 O
to	269 2 O
castrated	272 9 O
and	282 3 O
noncastrated	286 12 O
rats	299 4 O
caused	304 6 O
hyperprolactinemia	311 18 B-Disease
and	330 3 O
its	334 3 O
effects	338 7 O
with	346 4 O
respect	351 7 O
to	359 2 O
adenomyosis	362 11 B-Disease
.	373 1 O

DESIGN	375 6 O
:	381 1 O
Fluoxetine	383 10 B-Chemical
,	393 1 O
a	395 1 O
serotonin	397 9 B-Chemical
reuptake	407 8 O
inhibitor	416 9 O
,	425 1 O
was	427 3 O
given	431 5 O
to	437 2 O
Wistar	440 6 O
Albino	447 6 O
rats	454 4 O
for	459 3 O
98	463 2 O
days	466 4 O
to	471 2 O
produce	474 7 O
hyperprolactinemia	482 18 B-Disease
.	500 1 O

The	502 3 O
drug	506 4 O
was	511 3 O
given	515 5 O
to	521 2 O
two	524 3 O
groups	528 6 O
consisting	535 10 O
of	546 2 O
castrated	549 9 O
and	559 3 O
noncastrated	563 12 O
rats	576 4 O
and	581 3 O
compared	585 8 O
to	594 2 O
two	597 3 O
groups	601 6 O
of	608 2 O
castrated	611 9 O
and	621 3 O
noncastrated	625 12 O
controls	638 8 O
.	646 1 O

Prolactin	648 9 O
levels	658 6 O
were	665 4 O
measured	670 8 O
and	679 3 O
the	683 3 O
uteri	687 5 O
of	693 2 O
the	696 3 O
rats	700 4 O
were	705 4 O
removed	710 7 O
for	718 3 O
histopathological	722 17 O
analysis	740 8 O
at	749 2 O
the	752 3 O
end	756 3 O
of	760 2 O
98	763 2 O
days	766 4 O
.	770 1 O

SETTING	772 7 O
:	779 1 O
Marmara	781 7 O
University	789 10 O
School	800 6 O
of	807 2 O
Medicine	810 8 O
,	818 1 O
Department	820 10 O
of	831 2 O
Histology	834 9 O
and	844 3 O
Embryology	848 10 O
,	858 1 O
Zeynep	860 6 O
Kamil	867 5 O
Women	873 5 O
and	879 3 O
Children	883 8 O
'	891 1 O
s	892 1 O
Hospital	894 8 O
.	902 1 O

MAIN	904 4 O
OUTCOME	909 7 O
MEASURES	917 8 O
:	925 1 O
Serum	927 5 O
prolactin	933 9 O
levels	943 6 O
,	949 1 O
uterine	951 7 O
histopathology	959 14 O
.	973 1 O

RESULTS	975 7 O
:	982 1 O
The	984 3 O
prolactin	988 9 O
levels	998 6 O
of	1005 2 O
castrated	1008 9 O
and	1018 3 O
noncastrated	1022 12 O
groups	1035 6 O
treated	1042 7 O
with	1050 4 O
fluoxetine	1055 10 B-Chemical
were	1066 4 O
statistically	1071 13 O
significantly	1085 13 O
higher	1099 6 O
when	1106 4 O
compared	1111 8 O
to	1120 2 O
their	1123 5 O
respective	1129 10 O
control	1140 7 O
groups	1148 6 O
.	1154 1 O

Histological	1156 12 O
studies	1169 7 O
revealed	1177 8 O
11	1186 2 O
cases	1189 5 O
of	1195 2 O
adenomyosis	1198 11 B-Disease
,	1209 1 O
all	1211 3 O
within	1215 6 O
the	1222 3 O
noncastrated	1226 12 O
group	1239 5 O
receiving	1245 9 O
fluoxetine	1255 10 B-Chemical
.	1265 1 O

CONCLUSION	1267 10 O
:	1277 1 O
It	1279 2 O
was	1282 3 O
suggested	1286 9 O
that	1296 4 O
high	1301 4 O
serum	1306 5 O
prolactin	1312 9 O
levels	1322 6 O
cause	1329 5 O
degeneration	1335 12 O
of	1348 2 O
myometrial	1351 10 O
cells	1362 5 O
in	1368 2 O
the	1371 3 O
presence	1375 8 O
of	1384 2 O
ovarian	1387 7 O
steroids	1395 8 B-Chemical
that	1404 4 O
results	1409 7 O
in	1417 2 O
a	1420 1 O
myometrial	1422 10 O
invasion	1433 8 O
by	1442 2 O
endometrial	1445 11 O
stroma	1457 6 O
.	1463 1 O

This	1465 4 O
invasion	1470 8 O
eventually	1479 10 O
progresses	1490 10 O
to	1501 2 O
adenomyosis	1504 11 B-Disease
.	1515 1 O

Effects	0 7 O
of	8 2 O
deliberate	11 10 O
hypotension	22 11 B-Disease
induced	34 7 O
by	42 2 O
labetalol	45 9 B-Chemical
with	55 4 O
isoflurane	60 10 B-Chemical
on	71 2 O
neuropsychological	74 18 O
function	93 8 O
.	101 1 O

The	103 3 O
effect	107 6 O
of	114 2 O
deliberate	117 10 O
hypotension	128 11 B-Disease
on	140 2 O
brain	143 5 O
function	149 8 O
measured	158 8 O
by	167 2 O
neuropsychological	170 18 O
tests	189 5 O
was	195 3 O
studied	199 7 O
in	207 2 O
41	210 2 O
adult	213 5 O
patients	219 8 O
.	227 1 O

Twenty	229 6 O
-	235 1 O
four	236 4 O
patients	241 8 O
were	250 4 O
anaesthetized	255 13 O
for	269 3 O
middle	273 6 O
-	279 1 O
ear	280 3 O
surgery	284 7 O
with	292 4 O
deliberate	297 10 O
hypotension	308 11 B-Disease
induced	320 7 O
by	328 2 O
labetalol	331 9 B-Chemical
with	341 4 O
isoflurane	346 10 B-Chemical
(	357 1 O
hypotensive	358 11 B-Disease
group	370 5 O
)	375 1 O
.	376 1 O

Seventeen	378 9 O
patients	388 8 O
without	397 7 O
hypotension	405 11 B-Disease
served	417 6 O
as	424 2 O
a	427 1 O
control	429 7 O
group	437 5 O
.	442 1 O

The	444 3 O
mean	448 4 O
arterial	453 8 O
pressure	462 8 O
was	471 3 O
77	475 2 O
+	478 1 O
/	479 1 O
-	480 1 O
2	482 1 O
mmHg	484 4 O
(	489 1 O
10	490 2 O
.	492 1 O
3	493 1 O
+	495 1 O
/	496 1 O
-	497 1 O
0	499 1 O
.	500 1 O
3	501 1 O
kPa	503 3 O
)	506 1 O
before	508 6 O
hypotension	515 11 B-Disease
and	527 3 O
50	531 2 O
+	534 1 O
/	535 1 O
-	536 1 O
0	538 1 O
mmHg	540 4 O
(	545 1 O
6	546 1 O
.	547 1 O
7	548 1 O
+	550 1 O
/	551 1 O
-	552 1 O
0	554 1 O
.	555 1 O
0	556 1 O
kPa	558 3 O
)	561 1 O
during	563 6 O
hypotension	570 11 B-Disease
in	582 2 O
the	585 3 O
hypotensive	589 11 B-Disease
group	601 5 O
,	606 1 O
and	608 3 O
86	612 2 O
+	615 1 O
/	616 1 O
-	617 1 O
2	619 1 O
mmHg	621 4 O
(	626 1 O
11	627 2 O
.	629 1 O
5	630 1 O
+	632 1 O
/	633 1 O
-	634 1 O
0	636 1 O
.	637 1 O
3	638 1 O
kPa	640 3 O
)	643 1 O
during	645 6 O
anaesthesia	652 11 O
in	664 2 O
the	667 3 O
control	671 7 O
group	679 5 O
.	684 1 O

The	686 3 O
following	690 9 O
psychological	700 13 O
tests	714 5 O
were	720 4 O
performed	725 9 O
:	734 1 O
four	736 4 O
subtests	741 8 O
of	750 2 O
the	753 3 O
Wechsler	757 8 O
Adult	766 5 O
Intelligence	772 12 O
Scale	785 5 O
(	791 1 O
similarities	792 12 O
,	804 1 O
digit	806 5 O
span	812 4 O
,	816 1 O
vocabulary	818 10 O
and	829 3 O
digit	833 5 O
symbol	839 6 O
)	845 1 O
,	846 1 O
Trail	848 5 O
-	853 1 O
Making	854 6 O
tests	861 5 O
A	867 1 O
and	869 3 O
B	873 1 O
,	874 1 O
Zung	876 4 O
tests	881 5 O
(	887 1 O
self	888 4 O
-	892 1 O
rating	893 6 O
anxiety	900 7 B-Disease
scale	908 5 O
and	914 3 O
self	918 4 O
-	922 1 O
rating	923 6 O
depression	930 10 B-Disease
scale	941 5 O
)	946 1 O
and	948 3 O
two	952 3 O
-	955 1 O
part	956 4 O
memory	961 6 O
test	968 4 O
battery	973 7 O
with	981 4 O
immediate	986 9 O
and	996 3 O
delayed	1000 7 O
recall	1008 6 O
.	1014 1 O

The	1016 3 O
tests	1020 5 O
were	1026 4 O
performed	1031 9 O
preoperatively	1041 14 O
and	1056 3 O
2	1060 1 O
days	1062 4 O
postoperatively	1067 15 O
.	1082 1 O

There	1084 5 O
were	1090 4 O
no	1095 2 O
statistically	1098 13 O
significant	1112 11 O
differences	1124 11 O
between	1136 7 O
the	1144 3 O
groups	1148 6 O
in	1155 2 O
any	1158 3 O
of	1162 2 O
the	1165 3 O
tests	1169 5 O
in	1175 2 O
the	1178 3 O
changes	1182 7 O
from	1190 4 O
preoperative	1195 12 O
value	1208 5 O
to	1214 2 O
postoperative	1217 13 O
value	1231 5 O
.	1236 1 O

The	1238 3 O
results	1242 7 O
indicate	1250 8 O
that	1259 4 O
hypotension	1264 11 B-Disease
induced	1276 7 O
by	1284 2 O
labetalol	1287 9 B-Chemical
with	1297 4 O
isoflurane	1302 10 B-Chemical
has	1313 3 O
no	1317 2 O
significant	1320 11 O
harmful	1332 7 O
effects	1340 7 O
on	1348 2 O
mental	1351 6 O
functions	1358 9 O
compared	1368 8 O
to	1377 2 O
normotensive	1380 12 O
anaesthesia	1393 11 O
.	1404 1 O

Auditory	0 8 O
disturbance	9 11 O
associated	21 10 O
with	32 4 O
interscalene	37 12 O
brachial	50 8 O
plexus	59 6 O
block	66 5 O
.	71 1 O

We	73 2 O
performed	76 9 O
an	86 2 O
audiometric	89 11 O
study	101 5 O
in	107 2 O
20	110 2 O
patients	113 8 O
who	122 3 O
underwent	126 9 O
surgery	136 7 O
of	144 2 O
the	147 3 O
shoulder	151 8 O
region	160 6 O
under	167 5 O
an	173 2 O
interscalene	176 12 O
brachial	189 8 O
plexus	198 6 O
block	205 5 O
(	211 1 O
IBPB	212 4 O
)	216 1 O
.	217 1 O

Bupivacaine	219 11 B-Chemical
0	231 1 O
.	232 1 O
75	233 2 O
%	235 1 O
with	237 4 O
adrenaline	242 10 B-Chemical
was	253 3 O
given	257 5 O
followed	263 8 O
by	272 2 O
a	275 1 O
24	277 2 O
-	279 1 O
hr	280 2 O
continuous	283 10 O
infusion	294 8 O
of	303 2 O
0	306 1 O
.	307 1 O
25	308 2 O
%	310 1 O
bupivacaine	312 11 B-Chemical
.	323 1 O

Three	325 5 O
audiometric	331 11 O
threshold	343 9 O
measurements	353 12 O
(	366 1 O
0	367 1 O
.	368 1 O
25	369 2 O
-	371 1 O
18	372 2 O
kHz	375 3 O
)	378 1 O
were	380 4 O
made	385 4 O
:	389 1 O
the	391 3 O
first	395 5 O
before	401 6 O
IBPB	408 4 O
,	412 1 O
the	414 3 O
second	418 6 O
2	425 1 O
-	426 1 O
6	427 1 O
h	429 1 O
after	431 5 O
surgery	437 7 O
and	445 3 O
the	449 3 O
third	453 5 O
on	459 2 O
the	462 3 O
first	466 5 O
day	472 3 O
after	476 5 O
operation	482 9 O
.	491 1 O

In	493 2 O
four	496 4 O
patients	501 8 O
hearing	510 7 B-Disease
impairment	518 10 I-Disease
on	529 2 O
the	532 3 O
side	536 4 O
of	541 2 O
the	544 3 O
block	548 5 O
was	554 3 O
demonstrated	558 12 O
after	571 5 O
operation	577 9 O
,	586 1 O
in	588 2 O
three	591 5 O
measurements	597 12 O
on	610 2 O
the	613 3 O
day	617 3 O
of	621 2 O
surgery	624 7 O
and	632 3 O
in	636 2 O
one	639 3 O
on	643 2 O
the	646 3 O
following	650 9 O
day	660 3 O
.	663 1 O

The	665 3 O
frequencies	669 11 O
at	681 2 O
which	684 5 O
the	690 3 O
impairment	694 10 O
occurred	705 8 O
varied	714 6 O
between	721 7 O
patients	729 8 O
;	737 1 O
in	739 2 O
one	742 3 O
only	746 4 O
low	751 3 O
frequencies	755 11 O
(	767 1 O
0	768 1 O
.	769 1 O
25	770 2 O
-	772 1 O
0	773 1 O
.	774 1 O
5	775 1 O
kHz	777 3 O
)	780 1 O
were	782 4 O
involved	787 8 O
.	795 1 O

The	797 3 O
maximum	801 7 O
change	809 6 O
in	816 2 O
threshold	819 9 O
was	829 3 O
35	833 2 O
dB	836 2 O
at	839 2 O
6	842 1 O
kHz	844 3 O
measured	848 8 O
at	857 2 O
the	860 3 O
end	864 3 O
of	868 2 O
the	871 3 O
continuous	875 10 O
infusion	886 8 O
of	895 2 O
bupivacaine	898 11 B-Chemical
.	909 1 O

This	911 4 O
patient	916 7 O
had	924 3 O
hearing	928 7 O
threshold	936 9 O
changes	946 7 O
(	954 1 O
15	955 2 O
-	957 1 O
20	958 2 O
dB	961 2 O
)	963 1 O
at	965 2 O
6	968 1 O
-	969 1 O
10	970 2 O
kHz	973 3 O
on	977 2 O
the	980 3 O
opposite	984 8 O
side	993 4 O
also	998 4 O
.	1002 1 O

IBPB	1004 4 O
may	1009 3 O
cause	1013 5 O
transient	1019 9 O
auditory	1029 8 B-Disease
dysfunction	1038 11 I-Disease
in	1050 2 O
the	1053 3 O
ipsilateral	1057 11 O
ear	1069 3 O
,	1072 1 O
possibly	1074 8 O
via	1083 3 O
an	1087 2 O
effect	1090 6 O
on	1097 2 O
sympathetic	1100 11 O
innervation	1112 11 O
.	1123 1 O

Midazolam	0 9 B-Chemical
compared	10 8 O
with	19 4 O
thiopentone	24 11 B-Chemical
as	36 2 O
an	39 2 O
induction	42 9 O
agent	52 5 O
.	57 1 O

In	59 2 O
patients	62 8 O
premedicated	71 12 O
with	84 4 O
scopolamine	89 11 B-Chemical
+	101 1 O
morphine	103 8 B-Chemical
(	112 1 O
+	113 1 O
5	114 1 O
mg	116 2 O
nitrazepam	119 10 B-Chemical
the	130 3 O
evening	134 7 O
before	142 6 O
surgery	149 7 O
)	156 1 O
,	157 1 O
the	159 3 O
sleep	163 5 O
-	168 1 O
inducing	169 8 O
effect	178 6 O
of	185 2 O
midazolam	188 9 B-Chemical
0	198 1 O
.	199 1 O
15	200 2 O
mg	203 2 O
/	205 1 O
kg	206 2 O
i	209 1 O
.	210 1 O
v	211 1 O
.	212 1 O
was	214 3 O
clearly	218 7 O
slower	226 6 O
in	233 2 O
onset	236 5 O
than	242 4 O
that	247 4 O
of	252 2 O
thiopentone	255 11 B-Chemical
4	267 1 O
.	268 1 O
67	269 2 O
mg	272 2 O
/	274 1 O
kg	275 2 O
i	278 1 O
.	279 1 O
v	280 1 O
.	281 1 O
Somewhat	283 8 O
fewer	292 5 O
cardiovascular	298 14 O
and	313 3 O
local	317 5 O
sequelae	323 8 O
were	332 4 O
found	337 5 O
in	343 2 O
the	346 3 O
midazolam	350 9 B-Chemical
group	360 5 O
,	365 1 O
but	367 3 O
,	370 1 O
although	372 8 O
apnoea	381 6 B-Disease
occurred	388 8 O
less	397 4 O
often	402 5 O
in	408 2 O
the	411 3 O
midazolam	415 9 B-Chemical
group	425 5 O
it	431 2 O
lasted	434 6 O
longer	441 6 O
.	447 1 O

On	449 2 O
the	452 3 O
whole	456 5 O
,	461 1 O
the	463 3 O
differences	467 11 O
between	479 7 O
midazolam	487 9 B-Chemical
and	497 3 O
thiopentone	501 11 B-Chemical
had	513 3 O
no	517 2 O
apparent	520 8 O
clinical	529 8 O
consequences	538 12 O
.	550 1 O

Midazolam	552 9 B-Chemical
is	562 2 O
a	565 1 O
new	567 3 O
alternative	571 11 O
agent	583 5 O
for	589 3 O
induction	593 9 O
in	603 2 O
combination	606 11 O
anaesthesia	618 11 O
.	629 1 O

Cardiotoxic	0 11 B-Disease
and	12 3 O
possible	16 8 O
leukemogenic	25 12 O
effects	38 7 O
of	46 2 O
adriamycin	49 10 B-Chemical
in	60 2 O
nonhuman	63 8 O
primates	72 8 O
.	80 1 O

10	82 2 O
monkeys	85 7 O
(	93 1 O
macaques	94 8 O
)	102 1 O
received	104 8 O
adriamycin	113 10 B-Chemical
by	124 2 O
monthly	127 7 O
intravenous	135 11 O
injections	147 10 O
at	158 2 O
12	161 2 O
mg	164 2 O
/	166 1 O
m2	167 2 O
(	170 1 O
1	171 1 O
mg	173 2 O
/	175 1 O
kg	176 2 O
)	178 1 O
.	179 1 O

8	181 1 O
of	183 2 O
the	186 3 O
10	190 2 O
monkeys	193 7 O
developed	201 9 O
congestive	211 10 B-Disease
heart	222 5 I-Disease
failure	228 7 I-Disease
at	236 2 O
an	239 2 O
average	242 7 O
cumulative	250 10 O
adriamycin	261 10 B-Chemical
dose	272 4 O
(	277 1 O
310	278 3 O
mg	282 2 O
/	284 1 O
m2	285 2 O
)	287 1 O
well	289 4 O
below	294 5 O
that	300 4 O
considered	305 10 O
the	316 3 O
safe	320 4 O
upper	325 5 O
limit	331 5 O
(	337 1 O
550	338 3 O
mg	342 2 O
/	344 1 O
m2	345 2 O
)	347 1 O
in	349 2 O
man	352 3 O
.	355 1 O

Histologically	357 14 O
,	371 1 O
the	373 3 O
myocardial	377 10 B-Disease
lesions	388 7 I-Disease
resembled	396 9 O
those	406 5 O
found	412 5 O
in	418 2 O
human	421 5 O
anthracycline	427 13 B-Chemical
-	440 1 O
induced	441 7 O
cardiomyopathy	449 14 B-Disease
.	463 1 O

1	465 1 O
of	467 2 O
the	470 3 O
10	474 2 O
monkeys	477 7 O
developed	485 9 O
acute	495 5 B-Disease
myeloblastic	501 12 I-Disease
leukemia	514 8 I-Disease
after	523 5 O
receiving	529 9 O
324	539 3 O
mg	543 2 O
/	545 1 O
m2	546 2 O
of	549 2 O
adriamycin	552 10 B-Chemical
;	562 1 O
the	564 3 O
10th	568 4 O
monkey	573 6 O
is	580 2 O
alive	583 5 O
and	589 3 O
well	593 4 O
26	598 2 O
months	601 6 O
after	608 5 O
the	614 3 O
last	618 4 O
dose	623 4 O
of	628 2 O
drug	631 4 O
.	635 1 O

Our	637 3 O
results	641 7 O
suggest	649 7 O
that	657 4 O
adriamycin	662 10 B-Chemical
is	673 2 O
a	676 1 O
more	678 4 O
potent	683 6 O
cardiotoxin	690 11 O
in	702 2 O
monkeys	705 7 O
than	713 4 O
in	718 2 O
man	721 3 O
,	724 1 O
and	726 3 O
that	730 4 O
leukemia	735 8 B-Disease
may	744 3 O
be	748 2 O
a	751 1 O
consequence	753 11 O
of	765 2 O
prolonged	768 9 O
treatment	778 9 O
with	788 4 O
this	793 4 O
drug	798 4 O
.	802 1 O

Doxorubicin	0 11 B-Chemical
cardiomyopathy	12 14 B-Disease
in	27 2 O
children	30 8 O
with	39 4 O
left	44 4 O
-	48 1 O
sided	49 5 O
Wilms	55 5 B-Disease
tumor	61 5 I-Disease
.	66 1 O

Two	68 3 O
children	72 8 O
with	81 4 O
Wilms	86 5 B-Disease
tumor	92 5 I-Disease
of	98 2 O
the	101 3 O
left	105 4 O
kidney	110 6 O
experienced	117 11 O
severe	129 6 O
anthracycline	136 13 B-Chemical
cardiomyopathy	150 14 B-Disease
after	165 5 O
irradiation	171 11 O
to	183 2 O
the	186 3 O
tumor	190 5 B-Disease
bed	196 3 O
and	200 3 O
conventional	204 12 O
dosage	217 6 O
of	224 2 O
doxorubicin	227 11 B-Chemical
.	238 1 O

The	240 3 O
cardiomyopathy	244 14 B-Disease
is	259 2 O
attributed	262 10 O
1	273 1 O
)	274 1 O
to	276 2 O
the	279 3 O
fact	283 4 O
that	288 4 O
radiation	293 9 O
fields	303 6 O
for	310 3 O
left	314 4 O
Wilms	319 5 B-Disease
tumor	325 5 I-Disease
include	331 7 O
the	339 3 O
lower	343 5 O
portion	349 7 O
of	357 2 O
the	360 3 O
heart	364 5 O
and	370 3 O
2	374 1 O
)	375 1 O
to	377 2 O
the	380 3 O
interaction	384 11 O
of	396 2 O
doxorubicin	399 11 B-Chemical
and	411 3 O
irradiation	415 11 O
on	427 2 O
cardiac	430 7 O
muscle	438 6 O
.	444 1 O

It	446 2 O
is	449 2 O
recommended	452 11 O
that	464 4 O
doxorubicin	469 11 B-Chemical
dosage	481 6 O
be	488 2 O
sharply	491 7 O
restricted	499 10 O
in	510 2 O
children	513 8 O
with	522 4 O
Wilms	527 5 B-Disease
tumor	533 5 I-Disease
of	539 2 O
the	542 3 O
left	546 4 O
kidney	551 6 O
who	558 3 O
receive	562 7 O
postoperative	570 13 O
irradiation	584 11 O
.	595 1 O

Promotional	0 11 O
effects	12 7 O
of	20 2 O
testosterone	23 12 B-Chemical
and	36 3 O
dietary	40 7 O
fat	48 3 O
on	52 2 O
prostate	55 8 O
carcinogenesis	64 14 B-Disease
in	79 2 O
genetically	82 11 O
susceptible	94 11 O
rats	106 4 O
.	110 1 O

Germfree	112 8 O
(	121 1 O
GF	122 2 O
)	124 1 O
Lobund	126 6 O
strain	133 6 O
Wistar	140 6 O
(	147 1 O
LW	148 2 O
)	150 1 O
rats	152 4 O
,	156 1 O
fed	158 3 O
vegetable	162 9 O
diet	172 4 O
L	177 1 O
-	178 1 O
485	179 3 O
,	182 1 O
have	184 4 O
developed	189 9 O
prostate	199 8 B-Disease
adenocarcinomas	208 15 I-Disease
spontaneously	224 13 O
(	238 1 O
10	239 2 O
%	241 1 O
incidence	243 9 O
)	252 1 O
at	254 2 O
average	257 7 O
age	265 3 O
34	269 2 O
months	272 6 O
.	278 1 O

Conventional	280 12 O
LW	293 2 O
rats	296 4 O
,	300 1 O
implanted	302 9 O
with	312 4 O
testosterone	317 12 B-Chemical
at	330 2 O
age	333 3 O
4	337 1 O
months	339 6 O
,	345 1 O
developed	347 9 O
a	357 1 O
higher	359 6 O
incidence	366 9 O
of	376 2 O
prostate	379 8 B-Disease
cancer	388 6 I-Disease
after	395 5 O
an	401 2 O
average	404 7 O
interval	412 8 O
of	421 2 O
14	424 2 O
months	427 6 O
:	433 1 O
24	435 2 O
%	437 1 O
had	439 3 O
developed	443 9 O
gross	453 5 O
tumors	459 6 B-Disease
,	465 1 O
and	467 3 O
40	471 2 O
%	473 1 O
when	475 4 O
it	480 2 O
included	483 8 O
microscopic	492 11 O
tumors	504 6 B-Disease
.	510 1 O

Preliminary	512 11 O
results	524 7 O
indicate	532 8 O
that	541 4 O
testosterone	546 12 B-Chemical
-	558 1 O
treated	559 7 O
LW	567 2 O
rats	570 4 O
that	575 4 O
were	580 4 O
fed	585 3 O
the	589 3 O
same	593 4 O
diet	598 4 O
,	602 1 O
which	604 5 O
was	610 3 O
supplemented	614 12 O
with	627 4 O
corn	632 4 O
oil	637 3 O
up	641 2 O
to	644 2 O
20	647 2 O
%	649 1 O
fat	651 3 O
,	654 1 O
developed	656 9 O
prostate	666 8 B-Disease
cancer	675 6 I-Disease
after	682 5 O
intervals	688 9 O
of	698 2 O
6	701 1 O
-	702 1 O
12	703 2 O
months	706 6 O
.	712 1 O

Aged	714 4 O
GF	719 2 O
Sprague	722 7 O
-	729 1 O
Dawley	730 6 O
(	737 1 O
SD	738 2 O
)	740 1 O
rats	742 4 O
have	747 4 O
not	752 3 O
developed	756 9 O
prostate	766 8 B-Disease
cancer	775 6 I-Disease
spontaneously	782 13 O
.	795 1 O

Conventional	797 12 O
SD	810 2 O
rats	813 4 O
fed	818 3 O
diet	822 4 O
L	827 1 O
-	828 1 O
485	829 3 O
and	833 3 O
treated	837 7 O
with	845 4 O
testosterone	850 12 B-Chemical
developed	863 9 O
only	873 4 O
prostatitis	878 11 B-Disease
.	889 1 O

Experimental	891 12 O
designs	904 7 O
should	912 6 O
consider	919 8 O
genetic	928 7 O
susceptibility	936 14 O
as	951 2 O
a	954 1 O
basic	956 5 O
prerequisite	962 12 O
for	975 3 O
studies	979 7 O
on	987 2 O
experimental	990 12 O
prostate	1003 8 B-Disease
cancer	1012 6 I-Disease
.	1018 1 O

Mitomycin	0 9 B-Chemical
C	10 1 I-Chemical
associated	12 10 O
hemolytic	23 9 B-Disease
uremic	33 6 I-Disease
syndrome	40 8 I-Disease
.	48 1 O

Mitomycin	50 9 B-Chemical
C	60 1 I-Chemical
associated	62 10 O
Hemolytic	73 9 B-Disease
Uremic	83 6 I-Disease
Syndrome	90 8 I-Disease
(	99 1 O
HUS	100 3 B-Disease
)	103 1 O
is	105 2 O
a	108 1 O
potentially	110 11 O
fatal	122 5 O
but	128 3 O
uncommon	132 8 O
condition	141 9 O
that	151 4 O
is	156 2 O
not	159 3 O
yet	163 3 O
widely	167 6 O
recognised	174 10 O
.	184 1 O

It	186 2 O
consists	189 8 O
of	198 2 O
microangiopathic	201 16 O
hemolytic	218 9 B-Disease
anemia	228 6 I-Disease
,	234 1 O
thrombocytopenia	236 16 B-Disease
and	253 3 O
progressive	257 11 O
renal	269 5 B-Disease
failure	275 7 I-Disease
associated	283 10 O
with	294 4 O
mitomycin	299 9 B-Chemical
C	309 1 I-Chemical
treatment	311 9 O
and	321 3 O
affects	325 7 O
about	333 5 O
10	339 2 O
%	341 1 O
of	343 2 O
patients	346 8 O
treated	355 7 O
with	363 4 O
this	368 4 O
agent	373 5 O
.	378 1 O

The	380 3 O
renal	384 5 B-Disease
failure	390 7 I-Disease
usually	398 7 O
develops	406 8 O
about	415 5 O
8	421 1 O
-	422 1 O
10	423 2 O
mth	426 3 O
after	430 5 O
start	436 5 O
of	442 2 O
mitomycin	445 9 B-Chemical
C	455 1 I-Chemical
treatment	457 9 O
and	467 3 O
the	471 3 O
mortality	475 9 O
is	485 2 O
approximately	488 13 O
60	502 2 O
%	504 1 O
from	506 4 O
renal	511 5 B-Disease
failure	517 7 I-Disease
or	525 2 O
pulmonary	528 9 B-Disease
edema	538 5 I-Disease
.	543 1 O

Renal	545 5 B-Disease
lesions	551 7 I-Disease
are	559 3 O
similar	563 7 O
to	571 2 O
those	574 5 O
seen	580 4 O
in	585 2 O
idiopathic	588 10 O
HUS	599 3 B-Disease
and	603 3 O
include	607 7 O
arteriolar	615 10 O
fibrin	626 6 O
thrombi	633 7 B-Disease
,	640 1 O
expanded	642 8 O
subendothelial	651 14 O
zones	666 5 O
in	672 2 O
glomerular	675 10 O
capillary	686 9 O
walls	696 5 O
,	701 1 O
ischemic	703 8 B-Disease
wrinkling	712 9 O
of	722 2 O
glomerular	725 10 O
basement	736 8 O
membranes	745 9 O
and	755 3 O
mesangiolysis	759 13 O
.	772 1 O

The	774 3 O
mechanism	778 9 O
of	788 2 O
action	791 6 O
is	798 2 O
postulated	801 10 O
as	812 2 O
mitomycin	815 9 B-Chemical
C	825 1 I-Chemical
-	826 1 O
induced	827 7 O
endothelial	835 11 O
cell	847 4 O
damage	852 6 O
.	858 1 O

We	860 2 O
describe	863 8 O
the	872 3 O
clinical	876 8 O
course	885 6 O
and	892 3 O
pathological	896 12 O
findings	909 8 O
in	918 2 O
a	921 1 O
65	923 2 O
yr	926 2 O
-	928 1 O
old	929 3 O
man	933 3 O
with	937 4 O
gastric	942 7 B-Disease
adenocarcinoma	950 14 I-Disease
who	965 3 O
developed	969 9 O
renal	979 5 B-Disease
failure	985 7 I-Disease
and	993 3 O
thrombocytopenia	997 16 B-Disease
while	1014 5 O
on	1020 2 O
treatment	1023 9 O
with	1033 4 O
mitomycin	1038 9 B-Chemical
C	1048 1 I-Chemical
and	1050 3 O
died	1054 4 O
in	1059 2 O
pulmonary	1062 9 B-Disease
edema	1072 5 I-Disease
.	1077 1 O

Continuous	0 10 O
ambulatory	11 10 O
ECG	22 3 O
monitoring	26 10 O
during	37 6 O
fluorouracil	44 12 B-Chemical
therapy	57 7 O
:	64 1 O
a	66 1 O
prospective	68 11 O
study	80 5 O
.	85 1 O

Although	87 8 O
there	96 5 O
have	102 4 O
been	107 4 O
anecdotal	112 9 O
reports	122 7 O
of	130 2 O
cardiac	133 7 B-Disease
toxicity	141 8 I-Disease
associated	150 10 O
with	161 4 O
fluorouracil	166 12 B-Chemical
(	179 1 O
5	180 1 B-Chemical
-	181 1 I-Chemical
FU	182 2 I-Chemical
)	184 1 O
therapy	186 7 O
,	193 1 O
this	195 4 O
phenomenon	200 10 O
has	211 3 O
not	215 3 O
been	219 4 O
studied	224 7 O
in	232 2 O
a	235 1 O
systematic	237 10 O
fashion	248 7 O
.	255 1 O

We	257 2 O
prospectively	260 13 O
performed	274 9 O
continuous	284 10 O
ambulatory	295 10 O
ECG	306 3 O
monitoring	310 10 O
on	321 2 O
25	324 2 O
patients	327 8 O
undergoing	336 10 O
5	347 1 B-Chemical
-	348 1 I-Chemical
FU	349 2 I-Chemical
infusion	352 8 O
for	361 3 O
treatment	365 9 O
of	375 2 O
solid	378 5 O
tumors	384 6 B-Disease
in	391 2 O
order	394 5 O
to	400 2 O
assess	403 6 O
the	410 3 O
incidence	414 9 O
of	424 2 O
ischemic	427 8 B-Disease
ST	436 2 O
changes	439 7 O
.	446 1 O

Patients	448 8 O
were	457 4 O
monitored	462 9 O
for	472 3 O
23	476 2 O
+	479 1 O
/	480 1 O
-	481 1 O
4	483 1 O
hours	485 5 O
before	491 6 O
5	498 1 B-Chemical
-	499 1 I-Chemical
FU	500 2 I-Chemical
infusion	503 8 O
,	511 1 O
and	513 3 O
98	517 2 O
+	520 1 O
/	521 1 O
-	522 1 O
9	524 1 O
hours	526 5 O
during	532 6 O
5	539 1 B-Chemical
-	540 1 I-Chemical
FU	541 2 I-Chemical
infusion	544 8 O
.	552 1 O

Anginal	554 7 B-Disease
episodes	562 8 O
were	571 4 O
rare	576 4 O
:	580 1 O
only	582 4 O
one	587 3 O
patient	591 7 O
had	599 3 O
angina	603 6 B-Disease
(	610 1 O
during	611 6 O
5	618 1 B-Chemical
-	619 1 I-Chemical
FU	620 2 I-Chemical
infusion	623 8 O
)	631 1 O
.	632 1 O

However	634 7 O
,	641 1 O
asymptomatic	643 12 O
ST	656 2 O
changes	659 7 O
(	667 1 O
greater	668 7 O
than	676 4 O
or	681 2 O
equal	684 5 O
to	690 2 O
1	693 1 O
mm	695 2 O
ST	698 2 O
deviation	701 9 O
)	710 1 O
were	712 4 O
common	717 6 O
:	723 1 O
six	725 3 O
of	729 2 O
25	732 2 O
patients	735 8 O
(	744 1 O
24	745 2 O
%	747 1 O
)	748 1 O
had	750 3 O
ST	754 2 O
changes	757 7 O
before	765 6 O
5	772 1 B-Chemical
-	773 1 I-Chemical
FU	774 2 I-Chemical
infusion	777 8 O
v	786 1 O
17	788 2 O
(	791 1 O
68	792 2 O
%	794 1 O
)	795 1 O
during	797 6 O
5	804 1 B-Chemical
-	805 1 I-Chemical
FU	806 2 I-Chemical
infusion	809 8 O
(	818 1 O
P	819 1 O
less	821 4 O
than	826 4 O
.	831 1 O
002	832 3 O
)	835 1 O
.	836 1 O

The	838 3 O
incidence	842 9 O
of	852 2 O
ischemic	855 8 B-Disease
episodes	864 8 O
per	873 3 O
patient	877 7 O
per	885 3 O
hour	889 4 O
was	894 3 O
0	898 1 O
.	899 1 O
05	900 2 O
+	903 1 O
/	904 1 O
-	905 1 O
0	907 1 O
.	908 1 O
02	909 2 O
prior	912 5 O
to	918 2 O
5	921 1 B-Chemical
-	922 1 I-Chemical
FU	923 2 I-Chemical
infusion	926 8 O
v	935 1 O
0	937 1 O
.	938 1 O
13	939 2 O
+	942 1 O
/	943 1 O
-	944 1 O
0	946 1 O
.	947 1 O
03	948 2 O
during	951 6 O
5	958 1 B-Chemical
-	959 1 I-Chemical
FU	960 2 I-Chemical
infusion	963 8 O
(	972 1 O
P	973 1 O
less	975 4 O
than	980 4 O
.	985 1 O
001	986 3 O
)	989 1 O
;	990 1 O
the	992 3 O
duration	996 8 O
of	1005 2 O
ECG	1008 3 O
changes	1012 7 O
was	1020 3 O
0	1024 1 O
.	1025 1 O
6	1026 1 O
+	1028 1 O
/	1029 1 O
-	1030 1 O
0	1032 1 O
.	1033 1 O
3	1034 1 O
minutes	1036 7 O
per	1044 3 O
patient	1048 7 O
per	1056 3 O
hour	1060 4 O
before	1065 6 O
5	1072 1 B-Chemical
-	1073 1 I-Chemical
FU	1074 2 I-Chemical
v	1077 1 O
1	1079 1 O
.	1080 1 O
9	1081 1 O
+	1083 1 O
/	1084 1 O
-	1085 1 O
0	1087 1 O
.	1088 1 O
5	1089 1 O
minutes	1091 7 O
per	1099 3 O
patient	1103 7 O
per	1111 3 O
hour	1115 4 O
during	1120 6 O
5	1127 1 B-Chemical
-	1128 1 I-Chemical
FU	1129 2 I-Chemical
(	1132 1 O
P	1133 1 O
less	1135 4 O
than	1140 4 O
.	1145 1 O
01	1146 2 O
)	1148 1 O
.	1149 1 O

ECG	1151 3 O
changes	1155 7 O
were	1163 4 O
more	1168 4 O
common	1173 6 O
among	1180 5 O
patients	1186 8 O
with	1195 4 O
known	1200 5 O
coronary	1206 8 B-Disease
artery	1215 6 I-Disease
disease	1222 7 I-Disease
.	1229 1 O

There	1231 5 O
were	1237 4 O
two	1242 3 O
cases	1246 5 O
of	1252 2 O
sudden	1255 6 B-Disease
death	1262 5 I-Disease
,	1267 1 O
both	1269 4 O
of	1274 2 O
which	1277 5 O
occurred	1283 8 O
at	1292 2 O
the	1295 3 O
end	1299 3 O
of	1303 2 O
the	1306 3 O
chemotherapy	1310 12 O
course	1323 6 O
.	1329 1 O

We	1331 2 O
conclude	1334 8 O
that	1343 4 O
5	1348 1 B-Chemical
-	1349 1 I-Chemical
FU	1350 2 I-Chemical
infusion	1353 8 O
is	1362 2 O
associated	1365 10 O
with	1376 4 O
a	1381 1 O
significant	1383 11 O
increase	1395 8 O
in	1404 2 O
silent	1407 6 O
ST	1414 2 O
segment	1417 7 O
deviation	1425 9 O
suggestive	1435 10 O
of	1446 2 O
ischemia	1449 8 B-Disease
,	1457 1 O
particularly	1459 12 O
among	1472 5 O
patients	1478 8 O
with	1487 4 O
coronary	1492 8 B-Disease
artery	1501 6 I-Disease
disease	1508 7 I-Disease
.	1515 1 O

The	1517 3 O
mechanism	1521 9 O
and	1531 3 O
clinical	1535 8 O
significance	1544 12 O
of	1557 2 O
these	1560 5 O
ECG	1566 3 O
changes	1570 7 O
remain	1578 6 O
to	1585 2 O
be	1588 2 O
determined	1591 10 O
.	1601 1 O

Lethal	0 6 O
anuria	7 6 B-Disease
complicating	14 12 O
high	27 4 O
dose	32 4 O
ifosfamide	37 10 B-Chemical
chemotherapy	48 12 O
in	61 2 O
a	64 1 O
breast	66 6 B-Disease
cancer	73 6 I-Disease
patient	80 7 O
with	88 4 O
an	93 2 O
impaired	96 8 B-Disease
renal	105 5 I-Disease
function	111 8 I-Disease
.	119 1 O

A	121 1 O
sixty	123 5 O
-	128 1 O
year	129 4 O
-	133 1 O
old	134 3 O
woman	138 5 O
with	144 4 O
advanced	149 8 O
breast	158 6 B-Disease
cancer	165 6 I-Disease
,	171 1 O
previously	173 10 O
treated	184 7 O
with	192 4 O
cisplatin	197 9 B-Chemical
,	206 1 O
developed	208 9 O
an	218 2 O
irreversible	221 12 O
lethal	234 6 O
renal	241 5 B-Disease
failure	247 7 I-Disease
with	255 4 O
anuria	260 6 B-Disease
,	266 1 O
the	268 3 O
day	272 3 O
after	276 5 O
5	282 1 O
g	284 1 O
/	285 1 O
m2	286 2 O
bolus	289 5 O
ifosfamide	295 10 B-Chemical
.	305 1 O

Postrenal	307 9 B-Disease
failure	317 7 I-Disease
was	325 3 O
excluded	329 8 O
by	338 2 O
echography	341 10 O
.	351 1 O

A	353 1 O
prerenal	355 8 O
component	364 9 O
could	374 5 O
have	380 4 O
contributed	385 11 O
to	397 2 O
renal	400 5 B-Disease
failure	406 7 I-Disease
because	414 7 O
of	422 2 O
a	425 1 O
transient	427 9 O
hypotension	437 11 B-Disease
,	448 1 O
due	450 3 O
to	454 2 O
an	457 2 O
increasing	460 10 O
ascitis	471 7 O
,	478 1 O
occurring	480 9 O
just	490 4 O
before	495 6 O
anuria	502 6 B-Disease
.	508 1 O

However	510 7 O
,	517 1 O
correction	519 10 O
of	530 2 O
the	533 3 O
hemodynamic	537 11 O
parameters	549 10 O
did	560 3 O
not	564 3 O
improve	568 7 O
renal	576 5 O
function	582 8 O
.	590 1 O

Ifosfamide	592 10 B-Chemical
is	603 2 O
a	606 1 O
known	608 5 O
nephrotoxic	614 11 B-Disease
drug	626 4 O
with	631 4 O
demonstrated	636 12 O
tubulopathies	649 13 B-Disease
.	662 1 O

We	664 2 O
strongly	667 8 O
suspect	676 7 O
that	684 4 O
this	689 4 O
lethal	694 6 O
anuria	701 6 B-Disease
was	708 3 O
mainly	712 6 O
due	719 3 O
to	723 2 O
ifosfamide	726 10 B-Chemical
,	736 1 O
occurring	738 9 O
in	748 2 O
a	751 1 O
patient	753 7 O
having	761 6 O
received	768 8 O
previous	777 8 O
cisplatin	786 9 B-Chemical
chemotherapy	796 12 O
and	809 3 O
with	813 4 O
poor	818 4 O
kidney	823 6 O
perfusion	830 9 O
due	840 3 O
to	844 2 O
transient	847 9 O
hypotension	857 11 B-Disease
.	868 1 O

We	870 2 O
recommend	873 9 O
careful	883 7 O
use	891 3 O
of	895 2 O
ifosfamide	898 10 B-Chemical
in	909 2 O
patients	912 8 O
pretreated	921 10 O
with	932 4 O
nephrotoxic	937 11 B-Disease
chemotherapy	949 12 O
and	962 3 O
inadequate	966 10 O
renal	977 5 O
perfusion	983 9 O
.	992 1 O

Central	0 7 O
vein	8 4 B-Disease
thrombosis	13 10 I-Disease
and	24 3 O
topical	28 7 O
dipivalyl	36 9 B-Chemical
epinephrine	46 11 I-Chemical
.	57 1 O

A	59 1 O
report	61 6 O
is	68 2 O
given	71 5 O
on	77 2 O
an	80 2 O
83	83 2 O
-	85 1 O
year	86 4 O
-	90 1 O
old	91 3 O
female	95 6 O
who	102 3 O
acquired	106 8 O
central	115 7 O
vein	123 4 B-Disease
thrombosis	128 10 I-Disease
in	139 2 O
her	142 3 O
seeing	146 6 O
eye	153 3 O
one	157 3 O
day	161 3 O
after	165 5 O
having	171 6 O
started	178 7 O
topical	186 7 O
medication	194 10 O
with	205 4 O
dipivalyl	210 9 B-Chemical
epinephrine	220 11 I-Chemical
for	232 3 O
advanced	236 8 O
glaucoma	245 8 B-Disease
discovered	254 10 O
in	265 2 O
the	268 3 O
other	272 5 O
eye	278 3 O
.	281 1 O

From	283 4 O
present	288 7 O
knowledge	296 9 O
about	306 5 O
the	312 3 O
effects	316 7 O
of	324 2 O
adrenergic	327 10 O
eye	338 3 O
drops	342 5 O
on	348 2 O
ocular	351 6 O
blood	358 5 O
circulation	364 11 O
,	375 1 O
it	377 2 O
is	380 2 O
difficult	383 9 O
to	393 2 O
suggest	396 7 O
an	404 2 O
association	407 11 O
between	419 7 O
the	427 3 O
two	431 3 O
events	435 6 O
,	441 1 O
which	443 5 O
may	449 3 O
be	453 2 O
coincidental	456 12 O
only	469 4 O
.	473 1 O

Amelioration	0 12 O
of	13 2 O
bendrofluazide	16 14 B-Chemical
-	30 1 O
induced	31 7 O
hypokalemia	39 11 B-Disease
by	51 2 O
timolol	54 7 B-Chemical
.	61 1 O

The	63 3 O
beta	67 4 O
adrenergic	72 10 O
blocking	83 8 O
drug	92 4 O
,	96 1 O
timolol	98 7 B-Chemical
,	105 1 O
tended	107 6 O
to	114 2 O
correct	117 7 O
the	125 3 O
hypokalemia	129 11 B-Disease
of	141 2 O
short	144 5 O
-	149 1 O
term	150 4 O
bendrofluazide	155 14 B-Chemical
treatment	170 9 O
in	180 2 O
6	183 1 O
healthy	185 7 O
male	193 4 O
subjects	198 8 O
and	207 3 O
although	211 8 O
the	220 3 O
effect	224 6 O
was	231 3 O
small	235 5 O
it	241 2 O
was	244 3 O
significant	248 11 O
.	259 1 O

Timolol	261 7 B-Chemical
also	269 4 O
reduced	274 7 O
the	282 3 O
rise	286 4 O
in	291 2 O
plasma	294 6 O
aldosterone	301 11 B-Chemical
and	313 3 O
urine	317 5 O
potassium	323 9 B-Chemical
excretion	333 9 O
following	343 9 O
bendrofluazide	353 14 B-Chemical
and	368 3 O
increased	372 9 O
the	382 3 O
urine	386 5 O
sodium	392 6 B-Chemical
/	398 1 O
potassium	399 9 B-Chemical
ratio	409 5 O
.	414 1 O

There	416 5 O
was	422 3 O
no	426 2 O
evidence	429 8 O
of	438 2 O
a	441 1 O
shift	443 5 O
of	449 2 O
potassium	452 9 B-Chemical
from	462 4 O
the	467 3 O
intracellular	471 13 O
to	485 2 O
the	488 3 O
extracellular	492 13 O
space	506 5 O
.	511 1 O

A	0 1 O
cross	2 5 O
-	7 1 O
sectional	8 9 O
evaluation	18 10 O
of	29 2 O
the	32 3 O
effect	36 6 O
of	43 2 O
risperidone	46 11 B-Chemical
and	58 3 O
selective	62 9 O
serotonin	72 9 B-Chemical
reuptake	82 8 O
inhibitors	91 10 O
on	102 2 O
bone	105 4 O
mineral	110 7 O
density	118 7 O
in	126 2 O
boys	129 4 O
.	133 1 O

OBJECTIVE	135 9 O
:	144 1 O
The	146 3 O
aim	150 3 O
of	154 2 O
the	157 3 O
present	161 7 O
study	169 5 O
was	175 3 O
to	179 2 O
investigate	182 11 O
the	194 3 O
effect	198 6 O
of	205 2 O
risperidone	208 11 B-Chemical
-	219 1 O
induced	220 7 O
hyperprolactinemia	228 18 B-Disease
on	247 2 O
trabecular	250 10 O
bone	261 4 O
mineral	266 7 O
density	274 7 O
(	282 1 O
BMD	283 3 O
)	286 1 O
in	288 2 O
children	291 8 O
and	300 3 O
adolescents	304 11 O
.	315 1 O

METHOD	317 6 O
:	323 1 O
Medically	325 9 O
healthy	335 7 O
7	343 1 O
-	344 1 O
to	346 2 O
17	349 2 O
-	351 1 O
year	352 4 O
-	356 1 O
old	357 3 O
males	361 5 O
chronically	367 11 O
treated	379 7 O
,	386 1 O
in	388 2 O
a	391 1 O
naturalistic	393 12 O
setting	406 7 O
,	413 1 O
with	415 4 O
risperidone	420 11 B-Chemical
were	432 4 O
recruited	437 9 O
for	447 3 O
this	451 4 O
cross	456 5 O
-	461 1 O
sectional	462 9 O
study	472 5 O
through	478 7 O
child	486 5 O
psychiatry	492 10 O
outpatient	503 10 O
clinics	514 7 O
between	522 7 O
November	530 8 O
2005	539 4 O
and	544 3 O
June	548 4 O
2007	553 4 O
.	557 1 O

Anthropometric	559 14 O
measurements	574 12 O
and	587 3 O
laboratory	591 10 O
testing	602 7 O
were	610 4 O
conducted	615 9 O
.	624 1 O

The	626 3 O
clinical	630 8 O
diagnoses	639 9 O
were	649 4 O
based	654 5 O
on	660 2 O
chart	663 5 O
review	669 6 O
,	675 1 O
and	677 3 O
developmental	681 13 O
and	695 3 O
treatment	699 9 O
history	709 7 O
was	717 3 O
obtained	721 8 O
from	730 4 O
the	735 3 O
medical	739 7 O
record	747 6 O
.	753 1 O

Volumetric	755 10 O
BMD	766 3 O
of	770 2 O
the	773 3 O
ultradistal	777 11 O
radius	789 6 O
was	796 3 O
measured	800 8 O
using	809 5 O
peripheral	815 10 O
quantitative	826 12 O
computed	839 8 O
tomography	848 10 O
,	858 1 O
and	860 3 O
areal	864 5 O
BMD	870 3 O
of	874 2 O
the	877 3 O
lumbar	881 6 O
spine	888 5 O
was	894 3 O
estimated	898 9 O
using	908 5 O
dual	914 4 O
-	918 1 O
energy	919 6 O
x	926 1 O
-	927 1 O
ray	928 3 O
absorptiometry	932 14 O
.	946 1 O

RESULTS	948 7 O
:	955 1 O
Hyperprolactinemia	957 18 B-Disease
was	976 3 O
present	980 7 O
in	988 2 O
49	991 2 O
%	993 1 O
of	995 2 O
83	998 2 O
boys	1001 4 O
(	1006 1 O
n	1007 1 O
=	1009 1 O
41	1011 2 O
)	1013 1 O
treated	1015 7 O
with	1023 4 O
risperidone	1028 11 B-Chemical
for	1040 3 O
a	1044 1 O
mean	1046 4 O
of	1051 2 O
2	1054 1 O
.	1055 1 O
9	1056 1 O
years	1058 5 O
.	1063 1 O

Serum	1065 5 O
testosterone	1071 12 B-Chemical
concentration	1084 13 O
increased	1098 9 O
with	1108 4 O
pubertal	1113 8 O
status	1122 6 O
but	1129 3 O
was	1133 3 O
not	1137 3 O
affected	1141 8 O
by	1150 2 O
hyperprolactinemia	1153 18 B-Disease
.	1171 1 O

As	1173 2 O
expected	1176 8 O
,	1184 1 O
bone	1186 4 O
mineral	1191 7 O
content	1199 7 O
and	1207 3 O
BMD	1211 3 O
increased	1215 9 O
with	1225 4 O
sexual	1230 6 O
maturity	1237 8 O
.	1245 1 O

After	1247 5 O
adjusting	1253 9 O
for	1263 3 O
the	1267 3 O
stage	1271 5 O
of	1277 2 O
sexual	1280 6 O
development	1287 11 O
and	1299 3 O
height	1303 6 O
and	1310 3 O
BMI	1314 3 O
z	1318 1 O
scores	1320 6 O
,	1326 1 O
serum	1328 5 O
prolactin	1334 9 O
was	1344 3 O
negatively	1348 10 O
associated	1359 10 O
with	1370 4 O
trabecular	1375 10 O
volumetric	1386 10 O
BMD	1397 3 O
at	1401 2 O
the	1404 3 O
ultradistal	1408 11 O
radius	1420 6 O
(	1427 1 O
P	1428 1 O
<	1430 1 O
.	1432 1 O
03	1433 2 O
)	1435 1 O
.	1436 1 O

Controlling	1438 11 O
for	1450 3 O
relevant	1454 8 O
covariates	1463 10 O
,	1473 1 O
we	1475 2 O
also	1478 4 O
found	1483 5 O
treatment	1489 9 O
with	1499 4 O
selective	1504 9 O
serotonin	1514 9 B-Chemical
reuptake	1524 8 O
inhibitors	1533 10 O
(	1544 1 O
SSRIs	1545 5 O
)	1550 1 O
to	1552 2 O
be	1555 2 O
associated	1558 10 O
with	1569 4 O
lower	1574 5 O
trabecular	1580 10 O
BMD	1591 3 O
at	1595 2 O
the	1598 3 O
radius	1602 6 O
(	1609 1 O
P	1610 1 O
=	1612 1 O
.	1614 1 O
03	1615 2 O
)	1617 1 O
and	1619 3 O
BMD	1623 3 O
z	1627 1 O
score	1629 5 O
at	1635 2 O
the	1638 3 O
lumbar	1642 6 O
spine	1649 5 O
(	1655 1 O
P	1656 1 O
<	1658 1 O
.	1660 1 O
05	1661 2 O
)	1663 1 O
.	1664 1 O

These	1666 5 O
findings	1672 8 O
became	1681 6 O
more	1688 4 O
marked	1693 6 O
when	1700 4 O
the	1705 3 O
analysis	1709 8 O
was	1718 3 O
restricted	1722 10 O
to	1733 2 O
non	1736 3 O
-	1739 1 O
Hispanic	1740 8 O
white	1749 5 O
patients	1755 8 O
.	1763 1 O

Of	1765 2 O
13	1768 2 O
documented	1771 10 O
fractures	1782 9 B-Disease
,	1791 1 O
3	1793 1 O
occurred	1795 8 O
after	1804 5 O
risperidone	1810 11 B-Chemical
and	1822 3 O
SSRIs	1826 5 O
were	1832 4 O
started	1837 7 O
,	1844 1 O
and	1846 3 O
none	1850 4 O
occurred	1855 8 O
in	1864 2 O
patients	1867 8 O
with	1876 4 O
hyperprolactinemia	1881 18 B-Disease
.	1899 1 O

CONCLUSIONS	1901 11 O
:	1912 1 O
This	1914 4 O
is	1919 2 O
the	1922 3 O
first	1926 5 O
study	1932 5 O
to	1938 2 O
link	1941 4 O
risperidone	1946 11 B-Chemical
-	1957 1 O
induced	1958 7 O
hyperprolactinemia	1966 18 B-Disease
and	1985 3 O
SSRI	1989 4 O
treatment	1994 9 O
to	2004 2 O
lower	2007 5 O
BMD	2013 3 O
in	2017 2 O
children	2020 8 O
and	2029 3 O
adolescents	2033 11 O
.	2044 1 O

Future	2046 6 O
research	2053 8 O
should	2062 6 O
evaluate	2069 8 O
the	2078 3 O
longitudinal	2082 12 O
course	2095 6 O
of	2102 2 O
this	2105 4 O
adverse	2110 7 O
event	2118 5 O
to	2124 2 O
determine	2127 9 O
its	2137 3 O
temporal	2141 8 O
stability	2150 9 O
and	2160 3 O
whether	2164 7 O
a	2172 1 O
higher	2174 6 O
fracture	2181 8 O
rate	2190 4 O
ensues	2195 6 O
.	2201 1 O

Seizures	0 8 B-Disease
associated	9 10 O
with	20 4 O
levofloxacin	25 12 B-Chemical
:	37 1 O
case	39 4 O
presentation	44 12 O
and	57 3 O
literature	61 10 O
review	72 6 O
.	78 1 O

PURPOSE	80 7 O
:	87 1 O
We	89 2 O
present	92 7 O
a	100 1 O
case	102 4 O
of	107 2 O
a	110 1 O
patient	112 7 O
who	120 3 O
developed	124 9 O
seizures	134 8 B-Disease
shortly	143 7 O
after	151 5 O
initiating	157 10 O
treatment	168 9 O
with	178 4 O
levofloxacin	183 12 B-Chemical
and	196 3 O
to	200 2 O
discuss	203 7 O
the	211 3 O
potential	215 9 O
drug	225 4 O
-	229 1 O
drug	230 4 O
interactions	235 12 O
related	248 7 O
to	256 2 O
the	259 3 O
inhibition	263 10 O
of	274 2 O
cytochrome	277 10 O
P450	288 4 O
(	293 1 O
CYP	294 3 O
)	297 1 O
1A2	299 3 O
in	303 2 O
this	306 4 O
case	311 4 O
,	315 1 O
as	317 2 O
well	320 4 O
as	325 2 O
in	328 2 O
other	331 5 O
cases	337 5 O
,	342 1 O
of	344 2 O
levofloxacin	347 12 B-Chemical
-	359 1 O
induced	360 7 O
seizures	368 8 B-Disease
.	376 1 O

METHODS	378 7 O
:	385 1 O
Several	387 7 O
biomedical	395 10 O
databases	406 9 O
were	416 4 O
searched	421 8 O
including	430 9 O
MEDLINE	440 7 O
,	447 1 O
Cochrane	449 8 O
and	458 3 O
Ovid	462 4 O
.	466 1 O

The	468 3 O
main	472 4 O
search	477 6 O
terms	484 5 O
utilized	490 8 O
were	499 4 O
case	504 4 O
report	509 6 O
and	516 3 O
levofloxacin	520 12 B-Chemical
.	532 1 O

The	534 3 O
search	538 6 O
was	545 3 O
limited	549 7 O
to	557 2 O
studies	560 7 O
published	568 9 O
in	578 2 O
English	581 7 O
.	588 1 O

RESULTS	590 7 O
:	597 1 O
Six	599 3 O
cases	603 5 O
of	609 2 O
levofloxacin	612 12 B-Chemical
-	624 1 O
induced	625 7 O
seizures	633 8 B-Disease
have	642 4 O
been	647 4 O
reported	652 8 O
in	661 2 O
the	664 3 O
literature	668 10 O
.	678 1 O

Drug	680 4 O
-	684 1 O
drug	685 4 O
interactions	690 12 O
related	703 7 O
to	711 2 O
the	714 3 O
inhibition	718 10 O
of	729 2 O
CYP1A2	732 6 O
by	739 2 O
levofloxacin	742 12 B-Chemical
are	755 3 O
likely	759 6 O
involved	766 8 O
in	775 2 O
the	778 3 O
clinical	782 8 O
outcome	791 7 O
of	799 2 O
these	802 5 O
cases	808 5 O
.	813 1 O

CONCLUSIONS	815 11 O
:	826 1 O
Clinicians	828 10 O
are	839 3 O
exhorted	843 8 O
to	852 2 O
pay	855 3 O
close	859 5 O
attention	865 9 O
when	875 4 O
initiating	880 10 O
levofloxacin	891 12 B-Chemical
therapy	904 7 O
in	912 2 O
patients	915 8 O
taking	924 6 O
medications	931 11 O
with	943 4 O
epileptogenic	948 13 O
properties	962 10 O
that	973 4 O
are	978 3 O
CYP1A2	982 6 O
substrates	989 10 O
.	999 1 O

Mice	0 4 O
lacking	5 7 O
mPGES	13 5 O
-	18 1 O
1	19 1 O
are	21 3 O
resistant	25 9 O
to	35 2 O
lithium	38 7 B-Chemical
-	45 1 O
induced	46 7 O
polyuria	54 8 B-Disease
.	62 1 O

Cyclooxygenase	64 14 O
-	78 1 O
2	79 1 O
activity	81 8 O
is	90 2 O
required	93 8 O
for	102 3 O
the	106 3 O
development	110 11 O
of	122 2 O
lithium	125 7 B-Chemical
-	132 1 O
induced	133 7 O
polyuria	141 8 B-Disease
.	149 1 O

However	151 7 O
,	158 1 O
the	160 3 O
involvement	164 11 O
of	176 2 O
a	179 1 O
specific	181 8 O
,	189 1 O
terminal	191 8 O
prostaglandin	200 13 B-Chemical
(	214 1 O
PG	215 2 B-Chemical
)	217 1 O
isomerase	219 9 O
has	229 3 O
not	233 3 O
been	237 4 O
evaluated	242 9 O
.	251 1 O

The	253 3 O
present	257 7 O
study	265 5 O
was	271 3 O
undertaken	275 10 O
to	286 2 O
assess	289 6 O
lithium	296 7 B-Chemical
-	303 1 O
induced	304 7 O
polyuria	312 8 B-Disease
in	321 2 O
mice	324 4 O
deficient	329 9 O
in	339 2 O
microsomal	342 10 O
prostaglandin	353 13 B-Chemical
E	367 1 I-Chemical
synthase	369 8 O
-	377 1 O
1	378 1 O
(	380 1 O
mPGES	381 5 O
-	386 1 O
1	387 1 O
)	388 1 O
.	389 1 O

A	391 1 O
2	393 1 O
-	394 1 O
wk	395 2 O
administration	398 14 O
of	413 2 O
LiCl	416 4 B-Chemical
(	421 1 O
4	422 1 O
mmol	424 4 O
.	428 1 O
kg	429 2 O
(	431 1 O
-	432 1 O
1	433 1 O
)	434 1 O
.	435 1 O
day	436 3 O
(	439 1 O
-	440 1 O
1	441 1 O
)	442 1 O
ip	444 2 O
)	446 1 O
in	448 2 O
mPGES	451 5 O
-	456 1 O
1	457 1 O
+	459 1 O
/	460 1 O
+	461 1 O
mice	463 4 O
led	468 3 O
to	472 2 O
a	475 1 O
marked	477 6 O
polyuria	484 8 B-Disease
with	493 4 O
hyposmotic	498 10 O
urine	509 5 O
.	514 1 O

This	516 4 O
was	521 3 O
associated	525 10 O
with	536 4 O
elevated	541 8 O
renal	550 5 O
mPGES	556 5 O
-	561 1 O
1	562 1 O
protein	564 7 O
expression	572 10 O
and	583 3 O
increased	587 9 O
urine	597 5 O
PGE	603 3 B-Chemical
(	606 1 I-Chemical
2	607 1 I-Chemical
)	608 1 I-Chemical
excretion	610 9 O
.	619 1 O

In	621 2 O
contrast	624 8 O
,	632 1 O
mPGES	634 5 O
-	639 1 O
1	640 1 O
-	642 1 O
/	643 1 O
-	644 1 O
mice	646 4 O
were	651 4 O
largely	656 7 O
resistant	664 9 O
to	674 2 O
lithium	677 7 B-Chemical
-	684 1 O
induced	685 7 O
polyuria	693 8 B-Disease
and	702 3 O
a	706 1 O
urine	708 5 O
concentrating	714 13 O
defect	728 6 O
,	734 1 O
accompanied	736 11 O
by	748 2 O
nearly	751 6 O
complete	758 8 O
blockade	767 8 O
of	776 2 O
high	779 4 O
urine	784 5 O
PGE	790 3 B-Chemical
(	793 1 I-Chemical
2	794 1 I-Chemical
)	795 1 I-Chemical
and	797 3 O
cAMP	801 4 O
output	806 6 O
.	812 1 O

Immunoblotting	814 14 O
,	828 1 O
immunohistochemistry	830 20 O
,	850 1 O
and	852 3 O
quantitative	856 12 O
(	869 1 O
q	870 1 O
)	871 1 O
RT	873 2 O
-	875 1 O
PCR	876 3 O
consistently	880 12 O
detected	893 8 O
a	902 1 O
significant	904 11 O
decrease	916 8 O
in	925 2 O
aquaporin	928 9 O
-	937 1 O
2	938 1 O
(	940 1 O
AQP2	941 4 O
)	945 1 O
protein	947 7 O
expression	955 10 O
in	966 2 O
both	969 4 O
the	974 3 O
renal	978 5 O
cortex	984 6 O
and	991 3 O
medulla	995 7 O
of	1003 2 O
lithium	1006 7 B-Chemical
-	1013 1 O
treated	1014 7 O
+	1022 1 O
/	1023 1 O
+	1024 1 O
mice	1026 4 O
.	1030 1 O

This	1032 4 O
decrease	1037 8 O
was	1046 3 O
significantly	1050 13 O
attenuated	1064 10 O
in	1075 2 O
the	1078 3 O
-	1082 1 O
/	1083 1 O
-	1084 1 O
mice	1086 4 O
.	1090 1 O

qRT	1092 3 O
-	1095 1 O
PCR	1096 3 O
detected	1100 8 O
similar	1109 7 O
patterns	1117 8 O
of	1126 2 O
changes	1129 7 O
in	1137 2 O
AQP2	1140 4 O
mRNA	1145 4 O
in	1150 2 O
the	1153 3 O
medulla	1157 7 O
but	1165 3 O
not	1169 3 O
in	1173 2 O
the	1176 3 O
cortex	1180 6 O
.	1186 1 O

Similarly	1188 9 O
,	1197 1 O
the	1199 3 O
total	1203 5 O
protein	1209 7 O
abundance	1217 9 O
of	1227 2 O
the	1230 3 O
Na	1234 2 B-Chemical
-	1236 1 O
K	1237 1 B-Chemical
-	1238 1 O
2Cl	1239 3 O
cotransporter	1243 13 O
(	1257 1 O
NKCC2	1258 5 O
)	1263 1 O
in	1265 2 O
the	1268 3 O
medulla	1272 7 O
but	1280 3 O
not	1284 3 O
in	1288 2 O
the	1291 3 O
cortex	1295 6 O
of	1302 2 O
the	1305 3 O
+	1309 1 O
/	1310 1 O
+	1311 1 O
mice	1313 4 O
was	1318 3 O
significantly	1322 13 O
reduced	1336 7 O
by	1344 2 O
lithium	1347 7 B-Chemical
treatment	1355 9 O
.	1364 1 O

In	1366 2 O
contrast	1369 8 O
,	1377 1 O
the	1379 3 O
dowregulation	1383 13 O
of	1397 2 O
renal	1400 5 O
medullary	1406 9 O
NKCC2	1416 5 O
expression	1422 10 O
was	1433 3 O
significantly	1437 13 O
attenuated	1451 10 O
in	1462 2 O
the	1465 3 O
-	1469 1 O
/	1470 1 O
-	1471 1 O
mice	1473 4 O
.	1477 1 O

We	1479 2 O
conclude	1482 8 O
that	1491 4 O
mPGES	1496 5 O
-	1501 1 O
1	1502 1 O
-	1503 1 O
derived	1504 7 O
PGE	1512 3 B-Chemical
(	1515 1 I-Chemical
2	1516 1 I-Chemical
)	1517 1 I-Chemical
mediates	1519 8 O
lithium	1528 7 B-Chemical
-	1535 1 O
induced	1536 7 O
polyuria	1544 8 B-Disease
likely	1553 6 O
via	1560 3 O
inhibition	1564 10 O
of	1575 2 O
AQP2	1578 4 O
and	1583 3 O
NKCC2	1587 5 O
expression	1593 10 O
.	1603 1 O

Identification	0 14 O
of	15 2 O
a	18 1 O
simple	20 6 O
and	27 3 O
sensitive	31 9 O
microplate	41 10 O
method	52 6 O
for	59 3 O
the	63 3 O
detection	67 9 O
of	77 2 O
oversulfated	80 12 O
chondroitin	93 11 B-Chemical
sulfate	105 7 I-Chemical
in	113 2 O
heparin	116 7 B-Chemical
products	124 8 O
.	132 1 O

Heparin	134 7 B-Chemical
is	142 2 O
a	145 1 O
commonly	147 8 O
implemented	156 11 O
anticoagulant	168 13 O
used	182 4 O
to	187 2 O
treat	190 5 O
critically	196 10 O
ill	207 3 O
patients	211 8 O
.	219 1 O

Recently	221 8 O
,	229 1 O
a	231 1 O
number	233 6 O
of	240 2 O
commercial	243 10 O
lots	254 4 O
of	259 2 O
heparin	262 7 B-Chemical
products	270 8 O
were	279 4 O
found	284 5 O
to	290 2 O
be	293 2 O
contaminated	296 12 O
with	309 4 O
an	314 2 O
oversulfated	317 12 O
chondroitin	330 11 B-Chemical
sulfate	342 7 I-Chemical
(	350 1 O
OSCS	351 4 O
)	355 1 O
derivative	357 10 O
that	368 4 O
could	373 5 O
elicit	379 6 O
a	386 1 O
hypotensive	388 11 B-Disease
response	400 8 O
in	409 2 O
pigs	412 4 O
following	417 9 O
a	427 1 O
single	429 6 O
high	436 4 O
-	440 1 O
dose	441 4 O
infusion	446 8 O
.	454 1 O

Using	456 5 O
both	462 4 O
contaminated	467 12 O
heparin	480 7 B-Chemical
products	488 8 O
and	497 3 O
the	501 3 O
synthetically	505 13 O
produced	519 8 O
derivative	528 10 O
,	538 1 O
we	540 2 O
showed	543 6 O
that	550 4 O
the	555 3 O
OSCS	559 4 O
produces	564 8 O
dose	573 4 O
-	577 1 O
dependent	578 9 O
hypotension	588 11 B-Disease
in	600 2 O
pigs	603 4 O
.	607 1 O

The	609 3 O
no	613 2 O
observed	616 8 O
effect	625 6 O
level	632 5 O
(	638 1 O
NOEL	639 4 O
)	643 1 O
for	645 3 O
this	649 4 O
contaminant	654 11 O
appears	666 7 O
to	674 2 O
be	677 2 O
approximately	680 13 O
1mg	694 3 O
/	697 1 O
kg	698 2 O
,	700 1 O
corresponding	702 13 O
to	716 2 O
a	719 1 O
contamination	721 13 O
level	735 5 O
of	741 2 O
approximately	744 13 O
3	758 1 O
%	759 1 O
.	760 1 O

We	762 2 O
also	765 4 O
demonstrated	770 12 O
that	783 4 O
OSCS	788 4 O
can	793 3 O
be	797 2 O
identified	800 10 O
in	811 2 O
heparin	814 7 B-Chemical
products	822 8 O
using	831 5 O
a	837 1 O
simple	839 6 O
,	845 1 O
inexpensive	847 11 O
,	858 1 O
commercially	860 12 O
available	873 9 O
heparin	883 7 B-Chemical
enzyme	891 6 O
immunoassay	898 11 O
(	910 1 O
EIA	911 3 O
)	914 1 O
kit	916 3 O
that	920 4 O
has	925 3 O
a	929 1 O
limit	931 5 O
of	937 2 O
detection	940 9 O
of	950 2 O
approximately	953 13 O
0	967 1 O
.	968 1 O
1	969 1 O
%	970 1 O
,	971 1 O
well	973 4 O
below	978 5 O
the	984 3 O
NOEL	988 4 O
.	992 1 O

This	994 4 O
kit	999 3 O
may	1003 3 O
provide	1007 7 O
a	1015 1 O
useful	1017 6 O
method	1024 6 O
to	1031 2 O
test	1034 4 O
heparin	1039 7 B-Chemical
products	1047 8 O
for	1056 3 O
contamination	1060 13 O
with	1074 4 O
oversulfated	1079 12 O
GAG	1092 3 O
derivatives	1096 11 O
.	1107 1 O

Doxorubicin	0 11 B-Chemical
cardiomyopathy	12 14 B-Disease
-	26 1 O
induced	27 7 O
inflammation	35 12 B-Disease
and	48 3 O
apoptosis	52 9 O
are	62 3 O
attenuated	66 10 O
by	77 2 O
gene	80 4 O
deletion	85 8 O
of	94 2 O
the	97 3 O
kinin	101 5 O
B1	107 2 O
receptor	110 8 O
.	118 1 O

Clinical	120 8 O
use	129 3 O
of	133 2 O
the	136 3 O
anthracycline	140 13 B-Chemical
doxorubicin	154 11 B-Chemical
(	166 1 O
DOX	167 3 B-Chemical
)	170 1 O
is	172 2 O
limited	175 7 O
by	183 2 O
its	186 3 O
cardiotoxic	190 11 B-Disease
effects	202 7 O
,	209 1 O
which	211 5 O
are	217 3 O
attributed	221 10 O
to	232 2 O
the	235 3 O
induction	239 9 O
of	249 2 O
apoptosis	252 9 O
.	261 1 O

To	263 2 O
elucidate	266 9 O
the	276 3 O
possible	280 8 O
role	289 4 O
of	294 2 O
the	297 3 O
kinin	301 5 O
B1	307 2 O
receptor	310 8 O
(	319 1 O
B1R	320 3 O
)	323 1 O
during	325 6 O
the	332 3 O
development	336 11 O
of	348 2 O
DOX	351 3 B-Chemical
cardiomyopathy	355 14 B-Disease
,	369 1 O
we	371 2 O
studied	374 7 O
B1R	382 3 O
knockout	386 8 O
mice	395 4 O
(	400 1 O
B1R	401 3 O
(	404 1 O
-	405 1 O
/	406 1 O
-	407 1 O
)	408 1 O
)	409 1 O
by	411 2 O
investigating	414 13 O
cardiac	428 7 O
inflammation	436 12 B-Disease
and	449 3 O
apoptosis	453 9 O
after	463 5 O
induction	469 9 O
of	479 2 O
DOX	482 3 B-Chemical
-	485 1 O
induced	486 7 O
cardiomyopathy	494 14 B-Disease
.	508 1 O

DOX	510 3 B-Chemical
control	514 7 O
mice	522 4 O
showed	527 6 O
cardiac	534 7 B-Disease
dysfunction	542 11 I-Disease
measured	554 8 O
by	563 2 O
pressure	566 8 O
-	574 1 O
volume	575 6 O
loops	582 5 O
in	588 2 O
vivo	591 4 O
.	595 1 O

This	597 4 O
was	602 3 O
associated	606 10 O
with	617 4 O
a	622 1 O
reduced	624 7 O
activation	632 10 O
state	643 5 O
of	649 2 O
AKT	652 3 O
,	655 1 O
as	657 2 O
well	660 4 O
as	665 2 O
an	668 2 O
increased	671 9 O
bax	681 3 O
/	684 1 O
bcl2	685 4 O
ratio	690 5 O
in	696 2 O
Western	699 7 O
blots	707 5 O
,	712 1 O
indicating	714 10 O
cardiac	725 7 B-Disease
apoptosis	733 9 I-Disease
.	742 1 O

Furthermore	744 11 O
,	755 1 O
mRNA	757 4 O
levels	762 6 O
of	769 2 O
the	772 3 O
proinflammatory	776 15 O
cytokine	792 8 O
interleukin	801 11 O
6	813 1 O
were	815 4 O
increased	820 9 O
in	830 2 O
the	833 3 O
cardiac	837 7 O
tissue	845 6 O
.	851 1 O

In	853 2 O
DOX	856 3 B-Chemical
B1R	860 3 O
(	863 1 O
-	864 1 O
/	865 1 O
-	866 1 O
)	867 1 O
mice	869 4 O
,	873 1 O
cardiac	875 7 B-Disease
dysfunction	883 11 I-Disease
was	895 3 O
improved	899 8 O
compared	908 8 O
to	917 2 O
DOX	920 3 B-Chemical
control	924 7 O
mice	932 4 O
,	936 1 O
which	938 5 O
was	944 3 O
associated	948 10 O
with	959 4 O
normalization	964 13 O
of	978 2 O
the	981 3 O
bax	985 3 O
/	988 1 O
bcl	989 3 O
-	992 1 O
2	993 1 O
ratio	995 5 O
and	1001 3 O
interleukin	1005 11 O
6	1017 1 O
,	1018 1 O
as	1020 2 O
well	1023 4 O
as	1028 2 O
AKT	1031 3 O
activation	1035 10 O
state	1046 5 O
.	1051 1 O

These	1053 5 O
findings	1059 8 O
suggest	1068 7 O
that	1076 4 O
B1R	1081 3 O
is	1085 2 O
detrimental	1088 11 O
in	1100 2 O
DOX	1103 3 B-Chemical
cardiomyopathy	1107 14 B-Disease
in	1122 2 O
that	1125 4 O
it	1130 2 O
mediates	1133 8 O
the	1142 3 O
inflammatory	1146 12 O
response	1159 8 O
and	1168 3 O
apoptosis	1172 9 O
.	1181 1 O

These	1183 5 O
insights	1189 8 O
might	1198 5 O
have	1204 4 O
useful	1209 6 O
implications	1216 12 O
for	1229 3 O
future	1233 6 O
studies	1240 7 O
utilizing	1248 9 O
B1R	1258 3 O
antagonists	1262 11 O
for	1274 3 O
treatment	1278 9 O
of	1288 2 O
human	1291 5 O
DOX	1297 3 B-Chemical
cardiomyopathy	1301 14 B-Disease
.	1315 1 O

Hepatotoxicity	0 14 B-Disease
associated	15 10 O
with	26 4 O
sulfasalazine	31 13 B-Chemical
in	45 2 O
inflammatory	48 12 O
arthritis	61 9 B-Disease
:	70 1 O
A	72 1 O
case	74 4 O
series	79 6 O
from	86 4 O
a	91 1 O
local	93 5 O
surveillance	99 12 O
of	112 2 O
serious	115 7 O
adverse	123 7 O
events	131 6 O
.	137 1 O

BACKGROUND	139 10 O
:	149 1 O
Spontaneous	151 11 O
reporting	163 9 O
systems	173 7 O
for	181 3 O
adverse	185 7 O
drug	193 4 O
reactions	198 9 O
(	208 1 O
ADRs	209 4 O
)	213 1 O
are	215 3 O
handicapped	219 11 O
by	231 2 O
under	234 5 O
-	239 1 O
reporting	240 9 O
and	250 3 O
limited	254 7 O
detail	262 6 O
on	269 2 O
individual	272 10 O
cases	283 5 O
.	288 1 O

We	290 2 O
report	293 6 O
an	300 2 O
investigation	303 13 O
from	317 4 O
a	322 1 O
local	324 5 O
surveillance	330 12 O
for	343 3 O
serious	347 7 O
adverse	355 7 O
drug	363 4 O
reactions	368 9 O
associated	378 10 O
with	389 4 O
disease	394 7 O
modifying	402 9 O
anti	412 4 O
-	416 1 O
rheumatic	417 9 O
drugs	427 5 O
that	433 4 O
was	438 3 O
triggered	442 9 O
by	452 2 O
the	455 3 O
occurrence	459 10 O
of	470 2 O
liver	473 5 B-Disease
failure	479 7 I-Disease
in	487 2 O
two	490 3 O
of	494 2 O
our	497 3 O
patients	501 8 O
.	509 1 O

METHODS	511 7 O
:	518 1 O
Serious	520 7 O
ADR	528 3 O
reports	532 7 O
have	540 4 O
been	545 4 O
solicited	550 9 O
from	560 4 O
local	565 5 O
clinicians	571 10 O
by	582 2 O
regular	585 7 O
postcards	593 9 O
over	603 4 O
the	608 3 O
past	612 4 O
seven	617 5 O
years	623 5 O
.	628 1 O

Patients	630 8 O
'	638 1 O
,	639 1 O
who	641 3 O
had	645 3 O
hepatotoxicity	649 14 B-Disease
on	664 2 O
sulfasalazine	667 13 B-Chemical
and	681 3 O
met	685 3 O
a	689 1 O
definition	691 10 O
of	702 2 O
a	705 1 O
serious	707 7 O
ADR	715 3 O
,	718 1 O
were	720 4 O
identified	725 10 O
.	735 1 O

Two	737 3 O
clinicians	741 10 O
reviewed	752 8 O
structured	761 10 O
case	772 4 O
reports	777 7 O
and	785 3 O
assessed	789 8 O
causality	798 9 O
by	808 2 O
consensus	811 9 O
and	821 3 O
by	825 2 O
using	828 5 O
a	834 1 O
causality	836 9 O
assessment	846 10 O
instrument	857 10 O
.	867 1 O

The	869 3 O
likely	873 6 O
frequency	880 9 O
of	890 2 O
hepatotoxicity	893 14 B-Disease
with	908 4 O
sulfasalazine	913 13 B-Chemical
was	927 3 O
estimated	931 9 O
by	941 2 O
making	944 6 O
a	951 1 O
series	953 6 O
of	960 2 O
conservative	963 12 O
assumptions	976 11 O
.	987 1 O

RESULTS	989 7 O
:	996 1 O
Ten	998 3 O
cases	1002 5 O
were	1008 4 O
identified	1013 10 O
:	1023 1 O
eight	1025 5 O
occurred	1031 8 O
during	1040 6 O
surveillance	1047 12 O
.	1059 1 O

Eight	1061 5 O
patients	1067 8 O
were	1076 4 O
hospitalised	1081 12 O
,	1093 1 O
two	1095 3 O
in	1099 2 O
hepatic	1102 7 B-Disease
failure	1110 7 I-Disease
-	1118 1 O
one	1120 3 O
died	1124 4 O
after	1129 5 O
a	1135 1 O
liver	1137 5 O
transplant	1143 10 O
.	1153 1 O

All	1155 3 O
but	1159 3 O
one	1163 3 O
event	1167 5 O
occurred	1173 8 O
within	1182 6 O
6	1189 1 O
weeks	1191 5 O
of	1197 2 O
treatment	1200 9 O
.	1209 1 O

Seven	1211 5 O
patients	1217 8 O
had	1226 3 O
a	1230 1 O
skin	1232 4 B-Disease
rash	1237 4 I-Disease
,	1241 1 O
three	1243 5 O
eosinophilia	1249 12 B-Disease
and	1262 3 O
one	1266 3 O
interstitial	1270 12 B-Disease
nephritis	1283 9 I-Disease
.	1292 1 O

Five	1294 4 O
patients	1299 8 O
were	1308 4 O
of	1313 2 O
Black	1316 5 O
British	1322 7 O
of	1330 2 O
African	1333 7 O
or	1341 2 O
Caribbean	1344 9 O
descent	1354 7 O
.	1361 1 O

Liver	1363 5 O
enzymes	1369 7 O
showed	1377 6 O
a	1384 1 O
hepatocellular	1386 14 O
pattern	1401 7 O
in	1409 2 O
four	1412 4 O
cases	1417 5 O
and	1423 3 O
a	1427 1 O
mixed	1429 5 O
pattern	1435 7 O
in	1443 2 O
six	1446 3 O
.	1449 1 O

Drug	1451 4 O
-	1455 1 O
related	1456 7 O
hepatotoxicity	1464 14 B-Disease
was	1479 3 O
judged	1483 6 O
probable	1490 8 O
or	1499 2 O
highly	1502 6 O
probable	1509 8 O
in	1518 2 O
8	1521 1 O
patients	1523 8 O
.	1531 1 O

The	1533 3 O
likely	1537 6 O
frequency	1544 9 O
of	1554 2 O
serious	1557 7 O
hepatotoxicity	1565 14 B-Disease
with	1580 4 O
sulfasalazine	1585 13 B-Chemical
was	1599 3 O
estimated	1603 9 O
at	1613 2 O
0	1616 1 O
.	1617 1 O
4	1618 1 O
%	1619 1 O
of	1621 2 O
treated	1624 7 O
patients	1632 8 O
.	1640 1 O

CONCLUSION	1642 10 O
:	1652 1 O
Serious	1654 7 O
hepatotoxicity	1662 14 B-Disease
associated	1677 10 O
with	1688 4 O
sulfasalazine	1693 13 B-Chemical
appears	1707 7 O
to	1715 2 O
be	1718 2 O
under	1721 5 O
-	1726 1 O
appreciated	1727 11 O
and	1739 3 O
intensive	1743 9 O
monitoring	1753 10 O
and	1764 3 O
vigilance	1768 9 O
in	1778 2 O
the	1781 3 O
first	1785 5 O
6	1791 1 O
weeks	1793 5 O
of	1799 2 O
treatment	1802 9 O
is	1812 2 O
especially	1815 10 O
important	1826 9 O
.	1835 1 O

An	0 2 O
evaluation	3 10 O
of	14 2 O
amikacin	17 8 B-Chemical
nephrotoxicity	26 14 B-Disease
in	41 2 O
the	44 3 O
hematology	48 10 O
/	58 1 O
oncology	59 8 O
population	68 10 O
.	78 1 O

Amikacin	80 8 B-Chemical
is	89 2 O
an	92 2 O
aminoglycoside	95 14 B-Chemical
commonly	110 8 O
used	119 4 O
to	124 2 O
provide	127 7 O
empirical	135 9 O
double	145 6 O
gram	152 4 O
-	156 1 O
negative	157 8 O
treatment	166 9 O
for	176 3 O
febrile	180 7 B-Disease
neutropenia	188 11 I-Disease
and	200 3 O
other	204 5 O
suspected	210 9 O
infections	220 10 B-Disease
.	230 1 O

Strategies	232 10 O
of	243 2 O
extended	246 8 O
-	254 1 O
interval	255 8 O
and	264 3 O
conventional	268 12 O
dosing	281 6 O
have	288 4 O
been	293 4 O
utilized	298 8 O
extensively	307 11 O
in	319 2 O
the	322 3 O
general	326 7 O
medical	334 7 O
population	342 10 O
;	352 1 O
however	354 7 O
,	361 1 O
data	363 4 O
are	368 3 O
lacking	372 7 O
to	380 2 O
support	383 7 O
a	391 1 O
dosing	393 6 O
strategy	400 8 O
in	409 2 O
the	412 3 O
hematology	416 10 O
/	426 1 O
oncology	427 8 O
population	436 10 O
.	446 1 O

To	448 2 O
evaluate	451 8 O
amikacin	460 8 B-Chemical
-	468 1 O
associated	469 10 O
nephrotoxicity	480 14 B-Disease
in	495 2 O
an	498 2 O
adult	501 5 O
hematology	507 10 O
/	517 1 O
oncology	518 8 O
population	527 10 O
,	537 1 O
a	539 1 O
prospective	541 11 O
,	552 1 O
randomized	554 10 O
,	564 1 O
open	566 4 O
-	570 1 O
label	571 5 O
trial	577 5 O
was	583 3 O
conducted	587 9 O
at	597 2 O
a	600 1 O
university	602 10 O
-	612 1 O
affiliated	613 10 O
medical	624 7 O
center	632 6 O
.	638 1 O

Forty	640 5 O
patients	646 8 O
with	655 4 O
a	660 1 O
diagnosis	662 9 O
consistent	672 10 O
with	683 4 O
a	688 1 O
hematologic	690 11 B-Disease
/	701 1 I-Disease
oncologic	702 9 I-Disease
disorder	712 8 I-Disease
that	721 4 O
required	726 8 O
treatment	735 9 O
with	745 4 O
an	750 2 O
aminoglycoside	753 14 B-Chemical
were	768 4 O
randomized	773 10 O
to	784 2 O
either	787 6 O
conventional	794 12 O
or	807 2 O
extended	810 8 O
-	818 1 O
interval	819 8 O
amikacin	828 8 B-Chemical
.	836 1 O

The	838 3 O
occurrence	842 10 O
of	853 2 O
nephrotoxicity	856 14 B-Disease
by	871 2 O
means	874 5 O
of	880 2 O
an	883 2 O
increase	886 8 O
in	895 2 O
serum	898 5 O
creatinine	904 10 B-Chemical
and	915 3 O
evaluation	919 10 O
of	930 2 O
efficacy	933 8 O
via	942 3 O
amikacin	946 8 B-Chemical
serum	955 5 O
concentrations	961 14 O
with	976 4 O
respective	981 10 O
pathogens	992 9 O
were	1002 4 O
assessed	1007 8 O
.	1015 1 O

The	1017 3 O
occurrence	1021 10 O
of	1032 2 O
nephrotoxicity	1035 14 B-Disease
was	1050 3 O
similar	1054 7 O
between	1062 7 O
the	1070 3 O
conventional	1074 12 O
and	1087 3 O
extended	1091 8 O
-	1099 1 O
interval	1100 8 O
groups	1109 6 O
,	1115 1 O
at	1117 2 O
10	1120 2 O
%	1122 1 O
and	1124 3 O
5	1128 1 O
%	1129 1 O
,	1130 1 O
respectively	1132 12 O
(	1145 1 O
P	1146 1 O
=	1148 1 O
1	1150 1 O
.	1151 1 O
00	1152 2 O
)	1154 1 O
.	1155 1 O

Six	1157 3 O
patients	1161 8 O
in	1170 2 O
the	1173 3 O
conventional	1177 12 O
group	1190 5 O
had	1196 3 O
a	1200 1 O
positive	1202 8 O
culture	1211 7 O
,	1218 1 O
compared	1220 8 O
with	1229 4 O
none	1234 4 O
in	1239 2 O
the	1242 3 O
extended	1246 8 O
-	1254 1 O
interval	1255 8 O
group	1264 5 O
(	1270 1 O
P	1271 1 O
=	1273 1 O
0	1275 1 O
.	1276 1 O
002	1277 3 O
)	1280 1 O
.	1281 1 O

The	1283 3 O
occurrence	1287 10 O
of	1298 2 O
nephrotoxicity	1301 14 B-Disease
was	1316 3 O
similar	1320 7 O
between	1328 7 O
the	1336 3 O
two	1340 3 O
dosing	1344 6 O
regimens	1351 8 O
,	1359 1 O
but	1361 3 O
the	1365 3 O
distribution	1369 12 O
of	1382 2 O
risk	1385 4 O
factors	1390 7 O
was	1398 3 O
variable	1402 8 O
between	1411 7 O
the	1419 3 O
two	1423 3 O
groups	1427 6 O
.	1433 1 O

Efficacy	1435 8 O
could	1444 5 O
not	1450 3 O
be	1454 2 O
assessed	1457 8 O
.	1465 1 O

Memory	0 6 O
function	7 8 O
and	16 3 O
serotonin	20 9 B-Chemical
transporter	30 11 O
promoter	42 8 O
gene	51 4 O
polymorphism	56 12 O
in	69 2 O
ecstasy	72 7 B-Chemical
(	80 1 O
MDMA	81 4 B-Chemical
)	85 1 O
users	87 5 O
.	92 1 O

Although	94 8 O
3	103 1 B-Chemical
,	104 1 I-Chemical
4	105 1 I-Chemical
-	106 1 I-Chemical
methylenedioxymethamphetamine	107 29 I-Chemical
(	137 1 O
MDMA	138 4 B-Chemical
or	143 2 O
ecstasy	146 7 B-Chemical
)	153 1 O
has	155 3 O
been	159 4 O
shown	164 5 O
to	170 2 O
damage	173 6 O
brain	180 5 O
serotonin	186 9 B-Chemical
(	196 1 O
5	197 1 B-Chemical
-	198 1 I-Chemical
HT	199 2 I-Chemical
)	201 1 O
neurons	203 7 O
in	211 2 O
animals	214 7 O
and	222 3 O
possibly	226 8 O
humans	235 6 O
,	241 1 O
little	243 6 O
is	250 2 O
known	253 5 O
about	259 5 O
the	265 3 O
long	269 4 O
-	273 1 O
term	274 4 O
consequences	279 12 O
of	292 2 O
MDMA	295 4 B-Chemical
-	299 1 O
induced	300 7 O
5	308 1 B-Chemical
-	309 1 I-Chemical
HT	310 2 I-Chemical
neurotoxic	313 10 B-Disease
lesions	324 7 I-Disease
on	332 2 O
functions	335 9 O
in	345 2 O
which	348 5 O
5	354 1 B-Chemical
-	355 1 I-Chemical
HT	356 2 I-Chemical
is	359 2 O
involved	362 8 O
,	370 1 O
such	372 4 O
as	377 2 O
cognitive	380 9 O
function	390 8 O
.	398 1 O

Because	400 7 O
5	408 1 B-Chemical
-	409 1 I-Chemical
HT	410 2 I-Chemical
transporters	413 12 O
play	426 4 O
a	431 1 O
key	433 3 O
element	437 7 O
in	445 2 O
the	448 3 O
regulation	452 10 O
of	463 2 O
synaptic	466 8 O
5	475 1 B-Chemical
-	476 1 I-Chemical
HT	477 2 I-Chemical
transmission	480 12 O
it	493 2 O
may	496 3 O
be	500 2 O
important	503 9 O
to	513 2 O
control	516 7 O
for	524 3 O
the	528 3 O
potential	532 9 O
covariance	542 10 O
effect	553 6 O
of	560 2 O
a	563 1 O
polymorphism	565 12 O
in	578 2 O
the	581 3 O
5	585 1 B-Chemical
-	586 1 I-Chemical
HT	587 2 I-Chemical
transporter	590 11 O
promoter	602 8 O
gene	611 4 O
region	616 6 O
(	623 1 O
5	624 1 O
-	625 1 O
HTTLPR	626 6 O
)	632 1 O
when	634 4 O
studying	639 8 O
the	648 3 O
effects	652 7 O
of	660 2 O
MDMA	663 4 B-Chemical
as	668 2 O
well	671 4 O
as	676 2 O
cognitive	679 9 O
functioning	689 11 O
.	700 1 O

The	702 3 O
aim	706 3 O
of	710 2 O
the	713 3 O
study	717 5 O
was	723 3 O
to	727 2 O
investigate	730 11 O
the	742 3 O
effects	746 7 O
of	754 2 O
moderate	757 8 O
and	766 3 O
heavy	770 5 O
MDMA	776 4 B-Chemical
use	781 3 O
on	785 2 O
cognitive	788 9 O
function	798 8 O
,	806 1 O
as	808 2 O
well	811 4 O
as	816 2 O
the	819 3 O
effects	823 7 O
of	831 2 O
long	834 4 O
-	838 1 O
term	839 4 O
abstention	844 10 O
from	855 4 O
MDMA	860 4 B-Chemical
,	864 1 O
in	866 2 O
subjects	869 8 O
genotyped	878 9 O
for	888 3 O
5	892 1 O
-	893 1 O
HTTLPR	894 6 O
.	900 1 O

A	902 1 O
second	904 6 O
aim	911 3 O
of	915 2 O
the	918 3 O
study	922 5 O
was	928 3 O
to	932 2 O
determine	935 9 O
whether	945 7 O
these	953 5 O
effects	959 7 O
differ	967 6 O
for	974 3 O
females	978 7 O
and	986 3 O
males	990 5 O
.	995 1 O

Fifteen	997 7 O
moderate	1005 8 O
MDMA	1014 4 B-Chemical
users	1019 5 O
(	1025 1 O
<	1026 1 O
55	1027 2 O
lifetime	1030 8 O
tablets	1039 7 O
)	1046 1 O
,	1047 1 O
22	1049 2 O
heavy	1052 5 O
MDMA	1058 4 B-Chemical
+	1062 1 O
users	1064 5 O
(	1070 1 O
>	1071 1 O
55	1072 2 O
lifetime	1075 8 O
tablets	1084 7 O
)	1091 1 O
,	1092 1 O
16	1094 2 O
ex	1097 2 O
-	1099 1 O
MDMA	1100 4 B-Chemical
+	1104 1 O
users	1106 5 O
(	1112 1 O
last	1113 4 O
tablet	1118 6 O
>	1125 1 O
1	1127 1 O
year	1129 4 O
ago	1134 3 O
)	1137 1 O
and	1139 3 O
13	1143 2 O
controls	1146 8 O
were	1155 4 O
compared	1160 8 O
on	1169 2 O
a	1172 1 O
battery	1174 7 O
of	1182 2 O
neuropsychological	1185 18 O
tests	1204 5 O
.	1209 1 O

DNA	1211 3 O
from	1215 4 O
peripheral	1220 10 O
nuclear	1231 7 O
blood	1239 5 O
cells	1245 5 O
was	1251 3 O
genotyped	1255 9 O
for	1265 3 O
5	1269 1 O
-	1270 1 O
HTTLPR	1271 6 O
using	1278 5 O
standard	1284 8 O
polymerase	1293 10 O
chain	1304 5 O
reaction	1310 8 O
methods	1319 7 O
.	1326 1 O
A	1327 1 O
significant	1329 11 O
group	1341 5 O
effect	1347 6 O
was	1354 3 O
observed	1358 8 O
only	1367 4 O
on	1372 2 O
memory	1375 6 O
function	1382 8 O
tasks	1391 5 O
(	1397 1 O
p	1398 1 O
=	1400 1 O
0	1402 1 O
.	1403 1 O
04	1404 2 O
)	1406 1 O
but	1408 3 O
not	1412 3 O
on	1416 2 O
reaction	1419 8 O
times	1428 5 O
(	1434 1 O
p	1435 1 O
=	1437 1 O
0	1439 1 O
.	1440 1 O
61	1441 2 O
)	1443 1 O
or	1445 2 O
attention	1448 9 O
/	1457 1 O
executive	1458 9 O
functioning	1468 11 O
(	1480 1 O
p	1481 1 O
=	1483 1 O
0	1485 1 O
.	1486 1 O
59	1487 2 O
)	1489 1 O
.	1490 1 O

Heavy	1492 5 O
and	1498 3 O
ex	1502 2 O
-	1504 1 O
MDMA	1505 4 B-Chemical
+	1509 1 O
users	1511 5 O
performed	1517 9 O
significantly	1527 13 O
poorer	1541 6 O
on	1548 2 O
memory	1551 6 O
tasks	1558 5 O
than	1564 4 O
controls	1569 8 O
.	1577 1 O

In	1579 2 O
contrast	1582 8 O
,	1590 1 O
no	1592 2 O
evidence	1595 8 O
of	1604 2 O
memory	1607 6 B-Disease
impairment	1614 10 I-Disease
was	1625 3 O
observed	1629 8 O
in	1638 2 O
moderate	1641 8 O
MDMA	1650 4 B-Chemical
users	1655 5 O
.	1660 1 O

No	1662 2 O
significant	1665 11 O
effect	1677 6 O
of	1684 2 O
5	1687 1 O
-	1688 1 O
HTTLPR	1689 6 O
or	1696 2 O
gender	1699 6 O
was	1706 3 O
observed	1710 8 O
.	1718 1 O

While	1720 5 O
the	1726 3 O
use	1730 3 O
of	1734 2 O
MDMA	1737 4 B-Chemical
in	1742 2 O
quantities	1745 10 O
that	1756 4 O
may	1761 3 O
be	1765 2 O
considered	1768 10 O
"	1779 1 O
moderate	1780 8 O
"	1788 1 O
is	1790 2 O
not	1793 3 O
associated	1797 10 O
with	1808 4 O
impaired	1813 8 B-Disease
memory	1822 6 I-Disease
functioning	1829 11 I-Disease
,	1840 1 O
heavy	1842 5 O
use	1848 3 O
of	1852 2 O
MDMA	1855 4 B-Chemical
use	1860 3 O
may	1864 3 O
lead	1868 4 O
to	1873 2 O
long	1876 4 O
lasting	1881 7 O
memory	1889 6 B-Disease
impairments	1896 11 I-Disease
.	1907 1 O

No	1909 2 O
effect	1912 6 O
of	1919 2 O
5	1922 1 O
-	1923 1 O
HTTLPR	1924 6 O
or	1931 2 O
gender	1934 6 O
on	1941 2 O
memory	1944 6 O
function	1951 8 O
or	1960 2 O
MDMA	1963 4 B-Chemical
use	1968 3 O
was	1972 3 O
observed	1976 8 O
.	1984 1 O

Aging	0 5 O
process	6 7 O
of	14 2 O
epithelial	17 10 O
cells	28 5 O
of	34 2 O
the	37 3 O
rat	41 3 O
prostate	45 8 O
lateral	54 7 O
lobe	62 4 O
in	67 2 O
experimental	70 12 O
hyperprolactinemia	83 18 B-Disease
induced	102 7 O
by	110 2 O
haloperidol	113 11 B-Chemical
.	124 1 O

The	126 3 O
aim	130 3 O
of	134 2 O
the	137 3 O
study	141 5 O
was	147 3 O
to	151 2 O
examine	154 7 O
the	162 3 O
influence	166 9 O
of	176 2 O
hyperprolactinemia	179 18 B-Disease
,	197 1 O
induced	199 7 O
by	207 2 O
haloperidol	210 11 B-Chemical
(	222 1 O
HAL	223 3 B-Chemical
)	226 1 O
on	228 2 O
age	231 3 O
related	235 7 O
morphology	243 10 O
and	254 3 O
function	258 8 O
changes	267 7 O
of	275 2 O
epithelial	278 10 O
cells	289 5 O
in	295 2 O
rat	298 3 O
prostate	302 8 O
lateral	311 7 O
lobe	319 4 O
.	323 1 O

The	325 3 O
study	329 5 O
was	335 3 O
performed	339 9 O
on	349 2 O
sexually	352 8 O
mature	361 6 O
male	368 4 O
rats	373 4 O
.	377 1 O

Serum	379 5 O
concentrations	385 14 O
of	400 2 O
prolactin	403 9 O
(	413 1 O
PRL	414 3 B-Chemical
)	417 1 O
and	419 3 O
testosterone	423 12 B-Chemical
(	436 1 O
T	437 1 B-Chemical
)	438 1 O
were	440 4 O
measured	445 8 O
.	453 1 O

Tissue	455 6 O
sections	462 8 O
were	471 4 O
evaluated	476 9 O
with	486 4 O
light	491 5 O
and	497 3 O
electron	501 8 O
microscopy	510 10 O
.	520 1 O

Immunohistochemical	522 19 O
reactions	542 9 O
for	552 3 O
Anti	556 4 O
-	560 1 O
Proliferating	561 13 O
Cell	575 4 O
Nuclear	580 7 O
Antigen	588 7 O
(	596 1 O
PCNA	597 4 O
)	601 1 O
were	603 4 O
performed	608 9 O
.	617 1 O

In	619 2 O
rats	622 4 O
of	627 2 O
the	630 3 O
experimental	634 12 O
group	647 5 O
,	652 1 O
the	654 3 O
mean	658 4 O
concentration	663 13 O
of	677 2 O
:	679 1 O
PRL	681 3 B-Chemical
was	685 3 O
more	689 4 O
than	694 4 O
twice	699 5 O
higher	705 6 O
,	711 1 O
whereas	713 7 O
T	721 1 B-Chemical
concentration	723 13 O
was	737 3 O
almost	741 6 O
twice	748 5 O
lower	754 5 O
than	760 4 O
that	765 4 O
in	770 2 O
the	773 3 O
control	777 7 O
group	785 5 O
.	790 1 O

Light	792 5 O
microscopy	798 10 O
visualized	809 10 O
the	820 3 O
following	824 9 O
:	833 1 O
hypertrophy	835 11 B-Disease
and	847 3 O
epithelium	851 10 O
hyperplasia	862 11 B-Disease
of	874 2 O
the	877 3 O
glandular	881 9 O
ducts	891 5 O
,	896 1 O
associated	898 10 O
with	909 4 O
increased	914 9 O
PCNA	924 4 O
expression	929 10 O
.	939 1 O

Electron	941 8 O
microscopy	950 10 O
revealed	961 8 O
changes	970 7 O
in	978 2 O
columnar	981 8 O
epithelial	990 10 O
cells	1001 5 O
,	1006 1 O
concerning	1008 10 O
organelles	1019 10 O
,	1029 1 O
engaged	1031 7 O
in	1039 2 O
protein	1042 7 O
synthesis	1050 9 O
and	1060 3 O
secretion	1064 9 O
.	1073 1 O

Does	0 4 O
supplemental	5 12 O
vitamin	18 7 B-Chemical
C	26 1 I-Chemical
increase	28 8 O
cardiovascular	37 14 B-Disease
disease	52 7 I-Disease
risk	60 4 O
in	65 2 O
women	68 5 O
with	74 4 O
diabetes	79 8 B-Disease
?	87 1 O

BACKGROUND	89 10 O
:	99 1 O
Vitamin	101 7 B-Chemical
C	109 1 I-Chemical
acts	111 4 O
as	116 2 O
a	119 1 O
potent	121 6 O
antioxidant	128 11 O
;	139 1 O
however	141 7 O
,	148 1 O
it	150 2 O
can	153 3 O
also	157 4 O
be	162 2 O
a	165 1 O
prooxidant	167 10 O
and	178 3 O
glycate	182 7 O
protein	190 7 O
under	198 5 O
certain	204 7 O
circumstances	212 13 O
in	226 2 O
vitro	229 5 O
.	234 1 O

These	236 5 O
observations	242 12 O
led	255 3 O
us	259 2 O
to	262 2 O
hypothesize	265 11 O
that	277 4 O
a	282 1 O
high	284 4 O
intake	289 6 O
of	296 2 O
vitamin	299 7 B-Chemical
C	307 1 I-Chemical
in	309 2 O
diabetic	312 8 B-Disease
persons	321 7 O
might	329 5 O
promote	335 7 O
atherosclerosis	343 15 B-Disease
.	358 1 O

OBJECTIVE	360 9 O
:	369 1 O
The	371 3 O
objective	375 9 O
was	385 3 O
to	389 2 O
examine	392 7 O
the	400 3 O
relation	404 8 O
between	413 7 O
vitamin	421 7 B-Chemical
C	429 1 I-Chemical
intake	431 6 O
and	438 3 O
mortality	442 9 O
from	452 4 O
cardiovascular	457 14 B-Disease
disease	472 7 I-Disease
.	479 1 O

DESIGN	481 6 O
:	487 1 O
We	489 2 O
studied	492 7 O
the	500 3 O
relation	504 8 O
between	513 7 O
vitamin	521 7 B-Chemical
C	529 1 I-Chemical
intake	531 6 O
and	538 3 O
mortality	542 9 O
from	552 4 O
total	557 5 O
cardiovascular	563 14 B-Disease
disease	578 7 I-Disease
(	586 1 O
n	587 1 O
=	589 1 O
281	591 3 O
)	594 1 O
,	595 1 O
coronary	597 8 B-Disease
artery	606 6 I-Disease
disease	613 7 I-Disease
(	621 1 O
n	622 1 O
=	624 1 O
175	626 3 O
)	629 1 O
,	630 1 O
and	632 3 O
stroke	636 6 B-Disease
(	643 1 O
n	644 1 O
=	646 1 O
57	648 2 O
)	650 1 O
in	652 2 O
1923	655 4 O
postmenopausal	660 14 O
women	675 5 O
who	681 3 O
reported	685 8 O
being	694 5 O
diabetic	700 8 B-Disease
at	709 2 O
baseline	712 8 O
.	720 1 O

Diet	722 4 O
was	727 3 O
assessed	731 8 O
with	740 4 O
a	745 1 O
food	747 4 O
-	751 1 O
frequency	752 9 O
questionnaire	762 13 O
at	776 2 O
baseline	779 8 O
,	787 1 O
and	789 3 O
subjects	793 8 O
initially	802 9 O
free	812 4 O
of	817 2 O
coronary	820 8 B-Disease
artery	829 6 I-Disease
disease	836 7 I-Disease
were	844 4 O
prospectively	849 13 O
followed	863 8 O
for	872 3 O
15	876 2 O
y	879 1 O
.	880 1 O

RESULTS	882 7 O
:	889 1 O
After	891 5 O
adjustment	897 10 O
for	908 3 O
cardiovascular	912 14 B-Disease
disease	927 7 I-Disease
risk	935 4 O
factors	940 7 O
,	947 1 O
type	949 4 O
of	954 2 O
diabetes	957 8 B-Disease
medication	966 10 O
used	977 4 O
,	981 1 O
duration	983 8 O
of	992 2 O
diabetes	995 8 B-Disease
,	1003 1 O
and	1005 3 O
intakes	1009 7 O
of	1017 2 O
folate	1020 6 B-Chemical
,	1026 1 O
vitamin	1028 7 B-Chemical
E	1036 1 I-Chemical
,	1037 1 O
and	1039 3 O
beta	1043 4 B-Chemical
-	1047 1 I-Chemical
carotene	1048 8 I-Chemical
,	1056 1 O
the	1058 3 O
adjusted	1062 8 O
relative	1071 8 O
risks	1080 5 O
of	1086 2 O
total	1089 5 O
cardiovascular	1095 14 B-Disease
disease	1110 7 I-Disease
mortality	1118 9 O
were	1128 4 O
1	1133 1 O
.	1134 1 O
0	1135 1 O
,	1136 1 O
0	1138 1 O
.	1139 1 O
97	1140 2 O
,	1142 1 O
1	1144 1 O
.	1145 1 O
11	1146 2 O
,	1148 1 O
1	1150 1 O
.	1151 1 O
47	1152 2 O
,	1154 1 O
and	1156 3 O
1	1160 1 O
.	1161 1 O
84	1162 2 O
(	1165 1 O
P	1166 1 O
for	1168 3 O
trend	1172 5 O
<	1178 1 O
0	1180 1 O
.	1181 1 O
01	1182 2 O
)	1184 1 O
across	1186 6 O
quintiles	1193 9 O
of	1203 2 O
total	1206 5 O
vitamin	1212 7 B-Chemical
C	1220 1 I-Chemical
intake	1222 6 O
from	1229 4 O
food	1234 4 O
and	1239 3 O
supplements	1243 11 O
.	1254 1 O

Adjusted	1256 8 O
relative	1265 8 O
risks	1274 5 O
of	1280 2 O
coronary	1283 8 B-Disease
artery	1292 6 I-Disease
disease	1299 7 I-Disease
were	1307 4 O
1	1312 1 O
.	1313 1 O
0	1314 1 O
,	1315 1 O
0	1317 1 O
.	1318 1 O
81	1319 2 O
,	1321 1 O
0	1323 1 O
.	1324 1 O
99	1325 2 O
,	1327 1 O
1	1329 1 O
.	1330 1 O
26	1331 2 O
,	1333 1 O
and	1335 3 O
1	1339 1 O
.	1340 1 O
91	1341 2 O
(	1344 1 O
P	1345 1 O
for	1347 3 O
trend	1351 5 O
=	1357 1 O
0	1359 1 O
.	1360 1 O
01	1361 2 O
)	1363 1 O
and	1365 3 O
of	1369 2 O
stroke	1372 6 B-Disease
were	1379 4 O
1	1384 1 O
.	1385 1 O
0	1386 1 O
,	1387 1 O
0	1389 1 O
.	1390 1 O
52	1391 2 O
,	1393 1 O
1	1395 1 O
.	1396 1 O
23	1397 2 O
,	1399 1 O
2	1401 1 O
.	1402 1 O
22	1403 2 O
,	1405 1 O
and	1407 3 O
2	1411 1 O
.	1412 1 O
57	1413 2 O
(	1416 1 O
P	1417 1 O
for	1419 3 O
trend	1423 5 O
<	1429 1 O
0	1431 1 O
.	1432 1 O
01	1433 2 O
)	1435 1 O
.	1436 1 O

When	1438 4 O
dietary	1443 7 O
and	1451 3 O
supplemental	1455 12 O
vitamin	1468 7 B-Chemical
C	1476 1 I-Chemical
were	1478 4 O
analyzed	1483 8 O
separately	1492 10 O
,	1502 1 O
only	1504 4 O
supplemental	1509 12 O
vitamin	1522 7 B-Chemical
C	1530 1 I-Chemical
showed	1532 6 O
a	1539 1 O
positive	1541 8 O
association	1550 11 O
with	1562 4 O
mortality	1567 9 O
endpoints	1577 9 O
.	1586 1 O

Vitamin	1588 7 B-Chemical
C	1596 1 I-Chemical
intake	1598 6 O
was	1605 3 O
unrelated	1609 9 O
to	1619 2 O
mortality	1622 9 O
from	1632 4 O
cardiovascular	1637 14 B-Disease
disease	1652 7 I-Disease
in	1660 2 O
the	1663 3 O
nondiabetic	1667 11 O
subjects	1679 8 O
at	1688 2 O
baseline	1691 8 O
.	1699 1 O

CONCLUSION	1701 10 O
:	1711 1 O
A	1713 1 O
high	1715 4 O
vitamin	1720 7 B-Chemical
C	1728 1 I-Chemical
intake	1730 6 O
from	1737 4 O
supplements	1742 11 O
is	1754 2 O
associated	1757 10 O
with	1768 4 O
an	1773 2 O
increased	1776 9 O
risk	1786 4 O
of	1791 2 O
cardiovascular	1794 14 B-Disease
disease	1809 7 I-Disease
mortality	1817 9 O
in	1827 2 O
postmenopausal	1830 14 O
women	1845 5 O
with	1851 4 O
diabetes	1856 8 B-Disease
.	1864 1 O

Absolute	0 8 O
and	9 3 O
attributable	13 12 O
risk	26 4 O
of	31 2 O
venous	34 6 B-Disease
thromboembolism	41 15 I-Disease
in	57 2 O
women	60 5 O
on	66 2 O
combined	69 8 O
cyproterone	78 11 B-Chemical
acetate	90 7 I-Chemical
and	98 3 O
ethinylestradiol	102 16 B-Chemical
.	118 1 O

OBJECTIVE	120 9 O
:	129 1 O
To	131 2 O
achieve	134 7 O
absolute	142 8 O
risk	151 4 O
estimates	156 9 O
of	166 2 O
venous	169 6 B-Disease
thromboembolism	176 15 I-Disease
(	192 1 O
VTE	193 3 B-Disease
)	196 1 O
among	198 5 O
women	204 5 O
on	210 2 O
cyproterone	213 11 B-Chemical
acetate	225 7 I-Chemical
plus	233 4 O
ethinylestradiol	238 16 B-Chemical
(	255 1 O
CPA	256 3 B-Chemical
/	259 1 O
EE	260 2 B-Chemical
)	262 1 O
,	263 1 O
and	265 3 O
among	269 5 O
women	275 5 O
on	281 2 O
combined	284 8 B-Chemical
oral	293 4 I-Chemical
contraceptives	298 14 I-Chemical
(	313 1 O
COCs	314 4 B-Chemical
)	318 1 O
.	319 1 O

METHODS	321 7 O
:	328 1 O
From	330 4 O
the	335 3 O
Danish	339 6 O
National	346 8 O
Register	355 8 O
of	364 2 O
Patients	367 8 O
(	376 1 O
NRP	377 3 O
)	380 1 O
,	381 1 O
1996	383 4 O
to	388 2 O
1998	391 4 O
,	395 1 O
the	397 3 O
records	401 7 O
of	409 2 O
1	412 1 O
.	413 1 O
1	414 1 O
million	416 7 O
Danish	424 6 O
women	431 5 O
,	436 1 O
ages	438 4 O
15	443 2 O
to	446 2 O
44	449 2 O
years	452 5 O
,	457 1 O
were	459 4 O
searched	464 8 O
for	473 3 O
evidence	477 8 O
of	486 2 O
VTE	489 3 B-Disease
.	492 1 O

COC	494 3 B-Chemical
use	498 3 O
was	502 3 O
ascertained	506 11 O
through	518 7 O
mailed	526 6 O
questionnaires	533 14 O
.	547 1 O

Sales	549 5 O
statistics	555 10 O
of	566 2 O
COCs	569 4 B-Chemical
and	574 3 O
CPA	578 3 B-Chemical
/	581 1 O
EE	582 2 B-Chemical
were	585 4 O
provided	590 8 O
through	599 7 O
Danish	607 6 O
Drug	614 4 O
Statistics	619 10 O
.	629 1 O

RESULTS	631 7 O
:	638 1 O
During	640 6 O
the	647 3 O
time	651 4 O
frame	656 5 O
of	662 2 O
the	665 3 O
study	669 5 O
,	674 1 O
330	676 3 O
women	680 5 O
were	686 4 O
found	691 5 O
to	697 2 O
have	700 4 O
had	705 3 O
VTE	709 3 B-Disease
while	713 5 O
on	719 2 O
COCs	722 4 B-Chemical
.	726 1 O

Of	728 2 O
these	731 5 O
women	737 5 O
,	742 1 O
67	744 2 O
were	747 4 O
on	752 2 O
levonorgestrel	755 14 B-Chemical
-	769 1 O
containing	770 10 O
COCs	781 4 B-Chemical
.	785 1 O

Eleven	787 6 O
were	794 4 O
on	799 2 O
CPA	802 3 B-Chemical
/	805 1 O
EE	806 2 B-Chemical
.	808 1 O

The	810 3 O
corresponding	814 13 O
absolute	828 8 O
risk	837 4 O
of	842 2 O
VTE	845 3 B-Disease
was	849 3 O
3	853 1 O
.	854 1 O
4	855 1 O
(	857 1 O
range	858 5 O
,	863 1 O
3	865 1 O
.	866 1 O
1	867 1 O
-	868 1 O
3	869 1 O
.	870 1 O
8	871 1 O
)	872 1 O
per	874 3 O
10	878 2 O
000	881 3 O
women	885 5 O
years	891 5 O
among	897 5 O
the	903 3 O
women	907 5 O
on	913 2 O
COCs	916 4 B-Chemical
,	920 1 O
4	922 1 O
.	923 1 O
2	924 1 O
(	926 1 O
range	927 5 O
,	932 1 O
3	934 1 O
.	935 1 O
2	936 1 O
-	937 1 O
5	938 1 O
.	939 1 O
2	940 1 O
)	941 1 O
per	943 3 O
10	947 2 O
000	950 3 O
women	954 5 O
years	960 5 O
among	966 5 O
women	972 5 O
on	978 2 O
levonorgestrel	981 14 B-Chemical
-	995 1 O
containing	996 10 O
COCs	1007 4 B-Chemical
,	1011 1 O
and	1013 3 O
3	1017 1 O
.	1018 1 O
1	1019 1 O
(	1021 1 O
range	1022 5 O
,	1027 1 O
1	1029 1 O
.	1030 1 O
3	1031 1 O
-	1032 1 O
4	1033 1 O
.	1034 1 O
9	1035 1 O
)	1036 1 O
per	1038 3 O
10	1042 2 O
000	1045 3 O
women	1049 5 O
years	1055 5 O
among	1061 5 O
the	1067 3 O
women	1071 5 O
on	1077 2 O
CPA	1080 3 B-Chemical
/	1083 1 O
EE	1084 2 B-Chemical
.	1086 1 O

CONCLUSION	1088 10 O
:	1098 1 O
Our	1100 3 O
results	1104 7 O
suggest	1112 7 O
the	1120 3 O
absolute	1124 8 O
risk	1133 4 O
of	1138 2 O
VTE	1141 3 B-Disease
among	1145 5 O
Danish	1151 6 O
women	1158 5 O
on	1164 2 O
COCs	1167 4 B-Chemical
is	1172 2 O
similar	1175 7 O
to	1183 2 O
that	1186 4 O
among	1191 5 O
women	1197 5 O
taking	1203 6 O
CPA	1210 3 B-Chemical
/	1213 1 O
EE	1214 2 B-Chemical
.	1216 1 O

Effect	0 6 O
of	7 2 O
lindane	10 7 B-Chemical
on	18 2 O
hepatic	21 7 O
and	29 3 O
brain	33 5 O
cytochrome	39 10 O
P450s	50 5 O
and	56 3 O
influence	60 9 O
of	70 2 O
P450	73 4 O
modulation	78 10 O
in	89 2 O
lindane	92 7 B-Chemical
induced	100 7 O
neurotoxicity	108 13 B-Disease
.	121 1 O

Oral	123 4 O
administration	128 14 O
of	143 2 O
lindane	146 7 B-Chemical
(	154 1 O
2	155 1 O
.	156 1 O
5	157 1 O
,	158 1 O
5	160 1 O
,	161 1 O
10	163 2 O
and	166 3 O
15	170 2 O
mg	173 2 O
/	175 1 O
kg	176 2 O
,	178 1 O
body	180 4 O
weight	185 6 O
)	191 1 O
for	193 3 O
5	197 1 O
days	199 4 O
was	204 3 O
found	208 5 O
to	214 2 O
produce	217 7 O
a	225 1 O
dose	227 4 O
-	231 1 O
dependent	232 9 O
increase	242 8 O
in	251 2 O
the	254 3 O
activity	258 8 O
of	267 2 O
P450	270 4 O
dependent	275 9 O
7	285 1 O
-	286 1 O
ethoxyresorufin	287 15 O
-	302 1 O
O	303 1 O
-	304 1 O
deethylase	305 10 O
(	316 1 O
EROD	317 4 O
)	321 1 O
,	322 1 O
7	324 1 O
-	325 1 O
pentoxyresorufin	326 16 O
-	342 1 O
O	343 1 O
-	344 1 O
dealkylase	345 10 O
(	356 1 O
PROD	357 4 O
)	361 1 O
and	363 3 O
N	367 1 B-Chemical
-	368 1 I-Chemical
nitrosodimethylamine	369 20 I-Chemical
demethylase	390 11 O
(	402 1 O
NDMA	403 4 B-Chemical
-	407 1 O
d	408 1 O
)	409 1 O
in	411 2 O
rat	414 3 O
brain	418 5 O
and	424 3 O
liver	428 5 O
.	433 1 O

A	435 1 O
significant	437 11 O
increase	449 8 O
in	458 2 O
the	461 3 O
hepatic	465 7 O
and	473 3 O
brain	477 5 O
P450	483 4 O
monooxygenases	488 14 O
was	503 3 O
also	507 4 O
observed	512 8 O
when	521 4 O
the	526 3 O
duration	530 8 O
of	539 2 O
exposure	542 8 O
of	551 2 O
low	554 3 O
dose	558 4 O
(	563 1 O
2	564 1 O
.	565 1 O
5	566 1 O
mg	568 2 O
/	570 1 O
kg	571 2 O
)	573 1 O
of	575 2 O
lindane	578 7 B-Chemical
was	586 3 O
increased	590 9 O
from	600 4 O
5	605 1 O
days	607 4 O
to	612 2 O
15	615 2 O
or	618 2 O
21	621 2 O
days	624 4 O
.	628 1 O

As	630 2 O
observed	633 8 O
with	642 4 O
different	647 9 O
doses	657 5 O
,	662 1 O
the	664 3 O
magnitude	668 9 O
of	678 2 O
induction	681 9 O
in	691 2 O
the	694 3 O
activity	698 8 O
of	707 2 O
P450	710 4 O
monooxygenases	715 14 O
was	730 3 O
several	734 7 O
fold	742 4 O
higher	747 6 O
in	754 2 O
liver	757 5 O
microsomes	763 10 O
when	774 4 O
compared	779 8 O
with	788 4 O
the	793 3 O
brain	797 5 O
.	802 1 O

Western	804 7 O
blotting	812 8 O
studies	821 7 O
have	829 4 O
indicated	834 9 O
that	844 4 O
the	849 3 O
increase	853 8 O
in	862 2 O
the	865 3 O
P450	869 4 O
enzymes	874 7 O
could	882 5 O
be	888 2 O
due	891 3 O
to	895 2 O
the	898 3 O
increase	902 8 O
in	911 2 O
the	914 3 O
expression	918 10 O
of	929 2 O
P450	932 4 O
1A1	937 3 O
/	940 1 O
1A2	941 3 O
,	944 1 O
2B1	946 3 O
/	949 1 O
2B2	950 3 O
and	954 3 O
2E1	958 3 O
isoenzymes	962 10 O
.	972 1 O

In	974 2 O
vitro	977 5 O
studies	983 7 O
using	991 5 O
organic	997 7 O
inhibitors	1005 10 O
specific	1016 8 O
for	1025 3 O
individual	1029 10 O
P450	1040 4 O
isoenzymes	1045 10 O
and	1056 3 O
antibody	1060 8 O
inhibition	1069 10 O
experiments	1080 11 O
have	1092 4 O
further	1097 7 O
demonstrated	1105 12 O
that	1118 4 O
the	1123 3 O
increase	1127 8 O
in	1136 2 O
the	1139 3 O
activity	1143 8 O
of	1152 2 O
PROD	1155 4 O
,	1159 1 O
EROD	1161 4 O
and	1166 3 O
NDMA	1170 4 B-Chemical
-	1174 1 O
d	1175 1 O
are	1177 3 O
due	1181 3 O
to	1185 2 O
the	1188 3 O
increase	1192 8 O
in	1201 2 O
the	1204 3 O
levels	1208 6 O
of	1215 2 O
P450	1218 4 O
2B1	1223 3 O
/	1226 1 O
2B2	1227 3 O
,	1230 1 O
1A1	1232 3 O
/	1235 1 O
1A2	1236 3 O
and	1240 3 O
2E1	1244 3 O
isoenzymes	1248 10 O
,	1258 1 O
respectively	1260 12 O
.	1272 1 O

Induction	1274 9 O
studies	1284 7 O
have	1292 4 O
further	1297 7 O
shown	1305 5 O
that	1311 4 O
while	1316 5 O
pretreatment	1322 12 O
of	1335 2 O
3	1338 1 B-Chemical
-	1339 1 I-Chemical
methylcholanthrene	1340 18 I-Chemical
(	1359 1 O
MC	1360 2 B-Chemical
)	1362 1 O
,	1363 1 O
an	1365 2 O
inducer	1368 7 O
of	1376 2 O
P4501A1	1379 7 O
/	1386 1 O
1A2	1387 3 O
,	1390 1 O
did	1392 3 O
not	1396 3 O
produce	1400 7 O
any	1408 3 O
significant	1412 11 O
effect	1424 6 O
in	1431 2 O
the	1434 3 O
incidence	1438 9 O
of	1448 2 O
lindane	1451 7 B-Chemical
induced	1459 7 O
convulsions	1467 11 B-Disease
,	1478 1 O
pretreatment	1480 12 O
with	1493 4 O
phenobarbital	1498 13 B-Chemical
(	1512 1 O
PB	1513 2 O
)	1515 1 O
,	1516 1 O
an	1518 2 O
inducer	1521 7 O
of	1529 2 O
P450	1532 4 O
2B1	1537 3 O
/	1540 1 O
2B2	1541 3 O
or	1545 2 O
ethanol	1548 7 B-Chemical
,	1555 1 O
an	1557 2 O
inducer	1560 7 O
of	1568 2 O
P450	1571 4 O
2E1	1576 3 O
catalysed	1580 9 O
reactions	1590 9 O
,	1599 1 O
significantly	1601 13 O
increased	1615 9 O
the	1625 3 O
incidence	1629 9 O
of	1639 2 O
lindane	1642 7 B-Chemical
induced	1650 7 O
convulsions	1658 11 B-Disease
.	1669 1 O

Similarly	1671 9 O
,	1680 1 O
when	1682 4 O
the	1687 3 O
P450	1691 4 O
-	1695 1 O
mediated	1696 8 O
metabolism	1705 10 O
of	1716 2 O
lindane	1719 7 B-Chemical
was	1727 3 O
blocked	1731 7 O
by	1739 2 O
cobalt	1742 6 B-Chemical
chloride	1749 8 I-Chemical
incidence	1758 9 O
of	1768 2 O
convulsions	1771 11 B-Disease
was	1783 3 O
increased	1787 9 O
in	1797 2 O
animals	1800 7 O
treated	1808 7 O
with	1816 4 O
lindane	1821 7 B-Chemical
indicating	1829 10 O
that	1840 4 O
lindane	1845 7 B-Chemical
per	1853 3 O
se	1857 2 O
or	1860 2 O
its	1863 3 O
metabolites	1867 11 O
formed	1879 6 O
by	1886 2 O
PB	1889 2 O
or	1892 2 O
ethanol	1895 7 B-Chemical
inducible	1903 9 O
P450	1913 4 O
isoenzymes	1918 10 O
are	1929 3 O
involved	1933 8 O
in	1942 2 O
its	1945 3 O
neurobehavioral	1949 15 O
toxicity	1965 8 B-Disease
.	1973 1 O

Seizure	0 7 B-Disease
associated	8 10 O
with	19 4 O
sleep	24 5 B-Disease
deprivation	30 11 I-Disease
and	42 3 O
sustained	46 9 O
-	55 1 O
release	56 7 O
bupropion	64 9 B-Chemical
.	73 1 O

This	75 4 O
case	80 4 O
report	85 6 O
describes	92 9 O
a	102 1 O
generalized	104 11 O
seizure	116 7 B-Disease
associated	124 10 O
with	135 4 O
sustained	140 9 O
-	149 1 O
release	150 7 O
bupropion	158 9 B-Chemical
use	168 3 O
and	172 3 O
sleep	176 5 B-Disease
deprivation	182 11 I-Disease
.	193 1 O

The	195 3 O
subject	199 7 O
,	206 1 O
a	208 1 O
31	210 2 O
-	212 1 O
year	213 4 O
-	217 1 O
old	218 3 O
female	222 6 O
smoker	229 6 O
,	235 1 O
was	237 3 O
participating	241 13 O
in	255 2 O
a	258 1 O
clinical	260 8 O
trial	269 5 O
evaluating	275 10 O
an	286 2 O
investigational	289 15 O
medication	305 10 O
for	316 3 O
smoking	320 7 O
cessation	328 9 O
that	338 4 O
used	343 4 O
sustained	348 9 O
-	357 1 O
release	358 7 O
bupropion	366 9 B-Chemical
as	376 2 O
an	379 2 O
active	382 6 O
control	389 7 O
.	396 1 O

After	398 5 O
5	404 1 O
weeks	406 5 O
of	412 2 O
bupropion	415 9 B-Chemical
use	425 3 O
,	428 1 O
the	430 3 O
subject	434 7 O
experienced	442 11 O
a	454 1 O
generalized	456 11 O
tonic	468 5 O
clonic	474 6 O
seizure	481 7 B-Disease
after	489 5 O
staying	495 7 O
up	503 2 O
nearly	506 6 O
all	513 3 O
night	517 5 O
packing	523 7 O
and	531 3 O
moving	535 6 O
to	542 2 O
a	545 1 O
new	547 3 O
residence	551 9 O
.	560 1 O

The	562 3 O
patient	566 7 O
had	574 3 O
no	578 2 O
other	581 5 O
risk	587 4 O
factors	592 7 O
for	600 3 O
seizures	604 8 B-Disease
.	612 1 O

We	614 2 O
suggest	617 7 O
that	625 4 O
sleep	630 5 B-Disease
deprivation	636 11 I-Disease
may	648 3 O
add	652 3 O
to	656 2 O
the	659 3 O
risk	663 4 O
of	668 2 O
bupropion	671 9 B-Chemical
-	680 1 O
associated	681 10 O
seizures	692 8 B-Disease
.	700 1 O

Nephrotoxic	0 11 B-Disease
effects	12 7 O
in	20 2 O
high	23 4 O
-	27 1 O
risk	28 4 O
patients	33 8 O
undergoing	42 10 O
angiography	53 11 O
.	64 1 O

BACKGROUND	66 10 O
:	76 1 O
The	78 3 O
use	82 3 O
of	86 2 O
iodinated	89 9 O
contrast	99 8 O
medium	108 6 O
can	115 3 O
result	119 6 O
in	126 2 O
nephropathy	129 11 B-Disease
.	140 1 O

Whether	142 7 O
iso	150 3 O
-	153 1 O
osmolar	154 7 O
contrast	162 8 O
medium	171 6 O
is	178 2 O
less	181 4 O
nephrotoxic	186 11 B-Disease
than	198 4 O
low	203 3 O
-	206 1 O
osmolar	207 7 O
contrast	215 8 O
medium	224 6 O
in	231 2 O
high	234 4 O
-	238 1 O
risk	239 4 O
patients	244 8 O
is	253 2 O
uncertain	256 9 O
.	265 1 O

METHODS	267 7 O
:	274 1 O
We	276 2 O
conducted	279 9 O
a	289 1 O
randomized	291 10 O
,	301 1 O
double	303 6 O
-	309 1 O
blind	310 5 O
,	315 1 O
prospective	317 11 O
,	328 1 O
multicenter	330 11 O
study	342 5 O
comparing	348 9 O
the	358 3 O
nephrotoxic	362 11 B-Disease
effects	374 7 O
of	382 2 O
an	385 2 O
iso	388 3 O
-	391 1 O
osmolar	392 7 O
,	399 1 O
dimeric	401 7 O
,	408 1 O
nonionic	410 8 O
contrast	419 8 O
medium	428 6 O
,	434 1 O
iodixanol	436 9 B-Chemical
,	445 1 O
with	447 4 O
those	452 5 O
of	458 2 O
a	461 1 O
low	463 3 O
-	466 1 O
osmolar	467 7 O
,	474 1 O
nonionic	476 8 O
,	484 1 O
monomeric	486 9 O
contrast	496 8 O
medium	505 6 O
,	511 1 O
iohexol	513 7 B-Chemical
.	520 1 O

The	522 3 O
study	526 5 O
involved	532 8 O
129	541 3 O
patients	545 8 O
with	554 4 O
diabetes	559 8 B-Disease
with	568 4 O
serum	573 5 O
creatinine	579 10 B-Chemical
concentrations	590 14 O
of	605 2 O
1	608 1 O
.	609 1 O
5	610 1 O
to	612 2 O
3	615 1 O
.	616 1 O
5	617 1 O
mg	619 2 O
per	622 3 O
deciliter	626 9 O
who	636 3 O
underwent	640 9 O
coronary	650 8 O
or	659 2 O
aortofemoral	662 12 O
angiography	675 11 O
.	686 1 O

The	688 3 O
primary	692 7 O
end	700 3 O
point	704 5 O
was	710 3 O
the	714 3 O
peak	718 4 O
increase	723 8 O
from	732 4 O
base	737 4 O
line	742 4 O
in	747 2 O
the	750 3 O
creatinine	754 10 B-Chemical
concentration	765 13 O
during	779 6 O
the	786 3 O
three	790 5 O
days	796 4 O
after	801 5 O
angiography	807 11 O
.	818 1 O

Other	820 5 O
end	826 3 O
points	830 6 O
were	837 4 O
an	842 2 O
increase	845 8 O
in	854 2 O
the	857 3 O
creatinine	861 10 B-Chemical
concentration	872 13 O
of	886 2 O
0	889 1 O
.	890 1 O
5	891 1 O
mg	893 2 O
per	896 3 O
deciliter	900 9 O
or	910 2 O
more	913 4 O
,	917 1 O
an	919 2 O
increase	922 8 O
of	931 2 O
1	934 1 O
.	935 1 O
0	936 1 O
mg	938 2 O
per	941 3 O
deciliter	945 9 O
or	955 2 O
more	958 4 O
,	962 1 O
and	964 3 O
a	968 1 O
change	970 6 O
in	977 2 O
the	980 3 O
creatinine	984 10 B-Chemical
concentration	995 13 O
from	1009 4 O
day	1014 3 O
0	1018 1 O
to	1020 2 O
day	1023 3 O
7	1027 1 O
.	1028 1 O

RESULTS	1030 7 O
:	1037 1 O
The	1039 3 O
creatinine	1043 10 B-Chemical
concentration	1054 13 O
increased	1068 9 O
significantly	1078 13 O
less	1092 4 O
in	1097 2 O
patients	1100 8 O
who	1109 3 O
received	1113 8 O
iodixanol	1122 9 B-Chemical
.	1131 1 O

From	1133 4 O
day	1138 3 O
0	1142 1 O
to	1144 2 O
day	1147 3 O
3	1151 1 O
,	1152 1 O
the	1154 3 O
mean	1158 4 O
peak	1163 4 O
increase	1168 8 O
in	1177 2 O
creatinine	1180 10 B-Chemical
was	1191 3 O
0	1195 1 O
.	1196 1 O
13	1197 2 O
mg	1200 2 O
per	1203 3 O
deciliter	1207 9 O
in	1217 2 O
the	1220 3 O
iodixanol	1224 9 B-Chemical
group	1234 5 O
and	1240 3 O
0	1244 1 O
.	1245 1 O
55	1246 2 O
mg	1249 2 O
per	1252 3 O
deciliter	1256 9 O
in	1266 2 O
the	1269 3 O
iohexol	1273 7 B-Chemical
group	1281 5 O
(	1287 1 O
P	1288 1 O
=	1289 1 O
0	1290 1 O
.	1291 1 O
001	1292 3 O
;	1295 1 O
the	1297 3 O
increase	1301 8 O
with	1310 4 O
iodixanol	1315 9 B-Chemical
minus	1325 5 O
the	1331 3 O
increase	1335 8 O
with	1344 4 O
iohexol	1349 7 B-Chemical
,	1356 1 O
-	1358 1 O
0	1359 1 O
.	1360 1 O
42	1361 2 O
mg	1364 2 O
per	1367 3 O
deciliter	1371 9 O
[	1381 1 O
95	1382 2 O
percent	1385 7 O
confidence	1393 10 O
interval	1404 8 O
,	1412 1 O
-	1414 1 O
0	1415 1 O
.	1416 1 O
73	1417 2 O
to	1420 2 O
-	1423 1 O
0	1424 1 O
.	1425 1 O
22	1426 2 O
]	1428 1 O
)	1429 1 O
.	1430 1 O

Two	1432 3 O
of	1436 2 O
the	1439 3 O
64	1443 2 O
patients	1446 8 O
in	1455 2 O
the	1458 3 O
iodixanol	1462 9 B-Chemical
group	1472 5 O
(	1478 1 O
3	1479 1 O
percent	1481 7 O
)	1488 1 O
had	1490 3 O
an	1494 2 O
increase	1497 8 O
in	1506 2 O
the	1509 3 O
creatinine	1513 10 B-Chemical
concentration	1524 13 O
of	1538 2 O
0	1541 1 O
.	1542 1 O
5	1543 1 O
mg	1545 2 O
per	1548 3 O
deciliter	1552 9 O
or	1562 2 O
more	1565 4 O
,	1569 1 O
as	1571 2 O
compared	1574 8 O
with	1583 4 O
17	1588 2 O
of	1591 2 O
the	1594 3 O
65	1598 2 O
patients	1601 8 O
in	1610 2 O
the	1613 3 O
iohexol	1617 7 B-Chemical
group	1625 5 O
(	1631 1 O
26	1632 2 O
percent	1635 7 O
)	1642 1 O
(	1644 1 O
P	1645 1 O
=	1646 1 O
0	1647 1 O
.	1648 1 O
002	1649 3 O
;	1652 1 O
odds	1654 4 O
ratio	1659 5 O
for	1665 3 O
such	1669 4 O
an	1674 2 O
increase	1677 8 O
in	1686 2 O
the	1689 3 O
iodixanol	1693 9 B-Chemical
group	1703 5 O
,	1708 1 O
0	1710 1 O
.	1711 1 O
09	1712 2 O
[	1715 1 O
95	1716 2 O
percent	1719 7 O
confidence	1727 10 O
interval	1738 8 O
,	1746 1 O
0	1748 1 O
.	1749 1 O
02	1750 2 O
to	1753 2 O
0	1756 1 O
.	1757 1 O
41	1758 2 O
]	1760 1 O
)	1761 1 O
.	1762 1 O

No	1764 2 O
patient	1767 7 O
receiving	1775 9 O
iodixanol	1785 9 B-Chemical
had	1795 3 O
an	1799 2 O
increase	1802 8 O
of	1811 2 O
1	1814 1 O
.	1815 1 O
0	1816 1 O
mg	1818 2 O
per	1821 3 O
deciliter	1825 9 O
or	1835 2 O
more	1838 4 O
,	1842 1 O
but	1844 3 O
10	1848 2 O
patients	1851 8 O
in	1860 2 O
the	1863 3 O
iohexol	1867 7 B-Chemical
group	1875 5 O
(	1881 1 O
15	1882 2 O
percent	1885 7 O
)	1892 1 O
did	1894 3 O
.	1897 1 O

The	1899 3 O
mean	1903 4 O
change	1908 6 O
in	1915 2 O
the	1918 3 O
creatinine	1922 10 B-Chemical
concentration	1933 13 O
from	1947 4 O
day	1952 3 O
0	1956 1 O
to	1958 2 O
day	1961 3 O
7	1965 1 O
was	1967 3 O
0	1971 1 O
.	1972 1 O
07	1973 2 O
mg	1976 2 O
per	1979 3 O
deciliter	1983 9 O
in	1993 2 O
the	1996 3 O
iodixanol	2000 9 B-Chemical
group	2010 5 O
and	2016 3 O
0	2020 1 O
.	2021 1 O
24	2022 2 O
mg	2025 2 O
per	2028 3 O
deciliter	2032 9 O
in	2042 2 O
the	2045 3 O
iohexol	2049 7 B-Chemical
group	2057 5 O
(	2063 1 O
P	2064 1 O
=	2065 1 O
0	2066 1 O
.	2067 1 O
003	2068 3 O
;	2071 1 O
value	2073 5 O
in	2079 2 O
the	2082 3 O
iodixanol	2086 9 B-Chemical
group	2096 5 O
minus	2102 5 O
the	2108 3 O
value	2112 5 O
in	2118 2 O
the	2121 3 O
iohexol	2125 7 B-Chemical
group	2133 5 O
,	2138 1 O
-	2140 1 O
0	2141 1 O
.	2142 1 O
17	2143 2 O
mg	2146 2 O
per	2149 3 O
deciliter	2153 9 O
[	2163 1 O
95	2164 2 O
percent	2167 7 O
confidence	2175 10 O
interval	2186 8 O
,	2194 1 O
-	2196 1 O
0	2197 1 O
.	2198 1 O
34	2199 2 O
to	2202 2 O
-	2205 1 O
0	2206 1 O
.	2207 1 O
07	2208 2 O
]	2210 1 O
)	2211 1 O
.	2212 1 O

CONCLUSIONS	2214 11 O
:	2225 1 O
Nephropathy	2227 11 B-Disease
induced	2239 7 O
by	2247 2 O
contrast	2250 8 O
medium	2259 6 O
may	2266 3 O
be	2270 2 O
less	2273 4 O
likely	2278 6 O
to	2285 2 O
develop	2288 7 O
in	2296 2 O
high	2299 4 O
-	2303 1 O
risk	2304 4 O
patients	2309 8 O
when	2318 4 O
iodixanol	2323 9 B-Chemical
is	2333 2 O
used	2336 4 O
rather	2341 6 O
than	2348 4 O
a	2353 1 O
low	2355 3 O
-	2358 1 O
osmolar	2359 7 O
,	2366 1 O
nonionic	2368 8 O
contrast	2377 8 O
medium	2386 6 O
.	2392 1 O

Experimental	0 12 O
cranial	13 7 O
pain	21 4 B-Disease
elicited	26 8 O
by	35 2 O
capsaicin	38 9 B-Chemical
:	47 1 O
a	49 1 O
PET	51 3 O
study	55 5 O
.	60 1 O

Using	62 5 O
a	68 1 O
positron	70 8 O
emission	79 8 O
tomography	88 10 O
(	99 1 O
PET	100 3 O
)	103 1 O
study	105 5 O
it	111 2 O
was	114 3 O
shown	118 5 O
recently	124 8 O
that	133 4 O
in	138 2 O
migraine	141 8 B-Disease
without	150 7 O
aura	158 4 O
certain	163 7 O
areas	171 5 O
in	177 2 O
the	180 3 O
brain	184 5 O
stem	190 4 O
were	195 4 O
activated	200 9 O
during	210 6 O
the	217 3 O
headache	221 8 B-Disease
state	230 5 O
,	235 1 O
but	237 3 O
not	241 3 O
in	245 2 O
the	248 3 O
headache	252 8 B-Disease
free	261 4 O
interval	266 8 O
.	274 1 O

It	276 2 O
was	279 3 O
suggested	283 9 O
that	293 4 O
this	298 4 O
brain	303 5 O
stem	309 4 O
activation	314 10 O
is	325 2 O
inherent	328 8 O
to	337 2 O
the	340 3 O
migraine	344 8 B-Disease
attack	353 6 O
itself	360 6 O
and	367 3 O
represents	371 10 O
the	382 3 O
so	386 2 O
called	389 6 O
'	396 1 O
migraine	397 8 B-Disease
generator	406 9 O
'	415 1 O
.	416 1 O

To	418 2 O
test	421 4 O
this	426 4 O
hypothesis	431 10 O
we	442 2 O
performed	445 9 O
an	455 2 O
experimental	458 12 O
pain	471 4 B-Disease
study	476 5 O
in	482 2 O
seven	485 5 O
healthy	491 7 O
volunteers	499 10 O
,	509 1 O
using	511 5 O
the	517 3 O
same	521 4 O
positioning	526 11 O
in	538 2 O
the	541 3 O
PET	545 3 O
scanner	549 7 O
as	557 2 O
in	560 2 O
the	563 3 O
migraine	567 8 B-Disease
patients	576 8 O
.	584 1 O

A	586 1 O
small	588 5 O
amount	594 6 O
of	601 2 O
capsaicin	604 9 B-Chemical
was	614 3 O
administered	618 12 O
subcutaneously	631 14 O
in	646 2 O
the	649 3 O
right	653 5 O
forehead	659 8 O
to	668 2 O
evoke	671 5 O
a	677 1 O
burning	679 7 O
painful	687 7 B-Disease
sensation	695 9 O
in	705 2 O
the	708 3 O
first	712 5 O
division	718 8 O
of	727 2 O
the	730 3 O
trigeminal	734 10 O
nerve	745 5 O
.	750 1 O

Increases	752 9 O
of	762 2 O
regional	765 8 O
cerebral	774 8 O
blood	783 5 O
flow	789 4 O
(	794 1 O
rCBF	795 4 O
)	799 1 O
were	801 4 O
found	806 5 O
bilaterally	812 11 O
in	824 2 O
the	827 3 O
insula	831 6 O
,	837 1 O
in	839 2 O
the	842 3 O
anterior	846 8 O
cingulate	855 9 O
cortex	865 6 O
,	871 1 O
the	873 3 O
cavernous	877 9 O
sinus	887 5 O
and	893 3 O
the	897 3 O
cerebellum	901 10 O
.	911 1 O

Using	913 5 O
the	919 3 O
same	923 4 O
stereotactic	928 12 O
space	941 5 O
limits	947 6 O
as	954 2 O
in	957 2 O
the	960 3 O
above	964 5 O
mentioned	970 9 O
migraine	980 8 B-Disease
study	989 5 O
no	995 2 O
brain	998 5 O
stem	1004 4 O
activation	1009 10 O
was	1020 3 O
found	1024 5 O
in	1030 2 O
the	1033 3 O
acute	1037 5 O
pain	1043 4 B-Disease
state	1048 5 O
compared	1054 8 O
to	1063 2 O
the	1066 3 O
pain	1070 4 B-Disease
free	1075 4 O
state	1080 5 O
.	1085 1 O

The	1087 3 O
increase	1091 8 O
of	1100 2 O
activation	1103 10 O
in	1114 2 O
the	1117 3 O
region	1121 6 O
of	1128 2 O
the	1131 3 O
cavernous	1135 9 O
sinus	1145 5 O
however	1151 7 O
,	1158 1 O
suggests	1160 8 O
that	1169 4 O
this	1174 4 O
structure	1179 9 O
is	1189 2 O
more	1192 4 O
likely	1197 6 O
to	1204 2 O
be	1207 2 O
involved	1210 8 O
in	1219 2 O
trigeminal	1222 10 O
transmitted	1233 11 O
pain	1245 4 B-Disease
as	1250 2 O
such	1253 4 O
,	1257 1 O
rather	1259 6 O
than	1266 4 O
in	1271 2 O
a	1274 1 O
specific	1276 8 O
type	1285 4 O
of	1290 2 O
headache	1293 8 B-Disease
as	1302 2 O
was	1305 3 O
suggested	1309 9 O
for	1319 3 O
cluster	1323 7 B-Disease
headache	1331 8 I-Disease
.	1339 1 O

Neuroleptic	0 11 B-Disease
malignant	12 9 I-Disease
syndrome	22 8 I-Disease
with	31 4 O
risperidone	36 11 B-Chemical
.	47 1 O

Neuroleptic	49 11 B-Disease
malignant	61 9 I-Disease
syndrome	71 8 I-Disease
is	80 2 O
thought	83 7 O
to	91 2 O
be	94 2 O
a	97 1 O
result	99 6 O
of	106 2 O
dopamine	109 8 B-Chemical
D2	118 2 O
receptor	121 8 O
blockade	130 8 O
in	139 2 O
the	142 3 O
striatum	146 8 O
of	155 2 O
the	158 3 O
basal	162 5 O
ganglia	168 7 O
.	175 1 O

Risperidone	177 11 B-Chemical
,	188 1 O
a	190 1 O
benzisoxazole	192 13 B-Chemical
derivative	206 10 O
antipsychotic	217 13 O
,	230 1 O
has	232 3 O
high	236 4 O
serotonin	241 9 B-Chemical
5	251 1 O
-	252 1 O
HT2	253 3 O
receptor	257 8 O
blockade	266 8 O
and	275 3 O
dose	279 4 O
-	283 1 O
related	284 7 O
D2	292 2 O
receptor	295 8 O
blockade	304 8 O
.	312 1 O

The	314 3 O
high	318 4 O
ratio	323 5 O
is	329 2 O
believed	332 8 O
to	341 2 O
impart	344 6 O
the	351 3 O
low	355 3 O
frequency	359 9 O
of	369 2 O
extrapyramidal	372 14 B-Disease
symptoms	387 8 I-Disease
with	396 4 O
risperidone	401 11 B-Chemical
at	413 2 O
low	416 3 O
dosages	420 7 O
.	427 1 O

With	429 4 O
this	434 4 O
low	439 3 O
frequency	443 9 O
of	453 2 O
extrapyramidal	456 14 B-Disease
symptoms	471 8 I-Disease
,	479 1 O
it	481 2 O
was	484 3 O
thought	488 7 O
the	496 3 O
frequency	500 9 O
of	510 2 O
neuroleptic	513 11 B-Disease
malignant	525 9 I-Disease
syndrome	535 8 I-Disease
might	544 5 O
also	550 4 O
be	555 2 O
lowered	558 7 O
.	565 1 O

A	567 1 O
73	569 2 O
-	571 1 O
year	572 4 O
-	576 1 O
old	577 3 O
woman	581 5 O
developed	587 9 O
neuroleptic	597 11 B-Disease
malignant	609 9 I-Disease
syndrome	619 8 I-Disease
after	628 5 O
monotherapy	634 11 O
with	646 4 O
risperidone	651 11 B-Chemical
.	662 1 O

The	664 3 O
syndrome	668 8 O
reversed	677 8 O
after	686 5 O
discontinuing	692 13 O
risperidone	706 11 B-Chemical
and	718 3 O
starting	722 8 O
treatment	731 9 O
with	741 4 O
dantrolene	746 10 B-Chemical
and	757 3 O
bromocriptine	761 13 B-Chemical
.	774 1 O

It	776 2 O
appears	779 7 O
that	787 4 O
the	792 3 O
protection	796 10 O
from	807 4 O
extrapyramidal	812 14 O
side	827 4 O
effects	832 7 O
observed	840 8 O
with	849 4 O
risperidone	854 11 B-Chemical
does	866 4 O
not	871 3 O
ensure	875 6 O
protection	882 10 O
from	893 4 O
neuroleptic	898 11 B-Disease
malignant	910 9 I-Disease
syndrome	920 8 I-Disease
.	928 1 O

Hepatic	0 7 O
and	8 3 O
extrahepatic	12 12 O
angiotensinogen	25 15 O
gene	41 4 O
expression	46 10 O
in	57 2 O
rats	60 4 O
with	65 4 O
acute	70 5 O
nephrotic	76 9 B-Disease
syndrome	86 8 I-Disease
.	94 1 O

Plasma	96 6 O
concentration	103 13 O
and	117 3 O
urine	121 5 O
excretion	127 9 O
of	137 2 O
the	140 3 O
renin	144 5 O
-	149 1 O
angiotensin	150 11 B-Chemical
system	162 6 O
proteins	169 8 O
are	178 3 O
altered	182 7 O
in	190 2 O
rats	193 4 O
with	198 4 O
nephrotic	203 9 B-Disease
syndrome	213 8 I-Disease
(	222 1 O
NS	223 2 B-Disease
)	225 1 O
.	226 1 O

In	228 2 O
this	231 4 O
work	236 4 O
the	241 3 O
messenger	245 9 O
ribonucleic	255 11 O
acid	267 4 O
(	272 1 O
mRNA	273 4 O
)	277 1 O
levels	279 6 O
of	286 2 O
angiotensinogen	289 15 O
(	305 1 O
Ao	306 2 O
)	308 1 O
were	310 4 O
analyzed	315 8 O
with	324 4 O
the	329 3 O
slot	333 4 O
-	337 1 O
blot	338 4 O
hybridization	343 13 O
technique	357 9 O
in	367 2 O
liver	370 5 O
and	376 3 O
other	380 5 O
extrahepatic	386 12 O
tissues	399 7 O
:	406 1 O
kidney	408 6 O
,	414 1 O
heart	416 5 O
,	421 1 O
brain	423 5 O
,	428 1 O
and	430 3 O
adrenal	434 7 O
gland	442 5 O
from	448 4 O
control	453 7 O
,	460 1 O
nephrotic	462 9 B-Disease
,	471 1 O
and	473 3 O
pair	477 4 O
-	481 1 O
fed	482 3 O
(	486 1 O
PF	487 2 O
)	489 1 O
rats	491 4 O
.	495 1 O

NS	497 2 B-Disease
was	500 3 O
induced	504 7 O
by	512 2 O
a	515 1 O
single	517 6 O
injection	524 9 O
of	534 2 O
puromycin	537 9 B-Chemical
amino	547 5 I-Chemical
-	552 1 I-Chemical
nucleoside	553 10 I-Chemical
(	564 1 O
PAN	565 3 B-Chemical
)	568 1 O
.	569 1 O

Although	571 8 O
a	580 1 O
great	582 5 O
urinary	588 7 O
excretion	596 9 O
and	606 3 O
half	610 4 O
-	614 1 O
normal	615 6 O
plasma	622 6 O
levels	629 6 O
of	636 2 O
Ao	639 2 O
were	642 4 O
observed	647 8 O
on	656 2 O
day	659 3 O
6	663 1 O
after	665 5 O
PAN	671 3 B-Chemical
injection	675 9 O
,	684 1 O
when	686 4 O
NS	691 2 B-Disease
was	694 3 O
clearly	698 7 O
established	706 11 O
,	717 1 O
hepatic	719 7 O
Ao	727 2 O
mRNA	730 4 O
levels	735 6 O
did	742 3 O
not	746 3 O
change	750 6 O
.	756 1 O

Furthermore	758 11 O
,	769 1 O
the	771 3 O
Ao	775 2 O
mRNA	778 4 O
levels	783 6 O
did	790 3 O
not	794 3 O
change	798 6 O
in	805 2 O
any	808 3 O
of	812 2 O
the	815 3 O
extrahepatic	819 12 O
tissues	832 7 O
studied	840 7 O
on	848 2 O
day	851 3 O
6	855 1 O
,	856 1 O
nor	858 3 O
did	862 3 O
its	866 3 O
hepatic	870 7 O
levels	878 6 O
at	885 2 O
days	888 4 O
1	893 1 O
,	894 1 O
3	896 1 O
,	897 1 O
5	899 1 O
,	900 1 O
or	902 2 O
7	905 1 O
after	907 5 O
PAN	913 3 B-Chemical
injection	917 9 O
.	926 1 O

These	928 5 O
data	934 4 O
suggest	939 7 O
that	947 4 O
the	952 3 O
hepatic	956 7 O
and	964 3 O
extrahepatic	968 12 O
Ao	981 2 O
mRNA	984 4 O
levels	989 6 O
are	996 3 O
unaltered	1000 9 O
during	1010 6 O
the	1017 3 O
development	1021 11 O
of	1033 2 O
the	1036 3 O
acute	1040 5 O
NS	1046 2 B-Disease
induced	1049 7 O
by	1057 2 O
PAN	1060 3 B-Chemical
.	1063 1 O

Cyclophosphamide	0 16 B-Chemical
associated	17 10 O
bladder	28 7 B-Disease
cancer	36 6 I-Disease
-	42 1 O
-	43 1 O
a	44 1 O
highly	46 6 O
aggressive	53 10 O
disease	64 7 O
:	71 1 O
analysis	73 8 O
of	82 2 O
12	85 2 O
cases	88 5 O
.	93 1 O

PURPOSE	95 7 O
:	102 1 O
We	104 2 O
gained	107 6 O
knowledge	114 9 O
of	124 2 O
the	127 3 O
etiology	131 8 O
,	139 1 O
treatment	141 9 O
and	151 3 O
prevention	155 10 O
of	166 2 O
cyclophosphamide	169 16 B-Chemical
associated	186 10 O
urothelial	197 10 B-Disease
cancer	208 6 I-Disease
.	214 1 O

MATERIALS	216 9 O
AND	226 3 O
METHODS	230 7 O
:	237 1 O
The	239 3 O
medical	243 7 O
records	251 7 O
of	259 2 O
6	262 1 O
men	264 3 O
and	268 3 O
6	272 1 O
women	274 5 O
(	280 1 O
mean	281 4 O
age	286 3 O
55	290 2 O
years	293 5 O
)	298 1 O
with	300 4 O
cyclophosphamide	305 16 B-Chemical
associated	322 10 O
bladder	333 7 B-Disease
cancer	341 6 I-Disease
were	348 4 O
reviewed	353 8 O
.	361 1 O

RESULTS	363 7 O
:	370 1 O
All	372 3 O
tumors	376 6 B-Disease
were	383 4 O
grade	388 5 O
3	394 1 O
or	396 2 O
4	399 1 O
transitional	401 12 O
cell	414 4 O
carcinoma	419 9 B-Disease
.	428 1 O

Of	430 2 O
the	433 3 O
5	437 1 O
patients	439 8 O
initially	448 9 O
treated	458 7 O
with	466 4 O
endoscopic	471 10 O
resection	482 9 O
alone	492 5 O
only	498 4 O
1	503 1 O
is	505 2 O
alive	508 5 O
without	514 7 O
disease	522 7 O
.	529 1 O

Of	531 2 O
the	534 3 O
6	538 1 O
patients	540 8 O
who	549 3 O
underwent	553 9 O
early	563 5 O
cystectomy	569 10 O
4	580 1 O
were	582 4 O
alive	587 5 O
at	593 2 O
24	596 2 O
to	599 2 O
111	602 3 O
months	606 6 O
.	612 1 O

The	614 3 O
remaining	618 9 O
patient	628 7 O
with	636 4 O
extensive	641 9 O
cancer	651 6 B-Disease
underwent	658 9 O
partial	668 7 O
cystectomy	676 10 O
for	687 3 O
palliation	691 10 O
and	702 3 O
died	706 4 O
3	711 1 O
months	713 6 O
later	720 5 O
.	725 1 O

CONCLUSIONS	727 11 O
:	738 1 O
Cyclophosphamide	740 16 B-Chemical
associated	757 10 O
bladder	768 7 B-Disease
tumor	776 5 I-Disease
is	782 2 O
an	785 2 O
aggressive	788 10 O
disease	799 7 O
.	806 1 O

However	808 7 O
,	815 1 O
long	817 4 O
-	821 1 O
term	822 4 O
survival	827 8 O
is	836 2 O
possible	839 8 O
when	848 4 O
radical	853 7 O
cystectomy	861 10 O
is	872 2 O
performed	875 9 O
for	885 3 O
bladder	889 7 B-Disease
tumors	897 6 I-Disease
with	904 4 O
any	909 3 O
sign	913 4 O
of	918 2 O
invasion	921 8 O
and	930 3 O
for	934 3 O
recurrent	938 9 O
high	948 4 O
grade	953 5 O
disease	959 7 O
,	966 1 O
even	968 4 O
when	973 4 O
noninvasive	978 11 O
.	989 1 O

Leg	0 3 B-Disease
and	4 3 I-Disease
back	8 4 I-Disease
pain	13 4 I-Disease
after	18 5 O
spinal	24 6 O
anaesthesia	31 11 O
involving	43 9 O
hyperbaric	53 10 O
5	64 1 O
%	65 1 O
lignocaine	67 10 B-Chemical
.	77 1 O

Fifty	79 5 O
-	84 1 O
four	85 4 O
patients	90 8 O
,	98 1 O
aged	100 4 O
27	105 2 O
-	107 1 O
90	108 2 O
years	111 5 O
,	116 1 O
who	118 3 O
were	122 4 O
given	127 5 O
lignocaine	133 10 B-Chemical
5	144 1 O
%	145 1 O
in	147 2 O
6	150 1 O
.	151 1 O
8	152 1 O
%	153 1 O
glucose	155 7 B-Chemical
solution	163 8 O
for	172 3 O
spinal	176 6 O
anaesthesia	183 11 O
were	195 4 O
studied	200 7 O
.	207 1 O

Thirteen	209 8 O
of	218 2 O
these	221 5 O
patients	227 8 O
experienced	236 11 O
pain	248 4 B-Disease
in	253 2 I-Disease
the	256 3 I-Disease
legs	260 4 I-Disease
and	265 3 I-Disease
/	268 1 I-Disease
or	269 2 I-Disease
back	272 4 I-Disease
after	277 5 O
recovery	283 8 O
from	292 4 O
anaesthesia	297 11 O
.	308 1 O

The	310 3 O
patients	314 8 O
affected	323 8 O
were	332 4 O
younger	337 7 O
(	345 1 O
p	346 1 O
<	348 1 O
0	350 1 O
.	351 1 O
05	352 2 O
)	354 1 O
and	356 3 O
the	360 3 O
site	364 4 O
of	369 2 O
the	372 3 O
dural	376 5 O
puncture	382 8 O
was	391 3 O
higher	395 6 O
(	402 1 O
p	403 1 O
<	405 1 O
0	407 1 O
.	408 1 O
01	409 2 O
)	411 1 O
than	413 4 O
those	418 5 O
individuals	424 11 O
without	436 7 O
pain	444 4 B-Disease
.	448 1 O

Five	450 4 O
of	455 2 O
the	458 3 O
13	462 2 O
patients	465 8 O
(	474 1 O
38	475 2 O
%	477 1 O
)	478 1 O
with	480 4 O
pain	485 4 B-Disease
and	490 3 O
seven	494 5 O
of	500 2 O
the	503 3 O
41	507 2 O
patients	510 8 O
(	519 1 O
17	520 2 O
%	522 1 O
)	523 1 O
without	525 7 O
pain	533 4 B-Disease
admitted	538 8 O
to	547 2 O
a	550 1 O
high	552 4 O
alcohol	557 7 B-Chemical
intake	565 6 O
,	571 1 O
which	573 5 O
might	579 5 O
be	585 2 O
a	588 1 O
contributing	590 12 O
factor	603 6 O
.	609 1 O

Leg	611 3 B-Disease
and	615 3 I-Disease
/	618 1 I-Disease
or	619 2 I-Disease
back	622 4 I-Disease
pain	627 4 I-Disease
is	632 2 O
associated	635 10 O
with	646 4 O
the	651 3 O
intrathecal	655 11 O
use	667 3 O
of	671 2 O
hyperbaric	674 10 O
5	685 1 O
%	686 1 O
lignocaine	688 10 B-Chemical
.	698 1 O

Acute	0 5 O
blood	6 5 O
pressure	12 8 O
elevations	21 10 O
with	32 4 O
caffeine	37 8 B-Chemical
in	46 2 O
men	49 3 O
with	53 4 O
borderline	58 10 O
systemic	69 8 O
hypertension	78 12 B-Disease
.	90 1 O

Whether	92 7 O
the	100 3 O
vasoconstrictive	104 16 O
actions	121 7 O
of	129 2 O
caffeine	132 8 B-Chemical
are	141 3 O
enhanced	145 8 O
in	154 2 O
hypertensive	157 12 B-Disease
persons	170 7 O
has	178 3 O
not	182 3 O
been	186 4 O
demonstrated	191 12 O
.	203 1 O

Thus	205 4 O
,	209 1 O
caffeine	211 8 B-Chemical
(	220 1 O
3	221 1 O
.	222 1 O
3	223 1 O
mg	225 2 O
/	227 1 O
kg	228 2 O
)	230 1 O
versus	232 6 O
placebo	239 7 O
was	247 3 O
tested	251 6 O
in	258 2 O
48	261 2 O
healthy	264 7 O
men	272 3 O
(	276 1 O
aged	277 4 O
20	282 2 O
to	285 2 O
35	288 2 O
years	291 5 O
)	296 1 O
selected	298 8 O
after	307 5 O
screening	313 9 O
on	323 2 O
2	326 1 O
separate	328 8 O
occasions	337 9 O
.	346 1 O

Borderline	348 10 O
hypertensive	359 12 B-Disease
men	372 3 O
(	376 1 O
n	377 1 O
=	379 1 O
24	381 2 O
)	383 1 O
were	385 4 O
selected	390 8 O
with	399 4 O
screening	404 9 O
systolic	414 8 O
blood	423 5 O
pressure	429 8 O
(	438 1 O
BP	439 2 O
)	441 1 O
of	443 2 O
140	446 3 O
to	450 2 O
160	453 3 O
mm	457 2 O
Hg	460 2 O
and	463 3 O
/	466 1 O
or	467 2 O
diastolic	470 9 O
BP	480 2 O
90	483 2 O
to	486 2 O
99	489 2 O
mm	492 2 O
Hg	495 2 O
.	497 1 O

Low	499 3 O
-	502 1 O
risk	503 4 O
controls	508 8 O
(	517 1 O
n	518 1 O
=	520 1 O
24	522 2 O
)	524 1 O
reported	526 8 O
no	535 2 O
parental	538 8 O
history	547 7 O
of	555 2 O
hypertension	558 12 B-Disease
and	571 3 O
had	575 3 O
screening	579 9 O
BP	589 2 O
<	592 1 O
130	594 3 O
/	597 1 O
85	598 2 O
mm	601 2 O
Hg	604 2 O
.	606 1 O

Participants	608 12 O
were	621 4 O
then	626 4 O
tested	631 6 O
on	638 2 O
2	641 1 O
occasions	643 9 O
after	653 5 O
12	659 2 O
-	661 1 O
hour	662 4 O
abstinence	667 10 O
from	678 4 O
caffeine	683 8 B-Chemical
in	692 2 O
each	695 4 O
of	700 2 O
2	703 1 O
protocols	705 9 O
;	714 1 O
this	716 4 O
required	721 8 O
a	730 1 O
total	732 5 O
of	738 2 O
4	741 1 O
laboratory	743 10 O
visits	754 6 O
.	760 1 O

Caffeine	762 8 B-Chemical
-	770 1 O
induced	771 7 O
changes	779 7 O
in	787 2 O
diastolic	790 9 O
BP	800 2 O
were	803 4 O
2	808 1 O
to	810 2 O
3	813 1 O
times	815 5 O
larger	821 6 O
in	828 2 O
borderline	831 10 O
subjects	842 8 O
than	851 4 O
in	856 2 O
controls	859 8 O
(	868 1 O
+	869 1 O
8	870 1 O
.	871 1 O
4	872 1 O
vs	874 2 O
+	877 1 O
3	878 1 O
.	879 1 O
8	880 1 O
mm	882 2 O
Hg	885 2 O
,	887 1 O
p	889 1 O
<	891 1 O
0	893 1 O
.	894 1 O
0001	895 4 O
)	899 1 O
,	900 1 O
and	902 3 O
were	906 4 O
attributable	911 12 O
to	924 2 O
larger	927 6 O
changes	934 7 O
in	942 2 O
impedance	945 9 O
-	954 1 O
derived	955 7 O
measures	963 8 O
of	972 2 O
systemic	975 8 O
vascular	984 8 O
resistance	993 10 O
(	1004 1 O
+	1005 1 O
135	1006 3 O
vs	1010 2 O
+	1013 1 O
45	1014 2 O
dynes	1017 5 O
.	1022 1 O
s	1023 1 O
.	1024 1 O
cm	1025 2 O
-	1027 1 O
5	1028 1 O
,	1029 1 O
p	1031 1 O
<	1033 1 O
0	1035 1 O
.	1036 1 O
004	1037 3 O
)	1040 1 O
.	1041 1 O

These	1043 5 O
findings	1049 8 O
were	1058 4 O
consistent	1063 10 O
and	1074 3 O
reached	1078 7 O
significance	1086 12 O
in	1099 2 O
both	1102 4 O
protocols	1107 9 O
.	1116 1 O

The	1118 3 O
percentage	1122 10 O
of	1133 2 O
borderline	1136 10 O
subjects	1147 8 O
in	1156 2 O
whom	1159 4 O
diastolic	1164 9 O
BP	1174 2 O
changes	1177 7 O
exceeded	1185 8 O
the	1194 3 O
median	1198 6 O
control	1205 7 O
response	1213 8 O
was	1222 3 O
96	1226 2 O
%	1228 1 O
.	1229 1 O

Consequently	1231 12 O
,	1243 1 O
whereas	1245 7 O
all	1253 3 O
participants	1257 12 O
exhibited	1270 9 O
normotensive	1280 12 O
levels	1293 6 O
during	1300 6 O
the	1307 3 O
resting	1311 7 O
predrug	1319 7 O
baseline	1327 8 O
,	1335 1 O
33	1337 2 O
%	1339 1 O
of	1341 2 O
borderline	1344 10 O
subjects	1355 8 O
achieved	1364 8 O
hypertensive	1373 12 B-Disease
BP	1386 2 O
levels	1389 6 O
after	1396 5 O
caffeine	1402 8 B-Chemical
ingestion	1411 9 O
.	1420 1 O

Thus	1422 4 O
,	1426 1 O
in	1428 2 O
borderline	1431 10 O
hypertensive	1442 12 B-Disease
men	1455 3 O
,	1458 1 O
exaggerated	1460 11 O
responses	1472 9 O
to	1482 2 O
caffeine	1485 8 B-Chemical
were	1494 4 O
:	1498 1 O
selective	1500 9 O
for	1510 3 O
diastolic	1514 9 O
BP	1524 2 O
,	1526 1 O
consistent	1528 10 O
with	1539 4 O
greater	1544 7 O
vasoconstriction	1552 16 O
,	1568 1 O
replicated	1570 10 O
in	1581 2 O
2	1584 1 O
protocols	1586 9 O
,	1595 1 O
and	1597 3 O
representative	1601 14 O
of	1616 2 O
nearly	1619 6 O
all	1626 3 O
borderline	1630 10 O
hypertensives	1641 13 B-Disease
.	1654 1 O

We	1656 2 O
suspect	1659 7 O
that	1667 4 O
the	1672 3 O
potential	1676 9 O
for	1686 3 O
caffeine	1690 8 B-Chemical
to	1699 2 O
stabilize	1702 9 O
high	1712 4 O
resistance	1717 10 O
states	1728 6 O
in	1735 2 O
susceptible	1738 11 O
persons	1750 7 O
suggests	1758 8 O
that	1767 4 O
its	1772 3 O
use	1776 3 O
may	1780 3 O
facilitate	1784 10 O
their	1795 5 O
disease	1801 7 O
progression	1809 11 O
,	1820 1 O
as	1822 2 O
well	1825 4 O
as	1830 2 O
hinder	1833 6 O
accurate	1840 8 O
diagnosis	1849 9 O
and	1859 3 O
treatment	1863 9 O
.	1872 1 O

Hallucinations	0 14 B-Disease
and	15 3 O
ifosfamide	19 10 B-Chemical
-	29 1 O
induced	30 7 O
neurotoxicity	38 13 B-Disease
.	51 1 O

BACKGROUND	53 10 O
:	63 1 O
Hallucinations	65 14 B-Disease
as	80 2 O
a	83 1 O
symptom	85 7 O
of	93 2 O
central	96 7 O
neurotoxicity	104 13 B-Disease
are	118 3 O
a	122 1 O
known	124 5 O
but	130 3 O
poorly	134 6 O
described	141 9 O
side	151 4 O
effect	156 6 O
of	163 2 O
ifosfamide	166 10 B-Chemical
.	176 1 O

Most	178 4 O
cases	183 5 O
of	189 2 O
ifosfamide	192 10 B-Chemical
-	202 1 O
induced	203 7 O
hallucinations	211 14 B-Disease
have	226 4 O
been	231 4 O
reported	236 8 O
with	245 4 O
other	250 5 O
mental	256 6 O
status	263 6 O
changes	270 7 O
.	277 1 O

METHODS	279 7 O
:	286 1 O
The	288 3 O
authors	292 7 O
interviewed	300 11 O
six	312 3 O
persons	316 7 O
with	324 4 O
ifosfamide	329 10 B-Chemical
-	339 1 O
induced	340 7 O
hallucinations	348 14 B-Disease
in	363 2 O
the	366 3 O
presence	370 8 O
of	379 2 O
a	382 1 O
clear	384 5 O
sensorium	390 9 O
.	399 1 O

All	401 3 O
patients	405 8 O
were	414 4 O
receiving	419 9 O
high	429 4 O
-	433 1 O
dose	434 4 O
ifosfamide	439 10 B-Chemical
as	450 2 O
part	453 4 O
of	458 2 O
their	461 5 O
bone	467 4 O
marrow	472 6 O
transplant	479 10 O
procedure	490 9 O
.	499 1 O

RESULTS	501 7 O
:	508 1 O
Hallucinations	510 14 B-Disease
occurred	525 8 O
only	534 4 O
when	539 4 O
the	544 3 O
patient	548 7 O
'	555 1 O
s	556 1 O
eyes	558 4 O
were	563 4 O
closed	568 6 O
and	575 3 O
,	578 1 O
in	580 2 O
all	583 3 O
but	587 3 O
one	591 3 O
case	595 4 O
,	599 1 O
were	601 4 O
reported	606 8 O
as	615 2 O
disturbing	618 10 O
or	629 2 O
frightening	632 11 O
.	643 1 O

Underreporting	645 14 O
of	660 2 O
these	663 5 O
hallucinations	669 14 B-Disease
by	684 2 O
patients	687 8 O
is	696 2 O
likely	699 6 O
.	705 1 O

CONCLUSIONS	707 11 O
:	718 1 O
Hallucinations	720 14 B-Disease
may	735 3 O
be	739 2 O
the	742 3 O
sole	746 4 O
or	751 2 O
first	754 5 O
manifestation	760 13 O
of	774 2 O
neurotoxicity	777 13 B-Disease
.	790 1 O

The	792 3 O
incidence	796 9 O
may	806 3 O
be	810 2 O
dose	813 4 O
and	818 3 O
infusion	822 8 O
-	830 1 O
time	831 4 O
related	836 7 O
.	843 1 O

The	845 3 O
clinician	849 9 O
should	859 6 O
be	866 2 O
alerted	869 7 O
for	877 3 O
possible	881 8 O
ifosfamide	890 10 B-Chemical
-	900 1 O
induced	901 7 O
hallucinations	909 14 B-Disease
,	923 1 O
which	925 5 O
may	931 3 O
occur	935 5 O
without	941 7 O
other	949 5 O
signs	955 5 O
of	961 2 O
neurotoxicity	964 13 B-Disease
.	977 1 O

"	979 1 O
Eyes	980 4 O
-	984 1 O
closed	985 6 O
"	991 1 O
hallucinatory	993 13 B-Disease
experiences	1007 11 O
appear	1019 6 O
to	1026 2 O
be	1029 2 O
an	1032 2 O
unusual	1035 7 O
feature	1043 7 O
of	1051 2 O
this	1054 4 O
presentation	1059 12 O
.	1071 1 O

Patients	1073 8 O
anxious	1082 7 O
about	1090 5 O
this	1096 4 O
experience	1101 10 O
respond	1112 7 O
well	1120 4 O
to	1125 2 O
support	1128 7 O
and	1136 3 O
education	1140 9 O
about	1150 5 O
this	1156 4 O
occurrence	1161 10 O
.	1171 1 O

Optimal	1173 7 O
pharmacologic	1181 13 O
management	1195 10 O
of	1206 2 O
disturbed	1209 9 O
patients	1219 8 O
is	1228 2 O
unclear	1231 7 O
.	1238 1 O

If	1240 2 O
agitation	1243 9 B-Disease
becomes	1253 7 O
marked	1261 6 O
,	1267 1 O
high	1269 4 O
-	1273 1 O
potency	1274 7 O
neuroleptics	1282 12 O
(	1295 1 O
i	1296 1 O
.	1297 1 O
e	1298 1 O
.	1299 1 O
,	1300 1 O
haloperidol	1302 11 B-Chemical
)	1313 1 O
may	1315 3 O
be	1319 2 O
effective	1322 9 O
.	1331 1 O

Chlorpropamide	0 14 B-Chemical
-	14 1 O
induced	15 7 O
optic	23 5 B-Disease
neuropathy	29 10 I-Disease
.	39 1 O

A	41 1 O
65	43 2 O
-	45 1 O
year	46 4 O
-	50 1 O
old	51 3 O
woman	55 5 O
with	61 4 O
adult	66 5 B-Disease
-	71 1 I-Disease
onset	72 5 I-Disease
diabetes	78 8 I-Disease
treated	87 7 O
with	95 4 O
chlorpropamide	100 14 B-Chemical
(	115 1 O
Diabenese	116 9 B-Chemical
)	125 1 O
had	127 3 O
a	131 1 O
toxic	133 5 B-Disease
optic	139 5 I-Disease
neuropathy	145 10 I-Disease
that	156 4 O
resolved	161 8 O
with	170 4 O
discontinuation	175 15 O
of	191 2 O
chlorpropamide	194 14 B-Chemical
therapy	209 7 O
.	216 1 O

Visual	218 6 B-Disease
loss	225 4 I-Disease
occurs	230 6 O
in	237 2 O
diabetics	240 9 B-Disease
for	250 3 O
a	254 1 O
variety	256 7 O
of	264 2 O
reasons	267 7 O
,	274 1 O
and	276 3 O
accurate	280 8 O
diagnosis	289 9 O
is	299 2 O
necessary	302 9 O
to	312 2 O
institute	315 9 O
appropriate	325 11 O
therapy	337 7 O
.	344 1 O

The	346 3 O
possibility	350 11 O
of	362 2 O
a	365 1 O
drug	367 4 O
-	371 1 O
induced	372 7 O
optic	380 5 B-Disease
neuropathy	386 10 I-Disease
should	397 6 O
be	404 2 O
considered	407 10 O
in	418 2 O
the	421 3 O
differential	425 12 O
diagnosis	438 9 O
of	448 2 O
visual	451 6 B-Disease
loss	458 4 I-Disease
in	463 2 O
diabetics	466 9 B-Disease
.	475 1 O

Levodopa	0 8 B-Chemical
-	8 1 O
induced	9 7 O
dyskinesia	17 10 B-Disease
and	28 3 O
thalamotomy	32 11 O
.	43 1 O

Levodopa	45 8 B-Chemical
-	53 1 O
induced	54 7 O
dyskinesia	62 10 B-Disease
of	73 2 O
the	76 3 O
limbs	80 5 O
in	86 2 O
thirteen	89 8 O
cases	98 5 O
of	104 2 O
Parkinsonism	107 12 B-Disease
,	119 1 O
which	121 5 O
was	127 3 O
choreic	131 7 O
,	138 1 O
ballistic	140 9 O
or	150 2 O
dystonic	153 8 B-Disease
in	162 2 O
type	165 4 O
,	169 1 O
was	171 3 O
alleviated	175 10 O
almost	186 6 O
completely	193 10 O
by	204 2 O
stereotaxic	207 11 O
surgery	219 7 O
using	227 5 O
a	233 1 O
microelectrode	235 14 O
technique	250 9 O
for	260 3 O
the	264 3 O
ventralis	268 9 O
oralis	278 6 O
anterior	285 8 O
and	294 3 O
posterior	298 9 O
nuclei	308 6 O
of	315 2 O
the	318 3 O
thalamus	322 8 O
,	330 1 O
but	332 3 O
much	336 4 O
less	341 4 O
by	346 2 O
the	349 3 O
ventralis	353 9 O
intermedius	363 11 O
nucleus	375 7 O
.	382 1 O

Control	384 7 O
of	392 2 O
levodopa	395 8 B-Chemical
-	403 1 O
induced	404 7 O
dyskinesias	412 11 B-Disease
by	424 2 O
thalamic	427 8 B-Disease
lesions	436 7 I-Disease
in	444 2 O
the	447 3 O
course	451 6 O
of	458 2 O
routine	461 7 O
treatment	469 9 O
of	479 2 O
Parkinsonism	482 12 B-Disease
is	495 2 O
discussed	498 9 O
.	507 1 O

Factors	0 7 O
associated	8 10 O
with	19 4 O
nephrotoxicity	24 14 B-Disease
and	39 3 O
clinical	43 8 O
outcome	52 7 O
in	60 2 O
patients	63 8 O
receiving	72 9 O
amikacin	82 8 B-Chemical
.	90 1 O

Data	92 4 O
from	97 4 O
60	102 2 O
patients	105 8 O
treated	114 7 O
with	122 4 O
amikacin	127 8 B-Chemical
were	136 4 O
analyzed	141 8 O
for	150 3 O
factors	154 7 O
associated	162 10 O
with	173 4 O
nephrotoxicity	178 14 B-Disease
.	192 1 O

In	194 2 O
42	197 2 O
of	200 2 O
these	203 5 O
patients	209 8 O
,	217 1 O
data	219 4 O
were	224 4 O
examined	229 8 O
for	238 3 O
factors	242 7 O
associated	250 10 O
with	261 4 O
clinical	266 8 O
outcome	275 7 O
.	282 1 O

Variables	284 9 O
evaluated	294 9 O
included	304 8 O
patient	313 7 O
weight	321 6 O
,	327 1 O
age	329 3 O
,	332 1 O
sex	334 3 O
,	337 1 O
serum	339 5 O
creatinine	345 10 B-Chemical
level	356 5 O
,	361 1 O
creatinine	363 10 B-Chemical
clearance	374 9 O
,	383 1 O
duration	385 8 O
of	394 2 O
therapy	397 7 O
,	404 1 O
total	406 5 O
dose	412 4 O
,	416 1 O
mean	418 4 O
daily	423 5 O
dose	429 4 O
,	433 1 O
organism	435 8 O
minimum	444 7 O
inhibitory	452 10 O
concentration	463 13 O
(	477 1 O
MIC	478 3 O
)	481 1 O
,	482 1 O
mean	484 4 O
peak	489 4 O
levels	494 6 O
,	500 1 O
mean	502 4 O
trough	507 6 O
levels	514 6 O
,	520 1 O
mean	522 4 O
area	527 4 O
under	532 5 O
the	538 3 O
serum	542 5 O
concentration	548 13 O
-	561 1 O
time	562 4 O
curve	567 5 O
(	573 1 O
AUC	574 3 O
)	577 1 O
,	578 1 O
total	580 5 O
AUC	586 3 O
,	589 1 O
mean	591 4 O
AUC	596 3 O
greater	600 7 O
than	608 4 O
MIC	613 3 O
,	616 1 O
total	618 5 O
AUC	624 3 O
greater	628 7 O
than	636 4 O
MIC	641 3 O
,	644 1 O
mean	646 4 O
Schumacher	651 10 O
'	661 1 O
s	662 1 O
intensity	664 9 O
factor	674 6 O
(	681 1 O
IF	682 2 O
)	684 1 O
,	685 1 O
total	687 5 O
IF	693 2 O
,	695 1 O
In	697 2 O
(	700 1 O
mean	701 4 O
maximum	706 7 O
concentration	714 13 O
[	728 1 O
Cmax	729 4 O
]	733 1 O
/	734 1 O
MIC	735 3 O
)	738 1 O
.	739 1 O

Model	741 5 O
-	746 1 O
dependent	747 9 O
pharmacokinetic	757 15 O
parameters	773 10 O
were	784 4 O
calculated	789 10 O
by	800 2 O
computer	803 8 O
based	812 5 O
on	818 2 O
a	821 1 O
one	823 3 O
-	826 1 O
compartment	827 11 O
model	839 5 O
.	844 1 O

When	846 4 O
the	851 3 O
parameters	855 10 O
were	866 4 O
examined	871 8 O
individually	880 12 O
,	892 1 O
duration	894 8 O
of	903 2 O
therapy	906 7 O
and	914 3 O
total	918 5 O
AUC	924 3 O
correlated	928 10 O
significantly	939 13 O
(	953 1 O
P	954 1 O
less	956 4 O
than	961 4 O
.	966 1 O
05	967 2 O
)	969 1 O
with	971 4 O
nephrotoxicity	976 14 B-Disease
.	990 1 O

In	992 2 O
contrast	995 8 O
,	1003 1 O
a	1005 1 O
stepwise	1007 8 O
discriminant	1016 12 O
function	1029 8 O
analysis	1038 8 O
identified	1047 10 O
only	1058 4 O
duration	1063 8 O
of	1072 2 O
therapy	1075 7 O
(	1083 1 O
P	1084 1 O
less	1086 4 O
than	1091 4 O
.	1096 1 O
001	1097 3 O
)	1100 1 O
as	1102 2 O
an	1105 2 O
important	1108 9 O
factor	1118 6 O
.	1124 1 O

Based	1126 5 O
on	1132 2 O
this	1135 4 O
model	1140 5 O
and	1146 3 O
on	1150 2 O
Bayes	1153 5 O
'	1158 1 O
theorem	1160 7 O
,	1167 1 O
the	1169 3 O
predictive	1173 10 O
accuracy	1184 8 O
of	1193 2 O
identifying	1196 11 O
"	1208 1 O
nephrotoxic	1209 11 B-Disease
"	1220 1 O
patients	1222 8 O
increased	1231 9 O
from	1241 4 O
0	1246 1 O
.	1247 1 O
17	1248 2 O
to	1251 2 O
0	1254 1 O
.	1255 1 O
39	1256 2 O
.	1258 1 O

When	1260 4 O
examined	1265 8 O
individually	1274 12 O
,	1286 1 O
mean	1288 4 O
IF	1293 2 O
,	1295 1 O
MIC	1297 3 O
,	1300 1 O
total	1302 5 O
dose	1308 4 O
,	1312 1 O
mean	1314 4 O
daily	1319 5 O
dose	1325 4 O
,	1329 1 O
and	1331 3 O
ln	1335 2 O
(	1338 1 O
mean	1339 4 O
Cmax	1344 4 O
/	1348 1 O
MIC	1349 3 O
)	1352 1 O
correlated	1354 10 O
significantly	1365 13 O
(	1379 1 O
P	1380 1 O
less	1382 4 O
than	1387 4 O
.	1392 1 O
05	1393 2 O
)	1395 1 O
with	1397 4 O
cure	1402 4 O
.	1406 1 O

In	1408 2 O
contrast	1411 8 O
,	1419 1 O
a	1421 1 O
simultaneous	1423 12 O
multivariable	1436 13 O
analysis	1450 8 O
identified	1459 10 O
IF	1470 2 O
,	1472 1 O
MIC	1474 3 O
,	1477 1 O
and	1479 3 O
total	1483 5 O
dose	1489 4 O
according	1494 9 O
to	1504 2 O
one	1507 3 O
model	1511 5 O
and	1517 3 O
ln	1521 2 O
(	1524 1 O
mean	1525 4 O
Cmax	1530 4 O
/	1534 1 O
MIC	1535 3 O
)	1538 1 O
according	1540 9 O
to	1550 2 O
a	1553 1 O
second	1555 6 O
statistical	1562 11 O
model	1574 5 O
of	1580 2 O
parameters	1583 10 O
selected	1594 8 O
to	1603 2 O
have	1606 4 O
the	1611 3 O
greatest	1615 8 O
prospective	1624 11 O
value	1636 5 O
.	1641 1 O

Based	1643 5 O
on	1649 2 O
Bayes	1652 5 O
'	1657 1 O
theorem	1659 7 O
and	1667 3 O
the	1671 3 O
first	1675 5 O
model	1681 5 O
,	1686 1 O
the	1688 3 O
predictive	1692 10 O
accuracy	1703 8 O
of	1712 2 O
identifying	1715 11 O
patients	1727 8 O
not	1736 3 O
cured	1740 5 O
increased	1746 9 O
from	1756 4 O
0	1761 1 O
.	1762 1 O
19	1763 2 O
to	1766 2 O
0	1769 1 O
.	1770 1 O
83	1771 2 O
.	1773 1 O

For	1775 3 O
the	1779 3 O
second	1783 6 O
model	1790 5 O
,	1795 1 O
the	1797 3 O
predictive	1801 10 O
accuracy	1812 8 O
increased	1821 9 O
from	1831 4 O
0	1836 1 O
.	1837 1 O
19	1838 2 O
to	1841 2 O
0	1844 1 O
.	1845 1 O
50	1846 2 O
.	1848 1 O
(	1849 1 O
ABSTRACT	1850 8 O
TRUNCATED	1859 9 O
AT	1869 2 O
250	1872 3 O
WORDS	1876 5 O
)	1881 1 O

Cardiac	0 7 O
transplantation	8 15 O
:	23 1 O
improved	25 8 O
quality	34 7 O
of	42 2 O
survival	45 8 O
with	54 4 O
a	59 1 O
modified	61 8 O
immunosuppressive	70 17 O
protocol	88 8 O
.	96 1 O

The	98 3 O
effects	102 7 O
on	110 2 O
renal	113 5 O
function	119 8 O
on	128 2 O
two	131 3 O
different	135 9 O
immunosuppressive	145 17 O
protocols	163 9 O
were	173 4 O
evaluated	178 9 O
retrospectively	188 15 O
in	204 2 O
two	207 3 O
subsequent	211 10 O
groups	222 6 O
of	229 2 O
heart	232 5 O
transplant	238 10 O
recipients	249 10 O
.	259 1 O

In	261 2 O
group	264 5 O
I	270 1 O
,	271 1 O
cyclosporine	273 12 B-Chemical
was	286 3 O
given	290 5 O
before	296 6 O
the	303 3 O
procedure	307 9 O
at	317 2 O
a	320 1 O
loading	322 7 O
dose	330 4 O
of	335 2 O
17	338 2 O
.	340 1 O
5	341 1 O
mg	343 2 O
/	345 1 O
kg	346 2 O
and	349 3 O
then	353 4 O
continued	358 9 O
after	368 5 O
the	374 3 O
procedure	378 9 O
to	388 2 O
keep	391 4 O
a	396 1 O
whole	398 5 O
blood	404 5 O
level	410 5 O
about	416 5 O
1000	422 4 O
ng	427 2 O
/	429 1 O
ml	430 2 O
.	432 1 O

In	434 2 O
group	437 5 O
II	443 2 O
,	445 1 O
cyclosporine	447 12 B-Chemical
was	460 3 O
started	464 7 O
only	472 4 O
after	477 5 O
the	483 3 O
procedure	487 9 O
at	497 2 O
a	500 1 O
lower	502 5 O
dosage	508 6 O
and	515 3 O
was	519 3 O
complemented	523 12 O
by	536 2 O
azathioprine	539 12 B-Chemical
,	551 1 O
which	553 5 O
was	559 3 O
used	563 4 O
for	568 3 O
the	572 3 O
first	576 5 O
postoperative	582 13 O
week	596 4 O
.	600 1 O

Group	602 5 O
II	608 2 O
showed	611 6 O
a	618 1 O
better	620 6 O
perioperative	627 13 O
renal	641 5 O
function	647 8 O
as	656 2 O
determined	659 10 O
by	670 2 O
serum	673 5 O
blood	679 5 O
urea	685 4 B-Chemical
nitrogen	690 8 I-Chemical
and	699 3 O
serum	703 5 O
creatinine	709 10 B-Chemical
levels	720 6 O
.	726 1 O

Group	728 5 O
II	734 2 O
also	737 4 O
showed	742 6 O
a	749 1 O
significant	751 11 O
decrease	763 8 O
of	772 2 O
chronic	775 7 O
nephrotoxicity	783 14 B-Disease
secondary	798 9 O
to	808 2 O
long	811 4 O
-	815 1 O
term	816 4 O
therapy	821 7 O
with	829 4 O
cyclosporine	834 12 B-Chemical
.	846 1 O

Despite	848 7 O
this	856 4 O
improvement	861 11 O
in	873 2 O
late	876 4 O
renal	881 5 O
function	887 8 O
,	895 1 O
group	897 5 O
II	903 2 O
still	906 5 O
shows	912 5 O
a	918 1 O
slow	920 4 O
rise	925 4 O
in	930 2 O
serum	933 5 O
creatinine	939 10 B-Chemical
.	949 1 O

We	951 2 O
think	954 5 O
that	960 4 O
even	965 4 O
these	970 5 O
lower	976 5 O
dosages	982 7 O
of	990 2 O
cyclosporine	993 12 B-Chemical
can	1006 3 O
cause	1010 5 O
chronic	1016 7 O
nephrotoxicity	1024 14 B-Disease
and	1039 3 O
that	1043 4 O
further	1048 7 O
modification	1056 12 O
of	1069 2 O
the	1072 3 O
immunosuppressive	1076 17 O
regimen	1094 7 O
is	1102 2 O
required	1105 8 O
to	1114 2 O
completely	1117 10 O
abolish	1128 7 O
this	1136 4 O
toxic	1141 5 O
side	1147 4 O
effect	1152 6 O
.	1158 1 O

Reversible	0 10 O
cholestasis	11 11 B-Disease
with	23 4 O
bile	28 4 B-Disease
duct	33 4 I-Disease
injury	38 6 I-Disease
following	45 9 O
azathioprine	55 12 B-Chemical
therapy	68 7 O
.	75 1 O

A	77 1 O
case	79 4 O
report	84 6 O
.	90 1 O

A	92 1 O
67	94 2 O
-	96 1 O
year	97 4 O
-	101 1 O
old	102 3 O
patient	106 7 O
,	113 1 O
with	115 4 O
primary	120 7 O
polymyositis	128 12 B-Disease
and	141 3 O
without	145 7 O
previous	153 8 O
evidence	162 8 O
of	171 2 O
liver	174 5 B-Disease
disease	180 7 I-Disease
,	187 1 O
developed	189 9 O
clinical	199 8 O
and	208 3 O
biochemical	212 11 O
features	224 8 O
of	233 2 O
severe	236 6 O
cholestasis	243 11 B-Disease
3	255 1 O
months	257 6 O
after	264 5 O
initiation	270 10 O
of	281 2 O
azathioprine	284 12 B-Chemical
therapy	297 7 O
.	304 1 O

Liver	306 5 O
biopsy	312 6 O
showed	319 6 O
cholestasis	326 11 B-Disease
with	338 4 O
both	343 4 O
cytological	348 11 O
and	360 3 O
architectural	364 13 O
alterations	378 11 O
of	390 2 O
interlobular	393 12 O
bile	406 4 O
ducts	411 5 O
.	416 1 O

Azathioprine	418 12 B-Chemical
withdrawal	431 10 O
resulted	442 8 O
after	451 5 O
7	457 1 O
weeks	459 5 O
in	465 2 O
the	468 3 O
resolution	472 10 O
of	483 2 O
clinical	486 8 O
and	495 3 O
biochemical	499 11 O
abnormalities	511 13 O
.	524 1 O

It	526 2 O
is	529 2 O
believed	532 8 O
that	541 4 O
this	546 4 O
is	551 2 O
the	554 3 O
first	558 5 O
reported	564 8 O
case	573 4 O
of	578 2 O
reversible	581 10 O
azathioprine	592 12 B-Chemical
-	604 1 O
induced	605 7 O
cholestasis	613 11 B-Disease
associated	625 10 O
with	636 4 O
histological	641 12 O
evidence	654 8 O
of	663 2 O
bile	666 4 B-Disease
duct	671 4 I-Disease
injury	676 6 I-Disease
.	682 1 O

Renal	0 5 O
function	6 8 O
and	15 3 O
hemodynamics	19 12 O
during	32 6 O
prolonged	39 9 O
isoflurane	49 10 B-Chemical
-	59 1 O
induced	60 7 O
hypotension	68 11 B-Disease
in	80 2 O
humans	83 6 O
.	89 1 O

The	91 3 O
effect	95 6 O
of	102 2 O
isoflurane	105 10 B-Chemical
-	115 1 O
induced	116 7 O
hypotension	124 11 B-Disease
on	136 2 O
glomerular	139 10 O
function	150 8 O
and	159 3 O
renal	163 5 O
blood	169 5 O
flow	175 4 O
was	180 3 O
investigated	184 12 O
in	197 2 O
20	200 2 O
human	203 5 O
subjects	209 8 O
.	217 1 O

Glomerular	219 10 O
filtration	230 10 O
rate	241 4 O
(	246 1 O
GFR	247 3 O
)	250 1 O
and	252 3 O
effective	256 9 O
renal	266 5 O
plasma	272 6 O
flow	279 4 O
(	284 1 O
ERPF	285 4 O
)	289 1 O
were	291 4 O
measured	296 8 O
by	305 2 O
inulin	308 6 O
and	315 3 O
para	319 4 B-Chemical
-	323 1 I-Chemical
aminohippurate	324 14 I-Chemical
(	339 1 O
PAH	340 3 B-Chemical
)	343 1 O
clearance	345 9 O
,	354 1 O
respectively	356 12 O
.	368 1 O

Anesthesia	370 10 O
was	381 3 O
maintained	385 10 O
with	396 4 O
fentanyl	401 8 B-Chemical
,	409 1 O
nitrous	411 7 B-Chemical
oxide	419 5 I-Chemical
,	424 1 O
oxygen	426 6 B-Chemical
,	432 1 O
and	434 3 O
isoflurane	438 10 B-Chemical
.	448 1 O

Hypotension	450 11 B-Disease
was	462 3 O
induced	466 7 O
for	474 3 O
236	478 3 O
.	481 1 O
9	482 1 O
+	484 1 O
/	485 1 O
-	486 1 O
15	488 2 O
.	490 1 O
1	491 1 O
min	493 3 O
by	497 2 O
increasing	500 10 O
the	511 3 O
isoflurane	515 10 B-Chemical
inspired	526 8 O
concentration	535 13 O
to	549 2 O
maintain	552 8 O
a	561 1 O
mean	563 4 O
arterial	568 8 O
pressure	577 8 O
of	586 2 O
59	589 2 O
.	591 1 O
8	592 1 O
+	594 1 O
/	595 1 O
-	596 1 O
0	598 1 O
.	599 1 O
4	600 1 O
mmHg	602 4 O
.	606 1 O

GFR	608 3 O
and	612 3 O
ERPF	616 4 O
decreased	621 9 O
with	631 4 O
the	636 3 O
induction	640 9 O
of	650 2 O
anesthesia	653 10 O
but	664 3 O
not	668 3 O
significantly	672 13 O
more	686 4 O
during	691 6 O
hypotension	698 11 B-Disease
.	709 1 O

Postoperatively	711 15 O
,	726 1 O
ERPF	728 4 O
returned	733 8 O
to	742 2 O
preoperative	745 12 O
values	758 6 O
,	764 1 O
whereas	766 7 O
GFR	774 3 O
was	778 3 O
higher	782 6 O
than	789 4 O
preoperative	794 12 O
values	807 6 O
.	813 1 O

Renal	815 5 O
vascular	821 8 O
resistance	830 10 O
increased	841 9 O
during	851 6 O
anesthesia	858 10 O
but	869 3 O
decreased	873 9 O
when	883 4 O
hypotension	888 11 B-Disease
was	900 3 O
induced	904 7 O
,	911 1 O
allowing	913 8 O
the	922 3 O
maintenance	926 11 O
of	938 2 O
renal	941 5 O
blood	947 5 O
flow	953 4 O
.	957 1 O

We	959 2 O
conclude	962 8 O
that	971 4 O
renal	976 5 O
compensatory	982 12 O
mechanisms	995 10 O
are	1006 3 O
preserved	1010 9 O
during	1020 6 O
isoflurane	1027 10 B-Chemical
-	1037 1 O
induced	1038 7 O
hypotension	1046 11 B-Disease
and	1058 3 O
that	1062 4 O
renal	1067 5 O
function	1073 8 O
and	1082 3 O
hemodynamics	1086 12 O
quickly	1099 7 O
return	1107 6 O
to	1114 2 O
normal	1117 6 O
when	1124 4 O
normotension	1129 12 O
is	1142 2 O
resumed	1145 7 O
.	1152 1 O

Debrisoquine	0 12 B-Chemical
phenotype	13 9 O
and	23 3 O
the	27 3 O
pharmacokinetics	31 16 O
and	48 3 O
beta	52 4 O
-	56 1 O
2	57 1 O
receptor	59 8 O
pharmacodynamics	68 16 O
of	85 2 O
metoprolol	88 10 B-Chemical
and	99 3 O
its	103 3 O
enantiomers	107 11 O
.	118 1 O

The	120 3 O
metabolism	124 10 O
of	135 2 O
the	138 3 O
cardioselective	142 15 O
beta	158 4 O
-	162 1 O
blocker	163 7 O
metoprolol	171 10 B-Chemical
is	182 2 O
under	185 5 O
genetic	191 7 O
control	199 7 O
of	207 2 O
the	210 3 O
debrisoquine	214 12 B-Chemical
/	226 1 O
sparteine	227 9 B-Chemical
type	237 4 O
.	241 1 O

The	243 3 O
two	247 3 O
metabolic	251 9 O
phenotypes	261 10 O
,	271 1 O
extensive	273 9 O
(	283 1 O
EM	284 2 O
)	286 1 O
and	288 3 O
poor	292 4 O
metabolizers	297 12 O
(	310 1 O
PM	311 2 O
)	313 1 O
,	314 1 O
show	316 4 O
different	321 9 O
stereoselective	331 15 O
metabolism	347 10 O
,	357 1 O
resulting	359 9 O
in	369 2 O
apparently	372 10 O
higher	383 6 O
beta	390 4 O
-	394 1 O
1	395 1 O
adrenoceptor	397 12 O
antagonistic	410 12 O
potency	423 7 O
of	431 2 O
racemic	434 7 O
metoprolol	442 10 B-Chemical
in	453 2 O
EMs	456 3 O
.	459 1 O

We	461 2 O
investigated	464 12 O
if	477 2 O
the	480 3 O
latter	484 6 O
also	491 4 O
applies	496 7 O
to	504 2 O
the	507 3 O
beta	511 4 O
-	515 1 O
2	516 1 O
adrenoceptor	518 12 O
antagonism	531 10 O
by	542 2 O
metoprolol	545 10 B-Chemical
.	555 1 O

The	557 3 O
drug	561 4 O
effect	566 6 O
studied	573 7 O
was	581 3 O
the	585 3 O
antagonism	589 10 O
by	600 2 O
metoprolol	603 10 B-Chemical
of	614 2 O
terbutaline	617 11 B-Chemical
-	628 1 O
induced	629 7 O
hypokalemia	637 11 B-Disease
.	648 1 O

By	650 2 O
using	653 5 O
pharmacokinetic	659 15 O
pharmacodynamic	675 15 O
modeling	691 8 O
the	700 3 O
pharmacodynamics	704 16 O
of	721 2 O
racemic	724 7 O
metoprolol	732 10 B-Chemical
and	743 3 O
the	747 3 O
active	751 6 O
S	758 1 O
-	759 1 O
isomer	760 6 O
,	766 1 O
were	768 4 O
quantitated	773 11 O
in	785 2 O
EMs	788 3 O
and	792 3 O
PMs	796 3 O
in	800 2 O
terms	803 5 O
of	809 2 O
IC50	812 4 O
values	817 6 O
,	823 1 O
representing	825 12 O
metoprolol	838 10 B-Chemical
plasma	849 6 O
concentrations	856 14 O
resulting	871 9 O
in	881 2 O
half	884 4 O
-	888 1 O
maximum	889 7 O
receptor	897 8 O
occupancy	906 9 O
.	915 1 O

Six	917 3 O
EMs	921 3 O
received	925 8 O
0	934 1 O
.	935 1 O
5	936 1 O
mg	938 2 O
of	941 2 O
terbutaline	944 11 B-Chemical
s	956 1 O
.	957 1 O
c	958 1 O
.	959 1 O
on	961 2 O
two	964 3 O
different	968 9 O
occasions	978 9 O
:	987 1 O
1	989 1 O
)	990 1 O
1	992 1 O
hr	994 2 O
after	997 5 O
administration	1003 14 O
of	1018 2 O
a	1021 1 O
placebo	1023 7 O
and	1031 3 O
2	1035 1 O
)	1036 1 O
1	1038 1 O
hr	1040 2 O
after	1043 5 O
150	1049 3 O
mg	1053 2 O
of	1056 2 O
metoprolol	1059 10 B-Chemical
p	1070 1 O
.	1071 1 O
o	1072 1 O
.	1073 1 O

Five	1075 4 O
PMs	1080 3 O
were	1084 4 O
studied	1089 7 O
according	1097 9 O
to	1107 2 O
the	1110 3 O
same	1114 4 O
protocol	1119 8 O
,	1127 1 O
except	1129 6 O
for	1136 3 O
a	1140 1 O
higher	1142 6 O
terbutaline	1149 11 B-Chemical
dose	1161 4 O
(	1166 1 O
0	1167 1 O
.	1168 1 O
75	1169 2 O
mg	1172 2 O
)	1174 1 O
on	1176 2 O
day	1179 3 O
2	1183 1 O
.	1184 1 O

Blood	1186 5 O
samples	1192 7 O
for	1200 3 O
the	1204 3 O
analysis	1208 8 O
of	1217 2 O
plasma	1220 6 O
potassium	1227 9 B-Chemical
,	1236 1 O
terbutaline	1238 11 B-Chemical
,	1249 1 O
metoprolol	1251 10 B-Chemical
(	1262 1 O
racemic	1263 7 O
,	1270 1 O
R	1272 1 O
-	1273 1 O
and	1275 3 O
S	1279 1 O
-	1280 1 O
isomer	1281 6 O
)	1287 1 O
,	1288 1 O
and	1290 3 O
alpha	1294 5 B-Chemical
-	1299 1 I-Chemical
hydroxymetoprolol	1300 17 I-Chemical
concentrations	1318 14 O
were	1333 4 O
taken	1338 5 O
at	1344 2 O
regular	1347 7 O
time	1355 4 O
intervals	1360 9 O
,	1369 1 O
during	1371 6 O
8	1378 1 O
hr	1380 2 O
after	1383 5 O
metoprolol	1389 10 B-Chemical
.	1399 1 O

In	1401 2 O
PMs	1404 3 O
,	1407 1 O
metoprolol	1409 10 B-Chemical
increased	1420 9 O
the	1430 3 O
terbutaline	1434 11 B-Chemical
area	1446 4 O
under	1451 5 O
the	1457 3 O
plasma	1461 6 O
concentration	1468 13 O
vs	1482 2 O
.	1484 1 O
time	1486 4 O
curve	1491 5 O
(	1497 1 O
+	1498 1 O
67	1499 2 O
%	1501 1 O
)	1502 1 O
.	1503 1 O

Higher	1505 6 O
metoprolol	1512 10 B-Chemical
/	1522 1 O
alpha	1523 5 B-Chemical
-	1528 1 I-Chemical
hydroxymetoprolol	1529 17 I-Chemical
ratios	1547 6 O
in	1554 2 O
PMs	1557 3 O
were	1561 4 O
predictive	1566 10 O
for	1577 3 O
higher	1581 6 O
R	1588 1 O
-	1589 1 O
/	1590 1 O
S	1591 1 O
-	1592 1 O
isomer	1593 6 O
ratios	1600 6 O
of	1607 2 O
unchanged	1610 9 O
drug	1620 4 O
.	1624 1 O

There	1626 5 O
was	1632 3 O
a	1636 1 O
difference	1638 10 O
in	1649 2 O
metoprolol	1652 10 B-Chemical
potency	1663 7 O
with	1671 4 O
higher	1676 6 O
racemic	1683 7 O
metoprolol	1691 10 B-Chemical
IC50	1702 4 O
values	1707 6 O
in	1714 2 O
PMs	1717 3 O
(	1721 1 O
72	1722 2 O
+	1725 1 O
/	1726 1 O
-	1727 1 O
7	1729 1 O
ng	1731 2 O
.	1733 1 O
ml	1734 2 O
-	1736 1 O
1	1737 1 O
)	1738 1 O
than	1740 4 O
EMs	1745 3 O
(	1749 1 O
42	1750 2 O
+	1753 1 O
/	1754 1 O
-	1755 1 O
8	1757 1 O
ng	1759 2 O
.	1761 1 O
ml	1762 2 O
-	1764 1 O
1	1765 1 O
,	1766 1 O
P	1768 1 O
less	1770 4 O
than	1775 4 O
.	1780 1 O
001	1781 3 O
)	1784 1 O
.	1785 1 O
(	1786 1 O
ABSTRACT	1787 8 O
TRUNCATED	1796 9 O
AT	1806 2 O
250	1809 3 O
WORDS	1813 5 O
)	1818 1 O

Cefotetan	0 9 B-Chemical
-	9 1 O
induced	10 7 O
immune	18 6 O
hemolytic	25 9 B-Disease
anemia	35 6 I-Disease
.	41 1 O

Immune	43 6 O
hemolytic	50 9 B-Disease
anemia	60 6 I-Disease
due	67 3 O
to	71 2 O
a	74 1 O
drug	76 4 O
-	80 1 O
adsorption	81 10 O
mechanism	92 9 O
has	102 3 O
been	106 4 O
described	111 9 O
primarily	121 9 O
in	131 2 O
patients	134 8 O
receiving	143 9 O
penicillins	153 11 B-Chemical
and	165 3 O
first	169 5 O
-	174 1 O
generation	175 10 O
cephalosporins	186 14 B-Chemical
.	200 1 O

We	202 2 O
describe	205 8 O
a	214 1 O
patient	216 7 O
who	224 3 O
developed	228 9 O
anemia	238 6 B-Disease
while	245 5 O
receiving	251 9 O
intravenous	261 11 O
cefotetan	273 9 B-Chemical
.	282 1 O

Cefotetan	284 9 B-Chemical
-	293 1 O
dependent	294 9 O
antibodies	304 10 O
were	315 4 O
detected	320 8 O
in	329 2 O
the	332 3 O
patient	336 7 O
'	343 1 O
s	344 1 O
serum	346 5 O
and	352 3 O
in	356 2 O
an	359 2 O
eluate	362 6 O
prepared	369 8 O
from	378 4 O
his	383 3 O
red	387 3 O
blood	391 5 O
cells	397 5 O
.	402 1 O

The	404 3 O
eluate	408 6 O
also	415 4 O
reacted	420 7 O
weakly	428 6 O
with	435 4 O
red	440 3 O
blood	444 5 O
cells	450 5 O
in	456 2 O
the	459 3 O
absence	463 7 O
of	471 2 O
cefotetan	474 9 B-Chemical
,	483 1 O
suggesting	485 10 O
the	496 3 O
concomitant	500 11 O
formation	512 9 O
of	522 2 O
warm	525 4 O
-	529 1 O
reactive	530 8 O
autoantibodies	539 14 O
.	553 1 O

These	555 5 O
observations	561 12 O
,	573 1 O
in	575 2 O
conjunction	578 11 O
with	590 4 O
clinical	595 8 O
and	604 3 O
laboratory	608 10 O
evidence	619 8 O
of	628 2 O
extravascular	631 13 O
hemolysis	645 9 B-Disease
,	654 1 O
are	656 3 O
consistent	660 10 O
with	671 4 O
drug	676 4 O
-	680 1 O
induced	681 7 O
hemolytic	689 9 B-Disease
anemia	699 6 I-Disease
,	705 1 O
possibly	707 8 O
involving	716 9 O
both	726 4 O
drug	731 4 O
-	735 1 O
adsorption	736 10 O
and	747 3 O
autoantibody	751 12 O
formation	764 9 O
mechanisms	774 10 O
.	784 1 O

This	786 4 O
case	791 4 O
emphasizes	796 10 O
the	807 3 O
need	811 4 O
for	816 3 O
increased	820 9 O
awareness	830 9 O
of	840 2 O
hemolytic	843 9 O
reactions	853 9 O
to	863 2 O
all	866 3 O
cephalosporins	870 14 B-Chemical
.	884 1 O

Acute	0 5 B-Disease
renal	6 5 I-Disease
failure	12 7 I-Disease
subsequent	20 10 O
to	31 2 O
the	34 3 O
administration	38 14 O
of	53 2 O
rifampicin	56 10 B-Chemical
.	66 1 O

A	68 1 O
follow	70 6 O
-	76 1 O
up	77 2 O
study	80 5 O
of	86 2 O
cases	89 5 O
reported	95 8 O
earlier	104 7 O
.	111 1 O

A	113 1 O
clinical	115 8 O
presentation	124 12 O
is	137 2 O
made	140 4 O
of	145 2 O
a	148 1 O
2	150 1 O
-	151 1 O
3	152 1 O
year	154 4 O
follow	159 6 O
-	165 1 O
up	166 2 O
of	169 2 O
six	172 3 O
cases	176 5 O
of	182 2 O
acute	185 5 B-Disease
renal	191 5 I-Disease
failure	197 7 I-Disease
that	205 4 O
have	210 4 O
been	215 4 O
reported	220 8 O
earlier	229 7 O
.	236 1 O

The	238 3 O
patients	242 8 O
had	251 3 O
developed	255 9 O
transient	265 9 O
renal	275 5 B-Disease
failure	281 7 I-Disease
after	289 5 O
the	295 3 O
intermittent	299 12 O
administration	312 14 O
of	327 2 O
rifampicin	330 10 B-Chemical
.	340 1 O

The	342 3 O
stage	346 5 O
of	352 2 O
olig	355 4 O
-	359 1 O
anuria	360 6 B-Disease
lasted	367 6 O
for	374 3 O
1	378 1 O
-	379 1 O
3	380 1 O
weeks	382 5 O
,	387 1 O
and	389 3 O
five	393 4 O
of	398 2 O
the	401 3 O
patients	405 8 O
were	414 4 O
treated	419 7 O
by	427 2 O
hemodialysis	430 12 O
.	442 1 O

Two	444 3 O
of	448 2 O
the	451 3 O
patients	455 8 O
died	464 4 O
due	469 3 O
to	473 2 O
unrelated	476 9 O
causes	486 6 O
during	493 6 O
the	500 3 O
follow	504 6 O
-	510 1 O
up	511 2 O
period	514 6 O
.	520 1 O

The	522 3 O
four	526 4 O
patients	531 8 O
re	540 2 O
-	542 1 O
examined	543 8 O
were	552 4 O
clinically	557 10 O
cured	568 5 O
.	573 1 O

Pathologic	575 10 O
findings	586 8 O
by	595 2 O
light	598 5 O
microscopy	604 10 O
and	615 3 O
immunofluorescence	619 18 O
at	638 2 O
biopsy	641 6 O
were	648 4 O
scarce	653 6 O
.	659 1 O

Nothing	661 7 O
abnormal	669 8 O
was	678 3 O
seen	682 4 O
by	687 2 O
electron	690 8 O
microscopy	699 10 O
in	710 2 O
two	713 3 O
of	717 2 O
the	720 3 O
cases	724 5 O
studied	730 7 O
.	737 1 O

Renal	739 5 O
function	745 8 O
was	754 3 O
normal	758 6 O
.	764 1 O

In	766 2 O
three	769 5 O
cases	775 5 O
the	781 3 O
excretion	785 9 O
at	795 2 O
131I	798 4 O
-	802 1 O
hippuran	803 8 O
renography	812 10 O
was	823 3 O
slightly	827 8 O
slowed	836 6 O
.	842 1 O

Although	844 8 O
in	853 2 O
the	856 3 O
acute	860 5 O
stage	866 5 O
the	872 3 O
renal	876 5 B-Disease
lesions	882 7 I-Disease
histologically	890 14 O
appeared	905 8 O
toxic	914 5 O
,	919 1 O
evidence	921 8 O
suggestive	930 10 O
of	941 2 O
an	944 2 O
immunological	947 13 O
mechanism	961 9 O
cannot	971 6 O
be	978 2 O
excluded	981 8 O
.	989 1 O

Type	0 4 B-Disease
B	5 1 I-Disease
hepatitis	7 9 I-Disease
after	17 5 O
needle	23 6 O
-	29 1 O
stick	30 5 O
exposure	36 8 O
:	44 1 O
prevention	46 10 O
with	57 4 O
hepatitis	62 9 B-Disease
B	72 1 I-Disease
immune	74 6 O
globulin	81 8 O
.	89 1 O

Final	91 5 O
report	97 6 O
of	104 2 O
the	107 3 O
Veterans	111 8 O
Administration	120 14 O
Cooperative	135 11 O
Study	147 5 O
.	152 1 O

Hepatitis	154 9 B-Disease
B	164 1 I-Disease
immune	166 6 O
globulin	173 8 O
(	182 1 O
HBIG	183 4 O
)	187 1 O
and	189 3 O
immune	193 6 O
serum	200 5 O
globulin	206 8 O
(	215 1 O
ISG	216 3 O
)	219 1 O
were	221 4 O
examined	226 8 O
in	235 2 O
a	238 1 O
randomized	240 10 O
,	250 1 O
double	252 6 O
-	258 1 O
blind	259 5 O
trial	265 5 O
to	271 2 O
assess	274 6 O
their	281 5 O
relative	287 8 O
efficacies	296 10 O
in	307 2 O
preventing	310 10 O
type	321 4 B-Disease
B	326 1 I-Disease
hepatitis	328 9 I-Disease
after	338 5 O
needle	344 6 O
-	350 1 O
stick	351 5 O
exposure	357 8 O
to	366 2 O
hepatitis	369 9 B-Chemical
B	379 1 I-Chemical
surface	381 7 I-Chemical
antigen	389 7 I-Chemical
(	397 1 O
HBsAG	398 5 B-Chemical
)	403 1 O
-	404 1 O
positive	405 8 O
donors	414 6 O
.	420 1 O

Clinical	422 8 O
hepatitis	431 9 B-Disease
developed	441 9 O
in	451 2 O
1	454 1 O
.	455 1 O
4	456 1 O
%	457 1 O
of	459 2 O
HBIG	462 4 O
and	467 3 O
in	471 2 O
5	474 1 O
.	475 1 O
9	476 1 O
%	477 1 O
of	479 2 O
ISG	482 3 O
recipients	486 10 O
(	497 1 O
P	498 1 O
=	500 1 O
0	502 1 O
.	503 1 O
016	504 3 O
)	507 1 O
,	508 1 O
and	510 3 O
seroconversion	514 14 O
(	529 1 O
anti	530 4 O
-	534 1 O
HBs	535 3 O
)	538 1 O
occurred	540 8 O
in	549 2 O
5	552 1 O
.	553 1 O
6	554 1 O
%	555 1 O
and	557 3 O
20	561 2 O
.	563 1 O
7	564 1 O
%	565 1 O
of	567 2 O
them	570 4 O
respectively	575 12 O
(	588 1 O
P	589 1 O
less	591 4 O
than	596 4 O
0	601 1 O
.	602 1 O
001	603 3 O
)	606 1 O
.	607 1 O

Mild	609 4 O
and	614 3 O
transient	618 9 O
side	628 4 O
-	632 1 O
effects	633 7 O
were	641 4 O
noted	646 5 O
in	652 2 O
3	655 1 O
.	656 1 O
0	657 1 O
%	658 1 O
of	660 2 O
ISG	663 3 O
and	667 3 O
in	671 2 O
3	674 1 O
.	675 1 O
2	676 1 O
%	677 1 O
of	679 2 O
HBIG	682 4 O
recipients	687 10 O
.	697 1 O

Available	699 9 O
donor	709 5 O
sera	715 4 O
were	720 4 O
examined	725 8 O
for	734 3 O
DNA	738 3 O
polymerase	742 10 O
(	753 1 O
DNAP	754 4 O
)	758 1 O
and	760 3 O
e	764 1 O
antigen	766 7 O
and	774 3 O
antibody	778 8 O
(	787 1 O
HBeAg	788 5 B-Chemical
;	793 1 O
anti	795 4 O
-	799 1 O
HBE	800 3 O
)	803 1 O
.	804 1 O

Both	806 4 O
DNAP	811 4 O
and	816 3 O
HBeAg	820 5 B-Chemical
showed	826 6 O
a	833 1 O
highly	835 6 O
statistically	842 13 O
significant	856 11 O
correlation	868 11 O
with	880 4 O
the	885 3 O
infectivity	889 11 O
of	901 2 O
HBsAg	904 5 B-Chemical
-	909 1 O
positive	910 8 O
donors	919 6 O
.	925 1 O

Hepatitis	927 9 B-Disease
B	937 1 I-Disease
immune	939 6 O
globulin	946 8 O
remained	955 8 O
significantly	964 13 O
superior	978 8 O
to	987 2 O
ISG	990 3 O
in	994 2 O
preventing	997 10 O
type	1008 4 B-Disease
B	1013 1 I-Disease
hepatitis	1015 9 I-Disease
even	1025 4 O
when	1030 4 O
the	1035 3 O
analysis	1039 8 O
was	1048 3 O
confined	1052 8 O
to	1061 2 O
these	1064 5 O
two	1070 3 O
high	1074 4 O
-	1078 1 O
risk	1079 4 O
subgroups	1084 9 O
.	1093 1 O

The	1095 3 O
efficacy	1099 8 O
of	1108 2 O
ISG	1111 3 O
in	1115 2 O
preventing	1118 10 O
type	1129 4 B-Disease
B	1134 1 I-Disease
hepatitis	1136 9 I-Disease
cannot	1146 6 O
be	1153 2 O
ascertained	1156 11 O
because	1168 7 O
a	1176 1 O
true	1178 4 O
placebo	1183 7 O
group	1191 5 O
was	1197 3 O
not	1201 3 O
included	1205 8 O
.	1213 1 O

Serotonin	0 9 B-Disease
syndrome	10 8 I-Disease
from	19 4 O
venlafaxine	24 11 B-Chemical
-	35 1 O
tranylcypromine	36 15 B-Chemical
interaction	52 11 O
.	63 1 O

Excessive	65 9 O
stimulation	75 11 O
of	87 2 O
serotonin	90 9 B-Chemical
5HT1A	100 5 O
receptors	106 9 O
causes	116 6 O
a	123 1 O
syndrome	125 8 O
of	134 2 O
serotonin	137 9 B-Chemical
excess	147 6 O
that	154 4 O
consists	159 8 O
of	168 2 O
shivering	171 9 O
,	180 1 O
muscle	182 6 B-Disease
rigidity	189 8 I-Disease
,	197 1 O
salivation	199 10 B-Disease
,	209 1 O
confusion	211 9 B-Disease
,	220 1 O
agitation	222 9 B-Disease
and	232 3 O
hyperthermia	236 12 B-Disease
.	248 1 O

The	250 3 O
most	254 4 O
common	259 6 O
cause	266 5 O
of	272 2 O
this	275 4 O
syndrome	280 8 O
is	289 2 O
an	292 2 O
interaction	295 11 O
between	307 7 O
a	315 1 O
monoamine	317 9 O
oxidase	327 7 O
inhibitor	335 9 O
(	345 1 O
MAOI	346 4 O
)	350 1 O
and	352 3 O
a	356 1 O
specific	358 8 O
serotonin	367 9 B-Chemical
reuptake	377 8 O
inhibitor	386 9 O
.	395 1 O

Venlafaxine	397 11 B-Chemical
is	409 2 O
a	412 1 O
new	414 3 O
antidepressant	418 14 O
agent	433 5 O
that	439 4 O
inhibits	444 8 O
the	453 3 O
reuptake	457 8 O
of	466 2 O
serotonin	469 9 B-Chemical
and	479 3 O
norepinephrine	483 14 B-Chemical
.	497 1 O

We	499 2 O
report	502 6 O
a	509 1 O
venlafaxine	511 11 B-Chemical
-	522 1 O
MAOI	523 4 O
interaction	528 11 O
that	540 4 O
resulted	545 8 O
in	554 2 O
the	557 3 O
serotonin	561 9 B-Disease
syndrome	571 8 I-Disease
in	580 2 O
a	583 1 O
23	585 2 O
-	587 1 O
y	588 1 O
-	589 1 O
old	590 3 O
male	594 4 O
who	599 3 O
was	603 3 O
taking	607 6 O
tranylcypromine	614 15 B-Chemical
for	630 3 O
depression	634 10 B-Disease
.	644 1 O

He	646 2 O
had	649 3 O
been	653 4 O
well	658 4 O
until	663 5 O
the	669 3 O
morning	673 7 O
of	681 2 O
presentation	684 12 O
when	697 4 O
he	702 2 O
took	705 4 O
1	710 1 O
/	711 1 O
2	712 1 O
tab	714 3 O
of	718 2 O
venlafaxine	721 11 B-Chemical
.	732 1 O

Within	734 6 O
2	741 1 O
h	743 1 O
he	745 2 O
became	748 6 O
confused	755 8 O
with	764 4 O
jerking	769 7 O
movements	777 9 O
of	787 2 O
his	790 3 O
extremities	794 11 O
,	805 1 O
tremors	807 7 B-Disease
and	815 3 O
rigidity	819 8 B-Disease
.	827 1 O

He	829 2 O
was	832 3 O
brought	836 7 O
directly	844 8 O
to	853 2 O
a	856 1 O
hospital	858 8 O
where	867 5 O
he	873 2 O
was	876 3 O
found	880 5 O
to	886 2 O
be	889 2 O
agitated	892 8 O
and	901 3 O
confused	905 8 O
with	914 4 O
shivering	919 9 O
,	928 1 O
myoclonic	930 9 B-Disease
jerks	940 5 I-Disease
,	945 1 O
rigidity	947 8 B-Disease
,	955 1 O
salivation	957 10 B-Disease
and	968 3 O
diaphoresis	972 11 O
.	983 1 O

His	985 3 O
pupils	989 6 O
were	996 4 O
7	1001 1 O
mm	1003 2 O
and	1006 3 O
sluggishly	1010 10 O
reactive	1021 8 O
to	1030 2 O
light	1033 5 O
.	1038 1 O

Vital	1040 5 O
signs	1046 5 O
were	1052 4 O
:	1056 1 O
blood	1058 5 O
pressure	1064 8 O
120	1073 3 O
/	1076 1 O
67	1077 2 O
mm	1080 2 O
Hg	1083 2 O
,	1085 1 O
heart	1087 5 O
rate	1093 4 O
127	1098 3 O
/	1101 1 O
min	1102 3 O
,	1105 1 O
respiratory	1107 11 O
rate	1119 4 O
28	1124 2 O
/	1126 1 O
min	1127 3 O
,	1130 1 O
and	1132 3 O
temperature	1136 11 O
97	1148 2 O
F	1151 1 O
.	1152 1 O

After	1154 5 O
180	1160 3 O
mg	1164 2 O
of	1167 2 O
diazepam	1170 8 B-Chemical
i	1179 1 O
.	1180 1 O
v	1181 1 O
.	1182 1 O
he	1184 2 O
remained	1187 8 O
tremulous	1196 9 O
with	1206 4 O
muscle	1211 6 B-Disease
rigidity	1218 8 I-Disease
and	1227 3 O
clenched	1231 8 O
jaws	1240 4 O
.	1244 1 O

He	1246 2 O
was	1249 3 O
intubated	1253 9 O
for	1263 3 O
airway	1267 6 O
protection	1274 10 O
and	1285 3 O
because	1289 7 O
of	1297 2 O
hypoventilation	1300 15 B-Disease
,	1315 1 O
and	1317 3 O
was	1321 3 O
paralyzed	1325 9 B-Disease
to	1335 2 O
control	1338 7 O
muscle	1346 6 B-Disease
rigidity	1353 8 I-Disease
.	1361 1 O

His	1363 3 O
subsequent	1367 10 O
course	1378 6 O
was	1385 3 O
remarkable	1389 10 O
for	1400 3 O
non	1404 3 O
-	1407 1 O
immune	1408 6 O
thrombocytopenia	1415 16 B-Disease
which	1432 5 O
resolved	1438 8 O
.	1446 1 O

The	1448 3 O
patient	1452 7 O
'	1459 1 O
s	1460 1 O
maximal	1462 7 O
temperature	1470 11 O
was	1482 3 O
101	1486 3 O
.	1489 1 O
2	1490 1 O
F	1492 1 O
and	1494 3 O
his	1498 3 O
CPK	1502 3 O
remained	1506 8 O
<	1515 1 O
500	1517 3 O
units	1521 5 O
/	1526 1 O
L	1527 1 O
with	1529 4 O
no	1534 2 O
other	1537 5 O
evidence	1543 8 O
of	1552 2 O
rhabdomyolysis	1555 14 B-Disease
.	1569 1 O

His	1571 3 O
mental	1575 6 O
status	1582 6 O
normalized	1589 10 O
and	1600 3 O
he	1604 2 O
was	1607 3 O
transferred	1611 11 O
to	1623 2 O
a	1626 1 O
psychiatry	1628 10 O
ward	1639 4 O
.	1643 1 O

This	1645 4 O
patient	1650 7 O
survived	1658 8 O
without	1667 7 O
sequelae	1675 8 O
due	1684 3 O
to	1688 2 O
the	1691 3 O
aggressive	1695 10 O
sedation	1706 8 O
and	1715 3 O
neuromuscular	1719 13 O
paralysis	1733 9 B-Disease
.	1742 1 O

Effect	0 6 O
of	7 2 O
nondopaminergic	10 15 O
drugs	26 5 O
on	32 2 O
L	35 1 B-Chemical
-	36 1 I-Chemical
dopa	37 4 I-Chemical
-	41 1 O
induced	42 7 O
dyskinesias	50 11 B-Disease
in	62 2 O
MPTP	65 4 B-Chemical
-	69 1 O
treated	70 7 O
monkeys	78 7 O
.	85 1 O

A	87 1 O
group	89 5 O
of	95 2 O
four	98 4 O
monkeys	103 7 O
was	111 3 O
rendered	115 8 O
parkinsonian	124 12 B-Disease
with	137 4 O
the	142 3 O
toxin	146 5 O
MPTP	152 4 B-Chemical
.	156 1 O

They	158 4 O
were	163 4 O
then	168 4 O
treated	173 7 O
chronically	181 11 O
with	193 4 O
L	198 1 B-Chemical
-	199 1 I-Chemical
DOPA	200 4 I-Chemical
/	204 1 I-Chemical
benserazide	205 11 I-Chemical
50	217 2 O
/	219 1 O
12	220 2 O
.	222 1 O
5	223 1 O
mg	225 2 O
/	227 1 O
kg	228 2 O
given	231 5 O
orally	237 6 O
daily	244 5 O
for	250 3 O
2	254 1 O
months	256 6 O
.	262 1 O

This	264 4 O
dose	269 4 O
produced	274 8 O
a	283 1 O
striking	285 8 O
antiparkinsonian	294 16 O
effect	311 6 O
,	317 1 O
but	319 3 O
all	323 3 O
animals	327 7 O
manifested	335 10 O
dyskinesia	346 10 B-Disease
.	356 1 O

A	358 1 O
series	360 6 O
of	367 2 O
agents	370 6 O
acting	377 6 O
primarily	384 9 O
on	394 2 O
neurotransmitters	397 17 O
other	415 5 O
than	421 4 O
dopamine	426 8 B-Chemical
were	435 4 O
then	440 4 O
tested	445 6 O
in	452 2 O
combination	455 11 O
with	467 4 O
L	472 1 B-Chemical
-	473 1 I-Chemical
DOPA	474 4 I-Chemical
to	479 2 O
see	482 3 O
if	486 2 O
the	489 3 O
dyskinetic	493 10 B-Disease
movements	504 9 O
would	514 5 O
be	520 2 O
modified	523 8 O
.	531 1 O

Several	533 7 O
drugs	541 5 O
,	546 1 O
including	548 9 O
clonidine	558 9 B-Chemical
,	567 1 O
physostigmine	569 13 B-Chemical
,	582 1 O
methysergide	584 12 B-Chemical
,	596 1 O
5	598 1 B-Chemical
-	599 1 I-Chemical
MDOT	600 4 I-Chemical
,	604 1 O
propranolol	606 11 B-Chemical
,	617 1 O
and	619 3 O
MK	623 2 B-Chemical
-	625 1 I-Chemical
801	626 3 I-Chemical
,	629 1 O
markedly	631 8 O
reduced	640 7 O
the	648 3 O
dyskinetic	652 10 B-Disease
movements	663 9 O
but	673 3 O
at	677 2 O
the	680 3 O
cost	684 4 O
of	689 2 O
a	692 1 O
return	694 6 O
of	701 2 O
parkinsonian	704 12 B-Disease
symptomatology	717 14 O
.	731 1 O

However	733 7 O
,	740 1 O
yohimbine	742 9 B-Chemical
and	752 3 O
meperidine	756 10 B-Chemical
reduced	767 7 O
predominantly	775 13 O
the	789 3 O
dyskinetic	793 10 B-Disease
movements	804 9 O
.	813 1 O

Baclofen	815 8 B-Chemical
was	824 3 O
also	828 4 O
useful	833 6 O
in	840 2 O
one	843 3 O
monkey	847 6 O
against	854 7 O
a	862 1 O
more	864 4 O
dystonic	869 8 B-Disease
form	878 4 O
of	883 2 O
dyskinesia	886 10 B-Disease
.	896 1 O

Atropine	898 8 B-Chemical
converted	907 9 O
the	917 3 O
dystonic	921 8 B-Disease
movements	930 9 O
into	940 4 O
chorea	945 6 B-Disease
.	951 1 O

CCNU	0 4 B-Chemical
(	5 1 O
lomustine	6 9 B-Chemical
)	15 1 O
toxicity	17 8 B-Disease
in	26 2 O
dogs	29 4 O
:	33 1 O
a	35 1 O
retrospective	37 13 O
study	51 5 O
(	57 1 O
2002	58 4 O
-	62 1 O
07	63 2 O
)	65 1 O
.	66 1 O

OBJECTIVE	68 9 O
:	77 1 O
To	79 2 O
describe	82 8 O
the	91 3 O
incidence	95 9 O
of	105 2 O
haematological	108 14 B-Disease
,	122 1 I-Disease
renal	124 5 I-Disease
,	129 1 I-Disease
hepatic	131 7 I-Disease
and	139 3 I-Disease
gastrointestinal	143 16 I-Disease
toxicities	160 10 I-Disease
in	171 2 O
tumour	174 6 O
-	180 1 O
bearing	181 7 O
dogs	189 4 O
receiving	194 9 O
1	204 1 B-Chemical
-	205 1 I-Chemical
(	206 1 I-Chemical
2	207 1 I-Chemical
-	208 1 I-Chemical
chloroethyl	209 11 I-Chemical
)	220 1 I-Chemical
-	221 1 I-Chemical
3	222 1 I-Chemical
-	223 1 I-Chemical
cyclohexyl	224 10 I-Chemical
-	234 1 I-Chemical
1	235 1 I-Chemical
-	236 1 I-Chemical
nitrosourea	237 11 I-Chemical
(	249 1 O
CCNU	250 4 B-Chemical
)	254 1 O
.	255 1 O

DESIGN	257 6 O
:	263 1 O
The	265 3 O
medical	269 7 O
records	277 7 O
of	285 2 O
206	288 3 O
dogs	292 4 O
that	297 4 O
were	302 4 O
treated	307 7 O
with	315 4 O
CCNU	320 4 B-Chemical
at	325 2 O
the	328 3 O
Melbourne	332 9 O
Veterinary	342 10 O
Specialist	353 10 O
Centre	364 6 O
between	371 7 O
February	379 8 O
2002	388 4 O
and	393 3 O
December	397 8 O
2007	406 4 O
were	411 4 O
retrospectively	416 15 O
evaluated	432 9 O
.	441 1 O

RESULTS	443 7 O
:	450 1 O
Of	452 2 O
the	455 3 O
206	459 3 O
dogs	463 4 O
treated	468 7 O
with	476 4 O
CCNU	481 4 B-Chemical
,	485 1 O
185	487 3 O
met	491 3 O
the	495 3 O
inclusion	499 9 O
criteria	509 8 O
for	518 3 O
at	522 2 O
least	525 5 O
one	531 3 O
class	535 5 O
of	541 2 O
toxicity	544 8 B-Disease
.	552 1 O

CCNU	554 4 B-Chemical
was	559 3 O
used	563 4 O
most	568 4 O
commonly	573 8 O
in	582 2 O
the	585 3 O
treatment	589 9 O
of	599 2 O
lymphoma	602 8 B-Disease
,	610 1 O
mast	612 4 B-Disease
cell	617 4 I-Disease
tumour	622 6 I-Disease
,	628 1 O
brain	630 5 B-Disease
tumour	636 6 I-Disease
,	642 1 O
histiocytic	644 11 B-Disease
tumours	656 7 I-Disease
and	664 3 O
epitheliotropic	668 15 B-Disease
lymphoma	684 8 I-Disease
.	692 1 O

Throughout	694 10 O
treatment	705 9 O
,	714 1 O
56	716 2 O
.	718 1 O
9	719 1 O
%	720 1 O
of	722 2 O
dogs	725 4 O
experienced	730 11 O
neutropenia	742 11 B-Disease
,	753 1 O
34	755 2 O
.	757 1 O
2	758 1 O
%	759 1 O
experienced	761 11 O
anaemia	773 7 B-Disease
and	781 3 O
14	785 2 O
.	787 1 O
2	788 1 O
%	789 1 O
experienced	791 11 O
thrombocytopenia	803 16 B-Disease
.	819 1 O

Gastrointestinal	821 16 B-Disease
toxicosis	838 9 I-Disease
was	848 3 O
detected	852 8 O
in	861 2 O
37	864 2 O
.	866 1 O
8	867 1 O
%	868 1 O
of	870 2 O
dogs	873 4 O
,	877 1 O
the	879 3 O
most	883 4 O
common	888 6 O
sign	895 4 O
of	900 2 O
which	903 5 O
was	909 3 O
vomiting	913 8 B-Disease
(	922 1 O
24	923 2 O
.	925 1 O
3	926 1 O
%	927 1 O
)	928 1 O
.	929 1 O

Potential	931 9 O
renal	941 5 O
toxicity	947 8 B-Disease
and	956 3 O
elevated	960 8 O
alanine	969 7 B-Chemical
transaminase	977 12 O
(	990 1 O
ALT	991 3 O
)	994 1 O
concentration	996 13 O
were	1010 4 O
reported	1015 8 O
in	1024 2 O
12	1027 2 O
.	1029 1 O
2	1030 1 O
%	1031 1 O
and	1033 3 O
48	1037 2 O
.	1039 1 O
8	1040 1 O
%	1041 1 O
of	1043 2 O
dogs	1046 4 O
,	1050 1 O
respectively	1052 12 O
.	1064 1 O

The	1066 3 O
incidence	1070 9 O
of	1080 2 O
hepatic	1083 7 B-Disease
failure	1091 7 I-Disease
was	1099 3 O
1	1103 1 O
.	1104 1 O
2	1105 1 O
%	1106 1 O
.	1107 1 O

CONCLUSIONS	1109 11 O
:	1120 1 O
CCNU	1122 4 B-Chemical
-	1126 1 O
associated	1127 10 O
toxicity	1138 8 B-Disease
in	1147 2 O
dogs	1150 4 O
is	1155 2 O
common	1158 6 O
,	1164 1 O
but	1166 3 O
is	1170 2 O
usually	1173 7 O
not	1181 3 O
life	1185 4 O
threatening	1190 11 O
.	1201 1 O

Neuroactive	0 11 O
steroids	12 8 B-Chemical
protect	21 7 O
against	29 7 O
pilocarpine	37 11 B-Chemical
-	48 1 O
and	50 3 O
kainic	54 6 B-Chemical
acid	61 4 I-Chemical
-	65 1 O
induced	66 7 O
limbic	74 6 O
seizures	81 8 B-Disease
and	90 3 O
status	94 6 B-Disease
epilepticus	101 11 I-Disease
in	113 2 O
mice	116 4 O
.	120 1 O

Several	122 7 O
structurally	130 12 O
related	143 7 O
metabolites	151 11 O
of	163 2 O
progesterone	166 12 B-Chemical
(	179 1 O
3	180 1 B-Chemical
alpha	182 5 I-Chemical
-	187 1 I-Chemical
hydroxy	188 7 I-Chemical
pregnane	196 8 I-Chemical
-	204 1 I-Chemical
20	205 2 I-Chemical
-	207 1 I-Chemical
ones	208 4 I-Chemical
)	212 1 O
and	214 3 O
deoxycorticosterone	218 19 B-Chemical
(	238 1 O
3	239 1 B-Chemical
alpha	241 5 I-Chemical
-	246 1 I-Chemical
hydroxy	247 7 I-Chemical
pregnane	255 8 I-Chemical
-	263 1 I-Chemical
21	264 2 I-Chemical
-	266 1 I-Chemical
diol	267 4 I-Chemical
-	271 1 I-Chemical
20	272 2 I-Chemical
-	274 1 I-Chemical
ones	275 4 I-Chemical
)	279 1 O
and	281 3 O
their	285 5 O
3	291 1 O
beta	293 4 O
-	297 1 O
epimers	298 7 O
were	306 4 O
evaluated	311 9 O
for	321 3 O
protective	325 10 O
activity	336 8 O
against	345 7 O
pilocarpine	353 11 B-Chemical
-	364 1 O
,	365 1 O
kainic	367 6 B-Chemical
acid	374 4 I-Chemical
-	378 1 O
and	380 3 O
N	384 1 B-Chemical
-	385 1 I-Chemical
methyl	386 6 I-Chemical
-	392 1 I-Chemical
D	393 1 I-Chemical
-	394 1 I-Chemical
aspartate	395 9 I-Chemical
(	405 1 O
NMDA	406 4 B-Chemical
)	410 1 O
-	411 1 O
induced	412 7 O
seizures	420 8 B-Disease
in	429 2 O
mice	432 4 O
.	436 1 O

Steroids	438 8 B-Chemical
with	447 4 O
the	452 3 O
3	456 1 O
-	457 1 O
hydroxy	458 7 O
group	466 5 O
in	472 2 O
the	475 3 O
alpha	479 5 O
-	484 1 O
position	485 8 O
and	494 3 O
5	498 1 O
-	499 1 O
H	500 1 O
in	502 2 O
the	505 3 O
alpha	509 5 O
-	514 1 O
or	516 2 O
beta	519 4 O
-	523 1 O
configurations	524 14 O
were	539 4 O
highly	544 6 O
effective	551 9 O
in	561 2 O
protecting	564 10 O
against	575 7 O
pilocarpine	583 11 B-Chemical
(	595 1 O
416	596 3 O
mg	600 2 O
/	602 1 O
kg	603 2 O
,	605 1 O
s	607 1 O
.	608 1 O
c	609 1 O
.	610 1 O
)	611 1 O
-	612 1 O
induced	613 7 O
limbic	621 6 O
motor	628 5 O
seizures	634 8 B-Disease
and	643 3 O
status	647 6 B-Disease
epilepticus	654 11 I-Disease
(	666 1 O
ED50	667 4 O
values	672 6 O
,	678 1 O
7	680 1 O
.	681 1 O
0	682 1 O
-	683 1 O
18	684 2 O
.	686 1 O
7	687 1 O
mg	689 2 O
/	691 1 O
kg	692 2 O
,	694 1 O
i	696 1 O
.	697 1 O
p	698 1 O
.	699 1 O
)	700 1 O
.	701 1 O

The	703 3 O
corresponding	707 13 O
epimers	721 7 O
with	729 4 O
the	734 3 O
3	738 1 O
-	739 1 O
hydroxy	740 7 O
group	748 5 O
in	754 2 O
the	757 3 O
beta	761 4 O
-	765 1 O
position	766 8 O
were	775 4 O
also	780 4 O
effective	785 9 O
but	795 3 O
less	799 4 O
potent	804 6 O
(	811 1 O
ED50	812 4 O
values	817 6 O
,	823 1 O
33	825 2 O
.	827 1 O
8	828 1 O
-	829 1 O
63	830 2 O
.	832 1 O
5	833 1 O
,	834 1 O
i	836 1 O
.	837 1 O
p	838 1 O
.	839 1 O
)	840 1 O
.	841 1 O

Although	843 8 O
the	852 3 O
neuroactive	856 11 O
steroids	868 8 B-Chemical
were	877 4 O
considerably	882 12 O
less	895 4 O
potent	900 6 O
than	907 4 O
the	912 3 O
benzodiazepine	916 14 B-Chemical
clonazepam	931 10 B-Chemical
in	942 2 O
protecting	945 10 O
against	956 7 O
pilocarpine	964 11 B-Chemical
seizures	976 8 B-Disease
,	984 1 O
steroids	986 8 B-Chemical
with	995 4 O
the	1000 3 O
5	1004 1 O
alpha	1006 5 O
,	1011 1 O
3	1012 1 O
alpha	1014 5 O
-	1019 1 O
configuration	1020 13 O
had	1034 3 O
comparable	1038 10 O
or	1049 2 O
higher	1052 6 O
protective	1059 10 O
index	1070 5 O
values	1076 6 O
(	1083 1 O
TD50	1084 4 O
for	1089 3 O
motor	1093 5 O
impairment	1099 10 O
divided	1110 7 O
by	1118 2 O
ED50	1121 4 O
for	1126 3 O
seizure	1130 7 B-Disease
protection	1138 10 O
)	1148 1 O
than	1150 4 O
clonazepam	1155 10 B-Chemical
,	1165 1 O
indicating	1167 10 O
that	1178 4 O
some	1183 4 O
neuroactive	1188 11 O
steroids	1200 8 B-Chemical
may	1209 3 O
have	1213 4 O
lower	1218 5 O
relative	1224 8 O
toxicity	1233 8 B-Disease
.	1241 1 O

Steroids	1243 8 B-Chemical
with	1252 4 O
the	1257 3 O
5	1261 1 O
alpha	1263 5 O
,	1268 1 O
3	1269 1 O
alpha	1271 5 O
-	1276 1 O
or	1278 2 O
5	1281 1 O
beta	1283 4 O
,	1287 1 O
3	1288 1 O
alpha	1290 5 O
-	1295 1 O
configurations	1296 14 O
also	1311 4 O
produced	1316 8 O
a	1325 1 O
dose	1327 4 O
-	1331 1 O
dependent	1332 9 O
delay	1342 5 O
in	1348 2 O
the	1351 3 O
onset	1355 5 O
of	1361 2 O
limbic	1364 6 O
seizures	1371 8 B-Disease
induced	1380 7 O
by	1388 2 O
kainic	1391 6 B-Chemical
acid	1398 4 I-Chemical
(	1403 1 O
32	1404 2 O
mg	1407 2 O
/	1409 1 O
kg	1410 2 O
,	1412 1 O
s	1414 1 O
.	1415 1 O
c	1416 1 O
.	1417 1 O
)	1418 1 O
,	1419 1 O
but	1421 3 O
did	1425 3 O
not	1429 3 O
completely	1433 10 O
protect	1444 7 O
against	1452 7 O
the	1460 3 O
seizures	1464 8 B-Disease
.	1472 1 O

However	1474 7 O
,	1481 1 O
when	1483 4 O
a	1488 1 O
second	1490 6 O
dose	1497 4 O
of	1502 2 O
the	1505 3 O
steroid	1509 7 B-Chemical
was	1517 3 O
administered	1521 12 O
1	1534 1 O
hr	1536 2 O
after	1539 5 O
the	1545 3 O
first	1549 5 O
dose	1555 4 O
,	1559 1 O
complete	1561 8 O
protection	1570 10 O
from	1581 4 O
the	1586 3 O
kainic	1590 6 B-Chemical
acid	1597 4 I-Chemical
-	1601 1 O
induced	1602 7 O
limbic	1610 6 O
seizures	1617 8 B-Disease
and	1626 3 O
status	1630 6 B-Disease
epilepticus	1637 11 I-Disease
was	1649 3 O
obtained	1653 8 O
.	1661 1 O

The	1663 3 O
steroids	1667 8 B-Chemical
also	1676 4 O
caused	1681 6 O
a	1688 1 O
dose	1690 4 O
-	1694 1 O
dependent	1695 9 O
delay	1705 5 O
in	1711 2 O
NMDA	1714 4 B-Chemical
(	1719 1 O
257	1720 3 O
mg	1724 2 O
/	1726 1 O
kg	1727 2 O
,	1729 1 O
s	1731 1 O
.	1732 1 O
c	1733 1 O
.	1734 1 O
)	1735 1 O
-	1736 1 O
induced	1737 7 O
lethality	1745 9 O
,	1754 1 O
but	1756 3 O
did	1760 3 O
not	1764 3 O
completely	1768 10 O
protect	1779 7 O
against	1787 7 O
NMDA	1795 4 B-Chemical
seizures	1800 8 B-Disease
or	1809 2 O
lethality	1812 9 O
.	1821 1 O

We	1823 2 O
conclude	1826 8 O
that	1835 4 O
neuroactive	1840 11 O
steroids	1852 8 B-Chemical
are	1861 3 O
highly	1865 6 O
effective	1872 9 O
in	1882 2 O
protecting	1885 10 O
against	1896 7 O
pilocarpine	1904 11 B-Chemical
-	1915 1 O
and	1917 3 O
kainic	1921 6 B-Chemical
acid	1928 4 I-Chemical
-	1932 1 O
induced	1933 7 O
seizures	1941 8 B-Disease
and	1950 3 O
status	1954 6 B-Disease
epilepticus	1961 11 I-Disease
in	1973 2 O
mice	1976 4 O
,	1980 1 O
and	1982 3 O
may	1986 3 O
be	1990 2 O
of	1993 2 O
utility	1996 7 O
in	2004 2 O
the	2007 3 O
treatment	2011 9 O
of	2021 2 O
some	2024 4 O
forms	2029 5 O
of	2035 2 O
status	2038 6 B-Disease
epilepticus	2045 11 I-Disease
in	2057 2 O
humans	2060 6 O
.	2066 1 O

The	0 3 O
safety	4 6 O
and	11 3 O
efficacy	15 8 O
of	24 2 O
combination	27 11 O
N	39 1 B-Chemical
-	40 1 I-Chemical
butyl	41 5 I-Chemical
-	46 1 I-Chemical
deoxynojirimycin	47 16 I-Chemical
(	64 1 O
SC	65 2 B-Chemical
-	67 1 I-Chemical
48334	68 5 I-Chemical
)	73 1 O
and	75 3 O
zidovudine	79 10 B-Chemical
in	90 2 O
patients	93 8 O
with	102 4 O
HIV	107 3 B-Disease
-	110 1 I-Disease
1	111 1 I-Disease
infection	113 9 I-Disease
and	123 3 O
200	127 3 O
-	130 1 O
500	131 3 O
CD4	135 3 O
cells	139 5 O
/	144 1 O
mm3	145 3 O
.	148 1 O

We	150 2 O
conducted	153 9 O
a	163 1 O
double	165 6 O
-	171 1 O
blind	172 5 O
,	177 1 O
randomized	179 10 O
phase	190 5 O
II	196 2 O
study	199 5 O
to	205 2 O
evaluate	208 8 O
the	217 3 O
safety	221 6 O
and	228 3 O
activity	232 8 O
of	241 2 O
combination	244 11 O
therapy	256 7 O
with	264 4 O
N	269 1 B-Chemical
-	270 1 I-Chemical
butyl	271 5 I-Chemical
-	276 1 I-Chemical
deoxynojirimycin	277 16 I-Chemical
(	294 1 O
SC	295 2 B-Chemical
-	297 1 I-Chemical
48334	298 5 I-Chemical
)	303 1 O
(	305 1 O
an	306 2 O
alpha	309 5 O
-	314 1 O
glucosidase	315 11 O
I	327 1 O
inhibitor	329 9 O
)	338 1 O
and	340 3 O
zidovudine	344 10 B-Chemical
versus	355 6 O
zidovudine	362 10 B-Chemical
alone	373 5 O
.	378 1 O

Patients	380 8 O
with	389 4 O
200	394 3 O
to	398 2 O
500	401 3 O
CD4	405 3 O
cells	409 5 O
/	414 1 O
mm3	415 3 O
who	419 3 O
tolerated	423 9 O
<	433 1 O
or	435 2 O
=	438 1 O
12	440 2 O
weeks	443 5 O
of	449 2 O
prior	452 5 O
zidovudine	458 10 B-Chemical
therapy	469 7 O
received	477 8 O
SC	486 2 B-Chemical
-	488 1 I-Chemical
48334	489 5 I-Chemical
(	495 1 O
1000	496 4 O
mg	501 2 O
every	504 5 O
8	510 1 O
h	512 1 O
)	513 1 O
and	515 3 O
zidovudine	519 10 B-Chemical
(	530 1 O
100	531 3 O
mg	535 2 O
every	538 5 O
8	544 1 O
h	546 1 O
)	547 1 O
or	549 2 O
zidovudine	552 10 B-Chemical
and	563 3 O
placebo	567 7 O
.	574 1 O

Sixty	576 5 O
patients	582 8 O
received	591 8 O
combination	600 11 O
therapy	612 7 O
and	620 3 O
58	624 2 O
,	626 1 O
zidovudine	628 10 B-Chemical
and	639 3 O
placebo	643 7 O
.	650 1 O

Twenty	652 6 O
-	658 1 O
three	659 5 O
patients	665 8 O
(	674 1 O
38	675 2 O
%	677 1 O
)	678 1 O
and	680 3 O
15	684 2 O
(	687 1 O
26	688 2 O
%	690 1 O
)	691 1 O
,	692 1 O
in	694 2 O
the	697 3 O
combination	701 11 O
and	713 3 O
zidovudine	717 10 B-Chemical
groups	728 6 O
,	734 1 O
respectively	736 12 O
,	748 1 O
discontinued	750 12 O
therapy	763 7 O
(	771 1 O
p	772 1 O
=	774 1 O
0	776 1 O
.	777 1 O
15	778 2 O
)	780 1 O
.	781 1 O

The	783 3 O
mean	787 4 O
SC	792 2 B-Chemical
-	794 1 I-Chemical
48334	795 5 I-Chemical
steady	801 6 O
-	807 1 O
state	808 5 O
trough	814 6 O
level	821 5 O
(	827 1 O
4	828 1 O
.	829 1 O
04	830 2 O
+	833 1 O
/	834 1 O
-	835 1 O
0	837 1 O
.	838 1 O
99	839 2 O
micrograms	842 10 O
/	852 1 O
ml	853 2 O
)	855 1 O
was	857 3 O
below	861 5 O
the	867 3 O
in	871 2 O
vitro	874 5 O
inhibitory	880 10 O
concentration	891 13 O
for	905 3 O
human	909 5 O
immunodeficiency	915 16 B-Disease
virus	932 5 O
(	938 1 O
HIV	939 3 O
)	942 1 O
.	943 1 O

The	945 3 O
mean	949 4 O
increase	954 8 O
in	963 2 O
CD4	966 3 O
cells	970 5 O
at	976 2 O
week	979 4 O
4	984 1 O
was	986 3 O
73	990 2 O
.	992 1 O
8	993 1 O
cells	995 5 O
/	1000 1 O
mm3	1001 3 O
and	1005 3 O
52	1009 2 O
.	1011 1 O
4	1012 1 O
cells	1014 5 O
/	1019 1 O
mm3	1020 3 O
for	1024 3 O
the	1028 3 O
combination	1032 11 O
and	1044 3 O
zidovudine	1048 10 B-Chemical
groups	1059 6 O
,	1065 1 O
respectively	1067 12 O
(	1080 1 O
p	1081 1 O
>	1083 1 O
0	1085 1 O
.	1086 1 O
36	1087 2 O
)	1089 1 O
.	1090 1 O

For	1092 3 O
patients	1096 8 O
with	1105 4 O
prior	1110 5 O
zidovudine	1116 10 B-Chemical
therapy	1127 7 O
,	1134 1 O
the	1136 3 O
mean	1140 4 O
change	1145 6 O
in	1152 2 O
CD4	1155 3 O
cells	1159 5 O
in	1165 2 O
the	1168 3 O
combination	1172 11 O
and	1184 3 O
zidovudine	1188 10 B-Chemical
groups	1199 6 O
was	1206 3 O
63	1210 2 O
.	1212 1 O
7	1213 1 O
cells	1215 5 O
/	1220 1 O
mm3	1221 3 O
and	1225 3 O
4	1229 1 O
.	1230 1 O
9	1231 1 O
cells	1233 5 O
/	1238 1 O
mm3	1239 3 O
at	1243 2 O
week	1246 4 O
8	1251 1 O
and	1253 3 O
6	1257 1 O
.	1258 1 O
8	1259 1 O
cells	1261 5 O
/	1266 1 O
mm3	1267 3 O
and	1271 3 O
-	1275 1 O
45	1276 2 O
.	1278 1 O
1	1279 1 O
cells	1281 5 O
/	1286 1 O
mm3	1287 3 O
at	1291 2 O
week	1294 4 O
16	1299 2 O
,	1301 1 O
respectively	1303 12 O
.	1315 1 O

The	1317 3 O
number	1321 6 O
of	1328 2 O
patients	1331 8 O
with	1340 4 O
suppression	1345 11 O
of	1357 2 O
HIV	1360 3 O
p24	1364 3 O
antigenemia	1368 11 O
in	1380 2 O
the	1383 3 O
combination	1387 11 O
and	1399 3 O
zidovudine	1403 10 B-Chemical
groups	1414 6 O
was	1421 3 O
six	1425 3 O
(	1429 1 O
40	1430 2 O
%	1432 1 O
)	1433 1 O
and	1435 3 O
two	1439 3 O
(	1443 1 O
11	1444 2 O
%	1446 1 O
)	1447 1 O
at	1449 2 O
week	1452 4 O
4	1457 1 O
(	1459 1 O
p	1460 1 O
=	1462 1 O
0	1464 1 O
.	1465 1 O
10	1466 2 O
)	1468 1 O
and	1470 3 O
five	1474 4 O
(	1479 1 O
45	1480 2 O
%	1482 1 O
)	1483 1 O
and	1485 3 O
two	1489 3 O
(	1493 1 O
14	1494 2 O
%	1496 1 O
)	1497 1 O
at	1499 2 O
week	1502 4 O
24	1507 2 O
(	1510 1 O
p	1511 1 O
=	1513 1 O
0	1515 1 O
.	1516 1 O
08	1517 2 O
)	1519 1 O
,	1520 1 O
respectively	1522 12 O
.	1534 1 O

Diarrhea	1536 8 B-Disease
,	1544 1 O
flatulence	1546 10 B-Disease
,	1556 1 O
abdominal	1558 9 B-Disease
pain	1568 4 I-Disease
,	1572 1 O
and	1574 3 O
weight	1578 6 B-Disease
loss	1585 4 I-Disease
were	1590 4 O
common	1595 6 O
for	1602 3 O
combination	1606 11 O
recipients	1618 10 O
.	1628 1 O
(	1629 1 O
ABSTRACT	1630 8 O
TRUNCATED	1639 9 O
AT	1649 2 O
250	1652 3 O
WORDS	1656 5 O
)	1661 1 O

Recent	0 6 O
preclinical	7 11 O
and	19 3 O
clinical	23 8 O
studies	32 7 O
with	40 4 O
the	45 3 O
thymidylate	49 11 O
synthase	61 8 O
inhibitor	70 9 O
N10	80 3 B-Chemical
-	83 1 I-Chemical
propargyl	84 9 I-Chemical
-	93 1 I-Chemical
5	94 1 I-Chemical
,	95 1 I-Chemical
8	96 1 I-Chemical
-	97 1 I-Chemical
dideazafolic	98 12 I-Chemical
acid	111 4 I-Chemical
(	116 1 O
CB	117 2 B-Chemical
3717	120 4 I-Chemical
)	124 1 O
.	125 1 O

CB	127 2 B-Chemical
3717	130 4 I-Chemical
,	134 1 O
N10	136 3 B-Chemical
-	139 1 I-Chemical
propargyl	140 9 I-Chemical
-	149 1 I-Chemical
5	150 1 I-Chemical
,	151 1 I-Chemical
8	152 1 I-Chemical
-	153 1 I-Chemical
dideazafolic	154 12 I-Chemical
acid	167 4 I-Chemical
,	171 1 O
is	173 2 O
a	176 1 O
tight	178 5 O
-	183 1 O
binding	184 7 O
inhibitor	192 9 O
of	202 2 O
thymidylate	205 11 O
synthase	217 8 O
(	226 1 O
TS	227 2 O
)	229 1 O
whose	231 5 O
cytotoxicity	237 12 B-Disease
is	250 2 O
mediated	253 8 O
solely	262 6 O
through	269 7 O
the	277 3 O
inhibition	281 10 O
of	292 2 O
this	295 4 O
enzyme	300 6 O
.	306 1 O

Recent	308 6 O
preclinical	315 11 O
studies	327 7 O
have	335 4 O
focused	340 7 O
on	348 2 O
the	351 3 O
intracellular	355 13 O
formation	369 9 O
of	379 2 O
CB	382 2 B-Chemical
3717	385 4 I-Chemical
polyglutamates	390 14 O
.	404 1 O

Following	406 9 O
a	416 1 O
12	418 2 O
-	420 1 O
hour	421 4 O
exposure	426 8 O
of	435 2 O
L1210	438 5 O
cells	444 5 O
to	450 2 O
50	453 2 O
microM	456 6 O
[	463 1 O
3H	464 2 O
]	466 1 O
CB	467 2 B-Chemical
3717	470 4 I-Chemical
,	474 1 O
30	476 2 O
%	478 1 O
of	480 2 O
the	483 3 O
extractable	487 11 O
radioactivity	499 13 O
could	513 5 O
be	519 2 O
accounted	522 9 O
for	532 3 O
as	536 2 O
CB	539 2 B-Chemical
3717	542 4 I-Chemical
tetra	547 5 O
-	552 1 O
and	554 3 O
pentaglutamate	558 14 O
,	572 1 O
as	574 2 O
determined	577 10 O
by	588 2 O
high	591 4 O
-	595 1 O
pressure	596 8 O
liquid	605 6 O
chromatography	612 14 O
(	627 1 O
HPLC	628 4 O
)	632 1 O
analyses	634 8 O
.	642 1 O

As	644 2 O
inhibitors	647 10 O
of	658 2 O
isolated	661 8 O
L1210	670 5 O
TS	676 2 O
,	678 1 O
CB	680 2 O
3717	683 4 O
di	688 2 O
-	690 1 O
,	691 1 O
tri	693 3 O
-	696 1 O
,	697 1 O
tetra	699 5 O
-	704 1 O
and	706 3 O
pentaglutamate	710 14 O
are	725 3 O
26	729 2 O
-	731 1 O
,	732 1 O
87	734 2 O
-	736 1 O
,	737 1 O
119	739 3 O
-	742 1 O
and	744 3 O
114	748 3 O
-	751 1 O
fold	752 4 O
more	757 4 O
potent	762 6 O
than	769 4 O
CB	774 2 B-Chemical
3717	777 4 I-Chemical
,	781 1 O
respectively	783 12 O
,	795 1 O
and	797 3 O
their	801 5 O
formation	807 9 O
may	817 3 O
,	820 1 O
therefore	822 9 O
,	831 1 O
be	833 2 O
an	836 2 O
important	839 9 O
determinant	849 11 O
of	861 2 O
CB	864 2 B-Chemical
3717	867 4 I-Chemical
cytotoxicity	872 12 B-Disease
.	884 1 O

In	886 2 O
early	889 5 O
clinical	895 8 O
studies	904 7 O
with	912 4 O
CB	917 2 B-Chemical
3717	920 4 I-Chemical
,	924 1 O
activity	926 8 O
has	935 3 O
been	939 4 O
seen	944 4 O
in	949 2 O
breast	952 6 B-Disease
cancer	959 6 I-Disease
,	965 1 O
ovarian	967 7 B-Disease
cancer	975 6 I-Disease
,	981 1 O
hepatoma	983 8 B-Disease
,	991 1 O
and	993 3 O
mesothelioma	997 12 B-Disease
.	1009 1 O

Toxicities	1011 10 B-Disease
included	1022 8 O
hepatotoxicity	1031 14 B-Disease
,	1045 1 O
malaise	1047 7 B-Disease
,	1054 1 O
and	1056 3 O
dose	1060 4 O
-	1064 1 O
limiting	1065 8 O
nephrotoxicity	1074 14 B-Disease
.	1088 1 O

This	1090 4 O
latter	1095 6 O
effect	1102 6 O
is	1109 2 O
thought	1112 7 O
to	1120 2 O
be	1123 2 O
due	1126 3 O
to	1130 2 O
drug	1133 4 O
precipitation	1138 13 O
within	1152 6 O
the	1159 3 O
renal	1163 5 O
tubule	1169 6 O
as	1176 2 O
a	1179 1 O
result	1181 6 O
of	1188 2 O
the	1191 3 O
poor	1195 4 O
solubility	1200 10 O
of	1211 2 O
CB	1214 2 B-Chemical
3717	1217 4 I-Chemical
under	1222 5 O
acidic	1228 6 O
conditions	1235 10 O
.	1245 1 O

In	1247 2 O
an	1250 2 O
attempt	1253 7 O
to	1261 2 O
overcome	1264 8 O
this	1273 4 O
problem	1278 7 O
,	1285 1 O
a	1287 1 O
clinical	1289 8 O
trial	1298 5 O
of	1304 2 O
CB	1307 2 B-Chemical
3717	1310 4 I-Chemical
administered	1315 12 O
with	1328 4 O
alkaline	1333 8 O
diuresis	1342 8 O
is	1351 2 O
under	1354 5 O
way	1360 3 O
.	1363 1 O

Preliminary	1365 11 O
results	1377 7 O
at	1385 2 O
400	1388 3 O
and	1392 3 O
500	1396 3 O
mg	1400 2 O
/	1402 1 O
m2	1403 2 O
suggest	1406 7 O
that	1414 4 O
a	1419 1 O
reduction	1421 9 O
in	1431 2 O
nephrotoxicity	1434 14 B-Disease
may	1449 3 O
have	1453 4 O
been	1458 4 O
achieved	1463 8 O
with	1472 4 O
only	1477 4 O
1	1482 1 O
instance	1484 8 O
of	1493 2 O
renal	1496 5 B-Disease
toxicity	1502 8 I-Disease
in	1511 2 O
10	1514 2 O
patients	1517 8 O
.	1525 1 O

Hepatotoxicity	1527 14 B-Disease
and	1542 3 O
malaise	1546 7 B-Disease
are	1554 3 O
again	1558 5 O
the	1564 3 O
most	1568 4 O
frequent	1573 8 O
side	1582 4 O
effects	1587 7 O
.	1594 1 O

Evidence	1596 8 O
of	1605 2 O
antitumor	1608 9 O
activity	1618 8 O
has	1627 3 O
been	1631 4 O
seen	1636 4 O
in	1641 2 O
3	1644 1 O
patients	1646 8 O
.	1654 1 O

Pharmacokinetic	1656 15 O
investigations	1672 14 O
have	1687 4 O
shown	1692 5 O
that	1698 4 O
alkaline	1703 8 O
diuresis	1712 8 O
does	1721 4 O
not	1726 3 O
alter	1730 5 O
CB	1736 2 B-Chemical
3717	1739 4 I-Chemical
plasma	1744 6 O
levels	1751 6 O
or	1758 2 O
urinary	1761 7 O
excretion	1769 9 O
and	1779 3 O
that	1783 4 O
satisfactory	1788 12 O
urinary	1801 7 O
alkalinization	1809 14 O
can	1824 3 O
be	1828 2 O
readily	1831 7 O
achieved	1839 8 O
.	1847 1 O

Ethopropazine	0 13 B-Chemical
and	14 3 O
benztropine	18 11 B-Chemical
in	30 2 O
neuroleptic	33 11 O
-	44 1 O
induced	45 7 O
parkinsonism	53 12 B-Disease
.	65 1 O

In	67 2 O
a	70 1 O
12	72 2 O
-	74 1 O
week	75 4 O
controlled	80 10 O
study	91 5 O
ethopropazine	97 13 B-Chemical
was	111 3 O
compared	115 8 O
to	124 2 O
benztropine	127 11 B-Chemical
in	139 2 O
the	142 3 O
treatment	146 9 O
of	156 2 O
parkinsonism	159 12 B-Disease
induced	172 7 O
by	180 2 O
fluphenazine	183 12 B-Chemical
enanthate	196 9 I-Chemical
in	206 2 O
60	209 2 O
schizophrenic	212 13 B-Disease
outpatients	226 11 O
.	237 1 O

Ethopropazine	239 13 B-Chemical
and	253 3 O
benztropine	257 11 B-Chemical
were	269 4 O
found	274 5 O
to	280 2 O
be	283 2 O
equally	286 7 O
effective	294 9 O
in	304 2 O
controlling	307 11 O
parkinsonian	319 12 B-Disease
symptoms	332 8 I-Disease
and	341 3 O
were	345 4 O
as	350 2 O
efficacious	353 11 O
as	365 2 O
procyclidine	368 12 B-Chemical
,	380 1 O
their	382 5 O
previous	388 8 O
antiparkinsonian	397 16 O
drug	414 4 O
.	418 1 O

However	420 7 O
,	427 1 O
benztropine	429 11 B-Chemical
treated	441 7 O
patients	449 8 O
had	458 3 O
a	462 1 O
significant	464 11 O
increase	476 8 O
in	485 2 O
tardive	488 7 B-Disease
dyskinesia	496 10 I-Disease
compared	507 8 O
to	516 2 O
their	519 5 O
condition	525 9 O
during	535 6 O
procyclindine	542 13 B-Chemical
treatment	556 9 O
,	565 1 O
and	567 3 O
significantly	571 13 O
more	585 4 O
anxiety	590 7 B-Disease
and	598 3 O
depression	602 10 B-Disease
than	613 4 O
ethopropazine	618 13 B-Chemical
treated	632 7 O
patients	640 8 O
.	648 1 O

This	650 4 O
suggests	655 8 O
that	664 4 O
benztropine	669 11 B-Chemical
is	681 2 O
not	684 3 O
the	688 3 O
anticholinergic	692 15 O
drug	708 4 O
of	713 2 O
choice	716 6 O
in	723 2 O
the	726 3 O
treatment	730 9 O
of	740 2 O
neuroleptic	743 11 O
-	754 1 O
induced	755 7 O
parkinsonian	763 12 B-Disease
symptoms	776 8 I-Disease
,	784 1 O
because	786 7 O
of	794 2 O
its	797 3 O
more	801 4 O
toxic	806 5 O
central	812 7 O
and	820 3 O
peripheral	824 10 O
atropinic	835 9 O
effect	845 6 O
.	851 1 O

Effect	0 6 O
of	7 2 O
alpha	10 5 B-Chemical
-	15 1 I-Chemical
tocopherol	16 10 I-Chemical
and	27 3 O
deferoxamine	31 12 B-Chemical
on	44 2 O
methamphetamine	47 15 B-Chemical
-	62 1 O
induced	63 7 O
neurotoxicity	71 13 B-Disease
.	84 1 O

Methamphetamine	86 15 B-Chemical
(	102 1 O
MA	103 2 B-Chemical
)	105 1 O
-	106 1 O
induced	107 7 O
dopaminergic	115 12 O
neurotoxicity	128 13 B-Disease
is	142 2 O
believed	145 8 O
to	154 2 O
be	157 2 O
associated	160 10 O
with	171 4 O
the	176 3 O
increased	180 9 O
formation	190 9 O
of	200 2 O
free	203 4 O
radicals	208 8 O
.	216 1 O

This	218 4 O
study	223 5 O
examined	229 8 O
the	238 3 O
effect	242 6 O
of	249 2 O
alpha	252 5 B-Chemical
-	257 1 I-Chemical
tocopherol	258 10 I-Chemical
(	269 1 O
alpha	270 5 B-Chemical
-	275 1 I-Chemical
TC	276 2 I-Chemical
)	278 1 O
,	279 1 O
a	281 1 O
scavenger	283 9 O
of	293 2 O
reactive	296 8 O
oxygen	305 6 B-Chemical
species	312 7 O
,	319 1 O
and	321 3 O
deferoxamine	325 12 B-Chemical
(	338 1 O
DFO	339 3 B-Chemical
)	342 1 O
,	343 1 O
an	345 2 O
iron	348 4 B-Chemical
chelator	353 8 O
,	361 1 O
on	363 2 O
the	366 3 O
MA	370 2 B-Chemical
-	372 1 O
induced	373 7 O
neurotoxicity	381 13 B-Disease
.	394 1 O

Male	396 4 O
rats	401 4 O
were	406 4 O
treated	411 7 O
with	419 4 O
MA	424 2 B-Chemical
(	427 1 O
10	428 2 O
mg	431 2 O
/	433 1 O
kg	434 2 O
,	436 1 O
every	438 5 O
2	444 1 O
h	446 1 O
for	448 3 O
four	452 4 O
injections	457 10 O
)	467 1 O
.	468 1 O

The	470 3 O
rat	474 3 O
received	478 8 O
either	487 6 O
alpha	494 5 B-Chemical
-	499 1 I-Chemical
TC	500 2 I-Chemical
(	503 1 O
20	504 2 O
mg	507 2 O
/	509 1 O
kg	510 2 O
)	512 1 O
intraperitoneally	514 17 O
for	532 3 O
3	536 1 O
days	538 4 O
and	543 3 O
30	547 2 O
min	550 3 O
prior	554 5 O
to	560 2 O
MA	563 2 B-Chemical
administration	566 14 O
or	581 2 O
DFO	584 3 B-Chemical
(	588 1 O
50	589 2 O
mg	592 2 O
/	594 1 O
kg	595 2 O
)	597 1 O
subcutaneously	599 14 O
30	614 2 O
min	617 3 O
before	621 6 O
MA	628 2 B-Chemical
administration	631 14 O
.	645 1 O

The	647 3 O
concentrations	651 14 O
of	666 2 O
dopamine	669 8 B-Chemical
(	678 1 O
DA	679 2 B-Chemical
)	681 1 O
,	682 1 O
serotonin	684 9 B-Chemical
and	694 3 O
their	698 5 O
metabolites	704 11 O
decreased	716 9 O
significantly	726 13 O
after	740 5 O
MA	746 2 B-Chemical
administration	749 14 O
,	763 1 O
which	765 5 O
was	771 3 O
inhibited	775 9 O
by	785 2 O
the	788 3 O
alpha	792 5 B-Chemical
-	797 1 I-Chemical
TC	798 2 I-Chemical
and	801 3 O
DFO	805 3 B-Chemical
pretreatment	809 12 O
.	821 1 O

alpha	823 5 B-Chemical
-	828 1 I-Chemical
TC	829 2 I-Chemical
and	832 3 O
DFO	836 3 B-Chemical
attenuated	840 10 O
the	851 3 O
MA	855 2 B-Chemical
-	857 1 O
induced	858 7 O
hyperthermia	866 12 B-Disease
as	879 2 O
well	882 4 O
as	887 2 O
the	890 3 O
alterations	894 11 O
in	906 2 O
the	909 3 O
locomotor	913 9 O
activity	923 8 O
.	931 1 O

The	933 3 O
level	937 5 O
of	943 2 O
lipid	946 5 O
peroxidation	952 12 O
was	965 3 O
higher	969 6 O
and	976 3 O
the	980 3 O
reduced	984 7 O
glutathione	992 11 B-Chemical
concentration	1004 13 O
was	1018 3 O
lower	1022 5 O
in	1028 2 O
the	1031 3 O
MA	1035 2 B-Chemical
-	1037 1 O
treated	1038 7 O
rats	1046 4 O
.	1050 1 O

These	1052 5 O
changes	1058 7 O
were	1066 4 O
significantly	1071 13 O
attenuated	1085 10 O
by	1096 2 O
alpha	1099 5 B-Chemical
-	1104 1 I-Chemical
TC	1105 2 I-Chemical
and	1108 3 O
DFO	1112 3 B-Chemical
.	1115 1 O

This	1117 4 O
suggests	1122 8 O
that	1131 4 O
alpha	1136 5 B-Chemical
-	1141 1 I-Chemical
TC	1142 2 I-Chemical
and	1145 3 O
DFO	1149 3 B-Chemical
ameliorate	1153 10 O
the	1164 3 O
MA	1168 2 B-Chemical
-	1170 1 O
induced	1171 7 O
neuronal	1179 8 B-Disease
damage	1188 6 I-Disease
by	1195 2 O
decreasing	1198 10 O
the	1209 3 O
level	1213 5 O
of	1219 2 O
oxidative	1222 9 O
stress	1232 6 O
.	1238 1 O

Use	0 3 O
of	4 2 O
dexamethasone	7 13 B-Chemical
with	21 4 O
mesna	26 5 B-Chemical
for	32 3 O
the	36 3 O
prevention	40 10 O
of	51 2 O
ifosfamide	54 10 B-Chemical
-	64 1 O
induced	65 7 O
hemorrhagic	73 11 B-Disease
cystitis	85 8 I-Disease
.	93 1 O

AIM	95 3 O
:	98 1 O
Hemorrhagic	100 11 B-Disease
cystitis	112 8 I-Disease
(	121 1 O
HC	122 2 B-Disease
)	124 1 O
is	126 2 O
a	129 1 O
limiting	131 8 O
side	140 4 O
-	144 1 O
effect	145 6 O
of	152 2 O
chemotherapy	155 12 O
with	168 4 O
ifosfamide	173 10 B-Chemical
(	184 1 O
IFS	185 3 B-Chemical
)	188 1 O
.	189 1 O

In	191 2 O
the	194 3 O
study	198 5 O
presented	204 9 O
here	214 4 O
,	218 1 O
we	220 2 O
investigated	223 12 O
the	236 3 O
use	240 3 O
of	244 2 O
dexamethasone	247 13 B-Chemical
in	261 2 O
combination	264 11 O
with	276 4 O
mesna	281 5 B-Chemical
for	287 3 O
the	291 3 O
prevention	295 10 O
of	306 2 O
IFS	309 3 B-Chemical
-	312 1 O
induced	313 7 O
HC	321 2 B-Disease
.	323 1 O

METHODS	325 7 O
:	332 1 O
Male	334 4 O
Wistar	339 6 O
rats	346 4 O
(	351 1 O
150	352 3 O
-	355 1 O
200	356 3 O
g	360 1 O
;	361 1 O
6	363 1 O
rats	365 4 O
per	370 3 O
group	374 5 O
)	379 1 O
were	381 4 O
treated	386 7 O
with	394 4 O
saline	399 6 O
or	406 2 O
mesna	409 5 B-Chemical
5	415 1 O
min	417 3 O
(	421 1 O
i	422 1 O
.	423 1 O
p	424 1 O
.	425 1 O
)	426 1 O
before	428 6 O
and	435 3 O
2	439 1 O
and	441 3 O
6	445 1 O
h	447 1 O
after	449 5 O
(	455 1 O
v	456 1 O
.	457 1 O
o	458 1 O
.	459 1 O
)	460 1 O
administration	462 14 O
of	477 2 O
IFS	480 3 B-Chemical
.	483 1 O

One	485 3 O
,	488 1 O
two	490 3 O
or	494 2 O
three	497 5 O
doses	503 5 O
of	509 2 O
mesna	512 5 B-Chemical
were	518 4 O
replaced	523 8 O
with	532 4 O
dexamethasone	537 13 B-Chemical
alone	551 5 O
or	557 2 O
with	560 4 O
dexamethasone	565 13 B-Chemical
plus	579 4 O
mesna	584 5 B-Chemical
.	589 1 O

Cystitis	591 8 B-Disease
was	600 3 O
evaluated	604 9 O
24	614 2 O
h	617 1 O
after	619 5 O
its	625 3 O
induction	629 9 O
by	639 2 O
the	642 3 O
changes	646 7 O
in	654 2 O
bladder	657 7 O
wet	665 3 O
weight	669 6 O
and	676 3 O
by	680 2 O
macroscopic	683 11 O
and	695 3 O
microscopic	699 11 O
analysis	711 8 O
.	719 1 O

RESULTS	721 7 O
:	728 1 O
The	730 3 O
replacement	734 11 O
of	746 2 O
the	749 3 O
last	753 4 O
dose	758 4 O
or	763 2 O
the	766 3 O
last	770 4 O
two	775 3 O
doses	779 5 O
of	785 2 O
mesna	788 5 B-Chemical
with	794 4 O
dexamethasone	799 13 B-Chemical
reduced	813 7 O
the	821 3 O
increase	825 8 O
in	834 2 O
bladder	837 7 O
wet	845 3 O
weight	849 6 O
induced	856 7 O
by	864 2 O
IFS	867 3 B-Chemical
by	871 2 O
84	874 2 O
.	876 1 O
79	877 2 O
%	879 1 O
and	881 3 O
89	885 2 O
.	887 1 O
13	888 2 O
%	890 1 O
,	891 1 O
respectively	893 12 O
.	905 1 O

In	907 2 O
addition	910 8 O
,	918 1 O
it	920 2 O
almost	923 6 O
abolished	930 9 O
the	940 3 O
macroscopic	944 11 O
and	956 3 O
microscopic	960 11 O
alterations	972 11 O
induced	984 7 O
by	992 2 O
IFS	995 3 B-Chemical
.	998 1 O

Moreover	1000 8 O
,	1008 1 O
the	1010 3 O
addition	1014 8 O
of	1023 2 O
dexamethasone	1026 13 B-Chemical
to	1040 2 O
the	1043 3 O
last	1047 4 O
two	1052 3 O
doses	1056 5 O
of	1062 2 O
mesna	1065 5 B-Chemical
was	1071 3 O
more	1075 4 O
efficient	1080 9 O
than	1090 4 O
three	1095 5 O
doses	1101 5 O
of	1107 2 O
mesna	1110 5 B-Chemical
alone	1116 5 O
when	1122 4 O
evaluated	1127 9 O
microscopically	1137 15 O
.	1152 1 O

CONCLUSION	1154 10 O
:	1164 1 O
Dexamethasone	1166 13 B-Chemical
in	1180 2 O
combination	1183 11 O
with	1195 4 O
mesna	1200 5 B-Chemical
was	1206 3 O
efficient	1210 9 O
in	1220 2 O
blocking	1223 8 O
IFS	1232 3 B-Chemical
-	1235 1 O
induced	1236 7 O
HC	1244 2 B-Disease
.	1246 1 O

However	1248 7 O
,	1255 1 O
the	1257 3 O
replacement	1261 11 O
of	1273 2 O
last	1276 4 O
two	1281 3 O
doses	1285 5 O
of	1291 2 O
mesna	1294 5 B-Chemical
with	1300 4 O
saline	1305 6 O
or	1312 2 O
all	1315 3 O
of	1319 2 O
the	1322 3 O
mesna	1326 5 B-Chemical
doses	1332 5 O
with	1338 4 O
dexamethasone	1343 13 B-Chemical
did	1357 3 O
not	1361 3 O
prevent	1365 7 O
HC	1373 2 B-Disease
.	1375 1 O

Behavioral	0 10 O
effects	11 7 O
of	19 2 O
MK	22 2 B-Chemical
-	24 1 I-Chemical
801	25 3 I-Chemical
on	29 2 O
reserpine	32 9 B-Chemical
-	41 1 O
treated	42 7 O
mice	50 4 O
.	54 1 O

The	56 3 O
effects	60 7 O
of	68 2 O
dizocilpine	71 11 B-Chemical
(	83 1 O
MK	84 2 B-Chemical
-	86 1 I-Chemical
801	87 3 I-Chemical
)	90 1 O
,	91 1 O
a	93 1 O
noncompetitive	95 14 O
N	110 1 B-Chemical
-	111 1 I-Chemical
methyl	112 6 I-Chemical
-	118 1 I-Chemical
D	119 1 I-Chemical
-	120 1 I-Chemical
aspartate	121 9 I-Chemical
(	131 1 O
NMDA	132 4 B-Chemical
)	136 1 O
receptor	138 8 O
antagonist	147 10 O
,	157 1 O
were	159 4 O
studied	164 7 O
on	172 2 O
dopamine	175 8 B-Chemical
-	183 1 O
related	184 7 O
behaviors	192 9 O
induced	202 7 O
by	210 2 O
reserpine	213 9 B-Chemical
treatments	223 10 O
.	233 1 O

This	235 4 O
study	240 5 O
focuses	246 7 O
on	254 2 O
behavioral	257 10 O
syndromes	268 9 O
that	278 4 O
may	283 3 O
used	287 4 O
as	292 2 O
models	295 6 O
for	302 3 O
Parkinson	306 9 B-Disease
'	315 1 I-Disease
s	316 1 I-Disease
disease	318 7 I-Disease
,	325 1 O
or	327 2 O
tardive	330 7 B-Disease
dyskinesia	338 10 I-Disease
,	348 1 O
and	350 3 O
its	354 3 O
response	358 8 O
after	367 5 O
glutamatergic	373 13 O
blockage	387 8 O
.	395 1 O

Reserpine	397 9 B-Chemical
(	407 1 O
1	408 1 O
mg	410 2 O
/	412 1 O
kg	413 2 O
)	415 1 O
,	416 1 O
administered	418 12 O
once	431 4 O
every	436 5 O
other	442 5 O
day	448 3 O
for	452 3 O
4	456 1 O
days	458 4 O
,	462 1 O
produced	464 8 O
increases	473 9 O
in	483 2 O
orofacial	486 9 B-Disease
dyskinesia	496 10 I-Disease
,	506 1 O
tongue	508 6 O
protrusion	515 10 O
and	526 3 O
vacuous	530 7 O
chewing	538 7 O
in	546 2 O
mice	549 4 O
,	553 1 O
which	555 5 O
are	561 3 O
signs	565 5 O
indicative	571 10 O
of	582 2 O
tardive	585 7 B-Disease
dyskinesia	593 10 I-Disease
.	603 1 O

Reserpine	605 9 B-Chemical
also	615 4 O
produced	620 8 O
tremor	629 6 B-Disease
and	636 3 O
catalepsy	640 9 B-Disease
,	649 1 O
which	651 5 O
are	657 3 O
signs	661 5 O
suggestive	667 10 O
of	678 2 O
Parkinson	681 9 B-Disease
'	690 1 I-Disease
s	691 1 I-Disease
disease	693 7 I-Disease
.	700 1 O

MK	702 2 B-Chemical
-	704 1 I-Chemical
801	705 3 I-Chemical
(	709 1 O
0	710 1 O
.	711 1 O
1	712 1 O
mg	714 2 O
/	716 1 O
kg	717 2 O
)	719 1 O
,	720 1 O
administered	722 12 O
30	735 2 O
min	738 3 O
before	742 6 O
the	749 3 O
observation	753 11 O
test	765 4 O
,	769 1 O
prevented	771 9 O
the	781 3 O
vacuous	785 7 O
chewing	793 7 O
movements	801 9 O
,	810 1 O
tongue	812 6 O
protrusions	819 11 O
and	831 3 O
catalepsy	835 9 B-Disease
induced	845 7 O
by	853 2 O
reserpine	856 9 B-Chemical
.	865 1 O

However	867 7 O
,	874 1 O
MK	876 2 B-Chemical
-	878 1 I-Chemical
801	879 3 I-Chemical
injection	883 9 O
produced	893 8 O
a	902 1 O
significant	904 11 O
increase	916 8 O
of	925 2 O
tremor	928 6 B-Disease
in	935 2 O
reserpine	938 9 B-Chemical
-	947 1 O
treated	948 7 O
mice	956 4 O
.	960 1 O

Reserpine	962 9 B-Chemical
(	972 1 O
1	973 1 O
mg	975 2 O
/	977 1 O
kg	978 2 O
)	980 1 O
,	981 1 O
administered	983 12 O
90	996 2 O
min	999 3 O
before	1003 6 O
the	1010 3 O
test	1014 4 O
and	1019 3 O
followed	1023 8 O
by	1032 2 O
apomophine	1035 10 B-Chemical
injection	1046 9 O
(	1056 1 O
0	1057 1 O
.	1058 1 O
1	1059 1 O
mg	1061 2 O
/	1063 1 O
kg	1064 2 O
)	1066 1 O
5	1068 1 O
min	1070 3 O
before	1074 6 O
the	1081 3 O
test	1085 4 O
,	1089 1 O
did	1091 3 O
not	1095 3 O
produce	1099 7 O
oral	1107 4 B-Disease
dyskinesia	1112 10 I-Disease
in	1123 2 O
mice	1126 4 O
.	1130 1 O

On	1132 2 O
the	1135 3 O
other	1139 5 O
hand	1145 4 O
,	1149 1 O
reserpine	1151 9 B-Chemical
induced	1161 7 O
increases	1169 9 O
in	1179 2 O
tremor	1182 6 B-Disease
and	1189 3 O
catalepsy	1193 9 B-Disease
compared	1203 8 O
to	1212 2 O
control	1215 7 O
mice	1223 4 O
.	1227 1 O

MK	1229 2 B-Chemical
-	1231 1 I-Chemical
801	1232 3 I-Chemical
(	1236 1 O
0	1237 1 O
.	1238 1 O
1	1239 1 O
mg	1241 2 O
/	1243 1 O
kg	1244 2 O
)	1246 1 O
administration	1248 14 O
attenuated	1263 10 O
the	1274 3 O
catalepsy	1278 9 B-Disease
and	1288 3 O
tremor	1292 6 B-Disease
induced	1299 7 O
by	1307 2 O
reserpine	1310 9 B-Chemical
.	1319 1 O

Pretreatment	1321 12 O
with	1334 4 O
reserpine	1339 9 B-Chemical
(	1349 1 O
1	1350 1 O
mg	1352 2 O
/	1354 1 O
kg	1355 2 O
)	1357 1 O
24	1359 2 O
h	1362 1 O
before	1364 6 O
the	1371 3 O
observation	1375 11 O
test	1387 4 O
produced	1392 8 O
increases	1401 9 O
in	1411 2 O
vacuous	1414 7 O
chewing	1422 7 O
movements	1430 9 O
and	1440 3 O
tongue	1444 6 O
protrusion	1451 10 O
,	1461 1 O
as	1463 2 O
well	1466 4 O
as	1471 2 O
increases	1474 9 O
in	1484 2 O
tremor	1487 6 B-Disease
and	1494 3 O
catalepsy	1498 9 B-Disease
,	1507 1 O
whereas	1509 7 O
MK	1517 2 B-Chemical
-	1519 1 I-Chemical
801	1520 3 I-Chemical
(	1524 1 O
0	1525 1 O
.	1526 1 O
1	1527 1 O
mg	1529 2 O
/	1531 1 O
kg	1532 2 O
)	1534 1 O
injection	1536 9 O
90	1546 2 O
min	1549 3 O
before	1553 6 O
the	1560 3 O
test	1564 4 O
reversed	1569 8 O
the	1578 3 O
effects	1582 7 O
of	1590 2 O
reserpine	1593 9 B-Chemical
.	1602 1 O

These	1604 5 O
results	1610 7 O
show	1618 4 O
that	1623 4 O
reserpine	1628 9 B-Chemical
produces	1638 8 O
different	1647 9 O
and	1657 3 O
abnormal	1661 8 B-Disease
movements	1670 9 I-Disease
,	1679 1 O
which	1681 5 O
are	1687 3 O
related	1691 7 O
to	1699 2 O
dose	1702 4 O
and	1707 3 O
schedule	1711 8 O
employed	1720 8 O
and	1729 3 O
can	1733 3 O
be	1737 2 O
considered	1740 10 O
as	1751 2 O
parkinsonian	1754 12 B-Disease
-	1766 1 O
like	1767 4 O
and	1772 3 O
tardive	1776 7 B-Disease
dsykinesia	1784 10 I-Disease
signs	1795 5 O
.	1800 1 O

The	1802 3 O
glutamatergic	1806 13 O
blockage	1820 8 O
produced	1829 8 O
by	1838 2 O
NMDA	1841 4 B-Chemical
can	1846 3 O
restore	1850 7 O
these	1858 5 O
signs	1864 5 O
,	1869 1 O
such	1871 4 O
as	1876 2 O
vacuous	1879 7 O
chewing	1887 7 O
movements	1895 9 O
,	1904 1 O
tongue	1906 6 O
protrusions	1913 11 O
,	1924 1 O
catalepsy	1926 9 B-Disease
and	1936 3 O
tremor	1940 6 B-Disease
according	1947 9 O
to	1957 2 O
the	1960 3 O
employed	1964 8 O
model	1973 5 O
.	1978 1 O

Effect	0 6 O
of	7 2 O
glyceryl	10 8 B-Chemical
trinitrate	19 10 I-Chemical
on	30 2 O
the	33 3 O
sphincter	37 9 B-Disease
of	47 2 I-Disease
Oddi	50 4 I-Disease
spasm	55 5 I-Disease
evoked	61 6 O
by	68 2 O
prostigmine	71 11 B-Chemical
-	82 1 O
morphine	83 8 B-Chemical
administration	92 14 O
.	106 1 O

OBJECTIVE	108 9 O
:	117 1 O
In	119 2 O
this	122 4 O
study	127 5 O
the	133 3 O
effect	137 6 O
of	144 2 O
glyceryl	147 8 B-Chemical
trinitrate	156 10 I-Chemical
on	167 2 O
the	170 3 O
prostigmine	174 11 B-Chemical
-	185 1 O
morphine	186 8 B-Chemical
-	194 1 O
induced	195 7 O
sphincter	203 9 B-Disease
of	213 2 I-Disease
Oddi	216 4 I-Disease
spasm	221 5 I-Disease
was	227 3 O
evaluated	231 9 O
in	241 2 O
nine	244 4 O
female	249 6 O
patients	256 8 O
with	265 4 O
sphincter	270 9 B-Disease
of	280 2 I-Disease
Oddi	283 4 I-Disease
dyskinesia	288 10 I-Disease
.	298 1 O

METHOD	300 6 O
:	306 1 O
Sphincter	308 9 B-Disease
of	318 2 I-Disease
Oddi	321 4 I-Disease
spasm	326 5 I-Disease
was	332 3 O
induced	336 7 O
by	344 2 O
prostigmine	347 11 B-Chemical
-	358 1 O
morphine	359 8 B-Chemical
administration	368 14 O
(	383 1 O
0	384 1 O
.	385 1 O
5	386 1 O
mg	388 2 O
prostigmine	391 11 B-Chemical
intramuscularly	403 15 O
and	419 3 O
10	423 2 O
mg	426 2 O
morphine	429 8 B-Chemical
subcutaneously	438 14 O
)	452 1 O
and	454 3 O
visualized	458 10 O
by	469 2 O
quantitative	472 12 O
hepatobiliary	485 13 O
scintigraphy	499 12 O
.	511 1 O

The	513 3 O
entire	517 6 O
procedure	524 9 O
was	534 3 O
repeated	538 8 O
during	547 6 O
glyceryl	554 8 B-Chemical
trinitrate	563 10 I-Chemical
infusion	574 8 O
(	583 1 O
Nitrolingual	584 12 B-Chemical
1	597 1 O
microg	599 6 O
/	605 1 O
kg	606 2 O
/	608 1 O
min	609 3 O
for	613 3 O
120	617 3 O
min	621 3 O
)	624 1 O
.	625 1 O

RESULTS	627 7 O
:	634 1 O
Prostigmine	636 11 B-Chemical
-	647 1 O
morphine	648 8 B-Chemical
provocation	657 11 O
caused	669 6 O
significant	676 11 O
increases	688 9 O
in	698 2 O
the	701 3 O
time	705 4 O
to	710 2 O
peak	713 4 O
activity	718 8 O
(	727 1 O
Tmax	728 4 O
)	732 1 O
over	734 4 O
the	739 3 O
hepatic	743 7 O
hilum	751 5 O
(	757 1 O
HH	758 2 O
:	760 1 O
34	762 2 O
.	764 1 O
33	765 2 O
+	768 1 O
/	769 1 O
-	770 1 O
5	772 1 O
.	773 1 O
05	774 2 O
vs	777 2 O
.	779 1 O
22	781 2 O
.	783 1 O
77	784 2 O
+	787 1 O
/	788 1 O
-	789 1 O
3	791 1 O
.	792 1 O
26	793 2 O
)	795 1 O
and	797 3 O
the	801 3 O
common	805 6 O
bile	812 4 O
duct	817 4 O
(	822 1 O
CBD	823 3 O
:	826 1 O
60	828 2 O
.	830 1 O
44	831 2 O
+	834 1 O
/	835 1 O
-	836 1 O
5	838 1 O
.	839 1 O
99	840 2 O
vs	843 2 O
.	845 1 O
40	847 2 O
.	849 1 O
0	850 1 O
+	852 1 O
/	853 1 O
-	854 1 O
2	856 1 O
.	857 1 O
88	858 2 O
)	860 1 O
and	862 3 O
in	866 2 O
the	869 3 O
half	873 4 O
-	877 1 O
time	878 4 O
of	883 2 O
excretion	886 9 O
(	896 1 O
T1	897 2 O
/	899 1 O
2	900 1 O
)	901 1 O
over	903 4 O
the	908 3 O
liver	912 5 O
parenchyma	918 10 O
(	929 1 O
LP	930 2 O
:	932 1 O
120	934 3 O
.	937 1 O
04	938 2 O
+	941 1 O
/	942 1 O
-	943 1 O
16	945 2 O
.	947 1 O
01	948 2 O
vs	951 2 O
.	953 1 O
27	955 2 O
.	957 1 O
37	958 2 O
+	961 1 O
/	962 1 O
-	963 1 O
2	965 1 O
.	966 1 O
19	967 2 O
)	969 1 O
,	970 1 O
HH	972 2 O
(	975 1 O
117	976 3 O
.	979 1 O
61	980 2 O
+	983 1 O
/	984 1 O
-	985 1 O
14	987 2 O
.	989 1 O
71	990 2 O
vs	993 2 O
.	995 1 O
31	997 2 O
.	999 1 O
85	1000 2 O
+	1003 1 O
/	1004 1 O
-	1005 1 O
3	1007 1 O
.	1008 1 O
99	1009 2 O
)	1011 1 O
and	1013 3 O
CBD	1017 3 O
(	1021 1 O
158	1022 3 O
.	1025 1 O
11	1026 2 O
+	1029 1 O
/	1030 1 O
-	1031 1 O
9	1033 1 O
.	1034 1 O
18	1035 2 O
vs	1038 2 O
.	1040 1 O
40	1042 2 O
.	1044 1 O
1	1045 1 O
+	1047 1 O
/	1048 1 O
-	1049 1 O
6	1051 1 O
.	1052 1 O
24	1053 2 O
)	1055 1 O
,	1056 1 O
indicating	1058 10 O
a	1069 1 O
complete	1071 8 O
spasm	1080 5 B-Disease
at	1086 2 O
the	1089 3 O
level	1093 5 O
of	1099 2 O
the	1102 3 O
sphincter	1106 9 O
of	1116 2 O
Oddi	1119 4 O
.	1123 1 O

Glyceryl	1125 8 B-Chemical
trinitrate	1134 10 I-Chemical
infusion	1145 8 O
completely	1154 10 O
normalized	1165 10 O
the	1176 3 O
prostigmine	1180 11 B-Chemical
-	1191 1 O
morphine	1192 8 B-Chemical
-	1200 1 O
induced	1201 7 O
alterations	1209 11 O
in	1221 2 O
these	1224 5 O
quantitative	1230 12 O
parameters	1243 10 O
(	1254 1 O
TmaX	1255 4 O
over	1260 4 O
the	1265 3 O
LP	1269 2 O
:	1271 1 O
11	1273 2 O
.	1275 1 O
33	1276 2 O
+	1279 1 O
/	1280 1 O
-	1281 1 O
1	1283 1 O
.	1284 1 O
13	1285 2 O
;	1287 1 O
over	1289 4 O
the	1294 3 O
HH	1298 2 O
:	1300 1 O
18	1302 2 O
.	1304 1 O
88	1305 2 O
+	1308 1 O
/	1309 1 O
-	1310 1 O
1	1312 1 O
.	1313 1 O
48	1314 2 O
;	1316 1 O
and	1318 3 O
over	1322 4 O
the	1327 3 O
CBD	1331 3 O
:	1334 1 O
36	1336 2 O
.	1338 1 O
22	1339 2 O
+	1342 1 O
/	1343 1 O
-	1344 1 O
1	1346 1 O
.	1347 1 O
92	1348 2 O
;	1350 1 O
and	1352 3 O
T1	1356 2 O
/	1358 1 O
2	1359 1 O
over	1361 4 O
the	1366 3 O
LP	1370 2 O
:	1372 1 O
28	1374 2 O
.	1376 1 O
21	1377 2 O
+	1380 1 O
/	1381 1 O
-	1382 1 O
1	1384 1 O
.	1385 1 O
83	1386 2 O
;	1388 1 O
over	1390 4 O
the	1395 3 O
HH	1399 2 O
:	1401 1 O
33	1403 2 O
.	1405 1 O
42	1406 2 O
+	1409 1 O
/	1410 1 O
-	1411 1 O
3	1413 1 O
.	1414 1 O
10	1415 2 O
;	1417 1 O
and	1419 3 O
over	1423 4 O
the	1428 3 O
CBD	1432 3 O
:	1435 1 O
41	1437 2 O
.	1439 1 O
66	1440 2 O
+	1443 1 O
/	1444 1 O
-	1445 1 O
6	1447 1 O
.	1448 1 O
33	1449 2 O
)	1451 1 O
,	1452 1 O
suggesting	1454 10 O
an	1465 2 O
effective	1468 9 O
sphincter	1478 9 O
-	1487 1 O
relaxing	1488 8 O
effect	1497 6 O
of	1504 2 O
glyceryl	1507 8 B-Chemical
trinitrate	1516 10 I-Chemical
.	1526 1 O

CONCLUSION	1528 10 O
:	1538 1 O
These	1540 5 O
results	1546 7 O
provide	1554 7 O
the	1562 3 O
first	1566 5 O
evidence	1572 8 O
of	1581 2 O
the	1584 3 O
effectiveness	1588 13 O
of	1602 2 O
glyceryl	1605 8 B-Chemical
trinitrate	1614 10 I-Chemical
on	1625 2 O
the	1628 3 O
morphine	1632 8 B-Chemical
-	1640 1 O
induced	1641 7 O
sphincter	1649 9 B-Disease
of	1659 2 I-Disease
Oddi	1662 4 I-Disease
spasm	1667 5 I-Disease
in	1673 2 O
humans	1676 6 O
.	1682 1 O

Since	1684 5 O
glyceryl	1690 8 B-Chemical
trinitrate	1699 10 I-Chemical
is	1710 2 O
able	1713 4 O
to	1718 2 O
overcome	1721 8 O
even	1730 4 O
the	1735 3 O
drastic	1739 7 O
effect	1747 6 O
of	1754 2 O
morphine	1757 8 B-Chemical
,	1765 1 O
it	1767 2 O
might	1770 5 O
be	1776 2 O
of	1779 2 O
relevance	1782 9 O
in	1792 2 O
the	1795 3 O
treatment	1799 9 O
of	1809 2 O
sphincter	1812 9 B-Disease
of	1822 2 I-Disease
Oddi	1825 4 I-Disease
dyskinesia	1830 10 I-Disease
.	1840 1 O

Effects	0 7 O
of	8 2 O
acute	11 5 O
steroid	17 7 B-Chemical
administration	25 14 O
on	40 2 O
ventilatory	43 11 O
and	55 3 O
peripheral	59 10 O
muscles	70 7 O
in	78 2 O
rats	81 4 O
.	85 1 O

Occasional	87 10 O
case	98 4 O
reports	103 7 O
have	111 4 O
shown	116 5 O
that	122 4 O
acute	127 5 O
myopathy	133 8 B-Disease
may	142 3 O
occur	146 5 O
in	152 2 O
patients	155 8 O
treated	164 7 O
with	172 4 O
massive	177 7 O
doses	185 5 O
of	191 2 O
corticosteroids	194 15 B-Chemical
.	209 1 O

The	211 3 O
mechanism	215 9 O
of	225 2 O
this	228 4 O
myopathy	233 8 B-Disease
is	242 2 O
poorly	245 6 O
understood	252 10 O
.	262 1 O

Therefore	264 9 O
,	273 1 O
60	275 2 O
male	278 4 O
rats	283 4 O
were	288 4 O
randomly	293 8 O
assigned	302 8 O
to	311 2 O
receive	314 7 O
daily	322 5 O
injection	328 9 O
of	338 2 O
saline	341 6 O
(	348 1 O
C	349 1 O
)	350 1 O
,	351 1 O
methylprednisolone	353 18 B-Chemical
(	372 1 O
M	373 1 B-Chemical
)	374 1 O
,	375 1 O
or	377 2 O
triamcinolone	380 13 B-Chemical
(	394 1 O
T	395 1 B-Chemical
)	396 1 O
80	398 2 O
mg	401 2 O
/	403 1 O
kg	404 2 O
/	406 1 O
d	407 1 O
for	409 3 O
5	413 1 O
d	415 1 O
.	416 1 O

Nutritional	418 11 O
intake	430 6 O
,	436 1 O
measured	438 8 O
daily	447 5 O
in	453 2 O
15	456 2 O
animals	459 7 O
,	466 1 O
showed	468 6 O
a	475 1 O
significant	477 11 O
reduction	489 9 B-Disease
of	499 2 I-Disease
food	502 4 I-Disease
intake	507 6 I-Disease
in	514 2 O
the	517 3 O
steroid	521 7 B-Chemical
-	528 1 O
treated	529 7 O
groups	537 6 O
(	544 1 O
-	545 1 O
50	546 2 O
and	549 3 O
-	553 1 O
79	554 2 O
%	556 1 O
in	558 2 O
M	561 1 B-Chemical
and	563 3 O
T	567 1 B-Chemical
,	568 1 O
respectively	570 12 O
)	582 1 O
.	583 1 O

This	585 4 O
was	590 3 O
associated	594 10 O
with	605 4 O
a	610 1 O
similar	612 7 O
loss	620 4 B-Disease
in	625 2 I-Disease
body	628 4 I-Disease
weight	633 6 I-Disease
.	639 1 O

In	641 2 O
the	644 3 O
45	648 2 O
remaining	651 9 O
animals	661 7 O
,	668 1 O
diaphragm	670 9 O
contractility	680 13 O
and	694 3 O
histopathologic	698 15 O
features	714 8 O
of	723 2 O
several	726 7 O
muscles	734 7 O
were	742 4 O
studied	747 7 O
.	754 1 O

Weights	756 7 O
of	764 2 O
respiratory	767 11 O
and	779 3 O
peripheral	783 10 O
muscles	794 7 O
were	802 4 O
similarly	807 9 O
decreased	817 9 O
after	827 5 O
steroid	833 7 B-Chemical
treatment	841 9 O
.	850 1 O

Maximal	852 7 O
twitches	860 8 O
of	869 2 O
the	872 3 O
diaphragm	876 9 O
were	886 4 O
lower	891 5 O
in	897 2 O
the	900 3 O
C	904 1 O
group	906 5 O
(	912 1 O
653	913 3 O
+	917 1 O
/	918 1 O
-	919 1 O
174	921 3 O
g	925 1 O
/	926 1 O
cm	927 2 O
(	929 1 O
2	930 1 O
)	931 1 O
)	932 1 O
than	934 4 O
in	939 2 O
the	942 3 O
M	946 1 B-Chemical
group	948 5 O
(	954 1 O
837	955 3 O
+	959 1 O
/	960 1 O
-	961 1 O
171	963 3 O
g	967 1 O
/	968 1 O
cm	969 2 O
(	971 1 O
2	972 1 O
)	973 1 O
;	974 1 O
p	976 1 O
<	978 1 O
0	980 1 O
.	981 1 O
05	982 2 O
)	984 1 O
and	986 3 O
the	990 3 O
T	994 1 B-Chemical
group	996 5 O
(	1002 1 O
765	1003 3 O
+	1007 1 O
/	1008 1 O
-	1009 1 O
145	1011 3 O
g	1015 1 O
/	1016 1 O
cm	1017 2 O
(	1019 1 O
2	1020 1 O
)	1021 1 O
,	1022 1 O
NS	1024 2 O
)	1026 1 O
.	1027 1 O

Half	1029 4 O
-	1033 1 O
relaxation	1034 10 O
time	1045 4 O
was	1050 3 O
prolonged	1054 9 O
in	1064 2 O
both	1067 4 O
steroid	1072 7 B-Chemical
groups	1080 6 O
,	1086 1 O
and	1088 3 O
time	1092 4 O
to	1097 2 O
peak	1100 4 O
tension	1105 7 O
was	1113 3 O
longer	1117 6 O
with	1124 4 O
M	1129 1 B-Chemical
,	1130 1 O
whereas	1132 7 O
tetanic	1140 7 B-Disease
tensions	1148 8 O
were	1157 4 O
similar	1162 7 O
.	1169 1 O

Steroid	1171 7 B-Chemical
treatment	1179 9 O
also	1189 4 O
induced	1194 7 O
a	1202 1 O
leftward	1204 8 O
shift	1213 5 O
of	1219 2 O
the	1222 3 O
force	1226 5 O
-	1231 1 O
frequency	1232 9 O
curve	1242 5 O
at	1248 2 O
25	1251 2 O
and	1254 3 O
50	1258 2 O
Hz	1261 2 O
when	1264 4 O
compared	1269 8 O
with	1278 4 O
saline	1283 6 O
treatment	1290 9 O
(	1300 1 O
p	1301 1 O
<	1303 1 O
0	1305 1 O
.	1306 1 O
05	1307 2 O
)	1309 1 O
.	1310 1 O

ATPase	1312 6 O
staining	1319 8 O
of	1328 2 O
the	1331 3 O
diaphragm	1335 9 O
,	1344 1 O
scalenus	1346 8 O
medius	1355 6 O
,	1361 1 O
and	1363 3 O
gastrocnemius	1367 13 O
showed	1381 6 O
type	1388 4 O
IIb	1393 3 O
fiber	1397 5 O
atrophy	1403 7 B-Disease
in	1411 2 O
the	1414 3 O
steroid	1418 7 B-Chemical
groups	1426 6 O
and	1433 3 O
also	1437 4 O
diaphragmatic	1442 13 O
type	1456 4 O
IIa	1461 3 O
atrophy	1465 7 B-Disease
with	1473 4 O
T	1478 1 B-Chemical
,	1479 1 O
whereas	1481 7 O
histologic	1489 10 O
examinations	1500 12 O
revealed	1513 8 O
a	1522 1 O
normal	1524 6 O
muscular	1531 8 O
pattern	1540 7 O
with	1548 4 O
absence	1553 7 O
of	1561 2 O
necrosis	1564 8 B-Disease
.	1572 1 O

Finally	1574 7 O
,	1581 1 O
a	1583 1 O
pair	1585 4 O
-	1589 1 O
fed	1590 3 O
(	1594 1 O
PF	1595 2 O
)	1597 1 O
study	1599 5 O
,	1604 1 O
performed	1606 9 O
in	1616 2 O
18	1619 2 O
rats	1622 4 O
(	1627 1 O
C	1628 1 O
,	1629 1 O
T	1631 1 B-Chemical
,	1632 1 O
and	1634 3 O
PF	1638 2 O
)	1640 1 O
,	1641 1 O
showed	1643 6 O
that	1650 4 O
muscle	1655 6 B-Disease
atrophy	1662 7 I-Disease
was	1670 3 O
considerably	1674 12 O
less	1687 4 O
pronounced	1692 10 O
in	1703 2 O
PF	1706 2 O
animals	1709 7 O
than	1717 4 O
in	1722 2 O
T	1725 1 B-Chemical
-	1726 1 O
treated	1727 7 O
animals	1735 7 O
.	1742 1 O

We	1744 2 O
conclude	1747 8 O
that	1756 4 O
(	1761 1 O
1	1762 1 O
)	1763 1 O
short	1765 5 O
-	1770 1 O
term	1771 4 O
treatment	1776 9 O
with	1786 4 O
massive	1791 7 O
doses	1799 5 O
of	1805 2 O
steroids	1808 8 B-Chemical
induced	1817 7 O
severe	1825 6 O
respiratory	1832 11 O
and	1844 3 O
limb	1848 4 O
muscle	1853 6 O
wasting	1860 7 O
;	1867 1 O
(	1869 1 O
2	1870 1 O
)	1871 1 O
both	1873 4 O
types	1878 5 O
of	1884 2 O
steroids	1887 8 B-Chemical
induced	1896 7 O
predominantly	1904 13 O
type	1918 4 O
IIb	1923 3 O
atrophy	1927 7 B-Disease
,	1934 1 O
resulting	1936 9 O
in	1946 2 O
the	1949 3 O
expected	1953 8 O
alterations	1962 11 O
in	1974 2 O
diaphragm	1977 9 O
contractile	1987 11 O
properties	1999 10 O
;	2009 1 O
(	2011 1 O
3	2012 1 O
)	2013 1 O
neither	2015 7 O
steroid	2023 7 B-Chemical
caused	2031 6 O
muscle	2038 6 O
necrosis	2045 8 B-Disease
;	2053 1 O
(	2055 1 O
4	2056 1 O
)	2057 1 O
type	2059 4 O
IIb	2064 3 O
atrophy	2068 7 B-Disease
was	2076 3 O
not	2080 3 O
caused	2084 6 O
by	2091 2 O
acute	2094 5 O
nutritional	2100 11 O
deprivation	2112 11 O
alone	2124 5 O
.	2129 1 O

Refractory	0 10 O
cardiogenic	11 11 B-Disease
shock	23 5 I-Disease
and	29 3 O
complete	33 8 O
heart	42 5 B-Disease
block	48 5 I-Disease
after	54 5 O
verapamil	60 9 B-Chemical
SR	70 2 O
and	73 3 O
metoprolol	77 10 B-Chemical
treatment	88 9 O
.	97 1 O

A	99 1 O
case	101 4 O
report	106 6 O
.	112 1 O

A	114 1 O
seventy	116 7 O
-	123 1 O
eight	124 5 O
-	129 1 O
year	130 4 O
-	134 1 O
old	135 3 O
woman	139 5 O
presented	145 9 O
with	155 4 O
complete	160 8 O
heart	169 5 B-Disease
block	175 5 I-Disease
and	181 3 O
refractory	185 10 O
hypotension	196 11 B-Disease
two	208 3 O
days	212 4 O
after	217 5 O
a	223 1 O
therapeutic	225 11 O
dose	237 4 O
of	242 2 O
sustained	245 9 O
-	254 1 O
release	255 7 O
verapamil	263 9 B-Chemical
with	273 4 O
concomitant	278 11 O
use	290 3 O
of	294 2 O
metoprolol	297 10 B-Chemical
.	307 1 O

The	309 3 O
patient	313 7 O
continued	321 9 O
to	331 2 O
remain	334 6 O
hypotensive	341 11 B-Disease
with	353 4 O
complete	358 8 O
heart	367 5 B-Disease
block	373 5 I-Disease
,	378 1 O
even	380 4 O
with	385 4 O
multiple	390 8 O
uses	399 4 O
of	404 2 O
intravenous	407 11 O
atropine	419 8 B-Chemical
as	428 2 O
well	431 4 O
as	436 2 O
high	439 4 O
doses	444 5 O
of	450 2 O
pressor	453 7 O
agents	461 6 O
such	468 4 O
as	473 2 O
dopamine	476 8 B-Chemical
and	485 3 O
dobutamine	489 10 B-Chemical
.	499 1 O

However	501 7 O
,	508 1 O
shortly	510 7 O
after	518 5 O
the	524 3 O
use	528 3 O
of	532 2 O
intravenous	535 11 O
calcium	547 7 B-Chemical
chloride	555 8 I-Chemical
,	563 1 O
the	565 3 O
refractory	569 10 O
hypotension	580 11 B-Disease
and	592 3 O
complete	596 8 O
heart	605 5 B-Disease
block	611 5 I-Disease
resolved	617 8 O
.	625 1 O

A	0 1 O
phase	2 5 O
I	8 1 O
clinical	10 8 O
study	19 5 O
of	25 2 O
the	28 3 O
antipurine	32 10 B-Chemical
antifolate	43 10 O
lometrexol	54 10 B-Chemical
(	65 1 O
DDATHF	66 6 B-Chemical
)	72 1 O
given	74 5 O
with	80 4 O
oral	85 4 O
folic	90 5 B-Chemical
acid	96 4 I-Chemical
.	100 1 O

Lometrexol	102 10 B-Chemical
is	113 2 O
an	116 2 O
antifolate	119 10 O
which	130 5 O
inhibits	136 8 O
glycinamide	145 11 B-Chemical
ribonucleotide	157 14 I-Chemical
formyltransferase	172 17 O
(	190 1 O
GARFT	191 5 O
)	196 1 O
,	197 1 O
an	199 2 O
enzyme	202 6 O
essential	209 9 O
for	219 3 O
de	223 2 O
novo	226 4 O
purine	231 6 B-Chemical
synthesis	238 9 O
.	247 1 O

Extensive	249 9 O
experimental	259 12 O
and	272 3 O
limited	276 7 O
clinical	284 8 O
data	293 4 O
have	298 4 O
shown	303 5 O
that	309 4 O
lometrexol	314 10 B-Chemical
has	325 3 O
activity	329 8 O
against	338 7 O
tumours	346 7 B-Disease
which	354 5 O
are	360 3 O
refractory	364 10 O
to	375 2 O
other	378 5 O
drugs	384 5 O
,	389 1 O
notably	391 7 O
methotrexate	399 12 B-Chemical
.	411 1 O

However	413 7 O
,	420 1 O
the	422 3 O
initial	426 7 O
clinical	434 8 O
development	443 11 O
of	455 2 O
lometrexol	458 10 B-Chemical
was	469 3 O
curtailed	473 9 O
because	483 7 O
of	491 2 O
severe	494 6 O
and	501 3 O
cumulative	505 10 O
antiproliferative	516 17 O
toxicities	534 10 B-Disease
.	544 1 O

Preclinical	546 11 O
murine	558 6 O
studies	565 7 O
demonstrated	573 12 O
that	586 4 O
the	591 3 O
toxicity	595 8 B-Disease
of	604 2 O
lometrexol	607 10 B-Chemical
can	618 3 O
be	622 2 O
prevented	625 9 O
by	635 2 O
low	638 3 O
dose	642 4 O
folic	647 5 B-Chemical
acid	653 4 I-Chemical
administration	658 14 O
,	672 1 O
i	674 1 O
.	675 1 O
e	676 1 O
.	677 1 O
for	679 3 O
7	683 1 O
days	685 4 O
prior	690 5 O
to	696 2 O
and	699 3 O
7	703 1 O
days	705 4 O
following	710 9 O
a	720 1 O
single	722 6 O
bolus	729 5 O
dose	735 4 O
.	739 1 O

This	741 4 O
observation	746 11 O
prompted	758 8 O
a	767 1 O
Phase	769 5 O
I	775 1 O
clinical	777 8 O
study	786 5 O
of	792 2 O
lometrexol	795 10 B-Chemical
given	806 5 O
with	812 4 O
folic	817 5 B-Chemical
acid	823 4 I-Chemical
supplementation	828 15 O
which	844 5 O
has	850 3 O
confirmed	854 9 O
that	864 4 O
the	869 3 O
toxicity	873 8 B-Disease
of	882 2 O
lometrexol	885 10 B-Chemical
can	896 3 O
be	900 2 O
markedly	903 8 O
reduced	912 7 O
by	920 2 O
folic	923 5 B-Chemical
acid	929 4 I-Chemical
supplementation	934 15 O
.	949 1 O

Thrombocytopenia	951 16 B-Disease
and	968 3 O
mucositis	972 9 B-Disease
were	982 4 O
the	987 3 O
major	991 5 O
toxicities	997 10 B-Disease
.	1007 1 O

There	1009 5 O
was	1015 3 O
no	1019 2 O
clear	1022 5 O
relationship	1028 12 O
between	1041 7 O
clinical	1049 8 O
toxicity	1058 8 B-Disease
and	1067 3 O
the	1071 3 O
extent	1075 6 O
of	1082 2 O
plasma	1085 6 O
folate	1092 6 B-Chemical
elevation	1099 9 O
.	1108 1 O

Associated	1110 10 O
studies	1121 7 O
demonstrated	1129 12 O
that	1142 4 O
lometrexol	1147 10 B-Chemical
plasma	1158 6 O
pharmacokinetics	1165 16 O
were	1182 4 O
not	1187 3 O
altered	1191 7 O
by	1199 2 O
folic	1202 5 B-Chemical
acid	1208 4 I-Chemical
administration	1213 14 O
indicating	1228 10 O
that	1239 4 O
supplementation	1244 15 O
is	1260 2 O
unlikely	1263 8 O
to	1272 2 O
reduce	1275 6 O
toxicity	1282 8 B-Disease
by	1291 2 O
enhancing	1294 9 O
lometrexol	1304 10 B-Chemical
plasma	1315 6 O
clearance	1322 9 O
.	1331 1 O

The	1333 3 O
work	1337 4 O
described	1342 9 O
in	1352 2 O
this	1355 4 O
report	1360 6 O
has	1367 3 O
identified	1371 10 O
for	1382 3 O
the	1386 3 O
first	1390 5 O
time	1396 4 O
a	1401 1 O
clinically	1403 10 O
acceptable	1414 10 O
schedule	1425 8 O
for	1434 3 O
the	1438 3 O
administration	1442 14 O
of	1457 2 O
a	1460 1 O
GARFT	1462 5 O
inhibitor	1468 9 O
.	1477 1 O

This	1479 4 O
information	1484 11 O
will	1496 4 O
facilitate	1501 10 O
the	1512 3 O
future	1516 6 O
evaluation	1523 10 O
of	1534 2 O
this	1537 4 O
class	1542 5 O
of	1548 2 O
compounds	1551 9 O
in	1561 2 O
cancer	1564 6 B-Disease
therapy	1571 7 O
.	1578 1 O

Involvement	0 11 O
of	12 2 O
the	15 3 O
mu	19 2 O
-	21 1 O
opiate	22 6 O
receptor	29 8 O
in	38 2 O
peripheral	41 10 O
analgesia	52 9 B-Disease
.	61 1 O

The	63 3 O
intradermal	67 11 O
injection	79 9 O
of	89 2 O
mu	92 2 O
(	95 1 O
morphine	96 8 B-Chemical
,	104 1 O
Tyr	106 3 B-Chemical
-	109 1 I-Chemical
D	110 1 I-Chemical
-	111 1 I-Chemical
Ala	112 3 I-Chemical
-	115 1 I-Chemical
Gly	116 3 I-Chemical
-	119 1 I-Chemical
NMe	120 3 I-Chemical
-	123 1 I-Chemical
Phe	124 3 I-Chemical
-	127 1 I-Chemical
Gly	128 3 I-Chemical
-	131 1 I-Chemical
ol	132 2 I-Chemical
and	135 3 O
morphiceptin	139 12 B-Chemical
)	151 1 O
,	152 1 O
kappa	154 5 O
(	160 1 O
trans	161 5 B-Chemical
-	166 1 I-Chemical
3	167 1 I-Chemical
,	168 1 I-Chemical
4	169 1 I-Chemical
-	170 1 I-Chemical
dichloro	171 8 I-Chemical
-	179 1 I-Chemical
N	180 1 I-Chemical
-	181 1 I-Chemical
methyl	182 6 I-Chemical
-	188 1 I-Chemical
N	189 1 I-Chemical
[	190 1 I-Chemical
2	191 1 I-Chemical
-	192 1 I-Chemical
(	193 1 I-Chemical
1	194 1 I-Chemical
-	195 1 I-Chemical
pyrrolidinyl	196 12 I-Chemical
)	208 1 I-Chemical
cyclohexyl	210 10 I-Chemical
]	220 1 I-Chemical
benzeneactemide	221 15 I-Chemical
)	236 1 O
and	238 3 O
delta	242 5 O
(	248 1 O
[	249 1 B-Chemical
D	250 1 I-Chemical
-	251 1 I-Chemical
Pen2	252 4 I-Chemical
.	256 1 I-Chemical
5	257 1 I-Chemical
]	258 1 I-Chemical
-	259 1 I-Chemical
enkephalin	260 10 I-Chemical
and	271 3 O
[	275 1 B-Chemical
D	276 1 I-Chemical
-	277 1 I-Chemical
Ser2	278 4 I-Chemical
]	282 1 I-Chemical
-	283 1 I-Chemical
[	284 1 I-Chemical
Leu	285 3 I-Chemical
]	288 1 I-Chemical
enkephalin	289 10 I-Chemical
-	299 1 I-Chemical
Thr	300 3 I-Chemical
)	303 1 O
selective	305 9 O
opioid	315 6 O
-	321 1 O
agonists	322 8 O
,	330 1 O
by	332 2 O
themselves	335 10 O
,	345 1 O
did	347 3 O
not	351 3 O
significantly	355 13 O
affect	369 6 O
the	376 3 O
mechanical	380 10 O
nociceptive	391 11 O
threshold	403 9 O
in	413 2 O
the	416 3 O
hindpaw	420 7 O
of	428 2 O
the	431 3 O
rat	435 3 O
.	438 1 O

Intradermal	440 11 O
injection	452 9 O
of	462 2 O
mu	465 2 O
,	467 1 O
but	469 3 O
not	473 3 O
delta	477 5 O
or	483 2 O
kappa	486 5 O
opioid	492 6 O
-	498 1 O
agonists	499 8 O
,	507 1 O
however	509 7 O
,	516 1 O
produced	518 8 O
dose	527 4 O
-	531 1 O
dependent	532 9 O
inhibition	542 10 O
of	553 2 O
prostaglandin	556 13 B-Chemical
E2	570 2 I-Chemical
-	572 1 O
induced	573 7 O
hyperalgesia	581 12 B-Disease
.	593 1 O

The	595 3 O
analgesic	599 9 O
effect	609 6 O
of	616 2 O
the	619 3 O
mu	623 2 O
-	625 1 O
agonist	626 7 O
morphine	634 8 B-Chemical
was	643 3 O
dose	647 4 O
-	651 1 O
dependently	652 11 O
antagonized	664 11 O
by	676 2 O
naloxone	679 8 B-Chemical
and	688 3 O
prevented	692 9 O
by	702 2 O
co	705 2 O
-	707 1 O
injection	708 9 O
of	718 2 O
pertussis	721 9 O
toxin	731 5 O
.	736 1 O

Morphine	738 8 B-Chemical
did	747 3 O
not	751 3 O
,	754 1 O
however	756 7 O
,	763 1 O
alter	765 5 O
the	771 3 O
hyperalgesia	775 12 B-Disease
induced	788 7 O
by	796 2 O
8	799 1 B-Chemical
-	800 1 I-Chemical
bromo	801 5 I-Chemical
cyclic	807 6 I-Chemical
adenosine	814 9 I-Chemical
monophosphate	824 13 I-Chemical
.	837 1 O

We	839 2 O
conclude	842 8 O
that	851 4 O
the	856 3 O
analgesic	860 9 O
action	870 6 O
of	877 2 O
opioids	880 7 O
on	888 2 O
the	891 3 O
peripheral	895 10 O
terminals	906 9 O
of	916 2 O
primary	919 7 O
afferents	927 9 O
is	937 2 O
via	940 3 O
a	944 1 O
binding	946 7 O
site	954 4 O
with	959 4 O
characteristics	964 15 O
of	980 2 O
the	983 3 O
mu	987 2 O
-	989 1 O
opioid	990 6 O
receptor	997 8 O
and	1006 3 O
that	1010 4 O
this	1015 4 O
action	1020 6 O
is	1027 2 O
mediated	1030 8 O
by	1039 2 O
inhibition	1042 10 O
of	1053 2 O
the	1056 3 O
cyclic	1060 6 B-Chemical
adenosine	1067 9 I-Chemical
monophosphate	1077 13 I-Chemical
second	1091 6 O
messenger	1098 9 O
system	1108 6 O
.	1114 1 O

Adequate	0 8 O
timing	9 6 O
of	16 2 O
ribavirin	19 9 B-Chemical
reduction	29 9 O
in	39 2 O
patients	42 8 O
with	51 4 O
hemolysis	56 9 B-Disease
during	66 6 O
combination	73 11 O
therapy	85 7 O
of	93 2 O
interferon	96 10 B-Chemical
and	107 3 O
ribavirin	111 9 B-Chemical
for	121 3 O
chronic	125 7 B-Disease
hepatitis	133 9 I-Disease
C	143 1 I-Disease
.	144 1 O

BACKGROUND	146 10 O
:	156 1 O
Hemolytic	158 9 B-Disease
anemia	168 6 I-Disease
is	175 2 O
one	178 3 O
of	182 2 O
the	185 3 O
major	189 5 O
adverse	195 7 O
events	203 6 O
of	210 2 O
the	213 3 O
combination	217 11 O
therapy	229 7 O
of	237 2 O
interferon	240 10 B-Chemical
and	251 3 O
ribavirin	255 9 B-Chemical
.	264 1 O

Because	266 7 O
of	274 2 O
ribavirin	277 9 B-Chemical
-	286 1 O
related	287 7 O
hemolytic	295 9 B-Disease
anemia	305 6 I-Disease
,	311 1 O
dose	313 4 O
reduction	318 9 O
is	328 2 O
a	331 1 O
common	333 6 O
event	340 5 O
in	346 2 O
this	349 4 O
therapy	354 7 O
.	361 1 O

In	363 2 O
this	366 4 O
clinical	371 8 O
retrospective	380 13 O
cohort	394 6 O
study	401 5 O
we	407 2 O
have	410 4 O
examined	415 8 O
the	424 3 O
suitable	428 8 O
timing	437 6 O
of	444 2 O
ribavirin	447 9 B-Chemical
reduction	457 9 O
in	467 2 O
patients	470 8 O
with	479 4 O
hemolysis	484 9 B-Disease
during	494 6 O
combination	501 11 O
therapy	513 7 O
.	520 1 O

METHODS	522 7 O
:	529 1 O
Thirty	531 6 O
-	537 1 O
seven	538 5 O
of	544 2 O
160	547 3 O
patients	551 8 O
who	560 3 O
had	564 3 O
HCV	568 3 O
-	571 1 O
genotype	572 8 O
1b	581 2 O
,	583 1 O
had	585 3 O
high	589 4 O
virus	594 5 O
load	600 4 O
,	604 1 O
and	606 3 O
received	610 8 O
24	619 2 O
-	621 1 O
week	622 4 O
combination	627 11 O
therapy	639 7 O
developed	647 9 O
anemia	657 6 B-Disease
with	664 4 O
hemoglobin	669 10 O
level	680 5 O
<	686 1 O
10	687 2 O
g	690 1 O
/	691 1 O
dl	692 2 O
or	695 2 O
anemia	698 6 B-Disease
-	704 1 O
related	705 7 O
signs	713 5 O
during	719 6 O
therapy	726 7 O
.	733 1 O

After	735 5 O
that	741 4 O
,	745 1 O
these	747 5 O
37	753 2 O
patients	756 8 O
were	765 4 O
reduced	770 7 O
one	778 3 O
tablet	782 6 O
of	789 2 O
ribavirin	792 9 B-Chemical
(	802 1 O
200	803 3 O
mg	807 2 O
)	809 1 O
per	811 3 O
day	815 3 O
.	818 1 O

After	820 5 O
reduction	826 9 O
of	836 2 O
ribavirin	839 9 B-Chemical
,	848 1 O
27	850 2 O
of	853 2 O
37	856 2 O
patients	859 8 O
could	868 5 O
continue	874 8 O
combination	883 11 O
therapy	895 7 O
for	903 3 O
a	907 1 O
total	909 5 O
of	915 2 O
24	918 2 O
weeks	921 5 O
(	927 1 O
group	928 5 O
A	934 1 O
)	935 1 O
.	936 1 O

However	938 7 O
,	945 1 O
10	947 2 O
of	950 2 O
37	953 2 O
patients	956 8 O
with	965 4 O
reduction	970 9 O
of	980 2 O
ribavirin	983 9 B-Chemical
could	993 5 O
not	999 3 O
continue	1003 8 O
combination	1012 11 O
therapy	1024 7 O
because	1032 7 O
their	1040 5 O
<	1046 1 O
8	1047 1 O
.	1048 1 O
5	1049 1 O
g	1051 1 O
/	1052 1 O
dl	1053 2 O
hemoglobin	1056 10 O
values	1067 6 O
decreased	1074 9 O
to	1084 2 O
or	1087 2 O
anemia	1090 6 B-Disease
-	1096 1 O
related	1097 7 O
severe	1105 6 O
side	1112 4 O
effects	1117 7 O
occurred	1125 8 O
(	1134 1 O
group	1135 5 O
B	1141 1 O
)	1142 1 O
.	1143 1 O

We	1145 2 O
assessed	1148 8 O
the	1157 3 O
final	1161 5 O
efficacy	1167 8 O
and	1176 3 O
safety	1180 6 O
after	1187 5 O
reduction	1193 9 O
of	1203 2 O
ribavirin	1206 9 B-Chemical
in	1216 2 O
groups	1219 6 O
A	1226 1 O
and	1228 3 O
B	1232 1 O
.	1233 1 O

RESULTS	1235 7 O
:	1242 1 O
A	1244 1 O
sustained	1246 9 O
virological	1256 11 O
response	1268 8 O
(	1277 1 O
SVR	1278 3 O
)	1281 1 O
was	1283 3 O
29	1287 2 O
.	1289 1 O
6	1290 1 O
%	1291 1 O
(	1293 1 O
8	1294 1 O
/	1295 1 O
27	1296 2 O
)	1298 1 O
in	1300 2 O
group	1303 5 O
A	1309 1 O
and	1311 3 O
10	1315 2 O
%	1317 1 O
(	1319 1 O
1	1320 1 O
/	1321 1 O
10	1322 2 O
)	1324 1 O
in	1326 2 O
group	1329 5 O
B	1335 1 O
,	1336 1 O
respectively	1338 12 O
.	1350 1 O

A	1352 1 O
34	1354 2 O
.	1356 1 O
4	1357 1 O
%	1358 1 O
(	1360 1 O
12	1361 2 O
/	1363 1 O
27	1364 2 O
)	1366 1 O
of	1368 2 O
SVR	1371 3 O
+	1375 1 O
biological	1377 10 O
response	1388 8 O
in	1397 2 O
group	1400 5 O
A	1406 1 O
was	1408 3 O
higher	1412 6 O
than	1419 4 O
10	1424 2 O
%	1426 1 O
(	1428 1 O
1	1429 1 O
/	1430 1 O
10	1431 2 O
)	1433 1 O
in	1435 2 O
group	1438 5 O
B	1444 1 O
(	1446 1 O
P	1448 1 O
=	1450 1 O
0	1452 1 O
.	1453 1 O
051	1454 3 O
)	1457 1 O
,	1458 1 O
with	1460 4 O
slight	1465 6 O
significance	1472 12 O
.	1484 1 O

With	1486 4 O
respect	1491 7 O
to	1499 2 O
hemoglobin	1502 10 O
level	1513 5 O
at	1519 2 O
the	1522 3 O
time	1526 4 O
of	1531 2 O
ribavirin	1534 9 B-Chemical
reduction	1544 9 O
,	1553 1 O
a	1555 1 O
rate	1557 4 O
of	1562 2 O
continuation	1565 12 O
of	1578 2 O
therapy	1581 7 O
in	1589 2 O
patients	1592 8 O
with	1601 4 O
>	1606 1 O
or	1608 2 O
=	1611 1 O
10	1612 2 O
g	1615 1 O
/	1616 1 O
dl	1617 2 O
hemoglobin	1620 10 O
was	1631 3 O
higher	1635 6 O
than	1642 4 O
that	1647 4 O
in	1652 2 O
patients	1655 8 O
with	1664 4 O
<	1669 1 O
10	1670 2 O
g	1673 1 O
/	1674 1 O
dl	1675 2 O
(	1678 1 O
P	1680 1 O
=	1682 1 O
0	1684 1 O
.	1685 1 O
036	1686 3 O
)	1689 1 O
.	1690 1 O

CONCLUSIONS	1692 11 O
:	1703 1 O
Reduction	1705 9 O
of	1715 2 O
ribavirin	1718 9 B-Chemical
at	1728 2 O
hemoglobin	1731 10 O
level	1742 5 O
>	1748 1 O
or	1750 2 O
=	1753 1 O
10	1754 2 O
g	1757 1 O
/	1758 1 O
dl	1759 2 O
is	1762 2 O
suitable	1765 8 O
in	1774 2 O
terms	1777 5 O
of	1783 2 O
efficacy	1786 8 O
and	1795 3 O
side	1799 4 O
effects	1804 7 O
.	1811 1 O

Increased	0 9 O
expression	10 10 O
and	21 3 O
apical	25 6 O
targeting	32 9 O
of	42 2 O
renal	45 5 O
ENaC	51 4 O
subunits	56 8 O
in	65 2 O
puromycin	68 9 B-Chemical
aminonucleoside	78 15 I-Chemical
-	93 1 O
induced	94 7 O
nephrotic	102 9 B-Disease
syndrome	112 8 I-Disease
in	121 2 O
rats	124 4 O
.	128 1 O

Nephrotic	130 9 B-Disease
syndrome	140 8 I-Disease
is	149 2 O
often	152 5 O
accompanied	158 11 O
by	170 2 O
sodium	173 6 B-Chemical
retention	180 9 O
and	190 3 O
generalized	194 11 O
edema	206 5 B-Disease
.	211 1 O

However	213 7 O
,	220 1 O
the	222 3 O
molecular	226 9 O
basis	236 5 O
for	242 3 O
the	246 3 O
decreased	250 9 O
renal	260 5 O
sodium	266 6 B-Chemical
excretion	273 9 O
remains	283 7 O
undefined	291 9 O
.	300 1 O

We	302 2 O
hypothesized	305 12 O
that	318 4 O
epithelial	323 10 O
Na	334 2 B-Chemical
channel	337 7 O
(	345 1 O
ENaC	346 4 O
)	350 1 O
subunit	352 7 O
dysregulation	360 13 O
may	374 3 O
be	378 2 O
responsible	381 11 O
for	393 3 O
the	397 3 O
increased	401 9 O
sodium	411 6 B-Chemical
retention	418 9 O
.	427 1 O

An	429 2 O
experimental	432 12 O
group	445 5 O
of	451 2 O
rats	454 4 O
was	459 3 O
treated	463 7 O
with	471 4 O
puromycin	476 9 B-Chemical
aminonucleoside	486 15 I-Chemical
(	502 1 O
PAN	503 3 B-Chemical
;	506 1 O
180	508 3 O
mg	512 2 O
/	514 1 O
kg	515 2 O
iv	518 2 O
)	520 1 O
,	521 1 O
whereas	523 7 O
the	531 3 O
control	535 7 O
group	543 5 O
received	549 8 O
only	558 4 O
vehicle	563 7 O
.	570 1 O

After	572 5 O
7	578 1 O
days	580 4 O
,	584 1 O
PAN	586 3 B-Chemical
treatment	590 9 O
induced	600 7 O
significant	608 11 O
proteinuria	620 11 B-Disease
,	631 1 O
hypoalbuminemia	633 15 B-Disease
,	648 1 O
decreased	650 9 O
urinary	660 7 O
sodium	668 6 B-Chemical
excretion	675 9 O
,	684 1 O
and	686 3 O
extensive	690 9 O
ascites	700 7 B-Disease
.	707 1 O

The	709 3 O
protein	713 7 O
abundance	721 9 O
of	731 2 O
alpha	734 5 O
-	739 1 O
ENaC	740 4 O
and	745 3 O
beta	749 4 O
-	753 1 O
ENaC	754 4 O
was	759 3 O
increased	763 9 O
in	773 2 O
the	776 3 O
inner	780 5 O
stripe	786 6 O
of	793 2 O
the	796 3 O
outer	800 5 O
medulla	806 7 O
(	814 1 O
ISOM	815 4 O
)	819 1 O
and	821 3 O
in	825 2 O
the	828 3 O
inner	832 5 O
medulla	838 7 O
(	846 1 O
IM	847 2 O
)	849 1 O
but	851 3 O
was	855 3 O
not	859 3 O
altered	863 7 O
in	871 2 O
the	874 3 O
cortex	878 6 O
.	884 1 O

gamma	886 5 O
-	891 1 O
ENaC	892 4 O
abundance	897 9 O
was	907 3 O
increased	911 9 O
in	921 2 O
the	924 3 O
cortex	928 6 O
,	934 1 O
ISOM	936 4 O
,	940 1 O
and	942 3 O
IM	946 2 O
.	948 1 O

Immunoperoxidase	950 16 O
brightfield	967 11 O
-	978 1 O
and	980 3 O
laser	984 5 O
-	989 1 O
scanning	990 8 O
confocal	999 8 O
fluorescence	1008 12 O
microscopy	1021 10 O
demonstrated	1032 12 O
increased	1045 9 O
targeting	1055 9 O
of	1065 2 O
alpha	1068 5 O
-	1073 1 O
ENaC	1074 4 O
,	1078 1 O
beta	1080 4 O
-	1084 1 O
ENaC	1085 4 O
,	1089 1 O
and	1091 3 O
gamma	1095 5 O
-	1100 1 O
ENaC	1101 4 O
subunits	1106 8 O
to	1115 2 O
the	1118 3 O
apical	1122 6 O
plasma	1129 6 O
membrane	1136 8 O
in	1145 2 O
the	1148 3 O
distal	1152 6 O
convoluted	1159 10 O
tubule	1170 6 O
(	1177 1 O
DCT2	1178 4 O
)	1182 1 O
,	1183 1 O
connecting	1185 10 O
tubule	1196 6 O
,	1202 1 O
and	1204 3 O
cortical	1208 8 O
and	1217 3 O
medullary	1221 9 O
collecting	1231 10 O
duct	1242 4 O
segments	1247 8 O
.	1255 1 O

Immunoelectron	1257 14 O
microscopy	1272 10 O
further	1283 7 O
revealed	1291 8 O
an	1300 2 O
increased	1303 9 O
labeling	1313 8 O
of	1322 2 O
alpha	1325 5 O
-	1330 1 O
ENaC	1331 4 O
in	1336 2 O
the	1339 3 O
apical	1343 6 O
plasma	1350 6 O
membrane	1357 8 O
of	1366 2 O
cortical	1369 8 O
collecting	1378 10 O
duct	1389 4 O
principal	1394 9 O
cells	1404 5 O
of	1410 2 O
PAN	1413 3 B-Chemical
-	1416 1 O
treated	1417 7 O
rats	1425 4 O
,	1429 1 O
indicating	1431 10 O
enhanced	1442 8 O
apical	1451 6 O
targeting	1458 9 O
of	1468 2 O
alpha	1471 5 O
-	1476 1 O
ENaC	1477 4 O
subunits	1482 8 O
.	1490 1 O

In	1492 2 O
contrast	1495 8 O
,	1503 1 O
the	1505 3 O
protein	1509 7 O
abundances	1517 10 O
of	1528 2 O
Na	1531 2 B-Chemical
(	1533 1 O
+	1534 1 O
)	1535 1 O
/	1536 1 O
H	1537 1 B-Chemical
(	1538 1 O
+	1539 1 O
)	1540 1 O
exchanger	1542 9 O
type	1552 4 O
3	1557 1 O
(	1559 1 O
NHE3	1560 4 O
)	1564 1 O
,	1565 1 O
Na	1567 2 B-Chemical
(	1569 1 O
+	1570 1 O
)	1571 1 O
-	1572 1 O
K	1573 1 B-Chemical
(	1574 1 O
+	1575 1 O
)	1576 1 O
-	1577 1 O
2Cl	1578 3 O
(	1581 1 O
-	1582 1 O
)	1583 1 O
cotransporter	1585 13 O
(	1599 1 O
BSC	1600 3 O
-	1603 1 O
1	1604 1 O
)	1605 1 O
,	1606 1 O
and	1608 3 O
thiazide	1612 8 B-Chemical
-	1620 1 O
sensitive	1621 9 O
Na	1631 2 B-Chemical
(	1633 1 O
+	1634 1 O
)	1635 1 O
-	1636 1 O
Cl	1637 2 B-Chemical
(	1639 1 O
-	1640 1 O
)	1641 1 O
cotransporter	1643 13 O
(	1657 1 O
TSC	1658 3 O
)	1661 1 O
were	1663 4 O
decreased	1668 9 O
.	1677 1 O

Moreover	1679 8 O
,	1687 1 O
the	1689 3 O
abundance	1693 9 O
of	1703 2 O
the	1706 3 O
alpha	1710 5 O
(	1715 1 O
1	1716 1 O
)	1717 1 O
-	1718 1 O
subunit	1719 7 O
of	1727 2 O
the	1730 3 O
Na	1734 2 B-Chemical
-	1736 1 O
K	1737 1 B-Chemical
-	1738 1 O
ATPase	1739 6 O
was	1746 3 O
decreased	1750 9 O
in	1760 2 O
the	1763 3 O
cortex	1767 6 O
and	1774 3 O
ISOM	1778 4 O
,	1782 1 O
but	1784 3 O
it	1788 2 O
remained	1791 8 O
unchanged	1800 9 O
in	1810 2 O
the	1813 3 O
IM	1817 2 O
.	1819 1 O

In	1821 2 O
conclusion	1824 10 O
,	1834 1 O
the	1836 3 O
increased	1840 9 O
or	1850 2 O
sustained	1853 9 O
expression	1863 10 O
of	1874 2 O
ENaC	1877 4 O
subunits	1882 8 O
combined	1891 8 O
with	1900 4 O
increased	1905 9 O
apical	1915 6 O
targeting	1922 9 O
in	1932 2 O
the	1935 3 O
DCT2	1939 4 O
,	1943 1 O
connecting	1945 10 O
tubule	1956 6 O
,	1962 1 O
and	1964 3 O
collecting	1968 10 O
duct	1979 4 O
are	1984 3 O
likely	1988 6 O
to	1995 2 O
play	1998 4 O
a	2003 1 O
role	2005 4 O
in	2010 2 O
the	2013 3 O
sodium	2017 6 B-Chemical
retention	2024 9 O
associated	2034 10 O
with	2045 4 O
PAN	2050 3 B-Chemical
-	2053 1 O
induced	2054 7 O
nephrotic	2062 9 B-Disease
syndrome	2072 8 I-Disease
.	2080 1 O

The	2082 3 O
decreased	2086 9 O
abundance	2096 9 O
of	2106 2 O
NHE3	2109 4 O
,	2113 1 O
BSC	2115 3 O
-	2118 1 O
1	2119 1 O
,	2120 1 O
TSC	2122 3 O
,	2125 1 O
and	2127 3 O
Na	2131 2 B-Chemical
-	2133 1 O
K	2134 1 B-Chemical
-	2135 1 O
ATPase	2136 6 O
may	2143 3 O
play	2147 4 O
a	2152 1 O
compensatory	2154 12 O
role	2167 4 O
to	2172 2 O
promote	2175 7 O
sodium	2183 6 B-Chemical
excretion	2190 9 O
.	2199 1 O

Does	0 4 O
hormone	5 7 O
therapy	13 7 O
for	21 3 O
the	25 3 O
treatment	29 9 O
of	39 2 O
breast	42 6 B-Disease
cancer	49 6 I-Disease
have	56 4 O
a	61 1 O
detrimental	63 11 B-Disease
effect	75 6 I-Disease
on	82 2 I-Disease
memory	85 6 I-Disease
and	92 3 I-Disease
cognition	96 9 I-Disease
?	105 1 O

A	107 1 O
pilot	109 5 O
study	115 5 O
.	120 1 O

This	122 4 O
pilot	127 5 O
study	133 5 O
examines	139 8 O
whether	148 7 O
hormone	156 7 O
therapy	164 7 O
for	172 3 O
breast	176 6 B-Disease
cancer	183 6 I-Disease
affects	190 7 O
cognition	198 9 O
.	207 1 O

Patients	209 8 O
participating	218 13 O
in	232 2 O
a	235 1 O
randomised	237 10 O
trial	248 5 O
of	254 2 O
anastrozole	257 11 B-Chemical
,	268 1 O
tamoxifen	270 9 B-Chemical
alone	280 5 O
or	286 2 O
combined	289 8 O
(	298 1 O
ATAC	299 4 O
)	303 1 O
(	305 1 O
n	306 1 O
=	307 1 O
94	308 2 O
)	310 1 O
and	312 3 O
a	316 1 O
group	318 5 O
of	324 2 O
women	327 5 O
without	333 7 O
breast	341 6 B-Disease
cancer	348 6 I-Disease
(	355 1 O
n	356 1 O
=	357 1 O
35	358 2 O
)	360 1 O
completed	362 9 O
a	372 1 O
battery	374 7 O
of	382 2 O
neuropsychological	385 18 O
measures	404 8 O
.	412 1 O

Compared	414 8 O
with	423 4 O
the	428 3 O
control	432 7 O
group	440 5 O
,	445 1 O
the	447 3 O
patients	451 8 O
were	460 4 O
impaired	465 8 O
on	474 2 O
a	477 1 O
processing	479 10 O
speed	490 5 O
task	496 4 O
(	501 1 O
p	502 1 O
=	503 1 O
0	504 1 O
.	505 1 O
032	506 3 O
)	509 1 O
and	511 3 O
on	515 2 O
a	518 1 O
measure	520 7 O
of	528 2 O
immediate	531 9 O
verbal	541 6 O
memory	548 6 O
(	555 1 O
p	556 1 O
=	557 1 O
0	558 1 O
.	559 1 O
026	560 3 O
)	563 1 O
after	565 5 O
controlling	571 11 O
for	583 3 O
the	587 3 O
use	591 3 O
of	595 2 O
hormone	598 7 O
replacement	606 11 O
therapy	618 7 O
in	626 2 O
both	629 4 O
groups	634 6 O
.	640 1 O

Patient	642 7 O
group	650 5 O
performance	656 11 O
was	668 3 O
not	672 3 O
significantly	676 13 O
related	690 7 O
to	698 2 O
length	701 6 O
of	708 2 O
treatment	711 9 O
or	721 2 O
measures	724 8 O
of	733 2 O
psychological	736 13 O
morbidity	750 9 O
.	759 1 O

The	761 3 O
results	765 7 O
showed	773 6 O
specific	780 8 O
impairments	789 11 O
in	801 2 O
processing	804 10 O
speed	815 5 O
and	821 3 O
verbal	825 6 O
memory	832 6 O
in	839 2 O
women	842 5 O
receiving	848 9 O
hormonal	858 8 O
therapy	867 7 O
for	875 3 O
the	879 3 O
treatment	883 9 O
of	893 2 O
breast	896 6 B-Disease
cancer	903 6 I-Disease
.	909 1 O

Verbal	911 6 O
memory	918 6 O
may	925 3 O
be	929 2 O
especially	932 10 O
sensitive	943 9 O
to	953 2 O
changes	956 7 O
in	964 2 O
oestrogen	967 9 B-Chemical
levels	977 6 O
,	983 1 O
a	985 1 O
finding	987 7 O
commonly	995 8 O
reported	1004 8 O
in	1013 2 O
studies	1016 7 O
of	1024 2 O
hormone	1027 7 O
replacement	1035 11 O
therapy	1047 7 O
in	1055 2 O
healthy	1058 7 O
women	1066 5 O
.	1071 1 O

In	1073 2 O
view	1076 4 O
of	1081 2 O
the	1084 3 O
increased	1088 9 O
use	1098 3 O
of	1102 2 O
hormone	1105 7 O
therapies	1113 9 O
in	1123 2 O
an	1126 2 O
adjuvant	1129 8 O
and	1138 3 O
preventative	1142 12 O
setting	1155 7 O
their	1163 5 O
impact	1169 6 O
on	1176 2 O
cognitive	1179 9 O
functioning	1189 11 O
should	1201 6 O
be	1208 2 O
investigated	1211 12 O
more	1224 4 O
thoroughly	1229 10 O
.	1239 1 O

Association	0 11 O
of	12 2 O
nitric	15 6 B-Chemical
oxide	22 5 I-Chemical
production	28 10 O
and	39 3 O
apoptosis	43 9 O
in	53 2 O
a	56 1 O
model	58 5 O
of	64 2 O
experimental	67 12 O
nephropathy	80 11 B-Disease
.	91 1 O

BACKGROUND	93 10 O
:	103 1 O
In	105 2 O
recent	108 6 O
studies	115 7 O
increased	123 9 O
amounts	133 7 O
of	141 2 O
nitric	144 6 B-Chemical
oxide	151 5 I-Chemical
(	157 1 O
NO	158 2 B-Chemical
)	160 1 O
and	162 3 O
apoptosis	166 9 O
have	176 4 O
been	181 4 O
implicated	186 10 O
in	197 2 O
various	200 7 O
pathological	208 12 O
conditions	221 10 O
in	232 2 O
the	235 3 O
kidney	239 6 O
.	245 1 O

We	247 2 O
have	250 4 O
studied	255 7 O
the	263 3 O
role	267 4 O
of	272 2 O
NO	275 2 B-Chemical
and	278 3 O
its	282 3 O
association	286 11 O
with	298 4 O
apoptosis	303 9 O
in	313 2 O
an	316 2 O
experimental	319 12 O
model	332 5 O
of	338 2 O
nephrotic	341 9 B-Disease
syndrome	351 8 I-Disease
induced	360 7 O
by	368 2 O
a	371 1 O
single	373 6 O
injection	380 9 O
of	390 2 O
adriamycin	393 10 B-Chemical
(	404 1 O
ADR	405 3 B-Chemical
)	408 1 O
.	409 1 O

METHODS	411 7 O
:	418 1 O
The	420 3 O
alteration	424 10 O
in	435 2 O
the	438 3 O
NO	442 2 B-Chemical
pathway	445 7 O
was	453 3 O
assessed	457 8 O
by	466 2 O
measuring	469 9 O
nitrite	479 7 B-Chemical
levels	487 6 O
in	494 2 O
serum	497 5 O
/	502 1 O
urine	503 5 O
and	509 3 O
by	513 2 O
evaluating	516 10 O
the	527 3 O
changes	531 7 O
in	539 2 O
vascular	542 8 O
reactivity	551 10 O
of	562 2 O
the	565 3 O
isolated	569 8 O
perfused	578 8 O
rat	587 3 O
kidney	591 6 O
(	598 1 O
IPRK	599 4 O
)	603 1 O
system	605 6 O
.	611 1 O

Rats	613 4 O
were	618 4 O
stratified	623 10 O
into	634 4 O
control	639 7 O
groups	647 6 O
and	654 3 O
ADR	658 3 B-Chemical
-	661 1 O
induced	662 7 O
nephropathy	670 11 B-Disease
groups	682 6 O
.	688 1 O

These	690 5 O
two	696 3 O
groups	700 6 O
were	707 4 O
then	712 4 O
divided	717 7 O
into	725 4 O
:	729 1 O
group	731 5 O
1	737 1 O
,	738 1 O
animals	740 7 O
receiving	748 9 O
saline	758 6 O
;	764 1 O
and	766 3 O
group	770 5 O
2	776 1 O
,	777 1 O
animals	779 7 O
receiving	787 9 O
aminoguanidine	797 14 B-Chemical
(	812 1 O
AG	813 2 B-Chemical
)	815 1 O
which	817 5 O
is	823 2 O
a	826 1 O
specific	828 8 O
inhibitor	837 9 O
of	847 2 O
inducible	850 9 O
-	859 1 O
NO	860 2 B-Chemical
synthase	863 8 O
.	871 1 O

On	873 2 O
day	876 3 O
21	880 2 O
,	882 1 O
rats	884 4 O
were	889 4 O
sacrificed	894 10 O
after	905 5 O
obtaining	911 9 O
material	921 8 O
for	930 3 O
biochemical	934 11 O
analysis	946 8 O
.	954 1 O

RESULTS	956 7 O
:	963 1 O
Histopathological	965 17 O
examination	983 11 O
of	995 2 O
the	998 3 O
kidneys	1002 7 O
of	1010 2 O
rats	1013 4 O
treated	1018 7 O
with	1026 4 O
ADR	1031 3 B-Chemical
revealed	1035 8 O
focal	1044 5 O
areas	1050 5 O
of	1056 2 O
mesangial	1059 9 B-Disease
proliferation	1069 13 I-Disease
and	1083 3 O
mild	1087 4 O
tubulointerstitial	1092 18 B-Disease
inflammation	1111 12 I-Disease
.	1123 1 O

They	1125 4 O
also	1130 4 O
had	1135 3 O
significantly	1139 13 O
higher	1153 6 O
levels	1160 6 O
of	1167 2 O
proteinuria	1170 11 B-Disease
compared	1182 8 O
with	1191 4 O
control	1196 7 O
and	1204 3 O
treatment	1208 9 O
groups	1218 6 O
(	1225 1 O
P	1226 1 O
<	1228 1 O
0	1230 1 O
.	1231 1 O
05	1232 2 O
)	1234 1 O
.	1235 1 O

Urine	1237 5 O
nitrite	1243 7 B-Chemical
levels	1251 6 O
were	1258 4 O
significantly	1263 13 O
increased	1277 9 O
in	1287 2 O
the	1290 3 O
ADR	1294 3 B-Chemical
-	1297 1 O
nephropathy	1298 11 B-Disease
group	1310 5 O
(	1316 1 O
P	1317 1 O
<	1319 1 O
0	1321 1 O
.	1322 1 O
05	1323 2 O
)	1325 1 O
.	1326 1 O

In	1328 2 O
the	1331 3 O
IPRK	1335 4 O
phenylephrine	1340 13 B-Chemical
and	1354 3 O
acetylcholine	1358 13 B-Chemical
related	1372 7 O
responses	1380 9 O
were	1390 4 O
significantly	1395 13 O
impaired	1409 8 O
in	1418 2 O
the	1421 3 O
ADR	1425 3 B-Chemical
-	1428 1 O
nephropathy	1429 11 B-Disease
group	1441 5 O
.	1446 1 O

Apoptosis	1448 9 O
was	1458 3 O
not	1462 3 O
detected	1466 8 O
in	1475 2 O
controls	1478 8 O
.	1486 1 O

However	1488 7 O
,	1495 1 O
in	1497 2 O
the	1500 3 O
ADR	1504 3 B-Chemical
-	1507 1 O
nephropathy	1508 11 B-Disease
group	1520 5 O
,	1525 1 O
numerous	1527 8 O
apoptotic	1536 9 O
cells	1546 5 O
were	1552 4 O
identified	1557 10 O
in	1568 2 O
the	1571 3 O
tubulointerstitial	1575 18 O
areas	1594 5 O
.	1599 1 O

Double	1601 6 O
staining	1608 8 O
revealed	1617 8 O
numerous	1626 8 O
interstitial	1635 12 O
apoptotic	1648 9 O
cells	1658 5 O
to	1664 2 O
stain	1667 5 O
for	1673 3 O
ED1	1677 3 O
,	1680 1 O
a	1682 1 O
marker	1684 6 O
for	1691 3 O
monocytes	1695 9 O
/	1704 1 O
macrophages	1705 11 O
.	1716 1 O

Treatment	1718 9 O
with	1728 4 O
AG	1733 2 B-Chemical
prevented	1736 9 O
the	1746 3 O
impairment	1750 10 O
of	1761 2 O
renal	1764 5 O
vascular	1770 8 O
bed	1779 3 O
responses	1783 9 O
and	1793 3 O
reduced	1797 7 O
both	1805 4 O
urine	1810 5 O
nitrite	1816 7 B-Chemical
levels	1824 6 O
and	1831 3 O
apoptosis	1835 9 O
to	1845 2 O
control	1848 7 O
levels	1856 6 O
.	1862 1 O

CONCLUSION	1864 10 O
:	1874 1 O
We	1876 2 O
suggest	1879 7 O
that	1887 4 O
interactions	1892 12 O
between	1905 7 O
NO	1913 2 B-Chemical
and	1916 3 O
apoptosis	1920 9 O
are	1930 3 O
important	1934 9 O
in	1944 2 O
the	1947 3 O
pathogenesis	1951 12 O
of	1964 2 O
the	1967 3 O
ADR	1971 3 B-Chemical
-	1974 1 O
induced	1975 7 O
nephrosis	1983 9 B-Disease
.	1992 1 O

The	0 3 O
attenuating	4 11 O
effect	16 6 O
of	23 2 O
carteolol	26 9 B-Chemical
hydrochloride	36 13 I-Chemical
,	49 1 O
a	51 1 O
beta	53 4 O
-	57 1 O
adrenoceptor	58 12 O
antagonist	71 10 O
,	81 1 O
on	83 2 O
neuroleptic	86 11 O
-	97 1 O
induced	98 7 O
catalepsy	106 9 B-Disease
in	116 2 O
rats	119 4 O
.	123 1 O

It	125 2 O
is	128 2 O
known	131 5 O
that	137 4 O
beta	142 4 O
-	146 1 O
adrenoceptor	147 12 O
antagonists	160 11 O
are	172 3 O
effective	176 9 O
in	186 2 O
the	189 3 O
treatment	193 9 O
of	203 2 O
akathisia	206 9 B-Disease
,	215 1 O
one	217 3 O
of	221 2 O
the	224 3 O
extrapyramidal	228 14 O
side	243 4 O
effects	248 7 O
that	256 4 O
occur	261 5 O
during	267 6 O
neuroleptic	274 11 O
treatment	286 9 O
.	295 1 O

Neuroleptic	297 11 O
-	308 1 O
induced	309 7 O
catalepsy	317 9 B-Disease
,	326 1 O
a	328 1 O
model	330 5 O
of	336 2 O
neuroleptic	339 11 O
-	350 1 O
induced	351 7 O
extrapyramidal	359 14 O
side	374 4 O
effects	379 7 O
,	386 1 O
was	388 3 O
considered	392 10 O
suitable	403 8 O
as	412 2 O
a	415 1 O
model	417 5 O
for	423 3 O
predicting	427 10 O
neuroleptic	438 11 O
-	449 1 O
induced	450 7 O
akathisia	458 9 B-Disease
in	468 2 O
humans	471 6 O
,	477 1 O
although	479 8 O
neuroleptic	488 11 O
-	499 1 O
induced	500 7 O
catalepsy	508 9 B-Disease
was	518 3 O
not	522 3 O
considered	526 10 O
a	537 1 O
specific	539 8 O
test	548 4 O
for	553 3 O
neuroleptic	557 11 O
-	568 1 O
induced	569 7 O
akathisia	577 9 B-Disease
.	586 1 O

Therefore	588 9 O
,	597 1 O
the	599 3 O
effects	603 7 O
of	611 2 O
carteolol	614 9 B-Chemical
,	623 1 O
a	625 1 O
beta	627 4 O
-	631 1 O
adrenoceptor	632 12 O
antagonist	645 10 O
,	655 1 O
on	657 2 O
haloperidol	660 11 B-Chemical
-	671 1 O
induced	672 7 O
catalepsy	680 9 B-Disease
in	690 2 O
rats	693 4 O
were	698 4 O
behaviorally	703 12 O
studied	716 7 O
and	724 3 O
compared	728 8 O
with	737 4 O
those	742 5 O
of	748 2 O
propranolol	751 11 B-Chemical
and	763 3 O
biperiden	767 9 B-Chemical
,	776 1 O
a	778 1 O
muscarinic	780 10 O
receptor	791 8 O
antagonist	800 10 O
.	810 1 O

Carteolol	812 9 B-Chemical
,	821 1 O
as	823 2 O
well	826 4 O
as	831 2 O
propranolol	834 11 B-Chemical
and	846 3 O
biperiden	850 9 B-Chemical
,	859 1 O
inhibited	861 9 O
the	871 3 O
haloperidol	875 11 B-Chemical
-	886 1 O
induced	887 7 O
catalepsy	895 9 B-Disease
.	904 1 O

The	906 3 O
inhibitory	910 10 O
effect	921 6 O
of	928 2 O
carteolol	931 9 B-Chemical
was	941 3 O
almost	945 6 O
comparable	952 10 O
to	963 2 O
that	966 4 O
of	971 2 O
propranolol	974 11 B-Chemical
,	985 1 O
but	987 3 O
was	991 3 O
weaker	995 6 O
than	1002 4 O
that	1007 4 O
of	1012 2 O
biperiden	1015 9 B-Chemical
.	1024 1 O

Carteolol	1026 9 B-Chemical
did	1036 3 O
not	1040 3 O
evoke	1044 5 O
postsynaptic	1050 12 O
dopamine	1063 8 B-Chemical
receptor	1072 8 O
-	1080 1 O
stimulating	1081 11 O
behavioral	1093 10 O
signs	1104 5 O
such	1110 4 O
as	1115 2 O
stereotypy	1118 10 O
and	1129 3 O
hyperlocomotion	1133 15 B-Disease
in	1149 2 O
rats	1152 4 O
.	1156 1 O

Carteolol	1158 9 B-Chemical
did	1168 3 O
not	1172 3 O
antagonize	1176 10 O
the	1187 3 O
inhibitory	1191 10 O
effects	1202 7 O
of	1210 2 O
haloperidol	1213 11 B-Chemical
on	1225 2 O
apomorphine	1228 11 B-Chemical
-	1239 1 O
induced	1240 7 O
stereotypy	1248 10 O
and	1259 3 O
locomotor	1263 9 O
activity	1273 8 O
in	1282 2 O
rats	1285 4 O
.	1289 1 O

In	1291 2 O
addition	1294 8 O
,	1302 1 O
carteolol	1304 9 B-Chemical
did	1314 3 O
not	1318 3 O
evoke	1322 5 O
5	1328 1 O
-	1329 1 O
HT1A	1330 4 O
receptor	1335 8 O
-	1343 1 O
stimulating	1344 11 O
behavioral	1356 10 O
signs	1367 5 O
such	1373 4 O
as	1378 2 O
flat	1381 4 O
body	1386 4 O
posture	1391 7 O
and	1399 3 O
forepaw	1403 7 O
treading	1411 8 O
and	1420 3 O
did	1424 3 O
not	1428 3 O
inhibit	1432 7 O
5	1440 1 B-Chemical
-	1441 1 I-Chemical
hydroxytryptophan	1442 17 I-Chemical
-	1459 1 O
induced	1460 7 O
head	1468 4 O
twitch	1473 6 O
in	1480 2 O
rats	1483 4 O
.	1487 1 O

Finally	1489 7 O
,	1496 1 O
carteolol	1498 9 B-Chemical
did	1508 3 O
not	1512 3 O
inhibit	1516 7 O
physostigmine	1524 13 B-Chemical
-	1537 1 O
induced	1538 7 O
lethality	1546 9 O
in	1556 2 O
rats	1559 4 O
.	1563 1 O

These	1565 5 O
results	1571 7 O
strongly	1579 8 O
suggest	1588 7 O
that	1596 4 O
carteolol	1601 9 B-Chemical
improves	1611 8 O
haloperidol	1620 11 B-Chemical
-	1631 1 O
induced	1632 7 O
catalepsy	1640 9 B-Disease
via	1650 3 O
its	1654 3 O
beta	1658 4 O
-	1662 1 O
adrenoceptor	1663 12 O
antagonistic	1676 12 O
activity	1689 8 O
and	1698 3 O
is	1702 2 O
expected	1705 8 O
to	1714 2 O
be	1717 2 O
effective	1720 9 O
in	1730 2 O
the	1733 3 O
treatment	1737 9 O
of	1747 2 O
akathisia	1750 9 B-Disease
without	1760 7 O
attenuating	1768 11 O
neuroleptic	1780 11 O
-	1791 1 O
induced	1792 7 O
antipsychotic	1800 13 O
effects	1814 7 O
due	1822 3 O
to	1826 2 O
its	1829 3 O
postsynaptic	1833 12 O
dopamine	1846 8 B-Chemical
receptor	1855 8 O
antagonistic	1864 12 O
activity	1877 8 O
.	1885 1 O

Penicillamine	0 13 B-Chemical
-	13 1 O
induced	14 7 O
rapidly	22 7 O
progressive	30 11 O
glomerulonephritis	42 18 B-Disease
in	61 2 O
a	64 1 O
patient	66 7 O
with	74 4 O
rheumatoid	79 10 B-Disease
arthritis	90 9 I-Disease
.	99 1 O

A	101 1 O
67	103 2 O
-	105 1 O
year	106 4 O
-	110 1 O
old	111 3 O
woman	115 5 O
with	121 4 O
rheumatoid	126 10 B-Disease
arthritis	137 9 I-Disease
presented	147 9 O
rapidly	157 7 O
progressive	165 11 O
glomerulonephritis	177 18 B-Disease
(	196 1 O
RPGN	197 4 B-Disease
)	201 1 O
after	203 5 O
5	209 1 O
months	211 6 O
of	218 2 O
D	221 1 B-Chemical
-	222 1 I-Chemical
penicillamine	223 13 I-Chemical
(	237 1 O
250	238 3 O
mg	242 2 O
/	244 1 O
day	245 3 O
)	248 1 O
treatment	250 9 O
.	259 1 O

Light	261 5 O
microscopy	267 10 O
study	278 5 O
showed	284 6 O
severe	291 6 O
glomerulonephritis	298 18 B-Disease
with	317 4 O
crescent	322 8 O
formation	331 9 O
in	341 2 O
60	344 2 O
%	346 1 O
of	348 2 O
the	351 3 O
glomeruli	355 9 O
and	365 3 O
infiltration	369 12 O
of	382 2 O
inflammatory	385 12 O
cells	398 5 O
in	404 2 O
the	407 3 O
wall	411 4 O
of	416 2 O
an	419 2 O
arteriole	422 9 O
.	431 1 O

Immunofluorescence	433 18 O
revealed	452 8 O
scanty	461 6 O
granular	468 8 O
IgG	477 3 O
,	480 1 O
IgA	482 3 O
and	486 3 O
C3	490 2 O
deposits	493 8 O
along	502 5 O
the	508 3 O
capillary	512 9 O
walls	522 5 O
and	528 3 O
mesangium	532 9 O
.	541 1 O

The	543 3 O
patient	547 7 O
was	555 3 O
treated	559 7 O
with	567 4 O
steroid	572 7 B-Chemical
pulse	580 5 O
,	585 1 O
plasmapheresis	587 14 O
,	601 1 O
cyclophosphamide	603 16 B-Chemical
and	620 3 O
antiplatelet	624 12 B-Chemical
agents	637 6 I-Chemical
.	643 1 O

A	645 1 O
complete	647 8 O
recovery	656 8 O
of	665 2 O
renal	668 5 O
function	674 8 O
was	683 3 O
achieved	687 8 O
in	696 2 O
a	699 1 O
few	701 3 O
weeks	705 5 O
.	710 1 O

This	712 4 O
new	717 3 O
case	721 4 O
of	726 2 O
RPGN	729 4 B-Disease
in	734 2 O
the	737 3 O
course	741 6 O
of	748 2 O
D	751 1 B-Chemical
-	752 1 I-Chemical
penicillamine	753 13 I-Chemical
treatment	767 9 O
emphasizes	777 10 O
the	788 3 O
need	792 4 O
for	797 3 O
frequent	801 8 O
monitoring	810 10 O
of	821 2 O
renal	824 5 O
function	830 8 O
and	839 3 O
evaluation	843 10 O
of	854 2 O
urinary	857 7 O
sediment	865 8 O
and	874 3 O
proteinuria	878 11 B-Disease
in	890 2 O
these	893 5 O
patients	899 8 O
.	907 1 O

The	909 3 O
prompt	913 6 O
discontinuation	920 15 O
of	936 2 O
D	939 1 B-Chemical
-	940 1 I-Chemical
penicillamine	941 13 I-Chemical
and	955 3 O
vigorous	959 8 O
treatment	968 9 O
measures	978 8 O
could	987 5 O
allow	993 5 O
for	999 3 O
a	1003 1 O
good	1005 4 O
prognosis	1010 9 O
as	1020 2 O
in	1023 2 O
this	1026 4 O
case	1031 4 O
.	1035 1 O

Nature	0 6 O
,	6 1 O
time	8 4 O
course	13 6 O
and	20 3 O
dose	24 4 O
dependence	29 10 O
of	40 2 O
zidovudine	43 10 B-Chemical
-	53 1 O
related	54 7 O
side	62 4 O
effects	67 7 O
:	74 1 O
results	76 7 O
from	84 4 O
the	89 3 O
Multicenter	93 11 O
Canadian	105 8 O
Azidothymidine	114 14 B-Chemical
Trial	129 5 O
.	134 1 O

To	136 2 O
characterize	139 12 O
the	152 3 O
nature	156 6 O
,	162 1 O
time	164 4 O
course	169 6 O
and	176 3 O
dose	180 4 O
dependency	185 10 O
of	196 2 O
zidovudine	199 10 B-Chemical
-	209 1 O
related	210 7 O
side	218 4 O
effects	223 7 O
,	230 1 O
we	232 2 O
undertook	235 9 O
a	245 1 O
multicenter	247 11 O
,	258 1 O
prospective	260 11 O
,	271 1 O
dose	273 4 O
-	277 1 O
range	278 5 O
finding	284 7 O
study	292 5 O
.	297 1 O

Our	299 3 O
study	303 5 O
group	309 5 O
consisted	315 9 O
of	325 2 O
74	328 2 O
HIV	331 3 O
-	334 1 O
positive	335 8 O
homosexual	344 10 O
men	355 3 O
belonging	359 9 O
to	369 2 O
groups	372 6 O
II	379 2 O
B	382 1 O
,	383 1 O
III	385 3 O
and	389 3 O
IV	393 2 O
C2	396 2 O
from	399 4 O
the	404 3 O
Centers	408 7 O
for	416 3 O
Disease	420 7 O
Control	428 7 O
(	436 1 O
CDC	437 3 O
)	440 1 O
classification	442 14 O
of	457 2 O
HIV	460 3 B-Disease
disease	464 7 I-Disease
.	471 1 O

Following	473 9 O
a	483 1 O
3	485 1 O
-	486 1 O
week	487 4 O
observation	492 11 O
period	504 6 O
,	510 1 O
volunteers	512 10 O
were	523 4 O
treated	528 7 O
with	536 4 O
zidovudine	541 10 B-Chemical
600	552 3 O
mg	556 2 O
/	558 1 O
day	559 3 O
for	563 3 O
18	567 2 O
weeks	570 5 O
,	575 1 O
900	577 3 O
mg	581 2 O
/	583 1 O
day	584 3 O
for	588 3 O
9	592 1 O
weeks	594 5 O
and	600 3 O
1200	604 4 O
mg	609 2 O
/	611 1 O
day	612 3 O
for	616 3 O
9	620 1 O
weeks	622 5 O
,	627 1 O
followed	629 8 O
by	638 2 O
a	641 1 O
washout	643 7 O
period	651 6 O
of	658 2 O
6	661 1 O
weeks	663 5 O
after	669 5 O
which	675 5 O
they	681 4 O
were	686 4 O
re	691 2 O
-	693 1 O
started	694 7 O
on	702 2 O
1200	705 4 O
mg	710 2 O
/	712 1 O
day	713 3 O
or	717 2 O
the	720 3 O
highest	724 7 O
tolerated	732 9 O
dose	742 4 O
at	747 2 O
8	750 1 O
-	751 1 O
hourly	752 6 O
intervals	759 9 O
.	768 1 O

Subjects	770 8 O
were	779 4 O
randomly	784 8 O
assigned	793 8 O
to	802 2 O
4	805 1 O
-	806 1 O
hourly	807 6 O
or	814 2 O
8	817 1 O
-	818 1 O
hourly	819 6 O
regimens	826 8 O
within	835 6 O
CDC	842 3 O
groups	846 6 O
while	853 5 O
taking	859 6 O
600	866 3 O
and	870 3 O
1200	874 4 O
mg	879 2 O
/	881 1 O
day	882 3 O
.	885 1 O

Clinical	887 8 O
and	896 3 O
laboratory	900 10 O
evaluations	911 11 O
were	923 4 O
performed	928 9 O
at	938 2 O
3	941 1 O
-	942 1 O
week	943 4 O
intervals	948 9 O
.	957 1 O

Symptomatic	959 11 O
adverse	971 7 O
effects	979 7 O
were	987 4 O
present	992 7 O
in	1000 2 O
96	1003 2 O
%	1005 1 O
of	1007 2 O
subjects	1010 8 O
,	1018 1 O
most	1020 4 O
commonly	1025 8 O
nausea	1034 6 B-Disease
(	1041 1 O
64	1042 2 O
%	1044 1 O
)	1045 1 O
,	1046 1 O
fatigue	1048 7 B-Disease
(	1056 1 O
55	1057 2 O
%	1059 1 O
)	1060 1 O
and	1062 3 O
headache	1066 8 B-Disease
(	1075 1 O
49	1076 2 O
%	1078 1 O
)	1079 1 O
.	1080 1 O

These	1082 5 O
were	1088 4 O
generally	1093 9 O
self	1103 4 O
-	1107 1 O
limited	1108 7 O
,	1115 1 O
reappearing	1117 11 O
briefly	1129 7 O
at	1137 2 O
each	1140 4 O
dose	1145 4 O
increment	1150 9 O
.	1159 1 O

A	1161 1 O
decrease	1163 8 O
in	1172 2 O
hemoglobin	1175 10 O
occurred	1186 8 O
shortly	1195 7 O
after	1203 5 O
initiation	1209 10 O
of	1220 2 O
therapy	1223 7 O
.	1230 1 O

This	1232 4 O
was	1237 3 O
not	1241 3 O
dose	1245 4 O
dependent	1250 9 O
and	1260 3 O
reversed	1264 8 O
rapidly	1273 7 O
upon	1281 4 O
discontinuation	1286 15 O
of	1302 2 O
treatment	1305 9 O
.	1314 1 O

A	1316 1 O
red	1318 3 O
blood	1322 5 O
cell	1328 4 O
count	1333 5 O
decrease	1339 8 O
,	1347 1 O
a	1349 1 O
mean	1351 4 O
cell	1356 4 O
volume	1361 6 O
increase	1368 8 O
and	1377 3 O
a	1381 1 O
granulocyte	1383 11 O
count	1395 5 O
decrease	1401 8 O
developed	1410 9 O
early	1420 5 O
in	1426 2 O
a	1429 1 O
dose	1431 4 O
-	1435 1 O
independent	1436 11 O
fashion	1448 7 O
,	1455 1 O
reverting	1457 9 O
at	1467 2 O
least	1470 5 O
partially	1476 9 O
during	1486 6 O
the	1493 3 O
washout	1497 7 O
phase	1505 5 O
.	1510 1 O

The	1512 3 O
decrease	1516 8 O
in	1525 2 O
reticulocyte	1528 12 O
count	1541 5 O
was	1547 3 O
dose	1551 4 O
related	1556 7 O
between	1564 7 O
600	1572 3 O
and	1576 3 O
900	1580 3 O
mg	1584 2 O
/	1586 1 O
day	1587 3 O
with	1591 4 O
no	1596 2 O
further	1599 7 O
change	1607 6 O
when	1614 4 O
the	1619 3 O
dose	1623 4 O
was	1628 3 O
escalated	1632 9 O
to	1642 2 O
1200	1645 4 O
mg	1650 2 O
/	1652 1 O
day	1653 3 O
.	1656 1 O

Bone	1658 4 O
marrow	1663 6 O
changes	1670 7 O
occurred	1678 8 O
rapidly	1687 7 O
as	1695 2 O
demonstrated	1698 12 O
by	1711 2 O
megaloblastosis	1714 15 B-Disease
in	1730 2 O
95	1733 2 O
%	1735 1 O
of	1737 2 O
65	1740 2 O
specimens	1743 9 O
at	1753 2 O
week	1756 4 O
18	1761 2 O
.	1763 1 O
(	1764 1 O
ABSTRACT	1765 8 O
TRUNCATED	1774 9 O
AT	1784 2 O
250	1787 3 O
WORDS	1791 5 O
)	1796 1 O

Bilateral	0 9 B-Disease
optic	10 5 I-Disease
neuropathy	16 10 I-Disease
due	27 3 O
to	31 2 O
combined	34 8 O
ethambutol	43 10 B-Chemical
and	54 3 O
isoniazid	58 9 B-Chemical
treatment	68 9 O
.	77 1 O

The	79 3 O
case	83 4 O
of	88 2 O
a	91 1 O
40	93 2 O
-	95 1 O
year	96 4 O
-	100 1 O
old	101 3 O
patient	105 7 O
who	113 3 O
underwent	117 9 O
an	127 2 O
unsuccessful	130 12 O
cadaver	143 7 O
kidney	151 6 O
transplantation	158 15 O
and	174 3 O
was	178 3 O
treated	182 7 O
with	190 4 O
ethambutol	195 10 B-Chemical
and	206 3 O
isoniazid	210 9 B-Chemical
is	220 2 O
reported	223 8 O
.	231 1 O

A	233 1 O
bilateral	235 9 B-Disease
retrobulbar	245 11 I-Disease
neuropathy	257 10 I-Disease
with	268 4 O
an	273 2 O
unusual	276 7 O
central	284 7 O
bitemporal	292 10 O
hemianopic	303 10 O
scotoma	314 7 B-Disease
was	322 3 O
found	326 5 O
.	331 1 O

Ethambutol	333 10 B-Chemical
was	344 3 O
stopped	348 7 O
and	356 3 O
only	360 4 O
small	365 5 O
improvement	371 11 O
of	383 2 O
the	386 3 O
visual	390 6 O
acuity	397 6 O
followed	404 8 O
.	412 1 O

Isoniazid	414 9 B-Chemical
was	424 3 O
discontinued	428 12 O
later	441 5 O
,	446 1 O
followed	448 8 O
by	457 2 O
a	460 1 O
dramatic	462 8 O
improvement	471 11 O
in	483 2 O
the	486 3 O
visual	490 6 O
acuity	497 6 O
.	503 1 O

The	505 3 O
hazards	509 7 O
of	517 2 O
optic	520 5 O
nerve	526 5 O
toxicity	532 8 B-Disease
due	541 3 O
to	545 2 O
ethambutol	548 10 B-Chemical
are	559 3 O
known	563 5 O
.	568 1 O

We	570 2 O
emphasize	573 9 O
the	583 3 O
potential	587 9 O
danger	597 6 O
in	604 2 O
the	607 3 O
use	611 3 O
of	615 2 O
ethambutol	618 10 B-Chemical
and	629 3 O
isoniazid	633 9 B-Chemical
.	642 1 O

Progestational	0 14 O
agents	15 6 O
and	22 3 O
blood	26 5 B-Disease
coagulation	32 11 I-Disease
.	43 1 O

VII	45 3 O
.	48 1 O

Thromboembolic	50 14 B-Disease
and	65 3 O
other	69 5 O
complications	75 13 O
of	89 2 O
oral	92 4 B-Chemical
contraceptive	97 13 I-Chemical
therapy	111 7 O
in	119 2 O
relationship	122 12 O
to	135 2 O
pretreatment	138 12 O
levels	151 6 O
of	158 2 O
blood	161 5 B-Disease
coagulation	167 11 I-Disease
factors	179 7 O
:	186 1 O
summary	188 7 O
report	196 6 O
of	203 2 O
a	206 1 O
ten	208 3 O
-	211 1 O
year	212 4 O
study	217 5 O
.	222 1 O

During	224 6 O
a	231 1 O
ten	233 3 O
-	236 1 O
year	237 4 O
period	242 6 O
,	248 1 O
348	250 3 O
women	254 5 O
were	260 4 O
studied	265 7 O
for	273 3 O
a	277 1 O
total	279 5 O
of	285 2 O
5	288 1 O
,	289 1 O
877	290 3 O
patient	294 7 O
months	302 6 O
in	309 2 O
four	312 4 O
separate	317 8 O
studies	326 7 O
relating	334 8 O
oral	343 4 B-Chemical
contraceptives	348 14 I-Chemical
to	363 2 O
changes	366 7 O
in	374 2 O
hematologic	377 11 O
parameters	389 10 O
.	399 1 O

Significant	401 11 O
increases	413 9 O
in	423 2 O
certain	426 7 O
factors	434 7 O
of	442 2 O
the	445 3 O
blood	449 5 B-Disease
coagulation	455 11 I-Disease
and	467 3 O
fibrinolysin	471 12 O
systems	484 7 O
(	492 1 O
factors	493 7 O
I	501 1 O
,	502 1 O
II	503 2 O
,	505 1 O
VII	506 3 O
,	509 1 O
VIII	510 4 O
,	514 1 O
IX	515 2 O
,	517 1 O
and	519 3 O
X	523 1 O
and	525 3 O
plasminogen	529 11 O
)	540 1 O
were	542 4 O
observed	547 8 O
in	556 2 O
the	559 3 O
treated	563 7 O
groups	571 6 O
.	577 1 O

Severe	579 6 O
complications	586 13 O
developed	600 9 O
in	610 2 O
four	613 4 O
patients	618 8 O
.	626 1 O

All	628 3 O
four	632 4 O
had	637 3 O
an	641 2 O
abnormal	644 8 O
blood	653 5 B-Disease
coagulation	659 11 I-Disease
profile	671 7 O
,	678 1 O
suggesting	680 10 O
"	691 1 O
hypercoagulability	692 18 B-Disease
"	710 1 O
before	712 6 O
initiation	719 10 O
of	730 2 O
therapy	733 7 O
.	740 1 O

Some	742 4 O
of	747 2 O
these	750 5 O
findings	756 8 O
represented	765 11 O
the	777 3 O
most	781 4 O
extreme	786 7 O
abnormalities	794 13 O
seen	808 4 O
in	813 2 O
the	816 3 O
entire	820 6 O
group	827 5 O
of	833 2 O
patients	836 8 O
;	844 1 O
some	846 4 O
increased	851 9 O
further	861 7 O
during	869 6 O
therapy	876 7 O
.	883 1 O

One	885 3 O
of	889 2 O
these	892 5 O
patients	898 8 O
developed	907 9 O
a	917 1 O
myocardial	919 10 B-Disease
infarction	930 10 I-Disease
before	941 6 O
receiving	948 9 O
any	958 3 O
medication	962 10 O
,	972 1 O
shortly	974 7 O
after	982 5 O
the	988 3 O
base	992 4 O
-	996 1 O
line	997 4 O
values	1002 6 O
were	1009 4 O
obtained	1014 8 O
.	1022 1 O

One	1024 3 O
patient	1028 7 O
developed	1036 9 O
retinopathy	1046 11 B-Disease
19	1058 2 O
months	1061 6 O
after	1068 5 O
she	1074 3 O
began	1078 5 O
therapy	1084 7 O
,	1091 1 O
and	1093 3 O
another	1097 7 O
developed	1105 9 O
thrombophlebitis	1115 16 B-Disease
after	1132 5 O
27	1138 2 O
months	1141 6 O
of	1148 2 O
therapy	1151 7 O
.	1158 1 O

The	1160 3 O
fourth	1164 6 O
patient	1171 7 O
developed	1179 9 O
thrombophlebitis	1189 16 B-Disease
14	1206 2 O
days	1209 4 O
after	1214 5 O
initiation	1220 10 O
of	1231 2 O
contraceptive	1234 13 O
therapy	1248 7 O
.	1255 1 O

All	1257 3 O
four	1261 4 O
patients	1266 8 O
were	1275 4 O
of	1280 2 O
the	1283 3 O
A	1287 1 O
or	1289 2 O
AB	1292 2 O
blood	1295 5 O
group	1301 5 O
.	1306 1 O

Previous	1308 8 O
studies	1317 7 O
suggested	1325 9 O
the	1335 3 O
possiblility	1339 12 O
of	1352 2 O
increased	1355 9 O
propensity	1365 10 O
for	1376 3 O
thromboembolic	1380 14 B-Disease
episodes	1395 8 I-Disease
in	1404 2 O
patients	1407 8 O
possessing	1416 10 O
the	1427 3 O
A	1431 1 O
antigen	1433 7 O
.	1440 1 O

It	1442 2 O
appears	1445 7 O
from	1453 4 O
these	1458 5 O
data	1464 4 O
that	1469 4 O
hematologic	1474 11 O
work	1486 4 O
-	1490 1 O
ups	1491 3 O
may	1495 3 O
be	1499 2 O
useful	1502 6 O
in	1509 2 O
women	1512 5 O
who	1518 3 O
are	1522 3 O
about	1526 5 O
to	1532 2 O
start	1535 5 O
long	1541 4 O
-	1545 1 O
term	1546 4 O
oral	1551 4 B-Chemical
contraceptive	1556 13 I-Chemical
therapy	1570 7 O
.	1577 1 O

Cardiac	0 7 B-Disease
arrest	8 6 I-Disease
in	15 2 O
a	18 1 O
child	20 5 O
with	26 4 O
cerebral	31 8 B-Disease
palsy	40 5 I-Disease
undergoing	46 10 O
sevoflurane	57 11 B-Chemical
induction	69 9 O
of	79 2 O
anesthesia	82 10 O
after	93 5 O
preoperative	99 12 O
clonidine	112 9 B-Chemical
.	121 1 O

Clonidine	123 9 B-Chemical
is	133 2 O
a	136 1 O
frequently	138 10 O
administered	149 12 O
alpha2	162 6 O
-	168 1 O
adrenergic	169 10 O
agonist	180 7 O
which	188 5 O
can	194 3 O
decrease	198 8 O
heart	207 5 O
rate	213 4 O
and	218 3 O
blood	222 5 O
pressure	228 8 O
.	236 1 O

We	238 2 O
present	241 7 O
a	249 1 O
case	251 4 O
of	256 2 O
a	259 1 O
5	261 1 O
-	262 1 O
year	263 4 O
-	267 1 O
old	268 3 O
child	272 5 O
with	278 4 O
cerebral	283 8 B-Disease
palsy	292 5 I-Disease
and	298 3 O
seizure	302 7 B-Disease
disorder	310 8 I-Disease
,	318 1 O
receiving	320 9 O
clonidine	330 9 B-Chemical
for	340 3 O
restlessness	344 12 B-Disease
,	356 1 O
who	358 3 O
presented	362 9 O
for	372 3 O
placement	376 9 O
of	386 2 O
a	389 1 O
baclofen	391 8 B-Chemical
pump	400 4 O
.	404 1 O

Without	406 7 O
the	414 3 O
knowledge	418 9 O
of	428 2 O
the	431 3 O
medical	435 7 O
personnel	443 9 O
,	452 1 O
the	454 3 O
patient	458 7 O
'	465 1 O
s	466 1 O
mother	468 6 O
administered	475 12 O
three	488 5 O
doses	494 5 O
of	500 2 O
clonidine	503 9 B-Chemical
during	513 6 O
the	520 3 O
evening	524 7 O
before	532 6 O
and	539 3 O
morning	543 7 O
of	551 2 O
surgery	554 7 O
to	562 2 O
reduce	565 6 O
anxiety	572 7 B-Disease
.	579 1 O

During	581 6 O
induction	588 9 O
of	598 2 O
anesthesia	601 10 O
,	611 1 O
the	613 3 O
patient	617 7 O
developed	625 9 O
bradycardia	635 11 B-Disease
and	647 3 O
hypotension	651 11 B-Disease
requiring	663 9 O
cardiac	673 7 O
resuscitation	681 13 O
.	694 1 O

There	696 5 O
are	702 3 O
no	706 2 O
previous	709 8 O
reports	718 7 O
of	726 2 O
clonidine	729 9 B-Chemical
-	738 1 O
associated	739 10 O
cardiac	750 7 B-Disease
arrest	758 6 I-Disease
in	765 2 O
a	768 1 O
child	770 5 O
undergoing	776 10 O
induction	787 9 O
of	797 2 O
anesthesia	800 10 O
.	810 1 O

Effects	0 7 O
of	8 2 O
UMB24	11 5 B-Chemical
and	17 3 O
(	21 1 O
+	22 1 O
/	23 1 O
-	24 1 O
)	25 1 O
-	26 1 O
SM	27 2 B-Chemical
21	30 2 I-Chemical
,	32 1 O
putative	34 8 O
sigma2	43 6 O
-	49 1 O
preferring	50 10 O
antagonists	61 11 O
,	72 1 O
on	74 2 O
behavioral	77 10 O
toxic	88 5 O
and	94 3 O
stimulant	98 9 O
effects	108 7 O
of	116 2 O
cocaine	119 7 B-Chemical
in	127 2 O
mice	130 4 O
.	134 1 O

Earlier	136 7 O
studies	144 7 O
have	152 4 O
demonstrated	157 12 O
that	170 4 O
antagonism	175 10 O
of	186 2 O
sigma1	189 6 O
receptors	196 9 O
attenuates	206 10 O
the	217 3 O
convulsive	221 10 B-Disease
,	231 1 O
lethal	233 6 O
,	239 1 O
locomotor	241 9 O
stimulatory	251 11 O
and	263 3 O
rewarding	267 9 O
actions	277 7 O
of	285 2 O
cocaine	288 7 B-Chemical
in	296 2 O
mice	299 4 O
.	303 1 O

In	305 2 O
contrast	308 8 O
,	316 1 O
the	318 3 O
contribution	322 12 O
of	335 2 O
sigma2	338 6 O
receptors	345 9 O
is	355 2 O
unclear	358 7 O
because	366 7 O
experimental	374 12 O
tools	387 5 O
to	393 2 O
selectively	396 11 O
target	408 6 O
this	415 4 O
subtype	420 7 O
are	428 3 O
unavailable	432 11 O
.	443 1 O

To	445 2 O
begin	448 5 O
addressing	454 10 O
this	465 4 O
need	470 4 O
,	474 1 O
we	476 2 O
characterized	479 13 O
UMB24	493 5 B-Chemical
(	499 1 O
1	500 1 B-Chemical
-	501 1 I-Chemical
(	502 1 I-Chemical
2	503 1 I-Chemical
-	504 1 I-Chemical
phenethyl	505 9 I-Chemical
)	514 1 I-Chemical
-	515 1 I-Chemical
4	516 1 I-Chemical
-	517 1 I-Chemical
(	518 1 I-Chemical
2	519 1 I-Chemical
-	520 1 I-Chemical
pyridyl	521 7 I-Chemical
)	528 1 I-Chemical
-	529 1 I-Chemical
piperazine	530 10 I-Chemical
)	540 1 O
and	542 3 O
(	546 1 O
+	547 1 O
/	548 1 O
-	549 1 O
)	550 1 O
-	551 1 O
SM	552 2 B-Chemical
21	555 2 I-Chemical
(	558 1 O
3alpha	559 6 B-Chemical
-	565 1 I-Chemical
tropanyl	566 8 I-Chemical
-	574 1 I-Chemical
2	575 1 I-Chemical
-	576 1 I-Chemical
(	577 1 I-Chemical
4	578 1 I-Chemical
-	579 1 I-Chemical
chorophenoxy	580 12 I-Chemical
)	592 1 I-Chemical
butyrate	593 8 I-Chemical
)	601 1 O
in	603 2 O
receptor	606 8 O
binding	615 7 O
and	623 3 O
behavioral	627 10 O
studies	638 7 O
.	645 1 O

Receptor	647 8 O
binding	656 7 O
studies	664 7 O
confirmed	672 9 O
that	682 4 O
UMB24	687 5 B-Chemical
and	693 3 O
(	697 1 O
+	698 1 O
/	699 1 O
-	700 1 O
)	701 1 O
-	702 1 O
SM	703 2 B-Chemical
21	706 2 I-Chemical
display	709 7 O
preferential	717 12 O
affinity	730 8 O
for	739 3 O
sigma2	743 6 O
over	750 4 O
sigma1	755 6 O
receptors	762 9 O
.	771 1 O

In	773 2 O
behavioral	776 10 O
studies	787 7 O
,	794 1 O
pretreatment	796 12 O
of	809 2 O
Swiss	812 5 O
Webster	818 7 O
mice	826 4 O
with	831 4 O
UMB24	836 5 B-Chemical
or	842 2 O
(	845 1 O
+	846 1 O
/	847 1 O
-	848 1 O
)	849 1 O
-	850 1 O
SM	851 2 B-Chemical
21	854 2 I-Chemical
significantly	857 13 O
attenuated	871 10 O
cocaine	882 7 B-Chemical
-	889 1 O
induced	890 7 O
convulsions	898 11 B-Disease
and	910 3 O
locomotor	914 9 O
activity	924 8 O
,	932 1 O
but	934 3 O
not	938 3 O
lethality	942 9 O
.	951 1 O

When	953 4 O
administered	958 12 O
alone	971 5 O
,	976 1 O
(	978 1 O
+	979 1 O
/	980 1 O
-	981 1 O
)	982 1 O
-	983 1 O
SM	984 2 B-Chemical
21	987 2 I-Chemical
produced	990 8 O
no	999 2 O
significant	1002 11 O
effects	1014 7 O
compared	1022 8 O
to	1031 2 O
control	1034 7 O
injections	1042 10 O
of	1053 2 O
saline	1056 6 O
,	1062 1 O
but	1064 3 O
UMB24	1068 5 B-Chemical
had	1074 3 O
locomotor	1078 9 O
depressant	1088 10 O
actions	1099 7 O
.	1106 1 O

Together	1108 8 O
,	1116 1 O
the	1118 3 O
data	1122 4 O
suggest	1127 7 O
that	1135 4 O
sigma2	1140 6 O
receptor	1147 8 O
antagonists	1156 11 O
have	1168 4 O
the	1173 3 O
potential	1177 9 O
to	1187 2 O
attenuate	1190 9 O
some	1200 4 O
of	1205 2 O
the	1208 3 O
behavioral	1212 10 O
effects	1223 7 O
of	1231 2 O
cocaine	1234 7 B-Chemical
,	1241 1 O
and	1243 3 O
further	1247 7 O
development	1255 11 O
of	1267 2 O
more	1270 4 O
selective	1275 9 O
,	1284 1 O
high	1286 4 O
affinity	1291 8 O
ligands	1300 7 O
are	1308 3 O
warranted	1312 9 O
.	1321 1 O

Methimazole	0 11 B-Chemical
-	11 1 O
induced	12 7 O
cholestatic	20 11 B-Disease
jaundice	32 8 I-Disease
.	40 1 O

Methimazole	42 11 B-Chemical
is	54 2 O
a	57 1 O
widely	59 6 O
used	66 4 O
and	71 3 O
generally	75 9 O
well	85 4 O
-	89 1 O
tolerated	90 9 O
antithyroid	100 11 O
agent	112 5 O
.	117 1 O

A	119 1 O
43	121 2 O
-	123 1 O
year	124 4 O
-	128 1 O
old	129 3 O
woman	133 5 O
had	139 3 O
severe	143 6 O
jaundice	150 8 B-Disease
and	159 3 O
itching	163 7 B-Disease
1	171 1 O
month	173 5 O
after	179 5 O
receiving	185 9 O
methimazole	195 11 B-Chemical
(	207 1 O
10	208 2 O
mg	211 2 O
tid	214 3 O
)	217 1 O
and	219 3 O
propranolol	223 11 B-Chemical
(	235 1 O
20	236 2 O
mg	239 2 O
tid	242 3 O
)	245 1 O
for	247 3 O
treatment	251 9 O
of	261 2 O
hyperthyroidism	264 15 B-Disease
.	279 1 O

The	281 3 O
patient	285 7 O
continued	293 9 O
treatment	303 9 O
for	313 3 O
another	317 7 O
4	325 1 O
days	327 4 O
after	332 5 O
the	338 3 O
appearance	342 10 O
of	353 2 O
jaundice	356 8 B-Disease
until	365 5 O
she	371 3 O
finished	375 8 O
both	384 4 O
medications	389 11 O
.	400 1 O

When	402 4 O
seen	407 4 O
at	412 2 O
the	415 3 O
emergency	419 9 O
department	429 10 O
2	440 1 O
weeks	442 5 O
later	448 5 O
,	453 1 O
she	455 3 O
still	459 5 O
had	465 3 O
severe	469 6 O
icterus	476 7 B-Disease
,	483 1 O
pruritus	485 8 B-Disease
,	493 1 O
and	495 3 O
hyperbilirubinemia	499 18 B-Disease
,	517 1 O
formed	519 6 O
mainly	526 6 O
of	533 2 O
the	536 3 O
conjugated	540 10 O
fraction	551 8 O
.	559 1 O

Methimazole	561 11 B-Chemical
-	572 1 O
induced	573 7 O
cholestasis	581 11 B-Disease
was	593 3 O
diagnosed	597 9 O
,	606 1 O
and	608 3 O
propranolol	612 11 B-Chemical
therapy	624 7 O
was	632 3 O
resumed	636 7 O
.	643 1 O

Over	645 4 O
the	650 3 O
following	654 9 O
9	664 1 O
days	666 4 O
,	670 1 O
the	672 3 O
symptoms	676 8 O
improved	685 8 O
and	694 3 O
plasma	698 6 O
bilirubin	705 9 B-Chemical
levels	715 6 O
were	722 4 O
normal	727 6 O
after	734 5 O
12	740 2 O
weeks	743 5 O
without	749 7 O
methimazole	757 11 B-Chemical
.	768 1 O

In	770 2 O
rare	773 4 O
cases	778 5 O
within	784 6 O
the	791 3 O
first	795 5 O
few	801 3 O
weeks	805 5 O
of	811 2 O
therapy	814 7 O
,	821 1 O
this	823 4 O
drug	828 4 O
can	833 3 O
cause	837 5 O
severe	843 6 O
and	850 3 O
reversible	854 10 O
cholestatic	865 11 B-Disease
jaundice	877 8 I-Disease
.	885 1 O

Physicians	887 10 O
and	898 3 O
patients	902 8 O
should	911 6 O
be	918 2 O
aware	921 5 O
of	927 2 O
this	930 4 O
adverse	935 7 O
effect	943 6 O
so	950 2 O
that	953 4 O
,	957 1 O
upon	959 4 O
occurrence	964 10 O
,	974 1 O
they	976 4 O
can	981 3 O
discontinue	985 11 O
methimazole	997 11 B-Chemical
therapy	1009 7 O
and	1017 3 O
avoid	1021 5 O
unnecessary	1027 11 O
invasive	1039 8 O
procedures	1048 10 O
.	1058 1 O

Ciprofloxacin	0 13 B-Chemical
-	13 1 O
induced	14 7 O
acute	22 5 O
interstitial	28 12 B-Disease
nephritis	41 9 I-Disease
and	51 3 O
autoimmune	55 10 B-Disease
hemolytic	66 9 I-Disease
anemia	76 6 I-Disease
.	82 1 O

Ciprofloxacin	84 13 B-Chemical
has	98 3 O
been	102 4 O
associated	107 10 O
with	118 4 O
several	123 7 O
side	131 4 O
effects	136 7 O
including	144 9 O
interstitial	154 12 B-Disease
nephritis	167 9 I-Disease
and	177 3 O
hemolytic	181 9 B-Disease
anemia	191 6 I-Disease
.	197 1 O

The	199 3 O
combination	203 11 O
of	215 2 O
both	218 4 O
side	223 4 O
effects	228 7 O
is	236 2 O
extremely	239 9 O
rare	249 4 O
.	253 1 O

In	255 2 O
this	258 4 O
report	263 6 O
,	269 1 O
we	271 2 O
describe	274 8 O
a	283 1 O
case	285 4 O
of	290 2 O
ciprofloxacin	293 13 B-Chemical
-	306 1 O
induced	307 7 O
interstitial	315 12 B-Disease
nephritis	328 9 I-Disease
and	338 3 O
autoimmune	342 10 B-Disease
hemolytic	353 9 I-Disease
anemia	363 6 I-Disease
.	369 1 O

Hemolytic	371 9 B-Disease
anemia	381 6 I-Disease
improved	388 8 O
after	397 5 O
stopping	403 8 O
the	412 3 O
drug	416 4 O
and	421 3 O
initiation	425 10 O
of	436 2 O
steroid	439 7 B-Chemical
therapy	447 7 O
.	454 1 O

Unfortunately	456 13 O
,	469 1 O
acute	471 5 O
interstitial	477 12 B-Disease
nephritis	490 9 I-Disease
was	500 3 O
irreversible	504 12 O
and	517 3 O
the	521 3 O
patient	525 7 O
developed	533 9 O
end	543 3 B-Disease
-	546 1 I-Disease
stage	547 5 I-Disease
renal	553 5 I-Disease
disease	559 7 I-Disease
.	566 1 O

Contribution	0 12 O
of	13 2 O
sodium	16 6 B-Chemical
valproate	23 9 I-Chemical
to	33 2 O
the	36 3 O
syndrome	40 8 B-Disease
of	49 2 I-Disease
inappropriate	52 13 I-Disease
secretion	66 9 I-Disease
of	76 2 I-Disease
antidiuretic	79 12 I-Disease
hormone	92 7 I-Disease
.	99 1 O

We	101 2 O
report	104 6 O
the	111 3 O
case	115 4 O
of	120 2 O
a	123 1 O
62	125 2 O
-	127 1 O
year	128 4 O
-	132 1 O
old	133 3 O
man	137 3 O
who	141 3 O
was	145 3 O
administered	149 12 O
sodium	162 6 B-Chemical
valproate	169 9 I-Chemical
(	179 1 O
VPA	180 3 B-Chemical
)	183 1 O
and	185 3 O
who	189 3 O
subsequently	193 12 O
developed	206 9 O
the	216 3 O
syndrome	220 8 B-Disease
of	229 2 I-Disease
inappropriate	232 13 I-Disease
secretion	246 9 I-Disease
of	256 2 I-Disease
antidiuretic	259 12 I-Disease
hormone	272 7 I-Disease
(	280 1 O
SIADH	281 5 B-Disease
)	286 1 O
.	287 1 O

He	289 2 O
had	292 3 O
been	296 4 O
taking	301 6 O
VPA	308 3 B-Chemical
for	312 3 O
treatment	316 9 O
of	326 2 O
idiopathic	329 10 O
generalized	340 11 O
tonic	352 5 B-Disease
-	357 1 I-Disease
clonic	358 6 I-Disease
convulsions	365 11 I-Disease
since	377 5 O
he	383 2 O
was	386 3 O
56	390 2 O
years	393 5 O
old	399 3 O
.	402 1 O

After	404 5 O
substituting	410 12 O
VPA	423 3 B-Chemical
with	427 4 O
zonisamide	432 10 B-Chemical
,	442 1 O
the	444 3 O
serum	448 5 O
sodium	454 6 B-Chemical
level	461 5 O
returned	467 8 O
to	476 2 O
normal	479 6 O
.	485 1 O

We	487 2 O
consider	490 8 O
this	499 4 O
episode	504 7 O
of	512 2 O
SIADH	515 5 B-Disease
to	521 2 O
be	524 2 O
the	527 3 O
result	531 6 O
of	538 2 O
a	541 1 O
combination	543 11 O
of	555 2 O
factors	558 7 O
including	566 9 O
a	576 1 O
weakness	578 8 B-Disease
of	587 2 I-Disease
the	590 3 I-Disease
central	594 7 I-Disease
nervous	602 7 I-Disease
system	610 6 I-Disease
and	617 3 O
the	621 3 O
long	625 4 O
-	629 1 O
term	630 4 O
administration	635 14 O
of	650 2 O
VPA	653 3 B-Chemical
.	656 1 O

Vasopressin	0 11 B-Chemical
in	12 2 O
the	15 3 O
treatment	19 9 O
of	29 2 O
milrinone	32 9 B-Chemical
-	41 1 O
induced	42 7 O
hypotension	50 11 B-Disease
in	62 2 O
severe	65 6 O
heart	72 5 B-Disease
failure	78 7 I-Disease
.	85 1 O

The	87 3 O
use	91 3 O
of	95 2 O
phosphodiesterase	98 17 O
inhibitors	116 10 O
such	127 4 O
as	132 2 O
milrinone	135 9 B-Chemical
in	145 2 O
the	148 3 O
treatment	152 9 O
of	162 2 O
severe	165 6 O
heart	172 5 B-Disease
failure	178 7 I-Disease
is	186 2 O
frequently	189 10 O
restricted	200 10 O
because	211 7 O
they	219 4 O
cause	224 5 O
vasodilation	230 12 O
and	243 3 O
hypotension	247 11 B-Disease
.	258 1 O

In	260 2 O
patients	263 8 O
with	272 4 O
decompensated	277 13 O
heart	291 5 B-Disease
failure	297 7 I-Disease
with	305 4 O
hypotension	310 11 B-Disease
after	322 5 O
treatment	328 9 O
with	338 4 O
milrinone	343 9 B-Chemical
,	352 1 O
low	354 3 O
doses	358 5 O
of	364 2 O
vasopressin	367 11 B-Chemical
restored	379 8 O
blood	388 5 O
pressure	394 8 O
without	403 7 O
inhibiting	411 10 O
the	422 3 O
inotropic	426 9 O
effect	436 6 O
of	443 2 O
milrinone	446 9 B-Chemical
.	455 1 O

Halogenated	0 11 O
anesthetics	12 11 O
form	24 4 O
liver	29 5 O
adducts	35 7 O
and	43 3 O
antigens	47 8 O
that	56 4 O
cross	61 5 O
-	66 1 O
react	67 5 O
with	73 4 O
halothane	78 9 B-Chemical
-	87 1 O
induced	88 7 O
antibodies	96 10 O
.	106 1 O

Two	108 3 O
halogenated	112 11 O
anesthetics	124 11 O
,	135 1 O
enflurane	137 9 B-Chemical
and	147 3 O
isoflurane	151 10 B-Chemical
,	161 1 O
have	163 4 O
been	168 4 O
associated	173 10 O
with	184 4 O
an	189 2 O
allergic	192 8 O
-	200 1 O
type	201 4 O
hepatic	206 7 B-Disease
injury	214 6 I-Disease
both	221 4 O
alone	226 5 O
and	232 3 O
following	236 9 O
previous	246 8 O
exposure	255 8 O
to	264 2 O
halothane	267 9 B-Chemical
.	276 1 O

Halothane	278 9 B-Chemical
hepatitis	288 9 B-Disease
appears	298 7 O
to	306 2 O
involve	309 7 O
an	317 2 O
aberrant	320 8 O
immune	329 6 O
response	336 8 O
.	344 1 O

An	346 2 O
antibody	349 8 O
response	358 8 O
to	367 2 O
a	370 1 O
protein	372 7 O
-	379 1 O
bound	380 5 O
biotransformation	386 17 O
product	404 7 O
(	412 1 O
trifluoroacetyl	413 15 B-Chemical
adduct	429 6 O
)	435 1 O
has	437 3 O
been	441 4 O
detected	446 8 O
on	455 2 O
halothane	458 9 B-Chemical
hepatitis	468 9 B-Disease
patients	478 8 O
.	486 1 O

This	488 4 O
study	493 5 O
was	499 3 O
performed	503 9 O
to	513 2 O
determine	516 9 O
cross	526 5 O
-	531 1 O
reactivity	532 10 O
between	543 7 O
enflurane	551 9 B-Chemical
and	561 3 O
isoflurane	565 10 B-Chemical
with	576 4 O
the	581 3 O
hypersensitivity	585 16 B-Disease
induced	602 7 O
by	610 2 O
halothane	613 9 B-Chemical
.	622 1 O

The	624 3 O
subcellular	628 11 O
and	640 3 O
lobular	644 7 O
production	652 10 O
of	663 2 O
hepatic	666 7 O
neoantigens	674 11 O
recognized	686 10 O
by	697 2 O
halothane	700 9 B-Chemical
-	709 1 O
induced	710 7 O
antibodies	718 10 O
following	729 9 O
enflurane	739 9 B-Chemical
and	749 3 O
isoflurane	753 10 B-Chemical
,	763 1 O
and	765 3 O
the	769 3 O
biochemical	773 11 O
nature	785 6 O
of	792 2 O
these	795 5 O
neoantigens	801 11 O
was	813 3 O
investigated	817 12 O
in	830 2 O
two	833 3 O
animal	837 6 O
models	844 6 O
.	850 1 O

Enflurane	852 9 B-Chemical
administration	862 14 O
resulted	877 8 O
in	886 2 O
neoantigens	889 11 O
detected	901 8 O
in	910 2 O
both	913 4 O
the	918 3 O
microsomal	922 10 O
and	933 3 O
cytosolic	937 9 O
fraction	947 8 O
of	956 2 O
liver	959 5 O
homogenates	965 11 O
and	977 3 O
in	981 2 O
the	984 3 O
centrilobular	988 13 O
region	1002 6 O
of	1009 2 O
the	1012 3 O
liver	1016 5 O
.	1021 1 O

In	1023 2 O
the	1026 3 O
same	1030 4 O
liver	1035 5 O
,	1040 1 O
biochemical	1042 11 O
analysis	1054 8 O
detected	1063 8 O
fluorinated	1072 11 O
liver	1084 5 O
adducts	1090 7 O
that	1098 4 O
were	1103 4 O
up	1108 2 O
to	1111 2 O
20	1114 2 O
-	1116 1 O
fold	1117 4 O
greater	1122 7 O
in	1130 2 O
guinea	1133 6 O
pigs	1140 4 O
than	1145 4 O
in	1150 2 O
rats	1153 4 O
.	1157 1 O

This	1159 4 O
supports	1164 8 O
and	1173 3 O
extends	1177 7 O
previous	1185 8 O
evidence	1194 8 O
for	1203 3 O
a	1207 1 O
mechanism	1209 9 O
by	1219 2 O
which	1222 5 O
enflurane	1228 9 B-Chemical
and	1238 3 O
/	1241 1 O
or	1242 2 O
isoflurane	1245 10 B-Chemical
could	1256 5 O
produce	1262 7 O
a	1270 1 O
hypersensitivity	1272 16 B-Disease
condition	1289 9 O
similar	1299 7 O
to	1307 2 O
that	1310 4 O
of	1315 2 O
halothane	1318 9 B-Chemical
hepatitis	1328 9 B-Disease
either	1338 6 O
alone	1345 5 O
or	1351 2 O
subsequent	1354 10 O
to	1365 2 O
halothane	1368 9 B-Chemical
administration	1378 14 O
.	1392 1 O

The	1394 3 O
guinea	1398 6 O
pig	1405 3 O
would	1409 5 O
appear	1415 6 O
to	1422 2 O
be	1425 2 O
a	1428 1 O
useful	1430 6 O
model	1437 5 O
for	1443 3 O
further	1447 7 O
investigations	1455 14 O
of	1470 2 O
the	1473 3 O
immunological	1477 13 O
response	1491 8 O
to	1500 2 O
these	1503 5 O
antigens	1509 8 O
.	1517 1 O

Induction	0 9 O
by	10 2 O
paracetamol	13 11 B-Chemical
of	25 2 O
bladder	28 7 B-Disease
and	36 3 I-Disease
liver	40 5 I-Disease
tumours	46 7 I-Disease
in	54 2 O
the	57 3 O
rat	61 3 O
.	64 1 O

Effects	66 7 O
on	74 2 O
hepatocyte	77 10 O
fine	88 4 O
structure	93 9 O
.	102 1 O

Groups	104 6 O
of	111 2 O
male	114 4 O
and	119 3 O
female	123 6 O
inbred	130 6 O
Leeds	137 5 O
strain	143 6 O
rats	150 4 O
were	155 4 O
fed	160 3 O
diets	164 5 O
containing	170 10 O
either	181 6 O
0	188 1 O
.	189 1 O
5	190 1 O
%	191 1 O
or	193 2 O
1	196 1 O
.	197 1 O
0	198 1 O
%	199 1 O
paracetamol	201 11 B-Chemical
by	213 2 O
weight	216 6 O
for	223 3 O
up	227 2 O
to	230 2 O
18	233 2 O
months	236 6 O
.	242 1 O

At	244 2 O
the	247 3 O
1	251 1 O
.	252 1 O
0	253 1 O
%	254 1 O
dosage	256 6 O
level	263 5 O
,	268 1 O
20	270 2 O
%	272 1 O
of	274 2 O
rats	277 4 O
of	282 2 O
both	285 4 O
sexes	290 5 O
developed	296 9 O
neoplastic	306 10 O
nodules	317 7 O
of	325 2 O
the	328 3 O
liver	332 5 O
,	337 1 O
a	339 1 O
statistically	341 13 O
significant	355 11 O
incidence	367 9 O
.	376 1 O

These	378 5 O
rats	384 4 O
also	389 4 O
showed	394 6 O
gross	401 5 O
enlargement	407 11 O
of	419 2 O
their	422 5 O
livers	428 6 O
and	435 3 O
an	439 2 O
increase	442 8 O
in	451 2 O
foci	454 4 O
of	459 2 O
cellular	462 8 O
alteration	471 10 O
,	481 1 O
the	483 3 O
latter	487 6 O
also	494 4 O
being	499 5 O
observed	505 8 O
in	514 2 O
the	517 3 O
low	521 3 O
dosage	525 6 O
male	532 4 O
rats	537 4 O
.	541 1 O

Papillomas	543 10 B-Disease
of	554 2 O
the	557 3 O
transitional	561 12 O
epithelium	574 10 O
of	585 2 O
the	588 3 O
bladder	592 7 O
developed	600 9 O
in	610 2 O
all	613 3 O
paracetamol	617 11 B-Chemical
-	628 1 O
treated	629 7 O
groups	637 6 O
,	643 1 O
and	645 3 O
three	649 5 O
rats	655 4 O
bore	660 4 O
bladder	665 7 B-Disease
carcinomas	673 10 I-Disease
.	683 1 O

However	685 7 O
,	692 1 O
significant	694 11 O
yields	706 6 O
of	713 2 O
bladder	716 7 B-Disease
tumours	724 7 I-Disease
were	732 4 O
only	737 4 O
obtained	742 8 O
from	751 4 O
low	756 3 O
dosage	760 6 O
females	767 7 O
and	775 3 O
high	779 4 O
dosage	784 6 O
males	791 5 O
.	796 1 O

Additionally	798 12 O
,	810 1 O
20	812 2 O
to	815 2 O
25	818 2 O
%	820 1 O
of	822 2 O
paracetamol	825 11 B-Chemical
-	836 1 O
treated	837 7 O
rats	845 4 O
developed	850 9 O
hyperplasia	860 11 B-Disease
of	872 2 O
the	875 3 O
bladder	879 7 O
epithelium	887 10 O
,	897 1 O
which	899 5 O
was	905 3 O
not	909 3 O
coincident	913 10 O
with	924 4 O
the	929 3 O
presence	933 8 O
of	942 2 O
bladder	945 7 B-Disease
calculi	953 7 I-Disease
.	960 1 O

A	962 1 O
low	964 3 O
yield	968 5 O
of	974 2 O
tumours	977 7 B-Disease
at	985 2 O
various	988 7 O
other	996 5 O
sites	1002 5 O
also	1008 4 O
arose	1013 5 O
following	1019 9 O
paracetamol	1029 11 B-Chemical
feeding	1041 7 O
.	1048 1 O

An	1050 2 O
electron	1053 8 O
microscope	1062 10 O
study	1073 5 O
of	1079 2 O
the	1082 3 O
livers	1086 6 O
of	1093 2 O
paracetamol	1096 11 B-Chemical
-	1107 1 O
treated	1108 7 O
rats	1116 4 O
revealed	1121 8 O
ultrastructural	1130 15 O
changes	1146 7 O
in	1154 2 O
the	1157 3 O
hepatocytes	1161 11 O
that	1173 4 O
resemble	1178 8 O
those	1187 5 O
that	1193 4 O
result	1198 6 O
from	1205 4 O
exposure	1210 8 O
to	1219 2 O
a	1222 1 O
variety	1224 7 O
of	1232 2 O
known	1235 5 O
hepatocarcinogens	1241 17 B-Disease
.	1258 1 O

Rat	0 3 O
extraocular	4 11 O
muscle	16 6 O
regeneration	23 12 O
.	35 1 O

Repair	37 6 O
of	44 2 O
local	47 5 O
anesthetic	53 10 O
-	63 1 O
induced	64 7 O
damage	72 6 O
.	78 1 O

Local	80 5 O
anesthetics	86 11 O
that	98 4 O
are	103 3 O
commonly	107 8 O
used	116 4 O
in	121 2 O
ophthalmic	124 10 O
surgery	135 7 O
(	143 1 O
0	144 1 O
.	145 1 O
75	146 2 O
%	148 1 O
bupivacaine	150 11 B-Chemical
hydrochloride	162 13 I-Chemical
,	175 1 O
2	177 1 O
.	178 1 O
0	179 1 O
%	180 1 O
mepivacaine	182 11 B-Chemical
hydrochloride	194 13 I-Chemical
,	207 1 O
and	209 3 O
2	213 1 O
.	214 1 O
0	215 1 O
%	216 1 O
lidocaine	218 9 B-Chemical
hydrochloride	228 13 I-Chemical
plus	242 4 O
1	247 1 O
:	248 1 O
100	249 3 O
,	252 1 O
000	253 3 O
epinephrine	257 11 B-Chemical
)	268 1 O
were	270 4 O
injected	275 8 O
into	284 4 O
the	289 3 O
retrobulbar	293 11 O
area	305 4 O
of	310 2 O
rat	313 3 O
eyes	317 4 O
.	321 1 O

Controls	323 8 O
were	332 4 O
injected	337 8 O
with	346 4 O
physiological	351 13 O
saline	365 6 O
.	371 1 O

All	373 3 O
three	377 5 O
anesthetics	383 11 O
produced	395 8 O
massive	404 7 O
degeneration	412 12 O
of	425 2 O
the	428 3 O
extraocular	432 11 O
muscles	444 7 O
.	451 1 O

Muscle	453 6 B-Disease
degeneration	460 12 I-Disease
is	473 2 O
followed	476 8 O
by	485 2 O
regeneration	488 12 O
of	501 2 O
the	504 3 O
damaged	508 7 O
muscle	516 6 O
fibers	523 6 O
.	529 1 O

In	531 2 O
addition	534 8 O
to	543 2 O
muscle	546 6 B-Disease
damage	553 6 I-Disease
,	559 1 O
severe	561 6 O
damage	568 6 O
was	575 3 O
also	579 4 O
seen	584 4 O
in	589 2 O
harderian	592 9 O
glands	602 6 O
,	608 1 O
especially	610 10 O
after	621 5 O
exposure	627 8 O
to	636 2 O
mepivacaine	639 11 B-Chemical
and	651 3 O
lidocaine	655 9 B-Chemical
plus	665 4 O
epinephrine	670 11 B-Chemical
.	681 1 O

With	683 4 O
these	688 5 O
findings	694 8 O
in	703 2 O
rats	706 4 O
,	710 1 O
it	712 2 O
is	715 2 O
hypothesized	718 12 O
that	731 4 O
the	736 3 O
temporary	740 9 O
diplopia	750 8 B-Disease
sometimes	759 9 O
seen	769 4 O
in	774 2 O
patients	777 8 O
after	786 5 O
ophthalmic	792 10 O
surgery	803 7 O
might	811 5 O
be	817 2 O
due	820 3 O
to	824 2 O
anesthetic	827 10 O
-	837 1 O
induced	838 7 O
damage	846 6 O
to	853 2 O
the	856 3 O
extraocular	860 11 O
muscles	872 7 O
.	879 1 O

Reversal	0 8 O
of	9 2 O
neuroleptic	12 11 O
-	23 1 O
induced	24 7 O
catalepsy	32 9 B-Disease
by	42 2 O
novel	45 5 O
aryl	51 4 B-Chemical
-	55 1 I-Chemical
piperazine	56 10 I-Chemical
anxiolytic	67 10 O
drugs	78 5 O
.	83 1 O

The	85 3 O
novel	89 5 O
anxiolytic	95 10 O
drug	106 4 O
,	110 1 O
buspirone	112 9 B-Chemical
,	121 1 O
reverses	123 8 O
catalepsy	132 9 B-Disease
induced	142 7 O
by	150 2 O
haloperidol	153 11 B-Chemical
.	164 1 O

A	166 1 O
series	168 6 O
of	175 2 O
aryl	178 4 B-Chemical
-	182 1 I-Chemical
piperazine	183 10 I-Chemical
analogues	194 9 O
of	204 2 O
buspirone	207 9 B-Chemical
and	217 3 O
other	221 5 O
5	227 1 B-Chemical
-	228 1 I-Chemical
hydroxytryptaminergic	229 21 I-Chemical
agonists	251 8 I-Chemical
were	260 4 O
tested	265 6 O
for	272 3 O
their	276 5 O
ability	282 7 O
to	290 2 O
reverse	293 7 O
haloperidol	301 11 B-Chemical
induced	313 7 O
catalepsy	321 9 B-Disease
.	330 1 O

Those	332 5 O
drugs	338 5 O
with	344 4 O
strong	349 6 O
affinity	356 8 O
for	365 3 O
5	369 1 B-Chemical
-	370 1 I-Chemical
hydroxytryptamine1a	371 19 O
receptors	391 9 O
were	401 4 O
able	406 4 O
to	411 2 O
reverse	414 7 O
catalepsy	422 9 B-Disease
.	431 1 O

Drugs	433 5 O
with	439 4 O
affinity	444 8 O
for	453 3 O
other	457 5 O
5	463 1 B-Chemical
-	464 1 I-Chemical
HT	465 2 I-Chemical
receptors	468 9 O
or	478 2 O
weak	481 4 O
affinity	486 8 O
were	495 4 O
ineffective	500 11 O
.	511 1 O

However	513 7 O
,	520 1 O
inhibition	522 10 O
of	533 2 O
postsynaptic	536 12 O
5	549 1 B-Chemical
-	550 1 I-Chemical
HT	551 2 I-Chemical
receptors	554 9 O
neither	564 7 O
inhibited	572 9 O
nor	582 3 O
potentiated	586 11 O
reversal	598 8 O
of	607 2 O
catalepsy	610 9 B-Disease
and	620 3 O
leaves	624 6 O
open	631 4 O
the	636 3 O
question	640 8 O
as	649 2 O
to	652 2 O
the	655 3 O
site	659 4 O
or	664 2 O
mechanism	667 9 O
for	677 3 O
this	681 4 O
effect	686 6 O
.	692 1 O

Diazepam	0 8 B-Chemical
facilitates	9 11 O
reflex	21 6 O
bradycardia	28 11 B-Disease
in	40 2 O
conscious	43 9 O
rats	53 4 O
.	57 1 O

The	59 3 O
effects	63 7 O
of	71 2 O
diazepam	74 8 B-Chemical
on	83 2 O
cardiovascular	86 14 O
function	101 8 O
were	110 4 O
assessed	115 8 O
in	124 2 O
conscious	127 9 O
rats	137 4 O
.	141 1 O

Intravenous	143 11 O
administration	155 14 O
of	170 2 O
diazepam	173 8 B-Chemical
(	182 1 O
1	183 1 O
-	184 1 O
30	185 2 O
mg	188 2 O
kg	191 2 O
-	193 1 O
1	194 1 O
)	195 1 O
produced	197 8 O
a	206 1 O
dose	208 4 O
-	212 1 O
dependent	213 9 O
decrease	223 8 O
in	232 2 O
both	235 4 O
the	240 3 O
mean	244 4 O
arterial	249 8 O
pressure	258 8 O
and	267 3 O
the	271 3 O
heart	275 5 O
rate	281 4 O
.	285 1 O

Also	287 4 O
,	291 1 O
reflex	293 6 O
bradycardia	300 11 B-Disease
was	312 3 O
produced	316 8 O
in	325 2 O
rats	328 4 O
by	333 2 O
intravenous	336 11 O
infusion	348 8 O
of	357 2 O
adrenaline	360 10 B-Chemical
(	371 1 O
1	372 1 O
.	373 1 O
25	374 2 O
-	376 1 O
2	377 1 O
.	378 1 O
5	379 1 O
micrograms	381 10 O
kg	392 2 O
-	394 1 O
1	395 1 O
)	396 1 O
.	397 1 O

Intravenous	399 11 O
pretreatment	411 12 O
of	424 2 O
the	427 3 O
rats	431 4 O
with	436 4 O
diazepam	441 8 B-Chemical
,	449 1 O
although	451 8 O
causing	460 7 O
no	468 2 O
change	471 6 O
in	478 2 O
the	481 3 O
adrenaline	485 10 B-Chemical
-	495 1 O
induced	496 7 O
pressor	504 7 O
effect	512 6 O
,	518 1 O
did	520 3 O
enhance	524 7 O
the	532 3 O
adrenaline	536 10 B-Chemical
-	546 1 O
induced	547 7 O
reflex	555 6 O
bradycardia	562 11 B-Disease
.	573 1 O

However	575 7 O
,	582 1 O
the	584 3 O
diazepam	588 8 B-Chemical
enhancement	597 11 O
of	609 2 O
adrenaline	612 10 B-Chemical
-	622 1 O
induced	623 7 O
reflex	631 6 O
bradycardia	638 11 B-Disease
was	650 3 O
antagonized	654 11 O
by	666 2 O
pretreatment	669 12 O
of	682 2 O
rats	685 4 O
with	690 4 O
an	695 2 O
intravenous	698 11 O
dose	710 4 O
of	715 2 O
picrotoxin	718 10 B-Chemical
(	729 1 O
an	730 2 O
agent	733 5 O
blocks	739 6 O
chloride	746 8 B-Chemical
channels	755 8 O
by	764 2 O
binding	767 7 O
to	775 2 O
sites	778 5 O
associated	784 10 O
with	795 4 O
the	800 3 O
benzodiazepine	804 14 B-Chemical
-	818 1 O
GABA	819 4 B-Chemical
-	823 1 O
chloride	824 8 B-Chemical
channel	833 7 O
macromolecular	841 14 O
complex	856 7 O
)	863 1 O
.	864 1 O

The	866 3 O
data	870 4 O
indicate	875 8 O
that	884 4 O
diazepam	889 8 B-Chemical
acts	898 4 O
through	903 7 O
the	911 3 O
benzodiazepine	915 14 B-Chemical
-	929 1 O
GABA	930 4 B-Chemical
-	934 1 O
chloride	935 8 B-Chemical
channel	944 7 O
macromolecular	952 14 O
complex	967 7 O
within	975 6 O
the	982 3 O
central	986 7 O
nervous	994 7 O
system	1002 6 O
to	1009 2 O
facilitate	1012 10 O
reflex	1023 6 O
bradycardia	1030 11 B-Disease
mediated	1042 8 O
through	1051 7 O
baroreceptor	1059 12 O
reflexes	1072 8 O
in	1081 2 O
response	1084 8 O
to	1093 2 O
an	1096 2 O
acute	1099 5 O
increase	1105 8 O
in	1114 2 O
arterial	1117 8 O
pressure	1126 8 O
.	1134 1 O

Chronic	0 7 O
carbamazepine	8 13 B-Chemical
inhibits	22 8 O
the	31 3 O
development	35 11 O
of	47 2 O
local	50 5 O
anesthetic	56 10 O
seizures	67 8 B-Disease
kindled	76 7 O
by	84 2 O
cocaine	87 7 B-Chemical
and	95 3 O
lidocaine	99 9 B-Chemical
.	108 1 O

The	110 3 O
effects	114 7 O
of	122 2 O
carbamazepine	125 13 B-Chemical
(	139 1 O
CBZ	140 3 B-Chemical
)	143 1 O
treatment	145 9 O
on	155 2 O
local	158 5 O
anesthetic	164 10 O
-	174 1 O
kindled	175 7 O
seizures	183 8 B-Disease
and	192 3 O
lethality	196 9 O
were	206 4 O
evaluated	211 9 O
in	221 2 O
different	224 9 O
stages	234 6 O
of	241 2 O
the	244 3 O
kindling	248 8 O
process	257 7 O
and	265 3 O
under	269 5 O
different	275 9 O
methods	285 7 O
of	293 2 O
CBZ	296 3 B-Chemical
administration	300 14 O
.	314 1 O

Chronic	316 7 O
oral	324 4 O
CBZ	329 3 B-Chemical
inhibited	333 9 O
the	343 3 O
development	347 11 O
of	359 2 O
both	362 4 O
lidocaine	367 9 B-Chemical
-	376 1 O
and	378 3 O
cocaine	382 7 B-Chemical
-	389 1 O
induced	390 7 O
seizures	398 8 B-Disease
,	406 1 O
but	408 3 O
had	412 3 O
little	416 6 O
effect	423 6 O
on	430 2 O
the	433 3 O
fully	437 5 O
developed	443 9 O
local	453 5 O
anesthetic	459 10 O
seizures	470 8 B-Disease
.	478 1 O

Chronic	480 7 O
CBZ	488 3 B-Chemical
also	492 4 O
decreased	497 9 O
the	507 3 O
incidence	511 9 O
of	521 2 O
seizure	524 7 B-Disease
-	531 1 O
related	532 7 O
mortality	540 9 O
in	550 2 O
the	553 3 O
cocaine	557 7 B-Chemical
-	564 1 O
injected	565 8 O
rats	574 4 O
.	578 1 O

Acute	580 5 O
CBZ	586 3 B-Chemical
over	590 4 O
a	595 1 O
range	597 5 O
of	603 2 O
doses	606 5 O
(	612 1 O
15	613 2 O
-	615 1 O
50	616 2 O
mg	619 2 O
/	621 1 O
kg	622 2 O
)	624 1 O
had	626 3 O
no	630 2 O
effect	633 6 O
on	640 2 O
completed	643 9 O
lidocaine	653 9 B-Chemical
-	662 1 O
kindled	663 7 O
or	671 2 O
acute	674 5 O
cocaine	680 7 B-Chemical
-	687 1 O
induced	688 7 O
seizures	696 8 B-Disease
.	704 1 O

Repeated	706 8 O
i	715 1 O
.	716 1 O
p	717 1 O
.	718 1 O
injection	720 9 O
of	730 2 O
CBZ	733 3 B-Chemical
(	737 1 O
15	738 2 O
mg	741 2 O
/	743 1 O
kg	744 2 O
)	746 1 O
also	748 4 O
was	753 3 O
without	757 7 O
effect	765 6 O
on	772 2 O
the	775 3 O
development	779 11 O
of	791 2 O
lidocaine	794 9 B-Chemical
-	803 1 O
or	805 2 O
cocaine	808 7 B-Chemical
-	815 1 O
kindled	816 7 O
seizures	824 8 B-Disease
.	832 1 O

The	834 3 O
differential	838 12 O
effects	851 7 O
of	859 2 O
CBZ	862 3 B-Chemical
depending	866 9 O
upon	876 4 O
stage	881 5 O
of	887 2 O
seizure	890 7 B-Disease
development	898 11 O
suggest	910 7 O
that	918 4 O
distinct	923 8 O
mechanisms	932 10 O
underlie	943 8 O
the	952 3 O
development	956 11 O
versus	968 6 O
maintenance	975 11 O
of	987 2 O
local	990 5 O
anesthetic	996 10 O
-	1006 1 O
kindled	1007 7 O
seizures	1015 8 B-Disease
.	1023 1 O

The	1025 3 O
effectiveness	1029 13 O
of	1043 2 O
chronic	1046 7 O
but	1054 3 O
not	1058 3 O
repeated	1062 8 O
,	1070 1 O
intermittent	1072 12 O
injections	1085 10 O
of	1096 2 O
CBZ	1099 3 B-Chemical
suggests	1103 8 O
that	1112 4 O
different	1117 9 O
biochemical	1127 11 O
consequences	1139 12 O
result	1152 6 O
from	1159 4 O
the	1164 3 O
different	1168 9 O
treatment	1178 9 O
regimens	1188 8 O
.	1196 1 O

The	1198 3 O
possible	1202 8 O
utility	1211 7 O
of	1219 2 O
chronic	1222 7 O
CBZ	1230 3 B-Chemical
in	1234 2 O
preventing	1237 10 O
the	1248 3 O
development	1252 11 O
of	1264 2 O
toxic	1267 5 O
side	1273 4 O
effects	1278 7 O
in	1286 2 O
human	1289 5 O
cocaine	1295 7 B-Chemical
users	1303 5 O
is	1309 2 O
suggested	1312 9 O
by	1322 2 O
these	1325 5 O
data	1331 4 O
,	1335 1 O
but	1337 3 O
remains	1341 7 O
to	1349 2 O
be	1352 2 O
directly	1355 8 O
evaluated	1364 9 O
.	1373 1 O

D	0 1 B-Chemical
-	1 1 I-Chemical
penicillamine	2 13 I-Chemical
in	16 2 O
the	19 3 O
treatment	23 9 O
of	33 2 O
localized	36 9 B-Disease
scleroderma	46 11 I-Disease
.	57 1 O

Localized	59 9 B-Disease
scleroderma	69 11 I-Disease
has	81 3 O
no	85 2 O
recognized	88 10 O
internal	99 8 O
organ	108 5 O
involvement	114 11 O
but	126 3 O
may	130 3 O
be	134 2 O
disfiguring	137 11 O
and	149 3 O
disabling	153 9 O
when	163 4 O
the	168 3 O
cutaneous	172 9 O
lesions	182 7 O
are	190 3 O
extensive	194 9 O
or	204 2 O
affect	207 6 O
children	214 8 O
.	222 1 O

There	224 5 O
is	230 2 O
no	233 2 O
accepted	236 8 O
or	245 2 O
proven	248 6 O
treatment	255 9 O
for	265 3 O
localized	269 9 B-Disease
scleroderma	279 11 I-Disease
.	290 1 O

Case	292 4 O
reports	297 7 O
of	305 2 O
11	308 2 O
patients	311 8 O
with	320 4 O
severe	325 6 O
,	331 1 O
extensive	333 9 O
localized	343 9 B-Disease
scleroderma	353 11 I-Disease
who	365 3 O
were	369 4 O
treated	374 7 O
with	382 4 O
D	387 1 B-Chemical
-	388 1 I-Chemical
penicillamine	389 13 I-Chemical
are	403 3 O
summarized	407 10 O
in	418 2 O
this	421 4 O
article	426 7 O
.	433 1 O

This	435 4 O
drug	440 4 O
was	445 3 O
judged	449 6 O
to	456 2 O
have	459 4 O
a	464 1 O
favorable	466 9 O
effect	476 6 O
on	483 2 O
the	486 3 O
disease	490 7 O
course	498 6 O
in	505 2 O
7	508 1 O
(	510 1 O
64	511 2 O
%	513 1 O
)	514 1 O
of	516 2 O
11	519 2 O
patients	522 8 O
.	530 1 O

Improvement	532 11 O
began	544 5 O
within	550 6 O
3	557 1 O
to	559 2 O
6	562 1 O
months	564 6 O
and	571 3 O
consisted	575 9 O
of	585 2 O
cessation	588 9 O
of	598 2 O
active	601 6 O
cutaneous	608 9 O
lesions	618 7 O
in	626 2 O
all	629 3 O
7	633 1 O
patients	635 8 O
,	643 1 O
skin	645 4 O
softening	650 9 O
in	660 2 O
5	663 1 O
,	664 1 O
and	666 3 O
more	670 4 O
normal	675 6 O
growth	682 6 O
of	689 2 O
the	692 3 O
affected	696 8 O
limb	705 4 O
in	710 2 O
2	713 1 O
of	715 2 O
3	718 1 O
children	720 8 O
.	728 1 O

Joint	730 5 O
stiffness	736 9 O
and	746 3 O
contractures	750 12 B-Disease
also	763 4 O
improved	768 8 O
.	776 1 O

The	778 3 O
dose	782 4 O
of	787 2 O
D	790 1 B-Chemical
-	791 1 I-Chemical
penicillamine	792 13 I-Chemical
associated	806 10 O
with	817 4 O
a	822 1 O
favorable	824 9 O
response	834 8 O
was	843 3 O
as	847 2 O
low	850 3 O
as	854 2 O
2	857 1 O
to	859 2 O
5	862 1 O
mg	864 2 O
/	866 1 O
kg	867 2 O
per	870 3 O
day	874 3 O
given	878 5 O
over	884 4 O
a	889 1 O
period	891 6 O
ranging	898 7 O
from	906 4 O
15	911 2 O
to	914 2 O
53	917 2 O
months	920 6 O
.	926 1 O

D	928 1 B-Chemical
-	929 1 I-Chemical
Penicillamine	930 13 I-Chemical
caused	944 6 O
nephrotic	951 9 B-Disease
syndrome	961 8 I-Disease
in	970 2 O
1	973 1 O
patient	975 7 O
and	983 3 O
milder	987 6 O
reversible	994 10 O
proteinuria	1005 11 B-Disease
in	1017 2 O
3	1020 1 O
other	1022 5 O
patients	1028 8 O
;	1036 1 O
none	1038 4 O
developed	1043 9 O
renal	1053 5 B-Disease
insufficiency	1059 13 I-Disease
.	1072 1 O

These	1074 5 O
data	1080 4 O
suggest	1085 7 O
that	1093 4 O
D	1098 1 B-Chemical
-	1099 1 I-Chemical
penicillamine	1100 13 I-Chemical
may	1114 3 O
be	1118 2 O
effective	1121 9 O
in	1131 2 O
severe	1134 6 O
cases	1141 5 O
of	1147 2 O
localized	1150 9 B-Disease
scleroderma	1160 11 I-Disease
.	1171 1 O

Preservation	0 12 O
of	13 2 O
renal	16 5 O
blood	22 5 O
flow	28 4 O
during	33 6 O
hypotension	40 11 B-Disease
induced	52 7 O
with	60 4 O
fenoldopam	65 10 B-Chemical
in	76 2 O
dogs	79 4 O
.	83 1 O

The	85 3 O
introduction	89 12 O
of	102 2 O
drugs	105 5 O
that	111 4 O
could	116 5 O
induce	122 6 O
hypotension	129 11 B-Disease
with	141 4 O
different	146 9 O
pharmacological	156 15 O
actions	172 7 O
would	180 5 O
be	186 2 O
advantageous	189 12 O
because	202 7 O
side	210 4 O
effects	215 7 O
unique	223 6 O
to	230 2 O
a	233 1 O
specific	235 8 O
drug	244 4 O
could	249 5 O
be	255 2 O
minimized	258 9 O
by	268 2 O
selecting	271 9 O
appropriate	281 11 O
therapy	293 7 O
.	300 1 O

Specific	302 8 O
dopamine	311 8 B-Chemical
-	319 1 O
1	320 1 O
,	321 1 O
(	323 1 O
DA1	324 3 B-Chemical
)	327 1 O
and	329 3 O
dopamine	333 8 B-Chemical
-	341 1 O
2	342 1 O
(	344 1 O
DA2	345 3 B-Chemical
)	348 1 O
receptor	350 8 O
agonists	359 8 O
are	368 3 O
now	372 3 O
under	376 5 O
clinical	382 8 O
investigation	391 13 O
.	404 1 O

Fenoldopam	406 10 B-Chemical
mesylate	417 8 I-Chemical
is	426 2 O
a	429 1 O
specific	431 8 O
DA1	440 3 O
receptor	444 8 O
agonist	453 7 O
that	461 4 O
lowers	466 6 O
blood	473 5 O
pressure	479 8 O
by	488 2 O
vasodilatation	491 14 O
.	505 1 O

The	507 3 O
hypothesis	511 10 O
that	522 4 O
fenoldopam	527 10 B-Chemical
could	538 5 O
be	544 2 O
used	547 4 O
to	552 2 O
induce	555 6 O
hypotension	562 11 B-Disease
and	574 3 O
preserve	578 8 O
blood	587 5 O
flow	593 4 O
to	598 2 O
the	601 3 O
kidney	605 6 O
was	612 3 O
tested	616 6 O
.	622 1 O

Systemic	624 8 O
aortic	633 6 O
blood	640 5 O
pressure	646 8 O
and	655 3 O
renal	659 5 O
blood	665 5 O
flow	671 4 O
were	676 4 O
measured	681 8 O
continuously	690 12 O
with	703 4 O
a	708 1 O
carotid	710 7 O
arterial	718 8 O
catheter	727 8 O
and	736 3 O
an	740 2 O
electromagnetic	743 15 O
flow	759 4 O
probe	764 5 O
respectively	770 12 O
,	782 1 O
in	784 2 O
order	787 5 O
to	793 2 O
compare	796 7 O
the	804 3 O
cardiovascular	808 14 O
and	823 3 O
renal	827 5 O
vascular	833 8 O
effects	842 7 O
of	850 2 O
fenoldopam	853 10 B-Chemical
and	864 3 O
sodium	868 6 B-Chemical
nitroprusside	875 13 B-Chemical
in	889 2 O
ten	892 3 O
dogs	896 4 O
under	901 5 O
halothane	907 9 B-Chemical
general	917 7 O
anaesthesia	925 11 O
.	936 1 O

Mean	938 4 O
arterial	943 8 O
pressure	952 8 O
was	961 3 O
decreased	965 9 O
30	975 2 O
+	978 1 O
/	979 1 O
-	980 1 O
8	982 1 O
per	984 3 O
cent	988 4 O
from	993 4 O
control	998 7 O
with	1006 4 O
infusion	1011 8 O
of	1020 2 O
fenoldopam	1023 10 B-Chemical
(	1034 1 O
3	1035 1 O
.	1036 1 O
4	1037 1 O
+	1039 1 O
/	1040 1 O
-	1041 1 O
2	1043 1 O
.	1044 1 O
0	1045 1 O
micrograms	1047 10 O
.	1057 1 O
kg	1058 2 O
-	1060 1 O
1	1061 1 O
.	1062 1 O
min	1063 3 O
-	1066 1 O
1	1067 1 O
)	1068 1 O
and	1070 3 O
34	1074 2 O
+	1077 1 O
/	1078 1 O
-	1079 1 O
4	1081 1 O
per	1083 3 O
cent	1087 4 O
with	1092 4 O
infusion	1097 8 O
of	1106 2 O
sodium	1109 6 B-Chemical
nitroprusside	1116 13 B-Chemical
(	1130 1 O
5	1131 1 O
.	1132 1 O
9	1133 1 O
micrograms	1135 10 O
.	1145 1 O
kg	1146 2 O
-	1148 1 O
1	1149 1 O
.	1150 1 O
min	1151 3 O
-	1154 1 O
1	1155 1 O
)	1156 1 O
(	1158 1 O
NS	1159 2 O
)	1161 1 O
.	1162 1 O

Renal	1164 5 O
blood	1170 5 O
flow	1176 4 O
(	1181 1 O
RBF	1182 3 O
)	1185 1 O
increased	1187 9 O
during	1197 6 O
fenoldopam	1204 10 B-Chemical
-	1214 1 O
induced	1215 7 O
hypotension	1223 11 B-Disease
11	1235 2 O
+	1238 1 O
/	1239 1 O
-	1240 1 O
7	1242 1 O
per	1244 3 O
cent	1248 4 O
and	1253 3 O
decreased	1257 9 O
21	1267 2 O
+	1270 1 O
/	1271 1 O
-	1272 1 O
8	1274 1 O
per	1276 3 O
cent	1280 4 O
during	1285 6 O
sodium	1292 6 B-Chemical
nitroprusside	1299 13 B-Chemical
-	1312 1 O
induced	1313 7 O
hypotension	1321 11 B-Disease
(	1333 1 O
P	1334 1 O
less	1336 4 O
than	1341 4 O
0	1346 1 O
.	1347 1 O
01	1348 2 O
)	1350 1 O
.	1351 1 O

Sodium	1353 6 O
nitroprusside	1360 13 B-Chemical
is	1374 2 O
a	1377 1 O
non	1379 3 O
-	1382 1 O
selective	1383 9 O
arteriolar	1393 10 O
and	1404 3 O
venous	1408 6 O
vasodilator	1415 11 O
that	1427 4 O
can	1432 3 O
produce	1436 7 O
redistribution	1444 14 O
of	1459 2 O
blood	1462 5 O
flow	1468 4 O
away	1473 4 O
from	1478 4 O
the	1483 3 O
kidney	1487 6 O
during	1494 6 O
induced	1501 7 O
hypotension	1509 11 B-Disease
.	1520 1 O

Fenoldopam	1522 10 O
is	1533 2 O
a	1536 1 O
selective	1538 9 O
dopamine	1548 8 B-Chemical
-	1556 1 O
1	1557 1 O
(	1559 1 O
DA1	1560 3 O
)	1563 1 O
receptor	1565 8 O
agonist	1574 7 O
that	1582 4 O
causes	1587 6 O
vasodilatation	1594 14 O
to	1609 2 O
the	1612 3 O
kidney	1616 6 O
and	1623 3 O
other	1627 5 O
organs	1633 6 O
with	1640 4 O
DA1	1645 3 O
receptors	1649 9 O
and	1659 3 O
preserves	1663 9 O
blood	1673 5 O
flow	1679 4 O
to	1684 2 O
the	1687 3 O
kidney	1691 6 O
during	1698 6 O
induced	1705 7 O
hypotension	1713 11 B-Disease
.	1724 1 O

Antiarrhythmic	0 14 O
effects	15 7 O
of	23 2 O
optical	26 7 O
isomers	34 7 O
of	42 2 O
cibenzoline	45 11 B-Chemical
on	57 2 O
canine	60 6 O
ventricular	67 11 B-Disease
arrhythmias	79 11 I-Disease
.	90 1 O

Antiarrhythmic	92 14 O
effects	107 7 O
of	115 2 O
(	118 1 O
+	119 1 O
)	120 1 O
-	121 1 O
cibenzoline	122 11 B-Chemical
and	134 3 O
(	138 1 O
-	139 1 O
)	140 1 O
-	141 1 O
cibenzoline	142 11 B-Chemical
were	154 4 O
examined	159 8 O
using	168 5 O
two	174 3 O
canine	178 6 O
ventricular	185 11 B-Disease
arrhythmia	197 10 I-Disease
models	208 6 O
.	214 1 O

Digitalis	216 9 B-Chemical
arrhythmia	226 10 B-Disease
,	236 1 O
which	238 5 O
is	244 2 O
suppressed	247 10 O
by	258 2 O
Na	261 2 B-Chemical
channel	264 7 O
blockers	272 8 O
,	280 1 O
was	282 3 O
induced	286 7 O
by	294 2 O
intermittent	297 12 O
intravenous	310 11 O
(	322 1 O
i	323 1 O
.	324 1 O
v	325 1 O
.	326 1 O
)	327 1 O
injection	329 9 O
of	339 2 O
ouabain	342 7 B-Chemical
in	350 2 O
pentobarbital	353 13 B-Chemical
-	366 1 O
anesthetized	367 12 O
dogs	380 4 O
.	384 1 O

Adrenaline	386 10 B-Disease
arrhythmia	397 10 I-Disease
,	407 1 O
which	409 5 O
is	415 2 O
suppressed	418 10 O
by	429 2 O
Ca	432 2 B-Chemical
channel	435 7 O
blockers	443 8 O
,	451 1 O
was	453 3 O
induced	457 7 O
by	465 2 O
adrenaline	468 10 B-Chemical
infusion	479 8 O
in	488 2 O
halothane	491 9 B-Chemical
-	500 1 O
anesthetized	501 12 O
dogs	514 4 O
.	518 1 O

Ten	520 3 O
and	524 3 O
5	528 1 O
mg	530 2 O
/	532 1 O
kg	533 2 O
i	536 1 O
.	537 1 O
v	538 1 O
.	539 1 O
(	541 1 O
+	542 1 O
)	543 1 O
-	544 1 O
cibenzoline	545 11 B-Chemical
suppressed	557 10 O
digitalis	568 9 B-Chemical
-	577 1 O
and	579 3 O
adrenaline	583 10 B-Chemical
-	593 1 O
induced	594 7 O
arrhythmias	602 11 B-Disease
,	613 1 O
respectively	615 12 O
.	627 1 O

The	629 3 O
minimum	633 7 O
effective	641 9 O
plasma	651 6 O
concentrations	658 14 O
of	673 2 O
(	676 1 O
+	677 1 O
)	678 1 O
-	679 1 O
cibenzoline	680 11 B-Chemical
for	692 3 O
digitalis	696 9 B-Chemical
-	705 1 O
and	707 3 O
adrenaline	711 10 B-Chemical
-	721 1 O
induced	722 7 O
arrhythmias	730 11 B-Disease
were	742 4 O
1	747 1 O
.	748 1 O
4	749 1 O
+	751 1 O
/	752 1 O
-	753 1 O
0	755 1 O
.	756 1 O
4	757 1 O
and	759 3 O
2	763 1 O
.	764 1 O
0	765 1 O
+	767 1 O
/	768 1 O
-	769 1 O
0	771 1 O
.	772 1 O
6	773 1 O
micrograms	775 10 O
/	785 1 O
ml	786 2 O
,	788 1 O
respectively	790 12 O
(	803 1 O
mean	804 4 O
+	809 1 O
/	810 1 O
-	811 1 O
SD	813 2 O
,	815 1 O
n	817 1 O
=	819 1 O
6	821 1 O
)	822 1 O
.	823 1 O

A	825 1 O
lower	827 5 O
dose	833 4 O
of	838 2 O
1	841 1 O
mg	843 2 O
/	845 1 O
kg	846 2 O
i	849 1 O
.	850 1 O
v	851 1 O
.	852 1 O
of	854 2 O
(	857 1 O
-	858 1 O
)	859 1 O
-	860 1 O
cibenzoline	861 11 B-Chemical
suppressed	873 10 O
the	884 3 O
digitalis	888 9 B-Chemical
-	897 1 O
induced	898 7 O
arrhythmia	906 10 B-Disease
,	916 1 O
whereas	918 7 O
5	926 1 O
mg	928 2 O
/	930 1 O
kg	931 2 O
i	934 1 O
.	935 1 O
v	936 1 O
.	937 1 O
was	939 3 O
needed	943 6 O
to	950 2 O
suppress	953 8 O
adrenaline	962 10 B-Chemical
-	972 1 O
induced	973 7 O
arrhythmias	981 11 B-Disease
.	992 1 O

The	994 3 O
minimum	998 7 O
effective	1006 9 O
plasma	1016 6 O
concentrations	1023 14 O
of	1038 2 O
(	1041 1 O
-	1042 1 O
)	1043 1 O
-	1044 1 O
cibenzoline	1045 11 B-Chemical
for	1057 3 O
digitalis	1061 9 B-Chemical
-	1070 1 O
and	1072 3 O
adrenaline	1076 10 B-Chemical
-	1086 1 O
induced	1087 7 O
arrhythmia	1095 10 B-Disease
were	1106 4 O
0	1111 1 O
.	1112 1 O
06	1113 2 O
+	1116 1 O
/	1117 1 O
-	1118 1 O
0	1120 1 O
.	1121 1 O
04	1122 2 O
and	1125 3 O
0	1129 1 O
.	1130 1 O
7	1131 1 O
+	1133 1 O
/	1134 1 O
-	1135 1 O
0	1137 1 O
.	1138 1 O
1	1139 1 O
micrograms	1141 10 O
/	1151 1 O
ml	1152 2 O
,	1154 1 O
respectively	1156 12 O
(	1169 1 O
mean	1170 4 O
+	1175 1 O
/	1176 1 O
-	1177 1 O
SD	1179 2 O
,	1181 1 O
n	1183 1 O
=	1185 1 O
6	1187 1 O
)	1188 1 O
.	1189 1 O

The	1191 3 O
stronger	1195 8 O
antiarrhythmic	1204 14 O
effect	1219 6 O
of	1226 2 O
(	1229 1 O
-	1230 1 O
)	1231 1 O
-	1232 1 O
cibenzoline	1233 11 B-Chemical
indicates	1245 9 O
that	1255 4 O
(	1260 1 O
-	1261 1 O
)	1262 1 O
-	1263 1 O
isomer	1264 6 O
may	1271 3 O
have	1275 4 O
an	1280 2 O
effect	1283 6 O
nearly	1290 6 O
5	1297 1 O
-	1298 1 O
20	1299 2 O
times	1302 5 O
stronger	1308 8 O
in	1317 2 O
suppressing	1320 11 O
Na	1332 2 B-Chemical
channels	1335 8 O
,	1343 1 O
but	1345 3 O
effects	1349 7 O
of	1357 2 O
both	1360 4 O
drugs	1365 5 O
on	1371 2 O
Ca	1374 2 B-Chemical
channels	1377 8 O
may	1386 3 O
be	1390 2 O
almost	1393 6 O
equipotent	1400 10 O
.	1410 1 O

Effect	0 6 O
of	7 2 O
Hibiscus	10 8 B-Chemical
rosa	19 4 I-Chemical
sinensis	24 8 I-Chemical
on	33 2 O
reserpine	36 9 B-Chemical
-	45 1 O
induced	46 7 O
neurobehavioral	54 15 O
and	70 3 O
biochemical	74 11 O
alterations	86 11 O
in	98 2 O
rats	101 4 O
.	105 1 O

Effect	107 6 O
of	114 2 O
methanolic	117 10 O
extract	128 7 O
of	136 2 O
Hibiscus	139 8 B-Chemical
rosa	148 4 I-Chemical
sinensis	153 8 I-Chemical
(	162 1 O
100	163 3 O
-	166 1 O
300	167 3 O
mg	171 2 O
/	173 1 O
kg	174 2 O
)	176 1 O
was	178 3 O
studied	182 7 O
on	190 2 O
reserpine	193 9 B-Chemical
-	202 1 O
induced	203 7 O
orofacial	211 9 O
dyskinesia	221 10 B-Disease
and	232 3 O
neurochemical	236 13 O
alterations	250 11 O
.	261 1 O

The	263 3 O
rats	267 4 O
were	272 4 O
treated	277 7 O
with	285 4 O
intraperitoneal	290 15 O
reserpine	306 9 B-Chemical
(	316 1 O
1	317 1 O
mg	319 2 O
/	321 1 O
kg	322 2 O
,	324 1 O
ip	326 2 O
)	328 1 O
for	330 3 O
3	334 1 O
days	336 4 O
every	341 5 O
other	347 5 O
day	353 3 O
.	356 1 O

On	358 2 O
day	361 3 O
5	365 1 O
,	366 1 O
vacuous	368 7 O
chewing	376 7 O
movements	384 9 O
and	394 3 O
tongue	398 6 O
protrusions	405 11 O
were	417 4 O
counted	422 7 O
for	430 3 O
5	434 1 O
min	436 3 O
.	439 1 O

Reserpine	441 9 B-Chemical
treated	451 7 O
rats	459 4 O
significantly	464 13 O
developed	478 9 O
vacuous	488 7 O
chewing	496 7 O
movements	504 9 O
and	514 3 O
tongue	518 6 O
protrusions	525 11 O
however	537 7 O
,	544 1 O
coadministration	546 16 O
of	563 2 O
Hibiscus	566 8 B-Chemical
rosa	575 4 I-Chemical
sinensis	580 8 I-Chemical
roots	589 5 O
extract	595 7 O
(	603 1 O
100	604 3 O
,	607 1 O
200	609 3 O
and	613 3 O
300	617 3 O
mg	621 2 O
/	623 1 O
kg	624 2 O
,	626 1 O
per	628 3 O
orally	632 6 O
)	638 1 O
attenuated	640 10 O
the	651 3 O
effects	655 7 O
.	662 1 O

Biochemical	664 11 O
analysis	676 8 O
of	685 2 O
brain	688 5 O
revealed	694 8 O
that	703 4 O
the	708 3 O
reserpine	712 9 B-Chemical
treatment	722 9 O
significantly	732 13 O
increased	746 9 O
lipid	756 5 O
peroxidation	762 12 O
and	775 3 O
decreased	779 9 O
levels	789 6 O
of	796 2 O
superoxide	799 10 B-Chemical
dismutase	810 9 O
(	820 1 O
SOD	821 3 O
)	824 1 O
,	825 1 O
catalase	827 8 O
(	836 1 O
CAT	837 3 O
)	840 1 O
and	842 3 O
glutathione	846 11 B-Chemical
reductase	858 9 O
(	868 1 O
GSH	869 3 O
)	872 1 O
,	873 1 O
an	875 2 O
index	878 5 O
of	884 2 O
oxidative	887 9 O
stress	897 6 O
process	904 7 O
.	911 1 O

Coadministration	913 16 O
of	930 2 O
extract	933 7 O
significantly	941 13 O
reduced	955 7 O
the	963 3 O
lipid	967 5 O
peroxidation	973 12 O
and	986 3 O
reversed	990 8 O
the	999 3 O
decrease	1003 8 O
in	1012 2 O
brain	1015 5 O
SOD	1021 3 O
,	1024 1 O
CAT	1026 3 O
and	1030 3 O
GSH	1034 3 O
levels	1038 6 O
.	1044 1 O

The	1046 3 O
results	1050 7 O
of	1058 2 O
the	1061 3 O
present	1065 7 O
study	1073 5 O
suggested	1079 9 O
that	1089 4 O
Hibiscus	1094 8 B-Chemical
rosa	1103 4 I-Chemical
sinensis	1108 8 I-Chemical
had	1117 3 O
a	1121 1 O
protective	1123 10 O
role	1134 4 O
against	1139 7 O
reserpine	1147 9 B-Chemical
-	1156 1 O
induced	1157 7 O
orofacial	1165 9 O
dyskinesia	1175 10 B-Disease
and	1186 3 O
oxidative	1190 9 O
stress	1200 6 O
.	1206 1 O

Comparison	0 10 O
of	11 2 O
aqueous	14 7 O
and	22 3 O
gellan	26 6 O
ophthalmic	33 10 O
timolol	44 7 B-Chemical
with	52 4 O
placebo	57 7 O
on	65 2 O
the	68 3 O
24	72 2 O
-	74 1 O
hour	75 4 O
heart	80 5 O
rate	86 4 O
response	91 8 O
in	100 2 O
patients	103 8 O
on	112 2 O
treatment	115 9 O
for	125 3 O
glaucoma	129 8 B-Disease
.	137 1 O

PURPOSE	139 7 O
:	146 1 O
Topical	148 7 O
beta	156 4 O
-	160 1 O
blocker	161 7 O
treatment	169 9 O
is	179 2 O
routine	182 7 O
therapy	190 7 O
in	198 2 O
the	201 3 O
management	205 10 O
of	216 2 O
patients	219 8 O
with	228 4 O
glaucoma	233 8 B-Disease
.	241 1 O

Therapy	243 7 O
results	251 7 O
in	259 2 O
systemic	262 8 O
absorption	271 10 O
,	281 1 O
however	283 7 O
,	290 1 O
the	292 3 O
degree	296 6 O
of	303 2 O
reduction	306 9 O
of	316 2 O
resting	319 7 O
and	327 3 O
peak	331 4 O
heart	336 5 O
rate	342 4 O
has	347 3 O
not	351 3 O
been	355 4 O
quantified	360 10 O
.	370 1 O

DESIGN	372 6 O
:	378 1 O
This	380 4 O
trial	385 5 O
evaluated	391 9 O
the	401 3 O
effect	405 6 O
of	412 2 O
placebo	415 7 O
,	422 1 O
0	424 1 O
.	425 1 O
5	426 1 O
%	427 1 O
aqueous	429 7 O
timolol	437 7 B-Chemical
(	445 1 O
timolol	446 7 B-Chemical
solution	454 8 O
)	462 1 O
and	464 3 O
a	468 1 O
0	470 1 O
.	471 1 O
5	472 1 O
%	473 1 O
timolol	475 7 B-Chemical
suspension	483 10 O
that	494 4 O
forms	499 5 O
a	505 1 O
gel	507 3 O
on	511 2 O
application	514 11 O
to	526 2 O
the	529 3 O
conjunctiva	533 11 O
(	545 1 O
timolol	546 7 B-Chemical
gellan	554 6 O
)	560 1 O
on	562 2 O
the	565 3 O
24	569 2 O
-	571 1 O
hour	572 4 O
heart	577 5 O
rate	583 4 O
in	588 2 O
patients	591 8 O
currently	600 9 O
being	610 5 O
treated	616 7 O
for	624 3 O
glaucoma	628 8 B-Disease
to	637 2 O
quantify	640 8 O
the	649 3 O
reduction	653 9 O
in	663 2 O
mean	666 4 O
heart	671 5 O
rate	677 4 O
.	681 1 O

METHODS	683 7 O
:	690 1 O
Forty	692 5 O
-	697 1 O
three	698 5 O
Caucasian	704 9 O
patients	714 8 O
with	723 4 O
primary	728 7 O
open	736 4 B-Disease
-	740 1 I-Disease
angle	741 5 I-Disease
glaucoma	747 8 I-Disease
or	756 2 O
ocular	759 6 B-Disease
hypertension	766 12 I-Disease
with	779 4 O
a	784 1 O
mean	786 4 O
(	791 1 O
+	792 1 O
/	793 1 O
-	794 1 O
SD	795 2 O
)	797 1 O
age	799 3 O
of	803 2 O
63	806 2 O
(	809 1 O
+	810 1 O
/	811 1 O
-	812 1 O
8	813 1 O
)	814 1 O
years	816 5 O
were	822 4 O
randomized	827 10 O
and	838 3 O
crossed	842 7 O
over	850 4 O
in	855 2 O
a	858 1 O
double	860 6 O
-	866 1 O
masked	867 6 O
manner	874 6 O
to	881 2 O
14	884 2 O
days	887 4 O
of	892 2 O
treatment	895 9 O
with	905 4 O
placebo	910 7 O
(	918 1 O
morning	919 7 O
and	927 3 O
evening	931 7 O
in	939 2 O
both	942 4 O
eyes	947 4 O
)	951 1 O
,	952 1 O
timolol	954 7 B-Chemical
solution	962 8 O
(	971 1 O
morning	972 7 O
and	980 3 O
evening	984 7 O
in	992 2 O
both	995 4 O
eyes	1000 4 O
)	1004 1 O
,	1005 1 O
or	1007 2 O
timolol	1010 7 B-Chemical
gellan	1018 6 O
(	1025 1 O
morning	1026 7 O
in	1034 2 O
both	1037 4 O
eyes	1042 4 O
with	1047 4 O
placebo	1052 7 O
in	1060 2 O
the	1063 3 O
evening	1067 7 O
)	1074 1 O
.	1075 1 O

On	1077 2 O
the	1080 3 O
13th	1084 4 O
day	1089 3 O
of	1093 2 O
each	1096 4 O
period	1101 6 O
,	1107 1 O
heart	1109 5 O
rate	1115 4 O
was	1120 3 O
recorded	1124 8 O
continuously	1133 12 O
during	1146 6 O
a	1153 1 O
typical	1155 7 O
,	1162 1 O
ambulant	1164 8 O
24	1173 2 O
-	1175 1 O
hour	1176 4 O
period	1181 6 O
.	1187 1 O

RESULTS	1189 7 O
:	1196 1 O
Both	1198 4 O
timolol	1203 7 B-Chemical
solution	1211 8 O
and	1220 3 O
timolol	1224 7 B-Chemical
gellan	1232 6 O
reduced	1239 7 O
the	1247 3 O
mean	1251 4 O
24	1256 2 O
-	1258 1 O
hour	1259 4 O
heart	1264 5 O
rate	1270 4 O
compared	1275 8 O
with	1284 4 O
placebo	1289 7 O
(	1297 1 O
P	1298 1 O
<	1300 1 O
or	1302 2 O
=	1305 1 O
.	1307 1 O
001	1308 3 O
)	1311 1 O
,	1312 1 O
and	1314 3 O
this	1318 4 O
reduction	1323 9 O
was	1333 3 O
most	1337 4 O
pronounced	1342 10 O
during	1353 6 O
the	1360 3 O
daytime	1364 7 O
(	1372 1 O
-	1373 1 O
7	1374 1 O
.	1375 1 O
5	1376 1 O
%	1377 1 O
change	1379 6 O
in	1386 2 O
mean	1389 4 O
heart	1394 5 O
rate	1400 4 O
,	1404 1 O
-	1406 1 O
5	1407 1 O
.	1408 1 O
7	1409 1 O
beats	1411 5 O
/	1416 1 O
min	1417 3 O
)	1420 1 O
.	1421 1 O

Timolol	1423 7 B-Chemical
gellan	1431 6 O
showed	1438 6 O
a	1445 1 O
numerically	1447 11 O
but	1459 3 O
not	1463 3 O
significantly	1467 13 O
smaller	1481 7 O
reduction	1489 9 O
in	1499 2 O
24	1502 2 O
-	1504 1 O
hour	1505 4 O
heart	1510 5 O
rate	1516 4 O
,	1520 1 O
compared	1522 8 O
with	1531 4 O
timolol	1536 7 B-Chemical
solution	1544 8 O
.	1552 1 O

During	1554 6 O
the	1561 3 O
night	1565 5 O
,	1570 1 O
the	1572 3 O
mean	1576 4 O
12	1581 2 O
-	1583 1 O
hour	1584 4 O
heart	1589 5 O
rate	1595 4 O
on	1600 2 O
placebo	1603 7 O
and	1611 3 O
timolol	1615 7 B-Chemical
gellan	1623 6 O
were	1630 4 O
both	1635 4 O
significantly	1640 13 O
less	1654 4 O
than	1659 4 O
on	1664 2 O
timolol	1667 7 B-Chemical
solution	1675 8 O
;	1683 1 O
the	1685 3 O
difference	1689 10 O
between	1700 7 O
solution	1708 8 O
and	1717 3 O
gellan	1721 6 O
treatments	1728 10 O
was	1739 3 O
statistically	1743 13 O
significant	1757 11 O
(	1769 1 O
P	1770 1 O
=	1772 1 O
.	1774 1 O
01	1775 2 O
)	1777 1 O
.	1778 1 O

CONCLUSIONS	1780 11 O
:	1791 1 O
Both	1793 4 O
timolol	1798 7 B-Chemical
solution	1806 8 O
and	1815 3 O
timolol	1819 7 B-Chemical
gellan	1827 6 O
decrease	1834 8 O
the	1843 3 O
mean	1847 4 O
24	1852 2 O
-	1854 1 O
hour	1855 4 O
heart	1860 5 O
rate	1866 4 O
compared	1871 8 O
with	1880 4 O
placebo	1885 7 O
.	1892 1 O

This	1894 4 O
response	1899 8 O
was	1908 3 O
most	1912 4 O
pronounced	1917 10 O
during	1928 6 O
the	1935 3 O
active	1939 6 O
daytime	1946 7 O
period	1954 6 O
.	1960 1 O

These	1962 5 O
data	1968 4 O
quantify	1973 8 O
the	1982 3 O
modest	1986 6 O
bradycardia	1993 11 B-Disease
associated	2005 10 O
with	2016 4 O
ophthalmic	2021 10 O
beta	2032 4 O
-	2036 1 O
blocker	2037 7 O
therapy	2045 7 O
in	2053 2 O
a	2056 1 O
typical	2058 7 O
patient	2066 7 O
population	2074 10 O
on	2085 2 O
therapy	2088 7 O
for	2096 3 O
glaucoma	2100 8 B-Disease
.	2108 1 O

Although	2110 8 O
exercise	2119 8 O
performance	2128 11 O
was	2140 3 O
not	2144 3 O
assessed	2148 8 O
in	2157 2 O
this	2160 4 O
trial	2165 5 O
,	2170 1 O
reductions	2172 10 O
of	2183 2 O
this	2186 4 O
magnitude	2191 9 O
should	2201 6 O
not	2208 3 O
have	2212 4 O
substantial	2217 11 O
clinical	2229 8 O
consequences	2238 12 O
.	2250 1 O

5	0 1 B-Chemical
flourouracil	2 12 I-Chemical
-	14 1 O
induced	15 7 O
apical	23 6 B-Disease
ballooning	30 10 I-Disease
syndrome	41 8 I-Disease
:	49 1 O
a	51 1 O
case	53 4 O
report	58 6 O
.	64 1 O

The	66 3 O
apical	70 6 B-Disease
ballooning	77 10 I-Disease
syndrome	88 8 I-Disease
(	97 1 O
ABS	98 3 B-Disease
)	101 1 O
is	103 2 O
a	106 1 O
recently	108 8 O
described	117 9 O
stress	127 6 O
-	133 1 O
mediated	134 8 O
acute	143 5 B-Disease
cardiac	149 7 I-Disease
syndrome	157 8 I-Disease
characterized	166 13 O
by	180 2 O
transient	183 9 O
wall	193 4 O
-	197 1 O
motion	198 6 O
abnormalities	205 13 O
involving	219 9 O
the	229 3 O
apex	233 4 O
and	238 3 O
midventricle	242 12 O
with	255 4 O
hyperkinesis	260 12 B-Disease
of	273 2 O
the	276 3 O
basal	280 5 O
left	286 4 O
ventricular	291 11 O
(	303 1 O
LV	304 2 O
)	306 1 O
segments	308 8 O
without	317 7 O
obstructive	325 11 O
epicardial	337 10 B-Disease
coronary	348 8 I-Disease
disease	357 7 I-Disease
.	364 1 O

Cardiotoxicity	366 14 B-Disease
is	381 2 O
not	384 3 O
an	388 2 O
uncommon	391 8 O
adverse	400 7 O
effect	408 6 O
of	415 2 O
chemotherapeutic	418 16 O
agents	435 6 O
.	441 1 O

However	443 7 O
,	450 1 O
there	452 5 O
are	458 3 O
no	462 2 O
reports	465 7 O
of	473 2 O
ABS	476 3 B-Disease
secondary	480 9 O
to	490 2 O
chemotherapeutic	493 16 O
agents	510 6 O
.	516 1 O

We	518 2 O
describe	521 8 O
the	530 3 O
case	534 4 O
of	539 2 O
a	542 1 O
woman	544 5 O
who	550 3 O
developed	554 9 O
the	564 3 O
syndrome	568 8 O
after	577 5 O
chemotherapy	583 12 O
for	596 3 O
metastatic	600 10 O
cancer	611 6 B-Disease
.	617 1 O

A	619 1 O
79	621 2 O
-	623 1 O
year	624 4 O
-	628 1 O
old	629 3 O
woman	633 5 O
presented	639 9 O
with	649 4 O
typical	654 7 O
ischemic	662 8 B-Disease
chest	671 5 B-Disease
pain	677 4 I-Disease
,	681 1 O
elevated	683 8 O
cardiac	692 7 O
enzymes	700 7 O
with	708 4 O
significant	713 11 O
ST	725 2 O
-	727 1 O
segment	728 7 O
abnormalities	736 13 O
on	750 2 O
her	753 3 O
electrocardiogram	757 17 O
.	774 1 O

She	776 3 O
underwent	780 9 O
recent	790 6 O
chemotherapy	797 12 O
with	810 4 O
fluorouracil	815 12 B-Chemical
for	828 3 O
metastatic	832 10 O
colorectal	843 10 B-Disease
cancer	854 6 I-Disease
.	860 1 O

Echocardiography	862 16 O
revealed	879 8 O
a	888 1 O
wall	890 4 O
-	894 1 O
motion	895 6 O
abnormality	902 11 O
involving	914 9 O
the	924 3 O
apical	928 6 O
and	935 3 O
periapical	939 10 O
segments	950 8 O
which	959 5 O
appeared	965 8 O
akinetic	974 8 B-Disease
.	982 1 O

Coronary	984 8 O
angiography	993 11 O
revealed	1005 8 O
no	1014 2 O
obstructive	1017 11 O
coronary	1029 8 O
lesions	1038 7 O
.	1045 1 O

The	1047 3 O
patient	1051 7 O
was	1059 3 O
stabilized	1063 10 O
with	1074 4 O
medical	1079 7 O
therapy	1087 7 O
.	1094 1 O

Four	1096 4 O
weeks	1101 5 O
later	1107 5 O
she	1113 3 O
remained	1117 8 O
completely	1126 10 O
asymptomatic	1137 12 O
.	1149 1 O

Echocardiogram	1151 14 O
revealed	1166 8 O
a	1175 1 O
normal	1177 6 O
ejection	1184 8 O
fraction	1193 8 O
and	1202 3 O
a	1206 1 O
resolution	1208 10 O
of	1219 2 O
the	1222 3 O
apical	1226 6 O
akinesis	1233 8 B-Disease
.	1241 1 O

Pathogenetic	1243 12 O
mechanisms	1256 10 O
of	1267 2 O
cardiac	1270 7 B-Disease
complications	1278 13 I-Disease
in	1292 2 O
cancer	1295 6 B-Disease
patients	1302 8 O
undergoing	1311 10 O
chemotherapy	1322 12 O
include	1335 7 O
coronary	1343 8 B-Disease
vasospasm	1352 9 I-Disease
,	1361 1 O
endothelial	1363 11 O
damage	1375 6 O
and	1382 3 O
consequent	1386 10 O
thrombus	1397 8 B-Disease
formation	1406 9 O
.	1415 1 O

In	1417 2 O
our	1420 3 O
patient	1424 7 O
,	1431 1 O
both	1433 4 O
supraphysiologic	1438 16 O
levels	1455 6 O
of	1462 2 O
plasma	1465 6 O
catecholamines	1472 14 B-Chemical
and	1487 3 O
stress	1491 6 O
related	1498 7 O
neuropeptides	1506 13 O
caused	1520 6 O
by	1527 2 O
cancer	1530 6 B-Disease
diagnosis	1537 9 O
as	1547 2 O
well	1550 4 O
as	1555 2 O
chemotherapy	1558 12 O
may	1571 3 O
have	1575 4 O
contributed	1580 11 O
the	1592 3 O
development	1596 11 O
of	1608 2 O
ABS	1611 3 B-Disease
.	1614 1 O

Reduction	0 9 O
of	10 2 O
pain	13 4 B-Disease
during	18 6 O
induction	25 9 O
with	35 4 O
target	40 6 O
-	46 1 O
controlled	47 10 O
propofol	58 8 B-Chemical
and	67 3 O
remifentanil	71 12 B-Chemical
.	83 1 O

BACKGROUND	85 10 O
:	95 1 O
Pain	97 4 B-Disease
on	102 2 O
injection	105 9 O
of	115 2 O
propofol	118 8 B-Chemical
is	127 2 O
unpleasant	130 10 O
.	140 1 O

We	142 2 O
hypothesized	145 12 O
that	158 4 O
propofol	163 8 B-Chemical
infusion	172 8 O
pain	181 4 B-Disease
might	186 5 O
be	192 2 O
prevented	195 9 O
by	205 2 O
infusing	208 8 O
remifentanil	217 12 B-Chemical
before	230 6 O
starting	237 8 O
the	246 3 O
propofol	250 8 B-Chemical
infusion	259 8 O
in	268 2 O
a	271 1 O
clinical	273 8 O
setting	282 7 O
where	290 5 O
target	296 6 O
-	302 1 O
controlled	303 10 O
infusions	314 9 O
(	324 1 O
TCI	325 3 O
)	328 1 O
of	330 2 O
both	333 4 O
drugs	338 5 O
were	344 4 O
used	349 4 O
.	353 1 O

A	355 1 O
prospective	357 11 O
,	368 1 O
randomized	370 10 O
,	380 1 O
double	382 6 O
-	388 1 O
blind	389 5 O
,	394 1 O
placebo	396 7 O
-	403 1 O
controlled	404 10 O
trial	415 5 O
was	421 3 O
performed	425 9 O
to	435 2 O
determine	438 9 O
the	448 3 O
effect	452 6 O
-	458 1 O
site	459 4 O
concentration	464 13 O
(	478 1 O
Ce	479 2 O
)	481 1 O
of	483 2 O
remifentanil	486 12 B-Chemical
to	499 2 O
prevent	502 7 O
the	510 3 O
pain	514 4 B-Disease
without	519 7 O
producing	527 9 O
complications	537 13 O
.	550 1 O

METHODS	552 7 O
:	559 1 O
A	561 1 O
total	563 5 O
of	569 2 O
128	572 3 O
patients	576 8 O
undergoing	585 10 O
general	596 7 O
surgery	604 7 O
were	612 4 O
randomly	617 8 O
allocated	626 9 O
to	636 2 O
receive	639 7 O
normal	647 6 O
saline	654 6 O
(	661 1 O
control	662 7 O
)	669 1 O
or	671 2 O
remifentanil	674 12 B-Chemical
to	687 2 O
a	690 1 O
target	692 6 O
Ce	699 2 O
of	702 2 O
2	705 1 O
ng	707 2 O
ml	710 2 O
(	712 1 O
-	713 1 O
1	714 1 O
)	715 1 O
(	717 1 O
R2	718 2 O
)	720 1 O
,	721 1 O
4	723 1 O
ng	725 2 O
ml	728 2 O
(	730 1 O
-	731 1 O
1	732 1 O
)	733 1 O
(	735 1 O
R4	736 2 O
)	738 1 O
,	739 1 O
or	741 2 O
6	744 1 O
ng	746 2 O
ml	749 2 O
(	751 1 O
-	752 1 O
1	753 1 O
)	754 1 O
(	756 1 O
R6	757 2 O
)	759 1 O
administered	761 12 O
via	774 3 O
TCI	778 3 O
.	781 1 O

After	783 5 O
the	789 3 O
target	793 6 O
Ce	800 2 O
was	803 3 O
achieved	807 8 O
,	815 1 O
the	817 3 O
infusion	821 8 O
of	830 2 O
propofol	833 8 B-Chemical
was	842 3 O
started	846 7 O
.	853 1 O

Remifentanil	855 12 B-Chemical
-	867 1 O
related	868 7 O
complications	876 13 O
were	890 4 O
assessed	895 8 O
during	904 6 O
the	911 3 O
remifentanil	915 12 B-Chemical
infusion	928 8 O
,	936 1 O
and	938 3 O
pain	942 4 B-Disease
caused	947 6 O
by	954 2 O
propofol	957 8 B-Chemical
was	966 3 O
evaluated	970 9 O
using	980 5 O
a	986 1 O
four	988 4 O
-	992 1 O
point	993 5 O
scale	999 5 O
during	1005 6 O
the	1012 3 O
propofol	1016 8 B-Chemical
infusion	1025 8 O
.	1033 1 O

RESULTS	1035 7 O
:	1042 1 O
The	1044 3 O
incidence	1048 9 O
of	1058 2 O
pain	1061 4 B-Disease
was	1066 3 O
significantly	1070 13 O
lower	1084 5 O
in	1090 2 O
Groups	1093 6 O
R4	1100 2 O
and	1103 3 O
R6	1107 2 O
than	1110 4 O
in	1115 2 O
the	1118 3 O
control	1122 7 O
and	1130 3 O
R2	1134 2 O
groups	1137 6 O
(	1144 1 O
12	1145 2 O
/	1147 1 O
32	1148 2 O
and	1151 3 O
6	1155 1 O
/	1156 1 O
31	1157 2 O
vs	1160 2 O
26	1163 2 O
/	1165 1 O
31	1166 2 O
and	1169 3 O
25	1173 2 O
/	1175 1 O
32	1176 2 O
,	1178 1 O
respectively	1180 12 O
,	1192 1 O
P	1194 1 O
<	1195 1 O
0	1196 1 O
.	1197 1 O
001	1198 3 O
)	1201 1 O
.	1202 1 O

Pain	1204 4 B-Disease
was	1209 3 O
less	1213 4 O
severe	1218 6 O
in	1225 2 O
Groups	1228 6 O
R4	1235 2 O
and	1238 3 O
R6	1242 2 O
than	1245 4 O
in	1250 2 O
the	1253 3 O
control	1257 7 O
and	1265 3 O
R2	1269 2 O
groups	1272 6 O
(	1279 1 O
P	1280 1 O
<	1281 1 O
0	1282 1 O
.	1283 1 O
001	1284 3 O
)	1287 1 O
.	1288 1 O

However	1290 7 O
,	1297 1 O
both	1299 4 O
incidence	1304 9 O
and	1314 3 O
severity	1318 8 O
of	1327 2 O
pain	1330 4 B-Disease
were	1335 4 O
not	1340 3 O
different	1344 9 O
between	1354 7 O
Groups	1362 6 O
R4	1369 2 O
and	1372 3 O
R6	1376 2 O
.	1378 1 O

No	1380 2 O
significant	1383 11 O
complications	1395 13 O
were	1409 4 O
observed	1414 8 O
during	1423 6 O
the	1430 3 O
study	1434 5 O
.	1439 1 O

CONCLUSIONS	1441 11 O
:	1452 1 O
During	1454 6 O
induction	1461 9 O
of	1471 2 O
anaesthesia	1474 11 O
with	1486 4 O
TCI	1491 3 O
of	1495 2 O
propofol	1498 8 B-Chemical
and	1507 3 O
remifentanil	1511 12 B-Chemical
,	1523 1 O
a	1525 1 O
significant	1527 11 O
reduction	1539 9 O
in	1549 2 O
propofol	1552 8 B-Chemical
infusion	1561 8 O
pain	1570 4 B-Disease
was	1575 3 O
achieved	1579 8 O
without	1588 7 O
significant	1596 11 O
complications	1608 13 O
by	1622 2 O
prior	1625 5 O
administration	1631 14 O
of	1646 2 O
remifentanil	1649 12 B-Chemical
at	1662 2 O
a	1665 1 O
target	1667 6 O
Ce	1674 2 O
of	1677 2 O
4	1680 1 O
ng	1682 2 O
ml	1685 2 O
(	1687 1 O
-	1688 1 O
1	1689 1 O
)	1690 1 O
.	1691 1 O

Prenatal	0 8 O
exposure	9 8 O
to	18 2 O
fluoxetine	21 10 B-Chemical
induces	32 7 O
fetal	40 5 B-Disease
pulmonary	46 9 I-Disease
hypertension	56 12 I-Disease
in	69 2 O
the	72 3 O
rat	76 3 O
.	79 1 O

RATIONALE	81 9 O
:	90 1 O
Fluoxetine	92 10 B-Chemical
is	103 2 O
a	106 1 O
selective	108 9 O
serotonin	118 9 B-Chemical
reuptake	128 8 O
inhibitor	137 9 O
antidepressant	147 14 O
widely	162 6 O
used	169 4 O
by	174 2 O
pregnant	177 8 O
women	186 5 O
.	191 1 O

Epidemiological	193 15 O
data	209 4 O
suggest	214 7 O
that	222 4 O
fluoxetine	227 10 B-Chemical
exposure	238 8 O
prenatally	247 10 O
increases	258 9 O
the	268 3 O
prevalence	272 10 O
of	283 2 O
persistent	286 10 O
pulmonary	297 9 B-Disease
hypertension	307 12 I-Disease
syndrome	320 8 I-Disease
of	329 2 O
the	332 3 O
newborn	336 7 O
.	343 1 O

The	345 3 O
mechanism	349 9 O
responsible	359 11 O
for	371 3 O
this	375 4 O
effect	380 6 O
is	387 2 O
unclear	390 7 O
and	398 3 O
paradoxical	402 11 O
,	413 1 O
considering	415 11 O
the	427 3 O
current	431 7 O
evidence	439 8 O
of	448 2 O
a	451 1 O
pulmonary	453 9 B-Disease
hypertension	463 12 I-Disease
protective	476 10 O
fluoxetine	487 10 B-Chemical
effect	498 6 O
in	505 2 O
adult	508 5 O
rodents	514 7 O
.	521 1 O

OBJECTIVES	523 10 O
:	533 1 O
To	535 2 O
evaluate	538 8 O
the	547 3 O
fluoxetine	551 10 B-Chemical
effect	562 6 O
on	569 2 O
fetal	572 5 O
rat	578 3 O
pulmonary	582 9 O
vascular	592 8 O
smooth	601 6 O
muscle	608 6 O
mechanical	615 10 O
properties	626 10 O
and	637 3 O
cell	641 4 O
proliferation	646 13 O
rate	660 4 O
.	664 1 O

METHODS	666 7 O
:	673 1 O
Pregnant	675 8 O
rats	684 4 O
were	689 4 O
treated	694 7 O
with	702 4 O
fluoxetine	707 10 B-Chemical
(	718 1 O
10	719 2 O
mg	722 2 O
/	724 1 O
kg	725 2 O
)	727 1 O
from	729 4 O
Day	734 3 O
11	738 2 O
through	741 7 O
Day	749 3 O
21	753 2 O
of	756 2 O
gestation	759 9 O
.	768 1 O

MEASUREMENTS	770 12 O
AND	783 3 O
MAIN	787 4 O
RESULTS	792 7 O
:	799 1 O
Fetuses	801 7 O
were	809 4 O
delivered	814 9 O
by	824 2 O
cesarean	827 8 O
section	836 7 O
.	843 1 O

As	845 2 O
compared	848 8 O
with	857 4 O
controls	862 8 O
,	870 1 O
fluoxetine	872 10 B-Chemical
exposure	883 8 O
resulted	892 8 O
in	901 2 O
fetal	904 5 B-Disease
pulmonary	910 9 I-Disease
hypertension	920 12 I-Disease
as	933 2 O
evidenced	936 9 O
by	946 2 O
an	949 2 O
increase	952 8 O
in	961 2 O
the	964 3 O
weight	968 6 O
ratio	975 5 O
of	981 2 O
the	984 3 O
right	988 5 O
ventricle	994 9 O
to	1004 2 O
the	1007 3 O
left	1011 4 O
ventricle	1016 9 O
plus	1026 4 O
septum	1031 6 O
(	1038 1 O
P	1039 1 O
=	1041 1 O
0	1043 1 O
.	1044 1 O
02	1045 2 O
)	1047 1 O
and	1049 3 O
by	1053 2 O
an	1056 2 O
increase	1059 8 O
in	1068 2 O
pulmonary	1071 9 O
arterial	1081 8 O
medial	1090 6 O
thickness	1097 9 O
(	1107 1 O
P	1108 1 O
<	1110 1 O
0	1112 1 O
.	1113 1 O
01	1114 2 O
)	1116 1 O
.	1117 1 O

Postnatal	1119 9 O
mortality	1129 9 O
was	1139 3 O
increased	1143 9 O
among	1153 5 O
experimental	1159 12 O
animals	1172 7 O
,	1179 1 O
and	1181 3 O
arterial	1185 8 O
oxygen	1194 6 B-Chemical
saturation	1201 10 O
was	1212 3 O
96	1216 2 O
+	1219 1 O
/	1220 1 O
-	1221 1 O
1	1223 1 O
%	1224 1 O
in	1226 2 O
1	1229 1 O
-	1230 1 O
day	1231 3 O
-	1234 1 O
old	1235 3 O
control	1239 7 O
animals	1247 7 O
and	1255 3 O
significantly	1259 13 O
lower	1273 5 O
(	1279 1 O
P	1280 1 O
<	1282 1 O
0	1284 1 O
.	1285 1 O
01	1286 2 O
)	1288 1 O
in	1290 2 O
fluoxetine	1293 10 B-Chemical
-	1303 1 O
exposed	1304 7 O
pups	1312 4 O
(	1317 1 O
79	1318 2 O
+	1321 1 O
/	1322 1 O
-	1323 1 O
2	1325 1 O
%	1326 1 O
)	1327 1 O
.	1328 1 O

In	1330 2 O
vitro	1333 5 O
,	1338 1 O
fluoxetine	1340 10 B-Chemical
induced	1351 7 O
pulmonary	1359 9 O
arterial	1369 8 O
muscle	1378 6 O
contraction	1385 11 O
in	1397 2 O
fetal	1400 5 O
,	1405 1 O
but	1407 3 O
not	1411 3 O
adult	1415 5 O
,	1420 1 O
animals	1422 7 O
(	1430 1 O
P	1431 1 O
<	1433 1 O
0	1435 1 O
.	1436 1 O
01	1437 2 O
)	1439 1 O
and	1441 3 O
reduced	1445 7 O
serotonin	1453 9 B-Chemical
-	1462 1 O
induced	1463 7 O
contraction	1471 11 O
at	1483 2 O
both	1486 4 O
ages	1491 4 O
(	1496 1 O
P	1497 1 O
<	1499 1 O
0	1501 1 O
.	1502 1 O
01	1503 2 O
)	1505 1 O
.	1506 1 O

After	1508 5 O
in	1514 2 O
utero	1517 5 O
exposure	1523 8 O
to	1532 2 O
a	1535 1 O
low	1537 3 O
fluoxetine	1541 10 B-Chemical
concentration	1552 13 O
the	1566 3 O
pulmonary	1570 9 O
arterial	1580 8 O
smooth	1589 6 O
muscle	1596 6 O
cell	1603 4 O
proliferation	1608 13 O
rate	1622 4 O
was	1627 3 O
significantly	1631 13 O
increased	1645 9 O
in	1655 2 O
fetal	1658 5 O
,	1663 1 O
but	1665 3 O
not	1669 3 O
adult	1673 5 O
,	1678 1 O
cells	1680 5 O
(	1686 1 O
P	1687 1 O
<	1689 1 O
0	1691 1 O
.	1692 1 O
01	1693 2 O
)	1695 1 O
.	1696 1 O

CONCLUSIONS	1698 11 O
:	1709 1 O
In	1711 2 O
contrast	1714 8 O
to	1723 2 O
the	1726 3 O
adult	1730 5 O
,	1735 1 O
fluoxetine	1737 10 B-Chemical
exposure	1748 8 O
in	1757 2 O
utero	1760 5 O
induces	1766 7 O
pulmonary	1774 9 B-Disease
hypertension	1784 12 I-Disease
in	1797 2 O
the	1800 3 O
fetal	1804 5 O
rat	1810 3 O
as	1814 2 O
a	1817 1 O
result	1819 6 O
of	1826 2 O
a	1829 1 O
developmentally	1831 15 O
regulated	1847 9 O
increase	1857 8 O
in	1866 2 O
pulmonary	1869 9 O
vascular	1879 8 O
smooth	1888 6 O
muscle	1895 6 O
proliferation	1902 13 O
.	1915 1 O

Syncope	0 7 B-Disease
and	8 3 O
QT	12 2 B-Disease
prolongation	15 12 I-Disease
among	28 5 O
patients	34 8 O
treated	43 7 O
with	51 4 O
methadone	56 9 B-Chemical
for	66 3 O
heroin	70 6 B-Chemical
dependence	77 10 O
in	88 2 O
the	91 3 O
city	95 4 O
of	100 2 O
Copenhagen	103 10 O
.	113 1 O

BACKGROUND	115 10 O
:	125 1 O
Methadone	127 9 B-Chemical
is	137 2 O
prescribed	140 10 O
to	151 2 O
heroin	154 6 B-Chemical
addicts	161 7 O
to	169 2 O
decrease	172 8 O
illicit	181 7 O
opioid	189 6 O
use	196 3 O
.	199 1 O

Prolongation	201 12 O
of	214 2 O
the	217 3 O
QT	221 2 O
interval	224 8 O
in	233 2 O
the	236 3 O
ECG	240 3 O
of	244 2 O
patients	247 8 O
with	256 4 O
torsade	261 7 B-Disease
de	269 2 I-Disease
pointes	272 7 I-Disease
(	280 1 O
TdP	281 3 B-Disease
)	284 1 O
has	286 3 O
been	290 4 O
reported	295 8 O
in	304 2 O
methadone	307 9 B-Chemical
users	317 5 O
.	322 1 O

As	324 2 O
heroin	327 6 B-Chemical
addicts	334 7 O
sometimes	342 9 O
faint	352 5 O
while	358 5 O
using	364 5 O
illicit	370 7 O
drugs	378 5 O
,	383 1 O
doctors	385 7 O
might	393 5 O
attribute	399 9 O
too	409 3 O
many	413 4 O
episodes	418 8 O
of	427 2 O
syncope	430 7 B-Disease
to	438 2 O
illicit	441 7 O
drug	449 4 O
use	454 3 O
and	458 3 O
thereby	462 7 O
underestimate	470 13 O
the	484 3 O
incidence	488 9 O
of	498 2 O
TdP	501 3 B-Disease
in	505 2 O
this	508 4 O
special	513 7 O
population	521 10 O
,	531 1 O
and	533 3 O
the	537 3 O
high	541 4 O
mortality	546 9 O
in	556 2 O
this	559 4 O
population	564 10 O
may	575 3 O
,	578 1 O
in	580 2 O
part	583 4 O
,	587 1 O
be	589 2 O
caused	592 6 O
by	599 2 O
the	602 3 O
proarrhythmic	606 13 O
effect	620 6 O
of	627 2 O
methadone	630 9 B-Chemical
.	639 1 O

METHODS	641 7 O
:	648 1 O
In	650 2 O
this	653 4 O
cross	658 5 O
-	663 1 O
sectional	664 9 O
study	674 5 O
interview	680 9 O
,	689 1 O
ECGs	691 4 O
and	696 3 O
blood	700 5 O
samples	706 7 O
were	714 4 O
collected	719 9 O
in	729 2 O
a	732 1 O
population	734 10 O
of	745 2 O
adult	748 5 O
heroin	754 6 B-Chemical
addicts	761 7 O
treated	769 7 O
with	777 4 O
methadone	782 9 B-Chemical
or	792 2 O
buprenorphine	795 13 B-Chemical
on	809 2 O
a	812 1 O
daily	814 5 O
basis	820 5 O
.	825 1 O

Of	827 2 O
the	830 3 O
patients	834 8 O
at	843 2 O
the	846 3 O
Drug	850 4 O
Addiction	855 9 O
Service	865 7 O
in	873 2 O
the	876 3 O
municipal	880 9 O
of	890 2 O
Copenhagen	893 10 O
,	903 1 O
450	905 3 O
(	909 1 O
approximately	910 13 O
52	924 2 O
%	926 1 O
)	927 1 O
were	929 4 O
included	934 8 O
.	942 1 O

The	944 3 O
QT	948 2 O
interval	951 8 O
was	960 3 O
estimated	964 9 O
from	974 4 O
12	979 2 O
lead	982 4 O
ECGs	987 4 O
.	991 1 O

All	993 3 O
participants	997 12 O
were	1010 4 O
interviewed	1015 11 O
about	1027 5 O
any	1033 3 O
experience	1037 10 O
of	1048 2 O
syncope	1051 7 B-Disease
.	1058 1 O

The	1060 3 O
association	1064 11 O
between	1076 7 O
opioid	1084 6 O
dose	1091 4 O
and	1096 3 O
QT	1100 2 O
,	1102 1 O
and	1104 3 O
methadone	1108 9 B-Chemical
dose	1118 4 O
and	1123 3 O
reporting	1127 9 O
of	1137 2 O
syncope	1140 7 B-Disease
was	1148 3 O
assessed	1152 8 O
using	1161 5 O
multivariate	1167 12 O
linear	1180 6 O
regression	1187 10 O
and	1198 3 O
logistic	1202 8 O
regression	1211 10 O
,	1221 1 O
respectively	1223 12 O
.	1235 1 O

RESULTS	1237 7 O
:	1244 1 O
Methadone	1246 9 B-Chemical
dose	1256 4 O
was	1261 3 O
associated	1265 10 O
with	1276 4 O
longer	1281 6 O
QT	1288 2 O
interval	1291 8 O
of	1300 2 O
0	1303 1 O
.	1304 1 O
140	1305 3 O
ms	1309 2 O
/	1311 1 O
mg	1312 2 O
(	1315 1 O
p	1316 1 O
=	1318 1 O
0	1320 1 O
.	1321 1 O
002	1322 3 O
)	1325 1 O
.	1326 1 O

No	1328 2 O
association	1331 11 O
between	1343 7 O
buprenorphine	1351 13 B-Chemical
and	1365 3 O
QTc	1369 3 O
was	1373 3 O
found	1377 5 O
.	1382 1 O

Among	1384 5 O
the	1390 3 O
subjects	1394 8 O
treated	1403 7 O
with	1411 4 O
methadone	1416 9 B-Chemical
,	1425 1 O
28	1427 2 O
%	1429 1 O
men	1431 3 O
and	1435 3 O
32	1439 2 O
%	1441 1 O
women	1443 5 O
had	1449 3 O
prolonged	1453 9 B-Disease
QTc	1463 3 I-Disease
interval	1467 8 I-Disease
.	1475 1 O

None	1477 4 O
of	1482 2 O
the	1485 3 O
subjects	1489 8 O
treated	1498 7 O
with	1506 4 O
buprenorphine	1511 13 B-Chemical
had	1525 3 O
QTc	1529 3 O
interval	1533 8 O
>	1542 1 O
0	1543 1 O
.	1544 1 O
440	1545 3 O
s	1549 1 O
(	1550 1 O
(	1551 1 O
1	1552 1 O
/	1553 1 O
2	1554 1 O
)	1555 1 O
)	1556 1 O
.	1557 1 O

A	1559 1 O
50	1561 2 O
mg	1564 2 O
higher	1567 6 O
methadone	1574 9 B-Chemical
dose	1584 4 O
was	1589 3 O
associated	1593 10 O
with	1604 4 O
a	1609 1 O
1	1611 1 O
.	1612 1 O
2	1613 1 O
(	1615 1 O
95	1616 2 O
%	1618 1 O
CI	1620 2 O
1	1623 1 O
.	1624 1 O
1	1625 1 O
to	1627 2 O
1	1630 1 O
.	1631 1 O
4	1632 1 O
)	1633 1 O
times	1635 5 O
higher	1641 6 O
odds	1648 4 O
for	1653 3 O
syncope	1657 7 B-Disease
.	1664 1 O

CONCLUSIONS	1666 11 O
:	1677 1 O
Methadone	1679 9 B-Chemical
is	1689 2 O
associated	1692 10 O
with	1703 4 O
QT	1708 2 B-Disease
prolongation	1711 12 I-Disease
and	1724 3 O
higher	1728 6 O
reporting	1735 9 O
of	1745 2 O
syncope	1748 7 B-Disease
in	1756 2 O
a	1759 1 O
population	1761 10 O
of	1772 2 O
heroin	1775 6 B-Chemical
addicts	1782 7 O
.	1789 1 O

Peripheral	0 10 B-Disease
neuropathy	11 10 I-Disease
caused	22 6 O
by	29 2 O
high	32 4 O
-	36 1 O
dose	37 4 O
cytosine	42 8 B-Chemical
arabinoside	51 11 I-Chemical
treatment	63 9 O
in	73 2 O
a	76 1 O
patient	78 7 O
with	86 4 O
acute	91 5 B-Disease
myeloid	97 7 I-Disease
leukemia	105 8 I-Disease
.	113 1 O

The	115 3 O
central	119 7 O
nervous	127 7 O
system	135 6 O
toxicity	142 8 B-Disease
of	151 2 O
high	154 4 O
-	158 1 O
dose	159 4 O
cytosine	164 8 B-Chemical
arabinoside	173 11 I-Chemical
is	185 2 O
well	188 4 O
recognized	193 10 O
,	203 1 O
but	205 3 O
the	209 3 O
toxicity	213 8 B-Disease
of	222 2 O
cytosine	225 8 B-Chemical
arabinoside	234 11 I-Chemical
in	246 2 O
the	249 3 O
peripheral	253 10 O
nervous	264 7 O
system	272 6 O
has	279 3 O
been	283 4 O
infrequently	288 12 O
reported	301 8 O
.	309 1 O

A	311 1 O
49	313 2 O
-	315 1 O
year	316 4 O
-	320 1 O
old	321 3 O
Japanese	325 8 O
man	334 3 O
was	338 3 O
diagnosed	342 9 O
with	352 4 O
acute	357 5 B-Disease
myeloid	363 7 I-Disease
leukemia	371 8 I-Disease
.	379 1 O

After	381 5 O
he	387 2 O
achieved	390 8 O
complete	399 8 O
remission	408 9 O
,	417 1 O
he	419 2 O
received	422 8 O
high	431 4 O
-	435 1 O
dose	436 4 O
cytosine	441 8 B-Chemical
arabinoside	450 11 I-Chemical
treatment	462 9 O
(	472 1 O
2	473 1 O
g	475 1 O
/	476 1 O
m2	477 2 O
twice	480 5 O
a	486 1 O
day	488 3 O
for	492 3 O
5	496 1 O
days	498 4 O
;	502 1 O
total	504 5 O
,	509 1 O
20	511 2 O
g	514 1 O
/	515 1 O
m2	516 2 O
)	518 1 O
as	520 2 O
consolidation	523 13 O
therapy	537 7 O
.	544 1 O

The	546 3 O
first	550 5 O
course	556 6 O
of	563 2 O
high	566 4 O
-	570 1 O
dose	571 4 O
cytosine	576 8 B-Chemical
arabinoside	585 11 I-Chemical
resulted	597 8 O
in	606 2 O
no	609 2 O
unusual	612 7 O
symptoms	620 8 O
,	628 1 O
but	630 3 O
on	634 2 O
day	637 3 O
21	641 2 O
of	644 2 O
the	647 3 O
second	651 6 O
course	658 6 O
of	665 2 O
treatment	668 9 O
,	677 1 O
the	679 3 O
patient	683 7 O
complained	691 10 O
of	702 2 O
numbness	705 8 B-Disease
in	714 2 O
his	717 3 O
right	721 5 O
foot	727 4 O
.	731 1 O

Electromyogram	733 14 O
and	748 3 O
nerve	752 5 O
-	757 1 O
conduction	758 10 O
studies	769 7 O
showed	777 6 O
peripheral	784 10 B-Disease
neuropathy	795 10 I-Disease
in	806 2 O
both	809 4 O
peroneal	814 8 O
nerves	823 6 O
.	829 1 O

This	831 4 O
neuropathy	836 10 B-Disease
was	847 3 O
gradually	851 9 O
resolving	861 9 O
;	870 1 O
however	872 7 O
,	879 1 O
after	881 5 O
the	887 3 O
patient	891 7 O
received	899 8 O
allogeneic	908 10 O
bone	919 4 O
marrow	924 6 O
transplantation	931 15 O
,	946 1 O
the	948 3 O
symptoms	952 8 O
worsened	961 8 O
,	969 1 O
with	971 4 O
the	976 3 O
development	980 11 O
of	992 2 O
graft	995 5 B-Disease
-	1000 1 I-Disease
versus	1001 6 I-Disease
-	1007 1 I-Disease
host	1008 4 I-Disease
disease	1013 7 I-Disease
,	1020 1 O
and	1022 3 O
the	1026 3 O
symptoms	1030 8 O
subsequently	1039 12 O
responded	1052 9 O
to	1062 2 O
methylprednisolone	1065 18 B-Chemical
.	1083 1 O

Although	1085 8 O
the	1094 3 O
mechanisms	1098 10 O
of	1109 2 O
peripheral	1112 10 B-Disease
neuropathy	1123 10 I-Disease
are	1134 3 O
still	1138 5 O
unclear	1144 7 O
,	1151 1 O
high	1153 4 O
-	1157 1 O
dose	1158 4 O
cytosine	1163 8 B-Chemical
arabinoside	1172 11 I-Chemical
is	1184 2 O
a	1187 1 O
therapy	1189 7 O
that	1197 4 O
is	1202 2 O
potentially	1205 11 O
toxic	1217 5 O
to	1223 2 O
the	1226 3 O
peripheral	1230 10 O
nervous	1241 7 O
system	1249 6 O
,	1255 1 O
and	1257 3 O
auto	1261 4 O
/	1265 1 O
alloimmunity	1266 12 O
may	1279 3 O
play	1283 4 O
an	1288 2 O
important	1291 9 O
role	1301 4 O
in	1306 2 O
these	1309 5 O
mechanisms	1315 10 O
.	1325 1 O

Atorvastatin	0 12 B-Chemical
prevented	13 9 O
and	23 3 O
reversed	27 8 O
dexamethasone	36 13 B-Chemical
-	49 1 O
induced	50 7 O
hypertension	58 12 B-Disease
in	71 2 O
the	74 3 O
rat	78 3 O
.	81 1 O

To	83 2 O
assess	86 6 O
the	93 3 O
antioxidant	97 11 O
effects	109 7 O
of	117 2 O
atorvastatin	120 12 B-Chemical
(	133 1 O
atorva	134 6 B-Chemical
)	140 1 O
on	142 2 O
dexamethasone	145 13 B-Chemical
(	159 1 O
dex	160 3 B-Chemical
)	163 1 O
-	164 1 O
induced	165 7 O
hypertension	173 12 B-Disease
,	185 1 O
60	187 2 O
male	190 4 O
Sprague	195 7 O
-	202 1 O
Dawley	203 6 O
rats	210 4 O
were	215 4 O
treated	220 7 O
with	228 4 O
atorva	233 6 B-Chemical
30	240 2 O
mg	243 2 O
/	245 1 O
kg	246 2 O
/	248 1 O
day	249 3 O
or	253 2 O
tap	256 3 O
water	260 5 O
for	266 3 O
15	270 2 O
days	273 4 O
.	277 1 O

Dex	279 3 B-Chemical
increased	283 9 O
systolic	293 8 O
blood	302 5 O
pressure	308 8 O
(	317 1 O
SBP	318 3 O
)	321 1 O
from	323 4 O
109	328 3 O
+	332 1 O
/	333 1 O
-	334 1 O
1	336 1 O
.	337 1 O
8	338 1 O
to	340 2 O
135	343 3 O
+	347 1 O
/	348 1 O
-	349 1 O
0	351 1 O
.	352 1 O
6	353 1 O
mmHg	355 4 O
and	360 3 O
plasma	364 6 O
superoxide	371 10 B-Chemical
(	382 1 O
5711	383 4 O
+	388 1 O
/	389 1 O
-	390 1 O
284	392 3 O
.	395 1 O
9	396 1 O
saline	398 6 O
,	404 1 O
7931	406 4 O
+	411 1 O
/	412 1 O
-	413 1 O
392	415 3 O
.	418 1 O
8	419 1 O
U	421 1 O
/	422 1 O
ml	423 2 O
dex	426 3 B-Chemical
,	429 1 O
P	431 1 O
<	433 1 O
0	435 1 O
.	436 1 O
001	437 3 O
)	440 1 O
.	441 1 O

In	443 2 O
this	446 4 O
prevention	451 10 O
study	462 5 O
,	467 1 O
SBP	469 3 O
in	473 2 O
the	476 3 O
atorva	480 6 B-Chemical
+	487 1 O
dex	489 3 B-Chemical
group	493 5 O
was	499 3 O
increased	503 9 O
from	513 4 O
115	518 3 O
+	522 1 O
/	523 1 O
-	524 1 O
0	526 1 O
.	527 1 O
4	528 1 O
to	530 2 O
124	533 3 O
+	537 1 O
/	538 1 O
-	539 1 O
1	541 1 O
.	542 1 O
5	543 1 O
mmHg	545 4 O
,	549 1 O
but	551 3 O
this	555 4 O
was	560 3 O
significantly	564 13 O
lower	578 5 O
than	584 4 O
in	589 2 O
the	592 3 O
dex	596 3 B-Chemical
-	599 1 O
only	600 4 O
group	605 5 O
(	611 1 O
P	612 1 O
'	613 1 O
<	615 1 O
0	617 1 O
.	618 1 O
05	619 2 O
)	621 1 O
.	622 1 O

Atorva	624 6 B-Chemical
reversed	631 8 O
dex	640 3 B-Chemical
-	643 1 O
induced	644 7 O
hypertension	652 12 B-Disease
(	665 1 O
129	666 3 O
+	670 1 O
/	671 1 O
-	672 1 O
0	674 1 O
.	675 1 O
6	676 1 O
mmHg	678 4 O
,	682 1 O
vs	684 2 O
.	686 1 O
135	688 3 O
+	692 1 O
/	693 1 O
-	694 1 O
0	696 1 O
.	697 1 O
6	698 1 O
mmHg	700 4 O
P	705 1 O
'	706 1 O
<	708 1 O
0	710 1 O
.	711 1 O
05	712 2 O
)	714 1 O
and	716 3 O
decreased	720 9 O
plasma	730 6 O
superoxide	737 10 B-Chemical
(	748 1 O
7931	749 4 O
+	754 1 O
/	755 1 O
-	756 1 O
392	758 3 O
.	761 1 O
8	762 1 O
dex	764 3 B-Chemical
,	767 1 O
1187	769 4 O
+	774 1 O
/	775 1 O
-	776 1 O
441	778 3 O
.	781 1 O
2	782 1 O
atorva	784 6 B-Chemical
+	791 1 O
dex	793 3 B-Chemical
,	796 1 O
P	798 1 O
<	800 1 O
0	802 1 O
.	803 1 O
0001	804 4 O
)	808 1 O
.	809 1 O

Plasma	811 6 O
nitrate	818 7 B-Chemical
/	825 1 O
nitrite	826 7 B-Chemical
(	834 1 O
NOx	835 3 O
)	838 1 O
was	840 3 O
decreased	844 9 O
in	854 2 O
dex	857 3 B-Chemical
-	860 1 O
treated	861 7 O
rats	869 4 O
compared	874 8 O
to	883 2 O
saline	886 6 O
-	892 1 O
treated	893 7 O
rats	901 4 O
(	906 1 O
11	907 2 O
.	909 1 O
2	910 1 O
+	912 1 O
/	913 1 O
-	914 1 O
1	916 1 O
.	917 1 O
08	918 2 O
microm	921 6 O
,	927 1 O
15	929 2 O
.	931 1 O
3	932 1 O
+	934 1 O
/	935 1 O
-	936 1 O
1	938 1 O
.	939 1 O
17	940 2 O
microm	943 6 O
,	949 1 O
respectively	951 12 O
,	963 1 O
P	965 1 O
<	967 1 O
0	969 1 O
.	970 1 O
05	971 2 O
)	973 1 O
.	974 1 O

Atorva	976 6 B-Chemical
affected	983 8 O
neither	992 7 O
plasma	1000 6 O
NOx	1007 3 O
nor	1011 3 O
thymus	1015 6 O
weight	1022 6 O
.	1028 1 O

Thus	1030 4 O
,	1034 1 O
atorvastatin	1036 12 B-Chemical
prevented	1049 9 O
and	1059 3 O
reversed	1063 8 O
dexamethasone	1072 13 B-Chemical
-	1085 1 O
induced	1086 7 O
hypertension	1094 12 B-Disease
in	1107 2 O
the	1110 3 O
rat	1114 3 O
.	1117 1 O

Two	0 3 O
prodrugs	4 8 O
of	13 2 O
potent	16 6 O
and	23 3 O
selective	27 9 O
GluR5	37 5 O
kainate	43 7 B-Chemical
receptor	51 8 O
antagonists	60 11 O
actives	72 7 O
in	80 2 O
three	83 5 O
animal	89 6 O
models	96 6 O
of	103 2 O
pain	106 4 B-Disease
.	110 1 O

Amino	112 5 O
acids	118 5 O
5	124 1 O
and	126 3 O
7	130 1 O
,	131 1 O
two	133 3 O
potent	137 6 O
and	144 3 O
selective	148 9 O
competitive	158 11 O
GluR5	170 5 O
KA	176 2 B-Chemical
receptor	179 8 O
antagonists	188 11 O
,	199 1 O
exhibited	201 9 O
high	211 4 O
GluR5	216 5 O
receptor	222 8 O
affinity	231 8 O
over	240 4 O
other	245 5 O
glutamate	251 9 B-Chemical
receptors	261 9 O
.	270 1 O

Their	272 5 O
ester	278 5 O
prodrugs	284 8 O
6	293 1 O
and	295 3 O
8	299 1 O
were	301 4 O
orally	306 6 O
active	313 6 O
in	320 2 O
three	323 5 O
models	329 6 O
of	336 2 O
pain	339 4 B-Disease
:	343 1 O
reversal	345 8 O
of	354 2 O
formalin	357 8 B-Chemical
-	365 1 O
induced	366 7 O
paw	374 3 O
licking	378 7 O
,	385 1 O
carrageenan	387 11 B-Chemical
-	398 1 O
induced	399 7 O
thermal	407 7 B-Disease
hyperalgesia	415 12 I-Disease
,	427 1 O
and	429 3 O
capsaicin	433 9 B-Chemical
-	442 1 O
induced	443 7 O
mechanical	451 10 B-Disease
hyperalgesia	462 12 I-Disease
.	474 1 O

Sirolimus	0 9 B-Chemical
and	10 3 O
mycophenolate	14 13 B-Chemical
mofetil	28 7 I-Chemical
for	36 3 O
calcineurin	40 11 O
-	51 1 O
free	52 4 O
immunosuppression	57 17 O
in	75 2 O
renal	78 5 O
transplant	84 10 O
recipients	95 10 O
.	105 1 O

Calcineurin	107 11 O
inhibitors	119 10 O
,	129 1 O
such	131 4 O
as	136 2 O
cyclosporine	139 12 B-Chemical
and	152 3 O
tacrolimus	156 10 B-Chemical
,	166 1 O
have	168 4 O
been	173 4 O
available	178 9 O
for	188 3 O
almost	192 6 O
20	199 2 O
years	202 5 O
.	207 1 O

Although	209 8 O
these	218 5 O
drugs	224 5 O
are	230 3 O
highly	234 6 O
effective	241 9 O
and	251 3 O
represent	255 9 O
the	265 3 O
mainstay	269 8 O
of	278 2 O
transplant	281 10 O
immunosuppression	292 17 O
,	309 1 O
they	311 4 O
are	316 3 O
associated	320 10 O
with	331 4 O
acute	336 5 O
and	342 3 O
chronic	346 7 O
nephrotoxicity	354 14 B-Disease
.	368 1 O

Acute	370 5 O
nephrotoxicity	376 14 B-Disease
,	390 1 O
which	392 5 O
occurs	398 6 O
in	405 2 O
the	408 3 O
early	412 5 O
period	418 6 O
after	425 5 O
transplantation	431 15 O
,	446 1 O
leads	448 5 O
to	454 2 O
a	457 1 O
higher	459 6 O
rate	466 4 O
of	471 2 O
dialysis	474 8 O
,	482 1 O
and	484 3 O
chronic	488 7 O
nephrotoxicity	496 14 B-Disease
may	511 3 O
eventually	515 10 O
result	526 6 O
in	533 2 O
graft	536 5 O
loss	542 4 O
.	546 1 O

Acute	548 5 O
and	554 3 O
chronic	558 7 O
nephrotoxicity	566 14 B-Disease
is	581 2 O
becoming	584 8 O
more	593 4 O
common	598 6 O
as	605 2 O
the	608 3 O
use	612 3 O
of	616 2 O
marginal	619 8 O
kidneys	628 7 O
for	636 3 O
transplantation	640 15 O
increases	656 9 O
.	665 1 O

Two	667 3 O
recently	671 8 O
available	680 9 O
immunosuppressive	690 17 O
agents	708 6 O
,	714 1 O
mycophenolate	716 13 B-Chemical
mofetil	730 7 I-Chemical
and	738 3 O
sirolimus	742 9 B-Chemical
(	752 1 O
rapamycin	753 9 B-Chemical
)	762 1 O
,	763 1 O
have	765 4 O
no	770 2 O
nephrotoxicity	773 14 B-Disease
.	787 1 O

The	789 3 O
use	793 3 O
of	797 2 O
these	800 5 O
drugs	806 5 O
in	812 2 O
combination	815 11 O
with	827 4 O
other	832 5 O
agents	838 6 O
has	845 3 O
led	849 3 O
to	853 2 O
the	856 3 O
development	860 11 O
of	872 2 O
new	875 3 O
paradigms	879 9 O
of	889 2 O
immunosuppressive	892 17 O
therapy	910 7 O
.	917 1 O

This	919 4 O
paper	924 5 O
reviews	930 7 O
the	938 3 O
results	942 7 O
of	950 2 O
clinical	953 8 O
trials	962 6 O
that	969 4 O
have	974 4 O
investigated	979 12 O
these	992 5 O
new	998 3 O
approaches	1002 10 O
to	1013 2 O
immunosuppression	1016 17 O
in	1034 2 O
renal	1037 5 O
transplant	1043 10 O
recipients	1054 10 O
.	1064 1 O

Erythropoietin	0 14 O
restores	15 8 O
the	24 3 O
anemia	28 6 B-Disease
-	34 1 O
induced	35 7 O
reduction	43 9 O
in	53 2 O
cyclophosphamide	56 16 B-Chemical
cytotoxicity	73 12 B-Disease
in	86 2 O
rat	89 3 O
tumors	93 6 B-Disease
.	99 1 O

The	101 3 O
aim	105 3 O
of	109 2 O
this	112 4 O
study	117 5 O
was	123 3 O
to	127 2 O
examine	130 7 O
the	138 3 O
impact	142 6 O
of	149 2 O
anemia	152 6 B-Disease
prevention	159 10 O
by	170 2 O
recombinant	173 11 O
human	185 5 O
erythropoietin	191 14 O
(	206 1 O
rHuEPO	207 6 O
)	213 1 O
treatment	215 9 O
on	225 2 O
the	228 3 O
cytotoxicity	232 12 B-Disease
of	245 2 O
cyclophosphamide	248 16 B-Chemical
in	265 2 O
solid	268 5 O
experimental	274 12 O
tumors	287 6 B-Disease
.	293 1 O

Anemia	295 6 B-Disease
was	302 3 O
induced	306 7 O
using	314 5 O
a	320 1 O
single	322 6 O
dose	329 4 O
of	334 2 O
carboplatin	337 11 B-Chemical
(	349 1 O
50	350 2 O
mg	353 2 O
/	355 1 O
kg	356 2 O
i	359 1 O
.	360 1 O
v	361 1 O
.	362 1 O
)	363 1 O
resulting	365 9 O
in	375 2 O
a	378 1 O
long	380 4 O
-	384 1 O
lasting	385 7 O
reduction	393 9 O
(	403 1 O
30	404 2 O
%	406 1 O
)	407 1 O
of	409 2 O
the	412 3 O
hemoglobin	416 10 O
concentration	427 13 O
.	440 1 O

In	442 2 O
a	445 1 O
second	447 6 O
group	454 5 O
,	459 1 O
the	461 3 O
development	465 11 O
of	477 2 O
anemia	480 6 B-Disease
was	487 3 O
prevented	491 9 O
by	501 2 O
rHuEPO	504 6 O
(	511 1 O
1000	512 4 O
IU	517 2 O
/	519 1 O
kg	520 2 O
)	522 1 O
administered	524 12 O
s	537 1 O
.	538 1 O
c	539 1 O
.	540 1 O
three	542 5 O
times	548 5 O
/	553 1 O
week	554 4 O
starting	559 8 O
7	568 1 O
days	570 4 O
before	575 6 O
carboplatin	582 11 B-Chemical
application	594 11 O
.	605 1 O

Four	607 4 O
days	612 4 O
after	617 5 O
carboplatin	623 11 B-Chemical
treatment	635 9 O
,	644 1 O
tumors	646 6 B-Disease
(	653 1 O
DS	654 2 O
-	656 1 O
sarcoma	657 7 B-Disease
of	665 2 O
the	668 3 O
rat	672 3 O
)	675 1 O
were	677 4 O
implanted	682 9 O
s	692 1 O
.	693 1 O
c	694 1 O
.	695 1 O
onto	697 4 O
the	702 3 O
hind	706 4 O
food	711 4 O
dorsum	716 6 O
.	722 1 O

Neither	724 7 O
carboplatin	732 11 B-Chemical
nor	744 3 O
rHuEPO	748 6 O
treatment	755 9 O
influenced	765 10 O
tumor	776 5 B-Disease
growth	782 6 O
rate	789 4 O
per	794 3 O
se	798 2 O
.	800 1 O

When	802 4 O
tumors	807 6 B-Disease
were	814 4 O
treated	819 7 O
with	827 4 O
a	832 1 O
single	834 6 O
dose	841 4 O
of	846 2 O
cyclophosphamide	849 16 B-Chemical
(	866 1 O
60	867 2 O
mg	870 2 O
/	872 1 O
kg	873 2 O
i	876 1 O
.	877 1 O
p	878 1 O
.	879 1 O
)	880 1 O
5	882 1 O
days	884 4 O
after	889 5 O
implantation	895 12 O
,	907 1 O
a	909 1 O
growth	911 6 O
delay	918 5 O
with	924 4 O
a	929 1 O
subsequent	931 10 O
regrowth	942 8 O
of	951 2 O
the	954 3 O
tumors	958 6 B-Disease
was	965 3 O
observed	969 8 O
.	977 1 O

In	979 2 O
the	982 3 O
anemia	986 6 B-Disease
group	993 5 O
,	998 1 O
the	1000 3 O
growth	1004 6 O
delay	1011 5 O
was	1017 3 O
significantly	1021 13 O
shorter	1035 7 O
compared	1043 8 O
with	1052 4 O
nonanemic	1057 9 O
controls	1067 8 O
(	1076 1 O
13	1077 2 O
.	1079 1 O
3	1080 1 O
days	1082 4 O
versus	1087 6 O
8	1094 1 O
.	1095 1 O
6	1096 1 O
days	1098 4 O
)	1102 1 O
.	1103 1 O

In	1105 2 O
the	1108 3 O
group	1112 5 O
where	1118 5 O
anemia	1124 6 B-Disease
was	1131 3 O
prevented	1135 9 O
by	1145 2 O
rHuEPO	1148 6 O
treatment	1155 9 O
,	1164 1 O
growth	1166 6 O
delay	1173 5 O
was	1179 3 O
comparable	1183 10 O
with	1194 4 O
that	1199 4 O
of	1204 2 O
nonanemic	1207 9 O
controls	1217 8 O
(	1226 1 O
13	1227 2 O
.	1229 1 O
3	1230 1 O
days	1232 4 O
)	1236 1 O
.	1237 1 O

These	1239 5 O
results	1245 7 O
suggest	1253 7 O
that	1261 4 O
chemotherapy	1266 12 O
-	1278 1 O
induced	1279 7 O
anemia	1287 6 B-Disease
reduces	1294 7 O
cytotoxicity	1302 12 B-Disease
of	1315 2 O
cyclophosphamide	1318 16 B-Chemical
in	1335 2 O
tumors	1338 6 B-Disease
,	1344 1 O
whereas	1346 7 O
correction	1354 10 O
of	1365 2 O
anemia	1368 6 B-Disease
by	1375 2 O
rHuEPO	1378 6 O
treatment	1385 9 O
(	1395 1 O
epoetin	1396 7 O
alpha	1404 5 O
)	1409 1 O
increases	1411 9 O
the	1421 3 O
sensitivity	1425 11 O
,	1436 1 O
probably	1438 8 O
as	1447 2 O
a	1450 1 O
result	1452 6 O
of	1459 2 O
an	1462 2 O
improved	1465 8 O
oxygen	1474 6 B-Chemical
supply	1481 6 O
to	1488 2 O
tumor	1491 5 B-Disease
tissue	1497 6 O
.	1503 1 O

The	0 3 O
role	4 4 O
of	9 2 O
nitrergic	12 9 O
system	22 6 O
in	29 2 O
lidocaine	32 9 B-Chemical
-	41 1 O
induced	42 7 O
convulsion	50 10 B-Disease
in	61 2 O
the	64 3 O
mouse	68 5 O
.	73 1 O

The	75 3 O
effects	79 7 O
of	87 2 O
N	90 1 B-Chemical
-	91 1 I-Chemical
nitro	92 5 I-Chemical
-	97 1 I-Chemical
L	98 1 I-Chemical
-	99 1 I-Chemical
arginine	100 8 I-Chemical
-	108 1 I-Chemical
methyl	109 6 I-Chemical
ester	116 5 I-Chemical
(	122 1 O
L	123 1 B-Chemical
-	124 1 I-Chemical
NAME	125 4 I-Chemical
)	129 1 O
a	131 1 O
nitric	133 6 B-Chemical
oxide	140 5 I-Chemical
(	146 1 O
NO	147 2 B-Chemical
)	149 1 O
synthase	151 8 O
inhibitor	160 9 O
and	170 3 O
L	174 1 B-Chemical
-	175 1 I-Chemical
arginine	176 8 I-Chemical
,	184 1 O
a	186 1 O
NO	188 2 B-Chemical
precursor	191 9 O
,	200 1 O
were	202 4 O
investigated	207 12 O
on	220 2 O
lidocaine	223 9 B-Chemical
-	232 1 O
induced	233 7 O
convulsions	241 11 B-Disease
.	252 1 O

In	254 2 O
the	257 3 O
first	261 5 O
experiment	267 10 O
,	277 1 O
four	279 4 O
groups	284 6 O
of	291 2 O
mice	294 4 O
received	299 8 O
physiological	308 13 O
saline	322 6 O
(	329 1 O
0	330 1 O
.	331 1 O
9	332 1 O
%	333 1 O
)	334 1 O
,	335 1 O
L	337 1 B-Chemical
-	338 1 I-Chemical
arginine	339 8 I-Chemical
(	348 1 O
300	349 3 O
mg	353 2 O
/	355 1 O
kg	356 2 O
,	358 1 O
i	360 1 O
.	361 1 O
p	362 1 O
.	363 1 O
)	364 1 O
,	365 1 O
L	367 1 B-Chemical
-	368 1 I-Chemical
NAME	369 4 I-Chemical
(	374 1 O
100	375 3 O
mg	379 2 O
/	381 1 O
kg	382 2 O
,	384 1 O
i	386 1 O
.	387 1 O
p	388 1 O
.	389 1 O
)	390 1 O
and	392 3 O
diazepam	396 8 B-Chemical
(	405 1 O
2	406 1 O
mg	408 2 O
/	410 1 O
kg	411 2 O
)	413 1 O
,	414 1 O
respectively	416 12 O
.	428 1 O

Thirty	430 6 O
minutes	437 7 O
after	445 5 O
these	451 5 O
injections	457 10 O
,	467 1 O
all	469 3 O
mice	473 4 O
received	478 8 O
lidocaine	487 9 B-Chemical
(	497 1 O
50	498 2 O
mg	501 2 O
/	503 1 O
kg	504 2 O
,	506 1 O
i	508 1 O
.	509 1 O
p	510 1 O
.	511 1 O
)	512 1 O
.	513 1 O

In	515 2 O
the	518 3 O
second	522 6 O
experiment	529 10 O
,	539 1 O
four	541 4 O
groups	546 6 O
of	553 2 O
mice	556 4 O
received	561 8 O
similar	570 7 O
treatment	578 9 O
in	588 2 O
the	591 3 O
first	595 5 O
experiment	601 10 O
,	611 1 O
and	613 3 O
30	617 2 O
min	620 3 O
after	624 5 O
these	630 5 O
injections	636 10 O
,	646 1 O
all	648 3 O
mice	652 4 O
received	657 8 O
a	666 1 O
higher	668 6 O
dose	675 4 O
of	680 2 O
lidocaine	683 9 B-Chemical
(	693 1 O
80	694 2 O
mg	697 2 O
/	699 1 O
kg	700 2 O
)	702 1 O
.	703 1 O

L	705 1 B-Chemical
-	706 1 I-Chemical
NAME	707 4 I-Chemical
(	712 1 O
100	713 3 O
mg	717 2 O
/	719 1 O
kg	720 2 O
,	722 1 O
i	724 1 O
.	725 1 O
p	726 1 O
.	727 1 O
)	728 1 O
and	730 3 O
diazepam	734 8 B-Chemical
(	743 1 O
2	744 1 O
mg	746 2 O
/	748 1 O
kg	749 2 O
)	751 1 O
significantly	753 13 O
decreased	767 9 O
the	777 3 O
incidence	781 9 O
of	791 2 O
lidocaine	794 9 B-Chemical
(	804 1 O
50	805 2 O
mg	808 2 O
/	810 1 O
kg	811 2 O
)	813 1 O
-	814 1 O
induced	815 7 O
convulsions	823 11 B-Disease
.	834 1 O

In	836 2 O
contrast	839 8 O
,	847 1 O
the	849 3 O
L	853 1 B-Chemical
-	854 1 I-Chemical
arginine	855 8 I-Chemical
treatment	864 9 O
increased	874 9 O
the	884 3 O
incidence	888 9 O
of	898 2 O
lidocaine	901 9 B-Chemical
(	911 1 O
80	912 2 O
mg	915 2 O
/	917 1 O
kg	918 2 O
,	920 1 O
i	922 1 O
.	923 1 O
p	924 1 O
.	925 1 O
)	926 1 O
-	927 1 O
induced	928 7 O
convulsions	936 11 B-Disease
significantly	948 13 O
.	961 1 O

These	963 5 O
results	969 7 O
may	977 3 O
suggest	981 7 O
that	989 4 O
NO	994 2 B-Chemical
is	997 2 O
a	1000 1 O
proconvulsant	1002 13 O
mediator	1016 8 O
in	1025 2 O
lidocaine	1028 9 B-Chemical
-	1037 1 O
induced	1038 7 O
convulsions	1046 11 B-Disease
.	1057 1 O

Effect	0 6 O
of	7 2 O
intravenous	10 11 O
metoprolol	22 10 B-Chemical
or	33 2 O
intravenous	36 11 O
metoprolol	48 10 B-Chemical
plus	59 4 O
glucagon	64 8 O
on	73 2 O
dobutamine	76 10 B-Chemical
-	86 1 O
induced	87 7 O
myocardial	95 10 B-Disease
ischemia	106 8 I-Disease
.	114 1 O

STUDY	116 5 O
OBJECTIVE	122 9 O
:	131 1 O
To	133 2 O
determine	136 9 O
the	146 3 O
effect	150 6 O
of	157 2 O
metoprolol	160 10 B-Chemical
on	171 2 O
dobutamine	174 10 B-Chemical
stress	185 6 O
testing	192 7 O
with	200 4 O
technetium	205 10 B-Chemical
-	215 1 I-Chemical
99m	216 3 I-Chemical
sestamibi	220 9 I-Chemical
single	230 6 O
-	236 1 O
photon	237 6 O
emission	244 8 O
computed	253 8 O
tomography	262 10 O
imaging	273 7 O
and	281 3 O
ST	285 2 O
-	287 1 O
segment	288 7 O
monitoring	296 10 O
,	306 1 O
and	308 3 O
to	312 2 O
assess	315 6 O
the	322 3 O
impact	326 6 O
of	333 2 O
intravenous	336 11 O
glucagon	348 8 O
on	357 2 O
metoprolol	360 10 B-Chemical
'	370 1 O
s	371 1 O
effects	373 7 O
.	380 1 O

DESIGN	382 6 O
:	388 1 O
Randomized	390 10 O
,	400 1 O
double	402 6 O
-	408 1 O
blind	409 5 O
,	414 1 O
placebo	416 7 O
-	423 1 O
controlled	424 10 O
trial	435 5 O
.	440 1 O

SETTING	442 7 O
:	449 1 O
Community	451 9 O
hospital	461 8 O
.	469 1 O

PATIENTS	471 8 O
:	479 1 O
Twenty	481 6 O
-	487 1 O
two	488 3 O
patients	492 8 O
with	501 4 O
known	506 5 O
reversible	512 10 O
perfusion	523 9 O
defects	533 7 O
.	540 1 O

INTERVENTION	542 12 O
:	554 1 O
Patients	556 8 O
underwent	565 9 O
dobutamine	575 10 B-Chemical
stress	586 6 O
tests	593 5 O
per	599 3 O
standard	603 8 O
protocol	612 8 O
.	620 1 O

Before	622 6 O
dobutamine	629 10 B-Chemical
was	640 3 O
begun	644 5 O
,	649 1 O
no	651 2 O
therapy	654 7 O
was	662 3 O
given	666 5 O
during	672 6 O
the	679 3 O
first	683 5 O
visit	689 5 O
,	694 1 O
and	696 3 O
patients	700 8 O
were	709 4 O
randomized	714 10 O
on	725 2 O
subsequent	728 10 O
visits	739 6 O
to	746 2 O
receive	749 7 O
metoprolol	757 10 B-Chemical
or	768 2 O
metoprolol	771 10 B-Chemical
plus	782 4 O
glucagon	787 8 O
1	796 1 O
mg	798 2 O
.	800 1 O

Metoprolol	802 10 B-Chemical
was	813 3 O
dosed	817 5 O
to	823 2 O
achieve	826 7 O
a	834 1 O
resting	836 7 O
predobutamine	844 13 B-Chemical
heart	858 5 O
rate	864 4 O
below	869 5 O
65	875 2 O
beats	878 5 O
/	883 1 O
minute	884 6 O
or	891 2 O
a	894 1 O
total	896 5 O
intravenous	902 11 O
dose	914 4 O
of	919 2 O
20	922 2 O
mg	925 2 O
.	927 1 O

MEASUREMENTS	929 12 O
AND	942 3 O
MAIN	946 4 O
RESULTS	951 7 O
:	958 1 O
Metoprolol	960 10 B-Chemical
reduced	971 7 O
maximum	979 7 O
heart	987 5 O
rate	993 4 O
31	998 2 O
%	1000 1 O
,	1001 1 O
summed	1003 6 O
stress	1010 6 O
scores	1017 6 O
29	1024 2 O
%	1026 1 O
,	1027 1 O
and	1029 3 O
summed	1033 6 O
difference	1040 10 O
scores	1051 6 O
43	1058 2 O
%	1060 1 O
versus	1062 6 O
control	1069 7 O
.	1076 1 O

Metoprolol	1078 10 B-Chemical
plus	1089 4 O
glucagon	1094 8 O
also	1103 4 O
reduced	1108 7 O
the	1116 3 O
maximum	1120 7 O
heart	1128 5 O
rate	1134 4 O
29	1139 2 O
%	1141 1 O
versus	1143 6 O
control	1150 7 O
.	1157 1 O

Summed	1159 6 O
stress	1166 6 O
and	1173 3 O
summed	1177 6 O
difference	1184 10 O
scores	1195 6 O
were	1202 4 O
not	1207 3 O
significantly	1211 13 O
reduced	1225 7 O
,	1232 1 O
although	1234 8 O
they	1243 4 O
were	1248 4 O
18	1253 2 O
%	1255 1 O
and	1257 3 O
30	1261 2 O
%	1263 1 O
lower	1265 5 O
,	1270 1 O
respectively	1272 12 O
,	1284 1 O
than	1286 4 O
control	1291 7 O
.	1298 1 O

No	1300 2 O
significant	1303 11 O
differences	1315 11 O
were	1327 4 O
found	1332 5 O
in	1338 2 O
any	1341 3 O
parameter	1345 9 O
between	1355 7 O
metoprolol	1363 10 B-Chemical
and	1374 3 O
metoprolol	1378 10 B-Chemical
-	1388 1 O
glucagon	1389 8 O
.	1397 1 O

CONCLUSION	1399 10 O
:	1409 1 O
During	1411 6 O
dobutamine	1418 10 B-Chemical
stress	1429 6 O
testing	1436 7 O
,	1443 1 O
metoprolol	1445 10 B-Chemical
attenuates	1456 10 O
or	1467 2 O
eliminates	1470 10 O
evidence	1481 8 O
of	1490 2 O
myocardial	1493 10 B-Disease
ischemia	1504 8 I-Disease
.	1512 1 O

Glucagon	1514 8 O
1	1523 1 O
mg	1525 2 O
,	1527 1 O
although	1529 8 O
somewhat	1538 8 O
effective	1547 9 O
,	1556 1 O
does	1558 4 O
not	1563 3 O
correct	1567 7 O
this	1575 4 O
effect	1580 6 O
to	1587 2 O
the	1590 3 O
extent	1594 6 O
that	1601 4 O
it	1606 2 O
can	1609 3 O
be	1613 2 O
administered	1616 12 O
clinically	1629 10 O
.	1639 1 O

Prednisolone	0 12 B-Chemical
-	12 1 O
induced	13 7 O
muscle	21 6 B-Disease
dysfunction	28 11 I-Disease
is	40 2 O
caused	43 6 O
more	50 4 O
by	55 2 O
atrophy	58 7 B-Disease
than	66 4 O
by	71 2 O
altered	74 7 O
acetylcholine	82 13 B-Chemical
receptor	96 8 O
expression	105 10 O
.	115 1 O

Large	117 5 O
doses	123 5 O
of	129 2 O
glucocorticoids	132 15 O
can	148 3 O
alter	152 5 O
muscle	158 6 O
physiology	165 10 O
and	176 3 O
susceptibility	180 14 O
to	195 2 O
neuromuscular	198 13 O
blocking	212 8 O
drugs	221 5 O
by	227 2 O
mechanisms	230 10 O
not	241 3 O
clearly	245 7 O
understood	253 10 O
.	263 1 O

We	265 2 O
investigated	268 12 O
the	281 3 O
effects	285 7 O
of	293 2 O
moderate	296 8 O
and	305 3 O
large	309 5 O
doses	315 5 O
of	321 2 O
prednisolone	324 12 B-Chemical
on	337 2 O
muscle	340 6 O
function	347 8 O
and	356 3 O
pharmacology	360 12 O
,	372 1 O
and	374 3 O
their	378 5 O
relationship	384 12 O
to	397 2 O
changes	400 7 O
in	408 2 O
muscle	411 6 O
size	418 4 O
and	423 3 O
acetylcholine	427 13 B-Chemical
receptor	441 8 O
(	450 1 O
AChR	451 4 O
)	455 1 O
expression	457 10 O
.	467 1 O

With	469 4 O
institutional	474 13 O
approval	488 8 O
,	496 1 O
35	498 2 O
Sprague	501 7 O
-	508 1 O
Dawley	509 6 O
rats	516 4 O
were	521 4 O
randomly	526 8 O
allocated	535 9 O
to	545 2 O
receive	548 7 O
daily	556 5 O
subcutaneous	562 12 O
doses	575 5 O
of	581 2 O
10	584 2 O
mg	587 2 O
/	589 1 O
kg	590 2 O
prednisolone	593 12 B-Chemical
(	606 1 O
P10	607 3 O
group	611 5 O
)	616 1 O
,	617 1 O
100	619 3 O
mg	623 2 O
/	625 1 O
kg	626 2 O
prednisolone	629 12 B-Chemical
(	642 1 O
P100	643 4 O
group	648 5 O
)	653 1 O
,	654 1 O
or	656 2 O
an	659 2 O
equal	662 5 O
volume	668 6 O
of	675 2 O
saline	678 6 O
(	685 1 O
S	686 1 O
group	688 5 O
)	693 1 O
for	695 3 O
7	699 1 O
days	701 4 O
.	705 1 O

A	707 1 O
fourth	709 6 O
group	716 5 O
of	722 2 O
rats	725 4 O
was	730 3 O
pair	734 4 O
fed	739 3 O
(	743 1 O
food	744 4 O
restricted	749 10 O
)	759 1 O
with	761 4 O
the	766 3 O
P100	770 4 O
rats	775 4 O
for	780 3 O
7	784 1 O
days	786 4 O
(	791 1 O
FR	792 2 O
group	795 5 O
)	800 1 O
.	801 1 O

On	803 2 O
Day	806 3 O
8	810 1 O
,	811 1 O
the	813 3 O
nerve	817 5 O
-	822 1 O
evoked	823 6 O
peak	830 4 O
twitch	835 6 O
tensions	842 8 O
,	850 1 O
tetanic	852 7 B-Disease
tensions	860 8 O
,	868 1 O
and	870 3 O
fatigability	874 12 O
,	886 1 O
and	888 3 O
the	892 3 O
dose	896 4 O
-	900 1 O
response	901 8 O
curves	910 6 O
of	917 2 O
d	920 1 B-Chemical
-	921 1 I-Chemical
tubocurarine	922 12 I-Chemical
in	935 2 O
the	938 3 O
tibialis	942 8 O
cranialis	951 9 O
muscle	961 6 O
were	968 4 O
measured	973 8 O
in	982 2 O
vivo	985 4 O
and	990 3 O
related	994 7 O
to	1002 2 O
muscle	1005 6 O
mass	1012 4 O
or	1017 2 O
expression	1020 10 O
of	1031 2 O
AChRs	1034 5 O
.	1039 1 O

Rate	1041 4 O
of	1046 2 O
body	1049 4 O
weight	1054 6 O
gain	1061 4 O
was	1066 3 O
depressed	1070 9 O
in	1080 2 O
the	1083 3 O
P100	1087 4 O
,	1091 1 O
FR	1093 2 O
,	1095 1 O
and	1097 3 O
P10	1101 3 O
groups	1105 6 O
compared	1112 8 O
with	1121 4 O
the	1126 3 O
S	1130 1 O
group	1132 5 O
.	1137 1 O

Tibialis	1139 8 O
muscle	1148 6 O
mass	1155 4 O
was	1160 3 O
smaller	1164 7 O
in	1172 2 O
the	1175 3 O
P100	1179 4 O
group	1184 5 O
than	1190 4 O
in	1195 2 O
the	1198 3 O
P10	1202 3 O
or	1206 2 O
S	1209 1 O
groups	1211 6 O
.	1217 1 O

The	1219 3 O
evoked	1223 6 O
peak	1230 4 O
twitch	1235 6 O
and	1242 3 O
tetanic	1246 7 B-Disease
tensions	1254 8 O
were	1263 4 O
less	1268 4 O
in	1273 2 O
the	1276 3 O
P100	1280 4 O
group	1285 5 O
than	1291 4 O
in	1296 2 O
the	1299 3 O
P10	1303 3 O
or	1307 2 O
S	1310 1 O
groups	1312 6 O
,	1318 1 O
however	1320 7 O
,	1327 1 O
tension	1329 7 O
per	1337 3 O
milligram	1341 9 O
of	1351 2 O
muscle	1354 6 O
mass	1361 4 O
was	1366 3 O
greater	1370 7 O
in	1378 2 O
the	1381 3 O
P100	1385 4 O
group	1390 5 O
than	1396 4 O
in	1401 2 O
the	1404 3 O
S	1408 1 O
group	1410 5 O
.	1415 1 O

The	1417 3 O
50	1421 2 O
%	1423 1 O
effective	1425 9 O
dose	1435 4 O
of	1440 2 O
d	1443 1 B-Chemical
-	1444 1 I-Chemical
tubocurarine	1445 12 I-Chemical
(	1458 1 O
microg	1459 6 O
/	1465 1 O
kg	1466 2 O
)	1468 1 O
in	1470 2 O
the	1473 3 O
tibialis	1477 8 O
muscle	1486 6 O
was	1493 3 O
smaller	1497 7 O
in	1505 2 O
the	1508 3 O
P10	1512 3 O
(	1516 1 O
33	1517 2 O
.	1519 1 O
6	1520 1 O
+	1522 1 O
/	1523 1 O
-	1524 1 O
5	1526 1 O
.	1527 1 O
4	1528 1 O
)	1529 1 O
than	1531 4 O
in	1536 2 O
the	1539 3 O
S	1543 1 O
(	1545 1 O
61	1546 2 O
.	1548 1 O
9	1549 1 O
+	1551 1 O
/	1552 1 O
-	1553 1 O
5	1555 1 O
.	1556 1 O
0	1557 1 O
)	1558 1 O
or	1560 2 O
the	1563 3 O
P100	1567 4 O
(	1572 1 O
71	1573 2 O
.	1575 1 O
3	1576 1 O
+	1578 1 O
/	1579 1 O
-	1580 1 O
9	1582 1 O
.	1583 1 O
6	1584 1 O
)	1585 1 O
groups	1587 6 O
.	1593 1 O

AChR	1595 4 O
expression	1600 10 O
was	1611 3 O
less	1615 4 O
in	1620 2 O
the	1623 3 O
P10	1627 3 O
group	1631 5 O
than	1637 4 O
in	1642 2 O
the	1645 3 O
S	1649 1 O
group	1651 5 O
.	1656 1 O

The	1658 3 O
evoked	1662 6 O
tensions	1669 8 O
correlated	1678 10 O
with	1689 4 O
muscle	1694 6 O
mass	1701 4 O
(	1706 1 O
r	1707 1 O
(	1708 1 O
2	1709 1 O
)	1710 1 O
=	1712 1 O
0	1714 1 O
.	1715 1 O
32	1716 2 O
,	1718 1 O
P	1720 1 O
<	1722 1 O
0	1724 1 O
.	1725 1 O
001	1726 3 O
)	1729 1 O
,	1730 1 O
however	1732 7 O
,	1739 1 O
not	1741 3 O
with	1745 4 O
expression	1750 10 O
of	1761 2 O
AChR	1764 4 O
.	1768 1 O

The	1770 3 O
50	1774 2 O
%	1776 1 O
effective	1778 9 O
dose	1788 4 O
of	1793 2 O
d	1796 1 B-Chemical
-	1797 1 I-Chemical
tubocurarine	1798 12 I-Chemical
did	1811 3 O
not	1815 3 O
correlate	1819 9 O
with	1829 4 O
muscle	1834 6 O
mass	1841 4 O
or	1846 2 O
AChR	1849 4 O
expression	1854 10 O
.	1864 1 O

Our	1866 3 O
results	1870 7 O
suggest	1878 7 O
that	1886 4 O
the	1891 3 O
neuromuscular	1895 13 B-Disease
dysfunction	1909 11 I-Disease
after	1921 5 O
prednisolone	1927 12 B-Chemical
is	1940 2 O
dose	1943 4 O
-	1947 1 O
dependent	1948 9 O
,	1957 1 O
and	1959 3 O
derives	1963 7 O
primarily	1971 9 O
from	1981 4 O
muscle	1986 6 B-Disease
atrophy	1993 7 I-Disease
and	2001 3 O
derives	2005 7 O
less	2013 4 O
so	2018 2 O
from	2021 4 O
changes	2026 7 O
in	2034 2 O
AChR	2037 4 O
expression	2042 10 O
.	2052 1 O

IMPLICATIONS	2054 12 O
:	2066 1 O
The	2068 3 O
mechanisms	2072 10 O
by	2083 2 O
which	2086 5 O
chronic	2092 7 O
glucocorticoid	2100 14 O
therapy	2115 7 O
alters	2123 6 O
neuromuscular	2130 13 O
physiology	2144 10 O
and	2155 3 O
pharmacology	2159 12 O
are	2172 3 O
unclear	2176 7 O
.	2183 1 O

We	2185 2 O
suggest	2188 7 O
that	2196 4 O
the	2201 3 O
observed	2205 8 O
effects	2214 7 O
are	2222 3 O
dose	2226 4 O
-	2230 1 O
dependent	2231 9 O
and	2241 3 O
derive	2245 6 O
primarily	2252 9 O
from	2262 4 O
muscle	2267 6 B-Disease
atrophy	2274 7 I-Disease
and	2282 3 O
derive	2286 6 O
less	2293 4 O
from	2298 4 O
changes	2303 7 O
in	2311 2 O
acetylcholine	2314 13 B-Chemical
receptor	2328 8 O
expression	2337 10 O
.	2347 1 O

Rapid	0 5 O
reversal	6 8 O
of	15 2 O
life	18 4 O
-	22 1 O
threatening	23 11 O
diltiazem	35 9 B-Chemical
-	44 1 O
induced	45 7 O
tetany	53 6 B-Disease
with	60 4 O
calcium	65 7 B-Chemical
chloride	73 8 I-Chemical
.	81 1 O

We	83 2 O
describe	86 8 O
a	95 1 O
patient	97 7 O
who	105 3 O
developed	109 9 O
tetany	119 6 B-Disease
with	126 4 O
sudden	131 6 O
respiratory	138 11 B-Disease
arrest	150 6 I-Disease
after	157 5 O
the	163 3 O
infusion	167 8 O
of	176 2 O
intravenous	179 11 O
diltiazem	191 9 B-Chemical
.	200 1 O

The	202 3 O
administration	206 14 O
of	221 2 O
calcium	224 7 B-Chemical
chloride	232 8 I-Chemical
rapidly	241 7 O
resolved	249 8 O
the	258 3 O
patient	262 7 O
'	269 1 O
s	270 1 O
tetany	272 6 B-Disease
with	279 4 O
prompt	284 6 O
recovery	291 8 O
of	300 2 O
respiratory	303 11 O
function	315 8 O
,	323 1 O
averting	325 8 O
the	334 3 O
need	338 4 O
for	343 3 O
more	347 4 O
aggressive	352 10 O
airway	363 6 O
management	370 10 O
and	381 3 O
ventilatory	385 11 O
support	397 7 O
.	404 1 O

The	406 3 O
emergency	410 9 O
physician	420 9 O
should	430 6 O
be	437 2 O
aware	440 5 O
that	446 4 O
life	451 4 O
-	455 1 O
threatening	456 11 O
tetany	468 6 B-Disease
may	475 3 O
accompany	479 9 O
the	489 3 O
administration	493 14 O
of	508 2 O
intravenous	511 11 O
diltiazem	523 9 B-Chemical
and	533 3 O
that	537 4 O
calcium	542 7 B-Chemical
chloride	550 8 I-Chemical
may	559 3 O
be	563 2 O
a	566 1 O
rapid	568 5 O
and	574 3 O
effective	578 9 O
remedy	588 6 O
.	594 1 O

Effects	0 7 O
of	8 2 O
nonsteroidal	11 12 O
anti	24 4 O
-	28 1 O
inflammatory	29 12 O
drugs	42 5 O
on	48 2 O
hemostasis	51 10 O
in	62 2 O
patients	65 8 O
with	74 4 O
aneurysmal	79 10 B-Disease
subarachnoid	90 12 I-Disease
hemorrhage	103 10 I-Disease
.	113 1 O

Platelet	115 8 O
function	124 8 O
is	133 2 O
impaired	136 8 O
by	145 2 O
nonsteroidal	148 12 O
anti	161 4 O
-	165 1 O
inflammatory	166 12 O
drugs	179 5 O
(	185 1 O
NSAIDs	186 6 O
)	192 1 O
with	194 4 O
prominent	199 9 O
anti	209 4 O
-	213 1 O
inflammatory	214 12 O
properties	227 10 O
.	237 1 O

Their	239 5 O
safety	245 6 O
in	252 2 O
patients	255 8 O
undergoing	264 10 O
intracranial	275 12 O
surgery	288 7 O
is	296 2 O
under	299 5 O
debate	305 6 O
.	311 1 O

Patients	313 8 O
with	322 4 O
aneurysmal	327 10 B-Disease
subarachnoid	338 12 I-Disease
hemorrhage	351 10 I-Disease
(	362 1 O
SAH	363 3 B-Disease
)	366 1 O
were	368 4 O
randomized	373 10 O
to	384 2 O
receive	387 7 O
either	395 6 O
ketoprofen	402 10 B-Chemical
,	412 1 O
100	414 3 O
mg	418 2 O
,	420 1 O
three	422 5 O
times	428 5 O
a	434 1 O
day	436 3 O
(	440 1 O
ketoprofen	441 10 B-Chemical
group	452 5 O
,	457 1 O
n	459 1 O
=	461 1 O
9	463 1 O
)	464 1 O
or	466 2 O
a	469 1 O
weak	471 4 O
NSAID	476 5 O
,	481 1 O
acetaminophen	483 13 B-Chemical
,	496 1 O
1	498 1 O
g	500 1 O
,	501 1 O
three	503 5 O
times	509 5 O
a	515 1 O
day	517 3 O
(	521 1 O
acetaminophen	522 13 B-Chemical
group	536 5 O
,	541 1 O
n	543 1 O
=	545 1 O
9	547 1 O
)	548 1 O
starting	550 8 O
immediately	559 11 O
after	571 5 O
the	577 3 O
diagnosis	581 9 O
of	591 2 O
aneurysmal	594 10 B-Disease
SAH	605 3 B-Disease
.	608 1 O

Treatment	610 9 O
was	620 3 O
continued	624 9 O
for	634 3 O
3	638 1 O
days	640 4 O
postoperatively	645 15 O
.	660 1 O

Test	662 4 O
blood	667 5 O
samples	673 7 O
were	681 4 O
taken	686 5 O
before	692 6 O
treatment	699 9 O
and	709 3 O
surgery	713 7 O
as	721 2 O
well	724 4 O
as	729 2 O
on	732 2 O
the	735 3 O
first	739 5 O
,	744 1 O
third	746 5 O
,	751 1 O
and	753 3 O
fifth	757 5 O
postoperative	763 13 O
mornings	777 8 O
.	785 1 O

Maximal	787 7 O
platelet	795 8 B-Disease
aggregation	804 11 I-Disease
induced	816 7 O
by	824 2 O
6	827 1 O
microM	829 6 O
of	836 2 O
adenosine	839 9 B-Chemical
diphosphate	849 11 I-Chemical
decreased	861 9 O
after	871 5 O
administration	877 14 O
of	892 2 O
ketoprofen	895 10 B-Chemical
.	905 1 O

Aggregation	907 11 O
was	919 3 O
lower	923 5 O
(	929 1 O
P	930 1 O
<	932 1 O
.	934 1 O
05	935 2 O
)	937 1 O
in	939 2 O
the	942 3 O
ketoprofen	946 10 B-Chemical
group	957 5 O
than	963 4 O
in	968 2 O
the	971 3 O
acetaminophen	975 13 B-Chemical
group	989 5 O
just	995 4 O
before	1000 6 O
surgery	1007 7 O
and	1015 3 O
on	1019 2 O
the	1022 3 O
third	1026 5 O
postoperative	1032 13 O
day	1046 3 O
.	1049 1 O

In	1051 2 O
contrast	1054 8 O
,	1062 1 O
maximal	1064 7 O
platelet	1072 8 B-Disease
aggregation	1081 11 I-Disease
increased	1093 9 O
in	1103 2 O
the	1106 3 O
acetaminophen	1110 13 B-Chemical
group	1124 5 O
on	1130 2 O
the	1133 3 O
third	1137 5 O
postoperative	1143 13 O
day	1157 3 O
as	1161 2 O
compared	1164 8 O
with	1173 4 O
the	1178 3 O
pretreatment	1182 12 O
platelet	1195 8 B-Disease
aggregation	1204 11 I-Disease
results	1216 7 O
(	1224 1 O
P	1225 1 O
<	1227 1 O
.	1229 1 O
05	1230 2 O
)	1232 1 O
.	1233 1 O

One	1235 3 O
patient	1239 7 O
in	1247 2 O
the	1250 3 O
ketoprofen	1254 10 B-Chemical
group	1265 5 O
developed	1271 9 O
a	1281 1 O
postoperative	1283 13 O
intracranial	1297 12 O
hematoma	1310 8 B-Disease
.	1318 1 O

Coagulation	1320 11 O
(	1332 1 O
prothrombin	1333 11 O
time	1345 4 O
[	1350 1 O
PT	1351 2 O
]	1353 1 O
,	1354 1 O
activated	1356 9 O
partial	1366 7 O
thromboplastin	1374 14 O
time	1389 4 O
[	1394 1 O
APPT	1395 4 O
]	1399 1 O
,	1400 1 O
fibrinogen	1402 10 O
concentration	1413 13 O
,	1426 1 O
and	1428 3 O
antithrombin	1432 12 O
III	1445 3 O
[	1449 1 O
AT	1450 2 O
III	1453 3 O
]	1456 1 O
)	1457 1 O
was	1459 3 O
comparable	1463 10 O
between	1474 7 O
the	1482 3 O
two	1486 3 O
groups	1490 6 O
.	1496 1 O

Ketoprofen	1498 10 B-Chemical
but	1509 3 O
not	1513 3 O
acetaminophen	1517 13 B-Chemical
impaired	1531 8 O
platelet	1540 8 O
function	1549 8 O
in	1558 2 O
patients	1561 8 O
with	1570 4 O
SAH	1575 3 B-Disease
.	1578 1 O

If	1580 2 O
ketoprofen	1583 10 B-Chemical
is	1594 2 O
used	1597 4 O
before	1602 6 O
surgery	1609 7 O
on	1617 2 O
cerebral	1620 8 O
artery	1629 6 B-Disease
aneurysms	1636 9 I-Disease
,	1645 1 O
it	1647 2 O
may	1650 3 O
pose	1654 4 O
an	1659 2 O
additional	1662 10 O
risk	1673 4 O
factor	1678 6 O
for	1685 3 O
hemorrhage	1689 10 B-Disease
.	1699 1 O

Value	0 5 O
of	6 2 O
methylprednisolone	9 18 B-Chemical
in	28 2 O
prevention	31 10 O
of	42 2 O
the	45 3 O
arthralgia	49 10 B-Disease
-	59 1 O
myalgia	60 7 B-Disease
syndrome	68 8 O
associated	77 10 O
with	88 4 O
the	93 3 O
total	97 5 O
dose	103 4 O
infusion	108 8 O
of	117 2 O
iron	120 4 B-Chemical
dextran	125 7 I-Chemical
:	132 1 O
a	134 1 O
double	136 6 O
blind	143 5 O
randomized	149 10 O
trial	160 5 O
.	165 1 O

The	167 3 O
safety	171 6 O
and	178 3 O
efficacy	182 8 O
of	191 2 O
total	194 5 O
dose	200 4 O
infusion	205 8 O
(	214 1 O
TDI	215 3 O
)	218 1 O
of	220 2 O
iron	223 4 B-Chemical
dextran	228 7 I-Chemical
has	236 3 O
been	240 4 O
well	245 4 O
documented	250 10 O
.	260 1 O

In	262 2 O
40	265 2 O
%	267 1 O
of	269 2 O
treated	272 7 O
patients	280 8 O
,	288 1 O
an	290 2 O
arthralgia	293 10 B-Disease
-	303 1 O
myalgia	304 7 B-Disease
syndrome	312 8 O
develops	321 8 O
.	329 1 O

The	331 3 O
purpose	335 7 O
of	343 2 O
this	346 4 O
randomized	351 10 O
,	361 1 O
double	363 6 O
-	369 1 O
blind	370 5 O
,	375 1 O
prospective	377 11 O
study	389 5 O
was	395 3 O
to	399 2 O
investigate	402 11 O
whether	414 7 O
intravenous	422 11 O
(	434 1 O
i	435 1 O
.	436 1 O
v	437 1 O
.	438 1 O
)	439 1 O
administration	441 14 O
of	456 2 O
methylprednisolone	459 18 B-Chemical
(	478 1 O
MP	479 2 B-Chemical
)	481 1 O
prevents	483 8 O
this	492 4 O
complication	497 12 O
.	509 1 O

Sixty	511 5 O
-	516 1 O
five	517 4 O
patients	522 8 O
,	530 1 O
34	532 2 O
women	535 5 O
and	541 3 O
31	545 2 O
men	548 3 O
,	551 1 O
ages	553 4 O
36	558 2 O
to	561 2 O
80	564 2 O
years	567 5 O
,	572 1 O
received	574 8 O
either	583 6 O
normal	590 6 O
saline	597 6 O
before	604 6 O
and	611 3 O
after	615 5 O
TDI	621 3 O
(	625 1 O
group	626 5 O
1	632 1 O
)	633 1 O
,	634 1 O
125	636 3 O
mg	640 2 O
i	643 1 O
.	644 1 O
v	645 1 O
.	646 1 O
MP	648 2 B-Chemical
before	651 6 O
and	658 3 O
saline	662 6 O
after	669 5 O
TDI	675 3 O
(	679 1 O
group	680 5 O
2	686 1 O
)	687 1 O
,	688 1 O
or	690 2 O
125	693 3 O
mg	697 2 O
i	700 1 O
.	701 1 O
v	702 1 O
.	703 1 O
MP	705 2 B-Chemical
before	708 6 O
and	715 3 O
after	719 5 O
TDI	725 3 O
(	729 1 O
group	730 5 O
3	736 1 O
)	737 1 O
.	738 1 O

Patients	740 8 O
were	749 4 O
observed	754 8 O
for	763 3 O
72	767 2 O
hours	770 5 O
and	776 3 O
reactions	780 9 O
were	790 4 O
recorded	795 8 O
and	804 3 O
graded	808 6 O
according	815 9 O
to	825 2 O
severity	828 8 O
.	836 1 O

Fifty	838 5 O
-	843 1 O
eight	844 5 O
percent	850 7 O
of	858 2 O
group	861 5 O
1	867 1 O
patients	869 8 O
,	877 1 O
33	879 2 O
%	881 1 O
of	883 2 O
group	886 5 O
2	892 1 O
,	893 1 O
and	895 3 O
26	899 2 O
%	901 1 O
of	903 2 O
group	906 5 O
3	912 1 O
had	914 3 O
reactions	918 9 O
to	928 2 O
TDI	931 3 O
.	934 1 O

The	936 3 O
severity	940 8 O
of	949 2 O
reactions	952 9 O
(	962 1 O
minimal	963 7 O
,	970 1 O
mild	972 4 O
,	976 1 O
and	978 3 O
moderate	982 8 O
,	990 1 O
respectively	992 12 O
)	1004 1 O
was	1006 3 O
as	1010 2 O
follows	1013 7 O
:	1020 1 O
group	1022 5 O
1	1028 1 O
-	1029 1 O
-	1030 1 O
6	1031 1 O
,	1032 1 O
6	1034 1 O
,	1035 1 O
and	1037 3 O
2	1041 1 O
;	1042 1 O
group	1044 5 O
2	1050 1 O
-	1051 1 O
-	1052 1 O
1	1053 1 O
,	1054 1 O
5	1056 1 O
,	1057 1 O
and	1059 3 O
0	1063 1 O
;	1064 1 O
group	1066 5 O
3	1072 1 O
-	1073 1 O
-	1074 1 O
5	1075 1 O
,	1076 1 O
1	1078 1 O
,	1079 1 O
and	1081 3 O
0	1085 1 O
.	1086 1 O

Data	1088 4 O
were	1093 4 O
analyzed	1098 8 O
by	1107 2 O
the	1110 3 O
two	1114 3 O
-	1117 1 O
sided	1118 5 O
Fisher	1124 6 O
'	1130 1 O
s	1131 1 O
exact	1133 5 O
test	1139 4 O
using	1144 5 O
95	1150 2 O
%	1152 1 O
confidence	1154 10 O
intervals	1165 9 O
with	1175 4 O
the	1180 3 O
approximation	1184 13 O
of	1198 2 O
Woolf	1201 5 O
.	1206 1 O

These	1208 5 O
data	1214 4 O
demonstrate	1219 11 O
that	1231 4 O
administration	1236 14 O
of	1251 2 O
MP	1254 2 B-Chemical
before	1257 6 O
and	1264 3 O
after	1268 5 O
TDI	1274 3 O
reduces	1278 7 O
the	1286 3 O
frequency	1290 9 O
and	1300 3 O
severity	1304 8 O
of	1313 2 O
the	1316 3 O
arthralgia	1320 10 B-Disease
-	1330 1 O
myalgia	1331 7 B-Disease
syndrome	1339 8 O
.	1347 1 O

We	1349 2 O
conclude	1352 8 O
that	1361 4 O
125	1366 3 O
mg	1370 2 O
i	1373 1 O
.	1374 1 O
v	1375 1 O
.	1376 1 O
MP	1378 2 B-Chemical
should	1381 6 O
be	1388 2 O
given	1391 5 O
routinely	1397 9 O
before	1407 6 O
and	1414 3 O
after	1418 5 O
TDI	1424 3 O
of	1428 2 O
iron	1431 4 B-Chemical
dextran	1436 7 I-Chemical
.	1443 1 O

Long	0 4 O
-	4 1 O
term	5 4 O
effects	10 7 O
of	18 2 O
vincristine	21 11 B-Chemical
on	33 2 O
the	36 3 O
peripheral	40 10 O
nervous	51 7 O
system	59 6 O
.	65 1 O

Forty	67 5 O
patients	73 8 O
with	82 4 O
Non	87 3 B-Disease
-	90 1 I-Disease
Hodgkin	91 7 I-Disease
'	98 1 I-Disease
s	99 1 I-Disease
Lymphoma	101 8 I-Disease
treated	110 7 O
with	118 4 O
vincristine	123 11 B-Chemical
between	135 7 O
1984	143 4 O
and	148 3 O
1990	152 4 O
(	157 1 O
cumulative	158 10 O
dose	169 4 O
12	174 2 O
mg	177 2 O
in	180 2 O
18	183 2 O
-	185 1 O
24	186 2 O
weeks	189 5 O
)	194 1 O
were	196 4 O
investigated	201 12 O
in	214 2 O
order	217 5 O
to	223 2 O
evaluate	226 8 O
the	235 3 O
long	239 4 O
term	244 4 O
effects	249 7 O
of	257 2 O
vincristine	260 11 B-Chemical
on	272 2 O
the	275 3 O
peripheral	279 10 O
nervous	290 7 O
system	298 6 O
.	304 1 O

The	306 3 O
patients	310 8 O
were	319 4 O
interviewed	324 11 O
with	336 4 O
emphasis	341 8 O
on	350 2 O
neuropathic	353 11 B-Disease
symptoms	365 8 I-Disease
.	373 1 O

Physical	375 8 O
and	384 3 O
quantitative	388 12 O
sensory	401 7 O
examination	409 11 O
with	421 4 O
determination	426 13 O
of	440 2 O
vibratory	443 9 O
perception	453 10 O
and	464 3 O
thermal	468 7 O
discrimination	476 14 O
thresholds	491 10 O
were	502 4 O
performed	507 9 O
,	516 1 O
four	518 4 O
to	523 2 O
77	526 2 O
months	529 6 O
(	536 1 O
median	537 6 O
34	544 2 O
months	547 6 O
)	553 1 O
after	555 5 O
vincristine	561 11 B-Chemical
treatment	573 9 O
.	582 1 O

Twenty	584 6 O
-	590 1 O
seven	591 5 O
patients	597 8 O
reported	606 8 O
neuropathic	615 11 B-Disease
symptoms	627 8 I-Disease
.	635 1 O

In	637 2 O
13	640 2 O
of	643 2 O
these	646 5 O
27	652 2 O
patients	655 8 O
symptoms	664 8 O
were	673 4 O
still	678 5 O
present	684 7 O
at	692 2 O
the	695 3 O
time	699 4 O
of	704 2 O
examination	707 11 O
.	718 1 O

In	720 2 O
these	723 5 O
patients	729 8 O
sensory	738 7 O
signs	746 5 O
and	752 3 O
symptoms	756 8 O
predominated	765 12 O
.	777 1 O

In	779 2 O
the	782 3 O
other	786 5 O
14	792 2 O
patients	795 8 O
symptoms	804 8 O
had	813 3 O
been	817 4 O
present	822 7 O
in	830 2 O
the	833 3 O
past	837 4 O
.	841 1 O

Symptoms	843 8 O
persisted	852 9 O
maximally	862 9 O
40	872 2 O
months	875 6 O
since	882 5 O
cessation	888 9 O
of	898 2 O
therapy	901 7 O
.	908 1 O

There	910 5 O
was	916 3 O
no	920 2 O
age	923 3 O
difference	927 10 O
between	938 7 O
patients	946 8 O
with	955 4 O
and	960 3 O
without	964 7 O
complaints	972 10 O
at	983 2 O
the	986 3 O
time	990 4 O
of	995 2 O
examination	998 11 O
.	1009 1 O

Normal	1011 6 O
reflexes	1018 8 O
were	1027 4 O
found	1032 5 O
in	1038 2 O
two	1041 3 O
third	1045 5 O
of	1051 2 O
patients	1054 8 O
.	1062 1 O

Neuropathic	1064 11 O
complaints	1076 10 O
were	1087 4 O
not	1092 3 O
very	1096 4 O
troublesome	1101 11 O
on	1113 2 O
the	1116 3 O
long	1120 4 O
term	1125 4 O
.	1129 1 O

It	1131 2 O
is	1134 2 O
concluded	1137 9 O
that	1147 4 O
with	1152 4 O
the	1157 3 O
above	1161 5 O
mentioned	1167 9 O
vincristine	1177 11 B-Chemical
dose	1189 4 O
schedule	1194 8 O
signs	1203 5 O
and	1209 3 O
symptoms	1213 8 O
of	1222 2 O
vincristine	1225 11 B-Chemical
neuropathy	1237 10 B-Disease
are	1248 3 O
reversible	1252 10 O
for	1263 3 O
a	1267 1 O
great	1269 5 O
deal	1275 4 O
and	1280 3 O
prognosis	1284 9 O
is	1294 2 O
fairly	1297 6 O
good	1304 4 O
.	1308 1 O

A	0 1 O
case	2 4 O
of	7 2 O
polymyositis	10 12 B-Disease
in	23 2 O
a	26 1 O
patient	28 7 O
with	36 4 O
primary	41 7 B-Disease
biliary	49 7 I-Disease
cirrhosis	57 9 I-Disease
treated	67 7 O
with	75 4 O
D	80 1 B-Chemical
-	81 1 I-Chemical
penicillamine	82 13 I-Chemical
.	95 1 O

Although	97 8 O
D	106 1 B-Chemical
-	107 1 I-Chemical
penicillamine	108 13 I-Chemical
has	122 3 O
been	126 4 O
used	131 4 O
for	136 3 O
many	140 4 O
rheumatologic	145 13 B-Disease
diseases	159 8 I-Disease
,	167 1 O
toxicity	169 8 B-Disease
limits	178 6 O
its	185 3 O
usefulness	189 10 O
in	200 2 O
many	203 4 O
patients	208 8 O
.	216 1 O

Polymyositis	218 12 B-Disease
/	230 1 O
dermatomyositis	231 15 B-Disease
can	247 3 O
develop	251 7 O
as	259 2 O
one	262 3 O
of	266 2 O
the	269 3 O
autoimmune	273 10 O
complications	284 13 O
of	298 2 O
D	301 1 B-Chemical
-	302 1 I-Chemical
penicillamine	303 13 I-Chemical
treatment	317 9 O
,	326 1 O
but	328 3 O
its	332 3 O
exact	336 5 O
pathogenesis	342 12 O
remains	355 7 O
unclear	363 7 O
.	370 1 O

We	372 2 O
report	375 6 O
a	382 1 O
patient	384 7 O
with	392 4 O
primary	397 7 B-Disease
biliary	405 7 I-Disease
cirrhosis	413 9 I-Disease
,	422 1 O
who	424 3 O
developed	428 9 O
polymyositis	438 12 B-Disease
while	451 5 O
receiving	457 9 O
D	467 1 B-Chemical
-	468 1 I-Chemical
penicillamine	469 13 I-Chemical
therapy	483 7 O
.	490 1 O

We	492 2 O
described	495 9 O
the	505 3 O
special	509 7 O
clinical	517 8 O
course	526 6 O
of	533 2 O
the	536 3 O
patient	540 7 O
.	547 1 O

Patients	549 8 O
receiving	558 9 O
D	568 1 B-Chemical
-	569 1 I-Chemical
penicillamine	570 13 I-Chemical
therapy	584 7 O
should	592 6 O
be	599 2 O
followed	602 8 O
carefully	611 9 O
for	621 3 O
the	625 3 O
development	629 11 O
of	641 2 O
autoimmune	644 10 O
complications	655 13 O
like	669 4 O
polymyositis	674 12 B-Disease
/	686 1 O
dermatomyositis	687 15 B-Disease
.	702 1 O

Photodistributed	0 16 O
nifedipine	17 10 B-Chemical
-	27 1 O
induced	28 7 O
facial	36 6 O
telangiectasia	43 14 B-Disease
.	57 1 O

Five	59 4 O
months	64 6 O
after	71 5 O
starting	77 8 O
nifedipine	86 10 B-Chemical
(	97 1 O
Adalat	98 6 B-Chemical
)	104 1 O
,	105 1 O
two	107 3 O
patients	111 8 O
developed	120 9 O
photodistributed	130 16 O
facial	147 6 O
telangiectasia	154 14 B-Disease
,	168 1 O
which	170 5 O
became	176 6 O
more	183 4 O
noticeable	188 10 O
with	199 4 O
time	204 4 O
.	208 1 O

Neither	210 7 O
patient	218 7 O
complained	226 10 O
of	237 2 O
photosensitivity	240 16 O
or	257 2 O
flushing	260 8 B-Disease
.	268 1 O

Both	270 4 O
patients	275 8 O
reported	284 8 O
a	293 1 O
significant	295 11 O
cosmetic	307 8 O
improvement	316 11 O
after	328 5 O
discontinuing	334 13 O
the	348 3 O
drug	352 4 O
.	356 1 O

One	358 3 O
commenced	362 9 O
the	372 3 O
closely	376 7 O
related	384 7 O
drug	392 4 O
amlodipine	397 10 B-Chemical
3	408 1 O
years	410 5 O
later	416 5 O
,	421 1 O
with	423 4 O
recurrence	428 10 O
of	439 2 O
telangiectasia	442 14 B-Disease
.	456 1 O

The	458 3 O
photodistribution	462 17 O
of	480 2 O
the	483 3 O
telangiectasia	487 14 B-Disease
suggests	502 8 O
a	511 1 O
significant	513 11 O
drug	525 4 O
/	529 1 O
light	530 5 O
interaction	536 11 O
.	547 1 O

Nephrotoxicity	0 14 B-Disease
of	15 2 O
cyclosporin	18 11 B-Chemical
A	30 1 I-Chemical
and	32 3 O
FK506	36 5 B-Chemical
:	41 1 O
inhibition	43 10 O
of	54 2 O
calcineurin	57 11 O
phosphatase	69 11 O
.	80 1 O

Cyclosporin	82 11 B-Chemical
A	94 1 I-Chemical
(	96 1 O
CsA	97 3 B-Chemical
;	100 1 O
50	102 2 O
mg	105 2 O
/	107 1 O
kg	108 2 O
)	110 1 O
and	112 3 O
Fujimycine	116 10 B-Chemical
(	127 1 O
FK506	128 5 B-Chemical
;	133 1 O
5	135 1 O
mg	137 2 O
/	139 1 O
kg	140 2 O
)	142 1 O
,	143 1 O
but	145 3 O
not	149 3 O
the	153 3 O
related	157 7 O
macrolide	165 9 B-Chemical
immunosuppressant	175 17 O
rapamycin	193 9 B-Chemical
(	203 1 O
5	204 1 O
mg	206 2 O
/	208 1 O
kg	209 2 O
)	211 1 O
,	212 1 O
caused	214 6 O
a	221 1 O
reduction	223 9 O
of	233 2 O
glomerular	236 10 O
filtration	247 10 O
rate	258 4 O
,	262 1 O
degenerative	264 12 O
changes	277 7 O
of	285 2 O
proximal	288 8 O
tubular	297 7 O
epithelium	305 10 O
,	315 1 O
and	317 3 O
hypertrophy	321 11 B-Disease
of	333 2 O
the	336 3 O
juxtaglomerular	340 15 O
apparatus	356 9 O
in	366 2 O
male	369 4 O
Wistar	374 6 O
rats	381 4 O
when	386 4 O
given	391 5 O
for	397 3 O
10	401 2 O
days	404 4 O
.	408 1 O

The	410 3 O
molecular	414 9 O
mechanisms	424 10 O
of	435 2 O
CsA	438 3 B-Chemical
and	442 3 O
FK506	446 5 B-Chemical
toxicity	452 8 B-Disease
were	461 4 O
investigated	466 12 O
.	478 1 O

Cyclophilin	480 11 O
A	492 1 O
and	494 3 O
FK506	498 5 B-Chemical
-	503 1 O
binding	504 7 O
protein	512 7 O
,	519 1 O
the	521 3 O
main	525 4 O
intracytoplasmic	530 16 O
receptors	547 9 O
for	557 3 O
CsA	561 3 B-Chemical
and	565 3 O
FK506	569 5 B-Chemical
,	574 1 O
respectively	576 12 O
,	588 1 O
were	590 4 O
each	595 4 O
detected	600 8 O
in	609 2 O
renal	612 5 O
tissue	618 6 O
extract	625 7 O
.	632 1 O

In	634 2 O
the	637 3 O
kidney	641 6 O
,	647 1 O
high	649 4 O
levels	654 6 O
of	661 2 O
immunoreactive	664 14 O
and	679 3 O
enzymatically	683 13 O
active	697 6 O
calcineurin	704 11 O
were	716 4 O
found	721 5 O
which	727 5 O
were	733 4 O
inhibited	738 9 O
by	748 2 O
the	751 3 O
immunosuppressants	755 18 O
CsA	774 3 B-Chemical
and	778 3 O
FK506	782 5 B-Chemical
,	787 1 O
but	789 3 O
not	793 3 O
by	797 2 O
rapamycin	800 9 B-Chemical
.	809 1 O

Finally	811 7 O
,	818 1 O
specific	820 8 O
immunophilin	829 12 O
-	841 1 O
drug	842 4 O
-	846 1 O
calcineurin	847 11 O
complexes	859 9 O
formed	869 6 O
only	876 4 O
in	881 2 O
the	884 3 O
presence	888 8 O
of	897 2 O
CsA	900 3 B-Chemical
and	904 3 O
FK506	908 5 B-Chemical
,	913 1 O
but	915 3 O
not	919 3 O
rapamycin	923 9 B-Chemical
.	932 1 O

These	934 5 O
results	940 7 O
suggest	948 7 O
that	956 4 O
the	961 3 O
nephrotoxic	965 11 B-Disease
effects	977 7 O
of	985 2 O
CsA	988 3 B-Chemical
and	992 3 O
FK506	996 5 B-Chemical
is	1002 2 O
likely	1005 6 O
mediated	1012 8 O
through	1021 7 O
binding	1029 7 O
to	1037 2 O
renal	1040 5 O
immunophilin	1046 12 O
and	1059 3 O
inhibiting	1063 10 O
calcineurin	1074 11 O
phosphatase	1086 11 O
.	1097 1 O

Massive	0 7 O
cerebral	8 8 B-Disease
edema	17 5 I-Disease
associated	23 10 O
with	34 4 O
fulminant	39 9 O
hepatic	49 7 B-Disease
failure	57 7 I-Disease
in	65 2 O
acetaminophen	68 13 B-Chemical
overdose	82 8 B-Disease
:	90 1 O
possible	92 8 O
role	101 4 O
of	106 2 O
cranial	109 7 O
decompression	117 13 O
.	130 1 O

Cerebral	132 8 B-Disease
edema	141 5 I-Disease
may	147 3 O
complicate	151 10 O
the	162 3 O
course	166 6 O
of	173 2 O
fulminant	176 9 B-Disease
hepatic	186 7 I-Disease
failure	194 7 I-Disease
.	201 1 O

Response	203 8 O
to	212 2 O
conventional	215 12 O
therapy	228 7 O
has	236 3 O
been	240 4 O
disappointing	245 13 O
.	258 1 O

We	260 2 O
present	263 7 O
a	271 1 O
patient	273 7 O
with	281 4 O
fatal	286 5 O
acetaminophen	292 13 B-Chemical
-	305 1 O
induced	306 7 O
fulminant	314 9 B-Disease
hepatic	324 7 I-Disease
failure	332 7 I-Disease
,	339 1 O
with	341 4 O
signs	346 5 O
and	352 3 O
symptoms	356 8 O
of	365 2 O
cerebral	368 8 B-Disease
edema	377 5 I-Disease
,	382 1 O
unresponsive	384 12 O
to	397 2 O
conventional	400 12 O
medical	413 7 O
therapy	421 7 O
.	428 1 O

Cranial	430 7 O
decompression	438 13 O
was	452 3 O
carried	456 7 O
out	464 3 O
.	467 1 O

A	469 1 O
justification	471 13 O
of	485 2 O
the	488 3 O
need	492 4 O
for	497 3 O
further	501 7 O
evaluation	509 10 O
of	520 2 O
cranial	523 7 O
decompression	531 13 O
in	545 2 O
such	548 4 O
patients	553 8 O
is	562 2 O
presented	565 9 O
.	574 1 O

Gentamicin	0 10 B-Chemical
nephropathy	11 11 B-Disease
in	23 2 O
a	26 1 O
neonate	28 7 O
.	35 1 O

The	37 3 O
clinical	41 8 O
and	50 3 O
autopsy	54 7 O
findings	62 8 O
in	71 2 O
a	74 1 O
premature	76 9 O
baby	86 4 O
who	91 3 O
died	95 4 O
of	100 2 O
acute	103 5 B-Disease
renal	109 5 I-Disease
failure	115 7 I-Disease
after	123 5 O
therapy	129 7 O
with	137 4 O
gentamicin	142 10 B-Chemical
(	153 1 O
5	154 1 O
mg	156 2 O
/	158 1 O
kg	159 2 O
/	161 1 O
day	162 3 O
)	165 1 O
and	167 3 O
penicillin	171 10 B-Chemical
are	182 3 O
presented	186 9 O
.	195 1 O

The	197 3 O
serum	201 5 O
gentamicin	207 10 B-Chemical
concentration	218 13 O
had	232 3 O
reached	236 7 O
toxic	244 5 O
levels	250 6 O
when	257 4 O
anuria	262 6 B-Disease
developed	269 9 O
.	278 1 O

Numerous	280 8 O
periodic	289 8 B-Chemical
acid	298 4 I-Chemical
Schiff	303 6 O
(	310 1 O
PAS	311 3 O
)	314 1 O
positive	316 8 O
,	324 1 O
diastase	326 8 O
resistant	335 9 O
cytoplasmic	345 11 O
inclusion	357 9 O
bodies	367 6 O
which	374 5 O
appeared	380 8 O
as	389 2 O
myelin	392 6 O
figures	399 7 O
in	407 2 O
cytosegresomes	410 14 O
under	425 5 O
the	431 3 O
electron	435 8 O
microscope	444 10 O
were	455 4 O
identified	460 10 O
in	471 2 O
the	474 3 O
proximal	478 8 O
convoluted	487 10 O
tubules	498 7 O
.	505 1 O

The	507 3 O
pathological	511 12 O
changes	524 7 O
induced	532 7 O
by	540 2 O
gentamicin	543 10 B-Chemical
in	554 2 O
the	557 3 O
human	561 5 O
neonatal	567 8 O
kidneys	576 7 O
have	584 4 O
not	589 3 O
been	593 4 O
previously	598 10 O
reported	609 8 O
.	617 1 O

Anti	0 4 O
-	4 1 O
carcinogenic	5 12 B-Disease
action	18 6 O
of	25 2 O
phenobarbital	28 13 B-Chemical
given	42 5 O
simultaneously	48 14 O
with	63 4 O
diethylnitrosamine	68 18 B-Chemical
in	87 2 O
the	90 3 O
rat	94 3 O
.	97 1 O

The	99 3 O
present	103 7 O
work	111 4 O
has	116 3 O
been	120 4 O
planned	125 7 O
in	133 2 O
order	136 5 O
to	142 2 O
elucidate	145 9 O
the	155 3 O
effect	159 6 O
of	166 2 O
phenobarbital	169 13 B-Chemical
(	183 1 O
PB	184 2 B-Chemical
:	186 1 O
15	188 2 O
mg	191 2 O
per	194 3 O
rat	198 3 O
of	202 2 O
ingested	205 8 O
dose	214 4 O
)	218 1 O
on	220 2 O
carcinogenesis	223 14 B-Disease
when	238 4 O
it	243 2 O
is	246 2 O
administered	249 12 O
simultaneously	262 14 O
with	277 4 O
diethylnitrosamine	282 18 B-Chemical
(	301 1 O
DEN	302 3 B-Chemical
:	305 1 O
10	307 2 O
mg	310 2 O
/	312 1 O
kg	313 2 O
/	315 1 O
day	316 3 O
)	319 1 O
.	320 1 O

Wistar	322 6 O
rats	329 4 O
(	334 1 O
180	335 3 O
g	339 1 O
)	340 1 O
were	342 4 O
treated	347 7 O
by	355 2 O
DEN	358 3 B-Chemical
alone	362 5 O
or	368 2 O
by	371 2 O
DEN	374 3 B-Chemical
+	378 1 O
PB	380 2 B-Chemical
during	383 6 O
2	390 1 O
,	391 1 O
4	393 1 O
and	395 3 O
6	399 1 O
weeks	401 5 O
according	407 9 O
to	417 2 O
our	420 3 O
schedule	424 8 O
for	433 3 O
hepatocarcinogenesis	437 20 B-Disease
.	457 1 O

After	459 5 O
the	465 3 O
end	469 3 O
of	473 2 O
the	476 3 O
treatment	480 9 O
,	489 1 O
the	491 3 O
number	495 6 O
and	502 3 O
the	506 3 O
size	510 4 O
of	515 2 O
induced	518 7 O
PAS	526 3 O
positive	530 8 O
preneoplastic	539 13 B-Disease
foci	553 4 I-Disease
was	558 3 O
significantly	562 13 O
reduced	576 7 O
when	584 4 O
PB	589 2 B-Chemical
was	592 3 O
given	596 5 O
simultaneously	602 14 O
with	617 4 O
DEN	622 3 B-Chemical
for	626 3 O
4	630 1 O
and	632 3 O
6	636 1 O
weeks	638 5 O
.	643 1 O

The	645 3 O
mitotic	649 7 O
inhibition	657 10 O
and	668 3 O
the	672 3 O
production	676 10 O
of	687 2 O
micronuclei	690 11 O
normally	702 8 O
observed	711 8 O
after	720 5 O
partial	726 7 O
hepatectomy	734 11 O
in	746 2 O
DEN	749 3 B-Chemical
treated	753 7 O
rats	761 4 O
were	766 4 O
also	771 4 O
significantly	776 13 O
decreased	790 9 O
in	800 2 O
DEN	803 3 B-Chemical
+	807 1 O
PB	809 2 B-Chemical
treated	812 7 O
rats	820 4 O
.	824 1 O

When	826 4 O
the	831 3 O
treatment	835 9 O
last	845 4 O
only	850 4 O
2	855 1 O
weeks	857 5 O
,	862 1 O
the	864 3 O
presence	868 8 O
of	877 2 O
PB	880 2 B-Chemical
did	883 3 O
not	887 3 O
change	891 6 O
significantly	898 13 O
the	912 3 O
last	916 4 O
parameters	921 10 O
.	931 1 O

In	933 2 O
DEN	936 3 B-Chemical
+	940 1 O
PB	942 2 B-Chemical
treated	945 7 O
rats	953 4 O
,	957 1 O
the	959 3 O
survival	963 8 O
was	972 3 O
prolonged	976 9 O
and	986 3 O
the	990 3 O
tumor	994 5 B-Disease
incidence	1000 9 O
decreased	1010 9 O
as	1020 2 O
compared	1023 8 O
with	1032 4 O
the	1037 3 O
results	1041 7 O
obtained	1049 8 O
by	1058 2 O
DEN	1061 3 B-Chemical
alone	1065 5 O
.	1070 1 O

It	1072 2 O
is	1075 2 O
concluded	1078 9 O
that	1088 4 O
PB	1093 2 B-Chemical
,	1095 1 O
which	1097 5 O
promotes	1103 8 O
carcinogenesis	1112 14 B-Disease
when	1127 4 O
administered	1132 12 O
after	1145 5 O
the	1151 3 O
DEN	1155 3 B-Chemical
treatment	1159 9 O
,	1168 1 O
reduces	1170 7 O
the	1178 3 O
carcinogen	1182 10 O
effect	1193 6 O
when	1200 4 O
given	1205 5 O
simultaneously	1211 14 O
with	1226 4 O
DEN	1231 3 B-Chemical
.	1234 1 O

This	1236 4 O
'	1241 1 O
anti	1242 4 O
-	1246 1 O
carcinogen	1247 10 O
'	1257 1 O
effect	1259 6 O
acts	1266 4 O
on	1271 2 O
the	1274 3 O
initiation	1278 10 O
as	1289 2 O
well	1292 4 O
as	1297 2 O
on	1300 2 O
the	1303 3 O
promotion	1307 9 O
of	1317 2 O
the	1320 3 O
precancerous	1324 12 B-Disease
lesions	1337 7 I-Disease
.	1344 1 O

Biochemical	1346 11 O
investigations	1358 14 O
are	1373 3 O
in	1377 2 O
progress	1380 8 O
to	1389 2 O
obtain	1392 6 O
more	1399 4 O
information	1404 11 O
about	1416 5 O
this	1422 4 O
'	1427 1 O
paradoxical	1428 11 O
'	1439 1 O
PB	1441 2 B-Chemical
effect	1444 6 O
.	1450 1 O

Post	0 4 O
-	4 1 O
operative	5 9 O
rigidity	15 8 B-Disease
after	24 5 O
fentanyl	30 8 B-Chemical
administration	39 14 O
.	53 1 O

A	55 1 O
case	57 4 O
of	62 2 O
thoraco	65 7 O
-	72 1 O
abdominal	73 9 O
rigidity	83 8 B-Disease
leading	92 7 O
to	100 2 O
respiratory	103 11 B-Disease
failure	115 7 I-Disease
is	123 2 O
described	126 9 O
in	136 2 O
the	139 3 O
post	143 4 O
-	147 1 O
operative	148 9 O
period	158 6 O
in	165 2 O
an	168 2 O
elderly	171 7 O
patient	179 7 O
who	187 3 O
received	191 8 O
a	200 1 O
moderate	202 8 O
dose	211 4 O
of	216 2 O
fentanyl	219 8 B-Chemical
.	227 1 O

This	229 4 O
was	234 3 O
successfully	238 12 O
reversed	251 8 O
by	260 2 O
naloxone	263 8 B-Chemical
.	271 1 O

The	273 3 O
mechanisms	277 10 O
possibly	288 8 O
implicated	297 10 O
in	308 2 O
this	311 4 O
accident	316 8 O
are	325 3 O
discussed	329 9 O
.	338 1 O

Postpartum	0 10 O
psychosis	11 9 B-Disease
induced	21 7 O
by	29 2 O
bromocriptine	32 13 B-Chemical
.	45 1 O

Two	47 3 O
multigravida	51 12 O
patients	64 8 O
with	73 4 O
no	78 2 O
prior	81 5 O
psychiatric	87 11 B-Disease
history	99 7 O
were	107 4 O
seen	112 4 O
with	117 4 O
postpartum	122 10 O
psychosis	133 9 B-Disease
,	142 1 O
having	144 6 O
received	151 8 O
bromocriptine	160 13 B-Chemical
for	174 3 O
inhibition	178 10 B-Disease
of	189 2 I-Disease
lactation	192 9 I-Disease
.	201 1 O

Bromocriptine	203 13 B-Chemical
given	217 5 O
in	223 2 O
high	226 4 O
doses	231 5 O
has	237 3 O
been	241 4 O
associated	246 10 O
with	257 4 O
psychosis	262 9 B-Disease
in	272 2 O
patients	275 8 O
receiving	284 9 O
the	294 3 O
drug	298 4 O
for	303 3 O
Parkinson	307 9 B-Disease
'	316 1 I-Disease
s	317 1 I-Disease
disease	319 7 I-Disease
.	326 1 O

These	328 5 O
cases	334 5 O
demonstrate	340 11 O
that	352 4 O
bromocriptine	357 13 B-Chemical
may	371 3 O
cause	375 5 O
psychosis	381 9 B-Disease
even	391 4 O
when	396 4 O
given	401 5 O
in	407 2 O
low	410 3 O
doses	414 5 O
.	419 1 O

A	0 1 O
prospective	2 11 O
study	14 5 O
on	20 2 O
the	23 3 O
dose	27 4 O
dependency	32 10 O
of	43 2 O
cardiotoxicity	46 14 B-Disease
induced	61 7 O
by	69 2 O
mitomycin	72 9 B-Chemical
C	82 1 I-Chemical
.	83 1 O

Since	85 5 O
1975	91 4 O
mitomycin	96 9 B-Chemical
C	106 1 I-Chemical
(	108 1 O
MMC	109 3 B-Chemical
)	112 1 O
has	114 3 O
been	118 4 O
suggested	123 9 O
to	133 2 O
be	136 2 O
cardiotoxic	139 11 B-Disease
,	150 1 O
especially	152 10 O
when	163 4 O
combined	168 8 O
with	177 4 O
or	182 2 O
given	185 5 O
following	191 9 O
doxorubicin	201 11 B-Chemical
.	212 1 O

Data	214 4 O
on	219 2 O
dose	222 4 O
dependency	227 10 O
or	238 2 O
incidence	241 9 O
concerning	251 10 O
this	262 4 O
side	267 4 O
effect	272 6 O
were	279 4 O
not	284 3 O
known	288 5 O
.	293 1 O

We	295 2 O
have	298 4 O
initiated	303 9 O
a	313 1 O
prospective	315 11 O
study	327 5 O
to	333 2 O
obtain	336 6 O
some	343 4 O
more	348 4 O
data	353 4 O
on	358 2 O
these	361 5 O
subjects	367 8 O
.	375 1 O

Forty	377 5 O
-	382 1 O
four	383 4 O
MMC	388 3 B-Chemical
-	391 1 O
treated	392 7 O
patients	400 8 O
were	409 4 O
studied	414 7 O
,	421 1 O
37	423 2 O
of	426 2 O
them	429 4 O
could	434 5 O
be	440 2 O
evaluated	443 9 O
.	452 1 O

All	454 3 O
patients	458 8 O
were	467 4 O
studied	472 7 O
by	480 2 O
repeated	483 8 O
physical	492 8 O
examinations	501 12 O
,	513 1 O
chest	515 5 O
X	521 1 O
-	522 1 O
rays	523 4 O
,	527 1 O
electro	529 7 O
-	536 1 O
and	538 3 O
echocardiography	542 16 O
and	559 3 O
radionuclide	563 12 O
left	576 4 O
ventricular	581 11 O
ejection	593 8 O
fraction	602 8 O
(	611 1 O
EF	612 2 O
)	614 1 O
determinations	616 14 O
.	630 1 O

The	632 3 O
results	636 7 O
were	644 4 O
evaluated	649 9 O
per	659 3 O
cumulative	663 10 O
dose	674 4 O
level	679 5 O
.	684 1 O

One	686 3 O
of	690 2 O
the	693 3 O
patients	697 8 O
developed	706 9 O
cardiac	716 7 B-Disease
failure	724 7 I-Disease
after	732 5 O
30	738 2 O
mg	741 2 O
m	744 1 O
-	745 1 O
2	746 1 O
MMC	748 3 B-Chemical
and	752 3 O
only	756 4 O
150	761 3 O
mg	765 2 O
m	768 1 O
-	769 1 O
2	770 1 O
doxorubicin	772 11 B-Chemical
.	783 1 O

The	785 3 O
cardiac	789 7 B-Disease
failure	797 7 I-Disease
was	805 3 O
predicted	809 9 O
by	819 2 O
a	822 1 O
drop	824 4 O
in	829 2 O
EF	832 2 O
determined	835 10 O
during	846 6 O
a	853 1 O
cold	855 4 O
pressor	860 7 O
test	868 4 O
.	872 1 O

None	874 4 O
of	879 2 O
the	882 3 O
other	886 5 O
patients	892 8 O
developed	901 9 O
clinical	911 8 O
cardiotoxicity	920 14 B-Disease
,	934 1 O
nor	936 3 O
did	940 3 O
the	944 3 O
studied	948 7 O
parameters	956 10 O
change	967 6 O
.	973 1 O

The	975 3 O
literature	979 10 O
on	990 2 O
this	993 4 O
subject	998 7 O
was	1006 3 O
also	1010 4 O
reviewed	1015 8 O
.	1023 1 O

Based	1025 5 O
on	1031 2 O
the	1034 3 O
combined	1038 8 O
data	1047 4 O
from	1052 4 O
the	1057 3 O
present	1061 7 O
study	1069 5 O
and	1075 3 O
the	1079 3 O
literature	1083 10 O
,	1093 1 O
we	1095 2 O
suggest	1098 7 O
that	1106 4 O
MMC	1111 3 B-Chemical
-	1114 1 O
related	1115 7 O
cardiotoxicity	1123 14 B-Disease
is	1138 2 O
dose	1141 4 O
dependent	1146 9 O
,	1155 1 O
occurring	1157 9 O
at	1167 2 O
cumulative	1170 10 O
dose	1181 4 O
levels	1186 6 O
of	1193 2 O
30	1196 2 O
mg	1199 2 O
m	1202 1 O
-	1203 1 O
2	1204 1 O
or	1206 2 O
more	1209 4 O
,	1213 1 O
mainly	1215 6 O
in	1222 2 O
patients	1225 8 O
also	1234 4 O
(	1239 1 O
previously	1240 10 O
or	1251 2 O
simultaneously	1254 14 O
)	1268 1 O
treated	1270 7 O
with	1278 4 O
doxorubicin	1283 11 B-Chemical
.	1294 1 O

The	1296 3 O
incidence	1300 9 O
is	1310 2 O
likely	1313 6 O
to	1320 2 O
be	1323 2 O
less	1326 4 O
than	1331 4 O
10	1336 2 O
%	1338 1 O
even	1340 4 O
for	1345 3 O
this	1349 4 O
risk	1354 4 O
group	1359 5 O
.	1364 1 O

Phlorizin	0 9 B-Chemical
-	9 1 O
induced	10 7 O
glycosuria	18 10 B-Disease
does	29 4 O
not	34 3 O
prevent	38 7 O
gentamicin	46 10 B-Chemical
nephrotoxicity	57 14 B-Disease
in	72 2 O
rats	75 4 O
.	79 1 O

Because	81 7 O
rats	89 4 O
with	94 4 O
streptozotocin	99 14 B-Chemical
-	113 1 O
induced	114 7 O
diabetes	122 8 B-Disease
mellitus	131 8 I-Disease
(	140 1 O
DM	141 2 B-Disease
)	143 1 O
have	145 4 O
a	150 1 O
high	152 4 O
solute	157 6 O
diuresis	164 8 O
(	173 1 O
glycosuria	174 10 B-Disease
of	185 2 O
10	188 2 O
to	191 2 O
12	194 2 O
g	197 1 O
/	198 1 O
day	199 3 O
)	202 1 O
,	203 1 O
we	205 2 O
have	208 4 O
suggested	213 9 O
that	223 4 O
this	228 4 O
may	233 3 O
in	237 2 O
part	240 4 O
be	245 2 O
responsible	248 11 O
for	260 3 O
their	264 5 O
resistance	270 10 O
to	281 2 O
gentamicin	284 10 B-Chemical
-	294 1 O
induced	295 7 O
acute	303 5 B-Disease
renal	309 5 I-Disease
failure	315 7 I-Disease
(	323 1 O
ARF	324 3 B-Disease
)	327 1 O
.	328 1 O

The	330 3 O
protection	334 10 O
from	345 4 O
gentamicin	350 10 B-Chemical
nephrotoxicity	361 14 B-Disease
was	376 3 O
studied	380 7 O
in	388 2 O
non	391 3 O
-	394 1 O
diabetic	395 8 B-Disease
rats	404 4 O
with	409 4 O
chronic	414 7 O
solute	422 6 O
diuresis	429 8 O
induced	438 7 O
by	446 2 O
blockage	449 8 O
of	458 2 O
tubular	461 7 O
glucose	469 7 B-Chemical
reabsorption	477 12 O
with	490 4 O
phlorizin	495 9 B-Chemical
(	505 1 O
P	506 1 B-Chemical
)	507 1 O
.	508 1 O

DM	510 2 B-Disease
rats	513 4 O
with	518 4 O
mild	523 4 O
glycosuria	528 10 B-Disease
(	539 1 O
similar	540 7 O
in	548 2 O
degree	551 6 O
to	558 2 O
that	561 4 O
of	566 2 O
the	569 3 O
P	573 1 B-Chemical
treated	575 7 O
animals	583 7 O
)	590 1 O
were	592 4 O
also	597 4 O
studied	602 7 O
.	609 1 O

Unanesthetized	611 14 O
adult	626 5 O
female	632 6 O
,	638 1 O
Sprague	640 7 O
-	647 1 O
Dawley	648 6 O
rats	655 4 O
were	660 4 O
divided	665 7 O
in	673 2 O
four	676 4 O
groups	681 6 O
and	688 3 O
studied	692 7 O
for	700 3 O
15	704 2 O
days	707 4 O
.	711 1 O

Group	713 5 O
1	719 1 O
(	721 1 O
P	722 1 B-Chemical
alone	724 5 O
)	729 1 O
received	731 8 O
P	740 1 B-Chemical
,	741 1 O
360	743 3 O
mg	747 2 O
/	749 1 O
day	750 3 O
,	753 1 O
for	755 3 O
15	759 2 O
days	762 4 O
;	766 1 O
Group	768 5 O
II	774 2 O
(	777 1 O
P	778 1 B-Chemical
+	780 1 O
gentamicin	782 10 B-Chemical
)	792 1 O
;	793 1 O
Group	795 5 O
III	801 3 O
(	805 1 O
gentamicin	806 10 B-Chemical
alone	817 5 O
)	822 1 O
and	824 3 O
Group	828 5 O
IV	834 2 O
(	837 1 O
mild	838 4 O
DM	843 2 B-Disease
+	846 1 O
gentamicin	848 10 B-Chemical
)	858 1 O
.	859 1 O

Nephrotoxic	861 11 B-Disease
doses	873 5 O
(	879 1 O
40	880 2 O
mg	883 2 O
/	885 1 O
kg	886 2 O
body	889 4 O
wt	894 2 O
/	896 1 O
day	897 3 O
)	900 1 O
of	902 2 O
gentamicin	905 10 B-Chemical
were	916 4 O
injected	921 8 O
during	930 6 O
the	937 3 O
last	941 4 O
nine	946 4 O
days	951 4 O
of	956 2 O
study	959 5 O
to	965 2 O
the	968 3 O
animals	972 7 O
of	980 2 O
groups	983 6 O
II	990 2 O
to	993 2 O
IV	996 2 O
.	998 1 O

In	1000 2 O
Group	1003 5 O
I	1009 1 O
,	1010 1 O
P	1012 1 B-Chemical
induced	1014 7 O
a	1022 1 O
moderate	1024 8 O
and	1033 3 O
stable	1037 6 O
glycosuria	1044 10 B-Disease
(	1055 1 O
3	1056 1 O
.	1057 1 O
9	1058 1 O
+	1060 1 O
/	1061 1 O
-	1062 1 O
0	1064 1 O
.	1065 1 O
1	1066 1 O
g	1068 1 O
/	1069 1 O
day	1070 3 O
,	1073 1 O
SE	1075 2 O
)	1077 1 O
,	1078 1 O
and	1080 3 O
no	1084 2 O
functional	1087 10 O
or	1098 2 O
morphologic	1101 11 O
evidence	1113 8 O
of	1122 2 O
renal	1125 5 B-Disease
dysfunction	1131 11 I-Disease
(	1143 1 O
baseline	1144 8 O
CCr	1153 3 O
2	1157 1 O
.	1158 1 O
1	1159 1 O
+	1161 1 O
/	1162 1 O
-	1163 1 O
0	1165 1 O
.	1166 1 O
1	1167 1 O
ml	1169 2 O
/	1171 1 O
min	1172 3 O
,	1175 1 O
undetectable	1177 12 O
lysozymuria	1190 11 O
)	1201 1 O
or	1203 2 O
damage	1206 6 O
(	1213 1 O
tubular	1214 7 B-Disease
necrosis	1222 8 I-Disease
score	1231 5 O
[	1237 1 O
maximum	1238 7 O
4	1246 1 O
]	1247 1 O
,	1248 1 O
zero	1250 4 O
)	1254 1 O
.	1255 1 O

In	1257 2 O
Group	1260 5 O
II	1266 2 O
,	1268 1 O
P	1270 1 B-Chemical
did	1272 3 O
not	1276 3 O
prevent	1280 7 O
gentamicin	1288 10 B-Chemical
-	1298 1 O
ARF	1299 3 B-Disease
(	1303 1 O
maximal	1304 7 O
decrease	1312 8 O
in	1321 2 O
CCr	1324 3 O
at	1328 2 O
day	1331 3 O
9	1335 1 O
.	1336 1 O
89	1337 2 O
%	1339 1 O
,	1340 1 O
P	1342 1 B-Chemical
less	1344 4 O
than	1349 4 O
0	1354 1 O
.	1355 1 O
001	1356 3 O
;	1359 1 O
peak	1361 4 O
lysozymuria	1366 11 O
,	1377 1 O
1863	1379 4 O
+	1384 1 O
/	1385 1 O
-	1386 1 O
321	1388 3 O
micrograms	1392 10 O
/	1402 1 O
day	1403 3 O
;	1406 1 O
and	1408 3 O
tubular	1412 7 B-Disease
necrosis	1420 8 I-Disease
score	1429 5 O
,	1434 1 O
3	1436 1 O
.	1437 1 O
9	1438 1 O
+	1440 1 O
/	1441 1 O
-	1442 1 O
0	1444 1 O
.	1445 1 O
1	1446 1 O
)	1447 1 O
.	1448 1 O

These	1450 5 O
values	1456 6 O
were	1463 4 O
not	1468 3 O
different	1472 9 O
from	1482 4 O
those	1487 5 O
of	1493 2 O
Group	1496 5 O
III	1502 3 O
:	1505 1 O
maximal	1507 7 O
decrease	1515 8 O
in	1524 2 O
CCr	1527 3 O
73	1531 2 O
%	1533 1 O
(	1535 1 O
P	1536 1 B-Chemical
less	1538 4 O
than	1543 4 O
0	1548 1 O
.	1549 1 O
001	1550 3 O
)	1553 1 O
;	1554 1 O
lysozymuria	1556 11 O
,	1567 1 O
2147	1569 4 O
+	1574 1 O
/	1575 1 O
-	1576 1 O
701	1578 3 O
micrograms	1582 10 O
/	1592 1 O
day	1593 3 O
;	1596 1 O
tubular	1598 7 B-Disease
necrosis	1606 8 I-Disease
score	1615 5 O
,	1620 1 O
3	1622 1 O
.	1623 1 O
8	1624 1 O
+	1626 1 O
/	1627 1 O
-	1628 1 O
0	1630 1 O
.	1631 1 O
1	1632 1 O
.	1633 1 O
(	1634 1 O
ABSTRACT	1635 8 O
TRUNCATED	1644 9 O
AT	1654 2 O
250	1657 3 O
WORDS	1661 5 O
)	1666 1 O

Tiapride	0 8 B-Chemical
in	9 2 O
levodopa	12 8 B-Chemical
-	20 1 O
induced	21 7 O
involuntary	29 11 B-Disease
movements	41 9 I-Disease
.	50 1 O

Tiapride	52 8 B-Chemical
,	60 1 O
a	62 1 O
substituted	64 11 O
benzamide	76 9 B-Chemical
derivative	86 10 O
closely	97 7 O
related	105 7 O
to	113 2 O
metoclopramide	116 14 B-Chemical
,	130 1 O
reduced	132 7 O
levodopa	140 8 B-Chemical
-	148 1 O
induced	149 7 O
peak	157 4 O
dose	162 4 O
involuntary	167 11 B-Disease
movements	179 9 I-Disease
in	189 2 O
16	192 2 O
patients	195 8 O
with	204 4 O
idiopathic	209 10 B-Disease
Parkinson	220 9 I-Disease
'	229 1 I-Disease
s	230 1 I-Disease
disease	232 7 I-Disease
.	239 1 O

However	241 7 O
,	248 1 O
an	250 2 O
unacceptable	253 12 O
increase	266 8 O
in	275 2 O
disability	278 10 O
from	289 4 O
Parkinsonism	294 12 B-Disease
with	307 4 O
aggravation	312 11 O
of	324 2 O
end	327 3 O
-	330 1 O
of	331 2 O
-	333 1 O
dose	334 4 O
akinesia	339 8 B-Disease
led	348 3 O
to	352 2 O
its	355 3 O
cessation	359 9 O
in	369 2 O
14	372 2 O
patients	375 8 O
.	383 1 O

Tiapride	385 8 B-Chemical
had	394 3 O
no	398 2 O
effect	401 6 O
on	408 2 O
levodopa	411 8 B-Chemical
-	419 1 O
induced	420 7 O
early	428 5 O
morning	434 7 O
of	442 2 O
"	445 1 O
off	446 3 O
-	449 1 O
period	450 6 O
"	456 1 O
segmental	458 9 O
dystonia	468 8 B-Disease
.	476 1 O

These	478 5 O
results	484 7 O
fail	492 4 O
to	497 2 O
support	500 7 O
the	508 3 O
notion	512 6 O
that	519 4 O
levodopa	524 8 B-Chemical
-	532 1 O
induced	533 7 O
dyskinesias	541 11 B-Disease
are	553 3 O
caused	557 6 O
by	564 2 O
overstimulation	567 15 O
of	583 2 O
a	586 1 O
separate	588 8 O
group	597 5 O
of	603 2 O
dopamine	606 8 B-Chemical
receptors	615 9 O
.	624 1 O

Effects	0 7 O
of	8 2 O
the	11 3 O
hippocampal	15 11 O
deep	27 4 O
brain	32 5 O
stimulation	38 11 O
on	50 2 O
cortical	53 8 O
epileptic	62 9 B-Disease
discharges	72 10 O
in	83 2 O
penicillin	86 10 B-Chemical
-	97 1 O
induced	99 7 O
epilepsy	107 8 B-Disease
model	116 5 O
in	122 2 O
rats	125 4 O
.	129 1 O

AIM	131 3 O
:	134 1 O
Experimental	136 12 O
and	149 3 O
clinical	153 8 O
studies	162 7 O
have	170 4 O
revealed	175 8 O
that	184 4 O
hippocampal	189 11 O
DBS	201 3 O
can	205 3 O
control	209 7 O
epileptic	217 9 B-Disease
activity	227 8 O
,	235 1 O
but	237 3 O
the	241 3 O
mechanism	245 9 O
of	255 2 O
action	258 6 O
is	265 2 O
obscure	268 7 O
and	276 3 O
optimal	280 7 O
stimulation	288 11 O
parameters	300 10 O
are	311 3 O
not	315 3 O
clearly	319 7 O
defined	327 7 O
.	334 1 O

The	336 3 O
aim	340 3 O
was	344 3 O
to	348 2 O
evaluate	351 8 O
the	360 3 O
effects	364 7 O
of	372 2 O
high	375 4 O
frequency	380 9 O
hippocampal	390 11 O
stimulation	402 11 O
on	414 2 O
cortical	417 8 O
epileptic	426 9 B-Disease
activity	436 8 O
in	445 2 O
penicillin	448 10 B-Chemical
-	458 1 O
induced	459 7 O
epilepsy	467 8 B-Disease
model	476 5 O
.	481 1 O

MATERIAL	483 8 O
AND	492 3 O
METHODS	496 7 O
:	503 1 O
Twenty	505 6 O
-	511 1 O
five	512 4 O
Sprague	517 7 O
-	524 1 O
Dawley	525 6 O
rats	532 4 O
were	537 4 O
implanted	542 9 O
DBS	552 3 O
electrodes	556 10 O
.	566 1 O

In	568 2 O
group	571 5 O
-	576 1 O
1	577 1 O
(	579 1 O
n	580 1 O
=	581 1 O
10	582 2 O
)	584 1 O
hippocampal	586 11 O
DBS	598 3 O
was	602 3 O
off	606 3 O
and	610 3 O
in	614 2 O
the	617 3 O
group	621 5 O
-	626 1 O
2	627 1 O
(	629 1 O
n	630 1 O
=	631 1 O
10	632 2 O
)	634 1 O
hippocampal	636 11 O
DBS	648 3 O
was	652 3 O
on	656 2 O
(	659 1 O
185	660 3 O
Hz	664 2 O
,	666 1 O
0	668 1 O
.	669 1 O
5V	670 2 O
,	672 1 O
1V	674 2 O
,	676 1 O
2V	678 2 O
,	680 1 O
and	682 3 O
5V	686 2 O
for	689 3 O
60	693 2 O
sec	696 3 O
)	699 1 O
following	701 9 O
penicillin	711 10 B-Chemical
G	722 1 I-Chemical
injection	724 9 O
intracortically	734 15 O
.	749 1 O

In	751 2 O
the	754 3 O
control	758 7 O
group	766 5 O
hippocampal	772 11 O
DBS	784 3 O
was	788 3 O
on	792 2 O
following	795 9 O
8	805 1 O
l	808 1 O
saline	810 6 O
injection	817 9 O
intracortically	827 15 O
.	842 1 O

EEG	844 3 O
recordings	848 10 O
were	859 4 O
obtained	864 8 O
before	873 6 O
and	880 3 O
15	884 2 O
minutes	887 7 O
following	895 9 O
penicillin	905 10 B-Chemical
-	915 1 I-Chemical
G	916 1 I-Chemical
injection	918 9 O
,	927 1 O
and	929 3 O
at	933 2 O
10th	936 4 O
minutes	941 7 O
following	949 9 O
each	959 4 O
stimulus	964 8 O
for	973 3 O
analysis	977 8 O
in	986 2 O
terms	989 5 O
of	995 2 O
frequency	998 9 O
,	1007 1 O
amplitude	1009 9 O
,	1018 1 O
and	1020 3 O
power	1024 5 O
spectrum	1030 8 O
.	1038 1 O

RESULTS	1040 7 O
:	1047 1 O
High	1049 4 O
frequency	1054 9 O
hippocampal	1064 11 O
DBS	1076 3 O
suppressed	1080 10 O
the	1091 3 O
acute	1095 5 O
penicillin	1101 10 B-Chemical
-	1111 1 O
induced	1112 7 O
cortical	1120 8 O
epileptic	1129 9 B-Disease
activity	1139 8 O
independent	1148 11 O
from	1160 4 O
stimulus	1165 8 O
intensity	1174 9 O
.	1183 1 O

In	1185 2 O
the	1188 3 O
control	1192 7 O
group	1200 5 O
,	1205 1 O
hippocampal	1207 11 O
stimulation	1219 11 O
alone	1231 5 O
lead	1237 4 O
only	1242 4 O
to	1247 2 O
diffuse	1250 7 O
slowing	1258 7 O
of	1266 2 O
cerebral	1269 8 O
bioelectrical	1278 13 O
activity	1292 8 O
at	1301 2 O
5V	1304 2 O
stimulation	1307 11 O
.	1318 1 O

CONCLUSION	1320 10 O
:	1330 1 O
Our	1332 3 O
results	1336 7 O
revealed	1344 8 O
that	1353 4 O
continuous	1358 10 O
high	1369 4 O
frequency	1374 9 O
stimulation	1384 11 O
of	1396 2 O
the	1399 3 O
hippocampus	1403 11 O
suppressed	1415 10 O
acute	1426 5 O
cortical	1432 8 O
epileptic	1441 9 B-Disease
activity	1451 8 O
effectively	1460 11 O
without	1472 7 O
causing	1480 7 O
secondary	1488 9 O
epileptic	1498 9 B-Disease
discharges	1508 10 O
.	1518 1 O

These	1520 5 O
results	1526 7 O
are	1534 3 O
important	1538 9 O
in	1548 2 O
terms	1551 5 O
of	1557 2 O
defining	1560 8 O
the	1569 3 O
optimal	1573 7 O
parameters	1581 10 O
of	1592 2 O
hippocampal	1595 11 O
DBS	1607 3 O
in	1611 2 O
patients	1614 8 O
with	1623 4 O
epilepsy	1628 8 B-Disease
.	1636 1 O

Neural	0 6 O
correlates	7 10 O
of	18 2 O
S	21 1 B-Chemical
-	22 1 I-Chemical
ketamine	23 8 I-Chemical
induced	32 7 O
psychosis	40 9 B-Disease
during	50 6 O
overt	57 5 O
continuous	63 10 O
verbal	74 6 O
fluency	81 7 O
.	88 1 O

The	90 3 O
glutamatergic	94 13 O
N	108 1 B-Chemical
-	109 1 I-Chemical
methyl	110 6 I-Chemical
-	116 1 I-Chemical
D	117 1 I-Chemical
-	118 1 I-Chemical
aspartate	119 9 I-Chemical
(	129 1 O
NMDA	130 4 B-Chemical
)	134 1 O
receptor	136 8 O
has	145 3 O
been	149 4 O
implicated	154 10 O
in	165 2 O
the	168 3 O
pathophysiology	172 15 O
of	188 2 O
schizophrenia	191 13 B-Disease
.	204 1 O

Administered	206 12 O
to	219 2 O
healthy	222 7 O
volunteers	230 10 O
,	240 1 O
a	242 1 O
subanesthetic	244 13 O
dose	258 4 O
of	263 2 O
the	266 3 O
non	270 3 O
-	273 1 O
competitive	274 11 O
NMDA	286 4 B-Chemical
receptor	291 8 O
antagonist	300 10 O
ketamine	311 8 B-Chemical
leads	320 5 O
to	326 2 O
psychopathological	329 18 O
symptoms	348 8 O
similar	357 7 O
to	365 2 O
those	368 5 O
observed	374 8 O
in	383 2 O
schizophrenia	386 13 B-Disease
.	399 1 O

In	401 2 O
patients	404 8 O
with	413 4 O
schizophrenia	418 13 B-Disease
,	431 1 O
ketamine	433 8 B-Chemical
exacerbates	442 11 O
the	454 3 O
core	458 4 O
symptoms	463 8 O
of	472 2 O
illness	475 7 O
,	482 1 O
supporting	484 10 O
the	495 3 O
hypothesis	499 10 O
of	510 2 O
a	513 1 O
glutamatergic	515 13 B-Disease
dysfunction	529 11 I-Disease
.	540 1 O

In	542 2 O
a	545 1 O
counterbalanced	547 15 O
,	562 1 O
placebo	564 7 O
-	571 1 O
controlled	572 10 O
,	582 1 O
double	584 6 O
-	590 1 O
blind	591 5 O
study	597 5 O
design	603 6 O
,	609 1 O
healthy	611 7 O
subjects	619 8 O
were	628 4 O
administered	633 12 O
a	646 1 O
continuous	648 10 O
subanesthetic	659 13 O
S	673 1 B-Chemical
-	674 1 I-Chemical
ketamine	675 8 I-Chemical
infusion	684 8 O
while	693 5 O
differences	699 11 O
in	711 2 O
BOLD	714 4 O
responses	719 9 O
measured	729 8 O
with	738 4 O
fMRI	743 4 O
were	748 4 O
detected	753 8 O
.	761 1 O

During	763 6 O
the	770 3 O
scanning	774 8 O
period	783 6 O
,	789 1 O
subjects	791 8 O
performed	800 9 O
continuous	810 10 O
overt	821 5 O
verbal	827 6 O
fluency	834 7 O
tasks	842 5 O
(	848 1 O
phonological	849 12 O
,	861 1 O
lexical	863 7 O
and	871 3 O
semantic	875 8 O
)	883 1 O
.	884 1 O

Ketamine	886 8 B-Chemical
-	894 1 O
induced	895 7 O
psychopathological	903 18 O
symptoms	922 8 O
were	931 4 O
assessed	936 8 O
with	945 4 O
the	950 3 O
Positive	954 8 O
and	963 3 O
Negative	967 8 O
Syndrome	976 8 O
Scale	985 5 O
(	991 1 O
PANSS	992 5 O
)	997 1 O
.	998 1 O

Ketamine	1000 8 B-Chemical
elicited	1009 8 O
psychosis	1018 9 B-Disease
like	1028 4 O
psychopathology	1033 15 O
.	1048 1 O

Post	1050 4 O
-	1054 1 O
hoc	1055 3 O
t	1059 1 O
-	1060 1 O
tests	1061 5 O
revealed	1067 8 O
significant	1076 11 O
differences	1088 11 O
between	1100 7 O
placebo	1108 7 O
and	1116 3 O
ketamine	1120 8 B-Chemical
for	1129 3 O
the	1133 3 O
amounts	1137 7 O
of	1145 2 O
words	1148 5 O
generated	1154 9 O
during	1164 6 O
lexical	1171 7 O
and	1179 3 O
semantic	1183 8 O
verbal	1192 6 O
fluency	1199 7 O
,	1206 1 O
while	1208 5 O
the	1214 3 O
phonological	1218 12 O
domain	1231 6 O
remained	1238 8 O
unaffected	1247 10 O
.	1257 1 O

Ketamine	1259 8 B-Chemical
led	1268 3 O
to	1272 2 O
enhanced	1275 8 O
cortical	1284 8 O
activations	1293 11 O
in	1305 2 O
supramarginal	1308 13 O
and	1322 3 O
frontal	1326 7 O
brain	1334 5 O
regions	1340 7 O
for	1348 3 O
phonological	1352 12 O
and	1365 3 O
lexical	1369 7 O
verbal	1377 6 O
fluency	1384 7 O
,	1391 1 O
but	1393 3 O
not	1397 3 O
for	1401 3 O
semantic	1405 8 O
verbal	1414 6 O
fluency	1421 7 O
.	1428 1 O

Ketamine	1430 8 B-Chemical
induces	1439 7 O
activation	1447 10 O
changes	1458 7 O
in	1466 2 O
healthy	1469 7 O
subjects	1477 8 O
similar	1486 7 O
to	1494 2 O
those	1497 5 O
observed	1503 8 O
in	1512 2 O
patients	1515 8 O
with	1524 4 O
schizophrenia	1529 13 B-Disease
,	1542 1 O
particularly	1544 12 O
in	1557 2 O
frontal	1560 7 O
and	1568 3 O
temporal	1572 8 O
brain	1581 5 O
regions	1587 7 O
.	1594 1 O

Our	1596 3 O
results	1600 7 O
provide	1608 7 O
further	1616 7 O
support	1624 7 O
for	1632 3 O
the	1636 3 O
hypothesis	1640 10 O
of	1651 2 O
an	1654 2 O
NMDA	1657 4 B-Chemical
receptor	1662 8 O
dysfunction	1671 11 O
in	1683 2 O
the	1686 3 O
pathophysiology	1690 15 O
of	1706 2 O
schizophrenia	1709 13 B-Disease
.	1722 1 O

Dopamine	0 8 B-Chemical
is	9 2 O
not	12 3 O
essential	16 9 O
for	26 3 O
the	30 3 O
development	34 11 O
of	46 2 O
methamphetamine	49 15 B-Chemical
-	64 1 O
induced	65 7 O
neurotoxicity	73 13 B-Disease
.	86 1 O

It	88 2 O
is	91 2 O
widely	94 6 O
believed	101 8 O
that	110 4 O
dopamine	115 8 B-Chemical
(	124 1 O
DA	125 2 B-Chemical
)	127 1 O
mediates	129 8 O
methamphetamine	138 15 B-Chemical
(	154 1 O
METH	155 4 B-Chemical
)	159 1 O
-	160 1 O
induced	161 7 O
toxicity	169 8 B-Disease
to	178 2 O
brain	181 5 O
dopaminergic	187 12 O
neurons	200 7 O
,	207 1 O
because	209 7 O
drugs	217 5 O
that	223 4 O
interfere	228 9 O
with	238 4 O
DA	243 2 B-Chemical
neurotransmission	246 17 O
decrease	264 8 O
toxicity	273 8 B-Disease
,	281 1 O
whereas	283 7 O
drugs	291 5 O
that	297 4 O
increase	302 8 O
DA	311 2 B-Chemical
neurotransmission	314 17 O
enhance	332 7 O
toxicity	340 8 B-Disease
.	348 1 O

However	350 7 O
,	357 1 O
temperature	359 11 O
effects	371 7 O
of	379 2 O
drugs	382 5 O
that	388 4 O
have	393 4 O
been	398 4 O
used	403 4 O
to	408 2 O
manipulate	411 10 O
brain	422 5 O
DA	428 2 B-Chemical
neurotransmission	431 17 O
confound	449 8 O
interpretation	458 14 O
of	473 2 O
the	476 3 O
data	480 4 O
.	484 1 O

Here	486 4 O
we	491 2 O
show	494 4 O
that	499 4 O
the	504 3 O
recently	508 8 O
reported	517 8 O
ability	526 7 O
of	534 2 O
L	537 1 B-Chemical
-	538 1 I-Chemical
dihydroxyphenylalanine	539 22 I-Chemical
to	562 2 O
reverse	565 7 O
the	573 3 O
protective	577 10 O
effect	588 6 O
of	595 2 O
alpha	598 5 B-Chemical
-	603 1 I-Chemical
methyl	604 6 I-Chemical
-	610 1 I-Chemical
para	611 4 I-Chemical
-	615 1 I-Chemical
tyrosine	616 8 I-Chemical
on	625 2 O
METH	628 4 B-Chemical
-	632 1 O
induced	633 7 O
DA	641 2 B-Chemical
neurotoxicity	644 13 B-Disease
is	658 2 O
also	661 4 O
confounded	666 10 O
by	677 2 O
drug	680 4 O
effects	685 7 O
on	693 2 O
body	696 4 O
temperature	701 11 O
.	712 1 O

Further	714 7 O
,	721 1 O
we	723 2 O
show	726 4 O
that	731 4 O
mice	736 4 O
genetically	741 11 O
engineered	753 10 O
to	764 2 O
be	767 2 O
deficient	770 9 O
in	780 2 O
brain	783 5 O
DA	789 2 B-Chemical
develop	792 7 O
METH	800 4 B-Chemical
neurotoxicity	805 13 B-Disease
,	818 1 O
as	820 2 O
long	823 4 O
as	828 2 O
the	831 3 O
thermic	835 7 O
effects	843 7 O
of	851 2 O
METH	854 4 B-Chemical
are	859 3 O
preserved	863 9 O
.	872 1 O

In	874 2 O
addition	877 8 O
,	885 1 O
we	887 2 O
demonstrate	890 11 O
that	902 4 O
mice	907 4 O
genetically	912 11 O
engineered	924 10 O
to	935 2 O
have	938 4 O
unilateral	943 10 O
brain	954 5 O
DA	960 2 B-Chemical
deficits	963 8 O
develop	972 7 O
METH	980 4 B-Chemical
-	984 1 O
induced	985 7 O
dopaminergic	993 12 B-Disease
deficits	1006 8 I-Disease
that	1015 4 O
are	1020 3 O
of	1024 2 O
comparable	1027 10 O
magnitude	1038 9 O
on	1048 2 O
both	1051 4 O
sides	1056 5 O
of	1062 2 O
the	1065 3 O
brain	1069 5 O
.	1074 1 O

Taken	1076 5 O
together	1082 8 O
,	1090 1 O
these	1092 5 O
findings	1098 8 O
demonstrate	1107 11 O
that	1119 4 O
DA	1124 2 B-Chemical
is	1127 2 O
not	1130 3 O
essential	1134 9 O
for	1144 3 O
the	1148 3 O
development	1152 11 O
of	1164 2 O
METH	1167 4 B-Chemical
-	1171 1 O
induced	1172 7 O
dopaminergic	1180 12 O
neurotoxicity	1193 13 B-Disease
and	1207 3 O
suggest	1211 7 O
that	1219 4 O
mechanisms	1224 10 O
independent	1235 11 O
of	1247 2 O
DA	1250 2 B-Chemical
warrant	1253 7 O
more	1261 4 O
intense	1266 7 O
investigation	1274 13 O
.	1287 1 O

Brainstem	0 9 B-Disease
dysgenesis	10 10 I-Disease
in	21 2 O
an	24 2 O
infant	27 6 O
prenatally	34 10 O
exposed	45 7 O
to	53 2 O
cocaine	56 7 B-Chemical
.	63 1 O

Many	65 4 O
authors	70 7 O
described	78 9 O
the	88 3 O
effects	92 7 O
on	100 2 O
the	103 3 O
fetus	107 5 O
of	113 2 O
maternal	116 8 O
cocaine	125 7 B-Disease
abuse	133 5 I-Disease
during	139 6 O
pregnancy	146 9 O
.	155 1 O

Vasoconstriction	157 16 O
appears	174 7 O
to	182 2 O
be	185 2 O
the	188 3 O
common	192 6 O
mechanism	199 9 O
of	209 2 O
action	212 6 O
leading	219 7 O
to	227 2 O
a	230 1 O
wide	232 4 O
range	237 5 O
of	243 2 O
fetal	246 5 B-Disease
anomalies	252 9 I-Disease
.	261 1 O

We	263 2 O
report	266 6 O
on	273 2 O
an	276 2 O
infant	279 6 O
with	286 4 O
multiple	291 8 B-Disease
cranial	300 7 I-Disease
-	307 1 I-Disease
nerve	308 5 I-Disease
involvement	314 11 I-Disease
attributable	326 12 O
to	339 2 O
brainstem	342 9 B-Disease
dysgenesis	352 10 I-Disease
,	362 1 O
born	364 4 O
to	369 2 O
a	372 1 O
cocaine	374 7 B-Disease
-	381 1 I-Disease
addicted	382 8 I-Disease
mother	391 6 O
.	397 1 O

The	0 3 O
protective	4 10 O
role	15 4 O
of	20 2 O
Nrf2	23 4 O
in	28 2 O
streptozotocin	31 14 B-Chemical
-	45 1 O
induced	46 7 O
diabetic	54 8 B-Disease
nephropathy	63 11 I-Disease
.	74 1 O

OBJECTIVE	76 9 O
:	85 1 O
Diabetic	87 8 B-Disease
nephropathy	96 11 I-Disease
is	108 2 O
one	111 3 O
of	115 2 O
the	118 3 O
major	122 5 O
causes	128 6 O
of	135 2 O
renal	138 5 B-Disease
failure	144 7 I-Disease
,	151 1 O
which	153 5 O
is	159 2 O
accompanied	162 11 O
by	174 2 O
the	177 3 O
production	181 10 O
of	192 2 O
reactive	195 8 O
oxygen	204 6 B-Chemical
species	211 7 O
(	219 1 O
ROS	220 3 O
)	223 1 O
.	224 1 O

Nrf2	226 4 O
is	231 2 O
the	234 3 O
primary	238 7 O
transcription	246 13 O
factor	260 6 O
that	267 4 O
controls	272 8 O
the	281 3 O
antioxidant	285 11 O
response	297 8 O
essential	306 9 O
for	316 3 O
maintaining	320 11 O
cellular	332 8 O
redox	341 5 O
homeostasis	347 11 O
.	358 1 O

Here	360 4 O
,	364 1 O
we	366 2 O
report	369 6 O
our	376 3 O
findings	380 8 O
demonstrating	389 13 O
a	403 1 O
protective	405 10 O
role	416 4 O
of	421 2 O
Nrf2	424 4 O
against	429 7 O
diabetic	437 8 B-Disease
nephropathy	446 11 I-Disease
.	457 1 O

RESEARCH	459 8 O
DESIGN	468 6 O
AND	475 3 O
METHODS	479 7 O
:	486 1 O
We	488 2 O
explore	491 7 O
the	499 3 O
protective	503 10 O
role	514 4 O
of	519 2 O
Nrf2	522 4 O
against	527 7 O
diabetic	535 8 B-Disease
nephropathy	544 11 I-Disease
using	556 5 O
human	562 5 O
kidney	568 6 O
biopsy	575 6 O
tissues	582 7 O
from	590 4 O
diabetic	595 8 B-Disease
nephropathy	604 11 I-Disease
patients	616 8 O
,	624 1 O
a	626 1 O
streptozotocin	628 14 B-Chemical
-	642 1 O
induced	643 7 O
diabetic	651 8 B-Disease
nephropathy	660 11 I-Disease
model	672 5 O
in	678 2 O
Nrf2	681 4 O
(	685 1 O
-	686 1 O
/	687 1 O
-	688 1 O
)	689 1 O
mice	691 4 O
,	695 1 O
and	697 3 O
cultured	701 8 O
human	710 5 O
mesangial	716 9 O
cells	726 5 O
.	731 1 O

RESULTS	733 7 O
:	740 1 O
The	742 3 O
glomeruli	746 9 O
of	756 2 O
human	759 5 O
diabetic	765 8 B-Disease
nephropathy	774 11 I-Disease
patients	786 8 O
were	795 4 O
under	800 5 O
oxidative	806 9 O
stress	816 6 O
and	823 3 O
had	827 3 O
elevated	831 8 O
Nrf2	840 4 O
levels	845 6 O
.	851 1 O

In	853 2 O
the	856 3 O
animal	860 6 O
study	867 5 O
,	872 1 O
Nrf2	874 4 O
was	879 3 O
demonstrated	883 12 O
to	896 2 O
be	899 2 O
crucial	902 7 O
in	910 2 O
ameliorating	913 12 O
streptozotocin	926 14 B-Chemical
-	940 1 O
induced	941 7 O
renal	949 5 B-Disease
damage	955 6 I-Disease
.	961 1 O

This	963 4 O
is	968 2 O
evident	971 7 O
by	979 2 O
Nrf2	982 4 O
(	986 1 O
-	987 1 O
/	988 1 O
-	989 1 O
)	990 1 O
mice	992 4 O
having	997 6 O
higher	1004 6 O
ROS	1011 3 O
production	1015 10 O
and	1026 3 O
suffering	1030 9 O
from	1040 4 O
greater	1045 7 O
oxidative	1053 9 O
DNA	1063 3 O
damage	1067 6 O
and	1074 3 O
renal	1078 5 B-Disease
injury	1084 6 I-Disease
compared	1091 8 O
with	1100 4 O
Nrf2	1105 4 O
(	1109 1 O
+	1110 1 O
/	1111 1 O
+	1112 1 O
)	1113 1 O
mice	1115 4 O
.	1119 1 O

Mechanistic	1121 11 O
studies	1133 7 O
in	1141 2 O
both	1144 4 O
in	1149 2 O
vivo	1152 4 O
and	1157 3 O
in	1161 2 O
vitro	1164 5 O
systems	1170 7 O
showed	1178 6 O
that	1185 4 O
the	1190 3 O
Nrf2	1194 4 O
-	1198 1 O
mediated	1199 8 O
protection	1208 10 O
against	1219 7 O
diabetic	1227 8 B-Disease
nephropathy	1236 11 I-Disease
is	1248 2 O
,	1250 1 O
at	1252 2 O
least	1255 5 O
,	1260 1 O
partially	1262 9 O
through	1272 7 O
inhibition	1280 10 O
of	1291 2 O
transforming	1294 12 O
growth	1307 6 O
factor	1314 6 O
-	1320 1 O
beta1	1321 5 O
(	1327 1 O
TGF	1328 3 O
-	1331 1 O
beta1	1332 5 O
)	1337 1 O
and	1339 3 O
reduction	1343 9 O
of	1353 2 O
extracellular	1356 13 O
matrix	1370 6 O
production	1377 10 O
.	1387 1 O

In	1389 2 O
human	1392 5 O
renal	1398 5 O
mesangial	1404 9 O
cells	1414 5 O
,	1419 1 O
high	1421 4 O
glucose	1426 7 B-Chemical
induced	1434 7 O
ROS	1442 3 O
production	1446 10 O
and	1457 3 O
activated	1461 9 O
expression	1471 10 O
of	1482 2 O
Nrf2	1485 4 O
and	1490 3 O
its	1494 3 O
downstream	1498 10 O
genes	1509 5 O
.	1514 1 O

Furthermore	1516 11 O
,	1527 1 O
activation	1529 10 O
or	1540 2 O
overexpression	1543 14 O
of	1558 2 O
Nrf2	1561 4 O
inhibited	1566 9 O
the	1576 3 O
promoter	1580 8 O
activity	1589 8 O
of	1598 2 O
TGF	1601 3 O
-	1604 1 O
beta1	1605 5 O
in	1611 2 O
a	1614 1 O
dose	1616 4 O
-	1620 1 O
dependent	1621 9 O
manner	1631 6 O
,	1637 1 O
whereas	1639 7 O
knockdown	1647 9 O
of	1657 2 O
Nrf2	1660 4 O
by	1665 2 O
siRNA	1668 5 O
enhanced	1674 8 O
TGF	1683 3 O
-	1686 1 O
beta1	1687 5 O
transcription	1693 13 O
and	1707 3 O
fibronectin	1711 11 O
production	1723 10 O
.	1733 1 O

CONCLUSIONS	1735 11 O
:	1746 1 O
This	1748 4 O
work	1753 4 O
clearly	1758 7 O
indicates	1766 9 O
a	1776 1 O
protective	1778 10 O
role	1789 4 O
of	1794 2 O
Nrf2	1797 4 O
in	1802 2 O
diabetic	1805 8 B-Disease
nephropathy	1814 11 I-Disease
,	1825 1 O
suggesting	1827 10 O
that	1838 4 O
dietary	1843 7 O
or	1851 2 O
therapeutic	1854 11 O
activation	1866 10 O
of	1877 2 O
Nrf2	1880 4 O
could	1885 5 O
be	1891 2 O
used	1894 4 O
as	1899 2 O
a	1902 1 O
strategy	1904 8 O
to	1913 2 O
prevent	1916 7 O
or	1924 2 O
slow	1927 4 O
down	1932 4 O
the	1937 3 O
progression	1941 11 O
of	1953 2 O
diabetic	1956 8 B-Disease
nephropathy	1965 11 I-Disease
.	1976 1 O

High	0 4 O
-	4 1 O
dose	5 4 O
tranexamic	10 10 B-Chemical
Acid	21 4 I-Chemical
is	26 2 O
associated	29 10 O
with	40 4 O
nonischemic	45 11 O
clinical	57 8 O
seizures	66 8 B-Disease
in	75 2 O
cardiac	78 7 O
surgical	86 8 O
patients	95 8 O
.	103 1 O

BACKGROUND	105 10 O
:	115 1 O
In	117 2 O
2	120 1 O
separate	122 8 O
centers	131 7 O
,	138 1 O
we	140 2 O
observed	143 8 O
a	152 1 O
notable	154 7 O
increase	162 8 O
in	171 2 O
the	174 3 O
incidence	178 9 O
of	188 2 O
postoperative	191 13 O
convulsive	205 10 B-Disease
seizures	216 8 B-Disease
from	225 4 O
1	230 1 O
.	231 1 O
3	232 1 O
%	233 1 O
to	235 2 O
3	238 1 O
.	239 1 O
8	240 1 O
%	241 1 O
in	243 2 O
patients	246 8 O
having	255 6 O
undergone	262 9 O
major	272 5 O
cardiac	278 7 O
surgical	286 8 O
procedures	295 10 O
.	305 1 O

These	307 5 O
events	313 6 O
were	320 4 O
temporally	325 10 O
coincident	336 10 O
with	347 4 O
the	352 3 O
initial	356 7 O
use	364 3 O
of	368 2 O
high	371 4 O
-	375 1 O
dose	376 4 O
tranexamic	381 10 B-Chemical
acid	392 4 I-Chemical
(	397 1 O
TXA	398 3 B-Chemical
)	401 1 O
therapy	403 7 O
after	411 5 O
withdrawal	417 10 O
of	428 2 O
aprotinin	431 9 O
from	441 4 O
general	446 7 O
clinical	454 8 O
usage	463 5 O
.	468 1 O

The	470 3 O
purpose	474 7 O
of	482 2 O
this	485 4 O
review	490 6 O
was	497 3 O
to	501 2 O
perform	504 7 O
a	512 1 O
retrospective	514 13 O
analysis	528 8 O
to	537 2 O
examine	540 7 O
whether	548 7 O
there	556 5 O
was	562 3 O
a	566 1 O
relation	568 8 O
between	577 7 O
TXA	585 3 B-Chemical
usage	589 5 O
and	595 3 O
seizures	599 8 B-Disease
after	608 5 O
cardiac	614 7 O
surgery	622 7 O
.	629 1 O

METHODS	631 7 O
:	638 1 O
An	640 2 O
in	643 2 O
-	645 1 O
depth	646 5 O
chart	652 5 O
review	658 6 O
was	665 3 O
undertaken	669 10 O
in	680 2 O
all	683 3 O
24	687 2 O
patients	690 8 O
who	699 3 O
developed	703 9 O
perioperative	713 13 O
seizures	727 8 B-Disease
.	735 1 O

Electroencephalographic	737 23 O
activity	761 8 O
was	770 3 O
recorded	774 8 O
in	783 2 O
11	786 2 O
of	789 2 O
these	792 5 O
patients	798 8 O
,	806 1 O
and	808 3 O
all	812 3 O
patients	816 8 O
had	825 3 O
a	829 1 O
formal	831 6 O
neurological	838 12 O
evaluation	851 10 O
and	862 3 O
brain	866 5 O
imaging	872 7 O
studies	880 7 O
.	887 1 O

RESULTS	889 7 O
:	896 1 O
Twenty	898 6 O
-	904 1 O
one	905 3 O
of	909 2 O
the	912 3 O
24	916 2 O
patients	919 8 O
did	928 3 O
not	932 3 O
have	936 4 O
evidence	941 8 O
of	950 2 O
new	953 3 O
cerebral	957 8 B-Disease
ischemic	966 8 I-Disease
injury	975 6 I-Disease
,	981 1 O
but	983 3 O
seizures	987 8 B-Disease
were	996 4 O
likely	1001 6 O
due	1008 3 O
to	1012 2 O
ischemic	1015 8 B-Disease
brain	1024 5 I-Disease
injury	1030 6 I-Disease
in	1037 2 O
3	1040 1 O
patients	1042 8 O
.	1050 1 O

All	1052 3 O
patients	1056 8 O
with	1065 4 O
seizures	1070 8 B-Disease
did	1079 3 O
not	1083 3 O
have	1087 4 O
permanent	1092 9 O
neurological	1102 12 B-Disease
abnormalities	1115 13 I-Disease
.	1128 1 O

All	1130 3 O
24	1134 2 O
patients	1137 8 O
with	1146 4 O
seizures	1151 8 B-Disease
received	1160 8 O
high	1169 4 O
doses	1174 5 O
of	1180 2 O
TXA	1183 3 B-Chemical
intraoperatively	1187 16 O
ranging	1204 7 O
from	1212 4 O
61	1217 2 O
to	1220 2 O
259	1223 3 O
mg	1227 2 O
/	1229 1 O
kg	1230 2 O
,	1232 1 O
had	1234 3 O
a	1238 1 O
mean	1240 4 O
age	1245 3 O
of	1249 2 O
69	1252 2 O
.	1254 1 O
9	1255 1 O
years	1257 5 O
,	1262 1 O
and	1264 3 O
21	1268 2 O
of	1271 2 O
24	1274 2 O
had	1277 3 O
undergone	1281 9 O
open	1291 4 O
chamber	1296 7 O
rather	1304 6 O
than	1311 4 O
coronary	1316 8 O
bypass	1325 6 O
procedures	1332 10 O
.	1342 1 O

All	1344 3 O
but	1348 3 O
one	1352 3 O
patient	1356 7 O
were	1364 4 O
managed	1369 7 O
using	1377 5 O
cardiopulmonary	1383 15 O
bypass	1399 6 O
.	1405 1 O

No	1407 2 O
evidence	1410 8 O
of	1419 2 O
brain	1422 5 B-Disease
ischemic	1428 8 I-Disease
,	1436 1 O
metabolic	1438 9 O
,	1447 1 O
or	1449 2 O
hyperthermia	1452 12 B-Disease
-	1464 1 O
induced	1465 7 O
causes	1473 6 O
for	1480 3 O
their	1484 5 O
seizures	1490 8 B-Disease
was	1499 3 O
apparent	1503 8 O
.	1511 1 O

CONCLUSION	1513 10 O
:	1523 1 O
Our	1525 3 O
results	1529 7 O
suggest	1537 7 O
that	1545 4 O
use	1550 3 O
of	1554 2 O
high	1557 4 O
-	1561 1 O
dose	1562 4 O
TXA	1567 3 B-Chemical
in	1571 2 O
older	1574 5 O
patients	1580 8 O
in	1589 2 O
conjunction	1592 11 O
with	1604 4 O
cardiopulmonary	1609 15 O
bypass	1625 6 O
and	1632 3 O
open	1636 4 O
-	1640 1 O
chamber	1641 7 O
cardiac	1649 7 O
surgery	1657 7 O
is	1665 2 O
associated	1668 10 O
with	1679 4 O
clinical	1684 8 O
seizures	1693 8 B-Disease
in	1702 2 O
susceptible	1705 11 O
patients	1717 8 O
.	1725 1 O

Recurrent	0 9 O
dysosmia	10 8 B-Disease
induced	19 7 O
by	27 2 O
pyrazinamide	30 12 B-Chemical
.	42 1 O

Pyrazinamide	44 12 B-Chemical
can	57 3 O
have	61 4 O
adverse	66 7 O
effects	74 7 O
such	82 4 O
as	87 2 O
hepatic	90 7 B-Disease
toxicity	98 8 I-Disease
,	106 1 O
hyperuricemia	108 13 B-Disease
or	122 2 O
digestive	125 9 O
disorders	135 9 O
.	144 1 O

In	146 2 O
rare	149 4 O
cases	154 5 O
,	159 1 O
alterations	161 11 O
in	173 2 O
taste	176 5 O
and	182 3 O
smell	186 5 O
function	192 8 O
have	201 4 O
been	206 4 O
reported	211 8 O
for	220 3 O
pyrazinamide	224 12 B-Chemical
when	237 4 O
combined	242 8 O
with	251 4 O
other	256 5 O
drugs	262 5 O
.	267 1 O

We	269 2 O
report	272 6 O
a	279 1 O
case	281 4 O
of	286 2 O
reversible	289 10 O
olfactory	300 9 B-Disease
disorder	310 8 I-Disease
related	319 7 O
to	327 2 O
pyrazinamide	330 12 B-Chemical
in	343 2 O
a	346 1 O
woman	348 5 O
,	353 1 O
with	355 4 O
a	360 1 O
positive	362 8 O
rechallenge	371 11 O
.	382 1 O

The	384 3 O
patient	388 7 O
presented	396 9 O
every	406 5 O
day	412 3 O
a	416 1 O
sensation	418 9 O
of	428 2 O
smelling	431 8 O
something	440 9 O
burning	450 7 O
15	458 2 O
min	461 3 O
after	465 5 O
drug	471 4 O
intake	476 6 O
.	482 1 O

Dysosmia	484 8 B-Disease
disappeared	493 11 O
completely	505 10 O
after	516 5 O
pyrazinamide	522 12 B-Chemical
withdrawal	535 10 O
and	546 3 O
recurred	550 8 O
after	559 5 O
its	565 3 O
rechallenge	569 11 O
.	580 1 O

The	582 3 O
case	586 4 O
was	591 3 O
reported	595 8 O
to	604 2 O
the	607 3 O
Tunisian	611 8 O
Centre	620 6 O
of	627 2 O
Pharmacovigilance	630 17 O
.	647 1 O

Longitudinal	0 12 O
assessment	13 10 O
of	24 2 O
air	27 3 O
conduction	31 10 O
audiograms	42 10 O
in	53 2 O
a	56 1 O
phase	58 5 O
III	64 3 O
clinical	68 8 O
trial	77 5 O
of	83 2 O
difluoromethylornithine	86 23 B-Chemical
and	110 3 O
sulindac	114 8 B-Chemical
for	123 3 O
prevention	127 10 O
of	138 2 O
sporadic	141 8 O
colorectal	150 10 B-Disease
adenomas	161 8 I-Disease
.	169 1 O

A	171 1 O
phase	173 5 O
III	179 3 O
clinical	183 8 O
trial	192 5 O
assessed	198 8 O
the	207 3 O
recurrence	211 10 O
of	222 2 O
adenomatous	225 11 B-Disease
polyps	237 6 I-Disease
after	244 5 O
treatment	250 9 O
for	260 3 O
36	264 2 O
months	267 6 O
with	274 4 O
difluoromethylornithine	279 23 B-Chemical
(	303 1 O
DFMO	304 4 B-Chemical
)	308 1 O
plus	310 4 O
sulindac	315 8 B-Chemical
or	324 2 O
matched	327 7 O
placebos	335 8 O
.	343 1 O

Temporary	345 9 O
hearing	355 7 B-Disease
loss	363 4 I-Disease
is	368 2 O
a	371 1 O
known	373 5 O
toxicity	379 8 B-Disease
of	388 2 O
treatment	391 9 O
with	401 4 O
DFMO	406 4 B-Chemical
,	410 1 O
thus	412 4 O
a	417 1 O
comprehensive	419 13 O
approach	433 8 O
was	442 3 O
developed	446 9 O
to	456 2 O
analyze	459 7 O
serial	467 6 O
air	474 3 O
conduction	478 10 O
audiograms	489 10 O
.	499 1 O

The	501 3 O
generalized	505 11 O
estimating	517 10 O
equation	528 8 O
method	537 6 O
estimated	544 9 O
the	554 3 O
mean	558 4 O
difference	563 10 O
between	574 7 O
treatment	582 9 O
arms	592 4 O
with	597 4 O
regard	602 6 O
to	609 2 O
change	612 6 O
in	619 2 O
air	622 3 O
conduction	626 10 O
pure	637 4 O
tone	642 4 O
thresholds	647 10 O
while	658 5 O
accounting	664 10 O
for	675 3 O
within	679 6 O
-	685 1 O
subject	686 7 O
correlation	694 11 O
due	706 3 O
to	710 2 O
repeated	713 8 O
measurements	722 12 O
at	735 2 O
frequencies	738 11 O
.	749 1 O

Based	751 5 O
on	757 2 O
290	760 3 O
subjects	764 8 O
,	772 1 O
there	774 5 O
was	780 3 O
an	784 2 O
average	787 7 O
difference	795 10 O
of	806 2 O
0	809 1 O
.	810 1 O
50	811 2 O
dB	814 2 O
between	817 7 O
subjects	825 8 O
treated	834 7 O
with	842 4 O
DFMO	847 4 B-Chemical
plus	852 4 O
sulindac	857 8 B-Chemical
compared	866 8 O
with	875 4 O
those	880 5 O
treated	886 7 O
with	894 4 O
placebo	899 7 O
(	907 1 O
95	908 2 O
%	910 1 O
confidence	912 10 O
interval	923 8 O
,	931 1 O
-	933 1 O
0	934 1 O
.	935 1 O
64	936 2 O
to	939 2 O
1	942 1 O
.	943 1 O
63	944 2 O
dB	947 2 O
;	949 1 O
P	951 1 O
=	953 1 O
0	955 1 O
.	956 1 O
39	957 2 O
)	959 1 O
,	960 1 O
adjusted	962 8 O
for	971 3 O
baseline	975 8 O
values	984 6 O
,	990 1 O
age	992 3 O
,	995 1 O
and	997 3 O
frequencies	1001 11 O
.	1012 1 O

In	1014 2 O
the	1017 3 O
normal	1021 6 O
speech	1028 6 O
range	1035 5 O
of	1041 2 O
500	1044 3 O
to	1048 2 O
3	1051 1 O
,	1052 1 O
000	1053 3 O
Hz	1057 2 O
,	1059 1 O
an	1061 2 O
estimated	1064 9 O
difference	1074 10 O
of	1085 2 O
0	1088 1 O
.	1089 1 O
99	1090 2 O
dB	1093 2 O
(	1096 1 O
-	1097 1 O
0	1098 1 O
.	1099 1 O
17	1100 2 O
to	1103 2 O
2	1106 1 O
.	1107 1 O
14	1108 2 O
dB	1111 2 O
;	1113 1 O
P	1115 1 O
=	1117 1 O
0	1119 1 O
.	1120 1 O
09	1121 2 O
)	1123 1 O
was	1125 3 O
detected	1129 8 O
.	1137 1 O

Dose	1139 4 O
intensity	1144 9 O
did	1154 3 O
not	1158 3 O
add	1162 3 O
information	1166 11 O
to	1178 2 O
models	1181 6 O
.	1187 1 O

There	1189 5 O
were	1195 4 O
14	1200 2 O
of	1203 2 O
151	1206 3 O
(	1210 1 O
9	1211 1 O
.	1212 1 O
3	1213 1 O
%	1214 1 O
)	1215 1 O
in	1217 2 O
the	1220 3 O
DFMO	1224 4 B-Chemical
plus	1229 4 O
sulindac	1234 8 B-Chemical
group	1243 5 O
and	1249 3 O
4	1253 1 O
of	1255 2 O
139	1258 3 O
(	1262 1 O
2	1263 1 O
.	1264 1 O
9	1265 1 O
%	1266 1 O
)	1267 1 O
in	1269 2 O
the	1272 3 O
placebo	1276 7 O
group	1284 5 O
who	1290 3 O
experienced	1294 11 O
at	1306 2 O
least	1309 5 O
15	1315 2 O
dB	1318 2 O
hearing	1321 7 O
reduction	1329 9 O
from	1339 4 O
baseline	1344 8 O
in	1353 2 O
2	1356 1 O
or	1358 2 O
more	1361 4 O
consecutive	1366 11 O
frequencies	1378 11 O
across	1390 6 O
the	1397 3 O
entire	1401 6 O
range	1408 5 O
tested	1414 6 O
(	1421 1 O
P	1422 1 O
=	1424 1 O
0	1426 1 O
.	1427 1 O
02	1428 2 O
)	1430 1 O
.	1431 1 O

Follow	1433 6 O
-	1439 1 O
up	1440 2 O
air	1443 3 O
conduction	1447 10 O
done	1458 4 O
at	1463 2 O
least	1466 5 O
6	1472 1 O
months	1474 6 O
after	1481 5 O
end	1487 3 O
of	1491 2 O
treatment	1494 9 O
showed	1504 6 O
an	1511 2 O
adjusted	1514 8 O
mean	1523 4 O
difference	1528 10 O
in	1539 2 O
hearing	1542 7 O
thresholds	1550 10 O
of	1561 2 O
1	1564 1 O
.	1565 1 O
08	1566 2 O
dB	1569 2 O
(	1572 1 O
-	1573 1 O
0	1574 1 O
.	1575 1 O
81	1576 2 O
to	1579 2 O
2	1582 1 O
.	1583 1 O
96	1584 2 O
dB	1587 2 O
;	1589 1 O
P	1591 1 O
=	1593 1 O
0	1595 1 O
.	1596 1 O
26	1597 2 O
)	1599 1 O
between	1601 7 O
treatment	1609 9 O
arms	1619 4 O
.	1623 1 O

There	1625 5 O
was	1631 3 O
no	1635 2 O
significant	1638 11 O
difference	1650 10 O
in	1661 2 O
the	1664 3 O
proportion	1668 10 O
of	1679 2 O
subjects	1682 8 O
in	1691 2 O
the	1694 3 O
DFMO	1698 4 B-Chemical
plus	1703 4 O
sulindac	1708 8 B-Chemical
group	1717 5 O
who	1723 3 O
experienced	1727 11 O
clinically	1739 10 O
significant	1750 11 O
hearing	1762 7 B-Disease
loss	1770 4 I-Disease
compared	1775 8 O
with	1784 4 O
the	1789 3 O
placebo	1793 7 O
group	1801 5 O
.	1806 1 O

The	1808 3 O
estimated	1812 9 O
attributable	1822 12 O
risk	1835 4 O
of	1840 2 O
ototoxicity	1843 11 B-Disease
from	1855 4 O
exposure	1860 8 O
to	1869 2 O
the	1872 3 O
drug	1876 4 O
is	1881 2 O
8	1884 1 O
.	1885 1 O
4	1886 1 O
%	1887 1 O
(	1889 1 O
95	1890 2 O
%	1892 1 O
confidence	1894 10 O
interval	1905 8 O
,	1913 1 O
-	1915 1 O
2	1916 1 O
.	1917 1 O
0	1918 1 O
%	1919 1 O
to	1921 2 O
18	1924 2 O
.	1926 1 O
8	1927 1 O
%	1928 1 O
;	1929 1 O
P	1931 1 O
=	1933 1 O
0	1935 1 O
.	1936 1 O
12	1937 2 O
)	1939 1 O
.	1940 1 O

There	1942 5 O
is	1948 2 O
a	1951 1 O
<	1953 1 O
2	1954 1 O
dB	1956 2 O
difference	1959 10 O
in	1970 2 O
mean	1973 4 O
threshold	1978 9 O
for	1988 3 O
patients	1992 8 O
treated	2001 7 O
with	2009 4 O
DFMO	2014 4 B-Chemical
plus	2019 4 O
sulindac	2024 8 B-Chemical
compared	2033 8 O
with	2042 4 O
those	2047 5 O
treated	2053 7 O
with	2061 4 O
placebo	2066 7 O
.	2073 1 O

Increased	0 9 O
mental	10 6 B-Disease
slowing	17 7 I-Disease
associated	25 10 O
with	36 4 O
the	41 3 O
APOE	45 4 O
epsilon4	50 8 O
allele	59 6 O
after	66 5 O
trihexyphenidyl	72 15 B-Chemical
oral	88 4 O
anticholinergic	93 15 O
challenge	109 9 O
in	119 2 O
healthy	122 7 O
elderly	130 7 O
.	137 1 O

OBJECTIVES	139 10 O
:	149 1 O
The	151 3 O
objectives	155 10 O
of	166 2 O
this	169 4 O
study	174 5 O
were	180 4 O
to	185 2 O
examine	188 7 O
the	196 3 O
relationship	200 12 O
between	213 7 O
APOE	221 4 O
epsilon4	226 8 O
and	235 3 O
subjective	239 10 O
effects	250 7 O
of	258 2 O
trihexyphenidyl	261 15 B-Chemical
on	277 2 O
measures	280 8 O
reflecting	289 10 O
sedation	300 8 O
and	309 3 O
confusion	313 9 B-Disease
and	323 3 O
to	327 2 O
investigate	330 11 O
the	342 3 O
relationship	346 12 O
between	359 7 O
trihexyphenidyl	367 15 B-Chemical
-	382 1 O
induced	383 7 O
subjective	391 10 O
effects	402 7 O
and	410 3 O
objective	414 9 O
memory	424 6 O
performance	431 11 O
.	442 1 O

METHODS	444 7 O
:	451 1 O
This	453 4 O
study	458 5 O
comprised	464 9 O
24	474 2 O
cognitively	477 11 O
intact	489 6 O
,	495 1 O
health	497 6 O
elderly	504 7 O
adults	512 6 O
(	519 1 O
12	520 2 O
APOE	523 4 O
epsilon4	528 8 O
carriers	537 8 O
)	545 1 O
at	547 2 O
an	550 2 O
outpatient	553 10 O
geriatric	564 9 O
psychiatry	574 10 O
research	585 8 O
clinic	594 6 O
.	600 1 O

This	602 4 O
was	607 3 O
a	611 1 O
randomized	613 10 O
,	623 1 O
double	625 6 O
blind	632 5 O
,	637 1 O
placebo	639 7 O
-	646 1 O
controlled	647 10 O
,	657 1 O
three	659 5 O
-	664 1 O
way	665 3 O
,	668 1 O
crossover	670 9 O
experimental	680 12 O
design	693 6 O
.	699 1 O

All	701 3 O
participants	705 12 O
received	718 8 O
1	727 1 O
.	728 1 O
0	729 1 O
mg	731 2 O
or	734 2 O
2	737 1 O
.	738 1 O
0	739 1 O
mg	741 2 O
trihexyphenidyl	744 15 B-Chemical
or	760 2 O
placebo	763 7 O
administered	771 12 O
in	784 2 O
counterbalanced	787 15 O
sequences	803 9 O
over	813 4 O
a	818 1 O
period	820 6 O
of	827 2 O
three	830 5 O
consecutive	836 11 O
weeks	848 5 O
.	853 1 O

Bond	855 4 O
and	860 3 O
Lader	864 5 O
'	869 1 O
s	870 1 O
visual	872 6 O
analog	879 6 O
scales	886 6 O
and	893 3 O
alternate	897 9 O
versions	907 8 O
of	916 2 O
the	919 3 O
Buschke	923 7 O
Selective	931 9 O
Reminding	941 9 O
Test	951 4 O
were	956 4 O
administered	961 12 O
in	974 2 O
a	977 1 O
repeated	979 8 O
measures	988 8 O
design	997 6 O
at	1004 2 O
baseline	1007 8 O
,	1015 1 O
1	1017 1 O
,	1018 1 O
2	1020 1 O
.	1021 1 O
5	1022 1 O
,	1023 1 O
and	1025 3 O
5	1029 1 O
hours	1031 5 O
postdrug	1037 8 O
administration	1046 14 O
.	1060 1 O

RESULTS	1062 7 O
:	1069 1 O
A	1071 1 O
2	1073 1 O
.	1074 1 O
0	1075 1 O
-	1076 1 O
mg	1077 2 O
oral	1080 4 O
dose	1085 4 O
of	1090 2 O
trihexyphenidyl	1093 15 B-Chemical
resulted	1109 8 O
in	1118 2 O
increased	1121 9 O
subjective	1131 10 O
ratings	1142 7 O
of	1150 2 O
mental	1153 6 B-Disease
slowness	1160 8 I-Disease
in	1169 2 O
carriers	1172 8 O
of	1181 2 O
the	1184 3 O
APOE	1188 4 O
epsilon4	1193 8 O
allele	1202 6 O
only	1209 4 O
.	1213 1 O

Drug	1215 4 O
effects	1220 7 O
as	1228 2 O
determined	1231 10 O
by	1242 2 O
difference	1245 10 O
scores	1256 6 O
between	1263 7 O
2	1271 1 O
.	1272 1 O
0	1273 1 O
mg	1275 2 O
trihexyphenidyl	1278 15 B-Chemical
and	1294 3 O
placebo	1298 7 O
on	1306 2 O
ratings	1309 7 O
of	1317 2 O
mental	1320 6 B-Disease
slowness	1327 8 I-Disease
significantly	1336 13 O
correlated	1350 10 O
with	1361 4 O
total	1366 5 O
and	1372 3 O
delayed	1376 7 O
recall	1384 6 O
on	1391 2 O
the	1394 3 O
Buschke	1398 7 O
Selective	1406 9 O
Reminding	1416 9 O
Test	1426 4 O
in	1431 2 O
carriers	1434 8 O
of	1443 2 O
the	1446 3 O
APOE	1450 4 O
epsilon4	1455 8 O
allele	1464 6 O
only	1471 4 O
.	1475 1 O

However	1477 7 O
,	1484 1 O
no	1486 2 O
significant	1489 11 O
effects	1501 7 O
were	1509 4 O
found	1514 5 O
with	1520 4 O
other	1525 5 O
visual	1531 6 O
analog	1538 6 O
scales	1545 6 O
reflecting	1552 10 O
subjective	1563 10 O
sedation	1574 8 O
and	1583 3 O
clear	1587 5 O
-	1592 1 O
headedness	1593 10 O
.	1603 1 O

CONCLUSION	1605 10 O
:	1615 1 O
The	1617 3 O
epsilon4	1621 8 O
allele	1630 6 O
in	1637 2 O
healthy	1640 7 O
elderly	1648 7 O
was	1656 3 O
associated	1660 10 O
with	1671 4 O
increased	1676 9 O
subjective	1686 10 O
mental	1697 6 B-Disease
slowing	1704 7 I-Disease
after	1712 5 O
trihexyphenidyl	1718 15 B-Chemical
anticholinergic	1734 15 O
challenge	1750 9 O
.	1759 1 O

Behavioral	0 10 O
effects	11 7 O
of	19 2 O
pubertal	22 8 O
anabolic	31 8 O
androgenic	40 10 O
steroid	51 7 B-Chemical
exposure	59 8 O
in	68 2 O
male	71 4 O
rats	76 4 O
with	81 4 O
low	86 3 O
serotonin	90 9 B-Chemical
.	99 1 O

The	101 3 O
goal	105 4 O
of	110 2 O
this	113 4 O
study	118 5 O
was	124 3 O
to	128 2 O
assess	131 6 O
the	138 3 O
interactive	142 11 O
effects	154 7 O
of	162 2 O
chronic	165 7 O
anabolic	173 8 O
androgenic	182 10 O
steroid	193 7 B-Chemical
(	201 1 O
AAS	202 3 O
)	205 1 O
exposure	207 8 O
and	216 3 O
brain	220 5 O
serotonin	226 9 B-Chemical
(	236 1 O
5	237 1 B-Chemical
-	238 1 I-Chemical
hydroxytryptamine	239 17 I-Chemical
,	256 1 O
5	258 1 B-Chemical
-	259 1 I-Chemical
HT	260 2 I-Chemical
)	262 1 O
depletion	264 9 O
on	274 2 O
behavior	277 8 O
of	286 2 O
pubertal	289 8 O
male	298 4 O
rats	303 4 O
.	307 1 O

Serotonin	309 9 B-Chemical
was	319 3 O
depleted	323 8 O
beginning	332 9 O
on	342 2 O
postnatal	345 9 O
day	355 3 O
26	359 2 O
with	362 4 O
parachlorophenylalanine	367 23 B-Chemical
(	391 1 O
PCPA	392 4 B-Chemical
100	397 3 O
mg	401 2 O
/	403 1 O
kg	404 2 O
,	406 1 O
every	408 5 O
other	414 5 O
day	420 3 O
)	423 1 O
;	424 1 O
controls	426 8 O
received	435 8 O
saline	444 6 O
.	450 1 O

At	452 2 O
puberty	455 7 O
(	463 1 O
P40	464 3 O
)	467 1 O
,	468 1 O
half	470 4 O
the	475 3 O
PCPA	479 4 B-Chemical
-	483 1 O
treated	484 7 O
rats	492 4 O
and	497 3 O
half	501 4 O
the	506 3 O
saline	510 6 O
-	516 1 O
treated	517 7 O
rats	525 4 O
began	530 5 O
treatment	536 9 O
with	546 4 O
testosterone	551 12 B-Chemical
(	564 1 O
T	565 1 B-Chemical
,	566 1 O
5	568 1 O
mg	570 2 O
/	572 1 O
kg	573 2 O
,	575 1 O
5	577 1 O
days	579 4 O
/	583 1 O
week	584 4 O
)	588 1 O
.	589 1 O

Behavioral	591 10 O
measures	602 8 O
included	611 8 O
locomotion	620 10 O
,	630 1 O
irritability	632 12 B-Disease
,	644 1 O
copulation	646 10 O
,	656 1 O
partner	658 7 O
preference	666 10 O
,	676 1 O
and	678 3 O
aggression	682 10 B-Disease
.	692 1 O

Animals	694 7 O
were	702 4 O
tested	707 6 O
for	714 3 O
aggression	718 10 B-Disease
in	729 2 O
their	732 5 O
home	738 4 O
cage	743 4 O
,	747 1 O
both	749 4 O
with	754 4 O
and	759 3 O
without	763 7 O
physical	771 8 O
provocation	780 11 O
(	792 1 O
mild	793 4 O
tail	798 4 O
pinch	803 5 O
)	808 1 O
.	809 1 O

Brain	811 5 O
levels	817 6 O
of	824 2 O
5	827 1 B-Chemical
-	828 1 I-Chemical
HT	829 2 I-Chemical
and	832 3 O
its	836 3 O
metabolite	840 10 O
,	850 1 O
5	852 1 B-Chemical
-	853 1 I-Chemical
hydroxyindoleacetic	854 19 I-Chemical
acid	874 4 I-Chemical
(	879 1 O
5	880 1 B-Chemical
-	881 1 I-Chemical
HIAA	882 4 I-Chemical
)	886 1 O
,	887 1 O
were	889 4 O
determined	894 10 O
using	905 5 O
HPLC	911 4 O
.	915 1 O

PCPA	917 4 B-Chemical
significantly	922 13 O
and	936 3 O
substantially	940 13 O
depleted	954 8 O
5	963 1 B-Chemical
-	964 1 I-Chemical
HT	965 2 I-Chemical
and	968 3 O
5	972 1 B-Chemical
-	973 1 I-Chemical
HIAA	974 4 I-Chemical
in	979 2 O
all	982 3 O
brain	986 5 O
regions	992 7 O
examined	1000 8 O
.	1008 1 O

Chronic	1010 7 O
T	1018 1 B-Chemical
treatment	1020 9 O
significantly	1030 13 O
decreased	1044 9 O
5	1054 1 B-Chemical
-	1055 1 I-Chemical
HT	1056 2 I-Chemical
and	1059 3 O
5	1063 1 B-Chemical
-	1064 1 I-Chemical
HIAA	1065 4 I-Chemical
in	1070 2 O
certain	1073 7 O
brain	1081 5 O
areas	1087 5 O
,	1092 1 O
but	1094 3 O
to	1098 2 O
a	1101 1 O
much	1103 4 O
lesser	1108 6 O
extent	1115 6 O
than	1122 4 O
PCPA	1127 4 B-Chemical
.	1131 1 O

Chronic	1133 7 O
exposure	1141 8 O
to	1150 2 O
PCPA	1153 4 B-Chemical
alone	1158 5 O
significantly	1164 13 O
decreased	1178 9 O
locomotor	1188 9 O
activity	1198 8 O
and	1207 3 O
increased	1211 9 O
irritability	1221 12 B-Disease
but	1234 3 O
had	1238 3 O
no	1242 2 O
effect	1245 6 O
on	1252 2 O
sexual	1255 6 O
behavior	1262 8 O
,	1270 1 O
partner	1272 7 O
preference	1280 10 O
,	1290 1 O
or	1292 2 O
aggression	1295 10 B-Disease
.	1305 1 O

T	1307 1 B-Chemical
alone	1309 5 O
had	1315 3 O
no	1319 2 O
effect	1322 6 O
on	1329 2 O
locomotion	1332 10 O
,	1342 1 O
irritability	1344 12 B-Disease
,	1356 1 O
or	1358 2 O
sexual	1361 6 O
behavior	1368 8 O
but	1377 3 O
increased	1381 9 O
partner	1391 7 O
preference	1399 10 O
and	1410 3 O
aggression	1414 10 B-Disease
.	1424 1 O

The	1426 3 O
most	1430 4 O
striking	1435 8 O
effect	1444 6 O
of	1451 2 O
combining	1454 9 O
T	1464 1 B-Chemical
+	1465 1 O
PCPA	1466 4 B-Chemical
was	1471 3 O
a	1475 1 O
significant	1477 11 O
increase	1489 8 O
in	1498 2 O
attack	1501 6 O
frequency	1508 9 O
as	1518 2 O
well	1521 4 O
as	1526 2 O
a	1529 1 O
significant	1531 11 O
decrease	1543 8 O
in	1552 2 O
the	1555 3 O
latency	1559 7 O
to	1567 2 O
attack	1570 6 O
,	1576 1 O
particularly	1578 12 O
following	1591 9 O
physical	1601 8 O
provocation	1610 11 O
.	1621 1 O

Based	1623 5 O
on	1629 2 O
these	1632 5 O
data	1638 4 O
,	1642 1 O
it	1644 2 O
can	1647 3 O
be	1651 2 O
speculated	1654 10 O
that	1665 4 O
pubertal	1670 8 O
AAS	1679 3 O
users	1683 5 O
with	1689 4 O
low	1694 3 O
central	1698 7 O
5	1706 1 B-Chemical
-	1707 1 I-Chemical
HT	1708 2 I-Chemical
may	1711 3 O
be	1715 2 O
especially	1718 10 O
prone	1729 5 O
to	1735 2 O
exhibit	1738 7 O
aggressive	1746 10 B-Disease
behavior	1757 8 I-Disease
.	1765 1 O

Intracavitary	0 13 O
chemotherapy	14 12 O
(	27 1 O
paclitaxel	28 10 B-Chemical
/	38 1 O
carboplatin	39 11 B-Chemical
liquid	51 6 O
crystalline	58 11 O
cubic	70 5 O
phases	76 6 O
)	82 1 O
for	84 3 O
recurrent	88 9 O
glioblastoma	98 12 B-Disease
-	111 1 O
-	112 1 O
clinical	114 8 O
observations	123 12 O
.	135 1 O

Human	137 5 O
malignant	143 9 O
brain	153 5 B-Disease
tumors	159 6 I-Disease
have	166 4 O
a	171 1 O
poor	173 4 O
prognosis	178 9 O
in	188 2 O
spite	191 5 O
of	197 2 O
surgery	200 7 O
and	208 3 O
radiation	212 9 O
therapy	222 7 O
.	229 1 O

Cubic	231 5 O
phases	237 6 O
consist	244 7 O
of	252 2 O
curved	255 6 O
biocontinuous	262 13 O
lipid	276 5 O
bilayers	282 8 O
,	290 1 O
separating	292 10 O
two	303 3 O
congruent	307 9 O
networks	317 8 O
of	326 2 O
water	329 5 O
channels	335 8 O
.	343 1 O

Used	345 4 O
as	350 2 O
a	353 1 O
host	355 4 O
for	360 3 O
cytotoxic	364 9 O
drugs	374 5 O
,	379 1 O
the	381 3 O
gel	385 3 O
-	388 1 O
like	389 4 O
matrix	394 6 O
can	401 3 O
easily	405 6 O
be	412 2 O
applied	415 7 O
to	423 2 O
the	426 3 O
walls	430 5 O
of	436 2 O
a	439 1 O
surgical	441 8 O
resection	450 9 O
cavity	460 6 O
.	466 1 O

For	468 3 O
human	472 5 O
glioblastoma	478 12 B-Disease
recurrences	491 11 O
,	502 1 O
the	504 3 O
feasibility	508 11 O
,	519 1 O
safety	521 6 O
,	527 1 O
and	529 3 O
short	533 5 O
-	538 1 O
term	539 4 O
effects	544 7 O
of	552 2 O
a	555 1 O
surgical	557 8 O
intracavitary	566 13 O
application	580 11 O
of	592 2 O
paclitaxel	595 10 B-Chemical
and	606 3 O
carboplatin	610 11 B-Chemical
encapsulated	622 12 O
by	635 2 O
liquid	638 6 O
crystalline	645 11 O
cubic	657 5 O
phases	663 6 O
are	670 3 O
examined	674 8 O
in	683 2 O
a	686 1 O
pilot	688 5 O
study	694 5 O
.	699 1 O

A	701 1 O
total	703 5 O
of	709 2 O
12	712 2 O
patients	715 8 O
with	724 4 O
a	729 1 O
recurrence	731 10 O
of	742 2 O
a	745 1 O
glioblastoma	747 12 B-Disease
multiforme	760 10 O
underwent	771 9 O
re	781 2 O
-	783 1 O
resection	784 9 O
and	794 3 O
received	798 8 O
an	807 2 O
intracavitary	810 13 O
application	824 11 O
of	836 2 O
paclitaxel	839 10 B-Chemical
and	850 3 O
carboplatin	854 11 B-Chemical
cubic	866 5 O
phases	872 6 O
in	879 2 O
different	882 9 O
dosages	892 7 O
.	899 1 O

Six	901 3 O
of	905 2 O
the	908 3 O
patients	912 8 O
received	921 8 O
more	930 4 O
than	935 4 O
15	940 2 O
mg	943 2 O
paclitaxel	946 10 B-Chemical
and	957 3 O
suffered	961 8 O
from	970 4 O
moderate	975 8 O
to	984 2 O
severe	987 6 O
brain	994 5 B-Disease
edema	1000 5 I-Disease
,	1005 1 O
while	1007 5 O
the	1013 3 O
remaining	1017 9 O
patients	1027 8 O
received	1036 8 O
only	1045 4 O
a	1050 1 O
total	1052 5 O
of	1058 2 O
15	1061 2 O
mg	1064 2 O
paclitaxel	1067 10 B-Chemical
.	1077 1 O

In	1079 2 O
the	1082 3 O
latter	1086 6 O
group	1093 5 O
,	1098 1 O
brain	1100 5 B-Disease
edema	1106 5 I-Disease
was	1112 3 O
markedly	1116 8 O
reduced	1125 7 O
and	1133 3 O
dealt	1137 5 O
medically	1143 9 O
.	1152 1 O

Intracavitary	1154 13 O
chemotherapy	1168 12 O
in	1181 2 O
recurrent	1184 9 O
glioblastoma	1194 12 B-Disease
using	1207 5 O
cubic	1213 5 O
phases	1219 6 O
is	1226 2 O
feasible	1229 8 O
and	1238 3 O
safe	1242 4 O
,	1246 1 O
yet	1248 3 O
the	1252 3 O
clinical	1256 8 O
benefit	1265 7 O
remains	1273 7 O
to	1281 2 O
be	1284 2 O
examined	1287 8 O
in	1296 2 O
a	1299 1 O
clinical	1301 8 O
phase	1310 5 O
II	1316 2 O
study	1319 5 O
.	1324 1 O

Methylphenidate	0 15 B-Chemical
-	15 1 O
induced	16 7 O
obsessive	24 9 B-Disease
-	33 1 I-Disease
compulsive	34 10 I-Disease
symptoms	45 8 I-Disease
in	54 2 O
an	57 2 O
elderly	60 7 O
man	68 3 O
.	71 1 O

An	73 2 O
82	76 2 O
-	78 1 O
year	79 4 O
-	83 1 O
old	84 3 O
man	88 3 O
with	92 4 O
treatment	97 9 B-Disease
-	106 1 I-Disease
resistant	107 9 I-Disease
depression	117 10 I-Disease
and	128 3 O
early	132 5 O
Alzheimer	138 9 B-Disease
'	147 1 I-Disease
s	148 1 I-Disease
disease	150 7 I-Disease
was	158 3 O
started	162 7 O
on	170 2 O
methylphenidate	173 15 B-Chemical
.	188 1 O

Significant	190 11 O
obsessive	202 9 B-Disease
-	211 1 I-Disease
compulsive	212 10 I-Disease
behavior	223 8 I-Disease
ensued	232 6 O
but	239 3 O
diminished	243 10 O
over	254 4 O
several	259 7 O
weeks	267 5 O
when	273 4 O
methylphenidate	278 15 B-Chemical
was	294 3 O
replaced	298 8 O
by	307 2 O
fluvoxamine	310 11 B-Chemical
.	321 1 O

The	323 3 O
patient	327 7 O
had	335 3 O
no	339 2 O
prior	342 5 O
psychiatric	348 11 B-Disease
history	360 7 O
,	367 1 O
but	369 3 O
he	373 2 O
had	376 3 O
a	380 1 O
sister	382 6 O
with	389 4 O
obsessive	394 9 B-Disease
-	403 1 I-Disease
compulsive	404 10 I-Disease
disorder	415 8 I-Disease
.	423 1 O

It	425 2 O
appears	428 7 O
that	436 4 O
methylphenidate	441 15 B-Chemical
precipitated	457 12 O
the	470 3 O
patient	474 7 O
'	481 1 O
s	482 1 O
pathological	484 12 O
behavior	497 8 O
.	505 1 O

Cardiac	0 7 B-Disease
arrest	8 6 I-Disease
after	15 5 O
intravenous	21 11 O
metoclopramide	33 14 B-Chemical
-	48 1 O
a	50 1 O
case	52 4 O
of	57 2 O
five	60 4 O
repeated	65 8 O
injections	74 10 O
of	85 2 O
metoclopramide	88 14 B-Chemical
causing	103 7 O
five	111 4 O
episodes	116 8 O
of	125 2 O
cardiac	128 7 B-Disease
arrest	136 6 I-Disease
.	142 1 O

We	144 2 O
describe	147 8 O
a	156 1 O
patient	158 7 O
where	166 5 O
intravenous	172 11 O
injection	184 9 O
of	194 2 O
metoclopramide	197 14 B-Chemical
was	212 3 O
immediately	216 11 O
followed	228 8 O
by	237 2 O
asystole	240 8 B-Disease
repeatedly	249 10 O
.	259 1 O

The	261 3 O
patient	265 7 O
received	273 8 O
metoclopramide	282 14 B-Chemical
10	297 2 O
mg	300 2 O
i	303 1 O
.	304 1 O
v	305 1 O
.	306 1 O
five	308 4 O
times	313 5 O
during	319 6 O
48	326 2 O
h	329 1 O
.	330 1 O

After	332 5 O
interviewing	338 12 O
the	351 3 O
attending	355 9 O
nurses	365 6 O
and	372 3 O
reviewing	376 9 O
the	386 3 O
written	390 7 O
documentation	398 13 O
,	411 1 O
it	413 2 O
is	416 2 O
clear	419 5 O
that	425 4 O
every	430 5 O
administration	436 14 O
of	451 2 O
metoclopramide	454 14 B-Chemical
was	469 3 O
immediately	473 11 O
(	485 1 O
within	486 6 O
s	493 1 O
)	494 1 O
followed	496 8 O
by	505 2 O
asystole	508 8 B-Disease
.	516 1 O

The	518 3 O
asystole	522 8 B-Disease
lasted	531 6 O
15	538 2 O
-	540 1 O
30	541 2 O
s	544 1 O
on	546 2 O
four	549 4 O
occasions	554 9 O
,	563 1 O
on	565 2 O
one	568 3 O
occasion	572 8 O
it	581 2 O
lasted	584 6 O
2	591 1 O
min	593 3 O
.	596 1 O

The	598 3 O
patient	602 7 O
received	610 8 O
atropine	619 8 B-Chemical
0	628 1 O
.	629 1 O
5	630 1 O
-	631 1 O
1	632 1 O
mg	634 2 O
and	637 3 O
chest	641 5 O
compressions	647 12 O
,	659 1 O
before	661 6 O
sinus	668 5 O
rhythm	674 6 O
again	681 5 O
took	687 4 O
over	692 4 O
.	696 1 O

We	698 2 O
interpret	701 9 O
this	711 4 O
as	716 2 O
episodes	719 8 O
of	728 2 O
cardiac	731 7 B-Disease
arrest	739 6 I-Disease
caused	746 6 O
by	753 2 O
metoclopramide	756 14 B-Chemical
.	770 1 O

The	772 3 O
rapid	776 5 O
injection	782 9 O
via	792 3 O
the	796 3 O
central	800 7 O
venous	808 6 O
route	815 5 O
and	821 3 O
the	825 3 O
concomitant	829 11 O
tapering	841 8 O
of	850 2 O
dopamine	853 8 B-Chemical
infusion	862 8 O
might	871 5 O
have	877 4 O
contributed	882 11 O
in	894 2 O
precipitating	897 13 O
the	911 3 O
adverse	915 7 O
drug	923 4 O
reaction	928 8 O
.	936 1 O

Severe	0 6 O
immune	7 6 O
hemolytic	14 9 B-Disease
anemia	24 6 I-Disease
associated	31 10 O
with	42 4 O
prophylactic	47 12 O
use	60 3 O
of	64 2 O
cefotetan	67 9 B-Chemical
in	77 2 O
obstetric	80 9 O
and	90 3 O
gynecologic	94 11 O
procedures	106 10 O
.	116 1 O

Second	118 6 O
-	124 1 O
and	126 3 O
third	130 5 O
-	135 1 O
generation	136 10 O
cephalosporins	147 14 B-Chemical
,	161 1 O
especially	163 10 O
cefotetan	174 9 B-Chemical
,	183 1 O
are	185 3 O
increasingly	189 12 O
associated	202 10 O
with	213 4 O
severe	218 6 O
,	224 1 O
sometimes	226 9 O
fatal	236 5 O
immune	242 6 O
hemolytic	249 9 B-Disease
anemia	259 6 I-Disease
.	265 1 O

We	267 2 O
noticed	270 7 O
that	278 4 O
10	283 2 O
of	286 2 O
our	289 3 O
35	293 2 O
cases	296 5 O
of	302 2 O
cefotetan	305 9 B-Chemical
-	314 1 O
induced	315 7 O
hemolytic	323 9 B-Disease
anemias	333 7 I-Disease
were	341 4 O
in	346 2 O
patients	349 8 O
who	358 3 O
had	362 3 O
received	366 8 O
cefotetan	375 9 B-Chemical
prophylactically	385 16 O
for	402 3 O
obstetric	406 9 O
and	416 3 O
gynecologic	420 11 O
procedures	432 10 O
.	442 1 O

Eight	444 5 O
of	450 2 O
these	453 5 O
cases	459 5 O
of	465 2 O
severe	468 6 O
immune	475 6 O
hemolytic	482 9 B-Disease
anemia	492 6 I-Disease
are	499 3 O
described	503 9 O
.	512 1 O

Cauda	0 5 B-Disease
equina	6 6 I-Disease
syndrome	13 8 I-Disease
after	22 5 O
spinal	28 6 O
anaesthesia	35 11 O
with	47 4 O
hyperbaric	52 10 O
5	63 1 O
%	64 1 O
lignocaine	66 10 B-Chemical
:	76 1 O
a	78 1 O
review	80 6 O
of	87 2 O
six	90 3 O
cases	94 5 O
of	100 2 O
cauda	103 5 B-Disease
equina	109 6 I-Disease
syndrome	116 8 I-Disease
reported	125 8 O
to	134 2 O
the	137 3 O
Swedish	141 7 O
Pharmaceutical	149 14 O
Insurance	164 9 O
1993	174 4 O
-	178 1 O
1997	179 4 O
.	183 1 O

Six	185 3 O
cases	189 5 O
of	195 2 O
cauda	198 5 B-Disease
equina	204 6 I-Disease
syndrome	211 8 I-Disease
with	220 4 O
varying	225 7 O
severity	233 8 O
were	242 4 O
reported	247 8 O
to	256 2 O
the	259 3 O
Swedish	263 7 O
Pharmaceutical	271 14 O
Insurance	286 9 O
during	296 6 O
the	303 3 O
period	307 6 O
1993	314 4 O
-	318 1 O
1997	319 4 O
.	323 1 O

All	325 3 O
were	329 4 O
associated	334 10 O
with	345 4 O
spinal	350 6 O
anaesthesia	357 11 O
using	369 5 O
hyperbaric	375 10 O
5	386 1 O
%	387 1 O
lignocaine	389 10 B-Chemical
.	399 1 O

Five	401 4 O
cases	406 5 O
had	412 3 O
single	416 6 O
-	422 1 O
shot	423 4 O
spinal	428 6 O
anaesthesia	435 11 O
and	447 3 O
one	451 3 O
had	455 3 O
a	459 1 O
repeat	461 6 O
spinal	468 6 O
anaesthetic	475 11 O
due	487 3 O
to	491 2 O
inadequate	494 10 O
block	505 5 O
.	510 1 O

The	512 3 O
dose	516 4 O
of	521 2 O
hyperbaric	524 10 O
5	535 1 O
%	536 1 O
lignocaine	538 10 B-Chemical
administered	549 12 O
ranged	562 6 O
from	569 4 O
60	574 2 O
to	577 2 O
120	580 3 O
mg	584 2 O
.	586 1 O

Three	588 5 O
of	594 2 O
the	597 3 O
cases	601 5 O
were	607 4 O
most	612 4 O
likely	617 6 O
caused	624 6 O
by	631 2 O
direct	634 6 O
neurotoxicity	641 13 B-Disease
of	655 2 O
hyperbaric	658 10 O
5	669 1 O
%	670 1 O
lignocaine	672 10 B-Chemical
.	682 1 O

In	684 2 O
the	687 3 O
other	691 5 O
3	697 1 O
cases	699 5 O
,	704 1 O
direct	706 6 O
neurotoxicity	713 13 B-Disease
was	727 3 O
also	731 4 O
probable	736 8 O
,	744 1 O
but	746 3 O
unfortunately	750 13 O
radiological	764 12 O
investigations	777 14 O
were	792 4 O
not	797 3 O
done	801 4 O
to	806 2 O
definitely	809 10 O
exclude	820 7 O
a	828 1 O
compressive	830 11 O
aetiology	842 9 O
.	851 1 O

All	853 3 O
cases	857 5 O
sustained	863 9 O
permanent	873 9 O
neurological	883 12 B-Disease
deficits	896 8 I-Disease
.	904 1 O

We	906 2 O
recommend	909 9 O
that	919 4 O
hyperbaric	924 10 O
lignocaine	935 10 B-Chemical
should	946 6 O
be	953 2 O
administered	956 12 O
in	969 2 O
concentrations	972 14 O
not	987 3 O
greater	991 7 O
than	999 4 O
2	1004 1 O
%	1005 1 O
and	1007 3 O
at	1011 2 O
a	1014 1 O
total	1016 5 O
dose	1022 4 O
preferably	1027 10 O
not	1038 3 O
exceeding	1042 9 O
60	1052 2 O
mg	1055 2 O
.	1057 1 O

Cortical	0 8 O
motor	9 5 O
overactivation	15 14 O
in	30 2 O
parkinsonian	33 12 B-Disease
patients	46 8 O
with	55 4 O
L	60 1 B-Chemical
-	61 1 I-Chemical
dopa	62 4 I-Chemical
-	66 1 O
induced	67 7 O
peak	75 4 O
-	79 1 O
dose	80 4 O
dyskinesia	85 10 B-Disease
.	95 1 O

We	97 2 O
have	100 4 O
studied	105 7 O
the	113 3 O
regional	117 8 O
cerebral	126 8 O
blood	135 5 O
flow	141 4 O
(	146 1 O
rCBF	147 4 O
)	151 1 O
changes	153 7 O
induced	161 7 O
by	169 2 O
the	172 3 O
execution	176 9 O
of	186 2 O
a	189 1 O
finger	191 6 O
-	197 1 O
to	198 2 O
-	200 1 O
thumb	201 5 O
opposition	207 10 O
motor	218 5 O
task	224 4 O
in	229 2 O
the	232 3 O
supplementary	236 13 O
and	250 3 O
primary	254 7 O
motor	262 5 O
cortex	268 6 O
of	275 2 O
two	278 3 O
groups	282 6 O
of	289 2 O
parkinsonian	292 12 B-Disease
patients	305 8 O
on	314 2 O
L	317 1 B-Chemical
-	318 1 I-Chemical
dopa	319 4 I-Chemical
medication	324 10 O
,	334 1 O
the	336 3 O
first	340 5 O
one	346 3 O
without	350 7 O
L	358 1 B-Chemical
-	359 1 I-Chemical
dopa	360 4 I-Chemical
induced	365 7 O
dyskinesia	373 10 B-Disease
(	384 1 O
n	385 1 O
=	387 1 O
23	389 2 O
)	391 1 O
and	393 3 O
the	397 3 O
other	401 5 O
with	407 4 O
moderate	412 8 O
peak	421 4 O
-	425 1 O
dose	426 4 O
dyskinesia	431 10 B-Disease
(	442 1 O
n	443 1 O
=	445 1 O
15	447 2 O
)	449 1 O
,	450 1 O
and	452 3 O
of	456 2 O
a	459 1 O
group	461 5 O
of	467 2 O
14	470 2 O
normal	473 6 O
subjects	480 8 O
.	488 1 O

Single	490 6 O
photon	497 6 O
emission	504 8 O
tomography	513 10 O
with	524 4 O
i	529 1 O
.	530 1 O
v	531 1 O
.	532 1 O
133Xe	534 5 O
was	540 3 O
used	544 4 O
to	549 2 O
measure	552 7 O
the	560 3 O
rCBF	564 4 O
changes	569 7 O
.	576 1 O

The	578 3 O
dyskinetic	582 10 B-Disease
parkinsonian	593 12 B-Disease
patients	606 8 O
exhibited	615 9 O
a	625 1 O
pattern	627 7 O
of	635 2 O
response	638 8 O
which	647 5 O
was	653 3 O
markedly	657 8 O
different	666 9 O
from	676 4 O
those	681 5 O
of	687 2 O
the	690 3 O
normal	694 6 O
subjects	701 8 O
and	710 3 O
non	714 3 O
-	717 1 O
dyskinetic	718 10 B-Disease
parkinsonian	729 12 B-Disease
patients	742 8 O
,	750 1 O
with	752 4 O
a	757 1 O
significant	759 11 O
overactivation	771 14 O
in	786 2 O
the	789 3 O
supplementary	793 13 O
motor	807 5 O
area	813 4 O
and	818 3 O
the	822 3 O
ipsi	826 4 O
-	830 1 O
and	832 3 O
contralateral	836 13 O
primary	850 7 O
motor	858 5 O
areas	864 5 O
.	869 1 O

These	871 5 O
results	877 7 O
are	885 3 O
compatible	889 10 O
with	900 4 O
the	905 3 O
hypothesis	909 10 O
that	920 4 O
an	925 2 O
hyperkinetic	928 12 B-Disease
abnormal	941 8 B-Disease
involuntary	950 11 I-Disease
movement	962 8 I-Disease
,	970 1 O
like	972 4 O
L	977 1 B-Chemical
-	978 1 I-Chemical
dopa	979 4 I-Chemical
-	983 1 O
induced	984 7 O
peak	992 4 O
dose	997 4 O
dyskinesia	1002 10 B-Disease
,	1012 1 O
is	1014 2 O
due	1017 3 O
to	1021 2 O
a	1024 1 O
disinhibition	1026 13 O
of	1040 2 O
the	1043 3 O
primary	1047 7 O
and	1055 3 O
associated	1059 10 O
motor	1070 5 O
cortex	1076 6 O
secondary	1083 9 O
to	1093 2 O
an	1096 2 O
excessive	1099 9 O
outflow	1109 7 O
of	1117 2 O
the	1120 3 O
pallidothalamocortical	1124 22 O
motor	1147 5 O
loop	1153 4 O
.	1157 1 O

Dexamethasone	0 13 B-Chemical
-	13 1 O
induced	14 7 O
ocular	22 6 B-Disease
hypertension	29 12 I-Disease
in	42 2 O
perfusion	45 9 O
-	54 1 O
cultured	55 8 O
human	64 5 O
eyes	70 4 O
.	74 1 O

PURPOSE	76 7 O
:	83 1 O
Glucocorticoid	85 14 O
administration	100 14 O
can	115 3 O
lead	119 4 O
to	124 2 O
the	127 3 O
development	131 11 O
of	143 2 O
ocular	146 6 B-Disease
hypertension	153 12 I-Disease
and	166 3 O
corticosteroid	170 14 B-Disease
glaucoma	185 8 I-Disease
in	194 2 O
a	197 1 O
subset	199 6 O
of	206 2 O
the	209 3 O
population	213 10 O
through	224 7 O
a	232 1 O
decrease	234 8 O
in	243 2 O
the	246 3 O
aqueous	250 7 O
humor	258 5 O
outflow	264 7 O
facility	272 8 O
.	280 1 O

The	282 3 O
purpose	286 7 O
of	294 2 O
this	297 4 O
study	302 5 O
was	308 3 O
to	312 2 O
determine	315 9 O
whether	325 7 O
glucocorticoid	333 14 O
treatment	348 9 O
can	358 3 O
directly	362 8 O
affect	371 6 O
the	378 3 O
outflow	382 7 O
facility	390 8 O
of	399 2 O
isolated	402 8 O
,	410 1 O
perfusion	412 9 O
-	421 1 O
cultured	422 8 O
human	431 5 O
eyes	437 4 O
.	441 1 O

METHODS	443 7 O
:	450 1 O
The	452 3 O
anterior	456 8 O
segments	465 8 O
of	474 2 O
human	477 5 O
donor	483 5 O
eyes	489 4 O
from	494 4 O
regional	499 8 O
eye	508 3 O
banks	512 5 O
were	518 4 O
placed	523 6 O
in	530 2 O
a	533 1 O
constant	535 8 O
flow	544 4 O
,	548 1 O
variable	550 8 O
pressure	559 8 O
perfusion	568 9 O
culture	578 7 O
system	586 6 O
.	592 1 O

Paired	594 6 O
eyes	601 4 O
were	606 4 O
perfused	611 8 O
in	620 2 O
serum	623 5 O
-	628 1 O
free	629 4 O
media	634 5 O
with	640 4 O
or	645 2 O
without	648 7 O
10	656 2 O
(	658 1 O
-	659 1 O
7	660 1 O
)	661 1 O
M	663 1 O
dexamethasone	665 13 B-Chemical
for	679 3 O
12	683 2 O
days	686 4 O
.	690 1 O

Intraocular	692 11 O
pressure	704 8 O
was	713 3 O
monitored	717 9 O
daily	727 5 O
.	732 1 O

After	734 5 O
incubation	740 10 O
,	750 1 O
the	752 3 O
eyes	756 4 O
were	761 4 O
morphologically	766 15 O
characterized	782 13 O
by	796 2 O
light	799 5 O
microscopy	805 10 O
,	815 1 O
transmission	817 12 O
and	830 3 O
scanning	834 8 O
electron	843 8 O
microscopy	852 10 O
,	862 1 O
and	864 3 O
scanning	868 8 O
laser	877 5 O
confocal	883 8 O
microscopy	892 10 O
.	902 1 O

RESULTS	904 7 O
:	911 1 O
A	913 1 O
significant	915 11 O
increase	927 8 O
in	936 2 O
intraocular	939 11 O
pressure	951 8 O
developed	960 9 O
in	970 2 O
13	973 2 O
of	976 2 O
the	979 3 O
44	983 2 O
pairs	986 5 O
of	992 2 O
eyes	995 4 O
perfused	1000 8 O
with	1009 4 O
dexamethasone	1014 13 B-Chemical
with	1028 4 O
an	1033 2 O
average	1036 7 O
pressure	1044 8 O
rise	1053 4 O
of	1058 2 O
17	1061 2 O
.	1063 1 O
5	1064 1 O
+	1066 1 O
/	1067 1 O
-	1068 1 O
3	1070 1 O
.	1071 1 O
8	1072 1 O
mm	1074 2 O
Hg	1077 2 O
after	1080 5 O
12	1086 2 O
days	1089 4 O
of	1094 2 O
dexamethasone	1097 13 B-Chemical
exposure	1111 8 O
.	1119 1 O

The	1121 3 O
contralateral	1125 13 O
control	1139 7 O
eyes	1147 4 O
,	1151 1 O
which	1153 5 O
did	1159 3 O
not	1163 3 O
receive	1167 7 O
dexamethasone	1175 13 B-Chemical
,	1188 1 O
maintained	1190 10 O
a	1201 1 O
stable	1203 6 O
intraocular	1210 11 O
pressure	1222 8 O
during	1231 6 O
the	1238 3 O
same	1242 4 O
period	1247 6 O
.	1253 1 O

The	1255 3 O
outflow	1259 7 O
pathway	1267 7 O
of	1275 2 O
the	1278 3 O
untreated	1282 9 O
eyes	1292 4 O
appeared	1297 8 O
morphologically	1306 15 O
normal	1322 6 O
.	1328 1 O

In	1330 2 O
contrast	1333 8 O
,	1341 1 O
the	1343 3 O
dexamethasone	1347 13 B-Chemical
-	1360 1 O
treated	1361 7 O
hypertensive	1369 12 B-Disease
eyes	1382 4 I-Disease
had	1387 3 O
thickened	1391 9 O
trabecular	1401 10 O
beams	1412 5 O
,	1417 1 O
decreased	1419 9 O
intertrabecular	1429 15 O
spaces	1445 6 O
,	1451 1 O
thickened	1453 9 O
juxtacanalicular	1463 16 O
tissue	1480 6 O
,	1486 1 O
activated	1488 9 O
trabecular	1498 10 O
meshwork	1509 8 O
cells	1518 5 O
,	1523 1 O
and	1525 3 O
increased	1529 9 O
amounts	1539 7 O
of	1547 2 O
amorphogranular	1550 15 O
extracellular	1566 13 O
material	1580 8 O
,	1588 1 O
especially	1590 10 O
in	1601 2 O
the	1604 3 O
juxtacanalicular	1608 16 O
tissue	1625 6 O
and	1632 3 O
beneath	1636 7 O
the	1644 3 O
endothelial	1648 11 O
lining	1660 6 O
of	1667 2 O
the	1670 3 O
canal	1674 5 O
of	1680 2 O
Schlemm	1683 7 O
.	1690 1 O

The	1692 3 O
dexamethasone	1696 13 B-Chemical
-	1709 1 O
treated	1710 7 O
nonresponder	1718 12 O
eyes	1731 4 O
appeared	1736 8 O
to	1745 2 O
be	1748 2 O
morphologically	1751 15 O
similar	1767 7 O
to	1775 2 O
the	1778 3 O
untreated	1782 9 O
eyes	1792 4 O
,	1796 1 O
although	1798 8 O
several	1807 7 O
subtle	1815 6 O
dexamethasone	1822 13 B-Chemical
-	1835 1 O
induced	1836 7 O
morphologic	1844 11 O
changes	1856 7 O
were	1864 4 O
evident	1869 7 O
.	1876 1 O

CONCLUSION	1878 10 O
:	1888 1 O
Dexamethasone	1890 13 B-Chemical
treatment	1904 9 O
of	1914 2 O
isolated	1917 8 O
,	1925 1 O
perfusion	1927 9 O
-	1936 1 O
cultured	1937 8 O
human	1946 5 O
eyes	1952 4 O
led	1957 3 O
to	1961 2 O
the	1964 3 O
generation	1968 10 O
of	1979 2 O
ocular	1982 6 B-Disease
hypertension	1989 12 I-Disease
in	2002 2 O
approximately	2005 13 O
30	2019 2 O
%	2021 1 O
of	2023 2 O
the	2026 3 O
dexamethasone	2030 13 B-Chemical
-	2043 1 O
treated	2044 7 O
eyes	2052 4 O
.	2056 1 O

Steroid	2058 7 B-Chemical
treatment	2066 9 O
resulted	2076 8 O
in	2085 2 O
morphologic	2088 11 O
changes	2100 7 O
in	2108 2 O
the	2111 3 O
trabecular	2115 10 O
meshwork	2126 8 O
similar	2135 7 O
to	2143 2 O
those	2146 5 O
reported	2152 8 O
for	2161 3 O
corticosteroid	2165 14 B-Disease
glaucoma	2180 8 I-Disease
and	2189 3 O
open	2193 4 B-Disease
angle	2198 5 I-Disease
glaucoma	2204 8 I-Disease
.	2212 1 O

This	2214 4 O
system	2219 6 O
may	2226 3 O
provide	2230 7 O
an	2238 2 O
acute	2241 5 O
model	2247 5 O
in	2253 2 O
which	2256 5 O
to	2262 2 O
study	2265 5 O
the	2271 3 O
pathogenic	2275 10 O
mechanisms	2286 10 O
involved	2297 8 O
in	2306 2 O
steroid	2309 7 B-Disease
glaucoma	2317 8 I-Disease
and	2326 3 O
primary	2330 7 B-Disease
open	2338 4 I-Disease
angle	2343 5 I-Disease
glaucoma	2349 8 I-Disease
.	2357 1 O

Cognitive	0 9 B-Disease
deterioration	10 13 I-Disease
from	24 4 O
long	29 4 O
-	33 1 O
term	34 4 O
abuse	39 5 O
of	45 2 O
dextromethorphan	48 16 B-Chemical
:	64 1 O
a	66 1 O
case	68 4 O
report	73 6 O
.	79 1 O

Dextromethorphan	81 16 B-Chemical
(	98 1 O
DM	99 2 B-Chemical
)	101 1 O
,	102 1 O
the	104 3 O
dextrorotatory	108 14 O
isomer	123 6 O
of	130 2 O
3	133 1 B-Chemical
-	134 1 I-Chemical
hydroxy	135 7 I-Chemical
-	142 1 I-Chemical
N	143 1 I-Chemical
-	144 1 I-Chemical
methylmorphinan	145 15 I-Chemical
,	160 1 O
is	162 2 O
the	165 3 O
main	169 4 O
ingredient	174 10 O
in	185 2 O
a	188 1 O
number	190 6 O
of	197 2 O
widely	200 6 O
available	207 9 O
,	216 1 O
over	218 4 O
-	222 1 O
the	223 3 O
-	226 1 O
counter	227 7 O
antitussives	235 12 O
.	247 1 O

Initial	249 7 O
studies	257 7 O
(	265 1 O
Bornstein	266 9 O
1968	276 4 O
)	280 1 O
showed	282 6 O
that	289 4 O
it	294 2 O
possessed	297 9 O
no	307 2 O
respiratory	310 11 O
suppressant	322 11 O
effects	334 7 O
and	342 3 O
no	346 2 O
addiction	349 9 O
liability	359 9 O
.	368 1 O

Subsequently	370 12 O
,	382 1 O
however	384 7 O
,	391 1 O
several	393 7 O
articles	401 8 O
reporting	410 9 O
abuse	420 5 O
of	426 2 O
this	429 4 O
drug	434 4 O
have	439 4 O
appeared	444 8 O
in	453 2 O
the	456 3 O
literature	460 10 O
.	470 1 O

The	472 3 O
drug	476 4 O
is	481 2 O
known	484 5 O
to	490 2 O
cause	493 5 O
a	499 1 O
variety	501 7 O
of	509 2 O
acute	512 5 O
toxic	518 5 O
effects	524 7 O
,	531 1 O
ranging	533 7 O
from	541 4 O
nausea	546 6 B-Disease
,	552 1 O
restlessness	554 12 B-Disease
,	566 1 O
insomnia	568 8 B-Disease
,	576 1 O
ataxia	578 6 B-Disease
,	584 1 O
slurred	586 7 O
speech	594 6 O
and	601 3 O
nystagmus	605 9 B-Disease
to	615 2 O
mood	618 4 O
changes	623 7 O
,	630 1 O
perceptual	632 10 O
alterations	643 11 O
,	654 1 O
inattention	656 11 O
,	667 1 O
disorientation	669 14 O
and	684 3 O
aggressive	688 10 B-Disease
behavior	699 8 I-Disease
(	708 1 O
Rammer	709 6 O
et	716 2 O
al	719 2 O
1988	722 4 O
;	726 1 O
Katona	728 6 O
and	735 3 O
Watson	739 6 O
1986	746 4 O
;	750 1 O
Isbell	752 6 O
and	759 3 O
Fraser	763 6 O
1953	770 4 O
;	774 1 O
Devlin	776 6 O
et	783 2 O
al	786 2 O
1985	789 4 O
;	793 1 O
McCarthy	795 8 O
1971	804 4 O
;	808 1 O
Dodds	810 5 O
and	816 3 O
Revai	820 5 O
1967	826 4 O
;	830 1 O
Degkwitz	832 8 O
1964	841 4 O
;	845 1 O
Hildebrand	847 10 O
et	858 2 O
al	861 2 O
1989	864 4 O
)	868 1 O
.	869 1 O

There	871 5 O
have	877 4 O
also	882 4 O
been	887 4 O
two	892 3 O
reported	896 8 O
fatalities	905 10 O
from	916 4 O
DM	921 2 B-Chemical
overdoses	924 9 O
(	934 1 O
Fleming	935 7 O
1986	943 4 O
)	947 1 O
.	948 1 O

However	950 7 O
,	957 1 O
there	959 5 O
are	965 3 O
no	969 2 O
reports	972 7 O
describing	980 10 O
the	991 3 O
effects	995 7 O
of	1003 2 O
chronic	1006 7 O
abuse	1014 5 O
.	1019 1 O

This	1021 4 O
report	1026 6 O
describes	1033 9 O
a	1043 1 O
case	1045 4 O
of	1050 2 O
cognitive	1053 9 B-Disease
deterioration	1063 13 I-Disease
resulting	1077 9 O
from	1087 4 O
prolonged	1092 9 O
use	1102 3 O
of	1106 2 O
DM	1109 2 B-Chemical
.	1111 1 O

Long	0 4 O
-	4 1 O
term	5 4 O
lithium	10 7 B-Chemical
treatment	18 9 O
and	28 3 O
the	32 3 O
kidney	36 6 O
.	42 1 O

Interim	44 7 O
report	52 6 O
on	59 2 O
fifty	62 5 O
patients	68 8 O
.	76 1 O

This	78 4 O
is	83 2 O
a	86 1 O
report	88 6 O
on	95 2 O
the	98 3 O
first	102 5 O
part	108 4 O
of	113 2 O
our	116 3 O
study	120 5 O
of	126 2 O
the	129 3 O
effects	133 7 O
of	141 2 O
long	144 4 O
-	148 1 O
term	149 4 O
lithium	154 7 B-Chemical
treatment	162 9 O
on	172 2 O
the	175 3 O
kidney	179 6 O
.	185 1 O

Creatinine	187 10 B-Chemical
clearance	198 9 O
,	207 1 O
maximum	209 7 O
urinary	217 7 O
osmolality	225 10 O
and	236 3 O
24	240 2 O
hour	243 4 O
urine	248 5 O
volume	254 6 O
have	261 4 O
been	266 4 O
tested	271 6 O
in	278 2 O
50	281 2 O
affectively	284 11 O
ill	296 3 O
patients	300 8 O
who	309 3 O
have	313 4 O
been	318 4 O
on	323 2 O
long	326 4 O
-	330 1 O
term	331 4 O
lithium	336 7 B-Chemical
for	344 3 O
more	348 4 O
than	353 4 O
one	358 3 O
year	362 4 O
.	366 1 O

These	368 5 O
findings	374 8 O
have	383 4 O
been	388 4 O
compared	393 8 O
with	402 4 O
norms	407 5 O
and	413 3 O
with	417 4 O
values	422 6 O
of	429 2 O
the	432 3 O
same	436 4 O
tests	441 5 O
from	447 4 O
screening	452 9 O
prior	462 5 O
to	468 2 O
lithium	471 7 B-Chemical
,	478 1 O
available	480 9 O
for	490 3 O
most	494 4 O
of	499 2 O
our	502 3 O
patients	506 8 O
.	514 1 O

No	516 2 O
evidence	519 8 O
was	528 3 O
found	532 5 O
for	538 3 O
any	542 3 O
reduction	546 9 O
of	556 2 O
glomerular	559 10 O
filtration	570 10 O
during	581 6 O
lithium	588 7 B-Chemical
treatment	596 9 O
.	605 1 O

Low	607 3 O
clearance	611 9 O
values	621 6 O
found	628 5 O
in	634 2 O
several	637 7 O
patients	645 8 O
could	654 5 O
be	660 2 O
accounted	663 9 O
for	673 3 O
by	677 2 O
their	680 5 O
age	686 3 O
and	690 3 O
their	694 5 O
pre	700 3 O
-	703 1 O
lithium	704 7 B-Chemical
values	712 6 O
.	718 1 O

Urinary	720 7 O
concentration	728 13 O
defect	742 6 O
appeared	749 8 O
frequent	758 8 O
but	767 3 O
the	771 3 O
extent	775 6 O
of	782 2 O
the	785 3 O
impairment	789 10 O
is	800 2 O
difficult	803 9 O
to	813 2 O
assess	816 6 O
because	823 7 O
of	831 2 O
the	834 3 O
uncertainty	838 11 O
about	850 5 O
the	856 3 O
norms	860 5 O
applicable	866 10 O
to	877 2 O
this	880 4 O
group	885 5 O
of	891 2 O
patients	894 8 O
.	902 1 O

The	904 3 O
concentration	908 13 O
defect	922 6 O
appeared	929 8 O
reversible	938 10 O
,	948 1 O
at	950 2 O
least	953 5 O
in	959 2 O
part	962 4 O
.	966 1 O

Polyuria	968 8 B-Disease
above	977 5 O
3	983 1 O
litres	985 6 O
/	991 1 O
24	992 2 O
hours	995 5 O
was	1001 3 O
found	1005 5 O
in	1011 2 O
10	1014 2 O
%	1016 1 O
of	1018 2 O
patients	1021 8 O
.	1029 1 O

An	1031 2 O
attempt	1034 7 O
is	1042 2 O
made	1045 4 O
to	1050 2 O
draw	1053 4 O
practical	1058 9 O
conclusions	1068 11 O
from	1080 4 O
the	1085 3 O
preliminary	1089 11 O
findings	1101 8 O
.	1109 1 O

Complete	0 8 O
heart	9 5 B-Disease
block	15 5 I-Disease
following	21 9 O
a	31 1 O
single	33 6 O
dose	40 4 O
of	45 2 O
trazodone	48 9 B-Chemical
.	57 1 O

Forty	59 5 O
minutes	65 7 O
after	73 5 O
receiving	79 9 O
a	89 1 O
single	91 6 O
starting	98 8 O
dose	107 4 O
of	112 2 O
trazodone	115 9 B-Chemical
,	124 1 O
a	126 1 O
patient	128 7 O
developed	136 9 O
complete	146 8 O
heart	155 5 B-Disease
block	161 5 I-Disease
.	166 1 O

The	168 3 O
case	172 4 O
illustrates	177 11 O
that	189 4 O
,	193 1 O
despite	195 7 O
the	203 3 O
results	207 7 O
of	215 2 O
earlier	218 7 O
studies	226 7 O
,	233 1 O
trazodone	235 9 B-Chemical
'	244 1 O
s	245 1 O
effect	247 6 O
on	254 2 O
cardiac	257 7 O
conduction	265 10 O
may	276 3 O
be	280 2 O
severe	283 6 O
in	290 2 O
individuals	293 11 O
at	305 2 O
risk	308 4 O
for	313 3 O
conduction	317 10 O
delay	328 5 O
.	333 1 O

Quinidine	0 9 B-Chemical
phenylethylbarbiturate	10 22 I-Chemical
-	32 1 O
induced	33 7 O
fulminant	41 9 O
hepatitis	51 9 B-Disease
in	61 2 O
a	64 1 O
pregnant	66 8 O
woman	75 5 O
.	80 1 O

A	82 1 O
case	84 4 O
report	89 6 O
.	95 1 O

We	97 2 O
report	100 6 O
the	107 3 O
case	111 4 O
of	116 2 O
a	119 1 O
19	121 2 O
-	123 1 O
year	124 4 O
-	128 1 O
old	129 3 O
Laotian	133 7 O
patient	141 7 O
affected	149 8 O
by	158 2 O
fulminant	161 9 O
hepatitis	171 9 B-Disease
during	181 6 O
the	188 3 O
third	192 5 O
trimester	198 9 O
of	208 2 O
her	211 3 O
pregnancy	215 9 O
after	225 5 O
a	231 1 O
1	233 1 O
-	234 1 O
month	235 5 O
administration	241 14 O
of	256 2 O
quinidine	259 9 B-Chemical
phenylethylbarbiturate	269 22 I-Chemical
.	291 1 O

After	293 5 O
delivery	299 8 O
,	307 1 O
the	309 3 O
patient	313 7 O
underwent	321 9 O
orthotopic	331 10 O
liver	342 5 O
transplantation	348 15 O
.	363 1 O

The	365 3 O
patient	369 7 O
was	377 3 O
in	381 2 O
good	384 4 O
condition	389 9 O
16	399 2 O
months	402 6 O
after	409 5 O
liver	415 5 O
transplantation	421 15 O
.	436 1 O

Quinidine	438 9 B-Chemical
itself	448 6 O
or	455 2 O
phenylethylbarbiturate	458 22 B-Chemical
may	481 3 O
be	485 2 O
responsible	488 11 O
for	500 3 O
fulminant	504 9 O
hepatitis	514 9 B-Disease
in	524 2 O
this	527 4 O
patient	532 7 O
.	539 1 O

The	0 3 O
epidemiology	4 12 O
of	17 2 O
the	20 3 O
acute	24 5 O
flank	30 5 B-Disease
pain	36 4 I-Disease
syndrome	41 8 O
from	50 4 O
suprofen	55 8 B-Chemical
.	63 1 O

Suprofen	65 8 B-Chemical
,	73 1 O
a	75 1 O
new	77 3 O
nonsteroidal	81 12 O
anti	94 4 O
-	98 1 O
inflammatory	99 12 O
drug	112 4 O
,	116 1 O
was	118 3 O
marketed	122 8 O
in	131 2 O
early	134 5 O
1986	140 4 O
as	145 2 O
an	148 2 O
analgesic	151 9 O
agent	161 5 O
.	166 1 O

Until	168 5 O
physicians	174 10 O
began	185 5 O
reporting	191 9 O
an	201 2 O
unusual	204 7 O
acute	212 5 O
flank	218 5 B-Disease
pain	224 4 I-Disease
syndrome	229 8 O
to	238 2 O
the	241 3 O
spontaneous	245 11 O
reporting	257 9 O
system	267 6 O
,	273 1 O
700	275 3 O
,	278 1 O
000	279 3 O
persons	283 7 O
used	291 4 O
the	296 3 O
drug	300 4 O
in	305 2 O
the	308 3 O
United	312 6 O
States	319 6 O
.	325 1 O

Through	327 7 O
August	335 6 O
1986	342 4 O
,	346 1 O
a	348 1 O
total	350 5 O
of	356 2 O
163	359 3 O
cases	363 5 O
of	369 2 O
this	372 4 O
syndrome	377 8 O
were	386 4 O
reported	391 8 O
.	399 1 O

To	401 2 O
elucidate	404 9 O
the	414 3 O
epidemiology	418 12 O
of	431 2 O
the	434 3 O
syndrome	438 8 O
,	446 1 O
a	448 1 O
case	450 4 O
-	454 1 O
control	455 7 O
study	463 5 O
was	469 3 O
performed	473 9 O
,	482 1 O
comparing	484 9 O
62	494 2 O
of	497 2 O
the	500 3 O
case	504 4 O
patients	509 8 O
who	518 3 O
had	522 3 O
been	526 4 O
reported	531 8 O
to	540 2 O
the	543 3 O
spontaneous	547 11 O
reporting	559 9 O
system	569 6 O
to	576 2 O
185	579 3 O
suprofen	583 8 B-Chemical
-	591 1 O
exposed	592 7 O
control	600 7 O
subjects	608 8 O
who	617 3 O
did	621 3 O
not	625 3 O
have	629 4 O
the	634 3 O
syndrome	638 8 O
.	646 1 O

Case	648 4 O
patients	653 8 O
were	662 4 O
more	667 4 O
likely	672 6 O
to	679 2 O
be	682 2 O
men	685 3 O
(	689 1 O
odds	690 4 O
ratio	695 5 O
,	700 1 O
3	702 1 O
.	703 1 O
8	704 1 O
;	705 1 O
95	707 2 O
%	709 1 O
confidence	711 10 O
interval	722 8 O
,	730 1 O
1	732 1 O
.	733 1 O
2	734 1 O
-	735 1 O
12	736 2 O
.	738 1 O
1	739 1 O
)	740 1 O
,	741 1 O
suffer	743 6 O
from	750 4 O
hay	755 3 B-Disease
fever	759 5 I-Disease
and	765 3 O
asthma	769 6 B-Disease
(	776 1 O
odds	777 4 O
ratio	782 5 O
,	787 1 O
3	789 1 O
.	790 1 O
4	791 1 O
;	792 1 O
95	794 2 O
%	796 1 O
confidence	798 10 O
interval	809 8 O
,	817 1 O
1	819 1 O
.	820 1 O
0	821 1 O
-	822 1 O
11	823 2 O
.	825 1 O
9	826 1 O
)	827 1 O
;	828 1 O
to	830 2 O
participate	833 11 O
in	845 2 O
regular	848 7 O
exercise	856 8 O
(	865 1 O
odds	866 4 O
ratio	871 5 O
,	876 1 O
5	878 1 O
.	879 1 O
9	880 1 O
;	881 1 O
95	883 2 O
%	885 1 O
confidence	887 10 O
interval	898 8 O
,	906 1 O
1	908 1 O
.	909 1 O
1	910 1 O
-	911 1 O
30	912 2 O
.	914 1 O
7	915 1 O
)	916 1 O
,	917 1 O
especially	919 10 O
in	930 2 O
the	933 3 O
use	937 3 O
of	941 2 O
Nautilus	944 8 O
equipment	953 9 O
(	963 1 O
p	964 1 O
=	966 1 O
0	968 1 O
.	969 1 O
02	970 2 O
)	972 1 O
;	973 1 O
and	975 3 O
to	979 2 O
use	982 3 O
alcohol	986 7 B-Chemical
(	994 1 O
odds	995 4 O
ratio	1000 5 O
,	1005 1 O
4	1007 1 O
.	1008 1 O
4	1009 1 O
;	1010 1 O
95	1012 2 O
%	1014 1 O
confidence	1016 10 O
interval	1027 8 O
,	1035 1 O
1	1037 1 O
.	1038 1 O
1	1039 1 O
-	1040 1 O
17	1041 2 O
.	1043 1 O
5	1044 1 O
)	1045 1 O
.	1046 1 O

Possible	1048 8 O
risk	1057 4 O
factors	1062 7 O
included	1070 8 O
young	1079 5 O
age	1085 3 O
,	1088 1 O
concurrent	1090 10 O
use	1101 3 O
of	1105 2 O
other	1108 5 O
analgesic	1114 9 O
agents	1124 6 O
(	1131 1 O
especially	1132 10 O
ibuprofen	1143 9 B-Chemical
)	1152 1 O
,	1153 1 O
preexisting	1155 11 O
renal	1167 5 B-Disease
disease	1173 7 I-Disease
,	1180 1 O
a	1182 1 O
history	1184 7 O
of	1192 2 O
kidney	1195 6 B-Disease
stones	1202 6 I-Disease
,	1208 1 O
a	1210 1 O
history	1212 7 O
of	1220 2 O
gout	1223 4 B-Disease
,	1227 1 O
a	1229 1 O
recent	1231 6 O
increase	1238 8 O
in	1247 2 O
activity	1250 8 O
,	1258 1 O
a	1260 1 O
recent	1262 6 O
increase	1269 8 O
in	1278 2 O
sun	1281 3 O
exposure	1285 8 O
,	1293 1 O
and	1295 3 O
residence	1299 9 O
in	1309 2 O
the	1312 3 O
Sunbelt	1316 7 O
.	1323 1 O

These	1325 5 O
were	1331 4 O
findings	1336 8 O
that	1345 4 O
were	1350 4 O
suggestive	1355 10 O
but	1366 3 O
did	1370 3 O
not	1374 3 O
reach	1378 5 O
conventional	1384 12 O
statistical	1397 11 O
significance	1409 12 O
.	1421 1 O

These	1423 5 O
findings	1429 8 O
are	1438 3 O
consistent	1442 10 O
with	1453 4 O
the	1458 3 O
postulated	1462 10 O
mechanism	1473 9 O
for	1483 3 O
this	1487 4 O
unusual	1492 7 O
syndrome	1500 8 O
:	1508 1 O
acute	1510 5 O
diffuse	1516 7 O
crystallization	1524 15 O
of	1540 2 O
uric	1543 4 B-Chemical
acid	1548 4 I-Chemical
in	1553 2 O
renal	1556 5 O
tubules	1562 7 O
.	1569 1 O

Hemolytic	0 9 B-Disease
-	9 1 I-Disease
uremic	10 6 I-Disease
syndrome	17 8 I-Disease
associated	26 10 O
with	37 4 O
ingestion	42 9 O
of	52 2 O
quinine	55 7 B-Chemical
.	62 1 O

Hemolytic	64 9 B-Disease
-	73 1 I-Disease
uremic	74 6 I-Disease
syndrome	81 8 I-Disease
following	90 9 O
quinine	100 7 B-Chemical
ingestion	108 9 O
is	118 2 O
a	121 1 O
newly	123 5 O
described	129 9 O
phenomenon	139 10 O
,	149 1 O
with	151 4 O
just	156 4 O
two	161 3 O
previous	165 8 O
descriptions	174 12 O
of	187 2 O
4	190 1 O
cases	192 5 O
in	198 2 O
the	201 3 O
literature	205 10 O
.	215 1 O

We	217 2 O
describe	220 8 O
a	229 1 O
5th	231 3 O
case	235 4 O
.	239 1 O

The	241 3 O
reaction	245 8 O
may	254 3 O
be	258 2 O
mediated	261 8 O
by	270 2 O
the	273 3 O
presence	277 8 O
of	286 2 O
antibodies	289 10 O
reactive	300 8 O
against	309 7 O
platelets	317 9 O
in	327 2 O
the	330 3 O
presence	334 8 O
of	343 2 O
quinine	346 7 B-Chemical
.	353 1 O

Treatment	355 9 O
has	365 3 O
included	369 8 O
use	378 3 O
of	382 2 O
plasma	385 6 O
exchange	392 8 O
,	400 1 O
prednisone	402 10 B-Chemical
,	412 1 O
aspirin	414 7 B-Chemical
,	421 1 O
and	423 3 O
dipyridamole	427 12 B-Chemical
.	439 1 O

The	441 3 O
patients	445 8 O
have	454 4 O
all	459 3 O
regained	463 8 O
some	472 4 O
degree	477 6 O
of	484 2 O
renal	487 5 O
function	493 8 O
.	501 1 O

However	503 7 O
,	510 1 O
it	512 2 O
is	515 2 O
unclear	518 7 O
whether	526 7 O
pharmacological	534 15 O
treatment	550 9 O
or	560 2 O
spontaneous	563 11 O
resolution	575 10 O
is	586 2 O
responsible	589 11 O
for	601 3 O
the	605 3 O
improvement	609 11 O
.	620 1 O

Quinine	622 7 B-Chemical
-	629 1 O
associated	630 10 O
hemolytic	641 9 B-Disease
-	650 1 I-Disease
uremic	651 6 I-Disease
syndrome	658 8 I-Disease
probably	667 8 O
occurs	676 6 O
more	683 4 O
often	688 5 O
than	694 4 O
is	699 2 O
recognized	702 10 O
.	712 1 O

It	714 2 O
is	717 2 O
important	720 9 O
to	730 2 O
recognize	733 9 O
this	743 4 O
reaction	748 8 O
when	757 4 O
it	762 2 O
occurs	765 6 O
and	772 3 O
to	776 2 O
avoid	779 5 O
further	785 7 O
quinine	793 7 B-Chemical
exposure	801 8 O
,	809 1 O
since	811 5 O
the	817 3 O
reaction	821 8 O
seems	830 5 O
to	836 2 O
be	839 2 O
recurrent	842 9 O
.	851 1 O

Pyeloureteral	0 13 O
filling	14 7 O
defects	22 7 O
associated	30 10 O
with	41 4 O
systemic	46 8 O
anticoagulation	55 15 O
:	70 1 O
a	72 1 O
case	74 4 O
report	79 6 O
.	85 1 O

The	87 3 O
etiology	91 8 O
of	100 2 O
pyeloureteritis	103 15 B-Disease
cystica	119 7 I-Disease
has	127 3 O
long	131 4 O
been	136 4 O
attributed	141 10 O
to	152 2 O
chronic	155 7 O
infection	163 9 B-Disease
and	173 3 O
inflammation	177 12 B-Disease
.	189 1 O

A	191 1 O
case	193 4 O
is	198 2 O
presented	201 9 O
that	211 4 O
is	216 2 O
unique	219 6 O
in	226 2 O
that	229 4 O
the	234 3 O
acute	238 5 O
onset	244 5 O
and	250 3 O
the	254 3 O
rapid	258 5 O
resolution	264 10 O
of	275 2 O
pyeloureteral	278 13 O
filling	292 7 O
defects	300 7 O
in	308 2 O
this	311 4 O
patient	316 7 O
were	324 4 O
documented	329 10 O
by	340 2 O
radiography	343 11 O
.	354 1 O

There	356 5 O
is	362 2 O
no	365 2 O
evidence	368 8 O
of	377 2 O
antecedent	380 10 O
or	391 2 O
concurrent	394 10 O
infection	405 9 B-Disease
in	415 2 O
this	418 4 O
patient	423 7 O
.	430 1 O

The	432 3 O
disease	436 7 O
occurred	444 8 O
subsequent	453 10 O
to	464 2 O
the	467 3 O
initiation	471 10 O
of	482 2 O
heparin	485 7 B-Chemical
therapy	493 7 O
for	501 3 O
suspected	505 9 O
pelvic	515 6 O
thrombophlebitis	522 16 B-Disease
and	539 3 O
cleared	543 7 O
rapidly	551 7 O
subsequent	559 10 O
to	570 2 O
its	573 3 O
discontinuation	577 15 O
.	592 1 O

The	594 3 O
rate	598 4 O
of	603 2 O
resolution	606 10 O
of	617 2 O
the	620 3 O
radiographic	624 12 O
findings	637 8 O
may	646 3 O
be	650 2 O
helpful	653 7 O
in	661 2 O
distinguishing	664 14 O
between	679 7 O
true	687 4 O
pyeloureteritis	692 15 B-Disease
cystica	708 7 I-Disease
and	716 3 O
submucosal	720 10 B-Disease
hemorrhage	731 10 I-Disease
.	741 1 O

Changes	0 7 O
in	8 2 O
peroxisomes	11 11 O
in	23 2 O
preneoplastic	26 13 O
liver	40 5 O
and	46 3 O
hepatoma	50 8 B-Disease
of	59 2 O
mice	62 4 O
induced	67 7 O
by	75 2 O
alpha	78 5 B-Chemical
-	83 1 I-Chemical
benzene	84 7 I-Chemical
hexachloride	92 12 I-Chemical
.	104 1 O

Peroxisomes	106 11 O
in	118 2 O
hepatomas	121 9 B-Disease
and	131 3 O
hyperplastic	135 12 O
preneoplastic	148 13 O
liver	162 5 B-Disease
lesions	168 7 I-Disease
induced	176 7 O
in	184 2 O
mice	187 4 O
by	192 2 O
500	195 3 O
ppm	199 3 O
alpha	203 5 B-Chemical
-	208 1 I-Chemical
benzene	209 7 I-Chemical
hexachloride	217 12 I-Chemical
were	230 4 O
examined	235 8 O
histochemically	244 15 O
and	260 3 O
electron	264 8 O
microscopically	273 15 O
.	288 1 O

Although	290 8 O
most	299 4 O
of	304 2 O
the	307 3 O
hepatomas	311 9 B-Disease
were	321 4 O
well	326 4 O
-	330 1 O
differentiated	331 14 O
tumors	346 6 B-Disease
and	353 3 O
contained	357 9 O
a	367 1 O
considerable	369 12 O
number	382 6 O
of	389 2 O
peroxisomes	392 11 O
,	403 1 O
the	405 3 O
tumor	409 5 B-Disease
cells	415 5 O
did	421 3 O
not	425 3 O
respond	429 7 O
to	437 2 O
ethyl	440 5 B-Chemical
-	445 1 I-Chemical
alpha	446 5 I-Chemical
-	451 1 I-Chemical
p	452 1 I-Chemical
-	453 1 I-Chemical
chlorophenoxyisobutyrate	454 24 I-Chemical
with	479 4 O
proliferation	484 13 O
of	498 2 O
peroxisomes	501 11 O
.	512 1 O

At	514 2 O
the	517 3 O
16th	521 4 O
week	526 4 O
of	531 2 O
carcinogen	534 10 O
feeding	545 7 O
,	552 1 O
hyperplastic	554 12 O
nodules	567 7 O
appeared	575 8 O
and	584 3 O
advanced	588 8 O
to	597 2 O
further	600 7 O
stages	608 6 O
.	614 1 O

A	616 1 O
majority	618 8 O
of	627 2 O
the	630 3 O
nodules	634 7 O
showed	642 6 O
a	649 1 O
considerable	651 12 O
number	664 6 O
of	671 2 O
peroxisomes	674 11 O
and	686 3 O
the	690 3 O
inductive	694 9 O
proliferation	704 13 O
of	718 2 O
peroxisomes	721 11 O
.	732 1 O

Within	734 6 O
the	741 3 O
nodules	745 7 O
,	752 1 O
foci	754 4 O
of	759 2 O
proliferation	762 13 O
of	776 2 O
the	779 3 O
cells	783 5 O
that	789 4 O
showed	794 6 O
no	801 2 O
inducibility	804 12 O
of	817 2 O
proliferation	820 13 O
of	834 2 O
peroxisomes	837 11 O
appeared	849 8 O
.	857 1 O

These	859 5 O
cells	865 5 O
proliferated	871 12 O
further	884 7 O
,	891 1 O
replacing	893 9 O
the	903 3 O
most	907 4 O
part	912 4 O
of	917 2 O
the	920 3 O
nodules	924 7 O
,	931 1 O
and	933 3 O
with	937 4 O
this	942 4 O
process	947 7 O
hepatomas	955 9 B-Disease
appeared	965 8 O
to	974 2 O
have	977 4 O
been	982 4 O
formed	987 6 O
.	993 1 O

No	995 2 O
abnormal	998 8 O
matrical	1007 8 O
inclusions	1016 10 O
of	1027 2 O
peroxisomes	1030 11 O
were	1042 4 O
formed	1047 6 O
in	1054 2 O
the	1057 3 O
cells	1061 5 O
of	1067 2 O
hyperplastic	1070 12 O
nodules	1083 7 O
by	1091 2 O
ethyl	1094 5 B-Chemical
-	1099 1 I-Chemical
alpha	1100 5 I-Chemical
-	1105 1 I-Chemical
p	1106 1 I-Chemical
-	1107 1 I-Chemical
chlorophenoxyisobutyrate	1108 24 I-Chemical
unlike	1133 6 O
in	1140 2 O
the	1143 3 O
case	1147 4 O
of	1152 2 O
rats	1155 4 O
.	1159 1 O

Quinidine	0 9 B-Chemical
hepatitis	10 9 B-Disease
.	19 1 O

Long	21 4 O
-	25 1 O
term	26 4 O
administration	31 14 O
of	46 2 O
quinidine	49 9 B-Chemical
was	59 3 O
associated	63 10 O
with	74 4 O
persistent	79 10 O
elevation	90 9 O
of	100 2 O
serum	103 5 O
concentrations	109 14 O
of	124 2 O
SGOT	127 4 O
,	131 1 O
lactic	133 6 B-Chemical
acid	140 4 I-Chemical
dehydrogenase	145 13 O
,	158 1 O
and	160 3 O
alkaline	164 8 O
phosphatase	173 11 O
.	184 1 O

Liver	186 5 O
biopsy	192 6 O
showed	199 6 O
active	206 6 O
hepatitis	213 9 B-Disease
.	222 1 O

Discontinuance	224 14 O
of	239 2 O
quinidine	242 9 B-Chemical
therapy	252 7 O
led	260 3 O
to	264 2 O
normalization	267 13 O
of	281 2 O
liver	284 5 O
function	290 8 O
tests	299 5 O
.	304 1 O

A	306 1 O
challenge	308 9 O
dose	318 4 O
of	323 2 O
quinidine	326 9 B-Chemical
caused	336 6 O
clinical	343 8 O
symptoms	352 8 O
and	361 3 O
abrupt	365 6 O
elevation	372 9 O
of	382 2 O
SGOT	385 4 O
,	389 1 O
alkaline	391 8 O
phosphatase	400 11 O
,	411 1 O
and	413 3 O
lactic	417 6 B-Chemical
acid	424 4 I-Chemical
dehydrogenase	429 13 O
values	443 6 O
.	449 1 O

We	451 2 O
concluded	454 9 O
that	464 4 O
this	469 4 O
patient	474 7 O
had	482 3 O
quinidine	486 9 B-Chemical
hepatotoxicity	496 14 B-Disease
and	511 3 O
believe	515 7 O
that	523 4 O
this	528 4 O
is	533 2 O
the	536 3 O
first	540 5 O
case	546 4 O
reported	551 8 O
with	560 4 O
liver	565 5 O
biopsy	571 6 O
documentation	578 13 O
.	591 1 O

This	593 4 O
report	598 6 O
also	605 4 O
suggests	610 8 O
that	619 4 O
,	623 1 O
even	625 4 O
after	630 5 O
long	636 4 O
-	640 1 O
term	641 4 O
administration	646 14 O
,	660 1 O
the	662 3 O
hepatic	666 7 B-Disease
toxicity	674 8 I-Disease
is	683 2 O
reversible	686 10 O
.	696 1 O

Cholesteryl	0 11 B-Chemical
hemisuccinate	12 13 I-Chemical
treatment	26 9 O
protects	36 8 O
rodents	45 7 O
from	53 4 O
the	58 3 O
toxic	62 5 O
effects	68 7 O
of	76 2 O
acetaminophen	79 13 B-Chemical
,	92 1 O
adriamycin	94 10 B-Chemical
,	104 1 O
carbon	106 6 B-Chemical
tetrachloride	113 13 I-Chemical
,	126 1 O
chloroform	128 10 B-Chemical
and	139 3 O
galactosamine	143 13 B-Chemical
.	156 1 O

In	158 2 O
addition	161 8 O
to	170 2 O
its	173 3 O
use	177 3 O
as	181 2 O
a	184 1 O
stabilizer	186 10 O
/	196 1 O
rigidifier	197 10 O
of	208 2 O
membranes	211 9 O
,	220 1 O
cholesteryl	222 11 B-Chemical
hemisuccinate	234 13 I-Chemical
,	247 1 O
tris	249 4 B-Chemical
salt	254 4 I-Chemical
(	259 1 O
CS	260 2 B-Chemical
)	262 1 O
administration	264 14 O
has	279 3 O
also	283 4 O
been	288 4 O
shown	293 5 O
to	299 2 O
protect	302 7 O
rats	310 4 O
from	315 4 O
the	320 3 O
hepatotoxic	324 11 B-Disease
effects	336 7 O
of	344 2 O
carbon	347 6 B-Chemical
tetrachloride	354 13 I-Chemical
(	368 1 O
CCl4	369 4 B-Chemical
)	373 1 O
.	374 1 O

To	376 2 O
further	379 7 O
our	387 3 O
understanding	391 13 O
of	405 2 O
the	408 3 O
mechanism	412 9 O
of	422 2 O
CS	425 2 B-Chemical
cytoprotection	428 14 O
,	442 1 O
we	444 2 O
examined	447 8 O
in	456 2 O
rats	459 4 O
and	464 3 O
mice	468 4 O
the	473 3 O
protective	477 10 O
abilities	488 9 O
of	498 2 O
CS	501 2 B-Chemical
and	504 3 O
the	508 3 O
non	512 3 O
-	515 1 O
hydrolyzable	516 12 O
ether	529 5 O
form	535 4 O
of	540 2 O
CS	543 2 B-Chemical
,	545 1 O
gamma	547 5 B-Chemical
-	552 1 I-Chemical
cholesteryloxybutyric	553 21 I-Chemical
acid	575 4 I-Chemical
,	579 1 O
tris	581 4 B-Chemical
salt	586 4 I-Chemical
(	591 1 O
CSE	592 3 B-Chemical
)	595 1 O
against	597 7 O
acetaminophen	605 13 B-Chemical
-	618 1 O
,	619 1 O
adriamycin	621 10 B-Chemical
-	631 1 O
,	632 1 O
carbon	634 6 B-Chemical
tetrachloride	641 13 I-Chemical
-	654 1 O
,	655 1 O
chloroform	657 10 B-Chemical
-	667 1 O
and	669 3 O
galactosamine	673 13 B-Chemical
-	686 1 O
induced	687 7 O
toxicity	695 8 B-Disease
.	703 1 O

The	705 3 O
results	709 7 O
of	717 2 O
these	720 5 O
studies	726 7 O
demonstrated	734 12 O
that	747 4 O
CS	752 2 B-Chemical
-	754 1 O
mediated	755 8 O
protection	764 10 O
is	775 2 O
not	778 3 O
selective	782 9 O
for	792 3 O
a	796 1 O
particular	798 10 O
species	809 7 O
,	816 1 O
organ	818 5 O
system	824 6 O
or	831 2 O
toxic	834 5 O
chemical	840 8 O
.	848 1 O

A	850 1 O
24	852 2 O
-	854 1 O
h	855 1 O
pretreatment	857 12 O
of	870 2 O
both	873 4 O
rats	878 4 O
and	883 3 O
mice	887 4 O
with	892 4 O
a	897 1 O
single	899 6 O
dose	906 4 O
of	911 2 O
CS	914 2 B-Chemical
(	917 1 O
100mg	918 5 O
/	923 1 O
kg	924 2 O
,	926 1 O
i	928 1 O
.	929 1 O
p	930 1 O
.	931 1 O
)	932 1 O
,	933 1 O
resulted	935 8 O
in	944 2 O
significant	947 11 O
protection	959 10 O
against	970 7 O
the	978 3 O
hepatotoxic	982 11 B-Disease
effects	994 7 O
of	1002 2 O
CCl4	1005 4 B-Chemical
,	1009 1 O
CHCl3	1011 5 B-Chemical
,	1016 1 O
acetaminophen	1018 13 B-Chemical
and	1032 3 O
galactosamine	1036 13 B-Chemical
and	1050 3 O
against	1054 7 O
the	1062 3 O
lethal	1066 6 O
(	1073 1 O
and	1074 3 O
presumably	1078 10 O
cardiotoxic	1089 11 B-Disease
)	1100 1 O
effect	1102 6 O
of	1109 2 O
adriamycin	1112 10 B-Chemical
administration	1123 14 O
.	1137 1 O

Maximal	1139 7 O
CS	1147 2 B-Chemical
-	1149 1 O
mediated	1150 8 O
protection	1159 10 O
was	1170 3 O
observed	1174 8 O
in	1183 2 O
experimental	1186 12 O
animals	1199 7 O
pretreated	1207 10 O
24	1218 2 O
h	1221 1 O
prior	1223 5 O
to	1229 2 O
the	1232 3 O
toxic	1236 5 O
insult	1242 6 O
.	1248 1 O

These	1250 5 O
data	1256 4 O
suggest	1261 7 O
that	1269 4 O
CS	1274 2 B-Chemical
intervenes	1277 10 O
in	1288 2 O
a	1291 1 O
critical	1293 8 O
cellular	1302 8 O
event	1311 5 O
that	1317 4 O
is	1322 2 O
an	1325 2 O
important	1328 9 O
common	1338 6 O
pathway	1345 7 O
to	1353 2 O
toxic	1356 5 O
cell	1362 4 O
death	1367 5 O
.	1372 1 O

The	1374 3 O
mechanism	1378 9 O
of	1388 2 O
CS	1391 2 B-Chemical
protection	1394 10 O
does	1405 4 O
not	1410 3 O
appear	1414 6 O
to	1421 2 O
be	1424 2 O
dependent	1427 9 O
on	1437 2 O
the	1440 3 O
inhibition	1444 10 O
of	1455 2 O
chemical	1458 8 O
bioactivation	1467 13 O
to	1481 2 O
a	1484 1 O
toxic	1486 5 O
reactive	1492 8 O
intermediate	1501 12 O
(	1514 1 O
in	1515 2 O
light	1518 5 O
of	1524 2 O
the	1527 3 O
protection	1531 10 O
observed	1542 8 O
against	1551 7 O
galactosamine	1559 13 B-Chemical
hepatotoxicity	1573 14 B-Disease
)	1587 1 O
.	1588 1 O

However	1590 7 O
,	1597 1 O
based	1599 5 O
on	1605 2 O
the	1608 3 O
data	1612 4 O
presented	1617 9 O
,	1626 1 O
we	1628 2 O
can	1631 3 O
not	1635 3 O
exclude	1639 7 O
the	1647 3 O
possibility	1651 11 O
that	1663 4 O
CS	1668 2 B-Chemical
administration	1671 14 O
inhibits	1686 8 O
chemical	1695 8 O
bioactivation	1704 13 O
.	1717 1 O

Our	1719 3 O
findings	1723 8 O
do	1732 2 O
suggest	1735 7 O
that	1743 4 O
CS	1748 2 B-Chemical
-	1750 1 O
mediated	1751 8 O
protection	1760 10 O
is	1771 2 O
dependent	1774 9 O
on	1784 2 O
the	1787 3 O
action	1791 6 O
of	1798 2 O
the	1801 3 O
intact	1805 6 O
anionic	1812 7 O
CS	1820 2 B-Chemical
molecule	1823 8 O
(	1832 1 O
non	1833 3 O
-	1836 1 O
hydrolyzable	1837 12 O
CSE	1850 3 B-Chemical
was	1854 3 O
as	1858 2 O
protective	1861 10 O
as	1872 2 O
CS	1875 2 B-Chemical
)	1877 1 O
,	1878 1 O
whose	1880 5 O
mechanism	1886 9 O
has	1896 3 O
yet	1900 3 O
to	1904 2 O
be	1907 2 O
defined	1910 7 O
.	1917 1 O

DSMM	0 4 O
XI	5 2 O
study	8 5 O
:	13 1 O
dose	15 4 O
definition	20 10 O
for	31 3 O
intravenous	35 11 O
cyclophosphamide	47 16 B-Chemical
in	64 2 O
combination	67 11 O
with	79 4 O
bortezomib	84 10 B-Chemical
/	94 1 O
dexamethasone	95 13 B-Chemical
for	109 3 O
remission	113 9 O
induction	123 9 O
in	133 2 O
patients	136 8 O
with	145 4 O
newly	150 5 O
diagnosed	156 9 O
myeloma	166 7 B-Disease
.	173 1 O

A	175 1 O
clinical	177 8 O
trial	186 5 O
was	192 3 O
initiated	196 9 O
to	206 2 O
evaluate	209 8 O
the	218 3 O
recommended	222 11 O
dose	234 4 O
of	239 2 O
cyclophosphamide	242 16 B-Chemical
in	259 2 O
combination	262 11 O
with	274 4 O
bortezomib	279 10 B-Chemical
and	290 3 O
dexamethasone	294 13 B-Chemical
as	308 2 O
induction	311 9 O
treatment	321 9 O
before	331 6 O
stem	338 4 O
cell	343 4 O
transplantation	348 15 O
for	364 3 O
younger	368 7 O
patients	376 8 O
with	385 4 O
newly	390 5 O
diagnosed	396 9 O
multiple	406 8 B-Disease
myeloma	415 7 I-Disease
(	423 1 O
MM	424 2 B-Disease
)	426 1 O
.	427 1 O

Thirty	429 6 O
patients	436 8 O
were	445 4 O
treated	450 7 O
with	458 4 O
three	463 5 O
21	469 2 O
-	471 1 O
day	472 3 O
cycles	476 6 O
of	483 2 O
bortezomib	486 10 B-Chemical
1	497 1 O
.	498 1 O
3	499 1 O
mg	501 2 O
/	503 1 O
m	504 1 O
(	505 1 O
2	506 1 O
)	507 1 O
on	509 2 O
days	512 4 O
1	517 1 O
,	518 1 O
4	520 1 O
,	521 1 O
8	523 1 O
,	524 1 O
and	526 3 O
11	530 2 O
plus	533 4 O
dexamethasone	538 13 B-Chemical
40	552 2 O
mg	555 2 O
on	558 2 O
the	561 3 O
day	565 3 O
of	569 2 O
bortezomib	572 10 B-Chemical
injection	583 9 O
and	593 3 O
the	597 3 O
day	601 3 O
after	605 5 O
plus	611 4 O
cyclophosphamide	616 16 B-Chemical
at	633 2 O
900	636 3 O
,	639 1 O
1	641 1 O
,	642 1 O
200	643 3 O
,	646 1 O
or	648 2 O
1	651 1 O
,	652 1 O
500	653 3 O
mg	657 2 O
/	659 1 O
m	660 1 O
(	661 1 O
2	662 1 O
)	663 1 O
on	665 2 O
day	668 3 O
1	672 1 O
.	673 1 O

The	675 3 O
maximum	679 7 O
tolerated	687 9 O
dose	697 4 O
of	702 2 O
cyclophosphamide	705 16 B-Chemical
was	722 3 O
defined	726 7 O
as	734 2 O
900	737 3 O
mg	741 2 O
/	743 1 O
m	744 1 O
(	745 1 O
2	746 1 O
)	747 1 O
.	748 1 O

At	750 2 O
this	753 4 O
dose	758 4 O
level	763 5 O
,	768 1 O
92	770 2 O
%	772 1 O
of	774 2 O
patients	777 8 O
achieved	786 8 O
at	795 2 O
least	798 5 O
a	804 1 O
partial	806 7 O
response	814 8 O
.	822 1 O

The	824 3 O
overall	828 7 O
response	836 8 O
rate	845 4 O
[	850 1 O
complete	851 8 O
response	860 8 O
(	869 1 O
CR	870 2 O
)	872 1 O
plus	874 4 O
partial	879 7 O
response	887 8 O
(	896 1 O
PR	897 2 O
)	899 1 O
]	900 1 O
across	902 6 O
all	909 3 O
dose	913 4 O
levels	918 6 O
was	925 3 O
77	929 2 O
%	931 1 O
,	932 1 O
with	934 4 O
a	939 1 O
10	941 2 O
%	943 1 O
CR	945 2 O
rate	948 4 O
.	952 1 O

No	954 2 O
patient	957 7 O
experienced	965 11 O
progressive	977 11 O
disease	989 7 O
.	996 1 O

The	998 3 O
most	1002 4 O
frequent	1007 8 O
adverse	1016 7 O
events	1024 6 O
were	1031 4 O
hematological	1036 13 B-Disease
and	1050 3 I-Disease
gastrointestinal	1054 16 I-Disease
toxicities	1071 10 I-Disease
as	1082 2 O
well	1085 4 O
as	1090 2 O
neuropathy	1093 10 B-Disease
.	1103 1 O

The	1105 3 O
results	1109 7 O
suggest	1117 7 O
that	1125 4 O
bortezomib	1130 10 B-Chemical
in	1141 2 O
combination	1144 11 O
with	1156 4 O
cyclophosphamide	1161 16 B-Chemical
at	1178 2 O
900	1181 3 O
mg	1185 2 O
/	1187 1 O
m	1188 1 O
(	1189 1 O
2	1190 1 O
)	1191 1 O
and	1193 3 O
dexamethasone	1197 13 B-Chemical
is	1211 2 O
an	1214 2 O
effective	1217 9 O
induction	1227 9 O
treatment	1237 9 O
for	1247 3 O
patients	1251 8 O
with	1260 4 O
newly	1265 5 O
diagnosed	1271 9 O
MM	1281 2 B-Disease
that	1284 4 O
warrants	1289 8 O
further	1298 7 O
investigation	1306 13 O
.	1319 1 O

Results	0 7 O
of	8 2 O
a	11 1 O
comparative	13 11 O
,	24 1 O
phase	26 5 O
III	32 3 O
,	35 1 O
12	37 2 O
-	39 1 O
week	40 4 O
,	44 1 O
multicenter	46 11 O
,	57 1 O
prospective	59 11 O
,	70 1 O
randomized	72 10 O
,	82 1 O
double	84 6 O
-	90 1 O
blind	91 5 O
assessment	97 10 O
of	108 2 O
the	111 3 O
efficacy	115 8 O
and	124 3 O
tolerability	128 12 O
of	141 2 O
a	144 1 O
fixed	146 5 O
-	151 1 O
dose	152 4 O
combination	157 11 O
of	169 2 O
telmisartan	172 11 B-Chemical
and	184 3 O
amlodipine	188 10 B-Chemical
versus	199 6 O
amlodipine	206 10 B-Chemical
monotherapy	217 11 O
in	229 2 O
Indian	232 6 O
adults	239 6 O
with	246 4 O
stage	251 5 O
II	257 2 O
hypertension	260 12 B-Disease
.	272 1 O

OBJECTIVE	274 9 O
:	283 1 O
The	285 3 O
aim	289 3 O
of	293 2 O
this	296 4 O
study	301 5 O
was	307 3 O
to	311 2 O
evaluate	314 8 O
the	323 3 O
efficacy	327 8 O
and	336 3 O
tolerability	340 12 O
of	353 2 O
a	356 1 O
new	358 3 O
fixed	362 5 O
-	367 1 O
dose	368 4 O
combination	373 11 O
(	385 1 O
FDC	386 3 O
)	389 1 O
of	391 2 O
telmisartan	394 11 B-Chemical
40	406 2 O
mg	409 2 O
+	412 1 O
amlodipine	414 10 B-Chemical
5	425 1 O
mg	427 2 O
(	430 1 O
T	431 1 O
+	432 1 O
A	433 1 O
)	434 1 O
compared	436 8 O
with	445 4 O
amlodipine	450 10 B-Chemical
5	461 1 O
-	462 1 O
mg	463 2 O
monotherapy	466 11 O
(	478 1 O
A	479 1 O
)	480 1 O
in	482 2 O
adult	485 5 O
Indian	491 6 O
patients	498 8 O
with	507 4 O
stage	512 5 O
II	518 2 O
hypertension	521 12 B-Disease
.	533 1 O

METHODS	535 7 O
:	542 1 O
This	544 4 O
comparative	549 11 O
,	560 1 O
Phase	562 5 O
III	568 3 O
,	571 1 O
12	573 2 O
-	575 1 O
week	576 4 O
,	580 1 O
multicenter	582 11 O
,	593 1 O
prospective	595 11 O
,	606 1 O
randomized	608 10 O
,	618 1 O
double	620 6 O
-	626 1 O
blind	627 5 O
study	633 5 O
was	639 3 O
conducted	643 9 O
in	653 2 O
Indian	656 6 O
patients	663 8 O
aged	672 4 O
18	677 2 O
to	680 2 O
65	683 2 O
years	686 5 O
with	692 4 O
established	697 11 O
stage	709 5 O
II	715 2 O
hypertension	718 12 B-Disease
.	730 1 O

Patients	732 8 O
were	741 4 O
treated	746 7 O
with	754 4 O
oral	759 4 O
FDC	764 3 O
of	768 2 O
T	771 1 O
+	772 1 O
A	773 1 O
or	775 2 O
A	778 1 O
QD	780 2 O
before	783 6 O
breakfast	790 9 O
for	800 3 O
12	804 2 O
weeks	807 5 O
;	812 1 O
blood	814 5 O
pressure	820 8 O
(	829 1 O
BP	830 2 O
)	832 1 O
and	834 3 O
heart	838 5 O
rate	844 4 O
were	849 4 O
measured	854 8 O
in	863 2 O
the	866 3 O
sitting	870 7 O
position	878 8 O
.	886 1 O

Primary	888 7 O
efficacy	896 8 O
end	905 3 O
points	909 6 O
were	916 4 O
reduction	921 9 O
in	931 2 O
clinical	934 8 O
systolic	943 8 O
BP	952 2 O
(	955 1 O
SBP	956 3 O
)	959 1 O
/	960 1 O
diastolic	962 9 O
BP	972 2 O
(	975 1 O
DBP	976 3 O
)	979 1 O
from	981 4 O
baseline	986 8 O
to	995 2 O
study	998 5 O
end	1004 3 O
and	1008 3 O
number	1012 6 O
of	1019 2 O
responders	1022 10 O
(	1033 1 O
ie	1034 2 O
,	1036 1 O
patients	1038 8 O
who	1047 3 O
achieved	1051 8 O
target	1060 6 O
SBP	1067 3 O
/	1070 1 O
DBP	1072 3 O
<	1076 1 O
130	1077 3 O
/	1080 1 O
<	1081 1 O
80	1082 2 O
mm	1085 2 O
Hg	1088 2 O
)	1090 1 O
at	1092 2 O
end	1095 3 O
of	1099 2 O
study	1102 5 O
.	1107 1 O

Tolerability	1109 12 O
was	1122 3 O
assessed	1126 8 O
by	1135 2 O
treatment	1138 9 O
-	1147 1 O
emergent	1148 8 O
adverse	1157 7 O
events	1165 6 O
,	1171 1 O
identified	1173 10 O
using	1184 5 O
physical	1190 8 O
examination	1199 11 O
,	1210 1 O
laboratory	1212 10 O
analysis	1223 8 O
,	1231 1 O
and	1233 3 O
electrocardiography	1237 19 O
.	1256 1 O

RESULTS	1258 7 O
:	1265 1 O
A	1267 1 O
total	1269 5 O
of	1275 2 O
210	1278 3 O
patients	1282 8 O
were	1291 4 O
enrolled	1296 8 O
in	1305 2 O
the	1308 3 O
study	1312 5 O
;	1317 1 O
203	1319 3 O
patients	1323 8 O
(	1332 1 O
143	1333 3 O
men	1337 3 O
,	1340 1 O
60	1342 2 O
women	1345 5 O
)	1350 1 O
completed	1352 9 O
the	1362 3 O
study	1366 5 O
while	1372 5 O
7	1378 1 O
were	1380 4 O
lost	1385 4 O
to	1390 2 O
follow	1393 6 O
-	1399 1 O
up	1400 2 O
(	1403 1 O
4	1404 1 O
patients	1406 8 O
in	1415 2 O
the	1418 3 O
T	1422 1 O
+	1423 1 O
A	1424 1 O
group	1426 5 O
and	1432 3 O
3	1436 1 O
in	1438 2 O
the	1441 3 O
A	1445 1 O
group	1447 5 O
)	1452 1 O
and	1454 3 O
considered	1458 10 O
with	1469 4 O
-	1473 1 O
drawn	1474 5 O
.	1479 1 O

At	1481 2 O
study	1484 5 O
end	1490 3 O
,	1493 1 O
statistically	1495 13 O
significant	1509 11 O
percentage	1521 10 O
reductions	1532 10 O
from	1543 4 O
baseline	1548 8 O
within	1557 6 O
groups	1564 6 O
and	1571 3 O
between	1575 7 O
groups	1583 6 O
were	1590 4 O
observed	1595 8 O
in	1604 2 O
SBP	1607 3 O
(	1611 1 O
T	1612 1 O
+	1613 1 O
A	1614 1 O
[	1616 1 O
-	1617 1 O
27	1618 2 O
.	1620 1 O
4	1621 1 O
%	1622 1 O
]	1623 1 O
;	1624 1 O
A	1626 1 O
[	1628 1 O
-	1629 1 O
16	1630 2 O
.	1632 1 O
6	1633 1 O
%	1634 1 O
]	1635 1 O
)	1636 1 O
and	1638 3 O
DBP	1642 3 O
(	1646 1 O
T	1647 1 O
+	1648 1 O
A	1649 1 O
[	1651 1 O
-	1652 1 O
20	1653 2 O
.	1655 1 O
1	1656 1 O
%	1657 1 O
]	1658 1 O
;	1659 1 O
A	1661 1 O
[	1663 1 O
-	1664 1 O
13	1665 2 O
.	1667 1 O
3	1668 1 O
%	1669 1 O
]	1670 1 O
)	1671 1 O
(	1673 1 O
all	1674 3 O
,	1677 1 O
P	1679 1 O
<	1681 1 O
0	1683 1 O
.	1684 1 O
05	1685 2 O
)	1687 1 O
.	1688 1 O

Response	1690 8 O
rates	1699 5 O
were	1705 4 O
87	1710 2 O
.	1712 1 O
3	1713 1 O
%	1714 1 O
(	1716 1 O
89	1717 2 O
/	1719 1 O
102	1720 3 O
)	1723 1 O
in	1725 2 O
the	1728 3 O
T	1732 1 O
+	1733 1 O
A	1734 1 O
group	1736 5 O
and	1742 3 O
69	1746 2 O
.	1748 1 O
3	1749 1 O
%	1750 1 O
(	1752 1 O
70	1753 2 O
/	1755 1 O
101	1756 3 O
)	1759 1 O
in	1761 2 O
the	1764 3 O
A	1768 1 O
group	1770 5 O
(	1776 1 O
P	1777 1 O
<	1779 1 O
0	1781 1 O
.	1782 1 O
05	1783 2 O
)	1785 1 O
.	1786 1 O

The	1788 3 O
prevalences	1792 11 O
of	1804 2 O
adverse	1807 7 O
events	1815 6 O
were	1822 4 O
not	1827 3 O
significantly	1831 13 O
different	1845 9 O
between	1855 7 O
the	1863 3 O
2	1867 1 O
treatment	1869 9 O
groups	1879 6 O
(	1886 1 O
T	1887 1 O
+	1888 1 O
A	1889 1 O
,	1890 1 O
16	1892 2 O
.	1894 1 O
0	1895 1 O
%	1896 1 O
[	1898 1 O
17	1899 2 O
/	1901 1 O
106	1902 3 O
]	1905 1 O
;	1906 1 O
A	1908 1 O
,	1909 1 O
15	1911 2 O
.	1913 1 O
4	1914 1 O
%	1915 1 O
[	1917 1 O
16	1918 2 O
/	1920 1 O
104	1921 3 O
]	1924 1 O
)	1925 1 O
.	1926 1 O

Peripheral	1928 10 O
edema	1939 5 B-Disease
was	1945 3 O
reported	1949 8 O
in	1958 2 O
8	1961 1 O
.	1962 1 O
5	1963 1 O
%	1964 1 O
patients	1966 8 O
(	1975 1 O
9	1976 1 O
/	1977 1 O
106	1978 3 O
)	1981 1 O
in	1983 2 O
the	1986 3 O
T	1990 1 O
+	1991 1 O
A	1992 1 O
group	1994 5 O
compared	2000 8 O
with	2009 4 O
13	2014 2 O
.	2016 1 O
5	2017 1 O
%	2018 1 O
(	2020 1 O
14	2021 2 O
/	2023 1 O
104	2024 3 O
)	2027 1 O
in	2029 2 O
the	2032 3 O
A	2036 1 O
group	2038 5 O
,	2043 1 O
and	2045 3 O
cough	2049 5 B-Disease
was	2055 3 O
reported	2059 8 O
in	2068 2 O
3	2071 1 O
.	2072 1 O
8	2073 1 O
%	2074 1 O
patients	2076 8 O
(	2085 1 O
4	2086 1 O
/	2087 1 O
106	2088 3 O
)	2091 1 O
in	2093 2 O
the	2096 3 O
T	2100 1 O
+	2101 1 O
A	2102 1 O
group	2104 5 O
and	2110 3 O
1	2114 1 O
.	2115 1 O
0	2116 1 O
%	2117 1 O
(	2119 1 O
1	2120 1 O
/	2121 1 O
104	2122 3 O
)	2125 1 O
patients	2127 8 O
in	2136 2 O
the	2139 3 O
A	2143 1 O
group	2145 5 O
;	2150 1 O
these	2152 5 O
differences	2158 11 O
did	2170 3 O
not	2174 3 O
reach	2178 5 O
statistical	2184 11 O
significance	2196 12 O
.	2208 1 O

The	2210 3 O
incidences	2214 10 O
of	2225 2 O
headache	2228 8 B-Disease
,	2236 1 O
dizziness	2238 9 B-Disease
,	2247 1 O
and	2249 3 O
diarrhea	2253 8 B-Disease
were	2262 4 O
similar	2267 7 O
between	2275 7 O
the	2283 3 O
2	2287 1 O
groups	2289 6 O
.	2295 1 O

CONCLUSIONS	2297 11 O
:	2308 1 O
Among	2310 5 O
these	2316 5 O
Indian	2322 6 O
patients	2329 8 O
with	2338 4 O
stage	2343 5 O
II	2349 2 O
hypertension	2352 12 B-Disease
,	2364 1 O
the	2366 3 O
FDC	2370 3 O
of	2374 2 O
T	2377 1 O
+	2378 1 O
A	2379 1 O
was	2381 3 O
found	2385 5 O
to	2391 2 O
be	2394 2 O
significantly	2397 13 O
more	2411 4 O
effective	2416 9 O
,	2425 1 O
with	2427 4 O
regard	2432 6 O
to	2439 2 O
BP	2442 2 O
reductions	2445 10 O
,	2455 1 O
than	2457 4 O
A	2462 1 O
,	2463 1 O
and	2465 3 O
both	2469 4 O
treatments	2474 10 O
were	2485 4 O
well	2490 4 O
tolerated	2495 9 O
.	2504 1 O

Cutaneous	0 9 B-Disease
leucocytoclastic	10 16 I-Disease
vasculitis	27 10 I-Disease
associated	38 10 O
with	49 4 O
oxacillin	54 9 B-Chemical
.	63 1 O

A	65 1 O
67	67 2 O
-	69 1 O
year	70 4 O
-	74 1 O
old	75 3 O
man	79 3 O
who	83 3 O
was	87 3 O
treated	91 7 O
with	99 4 O
oxacillin	104 9 B-Chemical
for	114 3 O
one	118 3 O
week	122 4 O
because	127 7 O
of	135 2 O
Staphylococcus	138 14 B-Disease
aureus	153 6 I-Disease
bacteremia	160 10 I-Disease
,	170 1 O
developed	172 9 O
renal	182 5 B-Disease
failure	188 7 I-Disease
and	196 3 O
diffuse	200 7 O
,	207 1 O
symmetric	209 9 O
,	218 1 O
palpable	220 8 O
purpuric	229 8 B-Disease
lesions	238 7 I-Disease
on	246 2 O
his	249 3 O
feet	253 4 O
.	257 1 O

Necrotic	259 8 B-Disease
blisters	268 8 I-Disease
were	277 4 O
noted	282 5 O
on	288 2 O
his	291 3 O
fingers	295 7 O
.	302 1 O

Skin	304 4 O
biopsies	309 8 O
showed	318 6 O
findings	325 8 O
diagnostic	334 10 O
of	345 2 O
leucocytoclastic	348 16 B-Disease
vasculitis	365 10 I-Disease
.	375 1 O

Oxacillin	377 9 B-Chemical
was	387 3 O
discontinued	391 12 O
and	404 3 O
patient	408 7 O
was	416 3 O
treated	420 7 O
with	428 4 O
corticosteroids	433 15 B-Chemical
.	448 1 O

The	450 3 O
rash	454 4 B-Disease
disappeared	459 11 O
after	471 5 O
three	477 5 O
weeks	483 5 O
and	489 3 O
renal	493 5 O
function	499 8 O
returned	508 8 O
to	517 2 O
normal	520 6 O
.	526 1 O

Leucocytoclastic	528 16 B-Disease
vasculitis	545 10 I-Disease
presents	556 8 O
as	565 2 O
palpable	568 8 O
purpura	577 7 B-Disease
of	585 2 O
the	588 3 O
lower	592 5 O
extremities	598 11 O
often	610 5 O
accompanied	616 11 O
by	628 2 O
abdominal	631 9 B-Disease
pain	641 4 I-Disease
,	645 1 O
arthralgia	647 10 B-Disease
,	657 1 O
and	659 3 O
renal	663 5 B-Disease
involvement	669 11 I-Disease
.	680 1 O

Etiologic	682 9 O
factors	692 7 O
or	700 2 O
associated	703 10 O
disorders	714 9 O
include	724 7 O
infections	732 10 B-Disease
,	742 1 O
medications	744 11 O
,	755 1 O
collagen	757 8 B-Disease
vascular	766 8 I-Disease
disease	775 7 I-Disease
and	783 3 O
neoplasia	787 9 B-Disease
.	796 1 O

However	798 7 O
,	805 1 O
in	807 2 O
half	810 4 O
of	815 2 O
the	818 3 O
cases	822 5 O
no	828 2 O
etiologic	831 9 O
factor	841 6 O
is	848 2 O
identified	851 10 O
.	861 1 O

Usually	863 7 O
it	871 2 O
is	874 2 O
a	877 1 O
self	879 4 O
-	883 1 O
limited	884 7 O
disorder	892 8 O
,	900 1 O
but	902 3 O
corticosteroid	906 14 B-Chemical
therapy	921 7 O
may	929 3 O
be	933 2 O
needed	936 6 O
in	943 2 O
life	946 4 O
-	950 1 O
threatening	951 11 O
cases	963 5 O
since	969 5 O
early	975 5 O
treatment	981 9 O
with	991 4 O
corticosteroids	996 15 B-Chemical
in	1012 2 O
severe	1015 6 O
cases	1022 5 O
can	1028 3 O
prevent	1032 7 O
complications	1040 13 O
.	1053 1 O

Oxacillin	1055 9 B-Chemical
should	1065 6 O
be	1072 2 O
included	1075 8 O
among	1084 5 O
the	1090 3 O
drugs	1094 5 O
that	1100 4 O
can	1105 3 O
cause	1109 5 O
leucocytoclastic	1115 16 B-Disease
vasculitis	1132 10 I-Disease
.	1142 1 O

Naloxazone	0 10 B-Chemical
pretreatment	11 12 O
modifies	24 8 O
cardiorespiratory	33 17 O
,	50 1 O
temperature	52 11 O
,	63 1 O
and	65 3 O
behavioral	69 10 O
effects	80 7 O
of	88 2 O
morphine	91 8 B-Chemical
.	99 1 O

Behavioral	101 10 O
and	112 3 O
cardiorespiratory	116 17 O
responses	134 9 O
to	144 2 O
a	147 1 O
lethal	149 6 O
dose	156 4 O
of	161 2 O
morphine	164 8 B-Chemical
were	173 4 O
evaluated	178 9 O
in	188 2 O
rats	191 4 O
pretreated	196 10 O
with	207 4 O
saline	212 6 O
or	219 2 O
naloxazone	222 10 B-Chemical
,	232 1 O
an	234 2 O
antagonist	237 10 O
of	248 2 O
high	251 4 O
-	255 1 O
affinity	256 8 O
mu	265 2 O
1	268 1 O
opioid	270 6 O
receptors	277 9 O
.	286 1 O

Pretreatment	288 12 O
with	301 4 O
naloxazone	306 10 B-Chemical
significantly	317 13 O
blocked	331 7 O
morphine	339 8 B-Chemical
analgesia	348 9 B-Disease
,	357 1 O
catalepsy	359 9 B-Disease
and	369 3 O
hypothermia	373 11 B-Disease
at	385 2 O
a	388 1 O
dose	390 4 O
which	395 5 O
completely	401 10 O
eliminated	412 10 O
high	423 4 O
-	427 1 O
affinity	428 8 O
binding	437 7 O
in	445 2 O
brain	448 5 O
membranes	454 9 O
.	463 1 O

Moreover	465 8 O
,	473 1 O
naloxazone	475 10 B-Chemical
significantly	486 13 O
attenuated	500 10 O
the	511 3 O
morphine	515 8 B-Chemical
-	523 1 O
induced	524 7 O
hypotension	532 11 B-Disease
and	544 3 O
respiratory	548 11 B-Disease
depression	560 10 I-Disease
,	570 1 O
whereas	572 7 O
morphine	580 8 B-Chemical
-	588 1 O
induced	589 7 O
bradycardia	597 11 B-Disease
was	609 3 O
less	613 4 O
affected	618 8 O
.	626 1 O

Results	628 7 O
indicate	636 8 O
that	645 4 O
subpopulations	650 14 O
of	665 2 O
mu	668 2 O
receptors	671 9 O
may	681 3 O
mediate	685 7 O
selective	693 9 O
behavioral	703 10 O
and	714 3 O
cardiorespiratory	718 17 O
responses	736 9 O
to	746 2 O
morphine	749 8 B-Chemical
.	757 1 O

Dexrazoxane	0 11 B-Chemical
protects	12 8 O
against	21 7 O
myelosuppression	29 16 B-Disease
from	46 4 O
the	51 3 O
DNA	55 3 O
cleavage	59 8 O
-	67 1 O
enhancing	68 9 O
drugs	78 5 O
etoposide	84 9 B-Chemical
and	94 3 O
daunorubicin	98 12 B-Chemical
but	111 3 O
not	115 3 O
doxorubicin	119 11 B-Chemical
.	130 1 O

PURPOSE	132 7 O
:	139 1 O
The	141 3 O
anthracyclines	145 14 B-Chemical
daunorubicin	160 12 B-Chemical
and	173 3 O
doxorubicin	177 11 B-Chemical
and	189 3 O
the	193 3 O
epipodophyllotoxin	197 18 B-Chemical
etoposide	216 9 B-Chemical
are	226 3 O
potent	230 6 O
DNA	237 3 O
cleavage	241 8 O
-	249 1 O
enhancing	250 9 O
drugs	260 5 O
that	266 4 O
are	271 3 O
widely	275 6 O
used	282 4 O
in	287 2 O
clinical	290 8 O
oncology	299 8 O
;	307 1 O
however	309 7 O
,	316 1 O
myelosuppression	318 16 B-Disease
and	335 3 O
cardiac	339 7 B-Disease
toxicity	347 8 I-Disease
limit	356 5 O
their	362 5 O
use	368 3 O
.	371 1 O

Dexrazoxane	373 11 B-Chemical
(	385 1 O
ICRF	386 4 B-Chemical
-	390 1 I-Chemical
187	391 3 I-Chemical
)	394 1 O
is	396 2 O
recommended	399 11 O
for	411 3 O
protection	415 10 O
against	426 7 O
anthracycline	434 13 B-Chemical
-	447 1 O
induced	448 7 O
cardiotoxicity	456 14 B-Disease
.	470 1 O

EXPERIMENTAL	472 12 O
DESIGN	485 6 O
:	491 1 O
Because	493 7 O
of	501 2 O
their	504 5 O
widespread	510 10 O
use	521 3 O
,	524 1 O
the	526 3 O
hematologic	530 11 B-Disease
toxicity	542 8 I-Disease
following	551 9 O
coadministration	561 16 O
of	578 2 O
dexrazoxane	581 11 B-Chemical
and	593 3 O
these	597 5 O
three	603 5 O
structurally	609 12 O
different	622 9 O
DNA	632 3 O
cleavage	636 8 O
enhancers	645 9 O
was	655 3 O
investigated	659 12 O
:	671 1 O
Sensitivity	673 11 O
of	685 2 O
human	688 5 O
and	694 3 O
murine	698 6 O
blood	705 5 O
progenitor	711 10 O
cells	722 5 O
to	728 2 O
etoposide	731 9 B-Chemical
,	740 1 O
daunorubicin	742 12 B-Chemical
,	754 1 O
and	756 3 O
doxorubicin	760 11 B-Chemical
+	772 1 O
/	773 1 O
-	774 1 O
dexrazoxane	776 11 B-Chemical
was	788 3 O
determined	792 10 O
in	803 2 O
granulocyte	806 11 O
-	817 1 O
macrophage	818 10 O
colony	829 6 O
forming	836 7 O
assays	844 6 O
.	850 1 O

Likewise	852 8 O
,	860 1 O
in	862 2 O
vivo	865 4 O
,	869 1 O
B6D2F1	871 6 O
mice	878 4 O
were	883 4 O
treated	888 7 O
with	896 4 O
etoposide	901 9 B-Chemical
,	910 1 O
daunorubicin	912 12 B-Chemical
,	924 1 O
and	926 3 O
doxorubicin	930 11 B-Chemical
,	941 1 O
with	943 4 O
or	948 2 O
without	951 7 O
dexrazoxane	959 11 B-Chemical
over	971 4 O
a	976 1 O
wide	978 4 O
range	983 5 O
of	989 2 O
doses	992 5 O
:	997 1 O
posttreatment	999 13 O
,	1012 1 O
a	1014 1 O
full	1016 4 O
hematologic	1021 11 O
evaluation	1033 10 O
was	1044 3 O
done	1048 4 O
.	1052 1 O

RESULTS	1054 7 O
:	1061 1 O
Nontoxic	1063 8 O
doses	1072 5 O
of	1078 2 O
dexrazoxane	1081 11 B-Chemical
reduced	1093 7 O
myelosuppression	1101 16 B-Disease
and	1118 3 O
weight	1122 6 B-Disease
loss	1129 4 I-Disease
from	1134 4 O
daunorubicin	1139 12 B-Chemical
and	1152 3 O
etoposide	1156 9 B-Chemical
in	1166 2 O
mice	1169 4 O
and	1174 3 O
antagonized	1178 11 O
their	1190 5 O
antiproliferative	1196 17 O
effects	1214 7 O
in	1222 2 O
the	1225 3 O
colony	1229 6 O
assay	1236 5 O
;	1241 1 O
however	1243 7 O
,	1250 1 O
dexrazoxane	1252 11 B-Chemical
neither	1264 7 O
reduced	1272 7 O
myelosuppression	1280 16 B-Disease
,	1296 1 O
weight	1298 6 B-Disease
loss	1305 4 I-Disease
,	1309 1 O
nor	1311 3 O
the	1315 3 O
in	1319 2 O
vitro	1322 5 O
cytotoxicity	1328 12 B-Disease
from	1341 4 O
doxorubicin	1346 11 B-Chemical
.	1357 1 O

CONCLUSION	1359 10 O
:	1369 1 O
Although	1371 8 O
our	1380 3 O
findings	1384 8 O
support	1393 7 O
the	1401 3 O
observation	1405 11 O
that	1417 4 O
dexrazoxane	1422 11 B-Chemical
reduces	1434 7 O
neither	1442 7 O
hematologic	1450 11 O
activity	1462 8 O
nor	1471 3 O
antitumor	1475 9 O
activity	1485 8 O
from	1494 4 O
doxorubicin	1499 11 B-Chemical
clinically	1511 10 O
,	1521 1 O
the	1523 3 O
potent	1527 6 O
antagonism	1534 10 O
of	1545 2 O
daunorubicin	1548 12 B-Chemical
activity	1561 8 O
raises	1570 6 O
concern	1577 7 O
;	1584 1 O
a	1586 1 O
possible	1588 8 O
interference	1597 12 O
with	1610 4 O
anticancer	1615 10 O
efficacy	1626 8 O
certainly	1635 9 O
would	1645 5 O
call	1651 4 O
for	1656 3 O
renewed	1660 7 O
attention	1668 9 O
.	1677 1 O

Our	1679 3 O
data	1683 4 O
also	1688 4 O
suggest	1693 7 O
that	1701 4 O
significant	1706 11 O
etoposide	1718 9 B-Chemical
dose	1728 4 O
escalation	1733 10 O
is	1744 2 O
perhaps	1747 7 O
possible	1755 8 O
by	1764 2 O
the	1767 3 O
use	1771 3 O
of	1775 2 O
dexrazoxane	1778 11 B-Chemical
.	1789 1 O

Clinical	1791 8 O
trials	1800 6 O
in	1807 2 O
patients	1810 8 O
with	1819 4 O
brain	1824 5 O
metastases	1830 10 B-Disease
combining	1841 9 O
dexrazoxane	1851 11 B-Chemical
and	1863 3 O
high	1867 4 O
doses	1872 5 O
of	1878 2 O
etoposide	1881 9 B-Chemical
is	1891 2 O
ongoing	1894 7 O
with	1902 4 O
the	1907 3 O
aim	1911 3 O
of	1915 2 O
improving	1918 9 O
efficacy	1928 8 O
without	1937 7 O
aggravating	1945 11 O
hematologic	1957 11 B-Disease
toxicity	1969 8 I-Disease
.	1977 1 O

If	1979 2 O
successful	1982 10 O
,	1992 1 O
this	1994 4 O
represents	1999 10 O
an	2010 2 O
exciting	2013 8 O
mechanism	2022 9 O
for	2032 3 O
pharmacologic	2036 13 O
regulation	2050 10 O
of	2061 2 O
side	2064 4 O
effects	2069 7 O
from	2077 4 O
cytotoxic	2082 9 O
chemotherapy	2092 12 O
.	2104 1 O

Effects	0 7 O
of	8 2 O
the	11 3 O
novel	15 5 O
compound	21 8 O
aniracetam	30 10 B-Chemical
(	41 1 O
Ro	42 2 B-Chemical
13	45 2 I-Chemical
-	47 1 I-Chemical
5057	48 4 I-Chemical
)	52 1 O
upon	54 4 O
impaired	59 8 B-Disease
learning	68 8 I-Disease
and	77 3 I-Disease
memory	81 6 I-Disease
in	88 2 O
rodents	91 7 O
.	98 1 O

The	100 3 O
effect	104 6 O
of	111 2 O
aniracetam	114 10 B-Chemical
(	125 1 O
Ro	126 2 B-Chemical
13	129 2 I-Chemical
-	131 1 I-Chemical
5057	132 4 I-Chemical
,	136 1 O
1	138 1 B-Chemical
-	139 1 I-Chemical
anisoyl	140 7 I-Chemical
-	147 1 I-Chemical
2	148 1 I-Chemical
-	149 1 I-Chemical
pyrrolidinone	150 13 I-Chemical
)	163 1 O
was	165 3 O
studied	169 7 O
on	177 2 O
various	180 7 O
forms	188 5 O
of	194 2 O
experimentally	197 14 O
impaired	212 8 B-Disease
cognitive	221 9 I-Disease
functions	231 9 I-Disease
(	241 1 O
learning	242 8 O
and	251 3 O
memory	255 6 O
)	261 1 O
in	263 2 O
rodents	266 7 O
and	274 3 O
produced	278 8 O
the	287 3 O
following	291 9 O
effects	301 7 O
:	308 1 O
(	310 1 O
1	311 1 O
)	312 1 O
almost	314 6 O
complete	321 8 O
prevention	330 10 O
of	341 2 O
the	344 3 O
incapacity	348 10 O
to	359 2 O
learn	362 5 O
a	368 1 O
discrete	370 8 O
escape	379 6 O
response	386 8 O
in	395 2 O
rats	398 4 O
exposed	403 7 O
to	411 2 O
sublethal	414 9 O
hypercapnia	424 11 B-Disease
immediately	436 11 O
before	448 6 O
the	455 3 O
acquisition	459 11 O
session	471 7 O
;	478 1 O
(	480 1 O
2	481 1 O
)	482 1 O
partial	484 7 O
(	492 1 O
rats	493 4 O
)	497 1 O
or	499 2 O
complete	502 8 O
(	511 1 O
mice	512 4 O
)	516 1 O
prevention	518 10 O
of	529 2 O
the	532 3 O
scopolamine	536 11 B-Chemical
-	547 1 O
induced	548 7 O
short	556 5 O
-	561 1 O
term	562 4 O
amnesia	567 7 B-Disease
for	575 3 O
a	579 1 O
passive	581 7 O
avoidance	589 9 O
task	599 4 O
;	603 1 O
(	605 1 O
3	606 1 O
)	607 1 O
complete	609 8 O
protection	618 10 O
against	629 7 O
amnesia	637 7 B-Disease
for	645 3 O
a	649 1 O
passive	651 7 O
avoidance	659 9 O
task	669 4 O
in	674 2 O
rats	677 4 O
submitted	682 9 O
to	692 2 O
electroconvulsive	695 17 O
shock	713 5 O
immediately	719 11 O
after	731 5 O
avoidance	737 9 O
acquisition	747 11 O
;	758 1 O
(	760 1 O
4	761 1 O
)	762 1 O
prevention	764 10 O
of	775 2 O
the	778 3 O
long	782 4 O
-	786 1 O
term	787 4 O
retention	792 9 O
-	801 1 O
or	803 2 O
retrieval	806 9 O
-	815 1 O
deficit	816 7 O
for	824 3 O
a	828 1 O
passive	830 7 O
avoidance	838 9 O
task	848 4 O
induced	853 7 O
in	861 2 O
rats	864 4 O
and	869 3 O
mice	873 4 O
by	878 2 O
chloramphenicol	881 15 B-Chemical
or	897 2 O
cycloheximide	900 13 B-Chemical
administered	914 12 O
immediately	927 11 O
after	939 5 O
acquisition	945 11 O
;	956 1 O
(	958 1 O
5	959 1 O
)	960 1 O
reversal	962 8 O
,	970 1 O
when	972 4 O
administered	977 12 O
as	990 2 O
late	993 4 O
as	998 2 O
1	1001 1 O
h	1003 1 O
before	1005 6 O
the	1012 3 O
retention	1016 9 O
test	1026 4 O
,	1030 1 O
of	1032 2 O
the	1035 3 O
deficit	1039 7 O
in	1047 2 O
retention	1050 9 O
or	1060 2 O
retrieval	1063 9 O
of	1073 2 O
a	1076 1 O
passive	1078 7 O
avoidance	1086 9 O
task	1096 4 O
induced	1101 7 O
by	1109 2 O
cycloheximide	1112 13 B-Chemical
injected	1126 8 O
2	1135 1 O
days	1137 4 O
previously	1142 10 O
;	1152 1 O
(	1154 1 O
6	1155 1 O
)	1156 1 O
prevention	1158 10 O
of	1169 2 O
the	1172 3 O
deficit	1176 7 O
in	1184 2 O
the	1187 3 O
retrieval	1191 9 O
of	1201 2 O
an	1204 2 O
active	1207 6 O
avoidance	1214 9 O
task	1224 4 O
induced	1229 7 O
in	1237 2 O
mice	1240 4 O
by	1245 2 O
subconvulsant	1248 13 O
electroshock	1262 12 O
or	1275 2 O
hypercapnia	1278 11 B-Disease
applied	1290 7 O
immediately	1298 11 O
before	1310 6 O
retrieval	1317 9 O
testing	1327 7 O
(	1335 1 O
24	1336 2 O
h	1339 1 O
after	1341 5 O
acquisition	1347 11 O
)	1358 1 O
.	1359 1 O

These	1361 5 O
improvements	1367 12 O
or	1380 2 O
normalizations	1383 14 O
of	1398 2 O
impaired	1401 8 B-Disease
cognitive	1410 9 I-Disease
functions	1420 9 I-Disease
were	1430 4 O
seen	1435 4 O
at	1440 2 O
oral	1443 4 O
aniracetam	1448 10 B-Chemical
doses	1459 5 O
of	1465 2 O
10	1468 2 O
-	1470 1 O
100	1471 3 O
mg	1475 2 O
/	1477 1 O
kg	1478 2 O
.	1480 1 O

Generally	1482 9 O
,	1491 1 O
the	1493 3 O
dose	1497 4 O
-	1501 1 O
response	1502 8 O
curves	1511 6 O
were	1518 4 O
bell	1523 4 O
-	1527 1 O
shaped	1528 6 O
.	1534 1 O

The	1536 3 O
mechanisms	1540 10 O
underlying	1551 10 O
the	1562 3 O
activity	1566 8 O
of	1575 2 O
aniracetam	1578 10 B-Chemical
and	1589 3 O
its	1593 3 O
'	1597 1 O
therapeutic	1598 11 O
window	1610 6 O
'	1616 1 O
are	1618 3 O
unknown	1622 7 O
.	1629 1 O

Piracetam	1631 9 B-Chemical
,	1640 1 O
another	1642 7 O
pyrrolidinone	1650 13 B-Chemical
derivative	1664 10 O
was	1675 3 O
used	1679 4 O
for	1684 3 O
comparison	1688 10 O
.	1698 1 O

It	1700 2 O
was	1703 3 O
active	1707 6 O
only	1714 4 O
in	1719 2 O
six	1722 3 O
of	1726 2 O
nine	1729 4 O
tests	1734 5 O
and	1740 3 O
had	1744 3 O
about	1748 5 O
one	1754 3 O
-	1757 1 O
tenth	1758 5 O
the	1764 3 O
potency	1768 7 O
of	1776 2 O
aniracetam	1779 10 B-Chemical
.	1789 1 O

The	1791 3 O
results	1795 7 O
indicate	1803 8 O
that	1812 4 O
aniracetam	1817 10 B-Chemical
improves	1828 8 O
cognitive	1837 9 O
functions	1847 9 O
which	1857 5 O
are	1863 3 O
impaired	1867 8 O
by	1876 2 O
different	1879 9 O
procedure	1889 9 O
and	1899 3 O
in	1903 2 O
different	1906 9 O
phases	1916 6 O
of	1923 2 O
the	1926 3 O
learning	1930 8 O
and	1939 3 O
memory	1943 6 O
process	1950 7 O
.	1957 1 O

Nicotine	0 8 B-Chemical
potentiation	9 12 O
of	22 2 O
morphine	25 8 B-Chemical
-	33 1 O
induced	34 7 O
catalepsy	42 9 B-Disease
in	52 2 O
mice	55 4 O
.	59 1 O

In	61 2 O
the	64 3 O
present	68 7 O
study	76 5 O
,	81 1 O
effects	83 7 O
of	91 2 O
nicotine	94 8 B-Chemical
on	103 2 O
catalepsy	106 9 B-Disease
induced	116 7 O
by	124 2 O
morphine	127 8 B-Chemical
in	136 2 O
mice	139 4 O
have	144 4 O
been	149 4 O
investigated	154 12 O
.	166 1 O

Morphine	168 8 B-Chemical
but	177 3 O
not	181 3 O
nicotine	185 8 B-Chemical
induced	194 7 O
a	202 1 O
dose	204 4 O
-	208 1 O
dependent	209 9 O
catalepsy	219 9 B-Disease
.	228 1 O

The	230 3 O
response	234 8 O
of	243 2 O
morphine	246 8 B-Chemical
was	255 3 O
potentiated	259 11 O
by	271 2 O
nicotine	274 8 B-Chemical
.	282 1 O

Intraperitoneal	284 15 O
administration	300 14 O
of	315 2 O
atropine	318 8 B-Chemical
,	326 1 O
naloxone	328 8 B-Chemical
,	336 1 O
mecamylamine	338 12 B-Chemical
,	350 1 O
and	352 3 O
hexamethonium	356 13 B-Chemical
to	370 2 O
mice	373 4 O
reduced	378 7 O
catalepsy	386 9 B-Disease
induced	396 7 O
by	404 2 O
a	407 1 O
combination	409 11 O
of	421 2 O
morphine	424 8 B-Chemical
with	433 4 O
nicotine	438 8 B-Chemical
.	446 1 O

Intracerebroventricular	448 23 O
injection	472 9 O
of	482 2 O
atropine	485 8 B-Chemical
,	493 1 O
hexamethonium	495 13 B-Chemical
,	508 1 O
and	510 3 O
naloxone	514 8 B-Chemical
also	523 4 O
decreased	528 9 O
catalepsy	538 9 B-Disease
induced	548 7 O
by	556 2 O
morphine	559 8 B-Chemical
plus	568 4 O
nicotine	573 8 B-Chemical
.	581 1 O

Intraperitoneal	583 15 O
administration	599 14 O
of	614 2 O
atropine	617 8 B-Chemical
,	625 1 O
but	627 3 O
not	631 3 O
intraperitoneal	635 15 O
or	651 2 O
intracerebroventricular	654 23 O
injection	678 9 O
of	688 2 O
hexamethonium	691 13 B-Chemical
,	704 1 O
decreased	706 9 O
the	716 3 O
effect	720 6 O
of	727 2 O
a	730 1 O
single	732 6 O
dose	739 4 O
of	744 2 O
morphine	747 8 B-Chemical
.	755 1 O

It	757 2 O
was	760 3 O
concluded	764 9 O
that	774 4 O
morphine	779 8 B-Chemical
catalepsy	788 9 B-Disease
can	798 3 O
be	802 2 O
elicited	805 8 O
by	814 2 O
opioid	817 6 O
and	824 3 O
cholinergic	828 11 O
receptors	840 9 O
,	849 1 O
and	851 3 O
the	855 3 O
potentiation	859 12 O
of	872 2 O
morphine	875 8 B-Chemical
induced	884 7 O
by	892 2 O
nicotine	895 8 B-Chemical
may	904 3 O
also	908 4 O
be	913 2 O
mediated	916 8 O
through	925 7 O
cholinergic	933 11 O
receptor	945 8 O
mechanisms	954 10 O
.	964 1 O

Reduced	0 7 O
cardiotoxicity	8 14 B-Disease
and	23 3 O
preserved	27 9 O
antitumor	37 9 O
efficacy	47 8 O
of	56 2 O
liposome	59 8 O
-	67 1 O
encapsulated	68 12 O
doxorubicin	81 11 B-Chemical
and	93 3 O
cyclophosphamide	97 16 B-Chemical
compared	114 8 O
with	123 4 O
conventional	128 12 O
doxorubicin	141 11 B-Chemical
and	153 3 O
cyclophosphamide	157 16 B-Chemical
in	174 2 O
a	177 1 O
randomized	179 10 O
,	189 1 O
multicenter	191 11 O
trial	203 5 O
of	209 2 O
metastatic	212 10 O
breast	223 6 B-Disease
cancer	230 6 I-Disease
.	236 1 O

PURPOSE	238 7 O
:	245 1 O
To	247 2 O
determine	250 9 O
whether	260 7 O
Myocet	268 6 B-Chemical
(	275 1 O
liposome	276 8 O
-	284 1 O
encapsulated	285 12 O
doxorubicin	298 11 B-Chemical
;	309 1 O
The	311 3 O
Liposome	315 8 O
Company	324 7 O
,	331 1 O
Elan	333 4 O
Corporation	338 11 O
,	349 1 O
Princeton	351 9 O
,	360 1 O
NJ	362 2 O
)	364 1 O
in	366 2 O
combination	369 11 O
with	381 4 O
cyclophosphamide	386 16 B-Chemical
significantly	403 13 O
reduces	417 7 O
doxorubicin	425 11 B-Chemical
cardiotoxicity	437 14 B-Disease
while	452 5 O
providing	458 9 O
comparable	468 10 O
antitumor	479 9 O
efficacy	489 8 O
in	498 2 O
first	501 5 O
-	506 1 O
line	507 4 O
treatment	512 9 O
of	522 2 O
metastatic	525 10 O
breast	536 6 B-Disease
cancer	543 6 I-Disease
(	550 1 O
MBC	551 3 B-Disease
)	554 1 O
.	555 1 O

PATIENTS	557 8 O
AND	566 3 O
METHODS	570 7 O
:	577 1 O
Two	579 3 O
hundred	583 7 O
ninety	591 6 O
-	597 1 O
seven	598 5 O
patients	604 8 O
with	613 4 O
MBC	618 3 B-Disease
and	622 3 O
no	626 2 O
prior	629 5 O
chemotherapy	635 12 O
for	648 3 O
metastatic	652 10 O
disease	663 7 O
were	671 4 O
randomized	676 10 O
to	687 2 O
receive	690 7 O
either	698 6 O
60	705 2 O
mg	708 2 O
/	710 1 O
m	711 1 O
(	712 1 O
2	713 1 O
)	714 1 O
of	716 2 O
Myocet	719 6 B-Chemical
(	726 1 O
M	727 1 O
)	728 1 O
or	730 2 O
conventional	733 12 O
doxorubicin	746 11 B-Chemical
(	758 1 O
A	759 1 O
)	760 1 O
,	761 1 O
in	763 2 O
combination	766 11 O
with	778 4 O
600	783 3 O
mg	787 2 O
/	789 1 O
m	790 1 O
(	791 1 O
2	792 1 O
)	793 1 O
of	795 2 O
cyclophosphamide	798 16 B-Chemical
(	815 1 O
C	816 1 O
)	817 1 O
,	818 1 O
every	820 5 O
3	826 1 O
weeks	828 5 O
until	834 5 O
disease	840 7 O
progression	848 11 O
or	860 2 O
unacceptable	863 12 O
toxicity	876 8 B-Disease
.	884 1 O

Cardiotoxicity	886 14 B-Disease
was	901 3 O
defined	905 7 O
by	913 2 O
reductions	916 10 O
in	927 2 O
left	930 4 O
-	934 1 O
ventricular	935 11 O
ejection	947 8 O
fraction	956 8 O
,	964 1 O
assessed	966 8 O
by	975 2 O
serial	978 6 O
multigated	985 10 O
radionuclide	996 12 O
angiography	1009 11 O
scans	1021 5 O
,	1026 1 O
or	1028 2 O
congestive	1031 10 B-Disease
heart	1042 5 I-Disease
failure	1048 7 I-Disease
(	1056 1 O
CHF	1057 3 B-Disease
)	1060 1 O
.	1061 1 O

Antitumor	1063 9 O
efficacy	1073 8 O
was	1082 3 O
assessed	1086 8 O
by	1095 2 O
objective	1098 9 O
tumor	1108 5 B-Disease
response	1114 8 O
rates	1123 5 O
(	1129 1 O
World	1130 5 O
Health	1136 6 O
Organization	1143 12 O
criteria	1156 8 O
)	1164 1 O
,	1165 1 O
time	1167 4 O
to	1172 2 O
progression	1175 11 O
,	1186 1 O
and	1188 3 O
survival	1192 8 O
.	1200 1 O

RESULTS	1202 7 O
:	1209 1 O
Six	1211 3 O
percent	1215 7 O
of	1223 2 O
MC	1226 2 O
patients	1229 8 O
versus	1238 6 O
21	1245 2 O
%	1247 1 O
(	1249 1 O
including	1250 9 O
five	1260 4 O
cases	1265 5 O
of	1271 2 O
CHF	1274 3 B-Disease
)	1277 1 O
of	1279 2 O
AC	1282 2 O
patients	1285 8 O
developed	1294 9 O
cardiotoxicity	1304 14 B-Disease
(	1319 1 O
P	1320 1 O
=	1322 1 O
.	1323 1 O
0002	1324 4 O
)	1328 1 O
.	1329 1 O

Median	1331 6 O
cumulative	1338 10 O
doxorubicin	1349 11 B-Chemical
dose	1361 4 O
at	1366 2 O
onset	1369 5 O
was	1375 3 O
more	1379 4 O
than	1384 4 O
2	1389 1 O
,	1390 1 O
220	1391 3 O
mg	1395 2 O
/	1397 1 O
m	1398 1 O
(	1399 1 O
2	1400 1 O
)	1401 1 O
for	1403 3 O
MC	1407 2 O
versus	1410 6 O
480	1417 3 O
mg	1421 2 O
/	1423 1 O
m	1424 1 O
(	1425 1 O
2	1426 1 O
)	1427 1 O
for	1429 3 O
AC	1433 2 O
(	1436 1 O
P	1437 1 O
=	1439 1 O
.	1440 1 O
0001	1441 4 O
,	1445 1 O
hazard	1447 6 O
ratio	1454 5 O
,	1459 1 O
5	1461 1 O
.	1462 1 O
04	1463 2 O
)	1465 1 O
.	1466 1 O

MC	1468 2 O
patients	1471 8 O
also	1480 4 O
experienced	1485 11 O
less	1497 4 O
grade	1502 5 O
4	1508 1 O
neutropenia	1510 11 B-Disease
.	1521 1 O

Antitumor	1523 9 O
efficacy	1533 8 O
of	1542 2 O
MC	1545 2 O
versus	1548 6 O
AC	1555 2 O
was	1558 3 O
comparable	1562 10 O
:	1572 1 O
objective	1574 9 O
response	1584 8 O
rates	1593 5 O
,	1598 1 O
43	1600 2 O
%	1602 1 O
versus	1604 6 O
43	1611 2 O
%	1613 1 O
;	1614 1 O
median	1616 6 O
time	1623 4 O
to	1628 2 O
progression	1631 11 O
,	1642 1 O
5	1644 1 O
.	1645 1 O
1	1646 1 O
%	1647 1 O
versus	1649 6 O
5	1656 1 O
.	1657 1 O
5	1658 1 O
months	1660 6 O
;	1666 1 O
median	1668 6 O
time	1675 4 O
to	1680 2 O
treatment	1683 9 O
failure	1693 7 O
,	1700 1 O
4	1702 1 O
.	1703 1 O
6	1704 1 O
versus	1706 6 O
4	1713 1 O
.	1714 1 O
4	1715 1 O
months	1717 6 O
;	1723 1 O
and	1725 3 O
median	1729 6 O
survival	1736 8 O
,	1744 1 O
19	1746 2 O
versus	1749 6 O
16	1756 2 O
months	1759 6 O
.	1765 1 O

CONCLUSION	1767 10 O
:	1777 1 O
Myocet	1779 6 B-Chemical
improves	1786 8 O
the	1795 3 O
therapeutic	1799 11 O
index	1811 5 O
of	1817 2 O
doxorubicin	1820 11 B-Chemical
by	1832 2 O
significantly	1835 13 O
reducing	1849 8 O
cardiotoxicity	1858 14 B-Disease
and	1873 3 O
grade	1877 5 O
4	1883 1 O
neutropenia	1885 11 B-Disease
and	1897 3 O
provides	1901 8 O
comparable	1910 10 O
antitumor	1921 9 O
efficacy	1931 8 O
,	1939 1 O
when	1941 4 O
used	1946 4 O
in	1951 2 O
combination	1954 11 O
with	1966 4 O
cyclophosphamide	1971 16 B-Chemical
as	1988 2 O
first	1991 5 O
-	1996 1 O
line	1997 4 O
therapy	2002 7 O
for	2010 3 O
MBC	2014 3 B-Disease
.	2017 1 O

Protective	0 10 O
effect	11 6 O
of	18 2 O
a	21 1 O
specific	23 8 O
platelet	32 8 O
-	40 1 O
activating	41 10 O
factor	52 6 O
antagonist	59 10 O
,	69 1 O
BN	71 2 B-Chemical
52021	74 5 I-Chemical
,	79 1 O
on	81 2 O
bupivacaine	84 11 B-Chemical
-	95 1 O
induced	96 7 O
cardiovascular	104 14 B-Disease
impairments	119 11 I-Disease
in	131 2 O
rats	134 4 O
.	138 1 O

Administration	140 14 O
of	155 2 O
the	158 3 O
local	162 5 O
anaesthetic	168 11 O
bupivacaine	180 11 B-Chemical
(	192 1 O
1	193 1 O
.	194 1 O
5	195 1 O
or	197 2 O
2	200 1 O
mg	202 2 O
/	204 1 O
kg	205 2 O
,	207 1 O
i	209 1 O
.	210 1 O
v	211 1 O
.	212 1 O
)	213 1 O
to	215 2 O
rats	218 4 O
elicited	223 8 O
a	232 1 O
marked	234 6 O
decrease	241 8 B-Disease
of	250 2 I-Disease
mean	253 4 I-Disease
arterial	258 8 I-Disease
blood	267 5 I-Disease
pressure	273 8 I-Disease
(	282 1 I-Disease
MBP	283 3 I-Disease
)	286 1 I-Disease
and	288 3 I-Disease
heart	292 5 I-Disease
rate	298 4 I-Disease
(	303 1 I-Disease
HR	304 2 I-Disease
)	306 1 I-Disease
leading	308 7 O
to	316 2 O
death	319 5 O
(	325 1 O
in	326 2 O
67	329 2 O
%	331 1 O
or	333 2 O
90	336 2 O
%	338 1 O
of	340 2 O
animals	343 7 O
respectively	351 12 O
)	363 1 O
.	364 1 O

Intravenous	366 11 O
injection	378 9 O
of	388 2 O
the	391 3 O
specific	395 8 O
platelet	404 8 O
-	412 1 O
activating	413 10 O
factor	424 6 O
(	431 1 O
PAF	432 3 O
)	435 1 O
antagonist	437 10 O
BN	448 2 B-Chemical
52021	451 5 I-Chemical
(	457 1 O
10	458 2 O
mg	461 2 O
/	463 1 O
kg	464 2 O
)	466 1 O
,	467 1 O
30	469 2 O
min	472 3 O
before	476 6 O
bupivacaine	483 11 B-Chemical
administration	495 14 O
(	510 1 O
2	511 1 O
mg	513 2 O
/	515 1 O
kg	516 2 O
i	519 1 O
.	520 1 O
v	521 1 O
.	522 1 O
)	523 1 O
suppressed	525 10 O
both	536 4 O
the	541 3 O
decrease	545 8 B-Disease
of	554 2 I-Disease
MBP	557 3 I-Disease
and	561 3 I-Disease
HR	565 2 I-Disease
.	567 1 O

In	569 2 O
contrast	572 8 O
,	580 1 O
doses	582 5 O
of	588 2 O
1	591 1 O
mg	593 2 O
/	595 1 O
kg	596 2 O
BN	599 2 B-Chemical
52021	602 5 I-Chemical
given	608 5 O
30	614 2 O
min	617 3 O
before	621 6 O
or	628 2 O
10	631 2 O
mg	634 2 O
/	636 1 O
kg	637 2 O
administered	640 12 O
5	653 1 O
min	655 3 O
before	659 6 O
i	666 1 O
.	667 1 O
v	668 1 O
.	669 1 O
injection	671 9 O
of	681 2 O
bupivacaine	684 11 B-Chemical
were	696 4 O
ineffective	701 11 O
.	712 1 O

When	714 4 O
BN	719 2 B-Chemical
52021	722 5 I-Chemical
(	728 1 O
20	729 2 O
mg	732 2 O
/	734 1 O
kg	735 2 O
i	738 1 O
.	739 1 O
v	740 1 O
.	741 1 O
)	742 1 O
was	744 3 O
injected	748 8 O
immediately	757 11 O
after	769 5 O
bupivacaine	775 11 B-Chemical
(	787 1 O
2	788 1 O
mg	790 2 O
/	792 1 O
kg	793 2 O
)	795 1 O
,	796 1 O
a	798 1 O
partial	800 7 O
reversion	808 9 O
of	818 2 O
the	821 3 O
decrease	825 8 B-Disease
of	834 2 I-Disease
MBP	837 3 I-Disease
and	841 3 I-Disease
HR	845 2 I-Disease
was	848 3 O
observed	852 8 O
,	860 1 O
whereas	862 7 O
the	870 3 O
dose	874 4 O
of	879 2 O
10	882 2 O
mg	885 2 O
/	887 1 O
kg	888 2 O
was	891 3 O
ineffective	895 11 O
.	906 1 O

A	908 1 O
partial	910 7 O
recovery	918 8 O
of	927 2 O
bupivacaine	930 11 B-Chemical
-	941 1 O
induced	942 7 O
ECG	950 3 O
alterations	954 11 O
was	966 3 O
observed	970 8 O
after	979 5 O
pretreatment	985 12 O
of	998 2 O
the	1001 3 O
rats	1005 4 O
with	1010 4 O
BN	1015 2 B-Chemical
52021	1018 5 I-Chemical
.	1023 1 O

Since	1025 5 O
the	1031 3 O
administration	1035 14 O
of	1050 2 O
BN	1053 2 B-Chemical
52021	1056 5 I-Chemical
,	1061 1 O
at	1063 2 O
all	1066 3 O
doses	1070 5 O
studied	1076 7 O
,	1083 1 O
did	1085 3 O
not	1089 3 O
alter	1093 5 O
MBP	1099 3 O
and	1103 3 O
HR	1107 2 O
at	1110 2 O
the	1113 3 O
doses	1117 5 O
used	1123 4 O
,	1127 1 O
the	1129 3 O
bulk	1133 4 O
of	1138 2 O
these	1141 5 O
results	1147 7 O
clearly	1155 7 O
demonstrate	1163 11 O
a	1175 1 O
protective	1177 10 O
action	1188 6 O
of	1195 2 O
BN	1198 2 B-Chemical
52021	1201 5 I-Chemical
,	1206 1 O
a	1208 1 O
specific	1210 8 O
antagonist	1219 10 O
of	1230 2 O
PAF	1233 3 O
,	1236 1 O
against	1238 7 O
bupivacaine	1246 11 B-Chemical
-	1257 1 O
induced	1258 7 O
cardiovascular	1266 14 B-Disease
toxicity	1281 8 I-Disease
.	1289 1 O

Thus	1291 4 O
,	1295 1 O
consistent	1297 10 O
with	1308 4 O
its	1313 3 O
direct	1317 6 O
effect	1324 6 O
on	1331 2 O
heart	1334 5 O
,	1339 1 O
PAF	1341 3 O
appears	1345 7 O
to	1353 2 O
be	1356 2 O
implicated	1359 10 O
in	1370 2 O
bupivacaine	1373 11 B-Chemical
-	1384 1 O
induced	1385 7 O
cardiovascular	1393 14 B-Disease
alterations	1408 11 I-Disease
.	1419 1 O

Benzylacyclouridine	0 19 B-Chemical
reverses	20 8 O
azidothymidine	29 14 B-Chemical
-	43 1 O
induced	44 7 O
marrow	52 6 B-Disease
suppression	59 11 I-Disease
without	71 7 O
impairment	79 10 O
of	90 2 O
anti	93 4 O
-	97 1 O
human	98 5 O
immunodeficiency	104 16 B-Disease
virus	121 5 O
activity	127 8 O
.	135 1 O

Increased	137 9 O
extracellular	147 13 O
concentrations	161 14 O
of	176 2 O
uridine	179 7 B-Chemical
(	187 1 O
Urd	188 3 B-Chemical
)	191 1 O
have	193 4 O
been	198 4 O
reported	203 8 O
to	212 2 O
reduce	215 6 O
,	221 1 O
in	223 2 O
vitro	226 5 O
,	231 1 O
azidothymidine	233 14 B-Chemical
(	248 1 O
AZT	249 3 B-Chemical
)	252 1 O
-	253 1 O
induced	254 7 O
inhibition	262 10 O
of	273 2 O
human	276 5 O
granulocyte	282 11 O
-	293 1 O
macrophage	294 10 O
progenitor	305 10 O
cells	316 5 O
without	322 7 O
impairment	330 10 O
of	341 2 O
its	344 3 O
antihuman	348 9 O
immunodeficiency	358 16 B-Disease
virus	375 5 O
(	381 1 O
HIV	382 3 O
)	385 1 O
activity	387 8 O
.	395 1 O

Because	397 7 O
of	405 2 O
the	408 3 O
clinical	412 8 O
toxicities	421 10 B-Disease
associated	432 10 O
with	443 4 O
chronic	448 7 O
Urd	456 3 B-Chemical
administration	460 14 O
,	474 1 O
the	476 3 O
ability	480 7 O
of	488 2 O
benzylacyclouridine	491 19 B-Chemical
(	511 1 O
BAU	512 3 B-Chemical
)	515 1 O
to	517 2 O
effect	520 6 O
,	526 1 O
in	528 2 O
vivo	531 4 O
,	535 1 O
AZT	537 3 B-Chemical
-	540 1 O
induced	541 7 O
anemia	549 6 B-Disease
and	556 3 O
leukopenia	560 10 B-Disease
was	571 3 O
assessed	575 8 O
.	583 1 O

This	585 4 O
agent	590 5 O
inhibits	596 8 O
Urd	605 3 B-Chemical
catabolism	609 10 O
and	620 3 O
,	623 1 O
in	625 2 O
vivo	628 4 O
,	632 1 O
increases	634 9 O
the	644 3 O
plasma	648 6 O
concentration	655 13 O
of	669 2 O
Urd	672 3 B-Chemical
in	676 2 O
a	679 1 O
dose	681 4 O
-	685 1 O
dependent	686 9 O
manner	696 6 O
,	702 1 O
without	704 7 O
Urd	712 3 B-Chemical
-	715 1 O
related	716 7 O
toxicity	724 8 B-Disease
.	732 1 O

In	734 2 O
mice	737 4 O
rendered	742 8 O
anemic	751 6 B-Disease
and	758 3 O
leukopenic	762 10 B-Disease
by	773 2 O
the	776 3 O
administration	780 14 O
of	795 2 O
AZT	798 3 B-Chemical
for	802 3 O
28	806 2 O
days	809 4 O
in	814 2 O
drinking	817 8 O
water	826 5 O
(	832 1 O
1	833 1 O
.	834 1 O
5	835 1 O
mg	837 2 O
/	839 1 O
mL	840 2 O
)	842 1 O
,	843 1 O
the	845 3 O
continued	849 9 O
administration	859 14 O
of	874 2 O
AZT	877 3 B-Chemical
plus	881 4 O
daily	886 5 O
BAU	892 3 B-Chemical
(	896 1 O
300	897 3 O
mg	901 2 O
/	903 1 O
kg	904 2 O
,	906 1 O
orally	908 6 O
)	914 1 O
partially	916 9 O
reversed	926 8 O
AZT	935 3 B-Chemical
-	938 1 O
induced	939 7 O
anemia	947 6 B-Disease
and	954 3 O
leukopenia	958 10 B-Disease
(	969 1 O
P	970 1 O
less	972 4 O
than	977 4 O
.	982 1 O
05	983 2 O
)	985 1 O
,	986 1 O
increased	988 9 O
peripheral	998 10 O
reticulocytes	1009 13 O
(	1023 1 O
to	1024 2 O
4	1027 1 O
.	1028 1 O
9	1029 1 O
%	1030 1 O
,	1031 1 O
P	1033 1 O
less	1035 4 O
than	1040 4 O
.	1045 1 O
01	1046 2 O
)	1048 1 O
,	1049 1 O
increased	1051 9 O
cellularity	1061 11 O
in	1073 2 O
the	1076 3 O
marrow	1080 6 O
,	1086 1 O
and	1088 3 O
improved	1092 8 O
megaloblastosis	1101 15 B-Disease
.	1116 1 O

When	1118 4 O
coadministered	1123 14 O
with	1138 4 O
AZT	1143 3 B-Chemical
from	1147 4 O
the	1152 3 O
onset	1156 5 O
of	1162 2 O
drug	1165 4 O
administration	1170 14 O
,	1184 1 O
BAU	1186 3 B-Chemical
reduced	1190 7 O
AZT	1198 3 B-Chemical
-	1201 1 O
induced	1202 7 O
marrow	1210 6 B-Disease
toxicity	1217 8 I-Disease
.	1225 1 O

In	1227 2 O
vitro	1230 5 O
,	1235 1 O
at	1237 2 O
a	1240 1 O
concentration	1242 13 O
of	1256 2 O
100	1259 3 O
mumol	1263 5 O
/	1268 1 O
L	1269 1 O
,	1270 1 O
BAU	1272 3 B-Chemical
possesses	1276 9 O
minimal	1286 7 O
anti	1294 4 O
-	1298 1 O
HIV	1299 3 O
activity	1303 8 O
and	1312 3 O
has	1316 3 O
no	1320 2 O
effect	1323 6 O
on	1330 2 O
the	1333 3 O
ability	1337 7 O
of	1345 2 O
AZT	1348 3 B-Chemical
to	1352 2 O
reverse	1355 7 O
the	1363 3 O
HIV	1367 3 O
-	1370 1 O
induced	1371 7 O
cytopathic	1379 10 O
effect	1390 6 O
in	1397 2 O
MT4	1400 3 O
cells	1404 5 O
.	1409 1 O

The	1411 3 O
clinical	1415 8 O
and	1424 3 O
biochemical	1428 11 O
implications	1440 12 O
of	1453 2 O
these	1456 5 O
findings	1462 8 O
are	1471 3 O
discussed	1475 9 O
.	1484 1 O

Cyclophosphamide	0 16 B-Chemical
-	16 1 O
induced	17 7 O
cystitis	25 8 B-Disease
in	34 2 O
freely	37 6 O
-	43 1 O
moving	44 6 O
conscious	51 9 O
rats	61 4 O
:	65 1 O
behavioral	67 10 O
approach	78 8 O
to	87 2 O
a	90 1 O
new	92 3 O
model	96 5 O
of	102 2 O
visceral	105 8 B-Disease
pain	114 4 I-Disease
.	118 1 O

PURPOSE	120 7 O
:	127 1 O
To	129 2 O
develop	132 7 O
a	140 1 O
model	142 5 O
of	148 2 O
visceral	151 8 B-Disease
pain	160 4 I-Disease
in	165 2 O
rats	168 4 O
using	173 5 O
a	179 1 O
behavioral	181 10 O
approach	192 8 O
.	200 1 O

Cyclophosphamide	202 16 B-Chemical
(	219 1 O
CP	220 2 B-Chemical
)	222 1 O
,	223 1 O
an	225 2 O
antitumoral	228 11 O
agent	240 5 O
known	246 5 O
to	252 2 O
produce	255 7 O
toxic	263 5 O
effects	269 7 O
on	277 2 O
the	280 3 O
bladder	284 7 O
wall	292 4 O
through	297 7 O
its	305 3 O
main	309 4 O
toxic	314 5 O
metabolite	320 10 O
acrolein	331 8 B-Chemical
,	339 1 O
was	341 3 O
used	345 4 O
to	350 2 O
induce	353 6 O
cystitis	360 8 B-Disease
.	368 1 O

MATERIALS	370 9 O
AND	380 3 O
METHODS	384 7 O
:	391 1 O
CP	393 2 B-Chemical
was	396 3 O
administered	400 12 O
at	413 2 O
doses	416 5 O
of	422 2 O
50	425 2 O
,	427 1 O
100	429 3 O
and	433 3 O
200	437 3 O
mg	441 2 O
.	443 1 O
/	444 1 O
kg	445 2 O
.	447 1 O

i	449 1 O
.	450 1 O
p	451 1 O
.	452 1 O
to	454 2 O
male	457 4 O
rats	462 4 O
,	466 1 O
and	468 3 O
their	472 5 O
behavior	478 8 O
observed	487 8 O
and	496 3 O
scored	500 6 O
.	506 1 O

The	508 3 O
effects	512 7 O
of	520 2 O
morphine	523 8 B-Chemical
(	532 1 O
0	533 1 O
.	534 1 O
5	535 1 O
to	537 2 O
4	540 1 O
mg	542 2 O
.	544 1 O
/	545 1 O
kg	546 2 O
.	548 1 O
i	550 1 O
.	551 1 O
v	552 1 O
.	553 1 O
)	554 1 O
on	556 2 O
CP	559 2 B-Chemical
-	561 1 O
induced	562 7 O
behavioral	570 10 O
modifications	581 13 O
were	595 4 O
tested	600 6 O
administered	607 12 O
alone	620 5 O
and	626 3 O
after	630 5 O
naloxone	636 8 B-Chemical
(	645 1 O
1	646 1 O
mg	648 2 O
.	650 1 O
/	651 1 O
kg	652 2 O
.	654 1 O
s	656 1 O
.	657 1 O
c	658 1 O
.	659 1 O
)	660 1 O
.	661 1 O

In	663 2 O
addition	666 8 O
,	674 1 O
90	676 2 O
minutes	679 7 O
after	687 5 O
CP	693 2 B-Chemical
injection	696 9 O
,	705 1 O
that	707 4 O
is	712 2 O
,	714 1 O
at	716 2 O
the	719 3 O
time	723 4 O
of	728 2 O
administration	731 14 O
of	746 2 O
morphine	749 8 B-Chemical
,	757 1 O
the	759 3 O
bladder	763 7 O
was	771 3 O
removed	775 7 O
in	783 2 O
some	786 4 O
rats	791 4 O
for	796 3 O
histological	800 12 O
examination	813 11 O
.	824 1 O

Finally	826 7 O
,	833 1 O
to	835 2 O
show	838 4 O
that	843 4 O
the	848 3 O
bladder	852 7 O
is	860 2 O
essential	863 9 O
for	873 3 O
the	877 3 O
CP	881 2 B-Chemical
-	883 1 O
induced	884 7 O
behavioral	892 10 O
modifications	903 13 O
,	916 1 O
female	918 6 O
rats	925 4 O
also	930 4 O
received	935 8 O
CP	944 2 B-Chemical
at	947 2 O
doses	950 5 O
of	956 2 O
200	959 3 O
mg	963 2 O
.	965 1 O
/	966 1 O
kg	967 2 O
.	969 1 O

i	971 1 O
.	972 1 O
p	973 1 O
.	974 1 O
and	976 3 O
of	980 2 O
20	983 2 O
mg	986 2 O
.	988 1 O
by	990 2 O
the	993 3 O
intravesical	997 12 O
route	1010 5 O
,	1015 1 O
and	1017 3 O
acrolein	1021 8 B-Chemical
at	1030 2 O
doses	1033 5 O
of	1039 2 O
0	1042 1 O
.	1043 1 O
5	1044 1 O
mg	1046 2 O
.	1048 1 O
by	1050 2 O
the	1053 3 O
intravesical	1057 12 O
route	1070 5 O
and	1076 3 O
of	1080 2 O
5	1083 1 O
mg	1085 2 O
.	1087 1 O
/	1088 1 O
kg	1089 2 O
.	1091 1 O

i	1093 1 O
.	1094 1 O
v	1095 1 O
.	1096 1 O
RESULTS	1098 7 O
:	1105 1 O
CP	1107 2 B-Chemical
dose	1110 4 O
-	1114 1 O
relatedly	1115 9 O
induced	1125 7 O
marked	1133 6 O
behavioral	1140 10 O
modifications	1151 13 O
in	1165 2 O
male	1168 4 O
rats	1173 4 O
:	1177 1 O
breathing	1179 9 O
rate	1189 4 O
decrease	1194 8 O
,	1202 1 O
closing	1204 7 O
of	1212 2 O
the	1215 3 O
eyes	1219 4 O
and	1224 3 O
occurrence	1228 10 O
of	1239 2 O
specific	1242 8 O
postures	1251 8 O
.	1259 1 O

Morphine	1261 8 B-Chemical
dose	1270 4 O
-	1274 1 O
dependently	1275 11 O
reversed	1287 8 O
these	1296 5 O
behavioral	1302 10 B-Disease
disorders	1313 9 I-Disease
.	1322 1 O

A	1324 1 O
dose	1326 4 O
of	1331 2 O
0	1334 1 O
.	1335 1 O
5	1336 1 O
mg	1338 2 O
.	1340 1 O
/	1341 1 O
kg	1342 2 O
.	1344 1 O
produced	1346 8 O
a	1355 1 O
reduction	1357 9 O
of	1367 2 O
almost	1370 6 O
50	1377 2 O
%	1379 1 O
of	1381 2 O
the	1384 3 O
behavioral	1388 10 O
score	1399 5 O
induced	1405 7 O
by	1413 2 O
CP	1416 2 B-Chemical
200	1419 3 O
mg	1423 2 O
.	1425 1 O
/	1426 1 O
kg	1427 2 O
.	1429 1 O

This	1431 4 O
effect	1436 6 O
was	1443 3 O
completely	1447 10 O
prevented	1458 9 O
by	1468 2 O
pretreatment	1471 12 O
with	1484 4 O
naloxone	1489 8 B-Chemical
.	1497 1 O

At	1499 2 O
the	1502 3 O
time	1506 4 O
of	1511 2 O
administration	1514 14 O
of	1529 2 O
morphine	1532 8 B-Chemical
,	1540 1 O
histological	1542 12 O
modifications	1555 13 O
of	1569 2 O
the	1572 3 O
bladder	1576 7 O
wall	1584 4 O
,	1588 1 O
such	1590 4 O
as	1595 2 O
chorionic	1598 9 O
and	1608 3 O
muscle	1612 6 O
layer	1619 5 O
edema	1625 5 B-Disease
,	1630 1 O
were	1632 4 O
observed	1637 8 O
.	1645 1 O

In	1647 2 O
female	1650 6 O
rats	1657 4 O
,	1661 1 O
CP	1663 2 B-Chemical
200	1666 3 O
mg	1670 2 O
.	1672 1 O
/	1673 1 O
kg	1674 2 O
.	1676 1 O

i	1678 1 O
.	1679 1 O
p	1680 1 O
.	1681 1 O
produced	1683 8 O
the	1692 3 O
same	1696 4 O
marked	1701 6 O
behavioral	1708 10 O
modifications	1719 13 O
as	1733 2 O
those	1736 5 O
observed	1742 8 O
in	1751 2 O
male	1754 4 O
rats	1759 4 O
.	1763 1 O

Administered	1765 12 O
at	1778 2 O
the	1781 3 O
dose	1785 4 O
of	1790 2 O
20	1793 2 O
mg	1796 2 O
.	1798 1 O
intravesically	1800 14 O
,	1814 1 O
CP	1816 2 B-Chemical
did	1819 3 O
not	1823 3 O
produce	1827 7 O
any	1835 3 O
behavioral	1839 10 O
effects	1850 7 O
,	1857 1 O
whereas	1859 7 O
acrolein	1867 8 B-Chemical
at	1876 2 O
0	1879 1 O
.	1880 1 O
5	1881 1 O
mg	1883 2 O
.	1885 1 O
intravesically	1887 14 O
induced	1902 7 O
behavioral	1910 10 O
modifications	1921 13 O
identical	1935 9 O
to	1945 2 O
those	1948 5 O
under	1954 5 O
CP	1960 2 B-Chemical
200	1963 3 O
mg	1967 2 O
.	1969 1 O
/	1970 1 O
kg	1971 2 O
.	1973 1 O

i	1975 1 O
.	1976 1 O
p	1977 1 O
.	1978 1 O
,	1979 1 O
with	1981 4 O
the	1986 3 O
same	1990 4 O
maximal	1995 7 O
levels	2003 6 O
.	2009 1 O

Conversely	2011 10 O
,	2021 1 O
acrolein	2023 8 B-Chemical
5	2032 1 O
mg	2034 2 O
.	2036 1 O
/	2037 1 O
kg	2038 2 O
.	2040 1 O

i	2042 1 O
.	2043 1 O
v	2044 1 O
.	2045 1 O
did	2047 3 O
not	2051 3 O
produce	2055 7 O
any	2063 3 O
behavioral	2067 10 O
effects	2078 7 O
at	2086 2 O
all	2089 3 O
.	2092 1 O

CONCLUSIONS	2094 11 O
:	2105 1 O
Overall	2107 7 O
,	2114 1 O
these	2116 5 O
results	2122 7 O
indicate	2130 8 O
that	2139 4 O
this	2144 4 O
experimental	2149 12 O
model	2162 5 O
of	2168 2 O
CP	2171 2 B-Chemical
-	2173 1 O
induced	2174 7 O
cystitis	2182 8 B-Disease
may	2191 3 O
be	2195 2 O
an	2198 2 O
interesting	2201 11 O
new	2213 3 O
behavioral	2217 10 O
model	2228 5 O
of	2234 2 O
inflammatory	2237 12 O
visceral	2250 8 B-Disease
pain	2259 4 I-Disease
,	2263 1 O
allowing	2265 8 O
a	2274 1 O
better	2276 6 O
understanding	2283 13 O
of	2297 2 O
these	2300 5 O
painful	2306 7 B-Disease
syndromes	2314 9 I-Disease
and	2324 3 O
thus	2328 4 O
a	2333 1 O
better	2335 6 O
therapeutic	2342 11 O
approach	2354 8 O
to	2363 2 O
them	2366 4 O
.	2370 1 O

Hyperalgesia	0 12 B-Disease
and	13 3 O
myoclonus	17 9 B-Disease
in	27 2 O
terminal	30 8 O
cancer	39 6 B-Disease
patients	46 8 O
treated	55 7 O
with	63 4 O
continuous	68 10 O
intravenous	79 11 O
morphine	91 8 B-Chemical
.	99 1 O

Eight	101 5 O
cancer	107 6 B-Disease
patients	114 8 O
in	123 2 O
the	126 3 O
terminal	130 8 O
stages	139 6 O
of	146 2 O
the	149 3 O
disease	153 7 O
treated	161 7 O
with	169 4 O
high	174 4 O
doses	179 5 O
of	185 2 O
intravenous	188 11 O
morphine	200 8 B-Chemical
developed	209 9 O
hyperalgesia	219 12 B-Disease
.	231 1 O

All	233 3 O
cases	237 5 O
were	243 4 O
retrospectively	248 15 O
sampled	264 7 O
from	272 4 O
three	277 5 O
different	283 9 O
hospitals	293 9 O
in	303 2 O
Copenhagen	306 10 O
.	316 1 O

Five	318 4 O
patients	323 8 O
developed	332 9 O
universal	342 9 O
hyperalgesia	352 12 B-Disease
and	365 3 O
hyperesthesia	369 13 B-Disease
which	383 5 O
in	389 2 O
2	392 1 O
cases	394 5 O
were	400 4 O
accompanied	405 11 O
by	417 2 O
myoclonus	420 9 B-Disease
.	429 1 O

In	431 2 O
3	434 1 O
patients	436 8 O
a	445 1 O
pre	447 3 O
-	450 1 O
existing	451 8 O
neuralgia	460 9 B-Disease
increased	470 9 O
to	480 2 O
excruciating	483 12 O
intensity	496 9 O
and	506 3 O
in	510 2 O
2	513 1 O
of	515 2 O
these	518 5 O
cases	524 5 O
myoclonus	530 9 B-Disease
occurred	540 8 O
simultaneously	549 14 O
.	563 1 O

Although	565 8 O
only	574 4 O
few	579 3 O
clinical	583 8 O
descriptions	592 12 O
of	605 2 O
the	608 3 O
relationship	612 12 O
between	625 7 O
hyperalgesia	633 12 B-Disease
/	645 1 O
myoclonus	646 9 B-Disease
and	656 3 O
high	660 4 O
doses	665 5 O
of	671 2 O
morphine	674 8 B-Chemical
are	683 3 O
available	687 9 O
,	696 1 O
experimental	698 12 O
support	711 7 O
from	719 4 O
animal	724 6 O
studies	731 7 O
indicates	739 9 O
that	749 4 O
morphine	754 8 B-Chemical
,	762 1 O
or	764 2 O
its	767 3 O
metabolites	771 11 O
,	782 1 O
plays	784 5 O
a	790 1 O
causative	792 9 O
role	802 4 O
for	807 3 O
the	811 3 O
observed	815 8 O
behavioural	824 11 O
syndrome	836 8 O
.	844 1 O

The	846 3 O
possible	850 8 O
mechanisms	859 10 O
are	870 3 O
discussed	874 9 O
and	884 3 O
treatment	888 9 O
proposals	898 9 O
given	908 5 O
suggesting	914 10 O
the	925 3 O
use	929 3 O
of	933 2 O
more	936 4 O
efficacious	941 11 O
opioids	953 7 O
with	961 4 O
less	966 4 O
excitatory	971 10 O
potency	982 7 O
in	990 2 O
these	993 5 O
situations	999 10 O
.	1009 1 O

A	0 1 O
prospective	2 11 O
study	14 5 O
of	20 2 O
adverse	23 7 O
reactions	31 9 O
associated	41 10 O
with	52 4 O
vancomycin	57 10 B-Chemical
therapy	68 7 O
.	75 1 O

A	77 1 O
prospective	79 11 O
evaluation	91 10 O
of	102 2 O
the	105 3 O
efficacy	109 8 O
and	118 3 O
safety	122 6 O
of	129 2 O
vancomycin	132 10 B-Chemical
was	143 3 O
conducted	147 9 O
in	157 2 O
54	160 2 O
consecutive	163 11 O
patients	175 8 O
over	184 4 O
a	189 1 O
16	191 2 O
-	193 1 O
month	194 5 O
period	200 6 O
.	206 1 O

Vancomycin	208 10 B-Chemical
was	219 3 O
curative	223 8 O
in	232 2 O
95	235 2 O
%	237 1 O
of	239 2 O
43	242 2 O
patients	245 8 O
with	254 4 O
proven	259 6 O
infection	266 9 B-Disease
.	275 1 O

Drugs	277 5 O
were	283 4 O
ceased	288 6 O
in	295 2 O
six	298 3 O
patients	302 8 O
because	311 7 O
of	319 2 O
adverse	322 7 O
reactions	330 9 O
;	339 1 O
in	341 2 O
three	344 5 O
of	350 2 O
these	353 5 O
vancomycin	359 10 B-Chemical
was	370 3 O
considered	374 10 O
the	385 3 O
likely	389 6 O
cause	396 5 O
.	401 1 O

Reactions	403 9 O
included	413 8 O
thrombophlebitis	422 16 B-Disease
(	439 1 O
20	440 2 O
of	443 2 O
54	446 2 O
patients	449 8 O
)	457 1 O
,	458 1 O
rash	460 4 B-Disease
(	465 1 O
4	466 1 O
of	468 2 O
54	471 2 O
)	473 1 O
,	474 1 O
nephrotoxicity	476 14 B-Disease
(	491 1 O
4	492 1 O
of	494 2 O
50	497 2 O
)	499 1 O
,	500 1 O
proteinuria	502 11 B-Disease
(	514 1 O
1	515 1 O
of	517 2 O
50	520 2 O
)	522 1 O
and	524 3 O
ototoxicity	528 11 B-Disease
(	540 1 O
1	541 1 O
of	543 2 O
11	546 2 O
patients	549 8 O
tested	558 6 O
by	565 2 O
audiometry	568 10 O
)	578 1 O
.	579 1 O

Thrombophlebitis	581 16 B-Disease
occurred	598 8 O
only	607 4 O
with	612 4 O
infusion	617 8 O
through	626 7 O
peripheral	634 10 O
cannulae	645 8 O
;	653 1 O
nephrotoxicity	655 14 B-Disease
and	670 3 O
ototoxicity	674 11 B-Disease
were	686 4 O
confined	691 8 O
to	700 2 O
patients	703 8 O
receiving	712 9 O
an	722 2 O
aminoglycoside	725 14 B-Chemical
plus	740 4 O
vancomycin	745 10 B-Chemical
.	755 1 O

We	757 2 O
conclude	760 8 O
that	769 4 O
vancomycin	774 10 B-Chemical
,	784 1 O
administered	786 12 O
appropriately	799 13 O
,	812 1 O
constitutes	814 11 O
safe	826 4 O
,	830 1 O
effective	832 9 O
therapy	842 7 O
for	850 3 O
infections	854 10 B-Disease
caused	865 6 O
by	872 2 O
susceptible	875 11 O
bacteria	887 8 O
.	895 1 O

Blockade	0 8 O
of	9 2 O
both	12 4 O
D	17 1 O
-	18 1 O
1	19 1 O
and	21 3 O
D	25 1 O
-	26 1 O
2	27 1 O
dopamine	29 8 B-Chemical
receptors	38 9 O
may	48 3 O
induce	52 6 O
catalepsy	59 9 B-Disease
in	69 2 O
mice	72 4 O
.	76 1 O

1	78 1 O
.	79 1 O

The	81 3 O
catalepsy	85 9 B-Disease
induced	95 7 O
by	103 2 O
dopamine	106 8 B-Chemical
antagonists	115 11 O
has	127 3 O
been	131 4 O
tested	136 6 O
and	143 3 O
the	147 3 O
possible	151 8 O
dopamine	160 8 B-Chemical
subtypes	169 8 O
involved	178 8 O
in	187 2 O
catalepsy	190 9 B-Disease
was	200 3 O
determined	204 10 O
.	214 1 O

2	216 1 O
.	217 1 O

Dopamine	219 8 B-Chemical
antagonist	228 10 O
fluphenazine	239 12 B-Chemical
,	251 1 O
D	253 1 O
-	254 1 O
1	255 1 O
antagonist	257 10 O
SCH	268 3 B-Chemical
23390	272 5 I-Chemical
or	278 2 O
D	281 1 O
-	282 1 O
2	283 1 O
antagonist	285 10 O
sulpiride	296 9 B-Chemical
induced	306 7 O
catalepsy	314 9 B-Disease
.	323 1 O

The	325 3 O
effect	329 6 O
of	336 2 O
fluphenazine	339 12 B-Chemical
and	352 3 O
sulpiride	356 9 B-Chemical
was	366 3 O
dose	370 4 O
-	374 1 O
dependent	375 9 O
.	384 1 O

Combination	386 11 O
of	398 2 O
SCH	401 3 B-Chemical
23390	405 5 I-Chemical
with	411 4 O
sulpiride	416 9 B-Chemical
did	426 3 O
not	430 3 O
induce	434 6 O
catalepsy	441 9 B-Disease
potentiation	451 12 O
.	463 1 O

3	465 1 O
.	466 1 O

D	468 1 O
-	469 1 O
1	470 1 O
agonist	472 7 O
SKF	480 3 B-Chemical
38393	484 5 I-Chemical
or	490 2 O
D	493 1 O
-	494 1 O
2	495 1 O
agonist	497 7 O
quinpirole	505 10 B-Chemical
decreased	516 9 O
the	526 3 O
catalepsy	530 9 B-Disease
induced	540 7 O
by	548 2 O
fluphenazine	551 12 B-Chemical
,	563 1 O
SCH	565 3 B-Chemical
23390	569 5 I-Chemical
or	575 2 O
sulpiride	578 9 B-Chemical
.	587 1 O

4	589 1 O
.	590 1 O

Combination	592 11 O
of	604 2 O
SKF	607 3 B-Chemical
38393	611 5 I-Chemical
with	617 4 O
quinpirole	622 10 B-Chemical
did	633 3 O
not	637 3 O
cause	641 5 O
potentiated	647 11 O
inhibitory	659 10 O
effect	670 6 O
on	677 2 O
catalepsy	680 9 B-Disease
induced	690 7 O
by	698 2 O
dopamine	701 8 B-Chemical
antagonists	710 11 O
.	721 1 O

5	723 1 O
.	724 1 O

The	726 3 O
data	730 4 O
may	735 3 O
indicate	739 8 O
that	748 4 O
although	753 8 O
D	762 1 O
-	763 1 O
2	764 1 O
receptor	766 8 O
blockade	775 8 O
is	784 2 O
involved	787 8 O
in	796 2 O
catalepsy	799 9 B-Disease
,	808 1 O
the	810 3 O
D	814 1 O
-	815 1 O
1	816 1 O
receptor	818 8 O
may	827 3 O
plan	831 4 O
a	836 1 O
role	838 4 O
.	842 1 O

Dextran	0 7 B-Chemical
-	7 1 O
etodolac	8 8 B-Chemical
conjugates	17 10 O
:	27 1 O
synthesis	29 9 O
,	38 1 O
in	40 2 O
vitro	43 5 O
and	49 3 O
in	53 2 O
vivo	56 4 O
evaluation	61 10 O
.	71 1 O

Etodolac	73 8 B-Chemical
(	82 1 O
E	83 1 B-Chemical
)	84 1 O
,	85 1 O
is	87 2 O
a	90 1 O
non	92 3 O
-	95 1 O
narcotic	96 8 O
analgesic	105 9 O
and	115 3 O
antiinflammatory	119 16 O
drug	136 4 O
.	140 1 O

A	142 1 O
biodegradable	144 13 O
polymer	158 7 O
dextran	166 7 B-Chemical
has	174 3 O
been	178 4 O
utilized	183 8 O
as	192 2 O
a	195 1 O
carrier	197 7 O
for	205 3 O
synthesis	209 9 O
of	219 2 O
etodolac	222 8 B-Chemical
-	230 1 O
dextran	231 7 B-Chemical
conjugates	239 10 O
(	250 1 O
ED	251 2 O
)	253 1 O
to	255 2 O
improve	258 7 O
its	266 3 O
aqueous	270 7 O
solubility	278 10 O
and	289 3 O
reduce	293 6 O
gastrointestinal	300 16 O
side	317 4 O
effects	322 7 O
.	329 1 O

An	331 2 O
activated	334 9 O
moiety	344 6 O
,	350 1 O
i	352 1 O
.	353 1 O
e	354 1 O
.	355 1 O
N	357 1 B-Chemical
-	358 1 I-Chemical
acylimidazole	359 13 I-Chemical
derivative	373 10 O
of	384 2 O
etodolac	387 8 B-Chemical
(	396 1 O
EAI	397 3 B-Chemical
)	400 1 O
,	401 1 O
was	403 3 O
condensed	407 9 O
with	417 4 O
the	422 3 O
polysaccharide	426 14 O
polymer	441 7 O
dextran	449 7 B-Chemical
of	457 2 O
different	460 9 O
molecular	470 9 O
weights	480 7 O
(	488 1 O
40000	489 5 O
,	494 1 O
60000	496 5 O
,	501 1 O
110000	503 6 O
and	510 3 O
200000	514 6 O
)	520 1 O
.	521 1 O

IR	523 2 O
spectral	526 8 O
data	535 4 O
confirmed	540 9 O
formation	550 9 O
of	560 2 O
ester	563 5 O
bonding	569 7 O
in	577 2 O
the	580 3 O
conjugates	584 10 O
.	594 1 O

Etodolac	596 8 B-Chemical
contents	605 8 O
were	614 4 O
evaluated	619 9 O
by	629 2 O
UV	632 2 O
-	634 1 O
spectrophotometric	635 18 O
analysis	654 8 O
.	662 1 O

The	664 3 O
molecular	668 9 O
weights	678 7 O
were	686 4 O
determined	691 10 O
by	702 2 O
measuring	705 9 O
viscosity	715 9 O
using	725 5 O
the	731 3 O
Mark	735 4 O
-	739 1 O
Howink	740 6 O
-	746 1 O
Sakurada	747 8 O
equation	756 8 O
.	764 1 O

In	766 2 O
vitro	769 5 O
hydrolysis	775 10 O
of	786 2 O
ED	789 2 O
was	792 3 O
done	796 4 O
in	801 2 O
aqueous	804 7 O
buffers	812 7 O
(	820 1 O
pH	821 2 O
1	824 1 O
.	825 1 O
2	826 1 O
,	827 1 O
7	829 1 O
.	830 1 O
4	831 1 O
,	832 1 O
9	834 1 O
)	835 1 O
and	837 3 O
in	841 2 O
80	844 2 O
%	846 1 O
(	848 1 O
v	849 1 O
/	850 1 O
v	851 1 O
)	852 1 O
human	854 5 O
plasma	860 6 O
(	867 1 O
pH	868 2 O
7	871 1 O
.	872 1 O
4	873 1 O
)	874 1 O
.	875 1 O

At	877 2 O
pH	880 2 O
9	883 1 O
,	884 1 O
a	886 1 O
higher	888 6 O
rate	895 4 O
of	900 2 O
etodolac	903 8 B-Chemical
release	912 7 O
from	920 4 O
ED	925 2 O
was	928 3 O
observed	932 8 O
as	941 2 O
compared	944 8 O
to	953 2 O
aqueous	956 7 O
buffer	964 6 O
of	971 2 O
pH	974 2 O
7	977 1 O
.	978 1 O
4	979 1 O
and	981 3 O
80	985 2 O
%	987 1 O
human	989 5 O
plasma	995 6 O
(	1002 1 O
pH	1003 2 O
7	1006 1 O
.	1007 1 O
4	1008 1 O
)	1009 1 O
,	1010 1 O
following	1012 9 O
first	1022 5 O
-	1027 1 O
order	1028 5 O
kinetics	1034 8 O
.	1042 1 O

In	1044 2 O
vivo	1047 4 O
investigations	1052 14 O
were	1067 4 O
performed	1072 9 O
in	1082 2 O
animals	1085 7 O
.	1092 1 O

Acute	1094 5 O
analgesic	1100 9 O
and	1110 3 O
antiinflammatory	1114 16 O
activities	1131 10 O
were	1142 4 O
ascertained	1147 11 O
using	1159 5 O
acetic	1165 6 B-Chemical
acid	1172 4 I-Chemical
induced	1177 7 O
writhing	1185 8 B-Disease
model	1194 5 O
(	1200 1 O
mice	1201 4 O
)	1205 1 O
and	1207 3 O
carrageenan	1211 11 B-Chemical
-	1222 1 O
induced	1223 7 O
rat	1231 3 O
paw	1235 3 O
edema	1239 5 B-Disease
model	1245 5 O
,	1250 1 O
respectively	1252 12 O
.	1264 1 O

In	1266 2 O
comparison	1269 10 O
to	1280 2 O
control	1283 7 O
,	1290 1 O
E	1292 1 B-Chemical
and	1294 3 O
ED1	1298 3 O
-	1301 1 O
ED4	1302 3 O
showed	1306 6 O
highly	1313 6 O
significant	1320 11 O
analgesic	1332 9 O
and	1342 3 O
antiinflammatory	1346 16 O
activities	1363 10 O
(	1374 1 O
p	1375 1 O
<	1377 1 O
0	1378 1 O
.	1379 1 O
001	1380 3 O
)	1383 1 O
.	1384 1 O

Biological	1386 10 O
evaluation	1397 10 O
suggested	1408 9 O
that	1418 4 O
conjugates	1423 10 O
(	1434 1 O
ED1	1435 3 O
-	1438 1 O
ED4	1439 3 O
)	1442 1 O
retained	1444 8 O
comparable	1453 10 O
analgesic	1464 9 O
and	1474 3 O
antiinflammatory	1478 16 O
activities	1495 10 O
with	1506 4 O
remarkably	1511 10 O
reduced	1522 7 O
ulcerogenicity	1530 14 O
as	1545 2 O
compared	1548 8 O
to	1557 2 O
their	1560 5 O
parent	1566 6 O
drug	1573 4 O
-	1577 1 O
-	1578 1 O
etodolac	1579 8 B-Chemical
.	1587 1 O

Hypersensitivity	0 16 B-Disease
myocarditis	17 11 B-Disease
complicating	29 12 O
hypertrophic	42 12 B-Disease
cardiomyopathy	55 14 I-Disease
heart	70 5 O
.	75 1 O

The	77 3 O
present	81 7 O
report	89 6 O
describes	96 9 O
a	106 1 O
case	108 4 O
of	113 2 O
eosinophilic	116 12 B-Disease
myocarditis	129 11 I-Disease
complicating	141 12 O
hypertrophic	154 12 B-Disease
cardiomyopathy	167 14 I-Disease
.	181 1 O

The	183 3 O
47	187 2 O
-	189 1 O
year	190 4 O
-	194 1 O
old	195 3 O
female	199 6 O
patient	206 7 O
,	213 1 O
known	215 5 O
to	221 2 O
have	224 4 O
hypertrophic	229 12 B-Disease
cardiomyopathy	242 14 I-Disease
,	256 1 O
was	258 3 O
admitted	262 8 O
with	271 4 O
biventricular	276 13 B-Disease
failure	290 7 I-Disease
and	298 3 O
managed	302 7 O
aggressively	310 12 O
with	323 4 O
dobutamine	328 10 B-Chemical
infusion	339 8 O
and	348 3 O
other	352 5 O
drugs	358 5 O
while	364 5 O
being	370 5 O
assessed	376 8 O
for	385 3 O
heart	389 5 O
transplantation	395 15 O
.	410 1 O

On	412 2 O
transthoracic	415 13 O
echocardiogram	429 14 O
,	443 1 O
she	445 3 O
had	449 3 O
moderate	453 8 O
left	462 4 B-Disease
ventricular	467 11 I-Disease
dysfunction	479 11 I-Disease
with	491 4 O
regional	496 8 O
variability	505 11 O
and	517 3 O
moderate	521 8 O
mitral	530 6 B-Disease
regurgitation	537 13 I-Disease
.	550 1 O

The	552 3 O
recipient	556 9 O
'	565 1 O
s	566 1 O
heart	568 5 O
showed	574 6 O
the	581 3 O
features	585 8 O
of	594 2 O
apical	597 6 O
hypertrophic	604 12 B-Disease
cardiomyopathy	617 14 I-Disease
and	632 3 O
myocarditis	636 11 B-Disease
with	648 4 O
abundant	653 8 O
eosinophils	662 11 O
.	673 1 O

Myocarditis	675 11 B-Disease
is	687 2 O
rare	690 4 O
and	695 3 O
eosinophilic	699 12 B-Disease
myocarditis	712 11 I-Disease
is	724 2 O
rarer	727 5 O
.	732 1 O

It	734 2 O
is	737 2 O
likely	740 6 O
that	747 4 O
the	752 3 O
hypersensitivity	756 16 B-Disease
(	773 1 O
eosinophilic	774 12 B-Disease
)	786 1 O
myocarditis	788 11 B-Disease
was	800 3 O
related	804 7 O
to	812 2 O
dobutamine	815 10 B-Chemical
infusion	826 8 O
therapy	835 7 O
.	842 1 O

Eosinophilic	844 12 B-Disease
myocarditis	857 11 I-Disease
has	869 3 O
been	873 4 O
reported	878 8 O
with	887 4 O
an	892 2 O
incidence	895 9 O
of	905 2 O
2	908 1 O
.	909 1 O
4	910 1 O
%	911 1 O
to	913 2 O
7	916 1 O
.	917 1 O
2	918 1 O
%	919 1 O
in	921 2 O
explanted	924 9 O
hearts	934 6 O
and	941 3 O
may	945 3 O
be	949 2 O
related	952 7 O
to	960 2 O
multidrug	963 9 O
therapy	973 7 O
.	980 1 O

All	0 3 B-Chemical
-	3 1 I-Chemical
trans	5 5 I-Chemical
-	10 1 I-Chemical
retinoic	11 8 I-Chemical
acid	20 4 I-Chemical
-	24 1 O
induced	25 7 O
erythema	33 8 B-Disease
nodosum	42 7 I-Disease
in	50 2 O
patients	53 8 O
with	62 4 O
acute	67 5 B-Disease
promyelocytic	73 13 I-Disease
leukemia	87 8 I-Disease
.	95 1 O

Erythema	97 8 B-Disease
nodosum	106 7 I-Disease
associated	114 10 O
with	125 4 O
all	130 3 B-Chemical
-	133 1 I-Chemical
trans	135 5 I-Chemical
-	140 1 I-Chemical
retinoic	141 8 I-Chemical
acid	150 4 I-Chemical
(	155 1 O
ATRA	156 4 B-Chemical
)	160 1 O
for	162 3 O
acute	166 5 B-Disease
promyelocytic	172 13 I-Disease
leukemia	186 8 I-Disease
(	195 1 O
APL	196 3 B-Disease
)	199 1 O
is	201 2 O
very	204 4 O
rare	209 4 O
.	213 1 O

We	215 2 O
describe	218 8 O
four	227 4 O
patients	232 8 O
with	241 4 O
classic	246 7 O
APL	254 3 B-Disease
who	258 3 O
developed	262 9 O
erythema	272 8 B-Disease
nodosum	281 7 I-Disease
during	289 6 O
ATRA	296 4 B-Chemical
therapy	301 7 O
.	308 1 O

Fever	310 5 B-Disease
and	316 3 O
subsequent	320 10 O
multiple	331 8 O
painful	340 7 B-Disease
erythematous	348 12 B-Disease
nodules	361 7 I-Disease
over	369 4 O
extremities	374 11 O
developed	386 9 O
on	396 2 O
D11	399 3 O
,	402 1 O
D16	404 3 O
,	407 1 O
D17	409 3 O
,	412 1 O
and	414 3 O
D19	418 3 O
,	421 1 O
respectively	423 12 O
,	435 1 O
after	437 5 O
ATRA	443 4 B-Chemical
therapy	448 7 O
.	455 1 O

The	457 3 O
skin	461 4 O
biopsy	466 6 O
taken	473 5 O
from	479 4 O
each	484 4 O
patient	489 7 O
was	497 3 O
consistent	501 10 O
with	512 4 O
erythema	517 8 B-Disease
nodosum	526 7 I-Disease
.	533 1 O

All	535 3 O
patients	539 8 O
received	548 8 O
short	557 5 O
course	563 6 O
of	570 2 O
steroids	573 8 B-Chemical
.	581 1 O

Fever	583 5 B-Disease
subsided	589 8 O
rapidly	598 7 O
and	606 3 O
the	610 3 O
skin	614 4 O
lesions	619 7 O
regressed	627 9 O
completely	637 10 O
.	647 1 O

All	649 3 O
patients	653 8 O
achieved	662 8 O
complete	671 8 O
remission	680 9 O
without	690 7 O
withdrawal	698 10 O
of	709 2 O
ATRA	712 4 B-Chemical
.	716 1 O

ATRA	718 4 B-Chemical
seemed	723 6 O
to	730 2 O
be	733 2 O
the	736 3 O
most	740 4 O
possible	745 8 O
etiology	754 8 O
of	763 2 O
erythema	766 8 B-Disease
nodosum	775 7 I-Disease
in	783 2 O
our	786 3 O
patients	790 8 O
.	798 1 O

Short	800 5 O
-	805 1 O
term	806 4 O
use	811 3 O
of	815 2 O
steroid	818 7 B-Chemical
is	826 2 O
very	829 4 O
effective	834 9 O
in	844 2 O
ATRA	847 4 B-Chemical
-	851 1 O
induced	852 7 O
erythema	860 8 B-Disease
nodosum	869 7 I-Disease
.	876 1 O

Delayed	0 7 O
-	7 1 O
onset	8 5 O
heparin	14 7 B-Chemical
-	21 1 O
induced	22 7 O
thrombocytopenia	30 16 B-Disease
.	46 1 O

BACKGROUND	48 10 O
:	58 1 O
Heparin	60 7 B-Chemical
-	67 1 O
induced	68 7 O
thrombocytopenia	76 16 B-Disease
presents	93 8 O
5	102 1 O
to	104 2 O
12	107 2 O
days	110 4 O
after	115 5 O
heparin	121 7 B-Chemical
exposure	129 8 O
,	137 1 O
with	139 4 O
or	144 2 O
without	147 7 O
arterial	155 8 B-Disease
or	164 2 I-Disease
venous	167 6 I-Disease
thromboemboli	174 13 I-Disease
.	187 1 O

Delayed	189 7 O
recognition	197 11 O
and	209 3 O
treatment	213 9 O
of	223 2 O
heparin	226 7 B-Chemical
-	233 1 O
induced	234 7 O
thrombocytopenia	242 16 B-Disease
contribute	259 10 O
to	270 2 O
poor	273 4 O
patient	278 7 O
outcomes	286 8 O
.	294 1 O

OBJECTIVE	296 9 O
:	305 1 O
To	307 2 O
describe	310 8 O
and	319 3 O
increase	323 8 O
awareness	332 9 O
of	342 2 O
a	345 1 O
clinical	347 8 O
scenario	356 8 O
in	365 2 O
which	368 5 O
the	374 3 O
onset	378 5 O
or	384 2 O
manifestations	387 14 O
of	402 2 O
heparin	405 7 B-Chemical
-	412 1 O
induced	413 7 O
thrombocytopenia	421 16 B-Disease
are	438 3 O
delayed	442 7 O
.	449 1 O

DESIGN	451 6 O
:	457 1 O
Retrospective	459 13 O
case	473 4 O
series	478 6 O
.	484 1 O

SETTING	486 7 O
:	493 1 O
Three	495 5 O
large	501 5 O
urban	507 5 O
hospitals	513 9 O
(	523 1 O
with	524 4 O
active	529 6 O
cardiovascular	536 14 O
surgery	551 7 O
programs	559 8 O
)	567 1 O
.	568 1 O

PATIENTS	570 8 O
:	578 1 O
14	580 2 O
patients	583 8 O
seen	592 4 O
over	597 4 O
a	602 1 O
3	604 1 O
-	605 1 O
year	606 4 O
period	611 6 O
in	618 2 O
whom	621 4 O
heparin	626 7 B-Chemical
-	633 1 O
induced	634 7 O
thrombocytopenia	642 16 B-Disease
became	659 6 O
apparent	666 8 O
on	675 2 O
delayed	678 7 O
presentation	686 12 O
with	699 4 O
thromboembolic	704 14 B-Disease
complications	719 13 O
.	732 1 O

MEASUREMENTS	734 12 O
:	746 1 O
Platelet	748 8 O
counts	757 6 O
,	763 1 O
onset	765 5 O
of	771 2 O
objectively	774 11 O
determined	786 10 O
thromboembolism	797 15 B-Disease
,	812 1 O
results	814 7 O
of	822 2 O
heparin	825 7 B-Chemical
-	832 1 O
induced	833 7 O
platelet	841 8 O
factor	850 6 O
4	857 1 O
antibody	859 8 O
tests	868 5 O
,	873 1 O
and	875 3 O
outcomes	879 8 O
.	887 1 O

RESULTS	889 7 O
:	896 1 O
Patients	898 8 O
went	907 4 O
home	912 4 O
after	917 5 O
hospitalizations	923 16 O
that	940 4 O
had	945 3 O
included	949 8 O
heparin	958 7 B-Chemical
exposure	966 8 O
-	974 1 O
-	975 1 O
in	976 2 O
most	979 4 O
cases	984 5 O
,	989 1 O
with	991 4 O
no	996 2 O
thrombocytopenia	999 16 B-Disease
recognized	1016 10 O
-	1026 1 O
-	1027 1 O
only	1028 4 O
to	1033 2 O
return	1036 6 O
to	1043 2 O
the	1046 3 O
hospital	1050 8 O
(	1059 1 O
median	1060 6 O
,	1066 1 O
day	1068 3 O
14	1072 2 O
)	1074 1 O
with	1076 4 O
thromboembolic	1081 14 B-Disease
complications	1096 13 O
.	1109 1 O

Thromboemboli	1111 13 B-Disease
were	1125 4 O
venous	1130 6 O
(	1137 1 O
12	1138 2 O
patients	1141 8 O
,	1149 1 O
7	1151 1 O
with	1153 4 O
pulmonary	1158 9 B-Disease
emboli	1168 6 I-Disease
)	1174 1 O
or	1176 2 O
arterial	1179 8 O
(	1188 1 O
4	1189 1 O
patients	1191 8 O
)	1199 1 O
or	1201 2 O
both	1204 4 O
.	1208 1 O

Platelet	1210 8 O
counts	1219 6 O
were	1226 4 O
mildly	1231 6 O
decreased	1238 9 O
in	1248 2 O
all	1251 3 O
but	1255 3 O
2	1259 1 O
patients	1261 8 O
on	1270 2 O
second	1273 6 O
presentation	1280 12 O
.	1292 1 O

On	1294 2 O
readmission	1297 11 O
,	1308 1 O
11	1310 2 O
patients	1313 8 O
received	1322 8 O
therapeutic	1331 11 O
heparin	1343 7 B-Chemical
,	1350 1 O
which	1352 5 O
worsened	1358 8 O
the	1367 3 O
patients	1371 8 O
'	1379 1 O
clinical	1381 8 O
condition	1390 9 O
and	1400 3 O
,	1403 1 O
in	1405 2 O
all	1408 3 O
11	1412 2 O
cases	1415 5 O
,	1420 1 O
decreased	1422 9 O
the	1432 3 O
platelet	1436 8 O
count	1445 5 O
(	1451 1 O
mean	1452 4 O
at	1457 2 O
readmission	1460 11 O
,	1471 1 O
143	1473 3 O
x	1477 1 O
10	1479 2 O
(	1481 1 O
9	1482 1 O
)	1483 1 O
cells	1485 5 O
/	1490 1 O
L	1491 1 O
;	1492 1 O
mean	1494 4 O
nadir	1499 5 O
after	1505 5 O
heparin	1511 7 B-Chemical
re	1519 2 O
-	1521 1 O
exposure	1522 8 O
,	1530 1 O
39	1532 2 O
x	1535 1 O
10	1537 2 O
(	1539 1 O
9	1540 1 O
)	1541 1 O
cells	1543 5 O
/	1548 1 O
L	1549 1 O
)	1550 1 O
.	1551 1 O

Results	1553 7 O
of	1561 2 O
serologic	1564 9 O
tests	1574 5 O
for	1580 3 O
heparin	1584 7 B-Chemical
-	1591 1 O
induced	1592 7 O
antibodies	1600 10 O
were	1611 4 O
positive	1616 8 O
in	1625 2 O
all	1628 3 O
patients	1632 8 O
.	1640 1 O

Subsequent	1642 10 O
treatments	1653 10 O
included	1664 8 O
alternative	1673 11 O
anticoagulants	1685 14 O
(	1700 1 O
11	1701 2 O
patients	1704 8 O
)	1712 1 O
,	1713 1 O
thrombolytic	1715 12 O
drugs	1728 5 O
(	1734 1 O
3	1735 1 O
patients	1737 8 O
)	1745 1 O
,	1746 1 O
inferior	1748 8 O
vena	1757 4 O
cava	1762 4 O
filters	1767 7 O
(	1775 1 O
3	1776 1 O
patients	1778 8 O
)	1786 1 O
and	1788 3 O
,	1791 1 O
eventually	1793 10 O
,	1803 1 O
warfarin	1805 8 B-Chemical
(	1814 1 O
11	1815 2 O
patients	1818 8 O
)	1826 1 O
.	1827 1 O

Three	1829 5 O
patients	1835 8 O
died	1844 4 O
.	1848 1 O

CONCLUSIONS	1850 11 O
:	1861 1 O
Delayed	1863 7 O
-	1870 1 O
onset	1871 5 O
heparin	1877 7 B-Chemical
-	1884 1 O
induced	1885 7 O
thrombocytopenia	1893 16 B-Disease
is	1910 2 O
increasingly	1913 12 O
being	1926 5 O
recognized	1932 10 O
.	1942 1 O

To	1944 2 O
avoid	1947 5 O
disastrous	1953 10 O
outcomes	1964 8 O
,	1972 1 O
physicians	1974 10 O
must	1985 4 O
consider	1990 8 O
heparin	1999 7 B-Chemical
-	2006 1 O
induced	2007 7 O
thrombocytopenia	2015 16 B-Disease
whenever	2032 8 O
a	2041 1 O
recently	2043 8 O
hospitalized	2052 12 O
patient	2065 7 O
returns	2073 7 O
with	2081 4 O
thromboembolism	2086 15 B-Disease
;	2101 1 O
therapy	2103 7 O
with	2111 4 O
alternative	2116 11 O
anticoagulants	2128 14 O
,	2142 1 O
not	2144 3 O
heparin	2148 7 B-Chemical
,	2155 1 O
should	2157 6 O
be	2164 2 O
initiated	2167 9 O
.	2176 1 O

Valsartan	0 9 B-Chemical
,	9 1 O
a	11 1 O
new	13 3 O
angiotensin	17 11 B-Chemical
II	29 2 I-Chemical
antagonist	32 10 O
for	43 3 O
the	47 3 O
treatment	51 9 O
of	61 2 O
essential	64 9 O
hypertension	74 12 B-Disease
:	86 1 O
a	88 1 O
comparative	90 11 O
study	102 5 O
of	108 2 O
the	111 3 O
efficacy	115 8 O
and	124 3 O
safety	128 6 O
against	135 7 O
amlodipine	143 10 B-Chemical
.	153 1 O

OBJECTIVE	155 9 O
:	164 1 O
To	166 2 O
compare	169 7 O
the	177 3 O
antihypertensive	181 16 O
efficacy	198 8 O
of	207 2 O
a	210 1 O
new	212 3 O
angiotensin	216 11 B-Chemical
II	228 2 I-Chemical
antagonist	231 10 O
,	241 1 O
valsartan	243 9 B-Chemical
,	252 1 O
with	254 4 O
a	259 1 O
reference	261 9 O
therapy	271 7 O
,	278 1 O
amlodipine	280 10 B-Chemical
.	290 1 O

METHODS	292 7 O
:	299 1 O
One	301 3 O
hundred	305 7 O
sixty	313 5 O
-	318 1 O
eight	319 5 O
adult	325 5 O
outpatients	331 11 O
with	343 4 O
mild	348 4 O
to	353 2 O
moderate	356 8 O
hypertension	365 12 B-Disease
were	378 4 O
randomly	383 8 O
allocated	392 9 O
in	402 2 O
double	405 6 O
-	411 1 O
blind	412 5 O
fashion	418 7 O
and	426 3 O
equal	430 5 O
number	436 6 O
to	443 2 O
receive	446 7 O
80	454 2 O
mg	457 2 O
valsartan	460 9 B-Chemical
or	470 2 O
5	473 1 O
mg	475 2 O
amlodipine	478 10 B-Chemical
for	489 3 O
12	493 2 O
weeks	496 5 O
.	501 1 O

After	503 5 O
8	509 1 O
weeks	511 5 O
of	517 2 O
therapy	520 7 O
,	527 1 O
in	529 2 O
patients	532 8 O
whose	541 5 O
blood	547 5 O
pressure	553 8 O
remained	562 8 O
uncontrolled	571 12 O
,	583 1 O
5	585 1 O
mg	587 2 O
amlodipine	590 10 B-Chemical
was	601 3 O
added	605 5 O
to	611 2 O
the	614 3 O
initial	618 7 O
therapy	626 7 O
.	633 1 O

Patients	635 8 O
were	644 4 O
assessed	649 8 O
at	658 2 O
4	661 1 O
,	662 1 O
8	664 1 O
,	665 1 O
and	667 3 O
12	671 2 O
weeks	674 5 O
.	679 1 O

The	681 3 O
primary	685 7 O
efficacy	693 8 O
variable	702 8 O
was	711 3 O
change	715 6 O
from	722 4 O
baseline	727 8 O
in	736 2 O
mean	739 4 O
sitting	744 7 O
diastolic	752 9 O
blood	762 5 O
pressure	768 8 O
at	777 2 O
8	780 1 O
weeks	782 5 O
.	787 1 O

Secondary	789 9 O
variables	799 9 O
included	809 8 O
change	818 6 O
in	825 2 O
sitting	828 7 O
systolic	836 8 O
blood	845 5 O
pressure	851 8 O
and	860 3 O
responder	864 9 O
rates	874 5 O
.	879 1 O

RESULTS	881 7 O
:	888 1 O
Both	890 4 O
valsartan	895 9 B-Chemical
and	905 3 O
amlodipine	909 10 B-Chemical
were	920 4 O
effective	925 9 O
at	935 2 O
lowering	938 8 O
blood	947 5 O
pressure	953 8 O
at	962 2 O
4	965 1 O
,	966 1 O
8	968 1 O
,	969 1 O
and	971 3 O
12	975 2 O
weeks	978 5 O
.	983 1 O

Similar	985 7 O
decreases	993 9 O
were	1003 4 O
observed	1008 8 O
in	1017 2 O
both	1020 4 O
groups	1025 6 O
,	1031 1 O
with	1033 4 O
no	1038 2 O
statistically	1041 13 O
significant	1055 11 O
differences	1067 11 O
between	1079 7 O
the	1087 3 O
groups	1091 6 O
for	1098 3 O
any	1102 3 O
variable	1106 8 O
analyzed	1115 8 O
.	1123 1 O

For	1125 3 O
the	1129 3 O
primary	1133 7 O
variable	1141 8 O
the	1150 3 O
difference	1154 10 O
was	1165 3 O
0	1169 1 O
.	1170 1 O
5	1171 1 O
mm	1173 2 O
Hg	1176 2 O
in	1179 2 O
favor	1182 5 O
of	1188 2 O
valsartan	1191 9 B-Chemical
(	1201 1 O
p	1202 1 O
=	1204 1 O
0	1206 1 O
.	1207 1 O
68	1208 2 O
;	1210 1 O
95	1212 2 O
%	1214 1 O
confidence	1216 10 O
interval	1227 8 O
,	1235 1 O
-	1237 1 O
2	1238 1 O
.	1239 1 O
7	1240 1 O
to	1242 2 O
1	1245 1 O
.	1246 1 O
7	1247 1 O
)	1248 1 O
.	1249 1 O

Responder	1251 9 O
rates	1261 5 O
at	1267 2 O
8	1270 1 O
weeks	1272 5 O
were	1278 4 O
66	1283 2 O
.	1285 1 O
7	1286 1 O
%	1287 1 O
for	1289 3 O
valsartan	1293 9 B-Chemical
and	1303 3 O
60	1307 2 O
.	1309 1 O
2	1310 1 O
%	1311 1 O
for	1313 3 O
amlodipine	1317 10 B-Chemical
(	1328 1 O
p	1329 1 O
=	1331 1 O
0	1333 1 O
.	1334 1 O
39	1335 2 O
)	1337 1 O
.	1338 1 O

Both	1340 4 O
treatments	1345 10 O
were	1356 4 O
well	1361 4 O
tolerated	1366 9 O
.	1375 1 O

The	1377 3 O
incidence	1381 9 O
of	1391 2 O
drug	1394 4 O
-	1398 1 O
related	1399 7 O
dependent	1407 9 O
edema	1417 5 B-Disease
was	1423 3 O
somewhat	1427 8 O
higher	1436 6 O
in	1443 2 O
the	1446 3 O
amlodipine	1450 10 B-Chemical
group	1461 5 O
,	1466 1 O
particularly	1468 12 O
at	1481 2 O
a	1484 1 O
dose	1486 4 O
of	1491 2 O
10	1494 2 O
mg	1497 2 O
per	1500 3 O
day	1504 3 O
(	1508 1 O
2	1509 1 O
.	1510 1 O
4	1511 1 O
%	1512 1 O
for	1514 3 O
80	1518 2 O
mg	1521 2 O
valsartan	1524 9 B-Chemical
;	1533 1 O
3	1535 1 O
.	1536 1 O
6	1537 1 O
%	1538 1 O
for	1540 3 O
5	1544 1 O
mg	1546 2 O
amlodipine	1549 10 B-Chemical
;	1559 1 O
0	1561 1 O
%	1562 1 O
for	1564 3 O
valsartan	1568 9 B-Chemical
plus	1578 4 O
5	1583 1 O
mg	1585 2 O
amlodipine	1588 10 B-Chemical
;	1598 1 O
14	1600 2 O
.	1602 1 O
3	1603 1 O
%	1604 1 O
for	1606 3 O
10	1610 2 O
mg	1613 2 O
amlodipine	1616 10 B-Chemical
)	1626 1 O
.	1627 1 O

CONCLUSIONS	1629 11 O
:	1640 1 O
The	1642 3 O
data	1646 4 O
show	1651 4 O
that	1656 4 O
valsartan	1661 9 B-Chemical
is	1671 2 O
at	1674 2 O
least	1677 5 O
as	1683 2 O
effective	1686 9 O
as	1696 2 O
amlodipine	1699 10 B-Chemical
in	1710 2 O
the	1713 3 O
treatment	1717 9 O
of	1727 2 O
mild	1730 4 O
to	1735 2 O
moderate	1738 8 O
hypertension	1747 12 B-Disease
.	1759 1 O

The	1761 3 O
results	1765 7 O
also	1773 4 O
show	1778 4 O
valsartan	1783 9 B-Chemical
to	1793 2 O
be	1796 2 O
well	1799 4 O
tolerated	1804 9 O
and	1814 3 O
suggest	1818 7 O
that	1826 4 O
it	1831 2 O
is	1834 2 O
not	1837 3 O
associated	1841 10 O
with	1852 4 O
side	1857 4 O
effects	1862 7 O
characteristic	1870 14 O
of	1885 2 O
this	1888 4 O
comparator	1893 10 O
class	1904 5 O
,	1909 1 O
dihydropyridine	1911 15 B-Chemical
calcium	1927 7 B-Chemical
antagonists	1935 11 O
.	1946 1 O

KF17837	0 7 B-Chemical
:	7 1 O
a	9 1 O
novel	11 5 O
selective	17 9 O
adenosine	27 9 B-Chemical
A2A	37 3 O
receptor	41 8 O
antagonist	50 10 O
with	61 4 O
anticataleptic	66 14 O
activity	81 8 O
.	89 1 O

KF17837	91 7 B-Chemical
is	99 2 O
a	102 1 O
novel	104 5 O
selective	110 9 O
adenosine	120 9 B-Chemical
A2A	130 3 O
receptor	134 8 O
antagonist	143 10 O
.	153 1 O

Oral	155 4 O
administration	160 14 O
of	175 2 O
KF17837	178 7 B-Chemical
(	186 1 O
2	187 1 O
.	188 1 O
5	189 1 O
,	190 1 O
10	192 2 O
.	194 1 O
0	195 1 O
and	197 3 O
30	201 2 O
.	203 1 O
0	204 1 O
mg	206 2 O
/	208 1 O
kg	209 2 O
)	211 1 O
significantly	213 13 O
ameliorated	227 11 O
the	239 3 O
cataleptic	243 10 B-Disease
responses	254 9 O
induced	264 7 O
by	272 2 O
intracerebroventricular	275 23 O
administration	299 14 O
of	314 2 O
an	317 2 O
adenosine	320 9 B-Chemical
A2A	330 3 O
receptor	334 8 O
agonist	343 7 O
,	350 1 O
CGS	352 3 B-Chemical
21680	356 5 I-Chemical
(	362 1 O
10	363 2 O
micrograms	366 10 O
)	376 1 O
,	377 1 O
in	379 2 O
a	382 1 O
dose	384 4 O
-	388 1 O
dependent	389 9 O
manner	399 6 O
.	405 1 O

KF17837	407 7 B-Chemical
also	415 4 O
reduced	420 7 O
the	428 3 O
catalepsy	432 9 B-Disease
induced	442 7 O
by	450 2 O
haloperidol	453 11 B-Chemical
(	465 1 O
1	466 1 O
mg	468 2 O
/	470 1 O
kg	471 2 O
i	474 1 O
.	475 1 O
p	476 1 O
.	477 1 O
)	478 1 O
and	480 3 O
by	484 2 O
reserpine	487 9 B-Chemical
(	497 1 O
5	498 1 O
mg	500 2 O
/	502 1 O
kg	503 2 O
i	506 1 O
.	507 1 O
p	508 1 O
.	509 1 O
)	510 1 O
.	511 1 O

These	513 5 O
anticataleptic	519 14 O
effects	534 7 O
were	542 4 O
exhibited	547 9 O
dose	557 4 O
dependently	562 11 O
at	574 2 O
doses	577 5 O
from	583 4 O
0	588 1 O
.	589 1 O
625	590 3 O
and	594 3 O
2	598 1 O
.	599 1 O
5	600 1 O
mg	602 2 O
/	604 1 O
kg	605 2 O
p	608 1 O
.	609 1 O
o	610 1 O
.	611 1 O
,	612 1 O
respectively	614 12 O
.	626 1 O

Moreover	628 8 O
,	636 1 O
KF17837	638 7 B-Chemical
(	646 1 O
0	647 1 O
.	648 1 O
625	649 3 O
mg	653 2 O
/	655 1 O
kg	656 2 O
p	659 1 O
.	660 1 O
o	661 1 O
.	662 1 O
)	663 1 O
potentiated	665 11 O
the	677 3 O
anticataleptic	681 14 O
effects	696 7 O
of	704 2 O
a	707 1 O
subthreshold	709 12 O
dose	722 4 O
of	727 2 O
L	730 1 B-Chemical
-	731 1 I-Chemical
3	732 1 I-Chemical
,	733 1 I-Chemical
4	734 1 I-Chemical
-	735 1 I-Chemical
dihydroxyphenylalanine	736 22 I-Chemical
(	759 1 O
L	760 1 B-Chemical
-	761 1 I-Chemical
DOPA	762 4 I-Chemical
;	766 1 O
25	768 2 O
mg	771 2 O
/	773 1 O
kg	774 2 O
i	777 1 O
.	778 1 O
p	779 1 O
.	780 1 O
)	781 1 O
plus	783 4 O
benserazide	788 11 B-Chemical
(	800 1 O
6	801 1 O
.	802 1 O
25	803 2 O
mg	806 2 O
/	808 1 O
kg	809 2 O
i	812 1 O
.	813 1 O
p	814 1 O
.	815 1 O
)	816 1 O
.	817 1 O

These	819 5 O
results	825 7 O
suggested	833 9 O
that	843 4 O
KF17837	848 7 B-Chemical
is	856 2 O
a	859 1 O
centrally	861 9 O
active	871 6 O
adenosine	878 9 B-Chemical
A2A	888 3 O
receptor	892 8 O
antagonist	901 10 O
and	912 3 O
that	916 4 O
the	921 3 O
dopaminergic	925 12 O
function	938 8 O
of	947 2 O
the	950 3 O
nigrostriatal	954 13 O
pathway	968 7 O
is	976 2 O
potentiated	979 11 O
by	991 2 O
adenosine	994 9 B-Chemical
A2A	1004 3 O
receptor	1008 8 O
antagonists	1017 11 O
.	1028 1 O

Furthermore	1030 11 O
,	1041 1 O
KF17837	1043 7 B-Chemical
may	1051 3 O
be	1055 2 O
a	1058 1 O
useful	1060 6 O
drug	1067 4 O
in	1072 2 O
the	1075 3 O
treatment	1079 9 O
of	1089 2 O
parkinsonism	1092 12 B-Disease
.	1104 1 O

Some	0 4 O
central	5 7 O
effects	13 7 O
of	21 2 O
repeated	24 8 O
treatment	33 9 O
with	43 4 O
fluvoxamine	48 11 B-Chemical
.	59 1 O

We	61 2 O
investigated	64 12 O
the	77 3 O
effect	81 6 O
of	88 2 O
repeated	91 8 O
treatment	100 9 O
with	110 4 O
fluvoxamine	115 11 B-Chemical
,	126 1 O
a	128 1 O
selective	130 9 O
serotonin	140 9 B-Chemical
uptake	150 6 O
inhibitor	157 9 O
,	166 1 O
on	168 2 O
behavioral	171 10 O
effects	182 7 O
of	190 2 O
dopaminomimetics	193 16 O
and	210 3 O
methoxamine	214 11 B-Chemical
and	226 3 O
on	230 2 O
the	233 3 O
animal	237 6 O
behavior	244 8 O
in	253 2 O
the	256 3 O
"	260 1 O
behavioral	261 10 O
despair	272 7 O
"	279 1 O
test	281 4 O
.	285 1 O

A	287 1 O
repeated	289 8 O
treatment	298 9 O
with	308 4 O
fluvoxamine	313 11 B-Chemical
(	325 1 O
twice	326 5 O
daily	332 5 O
for	338 3 O
14	342 2 O
days	345 4 O
)	349 1 O
potentiated	351 11 O
in	363 2 O
mice	366 4 O
and	371 3 O
in	375 2 O
rats	378 4 O
(	383 1 O
weaker	384 6 O
)	390 1 O
the	392 3 O
amphetamine	396 11 B-Chemical
-	407 1 O
induced	408 7 O
hyperactivity	416 13 B-Disease
.	429 1 O

The	431 3 O
hyperactivity	435 13 B-Disease
induced	449 7 O
by	457 2 O
nomifensine	460 11 B-Chemical
in	472 2 O
mice	475 4 O
remained	480 8 O
unaffected	489 10 O
by	500 2 O
fluvoxamine	503 11 B-Chemical
.	514 1 O

The	516 3 O
stimulation	520 11 O
of	532 2 O
locomotor	535 9 O
activity	545 8 O
by	554 2 O
intracerebroventricularly	557 25 O
administered	583 12 O
methoxamine	596 11 B-Chemical
was	608 3 O
not	612 3 O
affected	616 8 O
by	625 2 O
repeated	628 8 O
treatment	637 9 O
with	647 4 O
fluvoxamine	652 11 B-Chemical
.	663 1 O

Given	665 5 O
three	671 5 O
times	677 5 O
fluvoxamine	683 11 B-Chemical
had	695 3 O
no	699 2 O
effect	702 6 O
on	709 2 O
the	712 3 O
immobilization	716 14 O
time	731 4 O
in	736 2 O
the	739 3 O
"	743 1 O
behavioral	744 10 O
despair	755 7 O
"	762 1 O
test	764 4 O
in	769 2 O
rats	772 4 O
.	776 1 O

The	778 3 O
results	782 7 O
indicate	790 8 O
that	799 4 O
fluvoxamine	804 11 B-Chemical
given	816 5 O
repeatedly	822 10 O
acts	833 4 O
differently	838 11 O
than	850 4 O
citalopram	855 10 B-Chemical
,	865 1 O
another	867 7 O
selective	875 9 O
serotonin	885 9 B-Chemical
uptake	895 6 O
inhibitor	902 9 O
,	911 1 O
and	913 3 O
differs	917 7 O
also	925 4 O
from	930 4 O
other	935 5 O
antidepressant	941 14 O
drugs	956 5 O
.	961 1 O

Severe	0 6 O
congestive	7 10 B-Disease
heart	18 5 I-Disease
failure	24 7 I-Disease
patient	32 7 O
on	40 2 O
amiodarone	43 10 B-Chemical
presenting	54 10 O
with	65 4 O
myxedemic	70 9 B-Disease
coma	80 4 I-Disease
:	84 1 O
a	86 1 O
case	88 4 O
report	93 6 O
.	99 1 O

This	101 4 O
is	106 2 O
a	109 1 O
case	111 4 O
report	116 6 O
of	123 2 O
myxedema	126 8 B-Disease
coma	135 4 I-Disease
secondary	140 9 O
to	150 2 O
amiodarone	153 10 B-Chemical
-	163 1 O
induced	164 7 O
hypothyroidism	172 14 B-Disease
in	187 2 O
a	190 1 O
patient	192 7 O
with	200 4 O
severe	205 6 O
congestive	212 10 B-Disease
heart	223 5 I-Disease
failure	229 7 I-Disease
(	237 1 O
CHF	238 3 B-Disease
)	241 1 O
.	242 1 O

To	244 2 O
our	247 3 O
knowledge	251 9 O
and	261 3 O
after	265 5 O
reviewing	271 9 O
the	281 3 O
literature	285 10 O
there	296 5 O
is	302 2 O
one	305 3 O
case	309 4 O
report	314 6 O
of	321 2 O
myxedema	324 8 B-Disease
coma	333 4 I-Disease
during	338 6 O
long	345 4 O
term	350 4 O
amiodarone	355 10 B-Chemical
therapy	366 7 O
.	373 1 O

Myxedema	375 8 B-Disease
coma	384 4 I-Disease
is	389 2 O
a	392 1 O
life	394 4 O
threatening	399 11 O
condition	411 9 O
that	421 4 O
carries	426 7 O
a	434 1 O
mortality	436 9 O
reaching	446 8 O
as	455 2 O
high	458 4 O
as	463 2 O
20	466 2 O
%	468 1 O
with	470 4 O
treatment	475 9 O
.	484 1 O

The	486 3 O
condition	490 9 O
is	500 2 O
treated	503 7 O
with	511 4 O
intravenous	516 11 O
thyroxine	528 9 B-Chemical
(	538 1 O
T4	539 2 B-Chemical
)	541 1 O
or	543 2 O
intravenous	546 11 O
tri	558 3 B-Chemical
-	561 1 I-Chemical
iodo	562 4 I-Chemical
-	566 1 I-Chemical
thyronine	567 9 I-Chemical
(	577 1 O
T3	578 2 B-Chemical
)	580 1 O
.	581 1 O

Patients	583 8 O
with	592 4 O
CHF	597 3 B-Disease
on	601 2 O
amiodarone	604 10 B-Chemical
may	615 3 O
suffer	619 6 O
serious	626 7 O
morbidity	634 9 O
and	644 3 O
mortality	648 9 O
from	658 4 O
hypothyroidism	663 14 B-Disease
,	677 1 O
and	679 3 O
thus	683 4 O
may	688 3 O
deserve	692 7 O
closer	700 6 O
follow	707 6 O
up	714 2 O
for	717 3 O
thyroid	721 7 O
stimulating	729 11 O
hormone	741 7 O
(	749 1 O
TSH	750 3 O
)	753 1 O
levels	755 6 O
.	761 1 O

This	763 4 O
case	768 4 O
report	773 6 O
carries	780 7 O
an	788 2 O
important	791 9 O
clinical	801 8 O
application	810 11 O
given	822 5 O
the	828 3 O
frequent	832 8 O
usage	841 5 O
of	847 2 O
amiodarone	850 10 B-Chemical
among	861 5 O
CHF	867 3 B-Disease
patients	871 8 O
.	879 1 O

The	881 3 O
myriad	885 6 O
clinical	892 8 O
presentation	901 12 O
of	914 2 O
myxedema	917 8 B-Disease
coma	926 4 I-Disease
and	931 3 O
its	935 3 O
serious	939 7 O
morbidity	947 9 O
and	957 3 O
mortality	961 9 O
stresses	971 8 O
the	980 3 O
need	984 4 O
to	989 2 O
suspect	992 7 O
this	1000 4 O
clinical	1005 8 O
syndrome	1014 8 O
among	1023 5 O
CHF	1029 3 B-Disease
patients	1033 8 O
presenting	1042 10 O
with	1053 4 O
hypotension	1058 11 B-Disease
,	1069 1 O
weakness	1071 8 B-Disease
or	1080 2 O
other	1083 5 O
unexplained	1089 11 O
symptoms	1101 8 O
.	1109 1 O

Fear	0 4 O
-	4 1 O
potentiated	5 11 O
startle	17 7 B-Disease
,	24 1 O
but	26 3 O
not	30 3 O
light	34 5 O
-	39 1 O
enhanced	40 8 O
startle	49 7 B-Disease
,	56 1 O
is	58 2 O
enhanced	61 8 O
by	70 2 O
anxiogenic	73 10 O
drugs	84 5 O
.	89 1 O

RATIONALE	91 9 O
AND	101 3 O
OBJECTIVES	105 10 O
:	115 1 O
The	117 3 O
light	121 5 O
-	126 1 O
enhanced	127 8 O
startle	136 7 B-Disease
paradigm	144 8 O
(	153 1 O
LES	154 3 O
)	157 1 O
is	159 2 O
suggested	162 9 O
to	172 2 O
model	175 5 O
anxiety	181 7 B-Disease
,	188 1 O
because	190 7 O
of	198 2 O
the	201 3 O
non	205 3 O
-	208 1 O
specific	209 8 O
cue	218 3 O
and	222 3 O
the	226 3 O
long	230 4 O
-	234 1 O
term	235 4 O
effect	240 6 O
.	246 1 O

In	248 2 O
contrast	251 8 O
,	259 1 O
the	261 3 O
fear	265 4 O
-	269 1 O
potentiated	270 11 O
startle	282 7 B-Disease
(	290 1 O
FPS	291 3 O
)	294 1 O
is	296 2 O
suggested	299 9 O
to	309 2 O
model	312 5 O
conditioned	318 11 O
fear	330 4 O
.	334 1 O

However	336 7 O
,	343 1 O
the	345 3 O
pharmacological	349 15 O
profiles	365 8 O
of	374 2 O
these	377 5 O
two	383 3 O
paradigms	387 9 O
are	397 3 O
very	401 4 O
similar	406 7 O
.	413 1 O

The	415 3 O
present	419 7 O
study	427 5 O
investigated	433 12 O
the	446 3 O
effects	450 7 O
of	458 2 O
putative	461 8 O
anxiogenic	470 10 O
drugs	481 5 O
on	487 2 O
LES	490 3 O
and	494 3 O
FPS	498 3 O
and	502 3 O
aimed	506 5 O
at	512 2 O
determining	515 11 O
the	527 3 O
sensitivity	531 11 O
of	543 2 O
LES	546 3 O
for	550 3 O
anxiogenic	554 10 O
drugs	565 5 O
and	571 3 O
to	575 2 O
potentially	578 11 O
showing	590 7 O
a	598 1 O
pharmacological	600 15 O
differentiation	616 15 O
between	632 7 O
these	640 5 O
two	646 3 O
paradigms	650 9 O
.	659 1 O

METHODS	661 7 O
:	668 1 O
Male	670 4 O
Wistar	675 6 O
rats	682 4 O
received	687 8 O
each	696 4 O
dose	701 4 O
of	706 2 O
the	709 3 O
alpha	713 5 O
(	718 1 O
2	719 1 O
)	720 1 O
-	721 1 O
adrenoceptor	722 12 O
antagonist	735 10 O
yohimbine	746 9 B-Chemical
(	756 1 O
0	757 1 O
.	758 1 O
25	759 2 O
-	761 1 O
1	762 1 O
.	763 1 O
0mg	764 3 O
/	767 1 O
kg	768 2 O
)	770 1 O
,	771 1 O
the	773 3 O
5	777 1 B-Chemical
-	778 1 I-Chemical
HT	779 2 I-Chemical
(	781 1 O
2C	782 2 O
)	784 1 O
receptor	786 8 O
agonist	795 7 O
m	803 1 B-Chemical
-	804 1 I-Chemical
chlorophenylpiperazine	805 22 I-Chemical
(	828 1 O
mCPP	829 4 B-Chemical
,	833 1 O
0	835 1 O
.	836 1 O
5	837 1 O
-	838 1 O
2	839 1 O
.	840 1 O
0mg	841 3 O
/	844 1 O
kg	845 2 O
)	847 1 O
or	849 2 O
the	852 3 O
GABA	856 4 B-Chemical
(	860 1 O
A	861 1 O
)	862 1 O
inverse	864 7 O
receptor	872 8 O
agonist	881 7 O
pentylenetetrazole	889 18 B-Chemical
(	908 1 O
PTZ	909 3 B-Chemical
,	912 1 O
3	914 1 O
-	915 1 O
30mg	916 4 O
/	920 1 O
kg	921 2 O
)	923 1 O
and	925 3 O
were	929 4 O
subsequently	934 12 O
tested	947 6 O
in	954 2 O
either	957 6 O
LES	964 3 O
or	968 2 O
FPS	971 3 O
.	974 1 O

RESULTS	976 7 O
:	983 1 O
None	985 4 O
of	990 2 O
the	993 3 O
drugs	997 5 O
enhanced	1003 8 O
LES	1012 3 O
,	1015 1 O
whereas	1017 7 O
mCPP	1025 4 B-Chemical
increased	1030 9 O
percentage	1040 10 O
FPS	1051 3 O
and	1055 3 O
yohimbine	1059 9 B-Chemical
increased	1069 9 O
absolute	1079 8 O
FPS	1088 3 O
values	1092 6 O
.	1098 1 O

Furthermore	1100 11 O
,	1111 1 O
yohimbine	1113 9 B-Chemical
increased	1123 9 O
baseline	1133 8 O
startle	1142 7 B-Disease
amplitude	1150 9 O
in	1160 2 O
the	1163 3 O
LES	1167 3 O
,	1170 1 O
while	1172 5 O
mCPP	1178 4 B-Chemical
suppressed	1183 10 O
baseline	1194 8 O
startle	1203 7 B-Disease
in	1211 2 O
both	1214 4 O
the	1219 3 O
LES	1223 3 O
and	1227 3 O
FPS	1231 3 O
and	1235 3 O
PTZ	1239 3 B-Chemical
suppressed	1243 10 O
baseline	1254 8 O
startle	1263 7 B-Disease
in	1271 2 O
the	1274 3 O
FPS	1278 3 O
.	1281 1 O

CONCLUSIONS	1283 11 O
:	1294 1 O
In	1296 2 O
contrast	1299 8 O
to	1308 2 O
findings	1311 8 O
in	1320 2 O
the	1323 3 O
FPS	1327 3 O
paradigm	1331 8 O
,	1339 1 O
none	1341 4 O
of	1346 2 O
the	1349 3 O
drugs	1353 5 O
were	1359 4 O
able	1364 4 O
to	1369 2 O
exacerbate	1372 10 O
the	1383 3 O
LES	1387 3 O
response	1391 8 O
.	1399 1 O

Thus	1401 4 O
,	1405 1 O
a	1407 1 O
clear	1409 5 O
pharmacological	1415 15 O
differentiation	1431 15 O
was	1447 3 O
found	1451 5 O
between	1457 7 O
LES	1465 3 O
and	1469 3 O
FPS	1473 3 O
.	1476 1 O

Proteinase	0 10 O
3	11 1 O
-	12 1 O
antineutrophil	13 14 O
cytoplasmic	28 11 O
antibody	40 8 O
-	48 1 O
(	49 1 O
PR3	50 3 O
-	53 1 O
ANCA	54 4 O
)	58 1 O
positive	60 8 O
necrotizing	69 11 O
glomerulonephritis	81 18 B-Disease
after	100 5 O
restarting	106 10 O
sulphasalazine	117 14 B-Chemical
treatment	132 9 O
.	141 1 O

A	143 1 O
59	145 2 O
-	147 1 O
year	148 4 O
-	152 1 O
old	153 3 O
woman	157 5 O
with	163 4 O
ulcerative	168 10 B-Disease
colitis	179 7 I-Disease
developed	187 9 O
red	197 3 B-Disease
eyes	201 4 I-Disease
,	205 1 O
pleural	207 7 B-Disease
effusion	215 8 I-Disease
,	223 1 O
eosinophilia	225 12 B-Disease
and	238 3 O
urinary	242 7 B-Disease
abnormalities	250 13 I-Disease
after	264 5 O
restarting	270 10 O
of	281 2 O
sulphasalazine	284 14 B-Chemical
treatment	299 9 O
.	308 1 O

Light	310 5 O
microscopy	316 10 O
of	327 2 O
a	330 1 O
kidney	332 6 O
biopsy	339 6 O
revealed	346 8 O
segmental	355 9 B-Disease
necrotizing	365 11 I-Disease
glomerulonephritis	377 18 I-Disease
without	396 7 O
deposition	404 10 O
of	415 2 O
immunoglobulin	418 14 O
or	433 2 O
complement	436 10 O
.	446 1 O

Proteinase	448 10 O
3	459 1 O
-	460 1 O
antineutrophil	461 14 O
cytoplasmic	476 11 O
antibody	488 8 O
(	497 1 O
PR3	498 3 O
-	501 1 O
ANCA	502 4 O
)	506 1 O
titer	508 5 O
was	514 3 O
elevated	518 8 O
at	527 2 O
183	530 3 O
ELISA	534 5 O
units	540 5 O
(	546 1 O
EU	547 2 O
)	549 1 O
in	551 2 O
sera	554 4 O
(	559 1 O
normal	560 6 O
range	567 5 O
less	573 4 O
than	578 4 O
10	583 2 O
EU	586 2 O
)	588 1 O
,	589 1 O
myeloperoxidase	591 15 O
-	606 1 O
ANCA	607 4 O
was	612 3 O
negative	616 8 O
.	624 1 O

PR3	626 3 O
-	629 1 O
ANCA	630 4 O
titer	635 5 O
was	641 3 O
250	645 3 O
and	649 3 O
1	653 1 O
,	654 1 O
070	655 3 O
EU	659 2 O
in	662 2 O
pleural	665 7 B-Disease
effusions	673 9 I-Disease
on	683 2 O
right	686 5 O
and	692 3 O
left	696 4 O
side	701 4 O
,	705 1 O
respectively	707 12 O
.	719 1 O

Although	721 8 O
cessation	730 9 O
of	740 2 O
sulphasalazine	743 14 B-Chemical
treatment	758 9 O
resulted	768 8 O
in	777 2 O
improvements	780 12 O
in	793 2 O
fever	796 5 B-Disease
,	801 1 O
red	803 3 B-Disease
eyes	807 4 I-Disease
,	811 1 O
chest	813 5 B-Disease
pain	819 4 I-Disease
,	823 1 O
titer	825 5 O
of	831 2 O
C	834 1 O
-	835 1 O
reactive	836 8 O
protein	845 7 O
and	853 3 O
volume	857 6 O
of	864 2 O
the	867 3 O
pleural	871 7 B-Disease
effusions	879 9 I-Disease
,	888 1 O
we	890 2 O
initiated	893 9 O
steroid	903 7 B-Chemical
therapy	911 7 O
,	918 1 O
because	920 7 O
PR3	928 3 O
-	931 1 O
ANCA	932 4 O
titer	937 5 O
rose	943 4 O
to	948 2 O
320	951 3 O
EU	955 2 O
,	957 1 O
eosinophil	959 10 O
count	970 5 O
increased	976 9 O
to	986 2 O
1	989 1 O
,	990 1 O
100	991 3 O
cells	995 5 O
/	1000 1 O
microl	1001 6 O
,	1007 1 O
and	1009 3 O
the	1013 3 O
pleural	1017 7 B-Disease
effusion	1025 8 I-Disease
remained	1034 8 O
.	1042 1 O

One	1044 3 O
month	1048 5 O
after	1054 5 O
steroid	1060 7 B-Chemical
therapy	1068 7 O
,	1075 1 O
the	1077 3 O
pleural	1081 7 B-Disease
effusion	1089 8 I-Disease
disappeared	1098 11 O
,	1109 1 O
and	1111 3 O
PR3	1115 3 O
-	1118 1 O
ANCA	1119 4 O
titer	1124 5 O
normalized	1130 10 O
3	1141 1 O
months	1143 6 O
later	1150 5 O
.	1155 1 O

This	1157 4 O
case	1162 4 O
suggests	1167 8 O
that	1176 4 O
sulphasalazine	1181 14 B-Chemical
can	1196 3 O
induce	1200 6 O
PR3	1207 3 O
-	1210 1 O
ANCA	1211 4 O
-	1215 1 O
positive	1216 8 O
necrotizing	1225 11 O
glomerulonephritis	1237 18 B-Disease
.	1255 1 O

Is	0 2 O
phenytoin	3 9 B-Chemical
administration	13 14 O
safe	28 4 O
in	33 2 O
a	36 1 O
hypothermic	38 11 B-Disease
child	50 5 O
?	55 1 O

A	57 1 O
male	59 4 O
neonate	64 7 O
with	72 4 O
a	77 1 O
Chiari	79 6 B-Disease
malformation	86 12 I-Disease
and	99 3 O
a	103 1 O
leaking	105 7 O
myelomeningocoele	113 17 O
underwent	131 9 O
ventriculoperitoneal	141 20 O
shunt	162 5 O
insertion	168 9 O
followed	178 8 O
by	187 2 O
repair	190 6 O
of	197 2 O
myelomeningocoele	200 17 O
.	217 1 O

During	219 6 O
anaesthesia	226 11 O
and	238 3 O
surgery	242 7 O
,	249 1 O
he	251 2 O
inadvertently	254 13 O
became	268 6 O
moderately	275 10 O
hypothermic	286 11 B-Disease
.	297 1 O

Intravenous	299 11 O
phenytoin	311 9 B-Chemical
was	321 3 O
administered	325 12 O
during	338 6 O
the	345 3 O
later	349 5 O
part	355 4 O
of	360 2 O
the	363 3 O
surgery	367 7 O
for	375 3 O
seizure	379 7 B-Disease
prophylaxis	387 11 O
.	398 1 O

Following	400 9 O
phenytoin	410 9 B-Chemical
administration	420 14 O
,	434 1 O
the	436 3 O
patient	440 7 O
developed	448 9 O
acute	458 5 O
severe	464 6 O
bradycardia	471 11 B-Disease
,	482 1 O
refractory	484 10 O
to	495 2 O
atropine	498 8 B-Chemical
and	507 3 O
adrenaline	511 10 B-Chemical
.	521 1 O

The	523 3 O
cardiac	527 7 O
depressant	535 10 O
actions	546 7 O
of	554 2 O
phenytoin	557 9 B-Chemical
and	567 3 O
hypothermia	571 11 B-Disease
can	583 3 O
be	587 2 O
additive	590 8 O
.	598 1 O

Administration	600 14 O
of	615 2 O
phenytoin	618 9 B-Chemical
in	628 2 O
the	631 3 O
presence	635 8 O
of	644 2 O
hypothermia	647 11 B-Disease
may	659 3 O
lead	663 4 O
to	668 2 O
an	671 2 O
adverse	674 7 O
cardiac	682 7 O
event	690 5 O
in	696 2 O
children	699 8 O
.	707 1 O

As	709 2 O
phenytoin	712 9 B-Chemical
is	722 2 O
a	725 1 O
commonly	727 8 O
used	736 4 O
drug	741 4 O
,	745 1 O
clinicians	747 10 O
need	758 4 O
to	763 2 O
be	766 2 O
aware	769 5 O
of	775 2 O
this	778 4 O
interaction	783 11 O
.	794 1 O

Amisulpride	0 11 B-Chemical
related	12 7 O
tic	20 3 B-Disease
-	23 1 I-Disease
like	24 4 I-Disease
symptoms	29 8 I-Disease
in	38 2 O
an	41 2 O
adolescent	44 10 O
schizophrenic	55 13 B-Disease
.	68 1 O

Tic	70 3 B-Disease
disorders	74 9 I-Disease
can	84 3 O
be	88 2 O
effectively	91 11 O
treated	103 7 O
by	111 2 O
atypical	114 8 O
antipsychotics	123 14 O
such	138 4 O
as	143 2 O
risperidone	146 11 B-Chemical
,	157 1 O
olanzapine	159 10 B-Chemical
and	170 3 O
ziprasidone	174 11 B-Chemical
.	185 1 O

However	187 7 O
,	194 1 O
there	196 5 O
are	202 3 O
two	206 3 O
case	210 4 O
reports	215 7 O
that	223 4 O
show	228 4 O
tic	233 3 B-Disease
-	236 1 I-Disease
like	237 4 I-Disease
symptoms	242 8 I-Disease
,	250 1 O
including	252 9 O
motor	262 5 O
and	268 3 O
phonic	272 6 O
variants	279 8 O
,	287 1 O
occurring	289 9 O
during	299 6 O
treatment	306 9 O
with	316 4 O
quetiapine	321 10 B-Chemical
or	332 2 O
clozapine	335 9 B-Chemical
.	344 1 O

We	346 2 O
present	349 7 O
a	357 1 O
15	359 2 O
-	361 1 O
year	362 4 O
-	366 1 O
old	367 3 O
girl	371 4 O
schizophrenic	376 13 B-Disease
who	390 3 O
developed	394 9 O
frequent	404 8 O
involuntary	413 11 B-Disease
eye	425 3 I-Disease
-	428 1 I-Disease
blinking	429 8 I-Disease
movements	438 9 I-Disease
after	448 5 O
5	454 1 O
months	456 6 O
of	463 2 O
amisulpride	466 11 B-Chemical
treatment	478 9 O
(	488 1 O
1000	489 4 O
mg	494 2 O
per	497 3 O
day	501 3 O
)	504 1 O
.	505 1 O

The	507 3 O
tic	511 3 B-Disease
-	514 1 I-Disease
like	515 4 I-Disease
symptoms	520 8 I-Disease
resolved	529 8 O
completely	538 10 O
after	549 5 O
we	555 2 O
reduced	558 7 O
the	566 3 O
dose	570 4 O
of	575 2 O
amisulpride	578 11 B-Chemical
down	590 4 O
to	595 2 O
800	598 3 O
mg	602 2 O
per	605 3 O
day	609 3 O
.	612 1 O

However	614 7 O
,	621 1 O
her	623 3 O
psychosis	627 9 B-Disease
recurred	637 8 O
after	646 5 O
the	652 3 O
dose	656 4 O
reduction	661 9 O
.	670 1 O

We	672 2 O
then	675 4 O
placed	680 6 O
her	687 3 O
on	691 2 O
an	694 2 O
additional	697 10 O
100	708 3 O
mg	712 2 O
per	715 3 O
day	719 3 O
of	723 2 O
quetiapine	726 10 B-Chemical
.	736 1 O

She	738 3 O
has	742 3 O
been	746 4 O
in	751 2 O
complete	754 8 O
remission	763 9 O
under	773 5 O
the	779 3 O
combined	783 8 O
medications	792 11 O
for	804 3 O
more	808 4 O
than	813 4 O
one	818 3 O
year	822 4 O
and	827 3 O
maintains	831 9 O
a	841 1 O
fair	843 4 O
role	848 4 O
function	853 8 O
.	861 1 O

No	863 2 O
more	866 4 O
tic	871 3 B-Disease
-	874 1 I-Disease
like	875 4 I-Disease
symptoms	880 8 I-Disease
or	889 2 O
other	892 5 O
side	898 4 O
effects	903 7 O
have	911 4 O
been	916 4 O
reported	921 8 O
.	929 1 O

Together	931 8 O
with	940 4 O
previously	945 10 O
reported	956 8 O
cases	965 5 O
,	970 1 O
our	972 3 O
patient	976 7 O
suggests	984 8 O
that	993 4 O
tic	998 3 B-Disease
-	1001 1 I-Disease
like	1002 4 I-Disease
symptoms	1007 8 I-Disease
might	1016 5 O
occur	1022 5 O
in	1028 2 O
certain	1031 7 O
vulnerable	1039 10 O
individuals	1050 11 O
during	1062 6 O
treatment	1069 9 O
with	1079 4 O
atypical	1084 8 O
antipsychotics	1093 14 O
such	1108 4 O
as	1113 2 O
quetiapine	1116 10 B-Chemical
,	1126 1 O
clozapine	1128 9 B-Chemical
,	1137 1 O
or	1139 2 O
amisulpride	1142 11 B-Chemical
.	1153 1 O

Comparison	0 10 O
of	11 2 O
developmental	14 13 O
toxicology	28 10 O
of	39 2 O
aspirin	42 7 B-Chemical
(	50 1 O
acetylsalicylic	51 15 B-Chemical
acid	67 4 I-Chemical
)	71 1 O
in	73 2 O
rats	76 4 O
using	81 5 O
selected	87 8 O
dosing	96 6 O
paradigms	103 9 O
.	112 1 O

BACKGROUND	114 10 O
:	124 1 O
Analysis	126 8 O
of	135 2 O
the	138 3 O
literature	142 10 O
for	153 3 O
nonsteroidal	157 12 O
anti	170 4 O
-	174 1 O
inflammatory	175 12 O
drugs	188 5 O
(	194 1 O
NSAIDs	195 6 O
)	201 1 O
suggests	203 8 O
that	212 4 O
a	217 1 O
low	219 3 O
incidence	223 9 O
of	233 2 O
developmental	236 13 B-Disease
anomalies	250 9 I-Disease
occurs	260 6 O
in	267 2 O
rats	270 4 O
given	275 5 O
NSAIDs	281 6 O
on	288 2 O
specific	291 8 O
days	300 4 O
during	305 6 O
organogenesis	312 13 O
.	325 1 O

Aspirin	327 7 B-Chemical
(	335 1 O
acetylsalicylic	336 15 B-Chemical
acid	352 4 I-Chemical
[	357 1 O
ASA	358 3 B-Chemical
]	361 1 O
)	362 1 O
,	363 1 O
an	365 2 O
irreversible	368 12 O
cyclooxygenase	381 14 O
1	396 1 O
and	398 3 O
2	402 1 O
inhibitor	404 9 O
,	413 1 O
induces	415 7 O
developmental	423 13 B-Disease
anomalies	437 9 I-Disease
when	447 4 O
administered	452 12 O
to	465 2 O
Wistar	468 6 O
rats	475 4 O
on	480 2 O
gestational	483 11 O
day	495 3 O
(	499 1 O
GD	500 2 O
)	502 1 O
9	504 1 O
,	505 1 O
10	507 2 O
,	509 1 O
or	511 2 O
11	514 2 O
(	517 1 O
Kimmel	518 6 O
CA	525 2 O
,	527 1 O
Wilson	529 6 O
JG	536 2 O
,	538 1 O
Schumacher	540 10 O
HJ	551 2 O
.	553 1 O
Teratology	555 10 O
4	566 1 O
:	567 1 O
15	568 2 O
-	570 1 O
24	571 2 O
,	573 1 O
1971	575 4 O
)	579 1 O
.	580 1 O

There	582 5 O
are	588 3 O
no	592 2 O
published	595 9 O
ASA	605 3 B-Chemical
studies	609 7 O
using	617 5 O
the	623 3 O
multiple	627 8 O
dosing	636 6 O
paradigm	643 8 O
of	652 2 O
GDs	655 3 O
6	659 1 O
to	661 2 O
17	664 2 O
.	666 1 O

Objectives	668 10 O
of	679 2 O
the	682 3 O
current	686 7 O
study	694 5 O
were	700 4 O
to	705 2 O
compare	708 7 O
results	716 7 O
between	724 7 O
Sprague	732 7 O
-	739 1 O
Dawley	740 6 O
(	747 1 O
SD	748 2 O
)	750 1 O
and	752 3 O
Wistar	756 6 O
strains	763 7 O
when	771 4 O
ASA	776 3 B-Chemical
is	780 2 O
administered	783 12 O
on	796 2 O
GD	799 2 O
9	802 1 O
,	803 1 O
10	805 2 O
,	807 1 O
or	809 2 O
11	812 2 O
;	814 1 O
to	816 2 O
compare	819 7 O
the	827 3 O
malformation	831 12 O
patterns	844 8 O
following	853 9 O
single	863 6 O
and	870 3 O
multiple	874 8 O
dosings	883 7 O
during	891 6 O
organogenesis	898 13 O
in	912 2 O
SD	915 2 O
rats	918 4 O
;	922 1 O
and	924 3 O
to	928 2 O
test	931 4 O
the	936 3 O
hypothesis	940 10 O
that	951 4 O
maternal	956 8 O
gastrointestinal	965 16 B-Disease
toxicity	982 8 I-Disease
confounds	991 9 O
the	1001 3 O
detection	1005 9 O
of	1015 2 O
low	1018 3 O
incidence	1022 9 O
malformations	1032 13 B-Disease
with	1046 4 O
ASA	1051 3 B-Chemical
when	1055 4 O
a	1060 1 O
multiple	1062 8 O
dosing	1071 6 O
paradigm	1078 8 O
is	1087 2 O
used	1090 4 O
.	1094 1 O

METHODS	1096 7 O
:	1103 1 O
ASA	1105 3 B-Chemical
was	1109 3 O
administered	1113 12 O
as	1126 2 O
a	1129 1 O
single	1131 6 O
dose	1138 4 O
on	1143 2 O
GD	1146 2 O
9	1149 1 O
(	1151 1 O
0	1152 1 O
,	1153 1 O
250	1155 3 O
,	1158 1 O
500	1160 3 O
,	1163 1 O
or	1165 2 O
625	1168 3 O
mg	1172 2 O
/	1174 1 O
kg	1175 2 O
)	1177 1 O
,	1178 1 O
10	1180 2 O
(	1183 1 O
0	1184 1 O
,	1185 1 O
500	1187 3 O
,	1190 1 O
625	1192 3 O
,	1195 1 O
or	1197 2 O
750	1200 3 O
mg	1204 2 O
/	1206 1 O
kg	1207 2 O
)	1209 1 O
,	1210 1 O
or	1212 2 O
11	1215 2 O
(	1218 1 O
0	1219 1 O
,	1220 1 O
500	1222 3 O
,	1225 1 O
750	1227 3 O
,	1230 1 O
or	1232 2 O
1000	1235 4 O
mg	1240 2 O
/	1242 1 O
kg	1243 2 O
)	1245 1 O
and	1247 3 O
from	1251 4 O
GD	1256 2 O
6	1259 1 O
to	1261 2 O
GD	1264 2 O
17	1267 2 O
(	1270 1 O
0	1271 1 O
,	1272 1 O
50	1274 2 O
,	1276 1 O
125	1278 3 O
,	1281 1 O
or	1283 2 O
250	1286 3 O
mg	1290 2 O
/	1292 1 O
kg	1293 2 O
a	1296 1 O
day	1298 3 O
)	1301 1 O
in	1303 2 O
the	1306 3 O
multiple	1310 8 O
dose	1319 4 O
study	1324 5 O
to	1330 2 O
SD	1333 2 O
rats	1336 4 O
.	1340 1 O

Animals	1342 7 O
were	1350 4 O
killed	1355 6 O
on	1362 2 O
GD	1365 2 O
21	1368 2 O
,	1370 1 O
and	1372 3 O
fetuses	1376 7 O
were	1384 4 O
examined	1389 8 O
viscerally	1398 10 O
.	1408 1 O

RESULTS	1410 7 O
:	1417 1 O
The	1419 3 O
literature	1423 10 O
evaluation	1434 10 O
suggested	1445 9 O
that	1455 4 O
NSAIDs	1460 6 O
induce	1467 6 O
ventricular	1474 11 B-Disease
septal	1486 6 I-Disease
defects	1493 7 I-Disease
(	1501 1 O
VSDs	1502 4 B-Disease
)	1506 1 O
and	1508 3 O
midline	1512 7 B-Disease
defects	1520 7 I-Disease
(	1528 1 O
MDs	1529 3 B-Disease
)	1532 1 O
in	1534 2 O
rats	1537 4 O
and	1542 3 O
diaphragmatic	1546 13 B-Disease
hernia	1560 6 I-Disease
(	1567 1 O
DH	1568 2 B-Disease
)	1570 1 O
,	1571 1 O
MDs	1573 3 B-Disease
,	1576 1 O
and	1578 3 O
VSDs	1582 4 B-Disease
in	1587 2 O
rabbits	1590 7 O
(	1598 1 O
Cook	1599 4 O
JC	1604 2 O
et	1607 2 O
al	1610 2 O
.	1612 1 O
,	1613 1 O
2003	1615 4 O
)	1619 1 O
;	1620 1 O
hence	1622 5 O
,	1627 1 O
the	1629 3 O
present	1633 7 O
study	1641 5 O
focused	1647 7 O
on	1655 2 O
these	1658 5 O
malformations	1664 13 B-Disease
,	1677 1 O
even	1679 4 O
though	1684 6 O
ASA	1691 3 B-Chemical
induces	1695 7 O
several	1703 7 O
other	1711 5 O
low	1717 3 O
-	1720 1 O
incidence	1721 9 O
malformations	1731 13 B-Disease
.	1744 1 O

In	1746 2 O
single	1749 6 O
dose	1756 4 O
studies	1761 7 O
,	1768 1 O
DH	1770 2 B-Disease
,	1772 1 O
MD	1774 2 B-Disease
,	1776 1 O
and	1778 3 O
VSD	1782 3 B-Disease
were	1786 4 O
induced	1791 7 O
on	1799 2 O
GDs	1802 3 O
9	1806 1 O
and	1808 3 O
10	1812 2 O
.	1814 1 O

VSD	1816 3 B-Disease
also	1820 4 O
was	1825 3 O
noted	1829 5 O
following	1835 9 O
treatment	1845 9 O
on	1855 2 O
GD	1858 2 O
11	1861 2 O
.	1863 1 O

In	1865 2 O
contrast	1868 8 O
,	1876 1 O
DH	1878 2 B-Disease
and	1881 3 O
MD	1885 2 B-Disease
were	1888 4 O
noted	1893 5 O
in	1899 2 O
the	1902 3 O
multiple	1906 8 O
dose	1915 4 O
study	1920 5 O
design	1926 6 O
only	1933 4 O
in	1938 2 O
the	1941 3 O
high	1945 4 O
-	1949 1 O
dose	1950 4 O
group	1955 5 O
,	1960 1 O
and	1962 3 O
VSD	1966 3 B-Disease
was	1970 3 O
noted	1974 5 O
across	1980 6 O
all	1987 3 O
dose	1991 4 O
groups	1996 6 O
.	2002 1 O

CONCLUSIONS	2004 11 O
:	2015 1 O
High	2017 4 O
concordance	2022 11 O
in	2034 2 O
major	2037 5 O
developmental	2043 13 B-Disease
anomalies	2057 9 I-Disease
between	2067 7 O
Wistar	2075 6 O
and	2082 3 O
SD	2086 2 O
rats	2089 4 O
were	2094 4 O
noted	2099 5 O
with	2105 4 O
the	2110 3 O
exception	2114 9 O
of	2124 2 O
VSD	2127 3 B-Disease
in	2131 2 O
the	2134 3 O
SD	2138 2 O
rats	2141 4 O
and	2146 3 O
hydrocephalus	2150 13 B-Disease
in	2164 2 O
the	2167 3 O
Wistar	2171 6 O
rats	2178 4 O
.	2182 1 O

Variations	2184 10 O
and	2195 3 O
malformations	2199 13 B-Disease
were	2213 4 O
similar	2218 7 O
when	2226 4 O
ASA	2231 3 B-Chemical
was	2235 3 O
administered	2239 12 O
as	2252 2 O
a	2255 1 O
single	2257 6 O
dose	2264 4 O
or	2269 2 O
during	2272 6 O
the	2279 3 O
period	2283 6 O
of	2290 2 O
organogenesis	2293 13 O
(	2307 1 O
GDs	2308 3 O
6	2312 1 O
to	2314 2 O
17	2317 2 O
)	2319 1 O
.	2320 1 O

It	2322 2 O
was	2325 3 O
also	2329 4 O
evident	2334 7 O
that	2342 4 O
,	2346 1 O
by	2348 2 O
titrating	2351 9 O
the	2361 3 O
dose	2365 4 O
to	2370 2 O
achieve	2373 7 O
a	2381 1 O
maximum	2383 7 O
tolerated	2391 9 O
dose	2401 4 O
,	2405 1 O
malformations	2407 13 B-Disease
that	2421 4 O
normally	2426 8 O
occur	2435 5 O
at	2441 2 O
low	2444 3 O
incidence	2448 9 O
,	2457 1 O
as	2459 2 O
reported	2462 8 O
from	2471 4 O
previous	2476 8 O
single	2485 6 O
dose	2492 4 O
studies	2497 7 O
,	2504 1 O
could	2506 5 O
also	2512 4 O
be	2517 2 O
induced	2520 7 O
with	2528 4 O
ASA	2533 3 B-Chemical
given	2537 5 O
at	2543 2 O
multiple	2546 8 O
doses	2555 5 O
.	2560 1 O

Torsade	0 7 B-Disease
de	8 2 I-Disease
pointes	11 7 I-Disease
induced	19 7 O
by	27 2 O
metoclopramide	30 14 B-Chemical
in	45 2 O
an	48 2 O
elderly	51 7 O
woman	59 5 O
with	65 4 O
preexisting	70 11 O
complete	82 8 O
left	91 4 B-Disease
bundle	96 6 I-Disease
branch	103 6 I-Disease
block	110 5 I-Disease
.	115 1 O

There	117 5 O
is	123 2 O
a	126 1 O
growing	128 7 O
list	136 4 O
of	141 2 O
drugs	144 5 O
implicated	150 10 O
in	161 2 O
acquired	164 8 O
long	173 4 B-Disease
QT	178 2 I-Disease
syndrome	181 8 I-Disease
and	190 3 O
torsade	194 7 B-Disease
de	202 2 I-Disease
pointes	205 7 I-Disease
.	212 1 O

However	214 7 O
,	221 1 O
the	223 3 O
torsadogenic	227 12 O
potential	240 9 O
of	250 2 O
metoclopramide	253 14 B-Chemical
,	267 1 O
a	269 1 O
commonly	271 8 O
used	280 4 O
antiemetic	285 10 O
and	296 3 O
prokinetic	300 10 O
drug	311 4 O
,	315 1 O
has	317 3 O
not	321 3 O
been	325 4 O
reported	330 8 O
in	339 2 O
the	342 3 O
literature	346 10 O
,	356 1 O
despite	358 7 O
its	366 3 O
chemical	370 8 O
similarity	379 10 O
to	390 2 O
procainamide	393 12 B-Chemical
.	405 1 O

We	407 2 O
report	410 6 O
on	417 2 O
a	420 1 O
92	422 2 O
-	424 1 O
year	425 4 O
-	429 1 O
old	430 3 O
woman	434 5 O
with	440 4 O
preexisting	445 11 O
complete	457 8 O
left	466 4 B-Disease
bundle	471 6 I-Disease
branch	478 6 I-Disease
block	485 5 I-Disease
who	491 3 O
developed	495 9 O
torsade	505 7 B-Disease
de	513 2 I-Disease
pointes	516 7 I-Disease
after	524 5 O
intravenous	530 11 O
and	542 3 O
oral	546 4 O
administration	551 14 O
of	566 2 O
metoclopramide	569 14 B-Chemical
.	583 1 O

This	585 4 O
patient	590 7 O
also	598 4 O
developed	603 9 O
torsade	613 7 B-Disease
de	621 2 I-Disease
pointes	624 7 I-Disease
when	632 4 O
cisapride	637 9 B-Chemical
and	647 3 O
erythromycin	651 12 B-Chemical
were	664 4 O
given	669 5 O
simultaneously	675 14 O
.	689 1 O

These	691 5 O
two	697 3 O
episodes	701 8 O
were	710 4 O
suppressed	715 10 O
successfully	726 12 O
after	739 5 O
discontinuing	745 13 O
the	759 3 O
offending	763 9 O
drugs	773 5 O
and	779 3 O
administering	783 13 O
class	797 5 O
IB	803 2 O
drugs	806 5 O
.	811 1 O

This	813 4 O
is	818 2 O
the	821 3 O
first	825 5 O
documentation	831 13 O
that	845 4 O
metoclopramide	850 14 B-Chemical
provokes	865 8 O
torsade	874 7 B-Disease
de	882 2 I-Disease
pointes	885 7 I-Disease
clinically	893 10 O
.	903 1 O

Metoclopramide	905 14 B-Chemical
should	920 6 O
be	927 2 O
used	930 4 O
cautiously	935 10 O
in	946 2 O
patients	949 8 O
with	958 4 O
a	963 1 O
risk	965 4 O
of	970 2 O
torsade	973 7 B-Disease
de	981 2 I-Disease
pointes	984 7 I-Disease
.	991 1 O

Apomorphine	0 11 B-Chemical
:	11 1 O
an	13 2 O
underutilized	16 13 O
therapy	30 7 O
for	38 3 O
Parkinson	42 9 B-Disease
'	51 1 I-Disease
s	52 1 I-Disease
disease	54 7 I-Disease
.	61 1 O

Apomorphine	63 11 B-Chemical
was	75 3 O
the	79 3 O
first	83 5 O
dopaminergic	89 12 O
drug	102 4 O
ever	107 4 O
used	112 4 O
to	117 2 O
treat	120 5 O
symptoms	126 8 O
of	135 2 O
Parkinson	138 9 B-Disease
'	147 1 I-Disease
s	148 1 I-Disease
disease	150 7 I-Disease
.	157 1 O

While	159 5 O
powerful	165 8 O
antiparkinsonian	174 16 O
effects	191 7 O
had	199 3 O
been	203 4 O
observed	208 8 O
as	217 2 O
early	220 5 O
as	226 2 O
1951	229 4 O
,	233 1 O
the	235 3 O
potential	239 9 O
of	249 2 O
treating	252 8 O
fluctuating	261 11 O
Parkinson	273 9 B-Disease
'	282 1 I-Disease
s	283 1 I-Disease
disease	285 7 I-Disease
by	293 2 O
subcutaneous	296 12 O
administration	309 14 O
of	324 2 O
apomorphine	327 11 B-Chemical
has	339 3 O
only	343 4 O
recently	348 8 O
become	357 6 O
the	364 3 O
subject	368 7 O
of	376 2 O
systematic	379 10 O
study	390 5 O
.	395 1 O

A	397 1 O
number	399 6 O
of	406 2 O
small	409 5 O
scale	415 5 O
clinical	421 8 O
trials	430 6 O
have	437 4 O
unequivocally	442 13 O
shown	456 5 O
that	462 4 O
intermittent	467 12 O
subcutaneous	480 12 O
apomorphine	493 11 B-Chemical
injections	505 10 O
produce	516 7 O
antiparkinsonian	524 16 O
benefit	541 7 O
close	549 5 O
if	555 2 O
not	558 3 O
identical	562 9 O
to	572 2 O
that	575 4 O
seen	580 4 O
with	585 4 O
levodopa	590 8 B-Chemical
and	599 3 O
that	603 4 O
apomorphine	608 11 B-Chemical
rescue	620 6 O
injections	627 10 O
can	638 3 O
reliably	642 8 O
revert	651 6 O
off	658 3 O
-	661 1 O
periods	662 7 O
even	670 4 O
in	675 2 O
patients	678 8 O
with	687 4 O
complex	692 7 O
on	700 2 O
-	702 1 O
off	703 3 O
motor	707 5 O
swings	713 6 O
.	719 1 O

Continuous	721 10 O
subcutaneous	732 12 O
apomorphine	745 11 B-Chemical
infusions	757 9 O
can	767 3 O
reduce	771 6 O
daily	778 5 O
off	784 3 O
-	787 1 O
time	788 4 O
by	793 2 O
more	796 4 O
than	801 4 O
50	806 2 O
%	808 1 O
in	810 2 O
this	813 4 O
group	818 5 O
of	824 2 O
patients	827 8 O
,	835 1 O
which	837 5 O
appears	843 7 O
to	851 2 O
be	854 2 O
a	857 1 O
stronger	859 8 O
effect	868 6 O
than	875 4 O
that	880 4 O
generally	885 9 O
seen	895 4 O
with	900 4 O
add	905 3 O
-	908 1 O
on	909 2 O
therapy	912 7 O
with	920 4 O
oral	925 4 O
dopamine	930 8 B-Chemical
agonists	939 8 O
or	948 2 O
COMT	951 4 O
inhibitors	956 10 O
.	966 1 O

Extended	968 8 O
follow	977 6 O
-	983 1 O
up	984 2 O
studies	987 7 O
of	995 2 O
up	998 2 O
to	1001 2 O
8	1004 1 O
years	1006 5 O
have	1012 4 O
demonstrated	1017 12 O
long	1030 4 O
-	1034 1 O
term	1035 4 O
persistence	1040 11 O
of	1052 2 O
apomorphine	1055 11 B-Chemical
efficacy	1067 8 O
.	1075 1 O

In	1077 2 O
addition	1080 8 O
,	1088 1 O
there	1090 5 O
is	1096 2 O
convincing	1099 10 O
clinical	1110 8 O
evidence	1119 8 O
that	1128 4 O
monotherapy	1133 11 O
with	1145 4 O
continuous	1150 10 O
subcutaneous	1161 12 O
apomorphine	1174 11 B-Chemical
infusions	1186 9 O
is	1196 2 O
associated	1199 10 O
with	1210 4 O
marked	1215 6 O
reductions	1222 10 O
of	1233 2 O
preexisting	1236 11 O
levodopa	1248 8 B-Chemical
-	1256 1 O
induced	1257 7 O
dyskinesias	1265 11 B-Disease
.	1276 1 O

The	1278 3 O
main	1282 4 O
side	1287 4 O
effects	1292 7 O
of	1300 2 O
subcutaneous	1303 12 O
apomorphine	1316 11 B-Chemical
treatment	1328 9 O
are	1338 3 O
related	1342 7 O
to	1350 2 O
cutaneous	1353 9 O
tolerability	1363 12 O
problems	1376 8 O
,	1384 1 O
whereas	1386 7 O
sedation	1394 8 O
and	1403 3 O
psychiatric	1407 11 B-Disease
complications	1419 13 O
play	1433 4 O
a	1438 1 O
lesser	1440 6 O
role	1447 4 O
.	1451 1 O

Given	1453 5 O
the	1459 3 O
marked	1463 6 O
degree	1470 6 O
of	1477 2 O
efficacy	1480 8 O
of	1489 2 O
subcutaneous	1492 12 O
apomorphine	1505 11 B-Chemical
treatment	1517 9 O
in	1527 2 O
fluctuating	1530 11 O
Parkinson	1542 9 B-Disease
'	1551 1 I-Disease
s	1552 1 I-Disease
disease	1554 7 I-Disease
,	1561 1 O
this	1563 4 O
approach	1568 8 O
seems	1577 5 O
to	1583 2 O
deserve	1586 7 O
more	1594 4 O
widespread	1599 10 O
clinical	1610 8 O
use	1619 3 O
.	1622 1 O

Fatal	0 5 O
excited	6 7 O
delirium	14 8 B-Disease
following	23 9 O
cocaine	33 7 B-Chemical
use	41 3 O
:	44 1 O
epidemiologic	46 13 O
findings	60 8 O
provide	69 7 O
new	77 3 O
evidence	81 8 O
for	90 3 O
mechanisms	94 10 O
of	105 2 O
cocaine	108 7 B-Chemical
toxicity	116 8 B-Disease
.	124 1 O

We	126 2 O
describe	129 8 O
an	138 2 O
outbreak	141 8 O
of	150 2 O
deaths	153 6 O
from	160 4 O
cocaine	165 7 B-Chemical
-	172 1 O
induced	173 7 O
excited	181 7 O
delirium	189 8 B-Disease
(	198 1 O
EDDs	199 4 B-Disease
)	203 1 O
in	205 2 O
Dade	208 4 O
County	213 6 O
,	219 1 O
Florida	221 7 O
between	229 7 O
1979	237 4 O
and	242 3 O
1990	246 4 O
.	250 1 O

From	252 4 O
a	257 1 O
registry	259 8 O
of	268 2 O
all	271 3 O
cocaine	275 7 B-Chemical
-	282 1 O
related	283 7 O
deaths	291 6 O
in	298 2 O
Dade	301 4 O
County	306 6 O
,	312 1 O
Florida	314 7 O
,	321 1 O
from	323 4 O
1969	328 4 O
-	332 1 O
1990	333 4 O
,	337 1 O
58	339 2 O
EDDs	342 4 B-Disease
were	347 4 O
compared	352 8 O
with	361 4 O
125	366 3 O
victims	370 7 O
of	378 2 O
accidental	381 10 O
cocaine	392 7 B-Chemical
overdose	400 8 B-Disease
without	409 7 O
excited	417 7 O
delirium	425 8 B-Disease
.	433 1 O

Compared	435 8 O
with	444 4 O
controls	449 8 O
,	457 1 O
EDDs	459 4 B-Disease
were	464 4 O
more	469 4 O
frequently	474 10 O
black	485 5 O
,	490 1 O
male	492 4 O
,	496 1 O
and	498 3 O
younger	502 7 O
.	509 1 O

They	511 4 O
were	516 4 O
less	521 4 O
likely	526 6 O
to	533 2 O
have	536 4 O
a	541 1 O
low	543 3 O
body	547 4 O
mass	552 4 O
index	557 5 O
,	562 1 O
and	564 3 O
more	568 4 O
likely	573 6 O
to	580 2 O
have	583 4 O
died	588 4 O
in	593 2 O
police	596 6 O
custody	603 7 O
,	610 1 O
to	612 2 O
have	615 4 O
received	620 8 O
medical	629 7 O
treatment	637 9 O
immediately	647 11 O
before	659 6 O
death	666 5 O
,	671 1 O
to	673 2 O
have	676 4 O
survived	681 8 O
for	690 3 O
a	694 1 O
longer	696 6 O
period	703 6 O
,	709 1 O
to	711 2 O
have	714 4 O
developed	719 9 O
hyperthermia	729 12 B-Disease
,	741 1 O
and	743 3 O
to	747 2 O
have	750 4 O
died	755 4 O
in	760 2 O
summer	763 6 O
months	770 6 O
.	776 1 O

EDDs	778 4 B-Disease
had	783 3 O
concentrations	787 14 O
of	802 2 O
cocaine	805 7 B-Chemical
and	813 3 O
benzoylecgonine	817 15 B-Chemical
in	833 2 O
autopsy	836 7 O
blood	844 5 O
that	850 4 O
were	855 4 O
similar	860 7 O
to	868 2 O
those	871 5 O
for	877 3 O
controls	881 8 O
.	889 1 O

The	891 3 O
epidemiologic	895 13 O
findings	909 8 O
are	918 3 O
most	922 4 O
consistent	927 10 O
with	938 4 O
the	943 3 O
hypothesis	947 10 O
that	958 4 O
chronic	963 7 O
cocaine	971 7 B-Chemical
use	979 3 O
disrupts	983 8 O
dopaminergic	992 12 O
function	1005 8 O
and	1014 3 O
,	1017 1 O
when	1019 4 O
coupled	1024 7 O
with	1032 4 O
recent	1037 6 O
cocaine	1044 7 B-Chemical
use	1052 3 O
,	1055 1 O
may	1057 3 O
precipitate	1061 11 O
agitation	1073 9 B-Disease
,	1082 1 O
delirium	1084 8 B-Disease
,	1092 1 O
aberrant	1094 8 O
thermoregulation	1103 16 O
,	1119 1 O
rhabdomyolysis	1121 14 B-Disease
,	1135 1 O
and	1137 3 O
sudden	1141 6 B-Disease
death	1148 5 I-Disease
.	1153 1 O

Heparin	0 7 B-Chemical
-	7 1 O
induced	8 7 O
thrombocytopenia	16 16 B-Disease
,	32 1 O
thrombosis	34 10 B-Disease
,	44 1 O
and	46 3 O
hemorrhage	50 10 B-Disease
.	60 1 O

Sixty	62 5 O
-	67 1 O
two	68 3 O
patients	72 8 O
with	81 4 O
a	86 1 O
heparin	88 7 B-Chemical
-	95 1 O
induced	96 7 O
thrombocytopenia	104 16 B-Disease
are	121 3 O
reported	125 8 O
.	133 1 O

Clinical	135 8 O
manifestations	144 14 O
of	159 2 O
this	162 4 O
disorder	167 8 O
include	176 7 O
hemorrhage	184 10 B-Disease
or	195 2 O
,	197 1 O
more	199 4 O
frequently	204 10 O
,	214 1 O
thromboembolic	216 14 B-Disease
events	231 6 O
in	238 2 O
patients	241 8 O
receiving	250 9 O
heparin	260 7 B-Chemical
.	267 1 O

Laboratory	269 10 O
testing	280 7 O
has	288 3 O
revealed	292 8 O
a	301 1 B-Disease
falling	303 7 I-Disease
platelet	311 8 I-Disease
count	320 5 I-Disease
,	325 1 O
increased	327 9 O
resistance	337 10 O
to	348 2 O
heparin	351 7 B-Chemical
,	358 1 O
and	360 3 O
aggregation	364 11 O
of	376 2 O
platelets	379 9 O
by	389 2 O
the	392 3 O
patient	396 7 O
'	403 1 O
s	404 1 O
plasma	406 6 O
when	413 4 O
heparin	418 7 B-Chemical
is	426 2 O
added	429 5 O
.	434 1 O

Immunologic	436 11 O
testing	448 7 O
has	456 3 O
demonstrated	460 12 O
the	473 3 O
presence	477 8 O
of	486 2 O
a	489 1 O
heparin	491 7 B-Chemical
-	498 1 O
dependent	499 9 O
platelet	509 8 O
membrane	518 8 O
antibody	527 8 O
.	535 1 O

The	537 3 O
20	541 2 O
deaths	544 6 O
,	550 1 O
52	552 2 O
hemorrhagic	555 11 B-Disease
and	567 3 I-Disease
thromboembolic	571 14 I-Disease
complications	586 13 I-Disease
,	599 1 O
and	601 3 O
21	605 2 O
surgical	608 8 O
procedures	617 10 O
to	628 2 O
manage	631 6 O
the	638 3 O
complications	642 13 O
confirm	656 7 O
the	664 3 O
seriousness	668 11 O
of	680 2 O
the	683 3 O
disorder	687 8 O
.	695 1 O

Specific	697 8 O
risk	706 4 O
factors	711 7 O
have	719 4 O
not	724 3 O
been	728 4 O
identified	733 10 O
;	743 1 O
therefore	745 9 O
,	754 1 O
all	756 3 O
patients	760 8 O
receiving	769 9 O
heparin	779 7 B-Chemical
should	787 6 O
be	794 2 O
monitored	797 9 O
.	806 1 O

If	808 2 O
the	811 3 O
platelet	815 8 O
count	824 5 O
falls	830 5 O
to	836 2 O
less	839 4 O
than	844 4 O
100	849 3 O
,	852 1 O
000	853 3 O
/	856 1 O
mm3	857 3 O
,	860 1 O
while	862 5 O
the	868 3 O
patient	872 7 O
is	880 2 O
receiving	883 9 O
heparin	893 7 B-Chemical
,	900 1 O
platelet	902 8 B-Disease
aggregation	911 11 I-Disease
testing	923 7 O
,	930 1 O
using	932 5 O
the	938 3 O
patient	942 7 O
'	949 1 O
s	950 1 O
plasma	952 6 O
,	958 1 O
is	960 2 O
indicated	963 9 O
.	972 1 O

Management	974 10 O
consists	985 8 O
of	994 2 O
cessation	997 9 O
of	1007 2 O
heparin	1010 7 B-Chemical
,	1017 1 O
platelet	1019 8 O
anti	1028 4 O
-	1032 1 O
aggregating	1033 11 O
agents	1045 6 O
,	1051 1 O
and	1053 3 O
alternate	1057 9 O
forms	1067 5 O
of	1073 2 O
anticoagulation	1076 15 O
when	1092 4 O
indicated	1097 9 O
.	1106 1 O

Cardiac	0 7 B-Disease
toxicity	8 8 I-Disease
of	17 2 O
5	20 1 B-Chemical
-	21 1 I-Chemical
fluorouracil	22 12 I-Chemical
.	34 1 O

Report	36 6 O
of	43 2 O
a	46 1 O
case	48 4 O
of	53 2 O
spontaneous	56 11 O
angina	68 6 B-Disease
.	74 1 O

We	76 2 O
report	79 6 O
a	86 1 O
case	88 4 O
of	93 2 O
a	96 1 O
patient	98 7 O
with	106 4 O
colon	111 5 B-Disease
carcinoma	117 9 I-Disease
and	127 3 O
liver	131 5 O
metastasis	137 10 B-Disease
who	148 3 O
presented	152 9 O
chest	162 5 B-Disease
pain	168 4 I-Disease
after	173 5 O
5	179 1 B-Chemical
-	180 1 I-Chemical
fluorouracil	181 12 I-Chemical
(	194 1 O
5	195 1 B-Chemical
-	196 1 I-Chemical
FU	197 2 I-Chemical
)	199 1 O
administration	201 14 O
.	215 1 O

Clinical	217 8 O
electrocardiographic	226 20 O
evolution	247 9 O
was	257 3 O
similar	261 7 O
to	269 2 O
that	272 4 O
observed	277 8 O
in	286 2 O
Prinzmetal	289 10 B-Disease
'	299 1 I-Disease
s	300 1 I-Disease
angina	302 6 I-Disease
,	308 1 O
and	310 3 O
chest	314 5 B-Disease
pain	320 4 I-Disease
promptly	325 8 O
resolved	334 8 O
with	343 4 O
nifedipine	348 10 B-Chemical
.	358 1 O

These	360 5 O
data	366 4 O
suggest	371 7 O
that	379 4 O
coronary	384 8 B-Disease
spasm	393 5 I-Disease
may	399 3 O
be	403 2 O
the	406 3 O
cause	410 5 O
of	416 2 O
cardiotoxicity	419 14 B-Disease
due	434 3 O
to	438 2 O
5	441 1 B-Chemical
-	442 1 I-Chemical
FU	443 2 I-Chemical
,	445 1 O
and	447 3 O
that	451 4 O
calcium	456 7 B-Chemical
antagonists	464 11 O
may	476 3 O
probably	480 8 O
be	489 2 O
used	492 4 O
in	497 2 O
the	500 3 O
prevention	504 10 O
or	515 2 O
treatment	518 9 O
of	528 2 O
5	531 1 B-Chemical
-	532 1 I-Chemical
FU	533 2 I-Chemical
cardiotoxicity	536 14 B-Disease
.	550 1 O

Toxicity	0 8 B-Disease
due	9 3 O
to	13 2 O
remission	16 9 O
inducing	26 8 O
drugs	35 5 O
in	41 2 O
rheumatoid	44 10 B-Disease
arthritis	55 9 I-Disease
.	64 1 O

Association	66 11 O
with	78 4 O
HLA	83 3 O
-	86 1 O
B35	87 3 O
and	91 3 O
Cw4	95 3 O
antigens	99 8 O
.	107 1 O

Twenty	109 6 O
-	115 1 O
five	116 4 O
patients	121 8 O
with	130 4 O
rheumatoid	135 10 B-Disease
arthritis	146 9 I-Disease
(	156 1 O
RA	157 2 B-Disease
)	159 1 O
who	161 3 O
developed	165 9 O
toxicity	175 8 B-Disease
while	184 5 O
taking	190 6 O
remission	197 9 O
inducing	207 8 O
drugs	216 5 O
and	222 3 O
30	226 2 O
without	229 7 O
toxicity	237 8 B-Disease
were	246 4 O
studied	251 7 O
for	259 3 O
possible	263 8 O
associations	272 12 O
with	285 4 O
class	290 5 O
I	296 1 O
and	298 3 O
II	302 2 O
HLA	305 3 O
antigens	309 8 O
.	317 1 O

A	319 1 O
strong	321 6 O
association	328 11 O
has	340 3 O
been	344 4 O
found	349 5 O
between	355 7 O
nephritis	363 9 B-Disease
and	373 3 O
dermatitis	377 10 B-Disease
due	388 3 O
to	392 2 O
Tiopronin	395 9 B-Chemical
(	405 1 O
a	406 1 O
D	408 1 B-Chemical
-	409 1 I-Chemical
Penicillamine	410 13 I-Chemical
like	424 4 O
compound	429 8 O
)	437 1 O
and	439 3 O
class	443 5 O
I	449 1 O
antigens	451 8 O
B35	460 3 O
-	463 1 O
Cw4	464 3 O
,	467 1 O
and	469 3 O
between	473 7 O
dermatitis	481 10 B-Disease
due	492 3 O
to	496 2 O
gold	499 4 B-Chemical
thiosulphate	504 12 B-Chemical
and	517 3 O
B35	521 3 O
.	524 1 O

Compared	526 8 O
to	535 2 O
healthy	538 7 O
controls	546 8 O
a	555 1 O
lower	557 5 O
DR5	563 3 O
frequency	567 9 O
was	577 3 O
observed	581 8 O
in	590 2 O
patients	593 8 O
with	602 4 O
RA	607 2 B-Disease
except	610 6 O
for	617 3 O
the	621 3 O
Tiopronin	625 9 B-Chemical
related	635 7 O
nephritis	643 9 B-Disease
group	653 5 O
.	658 1 O

Transient	0 9 O
hemiparesis	10 11 B-Disease
:	21 1 O
a	23 1 O
rare	25 4 O
manifestation	30 13 O
of	44 2 O
diphenylhydantoin	47 17 B-Chemical
toxicity	65 8 B-Disease
.	73 1 O

Report	75 6 O
of	82 2 O
two	85 3 O
cases	89 5 O
.	94 1 O

Among	96 5 O
the	102 3 O
common	106 6 O
side	113 4 O
effects	118 7 O
of	126 2 O
diphenylhydantoin	129 17 B-Chemical
(	147 1 O
DPH	148 3 B-Chemical
)	151 1 O
overdose	153 8 B-Disease
,	161 1 O
the	163 3 O
most	167 4 O
frequently	172 10 O
encountered	183 11 O
neurological	195 12 O
signs	208 5 O
are	214 3 O
those	218 5 O
of	224 2 O
cerebellar	227 10 B-Disease
dysfunction	238 11 I-Disease
.	249 1 O

Very	251 4 O
rarely	256 6 O
,	262 1 O
the	264 3 O
toxic	268 5 O
neurological	274 12 O
manifestations	287 14 O
of	302 2 O
this	305 4 O
drug	310 4 O
are	315 3 O
of	319 2 O
cerebral	322 8 O
origin	331 6 O
.	337 1 O

Two	339 3 O
patients	343 8 O
are	352 3 O
presented	356 9 O
who	366 3 O
suffered	370 8 O
progressive	379 11 O
hemiparesis	391 11 B-Disease
due	403 3 O
to	407 2 O
DPH	410 3 B-Chemical
overdose	414 8 B-Disease
.	422 1 O

Both	424 4 O
had	429 3 O
brain	433 5 O
surgery	439 7 O
before	447 6 O
DPH	454 3 B-Chemical
treatment	458 9 O
.	467 1 O

It	469 2 O
is	472 2 O
assumed	475 7 O
that	483 4 O
patients	488 8 O
with	497 4 O
some	502 4 O
cerebral	507 8 B-Disease
damage	516 6 I-Disease
are	523 3 O
liable	527 6 O
to	534 2 O
manifest	537 8 O
DPH	546 3 B-Chemical
toxicity	550 8 B-Disease
as	559 2 O
focal	562 5 O
neurological	568 12 O
signs	581 5 O
.	586 1 O

Nerve	0 5 O
growth	6 6 O
factor	13 6 O
and	20 3 O
prostaglandins	24 14 B-Chemical
in	39 2 O
the	42 3 O
urine	46 5 O
of	52 2 O
female	55 6 O
patients	62 8 O
with	71 4 O
overactive	76 10 B-Disease
bladder	87 7 I-Disease
.	94 1 O

PURPOSE	96 7 O
:	103 1 O
NGF	105 3 O
and	109 3 O
PGs	113 3 B-Chemical
in	117 2 O
the	120 3 O
bladder	124 7 O
can	132 3 O
be	136 2 O
affected	139 8 O
by	148 2 O
pathological	151 12 O
changes	164 7 O
in	172 2 O
the	175 3 O
bladder	179 7 O
and	187 3 O
these	191 5 O
changes	197 7 O
can	205 3 O
be	209 2 O
detected	212 8 O
in	221 2 O
urine	224 5 O
.	229 1 O

We	231 2 O
investigated	234 12 O
changes	247 7 O
in	255 2 O
urinary	258 7 O
NGF	266 3 O
and	270 3 O
PGs	274 3 B-Chemical
in	278 2 O
women	281 5 O
with	287 4 O
OAB	292 3 B-Disease
.	295 1 O

MATERIALS	297 9 O
AND	307 3 O
METHODS	311 7 O
:	318 1 O
The	320 3 O
study	324 5 O
groups	330 6 O
included	337 8 O
65	346 2 O
women	349 5 O
with	355 4 O
OAB	360 3 B-Disease
and	364 3 O
20	368 2 O
without	371 7 O
bladder	379 7 O
symptoms	387 8 O
who	396 3 O
served	400 6 O
as	407 2 O
controls	410 8 O
.	418 1 O

Evaluation	420 10 O
included	431 8 O
patient	440 7 O
history	448 7 O
,	455 1 O
urinalysis	457 10 O
,	467 1 O
a	469 1 O
voiding	471 7 O
diary	479 5 O
and	485 3 O
urodynamic	489 10 O
studies	500 7 O
.	507 1 O

Urine	509 5 O
samples	515 7 O
were	523 4 O
collected	528 9 O
.	537 1 O

NGF	539 3 O
,	542 1 O
PGE2	544 4 B-Chemical
,	548 1 O
PGF2alpha	550 9 B-Chemical
and	560 3 O
PGI2	564 4 B-Chemical
were	569 4 O
measured	574 8 O
using	583 5 O
enzyme	589 6 O
-	595 1 O
linked	596 6 O
immunosorbent	603 13 O
assay	617 5 O
and	623 3 O
compared	627 8 O
between	636 7 O
the	644 3 O
groups	648 6 O
.	654 1 O

In	656 2 O
addition	659 8 O
,	667 1 O
correlations	669 12 O
between	682 7 O
urinary	690 7 O
NGF	698 3 O
and	702 3 O
PG	706 2 B-Chemical
,	708 1 O
and	710 3 O
urodynamic	714 10 O
parameters	725 10 O
in	736 2 O
patients	739 8 O
with	748 4 O
OAB	753 3 B-Disease
were	757 4 O
examined	762 8 O
.	770 1 O

RESULTS	772 7 O
:	779 1 O
Urinary	781 7 O
NGF	789 3 O
,	792 1 O
PGE2	794 4 B-Chemical
and	799 3 O
PGF2alpha	803 9 B-Chemical
were	813 4 O
significantly	818 13 O
increased	832 9 O
in	842 2 O
patients	845 8 O
with	854 4 O
OAB	859 3 B-Disease
compared	863 8 O
with	872 4 O
controls	877 8 O
(	886 1 O
p	887 1 O
<	889 1 O
0	890 1 O
.	891 1 O
05	892 2 O
)	894 1 O
.	895 1 O

However	897 7 O
,	904 1 O
urinary	906 7 O
PGI2	914 4 B-Chemical
was	919 3 O
not	923 3 O
different	927 9 O
between	937 7 O
controls	945 8 O
and	954 3 O
patients	958 8 O
with	967 4 O
OAB	972 3 B-Disease
.	975 1 O

In	977 2 O
patients	980 8 O
with	989 4 O
OAB	994 3 B-Disease
urinary	998 7 O
PGE2	1006 4 B-Chemical
positively	1011 10 O
correlated	1022 10 O
with	1033 4 O
volume	1038 6 O
at	1045 2 O
first	1048 5 O
desire	1054 6 O
to	1061 2 O
void	1064 4 O
and	1069 3 O
maximum	1073 7 O
cystometric	1081 11 O
capacity	1093 8 O
(	1102 1 O
p	1103 1 O
<	1105 1 O
0	1106 1 O
.	1107 1 O
05	1108 2 O
)	1110 1 O
.	1111 1 O

Urinary	1113 7 O
NGF	1121 3 O
,	1124 1 O
PGF2alpha	1126 9 B-Chemical
and	1136 3 O
PGI2	1140 4 B-Chemical
did	1145 3 O
not	1149 3 O
correlate	1153 9 O
with	1163 4 O
urodynamic	1168 10 O
parameters	1179 10 O
in	1190 2 O
patients	1193 8 O
with	1202 4 O
OAB	1207 3 B-Disease
.	1210 1 O

CONCLUSIONS	1212 11 O
:	1223 1 O
NGF	1225 3 O
and	1229 3 O
PGs	1233 3 B-Chemical
have	1237 4 O
important	1242 9 O
roles	1252 5 O
in	1258 2 O
the	1261 3 O
development	1265 11 O
of	1277 2 O
OAB	1280 3 B-Disease
symptoms	1284 8 O
in	1293 2 O
female	1296 6 O
patients	1303 8 O
.	1311 1 O

Urinary	1313 7 O
levels	1321 6 O
of	1328 2 O
these	1331 5 O
factors	1337 7 O
may	1345 3 O
be	1349 2 O
used	1352 4 O
as	1357 2 O
markers	1360 7 O
to	1368 2 O
evaluate	1371 8 O
OAB	1380 3 B-Disease
symptoms	1384 8 O
.	1392 1 O

Acute	0 5 O
low	6 3 B-Disease
back	10 4 I-Disease
pain	15 4 I-Disease
during	20 6 O
intravenous	27 11 O
administration	39 14 O
of	54 2 O
amiodarone	57 10 B-Chemical
:	67 1 O
a	69 1 O
report	71 6 O
of	78 2 O
two	81 3 O
cases	85 5 O
.	90 1 O

Amiodarone	92 10 B-Chemical
represents	103 10 O
an	114 2 O
effective	117 9 O
antiarrhythmic	127 14 O
drug	142 4 O
for	147 3 O
cardioversion	151 13 O
of	165 2 O
recent	168 6 O
-	174 1 O
onset	175 5 O
atrial	181 6 B-Disease
fibrillation	188 12 I-Disease
(	201 1 O
AF	202 2 B-Disease
)	204 1 O
and	206 3 O
maintenance	210 11 O
of	222 2 O
sinus	225 5 O
rhythm	231 6 O
.	237 1 O

We	239 2 O
briefly	242 7 O
describe	250 8 O
two	259 3 O
patients	263 8 O
suffering	272 9 O
from	282 4 O
recent	287 6 O
-	293 1 O
onset	294 5 O
atrial	300 6 B-Disease
fibrillation	307 12 I-Disease
,	319 1 O
who	321 3 O
experienced	325 11 O
an	337 2 O
acute	340 5 O
devastating	346 11 O
low	358 3 B-Disease
back	362 4 I-Disease
pain	367 4 I-Disease
a	372 1 O
few	374 3 O
minutes	378 7 O
after	386 5 O
initiation	392 10 O
of	403 2 O
intravenous	406 11 O
amiodarone	418 10 B-Chemical
loading	429 7 O
.	436 1 O

Notably	438 7 O
,	445 1 O
this	447 4 O
side	452 4 O
effect	457 6 O
has	464 3 O
not	468 3 O
been	472 4 O
ever	477 4 O
reported	482 8 O
in	491 2 O
the	494 3 O
medical	498 7 O
literature	506 10 O
.	516 1 O

Clinicians	518 10 O
should	529 6 O
be	536 2 O
aware	539 5 O
of	545 2 O
this	548 4 O
reaction	553 8 O
since	562 5 O
prompt	568 6 O
termination	575 11 O
of	587 2 O
parenteral	590 10 O
administration	601 14 O
leads	616 5 O
to	622 2 O
complete	625 8 O
resolution	634 10 O
.	644 1 O

Postoperative	0 13 B-Disease
myalgia	14 7 I-Disease
after	22 5 O
succinylcholine	28 15 B-Chemical
:	43 1 O
no	45 2 O
evidence	48 8 O
for	57 3 O
an	61 2 O
inflammatory	64 12 O
origin	77 6 O
.	83 1 O

A	85 1 O
common	87 6 O
side	94 4 O
effect	99 6 O
associated	106 10 O
with	117 4 O
succinylcholine	122 15 B-Chemical
is	138 2 O
postoperative	141 13 B-Disease
myalgia	155 7 I-Disease
.	162 1 O

The	164 3 O
pathogenesis	168 12 O
of	181 2 O
this	184 4 O
myalgia	189 7 B-Disease
is	197 2 O
still	200 5 O
unclear	206 7 O
;	213 1 O
inflammation	215 12 B-Disease
has	228 3 O
been	232 4 O
suggested	237 9 O
but	247 3 O
without	251 7 O
convincing	259 10 O
evidence	270 8 O
.	278 1 O

We	280 2 O
designed	283 8 O
the	292 3 O
present	296 7 O
study	304 5 O
to	310 2 O
investigate	313 11 O
whether	325 7 O
an	333 2 O
inflammatory	336 12 O
reaction	349 8 O
contributes	358 11 O
to	370 2 O
this	373 4 O
myalgia	378 7 B-Disease
.	385 1 O

The	387 3 O
incidence	391 9 O
and	401 3 O
severity	405 8 O
of	414 2 O
succinylcholine	417 15 B-Chemical
-	432 1 O
associated	433 10 O
myalgia	444 7 B-Disease
was	452 3 O
determined	456 10 O
in	467 2 O
64	470 2 O
patients	473 8 O
pretreated	482 10 O
with	493 4 O
saline	498 6 O
or	505 2 O
dexamethasone	508 13 B-Chemical
before	522 6 O
succinylcholine	529 15 B-Chemical
(	545 1 O
n	546 1 O
=	548 1 O
32	550 2 O
for	553 3 O
each	557 4 O
)	561 1 O
.	562 1 O

Incidence	564 9 O
and	574 3 O
severity	578 8 O
of	587 2 O
myalgia	590 7 B-Disease
did	598 3 O
not	602 3 O
differ	606 6 O
significantly	613 13 O
between	627 7 O
the	635 3 O
two	639 3 O
groups	643 6 O
:	649 1 O
15	651 2 O
patients	654 8 O
in	663 2 O
the	666 3 O
dexamethasone	670 13 B-Chemical
group	684 5 O
complained	690 10 O
of	701 2 O
myalgia	704 7 B-Disease
compared	712 8 O
with	721 4 O
18	726 2 O
patients	729 8 O
in	738 2 O
the	741 3 O
saline	745 6 O
group	752 5 O
,	757 1 O
and	759 3 O
severe	763 6 O
myalgia	770 7 B-Disease
was	778 3 O
reported	782 8 O
by	791 2 O
five	794 4 O
patients	799 8 O
and	808 3 O
three	812 5 O
patients	818 8 O
,	826 1 O
respectively	828 12 O
(	841 1 O
not	842 3 O
significant	846 11 O
)	857 1 O
.	858 1 O

At	860 2 O
48	863 2 O
h	866 1 O
after	868 5 O
surgery	874 7 O
,	881 1 O
12	883 2 O
patients	886 8 O
in	895 2 O
both	898 4 O
groups	903 6 O
still	910 5 O
suffered	916 8 O
from	925 4 O
myalgia	930 7 B-Disease
(	938 1 O
not	939 3 O
significant	943 11 O
)	954 1 O
.	955 1 O

In	957 2 O
addition	960 8 O
,	968 1 O
interleukin	970 11 O
-	981 1 O
6	982 1 O
(	984 1 O
IL	985 2 O
-	987 1 O
6	988 1 O
)	989 1 O
as	991 2 O
an	994 2 O
early	997 5 O
marker	1003 6 O
of	1010 2 O
inflammation	1013 12 B-Disease
was	1026 3 O
assessed	1030 8 O
in	1039 2 O
a	1042 1 O
subgroup	1044 8 O
of	1053 2 O
10	1056 2 O
patients	1059 8 O
pretreated	1068 10 O
with	1079 4 O
saline	1084 6 O
.	1090 1 O

We	1092 2 O
found	1095 5 O
an	1101 2 O
increase	1104 8 O
of	1113 2 O
IL	1116 2 O
-	1118 1 O
6	1119 1 O
for	1121 3 O
only	1125 4 O
three	1130 5 O
patients	1136 8 O
,	1144 1 O
but	1146 3 O
only	1150 4 O
one	1155 3 O
patient	1159 7 O
reported	1167 8 O
myalgia	1176 7 B-Disease
;	1183 1 O
no	1185 2 O
relationship	1188 12 O
between	1201 7 O
myalgia	1209 7 B-Disease
and	1217 3 O
the	1221 3 O
increase	1225 8 O
of	1234 2 O
IL	1237 2 O
-	1239 1 O
6	1240 1 O
was	1242 3 O
found	1246 5 O
.	1251 1 O

In	1253 2 O
conclusion	1256 10 O
,	1266 1 O
there	1268 5 O
is	1274 2 O
no	1277 2 O
evidence	1280 8 O
for	1289 3 O
an	1293 2 O
inflammatory	1296 12 O
origin	1309 6 O
of	1316 2 O
succinylcholine	1319 15 B-Chemical
-	1334 1 O
associated	1335 10 O
myalgia	1346 7 B-Disease
.	1353 1 O

IMPLICATIONS	1355 12 O
:	1367 1 O
Administration	1369 14 O
of	1384 2 O
dexamethasone	1387 13 B-Chemical
before	1401 6 O
succinylcholine	1408 15 B-Chemical
was	1424 3 O
not	1428 3 O
effective	1432 9 O
in	1442 2 O
decreasing	1445 10 O
the	1456 3 O
incidence	1460 9 O
or	1470 2 O
the	1473 3 O
severity	1477 8 O
of	1486 2 O
succinylcholine	1489 15 B-Chemical
-	1504 1 O
induced	1505 7 O
postoperative	1513 13 B-Disease
myalgia	1527 7 I-Disease
.	1534 1 O

Furthermore	1536 11 O
,	1547 1 O
there	1549 5 O
was	1555 3 O
no	1559 2 O
significant	1562 11 O
relationship	1574 12 O
between	1587 7 O
postoperative	1595 13 B-Disease
myalgia	1609 7 I-Disease
and	1617 3 O
time	1621 4 O
course	1626 6 O
of	1633 2 O
interleukin	1636 11 O
-	1647 1 O
6	1648 1 O
concentrations	1650 14 O
,	1664 1 O
a	1666 1 O
marker	1668 6 O
of	1675 2 O
inflammation	1678 12 B-Disease
.	1690 1 O

Pretreatment	1692 12 O
with	1705 4 O
dexamethasone	1710 13 B-Chemical
is	1724 2 O
not	1727 3 O
justified	1731 9 O
to	1741 2 O
prevent	1744 7 O
postoperative	1752 13 B-Disease
myalgia	1766 7 I-Disease
after	1774 5 O
succinylcholine	1780 15 B-Chemical
.	1795 1 O

Levodopa	0 8 B-Chemical
-	8 1 O
induced	9 7 O
oromandibular	17 13 O
dystonia	31 8 B-Disease
in	40 2 O
progressive	43 11 B-Disease
supranuclear	55 12 I-Disease
palsy	68 5 I-Disease
.	73 1 O

Levodopa	75 8 B-Chemical
-	83 1 O
induced	84 7 O
dyskinesias	92 11 B-Disease
have	104 4 O
been	109 4 O
reported	114 8 O
in	123 2 O
Parkinson	126 9 B-Disease
'	135 1 I-Disease
s	136 1 I-Disease
disease	138 7 I-Disease
and	146 3 O
multiple	150 8 B-Disease
system	159 6 I-Disease
atrophy	166 7 I-Disease
.	173 1 O

Cranial	175 7 O
dystonias	183 9 B-Disease
are	193 3 O
rare	197 4 O
in	202 2 O
patients	205 8 O
with	214 4 O
progressive	219 11 B-Disease
supranuclear	231 12 I-Disease
palsy	244 5 I-Disease
(	250 1 O
PSP	251 3 B-Disease
)	254 1 O
.	255 1 O

In	257 2 O
this	260 4 O
report	265 6 O
we	272 2 O
describe	275 8 O
an	284 2 O
unusual	287 7 O
case	295 4 O
of	300 2 O
reversible	303 10 O
levodopa	314 8 B-Chemical
-	322 1 O
induced	323 7 O
Oromandibular	331 13 B-Disease
dystonia	345 8 I-Disease
(	354 1 O
OMD	355 3 B-Disease
)	358 1 O
in	360 2 O
a	363 1 O
PSP	365 3 B-Disease
patient	369 7 O
to	377 2 O
highlight	380 9 O
the	390 3 O
importance	394 10 O
of	405 2 O
recognizing	408 11 O
this	420 4 O
drug	425 4 O
related	430 7 O
complication	438 12 O
in	451 2 O
the	454 3 O
management	458 10 O
of	469 2 O
PSP	472 3 B-Disease
,	475 1 O
and	477 3 O
discuss	481 7 O
the	489 3 O
possible	493 8 O
underlying	502 10 O
pathophysiology	513 15 O
.	528 1 O

Protective	0 10 O
effect	11 6 O
of	18 2 O
edaravone	21 9 B-Chemical
against	31 7 O
streptomycin	39 12 B-Chemical
-	51 1 O
induced	52 7 O
vestibulotoxicity	60 17 B-Disease
in	78 2 O
the	81 3 O
guinea	85 6 O
pig	92 3 O
.	95 1 O

This	97 4 O
study	102 5 O
investigated	108 12 O
alleviation	121 11 O
of	133 2 O
streptomycin	136 12 B-Chemical
-	148 1 O
induced	149 7 O
vestibulotoxicity	157 17 B-Disease
by	175 2 O
edaravone	178 9 B-Chemical
in	188 2 O
guinea	191 6 O
pigs	198 4 O
.	202 1 O

Edaravone	204 9 B-Chemical
,	213 1 O
a	215 1 O
free	217 4 O
radical	222 7 O
scavenger	230 9 O
,	239 1 O
has	241 3 O
potent	245 6 O
free	252 4 O
radical	257 7 O
quenching	265 9 O
action	275 6 O
and	282 3 O
is	286 2 O
used	289 4 O
in	294 2 O
clinical	297 8 O
practice	306 8 O
to	315 2 O
treat	318 5 O
cerebral	324 8 B-Disease
infarction	333 10 I-Disease
.	343 1 O

Streptomycin	345 12 B-Chemical
was	358 3 O
administered	362 12 O
to	375 2 O
the	378 3 O
inner	382 5 O
ear	388 3 O
by	392 2 O
osmotic	395 7 O
pump	403 4 O
for	408 3 O
24	412 2 O
h	415 1 O
,	416 1 O
and	418 3 O
edaravone	422 9 B-Chemical
(	432 1 O
n	433 1 O
=	434 1 O
8	435 1 O
)	436 1 O
or	438 2 O
saline	441 6 O
(	448 1 O
n	449 1 O
=	450 1 O
6	451 1 O
)	452 1 O
was	454 3 O
intraperitoneally	458 17 O
injected	476 8 O
once	485 4 O
a	490 1 O
day	492 3 O
for	496 3 O
7	500 1 O
days	502 4 O
.	506 1 O

We	508 2 O
observed	511 8 O
horizontal	520 10 O
vestibulo	531 9 O
-	540 1 O
ocular	541 6 O
reflex	548 6 O
as	555 2 O
a	558 1 O
marker	560 6 O
of	567 2 O
postoperative	570 13 O
vestibular	584 10 O
function	595 8 O
.	603 1 O

Animals	605 7 O
injected	613 8 O
with	622 4 O
saline	627 6 O
showed	634 6 O
statistically	641 13 O
smaller	655 7 O
gains	663 5 O
than	669 4 O
those	674 5 O
injected	680 8 O
with	689 4 O
edaravone	694 9 B-Chemical
.	703 1 O

These	705 5 O
results	711 7 O
suggest	719 7 O
that	727 4 O
edaravone	732 9 B-Chemical
suppresses	742 10 O
streptomycin	753 12 B-Chemical
-	765 1 O
induced	766 7 O
vestibulotoxicity	774 17 B-Disease
.	791 1 O

Ketamine	0 8 B-Chemical
in	9 2 O
war	12 3 O
/	15 1 O
tropical	16 8 O
surgery	25 7 O
(	33 1 O
a	34 1 O
final	36 5 O
tribute	42 7 O
to	50 2 O
the	53 3 O
racemic	57 7 O
mixture	65 7 O
)	72 1 O
.	73 1 O

A	75 1 O
technique	77 9 O
of	87 2 O
continuous	90 10 O
intravenous	101 11 O
anaesthesia	113 11 O
with	125 4 O
ketamine	130 8 B-Chemical
was	139 3 O
used	143 4 O
successfully	148 12 O
during	161 6 O
the	168 3 O
Somalia	172 7 O
civil	180 5 O
war	186 3 O
in	190 2 O
1994	193 4 O
and	198 3 O
in	202 2 O
north	205 5 O
Uganda	211 6 O
in	218 2 O
1999	221 4 O
for	226 3 O
64	230 2 O
operations	233 10 O
in	244 2 O
62	247 2 O
patients	250 8 O
,	258 1 O
aged	260 4 O
from	265 4 O
6	270 1 O
weeks	272 5 O
to	278 2 O
70	281 2 O
years	284 5 O
,	289 1 O
undergoing	291 10 O
limb	302 4 O
and	307 3 O
abdominal	311 9 O
surgery	321 7 O
including	329 9 O
caesarian	339 9 O
sections	349 8 O
and	358 3 O
interventions	362 13 O
in	376 2 O
neonates	379 8 O
.	387 1 O

Operations	389 10 O
lasting	400 7 O
up	408 2 O
to	411 2 O
2h	414 2 O
could	417 5 O
be	423 2 O
performed	426 9 O
in	436 2 O
the	439 3 O
absence	443 7 O
of	451 2 O
sophisticated	454 13 O
equipment	468 9 O
such	478 4 O
as	483 2 O
pulse	486 5 O
oximeters	492 9 O
or	502 2 O
ventilators	505 11 O
in	517 2 O
patients	520 8 O
on	529 2 O
spontaneous	532 11 O
ventilation	544 11 O
breathing	556 9 O
air	566 3 O
/	569 1 O
oxygen	570 6 B-Chemical
only	577 4 O
.	581 1 O

After	583 5 O
premedication	589 13 O
with	603 4 O
diazepam	608 8 B-Chemical
,	616 1 O
glycopyrrolate	618 14 B-Chemical
and	633 3 O
local	637 5 O
anaesthesia	643 11 O
,	654 1 O
and	656 3 O
induction	660 9 O
with	670 4 O
standard	675 8 O
doses	684 5 O
of	690 2 O
ketamine	693 8 B-Chemical
,	701 1 O
a	703 1 O
maintenance	705 11 O
dose	717 4 O
of	722 2 O
10	725 2 O
-	727 1 O
20	728 2 O
microg	731 6 O
/	737 1 O
kg	738 2 O
/	740 1 O
min	741 3 O
of	745 2 O
ketamine	748 8 B-Chemical
proved	757 6 O
safe	764 4 O
and	769 3 O
effective	773 9 O
.	782 1 O

Emphasis	784 8 O
was	793 3 O
placed	797 6 O
on	804 2 O
bedside	807 7 O
clinical	815 8 O
monitoring	824 10 O
,	834 1 O
relying	836 7 O
heavily	844 7 O
on	852 2 O
the	855 3 O
heart	859 5 O
rate	865 4 O
.	869 1 O

Diazepam	871 8 B-Chemical
,	879 1 O
unless	881 6 O
contraindicated	888 15 O
or	904 2 O
risky	907 5 O
,	912 1 O
remains	914 7 O
the	922 3 O
only	926 4 O
necessary	931 9 O
complementary	941 13 O
drug	955 4 O
to	960 2 O
ketamine	963 8 B-Chemical
as	972 2 O
it	975 2 O
buffers	978 7 O
its	986 3 O
cardiovascular	990 14 O
response	1005 8 O
and	1014 3 O
decreases	1018 9 O
the	1028 3 O
duration	1032 8 O
and	1041 3 O
intensity	1045 9 O
of	1055 2 O
operative	1058 9 O
and	1068 3 O
postoperative	1072 13 O
hallucinations	1086 14 B-Disease
.	1100 1 O

Local	1102 5 O
anaesthetic	1108 11 O
blocks	1120 6 O
were	1127 4 O
useful	1132 6 O
in	1139 2 O
decreasing	1142 10 O
the	1153 3 O
requirement	1157 11 O
for	1169 3 O
postoperative	1173 13 O
analgesia	1187 9 B-Disease
.	1196 1 O

An	1198 2 O
antisialogue	1201 12 O
was	1214 3 O
usually	1218 7 O
unnecessary	1226 11 O
in	1238 2 O
operations	1241 10 O
lasting	1252 7 O
up	1260 2 O
to	1263 2 O
2	1266 1 O
h	1268 1 O
,	1269 1 O
glycopyrrolate	1271 14 B-Chemical
being	1286 5 O
the	1292 3 O
best	1296 4 O
choice	1301 6 O
for	1308 3 O
its	1312 3 O
lowest	1316 6 O
psychotropic	1323 12 O
and	1336 3 O
chronotropic	1340 12 O
effects	1353 7 O
,	1360 1 O
especially	1362 10 O
in	1373 2 O
a	1376 1 O
hot	1378 3 O
climate	1382 7 O
.	1389 1 O

Experience	1391 10 O
in	1402 2 O
war	1405 3 O
/	1408 1 O
tropical	1409 8 O
settings	1418 8 O
suggests	1427 8 O
this	1436 4 O
technique	1441 9 O
could	1451 5 O
be	1457 2 O
useful	1460 6 O
in	1467 2 O
civilian	1470 8 O
contexts	1479 8 O
such	1488 4 O
as	1493 2 O
outdoor	1496 7 O
life	1504 4 O
-	1508 1 O
saving	1509 6 O
emergency	1516 9 O
surgery	1526 7 O
or	1534 2 O
in	1537 2 O
mass	1540 4 O
casualties	1545 10 O
where	1556 5 O
,	1561 1 O
e	1563 1 O
.	1564 1 O
g	1565 1 O
.	1566 1 O
amputation	1568 10 O
and	1579 3 O
rapid	1583 5 O
extrication	1589 11 O
were	1601 4 O
required	1606 8 O
.	1614 1 O

Steroid	0 7 B-Chemical
structure	8 9 O
and	18 3 O
pharmacological	22 15 O
properties	38 10 O
determine	49 9 O
the	59 3 O
anti	63 4 O
-	67 1 O
amnesic	68 7 B-Disease
effects	76 7 O
of	84 2 O
pregnenolone	87 12 B-Chemical
sulphate	100 8 I-Chemical
in	109 2 O
the	112 3 O
passive	116 7 O
avoidance	124 9 O
task	134 4 O
in	139 2 O
rats	142 4 O
.	146 1 O

Pregnenolone	148 12 B-Chemical
sulphate	161 8 I-Chemical
(	170 1 O
PREGS	171 5 B-Chemical
)	176 1 O
has	178 3 O
generated	182 9 O
interest	192 8 O
as	201 2 O
one	204 3 O
of	208 2 O
the	211 3 O
most	215 4 O
potent	220 6 O
memory	227 6 O
-	233 1 O
enhancing	234 9 O
neurosteroids	244 13 O
to	258 2 O
be	261 2 O
examined	264 8 O
in	273 2 O
rodent	276 6 O
learning	283 8 O
studies	292 7 O
,	299 1 O
with	301 4 O
particular	306 10 O
importance	317 10 O
in	328 2 O
the	331 3 O
ageing	335 6 O
process	342 7 O
.	349 1 O

The	351 3 O
mechanism	355 9 O
by	365 2 O
which	368 5 O
this	374 4 O
endogenous	379 10 O
steroid	390 7 B-Chemical
enhances	398 8 O
memory	407 6 O
formation	414 9 O
is	424 2 O
hypothesized	427 12 O
to	440 2 O
involve	443 7 O
actions	451 7 O
on	459 2 O
glutamatergic	462 13 O
and	476 3 O
GABAergic	480 9 O
systems	490 7 O
.	497 1 O

This	499 4 O
hypothesis	504 10 O
stems	515 5 O
from	521 4 O
findings	526 8 O
that	535 4 O
PREGS	540 5 B-Chemical
is	546 2 O
a	549 1 O
potent	551 6 O
positive	558 8 O
modulator	567 9 O
of	577 2 O
N	580 1 B-Chemical
-	581 1 I-Chemical
methyl	582 6 I-Chemical
-	588 1 I-Chemical
d	589 1 I-Chemical
-	590 1 I-Chemical
aspartate	591 9 I-Chemical
receptors	601 9 O
(	611 1 O
NMDARs	612 6 O
)	618 1 O
and	620 3 O
a	624 1 O
negative	626 8 O
modulator	635 9 O
of	645 2 O
gamma	648 5 B-Chemical
-	653 1 I-Chemical
aminobutyric	654 12 I-Chemical
acid	667 4 I-Chemical
(	671 1 O
A	672 1 O
)	673 1 O
receptors	675 9 O
(	685 1 O
GABA	686 4 B-Chemical
(	690 1 O
A	691 1 O
)	692 1 O
Rs	693 2 O
)	695 1 O
.	696 1 O

Moreover	698 8 O
,	706 1 O
PREGS	708 5 B-Chemical
is	714 2 O
able	717 4 O
to	722 2 O
reverse	725 7 O
the	733 3 O
amnesic	737 7 B-Disease
-	744 1 O
like	745 4 O
effects	750 7 O
of	758 2 O
NMDAR	761 5 O
and	767 3 O
GABA	771 4 B-Chemical
(	775 1 O
A	776 1 O
)	777 1 O
R	778 1 O
ligands	780 7 O
.	787 1 O

To	789 2 O
investigate	792 11 O
this	804 4 O
hypothesis	809 10 O
,	819 1 O
the	821 3 O
present	825 7 O
study	833 5 O
in	839 2 O
rats	842 4 O
examined	847 8 O
the	856 3 O
memory	860 6 O
-	866 1 O
altering	867 8 O
abilities	876 9 O
of	886 2 O
structural	889 10 O
analogs	900 7 O
of	908 2 O
PREGS	911 5 B-Chemical
,	916 1 O
which	918 5 O
differ	924 6 O
in	931 2 O
their	934 5 O
modulation	940 10 O
of	951 2 O
NMDAR	954 5 O
and	960 3 O
/	963 1 O
or	964 2 O
GABA	967 4 B-Chemical
(	971 1 O
A	972 1 O
)	973 1 O
R	974 1 O
function	976 8 O
.	984 1 O

The	986 3 O
analogs	990 7 O
tested	998 6 O
were	1005 4 O
:	1009 1 O
11	1011 2 B-Chemical
-	1013 1 I-Chemical
ketopregnenolone	1014 16 I-Chemical
sulphate	1031 8 I-Chemical
(	1040 1 O
an	1041 2 O
agent	1044 5 O
that	1050 4 O
is	1055 2 O
inactive	1058 8 O
at	1067 2 O
GABA	1070 4 B-Chemical
(	1074 1 O
A	1075 1 O
)	1076 1 O
Rs	1077 2 O
and	1080 3 O
NMDARs	1084 6 O
)	1090 1 O
,	1091 1 O
epipregnanolone	1093 15 B-Chemical
(	1109 1 I-Chemical
[	1110 1 I-Chemical
3beta	1111 5 I-Chemical
-	1116 1 I-Chemical
hydroxy	1117 7 I-Chemical
-	1124 1 I-Chemical
5beta	1125 5 I-Chemical
-	1130 1 I-Chemical
pregnan	1131 7 I-Chemical
-	1138 1 I-Chemical
20	1139 2 I-Chemical
-	1141 1 I-Chemical
one	1142 3 I-Chemical
]	1145 1 I-Chemical
sulphate	1147 8 I-Chemical
,	1155 1 O
an	1157 2 O
inhibitor	1160 9 O
of	1170 2 O
both	1173 4 O
GABA	1178 4 B-Chemical
(	1182 1 O
A	1183 1 O
)	1184 1 O
Rs	1185 2 O
and	1188 3 O
NMDARs	1192 6 O
)	1198 1 O
,	1199 1 O
and	1201 3 O
a	1205 1 O
newly	1207 5 O
synthesized	1213 11 O
(	1225 1 O
-	1226 1 O
)	1227 1 O
PREGS	1229 5 B-Chemical
enantiomer	1235 10 O
(	1246 1 O
which	1247 5 O
is	1253 2 O
identical	1256 9 O
to	1266 2 O
PREGS	1269 5 B-Chemical
in	1275 2 O
effects	1278 7 O
on	1286 2 O
GABA	1289 4 B-Chemical
(	1293 1 O
A	1294 1 O
)	1295 1 O
Rs	1296 2 O
and	1299 3 O
NMDARs	1303 6 O
)	1309 1 O
.	1310 1 O

The	1312 3 O
memory	1316 6 O
-	1322 1 O
enhancing	1323 9 O
effects	1333 7 O
of	1341 2 O
PREGS	1344 5 B-Chemical
and	1350 3 O
its	1354 3 O
analogs	1358 7 O
were	1366 4 O
tested	1371 6 O
in	1378 2 O
the	1381 3 O
passive	1385 7 O
avoidance	1393 9 O
task	1403 4 O
using	1408 5 O
the	1414 3 O
model	1418 5 O
of	1424 2 O
scopolamine	1427 11 B-Chemical
-	1438 1 O
induced	1439 7 O
amnesia	1447 7 B-Disease
.	1454 1 O

Both	1456 4 O
PREGS	1461 5 B-Chemical
and	1467 3 O
its	1471 3 O
(	1475 1 O
-	1476 1 O
)	1477 1 O
enantiomer	1479 10 O
blocked	1490 7 O
the	1498 3 O
effects	1502 7 O
of	1510 2 O
scopolamine	1513 11 B-Chemical
.	1524 1 O

The	1526 3 O
results	1530 7 O
show	1538 4 O
that	1543 4 O
,	1547 1 O
unlike	1549 6 O
PREGS	1556 5 B-Chemical
,	1561 1 O
11	1563 2 B-Chemical
-	1565 1 I-Chemical
ketopregnenolone	1566 16 I-Chemical
sulphate	1583 8 I-Chemical
and	1592 3 O
epipregnanolone	1596 15 B-Chemical
sulphate	1612 8 I-Chemical
failed	1621 6 O
to	1628 2 O
block	1631 5 O
the	1637 3 O
effect	1641 6 O
of	1648 2 O
scopolamine	1651 11 B-Chemical
,	1662 1 O
suggesting	1664 10 O
that	1675 4 O
altering	1680 8 O
the	1689 3 O
modulation	1693 10 O
of	1704 2 O
NMDA	1707 4 B-Chemical
receptors	1712 9 O
diminishes	1722 10 O
the	1733 3 O
memory	1737 6 O
-	1743 1 O
enhancing	1744 9 O
effects	1754 7 O
of	1762 2 O
PREGS	1765 5 B-Chemical
.	1770 1 O

Moreover	1772 8 O
,	1780 1 O
enantioselectivity	1782 18 O
was	1801 3 O
demonstrated	1805 12 O
by	1818 2 O
the	1821 3 O
ability	1825 7 O
of	1833 2 O
natural	1836 7 O
PREGS	1844 5 B-Chemical
to	1850 2 O
be	1853 2 O
an	1856 2 O
order	1859 5 O
of	1865 2 O
magnitude	1868 9 O
more	1878 4 O
effective	1883 9 O
than	1893 4 O
its	1898 3 O
synthetic	1902 9 O
enantiomer	1912 10 O
in	1923 2 O
reversing	1926 9 O
scopolamine	1936 11 B-Chemical
-	1947 1 O
induced	1948 7 O
amnesia	1956 7 B-Disease
.	1963 1 O

These	1965 5 O
results	1971 7 O
identify	1979 8 O
a	1988 1 O
novel	1990 5 O
neuropharmacological	1996 20 O
site	2017 4 O
for	2022 3 O
the	2026 3 O
modulation	2030 10 O
of	2041 2 O
memory	2044 6 O
processes	2051 9 O
by	2061 2 O
neuroactive	2064 11 O
steroids	2076 8 B-Chemical
.	2084 1 O

Preliminary	0 11 O
efficacy	12 8 O
assessment	21 10 O
of	32 2 O
intrathecal	35 11 O
injection	47 9 O
of	57 2 O
an	60 2 O
American	63 8 O
formulation	72 11 O
of	84 2 O
adenosine	87 9 B-Chemical
in	97 2 O
humans	100 6 O
.	106 1 O

BACKGROUND	108 10 O
:	118 1 O
Preclinical	120 11 O
studies	132 7 O
of	140 2 O
intrathecal	143 11 O
adenosine	155 9 B-Chemical
suggest	165 7 O
it	173 2 O
may	176 3 O
be	180 2 O
effective	183 9 O
in	193 2 O
the	196 3 O
treatment	200 9 O
of	210 2 O
acute	213 5 B-Disease
and	219 3 I-Disease
chronic	223 7 I-Disease
pain	231 4 I-Disease
in	236 2 O
humans	239 6 O
,	245 1 O
and	247 3 O
preliminary	251 11 O
studies	263 7 O
in	271 2 O
volunteers	274 10 O
and	285 3 O
patients	289 8 O
with	298 4 O
a	303 1 O
Swedish	305 7 O
formulation	313 11 O
of	325 2 O
adenosine	328 9 B-Chemical
suggests	338 8 O
it	347 2 O
may	350 3 O
be	354 2 O
effective	357 9 O
in	367 2 O
hypersensitivity	370 16 B-Disease
states	387 6 O
but	394 3 O
not	398 3 O
with	402 4 O
acute	407 5 O
noxious	413 7 O
stimulation	421 11 O
.	432 1 O

The	434 3 O
purpose	438 7 O
of	446 2 O
this	449 4 O
study	454 5 O
was	460 3 O
to	464 2 O
screen	467 6 O
for	474 3 O
efficacy	478 8 O
of	487 2 O
a	490 1 O
different	492 9 O
formulation	502 11 O
of	514 2 O
adenosine	517 9 B-Chemical
marketed	527 8 O
in	536 2 O
the	539 3 O
US	543 2 O
,	545 1 O
using	547 5 O
both	553 4 O
acute	558 5 O
noxious	564 7 O
stimulation	572 11 O
and	584 3 O
capsaicin	588 9 B-Chemical
-	597 1 O
evoked	598 6 O
mechanical	605 10 O
hypersensitivity	616 16 B-Disease
.	632 1 O

METHODS	634 7 O
:	641 1 O
Following	643 9 O
Food	653 4 O
and	658 3 O
Drug	662 4 O
Administration	667 14 O
and	682 3 O
institutional	686 13 O
review	700 6 O
board	707 5 O
approval	713 8 O
and	722 3 O
written	726 7 O
informed	734 8 O
consent	743 7 O
,	750 1 O
65	752 2 O
volunteers	755 10 O
were	766 4 O
studied	771 7 O
in	779 2 O
two	782 3 O
trials	786 6 O
:	792 1 O
an	794 2 O
open	797 4 O
-	801 1 O
label	802 5 O
,	807 1 O
dose	809 4 O
-	813 1 O
escalating	814 10 O
trial	825 5 O
with	831 4 O
intrathecal	836 11 O
adenosine	848 9 B-Chemical
doses	858 5 O
of	864 2 O
0	867 1 O
.	868 1 O
25	869 2 O
-	871 1 O
2	872 1 O
.	873 1 O
0	874 1 O
mg	876 2 O
and	879 3 O
a	883 1 O
double	885 6 O
-	891 1 O
blind	892 5 O
,	897 1 O
placebo	899 7 O
-	906 1 O
controlled	907 10 O
trial	918 5 O
of	924 2 O
adenosine	927 9 B-Chemical
,	936 1 O
2	938 1 O
mg	940 2 O
.	942 1 O

Cerebrospinal	944 13 O
fluid	958 5 O
was	964 3 O
obtained	968 8 O
for	977 3 O
pharmacokinetic	981 15 O
analysis	997 8 O
,	1005 1 O
and	1007 3 O
pain	1011 4 B-Disease
ratings	1016 7 O
in	1024 2 O
response	1027 8 O
to	1036 2 O
acute	1039 5 O
heat	1045 4 O
stimuli	1050 7 O
and	1058 3 O
areas	1062 5 O
of	1068 2 O
mechanical	1071 10 B-Disease
hyperalgesia	1082 12 I-Disease
and	1095 3 O
allodynia	1099 9 B-Disease
after	1109 5 O
intradermal	1115 11 O
capsaicin	1127 9 B-Chemical
injection	1137 9 O
were	1147 4 O
determined	1152 10 O
.	1162 1 O

RESULTS	1164 7 O
:	1171 1 O
Adenosine	1173 9 B-Chemical
produced	1183 8 O
no	1192 2 O
effect	1195 6 O
on	1202 2 O
pain	1205 4 B-Disease
report	1210 6 O
to	1217 2 O
acute	1220 5 O
noxious	1226 7 O
thermal	1234 7 O
or	1242 2 O
chemical	1245 8 O
stimulation	1254 11 O
but	1266 3 O
reduced	1270 7 O
mechanical	1278 10 B-Disease
hyperalgesia	1289 12 I-Disease
and	1302 3 O
allodynia	1306 9 B-Disease
from	1316 4 O
intradermal	1321 11 O
capsaicin	1333 9 B-Chemical
injection	1343 9 O
for	1353 3 O
at	1357 2 O
least	1360 5 O
24	1366 2 O
h	1369 1 O
.	1370 1 O

In	1372 2 O
contrast	1375 8 O
,	1383 1 O
residence	1385 9 O
time	1395 4 O
of	1400 2 O
adenosine	1403 9 B-Chemical
in	1413 2 O
cerebrospinal	1416 13 O
fluid	1430 5 O
was	1436 3 O
short	1440 5 O
(	1446 1 O
<	1447 1 O
4	1449 1 O
h	1451 1 O
)	1452 1 O
.	1453 1 O

CONCLUSIONS	1455 11 O
:	1466 1 O
These	1468 5 O
results	1474 7 O
show	1482 4 O
selective	1487 9 O
inhibition	1497 10 O
by	1508 2 O
intrathecal	1511 11 O
adenosine	1523 9 B-Chemical
of	1533 2 O
hypersensitivity	1536 16 B-Disease
,	1552 1 O
presumed	1554 8 O
to	1563 2 O
reflect	1566 7 O
central	1574 7 O
sensitization	1582 13 O
in	1596 2 O
humans	1599 6 O
after	1606 5 O
peripheral	1612 10 O
capsaicin	1623 9 B-Chemical
injection	1633 9 O
.	1642 1 O

The	1644 3 O
long	1648 4 O
-	1652 1 O
lasting	1653 7 O
effect	1661 6 O
is	1668 2 O
consistent	1671 10 O
with	1682 4 O
that	1687 4 O
observed	1692 8 O
in	1701 2 O
preliminary	1704 11 O
reports	1716 7 O
of	1724 2 O
patients	1727 8 O
with	1736 4 O
chronic	1741 7 O
neuropathic	1749 11 B-Disease
pain	1761 4 I-Disease
and	1766 3 O
is	1770 2 O
not	1773 3 O
due	1777 3 O
to	1781 2 O
prolonged	1784 9 O
residence	1794 9 O
of	1804 2 O
adenosine	1807 9 B-Chemical
in	1817 2 O
cerebrospinal	1820 13 O
fluid	1834 5 O
.	1839 1 O

Effect	0 6 O
of	7 2 O
lithium	10 7 B-Chemical
maintenance	18 11 O
therapy	30 7 O
on	38 2 O
thyroid	41 7 O
and	49 3 O
parathyroid	53 11 O
function	65 8 O
.	73 1 O

OBJECTIVES	75 10 O
:	85 1 O
To	87 2 O
assess	90 6 O
changes	97 7 O
induced	105 7 O
by	113 2 O
lithium	116 7 B-Chemical
maintenance	124 11 O
therapy	136 7 O
on	144 2 O
the	147 3 O
incidence	151 9 O
of	161 2 O
thyroid	164 7 O
,	171 1 O
parathyroid	173 11 O
and	185 3 O
ion	189 3 O
alterations	193 11 O
.	204 1 O

These	206 5 O
were	212 4 O
evaluated	217 9 O
with	227 4 O
respect	232 7 O
to	240 2 O
the	243 3 O
duration	247 8 O
of	256 2 O
lithium	259 7 B-Chemical
therapy	267 7 O
,	274 1 O
age	276 3 O
,	279 1 O
sex	281 3 O
,	284 1 O
and	286 3 O
family	290 6 O
history	297 7 O
(	305 1 O
whether	306 7 O
or	314 2 O
not	317 3 O
the	321 3 O
patient	325 7 O
had	333 3 O
a	337 1 O
first	339 5 O
-	344 1 O
degree	345 6 O
relative	352 8 O
with	361 4 O
thyroid	366 7 B-Disease
disease	374 7 I-Disease
)	381 1 O
.	382 1 O

DESIGN	384 6 O
:	390 1 O
Prospective	392 11 O
study	404 5 O
.	409 1 O

SETTING	411 7 O
:	418 1 O
Affective	420 9 O
Disorders	430 9 O
Clinic	440 6 O
at	447 2 O
St	450 2 O
.	452 1 O

Mary	454 4 O
'	458 1 O
s	459 1 O
Hospital	461 8 O
,	469 1 O
Montreal	471 8 O
.	479 1 O

PATIENTS	481 8 O
:	489 1 O
One	491 3 O
hundred	495 7 O
and	503 3 O
one	507 3 O
patients	511 8 O
(	520 1 O
28	521 2 O
men	524 3 O
and	528 3 O
73	532 2 O
women	535 5 O
)	540 1 O
with	542 4 O
bipolar	547 7 B-Disease
disorder	555 8 I-Disease
receiving	564 9 O
lithium	574 7 B-Chemical
maintenance	582 11 O
therapy	594 7 O
ranging	602 7 O
from	610 4 O
1	615 1 O
year	617 4 O
'	621 1 O
s	622 1 O
to	624 2 O
32	627 2 O
years	630 5 O
'	635 1 O
duration	637 8 O
.	645 1 O

The	647 3 O
control	651 7 O
group	659 5 O
consisted	665 9 O
of	675 2 O
82	678 2 O
patients	681 8 O
with	690 4 O
no	695 2 O
psychiatric	698 11 B-Disease
or	710 2 O
endocrinological	713 16 O
diagnoses	730 9 O
from	740 4 O
the	745 3 O
hospital	749 8 O
'	757 1 O
s	758 1 O
out	760 3 O
-	763 1 O
patient	764 7 O
clinics	772 7 O
.	779 1 O

OUTCOME	781 7 O
MEASURES	789 8 O
:	797 1 O
Laboratory	799 10 O
analyses	810 8 O
of	819 2 O
calcium	822 7 B-Chemical
,	829 1 O
magnesium	831 9 B-Chemical
and	841 3 O
thyroid	845 7 O
-	852 1 O
stimulating	853 11 O
hormone	865 7 O
levels	873 6 O
performed	880 9 O
before	890 6 O
beginning	897 9 O
lithium	907 7 B-Chemical
therapy	915 7 O
and	923 3 O
at	927 2 O
biannual	930 8 O
follow	939 6 O
-	945 1 O
up	946 2 O
.	948 1 O

RESULTS	950 7 O
:	957 1 O
Hypothyroidism	959 14 B-Disease
developed	974 9 O
in	984 2 O
40	987 2 O
patients	990 8 O
,	998 1 O
excluding	1000 9 O
8	1010 1 O
patients	1012 8 O
who	1021 3 O
were	1025 4 O
hypothyroid	1030 11 B-Disease
at	1042 2 O
baseline	1045 8 O
.	1053 1 O

All	1055 3 O
patients	1059 8 O
having	1068 6 O
first	1075 5 O
-	1080 1 O
degree	1081 6 O
relatives	1088 9 O
affected	1098 8 O
by	1107 2 O
thyroid	1110 7 B-Disease
illness	1118 7 I-Disease
had	1126 3 O
accelerated	1130 11 O
onset	1142 5 O
of	1148 2 O
hypothyroidism	1151 14 B-Disease
(	1166 1 O
3	1167 1 O
.	1168 1 O
7	1169 1 O
years	1171 5 O
after	1177 5 O
onset	1183 5 O
of	1189 2 O
lithium	1192 7 B-Chemical
therapy	1200 7 O
)	1207 1 O
compared	1209 8 O
with	1218 4 O
patients	1223 8 O
without	1232 7 O
a	1240 1 O
family	1242 6 O
history	1249 7 O
(	1257 1 O
8	1258 1 O
.	1259 1 O
6	1260 1 O
years	1262 5 O
after	1268 5 O
onset	1274 5 O
of	1280 2 O
lithium	1283 7 B-Chemical
therapy	1291 7 O
)	1298 1 O
.	1299 1 O

Women	1301 5 O
over	1307 4 O
60	1312 2 O
years	1315 5 O
of	1321 2 O
age	1324 3 O
were	1328 4 O
more	1333 4 O
often	1338 5 O
affected	1344 8 O
by	1353 2 O
hypothyroidism	1356 14 B-Disease
than	1371 4 O
women	1376 5 O
under	1382 5 O
60	1388 2 O
years	1391 5 O
of	1397 2 O
age	1400 3 O
(	1404 1 O
34	1405 2 O
.	1407 1 O
6	1408 1 O
%	1409 1 O
versus	1411 6 O
31	1418 2 O
.	1420 1 O
9	1421 1 O
%	1422 1 O
)	1423 1 O
.	1424 1 O

Magnesium	1426 9 B-Chemical
levels	1436 6 O
in	1443 2 O
patients	1446 8 O
on	1455 2 O
lithium	1458 7 B-Chemical
treatment	1466 9 O
were	1476 4 O
unchanged	1481 9 O
from	1491 4 O
baseline	1496 8 O
levels	1505 6 O
.	1511 1 O

After	1513 5 O
lithium	1519 7 B-Chemical
treatment	1527 9 O
,	1536 1 O
calcium	1538 7 B-Chemical
levels	1546 6 O
were	1553 4 O
higher	1558 6 O
than	1565 4 O
either	1570 6 O
baseline	1577 8 O
levels	1586 6 O
or	1593 2 O
control	1596 7 O
levels	1604 6 O
.	1610 1 O

Thus	1612 4 O
,	1616 1 O
lithium	1618 7 B-Chemical
treatment	1626 9 O
counteracted	1636 12 O
the	1649 3 O
decrease	1653 8 O
in	1662 2 O
plasma	1665 6 O
calcium	1672 7 B-Chemical
levels	1680 6 O
associated	1687 10 O
with	1698 4 O
aging	1703 5 O
.	1708 1 O

CONCLUSIONS	1710 11 O
:	1721 1 O
Familial	1723 8 O
thyroid	1732 7 B-Disease
illness	1740 7 I-Disease
is	1748 2 O
a	1751 1 O
risk	1753 4 O
factor	1758 6 O
for	1765 3 O
hypothyroidism	1769 14 B-Disease
and	1784 3 O
hypercalcemia	1788 13 B-Disease
during	1802 6 O
lithium	1809 7 B-Chemical
therapy	1817 7 O
.	1824 1 O

Systemic	0 8 O
toxicity	9 8 B-Disease
following	18 9 O
administration	28 14 O
of	43 2 O
sirolimus	46 9 B-Chemical
(	56 1 O
formerly	57 8 O
rapamycin	66 9 B-Chemical
)	75 1 O
for	77 3 O
psoriasis	81 9 B-Disease
:	90 1 O
association	92 11 O
of	104 2 O
capillary	107 9 B-Disease
leak	117 4 I-Disease
syndrome	122 8 I-Disease
with	131 4 O
apoptosis	136 9 O
of	146 2 O
lesional	149 8 O
lymphocytes	158 11 O
.	169 1 O

BACKGROUND	171 10 O
:	181 1 O
Sirolimus	183 9 B-Chemical
(	193 1 O
formerly	194 8 O
rapamycin	203 9 B-Chemical
)	212 1 O
is	214 2 O
an	217 2 O
immunosuppressive	220 17 O
agent	238 5 O
that	244 4 O
interferes	249 10 O
with	260 4 O
T	265 1 O
-	266 1 O
cell	267 4 O
activation	272 10 O
.	282 1 O

After	284 5 O
2	290 1 O
individuals	292 11 O
with	304 4 O
psoriasis	309 9 B-Disease
developed	319 9 O
a	329 1 O
capillary	331 9 B-Disease
leak	341 4 I-Disease
syndrome	346 8 I-Disease
following	355 9 O
treatment	365 9 O
with	375 4 O
oral	380 4 O
sirolimus	385 9 B-Chemical
lesional	395 8 O
skin	404 4 O
cells	409 5 O
and	415 3 O
activated	419 9 O
peripheral	429 10 O
blood	440 5 O
cells	446 5 O
were	452 4 O
analyzed	457 8 O
for	466 3 O
induction	470 9 O
of	480 2 O
apoptosis	483 9 O
.	492 1 O

OBSERVATIONS	494 12 O
:	506 1 O
A	508 1 O
keratome	510 8 O
skin	519 4 O
specimen	524 8 O
from	533 4 O
1	538 1 O
patient	540 7 O
with	548 4 O
sirolimus	553 9 B-Chemical
-	562 1 O
induced	563 7 O
capillary	571 9 B-Disease
leak	581 4 I-Disease
syndrome	586 8 I-Disease
had	595 3 O
a	599 1 O
2	601 1 O
.	602 1 O
3	603 1 O
-	604 1 O
fold	605 4 O
increase	610 8 O
in	619 2 O
percentage	622 10 O
of	633 2 O
apoptotic	636 9 O
cells	646 5 O
(	652 1 O
to	653 2 O
48	656 2 O
%	658 1 O
)	659 1 O
compared	661 8 O
with	670 4 O
an	675 2 O
unaffected	678 10 O
sirolimus	689 9 B-Chemical
-	698 1 O
treated	699 7 O
patient	707 7 O
with	715 4 O
psoriasis	720 9 B-Disease
(	730 1 O
21	731 2 O
%	733 1 O
)	734 1 O
.	735 1 O

Activated	737 9 O
peripheral	747 10 O
blood	758 5 O
T	764 1 O
cells	766 5 O
from	772 4 O
patients	777 8 O
with	786 4 O
psoriasis	791 9 B-Disease
tended	801 6 O
to	808 2 O
exhibit	811 7 O
greater	819 7 O
spontaneous	827 11 O
or	839 2 O
dexamethasone	842 13 B-Chemical
-	855 1 O
induced	856 7 O
apoptosis	864 9 O
than	874 4 O
did	879 3 O
normal	883 6 O
T	890 1 O
cells	892 5 O
,	897 1 O
particularly	899 12 O
in	912 2 O
the	915 3 O
presence	919 8 O
of	928 2 O
sirolimus	931 9 B-Chemical
.	940 1 O

CONCLUSIONS	942 11 O
:	953 1 O
Severe	955 6 O
adverse	962 7 O
effects	970 7 O
of	978 2 O
sirolimus	981 9 B-Chemical
include	991 7 O
fever	999 5 B-Disease
,	1004 1 O
anemia	1006 6 B-Disease
,	1012 1 O
and	1014 3 O
capillary	1018 9 B-Disease
leak	1028 4 I-Disease
syndrome	1033 8 I-Disease
.	1041 1 O

These	1043 5 O
symptoms	1049 8 O
may	1058 3 O
be	1062 2 O
the	1065 3 O
result	1069 6 O
of	1076 2 O
drug	1079 4 O
-	1083 1 O
induced	1084 7 O
apoptosis	1092 9 O
of	1102 2 O
lesional	1105 8 O
leukocytes	1114 10 O
,	1124 1 O
especially	1126 10 O
activated	1137 9 O
T	1147 1 O
lymphocytes	1149 11 O
,	1160 1 O
and	1162 3 O
possibly	1166 8 O
release	1175 7 O
of	1183 2 O
inflammatory	1186 12 O
mediators	1199 9 O
.	1208 1 O

Because	1210 7 O
patients	1218 8 O
with	1227 4 O
severe	1232 6 O
psoriasis	1239 9 B-Disease
may	1249 3 O
develop	1253 7 O
capillary	1261 9 B-Disease
leak	1271 4 I-Disease
from	1276 4 O
various	1281 7 O
systemic	1289 8 O
therapies	1298 9 O
,	1307 1 O
clinical	1309 8 O
monitoring	1318 10 O
is	1329 2 O
advisable	1332 9 O
for	1342 3 O
patients	1346 8 O
with	1355 4 O
inflammatory	1360 12 B-Disease
diseases	1373 8 I-Disease
who	1382 3 O
are	1386 3 O
treated	1390 7 O
with	1398 4 O
immune	1403 6 O
modulators	1410 10 O
.	1420 1 O

Contribution	0 12 O
of	13 2 O
the	16 3 O
glycine	20 7 B-Chemical
site	28 4 O
of	33 2 O
NMDA	36 4 B-Chemical
receptors	41 9 O
in	51 2 O
rostral	54 7 O
and	62 3 O
intermediate	66 12 O
-	78 1 O
caudal	79 6 O
parts	86 5 O
of	92 2 O
the	95 3 O
striatum	99 8 O
to	108 2 O
the	111 3 O
regulation	115 10 O
of	126 2 O
muscle	129 6 O
tone	136 4 O
in	141 2 O
rats	144 4 O
.	148 1 O

The	150 3 O
aim	154 3 O
of	158 2 O
the	161 3 O
present	165 7 O
study	173 5 O
was	179 3 O
to	183 2 O
assess	186 6 O
the	193 3 O
contribution	197 12 O
of	210 2 O
the	213 3 O
glycine	217 7 B-Chemical
site	225 4 O
of	230 2 O
NMDA	233 4 B-Chemical
receptors	238 9 O
in	248 2 O
the	251 3 O
striatum	255 8 O
to	264 2 O
the	267 3 O
regulation	271 10 O
of	282 2 O
muscle	285 6 O
tone	292 4 O
.	296 1 O

Muscle	298 6 O
tone	305 4 O
was	310 3 O
examined	314 8 O
using	323 5 O
a	329 1 O
combined	331 8 O
mechanoand	340 10 O
electromyographic	351 17 O
method	369 6 O
,	375 1 O
which	377 5 O
measured	383 8 O
simultaneously	392 14 O
the	407 3 O
muscle	411 6 O
resistance	418 10 O
(	429 1 O
MMG	430 3 O
)	433 1 O
of	435 2 O
the	438 3 O
rat	442 3 O
'	445 1 O
s	446 1 O
hind	448 4 O
foot	453 4 O
to	458 2 O
passive	461 7 O
extension	469 9 O
and	479 3 O
flexion	483 7 O
in	491 2 O
the	494 3 O
ankle	498 5 O
joint	504 5 O
and	510 3 O
the	514 3 O
electromyographic	518 17 O
activity	536 8 O
(	545 1 O
EMG	546 3 O
)	549 1 O
of	551 2 O
the	554 3 O
antagonistic	558 12 O
muscles	571 7 O
of	579 2 O
that	582 4 O
joint	587 5 O
:	592 1 O
gastrocnemius	594 13 O
and	608 3 O
tibialis	612 8 O
anterior	621 8 O
.	629 1 O

Muscle	631 6 B-Disease
rigidity	638 8 I-Disease
was	647 3 O
induced	651 7 O
by	659 2 O
haloperidol	662 11 B-Chemical
(	674 1 O
2	675 1 O
.	676 1 O
5	677 1 O
mg	679 2 O
/	681 1 O
kg	682 2 O
i	685 1 O
.	686 1 O
p	687 1 O
.	688 1 O
)	689 1 O
.	690 1 O

5	692 1 B-Chemical
,	693 1 I-Chemical
7	694 1 I-Chemical
-	695 1 I-Chemical
dichlorokynurenic	696 17 I-Chemical
acid	714 4 I-Chemical
(	719 1 O
5	720 1 B-Chemical
,	721 1 I-Chemical
7	722 1 I-Chemical
-	723 1 I-Chemical
DCKA	724 4 I-Chemical
)	728 1 O
,	729 1 O
a	731 1 O
selective	733 9 O
glycine	743 7 B-Chemical
site	751 4 O
antagonist	756 10 O
,	766 1 O
injected	768 8 O
in	777 2 O
doses	780 5 O
of	786 2 O
2	789 1 O
.	790 1 O
5	791 1 O
and	793 3 O
4	797 1 O
.	798 1 O
5	799 1 O
microg	801 6 O
/	807 1 O
0	808 1 O
.	809 1 O
5	810 1 O
microl	812 6 O
bilaterally	819 11 O
,	830 1 O
into	832 4 O
the	837 3 O
rostral	841 7 O
region	849 6 O
of	856 2 O
the	859 3 O
striatum	863 8 O
,	871 1 O
decreased	873 9 O
both	883 4 O
the	888 3 O
haloperidol	892 11 B-Chemical
-	903 1 O
induced	904 7 O
muscle	912 6 B-Disease
rigidity	919 8 I-Disease
(	928 1 O
MMG	929 3 O
)	932 1 O
and	934 3 O
the	938 3 O
enhanced	942 8 O
electromyographic	951 17 O
activity	969 8 O
(	978 1 O
EMG	979 3 O
)	982 1 O
.	983 1 O

5	985 1 B-Chemical
,	986 1 I-Chemical
7	987 1 I-Chemical
-	988 1 I-Chemical
DCKA	989 4 I-Chemical
injected	994 8 O
bilaterally	1003 11 O
in	1015 2 O
a	1018 1 O
dose	1020 4 O
of	1025 2 O
4	1028 1 O
.	1029 1 O
5	1030 1 O
microg	1032 6 O
/	1038 1 O
0	1039 1 O
.	1040 1 O
5	1041 1 O
microl	1043 6 O
into	1050 4 O
the	1055 3 O
intermediate	1059 12 O
-	1071 1 O
caudal	1072 6 O
region	1079 6 O
of	1086 2 O
the	1089 3 O
striatum	1093 8 O
of	1102 2 O
rats	1105 4 O
not	1110 3 O
pretreated	1114 10 O
with	1125 4 O
haloperidol	1130 11 B-Chemical
had	1142 3 O
no	1146 2 O
effect	1149 6 O
on	1156 2 O
the	1159 3 O
muscle	1163 6 O
tone	1170 4 O
.	1174 1 O

The	1176 3 O
present	1180 7 O
results	1188 7 O
suggest	1196 7 O
that	1204 4 O
blockade	1209 8 O
of	1218 2 O
the	1221 3 O
glycine	1225 7 B-Chemical
site	1233 4 O
of	1238 2 O
NMDA	1241 4 B-Chemical
receptors	1246 9 O
in	1256 2 O
the	1259 3 O
rostral	1263 7 O
part	1271 4 O
of	1276 2 O
the	1279 3 O
striatum	1283 8 O
may	1292 3 O
be	1296 2 O
mainly	1299 6 O
responsible	1306 11 O
for	1318 3 O
the	1322 3 O
antiparkinsonian	1326 16 O
action	1343 6 O
of	1350 2 O
this	1353 4 O
drug	1358 4 O
.	1362 1 O

Efficacy	0 8 O
and	9 3 O
tolerability	13 12 O
of	26 2 O
lovastatin	29 10 B-Chemical
in	40 2 O
3390	43 4 O
women	48 5 O
with	54 4 O
moderate	59 8 O
hypercholesterolemia	68 20 B-Disease
.	88 1 O

OBJECTIVE	90 9 O
:	99 1 O
To	101 2 O
evaluate	104 8 O
the	113 3 O
efficacy	117 8 O
and	126 3 O
safety	130 6 O
of	137 2 O
lovastatin	140 10 B-Chemical
in	151 2 O
women	154 5 O
with	160 4 O
moderate	165 8 O
hypercholesterolemia	174 20 B-Disease
.	194 1 O

DESIGN	196 6 O
:	202 1 O
The	204 3 O
Expanded	208 8 O
Clinical	217 8 O
Evaluation	226 10 O
of	237 2 O
Lovastatin	240 10 B-Chemical
(	251 1 O
EXCEL	252 5 O
)	257 1 O
Study	259 5 O
,	264 1 O
a	266 1 O
multicenter	268 11 O
,	279 1 O
double	281 6 O
-	287 1 O
blind	288 5 O
,	293 1 O
diet	295 4 O
-	299 1 O
and	301 3 O
placebo	305 7 O
-	312 1 O
controlled	313 10 O
trial	324 5 O
,	329 1 O
in	331 2 O
which	334 5 O
participants	340 12 O
were	353 4 O
randomly	358 8 O
assigned	367 8 O
to	376 2 O
receive	379 7 O
placebo	387 7 O
or	395 2 O
lovastatin	398 10 B-Chemical
at	409 2 O
doses	412 5 O
of	418 2 O
20	421 2 O
or	424 2 O
40	427 2 O
mg	430 2 O
once	433 4 O
daily	438 5 O
,	443 1 O
or	445 2 O
20	448 2 O
or	451 2 O
40	454 2 O
mg	457 2 O
twice	460 5 O
daily	466 5 O
for	472 3 O
48	476 2 O
weeks	479 5 O
.	484 1 O

SETTING	486 7 O
:	493 1 O
Ambulatory	495 10 O
patients	506 8 O
recruited	515 9 O
by	525 2 O
362	528 3 O
participating	532 13 O
centers	546 7 O
throughout	554 10 O
the	565 3 O
United	569 6 O
States	576 6 O
.	582 1 O

PATIENTS	584 8 O
:	592 1 O
Women	594 5 O
(	600 1 O
n	601 1 O
=	603 1 O
3390	605 4 O
)	609 1 O
from	611 4 O
the	616 3 O
total	620 5 O
cohort	626 6 O
of	633 2 O
8245	636 4 O
volunteers	641 10 O
.	651 1 O

MEASUREMENTS	653 12 O
:	665 1 O
Plasma	667 6 O
total	674 5 O
,	679 1 O
low	681 3 O
-	684 1 O
density	685 7 O
lipoprotein	693 11 O
(	705 1 O
LDL	706 3 O
)	709 1 O
,	710 1 O
and	712 3 O
high	716 4 O
-	720 1 O
density	721 7 O
lipoprotein	729 11 O
(	741 1 O
HDL	742 3 O
)	745 1 O
cholesterol	747 11 B-Chemical
,	758 1 O
and	760 3 O
triglycerides	764 13 B-Chemical
;	777 1 O
and	779 3 O
laboratory	783 10 O
and	794 3 O
clinical	798 8 O
evidence	807 8 O
of	816 2 O
adverse	819 7 O
events	827 6 O
monitored	834 9 O
periodically	844 12 O
throughout	857 10 O
the	868 3 O
study	872 5 O
.	877 1 O

RESULTS	879 7 O
:	886 1 O
Among	888 5 O
women	894 5 O
,	899 1 O
lovastatin	901 10 B-Chemical
(	912 1 O
20	913 2 O
to	916 2 O
80	919 2 O
mg	922 2 O
/	924 1 O
d	925 1 O
)	926 1 O
produced	928 8 O
sustained	937 9 O
(	947 1 O
12	948 2 O
-	950 1 O
to	952 2 O
48	955 2 O
-	957 1 O
week	958 4 O
)	962 1 O
,	963 1 O
dose	965 4 O
-	969 1 O
related	970 7 O
changes	978 7 O
(	986 1 O
P	987 1 O
<	989 1 O
0	991 1 O
.	992 1 O
001	993 3 O
)	996 1 O
:	997 1 O
decreases	999 9 O
in	1009 2 O
LDL	1012 3 O
cholesterol	1016 11 B-Chemical
(	1028 1 O
24	1029 2 O
%	1031 1 O
to	1033 2 O
40	1036 2 O
%	1038 1 O
)	1039 1 O
and	1041 3 O
triglycerides	1045 13 B-Chemical
(	1059 1 O
9	1060 1 O
%	1061 1 O
to	1063 2 O
18	1066 2 O
%	1068 1 O
)	1069 1 O
,	1070 1 O
and	1072 3 O
increases	1076 9 O
in	1086 2 O
HDL	1089 3 O
cholesterol	1093 11 B-Chemical
(	1105 1 O
6	1106 1 O
.	1107 1 O
7	1108 1 O
%	1109 1 O
to	1111 2 O
8	1114 1 O
.	1115 1 O
6	1116 1 O
%	1117 1 O
)	1118 1 O
.	1119 1 O

Depending	1121 9 O
on	1131 2 O
the	1134 3 O
dose	1138 4 O
,	1142 1 O
from	1144 4 O
82	1149 2 O
%	1151 1 O
to	1153 2 O
95	1156 2 O
%	1158 1 O
of	1160 2 O
lovastatin	1163 10 B-Chemical
-	1173 1 O
treated	1174 7 O
women	1182 5 O
achieved	1188 8 O
the	1197 3 O
National	1201 8 O
Cholesterol	1210 11 B-Chemical
Education	1222 9 O
Program	1232 7 O
goal	1240 4 O
of	1245 2 O
LDL	1248 3 O
cholesterol	1252 11 B-Chemical
levels	1264 6 O
less	1271 4 O
than	1276 4 O
4	1281 1 O
.	1282 1 O
14	1283 2 O
mmol	1286 4 O
/	1290 1 O
L	1291 1 O
(	1293 1 O
160	1294 3 O
mg	1298 2 O
/	1300 1 O
dL	1301 2 O
)	1303 1 O
,	1304 1 O
and	1306 3 O
40	1310 2 O
%	1312 1 O
to	1314 2 O
87	1317 2 O
%	1319 1 O
achieved	1321 8 O
the	1330 3 O
goal	1334 4 O
of	1339 2 O
3	1342 1 O
.	1343 1 O
36	1344 2 O
mmol	1347 4 O
/	1351 1 O
L	1352 1 O
(	1354 1 O
130	1355 3 O
mg	1359 2 O
/	1361 1 O
dL	1362 2 O
)	1364 1 O
.	1365 1 O

Successive	1367 10 O
transaminase	1378 12 O
elevations	1391 10 O
greater	1402 7 O
than	1410 4 O
three	1415 5 O
times	1421 5 O
the	1427 3 O
upper	1431 5 O
limit	1437 5 O
of	1443 2 O
normal	1446 6 O
occurred	1453 8 O
in	1462 2 O
0	1465 1 O
.	1466 1 O
1	1467 1 O
%	1468 1 O
of	1470 2 O
women	1473 5 O
and	1479 3 O
were	1483 4 O
dose	1488 4 O
dependent	1493 9 O
above	1503 5 O
the	1509 3 O
20	1513 2 O
-	1515 1 O
mg	1516 2 O
dose	1519 4 O
.	1523 1 O

Myopathy	1525 8 B-Disease
,	1533 1 O
defined	1535 7 O
as	1543 2 O
muscle	1546 6 O
symptoms	1553 8 O
with	1562 4 O
creatine	1567 8 B-Chemical
kinase	1576 6 O
elevations	1583 10 O
greater	1594 7 O
than	1602 4 O
10	1607 2 O
times	1610 5 O
the	1616 3 O
upper	1620 5 O
limit	1626 5 O
of	1632 2 O
normal	1635 6 O
,	1641 1 O
was	1643 3 O
rare	1647 4 O
and	1652 3 O
associated	1656 10 O
with	1667 4 O
the	1672 3 O
highest	1676 7 O
recommended	1684 11 O
daily	1696 5 O
dose	1702 4 O
of	1707 2 O
lovastatin	1710 10 B-Chemical
(	1721 1 O
80	1722 2 O
mg	1725 2 O
)	1727 1 O
.	1728 1 O

Estrogen	1730 8 O
-	1738 1 O
replacement	1739 11 O
therapy	1751 7 O
appeared	1759 8 O
to	1768 2 O
have	1771 4 O
no	1776 2 O
effect	1779 6 O
on	1786 2 O
either	1789 6 O
the	1796 3 O
efficacy	1800 8 O
or	1809 2 O
safety	1812 6 O
profile	1819 7 O
of	1827 2 O
lovastatin	1830 10 B-Chemical
.	1840 1 O

CONCLUSION	1842 10 O
:	1852 1 O
Lovastatin	1854 10 B-Chemical
is	1865 2 O
highly	1868 6 O
effective	1875 9 O
and	1885 3 O
generally	1889 9 O
well	1899 4 O
tolerated	1904 9 O
as	1914 2 O
therapy	1917 7 O
for	1925 3 O
primary	1929 7 O
hypercholesterolemia	1937 20 B-Disease
in	1958 2 O
women	1961 5 O
.	1966 1 O

REM	0 3 B-Disease
sleep	4 5 I-Disease
deprivation	10 11 I-Disease
changes	22 7 O
behavioral	30 10 O
response	41 8 O
to	50 2 O
catecholaminergic	53 17 O
and	71 3 O
serotonergic	75 12 O
receptor	88 8 O
activation	97 10 O
in	108 2 O
rats	111 4 O
.	115 1 O

The	117 3 O
effects	121 7 O
of	129 2 O
REM	132 3 B-Disease
sleep	136 5 I-Disease
deprivation	142 11 I-Disease
(	154 1 O
REMD	155 4 B-Disease
)	159 1 O
on	161 2 O
apomorphine	164 11 B-Chemical
-	175 1 O
induced	176 7 O
aggressiveness	184 14 B-Disease
and	199 3 O
quipazine	203 9 B-Chemical
-	212 1 O
induced	213 7 O
head	221 4 B-Disease
twitches	226 8 I-Disease
in	235 2 O
rats	238 4 O
were	243 4 O
determined	248 10 O
.	258 1 O

Forty	260 5 O
-	265 1 O
eight	266 5 O
hr	272 2 O
of	275 2 O
REMD	278 4 B-Disease
increased	283 9 O
apomorphine	293 11 B-Chemical
-	304 1 O
induced	305 7 O
aggressiveness	313 14 B-Disease
,	327 1 O
and	329 3 O
reduced	333 7 O
(	341 1 O
immediately	342 11 O
after	354 5 O
completing	360 10 O
of	371 2 O
REMD	374 4 B-Disease
)	378 1 O
or	380 2 O
increased	383 9 O
(	393 1 O
96	394 2 O
hr	397 2 O
after	400 5 O
completing	406 10 O
of	417 2 O
REMD	420 4 B-Disease
)	424 1 O
quipazine	426 9 B-Chemical
-	435 1 O
induced	436 7 O
head	444 4 B-Disease
twitches	449 8 I-Disease
.	457 1 O

Results	459 7 O
are	467 3 O
discussed	471 9 O
in	481 2 O
terms	484 5 O
of	490 2 O
similarity	493 10 O
to	504 2 O
pharmacological	507 15 O
effects	523 7 O
of	531 2 O
other	534 5 O
antidepressive	540 14 O
treatments	555 10 O
.	565 1 O

Extrapyramidal	0 14 O
side	15 4 O
effects	20 7 O
and	28 3 O
oral	32 4 O
haloperidol	37 11 B-Chemical
:	48 1 O
an	50 2 O
analysis	53 8 O
of	62 2 O
explanatory	65 11 O
patient	77 7 O
and	85 3 O
treatment	89 9 O
characteristics	99 15 O
.	114 1 O

The	116 3 O
incidence	120 9 O
of	130 2 O
extrapyramidal	133 14 O
side	148 4 O
effects	153 7 O
(	161 1 O
EPS	162 3 O
)	165 1 O
was	167 3 O
evaluated	171 9 O
in	181 2 O
98	184 2 O
patients	187 8 O
treated	196 7 O
with	204 4 O
haloperidol	209 11 B-Chemical
.	220 1 O

The	222 3 O
incidence	226 9 O
of	236 2 O
parkinsonism	239 12 B-Disease
was	252 3 O
higher	256 6 O
at	263 2 O
higher	266 6 O
doses	273 5 O
of	279 2 O
haloperidol	282 11 B-Chemical
and	294 3 O
in	298 2 O
younger	301 7 O
patients	309 8 O
.	317 1 O

Prophylactic	319 12 O
antiparkinsonian	332 16 O
medication	349 10 O
was	360 3 O
effective	364 9 O
in	374 2 O
younger	377 7 O
but	385 3 O
not	389 3 O
in	393 2 O
older	396 5 O
patients	402 8 O
.	410 1 O

However	412 7 O
,	419 1 O
these	421 5 O
medications	427 11 O
were	439 4 O
more	444 4 O
effective	449 9 O
in	459 2 O
both	462 4 O
young	467 5 O
and	473 3 O
old	477 3 O
patients	481 8 O
when	490 4 O
given	495 5 O
after	501 5 O
parkinsonism	507 12 B-Disease
developed	520 9 O
.	529 1 O

Akathisia	531 9 B-Disease
was	541 3 O
controlled	545 10 O
by	556 2 O
the	559 3 O
benzodiazepine	563 14 B-Chemical
lorazepam	578 9 B-Chemical
in	588 2 O
14	591 2 O
out	594 3 O
of	598 2 O
16	601 2 O
patients	604 8 O
,	612 1 O
while	614 5 O
prophylactic	620 12 O
antiparkinsonians	633 17 O
were	651 4 O
ineffective	656 11 O
.	667 1 O

The	669 3 O
present	673 7 O
study	681 5 O
points	687 6 O
to	694 2 O
patient	697 7 O
characteristics	705 15 O
that	721 4 O
may	726 3 O
be	730 2 O
of	733 2 O
significance	736 12 O
in	749 2 O
the	752 3 O
development	756 11 O
of	768 2 O
EPS	771 3 O
due	775 3 O
to	779 2 O
haloperidol	782 11 B-Chemical
.	793 1 O

Hepatic	0 7 B-Disease
veno	8 4 I-Disease
-	12 1 I-Disease
occlusive	13 9 I-Disease
disease	23 7 I-Disease
caused	31 6 O
by	38 2 O
6	41 1 B-Chemical
-	42 1 I-Chemical
thioguanine	43 11 I-Chemical
.	54 1 O

Clinically	56 10 O
reversible	67 10 O
veno	78 4 B-Disease
-	82 1 I-Disease
occlusive	83 9 I-Disease
disease	93 7 I-Disease
of	101 2 I-Disease
the	104 3 I-Disease
liver	108 5 I-Disease
developed	114 9 O
in	124 2 O
a	127 1 O
23	129 2 O
-	131 1 O
year	132 4 O
-	136 1 O
old	137 3 O
man	141 3 O
with	145 4 O
acute	150 5 B-Disease
lymphocytic	156 11 I-Disease
leukemia	168 8 I-Disease
after	177 5 O
10	183 2 O
months	186 6 O
of	193 2 O
maintenance	196 11 O
therapy	208 7 O
with	216 4 O
6	221 1 B-Chemical
-	222 1 I-Chemical
thioguanine	223 11 I-Chemical
.	234 1 O

Serial	236 6 O
liver	243 5 O
biopsies	249 8 O
showed	258 6 O
the	265 3 O
development	269 11 O
and	281 3 O
resolution	285 10 O
of	296 2 O
intense	299 7 O
sinusoidal	307 10 O
engorgement	318 11 O
.	329 1 O

Although	331 8 O
this	340 4 O
disease	345 7 O
was	353 3 O
clinically	357 10 O
reversible	368 10 O
,	378 1 O
some	380 4 O
subintimal	385 10 O
fibrosis	396 8 B-Disease
about	405 5 O
the	411 3 O
terminal	415 8 O
hepatic	424 7 O
veins	432 5 O
persisted	438 9 O
.	447 1 O

This	449 4 O
case	454 4 O
presented	459 9 O
a	469 1 O
unique	471 6 O
opportunity	478 11 O
to	490 2 O
observe	493 7 O
the	501 3 O
histologic	505 10 O
features	516 8 O
of	525 2 O
clinically	528 10 O
reversible	539 10 O
hepatic	550 7 B-Disease
veno	558 4 I-Disease
-	562 1 I-Disease
occlusive	563 9 I-Disease
disease	573 7 I-Disease
over	581 4 O
time	586 4 O
,	590 1 O
and	592 3 O
may	596 3 O
be	600 2 O
the	603 3 O
first	607 5 O
case	613 4 O
of	618 2 O
veno	621 4 O
-	625 1 O
occlusive	626 9 O
related	636 7 O
solely	644 6 O
to	651 2 O
6	654 1 B-Chemical
-	655 1 I-Chemical
thioguanine	656 11 I-Chemical
.	667 1 O

Treatment	0 9 O
of	10 2 O
ifosfamide	13 10 B-Chemical
-	23 1 O
induced	24 7 O
urothelial	32 10 B-Disease
toxicity	43 8 I-Disease
by	52 2 O
oral	55 4 O
administration	60 14 O
of	75 2 O
sodium	78 6 B-Chemical
2	85 1 I-Chemical
-	86 1 I-Chemical
mercaptoethane	87 14 I-Chemical
sulphonate	102 10 I-Chemical
(	113 1 O
MESNA	114 5 B-Chemical
)	119 1 O
to	121 2 O
patients	124 8 O
with	133 4 O
inoperable	138 10 O
lung	149 4 B-Disease
cancer	154 6 I-Disease
.	160 1 O

The	162 3 O
protective	166 10 O
effect	177 6 O
of	184 2 O
oral	187 4 O
administration	192 14 O
of	207 2 O
the	210 3 O
thiol	214 5 B-Chemical
compound	220 8 O
sodium	229 6 B-Chemical
2	236 1 I-Chemical
-	237 1 I-Chemical
mercaptoethane	238 14 I-Chemical
sulphonate	253 10 I-Chemical
(	264 1 O
MESNA	265 5 B-Chemical
)	270 1 O
against	272 7 O
urothelial	280 10 B-Disease
toxicity	291 8 I-Disease
induced	300 7 O
by	308 2 O
ifosfamide	311 10 B-Chemical
(	322 1 O
IF	323 2 B-Chemical
)	325 1 O
was	327 3 O
tested	331 6 O
in	338 2 O
a	341 1 O
group	343 5 O
of	349 2 O
45	352 2 O
patients	355 8 O
with	364 4 O
inoperable	369 10 O
lung	380 4 B-Disease
cancer	385 6 I-Disease
under	392 5 O
treatment	398 9 O
with	408 4 O
IF	413 2 B-Chemical
(	416 1 O
2250	417 4 O
mg	422 2 O
/	424 1 O
m2	425 2 O
on	428 2 O
days	431 4 O
2	436 1 O
-	437 1 O
5	438 1 O
)	439 1 O
as	441 2 O
part	444 4 O
of	449 2 O
a	452 1 O
polychemotherapy	454 16 O
regimen	471 7 O
repeated	479 8 O
in	488 2 O
a	491 1 O
4	493 1 O
-	494 1 O
week	495 4 O
cycle	500 5 O
.	505 1 O

MESNA	507 5 B-Chemical
was	513 3 O
given	517 5 O
orally	523 6 O
on	530 2 O
the	533 3 O
days	537 4 O
of	542 2 O
treatment	545 9 O
with	555 4 O
IF	560 2 B-Chemical
in	563 2 O
3	566 1 O
doses	568 5 O
of	574 2 O
840	577 3 O
mg	581 2 O
/	583 1 O
m2	584 2 O
,	586 1 O
each	588 4 O
administered	593 12 O
at	606 2 O
0	609 1 O
hr	611 2 O
(	614 1 O
=	615 1 O
injection	617 9 O
of	627 2 O
IF	630 2 B-Chemical
)	632 1 O
,	633 1 O
4	635 1 O
hr	637 2 O
and	640 3 O
8	644 1 O
hr	646 2 O
p	649 1 O
.	650 1 O
i	651 1 O
.	652 1 O

Out	654 3 O
of	658 2 O
a	661 1 O
total	663 5 O
of	669 2 O
88	672 2 O
courses	675 7 O
of	683 2 O
this	686 4 O
treatment	691 9 O
we	701 2 O
observed	704 8 O
10	713 2 O
episodes	716 8 O
of	725 2 O
asymptomatic	728 12 O
microscopic	741 11 O
haematuria	753 10 B-Disease
and	764 3 O
no	768 2 O
episodes	771 8 O
of	780 2 O
gross	783 5 O
haematuria	789 10 B-Disease
.	799 1 O

In	801 2 O
this	804 4 O
group	809 5 O
of	815 2 O
45	818 2 O
patients	821 8 O
under	830 5 O
protection	836 10 O
with	847 4 O
MESNA	852 5 B-Chemical
there	858 5 O
were	864 4 O
5	869 1 O
complete	871 8 O
remissions	880 10 O
and	891 3 O
9	895 1 O
partial	897 7 O
remissions	905 10 O
(	916 1 O
total	917 5 O
31	923 2 O
%	925 1 O
)	926 1 O
.	927 1 O

A	929 1 O
further	931 7 O
group	939 5 O
of	945 2 O
25	948 2 O
patients	951 8 O
under	960 5 O
polychemotherapy	966 16 O
with	983 4 O
IF	988 2 B-Chemical
were	991 4 O
treated	996 7 O
by	1004 2 O
conventional	1007 12 O
prophylactic	1020 12 O
measures	1033 8 O
(	1042 1 O
raised	1043 6 O
fluid	1050 5 O
intake	1056 6 O
and	1063 3 O
forced	1067 6 O
diuresis	1074 8 O
)	1082 1 O
.	1083 1 O

In	1085 2 O
this	1088 4 O
group	1093 5 O
there	1099 5 O
were	1105 4 O
1	1110 1 O
complete	1112 8 O
and	1121 3 O
5	1125 1 O
partial	1127 7 O
remissions	1135 10 O
(	1146 1 O
total	1147 5 O
24	1153 2 O
%	1155 1 O
)	1156 1 O
,	1157 1 O
but	1159 3 O
nearly	1163 6 O
all	1170 3 O
patients	1174 8 O
developed	1183 9 O
either	1193 6 O
gross	1200 5 O
haematuria	1206 10 B-Disease
and	1217 3 O
/	1220 1 O
or	1221 2 O
symptoms	1224 8 O
of	1233 2 O
bladder	1236 7 B-Disease
irritation	1244 10 I-Disease
(	1255 1 O
cystitis	1256 8 B-Disease
and	1265 3 O
pollakisuria	1269 12 B-Disease
)	1281 1 O
.	1282 1 O

There	1284 5 O
were	1290 4 O
no	1295 2 O
appreciable	1298 11 O
differences	1310 11 O
between	1322 7 O
the	1330 3 O
MESNA	1334 5 B-Chemical
series	1340 6 O
and	1347 3 O
the	1351 3 O
conventional	1355 12 O
prophylaxis	1368 11 O
series	1380 6 O
with	1387 4 O
respect	1392 7 O
to	1400 2 O
either	1403 6 O
haematological	1410 14 O
or	1425 2 O
systemic	1428 8 O
toxicity	1437 8 B-Disease
of	1446 2 O
the	1449 3 O
cytostatic	1453 10 O
treatment	1464 9 O
.	1473 1 O

Our	1475 3 O
results	1479 7 O
support	1487 7 O
the	1495 3 O
view	1499 4 O
that	1504 4 O
MESNA	1509 5 B-Chemical
,	1514 1 O
given	1516 5 O
orally	1522 6 O
in	1529 2 O
conjunction	1532 11 O
with	1544 4 O
combined	1549 8 O
cytostatic	1558 10 O
regimens	1569 8 O
which	1578 5 O
include	1584 7 O
IF	1592 2 B-Chemical
,	1594 1 O
simplifies	1596 10 O
the	1607 3 O
treatment	1611 9 O
and	1621 3 O
provides	1625 8 O
optimum	1634 7 O
protection	1642 10 O
for	1653 3 O
the	1657 3 O
urinary	1661 7 O
epithelium	1669 10 O
.	1679 1 O

Protection	1681 10 O
with	1692 4 O
oral	1697 4 O
MESNA	1702 5 B-Chemical
is	1708 2 O
particularly	1711 12 O
suitable	1724 8 O
for	1733 3 O
outpatients	1737 11 O
.	1748 1 O

Time	0 4 O
course	5 6 O
alterations	12 11 O
of	24 2 O
QTC	27 3 O
interval	31 8 O
due	40 3 O
to	44 2 O
hypaque	47 7 B-Chemical
76	55 2 I-Chemical
.	57 1 O

Sequential	59 10 O
measurement	70 11 O
of	82 2 O
QT	85 2 O
interval	88 8 O
during	97 6 O
left	104 4 O
ventricular	109 11 O
angiography	121 11 O
was	133 3 O
made	137 4 O
30	142 2 O
seconds	145 7 O
and	153 3 O
one	157 3 O
,	160 1 O
three	162 5 O
,	167 1 O
five	169 4 O
and	174 3 O
ten	178 3 O
minutes	182 7 O
after	190 5 O
injection	196 9 O
of	206 2 O
hypaque	209 7 B-Chemical
76	217 2 I-Chemical
.	219 1 O

The	221 3 O
subjects	225 8 O
were	234 4 O
ten	239 3 O
patients	243 8 O
found	252 5 O
to	258 2 O
have	261 4 O
normal	266 6 O
left	273 4 O
ventricles	278 10 O
and	289 3 O
coronary	293 8 O
arteries	302 8 O
.	310 1 O

Significant	312 11 O
QTC	324 3 B-Disease
prolongation	328 12 I-Disease
occurred	341 8 O
in	350 2 O
30	353 2 O
seconds	356 7 O
to	364 2 O
one	367 3 O
minute	371 6 O
in	378 2 O
association	381 11 O
with	393 4 O
marked	398 6 O
hypotension	405 11 B-Disease
and	417 3 O
elevation	421 9 O
of	431 2 O
cardiac	434 7 O
output	442 6 O
.	448 1 O

Production	0 10 O
of	11 2 O
autochthonous	14 13 O
prostate	28 8 B-Disease
cancer	37 6 I-Disease
in	44 2 O
Lobund	47 6 O
-	53 1 O
Wistar	54 6 O
rats	61 4 O
by	66 2 O
treatments	69 10 O
with	80 4 O
N	85 1 B-Chemical
-	86 1 I-Chemical
nitroso	87 7 I-Chemical
-	94 1 I-Chemical
N	95 1 I-Chemical
-	96 1 I-Chemical
methylurea	97 10 I-Chemical
and	108 3 O
testosterone	112 12 B-Chemical
.	124 1 O

More	126 4 O
than	131 4 O
50	136 2 O
%	138 1 O
of	140 2 O
Lobund	143 6 O
-	149 1 O
Wistar	150 6 O
(	157 1 O
L	158 1 O
-	159 1 O
W	160 1 O
)	161 1 O
strain	163 6 O
rats	170 4 O
developed	175 9 O
large	185 5 O
,	190 1 O
palpable	192 8 O
prostate	201 8 B-Disease
adenocarcinomas	210 15 I-Disease
(	226 1 O
PAs	227 3 B-Disease
)	230 1 O
following	232 9 O
treatments	242 10 O
with	253 4 O
N	258 1 B-Chemical
-	259 1 I-Chemical
nitroso	260 7 I-Chemical
-	267 1 I-Chemical
N	268 1 I-Chemical
-	269 1 I-Chemical
methylurea	270 10 I-Chemical
(	281 1 O
CAS	282 3 O
:	285 1 O
684	287 3 O
-	290 1 O
93	291 2 O
-	293 1 O
5	294 1 O
)	295 1 O
and	297 3 O
testosterone	301 12 B-Chemical
propionate	314 10 I-Chemical
[	325 1 O
(	326 1 O
TP	327 2 B-Chemical
)	329 1 O
CAS	331 3 O
:	334 1 O
57	336 2 O
-	338 1 O
85	339 2 O
-	341 1 O
2	342 1 O
]	343 1 O
,	344 1 O
and	346 3 O
most	350 4 O
of	355 2 O
the	358 3 O
tumor	362 5 B-Disease
-	367 1 O
bearing	368 7 O
rats	376 4 O
manifested	381 10 O
metastatic	392 10 O
lesions	403 7 O
.	410 1 O

The	412 3 O
incubation	416 10 O
periods	427 7 O
averaged	435 8 O
10	444 2 O
.	446 1 O
6	447 1 O
months	449 6 O
.	455 1 O

Within	457 6 O
the	464 3 O
same	468 4 O
timeframe	473 9 O
,	482 1 O
no	484 2 O
L	487 1 O
-	488 1 O
W	489 1 O
rat	491 3 O
developed	495 9 O
a	505 1 O
similar	507 7 O
palpable	515 8 O
PA	524 2 B-Disease
when	527 4 O
treated	532 7 O
only	540 4 O
with	545 4 O
TP	550 2 B-Chemical
.	552 1 O

In	554 2 O
L	557 1 O
-	558 1 O
W	559 1 O
rats	561 4 O
,	565 1 O
TP	567 2 B-Chemical
acted	570 5 O
as	576 2 O
a	579 1 O
tumor	581 5 B-Disease
enhancement	587 11 O
agent	599 5 O
,	604 1 O
with	606 4 O
primary	611 7 O
emphasis	619 8 O
on	628 2 O
the	631 3 O
development	635 11 O
of	647 2 O
prostate	650 8 B-Disease
cancer	659 6 I-Disease
.	665 1 O

A	0 1 O
dystonia	2 8 B-Disease
-	10 1 O
like	11 4 O
syndrome	16 8 O
after	25 5 O
neuropeptide	31 12 O
(	44 1 O
MSH	45 3 B-Chemical
/	48 1 O
ACTH	49 4 B-Chemical
)	53 1 O
stimulation	55 11 O
of	67 2 O
the	70 3 O
rat	74 3 O
locus	78 5 O
ceruleus	84 8 O
.	92 1 O

The	94 3 O
movement	98 8 B-Disease
disorder	107 8 I-Disease
investigated	116 12 O
in	129 2 O
these	132 5 O
studies	138 7 O
has	146 3 O
some	150 4 O
features	155 8 O
in	164 2 O
common	167 6 O
with	174 4 O
human	179 5 O
idiopathic	185 10 O
dystonia	196 8 B-Disease
,	204 1 O
and	206 3 O
information	210 11 O
obtained	222 8 O
in	231 2 O
these	234 5 O
studies	240 7 O
may	248 3 O
be	252 2 O
of	255 2 O
potential	258 9 O
clinical	268 8 O
benefit	277 7 O
.	284 1 O

The	286 3 O
present	290 7 O
experimental	298 12 O
results	311 7 O
indicated	319 9 O
that	329 4 O
peptidergic	334 11 O
stimulation	346 11 O
of	358 2 O
the	361 3 O
LC	365 2 O
resulted	368 8 O
in	377 2 O
a	380 1 O
NE	382 2 O
-	384 1 O
mediated	385 8 O
inhibition	394 10 O
of	405 2 O
cerebellar	408 10 O
Purkinje	419 8 O
cells	428 5 O
located	434 7 O
at	442 2 O
terminals	445 9 O
of	455 2 O
the	458 3 O
ceruleo	462 7 O
-	469 1 O
cerebellar	470 10 O
pathway	481 7 O
.	488 1 O

However	490 7 O
,	497 1 O
it	499 2 O
is	502 2 O
not	505 3 O
certain	509 7 O
as	517 2 O
to	520 2 O
the	523 3 O
following	527 9 O
:	536 1 O
(	538 1 O
a	539 1 O
)	540 1 O
what	542 4 O
receptors	547 9 O
were	557 4 O
stimulated	562 10 O
by	573 2 O
the	576 3 O
ACTH	580 4 B-Chemical
N	585 1 O
-	586 1 O
terminal	587 8 O
fragments	596 9 O
at	606 2 O
the	609 3 O
LC	613 2 O
that	616 4 O
resulted	621 8 O
in	630 2 O
this	633 4 O
disorder	638 8 O
;	646 1 O
(	648 1 O
b	649 1 O
)	650 1 O
whether	652 7 O
NE	660 2 O
,	662 1 O
released	664 8 O
onto	673 4 O
Purkinje	678 8 O
cell	687 4 O
synapses	692 8 O
located	701 7 O
at	709 2 O
terminals	712 9 O
of	722 2 O
the	725 3 O
ceruleo	729 7 O
-	736 1 O
cerebellar	737 10 O
pathway	748 7 O
,	755 1 O
did	757 3 O
indeed	761 6 O
cause	768 5 O
the	774 3 O
long	778 4 O
-	782 1 O
term	783 4 O
depression	788 10 B-Disease
at	799 2 O
Purkinje	802 8 O
cell	811 4 O
synapses	816 8 O
(	825 1 O
previously	826 10 O
described	837 9 O
by	847 2 O
others	850 6 O
)	856 1 O
that	858 4 O
resulted	863 8 O
in	872 2 O
the	875 3 O
long	879 4 O
duration	884 8 O
of	893 2 O
the	896 3 O
movement	900 8 B-Disease
disorder	909 8 I-Disease
;	917 1 O
(	919 1 O
c	920 1 O
)	921 1 O
whether	923 7 O
the	931 3 O
inhibition	935 10 O
of	946 2 O
inhibitory	949 10 O
Purkinje	960 8 O
cells	969 5 O
resulted	975 8 O
in	984 2 O
disinhibition	987 13 O
or	1001 2 O
increased	1004 9 O
excitability	1014 12 O
of	1027 2 O
the	1030 3 O
unilateral	1034 10 O
cerebellar	1045 10 O
fastigial	1056 9 O
or	1066 2 O
interpositus	1069 12 O
nuclei	1082 6 O
,	1088 1 O
the	1090 3 O
output	1094 6 O
targets	1101 7 O
of	1109 2 O
the	1112 3 O
Purkinje	1116 8 O
cell	1125 4 O
axons	1130 5 O
,	1135 1 O
that	1137 4 O
may	1142 3 O
have	1146 4 O
been	1151 4 O
an	1156 2 O
important	1159 9 O
contributing	1169 12 O
factor	1182 6 O
to	1189 2 O
this	1192 4 O
disorder	1197 8 O
.	1205 1 O

These	1207 5 O
questions	1213 9 O
are	1223 3 O
currently	1227 9 O
being	1237 5 O
investigated	1243 12 O
.	1255 1 O

Dexmedetomidine	0 15 B-Chemical
,	15 1 O
acting	17 6 O
through	24 7 O
central	32 7 O
alpha	40 5 O
-	45 1 O
2	46 1 O
adrenoceptors	48 13 O
,	61 1 O
prevents	63 8 O
opiate	72 6 O
-	78 1 O
induced	79 7 O
muscle	87 6 B-Disease
rigidity	94 8 I-Disease
in	103 2 O
the	106 3 O
rat	110 3 O
.	113 1 O

The	115 3 O
highly	119 6 O
-	125 1 O
selective	126 9 O
alpha	136 5 O
-	141 1 O
2	142 1 O
adrenergic	144 10 O
agonist	155 7 O
dexmedetomidine	163 15 B-Chemical
(	179 1 O
D	180 1 B-Chemical
-	181 1 I-Chemical
MED	182 3 I-Chemical
)	185 1 O
is	187 2 O
capable	190 7 O
of	198 2 O
inducing	201 8 O
muscle	210 6 B-Disease
flaccidity	217 10 I-Disease
and	228 3 O
anesthesia	232 10 O
in	243 2 O
rats	246 4 O
and	251 3 O
dogs	255 4 O
.	259 1 O

Intense	261 7 O
generalized	269 11 O
muscle	281 6 B-Disease
rigidity	288 8 I-Disease
is	297 2 O
an	300 2 O
undesirable	303 11 O
side	315 4 O
effect	320 6 O
of	327 2 O
potent	330 6 O
opiate	337 6 O
agonists	344 8 O
.	352 1 O

Although	354 8 O
the	363 3 O
neurochemistry	367 14 O
of	382 2 O
opiate	385 6 O
-	391 1 O
induced	392 7 O
rigidity	400 8 B-Disease
has	409 3 O
yet	413 3 O
to	417 2 O
be	420 2 O
fully	423 5 O
elucidated	429 10 O
,	439 1 O
recent	441 6 O
work	448 4 O
suggests	453 8 O
a	462 1 O
role	464 4 O
for	469 3 O
a	473 1 O
central	475 7 O
adrenergic	483 10 O
mechanism	494 9 O
.	503 1 O

In	505 2 O
the	508 3 O
present	512 7 O
study	520 5 O
,	525 1 O
the	527 3 O
authors	531 7 O
determined	539 10 O
if	550 2 O
treatment	553 9 O
with	563 4 O
D	568 1 B-Chemical
-	569 1 I-Chemical
MED	570 3 I-Chemical
prevents	574 8 O
the	583 3 O
muscle	587 6 B-Disease
rigidity	594 8 I-Disease
caused	603 6 O
by	610 2 O
high	613 4 O
-	617 1 O
dose	618 4 O
alfentanil	623 10 B-Chemical
anesthesia	634 10 O
in	645 2 O
the	648 3 O
rat	652 3 O
.	655 1 O

Animals	657 7 O
(	665 1 O
n	666 1 O
=	668 1 O
42	670 2 O
)	672 1 O
were	674 4 O
treated	679 7 O
intraperitoneally	687 17 O
with	705 4 O
one	710 3 O
of	714 2 O
the	717 3 O
following	721 9 O
six	731 3 O
regimens	735 8 O
:	743 1 O
1	745 1 O
)	746 1 O
L	748 1 O
-	749 1 O
MED	750 3 O
(	754 1 O
the	755 3 O
inactive	759 8 O
L	768 1 O
-	769 1 O
isomer	770 6 O
of	777 2 O
medetomidine	780 12 B-Chemical
)	792 1 O
,	793 1 O
30	795 2 O
micrograms	798 10 O
/	808 1 O
kg	809 2 O
;	811 1 O
2	813 1 O
)	814 1 O
D	816 1 B-Chemical
-	817 1 I-Chemical
MED	818 3 I-Chemical
,	821 1 O
10	823 2 O
micrograms	826 10 O
/	836 1 O
kg	837 2 O
;	839 1 O
3	841 1 O
)	842 1 O
D	844 1 B-Chemical
-	845 1 I-Chemical
MED	846 3 I-Chemical
,	849 1 O
30	851 2 O
micrograms	854 10 O
/	864 1 O
kg	865 2 O
;	867 1 O
4	869 1 O
)	870 1 O
D	872 1 B-Chemical
-	873 1 I-Chemical
MED	874 3 I-Chemical
[	878 1 O
30	879 2 O
micrograms	882 10 O
/	892 1 O
kg	893 2 O
]	895 1 O
and	897 3 O
the	901 3 O
central	905 7 O
-	912 1 O
acting	913 6 O
alpha	920 5 O
-	925 1 O
2	926 1 O
antagonist	928 10 O
,	938 1 O
idazoxan	940 8 B-Chemical
[	949 1 O
10	950 2 O
mg	953 2 O
/	955 1 O
kg	956 2 O
]	958 1 O
;	959 1 O
5	961 1 O
)	962 1 O
D	964 1 B-Chemical
-	965 1 I-Chemical
MED	966 3 I-Chemical
[	970 1 O
30	971 2 O
micrograms	974 10 O
/	984 1 O
kg	985 2 O
]	987 1 O
and	989 3 O
the	993 3 O
peripheral	997 10 O
-	1007 1 O
acting	1008 6 O
alpha	1015 5 O
-	1020 1 O
2	1021 1 O
antagonist	1023 10 O
DG	1034 2 B-Chemical
-	1036 1 I-Chemical
5128	1037 4 I-Chemical
[	1042 1 O
10	1043 2 O
mg	1046 2 O
/	1048 1 O
kg	1049 2 O
]	1051 1 O
,	1052 1 O
or	1054 2 O
;	1056 1 O
6	1058 1 O
)	1059 1 O
saline	1061 6 O
.	1067 1 O

Baseline	1069 8 O
electromyographic	1078 17 O
activity	1096 8 O
was	1105 3 O
recorded	1109 8 O
from	1118 4 O
the	1123 3 O
gastrocnemius	1127 13 O
muscle	1141 6 O
before	1148 6 O
and	1155 3 O
after	1159 5 O
drug	1165 4 O
treatment	1170 9 O
.	1179 1 O

Each	1181 4 O
rat	1186 3 O
was	1190 3 O
then	1194 4 O
injected	1199 8 O
with	1208 4 O
alfentanil	1213 10 B-Chemical
(	1224 1 O
ALF	1225 3 B-Chemical
,	1228 1 O
0	1230 1 O
.	1231 1 O
5	1232 1 O
mg	1234 2 O
/	1236 1 O
kg	1237 2 O
sc	1240 2 O
)	1242 1 O
.	1243 1 O

ALF	1245 3 B-Chemical
injection	1249 9 O
resulted	1259 8 O
in	1268 2 O
a	1271 1 O
marked	1273 6 O
increase	1280 8 O
in	1289 2 O
hindlimb	1292 8 O
EMG	1301 3 O
activity	1305 8 O
in	1314 2 O
the	1317 3 O
L	1321 1 O
-	1322 1 O
MED	1323 3 O
treatment	1327 9 O
group	1337 5 O
which	1343 5 O
was	1349 3 O
indistinguishable	1353 17 O
from	1371 4 O
that	1376 4 O
seen	1381 4 O
in	1386 2 O
animals	1389 7 O
treated	1397 7 O
with	1405 4 O
saline	1410 6 O
.	1416 1 O

In	1418 2 O
contrast	1421 8 O
,	1429 1 O
D	1431 1 B-Chemical
-	1432 1 I-Chemical
MED	1433 3 I-Chemical
prevented	1437 9 O
alfentanil	1447 10 B-Chemical
-	1457 1 O
induced	1458 7 O
muscle	1466 6 B-Disease
rigidity	1473 8 I-Disease
in	1482 2 O
a	1485 1 O
dose	1487 4 O
-	1491 1 O
dependent	1492 9 O
fashion	1502 7 O
.	1509 1 O

The	1511 3 O
small	1515 5 O
EMG	1521 3 O
values	1525 6 O
obtained	1532 8 O
in	1541 2 O
the	1544 3 O
high	1548 4 O
-	1552 1 O
dose	1553 4 O
D	1558 1 B-Chemical
-	1559 1 I-Chemical
MED	1560 3 I-Chemical
group	1564 5 O
were	1570 4 O
comparable	1575 10 O
with	1586 4 O
those	1591 5 O
recorded	1597 8 O
in	1606 2 O
earlier	1609 7 O
studies	1617 7 O
from	1625 4 O
control	1630 7 O
animals	1638 7 O
not	1646 3 O
given	1650 5 O
any	1656 3 O
opiate	1660 6 O
.	1666 1 O

The	1668 3 O
high	1672 4 O
-	1676 1 O
dose	1677 4 O
D	1682 1 B-Chemical
-	1683 1 I-Chemical
MED	1684 3 I-Chemical
animals	1688 7 O
were	1696 4 O
flaccid	1701 7 O
,	1708 1 O
akinetic	1710 8 B-Disease
,	1718 1 O
and	1720 3 O
lacked	1724 6 O
a	1731 1 O
startle	1733 7 B-Disease
response	1741 8 O
during	1750 6 O
the	1757 3 O
entire	1761 6 O
experimental	1768 12 O
period	1781 6 O
.	1787 1 O
(	1788 1 O
ABSTRACT	1789 8 O
TRUNCATED	1798 9 O
AT	1808 2 O
250	1811 3 O
WORDS	1815 5 O
)	1820 1 O

Seizure	0 7 B-Disease
activity	8 8 O
with	17 4 O
imipenem	22 8 B-Chemical
therapy	31 7 O
:	38 1 O
incidence	40 9 O
and	50 3 O
risk	54 4 O
factors	59 7 O
.	66 1 O

Two	68 3 O
elderly	72 7 O
patients	80 8 O
with	89 4 O
a	94 1 O
history	96 7 O
of	104 2 O
either	107 6 O
cerebral	114 8 B-Disease
vascular	123 8 I-Disease
accident	132 8 I-Disease
(	141 1 O
CVA	142 3 B-Disease
)	145 1 O
or	147 2 O
head	150 4 B-Disease
trauma	155 6 I-Disease
and	162 3 O
no	166 2 O
evidence	169 8 O
of	178 2 O
renal	181 5 B-Disease
disease	187 7 I-Disease
developed	195 9 O
seizures	205 8 B-Disease
while	214 5 O
receiving	220 9 O
maximum	230 7 O
doses	238 5 O
of	244 2 O
imipenem	247 8 B-Chemical
/	255 1 I-Chemical
cilastatin	256 10 I-Chemical
.	266 1 O

Neither	268 7 O
patient	276 7 O
had	284 3 O
reported	288 8 O
previous	297 8 O
seizures	306 8 B-Disease
or	315 2 O
seizure	318 7 B-Disease
-	325 1 O
like	326 4 O
activity	331 8 O
nor	340 3 O
was	344 3 O
receiving	348 9 O
anticonvulsant	358 14 O
agents	373 6 O
.	379 1 O

All	381 3 O
seizures	385 8 B-Disease
were	394 4 O
controlled	399 10 O
with	410 4 O
therapeutic	415 11 O
doses	427 5 O
of	433 2 O
phenytoin	436 9 B-Chemical
.	445 1 O

Both	447 4 O
patients	452 8 O
had	461 3 O
received	465 8 O
maximum	474 7 O
doses	482 5 O
of	488 2 O
other	491 5 O
beta	497 4 B-Chemical
-	501 1 I-Chemical
lactam	502 6 I-Chemical
antibiotics	509 11 O
without	521 7 O
evidence	529 8 O
of	538 2 O
seizure	541 7 B-Disease
activity	549 8 O
.	557 1 O

The	0 3 O
ability	4 7 O
of	12 2 O
insulin	15 7 O
treatment	23 9 O
to	33 2 O
reverse	36 7 O
or	44 2 O
prevent	47 7 O
the	55 3 O
changes	59 7 O
in	67 2 O
urinary	70 7 O
bladder	78 7 O
function	86 8 O
caused	95 6 O
by	102 2 O
streptozotocin	105 14 B-Chemical
-	119 1 O
induced	120 7 O
diabetes	128 8 B-Disease
mellitus	137 8 I-Disease
.	145 1 O

1	147 1 O
.	148 1 O

The	150 3 O
effects	154 7 O
of	162 2 O
insulin	165 7 O
treatment	173 9 O
on	183 2 O
in	186 2 O
vivo	189 4 O
and	194 3 O
in	198 2 O
vitro	201 5 O
urinary	207 7 O
bladder	215 7 O
function	223 8 O
in	232 2 O
streptozotocin	235 14 B-Chemical
-	249 1 O
diabetic	250 8 B-Disease
rats	259 4 O
were	264 4 O
investigated	269 12 O
.	281 1 O

2	283 1 O
.	284 1 O

Diabetes	286 8 B-Disease
of	295 2 O
2	298 1 O
months	300 6 O
duration	307 8 O
resulted	316 8 O
in	325 2 O
decreases	328 9 O
in	338 2 O
body	341 4 O
weight	346 6 O
and	353 3 O
increases	357 9 O
in	367 2 O
fluid	370 5 O
consumption	376 11 O
,	387 1 O
urine	389 5 O
volume	395 6 O
,	401 1 O
frequency	403 9 O
of	413 2 O
micturition	416 11 O
,	427 1 O
and	429 3 O
average	433 7 O
volume	441 6 O
per	448 3 O
micturition	452 11 O
;	463 1 O
effects	465 7 O
which	473 5 O
were	479 4 O
prevented	484 9 O
by	494 2 O
insulin	497 7 O
treatment	505 9 O
.	514 1 O

3	516 1 O
.	517 1 O

Insulin	519 7 O
treatment	527 9 O
also	537 4 O
prevented	542 9 O
the	552 3 O
increases	556 9 O
in	566 2 O
contractile	569 11 O
responses	581 9 O
of	591 2 O
bladder	594 7 O
body	602 4 O
strips	607 6 O
from	614 4 O
diabetic	619 8 B-Disease
rats	628 4 O
to	633 2 O
nerve	636 5 O
stimulation	642 11 O
,	653 1 O
ATP	655 3 B-Chemical
,	658 1 O
and	660 3 O
bethanechol	664 11 B-Chemical
.	675 1 O

4	677 1 O
.	678 1 O

Diabetes	680 8 B-Disease
of	689 2 O
4	692 1 O
months	694 6 O
duration	701 8 O
also	710 4 O
resulted	715 8 O
in	724 2 O
decreases	727 9 O
in	737 2 O
body	740 4 O
weight	745 6 O
,	751 1 O
and	753 3 O
increases	757 9 O
in	767 2 O
fluid	770 5 O
consumption	776 11 O
,	787 1 O
urine	789 5 O
volume	795 6 O
,	801 1 O
frequency	803 9 O
of	813 2 O
micturition	816 11 O
,	827 1 O
and	829 3 O
average	833 7 O
volume	841 6 O
per	848 3 O
micturition	852 11 O
,	863 1 O
effects	865 7 O
which	873 5 O
were	879 4 O
reversed	884 8 O
by	893 2 O
insulin	896 7 O
treatment	904 9 O
for	914 3 O
the	918 3 O
final	922 5 O
2	928 1 O
months	930 6 O
of	937 2 O
the	940 3 O
study	944 5 O
.	949 1 O

5	951 1 O
.	952 1 O

Insulin	954 7 O
treatment	962 9 O
reversed	972 8 O
the	981 3 O
increases	985 9 O
in	995 2 O
contractile	998 11 O
responses	1010 9 O
of	1020 2 O
bladder	1023 7 O
body	1031 4 O
strips	1036 6 O
from	1043 4 O
diabetic	1048 8 B-Disease
rats	1057 4 O
to	1062 2 O
nerve	1065 5 O
stimulation	1071 11 O
,	1082 1 O
ATP	1084 3 B-Chemical
,	1087 1 O
and	1089 3 O
bethanechol	1093 11 B-Chemical
.	1104 1 O

6	1106 1 O
.	1107 1 O

The	1109 3 O
data	1113 4 O
indicate	1118 8 O
that	1127 4 O
the	1132 3 O
effects	1136 7 O
of	1144 2 O
streptozotocin	1147 14 B-Chemical
-	1161 1 O
induced	1162 7 O
diabetes	1170 8 B-Disease
on	1179 2 O
urinary	1182 7 O
bladder	1190 7 O
function	1198 8 O
are	1207 3 O
both	1211 4 O
prevented	1216 9 O
and	1226 3 O
reversed	1230 8 O
by	1239 2 O
insulin	1242 7 O
treatment	1250 9 O
.	1259 1 O

Delayed	0 7 O
institution	8 11 O
of	20 2 O
hypertension	23 12 B-Disease
during	36 6 O
focal	43 5 O
cerebral	49 8 B-Disease
ischemia	58 8 I-Disease
:	66 1 O
effect	68 6 O
on	75 2 O
brain	78 5 B-Disease
edema	84 5 I-Disease
.	89 1 O

The	91 3 O
effect	95 6 O
of	102 2 O
induced	105 7 O
hypertension	113 12 B-Disease
instituted	126 10 O
after	137 5 O
a	143 1 O
2	145 1 O
-	146 1 O
h	147 1 O
delay	149 5 O
following	155 9 O
middle	165 6 B-Disease
cerebral	172 8 I-Disease
artery	181 6 I-Disease
occlusion	188 9 I-Disease
(	198 1 O
MCAO	199 4 B-Disease
)	203 1 O
on	205 2 O
brain	208 5 B-Disease
edema	214 5 I-Disease
formation	220 9 O
and	230 3 O
histochemical	234 13 O
injury	248 6 O
was	255 3 O
studied	259 7 O
.	266 1 O

Under	268 5 O
isoflurane	274 10 B-Chemical
anesthesia	285 10 O
,	295 1 O
the	297 3 O
MCA	301 3 O
of	305 2 O
14	308 2 O
spontaneously	311 13 O
hypertensive	325 12 B-Disease
rats	338 4 O
was	343 3 O
occluded	347 8 O
.	355 1 O

In	357 2 O
the	360 3 O
control	364 7 O
group	372 5 O
(	378 1 O
n	379 1 O
=	381 1 O
7	383 1 O
)	384 1 O
,	385 1 O
the	387 3 O
mean	391 4 O
arterial	396 8 O
pressure	405 8 O
(	414 1 O
MAP	415 3 O
)	418 1 O
was	420 3 O
not	424 3 O
manipulated	428 11 O
.	439 1 O

In	441 2 O
the	444 3 O
hypertensive	448 12 B-Disease
group	461 5 O
(	467 1 O
n	468 1 O
=	470 1 O
7	472 1 O
)	473 1 O
,	474 1 O
the	476 3 O
MAP	480 3 O
was	484 3 O
elevated	488 8 O
by	497 2 O
25	500 2 O
-	502 1 O
30	503 2 O
mm	506 2 O
Hg	509 2 O
beginning	512 9 O
2	522 1 O
h	524 1 O
after	526 5 O
MCAO	532 4 B-Disease
.	536 1 O

Four	538 4 O
hours	543 5 O
after	549 5 O
MCAO	555 4 B-Disease
,	559 1 O
the	561 3 O
rats	565 4 O
were	570 4 O
killed	575 6 O
and	582 3 O
the	586 3 O
brains	590 6 O
harvested	597 9 O
.	606 1 O

The	608 3 O
brains	612 6 O
were	619 4 O
sectioned	624 9 O
along	634 5 O
coronal	640 7 O
planes	648 6 O
spanning	655 8 O
the	664 3 O
distribution	668 12 O
of	681 2 O
ischemia	684 8 B-Disease
produced	693 8 O
by	702 2 O
MCAO	705 4 B-Disease
.	709 1 O

Specific	711 8 O
gravity	720 7 O
(	728 1 O
SG	729 2 O
)	731 1 O
was	733 3 O
determined	737 10 O
in	748 2 O
the	751 3 O
subcortex	755 9 O
and	765 3 O
in	769 2 O
two	772 3 O
sites	776 5 O
in	782 2 O
the	785 3 O
cortex	789 6 O
(	796 1 O
core	797 4 O
and	802 3 O
periphery	806 9 O
of	816 2 O
the	819 3 O
ischemic	823 8 B-Disease
territory	832 9 O
)	841 1 O
.	842 1 O

The	844 3 O
extent	848 6 O
of	855 2 O
neuronal	858 8 B-Disease
injury	867 6 I-Disease
was	874 3 O
determined	878 10 O
by	889 2 O
2	892 1 B-Chemical
,	893 1 I-Chemical
3	894 1 I-Chemical
,	895 1 I-Chemical
5	896 1 I-Chemical
-	897 1 I-Chemical
triphenyltetrazolium	898 20 I-Chemical
staining	919 8 O
.	927 1 O

In	929 2 O
the	932 3 O
ischemic	936 8 B-Disease
core	945 4 O
,	949 1 O
there	951 5 O
was	957 3 O
no	961 2 O
difference	964 10 O
in	975 2 O
SG	978 2 O
in	981 2 O
the	984 3 O
subcortex	988 9 O
and	998 3 O
cortex	1002 6 O
in	1009 2 O
the	1012 3 O
two	1016 3 O
groups	1020 6 O
.	1026 1 O

In	1028 2 O
the	1031 3 O
periphery	1035 9 O
of	1045 2 O
the	1048 3 O
ischemic	1052 8 B-Disease
territory	1061 9 O
,	1070 1 O
SG	1072 2 O
in	1075 2 O
the	1078 3 O
cortex	1082 6 O
was	1089 3 O
greater	1093 7 O
(	1101 1 O
less	1102 4 O
edema	1107 5 B-Disease
accumulation	1113 12 O
)	1125 1 O
in	1127 2 O
the	1130 3 O
hypertensive	1134 12 B-Disease
group	1147 5 O
(	1153 1 O
1	1154 1 O
.	1155 1 O
041	1156 3 O
+	1160 1 O
/	1161 1 O
-	1162 1 O
0	1164 1 O
.	1165 1 O
001	1166 3 O
vs	1170 2 O
1	1173 1 O
.	1174 1 O
039	1175 3 O
+	1179 1 O
/	1180 1 O
-	1181 1 O
0	1183 1 O
.	1184 1 O
001	1185 3 O
,	1188 1 O
P	1190 1 O
less	1192 4 O
than	1197 4 O
0	1202 1 O
.	1203 1 O
05	1204 2 O
)	1206 1 O
.	1207 1 O

The	1209 3 O
area	1213 4 O
of	1218 2 O
histochemical	1221 13 O
injury	1235 6 O
(	1242 1 O
as	1243 2 O
a	1246 1 O
percent	1248 7 O
of	1256 2 O
the	1259 3 O
cross	1263 5 O
-	1268 1 O
sectional	1269 9 O
area	1279 4 O
of	1284 2 O
the	1287 3 O
hemisphere	1291 10 O
)	1301 1 O
was	1303 3 O
less	1307 4 O
in	1312 2 O
the	1315 3 O
hypertensive	1319 12 B-Disease
group	1332 5 O
(	1338 1 O
33	1339 2 O
+	1342 1 O
/	1343 1 O
-	1344 1 O
3	1346 1 O
%	1347 1 O
vs	1349 2 O
21	1352 2 O
+	1355 1 O
/	1356 1 O
-	1357 1 O
2	1359 1 O
%	1360 1 O
,	1361 1 O
P	1363 1 O
less	1365 4 O
than	1370 4 O
0	1375 1 O
.	1376 1 O
05	1377 2 O
)	1379 1 O
.	1380 1 O

The	1382 3 O
data	1386 4 O
indicate	1391 8 O
that	1400 4 O
phenylephrine	1405 13 B-Chemical
-	1418 1 O
induced	1419 7 O
hypertension	1427 12 B-Disease
instituted	1440 10 O
2	1451 1 O
h	1453 1 O
after	1455 5 O
MCAO	1461 4 B-Disease
does	1466 4 O
not	1471 3 O
aggravate	1475 9 O
edema	1485 5 B-Disease
in	1491 2 O
the	1494 3 O
ischemic	1498 8 B-Disease
core	1507 4 O
,	1511 1 O
that	1513 4 O
it	1518 2 O
improves	1521 8 O
edema	1530 5 B-Disease
in	1536 2 O
the	1539 3 O
periphery	1543 9 O
of	1553 2 O
the	1556 3 O
ischemic	1560 8 B-Disease
territory	1569 9 O
,	1578 1 O
and	1580 3 O
that	1584 4 O
it	1589 2 O
reduces	1592 7 O
the	1600 3 O
area	1604 4 O
of	1609 2 O
histochemical	1612 13 O
neuronal	1626 8 B-Disease
dysfunction	1635 11 I-Disease
.	1646 1 O

Amiodarone	0 10 B-Chemical
pulmonary	11 9 B-Disease
toxicity	21 8 I-Disease
.	29 1 O

Amiodarone	31 10 B-Chemical
is	42 2 O
an	45 2 O
effective	48 9 O
antiarrhythmic	58 14 O
agent	73 5 O
whose	79 5 O
utility	85 7 O
is	93 2 O
limited	96 7 O
by	104 2 O
many	107 4 O
side	112 4 O
-	116 1 O
effects	117 7 O
,	124 1 O
the	126 3 O
most	130 4 O
problematic	135 11 O
being	147 5 O
pneumonitis	153 11 B-Disease
.	164 1 O

The	166 3 O
pulmonary	170 9 B-Disease
toxicity	180 8 I-Disease
of	189 2 O
amiodarone	192 10 B-Chemical
is	203 2 O
thought	206 7 O
to	214 2 O
result	217 6 O
from	224 4 O
direct	229 6 O
injury	236 6 O
related	243 7 O
to	251 2 O
the	254 3 O
intracellular	258 13 O
accumulation	272 12 O
of	285 2 O
phospholipid	288 12 O
and	301 3 O
T	305 1 O
cell	307 4 O
-	311 1 O
mediated	312 8 O
hypersensitivity	321 16 B-Disease
pneumonitis	338 11 I-Disease
.	349 1 O

The	351 3 O
clinical	355 8 O
and	364 3 O
radiographic	368 12 O
features	381 8 O
of	390 2 O
amiodarone	393 10 B-Chemical
-	403 1 O
induced	404 7 O
pulmonary	412 9 B-Disease
toxicity	422 8 I-Disease
are	431 3 O
characteristic	435 14 O
but	450 3 O
nonspecific	454 11 O
.	465 1 O

The	467 3 O
diagnosis	471 9 O
depends	481 7 O
on	489 2 O
exclusion	492 9 O
of	502 2 O
other	505 5 O
entities	511 8 O
,	519 1 O
such	521 4 O
as	526 2 O
heart	529 5 B-Disease
failure	535 7 I-Disease
,	542 1 O
infection	544 9 B-Disease
,	553 1 O
and	555 3 O
malignancy	559 10 B-Disease
.	569 1 O

While	571 5 O
withdrawal	577 10 O
of	588 2 O
amiodarone	591 10 B-Chemical
leads	602 5 O
to	608 2 O
clinical	611 8 O
improvement	620 11 O
in	632 2 O
majority	635 8 O
of	644 2 O
cases	647 5 O
,	652 1 O
this	654 4 O
is	659 2 O
not	662 3 O
always	666 6 O
possible	673 8 O
or	682 2 O
advisable	685 9 O
.	694 1 O

Dose	696 4 O
reduction	701 9 O
or	711 2 O
concomitant	714 11 O
steroid	726 7 B-Chemical
therapy	734 7 O
may	742 3 O
have	746 4 O
a	751 1 O
role	753 4 O
in	758 2 O
selected	761 8 O
patients	770 8 O
.	778 1 O

Light	0 5 O
chain	6 5 O
proteinuria	12 11 B-Disease
and	24 3 O
cellular	28 8 O
mediated	37 8 O
immunity	46 8 O
in	55 2 O
rifampin	58 8 B-Chemical
treated	67 7 O
patients	75 8 O
with	84 4 O
tuberculosis	89 12 B-Disease
.	101 1 O

Light	103 5 O
chain	109 5 O
proteinuria	115 11 B-Disease
was	127 3 O
found	131 5 O
in	137 2 O
9	140 1 O
of	142 2 O
17	145 2 O
tuberculosis	148 12 B-Disease
patients	161 8 O
treated	170 7 O
with	178 4 O
rifampin	183 8 B-Chemical
.	191 1 O

Concomitant	193 11 O
assay	205 5 O
of	211 2 O
cellular	214 8 O
mediated	223 8 O
immunity	232 8 O
in	241 2 O
these	244 5 O
patients	250 8 O
using	259 5 O
skin	265 4 O
test	270 4 O
antigen	275 7 O
and	283 3 O
a	287 1 O
lymphokine	289 10 O
in	300 2 O
vitro	303 5 O
test	309 4 O
provided	314 8 O
results	323 7 O
that	331 4 O
were	336 4 O
different	341 9 O
.	350 1 O

Response	352 8 O
to	361 2 O
Varidase	364 8 O
skin	373 4 O
test	378 4 O
antigen	383 7 O
was	391 3 O
negative	395 8 O
for	404 3 O
all	408 3 O
eight	412 5 O
tuberculosis	418 12 B-Disease
patients	431 8 O
tested	440 6 O
,	446 1 O
but	448 3 O
there	452 5 O
occurred	458 8 O
a	467 1 O
hyper	469 5 O
-	474 1 O
responsiveness	475 14 O
of	490 2 O
the	493 3 O
lymphocytes	497 11 O
of	509 2 O
these	512 5 O
eight	518 5 O
patients	524 8 O
to	533 2 O
phytomitogen	536 12 O
(	549 1 O
PHA	550 3 O
-	553 1 O
P	554 1 O
)	555 1 O
.	556 1 O
as	558 2 O
well	561 4 O
as	566 2 O
of	569 2 O
those	572 5 O
of	578 2 O
seven	581 5 O
other	587 5 O
tuberculous	593 11 B-Disease
patients	605 8 O
.	613 1 O

This	615 4 O
last	620 4 O
finding	625 7 O
may	633 3 O
be	637 2 O
related	640 7 O
to	648 2 O
time	651 4 O
of	656 2 O
testing	659 7 O
and	667 3 O
/	670 1 O
or	671 2 O
endogenous	674 10 O
serum	685 5 O
binding	691 7 O
of	699 2 O
rifampin	702 8 B-Chemical
which	711 5 O
could	717 5 O
have	723 4 O
inhibited	728 9 O
mitogen	738 7 O
activity	746 8 O
for	755 3 O
the	759 3 O
lymphocyte	763 10 O
.	773 1 O

Initial	0 7 O
potassium	8 9 B-Chemical
loss	18 4 O
and	23 3 O
hypokalaemia	27 12 B-Disease
during	40 6 O
chlorthalidone	47 14 B-Chemical
administration	62 14 O
in	77 2 O
patients	80 8 O
with	89 4 O
essential	94 9 O
hypertension	104 12 B-Disease
:	116 1 O
the	118 3 O
influence	122 9 O
of	132 2 O
dietary	135 7 O
sodium	143 6 B-Chemical
restriction	150 11 O
.	161 1 O

To	163 2 O
investigate	166 11 O
the	178 3 O
initial	182 7 O
potassium	190 9 B-Chemical
loss	200 4 O
and	205 3 O
development	209 11 O
of	221 2 O
hypokalaemia	224 12 B-Disease
during	237 6 O
the	244 3 O
administration	248 14 O
of	263 2 O
an	266 2 O
oral	269 4 O
diuretic	274 8 O
,	282 1 O
metabolic	284 9 O
balance	294 7 O
studies	302 7 O
were	310 4 O
performed	315 9 O
in	325 2 O
ten	328 3 O
patients	332 8 O
with	341 4 O
essential	346 9 O
hypertension	356 12 B-Disease
who	369 3 O
had	373 3 O
shown	377 5 O
hypokalaemia	383 12 B-Disease
under	396 5 O
prior	402 5 O
oral	408 4 O
diuretic	413 8 O
treatment	422 9 O
.	431 1 O

Chlorthalidone	433 14 B-Chemical
(	448 1 O
50	449 2 O
mg	452 2 O
daily	455 5 O
)	460 1 O
was	462 3 O
given	466 5 O
for	472 3 O
14	476 2 O
days	479 4 O
.	483 1 O

Six	485 3 O
patients	489 8 O
received	498 8 O
a	507 1 O
normal	509 6 O
-	515 1 O
sodium	516 6 B-Chemical
diet	523 4 O
and	528 3 O
four	532 4 O
a	537 1 O
low	539 3 O
-	542 1 O
sodium	543 6 B-Chemical
(	550 1 O
17	551 2 O
mmol	554 4 O
/	558 1 O
day	559 3 O
)	562 1 O
diet	564 4 O
.	568 1 O

All	570 3 O
patients	574 8 O
had	583 3 O
a	587 1 O
normal	589 6 O
initial	596 7 O
total	604 5 O
body	610 4 O
potassium	615 9 B-Chemical
(	625 1 O
40K	626 3 O
)	629 1 O
.	630 1 O

The	632 3 O
electrolyte	636 11 O
balances	648 8 O
,	656 1 O
weight	658 6 O
,	664 1 O
bromide	666 7 O
space	674 5 O
,	679 1 O
plasma	681 6 O
renin	688 5 O
activity	694 8 O
,	702 1 O
and	704 3 O
aldosterone	708 11 B-Chemical
secretion	720 9 O
rate	730 4 O
were	735 4 O
measured	740 8 O
.	748 1 O

In	750 2 O
both	753 4 O
groups	758 6 O
a	765 1 O
potassium	767 9 B-Chemical
deficit	777 7 O
developed	785 9 O
,	794 1 O
with	796 4 O
proportionally	801 14 O
larger	816 6 O
losses	823 6 O
from	830 4 O
the	835 3 O
extracellular	839 13 O
than	853 4 O
from	858 4 O
the	863 3 O
intracellular	867 13 O
compartment	881 11 O
.	892 1 O

In	894 2 O
the	897 3 O
normal	901 6 O
-	907 1 O
sodium	908 6 B-Chemical
group	915 5 O
the	921 3 O
highest	925 7 O
mean	933 4 O
potassium	938 9 B-Chemical
deficit	948 7 O
was	956 3 O
176	960 3 O
mmol	964 4 O
on	969 2 O
day	972 3 O
9	976 1 O
,	977 1 O
after	979 5 O
which	985 5 O
some	991 4 O
potassium	996 9 B-Chemical
was	1006 3 O
regained	1010 8 O
;	1018 1 O
in	1020 2 O
the	1023 3 O
low	1027 3 O
-	1030 1 O
sodium	1031 6 B-Chemical
group	1038 5 O
the	1044 3 O
highest	1048 7 O
deficit	1056 7 O
was	1064 3 O
276	1068 3 O
mmol	1072 4 O
on	1077 2 O
day	1080 3 O
13	1084 2 O
.	1086 1 O

The	1088 3 O
normal	1092 6 O
-	1098 1 O
sodium	1099 6 B-Chemical
group	1106 5 O
showed	1112 6 O
an	1119 2 O
immediate	1122 9 O
but	1132 3 O
temporary	1136 9 O
rise	1146 4 O
of	1151 2 O
the	1154 3 O
renin	1158 5 O
and	1164 3 O
aldosterone	1168 11 B-Chemical
levels	1180 6 O
;	1186 1 O
in	1188 2 O
the	1191 3 O
low	1195 3 O
-	1198 1 O
sodium	1199 6 B-Chemical
group	1206 5 O
renin	1212 5 O
and	1218 3 O
aldosterone	1222 11 B-Chemical
increased	1234 9 O
more	1244 4 O
slowly	1249 6 O
but	1256 3 O
remained	1260 8 O
elevated	1269 8 O
.	1277 1 O

It	1279 2 O
is	1282 2 O
concluded	1285 9 O
that	1295 4 O
dietary	1300 7 O
sodium	1308 6 B-Chemical
restriction	1315 11 O
increases	1327 9 O
diuretic	1337 8 O
-	1345 1 O
induced	1346 7 O
potassium	1354 9 B-Chemical
loss	1364 4 O
,	1368 1 O
presumably	1370 10 O
by	1381 2 O
an	1384 2 O
increased	1387 9 O
activity	1397 8 O
of	1406 2 O
the	1409 3 O
renin	1413 5 O
-	1418 1 O
angiotensin	1419 11 B-Chemical
-	1430 1 O
aldosterone	1431 11 B-Chemical
system	1443 6 O
,	1449 1 O
while	1451 5 O
sodium	1457 6 B-Chemical
delivery	1464 8 O
to	1473 2 O
the	1476 3 O
distal	1480 6 O
renal	1487 5 O
tubules	1493 7 O
remains	1501 7 O
sufficiently	1509 12 O
high	1522 4 O
to	1527 2 O
allow	1530 5 O
increased	1536 9 O
potassium	1546 9 B-Chemical
secretion	1556 9 O
.	1565 1 O

Dynamic	0 7 O
response	8 8 O
of	17 2 O
blood	20 5 O
vessel	26 6 O
in	33 2 O
acute	36 5 B-Disease
renal	42 5 I-Disease
failure	48 7 I-Disease
.	55 1 O

In	57 2 O
this	60 4 O
study	65 5 O
we	71 2 O
postulated	74 10 O
that	85 4 O
during	90 6 O
acute	97 5 B-Disease
renal	103 5 I-Disease
failure	109 7 I-Disease
induced	117 7 O
by	125 2 O
gentamicin	128 10 B-Chemical
the	139 3 O
transient	143 9 O
or	153 2 O
dynamic	156 7 O
response	164 8 O
of	173 2 O
blood	176 5 O
vessels	182 7 O
could	190 5 O
be	196 2 O
affected	199 8 O
,	207 1 O
and	209 3 O
that	213 4 O
antioxidants	218 12 O
can	231 3 O
prevent	235 7 O
the	243 3 O
changes	247 7 O
in	255 2 O
dynamic	258 7 O
responses	266 9 O
of	276 2 O
blood	279 5 O
vessels	285 7 O
.	292 1 O

The	294 3 O
new	298 3 O
approach	302 8 O
to	311 2 O
ex	314 2 O
vivo	317 4 O
blood	322 5 O
vessel	328 6 O
experiments	335 11 O
in	347 2 O
which	350 5 O
not	356 3 O
only	360 4 O
the	365 3 O
end	369 3 O
points	373 6 O
of	380 2 O
vessels	383 7 O
response	391 8 O
within	400 6 O
the	407 3 O
time	411 4 O
interval	416 8 O
is	425 2 O
considered	428 10 O
,	438 1 O
but	440 3 O
also	444 4 O
dynamics	449 8 O
of	458 2 O
this	461 4 O
response	466 8 O
,	474 1 O
was	476 3 O
used	480 4 O
in	485 2 O
this	488 4 O
paper	493 5 O
.	498 1 O

Our	500 3 O
results	504 7 O
confirm	512 7 O
the	520 3 O
alteration	524 10 O
in	535 2 O
dynamic	538 7 O
response	546 8 O
of	555 2 O
blood	558 5 O
vessels	564 7 O
during	572 6 O
the	579 3 O
change	583 6 O
of	590 2 O
pressure	593 8 O
in	602 2 O
gentamicin	605 10 B-Chemical
-	615 1 O
treated	616 7 O
animals	624 7 O
.	631 1 O

The	633 3 O
beneficial	637 10 O
effects	648 7 O
of	656 2 O
vitamin	659 7 B-Chemical
C	667 1 I-Chemical
administration	669 14 O
to	684 2 O
gentamicin	687 10 B-Chemical
-	697 1 O
treated	698 7 O
animals	706 7 O
are	714 3 O
also	718 4 O
confirmed	723 9 O
through	733 7 O
:	740 1 O
lower	742 5 O
level	748 5 O
of	754 2 O
blood	757 5 O
urea	763 4 B-Chemical
and	768 3 O
creatinine	772 10 B-Chemical
and	783 3 O
higher	787 6 O
level	794 5 O
of	800 2 O
potassium	803 9 B-Chemical
.	812 1 O

The	814 3 O
pressure	818 8 O
dynamic	827 7 O
responses	835 9 O
of	845 2 O
isolated	848 8 O
blood	857 5 O
vessels	863 7 O
show	871 4 O
a	876 1 O
faster	878 6 O
pressure	885 8 O
change	894 6 O
in	901 2 O
gentamicin	904 10 B-Chemical
-	914 1 O
treated	915 7 O
animals	923 7 O
(	931 1 O
8	932 1 O
.	933 1 O
07	934 2 O
+	937 1 O
/	938 1 O
-	939 1 O
1	941 1 O
.	942 1 O
7	943 1 O
s	945 1 O
vs	947 2 O
.	949 1 O
5	951 1 O
.	952 1 O
64	953 2 O
+	956 1 O
/	957 1 O
-	958 1 O
0	960 1 O
.	961 1 O
18	962 2 O
s	965 1 O
)	966 1 O
.	967 1 O

Vitamin	969 7 B-Chemical
C	977 1 I-Chemical
administration	979 14 O
induced	994 7 O
slowdown	1002 8 O
of	1011 2 O
pressure	1014 8 O
change	1023 6 O
back	1030 4 O
to	1035 2 O
the	1038 3 O
control	1042 7 O
values	1050 6 O
.	1056 1 O

The	1058 3 O
pressure	1062 8 O
dynamic	1071 7 O
properties	1079 10 O
,	1089 1 O
quantitatively	1091 14 O
defined	1106 7 O
by	1114 2 O
comparative	1117 11 O
pressure	1129 8 O
dynamic	1138 7 O
and	1146 3 O
total	1150 5 O
pressure	1156 8 O
dynamic	1165 7 O
,	1172 1 O
confirm	1174 7 O
the	1182 3 O
alteration	1186 10 O
in	1197 2 O
dynamic	1200 7 O
response	1208 8 O
of	1217 2 O
blood	1220 5 O
vessels	1226 7 O
during	1234 6 O
the	1241 3 O
change	1245 6 O
of	1252 2 O
pressure	1255 8 O
in	1264 2 O
gentamicin	1267 10 B-Chemical
-	1277 1 O
treated	1278 7 O
animals	1286 7 O
and	1294 3 O
beneficial	1298 10 O
effects	1309 7 O
of	1317 2 O
vitamin	1320 7 B-Chemical
C	1328 1 I-Chemical
administration	1330 14 O
.	1344 1 O

The	0 3 O
hemodynamics	4 12 O
of	17 2 O
oxytocin	20 8 B-Chemical
and	29 3 O
other	33 5 O
vasoactive	39 10 O
agents	50 6 O
during	57 6 O
neuraxial	64 9 O
anesthesia	74 10 O
for	85 3 O
cesarean	89 8 O
delivery	98 8 O
:	106 1 O
findings	108 8 O
in	117 2 O
six	120 3 O
cases	124 5 O
.	129 1 O

Oxytocin	131 8 B-Chemical
is	140 2 O
a	143 1 O
commonly	145 8 O
used	154 4 O
uterotonic	159 10 O
that	170 4 O
can	175 3 O
cause	179 5 O
significant	185 11 O
and	197 3 O
even	201 4 O
fatal	206 5 O
hypotension	212 11 B-Disease
,	223 1 O
particularly	225 12 O
when	238 4 O
given	243 5 O
as	249 2 O
a	252 1 O
bolus	254 5 O
.	259 1 O

The	261 3 O
resulting	265 9 O
hypotension	275 11 B-Disease
can	287 3 O
be	291 2 O
produced	294 8 O
by	303 2 O
a	306 1 O
decrease	308 8 O
in	317 2 O
systemic	320 8 O
vascular	329 8 O
resistance	338 10 O
or	349 2 O
cardiac	352 7 O
output	360 6 O
through	367 7 O
a	375 1 O
decrease	377 8 O
in	386 2 O
venous	389 6 O
return	396 6 O
.	402 1 O

Parturients	404 11 O
with	416 4 O
normal	421 6 O
volume	428 6 O
status	435 6 O
,	441 1 O
heart	443 5 O
valves	449 6 O
and	456 3 O
pulmonary	460 9 O
vasculature	470 11 O
most	482 4 O
often	487 5 O
respond	493 7 O
to	501 2 O
this	504 4 O
hypotension	509 11 B-Disease
with	521 4 O
a	526 1 O
compensatory	528 12 O
increase	541 8 O
in	550 2 O
heart	553 5 O
rate	559 4 O
and	564 3 O
stroke	568 6 B-Disease
volume	575 6 O
.	581 1 O

Oxytocin	583 8 B-Chemical
-	591 1 O
induced	592 7 O
hypotension	600 11 B-Disease
at	612 2 O
cesarean	615 8 O
delivery	624 8 O
may	633 3 O
be	637 2 O
incorrectly	640 11 O
attributed	652 10 O
to	663 2 O
blood	666 5 B-Disease
loss	672 4 I-Disease
.	676 1 O

Pulse	678 5 O
power	684 5 O
analysis	690 8 O
(	699 1 O
also	700 4 O
called	705 6 O
"	712 1 O
pulse	713 5 O
contour	719 7 O
analysis	727 8 O
"	735 1 O
)	736 1 O
of	738 2 O
an	741 2 O
arterial	744 8 O
pressure	753 8 O
wave	762 4 O
form	767 4 O
allows	772 6 O
continuous	779 10 O
evaluation	790 10 O
of	801 2 O
systemic	804 8 O
vascular	813 8 O
resistance	822 10 O
and	833 3 O
cardiac	837 7 O
output	845 6 O
in	852 2 O
real	855 4 O
time	860 4 O
,	864 1 O
thereby	866 7 O
elucidating	874 11 O
the	886 3 O
causative	890 9 O
factors	900 7 O
behind	908 6 O
changes	915 7 O
in	923 2 O
blood	926 5 O
pressure	932 8 O
.	940 1 O

Pulse	942 5 O
power	948 5 O
analysis	954 8 O
was	963 3 O
conducted	967 9 O
in	977 2 O
six	980 3 O
cases	984 5 O
of	990 2 O
cesarean	993 8 O
delivery	1002 8 O
performed	1011 9 O
under	1021 5 O
neuraxial	1027 9 O
anesthesia	1037 10 O
.	1047 1 O

Hypotension	1049 11 B-Disease
in	1061 2 O
response	1064 8 O
to	1073 2 O
oxytocin	1076 8 B-Chemical
was	1085 3 O
associated	1089 10 O
with	1100 4 O
a	1105 1 O
decrease	1107 8 O
in	1116 2 O
systemic	1119 8 O
vascular	1128 8 O
resistance	1137 10 O
and	1148 3 O
a	1152 1 O
compensatory	1154 12 O
increase	1167 8 O
in	1176 2 O
stroke	1179 6 B-Disease
volume	1186 6 O
,	1192 1 O
heart	1194 5 O
rate	1200 4 O
and	1205 3 O
cardiac	1209 7 O
output	1217 6 O
.	1223 1 O

Pulse	1225 5 O
power	1231 5 O
analysis	1237 8 O
may	1246 3 O
be	1250 2 O
helpful	1253 7 O
in	1261 2 O
determining	1264 11 O
the	1276 3 O
etiology	1280 8 O
of	1289 2 O
and	1292 3 O
treating	1296 8 O
hypotension	1305 11 B-Disease
during	1317 6 O
cesarean	1324 8 O
delivery	1333 8 O
under	1342 5 O
neuraxial	1348 9 O
anesthesia	1358 10 O
.	1368 1 O

Exaggerated	0 11 O
expression	12 10 O
of	23 2 O
inflammatory	26 12 O
mediators	39 9 O
in	49 2 O
vasoactive	52 10 O
intestinal	63 10 O
polypeptide	74 11 O
knockout	86 8 O
(	95 1 O
VIP	96 3 O
-	99 1 O
/	100 1 O
-	101 1 O
)	102 1 O
mice	104 4 O
with	109 4 O
cyclophosphamide	114 16 B-Chemical
(	131 1 O
CYP	132 3 B-Chemical
)	135 1 O
-	136 1 O
induced	137 7 O
cystitis	145 8 B-Disease
.	153 1 O

Vasoactive	155 10 O
intestinal	166 10 O
polypeptide	177 11 O
(	189 1 O
VIP	190 3 O
)	193 1 O
is	195 2 O
an	198 2 O
immunomodulatory	201 16 O
neuropeptide	218 12 O
distributed	231 11 O
in	243 2 O
micturition	246 11 O
pathways	258 8 O
.	266 1 O

VIP	268 3 O
(	271 1 O
-	272 1 O
/	273 1 O
-	274 1 O
)	275 1 O
mice	277 4 O
exhibit	282 7 O
altered	290 7 O
bladder	298 7 O
function	306 8 O
and	315 3 O
neurochemical	319 13 O
properties	333 10 O
in	344 2 O
micturition	347 11 O
pathways	359 8 O
after	368 5 O
cyclophosphamide	374 16 B-Chemical
(	391 1 O
CYP	392 3 B-Chemical
)	395 1 O
-	396 1 O
induced	397 7 O
cystitis	405 8 B-Disease
.	413 1 O

Given	415 5 O
VIP	421 3 O
'	424 1 O
s	425 1 O
role	427 4 O
as	432 2 O
an	435 2 O
anti	438 4 O
-	442 1 O
inflammatory	443 12 O
mediator	456 8 O
,	464 1 O
we	466 2 O
hypothesized	469 12 O
that	482 4 O
VIP	487 3 O
(	490 1 O
-	491 1 O
/	492 1 O
-	493 1 O
)	494 1 O
mice	496 4 O
would	501 5 O
exhibit	507 7 O
enhanced	515 8 O
inflammatory	524 12 O
mediator	537 8 O
expression	546 10 O
after	557 5 O
cystitis	563 8 B-Disease
.	571 1 O

A	573 1 O
mouse	575 5 O
inflammatory	581 12 O
cytokine	594 8 O
and	603 3 O
receptor	607 8 O
RT2	616 3 O
profiler	620 8 O
array	629 5 O
was	635 3 O
used	639 4 O
to	644 2 O
determine	647 9 O
regulated	657 9 O
transcripts	667 11 O
in	679 2 O
the	682 3 O
urinary	686 7 O
bladder	694 7 O
of	702 2 O
wild	705 4 O
type	710 4 O
(	715 1 O
WT	716 2 O
)	718 1 O
and	720 3 O
VIP	724 3 O
(	727 1 O
-	728 1 O
/	729 1 O
-	730 1 O
)	731 1 O
mice	733 4 O
with	738 4 O
or	743 2 O
without	746 7 O
CYP	754 3 B-Chemical
-	757 1 O
induced	758 7 O
cystitis	766 8 B-Disease
(	775 1 O
150	776 3 O
mg	780 2 O
/	782 1 O
kg	783 2 O
;	785 1 O
i	787 1 O
.	788 1 O
p	789 1 O
.	790 1 O
;	791 1 O
48	793 2 O
h	796 1 O
)	797 1 O
.	798 1 O

Four	800 4 O
binary	805 6 O
comparisons	812 11 O
were	824 4 O
made	829 4 O
:	833 1 O
WT	835 2 O
control	838 7 O
versus	846 6 O
CYP	853 3 B-Chemical
treatment	857 9 O
(	867 1 O
48	868 2 O
h	871 1 O
)	872 1 O
,	873 1 O
VIP	875 3 O
(	878 1 O
-	879 1 O
/	880 1 O
-	881 1 O
)	882 1 O
control	884 7 O
versus	892 6 O
CYP	899 3 B-Chemical
treatment	903 9 O
(	913 1 O
48	914 2 O
h	917 1 O
)	918 1 O
,	919 1 O
WT	921 2 O
control	924 7 O
versus	932 6 O
VIP	939 3 O
(	942 1 O
-	943 1 O
/	944 1 O
-	945 1 O
)	946 1 O
control	948 7 O
,	955 1 O
and	957 3 O
WT	961 2 O
with	964 4 O
CYP	969 3 B-Chemical
treatment	973 9 O
(	983 1 O
48	984 2 O
h	987 1 O
)	988 1 O
versus	990 6 O
VIP	997 3 O
(	1000 1 O
-	1001 1 O
/	1002 1 O
-	1003 1 O
)	1004 1 O
with	1006 4 O
CYP	1011 3 B-Chemical
treatment	1015 9 O
(	1025 1 O
48	1026 2 O
h	1029 1 O
)	1030 1 O
.	1031 1 O

The	1033 3 O
genes	1037 5 O
presented	1043 9 O
represent	1053 9 O
(	1063 1 O
1	1064 1 O
)	1065 1 O
greater	1067 7 O
than	1075 4 O
1	1080 1 O
.	1081 1 O
5	1082 1 O
-	1083 1 O
fold	1084 4 O
change	1089 6 O
in	1096 2 O
either	1099 6 O
direction	1106 9 O
and	1116 3 O
(	1120 1 O
2	1121 1 O
)	1122 1 O
the	1124 3 O
p	1128 1 O
value	1130 5 O
is	1136 2 O
less	1139 4 O
than	1144 4 O
0	1149 1 O
.	1150 1 O
05	1151 2 O
for	1154 3 O
the	1158 3 O
comparison	1162 10 O
being	1173 5 O
made	1179 4 O
.	1183 1 O

Several	1185 7 O
regulated	1193 9 O
genes	1203 5 O
were	1209 4 O
validated	1214 9 O
using	1224 5 O
enzyme	1230 6 O
-	1236 1 O
linked	1237 6 O
immunoassays	1244 12 O
including	1257 9 O
IL	1267 2 O
-	1269 1 O
1beta	1270 5 O
and	1276 3 O
CXCL1	1280 5 O
.	1285 1 O

CYP	1287 3 B-Chemical
treatment	1291 9 O
significantly	1301 13 O
(	1315 1 O
p	1316 1 O
<	1318 1 O
or	1320 2 O
=	1323 1 O
0	1325 1 O
.	1326 1 O
001	1327 3 O
)	1330 1 O
increased	1332 9 O
expression	1342 10 O
of	1353 2 O
CXCL1	1356 5 O
and	1362 3 O
IL	1366 2 O
-	1368 1 O
1beta	1369 5 O
in	1375 2 O
the	1378 3 O
urinary	1382 7 O
bladder	1390 7 O
of	1398 2 O
WT	1401 2 O
and	1404 3 O
VIP	1408 3 O
(	1411 1 O
-	1412 1 O
/	1413 1 O
-	1414 1 O
)	1415 1 O
mice	1417 4 O
,	1421 1 O
but	1423 3 O
expression	1427 10 O
in	1438 2 O
VIP	1441 3 O
(	1444 1 O
-	1445 1 O
/	1446 1 O
-	1447 1 O
)	1448 1 O
mice	1450 4 O
with	1455 4 O
CYP	1460 3 B-Chemical
treatment	1464 9 O
was	1474 3 O
significantly	1478 13 O
(	1492 1 O
p	1493 1 O
<	1495 1 O
or	1497 2 O
=	1500 1 O
0	1502 1 O
.	1503 1 O
001	1504 3 O
)	1507 1 O
greater	1509 7 O
(	1517 1 O
4	1518 1 O
.	1519 1 O
2	1520 1 O
-	1521 1 O
to	1523 2 O
13	1526 2 O
-	1528 1 O
fold	1529 4 O
increase	1534 8 O
)	1542 1 O
than	1544 4 O
that	1549 4 O
observed	1554 8 O
in	1563 2 O
WT	1566 2 O
urinary	1569 7 O
bladder	1577 7 O
(	1585 1 O
3	1586 1 O
.	1587 1 O
6	1588 1 O
-	1589 1 O
to	1591 2 O
5	1594 1 O
-	1595 1 O
fold	1596 4 O
increase	1601 8 O
)	1609 1 O
.	1610 1 O

The	1612 3 O
data	1616 4 O
suggest	1621 7 O
that	1629 4 O
in	1634 2 O
VIP	1637 3 O
(	1640 1 O
-	1641 1 O
/	1642 1 O
-	1643 1 O
)	1644 1 O
mice	1646 4 O
with	1651 4 O
bladder	1656 7 B-Disease
inflammation	1664 12 I-Disease
,	1676 1 O
inflammatory	1678 12 O
mediators	1691 9 O
are	1701 3 O
increased	1705 9 O
above	1715 5 O
that	1721 4 O
observed	1726 8 O
in	1735 2 O
WT	1738 2 O
with	1741 4 O
CYP	1746 3 B-Chemical
.	1749 1 O

This	1751 4 O
shift	1756 5 O
in	1762 2 O
balance	1765 7 O
may	1773 3 O
contribute	1777 10 O
to	1788 2 O
increased	1791 9 O
bladder	1801 7 B-Disease
dysfunction	1809 11 I-Disease
in	1821 2 O
VIP	1824 3 O
(	1827 1 O
-	1828 1 O
/	1829 1 O
-	1830 1 O
)	1831 1 O
mice	1833 4 O
with	1838 4 O
bladder	1843 7 B-Disease
inflammation	1851 12 I-Disease
and	1864 3 O
altered	1868 7 O
neurochemical	1876 13 O
expression	1890 10 O
in	1901 2 O
micturition	1904 11 O
pathways	1916 8 O
.	1924 1 O

Intraocular	0 11 O
pressure	12 8 O
in	21 2 O
patients	24 8 O
with	33 4 O
uveitis	38 7 B-Disease
treated	46 7 O
with	54 4 O
fluocinolone	59 12 B-Chemical
acetonide	72 9 I-Chemical
implants	82 8 O
.	90 1 O

OBJECTIVE	92 9 O
:	101 1 O
To	103 2 O
report	106 6 O
the	113 3 O
incidence	117 9 O
and	127 3 O
management	131 10 O
of	142 2 O
elevated	145 8 B-Disease
intraocular	154 11 I-Disease
pressure	166 8 I-Disease
(	175 1 O
IOP	176 3 O
)	179 1 O
in	181 2 O
patients	184 8 O
with	193 4 O
uveitis	198 7 B-Disease
treated	206 7 O
with	214 4 O
the	219 3 O
fluocinolone	223 12 B-Chemical
acetonide	236 9 I-Chemical
(	246 1 O
FA	247 2 B-Chemical
)	249 1 O
intravitreal	251 12 O
implant	264 7 O
.	271 1 O

DESIGN	273 6 O
:	279 1 O
Pooled	281 6 O
data	288 4 O
from	293 4 O
3	298 1 O
multicenter	300 11 O
,	311 1 O
double	313 6 O
-	319 1 O
masked	320 6 O
,	326 1 O
randomized	328 10 O
,	338 1 O
controlled	340 10 O
,	350 1 O
phase	352 5 O
2b	358 2 O
/	360 1 O
3	361 1 O
clinical	363 8 O
trials	372 6 O
evaluating	379 10 O
the	390 3 O
safety	394 6 O
and	401 3 O
efficacy	405 8 O
of	414 2 O
the	417 3 O
0	421 1 O
.	422 1 O
59	423 2 O
-	425 1 O
mg	426 2 O
or	429 2 O
2	432 1 O
.	433 1 O
1	434 1 O
-	435 1 O
mg	436 2 O
FA	439 2 B-Chemical
intravitreal	442 12 O
implant	455 7 O
or	463 2 O
standard	466 8 O
therapy	475 7 O
were	483 4 O
analyzed	488 8 O
.	496 1 O

RESULTS	498 7 O
:	505 1 O
During	507 6 O
the	514 3 O
3	518 1 O
-	519 1 O
year	520 4 O
follow	525 6 O
-	531 1 O
up	532 2 O
,	534 1 O
71	536 2 O
.	538 1 O
0	539 1 O
%	540 1 O
of	542 2 O
implanted	545 9 O
eyes	555 4 O
had	560 3 O
an	564 2 O
IOP	567 3 O
increase	571 8 O
of	580 2 O
10	583 2 O
mm	586 2 O
Hg	589 2 O
or	592 2 O
more	595 4 O
than	600 4 O
baseline	605 8 O
and	614 3 O
55	618 2 O
.	620 1 O
1	621 1 O
%	622 1 O
,	623 1 O
24	625 2 O
.	627 1 O
7	628 1 O
%	629 1 O
,	630 1 O
and	632 3 O
6	636 1 O
.	637 1 O
2	638 1 O
%	639 1 O
of	641 2 O
eyes	644 4 O
reached	649 7 O
an	657 2 O
IOP	660 3 O
of	664 2 O
30	667 2 O
mm	670 2 O
Hg	673 2 O
or	676 2 O
more	679 4 O
,	683 1 O
40	685 2 O
mm	688 2 O
Hg	691 2 O
or	694 2 O
more	697 4 O
,	701 1 O
and	703 3 O
50	707 2 O
mm	710 2 O
Hg	713 2 O
or	716 2 O
more	719 4 O
,	723 1 O
respectively	725 12 O
.	737 1 O

Topical	739 7 O
IOP	747 3 O
-	750 1 O
lowering	751 8 O
medication	760 10 O
was	771 3 O
administered	775 12 O
in	788 2 O
74	791 2 O
.	793 1 O
8	794 1 O
%	795 1 O
of	797 2 O
implanted	800 9 O
eyes	810 4 O
,	814 1 O
and	816 3 O
IOP	820 3 O
-	823 1 O
lowering	824 8 O
surgeries	833 9 O
,	842 1 O
most	844 4 O
of	849 2 O
which	852 5 O
were	858 4 O
trabeculectomies	863 16 O
(	880 1 O
76	881 2 O
.	883 1 O
2	884 1 O
%	885 1 O
)	886 1 O
,	887 1 O
were	889 4 O
performed	894 9 O
on	904 2 O
36	907 2 O
.	909 1 O
6	910 1 O
%	911 1 O
of	913 2 O
implanted	916 9 O
eyes	926 4 O
.	930 1 O

Intraocular	932 11 O
pressure	944 8 O
-	952 1 O
lowering	953 8 O
surgeries	962 9 O
were	972 4 O
considered	977 10 O
a	988 1 O
success	990 7 O
(	998 1 O
postoperative	999 13 O
IOP	1013 3 O
of	1017 2 O
6	1020 1 O
-	1021 1 O
21	1022 2 O
mm	1025 2 O
Hg	1028 2 O
with	1031 4 O
or	1036 2 O
without	1039 7 O
additional	1047 10 O
IOP	1058 3 O
-	1061 1 O
lowering	1062 8 O
medication	1071 10 O
)	1081 1 O
in	1083 2 O
85	1086 2 O
.	1088 1 O
1	1089 1 O
%	1090 1 O
of	1092 2 O
eyes	1095 4 O
at	1100 2 O
1	1103 1 O
year	1105 4 O
.	1109 1 O

The	1111 3 O
rate	1115 4 O
of	1120 2 O
hypotony	1123 8 B-Disease
(	1132 1 O
IOP	1133 3 O
<	1137 1 O
/	1138 1 O
=	1139 1 O
5	1141 1 O
mm	1143 2 O
Hg	1146 2 O
)	1148 1 O
following	1150 9 O
IOP	1160 3 O
-	1163 1 O
lowering	1164 8 O
surgery	1173 7 O
(	1181 1 O
42	1182 2 O
.	1184 1 O
5	1185 1 O
%	1186 1 O
)	1187 1 O
was	1189 3 O
not	1193 3 O
different	1197 9 O
from	1207 4 O
that	1212 4 O
of	1217 2 O
implanted	1220 9 O
eyes	1230 4 O
not	1235 3 O
subjected	1239 9 O
to	1249 2 O
surgery	1252 7 O
(	1260 1 O
35	1261 2 O
.	1263 1 O
4	1264 1 O
%	1265 1 O
)	1266 1 O
(	1268 1 O
P	1269 1 O
=	1271 1 O
.	1273 1 O
09	1274 2 O
)	1276 1 O
.	1277 1 O

CONCLUSION	1279 10 O
:	1289 1 O
Elevated	1291 8 O
IOP	1300 3 O
is	1304 2 O
a	1307 1 O
significant	1309 11 O
complication	1321 12 O
with	1334 4 O
the	1339 3 O
FA	1343 2 O
intravitreal	1346 12 O
implant	1359 7 O
but	1367 3 O
may	1371 3 O
be	1375 2 O
controlled	1378 10 O
with	1389 4 O
medication	1394 10 O
and	1405 3 O
surgery	1409 7 O
.	1416 1 O

Pallidal	0 8 O
stimulation	9 11 O
:	20 1 O
an	22 2 O
alternative	25 11 O
to	37 2 O
pallidotomy	40 11 O
?	51 1 O

A	53 1 O
resurgence	55 10 O
of	66 2 O
interest	69 8 O
in	78 2 O
the	81 3 O
surgical	85 8 O
treatment	94 9 O
of	104 2 O
Parkinson	107 9 B-Disease
'	116 1 I-Disease
s	117 1 I-Disease
disease	119 7 I-Disease
(	127 1 O
PD	128 2 B-Disease
)	130 1 O
came	132 4 O
with	137 4 O
the	142 3 O
rediscovery	146 11 O
of	158 2 O
posteroventral	161 14 O
pallidotomy	176 11 O
by	188 2 O
Laitinen	191 8 O
in	200 2 O
1985	203 4 O
.	207 1 O

Laitinen	209 8 O
'	217 1 O
s	218 1 O
procedure	220 9 O
improved	230 8 O
most	239 4 O
symptoms	244 8 O
in	253 2 O
drug	256 4 O
-	260 1 O
resistant	261 9 O
PD	271 2 B-Disease
,	273 1 O
which	275 5 O
engendered	281 10 O
wide	292 4 O
interest	297 8 O
in	306 2 O
the	309 3 O
neurosurgical	313 13 O
community	327 9 O
.	336 1 O

Another	338 7 O
lesioning	346 9 O
procedure	356 9 O
,	365 1 O
ventrolateral	367 13 O
thalamotomy	381 11 O
,	392 1 O
has	394 3 O
become	398 6 O
a	405 1 O
powerful	407 8 O
alternative	416 11 O
to	428 2 O
stimulate	431 9 O
the	441 3 O
nucleus	445 7 O
ventralis	453 9 O
intermedius	463 11 O
,	474 1 O
producing	476 9 O
high	486 4 O
long	491 4 O
-	495 1 O
term	496 4 O
success	501 7 O
rates	509 5 O
and	515 3 O
low	519 3 O
morbidity	523 9 O
rates	533 5 O
.	538 1 O

Pallidal	540 8 O
stimulation	549 11 O
has	561 3 O
not	565 3 O
met	569 3 O
with	573 4 O
the	578 3 O
same	582 4 O
success	587 7 O
.	594 1 O

According	596 9 O
to	606 2 O
the	609 3 O
literature	613 10 O
pallidotomy	624 11 O
improves	636 8 O
the	645 3 O
"	649 1 O
on	650 2 O
"	652 1 O
symptoms	654 8 O
of	663 2 O
PD	666 2 B-Disease
,	668 1 O
such	670 4 O
as	675 2 O
dyskinesias	678 11 B-Disease
,	689 1 O
as	691 2 O
well	694 4 O
as	699 2 O
the	702 3 O
"	706 1 O
off	707 3 O
"	710 1 O
symptoms	712 8 O
,	720 1 O
such	722 4 O
as	727 2 O
rigidity	730 8 B-Disease
,	738 1 O
bradykinesia	740 12 B-Disease
,	752 1 O
and	754 3 O
on	758 2 O
-	760 1 O
off	761 3 O
fluctuations	765 12 O
.	777 1 O

Pallidal	779 8 O
stimulation	788 11 O
improves	800 8 O
bradykinesia	809 12 B-Disease
and	822 3 O
rigidity	826 8 B-Disease
to	835 2 O
a	838 1 O
minor	840 5 O
extent	846 6 O
;	852 1 O
however	854 7 O
,	861 1 O
its	863 3 O
strength	867 8 O
seems	876 5 O
to	882 2 O
be	885 2 O
in	888 2 O
improving	891 9 O
levodopa	901 8 B-Chemical
-	909 1 O
induced	910 7 O
dyskinesias	918 11 B-Disease
.	929 1 O

Stimulation	931 11 O
often	943 5 O
produces	949 8 O
an	958 2 O
improvement	961 11 O
in	973 2 O
the	976 3 O
hyper	980 5 B-Disease
-	985 1 I-Disease
or	987 2 I-Disease
dyskinetic	990 10 I-Disease
upper	1001 5 O
limbs	1007 5 O
,	1012 1 O
but	1014 3 O
increases	1018 9 O
the	1028 3 O
"	1032 1 O
freezing	1033 8 O
"	1041 1 O
phenomenon	1043 10 O
in	1054 2 O
the	1057 3 O
lower	1061 5 O
limbs	1067 5 O
at	1073 2 O
the	1076 3 O
same	1080 4 O
time	1085 4 O
.	1089 1 O

Considering	1091 11 O
the	1103 3 O
small	1107 5 O
increase	1113 8 O
in	1122 2 O
the	1125 3 O
patient	1129 7 O
'	1136 1 O
s	1137 1 O
independence	1139 12 O
,	1151 1 O
the	1153 3 O
high	1157 4 O
costs	1162 5 O
of	1168 2 O
bilateral	1171 9 O
implants	1181 8 O
,	1189 1 O
and	1191 3 O
the	1195 3 O
difficulty	1199 10 O
most	1210 4 O
patients	1215 8 O
experience	1224 10 O
in	1235 2 O
handling	1238 8 O
the	1247 3 O
devices	1251 7 O
,	1258 1 O
the	1260 3 O
question	1264 8 O
arises	1273 6 O
as	1280 2 O
to	1283 2 O
whether	1286 7 O
bilateral	1294 9 O
pallidal	1304 8 O
stimulation	1313 11 O
is	1325 2 O
a	1328 1 O
real	1330 4 O
alternative	1335 11 O
to	1347 2 O
pallidotomy	1350 11 O
.	1361 1 O

Case	0 4 O
report	5 6 O
:	11 1 O
Dexatrim	13 8 B-Chemical
(	22 1 O
Phenylpropanolamine	23 19 B-Chemical
)	42 1 O
as	44 2 O
a	47 1 O
cause	49 5 O
of	55 2 O
myocardial	58 10 B-Disease
infarction	69 10 I-Disease
.	79 1 O

Phenylpropanolamine	81 19 B-Chemical
(	101 1 O
PPA	102 3 B-Chemical
)	105 1 O
is	107 2 O
a	110 1 O
sympathetic	112 11 O
amine	124 5 B-Chemical
used	130 4 O
in	135 2 O
over	138 4 O
-	142 1 O
the	143 3 O
-	146 1 O
counter	147 7 O
cold	155 4 O
remedies	160 8 O
and	169 3 O
weight	173 6 O
-	179 1 O
control	180 7 O
preparations	188 12 O
worldwide	201 9 O
.	210 1 O

Its	212 3 O
use	216 3 O
has	220 3 O
been	224 4 O
associated	229 10 O
with	240 4 O
hypertensive	245 12 B-Disease
episodes	258 8 O
and	267 3 O
hemorrhagic	271 11 B-Disease
strokes	283 7 I-Disease
in	291 2 O
younger	294 7 O
women	302 5 O
.	307 1 O

Several	309 7 O
reports	317 7 O
have	325 4 O
linked	330 6 O
the	337 3 O
abuse	341 5 O
of	347 2 O
PPA	350 3 B-Chemical
with	354 4 O
myocardial	359 10 B-Disease
injury	370 6 I-Disease
,	376 1 O
especially	378 10 O
when	389 4 O
overdose	394 8 B-Disease
is	403 2 O
involved	406 8 O
.	414 1 O

We	416 2 O
report	419 6 O
here	426 4 O
the	431 3 O
first	435 5 O
case	441 4 O
of	446 2 O
Dexatrim	449 8 B-Chemical
(	458 1 O
PPA	459 3 B-Chemical
)	462 1 O
-	463 1 O
induced	464 7 O
myocardial	472 10 B-Disease
injury	483 6 I-Disease
in	490 2 O
a	493 1 O
young	495 5 O
woman	501 5 O
who	507 3 O
was	511 3 O
using	515 5 O
it	521 2 O
at	524 2 O
recommended	527 11 O
doses	539 5 O
for	545 3 O
weight	549 6 O
control	556 7 O
.	563 1 O

In	565 2 O
addition	568 8 O
,	576 1 O
we	578 2 O
review	581 6 O
the	588 3 O
7	592 1 O
other	594 5 O
cases	600 5 O
of	606 2 O
PPA	609 3 B-Chemical
related	613 7 O
myocardial	621 10 B-Disease
injury	632 6 I-Disease
that	639 4 O
have	644 4 O
been	649 4 O
reported	654 8 O
so	663 2 O
far	666 3 O
.	669 1 O

Physicians	671 10 O
and	682 3 O
patients	686 8 O
should	695 6 O
be	702 2 O
alert	705 5 O
to	711 2 O
the	714 3 O
potential	718 9 O
cardiac	728 7 O
risk	736 4 O
associated	741 10 O
with	752 4 O
the	757 3 O
use	761 3 O
of	765 2 O
PPA	768 3 B-Chemical
,	771 1 O
even	773 4 O
at	778 2 O
doses	781 5 O
generally	787 9 O
considered	797 10 O
to	808 2 O
be	811 2 O
safe	814 4 O
.	818 1 O

Risperidone	0 11 B-Chemical
-	11 1 O
associated	12 10 O
,	22 1 O
benign	24 6 O
transient	31 9 O
visual	41 6 B-Disease
disturbances	48 12 I-Disease
in	61 2 O
schizophrenic	64 13 B-Disease
patients	78 8 O
with	87 4 O
a	92 1 O
past	94 4 O
history	99 7 O
of	107 2 O
LSD	110 3 B-Chemical
abuse	114 5 O
.	119 1 O

Two	121 3 O
schizophrenic	125 13 B-Disease
patients	139 8 O
,	147 1 O
who	149 3 O
had	153 3 O
a	157 1 O
prior	159 5 O
history	165 7 O
of	173 2 O
LSD	176 3 B-Chemical
abuse	180 5 O
and	186 3 O
who	190 3 O
had	194 3 O
previously	198 10 O
developed	209 9 O
EPS	219 3 B-Disease
with	223 4 O
classic	228 7 O
antipsychotics	236 14 O
,	250 1 O
were	252 4 O
successfully	257 12 O
treated	270 7 O
with	278 4 O
risperidone	283 11 B-Chemical
.	294 1 O

They	296 4 O
both	301 4 O
reported	306 8 O
short	315 5 O
episodes	321 8 O
of	330 2 O
transient	333 9 O
visual	343 6 B-Disease
disturbances	350 12 I-Disease
,	362 1 O
which	364 5 O
appeared	370 8 O
immediately	379 11 O
after	391 5 O
starting	397 8 O
treatment	406 9 O
with	416 4 O
risperidone	421 11 B-Chemical
.	432 1 O

This	434 4 O
imagery	439 7 O
resembled	447 9 O
visual	457 6 B-Disease
disturbances	464 12 I-Disease
previously	477 10 O
experienced	488 11 O
as	500 2 O
"	503 1 O
flashbacks	504 10 O
"	514 1 O
related	516 7 O
to	524 2 O
prior	527 5 O
LSD	533 3 B-Chemical
consumption	537 11 O
.	548 1 O

Risperidone	550 11 B-Chemical
administration	562 14 O
was	577 3 O
continued	581 9 O
and	591 3 O
the	595 3 O
visual	599 6 B-Disease
disturbances	606 12 I-Disease
gradually	619 9 O
wore	629 4 O
off	634 3 O
.	637 1 O

During	639 6 O
a	646 1 O
six	648 3 O
-	651 1 O
month	652 5 O
follow	658 6 O
-	664 1 O
up	665 2 O
period	668 6 O
,	674 1 O
there	676 5 O
was	682 3 O
no	686 2 O
recurrence	689 10 O
of	700 2 O
visual	703 6 B-Disease
disturbances	710 12 I-Disease
.	722 1 O

This	724 4 O
phenomenon	729 10 O
may	740 3 O
be	744 2 O
interpreted	747 11 O
as	759 2 O
a	762 1 O
benign	764 6 O
,	770 1 O
short	772 5 O
-	777 1 O
term	778 4 O
and	783 3 O
self	787 4 O
-	791 1 O
limiting	792 8 O
side	801 4 O
effect	806 6 O
which	813 5 O
does	819 4 O
not	824 3 O
contraindicate	828 14 O
the	843 3 O
use	847 3 O
of	851 2 O
risperidone	854 11 B-Chemical
or	866 2 O
interfere	869 9 O
with	879 4 O
treatment	884 9 O
.	893 1 O

Conclusions	895 11 O
based	907 5 O
on	913 2 O
two	916 3 O
case	920 4 O
reports	925 7 O
should	933 6 O
be	940 2 O
taken	943 5 O
with	949 4 O
appropriate	954 11 O
caution	966 7 O
.	973 1 O

Activation	0 10 O
of	11 2 O
poly	14 4 B-Chemical
(	18 1 I-Chemical
ADP	19 3 I-Chemical
-	22 1 I-Chemical
ribose	23 6 I-Chemical
)	29 1 I-Chemical
polymerase	31 10 O
contributes	42 11 O
to	54 2 O
development	57 11 O
of	69 2 O
doxorubicin	72 11 B-Chemical
-	83 1 O
induced	84 7 O
heart	92 5 B-Disease
failure	98 7 I-Disease
.	105 1 O

Activation	107 10 O
of	118 2 O
the	121 3 O
nuclear	125 7 O
enzyme	133 6 O
poly	140 4 B-Chemical
(	144 1 I-Chemical
ADP	145 3 I-Chemical
-	148 1 I-Chemical
ribose	149 6 I-Chemical
)	155 1 I-Chemical
polymerase	157 10 O
(	168 1 O
PARP	169 4 O
)	173 1 O
by	175 2 O
oxidant	178 7 O
-	185 1 O
mediated	186 8 O
DNA	195 3 O
damage	199 6 O
is	206 2 O
an	209 2 O
important	212 9 O
pathway	222 7 O
of	230 2 O
cell	233 4 O
dysfunction	238 11 O
and	250 3 O
tissue	254 6 O
injury	261 6 O
in	268 2 O
conditions	271 10 O
associated	282 10 O
with	293 4 O
oxidative	298 9 O
stress	308 6 O
.	314 1 O

Increased	316 9 O
oxidative	326 9 O
stress	336 6 O
is	343 2 O
a	346 1 O
major	348 5 O
factor	354 6 O
implicated	361 10 O
in	372 2 O
the	375 3 O
cardiotoxicity	379 14 B-Disease
of	394 2 O
doxorubicin	397 11 B-Chemical
(	409 1 O
DOX	410 3 B-Chemical
)	413 1 O
,	414 1 O
a	416 1 O
widely	418 6 O
used	425 4 O
antitumor	430 9 O
anthracycline	440 13 B-Chemical
antibiotic	454 10 O
.	464 1 O

Thus	466 4 O
,	470 1 O
we	472 2 O
hypothesized	475 12 O
that	488 4 O
the	493 3 O
activation	497 10 O
of	508 2 O
PARP	511 4 O
may	516 3 O
contribute	520 10 O
to	531 2 O
the	534 3 O
DOX	538 3 B-Chemical
-	541 1 O
induced	542 7 O
cardiotoxicity	550 14 B-Disease
.	564 1 O

Using	566 5 O
a	572 1 O
dual	574 4 O
approach	579 8 O
of	588 2 O
PARP	591 4 O
-	595 1 O
1	596 1 O
suppression	598 11 O
,	609 1 O
by	611 2 O
genetic	614 7 O
deletion	622 8 O
or	631 2 O
pharmacological	634 15 O
inhibition	650 10 O
with	661 4 O
the	666 3 O
phenanthridinone	670 16 O
PARP	687 4 O
inhibitor	692 9 O
PJ34	702 4 B-Chemical
,	706 1 O
we	708 2 O
now	711 3 O
demonstrate	715 11 O
the	727 3 O
role	731 4 O
of	736 2 O
PARP	739 4 O
in	744 2 O
the	747 3 O
development	751 11 O
of	763 2 O
cardiac	766 7 B-Disease
dysfunction	774 11 I-Disease
induced	786 7 O
by	794 2 O
DOX	797 3 B-Chemical
.	800 1 O

PARP	802 4 O
-	806 1 O
1	807 1 O
+	808 1 O
/	809 1 O
+	810 1 O
and	812 3 O
PARP	816 4 O
-	820 1 O
1	821 1 O
-	822 1 O
/	823 1 O
-	824 1 O
mice	826 4 O
received	831 8 O
a	840 1 O
single	842 6 O
injection	849 9 O
of	859 2 O
DOX	862 3 B-Chemical
(	866 1 O
25	867 2 O
mg	870 2 O
/	872 1 O
kg	873 2 O
i	876 1 O
.	877 1 O
p	878 1 O
)	879 1 O
.	880 1 O

Five	882 4 O
days	887 4 O
after	892 5 O
DOX	898 3 B-Chemical
administration	902 14 O
,	916 1 O
left	918 4 O
ventricular	923 11 O
performance	935 11 O
was	947 3 O
significantly	951 13 O
depressed	965 9 O
in	975 2 O
PARP	978 4 O
-	982 1 O
1	983 1 O
+	984 1 O
/	985 1 O
+	986 1 O
mice	988 4 O
,	992 1 O
but	994 3 O
only	998 4 O
to	1003 2 O
a	1006 1 O
smaller	1008 7 O
extent	1016 6 O
in	1023 2 O
PARP	1026 4 O
-	1030 1 O
1	1031 1 O
-	1032 1 O
/	1033 1 O
-	1034 1 O
ones	1036 4 O
.	1040 1 O

Similar	1042 7 O
experiments	1050 11 O
were	1062 4 O
conducted	1067 9 O
in	1077 2 O
BALB	1080 4 O
/	1084 1 O
c	1085 1 O
mice	1087 4 O
treated	1092 7 O
with	1100 4 O
PJ34	1105 4 B-Chemical
or	1110 2 O
vehicle	1113 7 O
.	1120 1 O

Treatment	1122 9 O
with	1132 4 O
a	1137 1 O
PJ34	1139 4 B-Chemical
significantly	1144 13 O
improved	1158 8 O
cardiac	1167 7 B-Disease
dysfunction	1175 11 I-Disease
and	1187 3 O
increased	1191 9 O
the	1201 3 O
survival	1205 8 O
of	1214 2 O
the	1217 3 O
animals	1221 7 O
.	1228 1 O

In	1230 2 O
addition	1233 8 O
PJ34	1242 4 B-Chemical
significantly	1247 13 O
reduced	1261 7 O
the	1269 3 O
DOX	1273 3 B-Chemical
-	1276 1 O
induced	1277 7 O
increase	1285 8 O
in	1294 2 O
the	1297 3 O
serum	1301 5 O
lactate	1307 7 B-Chemical
dehydrogenase	1315 13 O
and	1329 3 O
creatine	1333 8 B-Chemical
kinase	1342 6 O
activities	1349 10 O
but	1360 3 O
not	1364 3 O
metalloproteinase	1368 17 O
activation	1386 10 O
in	1397 2 O
the	1400 3 O
heart	1404 5 O
.	1409 1 O

Thus	1411 4 O
,	1415 1 O
PARP	1417 4 O
activation	1422 10 O
contributes	1433 11 O
to	1445 2 O
the	1448 3 O
cardiotoxicity	1452 14 B-Disease
of	1467 2 O
DOX	1470 3 B-Chemical
.	1473 1 O

PARP	1475 4 O
inhibitors	1480 10 O
may	1491 3 O
exert	1495 5 O
protective	1501 10 O
effects	1512 7 O
against	1520 7 O
the	1528 3 O
development	1532 11 O
of	1544 2 O
severe	1547 6 O
cardiac	1554 7 B-Disease
complications	1562 13 I-Disease
associated	1576 10 O
with	1587 4 O
the	1592 3 O
DOX	1596 3 B-Chemical
treatment	1600 9 O
.	1609 1 O

Fluconazole	0 11 B-Chemical
-	11 1 O
induced	12 7 O
torsade	20 7 B-Disease
de	28 2 I-Disease
pointes	31 7 I-Disease
.	38 1 O

OBJECTIVE	40 9 O
:	49 1 O
To	51 2 O
present	54 7 O
a	62 1 O
case	64 4 O
of	69 2 O
fluconazole	72 11 B-Chemical
-	83 1 O
associated	84 10 O
torsade	95 7 B-Disease
de	103 2 I-Disease
pointes	106 7 I-Disease
(	114 1 O
TDP	115 3 B-Disease
)	118 1 O
and	120 3 O
discuss	124 7 O
fluconazole	132 11 B-Chemical
'	143 1 O
s	144 1 O
role	146 4 O
in	151 2 O
causing	154 7 O
TDP	162 3 B-Disease
.	165 1 O

CASE	167 4 O
SUMMARY	172 7 O
:	179 1 O
A	181 1 O
68	183 2 O
-	185 1 O
year	186 4 O
-	190 1 O
old	191 3 O
white	195 5 O
woman	201 5 O
with	207 4 O
Candida	212 7 O
glabrata	220 8 O
isolated	229 8 O
from	238 4 O
a	243 1 O
presacral	245 9 O
abscess	255 7 O
developed	263 9 O
TDP	273 3 B-Disease
eight	277 5 O
days	283 4 O
after	288 5 O
commencing	294 10 O
oral	305 4 O
fluconazole	310 11 B-Chemical
The	322 3 O
patient	326 7 O
had	334 3 O
no	338 2 O
other	341 5 O
risk	347 4 O
factors	352 7 O
for	360 3 O
TDP	364 3 B-Disease
,	367 1 O
including	369 9 O
coronary	379 8 B-Disease
artery	388 6 I-Disease
disease	395 7 I-Disease
,	402 1 O
cardiomyopathy	404 14 B-Disease
,	418 1 O
congestive	420 10 B-Disease
heart	431 5 I-Disease
failure	437 7 I-Disease
,	444 1 O
and	446 3 O
electrolyte	450 11 O
abnormalities	462 13 O
There	476 5 O
was	482 3 O
a	486 1 O
temporal	488 8 O
association	497 11 O
between	509 7 O
the	517 3 O
initiation	521 10 O
of	532 2 O
fluconazole	535 11 B-Chemical
and	547 3 O
TDP	551 3 B-Disease
.	554 1 O

The	556 3 O
TDP	560 3 B-Disease
resolved	564 8 O
when	573 4 O
fluconazole	578 11 B-Chemical
was	590 3 O
discontinued	594 12 O
;	606 1 O
however	608 7 O
,	615 1 O
the	617 3 O
patient	621 7 O
continued	629 9 O
to	639 2 O
have	642 4 O
premature	647 9 B-Disease
ventricular	657 11 I-Disease
contractions	669 12 I-Disease
and	682 3 O
nonsustained	686 12 O
ventricular	699 11 B-Disease
tachycardia	711 11 I-Disease
(	723 1 O
NSVT	724 4 B-Disease
)	728 1 O
until	730 5 O
six	736 3 O
days	740 4 O
after	745 5 O
drug	751 4 O
cessation	756 9 O
DISCUSSION	766 10 O
:	776 1 O
Use	778 3 O
of	782 2 O
the	785 3 O
Naranjo	789 7 O
probability	797 11 O
scale	809 5 O
indicates	815 9 O
a	825 1 O
probable	827 8 O
relationship	836 12 O
between	849 7 O
the	857 3 O
use	861 3 O
of	865 2 O
fluconazole	868 11 B-Chemical
and	880 3 O
the	884 3 O
development	888 11 O
of	900 2 O
TDP	903 3 B-Disease
.	906 1 O

The	908 3 O
possible	912 8 O
mechanism	921 9 O
is	931 2 O
depression	934 10 B-Disease
of	945 2 O
rapidly	948 7 O
activating	956 10 O
delayed	967 7 O
rectifier	975 9 O
potassium	985 9 B-Chemical
currents	995 8 O
.	1003 1 O

In	1005 2 O
our	1008 3 O
patient	1012 7 O
,	1019 1 O
there	1021 5 O
was	1027 3 O
no	1031 2 O
other	1034 5 O
etiology	1040 8 O
identified	1049 10 O
that	1060 4 O
could	1065 5 O
explain	1071 7 O
QT	1079 2 B-Disease
prolongation	1082 12 I-Disease
or	1095 2 O
TDP	1098 3 B-Disease
The	1102 3 O
complete	1106 8 O
disappearance	1115 13 O
of	1129 2 O
NSVT	1132 4 B-Disease
and	1137 3 O
premature	1141 9 B-Disease
ventricular	1151 11 I-Disease
contractions	1163 12 I-Disease
followed	1176 8 O
by	1185 2 O
normalization	1188 13 O
of	1202 2 O
QT	1205 2 O
interval	1208 8 O
after	1217 5 O
the	1223 3 O
drug	1227 4 O
was	1232 3 O
stopped	1236 7 O
strongly	1244 8 O
suggests	1253 8 O
fluconazole	1262 11 B-Chemical
as	1274 2 O
the	1277 3 O
etiology	1281 8 O
.	1289 1 O

CONCLUSIONS	1291 11 O
:	1302 1 O
Clinicians	1304 10 O
should	1315 6 O
be	1322 2 O
aware	1325 5 O
that	1331 4 O
fluconazole	1336 11 B-Chemical
,	1347 1 O
even	1349 4 O
at	1354 2 O
low	1357 3 O
doses	1361 5 O
,	1366 1 O
may	1368 3 O
cause	1372 5 O
prolongation	1378 12 B-Disease
of	1391 2 I-Disease
the	1394 3 I-Disease
QT	1398 2 I-Disease
interval	1401 8 I-Disease
,	1409 1 O
leading	1411 7 O
to	1419 2 O
TDP	1422 3 B-Disease
.	1425 1 O

Serial	1427 6 O
electrocardiographic	1434 20 O
monitoring	1455 10 O
may	1466 3 O
be	1470 2 O
considered	1473 10 O
when	1484 4 O
fluconazole	1489 11 B-Chemical
is	1501 2 O
administered	1504 12 O
in	1517 2 O
patients	1520 8 O
who	1529 3 O
are	1533 3 O
at	1537 2 O
risk	1540 4 O
for	1545 3 O
ventricular	1549 11 B-Disease
arrhythmias	1561 11 I-Disease
.	1572 1 O

High	0 4 O
-	4 1 O
dose	5 4 O
methylprednisolone	10 18 B-Chemical
may	29 3 O
do	33 2 O
more	36 4 O
harm	41 4 O
for	46 3 O
spinal	50 6 B-Disease
cord	57 4 I-Disease
injury	62 6 I-Disease
.	68 1 O

Because	70 7 O
of	78 2 O
the	81 3 O
National	85 8 O
Acute	94 5 O
Spinal	100 6 B-Disease
Cord	107 4 I-Disease
Injury	112 6 I-Disease
Studies	119 7 O
(	127 1 O
NASCIS	128 6 O
)	134 1 O
,	135 1 O
high	137 4 O
-	141 1 O
dose	142 4 O
methylprednisolone	147 18 B-Chemical
became	166 6 O
the	173 3 O
standard	177 8 O
of	186 2 O
care	189 4 O
for	194 3 O
the	198 3 O
acute	202 5 O
spinal	208 6 B-Disease
cord	215 4 I-Disease
injury	220 6 I-Disease
.	226 1 O

In	228 2 O
the	231 3 O
NASCIS	235 6 O
,	241 1 O
there	243 5 O
was	249 3 O
no	253 2 O
mention	256 7 O
regarding	264 9 O
the	274 3 O
possibility	278 11 O
of	290 2 O
acute	293 5 O
corticosteroid	299 14 B-Chemical
myopathy	314 8 B-Disease
that	323 4 O
high	328 4 O
-	332 1 O
dose	333 4 O
methylprednisolone	338 18 B-Chemical
may	357 3 O
cause	361 5 O
.	366 1 O

The	368 3 O
dosage	372 6 O
of	379 2 O
methylprednisolone	382 18 B-Chemical
recommended	401 11 O
by	413 2 O
the	416 3 O
NASCIS	420 6 O
3	427 1 O
is	429 2 O
the	432 3 O
highest	436 7 O
dose	444 4 O
of	449 2 O
steroids	452 8 B-Chemical
ever	461 4 O
being	466 5 O
used	472 4 O
during	477 6 O
a	484 1 O
2	486 1 O
-	487 1 O
day	488 3 O
period	492 6 O
for	499 3 O
any	503 3 O
clinical	507 8 O
condition	516 9 O
.	525 1 O

We	527 2 O
hypothesize	530 11 O
that	542 4 O
it	547 2 O
may	550 3 O
cause	554 5 O
some	560 4 O
damage	565 6 B-Disease
to	572 2 I-Disease
the	575 3 I-Disease
muscle	579 6 I-Disease
of	586 2 O
spinal	589 6 B-Disease
cord	596 4 I-Disease
injury	601 6 I-Disease
patients	608 8 O
.	616 1 O

Further	618 7 O
,	625 1 O
steroid	627 7 B-Chemical
myopathy	635 8 B-Disease
recovers	644 8 O
naturally	653 9 O
and	663 3 O
the	667 3 O
neurological	671 12 O
improvement	684 11 O
shown	696 5 O
in	702 2 O
the	705 3 O
NASCIS	709 6 O
may	716 3 O
be	720 2 O
just	723 4 O
a	728 1 O
recording	730 9 O
of	740 2 O
this	743 4 O
natural	748 7 O
motor	756 5 O
recovery	762 8 O
from	771 4 O
the	776 3 O
steroid	780 7 B-Chemical
myopathy	788 8 B-Disease
,	796 1 O
instead	798 7 O
of	806 2 O
any	809 3 O
protection	813 10 O
that	824 4 O
methylprednisolone	829 18 B-Chemical
offers	848 6 O
to	855 2 O
the	858 3 O
spinal	862 6 B-Disease
cord	869 4 I-Disease
injury	874 6 I-Disease
.	880 1 O

To	882 2 O
our	885 3 O
knowledge	889 9 O
,	898 1 O
this	900 4 O
is	905 2 O
the	908 3 O
first	912 5 O
discussion	918 10 O
considering	929 11 O
the	941 3 O
possibility	945 11 O
that	957 4 O
the	962 3 O
methylprednisolone	966 18 B-Chemical
recommended	985 11 O
by	997 2 O
NASCIS	1000 6 O
may	1007 3 O
cause	1011 5 O
acute	1017 5 O
corticosteroid	1023 14 B-Chemical
myopathy	1038 8 B-Disease
.	1046 1 O

Probing	0 7 O
peripheral	8 10 O
and	19 3 O
central	23 7 O
cholinergic	31 11 O
system	43 6 O
responses	50 9 O
.	59 1 O

OBJECTIVE	61 9 O
:	70 1 O
The	72 3 O
pharmacological	76 15 O
response	92 8 O
to	101 2 O
drugs	104 5 O
that	110 4 O
act	115 3 O
on	119 2 O
the	122 3 O
cholinergic	126 11 O
system	138 6 O
of	145 2 O
the	148 3 O
iris	152 4 O
has	157 3 O
been	161 4 O
used	166 4 O
to	171 2 O
predict	174 7 O
deficits	182 8 O
in	191 2 O
central	194 7 O
cholinergic	202 11 O
functioning	214 11 O
due	226 3 O
to	230 2 O
diseases	233 8 O
such	242 4 O
as	247 2 O
Alzheimer	250 9 B-Disease
'	259 1 I-Disease
s	260 1 I-Disease
disease	262 7 I-Disease
,	269 1 O
yet	271 3 O
correlations	275 12 O
between	288 7 O
central	296 7 O
and	304 3 O
peripheral	308 10 O
responses	319 9 O
have	329 4 O
not	334 3 O
been	338 4 O
properly	343 8 O
studied	352 7 O
.	359 1 O

This	361 4 O
study	366 5 O
assessed	372 8 O
the	381 3 O
effect	385 6 O
of	392 2 O
normal	395 6 O
aging	402 5 O
on	408 2 O
(	411 1 O
1	412 1 O
)	413 1 O
the	415 3 O
tropicamide	419 11 B-Chemical
-	430 1 O
induced	431 7 O
increase	439 8 O
in	448 2 O
pupil	451 5 O
diameter	457 8 O
,	465 1 O
and	467 3 O
(	471 1 O
2	472 1 O
)	473 1 O
the	475 3 O
reversal	479 8 O
of	488 2 O
this	491 4 O
effect	496 6 O
with	503 4 O
pilocarpine	508 11 B-Chemical
.	519 1 O

Scopolamine	521 11 B-Chemical
was	533 3 O
used	537 4 O
as	542 2 O
a	545 1 O
positive	547 8 O
control	556 7 O
to	564 2 O
detect	567 6 O
age	574 3 O
-	577 1 O
dependent	578 9 O
changes	588 7 O
in	596 2 O
central	599 7 O
cholinergic	607 11 O
functioning	619 11 O
in	631 2 O
the	634 3 O
elderly	638 7 O
.	645 1 O

DESIGN	647 6 O
:	653 1 O
Randomized	655 10 O
double	666 6 O
-	672 1 O
blind	673 5 O
controlled	679 10 O
trial	690 5 O
.	695 1 O

PARTICIPANTS	697 12 O
:	709 1 O
Ten	711 3 O
healthy	715 7 O
elderly	723 7 O
(	731 1 O
mean	732 4 O
age	737 3 O
70	741 2 O
)	743 1 O
and	745 3 O
9	749 1 O
young	751 5 O
(	757 1 O
mean	758 4 O
age	763 3 O
33	767 2 O
)	769 1 O
volunteers	771 10 O
.	781 1 O

INTERVENTIONS	783 13 O
:	796 1 O
Pupil	798 5 O
diameter	804 8 O
was	813 3 O
monitored	817 9 O
using	827 5 O
a	833 1 O
computerized	835 12 O
infrared	848 8 O
pupillometer	857 12 O
over	870 4 O
4	875 1 O
hours	877 5 O
.	882 1 O

The	884 3 O
study	888 5 O
involved	894 8 O
4	903 1 O
sessions	905 8 O
.	913 1 O

In	915 2 O
1	918 1 O
session	920 7 O
,	927 1 O
tropicamide	929 11 B-Chemical
(	941 1 O
20	942 2 O
microL	945 6 O
,	951 1 O
0	953 1 O
.	954 1 O
01	955 2 O
%	957 1 O
)	958 1 O
was	960 3 O
administered	964 12 O
to	977 2 O
one	980 3 O
eye	984 3 O
and	988 3 O
placebo	992 7 O
to	1000 2 O
the	1003 3 O
other	1007 5 O
.	1012 1 O

In	1014 2 O
another	1017 7 O
session	1025 7 O
,	1032 1 O
tropicamide	1034 11 B-Chemical
(	1046 1 O
20	1047 2 O
microL	1050 6 O
,	1056 1 O
0	1058 1 O
.	1059 1 O
01	1060 2 O
%	1062 1 O
)	1063 1 O
was	1065 3 O
administered	1069 12 O
to	1082 2 O
both	1085 4 O
eyes	1090 4 O
,	1094 1 O
followed	1096 8 O
23	1105 2 O
minutes	1108 7 O
later	1116 5 O
by	1122 2 O
the	1125 3 O
application	1129 11 O
of	1141 2 O
pilocarpine	1144 11 B-Chemical
(	1156 1 O
20	1157 2 O
microL	1160 6 O
,	1166 1 O
0	1168 1 O
.	1169 1 O
1	1170 1 O
%	1171 1 O
)	1172 1 O
to	1174 2 O
one	1177 3 O
eye	1181 3 O
and	1185 3 O
placebo	1189 7 O
to	1197 2 O
the	1200 3 O
other	1204 5 O
.	1209 1 O

All	1211 3 O
eye	1215 3 O
drops	1219 5 O
were	1225 4 O
given	1230 5 O
in	1236 2 O
a	1239 1 O
randomized	1241 10 O
order	1252 5 O
.	1257 1 O

In	1259 2 O
2	1262 1 O
separate	1264 8 O
sessions	1273 8 O
,	1281 1 O
a	1283 1 O
single	1285 6 O
dose	1292 4 O
of	1297 2 O
scopolamine	1300 11 B-Chemical
(	1312 1 O
0	1313 1 O
.	1314 1 O
5	1315 1 O
mg	1317 2 O
,	1319 1 O
intravenously	1321 13 O
)	1334 1 O
or	1336 2 O
placebo	1339 7 O
was	1347 3 O
administered	1351 12 O
,	1363 1 O
and	1365 3 O
the	1369 3 O
effects	1373 7 O
on	1381 2 O
word	1384 4 O
recall	1389 6 O
were	1396 4 O
measured	1401 8 O
using	1410 5 O
the	1416 3 O
Buschke	1420 7 O
Selective	1428 9 O
Reminding	1438 9 O
Test	1448 4 O
over	1453 4 O
2	1458 1 O
hours	1460 5 O
.	1465 1 O

OUTCOME	1467 7 O
MEASURES	1475 8 O
:	1483 1 O
Pupil	1485 5 O
size	1491 4 O
at	1496 2 O
time	1499 4 O
points	1504 6 O
after	1511 5 O
administration	1517 14 O
of	1532 2 O
tropicamide	1535 11 B-Chemical
and	1547 3 O
pilocarpine	1551 11 B-Chemical
;	1562 1 O
scopolamine	1564 11 B-Chemical
-	1575 1 O
induced	1576 7 O
impairment	1584 10 B-Disease
in	1595 2 I-Disease
word	1598 4 I-Disease
recall	1603 6 I-Disease
.	1609 1 O

RESULTS	1611 7 O
:	1618 1 O
There	1620 5 O
was	1626 3 O
no	1630 2 O
significant	1633 11 O
difference	1645 10 O
between	1656 7 O
elderly	1664 7 O
and	1672 3 O
young	1676 5 O
volunteers	1682 10 O
in	1693 2 O
pupillary	1696 9 O
response	1706 8 O
to	1715 2 O
tropicamide	1718 11 B-Chemical
at	1730 2 O
any	1733 3 O
time	1737 4 O
point	1742 5 O
(	1748 1 O
p	1749 1 O
>	1751 1 O
0	1753 1 O
.	1754 1 O
05	1755 2 O
)	1757 1 O
.	1758 1 O

The	1760 3 O
elderly	1764 7 O
group	1772 5 O
had	1778 3 O
a	1782 1 O
significantly	1784 13 O
greater	1798 7 O
pilocarpine	1806 11 B-Chemical
-	1817 1 O
induced	1818 7 O
net	1826 3 O
decrease	1830 8 O
in	1839 2 O
pupil	1842 5 O
size	1848 4 O
85	1853 2 O
,	1855 1 O
125	1857 3 O
,	1860 1 O
165	1862 3 O
and	1866 3 O
215	1870 3 O
minutes	1874 7 O
after	1882 5 O
administration	1888 14 O
,	1902 1 O
compared	1904 8 O
with	1913 4 O
the	1918 3 O
young	1922 5 O
group	1928 5 O
(	1934 1 O
p	1935 1 O
<	1937 1 O
0	1939 1 O
.	1940 1 O
05	1941 2 O
)	1943 1 O
.	1944 1 O

Compared	1946 8 O
with	1955 4 O
the	1960 3 O
young	1964 5 O
group	1970 5 O
,	1975 1 O
the	1977 3 O
elderly	1981 7 O
group	1989 5 O
had	1995 3 O
greater	1999 7 O
scopolamine	2007 11 B-Chemical
-	2018 1 O
induced	2019 7 O
impairment	2027 10 B-Disease
in	2038 2 I-Disease
word	2041 4 I-Disease
recall	2046 6 I-Disease
60	2053 2 O
,	2055 1 O
90	2057 2 O
and	2060 3 O
120	2064 3 O
minutes	2068 7 O
after	2076 5 O
administration	2082 14 O
(	2097 1 O
p	2098 1 O
<	2100 1 O
0	2102 1 O
.	2103 1 O
05	2104 2 O
)	2106 1 O
.	2107 1 O

CONCLUSION	2109 10 O
:	2119 1 O
There	2121 5 O
is	2127 2 O
an	2130 2 O
age	2133 3 O
-	2136 1 O
related	2137 7 O
pupillary	2145 9 O
response	2155 8 O
to	2164 2 O
pilocarpine	2167 11 B-Chemical
that	2179 4 O
is	2184 2 O
not	2187 3 O
found	2191 5 O
with	2197 4 O
tropicamide	2202 11 B-Chemical
.	2213 1 O

Thus	2215 4 O
,	2219 1 O
pilocarpine	2221 11 B-Chemical
may	2233 3 O
be	2237 2 O
useful	2240 6 O
to	2247 2 O
assess	2250 6 O
variations	2257 10 O
in	2268 2 O
central	2271 7 O
cholinergic	2279 11 O
function	2291 8 O
in	2300 2 O
elderly	2303 7 O
patients	2311 8 O
.	2319 1 O

Acetazolamide	0 13 B-Chemical
-	13 1 O
induced	14 7 O
Gerstmann	22 9 B-Disease
syndrome	32 8 I-Disease
.	40 1 O

Acute	42 5 O
confusion	48 9 B-Disease
induced	58 7 O
by	66 2 O
acetazolamide	69 13 B-Chemical
is	83 2 O
a	86 1 O
well	88 4 O
known	93 5 O
adverse	99 7 O
drug	107 4 O
reaction	112 8 O
in	121 2 O
patients	124 8 O
with	133 4 O
renal	138 5 B-Disease
impairment	144 10 I-Disease
.	154 1 O

We	156 2 O
report	159 6 O
a	166 1 O
case	168 4 O
of	173 2 O
acetazolamide	176 13 B-Chemical
-	189 1 O
induced	190 7 O
Gerstmann	198 9 B-Disease
syndrome	208 8 I-Disease
in	217 2 O
a	220 1 O
patient	222 7 O
with	230 4 O
normal	235 6 O
renal	242 5 O
function	248 8 O
,	256 1 O
to	258 2 O
highlight	261 9 O
predisposing	271 12 O
factors	284 7 O
that	292 4 O
are	297 3 O
frequently	301 10 O
overlooked	312 10 O
.	322 1 O

Hypomania	0 9 B-Disease
-	9 1 O
like	10 4 O
syndrome	15 8 O
induced	24 7 O
by	32 2 O
olanzapine	35 10 B-Chemical
.	45 1 O

We	47 2 O
report	50 6 O
a	57 1 O
female	59 6 O
patient	66 7 O
with	74 4 O
a	79 1 O
diagnosis	81 9 O
of	91 2 O
a	94 1 O
not	96 3 O
otherwise	100 9 O
specified	110 9 O
psychotic	120 9 B-Disease
disorder	130 8 I-Disease
(	139 1 O
DSM	140 3 O
-	143 1 O
IV	144 2 O
)	146 1 O
who	148 3 O
developed	152 9 O
hypomania	162 9 B-Disease
shortly	172 7 O
after	180 5 O
the	186 3 O
introduction	190 12 O
of	203 2 O
olanzapine	206 10 B-Chemical
treatment	217 9 O
.	226 1 O

Neutrophil	0 10 O
superoxide	11 10 B-Chemical
and	22 3 O
hydrogen	26 8 B-Chemical
peroxide	35 8 I-Chemical
production	44 10 O
in	55 2 O
patients	58 8 O
with	67 4 O
acute	72 5 B-Disease
liver	78 5 I-Disease
failure	84 7 I-Disease
.	91 1 O

Defects	93 7 O
in	101 2 O
superoxide	104 10 B-Chemical
and	115 3 O
hydrogen	119 8 B-Chemical
peroxide	128 8 I-Chemical
production	137 10 O
may	148 3 O
be	152 2 O
implicated	155 10 O
in	166 2 O
the	169 3 O
high	173 4 O
incidence	178 9 O
of	188 2 O
bacterial	191 9 B-Disease
infections	201 10 I-Disease
in	212 2 O
patients	215 8 O
with	224 4 O
acute	229 5 B-Disease
liver	235 5 I-Disease
failure	241 7 I-Disease
(	249 1 O
ALF	250 3 B-Disease
)	253 1 O
.	254 1 O

In	256 2 O
the	259 3 O
present	263 7 O
study	271 5 O
,	276 1 O
oxygen	278 6 B-Chemical
radical	285 7 O
production	293 10 O
in	304 2 O
patients	307 8 O
with	316 4 O
ALF	321 3 B-Disease
due	325 3 O
to	329 2 O
paracetamol	332 11 B-Chemical
overdose	344 8 B-Disease
was	353 3 O
compared	357 8 O
with	366 4 O
that	371 4 O
of	376 2 O
healthy	379 7 O
volunteers	387 10 O
.	397 1 O

Neutrophils	399 11 O
from	411 4 O
14	416 2 O
ALF	419 3 B-Disease
patients	423 8 O
were	432 4 O
stimulated	437 10 O
via	448 3 O
the	452 3 O
complement	456 10 O
receptors	467 9 O
using	477 5 O
zymosan	483 7 O
opsonized	491 9 O
with	501 4 O
ALF	506 3 B-Disease
or	510 2 O
control	513 7 O
serum	521 5 O
.	526 1 O

Superoxide	528 10 B-Chemical
and	539 3 O
hydrogen	543 8 B-Chemical
peroxide	552 8 I-Chemical
production	561 10 O
by	572 2 O
ALF	575 3 B-Disease
neutrophils	579 11 O
stimulated	591 10 O
with	602 4 O
zymosan	607 7 O
opsonized	615 9 O
with	625 4 O
ALF	630 3 B-Disease
serum	634 5 O
was	640 3 O
significantly	644 13 O
reduced	658 7 O
compared	666 8 O
with	675 4 O
the	680 3 O
control	684 7 O
subjects	692 8 O
(	701 1 O
P	702 1 O
<	704 1 O
0	706 1 O
.	707 1 O
01	708 2 O
)	710 1 O
.	711 1 O

This	713 4 O
defect	718 6 O
persisted	725 9 O
when	735 4 O
zymosan	740 7 O
opsonized	748 9 O
by	758 2 O
control	761 7 O
serum	769 5 O
was	775 3 O
used	779 4 O
(	784 1 O
P	785 1 O
<	787 1 O
0	789 1 O
.	790 1 O
05	791 2 O
)	793 1 O
.	794 1 O

Superoxide	796 10 B-Chemical
and	807 3 O
hydrogen	811 8 B-Chemical
peroxide	820 8 I-Chemical
production	829 10 O
in	840 2 O
neutrophils	843 11 O
stimulated	855 10 O
with	866 4 O
formyl	871 6 B-Chemical
-	877 1 I-Chemical
methionyl	878 9 I-Chemical
-	887 1 I-Chemical
leucyl	888 6 I-Chemical
-	894 1 I-Chemical
phenylalanine	895 13 I-Chemical
(	909 1 O
fMLP	910 4 B-Chemical
)	914 1 O
from	916 4 O
a	921 1 O
further	923 7 O
18	931 2 O
ALF	934 3 B-Disease
patients	938 8 O
was	947 3 O
unaffected	951 10 O
compared	962 8 O
with	971 4 O
control	976 7 O
neutrophils	984 11 O
.	995 1 O

Serum	997 5 O
C3	1003 2 O
complement	1006 10 O
levels	1017 6 O
were	1024 4 O
significantly	1029 13 O
reduced	1043 7 O
in	1051 2 O
ALF	1054 3 B-Disease
patients	1058 8 O
compared	1067 8 O
with	1076 4 O
control	1081 7 O
subjects	1089 8 O
(	1098 1 O
P	1099 1 O
<	1101 1 O
0	1103 1 O
.	1104 1 O
0005	1105 4 O
)	1109 1 O
.	1110 1 O

These	1112 5 O
results	1118 7 O
demonstrate	1126 11 O
a	1138 1 O
neutrophil	1140 10 O
defect	1151 6 O
in	1158 2 O
ALF	1161 3 B-Disease
due	1165 3 O
to	1169 2 O
paracetamol	1172 11 B-Chemical
overdose	1184 8 B-Disease
,	1192 1 O
that	1194 4 O
is	1199 2 O
complement	1202 10 O
dependent	1213 9 O
but	1223 3 O
independent	1227 11 O
of	1239 2 O
serum	1242 5 O
complement	1248 10 O
,	1258 1 O
possibly	1260 8 O
connected	1269 9 O
to	1279 2 O
the	1282 3 O
complement	1286 10 O
receptor	1297 8 O
.	1305 1 O

Absence	0 7 O
of	8 2 O
effect	11 6 O
of	18 2 O
sertraline	21 10 B-Chemical
on	32 2 O
time	35 4 O
-	39 1 O
based	40 5 O
sensitization	46 13 O
of	60 2 O
cognitive	63 9 B-Disease
impairment	73 10 I-Disease
with	84 4 O
haloperidol	89 11 B-Chemical
.	100 1 O

This	102 4 O
double	107 6 O
-	113 1 O
blind	114 5 O
,	119 1 O
randomized	121 10 O
,	131 1 O
placebo	133 7 O
-	140 1 O
controlled	141 10 O
study	152 5 O
evaluated	158 9 O
the	168 3 O
effects	172 7 O
of	180 2 O
haloperidol	183 11 B-Chemical
alone	195 5 O
and	201 3 O
haloperidol	205 11 B-Chemical
plus	217 4 O
sertraline	222 10 B-Chemical
on	233 2 O
cognitive	236 9 O
and	246 3 O
psychomotor	250 11 O
function	262 8 O
in	271 2 O
24	274 2 O
healthy	277 7 O
male	285 4 O
subjects	290 8 O
.	298 1 O

METHOD	300 6 O
:	306 1 O
All	308 3 O
subjects	312 8 O
received	321 8 O
placebo	330 7 O
on	338 2 O
Day	341 3 O
1	345 1 O
and	347 3 O
haloperidol	351 11 B-Chemical
2	363 1 O
mg	365 2 O
on	368 2 O
Days	371 4 O
2	376 1 O
and	378 3 O
25	382 2 O
.	384 1 O

From	386 4 O
Days	391 4 O
9	396 1 O
to	398 2 O
25	401 2 O
,	403 1 O
subjects	405 8 O
were	414 4 O
randomly	419 8 O
assigned	428 8 O
to	437 2 O
either	440 6 O
sertraline	447 10 B-Chemical
(	458 1 O
12	459 2 O
subjects	462 8 O
)	470 1 O
or	472 2 O
placebo	475 7 O
(	483 1 O
12	484 2 O
subjects	487 8 O
)	495 1 O
;	496 1 O
the	498 3 O
sertraline	502 10 B-Chemical
dose	513 4 O
was	518 3 O
titrated	522 8 O
from	531 4 O
50	536 2 O
to	539 2 O
200	542 3 O
mg	546 2 O
/	548 1 O
day	549 3 O
from	553 4 O
Days	558 4 O
9	563 1 O
to	565 2 O
16	568 2 O
,	570 1 O
and	572 3 O
remained	576 8 O
at	585 2 O
200	588 3 O
mg	592 2 O
/	594 1 O
day	595 3 O
for	599 3 O
the	603 3 O
final	607 5 O
10	613 2 O
days	616 4 O
of	621 2 O
the	624 3 O
drug	628 4 O
administration	633 14 O
period	648 6 O
.	654 1 O

Cognitive	656 9 O
function	666 8 O
testing	675 7 O
was	683 3 O
performed	687 9 O
before	697 6 O
dosing	704 6 O
and	711 3 O
over	715 4 O
a	720 1 O
24	722 2 O
-	724 1 O
hour	725 4 O
period	730 6 O
after	737 5 O
dosing	743 6 O
on	750 2 O
Days	753 4 O
1	758 1 O
,	759 1 O
2	761 1 O
,	762 1 O
and	764 3 O
25	768 2 O
.	770 1 O

RESULTS	772 7 O
:	779 1 O
Impairment	781 10 B-Disease
of	792 2 I-Disease
cognitive	795 9 I-Disease
function	805 8 I-Disease
was	814 3 O
observed	818 8 O
6	827 1 O
to	829 2 O
8	832 1 O
hours	834 5 O
after	840 5 O
administration	846 14 O
of	861 2 O
haloperidol	864 11 B-Chemical
on	876 2 O
Day	879 3 O
2	883 1 O
but	885 3 O
was	889 3 O
not	893 3 O
evident	897 7 O
23	905 2 O
hours	908 5 O
after	914 5 O
dosing	920 6 O
.	926 1 O

When	928 4 O
single	933 6 O
-	939 1 O
dose	940 4 O
haloperidol	945 11 B-Chemical
was	957 3 O
given	961 5 O
again	967 5 O
25	973 2 O
days	976 4 O
later	981 5 O
,	986 1 O
greater	988 7 O
impairment	996 10 O
with	1007 4 O
earlier	1012 7 O
onset	1020 5 O
was	1026 3 O
noted	1030 5 O
in	1036 2 O
several	1039 7 O
tests	1047 5 O
in	1053 2 O
both	1056 4 O
treatment	1061 9 O
groups	1071 6 O
,	1077 1 O
suggesting	1079 10 O
enhancement	1090 11 O
of	1102 2 O
this	1105 4 O
effect	1110 6 O
.	1116 1 O

There	1118 5 O
was	1124 3 O
no	1128 2 O
indication	1131 10 O
that	1142 4 O
sertraline	1147 10 B-Chemical
exacerbated	1158 11 O
the	1170 3 O
impairment	1174 10 O
produced	1185 8 O
by	1194 2 O
haloperidol	1197 11 B-Chemical
since	1209 5 O
an	1215 2 O
equivalent	1218 10 O
effect	1229 6 O
also	1236 4 O
occurred	1241 8 O
in	1250 2 O
the	1253 3 O
placebo	1257 7 O
group	1265 5 O
.	1270 1 O

Three	1272 5 O
subjects	1278 8 O
(	1287 1 O
2	1288 1 O
on	1290 2 O
sertraline	1293 10 B-Chemical
and	1304 3 O
1	1308 1 O
on	1310 2 O
placebo	1313 7 O
)	1320 1 O
withdrew	1322 8 O
from	1331 4 O
the	1336 3 O
study	1340 5 O
because	1346 7 O
of	1354 2 O
side	1357 4 O
effects	1362 7 O
.	1369 1 O

Ten	1371 3 O
subjects	1375 8 O
in	1384 2 O
each	1387 4 O
group	1392 5 O
reported	1398 8 O
side	1407 4 O
effects	1412 7 O
related	1420 7 O
to	1428 2 O
treatment	1431 9 O
.	1440 1 O

The	1442 3 O
side	1446 4 O
effect	1451 6 O
profiles	1458 8 O
of	1467 2 O
sertraline	1470 10 B-Chemical
and	1481 3 O
of	1485 2 O
placebo	1488 7 O
were	1496 4 O
similar	1501 7 O
.	1508 1 O

CONCLUSION	1510 10 O
:	1520 1 O
Haloperidol	1522 11 B-Chemical
produced	1534 8 O
a	1543 1 O
clear	1545 5 O
profile	1551 7 O
of	1559 2 O
cognitive	1562 9 B-Disease
impairment	1572 10 I-Disease
that	1583 4 O
was	1588 3 O
not	1592 3 O
worsened	1596 8 O
by	1605 2 O
concomitant	1608 11 O
sertraline	1620 10 B-Chemical
administration	1631 14 O
.	1645 1 O

Ciprofloxacin	0 13 B-Chemical
-	13 1 O
induced	14 7 O
nephrotoxicity	22 14 B-Disease
in	37 2 O
patients	40 8 O
with	49 4 O
cancer	54 6 B-Disease
.	60 1 O

Nephrotoxicity	62 14 B-Disease
associated	77 10 O
with	88 4 O
ciprofloxacin	93 13 B-Chemical
is	107 2 O
uncommon	110 8 O
.	118 1 O

Five	120 4 O
patients	125 8 O
with	134 4 O
cancer	139 6 B-Disease
who	146 3 O
developed	150 9 O
acute	160 5 B-Disease
renal	166 5 I-Disease
failure	172 7 I-Disease
that	180 4 O
followed	185 8 O
treatment	194 9 O
with	204 4 O
ciprofloxacin	209 13 B-Chemical
are	223 3 O
described	227 9 O
and	237 3 O
an	241 2 O
additional	244 10 O
15	255 2 O
cases	258 5 O
reported	264 8 O
in	273 2 O
the	276 3 O
literature	280 10 O
are	291 3 O
reviewed	295 8 O
.	303 1 O

Other	305 5 O
than	311 4 O
elevation	316 9 O
of	326 2 O
serum	329 5 O
creatinine	335 10 B-Chemical
levels	346 6 O
,	352 1 O
characteristic	354 14 O
clinical	369 8 O
manifestations	378 14 O
and	393 3 O
abnormal	397 8 O
laboratory	406 10 O
findings	417 8 O
are	426 3 O
not	430 3 O
frequently	434 10 O
present	445 7 O
.	452 1 O

Allergic	454 8 O
interstitial	463 12 B-Disease
nephritis	476 9 I-Disease
is	486 2 O
believed	489 8 O
to	498 2 O
be	501 2 O
the	504 3 O
underlying	508 10 O
pathological	519 12 O
-	531 1 O
process	532 7 O
.	539 1 O

Definitive	541 10 O
diagnosis	552 9 O
requires	562 8 O
performance	571 11 O
of	583 2 O
renal	586 5 O
biopsy	592 6 O
,	598 1 O
although	600 8 O
this	609 4 O
is	614 2 O
not	617 3 O
always	621 6 O
feasible	628 8 O
.	636 1 O

An	638 2 O
improvement	641 11 O
in	653 2 O
renal	656 5 O
function	662 8 O
that	671 4 O
followed	676 8 O
the	685 3 O
discontinuation	689 15 O
of	705 2 O
the	708 3 O
offending	712 9 O
antibiotic	722 10 O
supports	733 8 O
the	742 3 O
presumptive	746 11 O
diagnosis	758 9 O
of	768 2 O
ciprofloxacin	771 13 B-Chemical
-	784 1 O
induced	785 7 O
acute	793 5 B-Disease
renal	799 5 I-Disease
failure	805 7 I-Disease
.	812 1 O

Case	0 4 O
report	5 6 O
:	11 1 O
pentamidine	13 11 B-Chemical
and	25 3 O
polymorphic	29 11 O
ventricular	41 11 B-Disease
tachycardia	53 11 I-Disease
revisited	65 9 O
.	74 1 O

Pentamidine	76 11 B-Chemical
isethionate	88 11 I-Chemical
has	100 3 O
been	104 4 O
associated	109 10 O
with	120 4 O
ventricular	125 11 B-Disease
tachyarrhythmias	137 16 I-Disease
,	153 1 O
including	155 9 O
torsade	165 7 B-Disease
de	173 2 I-Disease
pointes	176 7 I-Disease
.	183 1 O

This	185 4 O
article	190 7 O
reports	198 7 O
two	206 3 O
cases	210 5 O
of	216 2 O
this	219 4 O
complication	224 12 O
and	237 3 O
reviews	241 7 O
all	249 3 O
reported	253 8 O
cases	262 5 O
to	268 2 O
date	271 4 O
.	275 1 O

Pentamidine	277 11 B-Chemical
-	288 1 O
induced	289 7 O
torsade	297 7 B-Disease
de	305 2 I-Disease
pointes	308 7 I-Disease
may	316 3 O
be	320 2 O
related	323 7 O
to	331 2 O
serum	334 5 O
magnesium	340 9 B-Chemical
levels	350 6 O
and	357 3 O
hypomagnesemia	361 14 B-Disease
may	376 3 O
synergistically	380 15 O
induce	396 6 O
torsade	403 7 O
.	410 1 O

Torsade	412 7 B-Disease
de	420 2 I-Disease
pointes	423 7 I-Disease
occurred	431 8 O
after	440 5 O
an	446 2 O
average	449 7 O
of	457 2 O
10	460 2 O
days	463 4 O
of	468 2 O
treatment	471 9 O
with	481 4 O
pentamidine	486 11 B-Chemical
.	497 1 O

In	499 2 O
these	502 5 O
patients	508 8 O
,	516 1 O
no	518 2 O
other	521 5 O
acute	527 5 O
side	533 4 O
effects	538 7 O
of	546 2 O
pentamidine	549 11 B-Chemical
were	561 4 O
observed	566 8 O
.	574 1 O

Torsade	576 7 B-Disease
de	584 2 I-Disease
pointes	587 7 I-Disease
can	595 3 O
be	599 2 O
treated	602 7 O
when	610 4 O
recognized	615 10 O
early	626 5 O
,	631 1 O
possibly	633 8 O
without	642 7 O
discontinuation	650 15 O
of	666 2 O
pentamidine	669 11 B-Chemical
.	680 1 O

When	682 4 O
QTc	687 3 B-Disease
interval	691 8 I-Disease
prolongation	700 12 I-Disease
is	713 2 O
observed	716 8 O
,	724 1 O
early	726 5 O
magnesium	732 9 B-Chemical
supplementation	742 15 O
is	758 2 O
advocated	761 9 O
.	770 1 O

Time	0 4 O
dependence	5 10 O
of	16 2 O
plasma	19 6 O
malondialdehyde	26 15 B-Chemical
,	41 1 O
oxypurines	43 10 B-Chemical
,	53 1 O
and	55 3 O
nucleosides	59 11 B-Chemical
during	71 6 O
incomplete	78 10 O
cerebral	89 8 B-Disease
ischemia	98 8 I-Disease
in	107 2 O
the	110 3 O
rat	114 3 O
.	117 1 O

Incomplete	119 10 O
cerebral	130 8 B-Disease
ischemia	139 8 I-Disease
(	148 1 O
30	149 2 O
min	152 3 O
)	155 1 O
was	157 3 O
induced	161 7 O
in	169 2 O
the	172 3 O
rat	176 3 O
by	180 2 O
bilaterally	183 11 O
clamping	195 8 O
the	204 3 O
common	208 6 O
carotid	215 7 O
arteries	223 8 O
.	231 1 O

Peripheral	233 10 O
venous	244 6 O
blood	251 5 O
samples	257 7 O
were	265 4 O
withdrawn	270 9 O
from	280 4 O
the	285 3 O
femoral	289 7 O
vein	297 4 O
four	302 4 O
times	307 5 O
(	313 1 O
once	314 4 O
every	319 5 O
5	325 1 O
min	327 3 O
)	330 1 O
before	332 6 O
ischemia	339 8 B-Disease
(	348 1 O
0	349 1 O
time	351 4 O
)	355 1 O
and	357 3 O
5	361 1 O
,	362 1 O
15	364 2 O
,	366 1 O
and	368 3 O
30	372 2 O
min	375 3 O
after	379 5 O
ischemia	385 8 B-Disease
.	393 1 O

Plasma	395 6 O
extracts	402 8 O
were	411 4 O
analyzed	416 8 O
by	425 2 O
a	428 1 O
highly	430 6 O
sensitive	437 9 O
high	447 4 O
-	451 1 O
performance	452 11 O
liquid	464 6 O
chromatographic	471 15 O
method	487 6 O
for	494 3 O
the	498 3 O
direct	502 6 O
determination	509 13 O
of	523 2 O
malondialdehyde	526 15 B-Chemical
,	541 1 O
oxypurines	543 10 B-Chemical
,	553 1 O
and	555 3 O
nucleosides	559 11 B-Chemical
.	570 1 O

During	572 6 O
ischemia	579 8 B-Disease
,	587 1 O
a	589 1 O
time	591 4 O
-	595 1 O
dependent	596 9 O
increase	606 8 O
of	615 2 O
plasma	618 6 O
oxypurines	625 10 B-Chemical
and	636 3 O
nucleosides	640 11 B-Chemical
was	652 3 O
observed	656 8 O
.	664 1 O

Plasma	666 6 O
malondialdehyde	673 15 B-Chemical
,	688 1 O
which	690 5 O
was	696 3 O
present	700 7 O
in	708 2 O
minimal	711 7 O
amount	719 6 O
at	726 2 O
zero	729 4 O
time	734 4 O
(	739 1 O
0	740 1 O
.	741 1 O
058	742 3 O
mumol	746 5 O
/	751 1 O
liter	752 5 O
plasma	758 6 O
;	764 1 O
SD	766 2 O
0	769 1 O
.	770 1 O
015	771 3 O
)	774 1 O
,	775 1 O
increased	777 9 O
after	787 5 O
5	793 1 O
min	795 3 O
of	799 2 O
ischemia	802 8 B-Disease
,	810 1 O
resulting	812 9 O
in	822 2 O
a	825 1 O
fivefold	827 8 O
increase	836 8 O
after	845 5 O
30	851 2 O
min	854 3 O
of	858 2 O
carotid	861 7 O
occlusion	869 9 O
(	879 1 O
0	880 1 O
.	881 1 O
298	882 3 O
mumol	886 5 O
/	891 1 O
liter	892 5 O
plasma	898 6 O
;	904 1 O
SD	906 2 O
0	909 1 O
.	910 1 O
078	911 3 O
)	914 1 O
.	915 1 O

Increased	917 9 O
plasma	927 6 O
malondialdehyde	934 15 B-Chemical
was	950 3 O
also	954 4 O
recorded	959 8 O
in	968 2 O
two	971 3 O
other	975 5 O
groups	981 6 O
of	988 2 O
animals	991 7 O
subjected	999 9 O
to	1009 2 O
the	1012 3 O
same	1016 4 O
experimental	1021 12 O
model	1034 5 O
,	1039 1 O
one	1041 3 O
receiving	1045 9 O
20	1055 2 O
mg	1058 2 O
/	1060 1 O
kg	1061 2 O
b	1064 1 O
.	1065 1 O
w	1066 1 O
.	1067 1 O
of	1069 2 O
the	1072 3 O
cyclooxygenase	1076 14 O
inhibitor	1091 9 O
acetylsalicylate	1101 16 B-Chemical
intravenously	1118 13 O
immediately	1132 11 O
before	1144 6 O
ischemia	1151 8 B-Disease
,	1159 1 O
the	1161 3 O
other	1165 5 O
receiving	1171 9 O
650	1181 3 O
micrograms	1185 10 O
/	1195 1 O
kg	1196 2 O
b	1199 1 O
.	1200 1 O
w	1201 1 O
.	1202 1 O
of	1204 2 O
the	1207 3 O
hypotensive	1211 11 B-Disease
drug	1223 4 O
nitroprusside	1228 13 B-Chemical
at	1242 2 O
a	1245 1 O
flow	1247 4 O
rate	1252 4 O
of	1257 2 O
103	1260 3 O
microliters	1264 11 O
/	1275 1 O
min	1276 3 O
intravenously	1280 13 O
during	1294 6 O
ischemia	1301 8 B-Disease
,	1309 1 O
although	1311 8 O
in	1320 2 O
this	1323 4 O
latter	1328 6 O
group	1335 5 O
malondialdehyde	1341 15 B-Chemical
was	1357 3 O
significantly	1361 13 O
higher	1375 6 O
.	1381 1 O

The	1383 3 O
present	1387 7 O
data	1395 4 O
indicate	1400 8 O
that	1409 4 O
the	1414 3 O
determination	1418 13 O
of	1432 2 O
malondialdehyde	1435 15 B-Chemical
,	1450 1 O
oxypurines	1452 10 B-Chemical
,	1462 1 O
and	1464 3 O
nucleosides	1468 11 B-Chemical
in	1480 2 O
peripheral	1483 10 O
blood	1494 5 O
,	1499 1 O
may	1501 3 O
be	1505 2 O
used	1508 4 O
to	1513 2 O
monitor	1516 7 O
the	1524 3 O
metabolic	1528 9 O
alterations	1538 11 O
of	1550 2 O
tissues	1553 7 O
occurring	1561 9 O
during	1571 6 O
ischemic	1578 8 B-Disease
phenomena	1587 9 O
.	1596 1 O
(	1597 1 O
ABSTRACT	1598 8 O
TRUNCATED	1607 9 O
AT	1617 2 O
250	1620 3 O
WORDS	1624 5 O
)	1629 1 O

Cholinergic	0 11 O
toxicity	12 8 B-Disease
resulting	21 9 O
from	31 4 O
ocular	36 6 O
instillation	43 12 O
of	56 2 O
echothiophate	59 13 B-Chemical
iodide	73 6 I-Chemical
eye	80 3 O
drops	84 5 O
.	89 1 O

A	91 1 O
patient	93 7 O
developed	101 9 O
a	111 1 O
severe	113 6 O
cholinergic	120 11 O
syndrome	132 8 O
from	141 4 O
the	146 3 O
use	150 3 O
of	154 2 O
echothiophate	157 13 B-Chemical
iodide	171 6 I-Chemical
ophthalmic	178 10 O
drops	189 5 O
,	194 1 O
presented	196 9 O
with	206 4 O
profound	211 8 O
muscle	220 6 B-Disease
weakness	227 8 I-Disease
and	236 3 O
was	240 3 O
initially	244 9 O
given	254 5 O
the	260 3 O
diagnosis	264 9 O
of	274 2 O
myasthenia	277 10 B-Disease
gravis	288 6 I-Disease
.	294 1 O

Red	296 3 O
blood	300 5 O
cell	306 4 O
and	311 3 O
serum	315 5 O
cholinesterase	321 14 O
levels	336 6 O
were	343 4 O
severely	348 8 O
depressed	357 9 O
and	367 3 O
symptoms	371 8 O
resolved	380 8 O
spontaneously	389 13 O
following	403 9 O
discontinuation	413 15 O
of	429 2 O
the	432 3 O
eye	436 3 O
drops	440 5 O
.	445 1 O

Acute	0 5 B-Disease
renal	6 5 I-Disease
failure	12 7 I-Disease
in	20 2 O
high	23 4 O
dose	28 4 O
carboplatin	33 11 B-Chemical
chemotherapy	45 12 O
.	57 1 O

Carboplatin	59 11 B-Chemical
has	71 3 O
been	75 4 O
reported	80 8 O
to	89 2 O
cause	92 5 O
acute	98 5 B-Disease
renal	104 5 I-Disease
failure	110 7 I-Disease
when	118 4 O
administered	123 12 O
in	136 2 O
high	139 4 O
doses	144 5 O
to	150 2 O
adult	153 5 O
patients	159 8 O
.	167 1 O

We	169 2 O
report	172 6 O
a	179 1 O
4	181 1 O
1	183 1 O
/	184 1 O
2	185 1 O
-	186 1 O
year	187 4 O
-	191 1 O
old	192 3 O
girl	196 4 O
who	201 3 O
was	205 3 O
treated	209 7 O
with	217 4 O
high	222 4 O
-	226 1 O
dose	227 4 O
carboplatin	232 11 B-Chemical
for	244 3 O
metastatic	248 10 O
parameningeal	259 13 O
embryonal	273 9 B-Disease
rhabdomyosarcoma	283 16 I-Disease
.	299 1 O

Acute	301 5 B-Disease
renal	307 5 I-Disease
failure	313 7 I-Disease
developed	321 9 O
followed	331 8 O
by	340 2 O
a	343 1 O
slow	345 4 O
partial	350 7 O
recovery	358 8 O
of	367 2 O
renal	370 5 O
function	376 8 O
.	384 1 O

Possible	386 8 O
contributing	395 12 O
factors	408 7 O
are	416 3 O
discussed	420 9 O
.	429 1 O

Endometrial	0 11 B-Disease
carcinoma	12 9 I-Disease
after	22 5 O
Hodgkin	28 7 B-Disease
disease	36 7 I-Disease
in	44 2 O
childhood	47 9 O
.	56 1 O

A	58 1 O
34	60 2 O
-	62 1 O
year	63 4 O
-	67 1 O
old	68 3 O
patient	72 7 O
developed	80 9 O
metastic	90 8 O
endometrial	99 11 B-Disease
carcinoma	111 9 I-Disease
after	121 5 O
Hodgkin	127 7 B-Disease
disease	135 7 I-Disease
in	143 2 O
childhood	146 9 O
.	155 1 O

She	157 3 O
had	161 3 O
ovarian	165 7 B-Disease
failure	173 7 I-Disease
after	181 5 O
abdominal	187 9 O
irradiation	197 11 O
and	209 3 O
chemotherapy	213 12 O
for	226 3 O
Hodgkin	230 7 B-Disease
disease	238 7 I-Disease
,	245 1 O
and	247 3 O
received	251 8 O
exogenous	260 9 O
estrogens	270 9 B-Chemical
,	279 1 O
a	281 1 O
treatment	283 9 O
implicated	293 10 O
in	304 2 O
the	307 3 O
development	311 11 O
of	323 2 O
endometrial	326 11 B-Disease
cancer	338 6 I-Disease
in	345 2 O
menopausal	348 10 O
women	359 5 O
.	364 1 O

Young	366 5 O
women	372 5 O
on	378 2 O
replacement	381 11 O
estrogens	393 9 B-Chemical
for	403 3 O
ovarian	407 7 B-Disease
failure	415 7 I-Disease
after	423 5 O
cancer	429 6 B-Disease
therapy	436 7 O
may	444 3 O
also	448 4 O
have	453 4 O
increased	458 9 O
risk	468 4 O
of	473 2 O
endometrial	476 11 B-Disease
carcinoma	488 9 I-Disease
and	498 3 O
should	502 6 O
be	509 2 O
examined	512 8 O
periodically	521 12 O
.	533 1 O

Induction	0 9 O
of	10 2 O
the	13 3 O
obstructive	17 11 B-Disease
sleep	29 5 I-Disease
apnea	35 5 I-Disease
syndrome	41 8 I-Disease
in	50 2 O
a	53 1 O
woman	55 5 O
by	61 2 O
exogenous	64 9 O
androgen	74 8 B-Chemical
administration	83 14 O
.	97 1 O

We	99 2 O
documented	102 10 O
airway	113 6 O
occlusion	120 9 O
during	130 6 O
sleep	137 5 O
and	143 3 O
an	147 2 O
abnormally	150 10 O
high	161 4 O
supraglottic	166 12 O
resistance	179 10 O
while	190 5 O
awake	196 5 O
in	202 2 O
a	205 1 O
54	207 2 O
-	209 1 O
yr	210 2 O
-	212 1 O
old	213 3 O
woman	217 5 O
who	223 3 O
had	227 3 O
developed	231 9 O
physical	241 8 O
changes	250 7 O
and	258 3 O
the	262 3 O
syndrome	266 8 B-Disease
of	275 2 I-Disease
obstructive	278 11 I-Disease
sleep	290 5 I-Disease
apnea	296 5 I-Disease
while	302 5 O
being	308 5 O
administered	314 12 O
exogenous	327 9 O
androgens	337 9 B-Chemical
.	346 1 O

When	348 4 O
the	353 3 O
androgens	357 9 B-Chemical
were	367 4 O
withdrawn	372 9 O
,	381 1 O
the	383 3 O
patient	387 7 O
'	394 1 O
s	395 1 O
physical	397 8 O
changes	406 7 O
,	413 1 O
symptoms	415 8 O
,	423 1 O
sleep	425 5 O
study	431 5 O
,	436 1 O
and	438 3 O
supraglottic	442 12 O
resistance	455 10 O
all	466 3 O
returned	470 8 O
to	479 2 O
normal	482 6 O
.	488 1 O

A	490 1 O
rechallenge	492 11 O
with	504 4 O
androgen	509 8 B-Chemical
produced	518 8 O
symptoms	527 8 O
of	536 2 O
obstructive	539 11 B-Disease
sleep	551 5 I-Disease
apnea	557 5 I-Disease
that	563 4 O
abated	568 6 O
upon	575 4 O
withdrawal	580 10 O
of	591 2 O
the	594 3 O
hormone	598 7 O
.	605 1 O

Previous	607 8 O
reports	616 7 O
have	624 4 O
favored	629 7 O
a	637 1 O
role	639 4 O
of	644 2 O
androgens	647 9 B-Chemical
in	657 2 O
the	660 3 O
pathogenesis	664 12 O
of	677 2 O
sleep	680 5 B-Disease
apnea	686 5 I-Disease
.	691 1 O

Our	693 3 O
report	697 6 O
provides	704 8 O
direct	713 6 O
evidence	720 8 O
for	729 3 O
this	733 4 O
role	738 4 O
.	742 1 O

Structural	744 10 O
and	755 3 O
functional	759 10 O
measurements	770 12 O
indicate	783 8 O
that	792 4 O
androgens	797 9 B-Chemical
exert	807 5 O
a	813 1 O
permissive	815 10 O
or	826 2 O
necessary	829 9 O
action	839 6 O
on	846 2 O
the	849 3 O
structural	853 10 O
configuration	864 13 O
of	878 2 O
the	881 3 O
oropharynx	885 10 O
that	896 4 O
predisposes	901 11 O
to	913 2 O
obstruction	916 11 O
during	928 6 O
sleep	935 5 O
.	940 1 O

Development	942 11 O
of	954 2 O
the	957 3 O
obstructive	961 11 B-Disease
sleep	973 5 I-Disease
apnea	979 5 I-Disease
syndrome	985 8 I-Disease
must	994 4 O
be	999 2 O
considered	1002 10 O
a	1013 1 O
possible	1015 8 O
side	1024 4 O
effect	1029 6 O
of	1036 2 O
androgen	1039 8 B-Chemical
therapy	1048 7 O
.	1055 1 O

Effect	0 6 O
of	7 2 O
captopril	10 9 B-Chemical
on	20 2 O
pre	23 3 O
-	26 1 O
existing	27 8 O
and	36 3 O
aminonucleoside	40 15 B-Chemical
-	55 1 O
induced	56 7 O
proteinuria	64 11 B-Disease
in	76 2 O
spontaneously	79 13 O
hypertensive	93 12 B-Disease
rats	106 4 O
.	110 1 O

Proteinuria	112 11 B-Disease
is	124 2 O
a	127 1 O
side	129 4 O
effect	134 6 O
of	141 2 O
captopril	144 9 B-Chemical
treatment	154 9 O
in	164 2 O
hypertensive	167 12 B-Disease
patients	180 8 O
.	188 1 O

The	190 3 O
possibility	194 11 O
of	206 2 O
reproducing	209 11 O
the	221 3 O
same	225 4 O
renal	230 5 B-Disease
abnormality	236 11 I-Disease
with	248 4 O
captopril	253 9 B-Chemical
was	263 3 O
examined	267 8 O
in	276 2 O
SHR	279 3 O
.	282 1 O

Oral	284 4 O
administration	289 14 O
of	304 2 O
captopril	307 9 B-Chemical
at	317 2 O
100	320 3 O
mg	324 2 O
/	326 1 O
kg	327 2 O
for	330 3 O
14	334 2 O
days	337 4 O
failed	342 6 O
to	349 2 O
aggravate	352 9 O
proteinuria	362 11 B-Disease
pre	374 3 O
-	377 1 O
existing	378 8 O
in	387 2 O
SHR	390 3 O
.	393 1 O

Also	395 4 O
,	399 1 O
captopril	401 9 B-Chemical
treatment	411 9 O
failed	421 6 O
to	428 2 O
potentiate	431 10 O
or	442 2 O
facilitate	445 10 O
development	456 11 O
of	468 2 O
massive	471 7 O
proteinuria	479 11 B-Disease
invoked	491 7 O
by	499 2 O
puromycin	502 9 B-Chemical
aminonucleoside	512 15 I-Chemical
in	528 2 O
SHR	531 3 O
.	534 1 O

Captopril	536 9 B-Chemical
had	546 3 O
little	550 6 O
or	557 2 O
no	560 2 O
demonstrable	563 12 O
effects	576 7 O
on	584 2 O
serum	587 5 O
electrolyte	593 11 O
concentrations	605 14 O
,	619 1 O
excretion	621 9 O
of	631 2 O
urine	634 5 O
,	639 1 O
sodium	641 6 B-Chemical
and	648 3 O
potassium	652 9 B-Chemical
,	661 1 O
endogenous	663 10 O
creatinine	674 10 B-Chemical
clearance	685 9 O
,	694 1 O
body	696 4 O
weight	701 6 O
,	707 1 O
and	709 3 O
food	713 4 O
and	718 3 O
water	722 5 O
consumption	728 11 O
.	739 1 O

However	741 7 O
,	748 1 O
ketone	750 6 B-Chemical
bodies	757 6 O
were	764 4 O
consistently	769 12 O
present	782 7 O
in	790 2 O
urine	793 5 O
and	799 3 O
several	803 7 O
lethalities	811 11 O
occurred	823 8 O
during	832 6 O
multiple	839 8 O
dosing	848 6 O
of	855 2 O
captopril	858 9 B-Chemical
in	868 2 O
SHR	871 3 O
.	874 1 O

Epileptogenic	0 13 O
properties	14 10 O
of	25 2 O
enflurane	28 9 B-Chemical
and	38 3 O
their	42 5 O
clinical	48 8 O
interpretation	57 14 O
.	71 1 O

Three	73 5 O
cases	79 5 O
of	85 2 O
EEG	88 3 O
changes	92 7 O
induced	100 7 O
by	108 2 O
single	111 6 O
exposure	118 8 O
to	127 2 O
enflurane	130 9 B-Chemical
anesthesia	140 10 O
are	151 3 O
reported	155 8 O
.	163 1 O

In	165 2 O
one	168 3 O
patient	172 7 O
,	179 1 O
enflurane	181 9 B-Chemical
administered	191 12 O
during	204 6 O
a	211 1 O
donor	213 5 O
nephrectomy	219 11 O
resulted	231 8 O
in	240 2 O
unexpected	243 10 O
partial	254 7 O
motor	262 5 O
seizures	268 8 B-Disease
.	276 1 O

Until	278 5 O
the	284 3 O
cause	288 5 O
of	294 2 O
the	297 3 O
seizures	301 8 B-Disease
was	310 3 O
correctly	314 9 O
identified	324 10 O
,	334 1 O
the	336 3 O
patient	340 7 O
was	348 3 O
inappropriately	352 15 O
treated	368 7 O
with	376 4 O
anticonvulsants	381 15 O
.	396 1 O

Two	398 3 O
other	402 5 O
patients	408 8 O
suffered	417 8 O
from	426 4 O
partial	431 7 O
,	438 1 O
complex	440 7 O
and	448 3 O
generalized	452 11 O
seizures	464 8 B-Disease
uncontrolled	473 12 O
by	486 2 O
medication	489 10 O
.	499 1 O

Epileptic	501 9 B-Disease
foci	511 4 O
delineated	516 10 O
and	527 3 O
activated	531 9 O
by	541 2 O
enflurane	544 9 B-Chemical
were	554 4 O
surgically	559 10 O
ablated	570 7 O
and	578 3 O
the	582 3 O
patients	586 8 O
are	595 3 O
now	599 3 O
seizure	603 7 B-Disease
-	610 1 O
free	611 4 O
.	615 1 O

Previous	617 8 O
exposures	626 9 O
to	636 2 O
enflurane	639 9 B-Chemical
have	649 4 O
to	654 2 O
be	657 2 O
disclosed	660 9 O
to	670 2 O
avoid	673 5 O
mistakes	679 8 O
in	688 2 O
clinical	691 8 O
interpretation	700 14 O
of	715 2 O
the	718 3 O
EEG	722 3 O
.	725 1 O

On	727 2 O
the	730 3 O
other	734 5 O
hand	740 4 O
,	744 1 O
enflurane	746 9 B-Chemical
may	756 3 O
prove	760 5 O
to	766 2 O
be	769 2 O
a	772 1 O
safe	774 4 O
fast	779 4 O
acting	784 6 O
activator	791 9 O
of	801 2 O
epileptic	804 9 B-Disease
foci	814 4 O
during	819 6 O
corticography	826 13 O
or	840 2 O
depth	843 5 O
electrode	849 9 O
intraoperative	859 14 O
recordings	874 10 O
.	884 1 O

Reversible	0 10 O
cerebral	11 8 B-Disease
lesions	20 7 I-Disease
associated	28 10 O
with	39 4 O
tiazofurin	44 10 B-Chemical
usage	55 5 O
:	60 1 O
MR	62 2 O
demonstration	65 13 O
.	78 1 O

Tiazofurin	80 10 B-Chemical
is	91 2 O
an	94 2 O
experimental	97 12 O
chemotherapeutic	110 16 O
agent	127 5 O
currently	133 9 O
undergoing	143 10 O
clinical	154 8 O
evaluation	163 10 O
.	173 1 O

We	175 2 O
report	178 6 O
our	185 3 O
results	189 7 O
with	197 4 O
magnetic	202 8 O
resonance	211 9 O
(	221 1 O
MR	222 2 O
)	224 1 O
in	226 2 O
demonstrating	229 13 O
reversible	243 10 O
cerebral	254 8 B-Disease
abnormalities	263 13 I-Disease
concurrent	277 10 O
with	288 4 O
the	293 3 O
use	297 3 O
of	301 2 O
this	304 4 O
drug	309 4 O
.	313 1 O

The	315 3 O
abnormalities	319 13 O
on	333 2 O
MR	336 2 O
were	339 4 O
correlated	344 10 O
with	355 4 O
findings	360 8 O
on	369 2 O
CT	372 2 O
as	375 2 O
well	378 4 O
as	383 2 O
with	386 4 O
cerebral	391 8 O
angiography	400 11 O
.	411 1 O

The	413 3 O
utility	417 7 O
of	425 2 O
MR	428 2 O
in	431 2 O
the	434 3 O
evaluation	438 10 O
of	449 2 O
patients	452 8 O
receiving	461 9 O
this	471 4 O
new	476 3 O
agent	480 5 O
is	486 2 O
illustrated	489 11 O
.	500 1 O

Antagonism	0 10 O
of	11 2 O
diazepam	14 8 B-Chemical
-	22 1 O
induced	23 7 O
sedative	31 8 O
effects	40 7 O
by	48 2 O
Ro15	51 4 B-Chemical
-	55 1 I-Chemical
1788	56 4 I-Chemical
in	61 2 O
patients	64 8 O
after	73 5 O
surgery	79 7 O
under	87 5 O
lumbar	93 6 O
epidural	100 8 O
block	109 5 O
.	114 1 O

A	116 1 O
double	118 6 O
-	124 1 O
blind	125 5 O
placebo	131 7 O
-	138 1 O
controlled	139 10 O
investigation	150 13 O
of	164 2 O
efficacy	167 8 O
and	176 3 O
safety	180 6 O
.	186 1 O

The	188 3 O
aim	192 3 O
of	196 2 O
this	199 4 O
study	204 5 O
was	210 3 O
to	214 2 O
assess	217 6 O
the	224 3 O
efficacy	228 8 O
of	237 2 O
Ro15	240 4 B-Chemical
-	244 1 I-Chemical
1788	245 4 I-Chemical
and	250 3 O
a	254 1 O
placebo	256 7 O
in	264 2 O
reversing	267 9 O
diazepam	277 8 B-Chemical
-	285 1 O
induced	286 7 O
effects	294 7 O
after	302 5 O
surgery	308 7 O
under	316 5 O
epidural	322 8 O
block	331 5 O
,	336 1 O
and	338 3 O
to	342 2 O
evaluate	345 8 O
the	354 3 O
local	358 5 O
tolerance	364 9 O
and	374 3 O
general	378 7 O
safety	386 6 O
of	393 2 O
Ro15	396 4 B-Chemical
-	400 1 I-Chemical
1788	401 4 I-Chemical
.	405 1 O

Fifty	407 5 O
-	412 1 O
seven	413 5 O
patients	419 8 O
were	428 4 O
sedated	433 7 O
with	441 4 O
diazepam	446 8 B-Chemical
for	455 3 O
surgery	459 7 O
under	467 5 O
epidural	473 8 O
anaesthesia	482 11 O
.	493 1 O

Antagonism	495 10 O
of	506 2 O
diazepam	509 8 B-Chemical
-	517 1 O
induced	518 7 O
effects	526 7 O
by	534 2 O
Ro15	537 4 B-Chemical
-	541 1 I-Chemical
1788	542 4 I-Chemical
was	547 3 O
investigated	551 12 O
postoperatively	564 15 O
in	580 2 O
a	583 1 O
double	585 6 O
-	591 1 O
blind	592 5 O
placebo	598 7 O
-	605 1 O
controlled	606 10 O
trial	617 5 O
.	622 1 O

The	624 3 O
patient	628 7 O
'	635 1 O
s	636 1 O
subjective	638 10 O
assessment	649 10 O
of	660 2 O
mood	663 4 O
rating	668 6 O
,	674 1 O
an	676 2 O
objective	679 9 O
test	689 4 O
of	694 2 O
performance	697 11 O
,	708 1 O
a	710 1 O
test	712 4 O
for	717 3 O
amnesia	721 7 B-Disease
,	728 1 O
and	730 3 O
vital	734 5 O
signs	740 5 O
were	746 4 O
recorded	751 8 O
for	760 3 O
up	764 2 O
to	767 2 O
300	770 3 O
min	774 3 O
after	778 5 O
administration	784 14 O
of	799 2 O
the	802 3 O
trial	806 5 O
drug	812 4 O
.	816 1 O

No	818 2 O
significant	821 11 O
differences	833 11 O
between	845 7 O
the	853 3 O
two	857 3 O
groups	861 6 O
were	868 4 O
observed	873 8 O
for	882 3 O
mood	886 4 O
rating	891 6 O
,	897 1 O
amnesia	899 7 B-Disease
,	906 1 O
or	908 2 O
vital	911 5 O
signs	917 5 O
.	922 1 O

The	924 3 O
Ro15	928 4 B-Chemical
-	932 1 I-Chemical
1788	933 4 I-Chemical
group	938 5 O
showed	944 6 O
a	951 1 O
significant	953 11 O
improvement	965 11 O
in	977 2 O
the	980 3 O
performance	984 11 O
test	996 4 O
up	1001 2 O
to	1004 2 O
120	1007 3 O
min	1011 3 O
after	1015 5 O
administration	1021 14 O
of	1036 2 O
the	1039 3 O
drug	1043 4 O
.	1047 1 O

There	1049 5 O
was	1055 3 O
no	1059 2 O
evidence	1062 8 O
of	1071 2 O
reaction	1074 8 O
at	1083 2 O
the	1086 3 O
injection	1090 9 O
site	1100 4 O
.	1104 1 O

Enhanced	0 8 O
stimulus	9 8 O
-	17 1 O
induced	18 7 O
neurotransmitter	26 16 O
overflow	43 8 O
in	52 2 O
epinephrine	55 11 B-Chemical
-	66 1 O
induced	67 7 O
hypertensive	75 12 B-Disease
rats	88 4 O
is	93 2 O
not	96 3 O
mediated	100 8 O
by	109 2 O
prejunctional	112 13 O
beta	126 4 O
-	130 1 O
adrenoceptor	131 12 O
activation	144 10 O
.	154 1 O

The	156 3 O
present	160 7 O
study	168 5 O
examines	174 8 O
the	183 3 O
effect	187 6 O
of	194 2 O
6	197 1 O
-	198 1 O
day	199 3 O
epinephrine	203 11 B-Chemical
treatment	215 9 O
(	225 1 O
100	226 3 O
micrograms	230 10 O
/	240 1 O
kg	241 2 O
per	244 3 O
h	248 1 O
,	249 1 O
s	251 1 O
.	252 1 O
c	253 1 O
.	254 1 O
)	255 1 O
on	257 2 O
stimulus	260 8 O
-	268 1 O
induced	269 7 O
(	277 1 O
1	278 1 O
Hz	280 2 O
)	282 1 O
endogenous	284 10 O
neurotransmitter	295 16 O
overflow	312 8 O
from	321 4 O
the	326 3 O
isolated	330 8 O
perfused	339 8 O
kidney	348 6 O
of	355 2 O
vehicle	358 7 O
-	365 1 O
and	367 3 O
epinephrine	371 11 B-Chemical
-	382 1 O
treated	383 7 O
rats	391 4 O
.	395 1 O

Renal	397 5 O
catecholamine	403 13 B-Chemical
stores	417 6 O
and	424 3 O
stimulus	428 8 O
-	436 1 O
induced	437 7 O
overflow	445 8 O
in	454 2 O
the	457 3 O
vehicle	461 7 O
-	468 1 O
treated	469 7 O
group	477 5 O
consisted	483 9 O
of	493 2 O
norepinephrine	496 14 B-Chemical
only	511 4 O
.	515 1 O

However	517 7 O
,	524 1 O
epinephrine	526 11 B-Chemical
treatment	538 9 O
resulted	548 8 O
in	557 2 O
the	560 3 O
incorporation	564 13 O
of	578 2 O
epinephrine	581 11 B-Chemical
into	593 4 O
renal	598 5 O
catecholamine	604 13 B-Chemical
stores	618 6 O
such	625 4 O
that	630 4 O
approximately	635 13 O
40	649 2 O
%	651 1 O
of	653 2 O
the	656 3 O
catecholamine	660 13 B-Chemical
present	674 7 O
was	682 3 O
epinephrine	686 11 B-Chemical
while	698 5 O
the	704 3 O
norepinephrine	708 14 B-Chemical
content	723 7 O
was	731 3 O
reduced	735 7 O
by	743 2 O
a	746 1 O
similar	748 7 O
degree	756 6 O
.	762 1 O

Total	764 5 O
tissue	770 6 O
catecholamine	777 13 B-Chemical
content	791 7 O
of	799 2 O
the	802 3 O
kidney	806 6 O
on	813 2 O
a	816 1 O
molar	818 5 O
basis	824 5 O
was	830 3 O
unchanged	834 9 O
.	843 1 O

Stimulus	845 8 O
-	853 1 O
induced	854 7 O
fractional	862 10 O
overflow	873 8 O
of	882 2 O
neurotransmitter	885 16 O
from	902 4 O
the	907 3 O
epinephrine	911 11 B-Chemical
-	922 1 O
treated	923 7 O
kidneys	931 7 O
was	939 3 O
approximately	943 13 O
twice	957 5 O
normal	963 6 O
and	970 3 O
consisted	974 9 O
of	984 2 O
both	987 4 O
norepinephrine	992 14 B-Chemical
and	1007 3 O
epinephrine	1011 11 B-Chemical
in	1023 2 O
proportions	1026 11 O
similar	1038 7 O
to	1046 2 O
those	1049 5 O
found	1055 5 O
in	1061 2 O
the	1064 3 O
kidney	1068 6 O
.	1074 1 O

This	1076 4 O
difference	1081 10 O
in	1092 2 O
fractional	1095 10 O
overflow	1106 8 O
between	1115 7 O
groups	1123 6 O
was	1130 3 O
not	1134 3 O
affected	1138 8 O
by	1147 2 O
neuronal	1150 8 O
and	1159 3 O
extraneuronal	1163 13 O
uptake	1177 6 O
blockade	1184 8 O
.	1192 1 O

Propranolol	1194 11 B-Chemical
had	1206 3 O
no	1210 2 O
effect	1213 6 O
on	1220 2 O
stimulus	1223 8 O
-	1231 1 O
induced	1232 7 O
overflow	1240 8 O
in	1249 2 O
either	1252 6 O
group	1259 5 O
.	1264 1 O

Phentolamine	1266 12 B-Chemical
increased	1279 9 O
stimulus	1289 8 O
-	1297 1 O
induced	1298 7 O
overflow	1306 8 O
in	1315 2 O
both	1318 4 O
groups	1323 6 O
although	1330 8 O
the	1339 3 O
increment	1343 9 O
in	1353 2 O
overflow	1356 8 O
was	1365 3 O
greater	1369 7 O
in	1377 2 O
the	1380 3 O
epinephrine	1384 11 B-Chemical
-	1395 1 O
treated	1396 7 O
group	1404 5 O
.	1409 1 O

In	1411 2 O
conclusion	1414 10 O
,	1424 1 O
chronic	1426 7 O
epinephrine	1434 11 B-Chemical
treatment	1446 9 O
results	1456 7 O
in	1464 2 O
enhanced	1467 8 O
fractional	1476 10 O
neurotransmitter	1487 16 O
overflow	1504 8 O
.	1512 1 O

However	1514 7 O
,	1521 1 O
neither	1523 7 O
alterations	1531 11 O
in	1543 2 O
prejunctional	1546 13 O
beta	1560 4 O
-	1564 1 O
adrenoceptor	1565 12 O
influences	1578 10 O
nor	1589 3 O
alterations	1593 11 O
in	1605 2 O
neuronal	1608 8 O
and	1617 3 O
extraneuronal	1621 13 O
uptake	1635 6 O
mechanisms	1642 10 O
appear	1653 6 O
to	1660 2 O
be	1663 2 O
responsible	1666 11 O
for	1678 3 O
this	1682 4 O
alteration	1687 10 O
.	1697 1 O

Furthermore	1699 11 O
,	1710 1 O
data	1712 4 O
obtained	1717 8 O
with	1726 4 O
phentolamine	1731 12 B-Chemical
alone	1744 5 O
do	1750 2 O
not	1753 3 O
suggest	1757 7 O
alpha	1765 5 O
-	1770 1 O
adrenoceptor	1771 12 O
desensitization	1784 15 O
as	1800 2 O
the	1803 3 O
cause	1807 5 O
of	1813 2 O
the	1816 3 O
enhanced	1820 8 O
neurotransmitter	1829 16 O
overflow	1846 8 O
after	1855 5 O
epinephrine	1861 11 B-Chemical
treatment	1873 9 O
.	1882 1 O

Ocular	0 6 O
manifestations	7 14 O
of	22 2 O
juvenile	25 8 B-Disease
rheumatoid	34 10 I-Disease
arthritis	45 9 I-Disease
.	54 1 O

We	56 2 O
followed	59 8 O
210	68 3 O
cases	72 5 O
of	78 2 O
juvenile	81 8 B-Disease
rheumatoid	90 10 I-Disease
arthritis	101 9 I-Disease
closely	111 7 O
for	119 3 O
eleven	123 6 O
years	130 5 O
.	135 1 O

Thirty	137 6 O
-	143 1 O
six	144 3 O
of	148 2 O
the	151 3 O
210	155 3 O
patients	159 8 O
(	168 1 O
17	169 2 O
.	171 1 O
2	172 1 O
%	173 1 O
)	174 1 O
developed	176 9 O
iridocyclitis	186 13 B-Disease
.	199 1 O

Iridocyclitis	201 13 B-Disease
was	215 3 O
seen	219 4 O
most	224 4 O
frequently	229 10 O
in	240 2 O
young	243 5 O
female	249 6 O
patients	256 8 O
(	265 1 O
0	266 1 O
to	268 2 O
4	271 1 O
years	273 5 O
)	278 1 O
with	280 4 O
the	285 3 O
monoarticular	289 13 O
or	303 2 O
pauciatricular	306 14 O
form	321 4 O
of	326 2 O
the	329 3 O
arthritis	333 9 B-Disease
.	342 1 O

However	344 7 O
,	351 1 O
30	353 2 O
%	355 1 O
of	357 2 O
the	360 3 O
patients	364 8 O
developed	373 9 O
uveitis	383 7 B-Disease
after	391 5 O
16	397 2 O
years	400 5 O
of	406 2 O
age	409 3 O
.	412 1 O

Although	414 8 O
61	423 2 O
%	425 1 O
of	427 2 O
patients	430 8 O
had	439 3 O
a	443 1 O
noncontributory	445 15 O
ocular	461 6 O
history	468 7 O
on	476 2 O
entry	479 5 O
,	484 1 O
42	486 2 O
%	488 1 O
had	490 3 O
active	494 6 O
uveitis	501 7 B-Disease
on	509 2 O
entry	512 5 O
.	517 1 O

Our	519 3 O
approach	523 8 O
was	532 3 O
effective	536 9 O
in	546 2 O
detecting	549 9 O
uveitis	559 7 B-Disease
in	567 2 O
new	570 3 O
cases	574 5 O
and	580 3 O
exacerbations	584 13 O
of	598 2 O
uveitis	601 7 B-Disease
in	609 2 O
established	612 11 O
cases	624 5 O
.	629 1 O

Forty	631 5 O
-	636 1 O
four	637 4 O
percent	642 7 O
of	650 2 O
patients	653 8 O
with	662 4 O
uveitis	667 7 B-Disease
had	675 3 O
one	679 3 O
or	683 2 O
more	686 4 O
identifiable	691 12 O
signs	704 5 O
or	710 2 O
symptoms	713 8 O
,	721 1 O
such	723 4 O
as	728 2 O
red	731 3 O
eye	735 3 O
,	738 1 O
ocular	740 6 B-Disease
pain	747 4 I-Disease
,	751 1 O
decreased	753 9 B-Disease
visual	763 6 I-Disease
acuity	770 6 I-Disease
,	776 1 O
or	778 2 O
photophobia	781 11 B-Disease
,	792 1 O
in	794 2 O
order	797 5 O
of	803 2 O
decreasing	806 10 O
frequency	817 9 O
.	826 1 O

Even	828 4 O
after	833 5 O
early	839 5 O
detection	845 9 O
and	855 3 O
prompt	859 6 O
treatment	866 9 O
,	875 1 O
41	877 2 O
%	879 1 O
of	881 2 O
cases	884 5 O
of	890 2 O
uveitis	893 7 B-Disease
did	901 3 O
not	905 3 O
respond	909 7 O
to	917 2 O
more	920 4 O
than	925 4 O
six	930 3 O
months	934 6 O
of	941 2 O
intensive	944 9 O
topical	954 7 O
treatment	962 9 O
with	972 4 O
corticosteroids	977 15 B-Chemical
and	993 3 O
mydriatics	997 10 O
.	1007 1 O

Despite	1009 7 O
this	1017 4 O
,	1021 1 O
there	1023 5 O
was	1029 3 O
a	1033 1 O
dramatic	1035 8 O
decrease	1044 8 O
in	1053 2 O
the	1056 3 O
50	1060 2 O
%	1062 1 O
incidence	1064 9 O
of	1074 2 O
blinding	1077 8 O
complications	1086 13 O
of	1100 2 O
uveitis	1103 7 B-Disease
cited	1111 5 O
in	1117 2 O
earlier	1120 7 O
studies	1128 7 O
.	1135 1 O

Cataract	1137 8 B-Disease
and	1146 3 O
band	1150 4 B-Disease
keratopathy	1155 11 I-Disease
occurred	1167 8 O
in	1176 2 O
only	1179 4 O
22	1184 2 O
and	1187 3 O
13	1191 2 O
%	1193 1 O
of	1195 2 O
our	1198 3 O
group	1202 5 O
,	1207 1 O
respectively	1209 12 O
.	1221 1 O

We	1223 2 O
used	1226 4 O
chloroquine	1231 11 B-Chemical
or	1243 2 O
hydroxychloroquine	1246 18 B-Chemical
in	1265 2 O
173	1268 3 O
of	1272 2 O
210	1275 3 O
cases	1279 5 O
and	1285 3 O
found	1289 5 O
only	1295 4 O
one	1300 3 O
case	1304 4 O
of	1309 2 O
chorioretinopathy	1312 17 B-Disease
attributable	1330 12 O
to	1343 2 O
these	1346 5 O
drugs	1352 5 O
.	1357 1 O

Systemically	1359 12 O
administered	1372 12 O
corticosteroids	1385 15 B-Chemical
were	1401 4 O
used	1406 4 O
in	1411 2 O
75	1414 2 O
of	1417 2 O
210	1420 3 O
cases	1424 5 O
;	1429 1 O
a	1431 1 O
significant	1433 11 O
number	1445 6 O
of	1452 2 O
posterior	1455 9 O
subcapsular	1465 11 O
cataracts	1477 9 B-Disease
was	1487 3 O
found	1491 5 O
.	1496 1 O

Typical	1498 7 O
keratoconjunctivitis	1506 20 B-Disease
sicca	1527 5 O
developed	1533 9 O
in	1543 2 O
three	1546 5 O
of	1552 2 O
the	1555 3 O
uveitis	1559 7 B-Disease
cases	1567 5 O
.	1572 1 O

This	1574 4 O
association	1579 11 O
with	1591 4 O
uveitis	1596 7 B-Disease
and	1604 3 O
JRA	1608 3 O
was	1612 3 O
not	1616 3 O
noted	1620 5 O
previously	1626 10 O
.	1636 1 O

Surgical	1638 8 O
treatment	1647 9 O
of	1657 2 O
cataracts	1660 9 B-Disease
,	1669 1 O
band	1671 4 B-Disease
keratopathy	1676 11 I-Disease
,	1687 1 O
and	1689 3 O
glaucoma	1693 8 B-Disease
achieved	1702 8 O
uniformly	1711 9 O
discouraging	1721 12 O
results	1734 7 O
.	1741 1 O

Water	0 5 B-Disease
intoxication	6 12 I-Disease
associated	19 10 O
with	30 4 O
oxytocin	35 8 B-Chemical
administration	44 14 O
during	59 6 O
saline	66 6 O
-	72 1 O
induced	73 7 O
abortion	81 8 B-Disease
.	89 1 O

Four	91 4 O
cases	96 5 O
of	102 2 O
water	105 5 B-Disease
intoxication	111 12 I-Disease
in	124 2 O
connection	127 10 O
with	138 4 O
oxytocin	143 8 B-Chemical
administration	152 14 O
during	167 6 O
saline	174 6 O
-	180 1 O
induced	181 7 O
abortions	189 9 B-Disease
are	199 3 O
described	203 9 O
.	212 1 O

The	214 3 O
mechanism	218 9 O
of	228 2 O
water	231 5 B-Disease
intoxication	237 12 I-Disease
is	250 2 O
discussed	253 9 O
in	263 2 O
regard	266 6 O
to	273 2 O
these	276 5 O
cases	282 5 O
.	287 1 O

Oxytocin	289 8 B-Chemical
administration	298 14 O
during	313 6 O
midtrimester	320 12 O
-	332 1 O
induced	333 7 O
abortions	341 9 B-Disease
is	351 2 O
advocated	354 9 O
only	364 4 O
if	369 2 O
it	372 2 O
can	375 3 O
be	379 2 O
carried	382 7 O
out	390 3 O
under	394 5 O
careful	400 7 O
observations	408 12 O
of	421 2 O
an	424 2 O
alert	427 5 O
nursing	433 7 O
staff	441 5 O
,	446 1 O
aware	448 5 O
of	454 2 O
the	457 3 O
symptoms	461 8 O
of	470 2 O
water	473 5 B-Disease
intoxication	479 12 I-Disease
and	492 3 O
instructed	496 10 O
to	507 2 O
watch	510 5 O
the	516 3 O
diuresis	520 8 O
and	529 3 O
report	533 6 O
such	540 4 O
early	545 5 O
signs	551 5 O
of	557 2 O
the	560 3 O
syndrome	564 8 O
as	573 2 O
asthenia	576 8 B-Disease
,	584 1 O
muscular	586 8 O
irritability	595 12 B-Disease
,	607 1 O
or	609 2 O
headaches	612 9 B-Disease
.	621 1 O

The	623 3 O
oxytocin	627 8 B-Chemical
should	636 6 O
be	643 2 O
given	646 5 O
only	652 4 O
in	657 2 O
Ringers	660 7 O
lactate	668 7 B-Chemical
or	676 2 O
,	678 1 O
alternately	680 11 O
,	691 1 O
in	693 2 O
Ringers	696 7 O
lactate	704 7 B-Chemical
and	712 3 O
a	716 1 O
5	718 1 O
per	720 3 O
cent	724 4 O
dextrose	729 8 B-Chemical
and	738 3 O
water	742 5 O
solutions	748 9 O
.	757 1 O

The	759 3 O
urinary	763 7 O
output	771 6 O
should	778 6 O
be	785 2 O
monitored	788 9 O
and	798 3 O
the	802 3 O
oxytocin	806 8 B-Chemical
administration	815 14 O
discontinued	830 12 O
and	843 3 O
the	847 3 O
serum	851 5 O
electrolytes	857 12 O
checked	870 7 O
if	878 2 O
the	881 3 O
urinary	885 7 O
output	893 6 O
decreases	900 9 O
.	909 1 O

The	911 3 O
oxytocin	915 8 B-Chemical
should	924 6 O
not	931 3 O
be	935 2 O
administered	938 12 O
in	951 2 O
excess	954 6 O
of	961 2 O
36	964 2 O
hours	967 5 O
.	972 1 O

If	974 2 O
the	977 3 O
patient	981 7 O
has	989 3 O
not	993 3 O
aborted	997 7 O
by	1005 2 O
then	1008 4 O
the	1013 3 O
oxytocin	1017 8 B-Chemical
should	1026 6 O
be	1033 2 O
discontinued	1036 12 O
for	1049 3 O
10	1053 2 O
to	1056 2 O
12	1059 2 O
hours	1062 5 O
in	1068 2 O
order	1071 5 O
to	1077 2 O
perform	1080 7 O
electrolyte	1088 11 O
determinations	1100 14 O
and	1115 3 O
correct	1119 7 O
any	1127 3 O
electrolyte	1131 11 O
imbalance	1143 9 O
.	1152 1 O

